PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Akhter, SA; Milano, CA; Shotwell, KF; Cho, MC; Rockman, HA; Lefkowitz, RJ; Koch, WJ				Akhter, SA; Milano, CA; Shotwell, KF; Cho, MC; Rockman, HA; Lefkowitz, RJ; Koch, WJ			Transgenic mice with cardiac overexpression of alpha(1B)-adrenergic receptors - In vivo alpha(1)-adrenergic receptor-mediated regulation of beta-adrenergic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GENE-EXPRESSION; HYPERTROPHY; STIMULATION; MYOCYTES; IDENTIFICATION; ACTIVATION; INDUCTION; PROMOTER; FAMILY	Transgenic mice were generated with cardiac-specific overexpression of the wild-type (WT) alpha(1B)-adrenergic receptor (AR) using the murine alpha-myosin heavy chain gene promoter, Previously, we described transgenic mice with alpha-myosin heavy chain-directed expression of a constitutively active mutant alpha(1B)-AR that had a phenotype of myocardial hypertrophy (Milano, C, A., Dolber, P. C,, Rockman, H. A., Bond, R. A., Venable M, E,, Alien, L, F,, and Lefkowitz, R, J. (1994) Proc. Natl. Acad. Sci. U,S. A, 91, 10109-10113). In animals with >40-fold WT alpha(1)-AR overexpression, basal myocardial diacylglycerol content was significantly increased, indicating enhanced alpha(1)-adrenergic signaling and phospholipase C activity, In contrast to the mice overexpressing constitutively active mutant alpha(1B)-ARs, the hearts of these mice did not develop cardiac hypertrophy despite an 8-fold increase in ventricular mRNA for atrial natriuretic factor, In vivo physiology was studied in anesthetized intact animals and showed left ventricular contractility in response to the beta-agonist isoproterenol to be significantly depressed in animals overexpressing WT alpha(1B).ARs, Membranes purified from the hearts of WT alpha(1B).AR-overexpressing mice demonstrated significantly attenuated adenylyl cyclase activity basally and after stimulation with isoproterenol, norepinephrine, or phenylephrine, Interestingly, these in vitro changes in signaling were reversed after treating the mice with pertussis toxin, suggesting that the extraordinarily high levels of WT alpha(1B).ARs can lead to coupling to pertussis toxin-sensitive G proteins, Another potential contributor to the observed decreased myocardial signaling and function could be enhanced beta-AR desensitization as beta-adrenergic receptor kinase (beta ARK1) activity was found to be significantly elevated (>3-fold) in myocardial extracts isolated from WT alpha(1B)-AR-overexpressing mice, This type of altered signal transduction may become critical in disease conditions such as heart failure where beta ARK1 levels are elevated and beta-ARs are downregulated, leading to a higher percentage of cardiac alpha(1).Ars. Thus, these mice serve as a unique experimental model to study the in vivo interactions between alpha- and beta-ARs in the heart.	DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute; University of California System; University of California San Diego			Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL09436, HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037, F32HL009436] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODDE OE, 1993, PHARMACOL THERAPEUT, V60, P405, DOI 10.1016/0163-7258(93)90030-H; BRODINI A, 1991, BIOCHEM BIOPH RES CO, V174, P869; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; INGLESE J, 1993, J BIOL CHEM, V268, P23735; IWAKI K, 1990, J BIOL CHEM, V265, P13809; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Samama P, 1997, P NATL ACAD SCI USA, V94, P137, DOI 10.1073/pnas.94.1.137; STEINBERG SF, 1985, SCIENCE, V230, P186, DOI 10.1126/science.2994230; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; WEINBERG DH, 1994, BIOCHEM BIOPH RES CO, V201, P1296, DOI 10.1006/bbrc.1994.1845; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; WU DQ, 1992, J BIOL CHEM, V267, P25798	29	124	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21253	21259		10.1074/jbc.272.34.21253	http://dx.doi.org/10.1074/jbc.272.34.21253			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261135	hybrid			2022-12-25	WOS:A1997XR78900045
J	Feussner, I; Balkenhohl, TJ; Porzel, A; Kuhn, H; Wasternack, C				Feussner, I; Balkenhohl, TJ; Porzel, A; Kuhn, H; Wasternack, C			Structural elucidation of oxygenated storage lipids in cucumber cotyledons - Implication of lipid body lipoxygenase in lipid mobilization during germination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULOCYTE LIPOXYGENASE; MAMMALIAN LIPOXYGENASES; FATTY-ACIDS; PHOSPHOLIPIDS; PROTEIN; LIPOPROTEINS; LEUKOCYTE; MEMBRANES; OXIDATION; PLANTS	At early stages of germination, a special lipoxygenase is expressed in cotyledons of cucumber and several other plants, This enzyme is localized at the lipid storage organelles and oxygenates their storage triacylglycerols, We have isolated this lipid body lipoxygenase from cucumber seedlings and found that it is capable of oxygenating in vitro di- and trilinolein to the corresponding mono-, di-, and trihydroperoxy derivatives. To investigate the in vivo activity of this enzyme during germination, lipid bodies were isolated from cucumber seedlings at different stages of germination, and the triacylglycerols were analyzed for oxygenated derivatives by a combination of high pressure liquid chromatography, gas chromatography/mass spectrometry, and nuclear magnetic resonance spectroscopy, We identified as major oxygenation products triacylglycerols that contained one, two, or three 13S-hydroperoxy-9(Z),11(E)-octadecadienoic acid residues, During germination, the amount of oxygenated lipids increased strongly, reaching a maximum after 72 h and declining afterward. The highly specific pattern of hydroperoxy lipids formed suggested the involvement of the lipid body lipoxygenase in their biosynthesis. These data suggest that this lipoxygenase may play an important role during the germination process of cucumber and other plants and support our previous hypothesis that the specific oxygenation of the storage lipids may initiate their mobilization as a carbon and energy source for the growing seedling.	HUMBOLDT UNIV BERLIN,KLINIKUM CHAR,INST BIOCHEM,D-10115 BERLIN,GERMANY	Humboldt University of Berlin	Feussner, I (corresponding author), INST PFLANZENBIOL,WEINBERG 3,D-06120 HALLE,GERMANY.		Porzel, Andrea/B-1423-2014; Feussner, Ivo/H-9320-2013	Porzel, Andrea/0000-0002-8148-6895; Feussner, Ivo/0000-0002-9888-7003				BEEORTZAHAR T, 1995, FEBS LETT, V366, P151, DOI 10.1016/0014-5793(95)00521-A; BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; BELKNER J, 1991, FEBS LETT, V279, P110, DOI 10.1016/0014-5793(91)80263-3; Bergey DR, 1996, P NATL ACAD SCI USA, V93, P12053, DOI 10.1073/pnas.93.22.12053; Blee Elizabeth, 1996, P138, DOI 10.1201/9781439831977.ch8; BRASH AR, 1987, BIOCHEMISTRY-US, V26, P5465, DOI 10.1021/bi00391a038; FARMER EE, 1994, PLANT MOL BIOL, V26, P1423, DOI 10.1007/BF00016483; FEUSSNER I, 1995, P NATL ACAD SCI USA, V92, P11849, DOI 10.1073/pnas.92.25.11849; FEUSSNER I, 1992, FEBS LETT, V298, P223, DOI 10.1016/0014-5793(92)80062-L; Feussner I, 1997, FEBS LETT, V406, P1, DOI 10.1016/S0014-5793(97)00218-4; FEUSSNER I, 1994, PLANTA, V194, P22, DOI 10.1007/BF00201030; FISKUM G, 1985, PROSTAGLANDINS LEUKO, P87; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; FRANKEL EN, 1990, METHOD ENZYMOL, V186, P380; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; Kuhn H, 1996, PROG LIPID RES, V35, P203, DOI 10.1016/S0163-7827(96)00008-2; KUHN H, 1990, EUR J BIOCHEM, V191, P221, DOI 10.1111/j.1432-1033.1990.tb19113.x; KUHN H, 1990, J BIOL CHEM, V265, P18351; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; MACCARRONE M, 1994, BBA-BIOMEMBRANES, V1190, P164, DOI 10.1016/0005-2736(94)90046-9; MATSUI K, 1995, LIPIDS, V30, P733, DOI 10.1007/BF02537800; MURRAY JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P514, DOI 10.1016/0003-9861(88)90156-7; RAO SI, 1994, J BIOL CHEM, V269, P7210; Rosahl S, 1996, Z NATURFORSCH C, V51, P123; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; SEMBDNER G, 1993, ANNU REV PLANT PHYS, V44, P569, DOI 10.1146/annurev.pp.44.060193.003033; SHIBATA D, 1995, J LIPID MEDIAT CELL, V12, P213, DOI 10.1016/0929-7855(95)00020-Q; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; STAHL U, 1995, PLANT PHYSIOL, V107, P953, DOI 10.1104/pp.107.3.953; TAKAHASHI Y, 1993, EUR J BIOCHEM, V218, P165, DOI 10.1111/j.1432-1033.1993.tb18362.x; Upston JM, 1996, J LIPID RES, V37, P2650; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Wang CX, 1997, PHYSIOLOGY, BIOCHEMISTRY AND MOLECULAR BIOLOGY OF PLANT LIPIDS, P268; WEITZEL F, 1993, J BIOL CHEM, V268, P6288; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	38	66	70	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21635	21641		10.1074/jbc.272.34.21635	http://dx.doi.org/10.1074/jbc.272.34.21635			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261186	hybrid			2022-12-25	WOS:A1997XR78900096
J	Ji, CH; Casinghino, S; McCarthy, TL; Centrella, M				Ji, CH; Casinghino, S; McCarthy, TL; Centrella, M			Multiple and essential Sp1 binding sites in the promoter for transforming growth factor-beta type I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	18th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research	SEP 07-11, 1996	SEATTLE, WA	Amer Soc Bone & Mineral Res			TRANSCRIPTION FACTOR FAMILY; GENE; REGION; EXPRESSION; PROTEIN; MEMBERS; IDENTIFICATION; PURIFICATION; BONE	Maximal gene expression driven by the promoter for the transforming growth factor beta type I receptor (TGF-beta RI) occurs with a 1.0-kilobase pair fragment immediately upstream of exon 1, This region lacks a typical TATA box but contains CCAAT boxes, multiple Spl, and PEBP2/CBF alpha binding sites among other possible cis-acting elements, Alterations within two CCAAT box sequences do not mitigate reporter gene expression driven by the basal promoter, and no nuclear factor binds to oligonucleotides encompassing these sites, In contrast, other deletions or site-specific mutations reveal an essential Sal site in the basal promoter and several dispersed upstream Spl sites that contribute to maximal reporter gene expression, The proportions of transcription factors Sp1 and Sp3, and their ratios of binding to consensus Elements, are maintained in bone cells at different stages of differentiation, Finally, nuclear factor that binds to PEBP2/CBF alpha-related cis-acting elements in the basal promoter sequence also occurs in osteoblasts. Our studies reveal that constitutive expression of TGF-beta RI may be determined by constitutive nuclear factor binding to Spl sites, whereas other elements may account for the variations in TGF-beta RI levels that parallel. changes in bane cell differentiation or activity.	YALE UNIV, SCH MED, DEPT SURG, SECT PLAST SURG, NEW HAVEN, CT 06520 USA	Yale University					NIAMS NIH HHS [AR-39201] Funding Source: Medline; NIDDK NIH HHS [DK-47421] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039201, R01AR039201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1987, J BIOL CHEM, V262, P16186; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749-6632.1996.tb56267.x; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; CENTRELLA M, 1995, HORMONAL REGULATION, P211; CHEN XR, 1994, ONCOGENE, V9, P3179; COOKE DW, 1991, BIOCHEM BIOPH RES CO, V177, P1113, DOI 10.1016/0006-291X(91)90654-P; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hiebert SW, 1996, CURR TOP MICROBIOL, V211, P253; HUMPHRIES DE, 1994, BIOCHEM BIOPH RES CO, V203, P1020, DOI 10.1006/bbrc.1994.2284; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; Ji CH, 1996, J CELL BIOCHEM, V63, P478; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lian J B, 1993, J Oral Implantol, V19, P95; MAJELLO B, 1995, ONCOGENE, V10, P1841; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; PANG JHS, 1995, J BIOL CHEM, V270, P14123, DOI 10.1074/jbc.270.23.14123; SAITO H, 1992, BIOCHEM BIOPH RES CO, V183, P688, DOI 10.1016/0006-291X(92)90537-U; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SIF S, 1993, ONCOGENE, V8, P2501; Sjottem E, 1996, J VIROL, V70, P188; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; YE K, 1993, P NATL ACAD SCI USA, V90, P2295, DOI 10.1073/pnas.90.6.2295; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407	44	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21260	21267		10.1074/jbc.272.34.21260	http://dx.doi.org/10.1074/jbc.272.34.21260			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	XR789	9261136	hybrid			2022-12-25	WOS:A1997XR78900046
J	Lee, W; Jung, CY				Lee, W; Jung, CY			A synthetic peptide corresponding to the GLUT4 C-terminal cytoplasmic domain causes insulin-like glucose transport stimulation and GLUT4 recruitment in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; TRANSLOCATION; 3-O-METHYLGLUCOSE; MODULATION; SEQUENCE; CONSTANT; PROTEIN; BINDING; SIGNAL	In rat epididymal adipocytes, practically all of the major glucose transporter isoform GLUT4 is constitutively sequestered in intracellular membranes and moves to the plasma membrane in response to insulin, whereas about half of GLUT1, the minor isoform, is constitutively functional at the plasma membrane and thus less affected by insulin, Transfection studies using cells whose glucose transport is normally not regulated by insulin have suggested that the C-terminal cytoplasmic domain of GLUT4 is responsible for its constitutive intracellular sequestration, To test if this was also the case in a classical insulin target cell, we introduced synthetic peptides corresponding to the C-terminal cytoplasmic domain of GLUT4 and GLUT1 (GLUT4C and GLUT1C, respectively) into rat adipocytes and studied their effects on the glucose transport activity and the steady state GLUT4 and GLUT1 distribution between the plasma membrane and intracellular membranes in host cells. GLUT4C introduced into basal adipocytes caused a large (up to 4.5-fold) and dose-dependent increase in the plasma membrane GLUT4, with a proportional reduction in microsomal GLUT4, without affecting GLUT1 distribution, GLUT4C incorporation also caused a large (up to 3-fold) dose-dependent stimulation of 3-O-methyl D-glucose (3OMG) flux in host cells, GLUT4C caused little if any GLUT4 or GLUT1 redistribution and changes in 3OMG flux in insulin-stimulated adipocytes. GLUT1C, on the other hand, did not affect GLUT1 or GLUT4 targeting and 3OMG flux in host cells, These findings not only underscore the importance of the C-terminal cytoplasmic domain of GLUT4 in its constitutive intracellular sequestration in a classical insulin target cell but also suggest the existence of a regulatory protein in adipocytes that interacts with GLUT4 at its cytoplasmic domain, thus participating in the constitutive intracellular sequestration of GLUT4.	VET ADM MED CTR, BIOPHYS LAB, BUFFALO, NY 14215 USA; SUNY BUFFALO, DEPT BIOPHYS SCI, BUFFALO, NY 14215 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Lee, Wan/B-6252-2013	Lee, Wan/0000-0002-5181-2135				ASANO T, 1992, J BIOL CHEM, V267, P19636; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JHUN BH, 1992, J BIOL CHEM, V267, P17710; JHUN BH, 1991, J BIOL CHEM, V266, P22260; JO L, 1992, BIOCHIM BIOPHYS ACTA, V1106, P45; JUNG CY, 1973, BIOCHIM BIOPHYS ACTA, V298, P101, DOI 10.1016/0005-2736(73)90014-X; LACHAAL M, 1990, J BIOL CHEM, V265, P15449; LACHAAL M, 1993, J CELL PHYSIOL, V156, P326, DOI 10.1002/jcp.1041560215; LIU HZ, 1995, J BIOL CHEM, V270, P7869, DOI 10.1074/jbc.270.14.7869; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MARTZ A, 1986, J BIOL CHEM, V261, P3606; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; RAMPAL AL, 1995, J BIOL CHEM, V270, P3938, DOI 10.1074/jbc.270.8.3938; SHI YW, 1995, J BIOL CHEM, V270, P21772, DOI 10.1074/jbc.270.37.21772; SHI YW, 1996, DIABETES S2, V45, P93; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276	31	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21427	21431		10.1074/jbc.272.34.21427	http://dx.doi.org/10.1074/jbc.272.34.21427			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261158	hybrid			2022-12-25	WOS:A1997XR78900068
J	Alkhatib, G; Berger, EA; Murphy, PM; Pease, JE				Alkhatib, G; Berger, EA; Murphy, PM; Pease, JE			Determinants of HIV-1 coreceptor function on CC chemokine receptor 3 - Importance of both extracellular and transmembrane/cytoplasmic regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RECOMBINANT VACCINIA VIRUS; ENVELOPE GLYCOPROTEIN; EXPRESSION; IDENTIFICATION; MACROPHAGES; CLONING; RANTES; FUSION; CELLS	The chemokine receptors CXCR4, CCR2b, CCR3, and CCR5 are cell entry coreceptors for HIV-1. Using an HIV-1 envelope (Env) dependent cell-cell fusion model of entry, we show that CCR3 can interact with Envs from certain macrophage (M)-tropic strains (which also use CCR5), T cell line (TCL)-tropic laboratory-adapted strains (which also use CXCR4), and a dual tropic primary isolate (which also uses CCR2b, CCR5, and CXCR4). Paradoxically, CCR1 is the closest homologue to CCR3 (63% amino acid identity), but lacked HIV-1 coreceptor activity, These results confirm and extend previous reports, Replacing the N-terminal segment of CCR3 with that of CCR1 abolished activity of the resulting chimera for M-tropic and TCL-tropic Envs, but not for the dual-tropic Env, Replacing extracellular loop 2 of CCR3 with that of CCR1 abolished activity for TCL-tropic Envs, but not for M- and dual-tropic Envs, A chimera containing all four extracellular regions of CCR3 on a backbone of CCR1 lacked any activity, Env-CCR3 interactions were strongly inhibited by the major CCR3 ligand eotaxin, but weakly or not at all by other CCR3 ligands, With primary macrophages, eotaxin induced transient calcium flux and partially inhibited fusion with cells expressing M-tropic Envs. We conclude that specificity determinants for different Envs are located in shared and distinct extracellular regions of CCR3, the transmembrane/cytoplasmic domains make major contributions to coreceptor function, and CCR3 may be used by certain HIV-1 strains as a cell fusion factor on macrophages.	NIAID,HOST DEF LAB,NIH,BETHESDA,MD 20892; NIAID,VIRAL DIS LAB,NIH,BETHESDA,MD 20892; UNIV SHEFFIELD,KREBS INST,DEPT MOL BIOL & BIOTECHNOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Sheffield			Pease, James/X-4521-2018	Pease, James/0000-0003-3749-0341				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1996, J VIROL, V70, P5487, DOI 10.1128/JVI.70.8.5487-5494.1996; ALKHATIB G, 1997, IN PRESS VIROLOGY, V234; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Berger EA, 1997, AIDS, V11, pS3; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COMBADIERE C, 1995, J BIOL CHEM, V270, P30235; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; Connor RI, 1996, J VIROL, V70, P8758, DOI 10.1128/JVI.70.12.8758-8764.1996; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dittmar MT, 1997, NATURE, V385, P495, DOI 10.1038/385495a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LAZDINS JK, 1990, AIDS RES HUM RETROV, V6, P1157, DOI 10.1089/aid.1990.6.1157; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; McKnight A, 1997, J VIROL, V71, P1692, DOI 10.1128/JVI.71.2.1692-1696.1997; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; PEASE JE, 1994, EUR J IMMUNOL, V24, P211, DOI 10.1002/eji.1830240133; Pleskoff O, 1997, J VIROL, V71, P3259, DOI 10.1128/JVI.71.4.3259-3262.1997; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Rana S, 1997, J VIROL, V71, P3219, DOI 10.1128/JVI.71.4.3219-3227.1997; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Sabroe I, 1997, J IMMUNOL, V158, P1361; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	54	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20420	20426		10.1074/jbc.272.33.20420	http://dx.doi.org/10.1074/jbc.272.33.20420			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252350	hybrid			2022-12-25	WOS:A1997XR22100020
J	Pearce, KH; Potts, BJ; Presta, LG; Bald, LN; Fendly, BM; Wells, JA				Pearce, KH; Potts, BJ; Presta, LG; Bald, LN; Fendly, BM; Wells, JA			Mutational analysis of thrombopoietin for identification of receptor and neutralizing antibody sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; C-MPL LIGAND; CRYSTAL-STRUCTURE; ANTIGEN INTERACTIONS; HUMAN INTERLEUKIN-4; FUNCTIONAL EPITOPE; CYTOPLASMIC DOMAIN; RESOLUTION; VARIANTS; PROTEINS	Thrombopoietin (TPO) is a hematopoietin important for megakaryocyte proliferation and production of blood platelets, We sought to characterize how TPO binds and activates its receptor, myeloproliferative leukemia virus receptor, The erythropoietin-like domain of TPO (TPO1-153) has been fused to the gIII coat protein of M13 bacteriophage. Forty residues were chosen for mutation to alanine using the criteria that they were charged residues or predicted to be solvent-exposed, based on a homology model, Phage enzyme-linked immunosorbent assay was used to determine affinities for binding to both the TPO receptor and five anti-TPO1-153 monoclonal antibodies, Mutations at mostly positively charged residues (Asp(8), Lys(14), Lys(52), Lys(59), Lys(136), Lys(138), Arg(140)) caused the greatest reduction in receptor-binding affinity. Most of these residues mapped to helices-1 and -4 and a loop region between helix-1 and helix-2. Two of the monoclonal antibodies that blocked TPO binding and bioactivity had determinants in helix-4. In contrast, the other three monoclonal antibodies, which were effective at blocking TPO activity but did not block initial binding of TPO to its receptor, had epitopes predominantly on helix or 3. These results suggest that TPO has two distinct receptor-binding sites that function to dimerize TPO receptors in a sequential fashion.	GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT ANTIBODY & BIOASSAY TECHNOL, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT IMMUNOL, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016					ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOISSEL JP, 1993, J BIOL CHEM, V268, P15983; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Feng YP, 1996, J MOL BIOL, V259, P524, DOI 10.1006/jmbi.1996.0337; GREEN JR, 1978, STATISTICAL TREATMEN, pCH7; GURNEY AL, 1995, BLOOD, V85, P981, DOI 10.1182/blood.V85.4.981.bloodjournal854981; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; MARK MR, 1994, J BIOL CHEM, V269, P10720; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; Sadick MD, 1996, ANAL BIOCHEM, V235, P207, DOI 10.1006/abio.1996.0114; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WADA T, 1995, BIOCHEM BIOPH RES CO, V213, P1091, DOI 10.1006/bbrc.1995.2239; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WLODAVER A, 1992, FEBS LETT, V309, P59, DOI 10.1016/0014-5793(92)80739-4	41	42	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20595	20602		10.1074/jbc.272.33.20595	http://dx.doi.org/10.1074/jbc.272.33.20595			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252374	hybrid			2022-12-25	WOS:A1997XR22100044
J	Connelly, JC; deLeau, ES; Okely, EA; Leach, DRF				Connelly, JC; deLeau, ES; Okely, EA; Leach, DRF			Overexpression, purification, and characterization of the SbcCD protein from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SMC FAMILY; GENE; RECOMBINATION; PALINDROMES; BINDING; REPAIR; RAD50	The sbcC and sbcD genes mediate palindrome inviability in Escherichia coli, The sbcCD operon has been cloned into the plasmid pTrc99A under the control of the strong trc promoter and introduced into a strain carrying a chromosomal deletion of sbcCD. The SbcC and SbcD polypeptides were overexpressed to 6% of total cell protein, and both polypeptides copurified in a four-step purification procedure. Purified SbcCD is a processive double-strand exonuclease that has an absolute requirement for Mn2+ and uses ATP as a preferred energy source, Gel filtration chromatography and sedimentation equilibrium analyses were used to show that the SbcC and SbcD polypeptides dissociate at some stage after purification and that this dissociation is reversed by the addition of Mn2+. We demonstrate that SbcD has the potential to form a secondary structural motif found in a number of protein phosphatases and suggest that it is a metalloprotein that contains the catalytic center of the SbcCD exonuclease.	UNIV EDINBURGH,INST CELL & MOL BIOL,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Leach, David R/H-7159-2012	Leach, David R/0000-0003-4964-6913				ALANI E, 1989, GENETICS, V122, P47; ALLERS T, 1995, J MOL BIOL, V252, P70, DOI 10.1006/jmbi.1994.0476; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; CHALKER AF, 1988, GENE, V71, P201, DOI 10.1016/0378-1119(88)90092-3; Chu YF, 1996, J BIOL CHEM, V271, P2574, DOI 10.1074/jbc.271.5.2574; Collick A, 1996, EMBO J, V15, P1163, DOI 10.1002/j.1460-2075.1996.tb00455.x; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; EGGLESTON AK, 1993, J MOL BIOL, V231, P605, DOI 10.1006/jmbi.1993.1313; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; EICHLER DC, 1977, J BIOL CHEM, V252, P499; GIBSON FP, 1992, J BACTERIOL, V174, P1222, DOI 10.1128/jb.174.4.1222-1228.1992; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GORDENIN DA, 1993, MOL CELL BIOL, V13, P5315, DOI 10.1128/MCB.13.9.5315; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HENDERSON ST, 1993, GENETICS, V133, P57; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; JOHZUKA K, 1995, GENETICS, V139, P1521; Kim KK, 1996, J BIOL CHEM, V271, P29255, DOI 10.1074/jbc.271.46.29255; KULKARNI SK, 1989, GENETICS, V123, P249; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LEACH DRF, 1992, GENETICA, V87, P95, DOI 10.1007/BF00120998; LEACH DRF, 1994, BIOESSAYS, V16, pS93; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; NAG DK, 1991, GENETICS, V129, P669; NAG DK, 1989, NATURE, V340, P318, DOI 10.1038/340318a0; NAOM IS, 1989, NUCLEIC ACIDS RES, V17, P8033, DOI 10.1093/nar/17.20.8033; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; PAPANICOLAOU C, 1989, J MOL BIOL, V207, P335, DOI 10.1016/0022-2836(89)90258-1; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; RUSKIN B, 1993, GENETICS, V133, P43; Sambrook J., 2002, MOL CLONING LAB MANU; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; TAVASSOLI M, 1995, NUCLEIC ACIDS RES, V23, P383, DOI 10.1093/nar/23.3.383; WEAVER DT, 1984, J MOL BIOL, V180, P961, DOI 10.1016/0022-2836(84)90266-3; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	41	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19819	19826		10.1074/jbc.272.32.19819	http://dx.doi.org/10.1074/jbc.272.32.19819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242643	hybrid			2022-12-25	WOS:A1997XQ05900030
J	Hughes, CE; Buttner, FH; Eidenmuller, B; Caterson, B; Bartnik, E				Hughes, CE; Buttner, FH; Eidenmuller, B; Caterson, B; Bartnik, E			Utilization of a recombinant substrate rAgg1 to study the biochemical properties of aggrecanase in cell culture systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-FLUID; ARTICULAR-CARTILAGE; INTERGLOBULAR DOMAIN; MONOCLONAL-ANTIBODIES; CLEAVAGE SITE; PROTEOGLYCAN; CATABOLISM; IDENTIFICATION; DEGRADATION; FRAGMENTS	This paper describes the first report of the production and use of an artificial recombinant protein substrate to study ''aggrecanase'' activity. The substrate (rAgg1) is composed of the complete interglobular domain (IGD) of human aggrecan flanked by the ''marker'' sequences FLAG(TM) at the amino terminus and the human immunoglobulin GI constant region at the carboxyl terminus. The expressed protein occurs as large multimolecular aggregates (>120 kDa) that, upon reduction, consist of a major isoform of 72 kDa (containing the IGD) and a minor 39-kDa species that through alternative splicing has had the IGD deleted. Using this recombinant substrate we developed a novel agarose cell culture system containing either rat chondrosarcoma or bovine chondrocytes that could be used in studies of the biochemical characterization of aggrecanase activities. These studies showed the following. (i) rAgg1 is a suitable substrate for aggrecanase proteolysis. (ii) Aggrecanase activity was specifically induced by exposing chondrocytes to retinoic acid. (iii) A considerable time period was required to synthesize and/or activate aggrecanase, with considerable differences in that found in rat chondrosarcoma versus bovine chondrocyte culture systems. (iv) Aggrecanase cleavage of the aggrecan IGD does not require the presence of the G1 or G2 globular domains or keratan sulfate post-translational modification in the IGD. (v) Aggrecanase is a diffusible activity that does not require association with the chondrocyte plasma membrane or immediate pericellular matrix for its action.	HOECHST AG,TA RHEUMATOL IMMUNOL,D-65174 WIESBADEN,GERMANY	Sanofi-Aventis	Hughes, CE (corresponding author), UNIV WALES COLL CARDIFF,SCH MOL & MED BIOSCI,CONNECT TISSUE BIOL LABS,POB 911,MUSEUM AVE,CARDIFF CF1 3US,S GLAM,WALES.		Hughes, Clare E/A-4526-2010; Caterson, Bruce/A-8085-2010	Hughes, Clare/0000-0003-4726-5877; Caterson, Bruce/0000-0001-6016-0661				ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P205, DOI 10.3109/03008208809016808; AYDELOTTE MB, 1992, CONNECT TISSUE RES, V27, P1; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, ORTHOP T, V17, P677; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; FOSANG AJ, 1991, MATRIX, V11, P17, DOI 10.1016/S0934-8832(11)80223-4; HANDLEY CJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P441, DOI 10.1016/0304-4165(78)90111-3; HANDLEY CJ, 1977, BIOCHIM BIOPHYS ACTA, V500, P132; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Maniglia C. A., 1991, T ORTHOP RES SOC, V16, P193; MORALES TI, 1992, ARCH BIOCHEM BIOPHYS, V293, P79, DOI 10.1016/0003-9861(92)90368-7; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; Saiki R.K., 1989, PCR TECHNOLOGY, P7; SANDY JD, 1978, BIOCHIM BIOPHYS ACTA, V543, P536, DOI 10.1016/0304-4165(78)90308-2; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; TYLER JA, 1985, BIOCHEM J, V225, P493, DOI 10.1042/bj2250493; VALHMU WB, 1995, BIOCHEM J, V309, P535, DOI 10.1042/bj3090535	31	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20269	20274		10.1074/jbc.272.32.20269	http://dx.doi.org/10.1074/jbc.272.32.20269			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242707	hybrid			2022-12-25	WOS:A1997XQ05900094
J	Mandal, A; Wang, YZ; Ernsberger, P; Kester, M				Mandal, A; Wang, YZ; Ernsberger, P; Kester, M			Interleukin-1-induced ether-linked diglycerides inhibit calcium-insensitive protein kinase C isotypes - Implications for growth senescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MESANGIAL CELLS; CANINE KIDNEY-CELLS; PHOSPHOLIPASE-D; EPSILON-ISOFORM; ACTIVATION; ALPHA; DIFFERENTIATION; EXPRESSION; PHOSPHATIDYLCHOLINE; DIACYLGLYCEROLS	It is hypothesized that inflammatory cytokines and vasoactive peptides stimulate distinct species of diglycerides that differentially regulate protein kinase C isotypes, In published data, we demonstrated that interleukin-1, in contrast to endothelin, selectively generates ether-linked diglyceride species (alkyl, acyl- and alkenyl, acylglycerols) in rat mesangial cells, a smooth muscle-like pericyte in the glomerulus. We now demonstrate both in intact cell and in cell-free preparations that these interleukin-l receptor-generated ether-linked diglycerides inhibit immunoprecipitated protein kinase C delta and epsilon but not zeta activity. Neither interleukin-1 not endothelin affect de novo protein expression of these protein kinase C isotypes. As down-regulation of calcium-insensitive protein kinase C isotypes has been linked to antimitogenic activity, we investigated growth arrest as a functional correlate for IL-l-generated ether-linked diglycerides. Cell-permeable ether-linked diglycerides mimic the effects of interleukin-1 to, induce a growth-arrested state in both G-protein-linked receptor- and tyrosine kinase receptor-stimulated mesangial cells. This signaling mechanism implicates cytokine receptor-induced ether-linked diglycerides as second messengers that inhibit the bioactivity of calcium-insensitive protein kinase C isotypes resulting in growth arrest.	CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA,ON K1A 0R6,CANADA	Case Western Reserve University; Case Western Reserve University; National Research Council Canada			Ernsberger, Paul/O-2702-2014	Ernsberger, Paul/0000-0003-2372-2500	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040225] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40225] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARAKI S, 1994, J BIOCHEM-TOKYO, V115, P245, DOI 10.1093/oxfordjournals.jbchem.a124325; BALDI E, 1994, AM J PHYSIOL, V269, P22574; BERKOVIC D, 1994, EUR J CANCER, V30A, P509, DOI 10.1016/0959-8049(94)90428-6; BISWAS P, 1995, FEBS LETT, V373, P146, DOI 10.1016/0014-5793(95)01025-A; CABOT MC, 1984, BIOCHEM BIOPH RES CO, V125, P163, DOI 10.1016/S0006-291X(84)80349-6; CACACE AM, 1993, ONCOGENE, V8, P2095; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CLARK KJ, 1995, J BIOL CHEM, V270, P7097, DOI 10.1074/jbc.270.13.7097; Coroneos E, 1996, BIOCHEM J, V316, P13, DOI 10.1042/bj3160013; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; FORD DA, 1989, J BIOL CHEM, V264, P13818; GALLELA G, 1992, BIOCHEM PHARMACOL, V44, P715; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; Ganz MB, 1996, AM J PHYSIOL-RENAL, V271, pF108, DOI 10.1152/ajprenal.1996.271.1.F108; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; HEYMANS F, 1987, FEBS LETT, V218, P35, DOI 10.1016/0014-5793(87)81013-X; HUWILER A, 1993, EXP NEPHROL, V1, P19; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; KESTER M, 1994, J BIOL CHEM, V269, P22574; KESTER M, 1993, J CELL PHYSIOL, V156, P317, DOI 10.1002/jcp.1041560214; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; MAHONEY CW, 1993, FASEB J, V7, pA1118; MANGOURA D, 1993, P NATL ACAD SCI USA, V90, P2915, DOI 10.1073/pnas.90.7.2915; MCNAMARA MJC, 1984, BIOCHEM BIOPH RES CO, V122, P824, DOI 10.1016/S0006-291X(84)80108-4; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Motulsky M. D. H., 1995, INTUITIVE BIOSTATIST; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; MUSIAL A, 1995, J BIOL CHEM, V270, P21632, DOI 10.1074/jbc.270.37.21632; PESSINO A, 1995, BIOCHEM J, V312, P549, DOI 10.1042/bj3120549; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; Rzymkiewicz DM, 1996, J BIOL CHEM, V271, P17241, DOI 10.1074/jbc.271.29.17241; SASSAGURI T, 1993, EXP CELL RES, V208, P311; SEDOR JR, 1992, KIDNEY INT, V41, P595, DOI 10.1038/ki.1992.89; STEVENSON FT, 1993, J AM SOC NEPHROL, V4, pA636; WARNE TR, 1995, J BIOL CHEM, V270, P11147, DOI 10.1074/jbc.270.19.11147; WEITZMANN MN, 1992, BIOCHEM BIOPH RES CO, V187, P1166, DOI 10.1016/0006-291X(92)91319-L; WIEDER T, 1995, LIPIDS, V30, P389, DOI 10.1007/BF02536296; Zhou X, 1996, J CLIN INVEST, V98, P937, DOI 10.1172/JCI118877	43	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20306	20311		10.1074/jbc.272.32.20306	http://dx.doi.org/10.1074/jbc.272.32.20306			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242712	hybrid			2022-12-25	WOS:A1997XQ05900099
J	Werman, A; Hollenberg, A; Solanes, G; Bjorbaek, C; VidalPuig, AJ; Flier, JS				Werman, A; Hollenberg, A; Solanes, G; Bjorbaek, C; VidalPuig, AJ; Flier, JS			Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPAR gamma) - Differential activity of PPAR gamma 1 and -2 isoforms and influence of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE DIFFERENTIATION; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; GENE-EXPRESSION; PROTEIN-KINASE; ADIPOGENESIS; INDUCTION; APOPTOSIS; PROMOTER; CELLS	Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a member of the nuclear hormone receptor superfamily, and is an important regulator of adipogenesis and adipocyte gene expression. PPAR gamma exists as two isoforms, PPAR gamma 1 and PPAR gamma 2, that differ only in their N termini, Both isoforms are activated by ligands that include the antidiabetic thiazoladinedione drugs and 15-deoxy-Delta(12,14)-prostaglandin J2, and potential differences in their function have yet to be described. We report. that, in addition to a Ligand-activated transcriptional activity, when studied under conditions of ligand depletion, intact PPAR gamma has a ligand-independent activation domain. To identify the basis for this ligand-independent activation, we used GAL4-PPAR gamma chimeric expression constructs and UAS-TK-LUC in CV1 cells and isolated rat adipocytes. In both cell systems, isolated PPAR gamma 1 and PPAR gamma 2 N termini have activation domains, and the activation function of PPAR gamma 2 is 5-6-fold greater than that of PPAR gamma 1. Insulin enhances the transcriptional effect mediated by both PPAR gamma 1 and PPAR gamma 2 N-terminal domains. These data demonstrate that 1) PPAR gamma has an N-terminal (ligand-independent) activation domain; 2) PPAR gamma 1 and PPAR gamma 2 N terminal have distinct activation capacities; and 3) insulin can potentiate the activity of the N-terminal domain of PPAR gamma.	BETH ISRAEL DEACONESS MED CTR,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center			Flier, jeffrey/AAG-6223-2019; Bjorbaek, Christian/S-4727-2019	Vidal-Puig, Antonio/0000-0003-4220-9577	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082, P30DK046200, R01DK028082, K08DK002354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 28082, DK 46200, DK 02354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; DIEKEN ES, 1992, MOL CELL BIOL, V12, P589, DOI 10.1128/MCB.12.2.589; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GULLER S, 1988, ENDOCRINOLOGY, V122, P2084, DOI 10.1210/endo-122-5-2084; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWELL BB, 1990, ENDOCRINOLOGY, V127, P2898, DOI 10.1210/endo-127-6-2898; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKHAM BE, 1990, J BIOL CHEM, V265, P6489; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; OMALLEY BW, 1995, RECENT PROG HORM RES, V50, P333; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; RODBELL M, 1964, J BIOL CHEM, V239, P375; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; VIDALPUIG P, 1997, J CLIN INVEST, V99, P2416; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	35	244	253	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20230	20235		10.1074/jbc.272.32.20230	http://dx.doi.org/10.1074/jbc.272.32.20230			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242701	hybrid			2022-12-25	WOS:A1997XQ05900088
J	Branchini, BR; Magyar, RA; Marcantonio, KM; Newberry, KJ; Stroh, JG; Hinz, LK; Murtiashaw, MH				Branchini, BR; Magyar, RA; Marcantonio, KM; Newberry, KJ; Stroh, JG; Hinz, LK; Murtiashaw, MH			Identification of a firefly luciferase active site peptide using a benzophenone-based photooxidation reagent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLET OXYGEN; BIOLUMINESCENCE; LIGHT; ATP	Firefly luciferase catalyzes the highly efficient emission of yellow-green light from substrate luciferin by a series of reactions that require MgATP and molecular oxygen, We prepared 2-(4-benzoylphenyl)thiazole-4-carboxylic acid (BPTC), a novel benzophenone-based substrate analog, intending to use it in photoaffinity labeling studies to probe the luciferase active site, Instead, we found that while BPTC was a potent photoinactivating reagent for firefly luciferase, it was not a photoaffinity labeling agent. Using proteolysis, reverse phase high-performance liquid chromatography, tandem high performance liquid chromatography-electrospray ionization mass spectrometry, and Edman sequencing, we identified a single luciferase peptide, 244HHGF247, the degradation of which was directly correlated to luciferase photoinactivation. Results of enzyme kinetics and related studies were consistent with this peptide being at or near the luciferin binding site, Further, peptide model studies and additional investigations on the nature of the photoinactivation process strongly suggested that BPTC catalyzed the formation of singlet oxygen at the active site of the enzyme. We describe here an uncommon example of active site-directed photooxidation of an enzyme by singlet oxygen.	PFIZER INC,DIV CENT RES,GROTON,CT 06340	Pfizer	Branchini, BR (corresponding author), CONNECTICUT COLL,DEPT CHEM,270 MOHEGAN AVE,NEW LONDON,CT 06320, USA.							AULTZ DE, 1977, J MED CHEM, V20, P1499, DOI 10.1021/jm00221a028; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Branchini BR, 1997, ARCH BIOCHEM BIOPHYS, V340, P52, DOI 10.1006/abbi.1997.9894; BRANCHINI BR, 1989, PHOTOCHEM PHOTOBIOL, V49, P689, DOI 10.1111/j.1751-1097.1989.tb08442.x; CAMPBELL AK, 1993, FLUORESCENT LUMINESC, P58; CHATTOPADHYAY SK, 1985, J PHOTOCHEM, V30, P81, DOI 10.1016/0047-2670(85)87007-6; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; DELUCA M, 1984, BIOCHEM BIOPH RES CO, V123, P764, DOI 10.1016/0006-291X(84)90295-X; Dementieva EI, 1996, BIOCHEMISTRY-MOSCOW+, V61, P115; DENBURG JL, 1969, ARCH BIOCHEM BIOPHYS, V134, P381, DOI 10.1016/0003-9861(69)90297-5; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIXON M, 1979, ENZYMES, P332; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; GREEN AA, 1956, BIOCHIM BIOPHYS ACTA, V20, P170, DOI 10.1016/0006-3002(56)90275-X; HSATINGS JW, 1995, CELL PHYSL SOURCE BO, P665; KAJIYAMA N, 1991, PROTEIN ENG, V4, P691, DOI 10.1093/protein/4.6.691; KRICKA LJ, 1988, ANAL BIOCHEM, V175, P14, DOI 10.1016/0003-2697(88)90354-5; LEMBERT N, 1995, BIOCHEM J, V305, P929, DOI 10.1042/bj3050929; Lloyd J.E., 1978, P241; Mamaev SV, 1996, J AM CHEM SOC, V118, P7243, DOI 10.1021/ja961053c; MATHESON IBC, 1979, PHOTOCHEM PHOTOBIOL, V29, P879, DOI 10.1111/j.1751-1097.1979.tb07786.x; MEANS GE, 1971, CHEM MODIFICATION PR, P165; OFallon JV, 1996, ANAL BIOCHEM, V239, P193, DOI 10.1006/abio.1996.0314; OHMIYA Y, 1993, FEBS LETT, V320, P267, DOI 10.1016/0014-5793(93)80600-Y; Ohmiya Y, 1996, FEBS LETT, V384, P83; PARHAM WE, 1976, J ORG CHEM, V41, P1187, DOI 10.1021/jo00869a023; RYANG HS, 1979, J AM CHEM SOC, V101, P6683, DOI 10.1021/ja00516a033; SELIGER HH, 1960, ARCH BIOCHEM BIOPHYS, V88, P136, DOI 10.1016/0003-9861(60)90208-3; SMITH SB, 1980, J BIOL CHEM, V255, P2690; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; THOMPSON A, 1986, BIOCHEM BIOPH RES CO, V140, P888, DOI 10.1016/0006-291X(86)90718-7; VELLOM DC, 1990, THESIS U CALIFORNIA; WAGNER PJ, 1981, J AM CHEM SOC, V103, P7329, DOI 10.1021/ja00414a048; WHITE E H, 1971, Bioorganic Chemistry, V1, P92, DOI 10.1016/0045-2068(71)90009-5; WOOD KV, 1995, PHOTOCHEM PHOTOBIOL, V62, P662, DOI 10.1111/j.1751-1097.1995.tb08714.x	36	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19359	19364		10.1074/jbc.272.31.19359	http://dx.doi.org/10.1074/jbc.272.31.19359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235934	hybrid			2022-12-25	WOS:A1997XP06300040
J	Carroll, SS; Cole, JL; Viscount, T; Geib, J; Gehman, J; Kuo, LC				Carroll, SS; Cole, JL; Viscount, T; Geib, J; Gehman, J; Kuo, LC			Activation of RNase L by 2',5'-oligoadenylates - Kinetic characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-TREATED CELLS; CONSTITUTIVE EXPRESSION; 2-5A-DEPENDENT RNASE; PROTEIN-SYNTHESIS; INHIBITOR; ENZYME	Ribonuclease L (RNase L), the 2',5'-oligoadenylate-dependent ribonuclease, is one of the cellular antiviral systems with enhanced activity in the presence of interferon, A reaction scheme has been developed to model the sequence of steps necessary for the activation of RNase L (Cole, J. L,, Carroll, S, S,, Blue, E, S,, Viscount, T,, and Kuo, L, C, (1997) J, Biol. Chem. 272, 19187-19192), The model comprises three sequential binding steps: the binding of activator to enzyme monomer, the subsequent dimerization of the activated monomer to form the active enzyme dimer, followed by the binding of substrate prior to catalysis, The model is used to evaluate the activation of RNase L by several synthetic analogs of the native activator, The 5'-phosphate of the activator has been determined to be an important structural determinant for the efficient activation of RNase L, and its loss caused a loss of activator affinity of 2-3 orders of magnitude. The length of activator is not an important determinant of activator potency for the activator analogs examined, The specific activity of the enzyme under conditions of saturation of activator binding and complete dimerization of the activated monomers varies only by about a factor of 3 for the activators examined, indicating that once dimerized in the presence of any of these activators, the enzyme exhibits a similar catalytic activity.			Carroll, SS (corresponding author), MERCK RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486, USA.		Cole, James/G-2586-2011	Gehman, John D/0000-0002-2599-6292				Carroll SS, 1996, J BIOL CHEM, V271, P4988; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; Cole JL, 1996, J BIOL CHEM, V271, P3979; Cole JL, 1997, J BIOL CHEM, V272, P19187, DOI 10.1074/jbc.272.31.19187; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; DONG BH, 1994, J BIOL CHEM, V269, P14153; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; HOVANESSIAN AG, 1980, VIROLOGY, V101, P81, DOI 10.1016/0042-6822(80)90485-7; KARIKO K, 1987, BIOCHEMISTRY-US, V26, P7136, DOI 10.1021/bi00396a040; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KNIGHT M, 1980, NATURE, V288, P189, DOI 10.1038/288189a0; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; Wong I, 1995, METHOD ENZYMOL, V259, P95; Wyman J., 1990, BINDING LINKAGE FUNC, P203	17	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19193	19198		10.1074/jbc.272.31.19193	http://dx.doi.org/10.1074/jbc.272.31.19193			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235910	hybrid			2022-12-25	WOS:A1997XP06300016
J	Kuge, O; Saito, K; Nishijima, M				Kuge, O; Saito, K; Nishijima, M			Cloning of a Chinese hamster ovary (CHO) cDNA encoding phosphatidylserine synthase (PSS) II, overexpression of which suppresses the phosphatidylserine biosynthetic defect of a PSS I-lacking mutant of CHO-K1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; PHOSPHATIDYLETHANOLAMINE; MEMBRANE; MITOCHONDRIA; RETENTION; MOTIF; DNA	Phosphatidylserine (PtdSer) in mammalian cells is synthesized through the exchange of free L-serine for the polar head group (base) of preexisting phospholipid, We previously showed the presence of two different enzymes catalyzing the serine base exchange in Chinese hamster ovary (CHO) cells and isolated the cDNA of one of the enzymes, PtdSer synthase (PSS) I, which also catalyzes the exchange of the base moiety of phospholipid(s) for ethanolamine and choline, In this study, we cloned a CHO cDNA, designated as pssB, which encodes a protein exhibiting 32% amino acid sequence identity with CHO PSS I. Introduction of the pssB cDNA into CHO-K1 cells resulted in striking increases in both the serine and ethanolamine base exchange activities, In contrast to the PSS I cDNA, the pssB cDNA was incapable of increasing the choline base exchange activity, The expression of the pssB gene in Sf9 insect cells also results in striking increases in both serine and ethanolamine base exchange activities. The pssB cDNA was found to transform a PtdSer-auxotrophic PSS I-lacking mutant of CHO-K1 cells to PtdSer prototrophy, The PtdSer content of the resultant transformant grown without exogenous PtdSer for 2 days was 4-fold that of the mutant and similar to that of CHO-K1 cells, indicating that the pssB cDNA complemented the PtdSer biosynthetic defect of the PSS I-lacking mutant, These results suggested that the pssB cDNA encoded the second PtdSer synthase PSS II, which catalyzed the serine and ethanol amine base exchange, but not the choline base exchange.			Kuge, O (corresponding author), NATL INST HLTH,DEPT BIOCHEM & CELL BIOL,SHINJUKU KU,TOYAMA 1-23-1,TOKYO 162,JAPAN.			Kuge, Osamu/0000-0003-4962-3519				GERLACH E, 1963, BIOCHEM Z, V337, P477; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1986, J BIOL CHEM, V261, P5795; KUGE O, 1991, J BIOL CHEM, V266, P24184; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEWIS WH, 1980, SOMAT CELL GENET, V6, P333, DOI 10.1007/BF01542787; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NISHIJIMA M, 1986, J BIOL CHEM, V261, P5784; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; Saito K, 1996, FEBS LETT, V395, P262, DOI 10.1016/0014-5793(96)01049-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669	21	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19133	19139		10.1074/jbc.272.31.19133	http://dx.doi.org/10.1074/jbc.272.31.19133			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235902	hybrid			2022-12-25	WOS:A1997XP06300008
J	Lass, A; Agarwal, S; Sohal, RS				Lass, A; Agarwal, S; Sohal, RS			Mitochondrial ubiquinone homologues, superoxide radical generation, and longevity in different mammalian species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; DROSOPHILA-MELANOGASTER; HEART-MITOCHONDRIA; OXIDATIVE DAMAGE; CHAIN-LENGTH; OVEREXPRESSION; DISMUTASE; REDUCTASE; CATALASE; VESICLES	Rates of mitochondrial superoxide anion radical (O-2(radical anion)) generation are known to be inversely correlated with the maximum life span potential of different mammalian species, The objective of this study was to understand the possible mechanism(s) underlying such variations in the rate of O-2(radical anion) generation, The hypothesis that the relative amounts of the ubiquinones or coenzyme Q (CoQ) homologues, CoQ(9) and CoQ(10), are related with the rate of O-2(radical anion) generation was tested. A comparison of nine different mammalian species, namely mouse, rat, guinea pig, rabbit, pig, goat, sheep, cow, and horse, which vary from 3.5 to 46 years in their maximum longevity, indicated that the rate of O-2(radical anion) generation in cardiac submitochondrial particles (SMPs) was directly related to the relative amount of CoQ(9) and inversely related to the amount of CoQ(10) extractable from their cardiac mito chondria. To directly test the relationship between CoQ homologues and the rate of O-2(radical anion) generation, rat heart SMPs, naturally containing mainly CoQ(9) and cow heart SMPs, with high natural CoQ(10), content, were chosen for depletion/reconstitution experiments. Repeated extractions of rat heart SMPs with pentane exponentially depleted both CoQ homologues while the corresponding rates of O-2(radical anion) generation and oxygen consumption were lowered linearly, Reconstitution of both rat and cow heart SMPs with different amounts of CoQ(9) or CoQ(10) caused an initial. increase in the rates of O-2(radical anion) generation, followed by a plateau at high concentrations, Within the physiological range of CoQ concentrations, there were no differences in the rates of O-2(radical anion) generation between SMPs reconstituted with CoQ(9) or CoQ(10). Only at concentrations that were considerably higher than the physiological level, the SMPs reconstituted with CoQ(9) exhibited higher rates of O-2(radical anion) generation than those obtained with CoQ(10). These in vitro findings do not support the hypothesis that differences in the distribution of CoQ homologues are responsible for the variations in the rates of mitochondrial O-2(radical anion) generation in different mammalian species.	SO METHODIST UNIV, DEPT BIOL SCI, DALLAS, TX 75275 USA	Southern Methodist University			Lass, Achim/C-3332-2008	Lass, Achim/0000-0002-8190-7151	NATIONAL INSTITUTE ON AGING [R01AG007657, R01AG013563] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG7657, R01 AG013563, R01 AG13563, R01 AG013563-13] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTMAN PL, 1972, BIOL DATA BOOK, V1, P229; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ARCOS JC, 1968, EXP MOL PATHOL, V8, P49, DOI 10.1016/0014-4800(68)90005-1; BEYER RE, 1990, FREE RADICAL BIO MED, V8, P545, DOI 10.1016/0891-5849(90)90154-B; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; COMFORT A, 1979, BIOL SENESCENCE, P60; EDLUND C, 1994, J NEUROCHEM, V63, P634; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; FATO R, 1985, FEBS LETT, V179, P238, DOI 10.1016/0014-5793(85)80526-3; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HATEFI Y, 1963, ADV ENZYMOL REL S BI, V25, P275; KAGAN VE, 1990, FREE RADICAL BIO MED, V9, P117, DOI 10.1016/0891-5849(90)90114-X; KATAYAMA K, 1980, BIOCHEM BIOPH RES CO, V95, P971, DOI 10.1016/0006-291X(80)91568-5; KATSIKAS H, 1982, BIOCHIM BIOPHYS ACTA, V689, P363, DOI 10.1016/0005-2736(82)90270-X; KU HH, 1993, MECH AGEING DEV, V72, P67, DOI 10.1016/0047-6374(93)90132-B; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; LENAZ G, 1985, BBA-BIOENERGETICS, P83; MAGUIRE JJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P47, DOI 10.1016/0003-9861(92)90049-3; MATSURA T, 1992, BIOCHIM BIOPHYS ACTA, V1123, P309, DOI 10.1016/0005-2760(92)90012-K; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; RAMASARMA T, 1985, COENZYME Q BIOCH BIO, P67; SOHAL RS, 1995, J BIOL CHEM, V270, P15671, DOI 10.1074/jbc.270.26.15671; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1989, MECH AGEING DEV, V49, P129, DOI 10.1016/0047-6374(89)90096-1; SOHAL RS, 1995, FREE RADICAL BIO MED, V19, P499, DOI 10.1016/0891-5849(95)00037-X; Sohal RS, 1995, LIFE SCI R, V56, P109; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1992, FREE RADICALS AGING, P64; TAKADA M, 1984, METHOD ENZYMOL, V105, P147; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; TURRENS JF, 1990, FREE RADICALS LIPOPR, P203; ULRICH EL, 1985, BIOCHEMISTRY-US, V24, P2501, DOI 10.1021/bi00331a016	35	95	99	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19199	19204		10.1074/jbc.272.31.19199	http://dx.doi.org/10.1074/jbc.272.31.19199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235911	hybrid, Green Accepted			2022-12-25	WOS:A1997XP06300017
J	Sijts, AJAM; Pilip, I; Pamer, EG				Sijts, AJAM; Pilip, I; Pamer, EG			The Listeria monocytogenes-secreted p60 protein is an N-end rule substrate in the cytosol of infected cells - Implications for major histocompatibility complex class I antigen processing of bacterial proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE; PROTEOLYTIC PATHWAY; PROTEASOME; UBIQUITIN; DEGRADATION; MOLECULES; PEPTIDES; INHIBITORS; EXPRESSION; SEQUENCES	Cytosolic antigen degradation is an initial step in the generation of major histocompatibility complex (MHC) class I-associated cytolytic T lymphocyte epitopes, Intracellular Listeria monocytogenes secretes p60, a murein hydrolase, into the host cell cytosol, where it is degraded by proteasomes, Roughly 3% of degraded p60 gives rise to p60 217-225, a nonamer peptide that is bound by H-2K(d) MHC class I molecules. Herein, we introduce targeted deletions throughout the p60 gene to identify potential proteolytic signals within p60. Degradation of mutant forms of p60 was investigated in macrophages infected with recombinant L. monocytogenes, We found that deletions within the amino-terminal two-thirds of p60 enhanced cytosolic degradation, In contrast, truncation of the C terminus resulted in modest stabilization of p60 in the host cell cytosol, Because a protein's N-terminal amino acid can determine its rate of degradation, we mutagenized this residue in p60 into known stabilizing and destabilizing residues, Valine substitution dramatically stabilized cytosolic p60 molecules, while substitution with aspartic acid resulted in rapid degradation, The number of p60 217-225 epitopes isolated from infected cells directly correlated with the rates of p60 degradation, Our data, therefore, indicate that the N-terminal amino acid and multiple internal regions of p60 influence its stability in the cytosol of infected cells, Antigen degradation and epitope generation are linked, and different degradation signals can channel bacterial proteins into the MHC class I antigen processing pathway.	YALE UNIV,SCH MED,INFECT DIS SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06520	Yale University; Yale University				Sijts, Alice/0000-0003-3815-4788	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI039031, R01AI039031, R29AI033143] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39031, AI33143] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Androlewicz MJ, 1996, IMMUNITY, V5, P1, DOI 10.1016/S1074-7613(00)80304-0; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CRESSWELL P, 1994, ANTIGEN PROCESSING P, P33; DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; EGGERS M, 1995, J EXP MED, V182, P1865, DOI 10.1084/jem.182.6.1865; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBEL W, 1988, INFECTION, V16, pS149, DOI 10.1007/BF01639739; GOETTRUP M, 1996, NATURE, V381, P166; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Goth S, 1996, J IMMUNOL, V157, P1894; GRANT EP, 1995, J IMMUNOL, V155, P3750; HARDING CV, 1995, J IMMUNOL, V155, P1767; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KOHLER S, 1990, INFECT IMMUN, V58, P1943; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; PALZKILL T, 1994, J BACTERIOL, V176, P563, DOI 10.1128/jb.176.3.563-568.1994; PAMER EG, 1993, CURR OPIN IMMUNOL, V5, P492, DOI 10.1016/0952-7915(93)90028-Q; PAMER EG, 1994, J IMMUNOL, V152, P686; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PORTNOY DA, 1994, ANN NY ACAD SCI, V730, P15, DOI 10.1111/j.1749-6632.1994.tb44235.x; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sijts AJAM, 1996, J IMMUNOL, V156, P1497; Sijts AJAM, 1996, J IMMUNOL, V156, P685; TOKUNAGA F, 1994, J BIOL CHEM, V269, P17382; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VILLANUEVA MS, 1995, J IMMUNOL, V155, P5227; VILLANUEVA MS, 1994, IMMUNITY, V1, P479, DOI 10.1016/1074-7613(94)90090-6; Yewdell JW, 1996, J IMMUNOL, V157, P1823	44	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19261	19268		10.1074/jbc.272.31.19261	http://dx.doi.org/10.1074/jbc.272.31.19261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235920	hybrid			2022-12-25	WOS:A1997XP06300026
J	Shepherd, PR; Nave, BT; Rincon, J; Nolte, LA; Bevan, AP; Siddle, K; Zierath, JR; WallbergHenriksson, H				Shepherd, PR; Nave, BT; Rincon, J; Nolte, LA; Bevan, AP; Siddle, K; Zierath, JR; WallbergHenriksson, H			Differential regulation of phosphoinositide 3-kinase adapter subunit variants by insulin in human skeletal muscle.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; P85 SUBUNIT; INHIBITOR WORTMANNIN; SIGNALING PATHWAYS; GLYCOGEN-SYNTHESIS; FAT-CELLS; TRANSLOCATION; STIMULATION	The role of phosphoinositide 3-kinase (PI 3-kinase) in insulin signaling was evaluated in human skeletal muscle. Insulin stimulated both antiphosphotyrosine-precipitable PI 3-kinase activity and 3-O-methylglucose transport in isolated skeletal muscle (both approximate to 2-3-fold). Insulin stimulation of 3-O-methylglucose transport was inhibited by the PI 3-kinase inhibitor LY294002 (IC50 = 2.5 mu M). The PI 3-kinase adapter subunits were purified from muscle lysates using phosphopeptide beads based on the Tyr-751 region of the platelet-derived growth factor receptor. Immunoblotting of the material adsorbed onto the phosphopeptide beads revealed the presence of p85 alpha, p85 beta, p55(PIK)/p55 gamma, and p50 adapter subunit isoforms. In addition, p85 alpha-NSH2 antibodies recognized four adapter subunit variants of 54, 53, 48, and 46 kDa, the latter corresponding to the p50 splice variant. Serial immunoprecipitations demonstrated that these four proteins were associated with a large proportion of the total PI 3-kinase activity immunoprecipitated by p85 alpha-NSH2 domain antibodies. Antibodies to p85 beta, p55(PIK)/p55 gamma, and the p50 adapter subunit also immunoprecipitated PI 3-kinase activity from human muscle lysates. A large proportion of the total cellular pool of the 53-kDa variant, p50, and p55(PIK) was present in antiphosphotyrosine immunoprecipitates from unstimulated muscle, whereas these immunoprecipitates contained only a very small proportion of the cellular pool of p85 alpha, p85 beta, and the 48-kDa variant, Insulin greatly increased the levels of the 48-kDa variant in antiphosphotyrosine immunoprecipitates and caused smaller -fold increases in the levels of p85 alpha, p85 beta, and the 53-kDa variant. The levels of p50 and p55(PIK) were not significantly changed. These properties indicate mechanisms by which specificity is achieved in the PI 3-kinase signaling system.	UNIV CAMBRIDGE, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QR, ENGLAND; KAROLINSKA HOSP, DEPT CLIN PHYSIOL, S-10401 STOCKHOLM, SWEDEN	University of Cambridge; Karolinska Institutet; Karolinska University Hospital	Shepherd, PR (corresponding author), UCL, DEPT BIOCHEM, GOWER ST, LONDON WC1E 6BT, ENGLAND.			Zierath, Juleen/0000-0001-6891-7497; Bevan, Paul/0000-0002-0656-9164				Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ELMENDORF JS, 1995, BIOCHEM BIOPH RES CO, V208, P1147, DOI 10.1006/bbrc.1995.1453; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; KALIMAN P, 1995, BIOCHEM J, V312, P471, DOI 10.1042/bj3120471; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KUROSU H, 1995, BIOCHEM BIOPH RES CO, V216, P655, DOI 10.1006/bbrc.1995.2672; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NOLTE LA, 1995, DIABETES, V44, P1345, DOI 10.2337/diabetes.44.11.1345; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PONS S, 1995, MOL CELL BIOL, V15, P4453; REIF K, 1993, J BIOL CHEM, V268, P10780; Shepherd PR, 1996, J MOL ENDOCRINOL, V17, P175, DOI 10.1677/jme.0.0170175; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WHITE MF, 1994, J BIOL CHEM, V269, P1; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; ZIERATH JR, 1992, FEBS LETT, V307, P379, DOI 10.1016/0014-5793(92)80717-U; ZIERATH JR, 1994, DIABETOLOGIA, V37, P270, DOI 10.1007/BF00398054	49	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19000	19007		10.1074/jbc.272.30.19000	http://dx.doi.org/10.1074/jbc.272.30.19000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228082	hybrid			2022-12-25	WOS:A1997XM34200073
J	Zou, AH; Elgort, MG; Allegretto, EA				Zou, AH; Elgort, MG; Allegretto, EA			Retinoid X receptor (RXR) ligands activate the human 25-hydroxyvitamin D-3-24-hydroxylase promoter via RXR heterodimer binding to two vitamin D-responsive elements and elicit additive effects with 1,25-dihydroxyvitamn D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; OSTEOCALCIN GENE; ACID RECEPTORS; ALL-TRANS; 24-HYDROXYLASE GENE; NUCLEAR RECEPTOR; LEUKEMIA-CELLS; BETA-GENE; 9-CIS; EXPRESSION	We have previously shown that RNA levels of kidney 25-hydroxyvitamin D-3-24-hydroxylase (24(OH)ase), a key metabolic enzyme for 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3), is up-regulated by retinoids in mice within hours, Deletion analysis of similar to 5500 base pairs of the human 24(OH)ase promoter showed that the sequence between -316 and -142 contained the information necessary and sufficient for retinoid-induced activation of the promoter, This region contains two previously defined vitamin D-responsive elements (VDREs) at -294 to -274 and -174 to -151, Mutation of either VDRE diminished responsiveness of the -316 to -22 promoter sequence to retinoids or 1,25(OH)(2)D-3, while mutation of both VDREs essentially abolished the activity of the ligands via the promoter, Heterologous promoter vectors driven by the VDREs were responsive to a retinoid X receptor (RXR)-selective ligand (LG100268), a retinoic acid receptor (RAR)-selective ligand (TTNPB), or 1,25(OH)(2)D-3, while combinations of LG100268 with either TTNPB or 1,25(OH)(2)D-3 resulted in additive increases in activity, Band shift analyses showed that vitamin D receptor, RAR, or RXR alone did not bind to the VDREs; however, the combination of either vitamin D receptor or RAR with RXR led to retardation of each of the labeled probes, Treatment of nontransfected CV-1 cells with retinoids or 1,25(OH)(2)D-3 resulted in induction of 24(OH)ase RNA, and ligand combinations led to increased RNA levels, These data imply that either dr both of the heterodimer partners can be occupied with ligand to induce this enzyme, with dual receptor occupation leading to increased activation.	LIGAND PHARMACEUT INC, DEPT RETINOID RES, SAN DIEGO, CA 92121 USA	Ligand Pharmaceuticals								ALLEGRETTO EA, 1995, J BIOL CHEM, V270, P23906, DOI 10.1074/jbc.270.41.23906; ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; BROWN G, 1994, LEUKEMIA, V8, P806; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Elgort MG, 1996, MOL ENDOCRINOL, V10, P477, DOI 10.1210/me.10.5.477; HARADA H, 1995, ENDOCRINOLOGY, V136, P5329, DOI 10.1210/en.136.12.5329; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; Hofmann Clementine, 1994, P387; JAMES SY, 1995, J MOL ENDOCRINOL, V14, P391, DOI 10.1677/jme.0.0140391; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Lemon BD, 1996, MOL CELL BIOL, V16, P1006; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOELIGER P, 1980, EUR J MED CHEM, V15, P9; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OLIVA A, 1993, BIOCHEM BIOPH RES CO, V191, P908, DOI 10.1006/bbrc.1993.1303; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PIKE JW, 1994, J BONE MINER RES, V9, pS144; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TAIMI M, 1991, LEUKEMIA RES, V15, P1145, DOI 10.1016/0145-2126(91)90183-T; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VERSTUYF A, 1995, J STEROID BIOCHEM, V53, P431, DOI 10.1016/0960-0760(95)00089-I; WALLINGTON LA, 1995, LEUKEMIA, V9, P1185; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	44	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19027	19034		10.1074/jbc.272.30.19027	http://dx.doi.org/10.1074/jbc.272.30.19027			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228086	Green Submitted, hybrid			2022-12-25	WOS:A1997XM34200077
J	Koch, G; Tanaka, K; Masuda, T; Yamochi, W; Nonaka, H; Takai, Y				Koch, G; Tanaka, K; Masuda, T; Yamochi, W; Nonaka, H; Takai, Y			Association of the Rho family small GTP-binding proteins with Rho GDP dissociation inhibitor (Rho GDI) in Saccharomyces cerevisiae	ONCOGENE			English	Article						small GTP binding protein; Rho GDI; Rho; S-cerevisiae	GDP/GTP EXCHANGE PROTEIN; REGULATORY PROTEIN; CELL POLARITY; MOLECULAR-CLONING; ADP-RIBOSYLATION; ONCOGENE PRODUCT; BUD FORMATION; YEAST-CELLS; PURIFICATION; CYTOSOL	The small GTP-binding proteins of the Rho family, consisting of the Rho, Rac, and Cdc42 subfamilies, are implicated in various cell functions, such as cell shape change, cell motility and cytokinesis, through reorganization of actin cytoskeleton. Rho GDI is a general regulator which forms a complex with the GDP-bound inactive form of the Rho family members and inhibits their activation. We have purified Rho GDI from the yeast Saccharomyces cerevisiae, cloned its gene, and named it RD11 (Rho GD). In this study, we have further characterized Beast Rho GDI, Rho GDI was found in the cytosol by immunoblot and immunofluorescence microscopic analyses. Rho1p and Cdc42p were co-immunoprecipitated with Rho GDI from the cytosol. This immunoprecipitated Rho1p was mainly bound to GDP. In the disruption mutant of Rho GDI, which did not show any apparent phenotype, both Rho1p and Cdc42p were also present in the cytosol. These results indicate that yeast Rho GDI possesses properties similar to those of mammalian Rho GDI, and that there is a cytosolic factor which functionally substitutes for Rho GDI in yeast.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University								ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BACKLUND PS, 1993, BIOCHEM BIOPH RES CO, V196, P534, DOI 10.1006/bbrc.1993.2283; BOIVIN D, 1995, AM J PHYSIOL, V269, P180; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOURMEYSTER N, 1992, BIOCHEMISTRY-US, V31, P12863, DOI 10.1021/bi00166a022; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hirano H, 1996, MOL CELL BIOL, V16, P4396; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; IMAMURA H, 1997, IN PRESS EMBO J; ISOMURA M, 1991, ONCOGENE, V6, P119; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; Mack D, 1996, MOL CELL BIOL, V16, P4387; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; Rubin G M, 1975, Methods Cell Biol, V12, P45; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; Sherman F., 1986, METHODS YEAST GENETI; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAPON M, 1997, CURR OPIN CELL BIOL, V9, P86; UEDA T, 1990, J BIOL CHEM, V265, P9373; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366	45	53	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					417	422		10.1038/sj.onc.1201194	http://dx.doi.org/10.1038/sj.onc.1201194			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242378				2022-12-25	WOS:A1997XM23800006
J	Miller, CW; Yeon, C; Aslo, A; Mendoza, S; Aytac, U; Koeffler, HP				Miller, CW; Yeon, C; Aslo, A; Mendoza, S; Aytac, U; Koeffler, HP			The p19(INK4D) Cyclin dependent kinase inhibitor gene is altered in osteosarcoma	ONCOGENE			English	Article						p19; osteosarcoma; rearrangement; mutation	CELL LUNG-CANCER; CDK6 INHIBITOR; P18 GENES; P53 GENE; RETINOBLASTOMA; PROTEIN; AMPLIFICATION; SUPPRESSION; EXPRESSION; P16(INK4)	Inhibition of cyclin dependent kinases (CDK) by cyclin dependent kinase inhibitors (CDKI) blocks cell cycle progression and inhibits cellular proliferation. The archetypical member of the INK4 CDKI family, p16(INK4A) (also called CDKN2), is a tumor suppressor frequently deleted or mutated in certain neoplasms and many cell lines. Because p19(INK4D) has strong structural and functional similarity to p16(INK4A), We have assessed its role as a tumor suppressor. This was accomplished by screening the p19(INK4D) coding region for mutations, deletions and rearrangements in sarcomas and non-small cell lung cancers. Alterations of the p19(INK4D) gene were found in samples from five of 67 (7%) patients with osteosarcomas and none were found in other types of sarcomas or in lung cancers. Five osteosarcoma samples had Southern blot patterns consistent with gene rearrangement. These samples included a primary and recurrent osteosarcoma from the same patient; both with the same rearrangement. Four samples had SSCP patterns consistent with sequence alterations, sequencing determined that three were due to silent base changes and apparently polymorphisms. Sequencing the fourth shifted band revealed a one base insertion causing a frameshift beginning with codon 27. In summary, these studies found alterations affecting the p19(INK4D) gene in a small but significant number of osteosarcomas. Presumably, abnormalities of this gene contribute to the development of cancer of bone cells.			Miller, CW (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,CEDARS SINAI RES INST,DEPT MED,DIV HEMATOL ONCOL,DAVIS 5019,LOS ANGELES,CA 90048, USA.							CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHIBA I, 1990, ONCOGENE, V5, P1603; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kawamata N, 1995, MOL CARCINOGEN, V14, P263, DOI 10.1002/mc.2940140406; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILLER CW, 1990, CANCER RES, V50, P7950; Miller CW, 1996, CANCER GENET CYTOGEN, V86, P136, DOI 10.1016/0165-4608(95)00216-2; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARK DH, IN PRESS; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RODENHUIS S, 1988, CANCER RES, V48, P5738; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; Shiohara M, 1996, LEUKEMIA, V10, P1897; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; STONE S, 1995, CANCER RES, V55, P2988; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; TAM SW, 1994, CANCER RES, V54, P5816; XU HJ, 1991, CANCER RES, V51, P2735; YAMAGUCHI T, 1992, CANCER RES, V52, P2419; YANG R, 1995, CANCER RES, V55, P2503; Zariwala M, 1996, ONCOGENE, V13, P2033	37	34	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					231	235		10.1038/sj.onc.1201185	http://dx.doi.org/10.1038/sj.onc.1201185			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244358				2022-12-25	WOS:A1997XK37200011
J	Dittmar, KD; Demady, DR; Stancato, LF; Krishna, P; Pratt, WB				Dittmar, KD; Demady, DR; Stancato, LF; Krishna, P; Pratt, WB			Folding of the glucocorticoid receptor by the heat shock protein (hsp) 90-based chaperone machinery - The role of p23 is to stabilize receptor-hsp90 heterocomplexes formed by hsp90-p60-hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PROGESTERONE-RECEPTOR; STEROID-RECEPTOR; COMPLEX; RECONSTITUTION; BINDING; IDENTIFICATION; STI1; P50	In cytosols from animal and plant cells, the abundant heat shock protein hsp90 is associated with several proteins that act together to assemble steroid receptors into receptor-hsp90 heterocomplexes. We have reconstituted a minimal receptor hsp90 assembly system containing four required components, hsp90, hsp70, p60, and p23 (Dittmar, K, D,, Hutchison, K, A., Owens-Grille, J, IG,, and Pratt, W, B, (1996) J, Biol. Chem, 271, 12833-12839), We have shown that hsp90, p60, and hsp70 are sufficient for carrying out the folding change that converts the glucocorticoid receptor (GR) hormone binding domain (HBD) from a non-steroid binding to a steroid binding conformation, but to form stable GR hsp90 heterocomplexes, p23 must also be present in the incubation mix (Dittmar, K, D,, and Pratt, W, B. (1997) J, Biol, Chem. 272, 13047-13054), In this work, we show that addition of p23 to native GR.hsp90 heterocomplexes immunoadsorbed from L cell cytosol or to GR.hsp90 heterocomplexes prepared with the minimal (hsp90.p60.hsp70) assembly system inhibits both receptor heterocomplex disassembly and loss of steroid binding activity, p23 stabilizes the GR.hsp90 heterocomplex in a dynamic and ATP-independent manner. In contrast to hsp90 that is bound to the GR, free hsp90 binds p23 in an ATP-dependent manner, and hsp90 in the hsp90 p60 hsp70 heterocomplex is in a conformation that does not bind p23 at all, The effect of p23 in the minimal GR heterocomplex assembly system is to stabilize GR.hsp90 heterocomplexes once they are formed and it does not appear to affect the rate of heterocomplex assembly, Molybdate has the same ability as p23 to stabilize GR heterocomplexes with mammalian hsp90, but GR heterocomplexes with plant hsp90 are stabilized by p23 and not by molybdate, We propose that incubation of the GR.with hsp90 p60]hsp70 forms a GR hsp90 heterocomplex in which hsp90 is in an ATP-dependent conformation, The ATP dependent conformation of hsp90 is required for the hormone binding domain to have a steroid binding site, and binding of p23 to that state of hsp90 stabilizes the GR.hsp90 heterocomplex to inactivation and disassembly.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV WESTERN ONTARIO,DEPT PLANT SCI,LONDON,ON N6A 5B7,CANADA	University of Michigan System; University of Michigan; Western University (University of Western Ontario)				Krishna, Priti/0000-0001-6394-3012	NIDDK NIH HHS [DK31573] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KRISHNA P, 1995, PLANT PHYSIOL, V107, P915, DOI 10.1104/pp.107.3.915; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OwensGrillo JK, 1996, BIOCHEMISTRY-US, V35, P15249, DOI 10.1021/bi9615349; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Stancato LF, 1996, BIOCHEMISTRY-US, V35, P554, DOI 10.1021/bi9511649; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007	34	213	221	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21213	21220		10.1074/jbc.272.34.21213	http://dx.doi.org/10.1074/jbc.272.34.21213			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261129	hybrid			2022-12-25	WOS:A1997XR78900039
J	Takayama, TK; Fujikawa, K; Davie, EW				Takayama, TK; Fujikawa, K; Davie, EW			Characterization of the precursor of prostate-specific antigen - Activation by trypsin and by human glandular kallikrein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SEMINAL PLASMA; PROTEIN-C INHIBITOR; PLASMINOGEN-ACTIVATOR; ESCHERICHIA-COLI; RADICAL PROSTATECTOMY; SERINE PROTEINASE; HUMAN-SEMEN; CANCER; MARKER; SERUM	The precursor or zymogen form of prostate specific antigen (pro-PSA) is composed of 244 amino acid residues including an amino-terminal propiece of 7 amino acids. Recombinant pro-PSA was expressed in Escherichia coli, isolated from inclusion bodies, refolded, and purified. The zymogen was readily activated by trypsin at a weight Patio of 50:1 to generate PSA, a serine protease that cleaves the chromogenic chymotrypsin substrate 3-carbomethoxypropionyl-L-arginyl-L-prolyl-L-tyrosine-p-nitroaniline-HCl (S-2586). In this activation, the amino-terminal propiece Ala-Pro-Leu-Ile-Leu-Ser-Arg was released by cleavage at the Arg-ne peptide bond. The recombinant pro-PSA was also activated by recombinant human glandular kallikrein, another prostate-specific serine protease, as well as by a partially purified protease(s) from seminal plasma, The recombinant PSA was inhibited by alpha 1-antichymotrypsin, forming an equimolar complex with a molecular mass of approximately 100 kDa, The recombinant PSA failed to activate single chain urokinase-type plasminogen activator, in contrast to the recombinant hK2, which readily activated single chain urokinase-type plasminogen activator, These results indicate that pro-PSA is converted to an active serine protease by minor proteolysis analogous to the activation of many of the proteases present in blood, pancreas, and other tissues. Furthermore, PSA is probably generated by a cascade system involving a series of precursor proteins. These proteins may interact in a stepwise manner similar to the generation of plasmin during fibrinolysis or thrombin during blood coagulation.	UNIV WASHINGTON,DEPT UROL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Takayama, TK (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,BOX 357350,SEATTLE,WA 98195, USA.				NHLBI NIH HHS [HL16919] Funding Source: Medline; NIDDK NIH HHS [DK02447] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002447] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA K, 1987, FEBS LETT, V225, P168, DOI 10.1016/0014-5793(87)81151-1; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHAUDHURI JB, 1994, ANN NY ACAD SCI, V721, P374, DOI 10.1111/j.1749-6632.1994.tb47409.x; CHRISTENSSON A, 1990, EUR J BIOCHEM, V194, P755, DOI 10.1111/j.1432-1033.1990.tb19466.x; CLEMENTS JA, 1994, MOL CELL ENDOCRINOL, V99, pC1, DOI 10.1016/0303-7207(94)90138-4; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; Cramer SD, 1996, J UROLOGY, V156, P526, DOI 10.1016/S0022-5347(01)65919-6; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Deperthes D, 1995, BBA-GEN SUBJECTS, V1245, P311, DOI 10.1016/0304-4165(95)00118-2; ESPANA F, 1991, THROMB RES, V64, P309, DOI 10.1016/0049-3848(91)90002-E; Hara M, 1972, Nihon Hoigaku Zasshi, V26, P85; HUDSON MA, 1989, J UROLOGY, V142, P1011, DOI 10.1016/S0022-5347(17)38972-3; Iki, 1969, NIPPON HOIGAKU ZASSH, V23, P333; Iwamura M, 1996, UROLOGY, V48, P317, DOI 10.1016/S0090-4295(96)00182-3; KEER HN, 1991, PROSTATE, V18, P201, DOI 10.1002/pros.2990180303; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE PH, 1989, J UROLOGY, V141, P873; LAURELL M, 1992, J CLIN INVEST, V89, P1094, DOI 10.1172/JCI115689; LI TS, 1973, FERTIL STERIL, V24, P134; LIJNEN HR, 1986, J BIOL CHEM, V261, P1253; LILJA H, 1991, CLIN CHEM, V37, P1618; LILJA H, 1987, J CLIN INVEST, V80, P281, DOI 10.1172/JCI113070; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; LOVGREN J, 1997, J UROL S4, V157; LUNDWALL A, 1987, FEBS LETT, V214, P317, DOI 10.1016/0014-5793(87)80078-9; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; ORSINI G, 1978, J BIOL CHEM, V253, P3453; ORSINI G, 1991, EUR J BIOCHEM, V195, P691, DOI 10.1111/j.1432-1033.1991.tb15755.x; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PAPSIDERO LD, 1981, J NATL CANCER I, V66, P37; PARRIES G, 1996, J UROLOGY, V155, P507; RIEGMAN PHJ, 1989, FEBS LETT, V247, P123, DOI 10.1016/0014-5793(89)81253-0; SCHEDLICH LJ, 1987, DNA-J MOLEC CELL BIO, V6, P429, DOI 10.1089/dna.1987.6.429; SCHNEIDER K, 1989, BIOL CHEM H-S, V370, P353, DOI 10.1515/bchm3.1989.370.1.353; SENSABAUGH GF, 1978, J FORENSIC SCI, V23, P106; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STENMAN UH, 1991, CANCER RES, V51, P222; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; WANG MC, 1979, INVEST UROL, V17, P159; WANG MC, 1981, PROSTATE, V2, P89, DOI 10.1002/pros.2990020109; WATT KWK, 1986, P NATL ACAD SCI USA, V83, P3166, DOI 10.1073/pnas.83.10.3166; WINKLER ME, 1986, BIOCHEMISTRY-US, V25, P4041, DOI 10.1021/bi00362a008; Yoshida E, 1995, INT J CANCER, V63, P863, DOI 10.1002/ijc.2910630618; YU JX, 1994, J BIOL CHEM, V269, P18843	53	197	213	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21582	21588		10.1074/jbc.272.34.21582	http://dx.doi.org/10.1074/jbc.272.34.21582			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261179	hybrid			2022-12-25	WOS:A1997XR78900089
J	vantVeer, C; Kalafatis, M; Bertina, RM; Simioni, P; Mann, KG				vantVeer, C; Kalafatis, M; Bertina, RM; Simioni, P; Mann, KG			Increased tissue factor-initiated prothrombin activation as a result of the Arg(506)->Gln mutation in factor V-LEIDEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	37th Annual Meeting of the American-Society-of-Hematology	DEC 01-05, 1995	SEATTLE, WA	Amer Soc Hematol			PEPTIDE-BOND CLEAVAGES; PROTEIN-C RESISTANCE; FACTOR-XA; BLOOD-COAGULATION; FACTOR VA(R506Q); FACTOR PATHWAY; RISK FACTOR; FACTOR-IX; INACTIVATION; THROMBIN	The effect of the Arg(506) --> Gln mutation in factor V-LEIDEN on thrombin generation was evaluated in a reconstituted system using the purified components of the tissue factor (TF) pathway to thrombin and the components of the protein C pathway, Recombinant full-length tissue factor pathway inhibitor (RTFPI) was included in the system because of a previously observed synergistic inhibitory effect of TFPI and the protein C pathway on TF-initiated thrombin generation, Thrombin generation initiated by 1.25 pM factor VIIa.TF in the absence of the protein C pathway components occurs following an initiation phase, after which prothrombin is quantitatively converted to 1.4 mu M thrombin, The factor V-LEIDEN mutation did not influence thrombin generation in the reconstituted model in the absence of the protein C pathway, In the presence of 2.5 nM TFPI, 65 nM protein C, and 10 nar recombinant soluble thrombomodulin (Tm), thrombin generation catalyzed by normal factor V was abolished after the initial formation of 25 nM thrombin, In contrast, persistent thrombin generation was observed in the presence of factor V-LEIDEN in the same system, although the rate of thrombin generation was slower compared with the reaction without protein C and Tm, The rate of thrombin generation with factor V-LEIDEN increased with time and ultimately resulted in quanti tative prothrombin activation, When the TFPI concentration was reduced to 1.25 nM, thrombin generation is still curtailed in the presence of normal factor V, In contrast, under similar conditions using factor V-LEIDEN, the protein C pathway totally failed to down-regulate thrombin generation. The dramatic effect of a 50% reduction in TFPI concentration on the inhibitory potential of the protein C pathway on thrombin generation catalyzed by factor V-LEIDEN suggests that the observed synergy between TFPI and the protein C pathway is directly governed by the TFPI concentration and by cleavage of the factor Va heavy chain at Arg(506). This cleavage appears to have a dramatic regulatory effect in the presence of low concentrations of TFPI, Markedly increased thrombin generation in the presence of both 1.25 nM TFPI and factor V-LEIDEN was also observed when antithrombin-III was added to the system to complete the natural set of coagulation inhibitors, Protein S (300 nM) had a minimal effect in the model on the inhibition of thrombin generation by protein C, Tm, and TFPI, with either normal factor V or factor V-LEIDEN. Protein S also failed to significantly potentiate the action of the protein C pathway in the presence of antithrombin-III in reactions employing normal factor V or factor V-LEIDEN. The absence of an effect of protein S in the model, which employs saturating concentrations of phospholipid, suggests that the reported interactions of protein S with coagulation factors are not decisive in the reaction, Altogether the data predict that TFPI levels in the lower range of normal values are a risk factor for thrombosis when combined with the Arg(506) --> Gln mutation in factor V-LEIDEN.	UNIV VERMONT,DEPT BIOCHEM,BURLINGTON,VT 05405; UNIV LEIDEN HOSP,CTR HEMOSTASIS & THROMBOSIS RES,NL-2300 RC LEIDEN,NETHERLANDS; UNIV PADUA,IST SEMEIOT MED,I-35100 PADUA,ITALY	University of Vermont; Leiden University; Leiden University Medical Center (LUMC); University of Padua			SIMIONI, PAOLO/AAC-5438-2022; Simioni, Paolo/AAC-5416-2022; Bertina, Rogier/AGQ-5246-2022	SIMIONI, PAOLO/0000-0002-6744-383X; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703, R37HL034575] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL-34575, HL-46703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLAJCHMAN MA, 1992, BLOOD, V80, P2159; BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; GRIFFIN JH, 1992, BLOOD, V79, P3203; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; HEEB MJ, 1994, P NATL ACAD SCI USA, V91, P2728, DOI 10.1073/pnas.91.7.2728; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; Huang Z.-F., 1996, Blood, V88, p470A; IKEDA K, 1985, THROMB RES, V39, P297, DOI 10.1016/0049-3848(85)90225-7; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; KOELEMAN BPC, 1994, BLOOD, V84, P1031; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; MANN KG, 1992, SEMIN HEMATOL, V29, P213; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; NOVOTNY WF, 1991, BLOOD, V78, P387; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PRATT CM, 1991, HEMOSTASIS SEMIN HEM, V28, P2; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P350; Van't Veer Cornelis, 1995, Blood, V86, p614A; vanBoven HH, 1996, THROMB HAEMOSTASIS, V75, P417; vantVeer C, 1997, J BIOL CHEM, V272, P4367, DOI 10.1074/jbc.272.7.4367; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; ZOLLER B, 1995, BLOOD, V85, P3518, DOI 10.1182/blood.V85.12.3518.bloodjournal85123518	42	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20721	20729		10.1074/jbc.272.33.20721	http://dx.doi.org/10.1074/jbc.272.33.20721			9	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252393	hybrid			2022-12-25	WOS:A1997XR22100063
J	Heyduk, E; Heyduk, T; Claus, P; Wisniewski, JR				Heyduk, E; Heyduk, T; Claus, P; Wisniewski, JR			Conformational changes of DNA induced by binding of Chironomus high mobility group protein 1a (cHMG1a) - Regions flanking an HMG1 box domain do not influence the bend angle of the DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; NUCLEOPROTEIN STRUCTURES; RECEPTOR PROTEIN; SRY; COMPLEX; MURINE; LEF-1	High mobility group (HMG) proteins are thought to facilitate assembly of higher order chromatin structure through modulation of DNA conformation. In this work we investigate the bending of a 30-base pair DNA fragment induced by Chironomus HMG1 (cHMG1a), and HMGI (cHMGI) proteins. The DNA bending was measured in solution by monitoring the end-to-end distance between fluorescence probes attached to opposite ends of the DNA fragment. The distance was measured by fluorescence energy transfer using a novel europium chelate as a fluorescence donor. These measurements revealed that the end-to-end distance in the 30-base pair DNA was decreased from similar to 100 Angstrom in free DNA to similar to 50.5 Angstrom in cHMG1a.DNA complex. The most probable DNA bending angle consistent with these distance measurements is about 150 degrees. The deletion of the charged regulatory domains located close to the C terminus of the HMG1 box domain of cHMG1a protein had no effect on the induced bend angle. The ability to induce a large DNA bend distinguishes the cHMG1 from the cHMGI protein. Only small perturbation of the DNA conformation was observed upon binding of the cHMGI protein. A strong DNA bending activity of cHMG1a and its relative abundance in the cell suggests that this protein plays a very important role in modulation of chromatin structure.	ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,ST LOUIS,MO 63104; UNIV GOTTINGEN,INST ZOOL ENTWICKLUNGSBIOL 3,D-37073 GOTTINGEN,GERMANY	Saint Louis University; University of Gottingen			Claus, Peter/A-7978-2008	Claus, Peter/0000-0003-3824-9445	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050514, R21GM050514] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50514] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CARBALLO M, 1983, EMBO J, V2, P1759, DOI 10.1002/j.1460-2075.1983.tb01654.x; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; CLAUS P, 1994, J BIOL CHEM, V269, P33042; CLEGG RM, 1993, P NATL ACAD SCI USA, V90, P2994, DOI 10.1073/pnas.90.7.2994; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Ghidelli S, 1997, CHROMOSOMA, V105, P369, DOI 10.1007/BF02529752; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1994, P NATL ACAD SCI USA, V91, P3368, DOI 10.1073/pnas.91.8.3368; GRASSER KD, 1995, PLANT J, V7, P185, DOI 10.1046/j.1365-313X.1995.7020185.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Hardman CH, 1995, BIOCHEMISTRY-US, V34, P16596, DOI 10.1021/bi00051a007; HEYDUK E, 1992, BIOCHEMISTRY-US, V31, P3682, DOI 10.1021/bi00129a017; Heyduk E, 1997, ANAL BIOCHEM, V248, P216, DOI 10.1006/abio.1997.2148; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; KUEHL L, 1984, J CELL BIOL, V99, P648, DOI 10.1083/jcb.99.2.648; LnenicekAllen M, 1996, NUCLEIC ACIDS RES, V24, P1047, DOI 10.1093/nar/24.6.1047; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; SELVIN PR, 1994, P NATL ACAD SCI USA, V91, P10024, DOI 10.1073/pnas.91.21.10024; SELVIN PR, 1994, J AM CHEM SOC, V116, P6029, DOI 10.1021/ja00092a088; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WISNIEWSKI JR, 1992, J BIOL CHEM, V267, P17170; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 1997, EUR J BIOCHEM, V243, P151, DOI 10.1111/j.1432-1033.1997.0151a.x; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P29261; WISNIEWSKI JR, 1994, EUR J BIOCHEM, V225, P687, DOI 10.1111/j.1432-1033.1994.00687.x	40	59	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19763	19770		10.1074/jbc.272.32.19763	http://dx.doi.org/10.1074/jbc.272.32.19763			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242635	hybrid			2022-12-25	WOS:A1997XQ05900022
J	Jang, YJ; Won, MS; Chung, KS; Kim, DU; Hoe, KL; Park, C; Yoo, HS				Jang, YJ; Won, MS; Chung, KS; Kim, DU; Hoe, KL; Park, C; Yoo, HS			A novel protein, Psp1, essential for cell cycle progression of Schizosaccharomyces pombe is phosphorylated by Cdc2-Cdc13 upon entry into G(0)-like stationary phase of cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; S-PHASE; DEPENDENT KINASES; SACCHAROMYCES-CEREVISIAE; CDK INHIBITORS; DIVISION CYCLE; G1 PHASE; MITOSIS; GENE; FAMILY	A novel gene, psp1(+), which functionally complements a temperature-sensitive mutant defective in cell cycle progression both in G(1)/S and G(2)/M has been isolated from the genomic and cDNA libraries of Schizosaccharomyces pombe, Disruption of this gene is lethal for cell growth at 30 degrees C indicating that it is an essential gene for vegetative cell growth, Western analysis of the protein by polyclonal antibody made from glutathione S-transferase-Psp1 fusion protein indicated that the Psp1 protein exists in two different molecular weight forms depending on the growth state of the cell, In vitro experiments with a phosphatase showed that this difference is due to phosphorylation. The dephosphorylated form of the protein is dominant in actively growing cells whereas the phosphorylated form becomes the major species when cells enter the stationary phase, The Cdc2-Cdc13 complex is shown to phosphorylate the GST-Psp1 fusion protein in vitro, and site-directed mutagenesis and phosphoamino acid analysis indicated that the serine residue at position 333 in the carboxyl-terminal region is required for phosphorylation. In situ fluorescein isothiocyanate-conjugated antibody staining showed that this protein tends to be localized to both ends of the cell upon entry into the stationary phase of cell growth, However, overexpression of the novel protein Psp1 in actively growing cells inhibits cell growth causing accumulation of DNA (4n or 8n), Thus we speculate that Psp1 can function at both G(1)/S and G(2)/M phases complementing the defect of the new mutant we have isolated, It is likely that Psp1 is required both for proper DNA replication and for the process of mitosis.	KIST, KOREA RES INST BIOSCI & BIOTECHNOL, CELL CYCLE & SIGNAL RES UNIT, TAEJON 305600, SOUTH KOREA; KOREA ADV INST SCI & TECHNOL, DEPT BIOL SCI, TAEJON 305608, SOUTH KOREA	Korea Institute of Science & Technology (KIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST)			Park, Chankyu/C-1936-2011	Hoe, Kwang Lae/0000-0002-3943-4549				ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; ALFA CE, 1990, J CELL SCI, V96, P71; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CLACKSON T, 1991, PCR PRACTICAL APPROA, P201; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Gutz H., 1974, HDB GENETICS, V1, P395; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Ishii K, 1996, EMBO J, V15, P6629, DOI 10.1002/j.1460-2075.1996.tb01053.x; JANG YJ, 1994, MOL CELLS, V4, P419; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MACNEIL SA, 1993, CELL CYCLE PRACTICAL, P93; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MITCHISON JM, 1971, EXP CELL RES, V69, P244, DOI 10.1016/0014-4827(71)90337-5; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARK SK, 1995, BBA-GENE STRUCT EXPR, V1262, P87, DOI 10.1016/0167-4781(95)00063-M; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TODA T, 1981, J CELL SCI, V52, P271; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHUO S, 1993, J BIOL CHEM, V268, P17754	77	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19993	20002		10.1074/jbc.272.32.19993	http://dx.doi.org/10.1074/jbc.272.32.19993			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242669	hybrid			2022-12-25	WOS:A1997XQ05900056
J	Dong, JA; Naito, M; Tsuruo, T				Dong, JA; Naito, M; Tsuruo, T			c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis in human monocytic leukemia U937 cells	ONCOGENE			English	Article						c-myc; TNF-alpha; Fas; antitumor agents; CPP32; apoptosis	AGENT-INDUCED APOPTOSIS; ANTICANCER DRUGS; INDUCTION; BCL-2; RESISTANCE; EXPRESSION; GENE; FAS; CYTOTOXICITY; HOMOLOG	Human monocytic leukemia U937 cells readily undergo apoptosis when they are treated with TNF-alpha, anti-Fas antibody and anticancer drugs such as etoposide and Ara-C, To study the mechanism of apoptosis, we developed a novel apoptosis-resistant variant, UC, from U937 cells, The UC cells showed resistance to apoptosis induced by TNF-alpha, anti-Fas antibody, etoposide and Ara-C, Somatic cell hybridization between U937 and UC showed that apoptosis-resistance to TNF-alpha in UC was genetically recessive and resistance to etoposide was dominant, suggesting that UC has at least two different mutations functionally involved in apoptosis, Mechanistic analysis revealed that UC cells expressed reduced amounts of c-Myc, Transfection of the c-myc gene into UC cells restored the sensitivity of the cells to undergo apoptosis induced by TNF-alpha and anti-Fas, which attributes apoptosis-resistance in this circumstance to the reduced expression of c-Myc, On the other hand, c-myc transfection into UC cells could not restore their sensitivity to etoposide- and Ara-C-induced apoptosis, arguing against the role of c-myc in chemotherapy-induced apoptosis, However, treating the parental U937 cells with antisense oligonucleotides designed to reduce c-Myc expression rendered the cells resistant to etoposide-induced as well as to TNF-alpha-induced apoptosis, These results indicate that the reduced expression of c-Myc in UC is strongly associated with the resistance to etoposide-induced apoptosis, Our finding that c-myc transfection into UC could not restore the sensitivity to etoposide-induced apoptosis, suggests UC could have a second mutation that confers resistance to etoposide-induced apoptosis in a genetically dominant manner, Taken together, our present results indicate that c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research								AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Baker SJ, 1996, ONCOGENE, V12, P1; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chen ZH, 1996, CANCER RES, V56, P5224; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FUJITA M, 1995, ONCOGENE, V11, P15; FUJITA N, 1993, CANCER RES, V53, P5022; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; Mikami K, 1996, CANCER RES, V56, P2823; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; Noguchi K, 1996, ONCOGENE, V13, P39; NOGUCHI K, 1995, CELL GROWTH DIFFER, V6, P1271; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WOOD AC, 1995, BRIT J CANCER, V71, P937, DOI 10.1038/bjc.1995.181; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YONEHARA S, 1989, J EXP MED, V169, P1749	33	41	45	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					639	647		10.1038/sj.onc.1201237	http://dx.doi.org/10.1038/sj.onc.1201237			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264404				2022-12-25	WOS:A1997XP68300003
J	Gantt, SM; Clavijo, P; Bai, XM; Esko, JD; Sinnis, P				Gantt, SM; Clavijo, P; Bai, XM; Esko, JD; Sinnis, P			Cell adhesion to a motif shared by the malaria circumsporozoite protein and thrombospondin is mediated by its glycosaminoglycan-binding region and not by CSVTCG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE N-SULFOTRANSFERASE; PLATELET GLYCOPROTEIN-IIIB; HEPARAN-SULFATE; I REPEATS; PLASMODIUM-FALCIPARUM; SURFACE-ANTIGEN; SEQUENCE; PEPTIDES; SPOROZOITE; PROPERDIN	The malaria circumsporozoite protein (CS), thrombospondin (TSP) and several other proteins including the terminal complement proteins and the neural adhesion molecules F-spondin and Unc-5, share a cell adhesive sequence, In CS this sequence is designated as region II-plus (EWSPCSVTCGNGIQVRIK) and in TSP it is found in the type I repeats. Previous studies aimed at fine mapping the amino acid residues required for cell adhesion have yielded discrepant results. Here we show in three different cell lines that the downstream basic residues are required for cell adhesion whereas the CS-VTCG sequence is not, Using mutant Chinese hamster ovary cells selected for deficiencies in proteoglycan synthesis, we show that in wild type cells, heparan sulfate proteoglycans are the binding sites for this motif, This finding is supported by additional experiments with two other cell lines demonstrating that treatment with heparitinase but not chondroitinase abolishes cell adhesion to peptides representing this motif, Using Chinese hamster ovary cell mutants deficient in heparan sulfate proteoglycans but possessing chondroitin sulfate proteoglycans, we show that cell surface chondroitin sulfate proteoglycans can also mediate binding to this motif although higher concentrations of peptides are required for adhesion, Chondroitinase, but not heparitinase, treatment of these cells destroys cell surface-binding sites. Taken together, these results indicate that cell adhesion to this motif involves an interaction between the downstream positively-charged residues and the negatively charged glycosaminoglycan chains of heparan sulfate, or in some cases chondroitin sulfate, proteoglycans on the cell surface.	NYU, MED CTR, DEPT MED & MOL PARASITOL, NEW YORK, NY 10016 USA; UNIV CALIF SAN DIEGO, CTR CANC, DIV CELLULAR & MOL MED, GLYCOBIOL PROGRAM, SAN DIEGO, CA 92103 USA	New York University; University of California System; University of California San Diego				Gantt, Soren/0000-0001-5743-3606	NIAID NIH HHS [P01 AI35703, K11 AI001175-05] Funding Source: Medline; NIDDK NIH HHS [5T35-DK-07421] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001175, P01AI035703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T35DK007421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JC, 1994, MOL BIOL CELL, V5, P423, DOI 10.1091/mbc.5.4.423; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1991, J BIOL CHEM, V266, P12461; CATIMEL B, 1992, BIOCHEM J, V284, P231, DOI 10.1042/bj2840231; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1992, MOL BIOCHEM PARASIT, V54, P1, DOI 10.1016/0166-6851(92)90089-3; CERAMI C, 1994, J EXP MED, V179, P695, DOI 10.1084/jem.179.2.695; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELACRUZ VF, 1987, J BIOL CHEM, V262, P11935; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; ESKO JD, 1989, METHOD CELL BIOL, V32, P387; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HEDSTROM RC, 1990, B WORLD HEALTH ORGAN, V68, P152; HOLT GD, 1989, J BIOL CHEM, V264, P12138; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KIEFFER N, 1988, BIOCHIM BIOPHYS ACTA, V967, P408, DOI 10.1016/0304-4165(88)90104-3; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LI WX, 1993, J BIOL CHEM, V268, P16179; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; MCCUTCHAN TF, 1985, SCIENCE, V230, P1381, DOI 10.1126/science.2416057; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MOSHER DF, 1990, ANNU REV MED, V41, P85; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1986, J BIOL CHEM, V261, P3306; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROGERS WO, 1992, MOL BIOCHEM PARASIT, V53, P45, DOI 10.1016/0166-6851(92)90005-5; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; Sinnis P, 1996, J EXP MED, V184, P945, DOI 10.1084/jem.184.3.945; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	52	51	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19205	19213		10.1074/jbc.272.31.19205	http://dx.doi.org/10.1074/jbc.272.31.19205			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235912	Green Accepted, hybrid			2022-12-25	WOS:A1997XP06300018
J	Jiang, BH; Zheng, JZ; Leung, SW; Roe, R; Semenza, GL				Jiang, BH; Zheng, JZ; Leung, SW; Roe, R; Semenza, GL			Transactivation and inhibitory domains of hypoxia-inducible factor 1 alpha. Modulation of transcriptional activity by oxygen tension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; ENDOTHELIAL GROWTH-FACTOR; LACTATE-DEHYDROGENASE-A; FUNCTIONAL DOMAINS; ENHANCER ELEMENT; DNA-BINDING; FACTOR-I; V-MYB; C-MYB; ACTIVATION	Hypoxia-inducible factor 1 (HIF-1) binds to cis-acting hypoxia-response elements within the erythropoietin, vascular endothelial growth factor, and other genes to activate transcription in hypoxic cells, HIF-1 is a basic helix-loop-helix transcription factor composed of HIF-1 alpha and HIF-1 beta subunits, Here, we demonstrate that HIF-1 alpha contains two transactivation domains located between amino acids 531 and 826, When expressed as GAL4 fusion proteins, the transcriptional activity of these domains increased in response to hypoxia, Fusion protein levels were unaffected by changes in cellular O-2 tension, Two minimal transactivation domains were localized to amino acid residues 531-575 and 786-826, The transcriptional activation domains were separated by amino acid sequences that inhibited transactivation. Deletion analysis demonstrated that the gradual removal of inhibitory domain sequences (amino acids 576-785) was associated with progressively increased transcriptional activity of the fusion proteins, especially in cells cultured at 20% O-2. Transcriptional activity of GAL4/HIF-1 alpha fusion proteins was increased in cells exposed to 1% O-2, cobalt chloride, or desferrioxamine, each of which also increased levels of endogenous HIF-1 alpha protein but did not affect fusion protein levels, These results indicate that increased transcriptional activity mediated by HIF-1 in hypoxic cells results from both increased HIF-1 alpha protein levels and increased activity of HIF-1 alpha transactivation domains.	JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT PEDIAT,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT MED,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins University				Jiang, Bing-Hua/0000-0003-4526-2031	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039869] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL55338] Funding Source: Medline; NIDDK NIH HHS [R01-DK39869] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK I, 1991, J BIOL CHEM, V266, P15563; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Newton EM, 1996, MOL CELL BIOL, V16, P839; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; RATCLIFFE PJ, 1993, KIDNEY INT, V44, P887, DOI 10.1038/ki.1993.327; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 2002, MOL CLONING LAB MANU; SELDEN RF, 1987, CURRENT PROTOCOLS MO; Semenza GL, 1996, TRENDS CARDIOVAS MED, V6, P151, DOI 10.1016/1050-1738(96)00039-4; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117	43	497	528	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19253	19260		10.1074/jbc.272.31.19253	http://dx.doi.org/10.1074/jbc.272.31.19253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235919	hybrid			2022-12-25	WOS:A1997XP06300025
J	Tinti, C; Yang, CY; Seo, H; Conti, B; Kim, C; Joh, TH; Kim, KS				Tinti, C; Yang, CY; Seo, H; Conti, B; Kim, C; Joh, TH; Kim, KS			Structure/function relationship of the cAMP response element in tyrosine hydroxylase gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA CELL-LINE; DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; TRANSGENIC MICE; MESSENGER-RNA; BINDING PROTEIN; NERVOUS-SYSTEM; E-BOX; EXPRESSION; PROMOTER	Expression of tyrosine hydroxylase (TH) is limited to catecholamine-producing neurons and neuroendocrine cells in a cell type-specific manner and is inducible by the cAMP-regulated signaling pathway, Previous results indicated that the cAMP response element (CRE) residing at -45 to -38 base pairs upstream of the transcription initiation site is essential for both basal and cAMP-inducible promoter activity of the 2.4-kilobase or shorter upstream sequence of the TH gene (Kim, K. S., Lee, M. K., Carroll, J., and Joh, T. H. (1993) J. Biol. Chem. 268, 15689-15695; Lazaroff, M., Patankar, S., Yoon, S, O., and Chikaraishi, D. M. (1995) J. Biol. Chem, 270, 21579-21589). Here, we further report that the CRE is critical for the promoter activity of the 5.6- or 9.0-kilobase upstream sequences of the rat TH gene, which had been shown to direct the cell specific TH expression in vivo, To define the structure/function relationship of the CRE in transcriptional activation of the TH gene, we performed saturated mutational analyses of 12 nucleotides encompassing the CRE, Mutation of any nucleotide within the octamer motif results in a significant decrease of both basal and cAMP-inducible transcriptional activity of the TH reporter gene construct, Among the four nucleotides adjacent to the CRE (two 5' and two 3') only the G residue at the immediate 3' position is important for full transcriptional activity, DNase I footprint analysis indicates a positive correlation between in vivo promoter activity and in vitro interaction between the CRE motif and its cognate protein factor(s), Reconstruction experiments using a TH promoter in which the native CRE was rendered inactive show that the CRE can transactivate transcription in either orientation through a window of approximately 200 base pairs upstream of the transcription initiation site, suggesting that CRE supports transcriptional activation of the TH gene in a distance-dependent manner, Finally, when the distance between the CRE and TATA box was changed by inserting an additional 5 or 10 bases, it was observed that both insertional mutations increased activity by approximately 3-fold, The cAMP inducibility was as intact as the wild type construct. Together, these results are consistent with a model in which transcriptional activation of the TH gene by the CRE requires that it be located within a certain proximity of the CAP site but does not depend on a stringent stereospecific alignment in relationship to the TATA element.	UNIV TENNESSEE,COLL MED,DEPT ANAT & NEUROBIOL,MEMPHIS,TN 38163; UNIV TENNESSEE,COLL MED,DEPT NEUROL,MEMPHIS,TN 38163; CORNELL UNIV,COLL MED,MOL NEUROBIOL LAB,WM BURKE MED RES INST,NEW YORK,NY 10605	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Cornell University				Conti, Bruno/0000-0002-9185-5201	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH024285, R01MH024285, R01MH048866, R29MH048866] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48866, MH24285] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ANDRISANI OM, 1989, P NATL ACAD SCI USA, V86, P2181, DOI 10.1073/pnas.86.7.2181; BANERJEE SA, 1992, J NEUROSCI, V12, P4460; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CARRIER A, 1993, J NEUROCHEM, V61, P2215, DOI 10.1111/j.1471-4159.1993.tb07462.x; CARROLL JM, 1991, J MOL NEUROSCI, V3, P65, DOI 10.1007/BF02885527; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CICCARONE V, 1989, CANCER RES, V49, P219; COMB M, 1987, TRENDS NEUROSCI, V10, P473, DOI 10.1016/0166-2236(87)90103-2; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; D'MELLO SR, 1989, J NEUROSCI RES, V23, P31, DOI 10.1002/jnr.490230105; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAUQUET M, 1993, J NEUROCHEM, V60, P274, DOI 10.1111/j.1471-4159.1993.tb05848.x; FRANK DA, 1995, CELL, V79, P5; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; IWATA N, 1992, BIOCHEM BIOPH RES CO, V182, P348, DOI 10.1016/S0006-291X(05)80151-2; KIM KS, 1994, J NEUROCHEM, V63, P834; KIM KS, 1993, P NATL ACAD SCI USA, V90, P3471, DOI 10.1073/pnas.90.8.3471; KIM KS, 1993, J BIOL CHEM, V268, P15689; KIM KS, 1995, PRACTICAL APPROACH G, V2, P151; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MIN N, 1994, MOL BRAIN RES, V27, P281, DOI 10.1016/0169-328X(94)90011-6; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Seo HM, 1996, J NEUROSCI, V16, P4102; SHORT JM, 1986, J BIOL CHEM, V261, P9721; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; SURI C, 1993, J NEUROSCI, V13, P1280; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; TANK AW, 1986, MOL PHARMACOL, V30, P497; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; XIE WQ, 1992, MOL CELL BIOL, V12, P1266, DOI 10.1128/MCB.12.3.1266; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	53	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19158	19164		10.1074/jbc.272.31.19158	http://dx.doi.org/10.1074/jbc.272.31.19158			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235905	hybrid			2022-12-25	WOS:A1997XP06300011
J	Munoz, R; Klingenberg, O; Wiedlocha, A; Rapak, A; Falnes, PO; Olsnes, S				Munoz, R; Klingenberg, O; Wiedlocha, A; Rapak, A; Falnes, PO; Olsnes, S			Effect of mutation of cytoplasmic receptor domain and of genistein on transport of acidic fibroblast growth factor into cells	ONCOGENE			English	Article						acidic fibroblast growth factor; receptor mutant; genistein; farnesylation	NUCLEAR TRANSLOCATION SEQUENCE; TYROSINE KINASE-ACTIVITY; FACTOR-I; SIGNAL-TRANSDUCTION; DIPHTHERIA-TOXIN; BALB/C 3T3; PRELAMIN-A; FGF; INTERNALIZATION; LOCALIZATION	Acidic fibroblast growth factor (aFGF) binds to specific transmembrane receptors and is partly transported to a nuclear location, To study this transport we made a kinase-negative mutant of FGF receptor 4 as well as one where the major part of the cytoplasmic receptor domain was deleted, and expressed them in U2OSDr1 cells that lack functional FGF receptors. All receptors mediated endocytic uptake of aFGF. Translocation of the growth factor across cellular membranes was assayed using aFGF with a C-terminal CAAX-motif, which signals addition of a farnesyl group onto the protein once in the cytosol. CAAX-tagged aFGF was farnesylated when incubated with cells containing wild-type or kinase-negative receptors. It was not farnesylated in cells expressing the,deleted receptor, or when the incubation was in the presence of genistein, aFGF incubated with cells transfected with wild-type or kinase-negative receptors, but not with the deleted receptor, was partly recovered from the nuclear fraction in the absence, but not in the presence of genistein. The data indicate that the cytoplasmic receptor domain, but not the active kinase, is required for transport of the growth factor into cells, and that genistein inhibits the process.	NORWEGIAN RADIUM HOSP,INST CANC RES,N-0310 OSLO,NORWAY	University of Oslo			Falnes, Pål Ø./AAA-4581-2020; Rapak, Andrzej/ABE-6262-2021	Rapak, Andrzej/0000-0003-4897-0287; Falnes, Pal/0000-0001-8114-6025; Munoz, Raquel/0000-0001-9861-0349				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAO Y, 1993, J CELL SCI, V104, P77; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DUNN WA, 1980, J BIOL CHEM, V255, P5971; FALLON RJ, 1994, J BIOL CHEM, V269, P11011; FALNES PO, 1995, BIOCHEMISTRY-US, V34, P11152, DOI 10.1021/bi00035a021; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HILL T, 1990, SCIENCE, V248, P1661; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1992, J BIOL CHEM, V267, P5676; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; KOROMA BM, 1994, BIOCHEM PHARMACOL, V48, P809, DOI 10.1016/0006-2952(94)90060-4; LANDGREN E, 1995, ONCOGENE, V10, P2027; LINASSIER C, 1990, BIOCHEM PHARMACOL, V39, P187, DOI 10.1016/0006-2952(90)90664-7; LOMAZE C, 1993, MOL BIOL CELL, V4, P715; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; RIESE J, 1995, MECH DEVELOP, V49, P13, DOI 10.1016/0925-4773(94)00296-Y; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SINENSKY M, 1994, J CELL SCI, V107, P61; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; TROWBRIDGE IS, 1991, CURR OPIN CELL BIOL, V3, P634; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; Vera JC, 1996, J BIOL CHEM, V271, P8719, DOI 10.1074/jbc.271.15.8719; Wiedlocha A, 1995, J BIOL CHEM, V270, P30680, DOI 10.1074/jbc.270.51.30680; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611	53	31	33	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					525	536		10.1038/sj.onc.1201226	http://dx.doi.org/10.1038/sj.onc.1201226			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247306	Green Published			2022-12-25	WOS:A1997XN25500004
J	Lutz, W; Schwab, M				Lutz, W; Schwab, M			In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; N-myc; amplification; gene regulation; E2F; Spl	HUMAN NEURO-BLASTOMA; GROWTH-FACTOR RECEPTOR; LIGATION-MEDIATED PCR; ZINC-FINGER PROTEIN; C-MYC; TRANSCRIPTION FACTOR; IN-VIVO; GENE AMPLIFICATION; BINDING-PROTEIN; NUCLEAR FACTOR	Amplification with subsequent overexpression of N-myc is a recurrent genomic alteration of neuroblastoma cells, DMS-in-vivo-footprinting of the basal promoter of the human N-myc gene (positions -221 to +21) revealed three changes in promoter architecture that are clustered in a 50 bp region and included (1) protein binding to two overlapping E2F-sites, (2) extreme hypersensitivity of guanine -159, and (3) a short stretch of single stranded DNA with a single protected guanine. While in transient assays the basal promoter activated gene expression in all cell lines analysed, the changes at the endogenous promoter were restricted to neuroblastoma cells with strong N-myc expression. The hypersensitivity of guanine -159 could result from protein binding to a flanking, evolutionary conserved 5'-CCTCCC-3'-element, referred to as CT-box, that was bound in vitro in a Zn2+-requiring manner by a protein from nuclear extracts of neuroblastoma cells. Four copies of the CT-box in front of an N-myc minimal promoter (-60 to +18) activated expression of a reporter gene in transient transfections whereas four copies of the mutant element did not. Our data add N-myc to a growing list of mammalian genes with CT-boxes that bind proteins in a Zn2+-dependent manner. Moreover, the data suggest that a common mechanism controls N-myc expression in neuroblastomas irrespective of N-myc copy number, and that in cell lines with amplification all gene copies contribute to N-myc expression.			Lutz, W (corresponding author), GERMAN CANC RES CTR, DEPT CYTOGENET 0825, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY.							AMBER LC, 1989, MOL CELL BIOL, V9, P4903; AMBER LC, 1990, GENE CHROMOSOME CANC, V1, P181; Arts J, 1997, NUCLEIC ACIDS RES, V25, P311, DOI 10.1093/nar/25.2.311; ASSELIN C, 1989, ONCOGENE, V4, P549; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Bennett JD, 1996, ONCOGENE, V13, P1073; Bosher JM, 1996, ONCOGENE, V13, P1701; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Botz J, 1996, MOL CELL BIOL, V16, P3401; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; Brodeur G M, 1985, Prog Clin Biol Res, V175, P105; BUONO P, 1993, FEBS LETT, V328, P243, DOI 10.1016/0014-5793(93)80936-O; CHEN CJ, 1995, CANCER RES, V55, P3873; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; ELDER GA, 1992, MOL BRAIN RES, V15, P99, DOI 10.1016/0169-328X(92)90156-6; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FRENKEL B, 1994, P NATL ACAD SCI USA, V91, P10923, DOI 10.1073/pnas.91.23.10923; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HALL DJ, 1990, ONCOGENE, V5, P47; HARA E, 1993, ONCOGENE, V8, P1023; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILLER S, 1991, ONCOGENE, V6, P969; HIYAMA E, 1991, J PEDIATR SURG, V26, P838, DOI 10.1016/0022-3468(91)90151-I; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HORNSTRA IK, 1992, MOL CELL BIOL, V12, P5345, DOI 10.1128/MCB.12.12.5345; IBSON JM, 1988, ONCOGENE, V2, P399; IMAMURA Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P177, DOI 10.1016/0167-4781(92)90009-O; Ince TA, 1996, CANCER RES, V56, P2021; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEE SJ, 1995, J BIOL CHEM, V270, P16378, DOI 10.1074/jbc.270.27.16378; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI RS, 1994, J BIOL CHEM, V269, P7941; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Lutz W, 1996, ONCOGENE, V13, P803; MAJELLO B, 1995, ONCOGENE, V10, P1841; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; Minucci S, 1996, EMBO J, V15, P888, DOI 10.1002/j.1460-2075.1996.tb00423.x; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; OKAZAWA H, 1991, EMBO J, V10, P2997, DOI 10.1002/j.1460-2075.1991.tb07850.x; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PLET A, 1992, ONCOGENE, V7, P1847; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; QUIVY JP, 1993, NUCLEIC ACIDS RES, V21, P2779, DOI 10.1093/nar/21.11.2779; REIN T, 1994, NUCLEIC ACIDS RES, V22, P3033, DOI 10.1093/nar/22.15.3033; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SADEE W, 1987, CANCER RES, V47, P5207; SAWAI S, 1990, MOL CELL BIOL, V10, P2017, DOI 10.1128/MCB.10.5.2017; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWAB M, 1985, TRENDS GENET, V1, P271, DOI 10.1016/0168-9525(85)90103-9; Schwab M, 1995, NEUROSCIENTIST, V1, P277; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHAPIRO DN, 1993, AM J PATHOL, V142, P1339; Shi YG, 1996, BIOCHEMISTRY-US, V35, P3845, DOI 10.1021/bi952384p; SLAVC I, 1990, CANCER RES, V50, P1459; SMITH RK, 1992, MOL CELL BIOL, V12, P1578, DOI 10.1128/MCB.12.4.1578; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; WADA RK, 1992, ONCOGENE, V7, P711; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WOODRUFF KA, 1995, ONCOGENE, V10, P1335; XU L, 1995, ONCOGENE, V11, P1865; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	93	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					303	315		10.1038/sj.onc.1201195	http://dx.doi.org/10.1038/sj.onc.1201195			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233765	Bronze			2022-12-25	WOS:A1997XK99900007
J	Friedman, SL; Shaulian, E; Littlewood, T; Resnitzky, D; Oren, M				Friedman, SL; Shaulian, E; Littlewood, T; Resnitzky, D; Oren, M			Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells	ONCOGENE			English	Article						p53 tumor suppressor; pRb; hepatocellular carcinoma; apoptosis; differentiation	WILD-TYPE P53; HUMAN HEPATOCELLULAR-CARCINOMA; RETINOBLASTOMA GENE-PRODUCT; HEPATITIS-B VIRUS; MONOCLONAL-ANTIBODIES; IMMUNOCHEMICAL ANALYSIS; ERYTHROLEUKEMIA-CELLS; SUPPRESSOR GENES; PROTEIN; EXPRESSION	Mutations in the tumor suppressor p53 are a common event in hepatocellular carcinoma (HCC), Because HCCs typically occur in livers with chronic injury and impaired function, we have explored the role of mild-type p53 in regulating the growth and differentiation of Hep 3B hepatoma cells, a p53-negative line derived from a liver cancer, Stable Hep 3B cell lines were generated in which inducible p53 was introduced using either a temperature-sensitive mutant (p53val135) or a tamoxifen-regulated p53-estrogen receptor chimera (p53mER(tm)-pBabepuro), In both cell lines, induction of transcriptionally active p53 was confirmed by assessing several p53 targets: Mdm2 protein, p21(waf1) mRNA and protein, and the cyclin G promoter, Despite marked induction of p21(waf1), cells with active p53 failed to undergo growth arrest, which is probably due to the presence of a non-functional retinoblastoma protein (pRb) in these cells, Apoptosis also was not observed, even after prolonged (48 h) serum starvation or exposure to cisplatinum. Lack of apoptosis was correlated with unchanged bax mRNA levels following p53 induction, Additionally, albumin mRNA levels remained unchanged, and there was no change in basal transactivation of a reporter containing the promoter of the haptoglobin gene, encoding an acute phase protein, This suggests that growth arrest may be required to promote liver-specific gene expression, Overall, our data demonstrate that introduction of transcriptionally active p53 does not alter the malignant, dedifferentiated phenotype of Hep 3B hepatoma cells, Hence, not all cancer cells are equally responsive to the re-activation of wild-type 53, The ability of a cancer cell to undergo p53-mediated phenotypic alterations may depend on the retention of functional downstream effector pathways.	IMPERIAL CANC RES FUND,BIOCHEM CELL NUCLEUS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	Friedman, SL (corresponding author), WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL.				NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA40099] Funding Source: Medline; NIDDK NIH HHS [R01 DK37340] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUMANN H, 1987, J BIOL CHEM, V262, P9756; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chojkier M, 1995, Prog Liver Dis, V13, P37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Constance CM, 1996, MOL CELL BIOL, V16, P3878; DOERR R, 1989, CANCER RES, V49, P384; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HOSONO S, 1993, ONCOGENE, V8, P491; HSIA CC, 1994, J MED VIROL, V44, P67, DOI 10.1002/jmv.1890440113; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIYASHITA T, 1995, CELL, V80, P293; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NEVINS JR, 1992, SCIENCE, V258, P424; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PUISIEUX A, 1993, ONCOGENE, V8, P487; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; RAMSEY WH, 1995, DIGEST DIS, V13, P81, DOI 10.1159/000171490; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SEKI S, 1995, HUM PATHOL, V26, P366, DOI 10.1016/0046-8177(95)90135-3; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; TABOR E, 1994, J MED VIROL, V42, P357, DOI 10.1002/jmv.1890420406; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; Vater CA, 1996, ONCOGENE, V13, P739; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHANG X, 1994, CANCER RES, V54, P4177	61	46	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					63	70		10.1038/sj.onc.1201149	http://dx.doi.org/10.1038/sj.onc.1201149			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233778	Bronze			2022-12-25	WOS:A1997XH58600007
J	BenShahar, S; Cassouto, B; Novak, L; Porgador, A; Reiss, Y				BenShahar, S; Cassouto, B; Novak, L; Porgador, A; Reiss, Y			Production of a specific major histocompatibility complex class I-restricted epitope by ubiquitin-dependent degradation of modified ovalbumin in lymphocyte lysate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; PROTEOLYTIC PATHWAY; INTERFERON-GAMMA; 20-S PROTEASOME; PEPTIDES; ANTIGEN; ACTIVATOR; CELLS; PURIFICATION; MOLECULES	Peptide epitopes presented through class I major histocompatability complex (MHC class I) on the cell! surface, are generated by proteolytic processing of protein-antigens in the cytoplasm. The length and amino acid sequence determine whether a given peptide can fit into the peptide binding groove of class I heavy chain molecules and subsequently be presented to the immune system. The mode ai action of the processing pathway Is therefore of great interest. go study the processing mechanism of MHC class I-restricted intracellular antigens, me reconstituted the proteolytic processing of a model antigen in a cell-free system. Incubation of oxidized and urea-treated OVA in lymphocyte lysate resulted in partial degradation of the antigen, Degradation of the antigen depended on the presence of ATP, Addition of methylated ubiquitin abolished the reaction which was then restored by addition of am excess of native ubiquitin, indicating that the breakdown of the antigen in lymphocyte lysate is mediated by the ubiquitin proteolytic system, Upon incubation of modified OVA in lymphocyte lysate, a specific antigenic peptide was generated. The peptide was recognized by cytotoxic T lymphocytes directed against OVA-derived, H-2K(b)-restricted peptide (SIINFEKL), and by st monoclonal antibody that recognizes cell-bound K-b-SIINFEKL complexes. Formation of the peptide epitope depended on the presence of ATP and ubiquitin. These results indicate that proteolytic processing of modified OVA is carried out by the ubiquitin-mediated degradation system. The experimental system described provides a tool to analyze else molecular mechanisms underlying the generation of specific, MHC class I-restricted peptide epitopes.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL; NIAID,LYMPHOCYTE BIOL SECT,IMMUNOL LAB,BETHESDA,MD 20892	Tel Aviv University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Porgador, Angel/0000-0003-1540-4449				AKIYAMA K, 1994, FEBS LETT, V343, P85, DOI 10.1016/0014-5793(94)80612-8; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DICK LR, 1994, J IMMUNOL, V152, P3884; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Frisan T, 1996, INT J CANCER, V68, P251, DOI 10.1002/(SICI)1097-0215(19961009)68:2<251::AID-IJC19>3.0.CO;2-D; GRANT EP, 1995, J IMMUNOL, V155, P3750; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; MA CP, 1994, J BIOL CHEM, V269, P3539; Michalek MT, 1996, J IMMUNOL, V157, P617; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOTT JD, 1994, J BIOL CHEM, V269, P31466; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; REALINI C, 1994, J BIOL CHEM, V269, P20727; RESTIFO NP, 1995, J IMMUNOL, V154, P4414; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P4200, DOI 10.1073/pnas.88.10.4200; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TANAKA K, 1988, J BIOL CHEM, V263, P16209; Tobery TW, 1997, J EXP MED, V185, P909, DOI 10.1084/jem.185.5.909; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	43	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21060	21066		10.1074/jbc.272.34.21060	http://dx.doi.org/10.1074/jbc.272.34.21060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261108	hybrid			2022-12-25	WOS:A1997XR78900018
J	Chatterjee, R; Allen, RM; Ludden, PW; Shah, VK				Chatterjee, R; Allen, RM; Ludden, PW; Shah, VK			In vitro synthesis of the iron-molybdenum cofactor and maturation of the nif-encoded apodinitrogenase - Effect of substitution of VNFH for NIFH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND ALTERNATIVE NITROGENASE; AZOTOBACTER-VINELANDII; MUTATIONAL ANALYSIS; STRUCTURAL GENES; FEMO-COFACTOR; KLEBSIELLA-PNEUMONIAE; VANADIUM NITROGENASE; NUCLEOTIDE-SEQUENCE; PROTEIN; DINITROGENASE	NIFH (the nifH gene product) has several functions in the nitrogenase enzyme system. In addition to reducing dinitrogenase during nitrogenase turnover, NIFH functions in the biosynthesis of the iron-molybdenum cofactor (FeMo-co), and in the processing of alpha(2) beta(2) apodinitrogenase 1 (a catalytically inactive form of dinitrogenase 1 that lacks the FeMo-co) to the FeMo-co-activatable alpha(2) beta(2) gamma(2) form, The molybdenum-independent nitrogenase 2 (unf-encoded) has a distinct dinitrogenase reductase protein, VNFH, We investigated the ability of VNFH to function in the in vitro biosynthesis of FeMo-co and in the maturation of apodinitrogenase 1. VNFH can replace NIFH in both the biosynthesis of FeMo-co and in the maturation of apodinitrogenase 1. These results suggest that the dinitrogenase reductase proteins do not specify the heterometal incorporated into the cofactors of the respective nitrogenase enzymes, The specificity for the incorporation of molybdenum into FeMo-co was also examined using the in vitro FeMo-co synthesis assay system.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA; UNIV WISCONSIN, COLL AGR & LIFE SCI, CTR STUDY NITROGEN FIXAT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM35332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; Allen RM, 1996, J BIOL CHEM, V271, P4256; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; ARBER JM, 1989, BIOCHEM J, V258, P733, DOI 10.1042/bj2580733; BISHOP PE, 1990, ANNU REV PLANT PHYS, V41, P109; BISHOP PE, 1986, SCIENCE, V232, P92, DOI 10.1126/science.232.4746.92; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CHATTERJEE R, 1994, J BACTERIOL, V176, P2747, DOI 10.1128/JB.176.9.2747-2750.1994; Chatterjee R, 1996, J BIOL CHEM, V271, P6819, DOI 10.1074/jbc.271.12.6819; CHISNELL JR, 1988, J BACTERIOL, V170, P27, DOI 10.1128/jb.170.1.27-33.1988; Davis R, 1996, J BACTERIOL, V178, P1445, DOI 10.1128/jb.178.5.1445-1450.1996; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; EADY RR, 1991, ADV INORG CHEM, V36, P77, DOI 10.1016/S0898-8838(08)60037-9; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GOLLAN U, 1993, EUR J BIOCHEM, V215, P25, DOI 10.1111/j.1432-1033.1993.tb18003.x; HALES BJ, 1986, J BIOL CHEM, V261, P5301; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; JOERGER RD, 1986, J BACTERIOL, V168, P673, DOI 10.1128/jb.168.2.673-682.1986; JOERGER RD, 1990, J BACTERIOL, V172, P3400, DOI 10.1128/jb.172.6.3400-3408.1990; JOERGER RD, 1989, J BACTERIOL, V171, P1075, DOI 10.1128/jb.171.2.1075-1086.1989; KENNEDY C, 1992, MOL GEN GENET, V231, P494, DOI 10.1007/BF00292722; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LUDDEN PW, 1978, BIOCHEM J, V175, P251, DOI 10.1042/bj1750251; LUQUE F, 1991, MOL GEN GENET, V227, P481, DOI 10.1007/BF00273941; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V292, P246, DOI 10.1016/0005-2728(73)90269-7; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; SMITH BE, 1988, BIOCHEM J, V250, P299, DOI 10.1042/bj2500299; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; UGALDE RA, 1985, J BACTERIOL, V164, P1081, DOI 10.1128/JB.164.3.1081-1087.1985; WOLFINGER ED, 1991, J BACTERIOL, V173, P7565, DOI 10.1128/jb.173.23.7565-7572.1991; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; Wright DW, 1996, J BIOL INORG CHEM, V1, P143, DOI 10.1007/s007750050033	42	19	22	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21604	21608		10.1074/jbc.272.34.21604	http://dx.doi.org/10.1074/jbc.272.34.21604			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261182	hybrid			2022-12-25	WOS:A1997XR78900092
J	Zhang, DH; Cohn, L; Ray, P; Bottomly, K; Ray, A				Zhang, DH; Cohn, L; Ray, P; Bottomly, K; Ray, A			Transcription factor GATA-3 is differentially expressed murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CD4+ LYMPHOCYTES-T; RECEPTOR-ALPHA; MESSENGER-RNA; ASTHMA; ENHANCER; CAMP; PROMOTER; ELEMENTS; ANTIGEN	Interleukin-5 (IL-5), which is produced by CD4(+) T helper 2 (Th2) cells, but not by Th1 cells, plays a key role in the development of eosinophilia in asthma. Despite increasing evidence that the outcome of many diseases is determined by the ratio of the two subsets of CD4(+) T helper cells, Th1 and Th2, the molecular basis for Th1- and Th2-specific gene expression remains to be elucidated. We previously established a critical role for the transcription factor GATA-3 in IL-5 promoter activation in EL-4 cells, which express both Th1- and Th2-type cytokines. Our studies reported here demonstrate that GATA-3 is critical for expression of the IL-5 gene in bona fide Th2 cells, Whereas mutations in the GATA-3 site abolished antigen- or cAMP-stimulated IL-5 promoter activation in Th2 cells, ectopic expression of GATA-3 in Th1 cells or in a nonlymphoid, non-IL-5-producing cell line activated the IL-5 promoter. During the differentiation of naive CD4(+) T cells isolated from T cell receptor transgenic mice, GATA-3 gene expression was up-regulated in developing Th2 cells, but was down-regulated in Th1 cells, and antigen- or cAMP-activated Th2 cells (but not Th1 cells) expressed the GATA-3 protein. Thus, GATA-3 may play an important role in the balance between Th1 and Th2 subsets in immune responses. Inhibition of GATA-3 activity has therapeutic potential in the treatment of asthma and other hypereosinophilic diseases.	YALE UNIV, SCH MED, DEPT INTERNAL MED, PULM & CRIT CARE SECT, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, IMMUNOBIOL SECT, NEW HAVEN, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University; Yale University					NHLBI NIH HHS [P50 HL56389, HL52014] Funding Source: Medline; NIAID NIH HHS [AI31137] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056389, R29HL052014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031137] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Amato SF, 1996, J IMMUNOL, V157, P146; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BOHJANEN PR, 1990, P NATL ACAD SCI USA, V87, P5283, DOI 10.1073/pnas.87.14.5283; BOTTOMLY K, 1988, IMMUNOL TODAY, V9, P268, DOI 10.1016/0167-5699(88)91308-4; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; DAVYDOV IV, 1995, J IMMUNOL, V155, P5273; Feuerstein N, 1996, J IMMUNOL, V156, P4582; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FRICK WE, 1989, AM REV RESPIR DIS, V139, P1401, DOI 10.1164/ajrccm/139.6.1401; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; Hattori N, 1996, J EXP MED, V184, P1137, DOI 10.1084/jem.184.3.1137; HENDERSON AJ, 1994, MOL CELL BIOL, V14, P4286, DOI 10.1128/MCB.14.6.4286; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KAMEI T, 1993, AM J RESP CELL MOL, V9, P378, DOI 10.1165/ajrcmb/9.4.378; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; KRISHNASWAMY G, 1993, AM J RESP CELL MOL, V9, P279, DOI 10.1165/ajrcmb/9.3.279; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE HJ, 1993, J IMMUNOL, V151, P6135; LiWeber M, 1997, J IMMUNOL, V158, P1194; MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; Nakamura T, 1997, J IMMUNOL, V158, P1085; NOMA T, 1989, J EXP MED, V169, P1853, DOI 10.1084/jem.169.5.1853; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RAY A, 1991, P NATL ACAD SCI USA, V88, P7086, DOI 10.1073/pnas.88.16.7086; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; SMITH VM, 1995, J BIOL CHEM, V270, P1515, DOI 10.1074/jbc.270.4.1515; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; TAMIR A, 1994, J IMMUNOL, V152, P3391; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; WALKER C, 1991, J IMMUNOL, V146, P1829; Wenner CA, 1997, J IMMUNOL, V158, P765; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830	55	541	565	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21597	21603		10.1074/jbc.272.34.21597	http://dx.doi.org/10.1074/jbc.272.34.21597			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261181	hybrid			2022-12-25	WOS:A1997XR78900091
J	Alperin, ES; Shapiro, LJ				Alperin, ES; Shapiro, LJ			Characterization of point mutations in patients with X-linked ichthyosis - Effects on the structure and function of the steroid sulfatase protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARYLSULFATASE-B; FULL-LENGTH CDNA; NUCLEOTIDE-SEQUENCE; FREQUENT OCCURRENCE; SHORT ARM; EXPRESSION; CLONING; DEFICIENCY; DELETIONS; DNA	X-linked ichthyosis is the result of steroid sulfatase (STS) deficiency, While most affected individuals have extensive deletions of the STS gene, point mutations have been reported in three patients (1), In this study, we identify an additional three point mutations and characterize the effects of all six mutations on STS activity and expression. All six are unique single base pair substitutions, The mutations are located in a 105-amino acid region of the C-terminal half of the polypeptide, Five of the six mutations involve the substitutions of Pro or Arg for Trp(372), Arg for His(444), Tyr for Cys(446), or Leu for Cys(341). The other mutation is in a splice junction and results in a frameshift causing premature termination of the polypeptide at residue 427. All the affected residues are conserved to some degree within the sulfatase family, The six mutations were reproduced in normal STS cDNA and transiently expressed in STS-deficient cells. All six mutant vectors direct the expression of STS protein that lacks enzymatic activity, The mutant polypeptides show a shift in mobility on SDS-PAGE and resistance to proteinase K digestion when translated in the presence of dog pancreas microsomes, indicating glycosylation and normal translocation.	UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California Los Angeles					NIGMS NIH HHS [9ROI GM54907-17] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054907] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alperin E. S., 1994, American Journal of Human Genetics, V55, pA209; BALLABIO A, 1987, P NATL ACAD SCI USA, V84, P4519, DOI 10.1073/pnas.84.13.4519; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; BALLABIO A, 1989, GENOMICS, V4, P36, DOI 10.1016/0888-7543(89)90311-X; BALLABIO A, 1995, METABOLIC MOL BASES, P2999; BASLER E, 1990, AM J HUM GENET, V47, pA150; BONIFAS JM, 1987, P NATL ACAD SCI USA, V84, P9248, DOI 10.1073/pnas.84.24.9248; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONARY JT, 1987, BIOCHEM BIOPH RES CO, V144, P1010, DOI 10.1016/S0006-291X(87)80064-5; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; GILLARD EF, 1987, NUCLEIC ACIDS RES, V15, P3977, DOI 10.1093/nar/15.10.3977; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; Harlow E., 1988, ANTIBODIES LAB MANUA; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; HU ALW, 1920, FOCUS, V13, P26; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOLODNY EH, 1995, METABOLIC MOL BASES, V2, P2693; Li XM, 1996, SOMAT CELL MOLEC GEN, V22, P105, DOI 10.1007/BF02369901; Li XM, 1996, MAMM GENOME, V7, P420, DOI 10.1007/s003359900125; LI XM, 1992, NUCLEIC ACIDS RES, V20, P1117, DOI 10.1093/nar/20.5.1117; Maniatis T., 1982, MOL CLONING; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEUFELD EF, 1995, METABOLIC MOL BASIS, V2, P2645; PETERS C, 1990, J BIOL CHEM, V265, P3374; ROBERTSON DA, 1988, BIOCHEM BIOPH RES CO, V157, P218, DOI 10.1016/S0006-291X(88)80035-4; SALIDO EC, 1990, J CLIN ENDOCR METAB, V70, P1564, DOI 10.1210/jcem-70-6-1564; Salido EC, 1996, NAT GENET, V13, P83, DOI 10.1038/ng0596-83; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1988, EUR J BIOCHEM, V177, P9, DOI 10.1111/j.1432-1033.1988.tb14338.x; SCHUCHMAN EH, 1990, GENOMICS, V6, P149, DOI 10.1016/0888-7543(90)90460-C; SHAPIRO LJ, 1977, PEDIATR RES, V11, P894, DOI 10.1203/00006450-197708000-00008; SHAPIRO LJ, 1989, P NATL ACAD SCI USA, V86, P8477, DOI 10.1073/pnas.86.21.8477; SHAPIRO LJ, 1985, ADV HUM GENET, V14, P331; STEIN C, 1989, J BIOL CHEM, V264, P13865; STEIN C, 1989, J BIOL CHEM, V264, P1252; TOMATSU S, 1991, BIOCHEM BIOPH RES CO, V181, P677, DOI 10.1016/0006-291X(91)91244-7; VANDERLOOS CM, 1984, J INHERIT METAB DIS, V7, P97, DOI 10.1007/BF01801762; WILLEMSEN R, 1988, HISTOCHEM J, V20, P41, DOI 10.1007/BF01745968; WILSON PJ, 1990, P NATL ACAD SCI USA, V87, P8531, DOI 10.1073/pnas.87.21.8531; YANG Q, 1989, DEV BIOL, V135, P53, DOI 10.1016/0012-1606(89)90157-7; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q; YEN PH, 1987, CELL, V49, P443, DOI 10.1016/0092-8674(87)90447-8	44	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20756	20763		10.1074/jbc.272.33.20756	http://dx.doi.org/10.1074/jbc.272.33.20756			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252398	hybrid			2022-12-25	WOS:A1997XR22100068
J	Han, J; Ohno, N; Pasco, S; Monboisse, JC; Borel, JP; Kefalides, NA				Han, J; Ohno, N; Pasco, S; Monboisse, JC; Borel, JP; Kefalides, NA			A cell binding domain from the alpha 3 chain of type IV collagen inhibits proliferation of melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; GOODPASTURE ANTIGEN; IDENTIFICATION; ACTIVATION; ADHESION; LAMININ; PEPTIDE	Our previous studies have shown that a peptide corresponding to the residue sequence 185-203 of the NC1 domain of the alpha 3 chain of basement membrane collagen (type IV) inhibits the activation of polymorphonuclear leukocytes. Peptides from the same region of the alpha 1, alpha 2, alpha 4, and alpha 5(TV) chains did not exhibit this property, Because of the intimate relationship between metastasizing neoplastic cells and vascular as well as epithelial basement membranes, we measured the cell adhesion-promoting activity of peptides from the NC1 domain of type IV collagen and their effect on proliferation of human melanoma cells, We found that peptide alpha 3(IV)185-203 (CNYYSNSYSFWLASLNPER) not only promotes adhesion of human melanoma cells but also inhibits their proliferation. Adhesion increased by 50-60% over control. Melanoma cell proliferation was inhibited by 40% when cells were grown in a medium containing 5 mu g/ml peptide for 5 days, Studies showed that replacement of serine in position 189 or 191 by alanine resulted in significantly reduced adhesion. Similarly, serine replace ment resulted in reduced ability to inhibit proliferation. Our data suggest that a region of the NC1 domain of the alpha 3(TV) chain, contained within the sequence 185-203, not-only specifically promotes adhesion but also inhibits proliferation of melanoma cells. These properties appear to be dependent on the presence of the triplet sequence -SNS- (residues 189-191), which is unique to the alpha 3 chain and may represent an important functional epitope.	UNIV PENN,UNIV CITY SCI CTR,CTRI,DEPT MED,PHILADELPHIA,PA 19104; UNIV REIMS,CNRS EP89,BIOCHEM LAB,F-51095 REIMS,FRANCE	University of Pennsylvania; Universite de Reims Champagne-Ardenne				Brassart-Pasco, Sylvie/0000-0002-1340-7868	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553, T32AR007490] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29492] Funding Source: Medline; NIAMS NIH HHS [AR-07490, AR-20553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARANY G, 1980, PEPTIDES, V12, P1; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; CHARONIS AS, 1985, J CELL BIOL, V100, P1848, DOI 10.1083/jcb.100.6.1848; CHELBERG MK, 1989, CANCER RES, V49, P4796; CHELBERG MK, 1990, J CELL BIOL, V111, P261, DOI 10.1083/jcb.111.1.261; ENGVALL E, 1972, J IMMUNOL, V109, P129; FENG LL, 1994, J BIOL CHEM, V269, P2342; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; KEFALIDES NA, 1993, KIDNEY INT, V43, P94, DOI 10.1038/ki.1993.16; LAUNE JM, 1986, METHOD ENZYMOL, V121, P183; LAURIE GW, 1986, J MOL BIOL, V189, P205, DOI 10.1016/0022-2836(86)90391-8; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MONBOISSE JC, 1994, J BIOL CHEM, V269, P25475; RAO CN, 1990, BIOCHEMISTRY-US, V29, P6769; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; SAUS J, 1988, J BIOL CHEM, V263, P13374; SHAHAN TA, 1996, MOL BIOL CELL, V7, P415; TSILIBARY EC, 1990, J CELL BIOL, V111, P1583, DOI 10.1083/jcb.111.4.1583; TYAGI SR, 1991, J BIOL CHEM, V266, P3498; ZHOU J, 1994, J BIOL CHEM, V269, P13193	24	80	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20395	20401		10.1074/jbc.272.33.20395	http://dx.doi.org/10.1074/jbc.272.33.20395			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252346	hybrid			2022-12-25	WOS:A1997XR22100016
J	Lee, HC; Aarhus, R				Lee, HC; Aarhus, R			Structural determinants of nicotinic acid adenine dinucleotide phosphate important for its calcium-mobilizing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; INOSITOL TRISPHOSPHATE; METABOLITE; ENZYME; NAD+	Nicotinic acid adenine dinucleotide phosphate (NAADP) mobilizes Ca2+ through a mechanism totally independent of cyclic ADP-ribose or inositol trisphosphate, The structural determinants important for its Ca2+ release activity were investigated using a series of analogs, It is shown that changing the S-carboxyl group of the nicotinic acid (NA) moiety in NAADP to either an uncharged carbinol or from the 3-position to the 4-position of the pyridine ring totally eliminates the Ca2+ release activity, Conversion of the 3-carboxyl to other negatively charged groups, either 3-sulfonate, 3-acetate, or 3-quinoline carboxylate, retains the Ca2+ release activity, although their half-maximal effective concentrations (EC50) are 100-200-fold higher, Changing the 6-amino group of the adenine to a hydroxyl group results in more than a 1000-fold decrease in the Ca2+ release activity, Conversion of the 2'-phosphate to 2',3'-cyclic phosphate or 3'-phosphate likewise increases the EC50 by about 5- and 20-fold, respectively, Similar to NAADP, all of the active analogs can also desensitize the Ca2+ release mechanism at subthreshold concentrations, suggesting that this novel property is intrinsic to the release mechanism, The series of analogs used was produced by using ADP-ribosyl cyclase to catalyze the exchange of the nicotinamide group of various analogs of NADP with various analogs of NA. An important determinant in NA that is crucial to the base exchange reaction was shown to be the a-position of the pyridine ring, Neither pyridine-2-carboxylate nor 2-methyl-NA support the exchange reaction, The negative charge and the position of the 3-carboxyl group are nonessential since both pyridine-3-carbinol and pyridine-4-carboxylate support the base exchange reaction, In addition to the information on the structure-activity relationships of NAADP and NA, this study also demonstrates the utility of the base exchange reaction as a general approach for synthesizing NAADP analogs.			Lee, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,LYON LAB 6 182,MINNEAPOLIS,MN 55455, USA.		Lee, Hon Cheung/C-4329-2009		NICHD NIH HHS [HD17484] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Graeff RM, 1996, BIOCHEMISTRY-US, V35, P379, DOI 10.1021/bi952083f; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lee HC, 1997, METHOD ENZYMOL, V280, P331; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; Lee HC, 1996, RECENT PROG HORM RES, V51, P355; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; Prasad GS, 1996, PROTEINS, V24, P138, DOI 10.1002/(SICI)1097-0134(199601)24:1<138::AID-PROT10>3.3.CO;2-K; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; RUSINKO N, 1989, J BIOL CHEM, V264, P11725	16	48	50	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20378	20383		10.1074/jbc.272.33.20378	http://dx.doi.org/10.1074/jbc.272.33.20378			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252343	hybrid			2022-12-25	WOS:A1997XR22100013
J	Plaas, AHK; WongPalms, S; Roughley, PJ; Midura, RJ; Hascall, VC				Plaas, AHK; WongPalms, S; Roughley, PJ; Midura, RJ; Hascall, VC			Chemical and immunological assay of the nonreducing terminal residues of chondroitin sulfate from human aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; SYNOVIAL-FLUID; MONOCLONAL-ANTIBODIES; PROTEOGLYCANS; SERUM; GLYCOSAMINOGLYCANS; DETERMINANTS; CHAINS; OLIGOSACCHARIDES; OSTEOARTHRITIS	Samples of aggrecan chondroitin sulfate, isolated from normal human knee cartilages of individuals from fetal to 72 years of age, were digested with chondroitin lyases, The products were analyzed by fluorescence-based anion exchange high performance liquid chromatography to separate and quantitate nonreducing terminal structures, in addition to internal unsaturated disaccharide products, The predominant terminal structures mere the monosaccharides, GalNAc4S and GalNAc4,6S as they were present on 85-90% of all chains. The remaining chains terminated with the disaccharides GlcA beta 1,3GalNAc4S and GlcA beta 1,3GalNAc6S. Marked changes in the relative abundance of these terminals were identified in the transition from growth cartilage to adult articular cartilage, First, terminal GalNAc residues were almost exclusively 4-sulfated in aggrecan from fetal through 15 years of age, but were similar to 50% 4,6-disulfated in aggrecans from adults (22-72 years of age). Second, the terminal disaccharide GlcA beta 1,3GalNAc4S was on similar to 7% of chains on aggrecan from fetal through 15 years of age, but on only similar to 3% of chains on adult aggrecan. In contrast, the proportion of chains terminating in GlcA beta 1,3GalNAc6S, similar to 9%, was unchanged from fetal to 72 years of age, This terminal disaccharide is proposed to be recognized by the widely used monoclonal antibody 3B3, However, chemical quantitation of the structure together with solid phase 3B3(-) immunoassay of fetal and adult aggrecans showed that the content of the terminal disaccharide does not necessarily correlate with immunoreactivity of the proteoglycan, as chain density and presentation on the solid phase are critical factors for recognition of chain terminals by 3B3. The quantitative results obtained from chemical analyses of all nonreducing termini of aggrecan chondroitin sulfate chains revealed important changes in chain termination that occur when cellular activities are altered as adult articular cartilage is formed after removal of growth cartilage, These findings are discussed in relation to specific enzymatic steps that generate the nonreducing termini of chains in the biosynthesis pathway of chondroitin sulfate proteoglycans and their modulation in tissue development and pathology.	UNIV S FLORIDA,SCH MED,DEPT BIOCHEM & MOL BIOL,TAMPA,FL 33612; SHRINERS HOSP CRIPPLED CHILDREN,GENET UNIT,MONTREAL,PQ H3G 1A6,CANADA; CLEVELAND CLIN FDN,DEPT BIOMED ENGN,CLEVELAND,OH 44106	State University System of Florida; University of South Florida; McGill University; Cleveland Clinic Foundation	Plaas, AHK (corresponding author), SHRINERS HOSP CRIPPLED CHILDREN,CELL BIOL LAB,12502 N PINE DR,TAMPA,FL 33612, USA.							Archer CW, 1996, J ANAT, V189, P23; BAKER JR, 1991, BIOCHEM J, V273, P237, DOI 10.1042/bj2730237; Bayliss MT, 1995, ACTA ORTHOP SCAND, V66, P22, DOI 10.3109/17453679509157642; BUSCHMANN MD, 1995, J BIOMECH ENG-T ASME, V117, P179, DOI 10.1115/1.2796000; BYERS S, 1992, J HISTOCHEM CYTOCHEM, V40, P275, DOI 10.1177/40.2.1372629; CARDOSO LEM, 1992, LAB INVEST, V67, P588; CARLSON CS, 1995, J ORTHOP RES, V13, P399, DOI 10.1002/jor.1100130314; CATERSON B, 1990, J CELL SCI, V97, P411; CATERSON B, 1995, OSTEOARTHRITIC DISOR, P315; CHRISTNER JE, 1980, J BIOL CHEM, V255, P7102; COUCHMAN JR, 1984, MATRICES CELL DIFFER, P31; DEUTSCH AJ, 1995, J ORTHOPAED RES, V13, P230, DOI 10.1002/jor.1100130211; EVANKO SP, 1993, ARCH BIOCHEM BIOPHYS, V307, P153, DOI 10.1006/abbi.1993.1574; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; HARDINGHAM TE, 1994, CARBOHYD RES, V255, P241, DOI 10.1016/S0008-6215(00)90982-0; HASCALL VC, 1995, ADV EXP MED BIOL, V376, P205; INOUE H, 1986, J BIOL CHEM, V261, P4470; JENKINS RB, 1981, J BIOL CHEM, V256, P8279; KARAMANOS NK, 1995, ARCH BIOCHEM BIOPHYS, V316, P100, DOI 10.1006/abbi.1995.1015; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; KOVACK IS, 1994, BIOPHYS CHEM, V53, P181; MIDURA RJ, 1995, J BIOL CHEM, V270, P8009, DOI 10.1074/jbc.270.14.8009; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; PELLETIER JP, 1992, J ORTHOPAED RES, V10, P511, DOI 10.1002/jor.1100100406; Plaas AHK, 1996, GLYCOBIOLOGY, V6, P823, DOI 10.1093/glycob/6.8.823; POOLE AR, 1994, J CLIN INVEST, V94, P25, DOI 10.1172/JCI117314; RATCLIFFE A, 1993, ARTHRITIS RHEUM, V36, P543, DOI 10.1002/art.1780360416; RODEN L, 1980, BIOCH GLYCOPROTEINS, P39; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; ROUGHLEY PJ, 1987, PEDIATR RES, V22, P406; SCHONHERR E, 1993, ARTERIOSCLER THROMB, V13, P1026, DOI 10.1161/01.ATV.13.7.1026; SILBERT JE, 1978, J BIOL CHEM, V253, P6888; SLATER RR, 1995, ARTHRITIS RHEUM-US, V38, P655, DOI 10.1002/art.1780380513; SNOWDEN JM, 1976, BIOCHIM BIOPHYS ACTA, V428, P726; Sorrell JM, 1996, INT J DEV NEUROSCI, V14, P233, DOI 10.1016/0736-5748(96)00010-X; SZABO G, 1995, ARTHRITIS RHEUM, V38, P660; THONAR EJMA, 1986, J BIOL CHEM, V261, P2467; VANDENBERG WB, 1986, CLIN IMMUNOL IMMUNOP, V39, P187, DOI 10.1016/0090-1229(86)90083-8; VILIM V, 1994, BIOCHEM J, V304, P887, DOI 10.1042/bj3040887; VISCO DM, 1993, ARTHRITIS RHEUM, V36, P1718, DOI 10.1002/art.1780361211; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146	42	121	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20603	20610		10.1074/jbc.272.33.20603	http://dx.doi.org/10.1074/jbc.272.33.20603			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252375	hybrid			2022-12-25	WOS:A1997XR22100045
J	Armbruster, DW; Daniels, CJ				Armbruster, DW; Daniels, CJ			Splicing of intron-containing tRNATrp by the archaeon Haloferax volcanii occurs independent of mature tRNA structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA INTRON; ARCHAEBACTERIUM-DESULFUROCOCCUS-MOBILIS; HALOBACTERIUM-VOLCANII; EXTREME THERMOPHILE; SUBSTRATE RECOGNITION; STABLE RNA; ENDONUCLEASE; GENES; TRANSCRIPTION; PURIFICATION	We have investigated the requirements for mature tRNA structure in the in vivo splicing of the Haloferax volcanii, intron-containing tRNATrp RNA. A partial tRNATrp gene, which contained only the anticodon stem-loop region of the mature tRNA, Tvas fused to a carrier yeast tRNA gene far expression ins H, volcanii. Transcripts from this hybrid gene were found to be processed by endonuclease and ligase at the tRNATrp exon-intron boundaries, These results verify that the substrate recognition properties of the halobacterial endonuclease observed in vitro reflect the properties of this enzyme in vivo, namely that mature tRNA structure is not essential for recognition by the endonuclease. The independence of these reactions on mature tRNA provides further support for a relationship between archaeal tRNA and rRNA intron-processing systems and highlight a difference in the substrate recognition properties between the archaeal and eucaryal processing systems. The significance of these differences is discussed in light of the observation that the tRNA endonucleases of these organisms are related.	OHIO STATE UNIV,DEPT MICROBIOL,COLUMBUS,OH 43210	Ohio State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048665] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48665-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APIRION D, 1993, BIOESSAYS, V15, P113, DOI 10.1002/bies.950150207; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHARLEBOIS RL, 1987, P NATL ACAD SCI USA, V84, P8530, DOI 10.1073/pnas.84.23.8530; DALGAARD JZ, 1993, P NATL ACAD SCI USA, V90, P5414, DOI 10.1073/pnas.90.12.5414; DALGAARD JZ, 1994, J BIOL CHEM, V269, P28885; DANIELS CJ, 1985, J BIOL CHEM, V260, P3132; DATTA PK, 1989, CAN J MICROBIOL, V35, P189, DOI 10.1139/m89-029; GARRETT RA, 1991, TRENDS BIOCHEM SCI, V16, P22, DOI 10.1016/0968-0004(91)90011-J; GARRETT RA, 1994, SYST APPL MICROBIOL, V16, P680; HOLMES ML, 1991, J BACTERIOL, V173, P3807, DOI 10.1128/JB.173.12.3807-3813.1991; KAINE BP, 1987, J MOL EVOL, V25, P248, DOI 10.1007/BF02100018; KAINE BP, 1983, P NATL ACAD SCI-BIOL, V80, P3309, DOI 10.1073/pnas.80.11.3309; KAY R, 1987, NUCLEIC ACIDS RES, V15, P2778, DOI 10.1093/nar/15.6.2778; KJEMS J, 1989, CAN J MICROBIOL, V35, P210, DOI 10.1139/m89-033; KJEMS J, 1988, CELL, V54, P693, DOI 10.1016/S0092-8674(88)80014-X; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P439, DOI 10.1073/pnas.88.2.439; KJEMS J, 1989, J BIOL CHEM, V264, P17834; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; LYKKEANDERSEN J, 1994, NUCLEIC ACIDS RES, V22, P4583, DOI 10.1093/nar/22.22.4583; LYKKEANDERSEN J, 1994, J MOL BIOL, V243, P846, DOI 10.1006/jmbi.1994.1687; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; NIEUWLANDT DT, 1990, J BACTERIOL, V172, P7104, DOI 10.1128/jb.172.12.7104-7110.1990; NIEUWLANDT DT, 1993, MOL MICROBIOL, V8, P93, DOI 10.1111/j.1365-2958.1993.tb01206.x; PALMER JR, 1995, J BACTERIOL, V177, P1844, DOI 10.1128/jb.177.7.1844-1849.1995; PALMER JR, 1994, J BACTERIOL, V176, P3820, DOI 10.1128/JB.176.12.3820-3823.1994; PERKINS KK, 1985, P NATL ACAD SCI USA, V82, P684, DOI 10.1073/pnas.82.3.684; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; THOMPSON LD, 1988, J BIOL CHEM, V263, P17951; THOMPSON LD, 1990, J BIOL CHEM, V265, P18104; THOMPSON LD, 1989, CAN J MICROBIOL, V35, P36, DOI 10.1139/m89-006; THOMPSON LD, 1990, THESIS OHIO STAT U; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; Westaway Shawn K., 1995, P79; WICH G, 1987, EMBO J, V6, P523, DOI 10.1002/j.1460-2075.1987.tb04784.x	37	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19758	19762		10.1074/jbc.272.32.19758	http://dx.doi.org/10.1074/jbc.272.32.19758			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242634	hybrid			2022-12-25	WOS:A1997XQ05900021
J	Ferry, AE; Baliga, SB; Monteiro, C; Pace, BS				Ferry, AE; Baliga, SB; Monteiro, C; Pace, BS			Globin gene silencing in primary erythroid cultures - An inhibitory role for interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; DOMINANT CONTROL REGION; SMALL MAF PROTEINS; CELL-LINE K562; MEGAKARYOBLASTIC DIFFERENTIATION; MEGAKARYOCYTIC DIFFERENTIATION; RECOMBINANT INTERLEUKIN-6; BINDING PROTEINS; DNA-BINDING; EXPRESSION	There are numerous similarities between the erythroid and megakaryocytic lineages which suggest that commitment to either lineage occurs relatively late in hematopoiesis. Commitment toward megakaryocyte development requires obligatory silencing of erythroid-specific genes, Therefore, we investigated the effects of interleukin-6, a known inducer of thrombocyte production, on globin gene expression during erythroid differentiation, Studies in K562 cells demonstrated inhibition of gamma globin gene mRNA production and chain biosynthesis in the presence of exogenous interleukin-6 which was abrogated by anti-interleukin-6 monoclonal antibody, Similar studies in primary erythroid progenitors showed inhibition of burst-forming unit-erythroid colony formation when interleukin-6 was added late in cultures with decreased gamma and beta globin gene mRNA production. Protein binding studies demonstrated an increase in activator protein-1 binding to its consensus sequence by 24 h of interleukin-6 treatment, Inhibition of activator protein-1 gene activity had no effect on gamma gene silencing by interleukin-6. A potential interleukin-6 response element was identified in the gamma globin gene, Interleukin-6 treatment led to a rapid increase in protein binding to the target DNA sequence. These results suggest that interleukin-fi may play an important role in globin gene silencing during megakaryocytic lineage commitment.	UNIV S ALABAMA,DEPT CELLULAR & STRUCT BIOL,MOBILE,AL 36688; UNIV S ALABAMA,DEPT PEDIAT,MOBILE,AL 36688	University of South Alabama; University of South Alabama					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038639] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38639-09] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALITALO R, 1988, BLOOD, V71, P899; ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; ARONSON FR, 1993, P AN M AM SOC CLIN, V12, P292; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNO E, 1989, EXP HEMATOL, V17, P1038; CARRINGTON PA, 1991, BLOOD, V77, P34; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; DAI W, 1993, BLOOD, V81, P1214; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GORDON MS, 1993, BLOOD S1, V82, P318; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HATTORI M, 1993, AM J PHYSIOL, V264, pG95; HILL RJ, 1991, BLOOD, V77, P42; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; JELKMANN WEB, 1994, ANN NY ACAD SCI, V718, P300; JIMINEZ G, 1992, P NATL ACAD SCI USA, V89, P10618; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LONGMORE GD, 1993, BLOOD, V82, P2386; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MOUTHON MA, 1993, BLOOD, V81, P647; MURATE T, 1993, EXP CELL RES, V208, P35, DOI 10.1006/excr.1993.1219; NAVARRO S, 1991, EXP HEMATOL, V19, P11; NAVARRO S, 1991, BLOOD, V77, P461; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PAPAYANNOPOULOU T, 1987, J CLIN INVEST, V79, P859, DOI 10.1172/JCI112895; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHELTON JB, 1985, HEMOGLOBIN, V9, P325, DOI 10.3109/03630268508997008; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SOLOMON WB, 1993, J BIOL CHEM, V268, P5089; SORRENTINO B, 1990, NUCLEIC ACIDS RES, V18, P2721, DOI 10.1093/nar/18.9.2721; Stamatoyannopolous G., 1994, MOL BASIS BLOOD DIS, P107; SUDA T, 1983, P NATL ACAD SCI-BIOL, V80, P6689, DOI 10.1073/pnas.80.21.6689; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; VAINCHENKER W, 1982, BLOOD, V59, P514; WARREN MK, 1989, EXP HEMATOL, V17, P1095; WILLIAMS N, 1990, EXP HEMATOL, V18, P69; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	59	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20030	20037		10.1074/jbc.272.32.20030	http://dx.doi.org/10.1074/jbc.272.32.20030			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242673	hybrid			2022-12-25	WOS:A1997XQ05900060
J	Hyatt, SL; Aulak, KS; Malandro, M; Kilberg, MS; Hatzoglou, M				Hyatt, SL; Aulak, KS; Malandro, M; Kilberg, MS; Hatzoglou, M			Adaptive regulation of the cationic amino acid transporter-1 (Cat-1) in Fao cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETASE GENE-EXPRESSION; RAT HEPATOMA-CELLS; MESSENGER-RNA; ASPARAGINE SYNTHETASE; SYSTEM-A; C-FOS; PROTEINS; LIVER; IDENTIFICATION; SPECIFICITY	The regulation of the high affinity cationic amino acid transporter Cat-1 in Fao rat hepatoma cells by amino acid availability has been studied, Cat-1 mRNA level increased (3-fold) in 4 h in response to amino acid starvation and remained high for at least 24 h, This induction was independent of the presence of serum in the media and transcription and protein synthesis were required for induction to occur, When Fao cells were shifted from amino acid-depleted media to amino acid-fed media, the levels of the induced cat-1 mRNA returned to the basal level, In amino acid-fed cells, accumulation of cat-1 mRNA was dependent on protein synthesis, indicating that a labile protein is required to sustain cat-1 mRNA level, No change in the transcription rate of the cat-1 gene during amino acid starvation was observed, indicating that cat-1 is regulated at a post-transcriptional step. System y+ mediated trans port of arginine was reduced by 50% in 1 h and by 70% in 24 h after amino acid starvation, However, when 24-h amino acid-starved Fao cells were preloaded with a mM lysine or arginine for 1 h prior to the transport assays, arginine uptake was trans-stimulated by 5-fold, This stimulation was specific for cationic amino acids, since alanine, proline, or leucine had no effect, These data lead to the hypothesis that amino acid starvation results in an increased cat-1 mRNA level to support synthesis of additional Cat-1 protein, The following lines of evidence support the hypothesis: (i) the use of inhibitors of protein synthesis in starved cells inhibits the trans-zero transport of arginine; (ii) cells starved for 1-24 h exhibited an increase of trans-stimulated arginine transport activity for the first 6 h and had no loss of activity at 24 h, suggesting that constant replenishment of the transporter protein occurs; (iii) immunofluorescent staining of 24-h fed and starved cells for cat-1 showed similar cell surface distribution; (iv) new protein synthesis is not required for trans-stimulation of arginine transport upon refeeding of 24-h starved cells. We conclude that the increased level of cat-1 mRNA in response to amino acid starvation support the synthesis of Cat-1 protein during starvation and increased amino acid transport upon substrate presentation, Therefore, the cat-1 mRNA content is regulated by a derepression/repression mechanism in response to amino acid availability. We propose that the amino acid-signal transduction pathway consists of a series of steps which include the post-transcriptional regulation of amino acid transporter genes.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NUTR,CLEVELAND,OH 44106; UNIV FLORIDA,COLL MED,DEPT BIOCHEM & MOL BIOL,GAINESVILLE,FL 32610	Case Western Reserve University; State University System of Florida; University of Florida					NIDDK NIH HHS [DK47431-0182, DK-52064] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064, R29DK047431] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; BRACY DS, 1986, J BIOL CHEM, V261, P1514; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CHEN ZP, 1992, J BIOL CHEM, V267, P6946; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HATZOGLOU M, 1991, J BIOL CHEM, V266, P8416; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; KAKUDA DK, 1994, J EXP BIOL, V196, P93; Kakuda DK, 1993, TRANSGENE, V1, P91; KIBERG MS, 1994, FASEB J, V8, P13; KILBERG MS, 1985, J CELL PHYSIOL, V122, P290, DOI 10.1002/jcp.1041220219; KILBERG MS, 1996, TRENDS BIOCHEM SCI, V2, P183; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; LAINE RO, 1991, J BIOL CHEM, V266, P16969; LAINE RO, 1994, J BIOL CHEM, V269, P9693; LAWLESS K, 1987, AM J PHYSIOL, V253, pG637, DOI 10.1152/ajpgi.1987.253.5.G637; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Maniatis T., 1982, MOL CLONING; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; Miyamoto K, 1996, J BIOL CHEM, V271, P16758, DOI 10.1074/jbc.271.28.16758; OGAWA H, 1991, J BIOL CHEM, V266, P20412; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PONJANPELTO P, 1990, MOL CELL BIOL, V10, P5814; SHOTWELL MA, 1982, J BIOL CHEM, V257, P2974; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WOODARD MH, 1994, AM J PHYSIOL, V266, pE817, DOI 10.1152/ajpendo.1994.266.5.E817; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994	38	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19951	19957		10.1074/jbc.272.32.19951	http://dx.doi.org/10.1074/jbc.272.32.19951			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242663	hybrid			2022-12-25	WOS:A1997XQ05900050
J	Watanabe, M; Matsuo, M; Tanaka, S; Akimoto, H; Asahi, S; Nishimura, S; Katze, JR; Hashizume, T; Crain, PF; McCloskey, JA; Okada, N				Watanabe, M; Matsuo, M; Tanaka, S; Akimoto, H; Asahi, S; Nishimura, S; Katze, JR; Hashizume, T; Crain, PF; McCloskey, JA; Okada, N			Biosynthesis of archaeosine, a novel derivative of 7-deazaguanosine specific to archaeal tRNA, proceeds via a pathway involving base replacement on the tRNA polynucleotide chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-GUANINE TRANSGLYCOSYLASE; TRANSFER RIBONUCLEIC-ACID; COLI TRANSFER-RNA; ESCHERICHIA-COLI; MODIFIED NUCLEOSIDES; INSERTION ENZYME; SEQUENCE; QUEUINE; QUEUOSINE; PRECURSOR	Archaeosine is a novel derivative of 7-deazaguanosine found in transfer RNAs of most organisms exclusively in the archaeal phylogenetic lineage and is present ill the D-loop at position 15. me show that this modification is formed by a posttranscriptional base replacement reaction, catalyzed by a new tRNA-guanine transglycosylase (TGT), which has been isolated from Haloferax volcanii and purified nearly to homogeneity. The molecular weight of the enzyme was estimated to be 78 kDa by SDS-gel electrophoresis, The enzyme can insert free 7-cyano-7-deazaguanine (preQ(0) base) in vitro at position 15 of an H. volcanii tRNA T7 transcript, replacing the guanine originally located at that position without breakage of the phosphodiester backbone. Since archaeosine base and 7-aminomethyl-7-deazaguanine (preQ(1) base) were not incorporated into tRNA by this enzyme, preQ(0) base appears to be the actual substrate for the TGT of H. volcanii, a conclusion supported by characterization of preQ(0) base in all acid-soluble extract of H. volcanii cells. Thus, this novel TGT in H. volcanii is a key enzyme for the biosynthetic pathway leading to archaeosine in archaeal tRNAs.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; TAKEDA CHEM IND LTD,OSAKA 532,JAPAN; BANYU TSUKUBA RES INST MERCK,TSUKUBA,IBARAKI 30026,JAPAN; UNIV TENNESSEE,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163; UNIV UTAH,DEPT MED CHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112	Tokyo Institute of Technology; Takeda Chemical Industries; Merck & Company; University of Tennessee System; University of Tennessee Health Science Center; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			WATANABE, Masakatsu/V-9082-2019	WATANABE, Masakatsu/0000-0002-5744-197X				BEIER H, 1984, EMBO J, V3, P351, DOI 10.1002/j.1460-2075.1984.tb01810.x; BIENZ M, 1981, NATURE, V294, P188, DOI 10.1038/294188a0; BJORK GR, 1986, CHEM SCRIPTA, V26B, P91; BJORK GR, 1995, PROG NUCLEIC ACID RE, V50, P263, DOI 10.1016/S0079-6603(08)60817-X; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CURNOW AW, 1993, BIOCHEMISTRY-US, V32, P5239, DOI 10.1021/bi00070a036; Deshpande KL, 1996, ARCH BIOCHEM BIOPHYS, V326, P1, DOI 10.1006/abbi.1996.0039; DOCKBREGEON AC, 1989, J MOL BIOL, V206, P707, DOI 10.1016/0022-2836(89)90578-0; DURAND JM, 1994, J BACTERIOL, V176, P4627, DOI 10.1128/JB.176.15.4627-4634.1994; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; ELLIOTT MS, 1986, J BIOL CHEM, V261, P3019; FARKAS WR, 1980, J BIOL CHEM, V255, P6832; FREY B, 1988, J BACTERIOL, V170, P2078, DOI 10.1128/jb.170.5.2078-2082.1988; GREGSON JM, 1993, J BIOL CHEM, V268, P10076; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; GROSJEAN H, 1995, BIOCHIMIE, V77, P139, DOI 10.1016/0300-9084(96)88117-X; GUPTA R, 1984, J BIOL CHEM, V259, P9461; HARADA F, 1972, BIOCHEMISTRY-US, V11, P301, DOI 10.1021/bi00752a024; Hashizume T., 1994, NUCL ACIDS S SERIES, V31, P137; HATFIELD D, 1989, VIROLOGY, V173, P736, DOI 10.1016/0042-6822(89)90589-8; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; KASAI H, 1976, J AM CHEM SOC, V98, P5044, DOI 10.1021/ja00432a071; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KATZE JR, 1982, SCIENCE, V216, P55; KATZE JR, 1984, BIOCHEMISTRY-US, V23, P1171, DOI 10.1021/bi00301a022; KAURI T, 1990, SYST APPL MICROBIOL, V13, P14, DOI 10.1016/S0723-2020(11)80174-8; KILPATRICK MW, 1982, ZBL BAKT MIK HYG I C, V3, P79, DOI 10.1016/S0721-9571(82)80056-2; KONDO T, 1980, CHEM LETT, P559, DOI 10.1246/cl.1980.559; KRETZ KA, 1987, MOL CELL BIOL, V7, P3613, DOI 10.1128/MCB.7.10.3613; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; MORRIS RC, 1995, NUCLEIC ACIDS RES, V23, P2492, DOI 10.1093/nar/23.13.2492; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; NISHIMURA S, 1983, PROG NUCLEIC ACID RE, V28, P49, DOI 10.1016/S0079-6603(08)60082-3; NISHIMURA S, 1979, TRANSFER RNA STRUCTU, P59; NOGUCHI S, 1978, NUCLEIC ACIDS RES, V5, P4215, DOI 10.1093/nar/5.11.4215; OHGI T, 1979, CHEM LETT, P1283, DOI 10.1246/cl.1979.1283; OKADA N, 1977, NUCLEIC ACIDS RES, V4, P2931, DOI 10.1093/nar/4.8.2931; OKADA N, 1979, J BIOL CHEM, V254, P3067; OKADA N, 1978, NUCLEIC ACIDS RES, V5, P2289, DOI 10.1093/nar/5.7.2289; OKADA N, 1978, P NATL ACAD SCI USA, V75, P4247, DOI 10.1073/pnas.75.9.4247; OKADA N, 1979, J BIOL CHEM, V254, P3061; PHILLIPSON DW, 1987, J BIOL CHEM, V262, P3462; REUTER K, 1991, J BACTERIOL, V173, P2256, DOI 10.1128/JB.173.7.2256-2264.1991; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; ROMIER C, 1996, EMBO J, V15, P2580; SHINDOOKADA N, 1980, BIOCHEMISTRY-US, V19, P395, DOI 10.1021/bi00543a023; SHINDOOKADA N, 1981, EUR J BIOCHEM, V115, P423, DOI 10.1111/j.1432-1033.1981.tb05254.x; SILBERKLANG M, 1977, EUR J BIOCHEM, V72, P465, DOI 10.1111/j.1432-1033.1977.tb11270.x; SLANY RK, 1995, EUR J BIOCHEM, V230, P221, DOI 10.1111/j.1432-1033.1995.0221i.x; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028; Sprinzl M, 1996, NUCLEIC ACIDS RES, V24, P68, DOI 10.1093/nar/24.1.68; STANLEY J, 1978, NATURE, V274, P87, DOI 10.1038/274087a0; TSUNASAWA S, 1989, J BIOL CHEM, V264, P3832; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	56	67	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20146	20151		10.1074/jbc.272.32.20146	http://dx.doi.org/10.1074/jbc.272.32.20146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242689	hybrid			2022-12-25	WOS:A1997XQ05900076
J	Finkenzeller, G; Sparacio, A; Technau, A; Marme, D; Siemeister, G				Finkenzeller, G; Sparacio, A; Technau, A; Marme, D; Siemeister, G			Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression	ONCOGENE			English	Article						PDGF; promoter; Sp1; tumor angiogenesis; VEGF	SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; TRANSCRIPTIONAL ACTIVATION; TUMOR ANGIOGENESIS; PERMEABILITY FACTOR; MESSENGER-RNA; BINDING; INDUCTION; HYPOXIA; INVIVO	Stimulation of NIH3T3 cells with platelet-derived growth factor (PDGF)-BB enhances expression of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen and a key mediator of tumor angiogenesis. Here, we identified cis-acting VEGF promoter elements and trans-acting factors which are involved in PDGF-stimulated VEGF expression. By 5'-deletion and transient transfection analysis, a G + C-rich region at -85 to -50 of the human VEGF promoter was shown to be necessary and sufficient for both PDGF inducible and basal expression. The region contains three potential recognition sites for Spl transcription factors, which overlap with two Egr-1 sites. Mutations that abolish the ability of Spl to interact with the VEGF promoter element also abrogate expression induced by PDGF. Mutations of the potential Egr-1 binding sites did not affect PDGF responsiveness. Gel shift and antibody supershift analyses showed that Spl and Sp3 interact constitutively with the VEGF promoter element. Our data strongly suggest that enhanced VEGF gene expression in PDGF-induced NIH3T3 cells is mediated by Spl and/or Sp3 transcription factors bound to the -85 to -50 promoter region of the VEGF gene.	TUMOR BIOL CTR, INST MOL MED, D-79106 FREIBURG, GERMANY					, Gerhard/0000-0002-4712-0531				ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BASHEERUDDIN K, 1995, ARTERIOSCL THROM VAS, V15, P1248, DOI 10.1161/01.ATV.15.8.1248; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARSH GR, 1990, J NEURO-ONCOL, V8, P1; HECHT A, 1990, THESIS HEIDELBERG GE; HERMANSON M, 1992, CANCER RES, V52, P3213; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Janknecht R, 1996, ONCOGENE, V12, P1961; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KIESER A, 1994, ONCOGENE, V9, P963; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; Liang YX, 1996, ONCOGENE, V13, P863; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAJELLO B, 1995, ONCOGENE, V10, P1841; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAK J, 1995, CANCER RES, V55, P4575; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Siemeister G, 1996, CANCER RES, V56, P2299; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WEINDEL K, 1994, NEUROSURGERY, V35, P439, DOI 10.1227/00006123-199409000-00012	55	183	185	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	1997	15	6					669	676		10.1038/sj.onc.1201219	http://dx.doi.org/10.1038/sj.onc.1201219			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264407				2022-12-25	WOS:A1997XP68300006
J	Kolkman, MAB; vanderZeijst, BAM; Nuijten, PJM				Kolkman, MAB; vanderZeijst, BAM; Nuijten, PJM			Functional analysis of glycosyltransferases encoded by the capsular polysaccharide biosynthesis locus of Streptococcus pneumoniae serotype 14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; RHIZOBIUM-MELILOTI; TRANSPOSON TN916; ESCHERICHIA-COLI; GENES; TRANSFORMATION; IDENTIFICATION; SUCCINOGLYCAN; ORGANIZATION; INFLUENZAE	Bacteria belonging to the species Streptococcus pneumoniae vary in their capsule. Presently, 90 capsular serotypes are known, all possessing their own specific polysaccharide structure. Little is known about the biosynthesis of these capsular polysaccharides. The cps locus of S. pneumoniae serotype 14 was cloned. So far, 7 open reading frames have been sequenced, cps14B to cps14H. The gene products are similar to proteins involved in bacterial polysaccharide biosynthesis, both of Gram-negative and -positive micro-organisms. Gene-specific mutants were created for cps14D to cps14H by insertional mutagenesis. All mutants no longer agglutinated with a monoclonal antibody against type 14 capsule polysaccharides. The biosynthetic function of cps14E and cps14G was determined by analysis of the intermediates in the synthesis of the oligosaccharide subunit, formed in membrane preparations of the wild-type and mutant strains and in membrane preparations of Escherichia coli expressing the pneumococcal glycosyltransferases. The enzyme encoded by cps14E is a glucosyl-1-phosphate transferase that links glucose to a lipid carrier, the first step in the biosynthesis of the type 14 repeating unit. The gene product of cps14G encodes a beta-1,4-galactosyltransferase, the enzyme responsible for the second step in the subunit synthesis, the transfer of galactose to lipid-linked glucose.	UNIV UTRECHT, DEPT BACTERIOL, INST INFECT DIS & IMMUNOL, SCH VET MED, NL-3508 TD UTRECHT, NETHERLANDS	Utrecht University			Van der Zeijst, Bernard B.A./A-3847-2013; Van der Zeijst, Bernard/AAH-1415-2020	Van der Zeijst, Bernard B.A./0000-0001-9316-2161; Van der Zeijst, Bernard/0000-0001-9316-2161				ARAKAWA Y, 1995, J BACTERIOL, V177, P1788, DOI 10.1128/jb.177.7.1788-1796.1995; Arrecubieta C, 1995, GENE, V167, P1, DOI 10.1016/0378-1119(95)00657-5; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BECKER A, 1995, MOL MICROBIOL, V16, P191, DOI 10.1111/j.1365-2958.1995.tb02292.x; BOULNOIS GJ, 1990, CURR TOP MICROBIOL, V150, P1; BOULNOIS GJ, 1989, MOL MICROBIOL, V3, P1819, DOI 10.1111/j.1365-2958.1989.tb00168.x; BRUYN GAW, 1991, EUR J CLIN MICROBIOL, V10, P897, DOI 10.1007/BF02005442; BUGERT P, 1995, MOL MICROBIOL, V15, P917, DOI 10.1111/j.1365-2958.1995.tb02361.x; COFFEY TJ, 1991, MOL MICROBIOL, V5, P2255, DOI 10.1111/j.1365-2958.1991.tb02155.x; COLLINS LV, 1991, J BACTERIOL, V173, P2521, DOI 10.1128/jb.173.8.2521-2529.1991; CROSS AS, 1990, CURR TOP MICROBIOL, V150, P87; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; DISTLER J, 1964, P NATL ACAD SCI USA, V51, P897, DOI 10.1073/pnas.51.5.897; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; GAWRONBURKE C, 1984, J BACTERIOL, V159, P214, DOI 10.1128/JB.159.1.214-221.1984; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7045, DOI 10.1128/jb.175.21.7045-7055.1993; GUIDOLIN A, 1994, INFECT IMMUN, V62, P5384, DOI 10.1128/IAI.62.12.5384-5396.1994; HENRICHSEN J, 1995, J CLIN MICROBIOL, V33, P2759, DOI 10.1128/JCM.33.10.2759-2762.1995; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HUANG JZ, 1995, MOL MICROBIOL, V16, P977, DOI 10.1111/j.1365-2958.1995.tb02323.x; HUNDLE BS, 1992, P NATL ACAD SCI USA, V89, P9321, DOI 10.1073/pnas.89.19.9321; JENNINGS HJ, 1990, CURR TOP MICROBIOL, V150, P97; KENNEDY EP, 1976, J BIOL CHEM, V251, P4208; Kolkman MAB, 1996, J BACTERIOL, V178, P3736, DOI 10.1128/jb.178.13.3736-3741.1996; KROLL JS, 1990, J BACTERIOL, V172, P1374, DOI 10.1128/jb.172.3.1374-1379.1990; KROLL JS, 1989, J BACTERIOL, V171, P3343, DOI 10.1128/jb.171.6.3343-3347.1989; LIN WS, 1994, J BACTERIOL, V176, P7005, DOI 10.1128/JB.176.22.7005-7016.1994; MORONA R, 1994, J BACTERIOL, V176, P733, DOI 10.1128/jb.176.3.733-747.1994; MORRISON DA, 1983, J BACTERIOL, V156, P281, DOI 10.1128/JB.156.1.281-290.1983; MOXON ER, 1990, CURR TOP MICROBIOL, V150, P65; RUBENS CE, 1993, MOL MICROBIOL, V8, P843, DOI 10.1111/j.1365-2958.1993.tb01631.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIBER GR, 1994, SCIENCE, V265, P1385, DOI 10.1126/science.8073278; Stingele F, 1996, J BACTERIOL, V178, P1680, DOI 10.1128/jb.178.6.1680-1690.1996; VANDAM JEG, 1990, ANTON LEEUW INT J G, V58, P1; Wang L, 1996, J BACTERIOL, V178, P2598, DOI 10.1128/jb.178.9.2598-2604.1996; WATSON DA, 1990, INFECT IMMUN, V58, P3135, DOI 10.1128/IAI.58.9.3135-3138.1990; Yamazaki M, 1996, J BACTERIOL, V178, P2676, DOI 10.1128/jb.178.9.2676-2687.1996; YOTHER J, 1986, J BACTERIOL, V168, P1463, DOI 10.1128/jb.168.3.1463-1465.1986	41	65	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19502	19508		10.1074/jbc.272.31.19502	http://dx.doi.org/10.1074/jbc.272.31.19502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235953	hybrid			2022-12-25	WOS:A1997XP06300059
J	Nunez, MT; NunezMillacura, C; Beltran, M; Tapia, V; AlvarezHernandez, X				Nunez, MT; NunezMillacura, C; Beltran, M; Tapia, V; AlvarezHernandez, X			Apotransferrin and holotransferrin undergo different endocytic cycles in intestinal epithelia (Caco-2) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN; IRON; TRANSPORT; PATHWAY; BINDING	Previous studies have demonstrated that diferric transferrin and apotransferrin compete for the binding to basolateral transferrin receptors and that transferrin-mediated iron uptake by Caco-2 cells is inhibited by apotransferrin to a larger extent than that predicted solely by receptor competition, This inhibition can have important implications in determining the net exchange of iron between intestinal cells and the basolateral milieu. Accordingly, we further characterized the endocytic cycles of apotransferrin and diferric transferrin in Caco-2 cells. We found that after internalization both apotransferrin and diferric transferrin recycled to the cell exterior, but that apotransferrin had a protracted endocytic cycle. Confocal microscopy studies revealed a different cellular distribution of apotransferrin and diferric transferrin; both were found in a compartment close to the basal membrane, but apotransferrin reached as well regions closer to the apical membrane. Moreover, the intracellular distribution of transferrin receptors was influenced by the iron load of transferrin; cells incubated with apotransferrin presented a more apical distribution of transferrin receptors than cells incubated with diferric transferrin. These results indicate for the first time that the endocytic cycle of transferrin receptors in intestinal epithelial cells is determined by the iron content of transferrin. They explain also the marked inhibitory effect of apotransferrin on transferrin-mediated iron uptake by Caco-2 cells, since incubation of cells with apotransferrin resulted in the actual sequestration of the receptor in the cell interior.	LOUISIANA STATE UNIV, MED CTR, DEPT MED, SHREVEPORT, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Nunez, MT (corresponding author), UNIV CHILE, FAC CIENCIAS, DEPT BIOL, CASILLA 653, SANTIAGO, CHILE.		Nunez, Marco/H-6348-2014	Nunez, Marco/0000-0002-1967-8570				ALVAREZHERNANDEZ X, 1994, BBA-BIOMEMBRANES, V1192, P215, DOI 10.1016/0005-2736(94)90121-X; ALVAREZHERNANDEZ X, 1991, BIOCHIM BIOPHYS ACTA, V1070, P205, DOI 10.1016/0005-2736(91)90165-5; BALI PK, 1990, ARCH BIOCHEM BIOPHYS, V281, P251, DOI 10.1016/0003-9861(90)90440-A; CONRAD ME, 1993, AM J HEMATOL, V42, P67, DOI 10.1002/ajh.2830420114; FLANAGAN PR, 1990, ACTA PEDIAT SCAND S, V361, P21; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HUGHSON EJ, 1990, J CELL BIOL, V110, P337, DOI 10.1083/jcb.110.2.337; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCFARLANE AS, 1963, J CLIN INVEST, V42, P346, DOI 10.1172/JCI104721; Nunez MT, 1996, J NUTR, V126, P2151, DOI 10.1093/jn/126.9.2151; Tapia V, 1996, AM J PHYSIOL-GASTR L, V271, pG443, DOI 10.1152/ajpgi.1996.271.3.G443; WILLIAMS J, 1980, BIOCHEM J, V185, P483, DOI 10.1042/bj1850483; Wrigglesworth J.M, 1980, IRON BIOCH MED, P29; YOUNG SP, 1984, BIOCHEM J, V219, P505, DOI 10.1042/bj2190505	16	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19425	19428		10.1074/jbc.272.31.19425	http://dx.doi.org/10.1074/jbc.272.31.19425			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235943	hybrid			2022-12-25	WOS:A1997XP06300049
J	Reimer, DL; Kong, S; Bally, MB				Reimer, DL; Kong, S; Bally, MB			Analysis of cationic liposome-mediated interactions of plasmid DNA with murine and human melanoma cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYAMINE-COATED DNA; GENE-TRANSFER; MAMMALIAN-CELLS; EFFICIENT; LIPOFECTION; COMPLEX; REAGENT; SERIES	Lipid-based DNA transfer formulations are typically selected on the basis of in vitro transfection studies where the activity of specific formulations is defined by transgene expression. It is unclear, however, whether expression is directly related to the efficiency of DNA transfer, In an attempt to correlate DNA transfer with transgene expression, we used a simple assay consisting of measuring DNA (H-3-plasmid encoding for beta-galactosidase) binding to murine (B16/BL6) and human (KZ) melanoma cells in vitro at 4 and 37 degrees C. The difference in cell association at these temperatures was assumed to be a consequence of DNA uptake, an assumption that was confirmed by protease removal of cell surface-associated DNA, DNA associated with B16/BL6 melanoma cells (up to 30 ng or 12% of the added DNA) following incubation with dioleoyldimethylammonium chloride/dioleoylphosphatidylethanolamine (DOPE) liposome-DNA aggregates was comparable to that achieved with 1,2-dioleoyloxypropyl-3-trimethylammonium bromide/DOPE or dimethyldioctadecylammonium bromide/ DOPE liposomes; however, transgene expression was 2- and 5-fold less for the latter two formulations, respectively, Similarly, equivalent amounts of DNA delivery were achieved with B16/BL6 and KZ melanoma cells, yet the level of transgene expression in the KZ cells was undetectable. It was demonstrated that the lack of transgene expression was not a consequence of cell-specific differences in DNA degradation.			Reimer, DL (corresponding author), BRITISH COLUMBIA CANC AGCY,DIV MED ONCOL,600 W 10TH AVE,VANCOUVER,BC V5Z 4E6,CANADA.		Bally, Marta/G-8744-2011					BARTHEL F, 1993, DNA CELL BIOL, V12, P553, DOI 10.1089/dna.1993.12.553; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P647; BERTLING WM, 1991, BIOTECHNOL APPL BIOC, V13, P390; CULLIS PR, 1986, CHEM PHYS LIPIDS, V40, P127, DOI 10.1016/0009-3084(86)90067-8; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; FARHOOD H, 1992, BIOCHIM BIOPHYS ACTA, V1111, P239, DOI 10.1016/0005-2736(92)90316-E; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER P L, 1990, Advanced Drug Delivery Reviews, V5, P163, DOI 10.1016/0169-409X(90)90015-K; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; GRUNER SM, 1987, LIPOSOMES BIOPHYSICS, P1; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOFLAND H, 1995, BIOCHEM BIOPH RES CO, V207, P492, DOI 10.1006/bbrc.1995.1215; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; LOEFFLER JP, 1993, METHOD ENZYMOL, V217, P599; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; PONDER KP, 1991, HUM GENE THER, V2, P41, DOI 10.1089/hum.1991.2.1-41; REMY JS, 1994, BIOCONJUGATE CHEM, V5, P647, DOI 10.1021/bc00030a021; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SABBIONI S, 1995, ARCH VIROL, V140, P335, DOI 10.1007/BF01309866; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERPHOF GL, 1987, BIOCH SOC T S, V15, P625; SMITH JG, 1993, BIOCHIM BIOPHYS ACTA, V1154, P327, DOI 10.1016/0304-4157(93)90004-8; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; Wasan EK, 1996, J PHARM SCI-US, V85, P427, DOI 10.1021/js9504752; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3	31	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19480	19487		10.1074/jbc.272.31.19480	http://dx.doi.org/10.1074/jbc.272.31.19480			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235950	hybrid			2022-12-25	WOS:A1997XP06300056
J	Ubeda, M; Habener, JF				Ubeda, M; Habener, JF			The large subunit of the DNA replication complex C (DSEB/RF-C140) cleaved and inactivated by caspase-3 (CPP32/YAMA) during Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-SPECIFIC ELEMENT; SMALL NUCLEAR RIBONUCLEOPROTEIN; 70-KDA PROTEIN-COMPONENT; DEATH GENE CED-3; CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; ANGIOTENSINOGEN GENE; ICE/CED-3 PROTEASE; MAMMALIAN HOMOLOG; EXPRESSION	We report the identification of the large subunit of the DNA replication factor, DSEB/RF-C140, as a new substrate for caspase-3 (CPP32/YAMA), or a very closely related protease activated during Fas-induced apoptosis in Jurkat T cells, DSEB/RF-C140 is a multifunctional DNA-binding protein with sequence homology to poly-(ADP-ribose) polymerase (PARP), This similarity includes a consensus DEVD/G cleavage site for caspase-3. Cleavage of DSEB/RF-C140 is predicted to occurs between Asp(706) and Gly(707), generating 87-kDa and 53-kDa fragments. An antiserum raised against the amino-terminal domain of DSEB/RF-C140 detects a new 87-kDa protein in Jurkat T cells in which apoptosis is activated by a monoclonal antibody to Fas, This cleavage occurs shortly after PARR cleavage, In vitro translated DSEB/RF-C140 is specifically cleaved into the predicted fragments when incubated with a cytoplasmic extract from Fas antibody-treated cells, Proteolytic cleavage was prevented by substituting Asp(706) by an alanine in the DEVD706/G caspase-3 cleavage site, The cleavage of DSEB/RF-C140 is prevented by iodoacetamide and the specific caspase-3 inhibitor, tetrapeptide aldehyde Ac-DEVD-CHO, but not by the specific ICE (interleukin-1-converting enzyme) inhibitors: CrmA and Ac-YVAD-CHO, indicating that the protease responsible for the cleavage of DSEB/RF-C140 during Fas induced apoptosis in Jurkat cells is caspase-3, or a closely related protease, This conclusion is reinforced by the fact that recombinant caspase-3 but not caspase-1 reproduced the ''in vivo'' cleavage, Inasmuch as the cleavage of DSEB/ RF-C140 separates its DNA binding from its association domain, required for replication complex formation, we propose that such a cleavage will impair DNA replication, Recent in vitro mutagenesis support this proposal (Uhlmann, F., Cai, J., Gibbs, E., O'Donnel, M., and Hurwitz, J. (1997) J. Biol. Chem. 272, 10058-10064).	MASSACHUSETTS GEN HOSP,HOWARD HUGHES MED INST,MOL ENDOCRINOL LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			Ubeda, Mariano/ABB-2691-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030457] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK30457] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; Darmon AJ, 1996, J BIOL CHEM, V271, P21699, DOI 10.1074/jbc.271.36.21699; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FORTEDAR R, 1996, EMBO J, V15, P4423; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; HUPPI K, 1989, NUCLEIC ACIDS RES, V17, P3387, DOI 10.1093/nar/17.9.3387; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE SH, 1991, J BIOL CHEM, V266, P594; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MCGEHEE RE, 1995, MOL ENDOCRINOL, V9, P487, DOI 10.1210/me.9.4.487; MCGEHEE RE, 1993, MOL ENDOCRINOL, V7, P551, DOI 10.1210/me.7.4.551; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Stanger BZ, 1996, MOL MED, V2, P7, DOI 10.1007/BF03402198; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; 1996, CELL, V85, P817	49	32	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19562	19568		10.1074/jbc.272.31.19562	http://dx.doi.org/10.1074/jbc.272.31.19562			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235961	hybrid			2022-12-25	WOS:A1997XP06300067
J	Harry, A; Chen, YB; Magnusson, R; Iyengar, R; Weng, GZ				Harry, A; Chen, YB; Magnusson, R; Iyengar, R; Weng, GZ			Differential regulation of adenylyl cyclases by G alpha(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATION; TRANSLATION; EXPRESSION; CELLS	Regulation of adenylyl cyclases 1, 2, and 6 by G alpha(s) was studied, All three mammalian adenylyl cyclases were expressed in insect (Sf9 or Hi-5) cells by baculovirus infection. Membranes containing the different adenylyl cyclases were stimulated by varying concentrations of mutant (Q227L) activated G alpha(s) expressed in reticulocyte lysates, G alpha(s) stimulation of AC1 involved a single site and had an apparent K-act of 0.9 nM. G alpha(s) stimulation of AC2 was best explained by a non-interactive two site model with a ''high affinity'' site at 0.9 nM and a ''low affinity'' site at 15 nM, Occupancy of the high affinity site appears to be sufficient for G beta gamma stimulation of AC2. G alpha(s) stimulation of AC6 was also best explained by a two-site model with a high affinity site at 0.6-0.8 nM and a low affinity site at 8-22 nM; however, in contrast to AC2, only a model that assumed interactions between the two sites best fit the AC6 data, With 100 mu M forskolin, G alpha(s) stimulation of all three adenylyl cyclases showed very similar profiles, G alpha(s) stimulation in the presence of forskolin involved a single site with apparent K-act of 0.1-0.4 nM. These observations indicate a conserved mechanism by which forskolin regulates G alpha(s) coupling to the different adenylyl cyclases, However, there are fundamental differences in the mechanism of G alpha(s) stimulation of the different adenylyl cyclases with AC2 and AC6 having multiple interconvertible sites, These mechanistic differences may provide an explanation for the varied responses by different cells and tissues to hormones that elevate cAMP levels.			Harry, A (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,BOX 1215,NEW YORK,NY 10029, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM015599, R01GM054508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38761] Funding Source: Medline; NIGMS NIH HHS [GM15599, GM54508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDER JL, 1984, ADV CYCLIC NUCL PROT, V17, P101; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; Nielsen MD, 1996, J BIOL CHEM, V271, P33308, DOI 10.1074/jbc.271.52.33308; PFEUFFER E, 1989, J BIOL CHEM, V264, P18803; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; SANFORD J, 1991, J BIOL CHEM, V266, P9570; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	15	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19017	19021		10.1074/jbc.272.30.19017	http://dx.doi.org/10.1074/jbc.272.30.19017			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228084	hybrid			2022-12-25	WOS:A1997XM34200075
J	Collas, P; Thompson, L; Fields, AP; Poccia, DL; Courvalin, JC				Collas, P; Thompson, L; Fields, AP; Poccia, DL; Courvalin, JC			Protein kinase C-mediated interphase lamin B phosphorylation and solubilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ENVELOPE BREAKDOWN; SEA-URCHIN EGG; IN-VITRO; CHROMATIN DECONDENSATION; MALE PRONUCLEUS; HISTONE-H1 KINASE; LEUKEMIA-CELLS; ACTIVATION; MEMBRANE; IDENTIFICATION	Disassembly of the sperm nuclear envelope at fertilization is one of the earliest events in the development of the male pronucleus. We report that nuclear lamina disassembly in interphase sea urchin egg cytosol is a result of lamin B phosphorylation mediated by protein kinase C (PKC). Lamin B of permeabilized sea urchin sperm nuclei incubated in fertilized egg G(1) phase cytosolic extract is phosphorylated within 1 min of incubation and solubilized prior to sperm chromatin decondensation. Phosphorylation is Ca2+-dependent. It is reversibly inhibited by the PKC-specific inhibitor chelerythrine, a PKC pseudosubstrate inhibitor peptide, and a PKC substrate peptide, but not by inhibitors of PKA, p34(cdc2) or calmodulin kinase II. Phosphorylation is inhibited by immunodepletion of cytosolic PKC and restored by addition of purified rat brain PKC. Sperm lamin B is a substrate for rat brain PKC in vitro, resulting in lamin B solubilization. Two-dimensional phosphopeptide maps of lamin B phosphorylated by the cytosolic kinase and by purified rat PKC are virtually identical. These data suggest that PKC is the major kinase required for interphase disassembly of the sperm lamina.	UNIV TEXAS,MED BRANCH,SEALY CTR ONCOL,GALVESTON,TX 77555; AMHERST COLL,DEPT BIOL,AMHERST,MA 01002; UNIV PARIS 07,INST JACQUES MONOD,CNRS,F-75251 PARIS,FRANCE	University of Texas System; University of Texas Medical Branch Galveston; Amherst College; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Collas, P (corresponding author), NORWEGIAN COLL VET MED,DEPT BIOCHEM,POB 8146 DEP,N-0033 OSLO,NORWAY.				NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NCI NIH HHS [CA56869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; CAMERON LA, 1994, DEV BIOL, V162, P568, DOI 10.1006/dbio.1994.1110; COLLAS P, 1995, DEV BIOL, V169, P123, DOI 10.1006/dbio.1995.1132; Collas P, 1996, J CELL SCI, V109, P1275; COLLAS P, 1995, MOL REPROD DEV, V42, P106, DOI 10.1002/mrd.1080420114; COLLAS P, 1995, EXP CELL RES, V219, P687, DOI 10.1006/excr.1995.1280; Collas P, 1996, J CELL BIOL, V135, P1715, DOI 10.1083/jcb.135.6.1715; COTHREN CC, 1993, EXP CELL RES, V205, P126, DOI 10.1006/excr.1993.1066; DICHEVA N, 1993, CELL, V74, P405; Fields A P, 1995, Prog Cell Cycle Res, V1, P271; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GOSS VL, 1994, J BIOL CHEM, V269, P19074; GREEN GR, 1985, DEV BIOL, V108, P235, DOI 10.1016/0012-1606(85)90026-0; GREEN GR, 1995, SEMIN CELL BIOL, V6, P219, DOI 10.1006/scel.1995.0030; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOLY J, 1995, DEV BIOL, V168, P464, DOI 10.1006/dbio.1995.1095; HORNBECK P, 1988, P NATL ACAD SCI USA, V85, P2279, DOI 10.1073/pnas.85.7.2279; Kill IR, 1995, FEBS LETT, V377, P26, DOI 10.1016/0014-5793(95)01302-4; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LONGO FJ, 1968, J CELL BIOL, V39, P335; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; MEIJER L, 1996, TRENDS CELL BIOL, V6, P292; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Olds JL, 1995, DEV BIOL, V172, P675, DOI 10.1006/dbio.1995.8060; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; POCCIA D, 1990, EXP CELL RES, V188, P226, DOI 10.1016/0014-4827(90)90164-6; POCCIA DL, 1992, TRENDS BIOCHEM SCI, V17, P223, DOI 10.1016/0968-0004(92)90382-J; RAKOW TL, 1994, DEV GROWTH DIFFER, V36, P489; SCHATTEN G, 1985, P NATL ACAD SCI USA, V82, P4727, DOI 10.1073/pnas.82.14.4727; SHEN SS, 1990, DEV BIOL, V140, P272, DOI 10.1016/0012-1606(90)90077-V; SMITH DE, 1987, J CELL BIOL, V105, P771, DOI 10.1083/jcb.105.2.771; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; STUURMAN N, 1995, J CELL SCI, V108, P3137; Stuurman N, 1997, FEBS LETT, V401, P171, DOI 10.1016/S0014-5793(96)01464-0; TERASAKI M, 1991, J CELL BIOL, V114, P929, DOI 10.1083/jcb.114.5.929; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U	45	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21274	21280		10.1074/jbc.272.34.21274	http://dx.doi.org/10.1074/jbc.272.34.21274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261138	hybrid			2022-12-25	WOS:A1997XR78900048
J	Roder, K; Wolf, SS; Beck, KF; Schweizer, M				Roder, K; Wolf, SS; Beck, KF; Schweizer, M			Cooperative binding of NF-Y and Sp1 at the DNase I-hypersensitive site, fatty acid synthase insulin-responsive element 1, located at -500 in the rat fatty acid synthase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN; CCAAT-BINDING; GENE-EXPRESSION; TRANSCRIPTION; IDENTIFICATION; COMPLEX; ACTIVATION; CLONING; YEAST; DIFFERENTIATION	In vitro DNase I footprint analysis of the rat fatty acid synthase (FAS) promoter from -568 to -468 revealed four protein binding sites: A, B, and C boxes and She FAS insulin-responsive element 1 (FIRE1), As demonstrated by gel mobility shift analysis and supershift experiments, FIRE1, located between -516 and -498, is responsible for binding NF-Y, The C box located downstream of FIRE 1 was shown by in vitro footprinting to be a Spl binding site, and furthermore, competition with Spl also abolished FIRE1 binding, Since the half-life of the Sp1.NF-Y.DNA complex is significantly longer than the half-lives of the Sp1.DNA or NF-Y.DNA complexes, the two transcription factors are deemed to bind cooperatively in the FAS promoter at -500, It is unusual that NF-Y binds at this distance from the start site of transcription, NF-Y binding sites are found in the promoters of at least three other FAS genes, viz. goose, chicken, and man, A second NF-Y binding site is located in the PAS promoter at the more usual position of -103 to -87, and it too has a neighboring Spl site, CTF/NF-1 competes for proteins binding to the B box, The A box binds Spl and contains a 12/13 match of the inverted repeat sequence responsible far binding the nuclear factor EF-C/RFX-1. in the enhancer regions of hepatitis B virus and the major histocompatibility complex class II antigen promoter, The same relative positions of NF-Y and Sp1 binding sites in the promoters of FAS genes of goose, rat, chicken, and man emphasize the involvement of these transcription factors in the diet and hormonal regulation of FAS.	INST FOOD RES, DEPT GENET & MICROBIOL, NORWICH NR4 7UA, NORFOLK, ENGLAND; UNIV FRANKFURT KLINIKUM, INST ALLGEMEINE PHARMAKOL & TOXICOL, D-60590 FRANKFURT, GERMANY	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; Goethe University Frankfurt; Goethe University Frankfurt Hospital								AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; Beck K F, 1992, DNA Seq, V2, P359, DOI 10.3109/10425179209020817; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; CADILLA C, 1992, GENE, V118, P223, DOI 10.1016/0378-1119(92)90192-R; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; DANG VD, 1995, YEAST, V11, pS176; DAVID E, 1995, J BIOL CHEM, V270, P8353, DOI 10.1074/jbc.270.14.8353; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FOUFELLE F, 1995, BIOCHEM J, V308, P521, DOI 10.1042/bj3080521; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Hsu MH, 1996, J BIOL CHEM, V271, P13584, DOI 10.1074/jbc.271.23.13584; IRITANI N, 1992, EUR J BIOCHEM, V205, P433, DOI 10.1111/j.1432-1033.1992.tb16797.x; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JIANG SW, 1995, NUCLEIC ACIDS RES, V23, P3607, DOI 10.1093/nar/23.17.3607; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAMEDA K, 1991, J BIOL CHEM, V266, P419; KIM JB, 1995, MOL CELL BIOL, V15, P2582; LAUX T, 1990, BIOCHEM J, V266, P793; LeFur N, 1996, EUR J BIOCHEM, V240, P323; LIU ZR, 1993, J BIOL CHEM, V268, P12787; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NYE JA, 1990, P NATL ACAD SCI USA, V87, P3992, DOI 10.1073/pnas.87.10.3992; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; REED GE, 1995, BRAIN RES, V685, P1; Roder K, 1997, GENE, V184, P21, DOI 10.1016/S0378-1119(96)00568-9; RODER K, 1994, GENE, V144, P189, DOI 10.1016/0378-1119(94)90377-8; RODER K, 1992, THESIS U ERLANGEN NU; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHLOKAT U, 1987, THESIS U HEIDELBERG; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VASSEURCOGNET M, 1993, CURR OPIN GENET DEV, V3, P238, DOI 10.1016/0959-437X(93)90029-O; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4521; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; WOLF SS, 1994, BIOCHEM BIOPH RES CO, V203, P943, DOI 10.1006/bbrc.1994.2273; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873	55	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21616	21624		10.1074/jbc.272.34.21616	http://dx.doi.org/10.1074/jbc.272.34.21616			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261184	hybrid			2022-12-25	WOS:A1997XR78900094
J	Waldmann, R; Bassilana, F; deWeille, J; Champigny, G; Heurteaux, C; Lazdunski, M				Waldmann, R; Bassilana, F; deWeille, J; Champigny, G; Heurteaux, C; Lazdunski, M			Molecular cloning of a non-inactivating proton-gated Na+ channel specific for sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; SODIUM-CHANNEL; HOMOLOGOUS SUBUNITS; CELLS; RAT; EXPRESSION; NEURODEGENERATION; IDENTIFICATION; RECEPTOR; CURRENTS	We have cloned and expressed a novel proton-gated Na+ channel subunit that is specific for sensory neurons. In COS cells, it forms a Na+ channel that responds to a drop of the extracellular pH with both a rapidly inactivating and a sustained Na+ current, This biphasic kinetic closely resembles that of the H+-gated current described in sensory neurons of dorsal root ganglia (1). Both the abundance of this novel H+-gated Na+ channel subunit in sensory neurons and the kinetics of the channel suggest that it is part of the channel complex responsible for the sustained H+-activated cation current in sensory neurons that is thought to be important for the prolonged perception of pain that accompanies tissue acidosis (1, 2).	CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Waldmann, Rainer/Q-2108-2016; HEURTEAUX, Catherine/M-4947-2016; de Weille, Jan R/F-8103-2014	Waldmann, Rainer/0000-0002-4599-2926; HEURTEAUX, Catherine/0000-0002-9741-9777; de Weille, Jan R/0000-0002-0505-3166; Bassilana, Frederic/0000-0003-2063-8450				AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GRANTYN R, 1989, DEV BRAIN RES, V49, P150, DOI 10.1016/0165-3806(89)90070-9; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KONNERTH A, 1987, J PHYSIOL-LONDON, V386, P603, DOI 10.1113/jphysiol.1987.sp016553; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; RANG HP, 1991, BRIT MED BULL, V47, P534, DOI 10.1093/oxfordjournals.bmb.a072491; STEEN KH, 1992, J NEUROSCI, V12, P86; UENO S, 1992, J PHYSIOL-LONDON, V447, P309, DOI 10.1113/jphysiol.1992.sp019004; VOILLEY N, 1995, GENOMICS, V28, P560, DOI 10.1006/geno.1995.1188; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411	25	449	471	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20975	20978		10.1074/jbc.272.34.20975	http://dx.doi.org/10.1074/jbc.272.34.20975			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261094	hybrid			2022-12-25	WOS:A1997XR78900004
J	Gasman, S; ChasserotGolaz, S; Popoff, MR; Aunis, D; Bader, MF				Gasman, S; ChasserotGolaz, S; Popoff, MR; Aunis, D; Bader, MF			Trimeric G proteins control exocytosis in chromaffin cells - G(o) regulates the peripheral actin network and catecholamine secretion by a mechanism involving the small GTP-binding protein Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; ESCHERICHIA-COLI; ALPHA-SUBUNIT; CLOSTRIDIUM-BOTULINUM; SYNTHETIC PEPTIDES; CARBOXYL TERMINUS; MAST-CELLS; KINASE-C; RELEASE; CYTOSKELETON	Besides having a role in signal transduction, heterotrimeric G proteins may be involved in membrane trafficking events, In chromaffin cells, G(o) is associated with secretory organelles and its activation by mastoparan inhibits the ATP-dependent priming of exocytosis, The effecters by which G(o) controls exocytosis are currently unknown. The subplasmalemmal actin network is one candidate, since it modulates secretion by controlling the movement of secretory granules to the plasma membrane, In streptolysin-O-permeabilized chromaffin cells, activation of exocytosis produces disassembly of cortical actin filaments, Mastoparan blocks the calcium-evoked disruption of cortical actin, and this effect is specifically inhibited by antibodies against G alpha(o) and by a synthetic peptide corresponding to the COOH-terminal domain of G alpha(o). Disruption of actin filaments with cytochalasin E and Clostridium perfringens iota toxin partially reverses the mastoparan-induced inhibition of secretion, Furthermore, the effects of mastoparan on cortical actin and exocytosis are greatly reduced in cells treated with Clostridium botulinum C3 exoenzyme, which specifically inactivates the small G protein Rho. We propose that the control exerted by the granule-associated G(o) on exocytosis may be related to effects on the cortical actin network through a sequence of events which eventually involves the participation of Rho.	INST PASTEUR, F-75724 PARIS 15, FRANCE; INSERM, U338 BIOL COMMUN CELLULAIRE, F-67084 STRASBOURG, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			stéphane, gasman/Q-1145-2019; Gasman, Stephane/D-5113-2017; Bader, Marie-France/O-2098-2016; Chasserot-Golaz, Sylvette/K-7625-2017; Dominique, Aunis/W-1419-2019	stéphane, gasman/0000-0001-8415-1276; Gasman, Stephane/0000-0001-8415-1276; 				AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; AUNIS D, 1988, J EXP BIOL, V139, P253; BADER MF, 1986, J BIOL CHEM, V261, P5777; BADER MF, 1986, J CELL BIOL, V102, P636, DOI 10.1083/jcb.102.2.636; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BENGTSSON T, 1990, P NATL ACAD SCI USA, V87, P2921, DOI 10.1073/pnas.87.8.2921; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERNSTEIN BW, 1985, J NEUROSCI, V5, P2565; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BURGOYNE RD, 1989, CELL SIGNAL, V1, P323, DOI 10.1016/0898-6568(89)90051-X; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; CHEEK TR, 1987, J BIOL CHEM, V262, P11663; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DELCASTILLO AR, 1992, J CELL BIOL, V119, P797, DOI 10.1083/jcb.119.4.797; FLODGAARD H, 1974, J BIOL CHEM, V249, P3465; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; GRANT NJ, 1992, EUR J NEUROSCI, V8, P1789; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JUNGERMANN J, 1995, AM J PHYSIOL-GASTR L, V268, pG328, DOI 10.1152/ajpgi.1995.268.2.G328; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; LANG J, 1995, EMBO J, V14, P3636; LELKES PI, 1986, FEBS LETT, V208, P357, DOI 10.1016/0014-5793(86)81049-3; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Mariot P, 1996, EMBO J, V15, P6476, DOI 10.1002/j.1460-2075.1996.tb01038.x; MATTER K, 1989, J NEUROCHEM, V52, P370, DOI 10.1111/j.1471-4159.1989.tb09131.x; NORGAUER J, 1992, BIOCHEM J, V282, P393, DOI 10.1042/bj2820393; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; Nurnberg B, 1996, FEBS LETT, V389, P61, DOI 10.1016/0014-5793(96)00584-4; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; Ozawa K, 1996, FEBS LETT, V382, P159, DOI 10.1016/0014-5793(96)00162-7; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; PERRIN D, 1985, NATURE, V315, P589, DOI 10.1038/315589a0; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROUOT B, 1989, BIOCHEM J, V260, P307, DOI 10.1042/bj2600307; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SCHODER S, 1996, P NATL ACAD SCI USA, V93, P2100; SILLEN LG, 1971, SPECIAL PUBLICATION, V25; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; THERRIEN S, 1989, J CELL BIOL, V109, P1125, DOI 10.1083/jcb.109.3.1125; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TRIFARO JM, 1992, EUR J PHARM-MOLEC PH, V225, P83, DOI 10.1016/0922-4106(92)90088-D; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Vitale N, 1996, EUR J NEUROSCI, V8, P1275, DOI 10.1111/j.1460-9568.1996.tb01296.x; VITALE N, 1994, J BIOL CHEM, V269, P30293; VITALE N, 1993, J BIOL CHEM, V268, P14715; VITALE N, 1994, BIOCHEM J, V300, P217, DOI 10.1042/bj3000217; VITALE N, 1996, CELL MOL NEUROBIOL, V17, P71; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHANG L, 1995, J NEUROCHEM, V65, P1297; Zhang L, 1996, NEURON, V17, P287, DOI 10.1016/S0896-6273(00)80160-9	68	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20564	20571		10.1074/jbc.272.33.20564	http://dx.doi.org/10.1074/jbc.272.33.20564			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252370	hybrid			2022-12-25	WOS:A1997XR22100040
J	Fixman, ED; HolgadoMadruga, M; Nguyen, L; Kamikura, DM; Fournier, TM; Wong, AJ; Park, M				Fixman, ED; HolgadoMadruga, M; Nguyen, L; Kamikura, DM; Fournier, TM; Wong, AJ; Park, M			Efficient cellular transformation by the Met oncoprotein requires a functional Grb2 binding site and correlates with phosphorylation of the Grb2-associated proteins, Cbl and Gab1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; PRODUCT C-CBL; SCATTER FACTOR; PROTOONCOGENE PRODUCT; EGF RECEPTOR; NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; SH3 DOMAINS; ACTIVATION	The Tpr-Met oncoprotein consists of the catalytic kinase domain of the hepatocyte growth factor/scatter factor receptor tyrosine kinase (Met) fused downstream from sequences encoded by the tpr gene, Tpr-Met is a member of a family of tyrosine kinase oncoproteins generated following genomic rearrangement and has constitutive kinase activity, We have previously demonstrated that a single carboxyl-terminal tyrosine residue, Tyr(489), is essential for efficient transformation of Fr3T3 fibroblasts by Tpr-Met and forms a multisubstrate binding site for Grb2, phosphatidylinositol 3' kinase, phospholipase C gamma, SHP2, and an unknown protein of 110 kDa, A mutant Tpr-Met protein that selectively fails to bind Grba has reduced transforming activity, implicating pathways downstream of Grba in Tpr-Met mediated cell transformation, We show here that the 110-kDa Tpr-Met substrate corresponds to the recently identified Grb2-associated protein, Gab1, Moreover, we show that tyrosine phosphorylation of the Cbl protooncogene product as well as Gab1 required Tyr(489) and correlated with the ability of Tpr-Met to associate with Grba and to transform cells, providing evidence that pathways downstream of Gab1 and/or Cbl may Flay a role in Tpr-Met-mediated cell transformation.	MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT MED, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT ONCOL, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT BIOCHEM, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; KIMMEL CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA; KIMMEL CANC INST, DEPT PHARM, PHILADELPHIA, PA 19107 USA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Jefferson University; Jefferson University					NATIONAL CANCER INSTITUTE [R01CA069495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034514] Funding Source: NIH RePORTER; NCI NIH HHS [CA69495] Funding Source: Medline; NINDS NIH HHS [NS 34514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BASU T, 1994, ONCOGENE, V9, P3483; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FERRACINI R, 1995, ONCOGENE, V10, P739; Ferracini R, 1996, ONCOGENE, V12, P1697; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YANG XM, 1995, LAB INVEST, V73, P483; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	105	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20167	20172		10.1074/jbc.272.32.20167	http://dx.doi.org/10.1074/jbc.272.32.20167			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242692	hybrid			2022-12-25	WOS:A1997XQ05900079
J	Patel, BN; David, S				Patel, BN; David, S			A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ALZHEIMERS-DISEASE; SUBSTANTIA-NIGRA; GENE-EXPRESSION; PARKINSONS-DISEASE; LIPID-PEROXIDATION; RAT CERULOPLASMIN; RADICAL FORMATION; CHOROID-PLEXUS; FET3 GENE	Ceruloplasmin is a copper-binding protein, which is the major ferroxidase in plasma of hepatic origin, We now provide evidence for a novel membrane-bound form of ceruloplasmin expressed by astrocytes in the mammalian central nervous system. Using a monoclonal antibody (1A1), we show that the cell surface antigen recognized by this antibody is ceruloplasmin and that it is directly anchored to the cell surface via a glycosylphosphatidylinositol (GPI) anchor, Our peptide mapping and other immunochemical studies indicate that, except for the GPI anchor, the membrane-bound and secreted plasma forms are similar, We also show that the membrane-bound form of ceruloplasmin has oxidase activity. These studies therefore suggest that the GPI-anchored form of ceruloplasmin may play a role similar to the secreted form in oxidizing ferrous iron, The GPI-anchored form of ceruloplasmin expressed by astrocytes is likely to be the major form of this molecule in the central nervous system because serum ceruloplasmin does not cross the blood-brain barrier, Lack of this form of ceruloplasmin in the central nervous system could lead to the generation of highly toxic free radicals, which can cause neuronal degeneration as seen in aceruloplasminemia and other neurodegenerative diseases such as Parkinson's and Alzheimer's disease.	MONTREAL GEN HOSP,RES INST,CTR RES NEUROSCI,MONTREAL,PQ H3G 1A4,CANADA; MCGILL UNIV,MONTREAL,PQ H3G 1A4,CANADA	McGill University; McGill University								ALDRED AR, 1987, J BIOL CHEM, V262, P2875; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BENSHACHAR D, 1991, J NEUROCHEM, V56, P1441, DOI 10.1111/j.1471-4159.1991.tb11444.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONNOR JR, 1993, NEUROSCI LETT, V159, P88, DOI 10.1016/0304-3940(93)90805-U; CONNOR JR, 1992, J NEUROSCI RES, V31, P327, DOI 10.1002/jnr.490310214; DAIMON M, 1995, BIOCHEM BIOPH RES CO, V208, P1028, DOI 10.1006/bbrc.1995.1437; DELPRINCIPE D, 1989, ACTA PAEDIATR SCAND, V78, P327; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DESILVA DM, 1993, CAN J PHYSIOL PHARM, V71, P715, DOI 10.1139/y93-107; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; DEXTER DT, 1994, MOVEMENT DISORD, V9, P92, DOI 10.1002/mds.870090115; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FLEMING RE, 1990, J BIOL CHEM, V265, P7701; GAITSKHOKI V S, 1990, Biokhimiya, V55, P927; GERLACH M, 1994, J NEUROCHEM, V63, P793, DOI 10.1046/j.1471-4159.1994.63030793.x; GIOMETTO B, 1990, J NEUROL SCI, V98, P81, DOI 10.1016/0022-510X(90)90183-N; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; GUTTERIDGE JMC, 1983, FEBS LETT, V157, P37, DOI 10.1016/0014-5793(83)81111-9; GUTTERIDGE JMC, 1993, BIOCHIM BIOPHYS ACTA, V1156, P144, DOI 10.1016/0304-4165(93)90129-V; Halliday W, 1995, J NEUROL SCI, V134, P84, DOI 10.1016/0022-510X(95)00212-K; Harlow E., 1988, ANTIBODIES LAB MANUA; Harris ZL, 1996, QJM-MON J ASSOC PHYS, V89, P355; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HIRSCH EC, 1991, J NEUROCHEM, V56, P446, DOI 10.1111/j.1471-4159.1991.tb08170.x; Jefferies WA, 1996, TRENDS CELL BIOL, V6, P223, DOI 10.1016/0962-8924(96)10019-2; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; KASARSKIS EJ, 1995, J NEUROL SCI, V130, P203, DOI 10.1016/0022-510X(95)00037-3; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGAN JI, 1994, Q J MED, V87, P663; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; MITTAL B, 1994, MOL CELL NEUROSCI, V5, P78, DOI 10.1006/mcne.1994.1007; MITTAL B, 1994, MOL CELL NEUROSCI, V5, P63, DOI 10.1006/mcne.1994.1006; Miyajima H, 1996, FREE RADICAL BIO MED, V20, P757, DOI 10.1016/0891-5849(95)02178-7; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; MOLLGARD K, 1988, DEV BIOL, V128, P207, DOI 10.1016/0012-1606(88)90283-7; MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NONAKA M, 1995, J IMMUNOL, V155, P3037; NONAKA M, 1995, J IMMUNOL, V155, P3048; OBA H, 1993, RADIOLOGY, V189, P843, DOI 10.1148/radiology.189.3.8234713; Okamoto N, 1996, HUM GENET, V97, P755; OSAKI S, 1966, J BIOL CHEM, V241, P2746; POPE A, 1977, DYNAMIC PROPERTIES G, P13; Rothenberger S, 1996, BRAIN RES, V712, P117, DOI 10.1016/0006-8993(96)88505-2; RUSKAMS AJ, 1990, J NEUROSCI RES, V31, P421; SAMOKYSZYN VM, 1989, J BIOL CHEM, V264, P21; SHVARTSMAN A L, 1990, Molekulyarnaya Biologiya (Moscow), V24, P657; SOFIC E, 1991, J NEUROCHEM, V56, P978, DOI 10.1111/j.1471-4159.1991.tb02017.x; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STURROCK A, 1990, J BIOL CHEM, V265, P3139; Takahashi Y, 1996, HUM MOL GENET, V5, P81, DOI 10.1093/hmg/5.1.81; THOMAS T, 1989, DEV BIOL, V134, P38, DOI 10.1016/0012-1606(89)90076-6; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; YANG FM, 1990, J BIOL CHEM, V265, P10780; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; YU JL, 1995, BIOCHEM BIOPH RES CO, V215, P497, DOI 10.1006/bbrc.1995.2492; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZHOU Y, 1995, NEUROSCI LETT, V195, P89, DOI 10.1016/0304-3940(94)11787-J	64	268	279	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20185	20190		10.1074/jbc.272.32.20185	http://dx.doi.org/10.1074/jbc.272.32.20185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242695	hybrid			2022-12-25	WOS:A1997XQ05900082
J	Pike, RN; Potempa, J; Skinner, R; Fitton, HL; McGraw, WT; Travis, J; Owen, M; Jin, L; Carrell, RW				Pike, RN; Potempa, J; Skinner, R; Fitton, HL; McGraw, WT; Travis, J; Owen, M; Jin, L; Carrell, RW			Heparia-dependent modification of the reactive center arginine of antithrombin and consequent increase in heparin binding affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; ANTI-THROMBIN; ELASTASE; GLASGOW; VARIANT; ALPHA-1-ANTITRYPSIN; CLEAVAGE; PROTEINS; TRYPSIN; SITE	Antithrombin, the principal plasma inhibitor of coagulation proteinases, circulates in a form with low inhibitory activity due to partial insertion of its reactive site loop into the A-beta-sheet of the molecule. Recent crystallographic structures reveal the structural changes that occur when antithrombin is activated by the heparin pentasaccharide, with the exception of the final changes, which take place at the reactive center itself. Here we show that the side chain of the P-1 Arg of alpha-antithrombin is only accessible to modification by the enzyme peptidylarginine deiminase on addition of the heparin pentasaccharide, thereby inactivating the inhibitor, whereas the natural P-1 His variant, antithrombin Glasgow, is unaffected, indicating that only the P-1 Arg becomes accessible. Furthermore, the deimination of P-1 Arg converts antithrombin to a form with 4-fold higher affinity for the heparin pentasaccharide, similar to the affinity found for the P-1 His variant, due to a lowered dissociation rate constant for the antithrombin-pentasaccharide complex. The results support the proposal that antithrombin circulates in a constrained conformation, which when released, in this study by perturbation of the bonding of P-1 Arg to the body of the molecule, allows the reactive site loop to take up the active inhibitory conformation with exposure of the P-1 Arg.	UNIV CAMBRIDGE, CTR MRC, DEPT HAEMATOL, CAMBRIDGE CB2 2QH, ENGLAND; JAGIELLONIAN UNIV, INST MOL BIOL, DEPT MICROBIOL & IMMUNOL, PL-31120 KRAKOW, POLAND; BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA; UNIV GEORGIA, DEPT BIOCHEM & MOL BIOL, ATHENS, GA 30205 USA; CHRISTCHURCH HOSP, DEPT CLIN BIOCHEM, CHRISTCHURCH, NEW ZEALAND	University of Cambridge; Jagiellonian University; Boston University; University System of Georgia; University of Georgia; Christchurch Hospital New Zealand					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026148] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 26148] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission)		BAUGH RJ, 1976, BIOCHEMISTRY-US, V15, P836, DOI 10.1021/bi00649a017; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; Carrell R, 1997, THROMB HAEMOSTASIS, V78, P516; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1996, BIOCHEM J, V314, P647, DOI 10.1042/bj3140647; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; JORDAN RE, 1987, SCIENCE, V237, P777, DOI 10.1126/science.3649921; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1987, BRIT J HAEMATOL, V66, P523, DOI 10.1111/j.1365-2141.1987.tb01338.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCKAY EJ, 1981, THROMB RES, V21, P375, DOI 10.1016/0049-3848(81)90138-9; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; OWEN MC, 1988, FEBS LETT, V231, P317, DOI 10.1016/0014-5793(88)80841-X; OWEN MC, 1991, FEBS LETT, V280, P216, DOI 10.1016/0014-5793(91)80296-F; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; TAKAHARA H, 1985, J BIOL CHEM, V260, P8378	25	46	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19652	19655		10.1074/jbc.272.32.19652	http://dx.doi.org/10.1074/jbc.272.32.19652			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242619	hybrid			2022-12-25	WOS:A1997XQ05900006
J	Roy, C; Martin, M; Mangeat, P				Roy, C; Martin, M; Mangeat, P			A dual involvement of the amino-terminal domain of ezrin in F- and G-actin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-CYTOSKELETAL LINKER; EPIDERMAL GROWTH-FACTOR; GASTRIC PARIETAL-CELLS; ERM FAMILY MEMBERS; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; 80-KDA PHOSPHOPROTEIN; APICAL MICROVILLI; MARGINAL BAND; PROTEIN EZRIN	Human recombinant ezrin, or truncated forms, were coated in microtiter plate and their capacity to bind actin determined. F-actin bound ezrin with a K-d of 504 +/- 230 nM and a molecular stoichiometry of 10.6 actin per ezrin. Ezrin bound both alpha- and beta/gamma-actin essentially as F-form. F-actin binding was totally prevented or drastically reduced when residues 534-586 or 13-30 were deleted, respectively. An actin binding activity was detected in amino-terminal constructs (ezrin 1-310 and 1-333) provided the glutathione S-transferase moiety of the fusion protein was removed, Series of carboxyl-terminal truncations confirmed the presence of this actin-binding site which bound both F- and G-actin, The F- and G-actin-binding sites were differently sensitive to various chemical effecters and distinct specific ezrin antibodies. The internal actin-binding Site Was mapped between residues 281 and 333. The association of ezrin amino-terminal fragment to full-length ezrin blocked F-actin binding to ezrin. It is proposed that, in full-length ezrin, the F-actin-binding site required the juxtaposition of the distal-most amino- and carboxyl-terminal residues of the ezrin molecule.			Roy, C (corresponding author), UNIV MONTPELLIER 2, UMR 5539,CNRS,LAB DYNAM MOL INTERACT MEMBRANAIRES, CC 107, BAT 24, F-34095 MONTPELLIER 5, FRANCE.			MARTIN, Marianne/0000-0001-8932-3129				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; AMIEVA MR, 1994, EXP CELL RES, V210, P140, DOI 10.1006/excr.1994.1021; AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; ANDREOLI C, 1994, J CELL SCI, V107, P2509; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BIRGBAUER E, 1989, J CELL BIOL, V109, P1609, DOI 10.1083/jcb.109.4.1609; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1995, BIOCHEMISTRY-US, V34, P16830, DOI 10.1021/bi00051a034; CHEN J, 1994, AM J PHYSIOL, V267, pC784, DOI 10.1152/ajpcell.1994.267.3.C784; CHEN J, 1995, P NATL ACAD SCI USA, V92, P7495, DOI 10.1073/pnas.92.16.7495; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; EGERTON M, 1992, J IMMUNOL, V149, P1847; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FRANCK Z, 1993, J CELL SCI, V105, P219; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HANZEL DK, 1989, AM J PHYSIOL, V256, pG1082, DOI 10.1152/ajpgi.1989.256.6.G1082; HEIANDER TS, 1996, NATURE, V382, P265; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; KRIEG J, 1992, J BIOL CHEM, V267, P19258; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LANKES WT, 1993, BIOCHIM BIOPHYS ACTA, V1216, P479, DOI 10.1016/0167-4781(93)90018-9; Louvet S, 1996, DEV BIOL, V177, P568, DOI 10.1006/dbio.1996.0186; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; McCartney BM, 1996, J CELL BIOL, V133, P843, DOI 10.1083/jcb.133.4.843; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; PAKKANEN R, 1987, J HISTOCHEM CYTOCHEM, V35, P809, DOI 10.1177/35.8.3298422; PAKKANEN R, 1988, EUR J CELL BIOL, V46, P435; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; ROZYCKI M, 1991, METHOD ENZYMOL, V196, P100; SATO N, 1992, J CELL SCI, V103, P1; SCHWARTZALBIEZ R, 1995, EUR J CELL BIOL, V67, P189; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; THUILLIER L, 1994, CELL IMMUNOL, V156, P322, DOI 10.1006/cimm.1994.1178; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; WINCKLER B, 1994, J CELL SCI, V107, P2523; WOLF HJ, 1991, CELL TISSUE RES, V266, P385, DOI 10.1007/BF00318194; Yao XB, 1996, J BIOL CHEM, V271, P7224, DOI 10.1074/jbc.271.12.7224; YAO XB, 1995, MOL BIOL CELL, V6, P541, DOI 10.1091/mbc.6.5.541	61	88	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20088	20095		10.1074/jbc.272.32.20088	http://dx.doi.org/10.1074/jbc.272.32.20088			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242682	hybrid			2022-12-25	WOS:A1997XQ05900069
J	Platt, FM; Reinkensmeier, G; Dwek, RA; Butters, TD				Platt, FM; Reinkensmeier, G; Dwek, RA; Butters, TD			Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GANGLIOSIDE METABOLISM; GLUCOCEREBROSIDE SYNTHETASE; GLUCOSYLCERAMIDE SYNTHESIS; GLYCOLIPID BIOSYNTHESIS; TAY-SACHS; TOPOLOGY; INHIBITOR; SURFACE; CERAMIDE; DISEASE	The imino sugar N-butyldeoxynojirimycin is an inhibitor of the ceramide-specific glucosyltransferase that catalyzes the first step in glycosphingolipid biosynthesis, It results in extensive glycosphingolipid depletion in cells treated in vitro, without causing toxicity. However, we currently do not know the degree to which glycosphingolipids can be depleted in vivo in a mammalian species, We have therefore administered N-butyldeoxynojirimycin long term to young mice and have found that glycosphingolipid levels are reduced (50-70%) in all tissues examined, without resulting in any overt pathology, When the lymphoid tissues from these mice were examined, they were found to be 50% acellular relative to non-lymphoid tissues. These data implicate a role for glycosphingolipids in the biology of the immune system or indicate an additional as yet unknown activity of N-butyldeoxynojirimycin Extensive glycosphingolipid depletion resulting from N-butyldeoxynojirimycin administration is therefore well tolerated in adult mice, and this compound may be in an invaluable tool for probing glycosphingolipid functions in vivo. In addition, this drug may be effective in clinical situations where glycosphingolipid depletion would be desirable, such as the in the treatment of the human glycosphingolipidoses.			Platt, FM (corresponding author), UNIV OXFORD,DEPT BIOCHEM,GLYCOBIOL INST,S PARKS RD,OXFORD OX1 3QU,ENGLAND.		Platt, Frances/G-1004-2010	Platt, Frances/0000-0001-7614-0403				BEUTLER E, 1992, SCIENCE, V256, P794, DOI 10.1126/science.1589760; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; FENDERSON BA, 1992, EXP CELL RES, V198, P362, DOI 10.1016/0014-4827(92)90392-L; FISCHER P, 1995, J VIROL, V69, P5791, DOI 10.1128/JVI.69.9.5791-5797.1995; FISCHL MA, 1994, J ACQ IMMUN DEF SYND, V7, P139; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; GAHMBERG CG, 1977, J BIOL CHEM, V252, P5888; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Hidari KIPJ, 1996, J BIOL CHEM, V271, P14636, DOI 10.1074/jbc.271.24.14636; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; INOKUCHI JI, 1987, J LIPID RES, V28, P565; ISHIKAWA S, 1996, P NATL ACAD SCI USA, V93, P4638; JACOB GS, 1992, NATURAL PRODUCTS AS ANTIVIRAL AGENTS, P137; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; KALZFULLER B, 1995, EUR J BIOCHEM, V231, P344, DOI 10.1111/j.1432-1033.1995.tb20706.x; KARLSSON GB, 1993, J BIOL CHEM, V268, P570; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; PLATT FM, 1992, CELL IMMUNOL, V143, P449, DOI 10.1016/0008-8749(92)90039-R; PLATT FM, 1995, TRENDS GLYCOSCI GLYC, V7, P495, DOI 10.4052/tigg.7.495; PLATT FM, 1994, J BIOL CHEM, V269, P27108; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PLATT FM, 1994, J BIOL CHEM, V269, P8362; SANDHOFF K, 1993, ADV LIPID RES, V26, P119; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VUNNAM RR, 1980, CHEM PHYS LIPIDS, V26, P265; YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975	32	123	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19365	19372		10.1074/jbc.272.31.19365	http://dx.doi.org/10.1074/jbc.272.31.19365			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235935	hybrid			2022-12-25	WOS:A1997XP06300041
J	Guenal, I; SidotideFraisse, C; Gaumer, S; Mignotte, B				Guenal, I; SidotideFraisse, C; Gaumer, S; Mignotte, B			Bcl-2 and Hsp27 act at different levels to suppress programmed cell death	ONCOGENE			English	Article						apoptosis; p53; simian virus 40; Bcl-2; Hsp27; necrosis	TUMOR-NECROSIS-FACTOR; HEAT-SHOCK PROTEIN; ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; SUBCELLULAR-LOCALIZATION; MITOCHONDRIAL-MEMBRANES; OUTER-MEMBRANE; IN-VIVO; APOPTOSIS; EXPRESSION	Apoptosis and necrosis, two morphologically distinct forms of cell death, can be induced by common stimuli depending on the doses and the cell type, This study compares the protective effect of oncoprotein Bcl-2 and of the small stress protein Hsp27 on these two types of cell death, We use rat embryo fibroblasts conditionally immortalized by the tsA58 mutant of SV40 large T antigen as parental cells to develop cell lines carrying inducible bcl-2 or hsp27 genes. Two apoptotic stimuli were used: shift to the restrictive temperature that induced p53-mediated apoptosis and treatment with low doses of hydrogen peroxide, Necrosis was induced by high doses of hydrogen peroxide. Although Bcl-2 and Hsp27 protect these cells from necrotic death, only Bcl-2 appears capable of preventing apoptotic death, Bcl-2 protection is not mediated by a negative effect on the induction of the p53 responsive genes bax or waf1 but it slows down at least two stages of apoptosis: decrease of mitochondrial membrane potential and subsequent morphological changes, In contrast, although Hsp27 has been recently shown to inhibit apoptosis induced by various stimuli, its overexpression has no effect on apoptosis in this cell system. It should be also noticed that the apoptotic stimuli (temperature shift or hydrogen peroxide treatment) induce Hsp27, but not Bcl-2 accumulation suggesting that, in parental cells, Hsp27 might already provide some protection, However, taken together these results suggest that Hsp27, as well as Bcl-2, acts at several levels to inhibit cell death, but that their protective functions only partially overlap.	CNRS,CTR GENET MOL,UPR 9061,F-91198 GIF SUR YVETTE,FRANCE; UNIV VERSAILLES,F-78035 VERSAILLES,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay			Guenal, Isabelle/F-3415-2019; Mignotte, Bernard/A-3499-2009	Guenal, Isabelle/0000-0003-1186-1458; Mignotte, Bernard/0000-0002-8512-8518				AKAO Y, 1994, CANCER RES, V54, P2468; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; DEJONG D, 1994, CANCER RES, V54, P256; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GUENAL I, 1995, FEBS LETT, V374, P384, DOI 10.1016/0014-5793(95)01157-A; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENNET T, 1993, CANCER RES, V53, P1456; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUOT J, 1991, CANCER RES, V51, P5245; ITOH N, 1993, J IMMUNOL, V151, P621; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KONING AJ, 1993, CELL MOTIL CYTOSKEL, V25, P111, DOI 10.1002/cm.970250202; KORCHAK HM, 1982, BIOCHEM BIOPH RES CO, V108, P1495, DOI 10.1016/S0006-291X(82)80076-4; KORSMEYER SJ, 1992, BLOOD, V80, P879; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LASTER SM, 1988, J IMMUNOL, V141, P2629; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LU QL, 1994, J CELL SCI, V107, P363; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; NAKAI M, 1993, BIOCHEM BIOPH RES CO, V196, P233, DOI 10.1006/bbrc.1993.2239; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2045; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; SUSIN SA, 1996, J EXP MED, V184, P1; SUZUKI K, 1994, EUR J CELL BIOL, V63, P280; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UPADHYAY S, 1995, CANCER RES, V55, P4520; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZHENG DQ, 1994, ONCOGENE, V9, P3345; ZHENG LT, 1993, P NATL ACAD SCI USA, V90, P4533; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; [No title captured]	78	88	91	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					347	360		10.1038/sj.onc.1201182	http://dx.doi.org/10.1038/sj.onc.1201182			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233769	Bronze			2022-12-25	WOS:A1997XK99900011
J	Wang, HC; Shao, NS; Ding, QM; Cui, JQ; Reddy, ESP; Rao, VN				Wang, HC; Shao, NS; Ding, QM; Cui, JQ; Reddy, ESP; Rao, VN			BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases	ONCOGENE			English	Article						BRCA1a; BRCA1b; zinc finger; cyclins; CDKs; E2F	OVARIAN-CANCER INCIDENCE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; BREAST-CANCER; GENE-PRODUCT; EXPRESSION; LOCALIZATION; SEQUENCE; BINDING; CELL	BRCA1, a familial breast and ovarian canter susceptibility gene encodes nuclear phosphoproteins that function as tumor suppressors in human breast cancer cells, Previously, we have shown that overexpression of a BRCA1 splice variant BRCA1a accelerates apoptosis in human breast cancer cells, In an attempt to determine whether the subcellular localization of BRCA1 is cell cycle regulated, we have studied the subcellular distribution of BRCA1 in asynchronous and growth arrested normal, breast and ovarian cancer cells using different BRCA1 antibodies by immunofluorescence and immunohistochemical staining, Upon serum starvation of NIH3T3, some breast and ovarian cancer cells, most of the BRCA1 protein redistributed to the nucleus revealing a new type of regulation that may modulate the activity of BRCA1 gene, We have also characterized two new variant BRCA1 proteins (BRCA1a/p110 and BRCA1b/p100) which are phosphoproteins containing phosphotyrosine, Immunofluorescence and Western blotting analysis indicate cytoplasmic and nuclear localization of BRCA1a and BRCA1b proteins. To elucidate the biological function of BRCA1, we created a bacterial fusion protein of glutathione-transferase (GST) and BRCA1 zinc finger domain and detected two cellular proteins with molecular weights of approximately 32 and 65 kD, one of which contains phosphotyrosine designated p32 and p65 BRCA1 interacting proteins (BIP) that specifically interact with BRCA1, Western blot analysis of BIP with cyclins/CDKs and E2F antisera indicated association with cdc2, cdk2, cdk4, cyclin B, cyclin D, cyclin A and E2F-4 but not with cdk3, cdk5, cdk6, E2F-1, E2F-2, E2F-3, E2F-5 and cyclin E, Furthermore, we have also demonstrated a direct interaction of in vitro translated BRCA1a and BRCA1b proteins with recombinant cyclin A, cyclin B1, cyclin D1, cdc2, cdk2 and E2F fusion proteins in vitro, Taken together these results seem to suggest that BRCA1 could be an important negative regulator of cell cycle that functions through interaction with E2F transcriptional factors and phosphorylation by cyclins/cdk complexes with the zinc ring finger functioning as a major protein-protein interaction domain, If the interactions we observe in vitro is also seen in vivo then it may be possible that lack or impaired binding of the disrupted BRCA1 proteins to E2F, cyclins/CDKs in patients with mutations in the zinc finger domain could deprive the cell of an important mechanism for braking cell proliferation leading to the development of breast and ovarian cancers.	ALLEGHENY UNIV HLTH SCI, DEPT HUMAN GENET, DIV CANC GENET, PHILADELPHIA, PA 19102 USA	Drexel University					NCI NIH HHS [CA 57322, CA 51083, CA 50507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, P01CA050507, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; EASTON DF, 1995, AM J HUM GENET, V56, P265; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FORD D, 1995, AM J HUM GENET, V57, P1457; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Rao VN, 1996, ONCOGENE, V12, P523; RAO VN, 1993, CANCER RES, V53, P3449; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Shao NS, 1996, ONCOGENE, V13, P1; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SINGH H, 1989, BIOTECHNIQUES, V7, P252; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; WU CJ, 1996, NAT GENET, V14, P430	42	101	114	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	1997	15	2					143	157		10.1038/sj.onc.1201252	http://dx.doi.org/10.1038/sj.onc.1201252			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244350				2022-12-25	WOS:A1997XK37200003
J	Goss, SPA; Hogg, N; Kalyanaraman, B				Goss, SPA; Hogg, N; Kalyanaraman, B			The effect of nitric oxide release rates on the oxidation of human low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMULTANEOUS GENERATION; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; L-ARGININE; ENDOTHELIAL DYSFUNCTION; VITAMIN-C; SUPEROXIDE; INHIBITION; CELLS; HYPERCHOLESTEROLEMIA	1-Substituted diazen-1-ium-1,2-diolates, a class of nitric oxide (. NO) donor compounds that spontaneously release . NO at different rates, were used to investigate the effect of . NO release rate upon the oxidation of low density lipoprotein (LDL), All donor compounds conferred an inhibitory effect upon the oxidation of LDL; however, the effect exhibited a biphasic dependence upon the rate of . NO release, The . NO release rate that maximally inhibited oxidation was dependent upon the rate of oxidation, When LDL was rapidly oxidized by copper(II) sulfate, a faster release rate was more effective. In contrast, when LDL was oxidized slowly by 2,2'-azobis-2-amidinopropane hydrochloride, a slower release rate was most effective, This biphasic relationship between . NO release rate and the duration of inhibition was also demonstrated when LDL oxidation was initiated with 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium, a peroxynitrite generator, We conclude that the antioxidant ability of . NO is dependent not only upon the rate of its release from . NO donors, but also upon the rate of oxidation, This conclusion is supported by a kinetic model of LDL oxidation in the presence of . NO.	MED COLL WISCONSIN, BIOPHYS RES INST, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047250] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [HL47250] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; CHANG GJ, 1994, ARTERIOSCLER THROMB, V14, P1808, DOI 10.1161/01.ATV.14.11.1808; COOKE JP, 1991, BASIC RES CARDIOL, V86, P173; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GOSS SPA, 1995, CHEM RES TOXICOL, V8, P800, DOI 10.1021/tx00047a021; HABERLAND ME, 1984, J BIOL CHEM, V259, P1305; HATCH FT, 1968, ADV LIPID RES, V6, P2, DOI 10.1016/B978-1-4831-9942-9.50008-5; HINO M, 1989, J ANTIBIOT, V42, P1578, DOI 10.7164/antibiotics.42.1578; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; HOGG N, 1995, J LIPID RES, V36, P1756; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; HOGG N, 1994, ARCH BIOCHEM BIOPHYS, V314, P153, DOI 10.1006/abbi.1994.1423; Hogg N, 1996, BIOCHEM BIOPH RES CO, V224, P696, DOI 10.1006/bbrc.1996.1086; HOGG N, 1993, FEBS LETT, V326, P199, DOI 10.1016/0014-5793(93)81790-7; JESSUP W, 1990, BIOCHEM J, V265, P399, DOI 10.1042/bj2650399; JOSEPH J, 1993, BIOCHEM BIOPH RES CO, V192, P926, DOI 10.1006/bbrc.1993.1504; KAOUADJI MN, 1987, BIOELECTROCH BIOENER, V18, P59, DOI 10.1016/0302-4598(87)85008-0; LAGERCRANTZ C, 1993, FREE RADICAL RES COM, V19, P387, DOI 10.3109/10715769309056528; LEFER AM, 1993, ARTERIOSCLER THROMB, V13, P771, DOI 10.1161/01.ATV.13.6.771; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MOORADIAN DL, 1995, J CARDIOVASC PHARM, V25, P674, DOI 10.1097/00005344-199504000-00023; NARUSE K, 1994, ARTERIOSCLER THROMB, V14, P746, DOI 10.1161/01.ATV.14.5.746; NIKI E, 1984, J BIOL CHEM, V259, P4177; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P181, DOI 10.1111/j.1476-5381.1987.tb11310.x; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V279, P402, DOI 10.1016/0003-9861(90)90508-V; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STRUCK AT, 1995, FEBS LETT, V361, P291, DOI 10.1016/0014-5793(95)00178-C; TAMIR S, 1993, CHEM RES TOXICOL, V6, P895, DOI 10.1021/tx00036a021; THOMAS JP, 1993, J LIPID RES, V34, P479	40	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21647	21653		10.1074/jbc.272.34.21647	http://dx.doi.org/10.1074/jbc.272.34.21647			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261188	hybrid			2022-12-25	WOS:A1997XR78900098
J	Lavan, BE; Fantin, VR; Chang, ET; Lane, WS; Keller, SR; Lienhard, GE				Lavan, BE; Fantin, VR; Chang, ET; Lane, WS; Keller, SR; Lienhard, GE			A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; IN-VIVO; ADIPOCYTES; DOMAIN; SHC	We have previously identified a 160-kDa protein in human embryonic kidney (HEK) 293 cells that undergoes rapid tyrosine phosphorylation in response to insulin (PY160) (Kuhne, M. R., Zhao, Z., and Lienhard, G. E. (1995) Biochem. Biophys. Res. Commun. 211, 190-197). The phosphotyrosine form of PY160 was purified from insulin-treated HEK 293 cells by anti-phosphotyrosine immunoaffinity chromatography, the sequences of peptides determined, and its cDNA cloned, The PY160 cDNA encodes a 1257-amino acid protein that contains, in order from its N terminus, a pleckstrin homology (PH) domain, a phosphotyrosine binding (PTB) domain, and, spread over the C-terminal portion, 12 potential tyrosine phosphorylation sites. Several of these sites are in motifs expected to bind specific SH2 domain-containing proteins: YXXM (7 sites), phosphatidylinositol S-kinase; YVNM (1 site), Grb-2; and YIEV (1 site), either the protein-tyrosine phosphatase SHP-2 or phospholipase C gamma. Furthermore, the PH and PTB domains are highly homologous (at least 40% identical) to those found in insulin receptor substrates 1, 2, and 3 (IRS-1, IRS-2, and IRS-3). Thus, PY160 is a new member of the IRS family, which we have designated IRS-4.	DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; HARVARD UNIV, DEPT CELLULAR & MOL BIOL, HARVARD MICROCHEM FACIL, CAMBRIDGE, MA 02318 USA	Dartmouth College; Harvard University			Chang, Ellen/E-3168-2010; Chang, Ellen/G-5700-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042816, R01DK042816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Dalphin ME, 1996, NUCLEIC ACIDS RES, V24, P216, DOI 10.1093/nar/24.1.216; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KUHNE MR, 1995, BIOCHEM BIOPH RES CO, V211, P190, DOI 10.1006/bbrc.1995.1795; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lavan BE, 1997, J BIOL CHEM, V272, P11439; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	21	271	279	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21403	21407		10.1074/jbc.272.34.21403	http://dx.doi.org/10.1074/jbc.272.34.21403			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261155	hybrid			2022-12-25	WOS:A1997XR78900065
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; SUBSTRATE-SPECIFICITY; MULTIDRUG-RESISTANCE; CYSTEINE RESIDUES; BINDING-SITE; NUCLEOTIDE; MUTATIONS; MEMBRANE; MUTANTS; MDR1	Transmembrane segments (TM) 6 and 12 are directly connected to the ATP-binding domain in each homologous half of P-glycoprotein and are postulated to be important for drug-protein interactions, Cysteines introduced into TM6 (L332C, F343C, G346C, and P350C) were oxidatively cross-linked to cysteines introduced into TIM12 (L975C, M986C, G989C, and S993C, respectively), The pattern of cross-linking was consistent with a left-handed coiled coil arrangement of the two helices. To detect conformational changes between the helices during drug-stimulated ATPase activity, we tested the effects of substrates and ATP on cross-linking. Cyclosporin A, verapamil, vinblastine, and colchicine inhibited cross-linking of mutants F343C/M986C, G346C/G989C, and P350C/S993C. By contrast, ATP promoted cross-linking between only L332C/L975C. Enhanced cross-linking between L332C/L975C was due to ATP hydrolysis, since cross-linked product was not observed in the presence of ATP and vanadate, ADP, ADP and vanadate, or AMP-PNP. Cross-linking between P350C/S993C inhibited verapamil-stimulated ATPase activity by about 75%, Drug-stimulated ATPase activity, however, was fully restored in the presence of dithiothreitol, These results show that TM6 and TM12 undergo different. conformational changes upon drug binding or during ATP hydrolysis, and that movement between these two helices is essential for drug-stimulated ATPase activity.	UNIV TORONTO,DEPT MED,MED RES COUNCIL GRP MEMBRANE BIOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	30	103	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20986	20989		10.1074/jbc.272.34.20986	http://dx.doi.org/10.1074/jbc.272.34.20986			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261097	hybrid			2022-12-25	WOS:A1997XR78900007
J	Mendre, C; Dufour, MN; LeRoux, S; Seyer, R; Guillou, L; Calas, B; Guillon, G				Mendre, C; Dufour, MN; LeRoux, S; Seyer, R; Guillou, L; Calas, B; Guillon, G			Synthetic rat V-1a vasopressin receptor fragments interfere with vasopressin binding via specific interaction with the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTORS; ADENYLATE-CYCLASE; MOLECULAR-CLONING; HORMONE-BINDING; V1A RECEPTOR; PEPTIDES; PROTEIN; IDENTIFICATION; ANTAGONISTS; MEMBRANES	To study the vasopressin receptor domains involved in the hormonal binding, we synthesized natural and modified fragments of V-1a vasopressin receptor and tested their abilities to affect hormone-receptor interactions. Natural fragments mimicking the external loops one, two, and three were able to inhibit specific vasopressin binding to V-1a receptor, In contrast, the natural N-terminal part of the V-1a vasopressin receptor was found inactive, One fragment, derived from the external second loop and containing an additional C-terminal cysteine amide, was able to fully inhibit the specific binding of both labeled vasopressin agonist and antagonist to rat liver V-1a vasopressin receptor and the vasopressin-sensitive phospholipase C of WRK1 cells, The peptide-mediated inhibition involved specific interactions between the V-1a receptor and synthetic V-1a vasopressin receptor fragment since 1) it was dependent upon the vasopressin receptor subtype tested (K-i(app) for the peptide: 3.7, 14.6, and 64.5 mu M for displacing [H-3]vasopressin from rat V-1a, V-1b, and V-2 receptors, respectively; 2) it was specific and did not affect sarcosin 1-angiotensin II binding to rat liver membranes; 3) it was not mimicked by vasopressin receptor unrelated peptides exhibiting putative detergent properties; and 4) no direct interaction between [H-3]vasopressin and synthetic peptide linked to an affinity chromatography column could be observed, Such an inhibition affected both the maximal binding capacity of the V-1a vasopressin receptor and its affinity for the labeled hormone, depending upon the dose of synthetic peptide used and was partially irreversible, Structure-activity studies using a serie of synthetic fragments revealed the importance of their size and cysteinyl composition, These data indicate that some peptides mimicking extracellular loops of the V-1a vasopressin receptor may interact with the vasopressin receptor itself and modify its coupling with phospholipase C.	CTR PHARMACOL ENDOCRINOL, CNRS, UPR 9023, F-34095 MONTPELLIER 5, FRANCE; CNRS, CTR RECH BIOCHIM MACROMOL, UPR 9008, F-34033 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Mendre, C (corresponding author), CTR PHARMACOL ENDOCRINOL, INSERM, U469, RUE CARDONILLE, F-34095 MONTPELLIER 5, FRANCE.							AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; BUTLEN D, 1978, MOL PHARMACOL, V14, P1006; CANTAU B, 1980, J RECEPTOR RES, V1, P137, DOI 10.3109/10799898009044096; CARNAZZI E, 1994, J MED CHEM, V37, P1841, DOI 10.1021/jm00038a013; CARNAZZI E, 1997, IN PRESS EUR J BIOCH; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DATTATREYAMURTY B, 1993, MOL CELL ENDOCRINOL, V93, P39, DOI 10.1016/0303-7207(93)90137-9; DREIFUSS JJ, 1991, VASOPRESSIN, P159; EVERSHED RP, 1993, RAPID COMMUN MASS SP, V7, P882, DOI 10.1002/rcm.1290071005; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GUILLON G, 1995, ENDOCRINOLOGY, V136, P1285, DOI 10.1210/en.136.3.1285; GUILLON G, 1986, BIOCHEM J, V240, P189, DOI 10.1042/bj2400189; GUILLON G, 1989, ANN ENDOCRINOL-PARIS, V50, P425; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HERBERG JT, 1984, J BIOL CHEM, V259, P9285; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; Howl J, 1996, BIOCHEM J, V317, P577, DOI 10.1042/bj3170577; HWANG C, 1991, P ROY SOC B-BIOL SCI, V245, P115, DOI 10.1098/rspb.1991.0096; JARD S, 1986, MOL PHARMACOL, V30, P171; JARD S, 1988, INT CONGR SER, V799, P1183; KIRK CJ, 1986, BIOCHEM J, V240, P197, DOI 10.1042/bj2400197; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MANNING M, 1992, INT J PEPT PROT RES, V40, P261; Mendre C, 1996, PEPTIDES, V17, P521, DOI 10.1016/0196-9781(95)02128-0; MEZGUELDI M, 1995, J BIOL CHEM, V270, P8867, DOI 10.1074/jbc.270.15.8867; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MORRIS JC, 1993, J BIOL CHEM, V268, P10900; Mouillac B, 1995, ADV EXP MED BIOL, V395, P301; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; NEVILLE DM, 1968, BIOCHIM BIOPHYS ACTA, V154, P540, DOI 10.1016/0005-2795(68)90014-7; PAVO I, 1990, FEBS LETT, V272, P205, DOI 10.1016/0014-5793(90)80485-2; PRADELLE.P, 1972, FEBS LETT, V26, P189, DOI 10.1016/0014-5793(72)80570-2; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; ROY C, 1975, J BIOL CHEM, V250, P7885; SEYER R, 1990, J CHEM SOC PERK T, V1, P3289; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; THORNTON K, 1994, BIOCHEMISTRY-US, V33, P3532, DOI 10.1021/bi00178a009; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3445; VALEMBOIS C, 1992, TETRAHEDRON LETT, V33, P4005, DOI 10.1016/0040-4039(92)88085-J; VARRAULT A, 1994, J BIOL CHEM, V269, P16720; VENTER JC, 1983, TRENDS PHARMACOL SCI, V4, P256	47	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21027	21036		10.1074/jbc.272.34.21027	http://dx.doi.org/10.1074/jbc.272.34.21027			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261104	hybrid			2022-12-25	WOS:A1997XR78900014
J	Morita, K; Kitayama, S; Dohi, T				Morita, K; Kitayama, S; Dohi, T			Stimulation of cyclic ADP-ribose synthesis by acetylcholine and its role in catecholamine release in bovine adrenal chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INDUCED CA2+ RELEASE; DEPENDENT PROTEIN-KINASE; PANCREATIC BETA-CELLS; RYANODINE RECEPTOR; CALCIUM-RELEASE; SARCOPLASMIC-RETICULUM; CA2+-RELEASE CHANNEL; INSULIN-SECRETION; CARDIAC-MUSCLE; ACINAR-CELLS	Cyclic ADP-ribose (cADPR) is suggested to be a novel messenger of ryanodine receptors in various cellular systems, However, the regulation of its synthesis in response to cell stimulation and its functional roles are still unclear, We examined the physiological relevance of cADPR to the messenger role in stimulation-secretion coupling in cultured bovine adrenal chromaffin cells. Sensitization of Ca2+-induced Ca2+ release (CICR) and stimulation of catecholamine release by cADPR in permeabilized cells were demonstrated along with the contribution of CICR to intracellular Ca2+ dynamics and secretory response during stimulation of intact chromaffin cells, ADP-ribosyl cyclase was activated in the membrane preparation from chromaffin cells stimulated with acetylcholine (ACh), excess KCI depolarization, and 8-bromo-cyclic-AMP, ACh-induced activation of ADP-ribosyl cyclase was dependent on the influx of Ca2+ into cells and on the activation of cyclic AMP-dependent protein kinase. These and previous findings that ACh activates adenylate cyclase by Ca2+ influx in chromaffin cells suggested that ACh induces activation of ADP-ribosyl cyclase through Ca2+ influx and cyclic AMP-mediated pathways, These results provide evidence that the synthesis of cADPR is regulated by cell stimulation, and the cADPR/CICR. pathway forms a significant signal transduction for secretion.	HIROSHIMA UNIV, SCH DENT, DEPT PHARMACOL, MINAMI KU, HIROSHIMA 734, JAPAN	Hiroshima University								BURGOYNE RD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P174, DOI 10.1016/0304-4157(91)90024-Q; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; FENWICK EM, 1978, J CELL BIOL, V76, P12, DOI 10.1083/jcb.76.1.12; FRUEN BR, 1994, FEBS LETT, V352, P123, DOI 10.1016/0014-5793(94)00931-7; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Galione Antony, 1994, Trends in Cell Biology, V4, P431, DOI 10.1016/0962-8924(94)90104-X; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GROMADA J, 1995, FEBS LETT, V360, P303, DOI 10.1016/0014-5793(95)00131-R; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSE AH, 1995, J IMMUNOL, V155, P3353; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HIGASHIDA H, 1995, J PHYSIOL-LONDON, V482, P317, DOI 10.1113/jphysiol.1995.sp020520; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LI Q, 1994, BIOCHEM BIOPH RES CO, V202, P629, DOI 10.1006/bbrc.1994.1974; LINDEN DJ, 1995, J NEUROSCI, V15, P5098; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; MORITA K, 1987, J NEUROCHEM, V48, P243, DOI 10.1111/j.1471-4159.1987.tb13154.x; MORITA K, 1995, J LIPID MEDIAT CELL, V11, P219, DOI 10.1016/0929-7855(94)00038-E; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; Shibata K, 1996, BIOCHEM PHARMACOL, V52, P167, DOI 10.1016/0006-2952(96)00135-9; SIMPSON PB, 1995, TRENDS NEUROSCI, V18, P299, DOI 10.1016/0166-2236(95)93919-O; SIMPSON PB, 1993, J NEUROCHEM, V61, P760; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TANAKA Y, 1995, P NATL ACAD SCI USA, V92, P3244, DOI 10.1073/pnas.92.8.3244; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TSUJIMOTO A, 1991, PRESYNAPTIC REGULATI, P1085; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; VOLPE P, 1990, AM J PHYSIOL, V258, pC1086, DOI 10.1152/ajpcell.1990.258.6.C1086; VONEULER U, 1961, ACTA PHYSIOL SCAND, V51, P348, DOI 10.1111/j.1748-1716.1961.tb02145.x; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZHANG FJ, 1995, BIOORG MED CHEM LETT, V5, P2267, DOI 10.1016/0960-894X(95)00393-8	52	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21002	21009		10.1074/jbc.272.34.21002	http://dx.doi.org/10.1074/jbc.272.34.21002			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261101	hybrid			2022-12-25	WOS:A1997XR78900011
J	Saino, T; Daiho, T; Kanazawa, T				Saino, T; Daiho, T; Kanazawa, T			Modification or arginine-198 in sarcoplasmic reticulum Ca2+-ATPase by 1,2-cyclohexanedione causes inhibition of formation of the phosphoenzyme intermediate from inorganic phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ADENOSINE-TRIPHOSPHATASE; TIGHT-BINDING; FUNCTIONAL CONSEQUENCES; CONFORMATIONAL CHANGE; COMPLEMENTARY-DNA; MOLECULAR-CLONING; HIGH-AFFINITY; CA-2+ PUMP; ATPASE	Sarcoplasmic reticulum vesicles were modified with 1,2-cyclohexanedione (CHD), a specific arginine-modifying reagent, in sodium berate (pH 8.0 or 8.8). Phosphoenzyme formation ham P-i in the Ca2+-ATPase (reversal of hydrolysis of the phosphoenzyme intermediate) was almost completely inhibited by the modification with CHD. Tight binding of F- and Mg2+ and high affinity binding of vanadate in the presence of Mg2+, either of which produces a transition state analog for phosphoenzyme formation from the magnesium enzyme-phosphate complex, were also markedly inhibited, In contrast, phosphoenzyme formation from acetyl phosphate in the forward reaction was unaffected, The enzyme was appreciably protected by tight binding of F- and Mg2+ or by high affinity binding of vanadate in the presence of Mg2+, but not by the presence of 20 mM MgCl2 alone or 150 mm P-i alone, against the CHD-induced inhibition of phosphoenzyme formation from P-i. Peptide mapping of the tryptic digests, detection of peptides containing CHD-modified arginyl residues with Girard's reagent T, sequencing, and mass spectrometry showed that Arg-198 was a single major residue protected by tight binding of F- and Mg2+ against the modification with CHD. These results indicate that modification of Arg-198 with CHD is responsible for at least a part (the portion reduced by the transition state analogs) of the CHD-induced inhibition of phosphoenzyme formation from P-i and suggest that Arg-198 is located in or close to the catalytic site in the transition state for phosphoenzyme formation from the magnesium-enzyme-phosphate complex.	ASAHIKAWA MED COLL, DEPT BIOCHEM, ASAHIKAWA, HOKKAIDO 078, JAPAN	Asahikawa Medical College								ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, J BIOL CHEM, V248, P8485; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BURK SE, 1989, J BIOL CHEM, V264, P18561; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CHEN ZD, 1991, J BIOL CHEM, V266, P12386; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; DUX L, 1983, J BIOL CHEM, V258, P111; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; IMAMURA Y, 1989, J BIOCHEM-TOKYO, V105, P775, DOI 10.1093/oxfordjournals.jbchem.a122743; INESI G, 1984, J BIOL CHEM, V259, P996; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; Kimura K, 1996, J BIOL CHEM, V271, P28933, DOI 10.1074/jbc.271.46.28933; KOLASSA N, 1979, FEBS LETT, V108, P495, DOI 10.1016/0014-5793(79)80596-7; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MEDDA P, 1983, EUR J BIOCHEM, V137, P7, DOI 10.1111/j.1432-1033.1983.tb07788.x; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; NAKAMURA S, 1994, J BIOL CHEM, V269, P16015; PATTHY L, 1975, J BIOL CHEM, V250, P557; PATTHY L, 1979, EUR J BIOCHEM, V99, P309, DOI 10.1111/j.1432-1033.1979.tb13258.x; PUCELL A, 1971, J BIOL CHEM, V246, P3389; PUNZENGRUBER C, 1978, EUR J BIOCHEM, V92, P349, DOI 10.1111/j.1432-1033.1978.tb12754.x; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P228, DOI 10.1016/S0076-6879(57)03379-0; VERMA AK, 1988, J BIOL CHEM, V263, P14152; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; YAMASAKI K, 1991, J BIOCHEM, V110, P915, DOI 10.1093/oxfordjournals.jbchem.a123689	46	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21142	21150		10.1074/jbc.272.34.21142	http://dx.doi.org/10.1074/jbc.272.34.21142			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261119	hybrid			2022-12-25	WOS:A1997XR78900029
J	Somani, AK; Bignon, JS; Mills, GB; Siminovitch, KA; Branch, DR				Somani, AK; Bignon, JS; Mills, GB; Siminovitch, KA; Branch, DR			Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; CATALYTIC ACTIVITY; MONOCLONAL-ANTIBODIES; CELL-TRANSFORMATION; ACTIVATED PP60C-SRC; HOMOLOGY-2 DOMAINS; SH2 DOMAIN; PHOSPHORYLATION; EXPRESSION; PP60(C-SRC)	Activation of the cellular Src tyrosine kinase depends upon dephosphorylation of the carboxyl-terminal inhibitory tyrosine phosphorylation site. Herein we show that Src isolated from human platelets and Jurkat T cells is preferentially dephosphorylated at its inhibitory phosphotyrosine site by the SHP-1 tyrosine phosphatase. The data also revealed association of Src with SHP-1 in both platelets and lymphocytes and the capacity of Src to phosphorylate SHP-1 and interact with the SHP-1 NH2-terminal SH2 domain in vitro. Analysis of Src activity in thymocytes from SHP-1-deficient motheaten and viable motheaten mice revealed this kinase activity to be substantially lower than that detected in wild-type thymocytes, but to be enhanced by in vitro exposure to SHP-1. Similarly, immunoblotting analysis of thymocyte Src expression before and after selective depletion of active Src protein indicated that the proportion of active relative to inactive Src protein is markedly reduced in motheaten compared with wild-type cells. These observations, together with the finding of reduced Src activity in HEY cells expressing a dominant negative form of SHP-1, provide compelling evidence that SHP-1 functions include the positive regulation of Src activation.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT IMMUNOL & MED GENET,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MICROBIOL,TORONTO,ON M5G 1X5,CANADA; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL ONCOL,HOUSTON,TX 77030; TORONTO HOSP RES INST,TORONTO,ON M5G 2M1,CANADA; CANADIAN RED CROSS SOC,TORONTO,ON M5G 2M1,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Somani, ally-khan/AAA-9656-2020; Siminovitch, Katherine/K-1475-2013	Somani, Ally-Khan/0000-0003-2166-4896				BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BRANCH DR, 1995, J IMMUNOL, V154, P3678; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1983, J BIOL CHEM, V258, P1108; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; FANG KS, 1994, J BIOL CHEM, V269, P20194; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MILLS GB, 1992, INT IMMUNOL, V4, P1233, DOI 10.1093/intimm/4.11.1233; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PENG ZY, 1995, ONCOGENE, V11, P1955; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Stover DR, 1996, J BIOL CHEM, V271, P12481, DOI 10.1074/jbc.271.21.12481; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	52	143	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21113	21119		10.1074/jbc.272.34.21113	http://dx.doi.org/10.1074/jbc.272.34.21113			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261115	hybrid			2022-12-25	WOS:A1997XR78900025
J	Barnabas, S; Hai, TW; Andrisani, OM				Barnabas, S; Hai, TW; Andrisani, OM			The hepatitis B virus X protein enhances the DNA binding potential and transcription efficacy of bZip transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; 3 C/EBP ISOFORMS; TRANS-ACTIVATION; GENE-EXPRESSION; HBX PROTEIN; I TAX; HEPATOCELLULAR-CARCINOMA; ESCHERICHIA-COLI; VIRAL ENHANCERS	The hepatitis B virus X protein interacts with the basic-region, leucine zipper protein (bZip) domain of cAMP response element binding protein increasing its affinity for the cAMP response element site in vitro and its transcriptional efficacy in vivo (Williams, J. S., and Andrisani, O. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3819-3823). Here we examine pX interactions with bZip transcription factors ATF(3), gadd153/Chop10, ICER II gamma and NF-IL6. We demonstrate direct interactions in vitro between pX and the bZip proteins tested. In contrast MyoD and Gal4(1-147) fail to interact with pX. We also demonstrate by the mammalian two-hybrid assay the direct interaction of pX with cAMP response element-binding protein, ICER II gamma, ATF(3), and NF-IL6 in hepatocytes. In addition, pX increases the DNA binding potential of bZip proteins for their cognate DNA-binding site in vitro. In transient transfections in hepatocytes (AML12 cell line), pX increases the transcriptional efficacy of the bZip transcription factors. NF-IL6-mediated transcriptional activation is enhanced 3-fold by pX. Most interestingly, pX augments the repression mediated by bZip repressors ATF, and ICER IL gamma, by 6- and 7-fold, respectively, demonstrating for the first time the involvement of pX in gene repression. We conclude that pX is an enhancer of the DNA binding potential of bZip transcription factors, thereby increasing the transactivation or repression efficacy of bZip-responsive genes.	PURDUE UNIV, SCH VET MED, DEPT BASIC MED SCI, W LAFAYETTE, IN 47907 USA; OHIO STATE UNIV, OHIO STATE BIOCHEM PROGRAM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM MED, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, NEUROBIOTECHNOL CTR, COLUMBUS, OH 43210 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Hai, Tsonwin/H-4480-2011; Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315; Andrisani, Ourania/0000-0002-6230-0303	NIDDK NIH HHS [DK44533] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044533, R01DK044533] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ANDRISANI OM, 1991, J BIOL CHEM, V266, P21444; ANDRISANI OM, 1989, P NATL ACAD SCI USA, V86, P2181, DOI 10.1073/pnas.86.7.2181; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BALSANO C, 1993, ARCH VIROL, P63; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARRISON TJ, 1990, J MED VIROL, V31, P33, DOI 10.1002/jmv.1890310107; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; KAY A, 1985, EMBO J, V4, P1287, DOI 10.1002/j.1460-2075.1985.tb03774.x; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; LUBER B, 1991, VIROLOGY, V184, P808, DOI 10.1016/0042-6822(91)90458-N; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; LUETHY JD, 1992, CANCER RES, V52, P5; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MORIARTY AM, 1985, SCIENCE, V227, P429, DOI 10.1126/science.2981434; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PRICE BD, 1992, CANCER RES, V52, P3814; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; Servillo G, 1997, ONCOGENE, V14, P1601, DOI 10.1038/sj.onc.1200996; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tesmer VM, 1996, J MOL BIOL, V262, P327, DOI 10.1006/jmbi.1996.0516; TESMER VM, 1993, P NATL ACAD SCI USA, V90, P7298, DOI 10.1073/pnas.90.15.7298; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; TWU JS, 1990, VIROLOGY, V177, P406, DOI 10.1016/0042-6822(90)90501-H; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WILLIAMS JS, 1993, DNA CELL BIOL, V12, P183, DOI 10.1089/dna.1993.12.183; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; YEN TSB, 1993, SEMIN VIROL, V4, P33; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; ZHU Z, 1989, J BIOL CHEM, V264, P6550; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	80	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20684	20690		10.1074/jbc.272.33.20684	http://dx.doi.org/10.1074/jbc.272.33.20684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252388	hybrid			2022-12-25	WOS:A1997XR22100058
J	Edgerton, MD; Graber, P; Willard, D; Consler, T; McKinnon, M; Uings, I; Arod, CY; Borlat, F; Fish, R; Peitsch, MC; Wells, TNC; Proudfoot, AEI				Edgerton, MD; Graber, P; Willard, D; Consler, T; McKinnon, M; Uings, I; Arod, CY; Borlat, F; Fish, R; Peitsch, MC; Wells, TNC; Proudfoot, AEI			Spatial orientation of the alpha and beta(c) receptor chain binding sites on monomeric human interleukin-5 constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-5; MURINE INTERLEUKIN-5; HUMAN EOSINOPHILS; ESCHERICHIA-COLI; IL-5; RESIDUES; DISEASE; HYPERREACTIVITY; IDENTIFICATION; PURIFICATION	Interleukin-5 (IL-5), a disulfide-linked homodimer, can be induced to fold as a biological active monomer by extending the loop between its third and fourth helices (Dickason, R, R., and Huston, D, P, (1996) Nature 379, 652-655), We have designed eight monomeric IL-5 proteins to optimize biological activity and stability of the monomer, This was achieved by (i) inserting the joining loop at three different positions, (ii) by introducing an additional intramolecular disulfide bridge onto these backbones, and (iii) by creating circular permutations to fix the position of the carboxyl-terminal helix relative to the three other helices, The proteins dimerize with K-d values ranging from 20 to 200 mu M and are therefore monomeric at the picomolar concentrations where they are biologically active, Introduction of a second disulfide confers increased stability, but this increased rigidity results in lower activity of the protein, Contrary to wild type IL-5, mutation of the beta(c) contact residue on the first helix, Glu(12), to Lys, into the circularly permutated constructs, did not abolish TF-1 proliferative and eosinophil activation activities, These results indicate that activation of the IL-5 receptor complex is not mediated solely by Glu(12) on the first helix, and alternative mechanisms are discussed.	GLAXO WELLCOME RES & DEV LTD, GENEVA BIOMED RES INST, CH-1228 PLAN LES OUATES, GENEVA, SWITZERLAND; GLAXO WELLCOME INC, RES & DEV, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME RES & DEV LTD, STEVENAGE SG1 2NY, HERTS, ENGLAND	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline			Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X; Wells, Timothy/0000-0001-9796-847X				AZUMA C, 1986, NUCLEIC ACIDS RES, V14, P9149, DOI 10.1093/nar/14.22.9149; BANKS M, 1995, ANAL BIOCHEM, V230, P321, DOI 10.1006/abio.1995.1481; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; DEVOS R, 1993, J BIOL CHEM, V268, P6581; Dickason RR, 1996, NATURE, V379, P652, DOI 10.1038/379652a0; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, V11, P431; EGAN RW, 1995, INT ARCH ALLERGY IMM, V107, P321, DOI 10.1159/000237014; Fattah D, 1996, CYTOKINE, V8, P248, DOI 10.1006/cyto.1996.0034; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; GRABER P, 1993, EUR J BIOCHEM, V212, P751, DOI 10.1111/j.1432-1033.1993.tb17714.x; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; INGLEY E, 1991, BLOOD, V78, P339; Jenkins BJ, 1996, J BIOL CHEM, V271, P29707, DOI 10.1074/jbc.271.47.29707; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Li J, 1996, J BIOL CHEM, V271, P1817, DOI 10.1074/jbc.271.4.1817; Li J, 1996, J BIOL CHEM, V271, P31729, DOI 10.1074/jbc.271.49.31729; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; MCKENZIE ANJ, 1992, CHEM IMMUNOL, V51, P135; MCKENZIE DT, 1987, J IMMUNOL, V139, P2661; McKinnon M, 1997, J EXP MED, V186, P121, DOI 10.1084/jem.186.1.121; MIGITA M, 1991, CELL IMMUNOL, V133, P484, DOI 10.1016/0008-8749(91)90120-Z; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MORTON T, 1995, P NATL ACAD SCI USA, V92, P10879, DOI 10.1073/pnas.92.24.10879; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Proudfoot AEI, 1996, J PROTEIN CHEM, V15, P491, DOI 10.1007/BF01886857; PROUDFOOT AEI, 1990, BIOCHEM J, V270, P357, DOI 10.1042/bj2700357; REED CE, 1994, ANN ALLERGY, V72, P376; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; STRYDOM DJ, 1993, TECHNIQUES PROTEIN C; TAVERNIER J, 1989, DNA-J MOLEC CELL BIO, V8, P491, DOI 10.1089/dna.1.1989.8.491; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WARDLAW AJ, 1994, POSTGRAD MED J, V70, P536, DOI 10.1136/pgmj.70.826.536; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	46	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20611	20618		10.1074/jbc.272.33.20611	http://dx.doi.org/10.1074/jbc.272.33.20611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252376	hybrid			2022-12-25	WOS:A1997XR22100046
J	Ferrigno, O; Virolle, T; Galliano, MF; Chauvin, N; Ortonne, JP; Meneguzzi, G; Aberdam, D				Ferrigno, O; Virolle, T; Galliano, MF; Chauvin, N; Ortonne, JP; Meneguzzi, G; Aberdam, D			Murine laminin alpha 3A and alpha 3B isoform chains are generated by usage of two promoters and alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; EPITHELIAL BASEMENT-MEMBRANES; ADHESIVE LIGAND; INTEGRIN BETA-4; GENE LAMC2; B2 CHAIN; EXPRESSION; EPILIGRIN; MUTATIONS; NICEIN/KALININ	We already identified two distinct laminin alpha 3A and alpha 3B chain isoforms which differ in their amino-terminal ends and display different tissue-specific expression patterns, In this study we have investigated whether these two different isoforms are products of the same laminin alpha 3 (lama3) gene and transcribed from one or two separate promoters. Genomic clones were isolated that encompass the sequences upstream to the 5' ends of both the alpha 3A and the alpha 3B cDNAs, Sequence analysis of the region upstream to the alpha 3A open reading frame revealed the presence of a TATA box and potential binding sites for responsive elements. By primer extension analysis, the transcription start site of the alpha 3B mRNA isoform was defined. The sequences upstream to the alpha 3B mRNA transcription start site do not contain a TATA box near the transcription initiation sites, but AP-1, AP-2, and Sp1 consensus binding site sequences were identified, The genomic regions located immediately upstream of the alpha 3A and alpha 3B transcription start sites were shown to possess promoter activities in transfection experiments, In the promoter regions, response elements for the acute phase reactant signal and NF-interleukin 6 were found, and their possible relevance in the context of inflammation and wound healing is discussed, Our results demonstrate that the lama3 gene produces the two polypeptides by alternative splicing and contains two promoters, which regulate the production of the two isoforms alpha 3A and alpha 3B.	INSERM, U385, UFR MED, FAC MED, F-06107 NICE 2, FRANCE; HOP LARCHET, SERV DERMATOL, F-06002 NICE 1, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice			Virolle, Thierry/E-5838-2016; Aberdam, Daniel/G-3299-2013; ferrigno, olivier/GSN-8581-2022	ferrigno, olivier/0000-0001-7544-4384; Aberdam, Daniel/0000-0002-4019-5418; Meneguzzi, Guerrino/0000-0002-1609-6540				ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; Baker SE, 1996, J CELL SCI, V109, P2509; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; COMBATES NJ, 1994, J BIOL CHEM, V269, P29715; DELWEL GO, 1996, ADHESION RECEPTORS T, P9; DOMLOGEHULTSCH N, 1992, J CLIN INVEST, V90, P1628, DOI 10.1172/JCI116033; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; GagnouxPalacios L, 1996, J BIOL CHEM, V271, P18437, DOI 10.1074/jbc.271.31.18437; GALDIE J, 1991, CYTOKINES INFLAMMATI, P275; GALLIANO MF, 1995, J BIOL CHEM, V270, P21820, DOI 10.1074/jbc.270.37.21820; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GIL SG, 1994, J INVEST DERMATOL, V103, pS31, DOI 10.1111/1523-1747.ep12398953; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; JKJL, 1984, JKO, V8, P2313; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; McGrath JA, 1996, J INVEST DERMATOL, V106, P781, DOI 10.1111/1523-1747.ep12346349; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; RICHARDS AJ, 1994, GENOMICS, V22, P237, DOI 10.1006/geno.1994.1372; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seiffert D, 1996, J BIOL CHEM, V271, P5474, DOI 10.1074/jbc.271.10.5474; VAILLY J, 1995, J INVEST DERMATOL, V104, P462, DOI 10.1111/1523-1747.ep12605898; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; VERRANDO P, 1991, LAB INVEST, V64, P85; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141	39	39	39	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20502	20507		10.1074/jbc.272.33.20502	http://dx.doi.org/10.1074/jbc.272.33.20502			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252362	hybrid			2022-12-25	WOS:A1997XR22100032
J	Ivessa, NE; Gravotta, D; DeLemosChiarandini, C; Kreibich, G				Ivessa, NE; Gravotta, D; DeLemosChiarandini, C; Kreibich, G			Functional protein prenylation is required for the brefeldin a-dependent retrograde transport from the Golgi apparatus to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; SENSITIVE G-PROTEIN; O-GLYCOSYLATION; RAB GTPASES; MEMBRANE; CELLS; TRAFFICKING; CALCIUM; GTP; ER	In cells exposed to brefeldin A (BFA), enzymes of the Golgi apparatus are redistributed to the endoplasmic reticulum (ER) by retrograde membrane flow, where they may cause modifications on resident ER proteins. We have used a truncated form of the rough ER-specific type I transmembrane glycoprotein ribophorin I as a probe to detect Golgi glycosyltransferases relocated to the ER in a BFA-dependent fashion. This polypeptide (RI332) comprises the 332 amino-terminal amino acids of ribophorin I and behaves like a luminal ER protein when expressed in HeLa cells. Upon treatment of the cells with BFA, RI332 becomes quantitatively O-glycosylated by Golgi glycosyltransferases that are transported back to the ER. Here we demonstrate that pretreatment of the cells with lovastatin, an inhibitor of HMG-CoA reductase, abrogates this modification and that mevalonate, the product formed in the step inhibited by the drug, is able to counteract the effect of lovastatin. We also show by immunofluorescence using mannosidase II as a Golgi marker that the BFA-induced retrograde transport of Golgi enzymes is blocked by lovastatin, although electron microscopy indicates that BFA causes disassembly of the Golgi apparatus into swollen vesicles and tubules. Our observations support the role of a prenylated protein, such as the geranylgeranylated small G protein Rab6, in the retrograde transport from the Golgi apparatus to the ER, since lovastatin acts by inhibiting its prenylation.	BIOCTR, A-1030 VIENNA, AUSTRIA; NYU, SCH MED, DEPT CELL BIOL, NEW YORK, NY 10016 USA; NYU, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University	Ivessa, NE (corresponding author), UNIV VIENNA, DEPT MOL GENET, DR BOHR GASSE 9-2, A-1030 VIENNA, AUSTRIA.				NIGMS NIH HHS [5RO1 GM 43583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DELEMOSCHIARANDINI C, 1992, EUR J CELL BIOL, V58, P187; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GOLDSTEIN JL, 1979, J BIOL CHEM, V254, P5403; IVESSA NE, 1992, J CELL BIOL, V117, P949, DOI 10.1083/jcb.117.5.949; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LIPPINCOTTSCHWA.J, 1993, CELL, V3, P81; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MALTESE WA, 1985, J CELL PHYSIOL, V125, P540, DOI 10.1002/jcp.1041250326; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; RAO M, 1993, J CELL SCI, V106, P789; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SHEN BQ, 1995, J BIOL CHEM, V270, P25102, DOI 10.1074/jbc.270.42.25102; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; TAN A, 1992, J CELL BIOL, V116, P1357, DOI 10.1083/jcb.116.6.1357; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; WILSON BS, 1994, J CELL BIOL, V125, P557, DOI 10.1083/jcb.125.3.557; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; ZERIAL M, 1995, GUIDEBOOK SMALL GTPA, P295; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	41	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20828	20834		10.1074/jbc.272.33.20828	http://dx.doi.org/10.1074/jbc.272.33.20828			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252408	hybrid			2022-12-25	WOS:A1997XR22100078
J	Lamaze, C; Fujimoto, LM; Yin, HL; Schmid, SL				Lamaze, C; Fujimoto, LM; Yin, HL; Schmid, SL			The actin cytoskeleton is required for receptor-mediated endocytosis in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNALIZATION STEP; BINDING-PROTEINS; CYTOCHALASIN-D; EXOCYTOSIS; MICROFILAMENTS; ORGANIZATION; INHIBITION; FILAMENT; GROWTH; ASSAYS	Actin filament organization is essential for endocytosis in yeast. In contrast, the actin-depolymerizing agent cytochalasin D has yielded ambiguous results as to a role for actin in receptor mediated endocytosis in mammalian cells. We have therefore re-examined this issue using highly specific reagents known to sequester actin monomers. Two of these reagents, thymosin beta 4 and DNase I, potently inhibited the sequestration of transferrin receptors into coated pits as measured in a cell-free system using perforated A431 cells. At low concentrations, thymosin beta 4 but not DNase I was stimulatory, Importantly, the effects of both reagents were specifically neutralized by the addition of actin monomers. A role for the actin cytoskeleton was also detected in intact cells where latrunculin A, a drug that sequesters actin monomers, inhibited receptor-mediated endocytosis. Biochemical and morphological analyses suggest that these reagents inhibit later events in coated vesicle budding. These results provide new evidence that the actin cytoskeleton is required for receptor-mediated endocytosis in mammalian cells.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA	Scripps Research Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Lamaze, Christophe/M-4912-2017	LAMAZE, Christophe/0000-0001-5430-2707; Schmid, Sandra/0000-0002-1690-7024	NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042455, R01GM051112] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline; NIGMS NIH HHS [GM42455, GM51112] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Durrbach A, 1996, J CELL SCI, V109, P457; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; JACKMAN MR, 1994, J CELL SCI, V107, P2547; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SALISBURY JL, 1980, J CELL BIOL, V87, P132, DOI 10.1083/jcb.87.1.132; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SMYTHE E, 1992, METHOD ENZYMOL, V219, P223; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; TRIFARO JM, 1992, MOL NEUROBIOL, V6, P339, DOI 10.1007/BF02757940; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; WEBER A, 1994, BIOCHEMISTRY-US, V33, P4780, DOI 10.1021/bi00182a005; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; YU FX, 1993, J BIOL CHEM, V268, P502	29	324	328	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20332	20335		10.1074/jbc.272.33.20332	http://dx.doi.org/10.1074/jbc.272.33.20332			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252336	hybrid			2022-12-25	WOS:A1997XR22100006
J	Churchich, JE				Churchich, JE			Conformational changes at the nucleotide binding of GroEL induced by binding of protein substrates - Luminescence studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALATE-DEHYDROGENASE; CHAPERONINS; CYCLE; GENES	2'-Deoxy-3'-anthraniloyl adenosine-5-triphosphate (ANT-dATP) coordinated to Tb3+ was used as an environmentally sensitive probe of the nucleotide-binding site of GroEL. Tb3+ ANT-dATP recognizes the nucleotide-binding site of GroEL and inhibits ATPase activity. Sensitized luminescence, arising from resonance energy transfer from the anthraniloyl moiety to Tb3+, is substantially enhanced in the presence of GroEL. Binding of denatured mitochondrial malate dehydrogenase to the apical domain of GroEL causes a red shift in the fluorescence emitted by anthraniloyl and, further enhancement in the phosphorescence emitted by Tb3+ upon excitation at 320 nm. It is suggested that binding of the protein substrate initiates domain movement, which is extended to the nucleotide-binding site. The luminescence results are discussed in reference to the structure of GroEL derived from x-ray crystallographic studies.			Churchich, JE (corresponding author), UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996, USA.							AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHURCHICH JE, 1995, EUR J BIOCHEM, V231, P736, DOI 10.1111/j.1432-1033.1995.0736d.x; DEHARROCKS W, 1981, ACCOUNTS CHEM RES, V14, P384; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; Gibbons DL, 1996, J BIOL CHEM, V271, P31989, DOI 10.1074/jbc.271.50.31989; Gibbons DL, 1996, J BIOL CHEM, V271, P238, DOI 10.1074/jbc.271.1.238; GREGORY EM, 1971, J BIOL CHEM, V246, P5491; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HUTCHINSON JP, 1994, BIOCHEM J, V302, P405, DOI 10.1042/bj3020405; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JENKINS AJ, 1986, MOL GEN GENET, V202, P446, DOI 10.1007/BF00333275; Krauss O, 1996, EUR J BIOCHEM, V241, P538, DOI 10.1111/j.1432-1033.1996.00538.x; LI W, 1997, IN PRESS EUR J BIOCH; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINO Y, 1993, FEBS LETT, V336, P363, DOI 10.1016/0014-5793(93)80838-L; Mendoza JA, 1996, J BIOL CHEM, V271, P16344, DOI 10.1074/jbc.271.27.16344; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; VITANEN PV, 1992, PROTEIN SCI, V1, P363; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062	24	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19645	19648		10.1074/jbc.272.32.19645	http://dx.doi.org/10.1074/jbc.272.32.19645			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242617	hybrid			2022-12-25	WOS:A1997XQ05900004
J	Fujiwara, K; OkamuraIkeda, K; Packer, L; Motokawa, Y				Fujiwara, K; OkamuraIkeda, K; Packer, L; Motokawa, Y			Synthesis and characterization of selenolipoylated H-protein of the glycine cleavage system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LIPOIC ACID; LIVER-MITOCHONDRIA; T-PROTEIN; MECHANISM; PURIFICATION; METABOLISM	H-protein of the glycine cleavage system has a lipoic acid prosthetic group. Selenolipoic acid is a lipoic acid analog ire which both sulfur atoms sire replaced by selenium atoms. Two isoforms of bovine lipoyltransferase that are responsible for the attachment of lipoic acid to H-protein had an affinity for selenolipoyl-AMP and transferred the selenolipoyl moiety to bovine apoH-protein comparable to lipoyl-AMP. Selenolipoylated H-protein was overexpressed in Escherichia coli and purified. Selenolipoylated H-protein was 26% as effective as lipoylated H-protein in the glycine decarboxylation reaction, in which reduction of the diselenide bond of selenolipoylated H-protein is catalyzed by P-protein. The diselenide form of selenolipoylated H-protein was a poor substrate for L-protein, and the rate of reduction was 0.5% of that of lipoylated H-protein. The rate of the overall glycine cleavage reaction with selenolipoylated H-protein was <1% of that with lipoylated H-protein. These results are consistent with the difference in the redox potential between the diselenide and disulfide bonds, In contrast, selenolipoylated H-protein showed three times as high glycine-(CO2)-C-14 exchange activity as lipoylated H-protein, presumably because the rate of reoxidation of reduced selenolipoylated H-protein is much higher than that of lipoylated H-protein.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	Tokushima University; University of California System; University of California Berkeley								ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; FUJIWARA K, 1979, ARCH BIOCHEM BIOPHYS, V197, P454, DOI 10.1016/0003-9861(79)90267-4; FUJIWARA K, 1994, J BIOL CHEM, V269, P16605; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; FUJIWARA K, 1983, J BIOL CHEM, V258, P8156; FUJIWARA K, 1984, J BIOL CHEM, V259, P664; KE B, 1957, BIOCHIM BIOPHYS ACTA, V25, P650, DOI 10.1016/0006-3002(57)90544-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOTOKAWA Y, 1974, ARCH BIOCHEM BIOPHYS, V164, P624, DOI 10.1016/0003-9861(74)90074-5; OKAMURAIKEDA K, 1987, J BIOL CHEM, V262, P6746; OKAMURAIKEDA K, 1993, EUR J BIOCHEM, V216, P539, DOI 10.1111/j.1432-1033.1993.tb18172.x; OLIVER DJ, 1990, PLANT PHYSIOL, V94, P833, DOI 10.1104/pp.94.2.833; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED KE, 1994, P NATL ACAD SCI USA, V91, P3720, DOI 10.1073/pnas.91.9.3720; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1958, J BIOL CHEM, V232, P123; SCHEPKIN V, 1994, BIOCHEM MOL BIOL INT, V33, P879; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; TSUNODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395, DOI 10.1016/0003-9861(67)90366-9	20	3	4	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19880	19883		10.1074/jbc.272.32.19880	http://dx.doi.org/10.1074/jbc.272.32.19880			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242652	hybrid			2022-12-25	WOS:A1997XQ05900039
J	Guy, HI; Evans, DR				Guy, HI; Evans, DR			Trapping an activated conformation of mammalian carbamyl-phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; INITIATES PYRIMIDINE BIOSYNTHESIS; CARBONIC-PHOSPHORIC ANHYDRIDE; GLUTAMINE BINDING-SITE; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; REVERSIBLE DISSOCIATION; AMIDOTRANSFERASE DOMAIN; HAMSTER CELLS; GENE	The amidotransferase or glutaminase domain (GLN domain) of mammalian carbamyl-phosphate synthetase II (CPSase II) catalyzes glutamine hydrolysis and transfers ammonia to the synthetase domain (CPS domain), where carbamyl phosphate formation is catalyzed in three consecutive reactions, The GLN and CPS domains are part of a single polypeptide and are connected via a 29-amino acid chain segment (GC linker). In contrast, the two comparable domains of Escherichia coli CPSase are not fused, but are separate, noncovalently associated subunits, To establish the function of the GC linker in mammalian CPSase, it was deleted, and the two domains were directly fused, The deletion mutant not only catalyzed glutamine-dependent carbamyl phosphate synthesis, but was activated 10-fold relative to its wildtype counterpart, However, ammonia-dependent synthesis of carbamyl phosphate was abolished, indicating that ammonia no longer had access to the active site on the CPS domain, The mutant was still sensitive to inhibition by the allosteric effector UTP, but was no longer activated by the allosteric effector phosphoribosyl pyrophosphate, although evidence indicated that the latter could bind to the enzyme, The linker appears to serve as a spacer that allows the complex to cycle between two conformations, an open low activity form in which the ammonia site on the CPS domain is accessible and an activated conformation in which the ammonia generated in situ from glutamine is directly channeled to the CPS active site and access to exogenous ammonia is blocked.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA	Wayne State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47399] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1975, BIOCHEMISTRY-US, V14, P3688, DOI 10.1021/bi00687a027; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; BEIN K, 1991, J BIOL CHEM, V266, P3791; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; Guy HI, 1997, J BIOL CHEM, V272, P19913, DOI 10.1074/jbc.272.32.19913; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; GUY HI, 1994, J BIOL CHEM, V269, P23808; GUY HI, 1994, J BIOL CHEM, V269, P7702; HAGER SE, 1967, J BIOL CHEM, V242, P5674; HAGER SE, 1967, J BIOL CHEM, V242, P5667; Hanahan D, 1985, DNA CLONING PRACTICA; KERN CB, 1992, J MOL EVOL, V35, P217; KHEDOURI E, 1966, BIOCHEMISTRY-US, V5, P3552, DOI 10.1021/bi00875a024; KIM HS, 1992, J BIOL CHEM, V267, P7177; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1971, J BIOL CHEM, V246, P3694; LIU X, 1994, J BIOL CHEM, V269, P27747; MALEY JA, 1988, BIOCHEM BIOPH RES CO, V154, P1047, DOI 10.1016/0006-291X(88)90246-X; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MARSHALL M, 1958, J BIOL CHEM, V233, P102; MATTHEWS SL, 1972, BIOCHEMISTRY-US, V11, P1176, DOI 10.1021/bi00757a010; McCudden CR, 1996, J BIOL CHEM, V271, P18285, DOI 10.1074/jbc.271.30.18285; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; METZENBERG RL, 1957, J BIOL CHEM, V229, P1019; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; MORI M, 1975, J BIOCHEM, V78, P239; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; PINKUS LM, 1972, J BIOL CHEM, V247, P6119; POST LE, 1990, J BIOL CHEM, V265, P7742; POWERS SG, 1976, P NATL ACAD SCI USA, V73, P3020, DOI 10.1073/pnas.73.9.3020; POWERS SG, 1977, J BIOL CHEM, V252, P3558; POWERS SG, 1978, J BIOL CHEM, V253, P1258; POWERS SG, 1978, J BIOL CHEM, V253, P800; RAUSHEL FM, 1978, J BIOL CHEM, V253, P6627; RAUSHEL FM, 1979, BIOCHEMISTRY-US, V18, P3424, DOI 10.1021/bi00582a033; RAUSHEL FM, 1980, BIOCHEMISTRY-US, V19, P3170, DOI 10.1021/bi00555a009; RAUSHEL FM, 1978, BIOCHEMISTRY-US, V17, P5587, DOI 10.1021/bi00619a001; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; TATIBANA M, 1969, J BIOL CHEM, V244, P5403; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P482; TROTTA PP, 1974, J BIOL CHEM, V249, P492; WIMMER MJ, 1979, J BIOL CHEM, V254, P1854; ZALKIN H, 1993, BIOCHEM SOC T, V21, P203, DOI 10.1042/bst0210203; ZALKIN H, 1980, MULTIFUNCTIONAL PROT, P123	60	5	5	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19906	19912		10.1074/jbc.272.32.19906	http://dx.doi.org/10.1074/jbc.272.32.19906			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242656	hybrid			2022-12-25	WOS:A1997XQ05900043
J	Izu, H; Izumi, Y; Kurome, Y; Sano, M; Kondo, A; Kato, I; Ito, M				Izu, H; Izumi, Y; Kurome, Y; Sano, M; Kondo, A; Kato, I; Ito, M			Molecular cloning expression, and sequence analysis of the endoglycoceramidase II gene from Rhodococcus species strain M-777	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOSPHINGOLIPIDS; PERFORMANCE LIQUID-CHROMATOGRAPHY; NUCLEOTIDE-SEQUENCE; CERAMIDE-GLYCANASE; CLOSTRIDIUM-THERMOCELLUM; CELLULASE GENE; ENDOGLUCANASE; HYDROLYSIS; PROTEIN; OLIGOSACCHARIDES	Endoglycoceramidase (EGCase (EC 3.2.1.123)) is a hydrolase that hydrolyzes the linkage between the oligosaccharide and ceramide of various glycosphingolipids. This paper describes the molecular cloning and expression of EGCase II, one of the isoforms of EGCases. The gene encoding EGCase HP was obtained by screening of a genomic DNA library from Rhodococcus sp. strain M-777 constructed in pUC19 with oligonucleotide probes deduced from a partial amino acid sequence of the enzyme protein, Recombinant Escherichia coli cells in which the EGCase II gene was expressed produced 14 units of the enzyme per liter of culture medium but did not produce sphingomyelinase. Recombinant EGCase II was a functioning enzyme with substrate specificity identical to that of the wild-type enzyme. Sequence analysis showed the presence of an open reading frame of 1470 base pairs encoding 490 amino acids. The N-terminal region of the deduced amine, acid sequence had the general pattern of signal peptides of secreted prokaryotic proteins, Interestingly, the consensus sequence in the active site region of the endo-1,4-beta-glucanase family A was found in the amino acid sequence of EGCase II.	KYUSHU UNIV,FAC AGR,MARINE BIOCHEM LAB,HIGASHI KU,FUKUOKA 81281,JAPAN	Kyushu University	Izu, H (corresponding author), TAKARA SHUZO CO LTD,BIOTECHNOL RES LABS,SETA 3-4-1,OTSU,SHIGA 52021,JAPAN.		Ito, Makoto/Q-6164-2019	ito, Makoto/0000-0003-3159-7818				ABRAHMSEN L, 1985, EMBO J, V4, P3901, DOI 10.1002/j.1460-2075.1985.tb04164.x; ASHIDA H, 1992, EUR J BIOCHEM, V205, P72; BAIRD SD, 1990, BIOCHEM BIOPH RES CO, V169, P1035, DOI 10.1016/0006-291X(90)91998-8; BAIRD SD, 1990, J BACTERIOL, V172, P1576, DOI 10.1128/jb.172.3.1576-1586.1990; BASU SS, 1994, ANAL BIOCHEM, V222, P270, DOI 10.1006/abio.1994.1484; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; CUNNINGHAM C, 1991, MOL GEN GENET, V228, P320, DOI 10.1007/BF00282484; GOUGH CL, 1990, GENE, V89, P53, DOI 10.1016/0378-1119(90)90205-6; GREPINET O, 1986, NUCLEIC ACIDS RES, V14, P1791, DOI 10.1093/nar/14.4.1791; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HALL J, 1988, GENE, V69, P29, DOI 10.1016/0378-1119(88)90375-7; HANSSON GC, 1989, BIOCHEMISTRY-US, V28, P6672, DOI 10.1021/bi00442a021; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; HIGASHI H, 1990, ANAL BIOCHEM, V186, P355, DOI 10.1016/0003-2697(90)90094-P; HIGASHI H, 1990, TRENDS GLYCOSCI GLYC, V2, P514; ITO M, 1991, J BIOL CHEM, V266, P7919; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; Ito M, 1996, J BIOL CHEM, V271, P12655, DOI 10.1074/jbc.271.21.12655; ITO M, 1993, EUR J BIOCHEM, V218, P645, DOI 10.1111/j.1432-1033.1993.tb18418.x; ITO M, 1993, EUR J BIOCHEM, V218, P637, DOI 10.1111/j.1432-1033.1993.tb18417.x; Ito M., 1990, TRENDS GLYCOSCI GLYC, V2, P399; JI L, 1995, GLYCOBIOLOGY, V5, P343, DOI 10.1093/glycob/5.3.343; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMAIRE M, 1993, J BACTERIOL, V175, P3353, DOI 10.1128/jb.175.11.3353-3360.1993; LI YT, 1987, BIOCHEM BIOPH RES CO, V149, P167, DOI 10.1016/0006-291X(87)91619-6; MEINKE A, 1993, J BACTERIOL, V175, P1910, DOI 10.1128/JB.175.7.1910-1918.1993; MURAMOTO K, 1994, BIOCHEM BIOPH RES CO, V202, P398, DOI 10.1006/bbrc.1994.1941; OHARA K, 1991, J CHROMATOGR, V586, P35, DOI 10.1016/0021-9673(91)80022-9; POOLE DM, 1990, MOL GEN GENET, V223, P217, DOI 10.1007/BF00265057; PY B, 1991, PROTEIN ENG, V4, P325, DOI 10.1093/protein/4.3.325; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Sambrook J., 2002, MOL CLONING LAB MANU; SAUL DJ, 1989, NUCLEIC ACIDS RES, V17, P439, DOI 10.1093/nar/17.1.439; SHIMAMURA M, 1988, J BIOL CHEM, V263, P12124; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WESTERVELT C, 1989, GLYCOCONJUGATE J, V6, P405; YAMADA H, 1991, ANAL BIOCHEM, V198, P1, DOI 10.1016/0003-2697(91)90496-G; ZHOU B, 1989, J BIOL CHEM, V264, P12272; ZHOU LQ, 1994, BIOCHEM J, V297, P359, DOI 10.1042/bj2970359	41	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19846	19850		10.1074/jbc.272.32.19846	http://dx.doi.org/10.1074/jbc.272.32.19846			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242646	hybrid			2022-12-25	WOS:A1997XQ05900033
J	Kehres, DG; Subramanyan, GS; Hung, VS; Rogers, GW; Setzer, DR				Kehres, DG; Subramanyan, GS; Hung, VS; Rogers, GW; Setzer, DR			Energetically unfavorable interactions among the zinc fingers of transcription factor IIIA when bound to the 5 S rRNA gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CONTROL REGION; 5-S RNA GENE; DNA RECOGNITION; CRYSTAL-STRUCTURE; XENOPUS TFIIIA; RIBOSOMAL-RNA; BINDING DOMAINS; 5S-RNA GENE; COMPLEX; PROTEIN	Xenopus transcription factor IIIA (TFIIIA) binds to over 50 base pairs in the internal control region of the 5 S rRNA gene, yet the binding energy for this interaction (Delta G(0) = -12.8 kcal/mol) is no greater than that exhibited by many proteins that occupy much smaller DNA targets, Despite considerable study, the distribution of the DNA binding energy among the various zinc fingers of TFIIIA remains poorly understood By analyzing TFIIIA mutants with disruptions of individual zinc fingers, we have previously shown that each finger contributes favorably to binding (Del Rio, S., Menezes, S. R., and Setter, D. R. (1993) J. Mol. Biol. 233, 567-579), Those results also suggested, however, that simultaneous binding by all nine zinc fingers of TFIIIA may involve a substantial energetic cost, Using complementary N- and C-terminal fragments and full-length proteins containing pairs of disrupted fingers, we now show that energetic interference indeed occurs between zinc fingers when TFIIIA binds to the 5S rRNA gene and that the greatest interference occurs between fingers at opposite ends of the protein in the TFIIIA.5 S rRNA gene complex. Some, but not all, of the thermodynamically unfavorable strain in the TFIIIA.5 S rRNA gene complex may be derived from bending of the DNA that is necessary to accommodate simultaneous binding by all nine zinc fingers of TFIIIA, The energetics of DNA binding by TFIIIA thus emerges as a compromise between individual favorable contacts of importance along the length of the internal control region and long range strain or distortion in the protein, the 5 S rRNA gene, or both that is necessary to accommodate the various local interactions.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048035] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48035] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKAWA H, 1995, CYTOGENET CELL GENET, V70, P235, DOI 10.1159/000134041; ARCHAMBAULT J, 1992, J BIOL CHEM, V267, P3282; BAZETTJONES DP, 1989, MOL CELL BIOL, V9, P336, DOI 10.1128/MCB.9.1.336; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; Brown ML, 1996, J MOL BIOL, V262, P600, DOI 10.1006/jmbi.1996.0539; BROWN RS, 1988, P NATL ACAD SCI USA, V85, P3802, DOI 10.1073/pnas.85.11.3802; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; CAMPBELL FE, 1991, MOL CELL BIOL, V11, P3978, DOI 10.1128/MCB.11.8.3978; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; DARBY MK, 1988, P NATL ACAD SCI USA, V85, P5516, DOI 10.1073/pnas.85.15.5516; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; DELRIO S, 1993, J MOL BIOL, V233, P567, DOI 10.1006/jmbi.1993.1536; DELRIO S, 1991, NUCLEIC ACIDS RES, V19, P6197; DELRIO S, 1993, P NATL ACAD SCI USA, V90, P168, DOI 10.1073/pnas.90.1.168; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; DREW PD, 1995, GENE, V159, P215, DOI 10.1016/0378-1119(95)00145-V; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FISERLITTELL RM, 1988, J BIOL CHEM, V263, P1607; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; GASKINS CJ, 1992, GENE, V120, P197, DOI 10.1016/0378-1119(92)90094-6; GASKINS CJ, 1990, NUCLEIC ACIDS RES, V18, P2117, DOI 10.1093/nar/18.8.2117; GASKINS CJ, 1989, NUCLEIC ACIDS RES, V17, P781, DOI 10.1093/nar/17.2.781; HANAS JS, 1992, PROG NUCLEIC ACID RE, V43, P205, DOI 10.1016/S0079-6603(08)61048-X; HANAS JS, 1989, BIOCHEMISTRY-US, V28, P4083, DOI 10.1021/bi00435a068; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEE MS, 1991, FEBS LETT, V279, P289, DOI 10.1016/0014-5793(91)80170-8; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LIAO XB, 1994, J BIOMOL NMR, V4, P433; LUMPKIN OJ, 1985, BIOPOLYMERS, V24, P1573, DOI 10.1002/bip.360240812; MCBRYANT SJ, 1995, J MOL BIOL, V248, P44, DOI 10.1006/jmbi.1995.0201; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; OGILVIE MK, 1993, NUCLEIC ACIDS RES, V21, P4152, DOI 10.1093/nar/21.17.4152; OMICHINSKI JG, 1992, BIOCHEMISTRY-US, V31, P3907, DOI 10.1021/bi00131a004; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; PIELER T, 1993, TRENDS BIOCHEM SCI, V18, P226, DOI 10.1016/0968-0004(93)90194-R; QIAN XQ, 1992, BIOCHEMISTRY-US, V31, P7463, DOI 10.1021/bi00148a006; ROLLINS MB, 1993, MOL CELL BIOL, V13, P4776, DOI 10.1128/MCB.13.8.4776; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; SCHROTH GP, 1991, NUCLEIC ACIDS RES, V19, P511, DOI 10.1093/nar/19.3.511; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; Setzer DR, 1996, RNA, V2, P1254; SETZER DR, 1985, J BIOL CHEM, V260, P2483; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9	63	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20152	20161		10.1074/jbc.272.32.20152	http://dx.doi.org/10.1074/jbc.272.32.20152			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242690	hybrid			2022-12-25	WOS:A1997XQ05900077
J	Konieczny, I; Doran, KS; Helinski, DR; Blasina, A				Konieczny, I; Doran, KS; Helinski, DR; Blasina, A			Role of TrfA and DnaA proteins in origin opening during initiation of DNA replication of the broad host range plasmid RK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; OPEN-COMPLEX-FORMATION; NUCLEOTIDE-SEQUENCE; BINDING; INVITRO; MUTATIONS; BACTERIA; REGION; SITES; POLYMERASE	The Escherichia coli protein DnaA and the plasmid RK2-encoded TrfA protein are required for initiation of replication of the broad host range plasmid RK2, The TrfA protein has been shown to bind to five 17-base pair repeat sequences, referred to as iterons, at the minimal replication origin (oriV), Using DNase I footprinting and a gel mobility shift assay, purified DnaA protein was found to bind to four DnaA consensus binding sequences immediately upstream of the five iterons at the RK2 origin of replication. Binding of the TrfA protein to the iterons results in localized strand opening within the A+T-rich region of the replication origin as determined by reactivity of the top and bottom strands to potassium permanganate (KMnO4). The presence of either the E, coli DnaA or HU protein is required for the TrfA-mediated strand opening. Although the DnaA protein itself did not produce an RK2 open complex, it did enhance and/or stabilize the TrfA-induced strand opening.	UNIV CALIF SAN DIEGO,CTR GENET MOL,DEPT BIOL,SAN DIEGO,CA 92093	University of California System; University of California San Diego				Konieczny, Igor/0000-0002-1588-5601	NIAID NIH HHS [AI-07194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007194] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; BONNEFOY E, 1992, EMBO J, V11, P4489, DOI 10.1002/j.1460-2075.1992.tb05550.x; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CEREGHINO JL, 1993, J BIOL CHEM, V268, P24926; delSolar G, 1996, MOL MICROBIOL, V21, P661, DOI 10.1046/j.1365-2958.1996.6611376.x; DIEDERICH L, 1994, BIOTECHNIQUES, V16, P916; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GAYLO PJ, 1987, J BACTERIOL, V169, P4703, DOI 10.1128/jb.169.10.4703-4709.1987; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HELINSKI DR, 1996, ESCHERICHIA COLI SAL, V2, P2295; HOLZ A, 1992, MOL GEN GENET, V233, P81, DOI 10.1007/BF00587564; HSU J, 1994, MOL MICROBIOL, V11, P903, DOI 10.1111/j.1365-2958.1994.tb00369.x; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Kawasaki Y, 1996, MOL GEN GENET, V253, P42, DOI 10.1007/s004380050294; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; LIN J, 1992, J BACTERIOL, V174, P4110, DOI 10.1128/jb.174.12.4110-4119.1992; MASAI H, 1990, J BIOL CHEM, V265, P15134; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; MATSUI M, 1985, J MOL BIOL, V184, P529, DOI 10.1016/0022-2836(85)90299-2; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; MUKHOPADHYAY G, 1993, J MOL BIOL, V231, P19, DOI 10.1006/jmbi.1993.1253; MUKHOPADHYAY G, 1993, EMBO J, V12, P4547, DOI 10.1002/j.1460-2075.1993.tb06143.x; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; ORTEGAJIMENEZ S, 1992, NUCLEIC ACIDS RES, V20, P2547, DOI 10.1093/nar/20.10.2547; PANSEGRAU W, 1994, J MOL BIOL, V239, P623, DOI 10.1006/jmbi.1994.1404; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PERRI S, 1991, J BIOL CHEM, V266, P12536; PERRI S, 1993, J BIOL CHEM, V268, P3662; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; SCHMIDHAUSER TJ, 1983, PLASMID, V9, P325, DOI 10.1016/0147-619X(83)90010-0; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEUFERT W, 1987, CELL, V48, P73, DOI 10.1016/0092-8674(87)90357-6; SHAH DS, 1995, J MOL BIOL, V254, P608, DOI 10.1006/jmbi.1995.0642; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SMITH CA, 1984, J MOL BIOL, V175, P251, DOI 10.1016/0022-2836(84)90347-4; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMAS CM, 1980, J BACTERIOL, V141, P213, DOI 10.1128/JB.141.1.213-222.1980; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; Toukdarian AE, 1996, J BIOL CHEM, V271, P7072, DOI 10.1074/jbc.271.12.7072; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811	48	68	70	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20173	20178		10.1074/jbc.272.32.20173	http://dx.doi.org/10.1074/jbc.272.32.20173			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242693	hybrid			2022-12-25	WOS:A1997XQ05900080
J	Rolfs, A; Kvietikova, I; Gassmann, M; Wenger, RH				Rolfs, A; Kvietikova, I; Gassmann, M; Wenger, RH			Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATE-DEHYDROGENASE-A; GENE ENHANCER; TRANSCRIPTIONAL REGULATION; IRON-ABSORPTION; CELL-LINES; FACTOR-I; ERYTHROPOIETIN; LIVER; ACTIVATION; ELEMENTS	Transferrin (Tf) is a liver-derived iron transport protein whose plasma concentration increases following exposure to hypoxia, Here, we present a cell culture model capable of expressing Tf mRNA in an oxygen-dependent manner, A C-kilobase pair Tf promoter/enhancer fragment as well as the 300-base pair liver-specific Tf enhancer alone conveyed hypoxia responsiveness to a heterologous reporter gene construct in hepatoma but not HeLa cells. Within this enhancer, a 32-base pair hypoxia-responsive element was identified, which contained two hypoxia-inducible factor-1 (HIF-1) binding sites (HBSs). Mutation analysis showed that both HBSs function as oxygen-regulated enhancers in Tf-expressing as well as in non-Tf-expressing cell lines, Mutation of both HBSs was necessary to completely abolish hypoxic reporter gene activation, Transient co-expression of the two HIF-1 subunits HIF-1 alpha and aryl hydrocarbon receptor nuclear translocator (ARNT)/HIF-1 beta resulted in enhanced reporter gene expression even under normoxic conditions, Overexpression of a dominant-negative ARNT/HIF-1 beta mutant reduced hypoxic activation, DNA binding studies using nuclear extracts from the mouse hepatoma cell line Hepa1 and the ARNT/HIF-1 beta-deficient subline Hepa1C4, as well as antibodies raised against HIF-1 alpha and ARNT/HIF-1 beta confirmed that HIF-1 binds the Tf HBSs. Mutation analysis and competition experiments suggested that the 5' HBS was more efficient in binding HIF-1 than the 3' HBS. Finally, hypoxic induction of endogenous Tf mRNA was abrogated in Hepa1C4 cells, confirming that HIF-1 confers oxygen regulation of Tf gene expression by binding to the two HBSs present in the Tf enhancer.	UNIV ZURICH, INST PHYSIOL, CH-8057 ZURICH, SWITZERLAND	University of Zurich			Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839				AUGEGOUILLOU C, 1993, FEBS LETT, V323, P4, DOI 10.1016/0014-5793(93)81436-4; BOISSIER F, 1991, J BIOL CHEM, V266, P9822; BONKOVSKY HL, 1991, AM J MED SCI, V301, P32, DOI 10.1097/00000441-199101000-00006; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEHOUR JK, 1957, AM J PHYSIOL, V191, P113, DOI 10.1152/ajplegacy.1957.191.1.113; EBERT BL, 1995, J BIOL CHEM, V270, P29038; FINCH C, 1994, BLOOD, V84, P1697; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MENDEL GA, 1961, BLOOD, V18, P727, DOI 10.1182/blood.V18.6.727.727; OSTERLOH KRS, 1987, BLUT, V55, P421, DOI 10.1007/BF00367458; PETROPOULOS I, 1991, J BIOL CHEM, V266, P24220; Sambrook J., 2002, MOL CLONING LAB MANU; Sawaya BE, 1996, J NEUROSCI RES, V43, P261, DOI 10.1002/(SICI)1097-4547(19960201)43:3<261::AID-JNR1>3.0.CO;2-H; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SIMPSON RJ, 1992, ANN HEMATOL, V65, P260, DOI 10.1007/BF01836070; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Wenger RH, 1996, BIOCHEM BIOPH RES CO, V223, P54, DOI 10.1006/bbrc.1996.0845; Wenger RH, 1996, BLOOD, V87, P756, DOI 10.1182/blood.V87.2.756.bloodjournal872756; Wenger RH, 1997, BIOL CHEM, V378, P609; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117	42	314	328	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20055	20062		10.1074/jbc.272.32.20055	http://dx.doi.org/10.1074/jbc.272.32.20055			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242677	Green Accepted, hybrid			2022-12-25	WOS:A1997XQ05900064
J	Briant, L; Signoret, N; Gaubin, M; RobertHebmann, V; Zhang, X; Murali, R; Greene, MI; PiatierTonneau, D; Devaux, C				Briant, L; Signoret, N; Gaubin, M; RobertHebmann, V; Zhang, X; Murali, R; Greene, MI; PiatierTonneau, D; Devaux, C			Transduction of activation signal that follows HIV-1 binding to CD4 and CD4 dimerization involves the immunoglobulin CDR3-like region in domain 1 of CD4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; LONG TERMINAL REPEAT; ENVELOPE GLYCOPROTEIN; T-CELLS; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; TYPE-1; INFECTION; MOLECULE	The role of CD4 during the human immunodeficiency virus type 1 (HIV-1) life cycle in T cells is not restricted to binding functions, HIV-1 binding to CD4 also triggers signals that lead to nuclear translocation of NF-kappa B and are important to the productive infection process, In addition to its cytoplasmic tail, in the ectodomain, the immunoglobulin (Ig) CDR3-like region of CD4 domain 1 seemed to play a role in this cascade of signals, We demonstrate in this work that the structural integrity of the CDR3-like loop is required for signal transduction. Substitutions of negatively charged residues by positively charged residues within the CDR3-like loop either inhibited NF-kappa B translocation after HIV-1 and gp120-anti-gp120 immune complexes binding to E91K,E92K mutants or induced its constitutive activation for E87K,D88K mutants, Moreover, A2.01-3B cells expressing the E91K,E92K mutant exhibited a lower HIV-1(Lai) replication, These cells, however, expressed p56(lck), demonstrated NF-kappa B translocation upon PMA stimulation, bound HIV-1(Lai) envelope glycoprotein with high affinity, and contained HIV-1 DNA 24 h after exposure to virus. E91K, E92K, and E87K,D88K mutant CD4 molecules were unable to bind a CD4 synthetic aromatically modified exocyclic, CDR3.AME-(82-89), that mimics the CDR3-like loop structure and binds to native cell surface CD4, This result together with molecular modeling studies indicates that the CDR3.AME-(82-89) analog binds to the CDR3-like loop of CD4 and strongly suggests that this region represents a site for CD4 dimerization, The negative charges on the CDR3-like loop thus appear critical for CD4-mediated signal transduction most likely related to CD4 dimer formation.	INST BIOL, LAB IMMUNOL INFECT RETROVIRALES, CNRS, ERS 155, F-34060 MONTPELLIER, FRANCE; CTR IMMUNOL MARSEILLE LUMINY, F-13288 MARSEILLE, FRANCE; CNRS, UPR 420, F-94801 VILLEJUIF, FRANCE; UNIV PENN, SCH MED, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); University of Pennsylvania			Murali, Ramachandran/D-1132-2009; Briant, Laurence/AAB-9281-2021	Briant, Laurence/0000-0002-1995-3501; Murali, Ramachandran/0000-0002-8384-2793; Signoret, Nathalie Yvonne Micheline/0000-0003-4977-4149				ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BAHRAOUI E, 1988, AIDS, V2, P165; BEDINGER P, 1988, NATURE, V334, P162, DOI 10.1038/334162a0; BENKIRANE M, 1994, EMBO J, V13, P5559, DOI 10.1002/j.1460-2075.1994.tb06893.x; BENKIRANE M, 1995, J VIROL, V69, P6898, DOI 10.1128/JVI.69.11.6898-6903.1995; BENKIRANE M, 1993, EMBO J, V12, P4909, DOI 10.1002/j.1460-2075.1993.tb06185.x; BENKIRANE M, 1995, J VIROL, V69, P6904, DOI 10.1128/JVI.69.11.6904-6910.1995; BENKIRANE M, 1994, J VIROL, V68, P6332, DOI 10.1128/JVI.68.10.6332-6339.1994; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Briant L, 1996, J IMMUNOL, V156, P3994; Briant L, 1996, J VIROL, V70, P5213, DOI 10.1128/JVI.70.8.5213-5220.1996; CHIRMULE N, 1995, J BIOL CHEM, V270, P19364, DOI 10.1074/jbc.270.33.19364; CHIRMULE N, 1994, BIOCHEM BIOPH RES CO, V203, P498, DOI 10.1006/bbrc.1994.2210; CORBEAU P, 1990, J VIROL, V64, P1459, DOI 10.1128/JVI.64.4.1459-1464.1990; CORBEAU P, 1993, J IMMUNOL, V150, P290; ENGLUND G, 1991, VIROLOGY, V181, P150, DOI 10.1016/0042-6822(91)90479-U; FOLKS T, 1985, P NATL ACAD SCI USA, V82, P4539, DOI 10.1073/pnas.82.13.4539; GOLDING H, 1993, J VIROL, V67, P6469, DOI 10.1128/JVI.67.11.6469-6475.1993; HIVROZ C, 1993, EUR J IMMUNOL, V23, P600, DOI 10.1002/eji.1830230303; HOULGATTE R, 1994, J IMMUNOL, V152, P4475; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; LAMARRE D, 1989, EMBO J, V8, P3271, DOI 10.1002/j.1460-2075.1989.tb08487.x; LANGEDIJK JPM, 1993, J BIOL CHEM, V268, P16875; Lemasson I, 1996, J IMMUNOL, V156, P859; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; MALVOISIN E, 1994, J GEN VIROL, V75, P839, DOI 10.1099/0022-1317-75-4-839; MERZOUKI A, 1995, CELL MOL BIOL, V41, P445; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; NARA PL, 1989, P NATL ACAD SCI USA, V86, P7139, DOI 10.1073/pnas.86.18.7139; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHKI K, 1990, AIDS, V4, P1160, DOI 10.1097/00002030-199011000-00020; POULIN L, 1991, J VIROL, V65, P4893, DOI 10.1128/JVI.65.9.4893-4901.1991; REPKE H, 1992, J IMMUNOL, V149, P1809; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAKIHAMA T, 1995, P NATL ACAD SCI USA, V92, P6444, DOI 10.1073/pnas.92.14.6444; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SchmidAntomarchi H, 1996, EUR J IMMUNOL, V26, P717, DOI 10.1002/eji.1830260331; Signoret N, 1996, AIDS RES HUM RETROV, V12, P1001, DOI 10.1089/aid.1996.12.1001; SWEET RW, 1991, CURR OPIN BIOTECH, V2, P622, DOI 10.1016/0958-1669(91)90089-N; SZABO G, 1992, J IMMUNOL, V149, P3596; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150; Zhang X, 1996, NAT BIOTECHNOL, V14, P472, DOI 10.1038/nbt0496-472	48	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19441	19450		10.1074/jbc.272.31.19441	http://dx.doi.org/10.1074/jbc.272.31.19441			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235945	hybrid			2022-12-25	WOS:A1997XP06300051
J	Fukushima, Y; Asano, T; Takata, K; Funaki, M; Ogihara, T; Anai, M; Tsukuda, K; Saitoh, T; Katagiri, H; Aihara, M; Matsuhashi, N; Oka, Y; Yazaki, Y; Sugano, K				Fukushima, Y; Asano, T; Takata, K; Funaki, M; Ogihara, T; Anai, M; Tsukuda, K; Saitoh, T; Katagiri, H; Aihara, M; Matsuhashi, N; Oka, Y; Yazaki, Y; Sugano, K			Role of the C terminus in histamine H2 receptor signaling, desensitization, and agonist-induced internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIN-RELEASING PEPTIDE; CYTOPLASMIC TAIL; CANINE HISTAMINE-H2-RECEPTOR; PHOSPHORYLATION SITES; MOLECULAR-CLONING; H-2 RECEPTORS; TRUNCATION; ENDOCYTOSIS; EXPRESSION; CYCLASE	To evaluate the role of the histamine H2 receptor C terminus in signaling, desensitization, and agonist-induced internalization, canine H2 receptors with truncated C termini were generated. Wild-type (WT) and truncated receptors were tagged at their N termini with a hemagglutinin (HA) epitope and expressed in COS7 cells, Most of the C-terminal intracellular tail could be truncated (51 of 70 residues, termed T-308 mutant) without loss of functions: cAMP production, tiotidine binding, and plasma membrane targeting, In fact, the T-308 mutant produced more cAMP than the WT when cell-surface expression per cell was equivalent. Pretreat ment of cells with 10(-5) M histamine desensitized cAMP productions via WT and T-308 receptors 60 similar extents. Incubation of cells expressing WT receptors with 10(-5) M histamine reduced cell-surface anti-HA antibody binding by approximately 30% (by 30 min, t(1/2) similar to 15 min), but did not affect the B-max of tiotidine in membrane fractions, which represents total receptor amounts, suggesting that WT receptors were internalized from the cell surface, In contrast, no internalization was observed with T-308 receptors following histamine treatment. A mutant with a deletion of the 30 C-terminal amino acids, termed T-329, was functional but was as potent as the WT in terms of cAMP production. Apart from being desensitized by histamine, the internalization of the receptor was indistinguishable from that of the WT. Internalization was observed in the T-320 but not in T-313 mutant, narrowing the region involved in internalization to that between Glu(314) and Asn(320) (ETSLRSN). Of these seven residues, either Thr(315), Ser(316), or both, were replaced with Ala. Thr(315) and Ser(316) are conserved among species. The mutation at Thr(315) (but not that at Ser(316)) abolished internalization. Taken together, these results demonstrate that Thr(315) is involved in agonist-induced internalization. Furthermore, the finding that T-308 receptors were desensitized in the absence of internalization suggests that internalization and desensitization are meditated by independent mechanisms.	UNIV TOKYO,FAC MED,DEPT BIOCHEM 2,TOKYO 113,JAPAN; UNIV TOKYO,HLTH SERV CTR,TOKYO 113,JAPAN; GUNMA UNIV,INST MOL & CELLULAR REGULAT,LAB MOL & CELLULAR MORPHOL,MAEBASHI,GUMMA 371,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT INTERNAL MED 3,UBE,YAMAGUCHI 755,JAPAN	University of Tokyo; University of Tokyo; Gunma University; Yamaguchi University	Fukushima, Y (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.			Matsuhashi, Nobuyuki/0000-0002-0139-430X				ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ARIMA N, 1993, AM J PHYSIOL, V265, pG987, DOI 10.1152/ajpgi.1993.265.5.G987; ASANO T, 1992, J BIOL CHEM, V267, P19636; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; FUKUSHIMA Y, 1995, BIOCHEM J, V310, P553, DOI 10.1042/bj3100553; FUKUSHIMA Y, 1993, BIOCHEM BIOPH RES CO, V190, P1149, DOI 10.1006/bbrc.1993.1170; Fukushima Y, 1996, BIOCHEM J, V320, P27, DOI 10.1042/bj3200027; GAJTKOWSKI GA, 1983, NATURE, V304, P65, DOI 10.1038/304065a0; GANTZ I, 1991, BIOCHEM BIOPH RES CO, V178, P1386, DOI 10.1016/0006-291X(91)91047-G; GANTZ I, 1992, J BIOL CHEM, V267, P20840; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; Hermans E, 1996, MOL PHARMACOL, V49, P365; HOMMA M, 1977, BIOCH MED, V18, P257; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; LATTION AL, 1994, J BIOL CHEM, V269, P22887; PROST A, 1984, FEBS LETT, V177, P227, DOI 10.1016/0014-5793(84)81288-0; RUAT M, 1991, BIOCHEM BIOPH RES CO, V179, P1470, DOI 10.1016/0006-291X(91)91738-X; SANCHEZYAGUE J, 1992, J BIOL CHEM, V267, P7217; SMIT MJ, 1995, BIOCHEM BIOPH RES CO, V214, P1138, DOI 10.1006/bbrc.1995.2404; SMIT MJ, 1994, EUR J PHARM-MOLEC PH, V288, P17, DOI 10.1016/0922-4106(94)90005-1; SOLL AH, 1979, AM J PHYSIOL, V237, pE444, DOI 10.1152/ajpendo.1979.237.5.E444; TAKANO T, 1994, J BIOL CHEM, V269, P22453; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; WANG LH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P232, DOI 10.1016/0167-4889(93)90028-N	29	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19464	19470		10.1074/jbc.272.31.19464	http://dx.doi.org/10.1074/jbc.272.31.19464			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235948	hybrid			2022-12-25	WOS:A1997XP06300054
J	Schonbeck, U; Mach, F; Bonnefoy, JY; Loppnow, H; Flad, HD; Libby, P				Schonbeck, U; Mach, F; Bonnefoy, JY; Loppnow, H; Flad, HD; Libby, P			Ligation of CD40 activates interleukin 1 beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; T-CELLS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASE; CONVERTING-ENZYME; GENE-EXPRESSION; HUMAN IL-1-BETA; LIGAND; APOPTOSIS; IDENTIFICATION	Inflammation contributes to a variety of arterial diseases including atherosclerosis. Interleukin 1 beta (IL-1 beta) in its activated mature 17-kDa form may mediate aspects of vascular inflammation. As shown previously, human vascular wall cells, such as smooth muscle cells (SMC), express the IL-1 beta precursor upon stimulation and the IL-1 beta-converting enzyme (ICE) constitutively but do not produce mature IL-1 beta or express ICE activity. How SMC, the most numerous cell type in arteries, may release active IL-1 beta has therefore remained a perplexing problem, We report here that stimulation of human vascular SMC and endothelial cells (EC) through CD40 ligand, a mediator recently localized in human atheroma, induced elaboration of the IL-1 beta precursor as well as activation of cell-associated ICE, In addition to the constitutively expressed 45- and 30-kDa immunoreactive ICE proteins, vascular cells incubated with recombinant human CD40 ligand (rCD40L) (but not IL-1 or TNF) showed an increase of a 20-kDa immunoreactive ICE protein by Western blot analysis, Furthermore, SMC and EC stimulated through rCD40L processed recombinant human IL-1 beta precursor (pIL-1 beta), generating a cleavage product of approximately 17 kDa. Appearance of both the 20-kDa immunoreactive ICE protein and pIL-1 beta processing activity required at least 6 h of stimulation with 0.3 or 1.0 mu g/ml rCD40L, respectively, and was inhibited by pre-incubation of the ligand with an anti-CD40L antibody, Stimulation of vascular SMC and EC through rCD40L resulted in the release of biologically active IL-1 beta, indicating processing of the native IL-1 beta precursor induced by the ligand. These findings establish a novel mechanism of IL-1 beta activation in human vascular cells and, moreover, indicate a new pathway of ICE-activation, which could participate in inflammatory aspects of atherogenesis and other disease states.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CARDIOVASC DIV,BOSTON,MA 02115; GENEVA BIOMED RES INST,CH-1228 GENEVA,SWITZERLAND; RES CTR BORSTEL,DEPT IMMUNOL & CELL BIOL,D-23845 BORSTEL,GERMANY; UNIV HALLE WITTENBERG,D-06097 HALLE,GERMANY	Harvard University; Brigham & Women's Hospital; Harvard Medical School; GlaxoSmithKline; Forschungszentrum Borstel; Martin Luther University Halle Wittenberg			Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043364] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43364] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CLARK BD, 1987, NUCLEIC ACIDS RES, V15, P868, DOI 10.1093/nar/15.2.868-a; CLARK BD, 1986, NUCLEIC ACIDS RES, V14, P7897, DOI 10.1093/nar/14.20.7897; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GENG YJ, 1995, AM J PATHOL, V147, P251; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; HAZUDA DJ, 1991, J BIOL CHEM, V266, P7081; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HERZBECK H, 1989, SCAND J IMMUNOL, V30, P549, DOI 10.1111/j.1365-3083.1989.tb02462.x; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HOWARD AD, 1995, J IMMUNOL, V154, P2321; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUIJPERS TW, 1991, J IMMUNOL, V147, P1369; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; LIBBY P, 1986, J CLIN INVEST, V78, P1432, DOI 10.1172/JCI112732; LIBBY P, 1986, AM J PATHOL, V124, P179; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LONNEMANN G, 1989, EUR J IMMUNOL, V19, P1531, DOI 10.1002/eji.1830190903; LOPPNOW H, 1992, EXP CELL RES, V198, P283, DOI 10.1016/0014-4827(92)90381-H; LOPPNOW H, 1989, IMMUNOBIOLOGY, V179, P283, DOI 10.1016/S0171-2985(89)80023-3; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MERINO R, 1995, J IMMUNOL, V155, P3830; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOYER CF, 1991, AM J PATHOL, V138, P951; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; Orencole S F, 1989, Cytokine, V1, P14, DOI 10.1016/1043-4666(89)91044-2; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; ROSS R, 1980, HDB PHYSL CARDIOVA 2, P66; Ruggiero G, 1996, J IMMUNOL, V156, P3737; Schonbeck U, 1997, J EXP MED, V185, P1287, DOI 10.1084/jem.185.7.1287; SCHONBECK U, 1995, J IMMUNOL, V154, P2375; SIRONI M, 1989, J IMMUNOL, V142, P549; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WARNER SJC, 1987, J IMMUNOL, V139, P1911; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857	58	101	106	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19569	19574		10.1074/jbc.272.31.19569	http://dx.doi.org/10.1074/jbc.272.31.19569			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235962	hybrid			2022-12-25	WOS:A1997XP06300068
J	DeYoung, KL; Ray, ME; Su, YA; Anzick, SL; Johnstone, RW; Trapani, JA; Meltzer, PS; Trent, JM				DeYoung, KL; Ray, ME; Su, YA; Anzick, SL; Johnstone, RW; Trapani, JA; Meltzer, PS; Trent, JM			Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma	ONCOGENE			English	Article						interferon-inducible; melanoma; tumorigenicity	HUMAN-MALIGNANT MELANOMA; CHROMOSOME-6; IDENTIFICATION; CLUSTER; CELLS	Chromosome 6-mediated suppression of tumorigenicity in malignant melanoma cell lines provides a model system to identify genes associated with the reversion of the tumorigenic phenotype. Using subtractive cDNA selection, we recently identified a series of novel genes which are differentially expressed in association with chromosome 6-mediated suppression. We now report the molecular characterization of a novel gene termed AIM2 for (Absent In Melanoma), which represents a 1485 bp cDNA. An open reading frame of 1032 base pairs, corresponding to 344 amino acid residues, is predicted. The predicted protein shares a conserved sequence domain of approximately 200 amino acids with known interferon-inducible genes of both human and mouse. We demonstrate that the AIM2 gene encodes a transcript of approximately 2 kb which is expressed in spleen, small intestine, and peripheral blood leukocytes. In addition, we have localized AIM2 to the long arm of human chromosome 1 (band q22) in a highly conserved region which also contains the known interferon-inducible genes IFI16 and MNDA. We have also demonstrated that, like IFI16 and MNDA, AIM2 is induced in HL60 cells by interferon gamma. Our findings support the existence of a family of genes in this region similar to the well-characterized mouse Ifi200 gene family.	NATL HUMAN GENOME RES INST,CANC GENET LAB,NIH,BETHESDA,MD 20892; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; AUSTIN HOSP,AUSTIN RES INST,HEIDELBERG,VIC 3084,AUSTRALIA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Michigan System; University of Michigan; Austin Research Institute; Florey Institute of Neuroscience & Mental Health			Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Trapani, Joseph/0000-0003-0983-1532				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRIGGS RC, 1994, BLOOD, V83, P2153; BURDE S, 1996, IN PRESS CYTOMETRY; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; DAWSON MJ, 1995, IMMUNOGENETICS, V41, P40, DOI 10.1007/BF00188431; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; KINGSMORE SF, 1989, EMBO J, V8, P4073, DOI 10.1002/j.1460-2075.1989.tb08591.x; KINGSTON RE, 1991, CURRENT PROTOCOL S14, V1; KRAEHN GM, 1995, CANCER-AM CANCER SOC, V75, P1228, DOI 10.1002/1097-0142(19950315)75:6<1228::AID-CNCR2820750604>3.0.CO;2-T; MILLIKIN D, 1991, CANCER RES, V51, P5449; PETERS J, 1989, MOUSE NEWS LETT, V84, P52; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Ray ME, 1996, ONCOGENE, V12, P2527; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; Seldin MF, 1988, GENOMICS, V2, P48, DOI 10.1016/0888-7543(88)90108-5; SKOLNICK MH, 1994, EUR J CANCER, V30A, P1991, DOI 10.1016/0959-8049(94)00392-I; TANNENBAUM CS, 1993, J LEUKOCYTE BIOL, V53, P563, DOI 10.1002/jlb.53.5.563; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; YOU J, 1995, BIOCHEM BIOPH RES CO, V208, P476, DOI 10.1006/bbrc.1995.1363	23	193	213	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					453	457		10.1038/sj.onc.1201206	http://dx.doi.org/10.1038/sj.onc.1201206			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242382				2022-12-25	WOS:A1997XM23800010
J	ElAshry, D; Miller, DL; Kharbanda, S; Lippman, ME; Kern, FG				ElAshry, D; Miller, DL; Kharbanda, S; Lippman, ME; Kern, FG			Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis	ONCOGENE			English	Article						breast cancer; apoptosis; Raf-1 kinase; estrogen-independence	HUMAN MAMMARY TISSUES; PROTEIN-KINASE; MCF-7 CELLS; IN-VITRO; MAP KINASE; SIGNAL-TRANSDUCTION; DEPLETED CONDITIONS; PROGNOSTIC FACTORS; FACTOR SECRETION; RECEPTOR	Overexpression of many growth factor receptors, as well as growth factors, has been shown to confer varying degrees of estrogen-independent growth on estrogen receptor (ER) positive breast cancer cells. The protooncogene Raf-1 is a key intermediate in the signal transduction pathway of many of these growth factor receptors, and when constitutively activated in fibroblasts is transforming. To examine the effects of Raf-1 kinase activity on the estrogen-dependent growth of human breast cancer cells, ER+ MCF-7 breast cancer cells were stably transfected with an expression construct directing the expression of an amino-truncated protein having constitutive kinase activity. Expression of constitutively activated Raf in MCF-7 cells is incompatible with growth in the presence of estrogen; that is, cells down-regulate expression of the transfected Raf. Constitutive Raf activity does allow for growth of the cells in the absence of estrogen, suggesting that activation of growth factor signaling pathways through Raf may confer a selective advantage for growth of breast cancer cells under estrogen-deprived conditions. In addition, the high levels of Raf activity induce apoptosis in cells grown under either condition. This is a novel activity for Raf, and may occur because the levels of the constitutive Raf are extremely high in these cells.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20007	Georgetown University; Georgetown University	ElAshry, D (corresponding author), GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007, USA.				NCI NIH HHS [CA50376, 2P30-CA-51008, CA71465] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA071465, P30CA051008, R01CA050376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1992, CELL GROWTH DIFFER, V3, P731; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRACEY TS, 1995, ONCOGENE, V10, P2391; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK GM, 1988, SEMIN ONCOL, V15, P20; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DESOMBRE ER, 1986, CANCER RES, V46, P4256; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; HEERDT BG, 1994, CANCER RES, V54, P3288; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMAL S, 1995, ONCOGENE, V10, P2095; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KASID A, 1987, CANCER RES, V47, P5733; KNIGHT WA, 1977, CANCER RES, V37, P4669; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYPRIANOU N, 1991, CANCER RES, V51, P162; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIPPMAN ME, 1989, J STEROID BIOCHEM, V34, P107, DOI 10.1016/0022-4731(89)90071-X; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MCGUIRE WL, 1990, J NATL CANCER I, V82, P1006, DOI 10.1093/jnci/82.12.1006; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OHUCHI N, 1986, CANCER RES, V46, P2511; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SOMMERS CL, 1990, CANCER RES, V50, P67; STRANGE R, 1992, DEVELOPMENT, V115, P49; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOR A, 1986, LAB INVEST, V55, P603; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WANG HG, 1994, ONCOGENE, V9, P2751; WANG TTY, 1995, CANCER RES, V55, P2487; WARRI AM, 1993, JNCI-J NATL CANCER I, V85, P1412, DOI 10.1093/jnci/85.17.1412; WHITE E, 1994, COLD SPRING HARB SYM, V59, P395, DOI 10.1101/SQB.1994.059.01.044; WILSON JW, 1995, INT J CANCER, V61, P502, DOI 10.1002/ijc.2910610413; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	62	84	86	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					423	435		10.1038/sj.onc.1201198	http://dx.doi.org/10.1038/sj.onc.1201198			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242379				2022-12-25	WOS:A1997XM23800007
J	Nicholson, LJ; Hopwood, P; Johannessen, I; Salisbury, JR; Codd, J; ThorleyLawson, D; Crawford, DH				Nicholson, LJ; Hopwood, P; Johannessen, I; Salisbury, JR; Codd, J; ThorleyLawson, D; Crawford, DH			Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells	ONCOGENE			English	Article						EBV; LMP; epithelial cells; differentiation; tumorigenesis	NASOPHARYNGEAL CARCINOMA-CELLS; TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; GROWTH TRANSFORMATION; DECREASED EXPRESSION; P53 MUTATIONS; KAPPA-B; LMP1; GENE; TRANSCRIPTS	Latent membrane protein (LMP) is a latent Epstein-Barr virus (EBV) protein expressed in the EBV associated malignancy, nasopharyngeal carcinoma (NPC). Properties ascribed to this protein include inhibition of epithelial cell differentiation and deregulation of epithelial cellular gene expression, and are believed to contribute to the development of NPC, Studies to evaluate the oncogenic potential of LMP in epithelial cells have not been conclusive, We carried out studies to determine the tumorigenic activity of LMP in two human epithelial cell lines, SCC12F and HaCaT; while SCC12F LMP transfectants were non-tumorigenic in severe combined immunodeficient mice, HaCaT LMP transfectants were strongly oncogenic, The tumours produced were well differentiated, keratinising squamous cell carcinomas suggesting that LMP does not inhibit epithelial cell differentiation which conflicts with a previous report by Dawson et al. (1990), To resolve this discrepancy we examined the ability of HaCaT and SCC12F LMP transfectants to differentiate in a suspension culture assay, Both lines were able to differentiate to a similar extent as parental lines and control transfectants. Our results indicate that LMP is strongly oncogenic in human epithelial cells but that inhibition of differentiation is not necessarily a mechanism by which LMP contributes to the pathogenesis of NPC.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111	University of London; London School of Hygiene & Tropical Medicine; Tufts University	Nicholson, LJ (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT HISTOPATHOL,LONDON SE5 9PJ,ENGLAND.			Salisbury, Jonathan/0000-0002-5889-4276	NCI NIH HHS [CA31893] Funding Source: Medline; NIAID NIH HHS [AI18757] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031893, R01CA031893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; CHEN ML, 1992, ONCOGENE, V7, P2131; Chen WP, 1996, J VIROL, V70, P4849, DOI 10.1128/JVI.70.7.4849-4853.1996; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FAHRAEUS R, 1992, INT J CANCER, V52, P834, DOI 10.1002/ijc.2910520527; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GOLDEN HD, 1973, J INFECT DIS, V127, P471, DOI 10.1093/infdis/127.4.471; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HU LF, 1993, ONCOGENE, V8, P1575; KARIMI L, 1995, J GEN VIROL, V76, P759, DOI 10.1099/0022-1317-76-4-759; KARRAN L, 1992, P NATL ACAD SCI USA, V89, P8058, DOI 10.1073/pnas.89.17.8058; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KEG G, 1993, J CLIN PATHOL, V46, P1080; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li SN, 1996, ONCOGENE, V12, P2129; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; LOUVIDOU C, 1995, J CLIN PATHOL MOL PA, V48, P717; Lu JJY, 1996, J GEN VIROL, V77, P1883, DOI 10.1099/0022-1317-77-8-1883; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; NIEDERMAN JC, 1970, NEW ENGL J MED, V282, P361, DOI 10.1056/NEJM197002122820704; NIEDOBITEK G, 1993, J PATHOL, V170, P457, DOI 10.1002/path.1711700409; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PATHMANATHAN R, 1995, AM J PATHOL, V146, P1355; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RICKINSON AB, 1996, FIELDS VIROLOGY, V2; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; SCULLEY TB, 1997, IN PRESS J VIROL; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVAS SK, 1995, J VIROL, V69, P8155, DOI 10.1128/JVI.69.12.8155-8158.1995; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WOLF H, 1973, NATURE-NEW BIOL, V244, P245, DOI 10.1038/newbio244245a0; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	55	34	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					275	283		10.1038/sj.onc.1201187	http://dx.doi.org/10.1038/sj.onc.1201187			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233762				2022-12-25	WOS:A1997XK99900004
J	Takahashi, K; Suzuki, K; Tsukatani, Y				Takahashi, K; Suzuki, K; Tsukatani, Y			Induction of tyrosine phosphorylation and association of beta-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence	ONCOGENE			English	Article						tyrosine phosphorylated beta-catenin; EGF receptor; tryptic digestion; dissociation of alpha-catenin; dysfunction of E-cadherin; normal human breast epithelial cells	EPIDERMAL GROWTH-FACTOR; E-CADHERIN EXPRESSION; ADHESION MOLECULE UVOMORULIN; BREAST EPITHELIAL-CELLS; HUMAN CARCINOMA-CELLS; ALPHA-CATENIN; CYTOPLASMIC DOMAIN; COMPLEX; PROTEIN; CANCER	Normal human breast epithelial (HBE) cells which reached confluence ceased growth and tightly adhered to each other, forming a monolayer, In quiescent cells thus arrested by density, E-cadherin colocalized and coimmunoprecipitated with alpha- and beta-catenins in the boundary region between adjacent cells, By contrast, immunocytostaining and Western blot analyses revealed that E-cadherin colocalized and coprecipitated with beta-catenin but not with alpha-catenin in exponentially growing cells at low density. As a comparable amount of alpha-catenin was detected in the total cell lysate of cells at different densities, it is suggested that alpha-catenin is present but dissociates from the E-cadherin-beta-catenin complex in growing cells, beta-Catenin was tyrosine phosphorylated in growing cells at low density but not in quiescent cells at confluence, Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of beta-catenin with EGF receptor (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from E-cadherin, Both tyrosine phosphorylation and association of beta-catenin with EGFR were inhibited by tyrphostin, a specific inhibitor of the EGFR tyrosine kinase, whereas dissociation of beta-catenin from E-cadherin was not, The results suggest that tyrosine phosphorylation of beta-catenin is achieved by EGFR upon tryptic digestion of cells and concurrent with but independent of dissociation of alpha-catenin from E-cadherin, beta-Catenin thus phosphorylated at tyrosine is suggested to play the role in preventing alpha-catenin once dissociated from reassociating with E-cadherin until cells reach confluence.			Takahashi, K (corresponding author), KANAGAWA CANC CTR,RES INST,DEPT BIOCHEM,ASAHI KU,1-1-2 NAKAO,YOKOHAMA,KANAGAWA 241,JAPAN.							BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; KADOWAKI T, 1994, CANCER RES, V54, P291; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LINDBLOM A, 1993, CANCER RES, V53, P3707; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MORTON RA, 1993, CANCER RES, V53, P3585; NAGAFUCHI A, 1994, DEV GROWTH DIFFER, V36, P59; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PERCEALL WE, 1995, ONCOGENE, V11, P1319; SATO T, 1990, CANCER RES, V50, P7184; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TAKAHASHI K, 1989, INT J CANCER, V43, P870, DOI 10.1002/ijc.2910430522; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	43	77	78	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					71	78		10.1038/sj.onc.1201160	http://dx.doi.org/10.1038/sj.onc.1201160			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233779				2022-12-25	WOS:A1997XH58600008
J	Empson, RM; Galione, A				Empson, RM; Galione, A			Cyclic ADP-ribose enhances coupling between voltage-gated Ca2+ entry and intracellular Ca2+ release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM-RELEASE; BULLFROG SYMPATHETIC NEURONS; HYBRID NG108-15 CELLS; RYANODINE RECEPTOR; CHANNELS; STORES; BRAIN; DIFFERENTIATION; EXPRESSION; METABOLITE	Ca2+ release from intracellular stores can be activated in neurons by influx of Ca2+ through voltage-gated Ca2+ channels, This process, called Ca2+-induced Ca2+ release, relies on the properties of the ryanodine receptor and represents a mechanism by which Ca2+ influx during neuronal activity can be amplified into large intracellular Ca2+ signals, In a differentiated neuroblastoma cell line, we show that caffeine, a pharmacological activator of the ryanodine receptor, released Ca2+ from intracellular stores in a Ca2+-dependent and ryanodine-sensitive manner. The pyridine nucleotide, cyclic ADP-ribose, thought to be an endogenous modulator of ryanodine receptors also amplified Ca2+-induced Ca2+ release in these neurons. Cyclic ADP-ribose enhanced the total cytoplasmic Ca2+ levels during controlled Ca2+ influx through voltage gated channels, in a concentration-dependent and ryanodine-sensitive manner and also increased the sensitivity with which a small amount of Ca2+ influx could trigger additional release from the ryanodine sensitive intracellular Ca2+ stores, Single cell imaging showed that following the Ca2+ influx, cyclic ADP-ribose enhanced the spatial spread of the Ca2+ signal from the edge of the cell into its center. These powerful actions suggest a role for cyclic ADP-ribose in the functional coupling of neuronal depolarization, Ca2+ entry, and global intracellular Ca2+ signaling.			Empson, RM (corresponding author), UNIV OXFORD,DEPT PHARMACOL,MANSFIELD RD,OXFORD OX1 3QT,ENGLAND.		Galione, Antony/E-5884-2011	Empson, Ruth/0000-0002-0415-6083; Galione, Antony/0000-0002-4132-7646	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRORSON JR, 1991, J NEUROSCI, V11, P4024; CHU A, 1990, MOL PHARMACOL, V37, P735; CHUEH SH, 1990, J NEUROCHEM, V55, P1281, DOI 10.1111/j.1471-4159.1990.tb03136.x; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DOCHERTY RJ, 1988, J PHYSIOL-LONDON, V398, P33, DOI 10.1113/jphysiol.1988.sp017027; DOCHERTY RJ, 1991, CELLULAR NEUROBIOLOG, P75; ECKERT R, 1991, NEUROSCI LETT, V119, P123; FRIEL DD, 1992, J PHYSIOL-LONDON, V450, P217, DOI 10.1113/jphysiol.1992.sp019125; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P316; HOLLIDAY J, 1991, NEURON, V7, P787, DOI 10.1016/0896-6273(91)90281-4; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; HUA SY, 1993, J PHYSIOL-LONDON, V464, P245, DOI 10.1113/jphysiol.1993.sp019633; JIN WZ, 1993, BRAIN RES, V607, P17, DOI 10.1016/0006-8993(93)91484-A; KOHDA K, 1995, J NEUROPHYSIOL, V74, P2184, DOI 10.1152/jn.1995.74.5.2184; KOSTYUK PG, 1995, CALCIUM SIGNALLING N, P39; KUBA K, 1994, JPN J PHYSIOL, V44, P613, DOI 10.2170/jjphysiol.44.613; LAI FA, 1992, BIOCHEM J, V288, P553, DOI 10.1042/bj2880553; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; LO TM, 1993, AM J PHYSIOL, V264, pC641, DOI 10.1152/ajpcell.1993.264.3.C641; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; Peng YY, 1996, J NEUROSCI, V16, P6703; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; Reyes M, 1996, J NEUROSCI, V16, P5951; SAH P, 1993, NEUROSCIENCE, V54, P157, DOI 10.1016/0306-4522(93)90391-R; SAH P, 1991, NEURON, V7, P257, DOI 10.1016/0896-6273(91)90264-Z; SEYMOURLAURENT KJ, 1995, J NEUROSCI, V15, P2592; SHARP AH, 1993, J NEUROSCI, V13, P3051; Shmigol A, 1995, J PHYSIOL-LONDON, V489, P627, DOI 10.1113/jphysiol.1995.sp021078; SHMIGOL A, 1994, J PHYSIOL-LONDON, V433, pP63; TAKEMURA H, 1991, BIOCHEM BIOPH RES CO, V180, P1518, DOI 10.1016/S0006-291X(05)81368-3; THAYER SA, 1988, MOL PHARMACOL, V34, P664; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; USACHEV Y, 1993, NEUROSCIENCE, V57, P845, DOI 10.1016/0306-4522(93)90029-F; Verkhratsky A, 1996, CELL CALCIUM, V19, P1, DOI 10.1016/S0143-4160(96)90009-3; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; Wang Y, 1997, J NEUROPHYSIOL, V77, P812, DOI 10.1152/jn.1997.77.2.812	43	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20967	20970		10.1074/jbc.272.34.20967	http://dx.doi.org/10.1074/jbc.272.34.20967			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261092	hybrid			2022-12-25	WOS:A1997XR78900002
J	Kuroda, A; Murphy, H; Cashel, M; Kornberg, A				Kuroda, A; Murphy, H; Cashel, M; Kornberg, A			Guanosine tetra- and pentaphosphate promote accumulation of inorganic polyphosphate in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPGPP; EXOPOLYPHOSPHATASE; PURIFICATION; MUTANTS; GENE	High levels of guanosine tetraphosphate (ppGpp) and guanosine pentaphosphate (pppGpp), generated in response to amino acid starvation in Escherichia coli, lead to massive accumulations of inorganic polyphosphate (polyP). Inasmuch as the activities of the principal enzymes that synthesize and degrade polyP fluctuate only slightly, the polyP accumulation can be attributed to a singular and profound inhibition by pppGpp and/or ppGpp of the hydrolytic breakdown of polyP by exopolyphosphatase, thereby blocking the dynamic turnover of polyP. The K-i values of 10 mu M for pppGpp and 200 mu M for ppGpp are far below the concentrations of these nucleotides in nutritionally stressed cells. In the complex metabolic network of pppGpp and ppGpp, the greater inhibitory effect of pppGpp (compared with ppGpp) leading to the accumulation of polyP, may have some significance in the relative roles played by these regulatory compounds.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; NICHHD,MOL GENET LAB,NIH,BETHESDA,MD 20892	Stanford University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1993, J BIOL CHEM, V268, P633; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; Cashel M., 1994, METH MOL G, V3, P341; CROOKE E, 1994, J BIOL CHEM, V269, P6290; HARA A, 1983, J BIOL CHEM, V258, P1678; KALMAN M, 1991, NEW BIOL, V3, P886; KEASLING JD, 1993, P NATL ACAD SCI USA, V90, P7029, DOI 10.1073/pnas.90.15.7029; KOONIN EV, 1994, TRENDS BIOCHEM SCI, V19, P156, DOI 10.1016/0968-0004(94)90275-5; KROHN M, 1995, ANAL BIOCHEM, V225, P188, DOI 10.1006/abio.1995.1138; Kulaev IS, 1979, BIOCH INORGANIC POLY; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Rao NN, 1996, J BACTERIOL, V178, P1394, DOI 10.1128/jb.178.5.1394-1400.1996; Shinagawa H., 1987, PHOSPHATE METABOLISM, P20; SPIRA B, 1995, J BACTERIOL, V177, P4053, DOI 10.1128/jb.177.14.4053-4058.1995; VOELZ H, 1966, ARCH MIKROBIOL, V53, P371, DOI 10.1007/BF00409874; WOOD HG, 1988, ANNU REV BIOCHEM, V57, P235, DOI 10.1146/annurev.bi.57.070188.001315; WOODY AYM, 1987, BIOCHIM BIOPHYS ACTA, V909, P115, DOI 10.1016/0167-4781(87)90033-9; XIAO H, 1991, J BIOL CHEM, V266, P5980	19	183	189	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21240	21243		10.1074/jbc.272.34.21240	http://dx.doi.org/10.1074/jbc.272.34.21240			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261133	hybrid			2022-12-25	WOS:A1997XR78900043
J	Okamoto, Y; Ninomiya, H; Tanioka, M; Sakamoto, A; Miwa, S; Masaki, T				Okamoto, Y; Ninomiya, H; Tanioka, M; Sakamoto, A; Miwa, S; Masaki, T			Palmitoylation of human endothelin(B) - Its critical role in G protein coupling and a differential requirement for the cytoplasmic tail by G protein subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; SF9 CELLS; CARBOXYL-TERMINUS; DOWN-REGULATION; LIGAND-BINDING; EXPRESSION; CYSTEINE; PHOSPHORYLATION; MUTATION; CLONING	By site-directed mutagenesis, three cysteine residues (amino acids 402, 403, and 405) in the carboxyl terminus of human endothelin(B) (ETB) were identified as potential palmitoylation sites. Substitutions of all of the three cysteine residues with serine gave an unpalmitoylated mutant, C2S/C3S/C5S, When expressed in Chinese hamster ovary cells, C2S/C3S/C5S was localized on the cell surface, retained high affinities to ET-1 and ET-3, and was rapidly internalized when bound to the ligand, However, unlike the wild-type ETB, C2S/C3S/C5S transmitted neither an inhibitory effect on adenylate cyclase nor a stimulatory effect on phospholipase C, indicating a critical role of palmitoylation in the coupling with G proteins, regardless of the G protein subtypes. Truncation of the carboxyl terminus including Cys(403)/Cys(405) gave a deletion mutant Delta 403 that was palmitoylated ton Cys(402) and lacked the carboxyl terminus downstream to the palmitoylation site. Delta 403 did transmit a stimulatory effect on phospholipase C via a pertussis toxin-insensitive G protein but it failed to transmit an inhibitory effect on adenylate cyclase. These results indicated a differential requirement for the carboxyl terminus downstream to the palmitoylation site in the coupling with G protein subtypes, i.e. it is required for the coupling with G(i) but not for that with G(q).	KYOTO UNIV, FAC MED, DEPT PHARMACOL, KYOTO 606, JAPAN	Kyoto University			Miwa, Soichi/D-8468-2012; OKAMOTO, Yasuo/J-8438-2015					ALALUF S, 1995, J NEUROCHEM, V64, P1548; Aquilla E, 1996, J BIOL CHEM, V271, P31572, DOI 10.1074/jbc.271.49.31572; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; Elshourbagy NA, 1996, J BIOL CHEM, V271, P25300, DOI 10.1074/jbc.271.41.25300; FUKURODA T, 1994, BIOCHEM BIOPH RES CO, V199, P1461, DOI 10.1006/bbrc.1994.1395; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KOSHIMIZU T, 1995, BIOCHEM BIOPH RES CO, V217, P354, DOI 10.1006/bbrc.1995.2784; KOZUKA M, 1991, J BIOL CHEM, V266, P16892; MASAKI T, 1993, ENDOCR REV, V14, P256, DOI 10.1210/er.14.3.256; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NG GYK, 1994, J NEUROCHEM, V63, P1589; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; OZAKI S, 1995, BIOCHEM BIOPH RES CO, V209, P483, DOI 10.1006/bbrc.1995.1527; ROSE PM, 1995, FEBS LETT, V361, P243, DOI 10.1016/0014-5793(95)00164-5; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Sugawara F, 1996, MOL PHARMACOL, V49, P447; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; VANKOPPEN CJ, 1991, J NEUROCHEM, V57, P1873, DOI 10.1111/j.1471-4159.1991.tb06397.x; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	37	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21589	21596		10.1074/jbc.272.34.21589	http://dx.doi.org/10.1074/jbc.272.34.21589			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261180	hybrid			2022-12-25	WOS:A1997XR78900090
J	Pierce, JW; Schoenleber, R; Jesmok, G; Best, J; Moore, SA; Collins, T; Gerritsen, ME				Pierce, JW; Schoenleber, R; Jesmok, G; Best, J; Moore, SA; Collins, T; Gerritsen, ME			Novel inhibitors of cytokine-induced I kappa B alpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR; E-SELECTIN; TYROSINE-PHOSPHATASE; LEUKOCYTE ADHESION; REGULATORY SYSTEM; MONOCYTE ADHESION; GENE-EXPRESSION	We have identified two compounds that inhibit the expression of endothelial-leukocyte adhesion molecules intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin, These compounds act by inhibiting tumor necrosis factor-alpha-induced phosphorylation of I kappa B-alpha, resulting in decreased nuclear factor-kappa B and decreased expression of adhesion molecules, The effects on both I kappa B-alpha phosphorylation and surface expression of E-selectin were irreversible and occurred at an IC50 of approximately 10 mu M. These agents selectively and irreversibly inhibited the tumor necrosis factor-alpha-inducible phosphorylation of I kappa B-alpha without affecting the constitutive I kappa B-alpha Phosphorylation. Although these compounds exhibited other activities, including stimulation of the stress-activated protein kinases, p38 and JNK-1, and activation of tyrosine phosphorylation of a 130-140-kDa protein, these effects are probably distinct from the effects on adhesion molecule expression since they were reversible, One compound was evaluated in vivo and shown to be a potent anti-inflammatory drug in two animal models of inflammation, The compound reduced edema formation in a dose-dependent manner in the rat carrageenan paw edema assay and reduced pam swelling in a rat adjuvant arthritis model, These studies suggest that inhibitors of cytokine-inducible I kappa B alpha phosphorylation exert anti-inflammatory activity in vivo.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL, VASC RES DIV, BOSTON, MA 02115 USA; BAYER CORP, West Haven, CT 06516 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Bayer AG								ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bennett BL, 1996, J BIOL CHEM, V271, P19680, DOI 10.1074/jbc.271.33.19680; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CARLOS TM, 1994, BLOOD, V84, P2068; CHEN CC, 1995, J IMMUNOL, V155, P3538; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; COLLINS T, 1993, LAB INVEST, V68, P499; COLLINS T, 1993, TRENDS CARDIOVAS MED, V3, P92, DOI 10.1016/1050-1738(93)90030-A; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GERRITSEN ME, 1995, AM J PATHOL, V147, P278; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; IIGO Y, 1991, J IMMUNOL, V147, P4167; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIU J, 1994, J BIOL CHEM, V269, P3047; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MENON SD, 1995, J BIOL CHEM, V270, P18881; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; ORTHNER CL, 1995, BLOOD, V86, P436, DOI 10.1182/blood.V86.2.436.bloodjournal862436; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pierce JW, 1996, J IMMUNOL, V156, P3961; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; READ MA, 1995, IMMUNITY, V2, P493, DOI 10.1016/1074-7613(95)90030-6; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RICHTER SUK, 1924, Patent No. 1506186; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665; WEBER C, 1995, J IMMUNOL, V155, P445; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464	75	896	930	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21096	21103		10.1074/jbc.272.34.21096	http://dx.doi.org/10.1074/jbc.272.34.21096			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261113	hybrid			2022-12-25	WOS:A1997XR78900023
J	Wu, DY; Wallen, HD; Inohara, N; Nunez, G				Wu, DY; Wallen, HD; Inohara, N; Nunez, G			Interaction and regulation of the Caenorhabditis elegans death protease CED-3 by CED-4 and CED-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; GENE CED-3; ENCODES; HOMOLOG; ENZYME; BCL-2	In the nematode Caenorhabditis elegans, three genes, ced-3, ced-4, and ced-9, play critical roles in the induction and execution of the death pathway, Genetic studies have suggested that ced-9 controls programmed cell death by regulating ced-4 and ced-3, However, the mechanism by which CED-9 controls the activities of CED-4 and the cysteine protease CED-3, the effector arm of the cell-death pathway, remains poorly understood, Immunoprecipitation analysis demonstrates that CED-9 forms a multimeric protein complex with CED-4, and CED-3 in vivo. Expression of wild-type CED-4 promotes the ability of CED-3 to induce apoptosis in mammalian cells, which is inhibited by CED-9, The pro-apoptotic activity of CED-4 requires the expression of a functional CED-3 protease, Significantly, loss-of-function CED-4 mutants are impaired in their ability to promote CED-3-mediated apoptosis, Expression of CED-4 enhances the proteolytic activation of CED-3, We also show that CED-9 inhibits the formation of p13 and p15, two cleavage products of CED-3 associated with its proteolytic activation in vivo. Moreover, CED-9 inhibits the enzymatic activity of CED-3 promoted by CED-4. Thus, these results provide evidence that CED-4 and CED-9 regulate the activity of CED-3 through physical interactions, which may provide a molecular basis for the control of programmed cell death in C. elegans.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Nuñez, Gabriel/A-7160-2014		NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline; PHS HHS [T32A107413-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	19	108	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21449	21454		10.1074/jbc.272.34.21449	http://dx.doi.org/10.1074/jbc.272.34.21449			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261161	hybrid			2022-12-25	WOS:A1997XR78900071
J	Yamin, TT; Miller, DK				Yamin, TT; Miller, DK			The interleukin-1 receptor-associated kinase is degraded by proteasomes following its phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; DROSOPHILA EMBRYO; DORSOVENTRAL SIGNAL; ALPHA PROTEOLYSIS; IL-1 RECEPTOR; TNF RECEPTORS	Following interleukin (Lt)-1 stimulation, the majority of the cellular interleukin-1 receptor-associated kinase (IRAK) translocates to a discrete subset of the Type I IL-1 receptor (IL-IRI) in MRC-5 human lung fibroblasts. As the IRAK becomes multiphosphorylated, it is degraded by proteasomes at a rate comparable to that of the degradation of the phosphorylated I kappa B alpha protein, Proteasome inhibitors black the degradation of phosphorylated IRAK and correspondingly increase the amount of IL-1R1 that can be coimmunoprecipitated with IRAK. The nonspecific kinase inhibitor K-252b blocks IRAK phosphorylation and degradation, but does not inhibit IRAK association with She IL-1R1 indicating that translocation of IRAK to the IL-1R1 and its phosphorylation are independent events. The IL-1 specificity of these effects is indicated by the lack of IRAK phosphorylation and degradation by IL-1 in the presence of the IL-1 receptor antagonist or by the activation of MRC-B cells by tumor necrosis factor alpha. Long term exposure of MRC-5 cells to IL-1 desensitizes the resynthesized I kappa B alpha to IL-1, but not to tumor necrosis factor alpha stimulation, but no additional effects an IRAK are seen.	MERCK RES LABS, DEPT INFLAMMAT RES, RAHWAY, NJ 07065 USA	Merck & Company								ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chainy GBN, 1996, J IMMUNOL, V157, P2410; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIN J, 1987, J EXP MED, V165, P70, DOI 10.1084/jem.165.1.70; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1994, J BIOL CHEM, V269, P19687; DARNAY BG, 1995, J BIOL CHEM, V270, P14867, DOI 10.1074/jbc.270.25.14867; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DOWER SK, 1987, IMMUNOL TODAY, V8, P46, DOI 10.1016/0167-5699(87)90238-6; DOWER SK, 1990, J INVEST DERMATOL, V94, pS68, DOI 10.1111/1523-1747.ep12875154; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HEGUY A, 1992, J BIOL CHEM, V267, P2605; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; INGHAM P, 1994, NATURE, V372, P500, DOI 10.1038/372500a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; MILLER DK, 1993, J BIOL CHEM, V268, P18062; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TOCCI MJ, 1997, IN PRESS CYTOKINES H; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Traenckner EBM, 1995, J CELL SCI, P79; Trofimova M, 1996, J BIOL CHEM, V271, P17609, DOI 10.1074/jbc.271.30.17609; URDAL DL, 1988, J BIOL CHEM, V263, P2870; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273	58	241	260	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21540	21547		10.1074/jbc.272.34.21540	http://dx.doi.org/10.1074/jbc.272.34.21540			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261174	hybrid			2022-12-25	WOS:A1997XR78900084
J	Zhao, H; Li, YY; Fucini, RV; Ross, SE; Pessin, JE; Koretzky, GA				Zhao, H; Li, YY; Fucini, RV; Ross, SE; Pessin, JE; Koretzky, GA			T cell receptor-induced phosphorylation of Sos requires activity of CD45, Lck, and protein kinase C, but not EPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; TYROSINE PHOSPHATASE CD45; GRB2 ADAPTER PROTEIN; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; RAS ACTIVATION; GROWTH-FACTOR; ZETA-CHAIN; SUBSTRATE RECOGNITION	Stimulation of the T cell antigen receptor (TCR) activates signaling pathways involving protein kinases, phospholipase C gamma 1, and Has. How these second messengers interact to initiate distal activation events is an area of intense scrutiny, In this report, we confirm that TCR ligation results in phosphorylation of Sos, a guanine nucleotide exchange factor for Has, This requires expression of both the CD45 tyrosine phosphatase and the Lck protein tyrosine kinase and depends upon signaling via protein kinase C. In contrast to previous studies examining requirements for Sos phosphorylation following insulin and epidermal growth factor receptor engagement, we show that TCR-induced phosphorylation of Sos does not require activation of the mitogen-activated protein kinase/extracellular signal regulated kinase (MEK/ERK) pathway, However, the basal phosphorylation of Sos in T cells is affected by either MEK or MEK-dependent kinases, Although Sos phosphorylation results in its dissociation from Grb2 following insulin stimulation in Chinese hamster ovary cells, TCR engagement on the Jurkat T cell line fails to elicit a similar effect, These data demonstrate that the kinases responsible for Sos phosphorylation differ following ligation of various cell surface receptors and that the consequences of Sos phosphorylation relies, at Yeast in part, on sites of its phosphorylation.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,PROGRAM MOL BIOL,IOWA CITY,IA 52242; UNIV IOWA,INTERDISCIPLINARY PROGRAM IMMUNOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; University of Iowa			Koretzky, Gary/AAU-5381-2021		NCI NIH HHS [P01CA66570] Funding Source: Medline; NIDDK NIH HHS [DK25925, DK33823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, R37DK033823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COBB MH, 1994, CELL MOL BIOL RES, V40, P253; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Holt KH, 1996, MOL CELL BIOL, V16, P577; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Li YY, 1996, J IMMUNOL, V157, P1440; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Motto DG, 1996, MOL CELL BIOL, V16, P2823; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; NEL AE, 1990, J IMMUNOL, V144, P2683; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PASTOR MI, 1995, CANCER SURV, V22, P75; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REIF K, 1994, J BIOL CHEM, V269, P14081; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	59	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21625	21634		10.1074/jbc.272.34.21625	http://dx.doi.org/10.1074/jbc.272.34.21625			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261185	hybrid			2022-12-25	WOS:A1997XR78900095
J	Ehnis, T; Dieterich, W; Bauer, M; Kresse, H; Schuppan, D				Ehnis, T; Dieterich, W; Bauer, M; Kresse, H; Schuppan, D			Localization of a binding site for the proteoglycan decorin on collagen XIV (Undulin)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; TISSUE-SPECIFIC EXPRESSION; GROWTH-FACTOR-BETA; FIBROBLAST ADHESION; MATRIX PROTEIN; RAT-LIVER; FIBRONECTIN; CARTILAGE; PURIFICATION; INHIBITION	Through its ability to bind extracellular matrix constituents and growth factors the small leucine rich chondroitin/dermatan sulfate proteoglycan decorin which is present in many types of connective tissues may play an important biological role in remodeling and maintenance of extracellular matrices during inflammation, fibrosis, and cancer growth, In this study we investigated the known binding of decorin to human collagen XIV, This binding was unaffected when the small collagenous moiety of collagen XIV was removed with collagenase. Therefore, fragments covering the large noncollagenous domain NC3 of collagen XIV were expressed in Escherichia coli, each fused to a 26-kDa fragment of glutathione S-transferase. Using radioiodinated decorin as ligand for the immobilized fusion proteins, a binding site that interacted with the decorin core protein could be assigned to the NH2-terminal fibronectin type III repeat of collagen XIV. In addition, an auxiliary binding site located COOH terminal to this fibronectin type III repeat interacted with the glycosaminoglycan component of decorin.	FREE UNIV BERLIN, KLINIKUM BENJAMIN FRANKLIN, DEPT GASTROENTEROL & HEPATOL, D-12200 BERLIN, GERMANY; UNIV MUNSTER, INST PHYSIOL CHEM & PATHOBIOCHEM, D-48149 MUNSTER, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munster								AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CASTAGNOLA P, 1992, EUR J CELL BIOL, V59, P340; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DUBLET B, 1991, J BIOL CHEM, V266, P6853; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; FONT B, 1993, J BIOL CHEM, V268, P25015; GERECKE DR, 1993, J BIOL CHEM, V268, P12177; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; GORDON MK, 1991, EUR J BIOCHEM, V201, P333, DOI 10.1111/j.1432-1033.1991.tb16290.x; HAUSSER H, 1994, FEBS LETT, V353, P243, DOI 10.1016/0014-5793(94)01044-7; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JUST M, 1991, J BIOL CHEM, V266, P17326; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; KNITTEL T, 1992, LAB INVEST, V67, P779; KOCH M, 1995, J CELL BIOL, V130, P1005, DOI 10.1083/jcb.130.4.1005; KRUMDIECK R, 1992, J IMMUNOL, V149, P3695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNON DP, 1991, MATRIX, V11, P412, DOI 10.1016/S0934-8832(11)80196-4; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; LUNSTRUM GP, 1991, J CELL BIOL, V113, P963, DOI 10.1083/jcb.113.4.963; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MEYER DH, 1992, HEPATOLOGY, V16, P204, DOI 10.1002/hep.1840160131; NOYORI K, 1994, ARTHRITIS RHEUM, V37, P1656, DOI 10.1002/art.1780371115; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; SCOTT JE, 1992, FASEB J, V6, P2639, DOI 10.1096/fasebj.6.9.1612287; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; TRUEB J, 1992, EUR J BIOCHEM, V207, P549, DOI 10.1111/j.1432-1033.1992.tb17081.x; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WALCHLI C, 1994, J CELL SCI, V107, P669; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; WATT SL, 1992, J BIOL CHEM, V267, P20093; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZHANG XL, 1993, J HISTOCHEM CYTOCHEM, V41, P245, DOI 10.1177/41.2.7678270	54	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20414	20419		10.1074/jbc.272.33.20414	http://dx.doi.org/10.1074/jbc.272.33.20414			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252349	hybrid			2022-12-25	WOS:A1997XR22100019
J	Leroy, D; Heriche, JK; Filhol, O; Chambaz, EM; Cochet, C				Leroy, D; Heriche, JK; Filhol, O; Chambaz, EM; Cochet, C			Binding of polyamines to an autonomous domain of the regulatory subunit of protein kinase CK2 induces a conformational change in the holoenzyme - A proposed role for the kinase stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN-KINASE; BETA-SUBUNIT; CALMODULIN BINDING; PEPTIDES; PHOSPHORYLATION; ACTIVATION; CONTAINS; SITE; ONCOPROTEINS; PURIFICATION	The means by which the cell regulates protein kinase CK2 remain obscure, However, natural polyamines, cellular compounds required for cell proliferation, have been reported to strongly stimulate CK2-mediated phosphorylation of a number of substrates, Using spermine analogs, we have shown that polyamines directly interact with the CK2 beta subunit, and the chemical features of the highly acidic binding site (Asp(51)-Tyr(80)) have been determined, In the present study, we show that the isolated beta subunit region extending from residue Asp(51) to Pro(110) exhibits a specific and efficient polyamine binding activity similar to that of the entire beta subunit, Moreover, the replacement of Glu(60), Glu(61), and Glu(63) of the beta subunit by 3 alanine residues leads to a loss of the spermine-induced stimulation of CK2 activity which correlates with a decrease in spermine binding affinity, Thermal stability studies indicate that the binding of spermine induces a 4 degrees C decrease of the T-m value for the holoenzyme. This was confirmed by circular dichroism analyses, which show that the 6 degrees C negative shift of the CK2 T-m value provoked by spermine binding, reflects a conformational change in the kinase. Together, these observations strongly suggest that this newly defined polyamine binding domain is involved in the intrasteric regulation of CK2 activity.	CEA GRENOBLE, INSERM U244, DEPT BIOL MOL & STRUCT, LAB BIOCHIM REGULAT CELLULAIRES ENDOCRINES, F-38054 GRENOBLE 9, FRANCE	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)			Filhol-Cochet, Odile/I-3962-2016	Filhol, Odile/0000-0003-1964-7958; Cochet, Claude/0000-0002-1772-4270; Heriche, Jean-Karim/0000-0001-6867-9425				BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; BOLDYREFF B, 1994, J BIOL CHEM, V269, P4827; BUEB JL, 1992, BIOCHEM J, V282, P545, DOI 10.1042/bj2820545; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; COCHET C, 1981, BIOCHIM BIOPHYS ACTA, V658, P191, DOI 10.1016/0005-2744(81)90289-8; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; COCHET C, 1983, J BIOL CHEM, V258, P1403; DIGUAN C, 1988, GENE, V67, P21, DOI 10.1016/0378-1119(88)90004-2; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HATHAWAY GM, 1984, ARCH BIOCHEM BIOPHYS, V233, P133, DOI 10.1016/0003-9861(84)90609-X; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LEMONN MA, 1995, P NATL ACAD SCI USA, V92, P10472; Leroy D, 1997, BIOCHEMISTRY-US, V36, P1242, DOI 10.1021/bi961949u; LEROY D, 1995, J BIOL CHEM, V270, P17400, DOI 10.1074/jbc.270.29.17400; LEROY D, 1994, CELL MOL BIOL RES, V40, P441; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MORENO FJ, 1993, BIOCHEM J, V289, P631, DOI 10.1042/bj2890631; MORISHIMA Y, 1994, EUR J BIOCHEM, V219, P349, DOI 10.1111/j.1432-1033.1994.tb19946.x; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P995, DOI 10.1021/bi00429a012; SCALABRINO G, 1991, MOL CELL ENDOCRINOL, V77, P1, DOI 10.1016/0303-7207(91)90056-X; SRIVENUGOPAL KS, 1985, BIOCHEMISTRY-US, V24, P4766, DOI 10.1021/bi00339a009; TRAUGH JA, 1990, ADV SEC MESS PHOSPH, V24, P224; TUNG HYL, 1985, EUR J BIOCHEM, V149, P305, DOI 10.1111/j.1432-1033.1985.tb08927.x; WETZEL R, 1988, P NATL ACAD SCI USA, V85, P401, DOI 10.1073/pnas.85.2.401; XU QY, 1991, BIOCHEMISTRY-US, V30, P11811, DOI 10.1021/bi00115a011; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	40	82	84	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20820	20827		10.1074/jbc.272.33.20820	http://dx.doi.org/10.1074/jbc.272.33.20820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252407	hybrid			2022-12-25	WOS:A1997XR22100077
J	Stringer, SE; Gallagher, JT				Stringer, SE; Gallagher, JT			Specific binding of the chemokine platelet factor 4 to heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR-IV; MOLECULAR-ORGANIZATION; ENDOTHELIAL-CELLS; MURINE MELANOMA; RECEPTOR; PROTEOGLYCANS; INHIBITION; IDENTIFICATION; RESOLUTION	Platelet factor 4 is a tetrameric heparin binding chemokine released from the alpha-granules of activated platelets. In this study we show that platelet factor 4 binds with high affinity and specificity to an approximately 9-kDa sequence in heparan sulfate, which it protects from degradation by heparinase enzymes. This protected fragment is enriched in N-sulfated disaccharides and iduronate 2-O-sulfate residues, the latter being important for binding to platelet factor 4. The major structural motif of the fragment appears to consist of a pair of sulfated domains positioned at both ends separated by a central mainly N-acetylated region. On the basis of these findings, we propose a model in which the heparan sulfate fragment wraps around the ring of positive charges on platelet factor 4 with the iduronate 2-O-sulfates within the sulfated domains binding strongly to lysine clusters on opposite faces of the tetramer.	PATERSON INST CANC RES,DRUG DEV DEPT,MANCHESTER M20 9BX,LANCS,ENGLAND; UNIV MANCHESTER,CHRISTIE HOSP,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND	Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Stringer, SE (corresponding author), PATERSON INST CANC RES,CANC RES CAMPAIGN,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.							BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOCK PE, 1980, BIOCHEM J, V191, P769, DOI 10.1042/bj1910769; BUSCH C, 1980, THROMB RES, V19, P129, DOI 10.1016/0049-3848(80)90412-0; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HANSELL P, 1995, AM J PHYSIOL-HEART C, V269, pH829, DOI 10.1152/ajpheart.1995.269.3.H829; IBEL K, 1986, BIOCHIM BIOPHYS ACTA, V870, P58, DOI 10.1016/0167-4838(86)90008-7; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; KOLBER DL, 1995, J NATL CANCER I, V87, P304, DOI 10.1093/jnci/87.4.304; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LINDHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LOSCALZO J, 1985, ARCH BIOCHEM BIOPHYS, V240, P446, DOI 10.1016/0003-9861(85)90049-9; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MARSHALL SE, 1984, BIOCHIM BIOPHYS ACTA, V797, P34, DOI 10.1016/0304-4165(84)90379-9; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P925, DOI 10.1021/bi00218a007; MAYO KH, 1989, BIOCHEMISTRY-US, V28, P9469, DOI 10.1021/bi00450a034; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; SATO Y, 1993, JPN J CANCER RES, V84, P485, DOI 10.1111/j.1349-7006.1993.tb00163.x; SATO Y, 1990, BIOCHEM BIOPH RES CO, V172, P595, DOI 10.1016/0006-291X(90)90715-Y; SHARPE RJ, 1990, JNCI-J NATL CANCER I, V82, P848, DOI 10.1093/jnci/82.10.848; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; STRINGR SE, 1997, IN PRESS INT J BIOCH; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; TAYLOR RL, 1973, BIOCHEMISTRY-US, V12, P3633, DOI 10.1021/bi00743a010; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WHITSON RH, 1991, J CELL BIOCHEM, V47, P31, DOI 10.1002/jcb.240470105; ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P693	39	161	166	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20508	20514		10.1074/jbc.272.33.20508	http://dx.doi.org/10.1074/jbc.272.33.20508			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252363	hybrid			2022-12-25	WOS:A1997XR22100033
J	Guy, HI; Rotgeri, A; Evans, DR				Guy, HI; Rotgeri, A; Evans, DR			Activation by fusion of the glutaminase and synthetase subunits of Escherichia coli carbamyl-phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATES PYRIMIDINE BIOSYNTHESIS; MULTIFUNCTIONAL PROTEIN CAD; REVERSIBLE DISSOCIATION; MAMMALIAN-CELLS; HAMSTER CELLS; GENE; DOMAIN; ENZYME; ORGANIZATION; MECHANISM	Escherichia coli carbamyl-phosphate synthetase consists of two subunits that act in concert to synthesize carbamyl phosphate, The 40-kDa subunit is an amidotransferase (GLN subunit) that hydrolyzes glutamine and transfers ammonia to the 120-kDa synthetase subunit (CPS subunit), The enzyme can also catalyze ammonia-dependent carbamyl phosphate synthesis if provided with exogenous ammonia, In mammalian cells, homologous amidotransferase and synthetase domains are carried on a single polypeptide chain called CAD. Deletion of the 29-residue linker that bridges the GLN and CPS domains of CAD stimulates glutamine-dependent carbamyl phosphate synthesis and abolishes the ammonia-dependent reaction (Guy, H. I., and Evans, D. R. (1997) J. Biol. Chem. 272, 19906-19912), suggesting that the deletion mutant is trapped in at closed high activity conformation, Since the catalytic mechanisms of the mammalian and bacterial proteins are the same, we anticipated that similar changes in the function of the E. coli protein could be produced by direct fusion of the GLN and CPS subunits, A construct was made in which the intergenic region between the contiguous carA and carB genes was deleted and the sequences encoding the carbamyl-phosphate synthetase subunits were fused in frame, The resulting fusion protein was activated 10-fold relative to the native protein, was unresponsive to the allosteric activator ornithine, and could no longer use ammonia as a nitrogen donor, Moreover, the functional linkage that coordinates the rate of glutamine hydrolysis with the activation of bicarbonate was abolished, suggesting that the protein was locked in an activated conformation similar to that induced by the simultaneous binding of all substrates.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA	Wayne State University					NIGMS NIH HHS [GM47399] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1964, BIOCHEMISTRY-US, V3, P723, DOI 10.1021/bi00893a021; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1968, BIOCHEM BIOPH RES CO, V32, P928, DOI 10.1016/0006-291X(68)90116-2; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; BEIN K, 1991, J BIOL CHEM, V266, P3791; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; Guy HI, 1997, J BIOL CHEM, V272, P19906, DOI 10.1074/jbc.272.32.19906; Hanahan D, 1985, DNA CLONING PRACTICA; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; HONG J, 1995, J BIOL CHEM, V270, P14130, DOI 10.1074/jbc.270.23.14130; HORTON RM, 1991, DIRECTED MUTAGENESIS; KELLY RE, 1986, J BIOL CHEM, V261, P6073; KERN CB, 1992, J MOL EVOL, V35, P217; KIM HS, 1992, J BIOL CHEM, V267, P7177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSTY CJ, 1992, FEBS LETT, V314, P135, DOI 10.1016/0014-5793(92)80959-K; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; POST LE, 1990, J BIOL CHEM, V265, P7742; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; RAUSHEL FM, 1978, BIOCHEMISTRY-US, V17, P5587, DOI 10.1021/bi00619a001; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P482; TROTTA PP, 1974, J BIOL CHEM, V249, P492; WELLNER VP, 1973, BIOCHEMISTRY-US, V12, P2061, DOI 10.1021/bi00735a006	46	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19913	19918		10.1074/jbc.272.32.19913	http://dx.doi.org/10.1074/jbc.272.32.19913			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242657	hybrid			2022-12-25	WOS:A1997XQ05900044
J	Ricort, JM; Tanti, JF; VanObberghen, E; LaMarchandBrustel, Y				Ricort, JM; Tanti, JF; VanObberghen, E; LaMarchandBrustel, Y			Cross-talk between the platelet-derived growth factor and the insulin signaling pathways in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE KINASE PHOSPHORYLATES; RECEPTOR TYROSINE KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; SUBSTRATE IRS-1; PROTEIN; SUBUNIT; TRANSDUCTION; PI3-KINASE; BINDING; P85	Phosphatidylinositol (PI) 3-kinase is activated by various growth factors such as PDGF (platelet-derived growth factor) and insulin. The aim of the present study was to determine whether PDGF could modulate insulin activation of PI 3-kinase in 3T3-L1 adipocytes, When cells were preincubated for 5-15 min with PDGF, PI 3-kinase activity associated to insulin receptor substrate 1 (IRS 1) in response to insulin was decreased, due to reduced association of the PI 3-kinase p85 subunit with PRS 1, In addition, following this PDGF pretreatment, the tyrosine phosphorylation of IRS 1 in response to insulin and its electrophoretic mobility were diminished. The change in the mobility of PRS I could be attributed to PDGF-induced serine/threonine phosphorylation of the protein which was partly inhibited by PI 3-kinase inhibitors. By contrast, epidermal growth factor, which does not stimulate PI 3-kinase, had no effect on the association of PI 3-kinase with IRS 1 in response to insulin, This series of results indicates that the PDGF-induced serine/threonine phosphorylation of IRS 1 could be due to activation of PI 3-kinase pathway, Furthermore, this phosphorylation of IRS 1 is associated with a decrease in its tyrosine phosphorylation by insulin and in its association with the p85 subunit of PI 3-kinase. This study suggests that a cross-talk exists between the different pathways stimulated by PDGF and insulin in intact cells.	FAC MED NICE,INSERM,U145,F-06107 NICE 02,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur				Tanti, Jean-Francois/0000-0003-1782-1318				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FREUND GG, 1995, BIOCHEM BIOPH RES CO, V206, P272, DOI 10.1006/bbrc.1995.1038; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; LAM K, 1994, J BIOL CHEM, V269, P20648; LEVYTOLEDANO R, 1995, J BIOL CHEM, V270, P30018; Li PM, 1996, BIOCHEM BIOPH RES CO, V223, P80, DOI 10.1006/bbrc.1996.0849; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	34	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19814	19818		10.1074/jbc.272.32.19814	http://dx.doi.org/10.1074/jbc.272.32.19814			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242642	hybrid			2022-12-25	WOS:A1997XQ05900029
J	Xu, Y; Wong, SH; Zhang, T; Subramaniam, VN; Hong, WJ				Xu, Y; Wong, SH; Zhang, T; Subramaniam, VN; Hong, WJ			GS15, a 15-kilodalton Golgi soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) homologous to rbet1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSPORT; FUSION; YEAST; COMPLEX; MEMBERS; YPT1	Bet1p plays an essential role in vesicular transport from the endoplasmic reticulum (ER) to the Golgi in yeast, and it functions as a vesicle soluble N-ethylmaleimide-sensitive factor protein receptor (V-SNARE). A mammalian protein related to Bet1p has been reported. previously and was referred to as rbet1. Pie have now identified a new mammalian protein that is homologous to rbet1 (28% amino acid identity). mRNA for this rbet1 homologue is widely expressed in rat tissues. Affinity purified polyclonal antibodies raised against recombinant protein specifically recognized a <(15)under bar>-kilodalton integral membrane protein highly enriched in Golgi membranes. Indirect immunofluorescence microscopy revealed that this protein is specifically associated with the Golgi apparatus in diverse cell types. Biochemical characterization established that this protein behaves like a SNARE and was named GS15 (Golgi SNARE with a size of 15 kilodaltons). These properties raise the possibility that GS15 is a novel SNARE mediating a yet to be defined transport event associated with the Golgi apparatus.	INST MOL & CELL BIOL,MEMBRANE BIOL LAB,SINGAPORE 119067,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)			HONG, Wanjin/E-9927-2010; Subramaniam, V. Nathan/A-1901-2010	Subramaniam, V. Nathan/0000-0002-4583-7790				DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DASCHER C, 1994, J BIOL CHEM, V269, P29363; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; HAY JC, 1997, CELL, V89, P147; HONG W, 1996, PROTEIN TRAFFICKING; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; Lowe SL, 1996, J CELL SCI, V109, P209; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHELLER RH, 1995, NEURON, V14, P893; SEHEKMAN R, 1996, SCIENCE, V271, P1526; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; SUBRAMANIAM VN, 1995, J CELL SCI, V108, P2405; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	27	45	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20162	20166		10.1074/jbc.272.32.20162	http://dx.doi.org/10.1074/jbc.272.32.20162			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242691	hybrid			2022-12-25	WOS:A1997XQ05900078
J	Yin, TG; Sandhu, G; Wolfgang, CD; Burrier, A; Webb, RL; Rigel, DF; Hai, TW; Whelan, J				Yin, TG; Sandhu, G; Wolfgang, CD; Burrier, A; Webb, RL; Rigel, DF; Hai, TW; Whelan, J			Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ACUTE-RENAL-FAILURE; C-JUN; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MAPKAP KINASE-2; SHOCK PROTEINS; PHOSPHORYLATION; APOPTOSIS; MITOGEN	In this report we investigate the molecular mechanisms that contribute to tissue damage following ischemia and ischemia coupled with reperfusion (ischemia/reperfusion) in the rat heart and kidney, We observe the activation of three stress-inducible mitogen-activated protein (MAP) kinases in these tissues: p38 MAP kinase and the 46- and 55-kDa isoforms of Jun N-terminal kinase (JNK(46) and JNK(55)). The heart and kidney show distinct time courses in the activation of p38 MAP kinase during ischemia but no activation of either JNK(46) or JNK(55). These two tissues also respond differently to ischemia/reperfusion. In the heart we observe activation of JNK(55) and p38 MAP kinase, whereas in the kidney all three kinases are active. We also examined the expression pattern of two stress-responsive genes, c-Jun and ATF3. Our results indicate that in the heart both genes are induced by ischemia and ischemia/reperfusion. However, in the kidney c-Jun and ATF3 expression is induced only by ischemia/reperfusion. To correlate these molecular events with tissue damage we examined DNA laddering, a common marker of apoptosis. A significant increase in DNA laddering was evident in both heart and kidney following ischemia/reperfusion and correlated with the pattern of kinase activation, supporting a link between stress kinase activation and apoptotic cell death in these tissues.	NOVARTIS PHARMACEUT CORP,SUMMIT,NJ 07901; OHIO STATE UNIV,DEPT MED BIOCHEM,NEUROBIOTECHNOL CTR,COLUMBUS,OH 43210; OHIO STATE UNIV,OHIO STATE BIOCHEM PROGRAM,COLUMBUS,OH 43210	Novartis; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Hai, Tsonwin/E-3185-2011; Hai, Tsonwin/H-4480-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315				BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P102; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAYS SR, 1992, AM J MED SCI, V304, P93, DOI 10.1097/00000441-199208000-00005; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ITOH G, 1995, AM J PATHOL, V146, P1325; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kajstura J, 1996, LAB INVEST, V74, P86; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Knight RJ, 1996, BIOCHEM BIOPH RES CO, V218, P83, DOI 10.1006/bbrc.1996.0016; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; NEELY JR, 1984, CIRC RES, V55, P816, DOI 10.1161/01.RES.55.6.816; NOGUCHI S, 1993, J PHARMACOL EXP THER, V267, P919; POMBO CM, 1994, J BIOL CHEM, V269, P26546; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHUMER M, 1992, AM J PATHOL, V140, P831; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; UMANSKY SR, 1995, CELL DEATH DIFFER, V2, P235; UMANSKY SR, 1996, BASIC APPL MYOL, V6, P227; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Woodgett JR, 1996, PHILOS T R SOC B, V351, P135, DOI 10.1098/rstb.1996.0009; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	53	321	342	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19943	19950		10.1074/jbc.272.32.19943	http://dx.doi.org/10.1074/jbc.272.32.19943			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242662	hybrid			2022-12-25	WOS:A1997XQ05900049
J	Yun, CH; Song, M; Kim, H				Yun, CH; Song, M; Kim, H			Conformational change of cytochrome P450 1A2 induced by phospholipids and detergents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; BETA-NAPHTHOFLAVONE; CIRCULAR-DICHROISM; P-450 REDUCTASE; ENZYME SYSTEM; RAPID METHOD; PURIFICATION; FORMS; STIMULATION; EXPRESSION	Recently, it was reported that the activity of rabbit P450 1A2 is markedly increased at elevated salt concentration (Yun, C-H., Song, M., Ahn, T., and Kim, H. (1996) J. Biol, Chem, 271, 31312-31316), The activity increase of P450 1A2 coincides with the raised alpha-helix content and decreased beta-sheet content, The presence of phospholipid magnified this effect. Here, possible structural change of rabbit P450 1A2 accompanying the phospholipid-induced increase in its enzyme activity was investigated by circular dichroism, fluorescence spectroscopy, and absorption spectroscopy, Studies with the reconstituted system supported by cumene hydroperoxide or NADPH showed that the P450 1A2 activities were found to be dependent on the head group and hydrocarbon chain length of phospholipid, Phosphatidylcholines having short hydrocarbon chains with a carbon number of 8-12 were very efficient for reconstitution of the P450-catalyzed reactions supported by both cumene hydroperoxide and NADPH, It was found that the phospholipid increased the alpha-helix content and lowered the beta-sheet content of P450, Intrinsic fluorescence intensity is also increased in the presence of phospholipid. The low spin iron configuration of P450 1A2 shifted toward the high spin configuration by most of the phospholipids in the endoplasmic reticulum, Some synthetic phospholipids having short hydrocarbon chains with a carbon number of 10-12 caused a shift in the spin equilibrium of P450 1A2 toward low spin, The effect of detergents on the activity and conformation of P450 1A2 was also studied, It was found that the addition of detergents to P450 1A2 solution increased the enzyme activity of P450 1A2. Detergents also increased the alpha-helix content and lowered the beta-sheet content of P450 1A2, Intrinsic fluorescence emissions also increased with the presence of detergents, Octyl glucoside and deoxycholate caused a shift toward high spin, On the other hand, cholate caused a shift toward low spin, It was found that the activity increase of rabbit P450 1A2 coincides with the conformational change including raised alpha-helix content. It is proposed that the interaction with the phospholipid molecules surrounding P450 1A2 in the endoplasmic reticulum is important for a functional conformation of P450 1A2 in a monooxygenase system including NADPH-P450 reductase.	KOREA ADV INST SCI & TECHNOL,DEPT SCI BIOL,TAEJON 305701,SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST)	Yun, CH (corresponding author), PAI CHAI UNIV,DEPT BIOCHEM,SEO KU,439-6 DOMA DONG,TAEJON 302735,SOUTH KOREA.			Yun, Chul-Ho/0000-0003-2685-2968				ALTERMAN MA, 1990, BIOMED CHROMATOGR, V4, P221, DOI 10.1002/bmc.1130040510; CHIANG YL, 1979, ARCH BIOCHEM BIOPHYS, V195, P178, DOI 10.1016/0003-9861(79)90339-4; COLEMAN R, 1973, BIOCHIM BIOPHYS ACTA, V300, P1, DOI 10.1016/0304-4157(73)90010-5; COON MJ, 1971, CHEM-BIOL INTERACT, V3, P248, DOI 10.1016/0009-2797(71)90046-9; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; ESTABROOK RW, 1971, METABOLISM, V20, P187, DOI 10.1016/0026-0495(71)90091-6; FRENCH JS, 1980, J BIOL CHEM, V255, P4112; Guengerich F. Peter, 1994, P1259; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; GUENGERICH FP, 1979, BIOCHEMISTRY-US, V18, P5442, DOI 10.1021/bi00591a029; GUENGERICH FP, 1978, J BIOL CHEM, V253, P7931; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; INGELMANSUNDBERG M, 1980, BIOCHIM BIOPHYS ACTA, V599, P417, DOI 10.1016/0005-2736(80)90188-1; INGELMANSUNDBERG M, 1977, FEBS LETT, V78, P72, DOI 10.1016/0014-5793(77)80275-5; INGELMANSUNDBERG M, 1981, BIOCHEMISTRY-US, V20, P4100, DOI 10.1021/bi00517a024; INGELMANSUNDBERG M, 1980, BIOCHEMISTRY-US, V19, P4004, DOI 10.1021/bi00558a018; Jansson I, 1996, ARCH BIOCHEM BIOPHYS, V325, P265, DOI 10.1006/abbi.1996.0033; LU AYH, 1974, BIOCHEM BIOPH RES CO, V60, P266, DOI 10.1016/0006-291X(74)90200-9; LU AYH, 1968, J BIOL CHEM, V243, P1331; MIWA GT, 1984, ARCH BIOCHEM BIOPHYS, V234, P161, DOI 10.1016/0003-9861(84)90337-0; MIWA GT, 1981, ARCH BIOCHEM BIOPHYS, V211, P454, DOI 10.1016/0003-9861(81)90477-X; OMURA T, 1964, J BIOL CHEM, V239, P2370; PALMER G, 1992, J BIOL CHEM, V267, P665; PETERSON JA, 1976, J BIOL CHEM, V251, P4010; POHL RJ, 1980, ANAL BIOCHEM, V107, P150, DOI 10.1016/0003-2697(80)90505-9; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; PORTER TD, 1991, J BIOL CHEM, V266, P13469; SANDHU P, 1994, ARCH BIOCHEM BIOPHYS, V309, P168, DOI 10.1006/abbi.1994.1099; STIER A, 1973, BIOCHIM BIOPHYS ACTA, V311, P400, DOI 10.1016/0005-2736(73)90320-9; STROBEL HW, 1970, J BIOL CHEM, V245, P4851; TANIGUCHI H, 1984, ARCH BIOCHEM BIOPHYS, V232, P585, DOI 10.1016/0003-9861(84)90577-0; Timasheff S.N., 1989, PROTEIN STRUCTURE PR, P331; VASKOVSKY VE, 1975, J CHROMATOGR, V114, P129, DOI 10.1016/S0021-9673(00)85249-8; VESSEY DA, 1972, J BIOL CHEM, V247, P3023; Viner RL, 1995, BIOCHEM BIOPH RES CO, V217, P886, DOI 10.1006/bbrc.1995.2854; VOZNESENSKY AI, 1994, J BIOL CHEM, V269, P15724; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; WHITE RE, 1982, J BIOL CHEM, V257, P3073; WU ES, 1984, BIOCHEMISTRY-US, V23, P28, DOI 10.1021/bi00296a005; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yun CH, 1996, J BIOL CHEM, V271, P31312, DOI 10.1074/jbc.271.49.31312	43	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19725	19730		10.1074/jbc.272.32.19725	http://dx.doi.org/10.1074/jbc.272.32.19725			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242629	hybrid			2022-12-25	WOS:A1997XQ05900016
J	Tanaka, Y; Watanabe, T; Chiba, N; Niki, M; Kuroiwa, Y; Nishihira, T; Satomi, S; Ito, Y; Satake, M				Tanaka, Y; Watanabe, T; Chiba, N; Niki, M; Kuroiwa, Y; Nishihira, T; Satomi, S; Ito, Y; Satake, M			The protooncogene product, PEBP2 beta/CBF beta, is mainly located in the cytoplasm and has an affinity with cytoskeletal structures	ONCOGENE			English	Article						PEBP2 beta/CBF beta; proto-oncogene; acute myeloid leukemia; transcription factor; cytoskeleton; immunocytochemistry	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; NF-KAPPA-B; TRANSCRIPTION FACTOR; DNA-BINDING; E-CADHERIN; AML1 GENE; FUSION TRANSCRIPT; PROTEIN; RUNT	The Pebp62/Cbfb gene encodes the non-DNA binding beta subunit of the heterodimeric transcription factor, PEBP2/CBF, and has been implicated in a subtype of human acute myeloid leukemia, as well as being indispensable for the development of definitive hematopoiesis in the murine fetal liver, By examining a subcellular localization of the PEBP2 beta/CBF beta protein in tissue culture cells, we could reveal an additional aspect of the protein other than to be a subunit of a transcription factor, Immunoblot and immunocytochemical staining showed that PEBP2 beta/CBF beta was mostly present in the cytoplasm, This PEBP2 beta/CBF beta was free from its DNA-binding partner, the cc subunit of PEBP2/CBF, as judged by the electrophoretic mobility shift assays, Furthermore, a significant amount of PEBP2 beta 1/CBF beta was retained in the cytoskeleton preparation after detergent extraction of the cells and was found by double immunofluorescence to colocalize with the F-actin on stress fibers and the vinculin in membrane processes, Thus, the present study extends PEBP2 beta/CBF beta to be a cytoskeleton-affinitive as well as nuclear protein, The implications of these results are discussed.	TOHOKU UNIV,SCH MED,INST DEV AGING & CANC,DEPT MOL IMMUNOL,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; TOHOKU UNIV,SCH MED,DEPT SURG 2,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; HITACHI LTD,CHEM,PHARMACEUT RES LABS,HITACHI,IBARAKI 317,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 60601,JAPAN	Tohoku University; Tohoku University; Hitachi Limited; Kyoto University								ABERLE H, 1994, J CELL SCI, V107, P3655; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; ERICKSON P, 1992, BLOOD, V80, P1825; Geiger B, 1989, CURR OPIN CELL BIOL, V1, P103, DOI 10.1016/S0955-0674(89)80045-6; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NIKI M, 1997, IN PRESS P NATL ACAD; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PRATT WB, 1993, J BIOL CHEM, V268, P21455; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SALGIA R, 1995, ONCOGENE, V11, P1149; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89	39	34	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					677	683		10.1038/sj.onc.1201235	http://dx.doi.org/10.1038/sj.onc.1201235			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264408				2022-12-25	WOS:A1997XP68300007
J	Hwang, HY; Ullman, B				Hwang, HY; Ullman, B			Genetic analysis of purine metabolism in Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; MITOTIC RECOMBINATION; ADENINE PHOSPHORIBOSYLTRANSFERASE; STABLE TRANSFECTION; MOLECULAR-CLONING; TOXOPLASMA-GONDII; ADENOSINE KINASE; NULL MUTANTS; CELL HYBRIDS; EXPRESSION	To dissect the contributions of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and adenosine kinase (AK) to purine salvage in Leishmania donovani, null mutants genetically deficient in HGPRT and/or APRT were generated by targeted gene replacement in wild type cells and preexisting mutant strains lacking either APRT or AK activity, These knockouts were obtained either by double targeted gene replacement or by single gene replacement followed by negative selection for loss-of-heterozygosity. Genotypes were confirmed by Southern blotting and the resultant phenotypes evaluated by enzymatic assay, resistance to cytotoxic drugs, ability to incorporate radiolabeled purine bases, and growth on various purine sources. All mutant strains could propagate in defined growth medium containing any single purine source and could metabolize exogenous [H-3]hypoxanthine to the nucleotide level. The surprising ability of mutant L. donovani lacking HGPRT, APRT, and/or AK to incorporate and grow in hypoxanthine could be attributed to the ability of the parasite xanthine phosphoribosyltransferase enzyme to salvage hypoxanthine. These genetic studies indicate that HGPRT, APRT, and AK, individually or in any combination, are not essential for the survival and growth of the promastigote stage of L. donovani and intimate an important, if not crucial, role for xanthine phosphoribosyltransferase in purine salvage.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOL BIOL, PORTLAND, OR 97201 USA	Oregon Health & Science University				Hwang, Ho-Yon/0000-0003-0204-8932	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023682, R01AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen T, 1995, MOL BIOCHEM PARASIT, V74, P99, DOI 10.1016/0166-6851(95)02475-1; ALLEN T, 1989, MOL BIOCHEM PARASIT, V33, P273, DOI 10.1016/0166-6851(89)90089-3; ALLEN TE, 1995, MOL BIOCHEM PARASIT, V73, P133, DOI 10.1016/0166-6851(94)00105-V; BATES PA, 1992, PARASITOLOGY, V105, P193, DOI 10.1017/S0031182000074102; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; CAMPBELL CE, 1981, MOL CELL BIOL, V1, P336, DOI 10.1128/MCB.1.4.336; CASKEY CT, 1979, CELL, V16, P1, DOI 10.1016/0092-8674(79)90182-X; CHAN TS, 1978, SOMAT CELL GENET, V4, P1, DOI 10.1007/BF01546489; CHANG KP, 1980, SCIENCE, V209, P1240, DOI 10.1126/science.7403880; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; CRUZ AK, 1993, P NATL ACAD SCI USA, V90, P1599, DOI 10.1073/pnas.90.4.1599; DELAFAILLE MAC, 1992, J BIOL CHEM, V267, P23839; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; FREEDMAN DJ, 1993, MOL BIOCHEM PARASIT, V62, P37, DOI 10.1016/0166-6851(93)90175-W; GALLERANO RH, 1990, AM J TROP MED HYG, V43, P159, DOI 10.4269/ajtmh.1990.43.159; GEARY TG, 1986, CHEMOTHERAPY PARASIT, P87; GUIEROS FJ, 1996, MOL CELL BIOL, V16, P5655; HANSON S, 1992, J BIOL CHEM, V267, P2350; Hwang HY, 1996, J BIOL CHEM, V271, P30840, DOI 10.1074/jbc.271.48.30840; IOVANNISCI DM, 1989, MOL BIOCHEM PARASIT, V34, P177, DOI 10.1016/0166-6851(89)90009-1; IOVANNISCI DM, 1984, J BIOL CHEM, V259, P4617; IOVANNISCI DM, 1984, MOL BIOCHEM PARASIT, V12, P139, DOI 10.1016/0166-6851(84)90131-2; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; JOCHIMSEN B, 1975, MOL GEN GENET, V143, P85, DOI 10.1007/BF00269424; JOSHI PB, 1995, GENE, V156, P145, DOI 10.1016/0378-1119(95)00042-5; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KIDDER GW, 1979, P NATL ACAD SCI USA, V76, P3670, DOI 10.1073/pnas.76.8.3670; KOSZALKA GW, 1979, J BIOL CHEM, V254, P8185; KOVACS JA, 1986, CHEMOTHERAPY PARASIT, P139; KUSANO T, 1971, P NATL ACAD SCI USA, V68, P82, DOI 10.1073/pnas.68.1.82; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LAFON SW, 1982, BIOCHEM PHARMACOL, V31, P231, DOI 10.1016/0006-2952(82)90216-7; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; LOOKER DL, 1983, MOL BIOCHEM PARASIT, V9, P15, DOI 10.1016/0166-6851(83)90053-1; MARR JJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P360, DOI 10.1016/0304-4165(78)90104-6; MARR JJ, 1983, MOL BIOCHEM PARASIT, V7, P339, DOI 10.1016/0166-6851(83)90016-6; MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105; NELSON DJ, 1979, J BIOL CHEM, V254, P1544; NELSON FK, 1989, MOL CELL BIOL, V9, P1284, DOI 10.1128/MCB.9.3.1284; PALELLA TD, 1989, METABOLIC BASIS INHE, P965; PFEFFERKORN ER, 1994, EXP PARASITOL, V79, P374, DOI 10.1006/expr.1994.1099; SCHWARTZMAN JD, 1982, EXP PARASITOL, V53, P77, DOI 10.1016/0014-4894(82)90094-7; SOUZA AE, 1994, MOL BIOCHEM PARASIT, V63, P213, DOI 10.1016/0166-6851(94)90057-4; TOBIN JF, 1991, P NATL ACAD SCI USA, V88, P864, DOI 10.1073/pnas.88.3.864; TUTTLE JV, 1980, J BIOL CHEM, V255, P909; ULLMAN B, 1984, PHARM RES-DORDR, P194, DOI 10.1023/A:1016365128531; WASMUTH JJ, 1984, CELL, V36, P697, DOI 10.1016/0092-8674(84)90350-7; WILSON K, 1991, J BIOL CHEM, V266, P1665	49	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19488	19496		10.1074/jbc.272.31.19488	http://dx.doi.org/10.1074/jbc.272.31.19488			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235951	hybrid			2022-12-25	WOS:A1997XP06300057
J	Fitz, LJ; Morris, JC; Towler, P; Long, A; Burgess, P; Greco, R; Wang, J; Gassaway, R; Nickbarg, E; Kovacic, S; Ciarletta, A; Giannotti, J; Finnerty, H; Zollner, R; Beier, DR; Leak, LV; Turner, KJ; Wood, CR				Fitz, LJ; Morris, JC; Towler, P; Long, A; Burgess, P; Greco, R; Wang, J; Gassaway, R; Nickbarg, E; Kovacic, S; Ciarletta, A; Giannotti, J; Finnerty, H; Zollner, R; Beier, DR; Leak, LV; Turner, KJ; Wood, CR			Characterization of murine Flt4 ligand VEGF-C	ONCOGENE			English	Article						Flt41; Flt4 ligand; VEGF-C; BIAcore	LYMPHATIC ENDOTHELIUM; GENE	Flt4 is a receptor protein tyrosine kinase that is expressed in the adult lymphatic endothelium and high endothelial venules. We have used a BIAcore assay to identify rodent and human cell conditioned media containing the ligand of Flt4 (Flt4-L). Receptor-based affinity chromatography was used to purify this growth factor, followed by amino acid sequencing and molecular cloning of the murine cDNA, the orthologue of human vascular endothelial growth factor-C and vascular endothelial growth factor related protein. The murine flt4-L gene was localized to chromosome 8 and demonstrated to be widely expressed. Flt4-L was found to have a hydrophobic signal sequence and a pro-peptidelike sequence that is removed to generate the mature N-terminus. In addition, the C-terminal region of Flt4-L has four repeats of a cysteine-rich motif that is presumably also proteolytically processed to generate the 21 000 M-r polypeptide subunit of the Flt4-L homodimer. Recombinant Flt4-L activated Flt4 as judged by induction of tyrosyl phosphorylation, and induced mitogenesis in vitro of lymphatic endothelial cells.	GENET INST INC,CAMBRIDGE,MA 02140; BRIGHAM & WOMENS HOSP,DIV GENET,BOSTON,MA 02115; HOWARD UNIV,COLL MED,DEPT ANAT,WASHINGTON,DC 20059	Harvard University; Brigham & Women's Hospital; Howard University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029028] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000951] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG00951] Funding Source: Medline; NICHD NIH HHS [HD 29028] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEIER DR, 1993, MAMM GENOME, V4, P627, DOI 10.1007/BF00360898; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; FAN YS, 1992, CYTOGENET CELL GENET, V60, P29, DOI 10.1159/000133288; FINNERTY H, 1993, ONCOGENE, V8, P2293; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; LEAK LV, 1994, IN VITRO CELL DEV-AN, V30A, P512, DOI 10.1007/BF02631324; LEAK LV, 1993, ANAT RECORD, V236, P641, DOI 10.1002/ar.1092360408; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; MANLEY DF, 1991, MAMM GENOME, V4, P303; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; [No title captured]	13	40	46	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					613	618		10.1038/sj.onc.1201191	http://dx.doi.org/10.1038/sj.onc.1201191			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247316				2022-12-25	WOS:A1997XN25500014
J	Zindy, F; Quelle, DE; Roussel, MF; Sherr, CJ				Zindy, F; Quelle, DE; Roussel, MF; Sherr, CJ			Expression of the p16(INK4a) tumor suppressor versus other INK4 family members during mouse development and aging	ONCOGENE			English	Article						cell cycle; p16(INK4a); p15(INK4b); p18(INK4c); p19(INK4d); p19(ARF)	CELL-CYCLE ARREST; FUNCTIONAL RETINOBLASTOMA PROTEIN; D-CDK COMPLEXES; GROWTH SUPPRESSION; DEPENDENT KINASES; GENE-PRODUCT; TGF-BETA; INHIBITION; P16; DIFFERENTIATION	Four INK4 proteins can prevent cell proliferation by specifically inhibiting cyclin D-dependent kinases. Both p18(INK4c) and p19(INK4d) were widely expressed during mouse embryogenesis, but p16(INK4a) and p15(INK4b) were not readily detected prenatally. Although p15(INK4b), p18(INK4c) and p19(INK4d) were demonstrated in many tissues by 4 weeks after birth, p16(INK4a) protein expression was restricted to the lung and spleen of older mice, with increased, more widespread mRNA expression during aging. Transcripts encoding the INK4a alternative reading frame product p19(ARF) were not detected before birth but were ubiquitous postnatally. Expression of p16(INK4a) and p15(INK4b) was induced when mouse embryos were disrupted and cultured as mouse embryo 'fibroblasts' (MEFs). The levels of p16(INK4a) and p18(INK4c), but not p15(INK4b) or p19(INK4d), further increased as MEFs approached senescence. Following crisis and establishment, three of four independently-derived cell lines became polyploid and expressed higher levels of functional p16(INK4a). I, contrast, one MEF line that sustained bi-allelic deletions of INK4a initially remained diploid. Therefore, loss of p16(INK4a) and other events predisposing to polyploidy may represent alternative processes contributing to cell immortalization. Whereas p18(INK4a) and p19(INK4d) may regulate pre- and postnatal development, p16(INK4a) more likely plays a checkpoint function during cell senescence that underscores its selective role as a tumor suppressor.	ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital			Sherr, Charles J/N-8074-2018; Roussel, Martine F/F-1469-2016	Sherr, Charles J/0000-0002-5516-6206; Roussel, Martine F/0000-0002-1740-8139; Quelle, Dawn/0000-0001-8776-0122	NCI NIH HHS [P01 CA-76907] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACACHI M, 1997, IN PRESS BLOOD; BATES S, 1994, ONCOGENE, V9, P1633; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hirai H, 1996, MOL CELL BIOL, V16, P6457; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Lukas J, 1996, MOL CELL BIOL, V16, P6917; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Noble JR, 1996, ONCOGENE, V13, P1259; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Parry D, 1996, MOL CELL BIOL, V16, P3844; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; QUELLE DE, 1995, ONCOGENE, V11, P635; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; REYMOND A, 1995, ONCOGENE, V11, P1173; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WICK ST, 1995, ONCOGENE, V11, P2013	49	448	457	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					203	211		10.1038/sj.onc.1201178	http://dx.doi.org/10.1038/sj.onc.1201178			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244355				2022-12-25	WOS:A1997XK37200008
J	Suy, S; Anderson, WB; Dent, P; Chang, E; Kasid, U				Suy, S; Anderson, WB; Dent, P; Chang, E; Kasid, U			Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells	ONCOGENE			English	Article						ionizing radiation; Grb2; Sos; Ras; Raf; MAPK; breast cancer	GUANINE-NUCLEOTIDE EXCHANGE; MAP KINASE-KINASE; SIGNAL-TRANSDUCTION PATHWAY; SERINE-THREONINE KINASE; NIH 3T3 CELLS; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; ONCOGENIC P21(RAS); INDUCED ACTIVATION; MAMMALIAN-CELLS	Raf-1 protein serine/threonine kinase has been implicated in growth and damage-responsive signal transduction pathways. Several reports indicate an important role of Ras protein in the growth factor-induced activation of Raf-1. Here we investigated the possible involvement of Ras in ionizing radiation-induced activation of Raf-1. Irradiation of MDA-MB 231 human breast cancer cells caused an increase in GTP-binding and hydrolysis on Ras, and co-immunoprecipitations of endogenous Grb2 with Sos and Raf-1 with Ras. An increase in the level of membrane-bound Raf-1, and tyrosine-phosphorylation of Raf-1 were observed after irradiation. Consistent with these changes, irradiation of cells stimulated the catalytic activity of Raf-1, Finally, radiation treatment of breast cancer cells led to an increase in the phosphorylation and activity of the mitogen-activated protein kinase. Based on these biochemical modifications in vivo, me conclude that Raf-1 functions as an effector of Ras in the radiation-responsive signal transduction pathway leading to the activities of Raf-1 and mitogen-activated protein kinase.	GEORGETOWN UNIV,DEPT RADIAT MED,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT OTOLARYNGOL HEAD & NECK SURG,WASHINGTON,DC 20007; GEORGETOWN UNIV,LOMBARDI CANC CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007; NCI,CELLULAR ONCOL LAB,NIH,BETHESDA,MD 20892; UNIV VIRGINIA,DEPT MED,HOWARD HUGHES MED INST,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	Georgetown University; Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R55CA068322, P30CA051008, R01CA058984] Funding Source: NIH RePORTER; NCI NIH HHS [CA58984, CA68322, P30 CA51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bernhard EJ, 1996, CANCER RES, V56, P1727; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOWNWARD J, 1995, METHOD ENZYMOL, V255, P110; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KASID U, 1993, ADV CANCER RES, V61, P195, DOI 10.1016/S0065-230X(08)60959-8; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOLCH W, 1991, NATURE, V349, P536; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARIAS R, 1993, CELL, V73, P381; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1993, SCIENCE, V363, P15; MCKENNA WG, 1990, CANCER RES, V50, P97; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PIROLLO KF, 1989, INT J RADIAT BIOL, V55, P783, DOI 10.1080/09553008914550831; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAPP UR, 1991, ONCOGENE, V6, P495; Reed J C, 1993, Semin Immunol, V5, P327, DOI 10.1006/smim.1993.1039; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Soldatenkov VA, 1997, CANCER J SCI AM, V3, P13; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	68	47	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					53	61		10.1038/sj.onc.1201165	http://dx.doi.org/10.1038/sj.onc.1201165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233777				2022-12-25	WOS:A1997XH58600006
J	Ghoda, L; Lin, X; Greene, WC				Ghoda, L; Lin, X; Greene, WC			The 90-kDa ribosomal S6 kinase (pp90(rsk)) phosphorylates the N-terminal regulatory domain of I kappa B alpha and stimulates its degradation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED PHOSPHORYLATION; MOUSE ORNITHINE DECARBOXYLASE; ACTIVATED PROTEIN-KINASE; DNA-BINDING; DISSOCIATION; PROTEOLYSIS; SEQUENCES; REQUIRES; TRANSDUCTION; SUFFICIENT	Nuclear factor kappa B (NF-kappa B) is a eukaryotic member of the Rel family of transcription factors whose biological activity is post-translationally regulated by its assembly with various ankyrin-rich cytoplasmic inhibitors, including I kappa B alpha. Expression of NF-kappa B in the nucleus occurs after signal-induced phosphorylation, ubiquitination, and proteasome-mediated degradation of I kappa B alpha. The induced proteolysis of I kappa B alpha unmasks the nuclear localization signal within NF-kappa B, allowing its rapid migration into the nucleus, where it activates the transcription of many target genes, At present, the identity of the I kappa B alpha kinase(s) that triggers the first step in I kappa B alpha degradation remains unknown. We have investigated the potential function of the 90-kDa ribosomal S6 kinase, or pp90(rsk), as a signal-inducible I kappa B alpha kinase. pp90(rsk) lies downstream of mitogen-activated protein (MAP) kinase in the well characterized Ras-Raf-MEK-MAP kinase pathway that is induced by various growth factors and phorbol ester. We now show that pp90(rsk), but not pp70(S6K) Or MAP kinase, phosphorylates the regulatory N terminus of I kappa B alpha principally on serine 32 and triggers effective I kappa B alpha degradation in vitro. When co-expressed in vivo in COS cells, I kappa B alpha and pp90(rsk) readily assemble into a complex that is immunoprecipitated with antibodies specific for either partner. While phorbol 12-myristate 13-acetate produced rapid activation of pp90(rsk), in vivo, other potent NF-kappa B inducers, including tumor necrosis factor alpha and the Tax transactivator of human T-cell lymphotrophic virus, type I, failed to activate pp90(rsk). These data suggest that more than a single I kappa B alpha kinase exists within the cell and that these I kappa B alpha kinases are differentially activated by different NF-kappa B inducers.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, GLADSTONE INST VIROL & IMMUNOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, DEPT MED, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94141 USA; UNIV COLORADO, HLTH SCI CTR, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; The J David Gladstone Institutes; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM049055] Funding Source: NIH RePORTER; NIAID NIH HHS [P30 AI27763, P30 AI27763-08] Funding Source: Medline; NIGMS NIH HHS [5RO1 GM49055] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHEN RH, 1993, BIOCHEM SOC T, V21, P895, DOI 10.1042/bst0210895; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GROSS M, 1980, MOL CELL BIOCHEM, V31, P25, DOI 10.1007/BF00817888; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROSENBERGHASSON Y, 1991, BIOCHEM J, V277, P683, DOI 10.1042/bj2770683; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V197, P419, DOI 10.1111/j.1432-1033.1991.tb15927.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; STEWARD R, 1993, CURR OPIN GENET DEV, V3, P556, DOI 10.1016/0959-437X(93)90090-C; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WETTENHALL REH, 1992, J BIOL CHEM, V267, P9021; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	47	177	185	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21281	21288		10.1074/jbc.272.34.21281	http://dx.doi.org/10.1074/jbc.272.34.21281			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261139	hybrid			2022-12-25	WOS:A1997XR78900049
J	Peterson, FC; Brooks, CL				Peterson, FC; Brooks, CL			Identification of a motif associated with the lactogenic actions of human growth hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; PROLACTIN RECEPTOR; CRYSTAL-STRUCTURE; RATIONAL DESIGN; BINDING; DNA; MUTAGENESIS; RESOLUTION; VARIANTS; COMPLEX	Human growth hormone (hGH) stimulates somatogenic and lactogenic actions through the GH and prolactin (PRL) receptors, respectively, In contrast, non-primate GHs stimulate only somatotropic action, Phe(44), of the human GH sequence is present in all hormones stimulating lactogenic action and absent in all hormones stimulating only somato tropic action, We speculate that the presence of Phe(44) is a feature necessary for specifying lactogenic activity, In this report, the role of Phe(44) was investigated by its deletion or substitution with alanine or leucine. Deletion of Phe(44) or substitution with leucine did not significantly change the structure of hGH as determined by circular dichroism, absorbance, and fluorescence spectroscopies, In contrast, substitution of alanine perturbed the structure. Deletion of Phe(44) reduced binding affinity for the lactogenic receptor, resulting in a reduced activation, Substitution with either alanine or leucine partially restored lactogenic receptor binding affinity, which correlated with the hormones' activity in the Nb2 rat lymphoma cells, All the recombinant hGHs had similar somatotropic activities in FDC-P1 cells transfected with the hGH receptor, These data indicate that the hydrophobic side chain of Phe(44) is required for lactogenic receptor binding and activation but is unnecessary for somatotropic action.	OHIO STATE UNIV, DIV CARDIOL, DEPT VET BIOSCI, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, OHIO STATE BIOCHEM PROGRAM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NIDDK NIH HHS [R01-DK42604, K04-DK01989] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001989, R01DK042604] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; HOLZMAN TF, 1986, BIOCHEMISTRY-US, V25, P6907, DOI 10.1021/bi00370a026; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWMAN HB, 1991, J BIOL CHEM, V266, P10982; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; MARTIAL JA, 1979, SCIENCE, V205, P602, DOI 10.1126/science.377496; MULKERRIN MG, 1993, ACS SYM SER, V526, P240; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SINHA YN, 1995, ENDOCR REV, V16, P354, DOI 10.1210/er.16.3.354; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553	29	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21444	21448		10.1074/jbc.272.34.21444	http://dx.doi.org/10.1074/jbc.272.34.21444			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261160	hybrid			2022-12-25	WOS:A1997XR78900070
J	Hisatsune, C; Umemori, H; Inoue, T; Michikawa, T; Kohda, K; Mikoshiba, K; Yamamoto, T				Hisatsune, C; Umemori, H; Inoue, T; Michikawa, T; Kohda, K; Mikoshiba, K; Yamamoto, T			Phosphorylation-dependent regulation of N-methyl-D-aspartate receptors by calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PROTEIN-KINASE-C; METABOTROPIC GLUTAMATE RECEPTORS; NMDA RECEPTOR; HIPPOCAMPAL-NEURONS; BINDING-PROTEIN; CHANNEL; ENHANCEMENT; MODULATION; EXPRESSION	The N-methyl-D-aspartate (NMDA) receptor plays important roles in synaptic plasticity and brain development. The NMDA receptor subunits have large intracellular domains in the COOH-terminal region that may interact with signal-transducing proteins. By using the yeast two-hybrid system, we found that calmodulin interacts with the COOH terminus of the NR1 subunit and inactivates the channels in a Ca2+-dependent manner, Here we show that protein kinase C (PKC)-mediated phosphorylation on serine residues of NR1 decreases its affinity for calmodulin. This suggests that PKC-mediated phosphorylation of NR1 prevents calmodulin from binding to the NR1 subunit and thereby inhibits the inactivation of NMDA receptors by calmodulin, In addition, we show that stimulation of metabotropic glutamate receptor 1 alpha, which potentiates NMDA channels through PKC, decreases the ability of NR1 to bind to calmodulin, Thus, our data provide clues to understanding the basis of cross-talk between two types of receptors, metabotropic glutamate receptors and the NR1 subunit, in NMDA channel potentiation.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo; University of Tokyo			Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015; Hisatsune, Chihiro/C-6661-2017; Kohda, Kazuhisa/L-4731-2013	Inoue, Takafumi/0000-0002-2728-0060; Hisatsune, Chihiro/0000-0001-7811-7784; Umemori, Hisashi/0000-0001-7198-2062				ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; ANIKSZTEJN L, 1991, EUR J PHARMACOL, V205, P327, DOI 10.1016/0014-2999(91)90921-C; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; ASZTELY F, 1992, EUR J NEUROSCI, V4, P681, DOI 10.1111/j.1460-9568.1992.tb00177.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BORTOLOTTO ZA, 1994, NATURE, V368, P740, DOI 10.1038/368740a0; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOI DW, 1988, J NEUROSCI, V8, P185; CIMLER BM, 1985, J BIOL CHEM, V260, P784; CLARK KA, 1995, J PHYSIOL-LONDON, V482, P39, DOI 10.1113/jphysiol.1995.sp020498; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GERBER G, 1989, J NEUROSCI, V9, P3606; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MEDINA I, 1995, J PHYSIOL-LONDON, V482, P567, DOI 10.1113/jphysiol.1995.sp020540; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; OCONNOR JJ, 1994, NATURE, V367, P557, DOI 10.1038/367557a0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; RADPOUR S, 1992, NEUROSCI LETT, V138, P119, DOI 10.1016/0304-3940(92)90486-Q; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VYKLICKY L, 1993, J PHYSIOL-LONDON, V470, P575, DOI 10.1113/jphysiol.1993.sp019876; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154	46	111	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20805	20810		10.1074/jbc.272.33.20805	http://dx.doi.org/10.1074/jbc.272.33.20805			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252405	hybrid			2022-12-25	WOS:A1997XR22100075
J	Lebrun, B; Sakaitani, M; Shimamoto, K; YasudaKamatani, Y; Nakajima, T				Lebrun, B; Sakaitani, M; Shimamoto, K; YasudaKamatani, Y; Nakajima, T			New beta-hydroxyaspartate derivatives are competitive blockers for the bovine glutamate/aspartate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROGENIC GLUTAMATE UPTAKE; RAT-BRAIN; ASPARTATE TRANSPORTER; GLIAL-CELLS; EXPRESSION; CLONING; SPECIFICITY; SALAMANDER; MEMBRANE; OOCYTES	Four subtypes of excitatory amino acid transporters (EAAT1-4) have been identified in the mammalian brain, A number of pharmacological agents have been developed to study their intrinsic properties and function, Up to now, blockers were available only for EAAT2, whereas all the inhibitors of glutamate uptake active on the other subtypes were proved to be substrates of the transporters, We synthesized five new derivatives of DL-threo-beta-hydroxyaspartic acid, a well known general substrate of EAATs, and investigated their potential blocking activity on the cloned bovine EAAT1 expressed in the Xenopus oocyte system, by using radiotracer and voltage-clamp techniques. Two of our derivatives proved to be substrates for bovine EAAT1, with reduced electrogenicity compared with their parent compound, and an affinity of 40 and 64 mu M. The last three derivatives displayed a blocking activity on bovine EAAT1. The affinity of DL-threo-beta-benzoyloxyaspartate and DL-threo-beta-(1-naphthoyl)oxyaspartate was determined by Schild analysis as 17.2 and 52.1 mu M, respectively, These blockers should help in the better understanding of the key intrinsic properties of EAAT1, Moreover, they appear as good candidates for a general blocking activity on EAATs.	SUNTORY INST BIOORGAN RES,SUNBOR,SHIMAMOTO,OSAKA 618,JAPAN	Suntory Holdings Ltd								ARRIZA JL, 1994, J NEUROSCI, V14, P5559; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BALCAR VJ, 1972, J NEUROCHEM, V19, P2657, DOI 10.1111/j.1471-4159.1972.tb01325.x; BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; Billups B, 1996, J NEUROSCI, V16, P6722; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; BRIDGES RJ, 1993, BIOORG MED CHEM LETT, V3, P115, DOI 10.1016/S0960-894X(00)80103-1; BRIDGES RJ, 1994, NEUROSCI LETT, V174, P193, DOI 10.1016/0304-3940(94)90019-1; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FERKANY J, 1986, J NEUROSCI RES, V16, P491, DOI 10.1002/jnr.490160305; GRANT GB, 1992, THESIS U CALIFORNIA; INOUE K, 1995, MOL BRAIN RES, V28, P343, DOI 10.1016/0169-328X(94)00244-9; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KAWAKAMI H, 1994, BIOCHEM BIOPH RES CO, V199, P171, DOI 10.1006/bbrc.1994.1210; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; KLOCKNER U, 1994, J NEUROSCI, V14, P5759; Larsson HP, 1996, BIOPHYS J, V70, P733, DOI 10.1016/S0006-3495(96)79613-3; LEHRE KP, 1995, J NEUROSCI, V15, P1835; PICAUD S, 1995, P NATL ACAD SCI USA, V92, P9417, DOI 10.1073/pnas.92.20.9417; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; SHASHIDHARAN P, 1993, BIOCHIM BIOPHYS ACTA, V1216, P161, DOI 10.1016/0167-4781(93)90057-K; SHASHIDHARAN P, 1994, BBA-BIOMEMBRANES, V1191, P393, DOI 10.1016/0005-2736(94)90192-9; Sonnenberg JD, 1996, BIOORG MED CHEM LETT, V6, P1607, DOI 10.1016/S0960-894X(96)00284-3; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TANAKA K, 1993, NEUROSCI LETT, V159, P183, DOI 10.1016/0304-3940(93)90829-A; TANAKA K, 1993, NEUROSCI RES, V16, P149, DOI 10.1016/0168-0102(93)90082-2; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	35	70	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20336	20339		10.1074/jbc.272.33.20336	http://dx.doi.org/10.1074/jbc.272.33.20336			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252337	hybrid			2022-12-25	WOS:A1997XR22100007
J	Scherer, PE; Lisanti, MP				Scherer, PE; Lisanti, MP			Association of phosphofructokinase-M with caveolin-3 in differentiated skeletal myotubes - Dynamic regulation by extracellular glucose and intracellular metabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; ALLOSTERIC PROPERTIES; GLYCOLYTIC-ENZYMES; RECEPTOR KINASE; PROTEIN-KINASE; LINKED PROTEIN; GROWTH-FACTORS; BLOOD-CELLS; MUSCLE; PHOSPHORYLATION	Caveolin-3 is a member of the caveolin family of proteins that is primarily expressed in striated muscle cell types (skeletal and cardiac). Here, we show that an similar to 80-kDa protein specifically co-immunoprecipitates with caveolin-3 expressed in differentiated skeletal C2C12 myotubes. Microsequence analysis of this similar to 80-kDa polypeptide revealed its identity as a key regulatory enzyme in the glycolytic pathway, namely phosphofructokinase M (PFK-M). Pulse-chase experiments demonstrate that PFK-M associates with caveolin-3 with a significant time lag after the biosynthesis of PFK-M. In addition, we show that this interaction is (i) highly regulated by the extracellular concentration of glucose and (ii) can be stabilized by a number of relevant intracellular metabolites, such as fructose 1,6-bisphosphate and fructose 2,6-bisphosphate, which are known allosteric activators of PFK. While the bulk of these experiments were performed in C2C12 cells, identical results were obtained using mouse skeletal muscle extracts. Taken together, our results suggest that glucose-dependent plasma membrane recruitment of activated PFK-M by caveolin-3 could have important implications for understanding the mechanisms that regulate energy metabolism in skeletal muscle fibers.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRONSTEIN WW, 1981, CAN J BIOCHEM CELL B, V59, P494, DOI 10.1139/o81-069; CHENZION M, 1992, INT J BIOCHEM, V24, P1661, DOI 10.1016/0020-711X(92)90185-4; CLARKE FM, 1975, BIOCHIM BIOPHYS ACTA, V381, P37, DOI 10.1016/0304-4165(75)90187-7; COLE F, 1993, J BIOL CHEM, V268, P1580; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DOHM GL, 1993, J CELL BIOCHEM, V52, P1, DOI 10.1002/jcb.240520102; DUNAWAY GA, 1983, MOL CELL BIOCHEM, V52, P75; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GEKAKIS N, 1989, J BIOL CHEM, V264, P3658; GUSTAVSSON J, 1996, J BIOL CHEM, V271, P367; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HOFER HW, 1985, BIOCHEM BIOPH RES CO, V129, P892, DOI 10.1016/0006-291X(85)91975-8; HUE L, 1993, ADV ENZYME REGUL, V33, P97; LEHOTZKY A, 1993, J BIOL CHEM, V268, P10888; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LILLING G, 1991, BIOCHEM MED METAB B, V45, P319, DOI 10.1016/0885-4505(91)90036-K; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MAHRENHOLZ AM, 1991, BIOCHEM BIOPH RES CO, V174, P1255, DOI 10.1016/0006-291X(91)91556-R; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; OVADI J, 1988, TRENDS BIOCHEM SCI, V13, P486, DOI 10.1016/0968-0004(88)90237-X; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; REISS N, 1986, BIOCHEM J, V239, P691, DOI 10.1042/bj2390691; SALE EM, 1987, J CELL BIOCHEM, V33, P15, DOI 10.1002/jcb.240330103; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHWEIZER E, 1982, BIOCHEMISTRY-US, V21, P6807, DOI 10.1021/bi00269a029; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TSAI MY, 1973, J BIOL CHEM, V248, P785; VORA S, 1981, P NATL ACAD SCI-BIOL, V78, P3738, DOI 10.1073/pnas.78.6.3738; VORA S, 1981, BLOOD, V57, P724; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WEIL D, 1980, ANN HUM GENET, V44, P11, DOI 10.1111/j.1469-1809.1980.tb00941.x	54	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20698	20705		10.1074/jbc.272.33.20698	http://dx.doi.org/10.1074/jbc.272.33.20698			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252390	hybrid			2022-12-25	WOS:A1997XR22100060
J	Hasegawa, K; Meyers, MB; Kitsis, RN				Hasegawa, K; Meyers, MB; Kitsis, RN			Transcriptional coactivator p300 stimulates cell type-specific gene expression in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; E1A-ASSOCIATED PROTEIN P300; MUSCLE-SPECIFIC EXPRESSION; BINDING FACTOR MEF-2; ADENOVIRUS E1A; IN-VIVO; TERMINAL DIFFERENTIATION; RETINOBLASTOMA PROTEIN; DNA-SYNTHESIS; BETA GENE	Terminal differentiation is characterized by cell cycle arrest and the expression of cell type-specific genes, Previous work has suggested that the p300 family of transcriptional coactivators plays an important role in preventing the re-initiation of DNA synthesis in terminally differentiated cardiac myocytes, In this study, we investigated whether p300 proteins are also involved in the transcriptional activation of cell type-specific genes in these cells. Since p300 function can be abrogated through direct binding by the adenovirus E1A protein, we overexpressed E1A in cardiac myocytes using recombinant adenoviral vectors, The expression of transfected reporter genes driven by alpha- or beta-myosin heavy chain promoters was markedly diminished by expression of the 12 S E1A protein, In contrast, the activity of a promoter derived from the ubiquitously expressed beta-actin gene was affected only modestly, While an E1A mutant unable to bind members of the retinoblastoma family of pocket proteins decreased the activity of alpha- and beta-myosin heavy chain promoters to nearly the same extent as wild type 12 S E1A, transcriptional repression by a mutant defective for p300 binding was severely impaired, Furthermore, overexpression of p300 and, to an even greater extent, p300de133, a mutant lacking residues required for binding by E1A, relieved E1A's repression of beta-myosin heavy chain promoter activity while having no effect on the activity of the beta-actin promoter, Thus, E1A's transcriptional repression of cell type-specific genes in cardiac myocytes is mediated through its binding of p300 proteins, and these proteins appear to be involved in maintaining both cell type-specific gene expression and cell cycle arrest in cardiac myocytes.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED CARDIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NHLBI NIH HHS [HL-02699] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BUTTRICK PM, 1993, CIRC RES, V72, P1211, DOI 10.1161/01.RES.72.6.1211; CARUSO M, 1993, ONCOGENE, V8, P267; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLAYCOMB WC, 1975, J BIOL CHEM, V250, P3229; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ENKEMANN SA, 1990, CELL GROWTH DIFFER, V1, P375; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GOLDSTEIN MA, 1974, SCIENCE, V183, P212, DOI 10.1126/science.183.4121.212; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUANG WY, 1995, GENE, V155, P219, DOI 10.1016/0378-1119(94)00893-W; Janknecht R, 1996, ONCOGENE, V12, P1961; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KASSEISLER A, 1993, P NATL ACAD SCI USA, V90, P11498, DOI 10.1073/pnas.90.24.11498; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; KITSIS RN, 1993, METHODS MOL GENET, V1, P374; KNOTTS S, 1994, J BIOL CHEM, V269, P31275; KRAFT R, 1989, NUCLEIC ACIDS RES, V17, P7529, DOI 10.1093/nar/17.18.7529; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LITVIN J, 1992, TRENDS CARDIOVAS MED, V2, P27, DOI 10.1016/1050-1738(92)90041-P; Liu Y, 1996, J CELL BIOL, V133, P325, DOI 10.1083/jcb.133.2.325; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Rawles Mary E., 1943, PHYSIOL ZOOL, V16, P22; RUMYANTSEV PP, 1977, INT REV CYTOL, V51, P187; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIMIZU N, 1992, NUCLEIC ACIDS RES, V20, P1793, DOI 10.1093/nar/20.7.1793; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; STRACESKI AJ, 1994, P NATL ACAD SCI USA, V91, P589, DOI 10.1073/pnas.91.2.589; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	63	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20049	20054		10.1074/jbc.272.32.20049	http://dx.doi.org/10.1074/jbc.272.32.20049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242676	hybrid			2022-12-25	WOS:A1997XQ05900063
J	Koonce, MP				Koonce, MP			Identification of a microtubule-binding domain in a cytoplasmic dynein heavy chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR ANALYSIS; ATP-BINDING; DICTYOSTELIUM; SEQUENCE; PROTEINS; TUBULIN; SITES; YEAST; MOTIF	As a molecular motor, dynein must coordinate ATP hydrolysis with conformational changes that lead to processive interactions with a microtubule and generate force. To understand how these processes occur, we have begun to map functional domains of a dynein heavy chain from Dictyostelium. The carboxyl-terminal 10-kilobase region of the heavy chain encodes a 380-kDa polypeptide that approximates the globular head domain. Attempts to further truncate this region fail to produce polypeptides that either bind microtubules or UV-vanadate cleave, indicating that the entire 10-kilobase fragment is necessary to produce a properly folded functional dynein head. We have further identified a region just downstream from the fourth P-loop that appears to constitute at least part of the microtubule-binding domain (amino acids 3182-3818). When deleted, the resulted head domain polypeptide no longer binds microtubules; when the excised region is expressed in vitro, it cosediments with added tubulin polymer. This microtubule-binding domain falls within an area of the molecule predicted to form extended alpha-helices. At least four discrete sites appear to coordinate activities required to bind the tubulin polymer, indicating that the interaction of dynein with microtubules is complex.	SUNY ALBANY, DEPT BIOMED SCI, ALBANY, NY 12201 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany	Koonce, MP (corresponding author), WADSWORTH CTR, DIV MOL MED, EMPIRE STATE PLAZA, POB 509, ALBANY, NY 12201 USA.				NIGMS NIH HHS [GM51532] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051532, R29GM051532] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asai David J., 1993, Trends in Cell Biology, V3, P398, DOI 10.1016/0962-8924(93)90090-N; DOLL T, 1993, J CELL SCI, V106, P633; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GEE MA, 1996, MOL BIOL CELL S, V7, P566; Gepner J, 1996, GENETICS, V142, P865; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; Goldsmith M, 1995, BIOCHEM CELL BIOL, V73, P665, DOI 10.1139/o95-074; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; KNECHT DA, 1990, DEV GENET, V11, P403, DOI 10.1002/dvg.1020110513; KOONCE MP, 1994, J EUKARYOT MICROBIOL, V41, P645, DOI 10.1111/j.1550-7408.1994.tb01528.x; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; Koonce MP, 1996, MOL BIOL CELL, V7, P935, DOI 10.1091/mbc.7.6.935; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; MIKAMI A, 1993, NEURON, V10, P787, DOI 10.1016/0896-6273(93)90195-W; Mocz G, 1996, BIOCHEMISTRY-US, V35, P9204, DOI 10.1021/bi960662u; OGAWA K, 1991, NATURE, V352, P643, DOI 10.1038/352643a0; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; PORTER ME, 1994, J CELL BIOL, V126, P1495, DOI 10.1083/jcb.126.6.1495; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHLIWA M, 1986, CYTOSKELETON; SCHROER TA, 1994, CURR OPIN CELL BIOL, V6, P69, DOI 10.1016/0955-0674(94)90118-X; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; VALLEE R, 1993, P NATL ACAD SCI USA, V90, P8769, DOI 10.1073/pnas.90.19.8769; Warner F.D., 1989, CELL MOVEMENT, V1; WEINGARTEN MD, 1974, BIOCHEMISTRY-US, V13, P5529, DOI 10.1021/bi00724a012; WILKERSON CG, 1994, J CELL SCI, V107, P497; WILLIAMS RC, 1979, BIOCHEMISTRY-US, V18, P2499, DOI 10.1021/bi00579a010; WITMAN G B, 1992, Current Opinion in Cell Biology, V4, P74; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	40	89	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19714	19718		10.1074/jbc.272.32.19714	http://dx.doi.org/10.1074/jbc.272.32.19714			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242627	hybrid			2022-12-25	WOS:A1997XQ05900014
J	Odegaard, TJ; Kaltashov, IA; Cotter, RJ; Steeghs, L; vanderLey, P; Khan, S; Maskell, DJ; Raetz, CRH				Odegaard, TJ; Kaltashov, IA; Cotter, RJ; Steeghs, L; vanderLey, P; Khan, S; Maskell, DJ; Raetz, CRH			Shortened hydroxyacyl chains on lipid A of Escherichia coli cells expressing a foreign UDP-N-acetylglucosmaine O-acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION MASS-SPECTROMETRY; EUKARYOTIC SIGNAL-TRANSDUCTION; GRAM-NEGATIVE ENDOTOXIN; SALMONELLA-TYPHIMURIUM; LIPOPOLYSACCHARIDE LPS; NEISSERIA-GONORRHOEAE; BACTERIAL-ENDOTOXINS; A PRECURSORS; 1ST STEP; BIOSYNTHESIS	The first reaction of lipid A biosynthesis in Gram-negative bacteria is catalyzed by UDP-N-acetylglucosamine (UDP-GlcNAc) O-acyltransferase, the product of the lpxA gene. The reaction involves the transfer of an acyl chain from hydroxyacyl-acyl carrier protein (ACP) to the glucosamine 3-OH position of UDP-GlcNAc. The lipid A isolated from Escherichia coli contains (R)-3-hydroxymyristate at the 3 and 3' positions. Accordingly, LpxA of E. coli is highly selective for (R)-3-hydroxymyristoyl-ACP over ACP thioesters of longer or shorter acyl chains. We now demonstrate that the lpxA gene from Neisseria meningitidis encodes a similar acyltransferase that selectively utilizes 3-hydroxylauroyl-ACP. Strains of E. coli harboring the temperature-sensitive lpxA2 mutation make very little lipid A and lose viability rapidly at 42 degrees C. We have created an E. coli strain in which the chromosomal lpxA2 mutation is complemented by the N. meningitidis lpxA gene introduced on a plasmid. This strain, RO138/pTO6, grows similarly to wild type cells at 42 degrees C and produces wild type levels of lipid A. However, the lipid A isolated from RO138/pTO6 contains mostly hydroxylaurate and hydroxydecanoate in the 3 and 3' positions. The strain RO138/pTO6 is more susceptible than wild type to certain antibiotics at 42 degrees C. This is the first report of an E. coli strain growing with shortened hydroxyacyl chains on its lipid A. The lpxA gene product appears to be a critical determinant of the length of the ester-linked hydroxyacyl chains found on lipid A in living cells.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL,MIDDLE ATLANTIC MASS SPECTROMETRY LAB,BALTIMORE,MD 21205; NATL INST PUBL HLTH & ENVIRONM,LAB VACCINE DEV & IMMUNE MECHANISMS,NL-3720 BA BILTHOVEN,NETHERLANDS; UNIV CAMBRIDGE,DEPT CLIN VET MED,CTR VET SCI,CAMBRIDGE CB3 0ES,ENGLAND	Duke University; Johns Hopkins University; Netherlands National Institute for Public Health & the Environment; University of Cambridge					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310, R01GM033967] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310, GM-33967] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; CAROFF M, 1991, J BIOL CHEM, V266, P18543; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; CLEMENTZ T, 1997, IN PRESS J BIOL CHEM; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN RC, 1988, J BIOL CHEM, V263, P5217; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KARIBIAN D, 1991, INT J MASS SPECTROM, V111, P273, DOI 10.1016/0168-1176(91)85060-Y; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KULSHIN VA, 1992, J BACTERIOL, V174, P1793, DOI 10.1128/jb.174.6.1793-1800.1992; KUMADA H, 1995, J BACTERIOL, V177, P2098, DOI 10.1128/jb.177.8.2098-2106.1995; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J. H., 1972, EXPT MOL GENETICS, P433; MOHAN S, 1994, J BIOL CHEM, V269, P32896; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; QURESHI N, 1988, J BIOL CHEM, V263, P5502; QURESHI N, 1986, J MICROBIOL METH, V5, P65, DOI 10.1016/0167-7012(86)90002-3; QURESHI N, 1982, J BIOL CHEM, V257, P1808; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNAITMAN CA, 1971, J BACTERIOL, V108, P545, DOI 10.1128/JB.108.1.545-552.1971; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Sorensen PG, 1996, J BIOL CHEM, V271, P25898, DOI 10.1074/jbc.271.42.25898; STEAD A, 1975, J GEN MICROBIOL, V88, P123, DOI 10.1099/00221287-88-1-123; Steeghs L, 1997, GENE, V190, P263, DOI 10.1016/S0378-1119(97)00005-X; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; TAKAYAMA K, 1986, J BIOL CHEM, V261, P624; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; VANALPHEN L, 1979, EUR J BIOCHEM, V101, P571; VUORIO R, 1992, ANTIMICROB AGENTS CH, V37, P354; Wang Y, 1996, J MASS SPECTROM, V31, P138; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; YOUNG K, 1991, J BACTERIOL, V173, P3609, DOI 10.1128/JB.173.12.3609-3614.1991	58	55	59	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19688	19696		10.1074/jbc.272.32.19688	http://dx.doi.org/10.1074/jbc.272.32.19688			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242624	hybrid			2022-12-25	WOS:A1997XQ05900011
J	Persson, E; Olsen, OH; Ostergaard, A; Nielsen, LS				Persson, E; Olsen, OH; Ostergaard, A; Nielsen, LS			Ca2+ binding to the first epidermal growth factor-like domain of factor VIIa increases amidolytic activity and tissue factor affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR-IX; EGF-LIKE DOMAINS; CALCIUM-BINDING; FACTOR-X; BLOOD-COAGULATION; HEMOPHILIA-B; STRUCTURAL REQUIREMENTS; CONTAINING MODULE; PROTEASE DOMAIN	Coagulation factor VIIa belongs to a family of homologous enzymes, including factors Ma and Xa and activated protein C, composed of two epidermal growth factor-like domains located between an N-terminal domain rich in gamma-carboxyglutamic acid residues and a C-terminal serine protease domain. The first epidermal growth factor-like domain in factor VIIa contains a Ca2+ binding site, the function of which is largely unknown, Site-directed mutagenesis of two Ca2+-liganding Asp residues in this domain abolished Ca2+ binding and resulted in a 2-3-fold decrease in amidolytic activity at optimal Ca2+ concentrations, The lower amidolytic activity persisted in complex with soluble tissue factor, apparently due to a lower k(cat) of the mutant factor VIIa. Mutant and wild type factor VIIa bound to lipidated tissue factor were equally efficient activators of factor X. The dissociation constants, derived from amidolytic activity and surface plasmon resonance measurements, were 2-5 nM and 50-60 nM for the interactions between wild-type and mutant factor VIIa, respectively, and soluble tissue factor. Binding to lipidated tissue factor was characterized by dissociation constants of 7.5 pm for factor VIIa and 160 phl for the factor VIIa mutant. Hence, a functional Ca2+ binding site in the first epidermal growth factor-like domain added 7-8 kJ/mol to the total binding energy of the interaction with both lipidated and soluble tissue factor.	NOVO NORDISK AS,HLTH CARE DISCOVEY,MED CHEM RES 4,DK-2760 MALOV,DENMARK	Novo Nordisk	Persson, E (corresponding author), NOVO NORDISK AS,HLTH CARE DISCOVERY,VESSEL WALL BIOL,HAGEDORNSVEJ 1,HAB3-93,DK-2820 GENTOFTE,DENMARK.			Persson, Egon/0000-0003-3005-4926				ANDERSSEN T, 1993, THROMB HAEMOSTASIS, V70, P414; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BUTENAS S, 1993, BIOCHEMISTRY-US, V32, P6531, DOI 10.1021/bi00077a006; CHANG JY, 1995, BIOCHEMISTRY-US, V34, P12227, DOI 10.1021/bi00038a017; CLARKE BJ, 1992, FEBS LETT, V298, P206, DOI 10.1016/0014-5793(92)80058-O; DAVIS LM, 1987, BLOOD, V69, P140; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; DU ZJ, 1995, BIOTECHNIQUES, V18, P376; Freskgard PO, 1996, PROTEIN SCI, V5, P1531, DOI 10.1002/pro.5560050809; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HUANG LH, 1989, BIOCHEM BIOPH RES CO, V160, P133, DOI 10.1016/0006-291X(89)91631-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; McCallum CD, 1996, J BIOL CHEM, V271, P28168, DOI 10.1074/jbc.271.45.28168; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MEDVED LV, 1994, BIOCHEMISTRY-US, V33, P478, DOI 10.1021/bi00168a012; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; NISOLAISEN EM, 1993, FEBS LETT, V317, P245; NISOLAISEN EM, 1992, FEBS LETT, V806, P157; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; Persson E, 1996, HAEMOSTASIS, V26, P31; PERSSON E, 1992, FEBS LETT, V314, P5, DOI 10.1016/0014-5793(92)81447-T; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1993, J BIOL CHEM, V268, P22531; PERSSON E, 1995, EUR J BIOCHEM, V234, P293, DOI 10.1111/j.1432-1033.1995.293_c.x; Persson E, 1996, FEBS LETT, V385, P241, DOI 10.1016/0014-5793(96)00400-0; RAO LVM, 1996, BLOOD, V87, P3788; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SCHIODT J, 1992, FEBS LETT, V306, P265, DOI 10.1016/0014-5793(92)81014-D; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1991, BLOOD, V78, P1637; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605; Sunnerhagen M, 1996, BIOCHEMISTRY-US, V35, P11547, DOI 10.1021/bi960633j; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; VALCARCE C, 1994, J BIOL CHEM, V269, P26011; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; VYSOTCHIN A, 1993, J BIOL CHEM, V268, P8436; WALTER J, 1994, THROMB HAEMOSTASIS, V72, P74; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WINSHIP PR, 1991, BRIT J HAEMATOL, V77, P102, DOI 10.1111/j.1365-2141.1991.tb07955.x	57	37	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19919	19924		10.1074/jbc.272.32.19919	http://dx.doi.org/10.1074/jbc.272.32.19919			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242658	hybrid			2022-12-25	WOS:A1997XQ05900045
J	English, JD; Sweatt, JD				English, JD; Sweatt, JD			A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; MAINTENANCE; INDUCTION; CA1; INHIBITORS; BRAIN	The mitogen-activated protein kinase (MAPK) cascade has been intensely studied as a primary biochemical pathway through which a variety of extracellular stimuli initiate and regulate processes of cellular transformation. That MAPKs are abundantly expressed in postmitotic neurons, however, suggests different yet currently unknown functions for this cascade in the mature nervous system. Here we report that the MAPK cascade is required for hippocampal long term potentiation (LTP), a robust and widely studied form of synaptic plasticity, We observed that PD 098059, a selective inhibitor of the MAPK cascade, blocked MAPK activation in response to direct stimulation of the NMDA receptor as well as to LTP-inducing stimuli, Furthermore, inhibition of the MAPK cascade markedly attenuated the induction of LTP. PD 098059, however, had no effect on the expression of established LTP, and the MAPK cascade was not persistently activated during LTP expression. Our observations provide the first demonstration of a role for the MAPK cascade in the activity-dependent modification of synaptic connections between neurons in the adult mammalian nervous system.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine				Sweatt, J. David/0000-0003-3567-485X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057014] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57014] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HALEY JE, 1993, NEUROSCI LETT, V160, P85, DOI 10.1016/0304-3940(93)90919-C; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1991, J BIOL CHEM, V266, P24253; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; MURPHY TH, 1994, J NEUROSCI, V14, P1320, DOI 10.1523/JNEUROSCI.14-03-01320.1994; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; WILLIAMS JH, 1989, NEUROSCI LETT, V107, P301, DOI 10.1016/0304-3940(89)90835-5; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	26	723	739	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19103	19106		10.1074/jbc.272.31.19103	http://dx.doi.org/10.1074/jbc.272.31.19103			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235897	hybrid			2022-12-25	WOS:A1997XP06300003
J	Feaver, WJ; Henry, NL; Wang, ZG; Wu, XH; Svejstrup, JQ; Bushnell, DA; Friedberg, EC; Kornberg, RD				Feaver, WJ; Henry, NL; Wang, ZG; Wu, XH; Svejstrup, JQ; Bushnell, DA; Friedberg, EC; Kornberg, RD			Genes for Tfb2, Tfb3, and Tfb4 subunits of yeast transcription/repair factor IIH - Homology to human cyclin-dependent kinase activating kinase and IIH subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; FACTOR-B; CRYSTAL-STRUCTURE; EXCISION-REPAIR; PROTEIN-KINASE; RING FINGER; CTD KINASE; TFIIH	Genes for the Tfb2, Tfb3, and Tfb4 subunits of yeast RNA polymerase transcription factor IIH (TFIIH) are described, All three genes are essential for cell viability, and antibodies against Tfb3 specifically inhibit transcription in vitro. A C-terminal deletion of Tfb2 caused a defect in nucleotide excision repair, as shown by UV sensitivity of the mutant strain and loss of nucleotide excision repair activity in cell extracts (restored by the addition of purified TFIIH). An interaction between Tfb3 and the Kin28 subunit of TFIIH was detected by the two-hybrid approach, consistent with a role for Tfb3 in linking kinase and core domains of the factor, The deduced amino acid sequence of Tfb2 is similar to that of the 52-kDa subunit of human TFIIH, while Tfb3 is identified as a RING finger protein homologous to the 36-kDa subunit of murine CAK (cyclin-dependent kinase activating kinase) and to the 32-kDa subunit of human TFIIH, Tfb4 is homologous to p34 of human TFIIH and is identified as the weakly associated 37-kDa subunit of the yeast factor. These and other findings reveal a one-to-one correspondence and high degree of sequence similarity between the entire set of yeast and human TFIIH polypeptides.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA; UNIV TEXAS, SW MED CTR, DEPT PATHOL, LAB MOL PATHOL, DALLAS, TX 75235 USA; UNIV KENTUCKY, DEPT TOXICOL, LEXINGTON, KY 40536 USA	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Kentucky				Svejstrup, Jesper/0000-0003-4964-6147	NATIONAL CANCER INSTITUTE [R01CA012428, R37CA012428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER; NCI NIH HHS [CA12428] Funding Source: Medline; NIGMS NIH HHS [GM36659] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FLANAGAN PM, 1992, P NATL ACAD SCI USA, V89, P7659, DOI 10.1073/pnas.89.16.7659; FRIEDBERG EC, 1995, DNA REPAIR; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SIKORSKI RS, 1989, GENETICS, V122, P19; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; WANG Z, 1996, MUTAT RES, V364, P51; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; Wang Zhigang, 1995, Methods (Orlando), V7, P177, DOI 10.1006/meth.1995.1023	46	64	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19319	19327		10.1074/jbc.272.31.19319	http://dx.doi.org/10.1074/jbc.272.31.19319			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235928	hybrid			2022-12-25	WOS:A1997XP06300034
J	Heckman, C; Mochon, E; Arcinas, M; Boxer, LM				Heckman, C; Mochon, E; Arcinas, M; Boxer, LM			The WT1 protein is a negative regulator of the normal bcl-2 allele in t(14;18) lymphomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; WILMS-TUMOR SUPPRESSOR; C-MYC; MALIGNANT-LYMPHOMA; GENE; EXPRESSION; BINDING; CELLS; LOCUS; TRANSLOCATION	The translocated and normal bcl-2 alleles in the DHL-4 cell line with the t(14;18) translocation were separated by pulsed field electrophoresis. An in vivo footprint over a potential WT1 binding site in the bcl-2 5'-flanking sequence was identified on the normal silent allele. Electrophoretic mobility shift assays with the bcl-2 WT1 site demonstrated a single specific complex. UV cross-linking and Western analysis revealed that this gel shift complex contained WT1 protein. Deletion or mutation of the WT1 site resulted in an increase in activity of the bcl-2 promoter in DHL-4 cells. Cotransfection with a 3:1 ratio of a WT1 expression vector to the bcl-2 promoter construct led to a 3.0-fold repression of the bcl-2 promoter. Cotransfection with a WT1 expression vector and the bcl-2 promoter with the mutated WT1 site resulted in only 1.2-fold repression. We conclude that the WT1 site functions as a negative regulatory site for the normal silent bcl-2 allele in t(14;18) lymphomas, The WT1 site is not occupied on the translocated bcl-2 allele.	STANFORD UNIV,SCH MED,DIV HEMATOL,DEPT MED,STANFORD,CA 94305; VET ADM MED CTR,CTR MOL BIOL MED,STANFORD,CA 94305	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Heckman, Caroline/0000-0002-4324-8706	NCI NIH HHS [CA56764, 5T32 CA09302-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764, T32CA009302] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCINAS M, 1994, ONCOGENE, V9, P2699; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; FRAIZER GC, 1995, BLOOD, V86, P4704, DOI 10.1182/blood.V86.12.4704.bloodjournal86124704; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HEWITT SM, 1995, CANCER RES, V55, P5386; Higuchi R., 1990, RECOMBINANT PCR PCR, P177; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maxam A M, 1980, Methods Enzymol, V65, P499; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIYASHITA T, 1994, CANCER RES, V54, P3131; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZELENETZ AD, 1991, BLOOD, V78, P1552	32	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19609	19614		10.1074/jbc.272.31.19609	http://dx.doi.org/10.1074/jbc.272.31.19609			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235968	hybrid			2022-12-25	WOS:A1997XP06300074
J	Li, ZY; Hiasa, H; Kumar, U; DiGate, RJ				Li, ZY; Hiasa, H; Kumar, U; DiGate, RJ			The traE gene of plasmid RP4 encodes a homologue of Escherichia coli DNA topoisomerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; REPLICATION IN-VITRO; BACILLUS-SUBTILIS; TRANSFER REGION; GYRASE GENES; SITE; BINDING; CLONING; SYSTEM; RK2	The polypeptide encoded by the plasmid RP4 traE gene shows extensive protein sequence similarity to Escherichia coli topB, the gene encoding DNA topoisomerase III (Topo III), The traE gene product has been cloned into a bacteriophage T7-based transient expression system, and the polypeptide has been expressed and purified, The TraE protein exhibits topoisomerase activity similar to that of Topo III, Relaxation is stimulated by high temperature and low concentrations of Mg2+. In addition, similar to E. coli Topo III, the TraE protein is a potent decatenase and can substitute for Topo III activity in vivo. The biochemical properties of the TraE protein in vitro suggest that the protein may be involved in the resolution of plasmid DNA replication intermediates either during vegetative replication or in conjugative DNA transfer, Putative homologues of Topo III have been found to be encoded by other broad host range, conjugative plasmids isolated from both Gram-negative and Gram-positive organisms, suggesting that Topo III-like polypeptides may have an essential role in the propagation of many promiscuous plasmids.	UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR MED BIOTECHNOL, DEPT MOL BIOL & BIOPHYS, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH PHARM, DEPT PHARMACEUT SCI, BALTIMORE, MD 21201 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOL BIOL, NEW YORK, NY 10021 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048445, R01GM048445] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48445] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARTH PT, 1978, J BACTERIOL, V133, P43, DOI 10.1128/JB.133.1.43-52.1978; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANTL S, 1994, GENE, V142, P155, DOI 10.1016/0378-1119(94)90372-7; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Caron Paul R., 1994, V29B, P271; CEGLOWSKI P, 1993, GENE, V136, P1, DOI 10.1016/0378-1119(93)90441-5; Clewell DB, 1993, BACTERIAL CONJUGATIO, P75; Clewell DB, 1993, BACTERIAL CONJUGATIO, P349; DEAN F, 1984, THESIS U CHICAGO; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V79, P1935; FIRTH N, 1993, GENE, V136, P13, DOI 10.1016/0378-1119(93)90442-6; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOUET A, 1994, MOL MICROBIOL, V11, P471, DOI 10.1111/j.1365-2958.1994.tb00328.x; GERLITZ M, 1990, J BACTERIOL, V172, P6194, DOI 10.1128/jb.172.11.6194-6203.1990; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P2093; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hopwood D.A., 1993, BACTERIAL CONJUGATIO, P293, DOI DOI 10.1007/978-1-4757-9357-4_11; IVEY DM, 1992, NUCLEIC ACIDS RES, V20, P4928, DOI 10.1093/nar/20.18.4928; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESSL M, 1992, J BACTERIOL, V174, P2493, DOI 10.1128/jb.174.8.2493-2500.1992; Macrina FL, 1993, BACTERIAL CONJUGATIO, P313, DOI [DOI 10.1007/978-1-4757-9357-4_12, 10.1007/978-1-4757-9357-4_12]; MARGOLIN P, 1985, P NATL ACAD SCI USA, V82, P5437, DOI 10.1073/pnas.82.16.5437; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MILLER JH, 1992, SHORT COURSE BACTERI, P268; MORTON TM, 1993, J BACTERIOL, V175, P4436, DOI 10.1128/JB.175.14.4436-4447.1993; PALOMBO EA, 1989, PLASMID, V22, P59, DOI 10.1016/0147-619X(89)90036-X; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; PANSEGRAU W, 1994, J MOL BIOL, V239, P623, DOI 10.1006/jmbi.1994.1404; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P2925, DOI 10.1073/pnas.90.7.2925; PANSEGRAU W, 1990, P NATL ACAD SCI USA, V87, P6555, DOI 10.1073/pnas.87.17.6555; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; ROBERTS RC, 1990, J BACTERIOL, V172, P6204, DOI 10.1128/jb.172.11.6204-6216.1990; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWINFIELD TJ, 1991, PLASMID, V26, P209, DOI 10.1016/0147-619X(91)90044-W; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMAS CM, 1980, J BACTERIOL, V141, P213, DOI 10.1128/JB.141.1.213-222.1980; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; ZHANG HL, 1994, J BIOL CHEM, V269, P9052; ZHANG HL, 1995, J BIOL CHEM, V270, P23700, DOI 10.1074/jbc.270.40.23700	52	28	33	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19582	19587		10.1074/jbc.272.31.19582	http://dx.doi.org/10.1074/jbc.272.31.19582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235964	hybrid			2022-12-25	WOS:A1997XP06300070
J	Loo, RW; CondeFrieboes, K; Reynolds, LJ; Dennis, EA				Loo, RW; CondeFrieboes, K; Reynolds, LJ; Dennis, EA			Activation, inhibition, and regiospecificity of the lysophospholipase activity of the 85-kDa group IV cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; PURIFICATION; PROTEIN; P388D1; U937; ACYL	The 85-kDa Group IV calcium-dependent cytosolic phospholipase A(2) (cPLA(2)) catalyzes the hydrolysis of palmitoylglycero-3-phosphocholine to palmitic acid and glycero-3-phosphocholine. Palmitoylglycero-3-phosphocholine exists as a 9:1 equilibrium mixture of the sn-1 and sn-2 isomers, with the fatty acid predominately at the sn-1 position, We have monitored this reaction by P-31 NMR to determine which palmitoylglycero-3-phosphocholine isomer is processed by cPLA(2). When both lysophospholipid isomers are present in a 1:1 mixture under conditions in which acyl migration is minimized, cPLA(2) rapidly consumes both isomers, However, 1-palmitoylglycero-3-phosphocholine is consumed seven times faster than the 2-palmitoylglycero-3-phosphocholine isomer, We have previously reported that this lysophospholipase reaction is accelerated in the presence of glycerol, We now find that this apparent increase in activity is accounted for, in part, by glycerol acting as an alternative acceptor for the cleaved fatty acid, as is the case for this enzyme's phospholipase A(2) (PLA(2)) activity, In contrast, dioleoylglycerol, which accelerates the PLA(2) activity, does not act as an acceptor in either the lysophospholipase or the PLA(2) reaction, but can affect enzyme activities by altering substrate presentation, We also show that a known inhibitor of the PLA(2) activity of cPLA(2) is able to inhibit its lysophospholipase activity with a similar IC50 60 its PLA(2) activity, However the effect of inhibitors is dependent on the manner in which they are presented to the enzyme.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego			Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140; Conde-Frieboes, Kilian/0000-0001-5303-4448	NIGMS NIH HHS [GM20501, GM51606] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN HC, 1949, J AM CHEM SOC, V71, P1845, DOI 10.1021/ja01173a093; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CondeFrieboes K, 1996, J AM CHEM SOC, V118, P5519, DOI 10.1021/ja953553w; DECARVALHO MGS, 1995, J BIOL CHEM, V270, P20439, DOI 10.1074/jbc.270.35.20439; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIEZ E, 1992, J BIOL CHEM, V267, P18342; FUJIMORI Y, 1993, EUR J BIOCHEM, V218, P629, DOI 10.1111/j.1432-1033.1993.tb18416.x; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; HUANG Z, 1994, ANAL BIOCHEM, V222, P110, DOI 10.1006/abio.1994.1461; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; PLUCKTHUN A, 1981, J PHYS CHEM-US, V85, P678; PLUCKTHUN A, 1982, BIOCHEMISTRY-US, V21, P1743; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; STAFFORD RE, 1988, COLLOID SURFACE, V30, P47; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; ZHANG Y, 1988, J BIOL CHEM, V263, P9965	26	34	36	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19214	19219		10.1074/jbc.272.31.19214	http://dx.doi.org/10.1074/jbc.272.31.19214			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235913	Green Published, hybrid			2022-12-25	WOS:A1997XP06300019
J	Nitta, M; Okamura, H; Aizawa, S; Yamaizumi, M				Nitta, M; Okamura, H; Aizawa, S; Yamaizumi, M			Heat shock induces transient p53-dependent cell cycle arrest at G1/S	ONCOGENE			English	Article						p53; heat shock; cell cycle arrest	NUCLEAR ACCUMULATION; P53 PROTEIN; DNA-DAMAGE; DEPENDENT KINASES; HUMAN FIBROBLASTS; TUMOR-ANTIGEN; UV; DEGRADATION; REPLICATION; CHECKPOINT	Heat shock (43 degrees C, 45 min) induced transient nuclear accumulation of p53 in primary human fibroblasts without any clonogenically toxic effects, The accumulation of p53 reached a maximal level 3 similar to 5 h after heat shock, and returned to the basal level within 12 h. Following the increase in p53 level, cell cycle arrest at G1/S was observed in normal fibroblasts, whereas neither nuclear accumulation of p53 nor cell cycle arrest were observed in HeLa cells. By comparing cell cycle patterns of heat-treated mouse cells with different genotypes at the p53 locus (+/+, +/-, -/-), the observed cell cycle arrest at G1/S was demonstrated to be p53-dependent, Cell cycle arrest in normal human fibroblasts continued for nearly 24 h, resulting in a one day delay of cell growth compared with non-treated cells, Following enhancement of the p53 level, the amount of p21/WAF1/CIP1 increased, and the high level of p21 was sustained for almost one day in a cell cycle-independent manner, suggesting the involvement of p21 in the inhibition of cell cycle progression by heat shock.	KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,KUMAMOTO 862,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT OBSTET & GYNECOL,KUMAMOTO 862,JAPAN	Kumamoto University; Kumamoto University								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Brown CR, 1996, J BIOL CHEM, V271, P833, DOI 10.1074/jbc.271.2.833; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MINISINI MP, 1994, MUTAT RES-DNA REPAIR, V315, P169, DOI 10.1016/0921-8777(94)90016-7; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shivji KK, 1992, CELL, V69, P367, DOI DOI 10.1016/0092-8674(92)90416-A; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; TSUKADA T, 1993, ONCOGENE, V8, P3313; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	32	78	81	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					561	568		10.1038/sj.onc.1201210	http://dx.doi.org/10.1038/sj.onc.1201210			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247309				2022-12-25	WOS:A1997XN25500007
J	Glerum, DM; Muroff, I; Jin, C; Tzagoloff, A				Glerum, DM; Muroff, I; Jin, C; Tzagoloff, A			COX15 codes for a mitochondrial protein essential for the assembly of yeast cytochrome oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE NUCLEAR GENE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MEMBRANE SYSTEM; MESSENGER-RNA; PET GENES; MUTANTS; TRANSFORMATION; EXPRESSION; CLONING	The respiratory defect of Saccharomyces cerevisiae mutants assigned to complementation group G4 of a pet strain collection stems from their failure to synthesize cytochrome oxidase. The mutations do not affect expression of either the mitochondrially or nuclearly encoded subunits of the enzyme, The cytochrome oxidase deficiency also does not appear to be related to mitochondrial copper metabolism or heme a biosynthesis, These data suggest that the mutants are likely to be impaired in assembly of the enzyme, A gene designated COX15 has been cloned by transformation of mutants from complementation group G4. This gene is identical to reading frame YER141w on chromosome 5, To facilitate further studies, Cox15p has been expressed as a biotinylated protein, Biotinylated Cox15p fully restores cytochrome oxidase in cox15 mutants, indicating that the carboxyl-terminal sequence with biotin does not affect its function. Cox15p is a constituent of the mitochondrial inner membrane and, because of its resistance to proteolysis, probably is largely embedded in the phospholipid bilayer of the membrane, The present studies further emphasize the complexity of cytochrome oxidase assembly and report a new constituent of mitochondria involved in this process. The existence of COX15 homologs in Schizosaccharomyces pombe and Caenorhabditis elegans suggests that it may be widely distributed in eucaryotic organisms.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University			Glerum, Moira/AHD-3271-2022	Muroff, Ivor/0000-0003-3721-5278	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50187, R01 GM050187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BURKL G, 1976, GENETICS BIOGENESIS, P39; CHEN J, 1990, EMBO J, V9, P4569, DOI 10.1002/j.1460-2075.1990.tb07910.x; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; COSTANZO MC, 1986, EMBO J, V5, P3637, DOI 10.1002/j.1460-2075.1986.tb04693.x; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DUJON B, 1981, MOL BIOL YEAST SACCH, P506; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MCEWEN JE, 1985, J BACTERIOL, V161, P831, DOI 10.1128/JB.161.3.831-835.1985; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; POUTRE CG, 1987, GENETICS, V115, P637; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; SHERMAN F, 1964, BIOCHIM BIOPHYS ACTA, V90, P1, DOI 10.1016/0304-4165(64)90113-8; SHERMAN F, 1963, GENETICS, V48, P375; SONE N, 1991, J BIOCHEM-TOKYO, V110, P1016, DOI 10.1093/oxfordjournals.jbchem.a123671; ten Berge A M, 1974, Mol Gen Genet, V131, P113; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; VINGRON M, 1991, J MOL BIOL, V218, P33, DOI 10.1016/0022-2836(91)90871-3	47	93	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19088	19094		10.1074/jbc.272.30.19088	http://dx.doi.org/10.1074/jbc.272.30.19088			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228094	hybrid			2022-12-25	WOS:A1997XM34200085
J	Rumsey, SC; Kwon, O; Xu, GW; Burant, CF; Simpson, I; Levine, M				Rumsey, SC; Kwon, O; Xu, GW; Burant, CF; Simpson, I; Levine, M			Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ASCORBIC-ACID; VITAMIN-C; HUMAN-NEUTROPHILS; XENOPUS OOCYTES; FRUCTOSE TRANSPORTER; TISSUE DISTRIBUTION; HUMAN-ERYTHROCYTES; GENE LOCALIZATION; DIABETES-MELLITUS; SKELETAL-MUSCLE	Dehydroascorbic acid (DHA) is rapidly taken up by cells and reduced to ascorbic acid (AA). Using the Xenopus laevis oocyte expression system we examined transport of DHA and AA via glucose transporter isoforms GLUT1-5 and SGLT1, The apparent K-m of DHA transport via GLUT1 and GLUT3 was 1.1 +/- 0.2 and 1.7 +/- 0.3 mM, respectively, High performance liquid chromatography analysis confirmed 100% reduction of DHA to AA within oocytes, GLUT4 transport of DHA was only 2-4-fold above control and transport kinetics could not be calculated, GLUT2, GLUT5, and SGLT1 did not transport DHA and none of the isoforms transported AA. Radiolabeled sugar transport confirmed transporter function and identity of all cDNA clones was confirmed by restriction fragment mapping. GLUT1 and GLUT3 cDNA were further verified by polymerase chain reaction, DHA transport activity in both GLUT1 and GLUT3 was inhibited by 2-deoxyglucose, D-glucose, and S-O-methylglucose among other hexoses while fructose and L-glucose showed no inhibition, Inhibition by the endofacial inhibitor, cytochalasin B, was non-competitive and inhibition by the exofacial inhibitor, 4,6-O-ethylidene-alpha-glucose, was competitive. Expressed mutant constructs of GLUT1 and GLUT3 did not transport DHA. DHA and a-deoxyglucose uptake by Chinese hamster ovary cells overexpressing either GLUT1 or GLUT3 was increased 2-8 fold over control cells. These studies suggest GLUT1 and GLUT3 isoforms are the specific glucose transporter isoforms which mediate DHA transport and subsequent accumulation of AA.	NIDDK,NIH,MOL & CLIN NUTR SECT,BETHESDA,MD 20892; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Chicago			Burant, Charles/GPC-5690-2022	Burant, Charles/0000-0001-9189-5003				ASANO T, 1992, BIOCHEM J, V288, P189, DOI 10.1042/bj2880189; BANERJEE A, 1982, ANN CLIN BIOCHEM, V19, P65, DOI 10.1177/000456328201900201; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; BASKETTER DA, 1978, J PHYSIOL-LONDON, V278, P389, DOI 10.1113/jphysiol.1978.sp012311; BERGSTEN P, 1995, ARCH BIOCHEM BIOPHYS, V317, P208, DOI 10.1006/abbi.1995.1155; BIANCHI J, 1986, P SOC EXP BIOL MED, V181, P333; BIANCHI J, 1986, AM J PHYSIOL, V250, pG461, DOI 10.1152/ajpgi.1986.250.4.G461; BIGLEY R, 1983, DIABETES, V32, P545, DOI 10.2337/diabetes.32.6.545; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3907, DOI 10.1021/bi00230a015; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CHATTERJEE IB, 1979, ANAL BIOCHEM, V98, P368, DOI 10.1016/0003-2697(79)90155-6; CHOI JL, 1989, AM J PHYSIOL, V257, pC110, DOI 10.1152/ajpcell.1989.257.1.C110; COX BD, 1975, BIOCHEM MED METAB B, V12, P183, DOI 10.1016/0006-2944(75)90110-6; CRAIK JD, 1995, THROMB RES, V79, P461, DOI 10.1016/0049-3848(95)00136-F; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; DHARIWAL KR, 1990, ANAL BIOCHEM, V189, P18, DOI 10.1016/0003-2697(90)90037-A; DIXON SJ, 1992, J BONE MINER RES, V7, P675; DYER DL, 1994, AM J PHYSIOL, V267, pC301, DOI 10.1152/ajpcell.1994.267.1.C301; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HABER RS, 1993, ENDOCRINOLOGY, V132, P2538, DOI 10.1210/en.132.6.2538; HEATH H, 1966, EXP EYE RES, V5, P156, DOI 10.1016/S0014-4835(66)80002-7; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HELBIG H, 1989, AM J PHYSIOL, V256, pC44, DOI 10.1152/ajpcell.1989.256.1.C44; HORNIG D, 1971, CLIN CHIM ACTA, V33, P187, DOI 10.1016/0009-8981(71)90267-1; INGERMANN RL, 1986, AM J PHYSIOL, V250, pC637, DOI 10.1152/ajpcell.1986.250.4.C637; INUKAI K, 1995, ENDOCRINOLOGY, V136, P4850, DOI 10.1210/en.136.11.4850; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KELLER K, 1990, BIOMED BIOCHIM ACTA, V49, P1201; KERN HL, 1987, CURR EYE RES, V6, P885, DOI 10.3109/02713688709034857; MAHER F, 1992, BIOCHEM BIOPH RES CO, V182, P703, DOI 10.1016/0006-291X(92)91789-S; MAHER F, 1994, FASEB J, V8, P1003, DOI 10.1096/fasebj.8.13.7926364; MANN GV, 1975, ANN NY ACAD SCI, V258, P243, DOI 10.1111/j.1749-6632.1975.tb29285.x; MERRALL NW, 1993, CELL SIGNAL, V5, P667, DOI 10.1016/0898-6568(93)90028-K; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; NEWILL A, 1984, ANN CLIN BIOCHEM, V21, P488, DOI 10.1177/000456328402100608; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; SHEPHERD PR, 1992, BIOCHEM BIOPH RES CO, V188, P149, DOI 10.1016/0006-291X(92)92362-2; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SINCLAIR AJ, 1991, DIABETOLOGIA, V34, P171, DOI 10.1007/BF00418271; SOM S, 1981, METABOLISM, V30, P572, DOI 10.1016/0026-0495(81)90133-5; SOREQ H, 1992, METHOD ENZYMOL, V207, P225; STEVENSON NR, 1974, GASTROENTEROLOGY, V67, P952; THORN NA, 1991, ACTA PHYSIOL SCAND, V141, P97, DOI 10.1111/j.1748-1716.1991.tb09049.x; VERA JC, 1994, BLOOD, V84, P1628; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173; WANG JF, 1986, P NATL ACAD SCI USA, V83, P3277, DOI 10.1073/pnas.83.10.3277; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WASHKO PW, 1992, ANAL BIOCHEM, V204, P1, DOI 10.1016/0003-2697(92)90131-P; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WELCH RW, 1995, J BIOL CHEM, V270, P12584, DOI 10.1074/jbc.270.21.12584; WELCH RW, 1993, BIOCHEM J, V294, P505, DOI 10.1042/bj2940505; WELLS WW, 1994, J BIOENERG BIOMEMBR, V26, P369, DOI 10.1007/BF00762777; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; WRIGHT JR, 1981, J APPL PHYSIOL, V51, P1477, DOI 10.1152/jappl.1981.51.6.1477; YAMAMOTO I, 1990, J PHARMACOBIO-DYNAM, V13, P688, DOI 10.1248/bpb1978.13.688; ZHOU J, 1993, J CLIN INVEST, V91, P845, DOI 10.1172/JCI116305	67	373	388	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18982	18989		10.1074/jbc.272.30.18982	http://dx.doi.org/10.1074/jbc.272.30.18982			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228080	hybrid			2022-12-25	WOS:A1997XM34200071
J	Hagg, R; Hedbom, E; Mollers, U; Aszodi, A; Fassler, R; Bruckner, P				Hagg, R; Hedbom, E; Mollers, U; Aszodi, A; Fassler, R; Bruckner, P			Absence of the alpha 1(IX) chain leads to a functional knock-out of the entire collagen IX protein in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO CARTILAGE; MESSENGER-RNAS; FIBRILS; PROTEOGLYCAN; POLYPEPTIDE; ALPHA-2(IX); ANTIBODIES; SEQUENCE; MATRIX; DOMAIN	Cartilage fibrils contain collagen II as well as smaller amounts of collagens IX and XI, The three collagens are thought to co-assemble into cartilage-specific arrays, The precise role of collagen IX in cartilage has been addressed previously by generating mice harboring an inactivated Col9a1 gene encoding the alpha 1(IX) chain, i.e. one of the three constituent chains of collagen IX (Fassler, R., Schnegelsberg, P. N. J., Dausman, J., Shinya, T,, Muragaki, Y,, McCarthy, M, T,, Olsen, B, R,, and Jaenisch, R, (1994) Proc. Natl, Acad. Sci, U, S, A. 91, 5070-5074), The animals did not produce alpha 1(M) mRNA or polypeptides and were born with no conspicuous skeletal abnormality but post-natally developed early onset osteoarthritis, Here we show that the deficiency in alpha 1(M) chains leads to a functional knock-out of all polypeptides of collagen IX, whereas the Col9a2 and Col9a3 genes were normally transcribed, Therefore, synthesis of alpha 1(M) polypeptides is essential for the assembly of heterotrimeric collagen IX molecules, Surprisingly, cartilage fibrils of all shapes and banding patterns found in normal newborn, adolescent, or adult mice were formed in transgenic animals, although they lacked collagen IX. Therefore, collagen IX is not essen tial, and may be functionally redundant, in fibrillogenesis in cartilage in vivo, The protein is required, however, for long term tissue stability, presumably by mediating interactions between fibrillar and extrafibrillar macromolecules.	UNIV MUNSTER,INST PHYSIOL CHEM & PATHOBIOCHEM,D-48149 MUNSTER,GERMANY; MAX PLANCK INST BIOCHEM,PROT CHEM ABT,D-82152 MARTINSRIED,GERMANY	University of Munster; Max Planck Society			Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; BRUCKNER P, 1988, J BIOL CHEM, V263, P16911; BRUCKNER P, 1983, EUR J BIOCHEM, V136, P333, DOI 10.1111/j.1432-1033.1983.tb07746.x; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; ELIMA K, 1992, BIOCHIM BIOPHYS ACTA, V1130, P78, DOI 10.1016/0167-4781(92)90465-C; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; Haimes H. B., 1995, INFLAMM RES S2, V44, P127; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HOLMDAHL R, 1986, ARTHRITIS RHEUM, V29, P400, DOI 10.1002/art.1780290314; HUBER S, 1986, J BIOL CHEM, V261, P5965; HUBER S, 1988, J BIOL CHEM, V263, P752; HUNZIKER EB, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P183; JACENKO O, 1995, J RHEUMATOL, V22, P39; KEENE DR, 1995, J HISTOCHEM CYTOCHEM, V43, P967, DOI 10.1177/43.10.7560887; LABOURDETTE L, 1993, FEBS LETT, V320, P211, DOI 10.1016/0014-5793(93)80588-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; MAYNE R, 1995, EXTRACELLULAR MATRIX, P73; MAYNE R, 1996, ARTHRITIS ALLIED CON, P207; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; Mechling DE, 1996, J BIOL CHEM, V271, P13781, DOI 10.1074/jbc.271.23.13781; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; NORO A, 1983, J BIOL CHEM, V258, P9323; TIMPL R, 1982, METHOD ENZYMOL, V82, P472; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105	33	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20650	20654		10.1074/jbc.272.33.20650	http://dx.doi.org/10.1074/jbc.272.33.20650			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252382	hybrid			2022-12-25	WOS:A1997XR22100052
J	Maisner, A; Zimmer, G; Liszewski, MK; Lublin, DM; Atkinson, JP; Herrler, G				Maisner, A; Zimmer, G; Liszewski, MK; Lublin, DM; Atkinson, JP; Herrler, G			Membrane cofactor protein (CD46) is a basolateral protein that is not endocytosed - Importance of the tetrapeptide FTSL at the carboxyl terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; LYSOSOMAL ACID-PHOSPHATASE; TRANS-GOLGI NETWORK; CANINE KIDNEY-CELLS; MEASLES-VIRUS; MDCK CELLS; PLASMA-MEMBRANE; N-GLYCANS; CYTOPLASMIC DOMAIN; TARGETING SIGNAL	Membrane cofactor protein (MCP) is a widely distributed complement regulatory protein that is expressed on the basolateral surface of polarized epithelial cells. The basolateral targeting of the BC1 isoform of MCP was analyzed by generating deletion mutants and point mutants within the cytoplasmic tail of 16 amino acids, A sequence of four amino acids, FTSL, was found to be indispensable for the basolateral transport of MCP. This tetrapeptide has two unique features compared with the targeting motifs of other basolateral proteins: (i) it contains a phenylalanine rather than a tyrosine at position 1; (ii) it is located at the very COOH-terminal end, Replacement of the phenylalanine or the leucine by an alanine resulted in a nonpolarized delivery to the cell surface, On the other hand, substitution of a tyrosine for the phenylalanine did not affect the basolateral transport of MCP, The latter mutant, however, was efficiently internalized, whereas the wild type protein was not subject to endocytosis. Our results indicate that the targeting signal YXX-large aliphatic that is involved in various sorting events has been modulated in MCP in such a way that it allows basolateral transport but not endocytosis.	UNIV MARBURG,INST VIROL,D-35037 MARBURG,GERMANY; WASHINGTON UNIV,SCH MED,DEPT PATHOL & MED,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV RHEUMATOL,ST LOUIS,MO 63110	Philipps University Marburg; Washington University (WUSTL); Washington University (WUSTL)				Atkinson, John/0000-0002-2514-3441; Zimmer, Gert/0000-0002-2708-2507				BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Lazarovits J, 1996, J CELL BIOL, V134, P339, DOI 10.1083/jcb.134.2.339; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LISZEWSKI MK, 1994, J BIOL CHEM, V269, P10776; LISZEWSKI MK, 1992, CURR TOP MICROBIOL, V178, P45; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; Maisner A, 1996, J VIROL, V70, P4973, DOI 10.1128/JVI.70.8.4973-4977.1996; Maisner A, 1996, J BIOL CHEM, V271, P18853, DOI 10.1074/jbc.271.31.18853; MAISNER A, 1995, VIROLOGY, V210, P479, DOI 10.1006/viro.1995.1365; MAISNER A, 1994, J VIROL, V68, P6299, DOI 10.1128/JVI.68.10.6299-6304.1994; MANCHESTER M, 1995, P NATL ACAD SCI USA, V92, P2303, DOI 10.1073/pnas.92.6.2303; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; OGLESBY TJ, 1992, J EXP MED, V175, P1547, DOI 10.1084/jem.175.6.1547; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; ROTH MG, 1986, J CELL BIOL, V103, P2607; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHNORR JJ, 1995, EUR J IMMUNOL, V25, P976, DOI 10.1002/eji.1830250418; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TUCKER SP, 1993, ADV VIRUS RES, V42, P187, DOI 10.1016/S0065-3527(08)60086-X; VANTHOF W, 1995, J BIOL CHEM, V270, P24150; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987	41	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20793	20799		10.1074/jbc.272.33.20793	http://dx.doi.org/10.1074/jbc.272.33.20793			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252403	hybrid			2022-12-25	WOS:A1997XR22100073
J	Park, JB; Farnsworth, CC; Glomset, JA				Park, JB; Farnsworth, CC; Glomset, JA			Ca2+/calmodulin causes Rab3A to dissociate from synaptic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; CALMODULIN-BINDING; SMG P25A; NERVE-TERMINALS; PHOSPHOLIPID-BINDING; REGULATORY PROTEIN; GLUTAMATE RELEASE; CHROMAFFIN CELLS; EXCHANGE PROTEIN	The GTPase Rab3A has been postulated to cycle on and off synaptic membranes during the course of neurotransmission. Moreover, a Rab guanine nucleotide dissociation inhibitor has been shown to cause Rab3A to dissociate from synaptic membranes in vitro, Pie demonstrate here that Ca2+/calmodulin also can cause Rab3A to dissociate from synaptic membranes in vitro. Like Rab guanine nucleotide dissociation inhibitor, it forms a 1:1 complex with Rab3A that requires both the lipidated C terminus of Rab3A and the presence of bound guanine nucleotide. In addition, a synthetic peptide corresponding to the Lys(62)-Arg(85) sequence of Rab3A can prevent the dissociating effect of each protein and disrupt complexes between each protein and Rab3A. However, Ca2+/calmodulin's effect differs from that of Rab guanine nucleotide dissociation inhibitor not only in being Ca2+-dependent but also in having a less stringent requirement for GDP as opposed to GTP and in involving a less complete dissociation of Rab3A The functional significance in vivo of Ca2+/calmodulin's effect remains to be determined; it may depend in part on the relative amounts of Ca2+/calmodulin and Rab guanine nucleotide dissociation inhibitor that are available for binding to Rab3A in individual, activated nerve termini.	UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, REG PRIMATE RES CTR, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BARRIE AP, 1991, J NEUROCHEM, V57, P1398, DOI 10.1111/j.1471-4159.1991.tb08306.x; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURSTEIN ES, 1992, BIOCHEM J, V282, P387, DOI 10.1042/bj2820387; CAMPAGNE MV, 1989, J NEUROCYTOL, V18, P479, DOI 10.1007/BF01474544; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Estep R P, 1990, Curr Top Cell Regul, V31, P161; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GIEDROC DP, 1985, BIOCHEMISTRY-US, V24, P1203, DOI 10.1021/bi00326a023; GISPEN WH, 1991, MOL NEUROBIOL, V5, P61, DOI 10.1007/BF02935540; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GUERINI D, 1991, ADV PROT PHOSPHATASE, V6, P391; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HENS JJH, 1995, J NEUROCHEM, V64, P1127; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KENIGSBERG RL, 1985, NEUROSCIENCE, V14, P335, DOI 10.1016/0306-4522(85)90183-6; KIM JY, 1994, J BIOL CHEM, V269, P28214; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAHY JC, 1993, NEUROSCIENCE, V52, P563, DOI 10.1016/0306-4522(93)90406-6; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LIU JP, 1994, J BIOL CHEM, V269, P21043; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; LLEDO PM, 1994, TRENDS NEUROSCI, V17, P426, DOI 10.1016/0166-2236(94)90017-5; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LOPEZ MF, 1994, BBA-PROTEIN STRUCT M, V1205, P29, DOI 10.1016/0167-4838(94)90088-4; Marme D., 1983, CALCIUM CELL FUNCTIO, VIV, p263 ; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P269; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; NONAKA H, 1991, BIOCHEM BIOPH RES CO, V174, P556, DOI 10.1016/0006-291X(91)91453-J; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKABE T, 1992, BIOCHEM BIOPH RES CO, V186, P1006, DOI 10.1016/0006-291X(92)90846-D; Park JB, 1996, EXP MOL MED, V28, P147, DOI 10.1038/emm.1996.23; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SKENE JHP, 1990, NEUROSCI RES       S, V13, pS113; STEELEMORTIMER O, 1993, FEBS LETT, V329, P313, DOI 10.1016/0014-5793(93)80244-O; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; STONTEN PFW, 1993, FEBS LETT, V320, P1; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZUCKER RS, 1993, BIOCHEM SOC T, V21, P395, DOI 10.1042/bst0210395	75	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20857	20865		10.1074/jbc.272.33.20857	http://dx.doi.org/10.1074/jbc.272.33.20857			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252412	hybrid			2022-12-25	WOS:A1997XR22100082
J	Bouton, C; Hirling, H; Drapier, JC				Bouton, C; Hirling, H; Drapier, JC			Redox modulation of iron regulatory proteins by peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; RECEPTOR MESSENGER-RNA; NITRIC-OXIDE; RESPONSIVE ELEMENT; ACTIVATED MACROPHAGES; CYTOSOLIC ACONITASE; TRYPANOSOMA-CRUZI; ESCHERICHIA-COLI; SUPEROXIDE; METABOLISM	Expression of several proteins of higher eukaryotes is post-transcriptionally regulated by interaction of iron-responsive elements (IREs) on their mRNAs and iron regulatory proteins (IRP1 and IRP2), IRP1 is a redox-sensitive iron-sulfur protein whose regulatory activity is modulated by iron depletion, synthesis of nitric oxide, or oxidative stress, IRP2 is closely related to IRP1, but it does not possess a [Fe-S] cluster, IRPS is also regulated by intracellular iron level, but it is assumed that regulation is achieved by accelerated turn-over, In this report, the effect of peroxynitrite, a strong oxidant produced when nitric oxide and O(2)radical anion are biosynthesized simultaneously, on the RNA binding activity of IRP1 and IRP2 was investigated in vitro. Macrophage cytosolic extracts were exposed directly to a bolus addition of peroxynitrite or to SIN-1, which releases a continuous flux of peroxynitrite. Under these two experimental conditions, IRP1 lost its aconitase activity but did not gain increased capacity to bind IRE. However, addition of low amounts of the disulfide-reducing agent 2-ME during the binding assay revealed formation of a complier between IRP1 and IRE. Substrates of aconitase, which bind to the cluster of IRP1, prevented this effect, pointing to the [Fe-S] cluster as the target of peroxynitrite, Moreover, single mutation of the redox active Cys(437) precluded oxidation of human recombinant IRP1 by SIN-1. Collectively, these results imply that peroxynitrite predisposes IRP1 to bind IREs under a suitable reducing environment, It is assumed that in addition to disrupting the cluster peroxynitrite also promotes disulfide bridge(s) between proximal cysteine residues in the vicinity of the IRE-binding domain, in particular Cys(437) When exposed to peroxynitrite, IRPS lost its spontaneous IRE binding activity, which was restored by further exposure to 2-mercaptoethanol, thus showing that peroxynitrite can also regulate IRP2 by a post-translational event.	INST CURIE,U365 INSERM,F-75005 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Bouton, Cecile/J-8663-2013					ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BECKER K, 1995, EUR J BIOCHEM, V234, P472, DOI 10.1111/j.1432-1033.1995.472_b.x; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; Cairo G, 1996, FASEB J, V10, P1326, DOI 10.1096/fasebj.10.11.8836047; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; CASTRO L, 1994, J BIOL CHEM, V269, P29409; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; DANDEKAR T, 1991, EMBO J, V10, P1003; DENICOLA A, 1993, ARCH BIOCHEM BIOPHYS, V304, P279, DOI 10.1006/abbi.1993.1350; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; Fukuyama N, 1996, BIOCHEM BIOPH RES CO, V224, P414, DOI 10.1006/bbrc.1996.1041; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P14735; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Henderson BR, 1996, BIOESSAYS, V18, P739, DOI 10.1002/bies.950180909; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JAFFREY SR, 1994, P NATL ACAD SCI USA, V91, P12994, DOI 10.1073/pnas.91.26.12994; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LAZZAZERA BA, 1996, J BIOL CHEM, V271, P2762; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Mannick EE, 1996, CANCER RES, V56, P3238; Melefors O, 1996, BIOCHEM BIOPH RES CO, V221, P437, DOI 10.1006/bbrc.1996.0613; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Phillips JD, 1996, BLOOD, V87, P2983, DOI 10.1182/blood.V87.7.2983.bloodjournal8772983; Phillips JD, 1996, BIOCHEMISTRY-US, V35, P15704, DOI 10.1021/bi960653l; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; RADI R, 1991, J BIOL CHEM, V266, P4244; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; RUBBO H, 1994, J BIOL CHEM, V269, P26066; RUBBO H, 1994, ARCH BIOCHEM BIOPHYS, V308, P96, DOI 10.1006/abbi.1994.1014; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SCHLOSS JV, 1980, BIOCHEMISTRY-US, V19, P2358, DOI 10.1021/bi00552a012; Sellers VM, 1996, BIOCHEMISTRY-US, V35, P2699, DOI 10.1021/bi952631p; STAMLER JS, 1994, CELL, V78, P831; SWENSON GR, 1994, NUCLEIC ACIDS RES, V22, P2627, DOI 10.1093/nar/22.13.2627; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; TOTH I, 1995, J BIOL CHEM, V270, P19540, DOI 10.1074/jbc.270.33.19540; VazquezTorres A, 1996, INFECT IMMUN, V64, P3127, DOI 10.1128/IAI.64.8.3127-3133.1996; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	67	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19969	19975		10.1074/jbc.272.32.19969	http://dx.doi.org/10.1074/jbc.272.32.19969			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242665	hybrid			2022-12-25	WOS:A1997XQ05900052
J	Nakajima, K; Murakami, M; Yanoshita, R; Samejima, Y; Karasawa, K; Setaka, M; Nojima, S; Kudo, I				Nakajima, K; Murakami, M; Yanoshita, R; Samejima, Y; Karasawa, K; Setaka, M; Nojima, S; Kudo, I			Activated mast cells release extracellular type platelet-activating factor acetylhydrolase that contributes to autocrine inactivation of platelet-activating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-1; CYTOSOLIC PHOSPHOLIPASE A(2); D-2 GENERATION; HL-60 CELLS; IGE; PURIFICATION; DEGRADATION; CHILDREN; PATHWAY; SUBUNIT	IgE-dependent and -independent activation of mouse bone marrow-derived mast cells (BMMC) elicited rapid and transient production of platelet-activating factor (PAF), which reached a maximal level by 2-5 min and was then degraded rapidly, returning to base-line levels by 10-20 min. Inactivation of PAF was preceded by the release of PAF acetylhydrolase (PAF-AH) activity, which reached a plateau by 3-5 min and paralleled the release of beta-hexosaminidase, a marker of mast cell exocytosis. Immunochemical and molecular biological studies revealed that the PAF-AH released from activated mast cells was identical to the plasma-type isoform. In support of the autocrine action of exocytosed PAF-AH, adding exogenous recombinant plasma-type PAF-AH markedly reduced PAF accumulation in activated BMMC. Furthermore, culture of BMMC with a combination of c-kit ligand, interleukin-1 beta and interleukin-10 for > 24 h led to an increase in plasma-type PAF-AH expression, accompanied by a reduction in stimulus-initiated PAF production. Collectively, these results suggest that plasma-type PAF-AH released from activated mast cells sequesters proinflammatory PAF produced by these cells, thereby revealing an intriguing anti-inflammatory aspect of mast cells.	SHOWA UNIV,SCH PHARMACEUT SCI,DEPT HLTH CHEM,SHINAGAWA KU,TOKYO 142,JAPAN; HOSHI UNIV,INST MED CHEM,SHINAGAWA KU,TOKYO 142,JAPAN; TEIKYO UNIV,FAC PHARMACEUT SCI,SAGAMIKO,KANAGAWA 19901,JAPAN	Showa University; Hoshi University; Teikyo University								Ashraf M, 1996, BIOCHEM J, V320, P965, DOI 10.1042/bj3200965; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GRAHAM RM, 1994, CRIT CARE MED, V22, P204, DOI 10.1097/00003246-199402000-00009; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HSIEH KH, 1993, J ALLERGY CLIN IMMUN, V91, P650, DOI 10.1016/0091-6749(93)90271-G; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Karasawa K, 1996, J BIOCHEM-TOKYO, V120, P838; LuKuo JM, 1996, J BIOL CHEM, V271, P22169, DOI 10.1074/jbc.271.36.22169; MARTIN TW, 1979, NATURE, V279, P250, DOI 10.1038/279250a0; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; NARAHARA H, 1993, ARCH BIOCHEM BIOPHYS, V301, P275, DOI 10.1006/abbi.1993.1144; Ogasawara T, 1997, J IMMUNOL, V158, P393; RAMESHA CS, 1986, J BIOL CHEM, V261, P7592; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; SUGA K, 1990, J BIOL CHEM, V265, P12363; TARBET EB, 1991, J BIOL CHEM, V266, P16667; TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; YASUDA K, 1992, ENDOCRINOLOGY, V130, P708, DOI 10.1210/en.130.2.708	41	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19708	19713		10.1074/jbc.272.32.19708	http://dx.doi.org/10.1074/jbc.272.32.19708			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242626	hybrid			2022-12-25	WOS:A1997XQ05900013
J	Martini, JF; Pezet, A; Guezennec, CY; Edery, M; PostelVinay, MC; Kelly, PA				Martini, JF; Pezet, A; Guezennec, CY; Edery, M; PostelVinay, MC; Kelly, PA			Monkey growth hormone (GH) receptor gene expression - Evidence for two mechanisms for the generation of the GH binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE JAK2; MESSENGER-RNA; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; TISSUE DISTRIBUTION; PROLACTIN RECEPTOR; HUMAN-PLASMA; FACTOR-I; PHOSPHORYLATION; IDENTIFICATION	The growth hormone receptor (GHR) cDNA was cloned from the liver of Rhesus macaque using polymerase chain reaction. As deduced from the nucleotide sequence, the mature GHR is a protein of 620 amino acids which presents 94.1% identity with the human receptor. The monkey GHR (mkGHR) expressed in 293 cells presented the expected specificity for a primate GHR and was able to transduce a transcriptional effect of GH. Human GH was able to activate tyrosine phosphorylation of both the tyrosine kinase JAK2 and the receptor in 293 cells co-transfected with mkGHR and JAK2 cDNAs. The GH binding protein (GHBP), the soluble short form of the GHR, was also present in monkey serum. Expression of the GHR cDNA in eucaryotic cells indicated that the GHBP can be produced by proteolytic cleavage of the membrane receptor. Northern blot analysis of GHR gene expression in different tissues allowed us to identify three different transcripts of 5.0 and 2.8 kilobase pairs and a smaller one of 1.7 kilobase pairs which could encode a GHBP. Rapid amplification of cDNA extremities (3'-RACE-polymerase chain reaction) was used to identify a cDNA encoding a protein in which the transmembrane and cytoplasmic domains of the receptor are substituted by a short sequence of 9 amino acids. This transcript was present in various tissues and could encode a GHBP as well, suggesting for the first time that two different mechanisms can coexist for the generation of the GHBP: proteolytic cleavage of the membrane receptor and a specific mRNA produced by alternative splicing.	FAC MED NECKER ENFANTS MALAD, INSERM, U344, F-75730 PARIS 15, FRANCE; CERMA, DEPT PHYSIOL SYST, F-91228 BRETIGNY SUR ORGE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Kelly, Paul/A-7951-2008					ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMANN G, 1991, ENDOCR REV, V12, P424, DOI 10.1210/edrv-12-4-424; BAUMANN G, 1986, J CLIN ENDOCR METAB, V62, P134, DOI 10.1210/jcem-62-1-134; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BILLESTRUP N, 1991, ENDOCRINOLOGY, V129, P883, DOI 10.1210/endo-129-2-883; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLOSI P, 1993, J BIOL CHEM, V268, P12617; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Dastot F, 1996, P NATL ACAD SCI USA, V93, P10723, DOI 10.1073/pnas.93.20.10723; DELEHAYEZERVAS MC, 1994, J CLIN ENDOCR METAB, V78, P1473; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; EDERY M, 1994, MOL CELL ENDOCRINOL, V102, P39, DOI 10.1016/0303-7207(94)90095-7; GOLOS TG, 1993, ENDOCRINOLOGY, V133, P1744, DOI 10.1210/en.133.4.1744; GOODMAN HM, 1981, ENDOCRINOLOGY, V109, P120, DOI 10.1210/endo-109-1-120; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HERINGTON AC, 1986, J CLIN INVEST, V77, P1817, DOI 10.1172/JCI112507; HOCQUETTE JF, 1989, ENDOCRINOLOGY, V125, P2167, DOI 10.1210/endo-125-4-2167; HOCQUETTE JF, 1990, ENDOCRINOLOGY, V127, P1665, DOI 10.1210/endo-127-4-1665; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LI CH, 1986, ARCH BIOCHEM BIOPHYS, V245, P287, DOI 10.1016/0003-9861(86)90216-X; LI CH, 1956, SCIENCE, V124, P1293, DOI 10.1126/science.124.3235.1293; MANN DR, 1992, J CLIN ENDOCR METAB, V74, P1263, DOI 10.1210/jc.74.6.1263; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MERCADO M, 1994, J CLIN ENDOCR METAB, V78, P731, DOI 10.1210/jc.78.3.731; MERTANI HC, 1995, ENDOCRINE, V3, P135, DOI 10.1007/BF02990065; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGANO M, 1995, AM J PHYSIOL-GASTR L, V268, pG431, DOI 10.1152/ajpgi.1995.268.3.G431; POSNER BI, 1974, ENDOCRINOLOGY, V95, P521, DOI 10.1210/endo-95-2-521; Ross RJM, 1997, MOL ENDOCRINOL, V11, P265, DOI 10.1210/me.11.3.265; RUI H, 1994, J BIOL CHEM, V269, P5364; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; SOTIROPOULOS A, 1993, ENDOCRINOLOGY, V132, P1863, DOI 10.1210/en.132.4.1863; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; TAR A, 1990, J CLIN ENDOCR METAB, V71, P1202, DOI 10.1210/jcem-71-5-1202; TIONG TS, 1989, BIOCHEM BIOPH RES CO, V158, P141, DOI 10.1016/S0006-291X(89)80189-5; TRIVEDI B, 1988, ENDOCRINOLOGY, V123, P2201, DOI 10.1210/endo-123-5-2201; URBANEK M, 1992, MOL ENDOCRINOL, V6, P279, DOI 10.1210/me.6.2.279; WANG XY, 1993, J BIOL CHEM, V268, P3573; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; YOON JB, 1987, J BIOL CHEM, V262, P4284	54	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18951	18958		10.1074/jbc.272.30.18951	http://dx.doi.org/10.1074/jbc.272.30.18951			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228076	hybrid			2022-12-25	WOS:A1997XM34200067
J	Chin, K; Kurashima, Y; Ogura, T; Tajiri, H; Yoshida, S; Esumi, H				Chin, K; Kurashima, Y; Ogura, T; Tajiri, H; Yoshida, S; Esumi, H			Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells	ONCOGENE			English	Article						vascular endothelial growth factor; nitric oxide; gene expression	HUMAN ERYTHROPOIETIN GENE; FACTOR EXPRESSION; TRANSCRIPTIONAL ACTIVATION; PERMEABILITY FACTOR; HYPOXIC INDUCTION; IN-VIVO; ENHANCER; ANGIOGENESIS; SIMILARITIES; PROMOTER	We evaluated the effect of nitric oxide (NO) on vascular endothelial growth factor (VEGF) gene expression in human A-172 glioblastoma cells and human HepG2 hepatocellular carcinoma cells, The mRNA level of VEGF increased in response to S-Nitroso-N-acetyl-D,L-penicillamine (SNAP) in both cell lines, and increased in mRNA level well coincided with VEGF protein production in A-172 cells. SNAP at 0.5 mM induced maximal stimulation of 4.4 and 3.7 kb VEGF mRNA expression after 6 h about 11 and 8 fold increase, respectively above control level. Similar VEGF mRNA accumulation was observed also with NOR3, another chemical NO generator. To evaluate the effect of SNAP on VEGF mRNA stability, half-lives of VEGF mRNA were measured in A-172 cells cultured with or without 0.5 mM SNAP and treated with actinomycin D (25 mu g/ml). Half-life for VEGF mRNA was found to be prolonged about 2.4 fold by SNAP, VEGF expression induced by SNAP was inhibited by guanylate cyclase inhibitors, methylene blue (10 mu M) and LY-83583 (1 mu M), and by the protein synthesis inhibitor, cycloheximide (25 mu g/ml). These results suggest that induction of VEGF gene expression by NO is mediated through guanylate cyclase activity and requires on-going protein synthesis.	NATL CANC CTR, RES INST E, INVEST TREATMENT DIV, KASHIWA, CHIBA, JAPAN; NATL CANC CTR HOSP E, DIV INTERNAL MED, KASHIWA, CHIBA, JAPAN	National Cancer Center - Japan; National Cancer Center - Japan								ADAIR TH, 1990, AM J PHYSIOL, V259, pR393, DOI 10.1152/ajpregu.1990.259.3.R393; BECK I, 1991, J BIOL CHEM, V266, P15563; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KONTUREK SJ, 1993, EUR J PHARMACOL, V239, P215, DOI 10.1016/0014-2999(93)90997-V; KRANTZ SB, 1991, BLOOD, V77, P419; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINCHENKO A, 1994, LAB INVEST, V71, P374; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; OHIGASHI T, 1993, J CLIN INVEST, V92, P1587, DOI 10.1172/JCI116740; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; POHL U, 1989, AM J PHYSIOL, V256, pH1595, DOI 10.1152/ajpheart.1989.256.6.H1595; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; ZICHE M, 1993, BIOCHEM BIOPH RES CO, V192, P1198, DOI 10.1006/bbrc.1993.1543	36	152	168	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	1997	15	4					437	442		10.1038/sj.onc.1201201	http://dx.doi.org/10.1038/sj.onc.1201201			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242380				2022-12-25	WOS:A1997XM23800008
J	Ziv, Y; BarShira, A; Pecker, I; Russell, P; Jorgensen, TJ; Tsarfati, I; Shiloh, Y				Ziv, Y; BarShira, A; Pecker, I; Russell, P; Jorgensen, TJ; Tsarfati, I; Shiloh, Y			Recombinant ATM protein complements the cellular A-T phenotype	ONCOGENE			English	Article						ataxia-telangiectasia; ATM; FLAG epitope; radiosensitivity; cell cycle checkpoints; mutations	ATAXIA-TELANGIECTASIA GENE; EPSTEIN-BARR VIRUS; PEPTIDE ELUTION; KINASE; PURIFICATION; EXPRESSION; CELLS; FIBROBLASTS; ACTIVATION; RADIATION	Ataxia-telangiectasia (A-T) is an autosomal recessive disorder characterized by neurodegeneration, immunodeficiency, cancer predisposition, genome instability and radiation sensitivity, The cellular phenotype of A-T points to defects in signal transduction pathways involved in activation of cell cycle checkpoints by free radical damage, and other pathways that mediate the transmission of specific mitogenic stimuli, The product of the responsible gene, ATM, belongs to a family of large proteins that contribute to maintaining genome stability and cell cycle progression in various organisms, A recombinant vector that stably expresses a full-length ATM protein is a valuable tool for its functional analysis, We constructed and cloned a recombinant, full-length open reading frame of ATM using a combination of vectors and hosts that overcame an inherent instability of this sequence, Recombinant ATM was stably expressed in insect cells using a baculovirus vector, albeit at a low level, and in human A-T cells using an episomal expression vector, An amino-terminal FLAG epitope added to the protein allowed highly specific detection of the recombinant molecule by immunoblotting, immunoprecipitation and immunostaining, and its isolation using immunoaffinity, Similar to endogenous ATM, the recombinant protein is located mainly in the nucleus, with low levels in the cytoplasm, Ectopic expression of ATM in A-T cells restored normal sensitivity to ionizing radiation and the radiomimetic drug neocarzinostatin, and a normal pattern of post-irradiation DNA synthesis, which represents an S-phase checkpoint. These observations indicate that the recombinant, epitope-tagged protein is functional, Introduction into this molecule of a known A-T missense mutation, Glu2904Gly, resulted in apparent instability of the protein and inability to complement the A-T phenotype, These findings indicate that the physiological defects characteristic of A-T cells result from the absence of the ATM protein, and that this deficiency can be corrected by ectopic expression of this protein.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 RAMAT AVIV,ISRAEL; GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,DEPT RADIAT MED,WASHINGTON,DC 20007	Tel Aviv University; Sackler Faculty of Medicine; Georgetown University	Ziv, Y (corresponding author), TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 RAMAT AVIV,ISRAEL.			Tsarfaty, Ilan/0000-0002-5230-7093	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31763] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALNABULSI I, 1994, CANCER RES, V54, P5614; ARTUSO M, 1995, ONCOGENE, V11, P1427; Baumer A, 1996, HUM GENET, V98, P246, DOI 10.1007/s004390050202; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; CHIANG CM, 1993, PEPTIDE RES, V6, P62; DENT P, 1995, MOL CELL BIOL, V15, P4125; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Gilad S, 1996, HUM MOL GENET, V5, P2033, DOI 10.1093/hmg/5.12.2033; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GILAD S, 1997, IN PRESS HUM MUTAT; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JORGENSEN TJ, 1995, RADIAT RES, V143, P219, DOI 10.2307/3579160; Jung M, 1997, CANCER RES, V57, P24; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KHANNA KK, 1997, IN PRESS J BIOL CHEM; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LIU F, 1995, MOL CELL BIOL, V15, P3479; Luckow Verne A., 1993, Current Opinion in Biotechnology, V4, P564, DOI 10.1016/0958-1669(93)90078-B; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; ROTMAN G, 1909, IN PRSS CANC SURVEYS; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SHILOH Y, 1982, CANCER RES, V42, P2247; Shiloh Y, 1996, J CLIN IMMUNOL, V16, P254, DOI 10.1007/BF01541389; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; TAYLOR AMR, 1994, INT J RADIAT BIOL, V65, P65, DOI 10.1080/09553009414550091; Telatar M, 1996, AM J HUM GENET, V59, P40; WATTERS D, 1997, IN PRESS ONCOGENE; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; Wright J, 1996, AM J HUM GENET, V59, P839; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZIV Y, 1989, CANCER RES, V49, P2495; ZIV Y, 1995, SOMAT CELL MOLEC GEN, V21, P99, DOI 10.1007/BF02255785	47	226	229	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					159	167		10.1038/sj.onc.1201319	http://dx.doi.org/10.1038/sj.onc.1201319			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244351				2022-12-25	WOS:A1997XK37200004
J	Han, JH; Hajjar, DP; Febbraio, M; Nicholson, AC				Han, JH; Hajjar, DP; Febbraio, M; Nicholson, AC			Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; VASCULAR ENDOTHELIUM; MEMBRANE-PROTEIN; HUMAN-MONOCYTES; BINDING-SITE; OXIDIZED LDL; FATTY-ACIDS; SR-BI	The uptake of oxidized low density lipoprotein (OxLDL) by macrophages is a key event implicated in the initiation and development of atherosclerotic lesions, Two macrophage surface receptors, CD36 (a class B scavenger receptor) and the macrophage scavenger receptor (a class A scavenger receptor), have been identified as the major receptors that bind and internalize OxLDL. Expression of CD36 in monocyte/macrophages in tissue culture is dependent both on the differentiation state as well as exposure to soluble mediators (cytokines and growth factors), The regulatory mechanisms of this receptor in vivo are undetermined as is the role of lipoproteins themselves in modulating CD36 expression. We studied the effect of lipoproteins, native LDL and modified LDL (acetylated LDL (AcLDL) and OxLDL) on the expression of CD36 in J774 cells, a murine macrophage cell line, Exposure to lipoproteins resulted in a marked induction of CD36 mRNA expression (4-8-fold), Time course studies showed that maximum induction was observed 2 h after treatment with AcLDL and at 4 h with LDL and OxLDL, Increased expression of CD36 mRNA persisted for 24 h with each treatment group, Induction of CD36: mRNA expression was paralleled by an increase in CD36 protein as determined by Western blot with the greatest induction by OxLDL (4-fold), In the presence of actinomycin D, treatment of macrophages with LDL, AcLDL, or OxLDL did not affect. CD36 mRNA stability, implying that CD36 mRNA was transcriptionally regulated by lipoproteins. To determine the mechanism(s) by which lipoproteins increased expression of CD36 we evaluated the effects of lipoprotein components on CD36 mRNA. expression, ApoB 100 increased CD36 mRNA expression significantly, whereas phospholipid/cholesterol liposomes had. less effect, Incubation of macrophages with bovine serum albumin or HDL reduced expression of CD36 mRNA in a dose-dependent manner. Finally, to evaluate the in vivo relevance of the induction of CD36 mRNA expression by lipoproteins, peritoneal macrophages were isolated from mice following intraperitoneal injection of lipoproteins. Macrophage expression of CD36 mRNA was significantly increased by LDL, AcLDL, or OxLDL in relation to mice infused with phosphate-buffered saline, with OxLDL causing the greatest induction (8-fold). This is the first demonstration that exposure to free and esterified lipids augments functional expression of the class B scavenger receptor, CD36, These data imply that lipoproteins can further contribute to foam cell development in atherosclerosis by up-regulating a major OxLDL receptor.	CORNELL UNIV, COLL MED, DEPT PATHOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DIV HEMATOL & ONCOL, DEPT MED, NEW YORK, NY 10021 USA	Cornell University; Cornell University					NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000085] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007423] Funding Source: NIH RePORTER; NCRR NIH HHS [K01 RR00085] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07423-17] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANDALIBI A, 1993, BIOCHEM SOC T, V21, P651, DOI 10.1042/bst0210651; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; Armesilla AL, 1996, J BIOL CHEM, V271, P7781, DOI 10.1074/jbc.271.13.7781; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BOCHKOV VN, 1993, ARTERIOSCLER THROMB, V13, P1261, DOI 10.1161/01.ATV.13.9.1261; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CALVO D, 1993, J BIOL CHEM, V268, P18929; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; EDELMAN P, 1986, BLOOD, V67, P56; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FEI HH, 1993, ARTERIOSCLER THROMB, V13, P1711, DOI 10.1161/01.ATV.13.11.1711; FOGELMAN AM, 1988, J CELL SCI, P135; GENG YJ, 1994, ARTERIOSCLER THROMB, V14, P798, DOI 10.1161/01.ATV.14.5.798; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOWN AM, 1986, AM J PATHOL, V125, P191; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; HIRAI A, 1994, J CLIN INVEST, V94, P2215, DOI 10.1172/JCI117583; HOFFER MJV, 1993, BIOCHEM BIOPH RES CO, V191, P880, DOI 10.1006/bbrc.1993.1299; HUH HY, 1995, J BIOL CHEM, V270, P6267, DOI 10.1074/jbc.270.11.6267; KASHIWAGI H, 1994, BLOOD, V83, P3545; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LI YS, 1993, MOL CELL BIOCHEM, V126, P61, DOI 10.1007/BF01772208; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSIS AJ, 1993, BIOCHEM PHARMACOL, V46, P2119, DOI 10.1016/0006-2952(93)90599-R; MAZZONE T, 1989, J LIPID RES, V30, P1055; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NICHOLSON AC, 1995, LEUKOCYTE TYPING, V5, P1278; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; PARHAMI F, 1993, J CLIN INVEST, V92, P471, DOI 10.1172/JCI116590; PARTHASARATHY S, 1986, ARTERIOSCLEROSIS, V6, P505, DOI 10.1161/01.ATV.6.5.505; PHILLIPS MC, 1980, ATHEROSCLEROSIS, V36, P409, DOI 10.1016/0021-9150(80)90220-8; PIETSCH A, 1995, CELL BIOCHEM FUNCT, V13, P211, DOI 10.1002/cbf.290130312; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Ryeom SW, 1996, J CELL SCI, V109, P387; SAKAI M, 1994, J BIOL CHEM, V269, P31430; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBERG D, 1987, CIRCULATION, V76, P508, DOI 10.1161/01.CIR.76.3.508; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; TERKELTAUB R, 1994, ARTERIOSCLER THROMB, V14, P47, DOI 10.1161/01.ATV.14.1.47; VEGA MA, 1991, J BIOL CHEM, V266, P16818; VIA DP, 1985, J BIOL CHEM, V260, P7379; Villanova JG, 1996, BBA-LIPID LIPID MET, V1300, P135, DOI 10.1016/0005-2760(96)00008-2; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Yesner LM, 1996, ARTERIOSCL THROM VAS, V16, P1019, DOI 10.1161/01.ATV.16.8.1019	56	215	225	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21654	21659		10.1074/jbc.272.34.21654	http://dx.doi.org/10.1074/jbc.272.34.21654			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261189	hybrid			2022-12-25	WOS:A1997XR78900099
J	Sugiura, N; Suga, T; Ozeki, Y; Mamiya, G; Takishima, K				Sugiura, N; Suga, T; Ozeki, Y; Mamiya, G; Takishima, K			The mouse extracellular signal-regulated kinase 2 gene - Gene structure and characterization of the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; REGIONAL DISTRIBUTION; BINDING-PROTEIN; MAP KINASE; TRANSCRIPTION; FAMILY; IDENTIFICATION; SPECIFICITY; SEQUENCE	ERK2 (extracellular-signal regulated kinase 2, also known as p42 mitogen-activated protein kinase) is an integral member of the mitogen-activated protein kinase cascade that is crucial for many cellular events such as proliferation and differentiation. Here, we determined the genomic organization of the Erk2 gene and characterized its promoter, The Erk2 gene spans over 60 kilobases, and the coding region is split into eight exons. In the coding region, exon-intron organization was exactly conserved between the two mouse genes for ERK2 and ERK1 except one junction shifted by one nucleotide. Primer extension and S1 nuclease analyses identified two major transcription start sites located at -219 and -223 relative to the translation start site, The 5'-flanking sequence lacked TATA box but contained a CCAAT box located approximately 60 base pairs upstream of transcription start sites, Sequencing of the 5'-flanking region also revealed potential cis acting elements for multiple transcriptional regulatory factors including Spl, zif268, Ets, CREB, and PuF sites, The promoter activity of the 5'-flanking region was examined using chloramphenicol acetyltransferase as a reporter gene, Transient transfection experiments using Chinese hamster ovary cells defined a maximal promoter activity in a 371-base pair region immediately upstream of the translation start site. Furthermore, we demonstrated, using mouse P19 embryonal carcinoma cells, that this 371-base pair sequence is likely to be sufficient to confer the transcriptional activation of the ERK2 promoter during the retinoic acid-induced differentiation of P19 cells.	NATL DEF MED COLL, DEPT BIOCHEM 1, TOKOROZAWA, SAITAMA 359, JAPAN	National Defense Medical College - Japan								AHN NG, 1991, J BIOL CHEM, V266, P4220; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BARABAN JM, 1993, J NEUROCHEM, V60, P330, DOI 10.1111/j.1471-4159.1993.tb05855.x; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAWLEY KC, 1993, J BIOL CHEM, V268, P1194; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIORE RS, 1993, J NEUROCHEM, V61, P1626, DOI 10.1111/j.1471-4159.1993.tb09796.x; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, NATURE, V245, P371; ORTIZ J, 1995, J NEUROSCI, V15, P1285; PAGES G, 1995, J BIOL CHEM, V270, P26986, DOI 10.1074/jbc.270.45.26986; PARKOFF J, 1994, MOL CELL BIOL, V14, P463; PENN RB, 1994, J BIOL CHEM, V269, P14924; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schramek H, 1996, AM J PHYSIOL-CELL PH, V270, pC40, DOI 10.1152/ajpcell.1996.270.1.C40; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; STERNBERG N, 1994, GENET ANAL-BIOMOL E, V11, P171, DOI 10.1016/1050-3862(94)90038-8; SUKHATME VP, 1992, KIDNEY INT, V41, P550, DOI 10.1038/ki.1992.79; THOMAS KL, 1993, NEUROSCIENCE, V56, P741, DOI 10.1016/0306-4522(93)90371-L; TSUKIYAMA T, 1992, NUCLEIC ACIDS RES, V20, P1477, DOI 10.1093/nar/20.7.1477; VOSS H, 1991, J BIOL CHEM, V266, P13706; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WINSTON BW, 1995, J IMMUNOL, V155, P1525; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	53	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21575	21581		10.1074/jbc.272.34.21575	http://dx.doi.org/10.1074/jbc.272.34.21575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261178	hybrid			2022-12-25	WOS:A1997XR78900088
J	Bose, S; Seetharam, B				Bose, S; Seetharam, B			Effect of disulfide bonds of transcobalamin II receptor on its activity and basolateral targeting in human intestinal epithelial Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; GOLGI-APPARATUS; PLASMA-MEMBRANE; KIDNEY-CELLS; PROTEIN; DITHIOTHREITOL; EXPRESSION; COBALAMIN; RAT	Transcobalamin II-receptor (TC II-R) contains 10 half-cysteines, of which 8 are involved in intramolecular disulfide bonding. Reduction followed by alkylation with N-ethylmaleimide (NEM) of the 62-kDa TC II-R monomer in vitro or treatment of human intestinal epithelial Caco-2 cells with low concentrations (10(-6) nr) of NEM resulted in TC II-R exhibiting a loss of ligand binding and an increase in its apparent molecular mass by 10 kDa to 72 kDa. Domain-specific biotinylation studies using NEM-treated filter-grown cells revealed loss of TC II-R but not cation-independent mannose 6-phosphate receptor protein at the basolateral cell surface. Pulse chase labeling of NEM-treated cells with [S-35]methionine revealed that the modified 72-kDa TC II-R, like the native 62-kDa TC II-R in untreated cells, turned over rapidly with a t(1/2) of 7.5 h and was sensitive to treatment with peptide N-glycosidase F, sialidase alone, or sialidase and O-glycanase but not to treatment with endoglycosidase H. Labeled 72-kDa TC II-R, which was retained intracellularly following treatment of Caco-2 cells with methyl methanethiosulfonate, returned to the basolateral cell surface following withdrawal of cells from methyl methanethiosulfonate treatment and exposure to dithiothreitol. Based on these results, we suggest that formation and maintenance of intramolecular disulfide bonds of TC II-R is important for its acquisition of ligand binding and post-trans-Golgi trafficking to basolateral surface membranes but not for its turnover and exit from the endoplasmic reticulum or trafficking through the Golgi.	MED COLL WISCONSIN, MACC, FUND CTR, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT MED, MILWAUKEE, WI 53226 USA; VET ADM MED CTR, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)				, Santanu/0000-0002-5501-3293	PHS HHS [50052] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bose S, 1996, J BIOL CHEM, V271, P4195; BOSE S, 1995, BIOCHEM J, V310, P923, DOI 10.1042/bj3100923; Bose S, 1997, J BIOL CHEM, V272, P3538, DOI 10.1074/jbc.272.6.3538; BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; Bose S, 1996, J BIOL CHEM, V271, P11718, DOI 10.1074/jbc.271.20.11718; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; Dahms NM, 1996, BBA-BIOMEMBRANES, V1279, P84, DOI 10.1016/0005-2736(95)00234-0; FINKLER AE, 1967, ARCH BIOCHEM BIOPHYS, V120, P79, DOI 10.1016/0003-9861(67)90600-5; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOIVU J, 1987, J BIOL CHEM, V262, P6159; KOLAND JG, 1982, J BIOL CHEM, V257, P6023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDEMANS J, 1986, SCAND J CLIN LAB INV, V46, P223, DOI 10.3109/00365518609083663; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LOSCH A, 1995, J BIOL CHEM, V270, P11543, DOI 10.1074/jbc.270.19.11543; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MILLS A, 1988, J BIOL CHEM, V263, P13; MOXHAM CP, 1988, MOL PHARMACOL, V33, P486; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PETERS T, 1982, J BIOL CHEM, V257, P8847; RAMANUJAM KS, 1991, AM J PHYSIOL, V260, pG416, DOI 10.1152/ajpgi.1991.260.3.G416; RAMANUJAM KS, 1994, ARCH BIOCHEM BIOPHYS, V315, P8, DOI 10.1006/abbi.1994.1464; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; SELIGMAN PA, 1978, J BIOL CHEM, V253, P1766; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P766, DOI 10.1021/bi00675a019; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; VOORBERG J, 1991, CELL, V57, P195; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; WIKSTROM L, 1992, J BIOL CHEM, V267, P5	45	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20920	20928		10.1074/jbc.272.33.20920	http://dx.doi.org/10.1074/jbc.272.33.20920			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252420	hybrid			2022-12-25	WOS:A1997XR22100090
J	Green, WN; Wanamaker, CP				Green, WN; Wanamaker, CP			The role of the cystine loop in acetylcholine receptor assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIN IMMUNOGENIC REGION; DISULFIDE BOND FORMATION; ALPHA-SUBUNIT; BINDING-SITE; FUNCTIONAL EXPRESSION; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; ION-CHANNEL; RESIDUES; PROTEIN	Nicotinic acetylcholine receptors (AChRs) are composed of alpha,beta,gamma, and delta subunits, assembled into alpha(2) beta gamma delta pentamers, A highly conserved feature of ionotropic neurotransmitter receptors, such as AChRs, is a 15-amino acid cystine ''loop.'' We find that an intact cystine loop is necessary for complete AChR assembly, By preventing formation of the loop with 5 mM dithiothreitol, AChR subunits assemble into alpha beta gamma trimers, but the subsequent steps in assembly are blocked, When alpha subunit loop cysteines are mutated to serines, assembly is blocked at the same step as with dithiothreitol, In contrast, when beta subunit loop cysteines are mutated to serines, assembly is blocked at a later step, i,e, after assembly of alpha beta gamma delta tetramers and before the addition of the second alpha subunit, After formation of the cystine loop, the alpha subunit undergoes a conformational change, which buries the loop, This conformational change is concurrent with the step in assembly blocked by removal of the disulfide bond of the cystine loop, i.e. after assembly of alpha beta gamma trimers and before the addition of the delta subunit, The data indicate that the alpha subunit conformational change involving the cystine loop is key to a series of folding events that allow the addition of unassembled subunits.			Green, WN (corresponding author), UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS033826] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS33826-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARCHAN D, 1992, P NATL ACAD SCI USA, V89, P7717, DOI 10.1073/pnas.89.16.7717; BARKAS T, 1988, J BIOL CHEM, V263, P5916; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CHATURVEDI V, 1992, BIOCHEMISTRY-US, V31, P1370, DOI 10.1021/bi00120a012; CLAUDIO T, 1977, ARCH BIOCHEM BIOPHYS, V181, P484, DOI 10.1016/0003-9861(77)90254-5; CLAUDIO T, 1987, SCIENCE, V238, P1688, DOI 10.1126/science.3686008; CRIADO M, 1986, BIOCHEMISTRY-US, V25, P2839, DOI 10.1021/bi00358a015; DENERIS ES, 1989, J BIOL CHEM, V264, P6268; Fu DX, 1996, J BIOL CHEM, V271, P31479, DOI 10.1074/jbc.271.49.31479; Gelman MS, 1996, J BIOL CHEM, V271, P10709, DOI 10.1074/jbc.271.18.10709; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KELLARIS KV, 1989, BIOCHEMISTRY-US, V28, P3469, DOI 10.1021/bi00434a048; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; PAULSON HL, 1990, J CELL BIOL, V110, P1705, DOI 10.1083/jcb.110.5.1705; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; SEGUELA P, 1993, J NEUROSCI, V13, P596; SUMIKAWA K, 1992, J BIOL CHEM, V267, P6286; TAKEYASU K, 1987, J BIOL CHEM, V262, P10733; TREININ M, 1995, NEURON, V14, P871, DOI 10.1016/0896-6273(95)90231-7; TZARTOS SJ, 1980, P NATL ACAD SCI-BIOL, V77, P755, DOI 10.1073/pnas.77.2.755; TZARTOS SJ, 1988, P NATL ACAD SCI USA, V85, P2899, DOI 10.1073/pnas.85.9.2899	40	68	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20945	20953		10.1074/jbc.272.33.20945	http://dx.doi.org/10.1074/jbc.272.33.20945			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252423	hybrid			2022-12-25	WOS:A1997XR22100093
J	Kennedy, HJ; Viollet, B; Rafiq, I; Kahn, A; Rutter, GA				Kennedy, HJ; Viollet, B; Rafiq, I; Kahn, A; Rutter, GA			Upstream stimulatory factor-2 (USF2) activity is required for glucose stimulation of L-pyruvate kinase promoter activity in single living islet beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; METABOLIC-REGULATION; TRANSCRIPTION; PROTEINS; INSULIN; DNA; LUCIFERASE; BINDING; TISSUE	Elevated glucose concentrations stimulate L-pyruvate kinase (L-PK) gene transcription in liver and islet beta-cells, A glucose response element termed the L4 box (two noncanonical E-boxes located -165 and -154 base pairs upstream of the transcriptional start point) has previously been defined within the proximal promoter region of the gene, However, the identity of the trans acting factor(s) which binds to this site remains unclear, We have used photon counting digital imaging of firefly luciferase activity to monitor promoter activity continuously in single living islet beta and derived INS-1 cells, and to analyze the molecular basis of the regulation by glucose, L-PK promoter activity, normalized to cytomegalovirus promoter activity using the distinct Renilla reniformis luciferase, was greater than or equal to 6-fold higher in cells cultured at 16 mM glucose or above compared with cells cultured at 3 mM glucose, Microinjection of antibodies against the ubiquitous transcription factor USF2 inhibited L-PK promoter activity in beta- and INS-1 cells incubated at 30 mm glucose by 71-87%. Anti-USF2 antibodies had a much smaller effect on promoter activity in INS-1 cells cultured at 3 mM glucose, and on the activity of a modified promoter construct lacking an L4 box, These data support the view that glucose enhances L-PK gene transcription in beta-cells by modifying the transactivational capacity of USF2 bound to the upstream L4 box.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV PARIS 05,U129 INSERM,INST COCHIN GENET MOL,F-75014 PARIS,FRANCE	University of Bristol; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Viollet, Benoit/N-2397-2019; Viollet, Benoit/O-6927-2017	Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; Rutter, Guy/0000-0001-6360-0343	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; COGNET M, 1991, J BIOL CHEM, V266, P7368; CUIF MH, 1993, J BIOL CHEM, V268, P13769; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; LAKE SP, 1987, TRANSPLANTATION, V43, P805, DOI 10.1097/00007890-198743060-00006; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Luo X, 1996, MOL CELL BIOL, V16, P1367; MARIE S, 1993, J BIOL CHEM, V268, P23881; MATTHEWS JC, 1977, BIOCHEMISTRY-US, V16, P85, DOI 10.1021/bi00620a014; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; RUTTER GA, 1997, IN PRESS IMAGING LIV; Sambrook J., 2002, MOL CLONING LAB MANU; SEKINE N, 1994, J BIOL CHEM, V269, P4895; Sherf BA, 1994, PROMEGA NOTES, V49, P14; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405	30	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20636	20640		10.1074/jbc.272.33.20636	http://dx.doi.org/10.1074/jbc.272.33.20636			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252379	hybrid			2022-12-25	WOS:A1997XR22100049
J	Leal, SM; Liu, QJ; Huang, SS; Huang, JS				Leal, SM; Liu, QJ; Huang, SS; Huang, JS			The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; TGF-BETA; IGF-I; FIBROBLASTS; INHIBITION; RESPONSIVENESS; EXPRESSION; MECHANISM	Insulin-like growth factor-binding protein 3 (IGFBP-3) has been shown to inhibit cell growth by IGF-dependent and -independent mechanisms, The putative cell-surface IGFBP-3 receptor that mediates the IGF-independent growth inhibition has not been identified, Here we show that recombinant human IGFBP-3 inhibits I-125-transforming growth factor (TGF)-beta(1) binding to the type V TGF-beta receptor (M-r 400,000) in mink lung epithelial cells, We also demonstrate that the similar to 400-kDa I-125-IGFBP-3 affinity-labeled putative IGFBP-3 receptor is immunoprecipitated by specific antiserum to the type V TGF-beta receptor, The I-125-IGFBP-3 affinity labeling of the putative receptor and IGFBP-3-induced growth inhibition as measured by DNA synthesis in these cells is blocked by a TGF-beta(1) peptide antagonist, The I-125-IGFBP-3 affinity-labeled putative receptor can only be detected in cells expressing the type V TGF-beta receptor, but not in cells lacking the type V TGF-beta receptor, These results indicate that the type V TGF-beta receptor is the putative IGFBP-3 receptor and that IGFBP-3 is a functional ligand for the type V TGF-beta receptor.	ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,ST LOUIS,MO 63104	Saint Louis University					NCI NIH HHS [CA 38808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; CONOVER CA, 1991, J CLIN INVEST, V88, P1354, DOI 10.1172/JCI115441; DELBE J, 1991, BIOCHEM BIOPH RES CO, V179, P495, DOI 10.1016/0006-291X(91)91398-V; Gucev ZS, 1996, CANCER RES, V56, P1545; HODGKINSON S, 1995, J ENDOCRINOL, V145, pR2; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIU L, 1992, J CELL PHYSIOL, V153, P15, DOI 10.1002/jcp.1041530104; LIU Q, 1997, IN PRESS J BIOL CHEM, V272; LIU QJ, 1994, J BIOL CHEM, V269, P9221; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; OGRADY P, 1992, J BIOL CHEM, V267, P21033; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; ROBERTS AB, 1991, PEPTIDE GROWTH FACTO, V1, P419; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	30	214	224	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20572	20576		10.1074/jbc.272.33.20572	http://dx.doi.org/10.1074/jbc.272.33.20572			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252371	hybrid			2022-12-25	WOS:A1997XR22100041
J	Li, CJ; Englund, PT				Li, CJ; Englund, PT			A mitochondrial DNA primase from the trypanosomatid Crithidia fasciculata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETOPLAST DNA; REPLICATION; MINICIRCLES; TOPOISOMERASE; LOCALIZATION; PURIFICATION; POLYMERASE; EVOLUTION; SITES	We have purified to near homogeneity a DNA primase from a mitochondrial fraction of the trypanosomatid Crithidia fasciculata. The enzyme is a single polypeptide chain of 28 kDa. Using a poly(dT) template and ATP as a substrate, the enzyme makes oligonucleotides of which the vast majority are about 10 nucleotides in size or smaller. With a single-stranded M13 DNA template and the four rNTPs as substrates, the enzyme makes heterogeneous oligonucleotides in the same size range. These oligonucleotides efficiently prime the synthesis of DNA by the Klenow DNA polymerase. Immunolocalization with antibodies against the purified enzyme confirms that the primase is mitochondrial. Furthermore, the enzyme localizes to specific regions of the cell's single mitochondrion, above and below the condensed kinetoplast DNA. The primase does not co-localize with the mitochondrial topoisomerase II and DNA polymerase beta, both of which are associated with two protein complexes positioned on opposite sides of the kinetoplast disc. These localization studies have significant implications for the mechanism of kinetoplast DNA replication.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University			Li, Cong-jun/J-8572-2014	Li, Cong-jun/0000-0003-1389-9820	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027608, R01GM027608] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27608] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		EFFRON PN, 1993, MOL BIOCHEM PARASIT, V59, P191, DOI 10.1016/0166-6851(93)90217-L; ENGMAN DM, 1989, MOL CELL BIOL, V9, P5163, DOI 10.1128/MCB.9.11.5163; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; HAJDUK SL, 1993, FASEB J, V7, P54, DOI 10.1096/fasebj.7.1.8422975; Harlow E, 1988, ANTIBODIES LAB MANUA, P418; KITCHIN PA, 1985, J BIOL CHEM, V260, P3844; LI C, 1995, NUCLEIC ACIDS RES, V23, P4426, DOI 10.1093/nar/23.21.4426; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; MELENDY T, 1987, MOL BIOCHEM PARASIT, V24, P215, DOI 10.1016/0166-6851(87)90108-3; Mendelman LV, 1995, METHOD ENZYMOL, V262, P405; PEREZMORGA DL, 1993, CELL, V74, P703, DOI 10.1016/0092-8674(93)90517-T; PODUST VN, 1991, FEBS LETT, V280, P281, DOI 10.1016/0014-5793(91)80312-Q; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; SHLOMAI J, 1994, PARASITOL TODAY, V10, P341, DOI 10.1016/0169-4758(94)90244-5; SIMPSON L, 1994, SCIENCE, V264, P1870, DOI 10.1126/science.8009214; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; STUART K, 1992, INT REV CYTOL, V141, P65, DOI 10.1016/S0074-7696(08)62063-X; TORRI AF, 1992, J BIOL CHEM, V267, P4786; TORRI AF, 1994, J BIOL CHEM, V269, P8165; Xu CW, 1996, MOL CELL BIOL, V16, P564	21	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20787	20792		10.1074/jbc.272.33.20787	http://dx.doi.org/10.1074/jbc.272.33.20787			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252402	hybrid			2022-12-25	WOS:A1997XR22100072
J	Tobin, AB; Totty, NF; Sterlin, AE; Nahorski, SR				Tobin, AB; Totty, NF; Sterlin, AE; Nahorski, SR			Stimulus-dependent phosphorylation of G-protein-coupled receptors by casein kinase 1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PURIFICATION; EXPRESSION; GRK5; IMMUNOPRECIPITATION; DESENSITIZATION; ACTIVATION; SUBUNITS; CLONING; MEMBER	We have previously demonstrated that the phospholipase C-coupled m3-muscarinic receptor is phosphorylated in an agonist sensitive manner by a protein kinase of similar to 40 kDa purified from porcine cerebellum (Tobin, A. B., Keys, B,, and Nahorski, S. R, (1996) J, Biol Chem. 271, 3907-3916), This kinase, called muscarinic receptor kinase (MRK), is distinct from second messenger-regulated protein kinases and from beta-adrenergic receptor kinase and other members of the G-protein-coupled re ceptor kinase family, In the present study we propose that MRK is casein kinase 1 alpha (CK1 alpha) based on the following evidence: 1) the amino acid sequence from two proteolytic peptide fragments derived from purified MRK corresponded exactly to sequences within CK1 alpha. 2) Casein kinase activity co-eluted with MRK activity from the final two chromatography steps in the purification of porcine brain MRK. 3) Recombinant CK1 alpha expressed in Sf9 cells is able to phosphorylate both casein and the bacterial fusion protein, Ex-m3, that contains a portion of the third intracellular loop of the m3-muscarinic receptor downstream of glutathione S-transferase, 4) Partially purified CK1 alpha increased the level of muscarinic receptor phosphorylation in an agonist-sensitive manner when reconstituted with membranes from Chinese hamster ovary-m3 cells expressing the human recombinant m3-muscarinic receptor, 5) Partially-purified CK1 alpha phosphorylated rhodopsin, contained in urea treated bovine rod outer segment membranes, and the extent of phosphorylation was increased in the presence of light, These data demonstrate that the kinase previously called MRK is CK1 alpha, and that CK1 alpha offers an alternative protein kinase pathway from that of the G-protein coupled receptor kinase family for the stimulus-dependent phosphorylation of the m3-muscarinic receptor, rhodopsin, and possibly other G-protein-coupled receptors.	UCL, LUDWIG INST CANC RES, SCH MED, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School	Tobin, AB (corresponding author), UNIV LEICESTER, DEPT CELL PHYSIOL & PHARMACOL, UNIV RD, LEICESTER LE1 9HN, LEICS, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Batty IH, 1996, BIOCHEM J, V317, P347, DOI 10.1042/bj3170347; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; Diviani D, 1996, J BIOL CHEM, V271, P5049; FISHER SK, 1994, NEUROCHEM RES, V19, P549, DOI 10.1007/BF00971329; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Haga K, 1997, BIOCHEMISTRY-US, V36, P1315, DOI 10.1021/bi961613k; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; JENKINSON S, 1994, MOL PHARMACOL, V46, P1138; KONG GH, 1994, J BIOL CHEM, V269, P13084; KOREH K, 1986, J BIOL CHEM, V261, P88; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; MILNE DM, 1992, ONCOGENE, V7, P1361; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PEI G, 1995, MOL PHARMACOL, V48, P173; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; TOBIN AB, 1995, BRIT J PHARMACOL, V116, P1723, DOI 10.1111/j.1476-5381.1995.tb16654.x; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; TOBIN AB, 1993, FEBS LETT, V335, P353, DOI 10.1016/0014-5793(93)80418-T; Tobin AB, 1996, J BIOL CHEM, V271, P3907; TOBIN AB, 1996, PHOSPHOLIPASE C PATH, P65; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WAUGH MG, 1997, IN PRESS MOL PHARM; Willars GB, 1996, BIOCHEM J, V316, P905, DOI 10.1042/bj3160905; WILSON DB, 1985, J BIOL CHEM, V260, P1046; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717	41	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20844	20849		10.1074/jbc.272.33.20844	http://dx.doi.org/10.1074/jbc.272.33.20844			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252410	hybrid			2022-12-25	WOS:A1997XR22100080
J	Tu, YQ; Bates, S; Pfeifer, GP				Tu, YQ; Bates, S; Pfeifer, GP			Sequence-specific and domain-specific DNA repair in xeroderma pigmentosum and Cockayne syndrome cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; C-JUN PROMOTER; TRANSCRIPTION-COUPLED REPAIR; HUMAN-SKIN-CANCER; PYRIMIDINE DIMERS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; UV PHOTOPRODUCTS; ACTIVE GENES; DHFR GENE	Xeroderma pigmentosum (XP) and Cockayne syndrome (CS) cells have specific DNA repair defects, We had previously analyzed repair rates of cyclobutane pyrimidine dimers at nucleotide resolution along the human JUN gene in normal fibroblasts and found very efficient repair of sequences near the transcription initiation site but slow repair along the promoter, To investigate sequence-specific repair rate patterns in XP and CS cells, we conducted a similar analysis in XPA XPB, XPC, XPD, and CSB fibroblasts, XPA cells were almost completely repair-deficient at all sequences analyzed, XPC cells repaired only the transcribed DNA strand beginning at position -20 relative to the transcription start site, Both XBP and XPD cells were deficient in repair of nontranscribed DNA and also very inefficiently repaired the transcribed strand including sequences near the transcription start site. CSB cells exhibited rapid repair near the transcription initiation site but were deficient in repair of sequences encountered by RNA polymerase during elongation (beginning at position +20). Since transcription of the JUN gene was UV-induced in all fibroblast strains, including CSB, the defective repair of the transcribed strand in CSB cannot be explained by a lack of transcription; rather, it appears to be a true DNA repair defect.	CITY HOPE NATL MED CTR,BECKMAN RES INST,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NIEHS NIH HHS [ES06070] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006070, R37ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bohr VA, 1995, CARCINOGENESIS, V16, P2885, DOI 10.1093/carcin/16.12.2885; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; Dammann R, 1997, MOL CELL BIOL, V17, P219, DOI 10.1128/MCB.17.1.219; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DRAPKIN R, 1994, NATURE, V368, P709; Drouin Regen, 1996, P37; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Friedberg EC, 1996, BIOESSAYS, V18, P731, DOI 10.1002/bies.950180908; FRIEDBERG EC, 1995, DNA REPAIR; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERRLICH P, 1994, CURR OPIN CELL BIOL, V6, P425, DOI 10.1016/0955-0674(94)90036-1; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KANTOR GJ, 1981, CANCER RES, V41, P819; KUNALA S, 1992, P NATL ACAD SCI USA, V89, P11031, DOI 10.1073/pnas.89.22.11031; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAEGELI H, 1995, FASEB J, V9, P1043, DOI 10.1096/fasebj.9.11.7649403; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; ROZEK D, 1995, J CELL BIOCHEM, V57, P479, DOI 10.1002/jcb.240570313; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; SUQUET C, 1995, J BIOL CHEM, V270, P16507, DOI 10.1074/jbc.270.28.16507; SWEDER KS, 1994, J BIOL CHEM, V269, P1852; Sweder KS, 1996, NUCLEIC ACIDS RES, V24, P1540, DOI 10.1093/nar/24.8.1540; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; Tijsterman M, 1996, NUCLEIC ACIDS RES, V24, P3499, DOI 10.1093/nar/24.18.3499; TORMANEN VT, 1992, ONCOGENE, V7, P1729; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Tornaletti Silvia, 1996, P199; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VONHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890; WANG ZG, 1991, J BIOL CHEM, V266, P22472; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	65	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20747	20755		10.1074/jbc.272.33.20747	http://dx.doi.org/10.1074/jbc.272.33.20747			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252397	hybrid			2022-12-25	WOS:A1997XR22100067
J	Bayle, D; Weeks, D; Sachs, G				Bayle, D; Weeks, D; Sachs, G			Identification of membrane insertion sequences of the rabbit gastric cholecystokinin-A receptor by in vitro translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; CHARGED RESIDUES; SPANNING PROTEINS; TOPOLOGY; ORIENTATION; TOPOGRAPHY; RHODOPSIN; HELICES; RULE	To determine which amino acid sequences account for transmembrane folding of G7 receptors, the membrane domain of the rabbit cholecystokinin-A (CCK-A) G-protein-coupled receptor has been investigated by in vitro transcription/translation of two types of fusion vectors containing sequences that include putative transmembrane segments. First, the seven putative transmembrane domains of the CCK-A receptor were inserted individually into pGEM vectors beginning with the cDNA encoding the first 101 (HK-M0) or 139 (HK-M1) amino acids of the alpha subunit of the gastric H,K-ATPase. These were separated by the cDNA for the inserted transmembrane domains from the cDNA encoding the last 177 amino acids of the beta subunit of the H,K-ATPase containing five N-linked glycosylation consensus sequences (Bamberg, K., and Sachs, G. (1994) J. Biol. Chem. 269, 16909-16919). Transcription/translation of these fusion vectors in rabbit reticulocyte lysate +/- dog pancreatic microsomes followed by SDS-polyacrylamide gel electrophoresis defined the presence of signal anchor sequences in HK-M0 by glycosylation and stop transfer sequences in HK-M1 by inhibition of glycosylation. Six out of the seven putative transmembrane domains had membrane insertion signals, but no membrane insertion activity was found for the H3 segment in these vectors. To test the effect of specific upstream and downstream sequences on membrane insertion, vectors were also made starting with the cDNA encoding the N terminus of the CCK-A receptor separated from the last 177 amino acids of the H,K-ATPase beta subunit by cDNA encoding CCK-A receptor sequences of different lengths. In addition to transcription/translation, endoglycosidase H treatment was used to verify glycosylation when multiple bands were found in the presence of microsomes. The four positive charges in the loop between H1 and H2 were required for the correct orientation of the first transmembrane domain. The H3 segment acted as a stop transfer sequence only when the whole N terminus and H3 were followed by the positive charges in the cytoplasmic loop between H3 and H4. The activity of H6 as a signal anchor sequence depended on preceding positive charges. These translation data using two types of fusion vectors establish a seven-transmembrane folding model using only in vitro translation for the CCK-A receptor beginning with two signal anchor sequences and then alternating stop transfer and signal anchor insertions. Positive charges between H1 and H2, H3 and H4, and H5 and H6 function as cytoplasmic anchors in the membrane folding of this receptor.	WADSWORTH VA HOSP,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles					NIDDK NIH HHS [DK41301, DK40615, DK17294] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017294, R01DK040615, R01DK017294, P30DK041301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P6780; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BIRNBAUMER M, 1996, MOL BIOL MEMBRANE TR, P321; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CRCNET P, 1993, PROTEIN ENG, V6, P59; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Izard JW, 1996, J BIOL CHEM, V271, P21579, DOI 10.1074/jbc.271.35.21579; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REUBEN M, 1994, BBA-GENE STRUCT EXPR, V1219, P321, DOI 10.1016/0167-4781(94)90055-8; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; SEAL AJ, 1994, NEUROPHARMACOLOGY, V33, P1065, DOI 10.1016/0028-3908(94)90144-9; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WANG HY, 1989, J BIOL CHEM, V264, P14424; WEISS ER, 1987, J BIOL CHEM, V262, P4319; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563	36	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19697	19707		10.1074/jbc.272.32.19697	http://dx.doi.org/10.1074/jbc.272.32.19697			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242625	hybrid			2022-12-25	WOS:A1997XQ05900012
J	Brodeur, SR; Cheng, GH; Baltimore, D; ThorleyLawson, DA				Brodeur, SR; Cheng, GH; Baltimore, D; ThorleyLawson, DA			Localization of the major NF-kappa B-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; NECROSIS-FACTOR RECEPTOR; CYTOPLASMIC DOMAIN; CELL ACTIVATION; EXPRESSION; TRANSFORMATION; GENE; CD40; INDUCTION	The TRAF3 molecule interacts with the cytoplasmic carboxyl terminus (COOH terminus) of the Epstein Barr virus-encoded oncogene LMP-1, NF-kappa B activation is a downstream signaling event of tumor necrosis factor receptor-associated factor (TRAF) molecules in other signaling systems (CD40 for example) and is an event caused by LMP-1 expression. One region capable of TRAF3 interaction in LMP-1 is the membrane-proximal 45 amino acids (188-242) of the COOH terminus, We show that this region contains the only site for binding of TRAF3 in the 200-amino acid COOH terminus of LMP-I, The site also binds TRAF2 and TRAF5, brit not TRAF6. TRAF3 binds to critical residues localized between amino acids 196 and 212 (HHDDSLPHPQQAT-DDSG), including the PXQX(T/S) motif, that share limited identity to the CD40 receptor TRAF binding site (TAAPVQETL), Mutation of critical residues in the TRAF3 binding site of LMP-1 that prevents binding of TRAF2, TRAF3, and TRAF5 does not affect NF-kappa B-activating potential, Deletion mapping localized the major NF-kappa B activating region of LMP-1 to critical residues in the distal 4 amino acids of the COOH terminus (385-386). Therefore, TRAF3 binding and NF-KB activation occur through two separate motifs at opposite ends of the LMP-1 COOH-terminal sequence.	TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Tufts University; Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA031893, R37CA031893, R01CA065883] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31893, CA 65883] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Baker SJ, 1996, ONCOGENE, V12, P1; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CORMACK B, 1991, CURRENT PROTOCOLS S, V15; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HU HM, 1994, J BIOL CHEM, V269, P30069; HUEN DS, 1995, ONCOGENE, V10, P549; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1996, VIROLOGY, V2, P2343; KLAMAN LD, 1995, J VIROL, V69, P871, DOI 10.1128/JVI.69.2.871-881.1995; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MILLER WE, 1995, J VIROL, V69, P4890; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; Moorthy R, 1992, Curr Top Microbiol Immunol, V182, P359; MOORTHY R, 1990, J VIROL, V64, P829, DOI 10.1128/JVI.64.2.829-837.1990; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NICHOLSON LJ, 1997, IN PRESS ONCOGENE; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; PENG M, 1992, ONCOGENE, V7, P1775; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; THORLEYLAWSON DA, 1985, J EXP MED, V162, P45, DOI 10.1084/jem.162.1.45; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; ZHANG Q, 1994, EUR J IMMUNOL, V24, P1467, DOI 10.1002/eji.1830240635	49	100	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19777	19784		10.1074/jbc.272.32.19777	http://dx.doi.org/10.1074/jbc.272.32.19777			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242637	hybrid, Green Accepted			2022-12-25	WOS:A1997XQ05900024
J	Enjo, F; Nosaka, K; Ogata, M; Iwashima, A; Nishimura, H				Enjo, F; Nosaka, K; Ogata, M; Iwashima, A; Nishimura, H			Isolation and characterization of a thiamin transport gene, THI10, from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVE REGULATORY GENE; ACID-PHOSPHATASE; HYDROXYETHYLTHIAZOLE KINASE; BINDING ACTIVITY; YEAST; PROTEIN; MEMBRANE; PYROPHOSPHORYLASE; BIOSYNTHESIS; METABOLISM	We isolated a thiamin transporter gene, THI10, from a genomic library of Saccharomyces cerevisiae by the complementation of a yeast mutant defective in thiamin transport activity, The THI10 gene contained an open reading frame of 1,794 base pairs encoding a 598-amino acid polypeptide with a calculated molecular weight of 66,903, The nucleotide sequence of THI10 is completely identical to that of an anonymous DNA (open reading frame L8083.2) mapped to chromosome XII; two other genes (open reading frames YOR071c and YOR192c) in chromosome XV are extremely similar to THI10, Moreover, the THI10 gene product showed significant sequence homology with yeast allantoin and uracil transporters, Hydropathy profile suggested that THI10 product is highly hydrophobic and contains many transmembrane regions. Gene disruption of the THI10 locus completely abolished the thiamin transport activity and thiamin binding activity in yeast plasma membrane fraction, Both the transport and thiamin binding activities were restored in the disrupted cells when the THI10 open reading frame was expressed by yeast GAL1 promoter, suggesting that the THI10 gene encodes for the thiamin transport carrier protein, Northern blot analysis demonstrated that THI10 gene expression is regulated at the mRNA level by intracellular thiamin pyrophosphate and that it requires a positive regulatory factor encoded by THI3 gene.	KYOTO PREFECTURAL INST HYG & ENVIRONM SCI,FUSHIMI KU,KYOTO 612,JAPAN		Enjo, F (corresponding author), KYOTO PREFECTURAL UNIV MED,DEPT BIOCHEM,KAMIGYO KU,KYOTO 602,JAPAN.							Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; COOPER TG, 1987, J BACTERIOL, V169, P4660, DOI 10.1128/jb.169.10.4660-4667.1987; IWASHIMA A, 1976, J BACTERIOL, V128, P855, DOI 10.1128/JB.128.3.855-857.1976; IWASHIMA A, 1979, BIOCHIM BIOPHYS ACTA, V557, P460, DOI 10.1016/0005-2736(79)90343-2; IWASHIMA A, 1986, J GEN MICROBIOL, V132, P1541; IWASHIMA A, 1990, BIOCHIM BIOPHYS ACTA, V1022, P211, DOI 10.1016/0005-2736(90)90116-6; IWASHIMA A, 1973, BIOCHIM BIOPHYS ACTA, V330, P222, DOI 10.1016/0005-2736(73)90227-7; IWASHIMA A, 1992, FEBS LETT, V311, P60, DOI 10.1016/0014-5793(92)81367-U; IWASHIMA A, 1981, EXPERIENTIA, V37, P473, DOI 10.1007/BF01986142; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; KAWASAKI Y, 1993, J BACTERIOL, V175, P5153, DOI 10.1128/JB.175.16.5153-5158.1993; KAWASAKI Y, 1990, J BACTERIOL, V172, P6145, DOI 10.1128/jb.172.10.6145-6147.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LEDER IG, 1975, METABOLIC PATHWAYS, V7, P57; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NISHIMURA H, 1986, EXPERIENTIA, V42, P607, DOI 10.1007/BF01955555; NISHIMURA H, 1992, J BACTERIOL, V174, P4701, DOI 10.1128/JB.174.14.4701-4706.1992; NISHIMURA H, 1991, J BACTERIOL, V173, P2716, DOI 10.1128/jb.173.8.2716-2719.1991; NISHIMURA H, 1992, FEBS LETT, V297, P155, DOI 10.1016/0014-5793(92)80349-L; NOSAKA K, 1990, BIOCHIM BIOPHYS ACTA, V1037, P147, DOI 10.1016/0167-4838(90)90160-H; NOSAKA K, 1993, J BIOL CHEM, V268, P17440; NOSAKA K, 1994, J BIOL CHEM, V269, P30510; NOSAKA K, 1992, FEBS LETT, V305, P244, DOI 10.1016/0014-5793(92)80678-A; NOSAKA K, 1989, FEMS MICROBIOL LETT, V60, P55, DOI 10.1016/0378-1097(89)90077-3; Rose MD., 1990, METHODS YEAST GENETI; Ruml T, 1996, YEAST, V12, P1279, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1279::AID-YEA23>3.0.CO;2-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWEINGRUBER ME, 1986, J BIOL CHEM, V261, P5877; SIKORSKI RS, 1989, GENETICS, V122, P19; STRUCK DK, 1978, J BIOL CHEM, V253, P5786; YOO HS, 1992, YEAST, V8, P997, DOI 10.1002/yea.320081202; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	38	48	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19165	19170		10.1074/jbc.272.31.19165	http://dx.doi.org/10.1074/jbc.272.31.19165			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235906	hybrid			2022-12-25	WOS:A1997XP06300012
J	ErsdalBadju, E; Lu, AQ; Zuo, YC; Picard, V; Bock, SC				ErsdalBadju, E; Lu, AQ; Zuo, YC; Picard, V; Bock, SC			Identification of the antithrombin III heparin binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ANTI-THROMBIN-III; CRYSTAL-STRUCTURE; BOVINE ANTITHROMBIN; MOLECULAR-MODEL; HIGH-AFFINITY; BETA-SHEET; GLYCOSYLATION; SERPINS; PENTASACCHARIDE	The heparin binding site of the anticoagulant protein antithrombin III (ATIII) has been defined at high resolution by alanine scanning mutagenesis of 17 basic residues previously thought to interact with the cofactor based on chemical modification experiments, analysis of naturally occurring dysfunctional antithrombins, and proximity to helix D. The baculovirus expression system employed for this study produces antithrombin which is highly similar to plasma ATIII in its inhibition of thrombin and factor Xa and which resembles the naturally occurring beta-ATIII isoform in its interactions with high affinity heparin and pentasaccharide (Ersdal-Badju, E., Lu, A., Peng, X., Picard, V., Zendehrouh, P., Turk, B., Bjork, I., Olson, S. T., and Beck, S. C. (1995) Biochem. J. 310, 323-330). Relative heparin affinities of basic-to-Ala substitution mutants were determined by NaCl gradient elution from heparin columns. The data show that only a subset of the previously implicated basic residues are critical for binding to heparin. The key heparin binding residues, Lys-ll, Arg-13, Arg-24, Arg-47, Lys-125, Arg-129, and Arg-145, line a 50-Angstrom long channel on the surface of ATIII. Comparisons of binding residue positions in the structure of P14-inserted ATIII and models of native antithrombin, derived from the structures of native ovalbumin and native antichymotrypsin, suggest that heparin may activate antithrombin by breaking salt bridges that stabilize its native conformation. Specifically, heparin release of intramolecular helix D-sheet B salt bridges may facilitate s123AhDEF movement and generation of an activated species that is conformationally primed for reactive loop uptake by central beta-sheet A and for inhibitory complex formation. In addition to providing a structural explanation for the conformational change observed upon heparin binding to antithrombin III, differences in the affinities of native, heparin-bound, complexed, and cleaved ATIII molecules for heparin can be explained based on the identified binding site and suggest why heparin functions catalytically and is released from antithrombin upon inhibitory complex formation.	TEMPLE UNIV,SCH MED,DEPT IMMUNOL MICROBIOL,PHILADELPHIA,PA 19140; SOL SHERRY THROMBOSIS RES CTR,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NHLBI NIH HHS [R01-HL30712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BJORK I, 1982, J BIOL CHEM, V257, P9487; BJORK I, 1992, BIOCHEM J, V286, P793; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BLINDER MA, 1990, J BIOL CHEM, V265, P5211; BORG JY, 1990, FEBS LETT, V266, P163, DOI 10.1016/0014-5793(90)81530-2; BRENNAN SO, 1988, FEBS LETT, V237, P118, DOI 10.1016/0014-5793(88)80183-2; BRENNAN SO, 1987, FEBS LETT, V219, P431, DOI 10.1016/0014-5793(87)80266-1; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; FAN BQ, 1994, BIOCHEMISTRY-US, V33, P14156, DOI 10.1021/bi00251a026; FAN BQ, 1993, J BIOL CHEM, V268, P17588; FRANZEN LE, 1980, J BIOL CHEM, V255, P5090; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; GROOTENHUIS PDJ, 1991, J AM CHEM SOC, V113, P2743, DOI 10.1021/ja00007a058; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; Meagher JL, 1996, J BIOL CHEM, V271, P29353, DOI 10.1074/jbc.271.46.29353; MIZUOCHI T, 1980, ARCH BIOCHEM BIOPHYS, V203, P458, DOI 10.1016/0003-9861(80)90199-X; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MOUREY L, 1993, J MOL BIOL, V232, P223, DOI 10.1006/jmbi.1993.1378; NORDENMAN B, 1981, BIOCHIM BIOPHYS ACTA, V672, P227, DOI 10.1016/0304-4165(81)90289-0; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; Permyakov E. A., 1993, LUMINESCENT SPECTROS, P57; PERRY DJ, 1991, FEBS LETT, V285, P248, DOI 10.1016/0014-5793(91)80809-H; PETERSON CB, 1987, J BIOL CHEM, V262, P8061; PHILLIPS JE, 1993, J BIOL CHEM, V268, P3321; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; RAGAZZI M, 1987, CARBOHYD RES, V165, pC1, DOI 10.1016/0008-6215(87)80093-9; SCHREUDER HA, 1994, STRUCT BIOL, V1, P48; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1991, J MOL BIOL, V221, P9541; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; SUN XJ, 1990, BIOCHEMISTRY-US, V29, P8957, DOI 10.1021/bi00490a011; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TURK B, 1997, IN PRESS BIOCHEMISTR; TURKO IV, 1993, FEBS LETT, V335, P9, DOI 10.1016/0014-5793(93)80429-X; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; WATTON J, 1995, THROMB HAEMOSTASIS, V73, pA936; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251	58	82	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19393	19400		10.1074/jbc.272.31.19393	http://dx.doi.org/10.1074/jbc.272.31.19393			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235938	hybrid			2022-12-25	WOS:A1997XP06300044
J	Urban, P; Mignotte, C; Kazmaier, M; Delorme, F; Pompon, D				Urban, P; Mignotte, C; Kazmaier, M; Delorme, F; Pompon, D			Cloning, yeast expression, and characterization of the coupling of two distantly related Arabidopsis thaliana NADPH-Cytochrome P450 reductases with P450 CYP73A5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; GENE FAMILY; NADPH-CYTOCHROME-P-450 OXIDOREDUCTASE; SACCHAROMYCES-CEREVISIAE; PLANT CYTOCHROME-P-450; P-450 REDUCTASE; CINNAMATE 4-HYDROXYLASE; CATHARANTHUS-ROSEUS; MOLECULAR-CLONING; 54-KDA SUBUNIT	Two NADPH-cytochrome P450 reductase-encoding cDNAs were isolated from an Arabidopsis cDNA library by metabolic interference in a Saccharomyces cerevisiae mutant disrupted for its endogenous cpr1 gene, ATR1 encodes a protein of 692 amino acids, while ATR2 encodes either a 712-residue protein (ATR2-1), or a 702-residue protein (ATR2-2) depending on the choice of the initiation codon, Comparative analysis of ATR1 and ATR2-1 indicates 64% amino acid sequence identity and the absence of conservation in the third base of conserved amino acid codons. The two Arabidopsis reductases are encoded by distinct genes whose divergence is expected an early event in angiosperms evolution, A poly(Ser/Thr) stretch reminiscent of a plant chloroplastic targeting signal is present at the ATR2-1 N-terminal end but absent in ATR1, The cDNA open reading frames were expressed in yeast, The recombinant polypeptides were found present in the yeast endoplasmic reticulum membrane and exhibited a high specific NADPH-cytochrome c reductase activity, To gain more insight into the respective functions of the two reductases, the Arabidopsis cDNA encoding cinnamate 4-hydroxylase (CYP73A5) was cloned and co-expressed with ATR1 or ATR2 in yeast, Biochemical characterization of the Arabidopsis ATR1/CYP73A5 and ATR2-1/CYP73A5 systems demonstrates that the two distantly related Arabidopsis reductases similarly support the first oxidative step of the phenylpropanoid general pathway.	CNRS, CTR GENET MOL, UPR 9061, F-91198 GIF SUR YVETTE, FRANCE; CTR ORSAN RECH BIOTECHNOL, F-91953 LES ULIS, FRANCE; CEA, SERV RADIOPHYSIOL VEGETALE, F-13108 ST PAUL LES DURANCE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA				Urban, Philippe/0000-0003-0557-839X				AKADA S, 1995, PLANT MOL BIOL, V29, P189, DOI 10.1007/BF00043645; BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; BENVENISTE I, 1991, BIOCHEM BIOPH RES CO, V177, P105, DOI 10.1016/0006-291X(91)91954-B; BLACK SD, 1982, J BIOL CHEM, V257, P5929; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOLWELL GP, 1994, PHYTOCHEMISTRY, V37, P1491, DOI 10.1016/S0031-9422(00)89567-9; CAO YW, 1995, PLANT PHYSIOL, V109, P1093, DOI 10.1104/pp.109.3.1093; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DURBIN ML, 1995, P NATL ACAD SCI USA, V92, P3338, DOI 10.1073/pnas.92.8.3338; DURST F, 1993, HDB EXPT PHARM, V10, P293; FAHRENDORF T, 1993, ARCH BIOCHEM BIOPHYS, V305, P509, DOI 10.1006/abbi.1993.1454; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; FUJITA M, 1985, PLANT CELL PHYSIOL, V26, P397, DOI 10.1093/oxfordjournals.pcp.a076923; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GONZALEZ FJ, 1994, DRUG METAB REV, V26, P165, DOI 10.3109/03602539409029789; GRAEBE JE, 1987, ANNU REV PLANT PHYS, V38, P419, DOI 10.1146/annurev.pp.38.060187.002223; HALLAHAN DL, 1993, BIOCHEM SOC T, V21, P1068, DOI 10.1042/bst0211068; HANSIKOVA H, 1994, GEN PHYSIOL BIOPHYS, V13, P149; HEDDEN P, 1978, ANNU REV PLANT PHYS, V29, P149, DOI 10.1146/annurev.pp.29.060178.001053; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HERZOG M, 1995, PLANT MOL BIOL, V27, P743, DOI 10.1007/BF00020227; HOTZE M, 1995, FEBS LETT, V374, P345, DOI 10.1016/0014-5793(95)01141-Z; Huang SR, 1996, PLANT PHYSIOL, V111, P115, DOI 10.1104/pp.111.1.115; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KINKEMA M, 1994, PLANT MOL BIOL, V26, P1139, DOI 10.1007/BF00040695; LESOT A, 1995, PLANT PHYSIOL BIOCH, V33, P751; LINDSTROM JT, 1993, PLANT MOL BIOL, V23, P1265, DOI 10.1007/BF00042359; MEIJER AH, 1993, PLANT J, V4, P47, DOI 10.1046/j.1365-313X.1993.04010047.x; MENTING JGT, 1994, PLANT PHYSIOL, V106, P643, DOI 10.1104/pp.106.2.643; MIGNOTTE C, 1993, Patent No. 92082454; MIGNOTTE C, 1992, Patent No. 13969; MINET M, 1992, PLANT J, V2, P417; MOORE TC, 1976, PHYTOCHEMISTRY, V15, P1241, DOI 10.1016/0031-9422(76)85085-6; MURPHY GJP, 1975, PHYTOCHEMISTRY, V14, P429, DOI 10.1016/0031-9422(75)85104-1; OMURA T, 1964, J BIOL CHEM, V239, P2370; PLEWA MJ, 1993, ANNU REV GENET, V27, P93; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; POMPON D, Patent No. 58796; PORTER TD, 1990, BIOCHEMISTRY-US, V29, P9814, DOI 10.1021/bi00494a009; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PORTER TD, 1991, J BIOL CHEM, V266, P13469; PURUGGANAN MD, 1995, GENETICS, V140, P345; SANDERMANN H, 1994, PHARMACOGENETICS, V4, P225, DOI 10.1097/00008571-199410000-00001; SHARROCK RA, 1989, GENE DEV, V3, P1745, DOI 10.1101/gad.3.11.1745; SHEN AL, 1993, HDB EXPT PHARM, V105, P35; SHET MS, 1993, P NATL ACAD SCI USA, V90, P2890, DOI 10.1073/pnas.90.7.2890; Shirley BW, 1996, TRENDS PLANT SCI, V1, P377, DOI 10.1016/1360-1385(96)10040-6; SIMMONS DL, 1985, J BIOL CHEM, V260, P515; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; SUTTER TR, 1989, BIOCHEM BIOPH RES CO, V160, P1257, DOI 10.1016/S0006-291X(89)80139-1; TAGUE BW, 1995, PLANT MOL BIOL, V28, P267, DOI 10.1007/BF00020246; TEUTSCH HG, 1993, P NATL ACAD SCI USA, V90, P4102, DOI 10.1073/pnas.90.9.4102; TRUAN G, 1994, GENE, V142, P123, DOI 10.1016/0378-1119(94)90366-2; URBAN P, 1994, EUR J BIOCHEM, V222, P843, DOI 10.1111/j.1432-1033.1994.tb18931.x; URBAN P, 1990, BIOCHIMIE, V72, P463, DOI 10.1016/0300-9084(90)90070-W; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; YOSHIDA Y, 1991, BIOCHEM SOC T, V19, P778, DOI 10.1042/bst0190778; ZHU DH, 1993, P NATL ACAD SCI USA, V90, P9310, DOI 10.1073/pnas.90.20.9310	62	268	294	4	61	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19176	19186		10.1074/jbc.272.31.19176	http://dx.doi.org/10.1074/jbc.272.31.19176			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235908	hybrid			2022-12-25	WOS:A1997XP06300014
J	Uhrbom, L; Nister, M; Westermark, B				Uhrbom, L; Nister, M; Westermark, B			Induction of senescence in human malignant glioma cells by p16(INK4A)	ONCOGENE			English	Article						senescence; glioma cells; CDKN2; p16(INK4A); CDK6; pRb phosphorylation	WILD-TYPE P53; RETINOBLASTOMA-PROTEIN; CYCLIN-D; CELLULAR-TRANSFORMATION; GENE; EXPRESSION; INHIBITION; APOPTOSIS; CDK4; IDENTIFICATION	p16(INK4A) is a G1-specific cell cycle inhibitor which maps to human chromosome 9p21, a region frequently mutated or deleted in cancer cell lines and primary tumors. In glioblastomas the frequency of homozygous deletions is 40-70% making it one of the most common mutations in this tumor type. We have analysed the significance of the loss of this gene in gliomas by introducing the cDNA for p16(INK4A) into the human glioma cell line U-1242 MG which has a deleted CDKN2 locus. We used the tetracycline repressable vector system and obtained two stably transfected clones that expressed p16(INK4A) upon induction. p16(INK4A) expression caused a G1 arrest and enlargement of the cells similar to that of senescent cells. When staining for Senescence-Associated beta-galactosidase activity, described to be specific for senescent cells, we could show that the enlarged cells specifically gave a positive staining reaction. This senescence phenotype was dependent on the continuous expression of p16(INK4A) since it was reversed upon reintroduction of tetracycline suppression. Thus, the induced expression of p16(INK4A) in these glioma cells reverted their immortal phenotype and caused an immediate cellular senescence.	UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital				Westermark, Bengt/0000-0001-7153-5545				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ARAP W, 1995, CANCER RES, V55, P1351; BATES S, 1994, ONCOGENE, V9, P1633; BONGCAMRUDLOFF E, 1991, CANCER RES, V51, P1553; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DREYLING MH, 1995, CANCER RES, V55, P984; Fueyo J, 1996, ONCOGENE, V12, P103; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hara E, 1996, MOL CELL BIOL, V16, P859; HAUPT Y, 1995, ONCOGENE, V10, P1563; HE J, 1995, CANCER RES, V55, P4833; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; HEDRUM A, 1994, BIOTECHNIQUES, V17, P122; HEDRUM A, 1994, BIOTECHNIQUES, V17, P126; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOGAN DAH, 1995, EMBO J, V14, P461; Loughran O, 1996, ONCOGENE, V13, P561; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LUBITZ W, 1980, INT J CANCER, V25, P53, DOI 10.1002/ijc.2910250107; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; Reznikoff CA, 1996, CANCER RES, V56, P2886; ROUACH EY, 1991, NATURE, V352, P345; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SONODA Y, 1995, ONCOGENE, V11, P2145; STEIN GH, 1982, P NATL ACAD SCI-BIOL, V79, P5287, DOI 10.1073/pnas.79.17.5287; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu Q, 1996, INT J CANCER, V65, P840, DOI 10.1002/(SICI)1097-0215(19960315)65:6<840::AID-IJC22>3.0.CO;2-6; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	53	117	122	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					505	514		10.1038/sj.onc.1201227	http://dx.doi.org/10.1038/sj.onc.1201227			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247304				2022-12-25	WOS:A1997XN25500002
J	Chazenbalk, GD; Jaume, JC; McLachlan, SM; Rapoport, B				Chazenbalk, GD; Jaume, JC; McLachlan, SM; Rapoport, B			Engineering the human thyrotropin receptor ectodomain from a non-secreted form to a secreted, highly immunoreactive glycoprotein that neutralizes autoantibodies in Graves' patients' sera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TSH RECEPTOR; LUTROPIN CHORIOGONADOTROPIN RECEPTOR; RECOMBINANT EXTRACELLULAR DOMAIN; THYROID-STIMULATING ANTIBODY; HAMSTER OVARY CELLS; MONOCLONAL-ANTIBODIES; RADIORECEPTOR ASSAY; MOLECULAR-CLONING; HORMONE RECEPTOR; BINDING-ACTIVITY	Previous attempts to generate autoantibody-reactive, secreted thyrotropin receptor (TSHR) ectodomain in mammalian cells have failed because of retention within the cell of material with immature carbohydrate. We have overcome this difficulty by performing progressive carboxyl-terminal truncations of the human TSHR ectodomain (418 amino acid residues including signal peptide). Three ectodomain variants (TSHR-261, TSHR-289, and TSHR-309) were truncated at residues 261, 289, and 309, respectively. Unlike the full ectodomain, ectodomain variants were secreted with an efficiency inversely proportional to their size, Secreted ectodomain variants contained similar to 20 kDa of complex carbohydrate. TSHR-261 was chosen for further study because it was secreted very efficiently and neutralized autoantibodies in Graves' patients' sera, This ectodomain variant was partially purified using sequential lectin and nickel-chelate chromatography, permitting the first direct visualization and quantitation of the mammalian TSHR. Most important, very small (nanogram) quantities of this material neutralized 70-100% of TSHR autoantibody activity in all 18 Graves' sera studied. In summary, carboxyl-terminal truncation of the human TSHR ectodomain generates a secreted protein with complex carbohydrate that neutralizes autoantibodies in Graves' patients' sera. Antigenically active TSHR will be valuable for future studies on the diagnosis, pathogenesis, and immunotherapy of Graves' disease.	VET ADM MED CTR,THYROID MOL BIOL UNIT 111T,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94121	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco				Jaume, Juan/0000-0002-2723-331X	NIDDK NIH HHS [DK19289, DK 48216] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019289, R01DK048216] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAZENBALK GD, 1995, J BIOL CHEM, V270, P1543, DOI 10.1074/jbc.270.4.1543; Chazenbalk GD, 1996, ENDOCRINOLOGY, V137, P4586, DOI 10.1210/en.137.11.4586; COSTAGLIOLA S, 1994, J MOL ENDOCRINOL, V13, P11, DOI 10.1677/jme.0.0130011; DIRMIKIS S, 1973, J ENDOCRINOL, V58, P577, DOI 10.1677/joe.0.0580577; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; ENDO T, 1992, BIOCHEM BIOPH RES CO, V186, P1391, DOI 10.1016/S0006-291X(05)81560-8; FILETTI S, 1991, J CLIN ENDOCR METAB, V72, P1096, DOI 10.1210/jcem-72-5-1096; FOTI D, 1991, J CLIN ENDOCR METAB, V73, P710, DOI 10.1210/jcem-73-4-710; GRAVES PN, 1995, ENDOCRINOLOGY, V136, P521, DOI 10.1210/en.136.2.521; GRAVES PN, 1992, BIOCHEM BIOPH RES CO, V187, P1135, DOI 10.1016/0006-291X(92)91315-H; HARFST E, 1992, MOL CELL ENDOCRINOL, V83, P117, DOI 10.1016/0303-7207(92)90152-V; HARFST E, 1992, J MOL ENDOCRINOL, V9, P227, DOI 10.1677/jme.0.0090227; HARFST E, 1992, LANCET, V339, P193, DOI 10.1016/0140-6736(92)90273-6; HUANG GC, 1992, J MOL ENDOCRINOL, V8, P137, DOI 10.1677/jme.0.0080137; HUANG GC, 1993, J MOL ENDOCRINOL, V10, P127, DOI 10.1677/jme.0.0100127; Jaume JC, 1997, J CLIN ENDOCR METAB, V82, P500, DOI 10.1210/jc.82.2.500; JOHNSTONE AP, 1994, MOL CELL ENDOCRINOL, V105, pR1, DOI 10.1016/0303-7207(94)90175-9; Kakinuma A, 1996, ENDOCRINOLOGY, V137, P2664, DOI 10.1210/en.137.7.2664; KAKINUMA A, 1997, IN PRESS J CLIN ENDO; KAUFMAN KD, 1991, MOL CELL ENDOCRINOL, V78, P107; KOO YB, 1994, ENDOCRINOLOGY, V134, P19, DOI 10.1210/en.134.1.19; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRESS BC, 1986, ENDOCRINOLOGY, V118, P974, DOI 10.1210/endo-118-3-974; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; LUDGATE M, 1990, MOL CELL ENDOCRINOL, V73, pR13, DOI 10.1016/0303-7207(90)90050-I; MATSUBA T, 1995, J BIOCHEM-TOKYO, V118, P265, DOI 10.1093/oxfordjournals.jbchem.a124901; MCLACHLAN SM, 1993, J INTERN MED, V234, P347, DOI 10.1111/j.1365-2796.1993.tb00756.x; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; Morgenthaler NG, 1996, J CLIN ENDOCR METAB, V81, P700, DOI 10.1210/jc.81.2.700; MORRIS JC, 1994, AUTOIMMUNITY, V17, P287, DOI 10.3109/08916939409010669; MURAKAMI M, 1995, EUR J ENDOCRINOL, V133, P80, DOI 10.1530/eje.0.1330080; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1150, DOI 10.1016/S0006-291X(05)80906-4; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAGY EV, 1992, BIOCHEM BIOPH RES CO, V188, P28, DOI 10.1016/0006-291X(92)92345-X; Nicholson LB, 1996, J MOL ENDOCRINOL, V16, P159, DOI 10.1677/jme.0.0160159; PERRET J, 1990, BIOCHEM BIOPH RES CO, V171, P1044, DOI 10.1016/0006-291X(90)90789-P; Rapoport B, 1996, J CLIN ENDOCR METAB, V81, P2525, DOI 10.1210/jc.81.7.2525; ROBBINS PW, 1977, CELL, V12, P893, DOI 10.1016/0092-8674(77)90153-2; Seetharamaiah GS, 1997, J IMMUNOL, V158, P2798; SEETHARAMAIAH GS, 1995, ENDOCRINOLOGY, V136, P2817, DOI 10.1210/en.136.7.2817; SEETHARAMAIAH GS, 1993, AUTOIMMUNITY, V14, P315, DOI 10.3109/08916939309079234; SEETHARAMAIAH GS, 1994, ENDOCRINOLOGY, V134, P549, DOI 10.1210/en.134.2.549; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHEWRING G, 1982, CLIN ENDOCRINOL, V17, P409, DOI 10.1111/j.1365-2265.1982.tb01607.x; SHI Y, 1983, THYROID, V3, P129; Shimojo N, 1996, P NATL ACAD SCI USA, V93, P11074, DOI 10.1073/pnas.93.20.11074; SMITH BR, 1988, ENDOCR REV, V9, P106, DOI 10.1210/edrv-9-1-106; SMITH BR, 1970, J ENDOCRINOL, V46, P45, DOI 10.1677/joe.0.0460045; TAHARA K, 1991, BIOCHEM BIOPH RES CO, V179, P70, DOI 10.1016/0006-291X(91)91335-A; TAKAI O, 1991, BIOCHEM BIOPH RES CO, V179, P319, DOI 10.1016/0006-291X(91)91372-J; TAKESHITA A, 1992, BIOCHEM BIOPH RES CO, V188, P1214, DOI 10.1016/0006-291X(92)91360-3; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; VLASE H, 1995, J CLIN ENDOCR METAB, V80, P46, DOI 10.1210/jc.80.1.46; VUHAILUUTHI MT, 1992, BIOCHEMISTRY-US, V31, P8377, DOI 10.1021/bi00150a035; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649	60	96	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18959	18965		10.1074/jbc.272.30.18959	http://dx.doi.org/10.1074/jbc.272.30.18959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228077	hybrid			2022-12-25	WOS:A1997XM34200068
J	Kamada, S; Washida, M; Hasegawa, J; Kusano, H; Funahashi, Y; Tsujimoto, Y				Kamada, S; Washida, M; Hasegawa, J; Kusano, H; Funahashi, Y; Tsujimoto, Y			Involvement of caspase-4(-like) protease in Fas-mediated apoptotic pathway	ONCOGENE			English	Article						apoptosis; cysteine protease; Fas(APO-1/CD95); caspase-4(TX/ICH-2/ICErelII)	INTERLEUKIN-1-BETA CONVERTING-ENZYME; CYSTEINE PROTEASES; CELL-DEATH; FAMILY; CED-3	Proteases of the caspase family, especially caspase-1 (ICE)(-like), caspase-3 (CPP32/Yama/apopain)(-like) and caspase-8 (MACH/FLICE/Mch5) proteases, are implicated in Pas (APO-1/CD95)-mediated apoptosis. Here, we show that the caspase-4 (TX/ICH-2/ICErelII)(-like) protease, another member of the caspase family, is also involved in Pas-mediated apoptosis, based upon the observations: (i) caspase-4 is processed in response to an agonistic anti-Pas antibody treatment, (ii) overexpression of a mutant caspase-4 with active site mutations in both p20 and p10 subunits delays Pas-mediated apoptosis, (iii) microinjected anti-caspase-4 antibodies inhibit Fas-mediated apoptosis. Together with our observations that the mutant caspase-4 inhibits the Pas-mediated activation of caspase-3(-like) proteases and purified caspase-4 cleaves pro-caspase-3 to generate a subunit of active form, these results suggest that Pas-mediated apoptosis is driven by a caspase cascade in which the caspase-4(like) protease transmits a death signal from caspase-8 to caspase-3(-like) proteases probably through directly cleaving pro-caspase-3(-like) proteases.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT MED GENET,SUITA,OSAKA 565,JAPAN	Osaka University								Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BEIDLER DR, 1995, J BIOL CHEM, V270, P16527; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Hasegawa J, 1996, CANCER RES, V56, P1713; ITOH N, 1993, J BIOL CHEM, V268, P10932; KAMADA S, 1995, CANCER RES, V55, P354; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shimizu S, 1996, ONCOGENE, V12, P2251; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	31	91	94	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					285	290		10.1038/sj.onc.1201192	http://dx.doi.org/10.1038/sj.onc.1201192			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233763				2022-12-25	WOS:A1997XK99900005
J	Sorsa, T; Salo, T; Koivunen, E; Tyynela, J; Konttinen, YT; Bergmann, U; Tuuttila, A; Niemi, E; Teronen, O; Heikkila, P; Tschesche, H; Leinonen, J; Osman, S; Stenman, UH				Sorsa, T; Salo, T; Koivunen, E; Tyynela, J; Konttinen, YT; Bergmann, U; Tuuttila, A; Niemi, E; Teronen, O; Heikkila, P; Tschesche, H; Leinonen, J; Osman, S; Stenman, UH			Activation of type IV procollagenases by human tumor-associated trypsin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL GELATINASE; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; EXTRACELLULAR-MATRIX; PROGELATINASE-A; CELL-LINES; 4-AMINOPHENYLMERCURIC ACETATE; 72-KDA GELATINASE; COMPLEX-FORMATION	Increased production of proteinases, such as matrix metalloproteinases (MMPs), is a characteristic feature of malignant tumors. Some human cancers :Ind cell lines derived from them also express trypsinogen, but the function of the extrapancreatic trypsin has remained unclear, In this study we cloned and sequenced trypsinogen-a cDNA from human COLO 205 colon carcinoma cells and characterized the ability of the enzyme to activate latent human type TV procollagenases (proMMP-2 and proMMP-9). As shown by cloning and N-terminal amino acid sequencing, the amino acid sequence of tumor associated trypsin-a is identical to that of pancreatic trypsin-a. We found that both pancreatic trypsin-a and tumor cell-derived trypsin-a are efficient activators of proMMP-9 and are capable of activating proMMP-9 at a molar ratio of 1:1000, the lowest reported so far. Human trypsin-a was a more efficient activator than widely used bovine trypsin and converted the 92-kDa proMMP-9 to a single 77-kDa product that was not fragmented further. The single peptide bond cleaved by trypsin-a in proMMP-9 was Arg(87)-Phe(88), The generation of the 77-kDa species coincided with the increase in specific activity of MMP-9. In contrast, trypsin-2 only partially activated proMMP-2. Trypsin-a cleaved the Arg(99)-Lys(100) peptide bond of proMMP-2 generating 62-65-kDa MMP-2 species. Trypsin-a-induced proMMP-2 and -9 conversions were inhibited by tumor-associated trypsin inhibitor added either prior to or during activation indicating that proMMPs were not activated autocatalytically. Trypsin-2 also activated proMMPs associated with tissue inhibitor of matrix metalloproteinases, the complexes of which are thought to be the major MMP forms in vivo. The ability of human tumor cell-derived trypsin-a to activate latent MMPs suggests a role fbr trypsin-a in initiating the proteinase cascade that mediates tumor invasion and metastasis formation.	UNIV HELSINKI, DEPT MED CHEM, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, DEPT CLIN CHEM, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, DIV BIOCHEM, FIN-00014 HELSINKI, FINLAND; UNIV OULU, DEPT ORAL SURG & PATHOL, FIN-99020 OULU, FINLAND; UNIV OULU, DEPT BIOCHEM, FIN-99020 OULU, FINLAND; UNIV OULU, BIOCTR, FIN-99020 OULU, FINLAND; UNIV HELSINKI, DEPT ANAT, HELSINKI, FINLAND; UNIV HELSINKI, DEPT MED 4, HELSINKI, FINLAND; UNIV HELSINKI, DEPT ORAL SURG, HELSINKI, FINLAND; UNIV HELSINKI, DEPT SURG, HELSINKI, FINLAND; UNIV HELSINKI, CENT HOSP, HELSINKI, FINLAND; UNIV BIELEFELD, DEPT BIOCHEM, D-33501 BIELEFELD, GERMANY	University of Helsinki; University of Helsinki; University of Helsinki; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Bielefeld	Sorsa, T (corresponding author), UNIV HELSINKI, INST DENT, DEPT PERIODONT, POB 41, MANNERHEIMINTIE 172, FIN-00014 HELSINKI, FINLAND.		, tuula/ABG-2051-2021	Heikkila, Pia/0000-0002-5925-1993; Stenman, Ulf-Hakan/0000-0002-2695-3454; Salo, Tuula/0000-0001-6039-0088; Koivunen, Erkki/0000-0002-6443-9595; Teronen, Olli/0000-0003-2211-9187				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BALLDIN G, 1981, SCAND J GASTROENTERO, V16, P603, DOI 10.3109/00365528109182018; BAUMANN M, 1990, ANAL BIOCHEM, V190, P198, DOI 10.1016/0003-2697(90)90181-8; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN PD, 1990, CANCER RES, V50, P6184; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; BU CH, 1995, J BIOL CHEM, V270, P18563, DOI 10.1074/jbc.270.31.18563; CHEN JM, 1991, J BIOL CHEM, V266, P5113; Chen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECARLO A, 1994, THESISU ALABAMA BIRM; EMI M, 1986, GENE, V41, P305; FIGARELLA C, 1975, EUR J BIOCHEM, V53, P457, DOI 10.1111/j.1432-1033.1975.tb04086.x; FRENCH DL, 1994, ANN NY ACAD SCI, V732, P324, DOI 10.1111/j.1749-6632.1994.tb24747.x; FRIDMAN R, 1995, CANCER RES, V55, P2548; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Hedstrom J, 1996, BRIT MED J, V313, P333, DOI 10.1136/bmj.313.7053.333; Hedstrom J, 1996, INT J CANCER, V66, P326, DOI 10.1002/(SICI)1097-0215(19960503)66:3<326::AID-IJC10>3.0.CO;2-9; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIRAHARA F, 1995, INT J CANCER, V63, P176, DOI 10.1002/ijc.2910630205; HUHTALA ML, 1982, J BIOL CHEM, V257, P13713; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; Itkonen O, 1996, J LAB CLIN MED, V128, P98, DOI 10.1016/S0022-2143(96)90118-3; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KNAUPER V, 1993, BIOCHEM J, V295, P581; Knauper V, 1996, EUR J BIOCHEM, V235, P187, DOI 10.1111/j.1432-1033.1996.00187.x; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; KOIVUNEN E, 1990, CANCER RES, V50, P2375; KOIVUNEN E, 1989, J BIOL CHEM, V264, P14095; KOIVUNEN E, 1991, INT J CANCER, V47, P592, DOI 10.1002/ijc.2910470419; KOIVUNEN E, 1991, CANCER RES, V51, P2107; KOSHIKAWA N, 1994, BIOCHEM J, V303, P187, DOI 10.1042/bj3030187; MAKELA M, 1994, J DENT RES, V73, P1397, DOI 10.1177/00220345940730080201; MASUI Y, 1977, BIOCHEM MED METAB B, V17, P215, DOI 10.1016/0006-2944(77)90026-6; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OGRADY RL, 1984, ANAL BIOCHEM, V140, P490, DOI 10.1016/0003-2697(84)90199-4; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; QUIGLEY JP, 1990, CELL DIFFER DEV, V32, P263, DOI 10.1016/0922-3371(90)90039-Y; RAMOSDESIMONE N, 1993, HYBRIDOMA, V12, P349, DOI 10.1089/hyb.1993.12.349; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; REINKE H, 1991, ADV LIF SCI, P55; RISTELI L, 1987, METHOD ENZYMOL, V145, P391; SAARI H, 1990, BIOCHEM BIOPH RES CO, V171, P979, DOI 10.1016/0006-291X(90)90780-Q; SALO T, 1991, J BIOL CHEM, V266, P11436; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHEELE G, 1981, GASTROENTEROLOGY, V80, P461; SORSA T, 1994, ANN NY ACAD SCI, V732, P112, DOI 10.1111/j.1749-6632.1994.tb24729.x; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STENMAN UH, 1988, BIOL CHEM H-S, V369, P9; STENMAN UH, 1990, SCAND J CLIN LAB INV, V50, P93, DOI 10.3109/00365519009085805; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; SUZUKI K, 1995, BIOCHEM J, V305, P301, DOI 10.1042/bj3050301; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TERADA T, 1995, AM J PATHOL, V147, P1207; TERADA T, 1995, HUM PATHOL, V26, P746, DOI 10.1016/0046-8177(95)90222-8; Terada T, 1996, PATHOL INT, V46, P183, DOI 10.1111/j.1440-1827.1996.tb03596.x; TRIEBEL S, 1992, FEBS LETT, V314, P386, DOI 10.1016/0014-5793(92)81511-J; TRIEBEL S, 1992, FEBS LETT, V298, P280, DOI 10.1016/0014-5793(92)80077-T; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; Tschesche H, 1992, Matrix Suppl, V1, P245; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YU M, 1995, CANCER RES, V55, P3272; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	91	177	179	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21067	21074		10.1074/jbc.272.34.21067	http://dx.doi.org/10.1074/jbc.272.34.21067			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261109	hybrid			2022-12-25	WOS:A1997XR78900019
J	Tselepis, VH; Green, LJ; Humphries, MJ				Tselepis, VH; Green, LJ; Humphries, MJ			An RGD to LDV motif conversion within the disintegrin kistrin generates an integrin antagonist that retains potency but exhibits altered receptor specificity - Evidence for a functional equivalence of acidic integrin-binding motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; CELL-ADHESION MOLECULE-1; GLYCOPROTEIN-IIB-IIIA; PLATELET-AGGREGATION; CONTAINING PEPTIDE; SNAKE-VENOM; INHIBITS ALPHA-4-BETA-1; VITRONECTIN RECEPTOR; PROTEIN ANTAGONISTS; PLASMA FIBRONECTIN	Integrin ligands almost invariably employ a variant of either the RGD or LDV motif as a key element of their receptor recognition site, These short acidic peptide sequences collaborate with specific nonhomologous flanking residues and spatially separate ''synergy'' sequences to determine receptor binding specificity, Although the consensus sequences for RGD and LDV motifs are quite different, their common use suggests that they might share a critical role in receptor-ligand engagement, To date, the effects of interconversion of the two motifs within a natural protein framework have not been tested; however, in this study, we have converted the natural RGD site found in the snake venom disintegrin kistrin into an LDV motif and examined the effects of the change on the specificity of integrin recognition and on disintegrin potency, While an assessment of receptor binding using cell adhesion and purified integrin solid-phase assays demonstrated recognition of recombinant RGD kistrin by alpha V beta 3 and alpha 5 beta 1, a series of LDV kistrin chimeras did not bind to these integrins, but instead were recognized specifically by alpha 4 beta 1. The minimal change to elicit this distinct switch in receptor specificity was found to involve alteration of only three residues within kistrin, Alanine scanning mutagenesis was used to provide further information on the functional contribution of the three residues, More important, the LDV kistrin chimeras also retained much of the characteristic potency of RGD kistrin, indicating that the kistrin scaffold is optimized for presentation of both RGD and LDV sequences, These findings provide evidence for similarities in motif pharmacophore and reinforce the hypothesis that RGD and LDV sites have an equivalent functional role in receptor binding, They also demonstrate the potential for other disintegrin-containing proteins, perhaps from the ADAM family, to employ LDV sequences for integrin binding.	UNIV MANCHESTER,SCH BIOL SCI,WELLCOME TRUST CTR CELL MATRIX RES,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester				Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AOTA S, 1994, J BIOL CHEM, V269, P24756; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; CALVETE JJ, 1991, BIOCHEMISTRY-US, V30, P5225, DOI 10.1021/bi00235a016; CARDARELLI PM, 1994, J BIOL CHEM, V269, P18668; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; DENNIS MS, 1993, PROTEINS, V15, P312, DOI 10.1002/prot.340150308; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; EDWARDS JG, 1988, J CELL SCI, V89, P507; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; GREEN LJ, 1995, BIOCH SOC T, V23; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HUMPHRIES M, 1994, EXPERT OPIN THER PAT, V4, P227; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KNAPP A, 1992, J BIOL CHEM, V267, P24230; KNUDSEN KA, 1988, EXP CELL RES, V179, P42, DOI 10.1016/0014-4827(88)90346-1; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; KRAIZSCHMAR J, 1996, J BIOL CHEM, V271, P4593; LAM SCT, 1987, J BIOL CHEM, V262, P947; Lazarus Robert A., 1993, Current Opinion in Biotechnology, V4, P438, DOI 10.1016/0958-1669(93)90009-L; LI R, 1993, J BIOL CHEM, V268, P17513; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LU XJ, 1994, BIOCHEM J, V304, P929, DOI 10.1042/bj3040929; Lu XJ, 1996, J BIOL CHEM, V271, P289, DOI 10.1074/jbc.271.1.289; MAEDA T, 1989, J BIOL CHEM, V264, P15165; MAEDA T, 1993, J BIOCHEM, V113, P29, DOI 10.1093/oxfordjournals.jbchem.a123998; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, J BIOL CHEM, V266, P3579; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; NOWLIN DM, 1993, J BIOL CHEM, V268, P20352; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RAHMAN S, 1995, BIOCHEM J, V312, P223, DOI 10.1042/bj3120223; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; RUCINSKI B, 1990, BIOCHIM BIOPHYS ACTA, V1054, P257, DOI 10.1016/0167-4889(90)90096-V; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH JW, 1990, J BIOL CHEM, V265, P2168; STAIANO N, 1995, BIOCHEM MOL BIOL INT, V35, P11; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YAMADA T, 1993, J BIOL CHEM, V268, P10588	63	56	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21341	21348		10.1074/jbc.272.34.21341	http://dx.doi.org/10.1074/jbc.272.34.21341			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261147	hybrid			2022-12-25	WOS:A1997XR78900057
J	Wu, JG; Ohta, N; Benson, AK; Ninfa, AJ; Newton, A				Wu, JG; Ohta, N; Benson, AK; Ninfa, AJ; Newton, A			Purification, characterization, and reconstitution of DNA-dependent RNA polymerases from Caulobacter crescentus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SIGMA-SUBUNIT; TRANSCRIPTION; GENE; SEQUENCE; CHROMATOGRAPHY; BACTERIAL; INVITRO; REGION; FLBD	Cell differentiation in the Caulobacter crescentus cell cycle requires differential gene expression that is regulated primarily at the transcriptional level. Until now, however, a defined in vitro transcription system for the biochemical study of developmentally regulated transcription factors had not been available in this bacterium, We report here the purification of C. crescentus RNA polymerase holoenzymes and resolution of the core RNA polymerase from holoenzymes by chromatography on single-stranded DNA cellulose, The three RNA polymerase holoenzymes E sigma(54), E sigma(32), and E sigma(73) were reconstituted exclusively from purified C. crescentus core and sigma factors. Reconstituted E sigma(54) initiated transcription from the sigma(54)-dependent fljK promoter of C. crescentus in the presence of the transcription activator flbD, and active E sigma(32) specifically initiated transcription from the sigma(32)-dependent promoter of the C. crescentus heat-shock gene dnaK. For reconstitution of the E sigma(73) holoenzyme, we overexpressed the C. crescentus rpoD gene in Escherichia coli and purified the full-length sigma(73) protein. The reconstituted E sigma(73) recognized the sigma(70)-dependent promoters of the E. coli lacUV5 and neo genes, as well as the sigma(73)-dependent housekeeping promoters of the C. crescentus pleC and rsaA genes. The ability of the C. crescentus E sigma(73) RNA polymerase to recognize E. coli sigma(70)-dependent promoters is consistent with relaxed promoter specificity of this holoenzyme previously observed in vivo.	PRINCETON UNIV, DEPT MOL BIOL, PRINCETON, NJ 08544 USA	Princeton University				Benson, Andrew/0000-0001-6330-0252; Wu, Jianguo/0000-0002-8326-2895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022299] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22299] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMEMIYA K, 1977, J BIOL CHEM, V252, P4157; ANDERSON DK, 1995, MOL GEN GENET, V246, P697, DOI 10.1007/BF00290715; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BENSON AK, 1994, P NATL ACAD SCI USA, V91, P4989, DOI 10.1073/pnas.91.11.4989; BERG D, 1971, METHOD ENZYMOL, V21, P506; BRUN YV, 1992, GENE DEV, V6, P2395, DOI 10.1101/gad.6.12a.2395; BRUN YV, 1994, ANNU REV BIOCHEM, V63, P419, DOI 10.1146/annurev.bi.63.070194.002223; Burgess R.R., 1987, RNA POLYM REGULATION, P3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; CHEUNG KK, 1978, J BIOL CHEM, V253, P2254; ELY B, 1989, GENETICS, V123, P649; ELY B, 1991, METHOD ENZYMOL, V204, P372; FISHER JA, 1988, J BACTERIOL, V170, P4706, DOI 10.1128/jb.170.10.4706-4713.1988; GILCHRIST A, 1991, J BACTERIOL, V173, P921, DOI 10.1128/jb.173.2.921-925.1991; GOMES SL, 1990, J BACTERIOL, V172, P3051, DOI 10.1128/jb.172.6.3051-3059.1990; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HALDENWANG WG, 1995, MICROBIOL REV, V59, P1; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; INOUYE S, 1990, J BACTERIOL, V172, P80, DOI 10.1128/JB.172.1.80-85.1990; JORGENSEN RA, 1979, MOL GEN GENET, V177, P65, DOI 10.1007/BF00267254; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; MALAKOOTI J, 1995, J BACTERIOL, V177, P4372, DOI 10.1128/jb.177.15.4372-4376.1995; MALAKOOTI J, 1995, J BACTERIOL, V177, P6854, DOI 10.1128/jb.177.23.6854-6860.1995; MASUI Y, 1983, EXPT MANIPULATION GE; NEWTON A, 1972, P NATL ACAD SCI USA, V69, P447, DOI 10.1073/pnas.69.2.447; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5905; NUSSLEIN C, 1972, BIOCHEM BIOPH RES CO, V47, P282, DOI 10.1016/S0006-291X(72)80040-8; Ohta N, 1996, TRENDS MICROBIOL, V4, P326, DOI 10.1016/0966-842X(96)10050-0; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; Reisenauer A, 1996, J BACTERIOL, V178, P1919, DOI 10.1128/jb.178.7.1919-1927.1996; STRAGIER P, 1990, MOL MICROBIOL, V4, P1801, DOI 10.1111/j.1365-2958.1990.tb02028.x; WANG SP, 1993, P NATL ACAD SCI USA, V90, P630, DOI 10.1073/pnas.90.2.630; WU JG, 1995, J BACTERIOL, V177, P3241, DOI 10.1128/jb.177.11.3241-3250.1995; Wu JG, 1997, MOL MICROBIOL, V24, P233, DOI 10.1046/j.1365-2958.1997.3281691.x; Wu JG, 1996, J BACTERIOL, V178, P2094, DOI 10.1128/jb.178.7.2094-2101.1996	40	8	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21558	21564		10.1074/jbc.272.34.21558	http://dx.doi.org/10.1074/jbc.272.34.21558			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261176	hybrid			2022-12-25	WOS:A1997XR78900086
J	Bevilacqua, MA; Faniello, MC; Quaresima, B; Tiano, MT; Giuliano, P; Feliciello, A; Avvedimento, VE; Cimino, F; Costanzo, F				Bevilacqua, MA; Faniello, MC; Quaresima, B; Tiano, MT; Giuliano, P; Feliciello, A; Avvedimento, VE; Cimino, F; Costanzo, F			A common mechanism underlying the E1A repression and the cAMP stimulation of the H ferritin transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E1A-ASSOCIATED PROTEIN P300; ENCODING GENE FERH; MESSENGER-RNA; HEAVY-CHAIN; ADENOVIRUS E1A; NUCLEAR FACTOR; CELLS; EXPRESSION; PROMOTER; CREB	Transcription of the H ferritin gene in vivo is stimulated by cAMP and repressed by the E1A oncoprotein. We report here the identification of the cis-element in the human promoter responsive to both cAMP- and E1A-mediated signals. This promoter region is included between positions -62 to -45 and binds a approximate 120-kDa transcription factor called Bbf. Bbf forms a complex in vivo with the coactivator molecules p300 and CBP. Recombinant E1A protein reduces the formation of these complexes. In vivo overexpression of p300 in HeLa cells reverses the E1A-mediated inhibition of the ferritin promoter transcription driven by Bbf. These data suggest the existence of a common mechanism for the cAMP activation and the E1A-mediated repression of H ferritin transcription.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CANTANZARO,ITALY; UNIV NAPLES FEDERICO II,CNR,CEOS,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,I-80131 NAPLES,ITALY	University of Naples Federico II; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II			Costanzo, Francesco Saverio/K-3168-2018	Costanzo, Francesco Saverio/0000-0002-3096-9416; FANIELLO, Concetta Maria/0000-0001-6938-2754; QUARESIMA, Barbara/0000-0003-3462-624X; Feliciello, Antonio/0000-0002-7932-2170				ALPERT E, 1973, NATURE, V242, P194, DOI 10.1038/242194a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEAUMONT C, 1987, J BIOL CHEM, V262, P10619; BEVILACQUA MA, 1994, GENE, V141, P287, DOI 10.1016/0378-1119(94)90587-8; BEVILACQUA MA, 1992, GENE, V111, P255, DOI 10.1016/0378-1119(92)90696-M; BEVILACQUA MA, 1995, BIOCHEM J, V311, P769, DOI 10.1042/bj3110769; BOMFORD AB, 1992, PATHOBIOLOGY, V60, P10, DOI 10.1159/000163691; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P666; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CORSI PS, 1988, GENE DEV, V2, P1529; DAMATO LGC, 1989, BIOCHEM BIOPH RES CO, V165, P506; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GALLO A, 1995, CELL GROWTH DIFFER, V6, P91; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IWASA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1279, DOI 10.1016/0006-291X(90)90662-7; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; NORDHEIM A, 1994, NATURE, V370, P177, DOI 10.1038/370177a0; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TSUJI Y, 1993, J BIOL CHEM, V268, P7270; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; YOKOMORI N, 1991, ENDOCRINOLOGY, V128, P1474, DOI 10.1210/endo-128-3-1474	32	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20736	20741		10.1074/jbc.272.33.20736	http://dx.doi.org/10.1074/jbc.272.33.20736			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252395	hybrid			2022-12-25	WOS:A1997XR22100065
J	Gschwendt, M; Johannes, FJ; Kittstein, W; Marks, F				Gschwendt, M; Johannes, FJ; Kittstein, W; Marks, F			Regulation of protein kinase C mu by basic peptides and heparin - Putative role of an acidic domain in the activation of the kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; POLYLYSINE; EXPRESSION; BINDING	Protein kinase C mu is a novel member of the protein kinase C (PKC) family that differs from the other isoenzymes in structural and enzymatic properties. No substrate proteins of PKC mu have been identified as yet. Moreover, the regulation of PKC mu activity remains obscure, since a structural region corresponding to the pseudosubstrate domains of other PKC isoenzymes has not been found for PKC mu. Here we show that aldolase is phosphorylated by PKC mu in vitro. Phosphorylation of aldolase and of two substrate peptides by PKC mu is inhibited by various proteins and peptides, including typical PKC substrates such as histone H1, myelin basic protein, and p53. This inhibitory activity seems to depend on clusters of basic amino acids in the protein/peptide structures. Moreover, in contrast to other PRC isoenzymes PKC mu is activated by heparin and dextran sulfate. Maximal activation by heparin is about twice and that by dextran sulfate four times as effective as maximal activation by phosphatidylserine plus 12-O-tetradecanoylphorbol-13-acetate, the conventional activators of c-and nPKC isoforms. We postulate that PKC mu contains an acidic domain, which is involved in the formation and stabilization of an active state and which, in the inactive enzyme, is blocked by an intramolecular interaction with a basic domain. This intramolecular block is thought to be released by heparin and possibly also by 12-P-tetradecanoylphorbol-13-acetate/phosphatidylserine, whereas basic peptides and proteins inhibit PKC mu activity by binding to the acidic domain of the active enzyme.	UNIV STUTTGART,INST CELL BIOL & IMMUNOL,D-70569 STUTTGART,GERMANY	University of Stuttgart	Gschwendt, M (corresponding author), GERMAN CANC RES CTR,DIV TUMOR CELL REGULAT,D-69009 HEIDELBERG,GERMANY.							BRUNATI AM, 1991, BIOCHIM BIOPHYS ACTA, V1091, P123, DOI 10.1016/0167-4889(91)90232-M; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P343; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Herbert JM, 1996, J BIOL CHEM, V271, P25928; HERBERT JM, 1991, BIOCHIM BIOPHYS ACTA, V1091, P432; HOUSE C, 1989, FEBS LETT, V249, P243, DOI 10.1016/0014-5793(89)80632-5; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; LIEBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; Marks Friedrich, 1996, P81, DOI 10.1002/9783527615032.ch3; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; PATEL RC, 1994, J BIOL CHEM, V269, P18593; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; PUKAC LA, 1992, J BIOL CHEM, V267, P3707; Rennecke J, 1996, EUR J BIOCHEM, V242, P428, DOI 10.1111/j.1432-1033.1996.0428r.x; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; ZHAI LM, 1992, BIOCHEM BIOPH RES CO, V189, P944, DOI 10.1016/0006-291X(92)92295-9	29	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20742	20746		10.1074/jbc.272.33.20742	http://dx.doi.org/10.1074/jbc.272.33.20742			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252396	hybrid			2022-12-25	WOS:A1997XR22100066
J	Kumar, AS; Venkatesh, VC; Planer, BC; Feinstein, SI; Ballard, PL				Kumar, AS; Venkatesh, VC; Planer, BC; Feinstein, SI; Ballard, PL			Phorbol ester down-regulation of lung surfactant protein B gene expression by cytoplasmic trapping of thyroid transcription factor-1 and hepatocyte nuclear factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; PULMONARY SURFACTANT; KINASE-C; LOCALIZATION SIGNAL; TNF-ALPHA; FACTOR-I; SP-A; PROMOTER; ENHANCER; INVITRO	The lung-specific surfactant protein B (SP-B) is essen tial for surfactant function and normal respiration, We investigated the role of thyroid transcription factor-1 (TTF-1) and hepatocyte nuclear factor 3 (HNFS) in the down-regulation of SP-B gene expression by phorbol ester in pulmonary adenocarcinoma H441 cells, Responsiveness to 12-O-tetradecanoylphorbol-13-acetate (TPA) localized to the SP-B proximal promoter (-140/-65 bp) and specifically to binding sites for TTF-1 and HNF3, which act as cell specific enhancers of SP-B expression. Treatment of cells with TPA (10 nM) caused a time-dependent decrease in both TTF-1 and HNF3 in nuclear extracts and accumulation of both factors in the cytoplasm as assessed by electromobility shift, Western, Southwestern, and immunofluorescence assays. Treatment did not alter the mRNA content or DNA binding activity for either transcription factor. We conclude that down-regulation of SP-B gene expression by phorbol ester involves cytoplasmic trapping and loss of TTF-1 and HNF3 from the nucleus, This mechanism of action is independent of AP-1 and other transcription factors known to be influenced by phorbol ester.	UNIV PENN,SCH MED,CHILDRENS HOSP,DEPT PEDIAT,ABRAMSON RES CTR 416,PHILADELPHIA,PA 19104; UNIV BRITISH COLUMBIA,DEPT PEDIAT,VANCOUVER,BC V5Z 4H4,CANADA; UNIV PENN,SCH MED,INST ENVIRONM MED,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of British Columbia; University of Pennsylvania					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737, T32HL007748, R01HL053566] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07748, R01 HL53566, PPG HL19737] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; Ballard P L, 1996, J Perinatol, V16, pS28; Ballard PL, 1996, AM J RESP CELL MOL, V14, P599, DOI 10.1165/ajrcmb.14.6.8652188; BALLARD PL, 1989, ENDOCR REV, V10, P165, DOI 10.1210/edrv-10-2-165; BEERS MF, 1995, PEDIATR RES, V38, P668, DOI 10.1203/00006450-199511000-00007; BEERS MF, 1992, AM J RESP CELL MOL, V7, P368, DOI 10.1165/ajrcmb/7.4.368; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; COSTA RH, 1994, LIVER GENE TRANSCRIP, P183; DEFRANCO D, 1986, MOL CELL BIOL, V6, P993, DOI 10.1128/MCB.6.4.993; DEKOWSKI SA, 1995, PEDIATR RES, V38, P513, DOI 10.1203/00006450-199510000-00007; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERALY SA, 1995, MOL ENDOCRINOL, V9, P848, DOI 10.1210/me.9.7.848; ERNST MK, 1994, EXP CELL RES, V214, P481; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HAYASHI Y, 1993, MOL ENDOCRINOL, V7, P1049, DOI 10.1210/me.7.8.1049; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KUMAR AS, 1997, AM J RESP CRIT CARE, V155, pA695; KUMAR AS, 1996, PEDIATR RES, V39, pA359; LEUKEL M, 1995, EUR J CELL BIOL, V68, P133; Lonigro R, 1996, CELL GROWTH DIFFER, V7, P251; MANISCALCO WM, 1994, AM J PHYSIOL-LUNG C, V267, pL569, DOI 10.1152/ajplung.1994.267.5.L569; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; McGonigle B, 1996, GENE DEV, V10, P1812, DOI 10.1101/gad.10.14.1812; NIELSEN HC, 1992, BIOCHIM BIOPHYS ACTA, V1175, P95, DOI 10.1016/0167-4889(92)90014-3; Ohe K, 1996, MOL ENDOCRINOL, V10, P826, DOI 10.1210/me.10.7.826; Planer BC, 1997, BBA-GENE STRUCT EXPR, V1353, P171, DOI 10.1016/S0167-4781(97)00070-5; PRYHUBER GS, 1994, AM J PHYSIOL, V267, pL16, DOI 10.1152/ajplung.1994.267.1.L16; PRYHUBER GS, 1990, J BIOL CHEM, V265, P20822; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; Ray MK, 1996, MOL CELL BIOL, V16, P2056; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Saito T, 1997, ENDOCRINOLOGY, V138, P602, DOI 10.1210/en.138.2.602; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; SINGH K, 1990, PLANT CELL, V2, P891, DOI 10.1105/tpc.2.9.891; Solarin KO, 1997, PEDIATR RES, V42, P356, DOI 10.1203/00006450-199709000-00017; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; Suh DS, 1996, MOL ENDOCRINOL, V10, P1227, DOI 10.1210/me.10.10.1227; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; VANDENBROUCK Y, 1995, FEBS LETT, V376, P99, DOI 10.1016/0014-5793(95)01252-X; VENKATESH VC, 1995, AM J PHYSIOL-LUNG C, V268, pL674, DOI 10.1152/ajplung.1995.268.4.L674; Wang DP, 1996, J LIPID RES, V37, P1831; WHITESIDE ST, 1993, J CELL SCI, V104, P949; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WHITSETT JA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P257, DOI 10.1016/0005-2760(92)90004-F; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249	60	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20764	20773		10.1074/jbc.272.33.20764	http://dx.doi.org/10.1074/jbc.272.33.20764			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252399	hybrid			2022-12-25	WOS:A1997XR22100069
J	Xie, XZ; Gillies, RJ; Gerner, EW				Xie, XZ; Gillies, RJ; Gerner, EW			Characterization of a diamine exporter in Chinese hamster ovary cells and identification of specific polyamine substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE; MAMMALIAN-CELLS; ORNITHINE DECARBOXYLASE; PUTRESCINE EXPORT; HEPATOMA-CELLS; RAW-264 CELLS; L1210 CELLS; RAT-LIVER; TRANSPORT; EXCRETION	Export of the diamine putrescine was studied using inside-out plasma membrane vesicles prepared from Chinese hamster cells, Putrescine uptake into vesicles was a saturable and an ATP- and antizyme-independent process, Excess amounts of a series of diamines or mono acetyl spermidine, but not monoacetyl putrescine, spermidine, or spermine, inhibited putrescine transport. Putrescine uptake into vesicles prepared at pH 7.4 was suppressed at pH 5, compared with pH 7.4; was stimulated similar to 2.5-fold at pH 7.4 in vesicles prepared at pH 6.25, compared with vesicles prepared at pH 7.4; and was not inhibited by valinomycin in the presence of potassium ions, Reserpine and verapamil blocked [H-3]putrescine uptake into inverted vesicles. Verapamil treatment caused an increase in intracellular contents of putrescine, cadaverine, and N-8-acetylspermidine, in unstressed proliferating cells, or of N-1-acetylspermidine, in cells subjected to heat shock to induce acetylation of spermidine at N-1, These data indicate that putrescine export in Chinese hamster cells is mediated by a non electrogenic antiporter capable of using protons as the counter ion. Physiological substrates for this exporter include putrescine, cadaverine, and monoacetyl spermidine and have the general structure NH3+-(CH2)(n)-NH2 + R at acidic or neutral pH.	UNIV ARIZONA,ARIZONA CANC CTR,COMM CANC BIOL,TUCSON,AZ 85724; UNIV ARIZONA,ARIZONA CANC CTR,DEPT RADIAT ONCOL,TUCSON,AZ 85724; UNIV ARIZONA,ARIZONA CANC CTR,DEPT BIOCHEM,TUCSON,AZ 85724	Arizona Center Cancer Care; University of Arizona; Arizona Center Cancer Care; University of Arizona; Arizona Center Cancer Care; University of Arizona				Gillies, Robert/0000-0002-8888-7747	NCI NIH HHS [CA-30052, CA-23074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030052, P30CA023074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED M, 1995, J BACTERIOL, V177, P3904, DOI 10.1128/jb.177.14.3904-3910.1995; AZIZ SM, 1994, BIOCHEM PHARMACOL, V48, P1611, DOI 10.1016/0006-2952(94)90206-2; CARPER SW, 1991, BIOCHEM J, V280, P289, DOI 10.1042/bj2800289; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; DAVIS RH, 1989, ARCH BIOCHEM BIOPHYS, V271, P315, DOI 10.1016/0003-9861(89)90281-6; DAVIS RH, 1990, J CELL BIOCHEM, V44, P199, DOI 10.1002/jcb.240440402; DELLARAGIONE F, 1983, BIOCHEM J, V213, P701, DOI 10.1042/bj2130701; DESIDERIO MA, 1992, EXP CELL RES, V202, P501, DOI 10.1016/0014-4827(92)90105-H; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fukumoto GH, 1996, BBA-BIOMEMBRANES, V1282, P48, DOI 10.1016/0005-2736(96)00036-3; Fukumoto GH, 1997, BBA-BIOMEMBRANES, V1324, P215, DOI 10.1016/S0005-2736(96)00227-1; FULGOSI B, 1991, BIOL CHEM H-S, V372, P79, DOI 10.1515/bchm3.1991.372.1.79; FULLER DJM, 1990, BIOCHEM J, V267, P601, DOI 10.1042/bj2670601; GERNER EW, 1980, ANN NY ACAD SCI, V333, P215; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; GRILLO MA, 1994, BIOCHEM SOC T, V22, P894, DOI 10.1042/bst0220894; HARARI PM, 1989, BIOCHEM J, V260, P487, DOI 10.1042/bj2600487; HAWEL L, 1994, J BIOL CHEM, V269, P7412; HAWEL L, 1994, BBA-MOL CELL RES, V1222, P15, DOI 10.1016/0167-4889(94)90020-5; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HYVONEN T, 1989, INT J BIOCHEM, V21, P313, DOI 10.1016/0020-711X(89)90189-4; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; KHAN NA, 1994, NEUROPHARMACOLOGY PO, P37; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; NG EYW, 1994, ANTIMICROB AGENTS CH, V38, P1345, DOI 10.1128/AAC.38.6.1345; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1990, BIOCHEM J, V267, P331, DOI 10.1042/bj2670331; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PEGG AE, 1988, CANCER RES, V48, P2678; SAXENA M, 1995, J BIOL CHEM, V270, P5312, DOI 10.1074/jbc.270.10.5312; SCHAUB T, 1991, FEBS LETT, V279, P83, DOI 10.1016/0014-5793(91)80256-3; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SEILER N, 1980, J CHROMATOGR, V221, P227, DOI 10.1016/S0378-4347(00)84307-8; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; Sha Q, 1996, J BIOL CHEM, V271, P3392; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TJANDRAWINATA RR, 1994, BIOCHEM PHARMACOL, V48, P2237, DOI 10.1016/0006-2952(94)00420-X; TJANDRAWINATA RR, 1995, BIOCHEM J, V305, P291, DOI 10.1042/bj3050291; TJANDRAWINATA RR, 1994, J IMMUNOL, V152, P3039; WALLACE HM, 1986, FEBS LETT, V194, P60, DOI 10.1016/0014-5793(86)80051-5; WARREN L, 1959, J BIOL CHEM, V234, P1971; Woolridge DP, 1997, J BIOL CHEM, V272, P8864; Xie XZ, 1997, EXP CELL RES, V230, P386, DOI 10.1006/excr.1996.3442	44	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20484	20489		10.1074/jbc.272.33.20484	http://dx.doi.org/10.1074/jbc.272.33.20484			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252359	hybrid			2022-12-25	WOS:A1997XR22100029
J	Massotte, D; Baroche, L; Simonin, F; Yu, L; Kieffer, B; Pattus, F				Massotte, D; Baroche, L; Simonin, F; Yu, L; Kieffer, B; Pattus, F			Characterization of delta, kappa, and mu human opioid receptors overexpressed in baculovirus-infected insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE G-PROTEINS; FUNCTIONAL EXPRESSION; SF9 CELLS; RECOMBINANT BACULOVIRUS; INTRINSIC ACTIVITY; ADENYLYL-CYCLASE; BINDING PROTEIN; BRAIN MEMBRANES; CHO CELLS; RECONSTITUTION	The cDNAs encoding human delta (hDOR), kappa (hKOR) and mu (hMOR) opioid receptors were cloned in the baculovirus Autographa californica (AcMNPV) under the control of the polyhedrin promoter with or without an amino-terminal hexahistidine tag, Expression levels were optimized in Spodoptera frugiperda (Sf9) cells and were in the following order hMOR > hDOR > hKOR, The receptors bound antagonists with affinity values similar to those published previously for the receptors expressed in mammalian cells, They also retained selectivity toward specific antagonists, The three receptors bound peptidic agonists with low affinity, suggesting that they might not be functionally coupled to intracellular effectors, Introduction of an amino-terminal hexahistidine tag decreased the levels of expression markedly, Only hMOR-his was expressed at a level allowing binding study, but no difference could be detected in the affinities of both agonists and antagonists compared with the nontagged protein, hMOR expression was also optimized in High Five cells leading to a further increase in protein production, The pharmacological profile was similar to the one obtained when the receptor was expressed in Sf9 cells. Our results show that the baculovirus expression system is suitable for large scale production of human opioid receptors.	INDIANA UNIV,SCH MED,DEPT MED & MOL GENET,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis	Massotte, D (corresponding author), ECOLE SUPER BIOTECHNOL STRASBOURG,DEPT RECEPTEURS & PROT MEMBRANAIRES,CNRS UPR 9050,F-67400 ILLKIRCH GRAFFENS,FRANCE.			massotte, dominique/0000-0002-8758-1009				Alkorta I, 1996, PROTEIN ENG, V9, P573, DOI 10.1093/protein/9.7.573; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Befort K, 1996, MOL PHARMACOL, V49, P216; CHAKRABARTI S, 1995, J NEUROCHEM, V64, P2534; CHEN XS, 1993, EUR J BIOCHEM, V214, P845, DOI 10.1111/j.1432-1033.1993.tb17988.x; CHILDERS SR, 1993, MOL PHARMACOL, V44, P827; DAVIS TR, 1993, IN VITRO CELL DEV-AN, V29A, P388; DONNELLY D, 1994, CURR OPIN STRUC BIOL, V4, P582, DOI 10.1016/S0959-440X(94)90221-6; EMMERSON PJ, 1994, J PHARMACOL EXP THER, V271, P1630; FAN LQ, 1995, J NEUROCHEM, V65, P2537; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; GRISSHAMMER R, 1995, Q REV BIOPHYS, V28, P315, DOI 10.1017/S0033583500003504; Gruenewald Sylvia, 1996, Biochemistry, V35, P15149; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HabibiNezhad B, 1996, J MOL MODEL, V2, P362, DOI 10.1007/s0089460020362; HEITZ F, 1995, J RECEPT SIGNAL TR R, V15, P55, DOI 10.3109/10799899509045207; HEITZ F, 1996, THESIS U STRASBOURG; HERBERT TE, 1996, J BIOL CHEM, V271, P16384; Hjorth SA, 1996, MOL PHARMACOL, V50, P977; JENKINS N, 1996, NAT BIOTECHNOL, V14, P976; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LAW PY, 1995, PHARM OPIOID PEPTIDE, P109; MASSOTTE D, 1995, PROTEIN EXPRES PURIF, V6, P220, DOI 10.1006/prep.1995.1028; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; MESTEK A, 1995, J NEUROSCI, V15, P501; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; NEBIGIL CG, 1995, BIOCHEMISTRY-US, V34, P11954, DOI 10.1021/bi00037a037; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; Obermeier H, 1996, EUR J PHARMACOL, V318, P161, DOI 10.1016/S0014-2999(96)00743-1; OKERBLOM C, 1993, BIOCHIM BIOPHYS ACTA, V1176, P269, DOI 10.1016/0167-4889(93)90055-T; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PAJOTAUGY E, 1995, J MOL ENDOCRINOL, V14, P51, DOI 10.1677/jme.0.0140051; PASTERNAK GW, 1986, LIFE SCI, V38, P1889, DOI 10.1016/0024-3205(86)90217-1; PATEL G, 1992, NUCLEIC ACIDS RES, V20, P97, DOI 10.1093/nar/20.1.97; PORTOGHESE PS, 1988, EUR J PHARMACOL, V146, P185, DOI 10.1016/0014-2999(88)90502-X; PRATHER PL, 1995, MOL BRAIN RES, V29, P336, DOI 10.1016/0169-328X(94)00264-F; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; REED L. J., 1938, AMER JOUR HYG, V27, P493; Schertler G. F. X., 1992, CURR OPIN STRUC BIOL, V2, P534, DOI DOI 10.1016/0959-440X(92)90083-J; SCHILLER PW, 1992, P NATL ACAD SCI USA, V89, P11871, DOI 10.1073/pnas.89.24.11871; SIMONIN F, 1995, P NATL ACAD SCI USA, V92, P7006, DOI 10.1073/pnas.92.15.7006; SIMONIN F, 1994, MOL PHARMACOL, V46, P1015; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; UEDA H, 1990, FEBS LETT, V266, P178, DOI 10.1016/0014-5793(90)81534-U; VASUDEVAN S, 1992, FEBS LETT, V311, P7, DOI 10.1016/0014-5793(92)81354-O; VASUDEVAN S, 1995, EUR J BIOCHEM, V227, P466, DOI 10.1111/j.1432-1033.1995.tb20411.x; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; WICKHAM TJ, 1992, BIOTECHNOL PROGR, V8, P391, DOI 10.1021/bp00017a003; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003; ZASTAWNY RL, 1994, 3 DIMENSIONAL CONFOC, P233	56	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19987	19992		10.1074/jbc.272.32.19987	http://dx.doi.org/10.1074/jbc.272.32.19987			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242668	hybrid			2022-12-25	WOS:A1997XQ05900055
J	Anand, G; Yin, XY; Shahidi, AK; Grove, L; Prochownik, EV				Anand, G; Yin, XY; Shahidi, AK; Grove, L; Prochownik, EV			Novel regulation of the helix-loop-helix protein Id1 by S5a, a subunit of the 26 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DNA-BINDING PROTEINS; MUSCLE DIFFERENTIATION PROGRAM; B-CELL DEVELOPMENT; C-MYC; IMMUNOGLOBULIN ENHANCER; TRANSCRIPTION FACTOR; NEGATIVE REGULATOR; LEUCINE-ZIPPER; GENE FAMILY; G(1) PROGRESSION	Id proteins negatively regulate the dimerization, DNA binding, and biological properties of basic helix-loop-helix proteins. In a search for novel factors that interact with Id1, we identified a component of the 26 S proteasome, S5a, that has previously been implicated only in the recognition of ubiquitinated polypeptides destined for proteolysis. S5a interacts strongly with Id1, less strongly with the basic helix loop-helix proteins MyoD and E12, and not at all with other Id proteins. S5a restores DNA binding by MyoD-Id1 and E12-Id1 heterodimers, enhances DNA binding by MyoD and E12 homodimers, and reverses Id1-mediated repression of the muscle creatine kinase promoter during myogenic differentiation. Mutagenesis experiments showed that amino acids flanking the helix-loop-helix domain plus three residues in the first helix of Id1 impart S5a recognition. This requires only the NH2-terminal half of S5a. S5a thus appears to promote the positive regulation of myogenic genes through ubiquitin-independent mechanisms involving inhibition of Id1 and the enhancement of DNA binding by MyoD and E12. This latter property may permit the selection of novel promoter binding sites during myogenesis.	CHILDRENS HOSP PITTSBURGH, HEMATOL ONCOL SECT, DEPT PEDIAT, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, MED CTR, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NHLBI NIH HHS [HL33741] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DONAGHUE M, 1988, GENE DEV, V2, P1779; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ENZINGER FM, 1988, SOFT TISSUE TUMORS, P448; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FAIRMAN R, 1993, P NATL ACAD SCI USA, V90, P10429, DOI 10.1073/pnas.90.22.10429; FARMER K, 1992, J BIOL CHEM, V267, P5631; FEARON ER, 1992, P NATL ACAD SCI USA, V89, P7958, DOI 10.1073/pnas.89.17.7958; FERELL K, 1996, FEBS LETT, V381, P143; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKEL T, 1993, J BIOL CHEM, V268, P5; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HARA E, 1994, J BIOL CHEM, V269, P2139; HARACSKA L, 1995, EUR J BIOCHEM, V231, P720, DOI 10.1111/j.1432-1033.1995.0720d.x; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P677, DOI 10.1093/nar/18.3.677; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2622; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRAY SS, 1992, J BONE MINER RES, V7, P1131; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OGATA T, 1991, BIOCHEM BIOPH RES CO, V180, P1194, DOI 10.1016/S0006-291X(05)81322-1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; PIEPER FR, 1987, EMBO J, V6, P3611, DOI 10.1002/j.1460-2075.1987.tb02692.x; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REICHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROSE MR, 1990, UCLA SYM BI, V123, P19; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Sambrook J., 2002, MOL CLONING LAB MANU; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAM SW, 1994, ONCOGENE, V9, P2663; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; VANDOREN M, 1991, DEVELOPMENT, V113, P245; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YOON SO, 1994, J BIOL CHEM, V269, P18453; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555	113	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19140	19151		10.1074/jbc.272.31.19140	http://dx.doi.org/10.1074/jbc.272.31.19140			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235903	hybrid			2022-12-25	WOS:A1997XP06300009
J	Glasgow, WC; Hui, RT; Everhart, AL; Jayawickreme, SP; AngermanStewart, J; Han, BB; Eling, TE				Glasgow, WC; Hui, RT; Everhart, AL; Jayawickreme, SP; AngermanStewart, J; Han, BB; Eling, TE			The linoleic acid metabolite, (13S)-hydroxyperoxyoctadecadienoic acid, augments the epidermal growth factor receptor signaling pathway by attenuation of receptor dephosphorylation - Differential response in Syrian hamster embryo tumor suppressor phenotypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ARACHIDONIC-ACID; DNA-SYNTHESIS; MAP KINASE; MITOGENIC RESPONSE; EGF RECEPTOR; CELLS; CANCER; MODULATION; EXPRESSION	In Syrian hamster embryo (SHE) fibroblasts, epidermal growth factor receptor (EGFR) tyrosine kinase activity regulates the metabolism of endogenous linoleic acid to (13S)-hydroperoxyoctadecadienoic acid (13S)-HPODE), (13S)-HPODE stimulates EGF-dependent mitogenesis in a SHE cell phenotype, which expresses tumor suppressor genes (supB(+)), but was not effective in a variant that does not express these suppressor genes (supB(-)). In the present study, we have investigated the potential effects of this lipid metabolite on the EGFR signaling pathways in these two SHE cell lines, Treatment of quiescent SHE cells with EGF produced a rapid, transient increase in the tyrosine phosphorylation of EGFR, Dependence on EGF concentration for EGFR tyrosine phosphorylation was similar in both SHE cell lines, but a more prolonged phosphorylation was detected in the supB(-) variant. Incubation of supB(+) cells with (13S)-HPODE and EGF increased EGFR autophosphorylation and tyrosine phosphorylation on several signaling proteins with Src homology-a domains including GTPase-activating protein, The lipid metabolite did not significantly alter EGF-dependent tyrosine phosphorylation in the supB(-) variant, Tyrosine phosphorylation of mitogen-activated protein (MAP) kinase was also measured, The addition of (13S)-HPODE increased the extent and duration of MAP kinase tyrosine phosphorylation in supB(+) cells but not in the supB(-) variant, MAP kinase activity in supB(+) cells, as measured in immunoprecipitates from cells after the addition of EGF, was increased by the presence of (13S)-HPODE. The addition of (1SS)-HPODE did not directly alter EGFR kinase activity or the internalization of the EGFR, However, the addition of (13S)-HPODE to supB(+) cells extended the tyrosine phosphorylation of the EGFR in response to EGF, The dephosphorylation of the EGFR was measured directly, and a slower rate was observed in the supB(-) compared with the supB(+) cells, Incubation of the supB(+) cells with (1SS)-HPODE attenuated the dephosphorylation of the EGFR. Thus, (13S)-HPODE stimulates EGF-dependent mitogenesis and up-regulation of EGF-dependent tyrosine phosphorylation by inhibiting the dephosphorylation of the EGFR. This study shows that a metabolite of an essential dietary fatty acid, linoleic acid, can modulate tyrosine phosphorylation and activity of key signal transduction proteins in a growth factor mitogenic pathway.	NIEHS,EICOSANOID BIOCHEM SECT,MOL CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; MERCER UNIV,SCH MED,DIV BASIC MED SCI,MACON,GA 31207	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Mercer University								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANGERMANSTEWART JA, 1995, ARCH BIOCHEM BIOPHYS, V318, P378, DOI 10.1006/abbi.1995.1243; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BOHMER FD, 1995, ANAL BIOCHEM, V228, P267, DOI 10.1006/abio.1995.1349; BOWEN S, 1991, J BIOL CHEM, V266, P1162; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COWLEN MS, 1993, BIOCHIM BIOPHYS ACTA, V1174, P234, DOI 10.1016/0167-4781(93)90192-G; COWLEN MS, 1992, CANCER RES, V52, P6912; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FUNK CD, 1993, BIOCHIM BIOPHYS ACTA, V754, P135; GLASGOW WC, 1990, MOL PHARMACOL, V38, P503; GLASGOW WC, 1994, ARCH BIOCHEM BIOPHYS, V311, P286, DOI 10.1006/abbi.1994.1239; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GRISWOLDPRENNER I, 1993, J BIOL CHEM, V268, P13050; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HERNANDEZSOTOMAYOR SMT, 1993, P NATL ACAD SCI USA, V90, P7691, DOI 10.1073/pnas.90.16.7691; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KOI M, 1986, P NATL ACAD SCI USA, V83, P5992, DOI 10.1073/pnas.83.16.5992; KOI M, 1989, P NATL ACAD SCI USA, V86, P8773, DOI 10.1073/pnas.86.22.8773; LASGOW WC, 1996, MOL PHARMACOL, V49, P1042; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NOLAN RD, 1988, MOL PHARMACOL, V33, P650; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; RAO GN, 1994, J BIOL CHEM, V269, P32586; ROSE DP, 1989, BIOCHEM BIOPH RES CO, V164, P277, DOI 10.1016/0006-291X(89)91714-2; ROSE DP, 1993, CANCER RES, V53, P4686; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SORKIN A, 1992, J BIOL CHEM, V267, P8672; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THUN MJ, 1993, CANCER RES, V53, P1322; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251	39	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19269	19276		10.1074/jbc.272.31.19269	http://dx.doi.org/10.1074/jbc.272.31.19269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235921	hybrid			2022-12-25	WOS:A1997XP06300027
J	Kostenis, E; Degtyarev, MY; Conklin, BR; Wess, J				Kostenis, E; Degtyarev, MY; Conklin, BR; Wess, J			The N-terminal extension of G alpha(q) is critical for constraining the selectivity of receptor coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; BETA-GAMMA; MUSCARINIC RECEPTOR; PHOSPHOLIPASE-C; PALMITOYLATION; CLONING; IDENTIFICATION; SPECIFICITY; EXPRESSION; MEMBRANE	Characteristically, an individual member of the superfamily of G protein coupled receptors can interact only with a limited number of the many structurally closely related G protein heterotrimers that are expressed within a cell. Interestingly, the N termini of two G protein a subunits, G alpha(q) and G alpha(11), differ from those of other or subunits in that they display a unique, highly conserved six-amino acid extension, To test the hypothesis that this sequence element is critical for proper receptor recognition, we prepared a G alpha(q) deletion mutant (-6q) lacking these first six amino acids. The -6q construct (or wild type G alpha(q) as a control) was coexpressed (in COS-7 cells) with several different G(i/o)- or G(s)-coupled receptors, and ligand-induced increases in inositol phosphate production were determined as a measure of G protein activation. Whereas these receptors did not efficiently interact with wild type G alpha(q), most of them gained the ability to productively couple to -6q. Additional experiments indicated that the observed functional promiscuity of -6q is not due to overexpression (as compared with wild type G alpha q) or to a lack of palmitoylation. We conclude that the N-terminal extension characteristic for G alpha(q/11) proteins is critical. for constraining the receptor coupling selectivity of these subunits, indicative of a novel mechanism by which the fidelity of receptor-G protein interactions can be regulated.	NIDDK,NIH,BIOORGAN CHEM LAB,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,DEPT PHARMACOL,SAN FRANCISCO,CA 94141	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes			Conklin, Bruce/E-4738-2019					ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Chen BW, 1996, BBA-BIOMEMBRANES, V1281, P125, DOI 10.1016/0005-2736(96)00039-9; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; JIANG MS, 1991, P NATL ACAD SCI USA, V88, P3907, DOI 10.1073/pnas.88.9.3907; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MCCALLUM JF, 1995, BIOCHEM J, V310, P1021, DOI 10.1042/bj3101021; NAKAMURA F, 1991, J BIOL CHEM, V266, P12676; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SHAPIRA H, 1994, FEBS LETT, V348, P89, DOI 10.1016/0014-5793(94)00570-2; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATSON S, 1994, G PROTEIN LINKED REC, P1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0; ZHU J, 1995, LIFE SCI, V56, P201	42	73	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19107	19110		10.1074/jbc.272.31.19107	http://dx.doi.org/10.1074/jbc.272.31.19107			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235898	hybrid			2022-12-25	WOS:A1997XP06300004
J	Souttou, B; Ahmad, S; Riegel, AT; Wellstein, A				Souttou, B; Ahmad, S; Riegel, AT; Wellstein, A			Signal transduction pathways involved in the mitogenic activity of pleiotrophin - Implication of mitogen-activated protein kinase and phosphoinositide 3-kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ASSOCIATED MOLECULE; AFFIN REGULATORY PEPTIDE; NIH 3T3; HEPARIN; CELLS; RECOMBINANT; EXPRESSION; CLONING; ACID; AKT	Pleiotrophin (PTN) is a developmentally regulated protein which exhibits neurite-outgrowth, mitogenic, and angiogenic properties. It has also been shown to be involved in tumor growth and metastasis, Here we used primary BEL (bovine epithelial lens) cells to investigate the signal transduction pathways involved in the mitogenic activity of recombinant PTN. PTN was purified from conditioned media of SW-13 cells transfected with the human PTN cDNA. We show that inhibitors of tyrosine kinase, mitogen-activated protein kinase, or phosphoinositide (PI) 3-kinase inhibit DNA synthesis stimulated by PTN. Analysis of tyrosine-phosphorylated proteins following PTN stimulation showed phosphorylation of two novel 190- and 215-kDa proteins in addition to SHC, ERK1, and ERK2. A mobility shift of phosphorylated ERK1 and ERK2 was detected with a panERK antibody confirming the phosphorylation of the two ERKs. Furthermore, in vitro immunocomplex kinase assay with Akt1, a natural substrate of PI 3-kinase, showed an activation of the kinase following PTN stimulation and a reversal by the PI 3-kinase inhibitor wortmannin, We conclude that the mitogenic activity of PTN is dependent on tyrosine kinase activation and utilizes the mitogen-activated protein kinase and the PI 3-kinase pathways to transduce a mitogenic signal.	GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC 20007	Georgetown University; Georgetown University				Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [CA58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; DELBE J, 1995, J CELL PHYSIOL, V164, P47, DOI 10.1002/jcp.1041640107; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOJIMA S, 1995, BIOCHEM BIOPH RES CO, V216, P574, DOI 10.1006/bbrc.1995.2661; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LI YS, 1993, BIOCHEM BIOPH RES CO, V195, P1089, DOI 10.1006/bbrc.1993.2156; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAULAIS D, 1991, BIOCHEM BIOPH RES CO, V174, P708, DOI 10.1016/0006-291X(91)91475-R; RAULO E, 1992, J BIOL CHEM, V267, P11408; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schulte AM, 1997, TUMOUR ANGIOGENESIS, P273; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; TAKAMATSU H, 1992, BIOCHEM BIOPH RES CO, V185, P224, DOI 10.1016/S0006-291X(05)80979-9; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63	30	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19588	19593		10.1074/jbc.272.31.19588	http://dx.doi.org/10.1074/jbc.272.31.19588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235965	hybrid			2022-12-25	WOS:A1997XP06300071
J	Giraldez, RR; Panda, A; Xia, Y; Sanders, SP; Zweier, JL				Giraldez, RR; Panda, A; Xia, Y; Sanders, SP; Zweier, JL			Decreased nitric-oxide synthase activity causes impaired endothelium-dependent relaxation in the postischemic heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXING FACTOR; MYOCARDIAL-ISCHEMIA; CORONARY-ARTERIES; TIME COURSE; REPERFUSION; CELLS; ACETYLCHOLINE; DYSFUNCTION; INJURY; PARTICULATE	Endothelial nitric-oxide synthase (eNOS) is an important regulator of endothelial function and vascular tone in biological tissues, While endothelial dysfunction occurs following ischemia and has been attributed to altered NO. formation, the biochemical basis for this dysfunction is unknown, Therefore, studies were performed to determine the effects of myocardial ischemia and reperfusion on eNOS in isolated rat hearts subjected to periods of global ischemia or ischemia followed by reperfusion. eNOS activity was assayed by L-[C-14]arginine to L-[C-14]citrulline conversion and alterations in the amount and distribution of eNOS determined by Western blotting and immunohistochemistry. While activity was preserved after 30 min of ischemia with a value of 1.1 +/- 0.1 pmol x min(-1) x mg of protein(-1), it decreased by 77% after 60 min and became nearly undetectable after 120 min. Reperfusion resulted in only a partial restoration of activity, The decline in activity with ischemia was due, in part, to a loss of eNOS protein, Hemodynamic studies showed that the onset of impaired vascular reactivity paralleled the loss of functional eNOS, Subjecting isolated eNOS to conditions of acidosis, which occur during ischemia, followed by restoration of pH as occurs on reperfusion, caused a combination of reversible and irreversible loss of activity similar 60 that seen in ischemic and reperfused hearts, Thus, Loss of endothelial function following ischemia is paralleled by a loss of eNOS activity due to a combination of pa-dependent denaturation and proteolysis.	JOHNS HOPKINS BAYVIEW MED CTR, JOHNS HOPKINS MED INST, DIV CARDIOL, DEPT MED, BALTIMORE, MD 21224 USA; JOHNS HOPKINS BAYVIEW MED CTR, JOHNS HOPKINS MED INST, ELECTRON PARAMAGNET RESONANCE CTR, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, R29HL038324, P50HL052315] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52315, HL-38324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; COSENTINO F, 1995, CIRCULATION, V91, P139, DOI 10.1161/01.CIR.91.1.139; FLEMING I, 1994, CIRC RES, V74, P1220, DOI 10.1161/01.RES.74.6.1220; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRIFFITH TM, 1986, CARDIOVASC RES, V20, P7, DOI 10.1093/cvr/20.1.7; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; JOHNS RA, 1989, CIRC RES, V65, P1508, DOI 10.1161/01.RES.65.6.1508; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEHTA JL, 1989, CIRC RES, V64, P43, DOI 10.1161/01.RES.64.1.43; MEHTA JL, 1989, AM J PHYSIOL, V257, pH1240, DOI 10.1152/ajpheart.1989.257.4.H1240; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH815, DOI 10.1152/ajpheart.1986.250.5.H815; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; SESSA WC, 1990, P NATL ACAD SCI USA, V87, P8607, DOI 10.1073/pnas.87.21.8607; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; TSAO PS, 1990, CIRCULATION, V82, P1402, DOI 10.1161/01.CIR.82.4.1402; TSAO PS, 1990, AM J PHYSIOL, V259, pH1660, DOI 10.1152/ajpheart.1990.259.6.H1660; URSELL PC, 1993, CARDIOVASC RES, V27, P1920, DOI 10.1093/cvr/27.11.1920; VALLANCE P, 1992, J VASC RES, V29, P217; VANBENTHUYSEN KM, 1987, J CLIN INVEST, V79, P265, DOI 10.1172/JCI112793; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; WEISS RG, 1990, J CLIN INVEST, V85, P757, DOI 10.1172/JCI114501; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; ZEIHER AM, 1993, J CLIN INVEST, V92, P652, DOI 10.1172/JCI116634; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304	35	146	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21420	21426		10.1074/jbc.272.34.21420	http://dx.doi.org/10.1074/jbc.272.34.21420			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261157	hybrid			2022-12-25	WOS:A1997XR78900067
J	Huber, M; Yee, VC; Burri, N; Vikerfors, E; Lavrijsen, APM; Paller, AS; Hohl, D				Huber, M; Yee, VC; Burri, N; Vikerfors, E; Lavrijsen, APM; Paller, AS; Hohl, D			Consequences of seven novel mutations on the expression and structure of keratinocyte transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL KERATINOCYTES; COAGULATION-FACTOR-XIII; RECESSIVE LAMELLAR ICHTHYOSIS; CORNIFIED CELL-ENVELOPE; CROSS-LINKING ENZYMES; MEMBRANE ANCHORAGE; SENSITIVE METHOD; A-SUBUNIT; GENE; PROTEIN	We report the molecular characterization of seven new keratinocyte transglutaminase mutations (R315C, S358R, V379L, G473S, R687C, deletion Delta 679-696, R127Stop) found in lamellar ichthyosis patients, Arg 315, Ser-358, Val-379, and Gly-473 are highly conserved residues in transglutaminases while Arg-687 and Delta 679-696 are not. All mutations strongly decreased transglutaminase activity and protein levels, The mutation R127Stop diminished the amount of mRNA, Structural analysis of these mutations based. on the factor XIII A-subunit crystal structure demonstrated that Arg-315, Ser-358, Val-379, and Gly-413 are located in the catalytic core domain, and Arg-687 and the deletion are in the beta-barrel domains, The side chains of amino acids Arg-315, Ser-358, and Gly-473 make ionic and hydrogen bonds important for folding and structural stability of the enzyme but are not directly involved in catalysis. Val-379 is two amino acids away from the active site cysteine, and its change into leucine disturbs the active site structure. The decreased activity and protein level after expression of the R687C and Delta 619-696 TGIC cDNA in TGK negative keratinocytes excluded that they are polymorphisms. These results identify important amino acids in the central core domain of transglutaminases and show that the C-terminal end influences the structural and functional integrity of TGK.	CHU VAUDOIS, DHURDV, DERMATOL SERV, CH-1011 LAUSANNE, SWITZERLAND; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; OREBRO MED CTR HOSP, DEPT DERMATOL, S-70185 OREBRO, SWEDEN; UNIV LEIDEN HOSP, DEPT DERMATOL, NL-2300 AK LEIDEN, NETHERLANDS; NORTHWESTERN UNIV, CHILDRENS MEM HOSP, SCH MED, DEPT DERMATOL, CHICAGO, IL 60614 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Washington; University of Washington Seattle; Leiden University; Leiden University Medical Center (LUMC); Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University			Huber, Marcel/M-8822-2016; Hohl, Daniel M/N-7554-2016	Huber, Marcel/0000-0003-3821-2378; Paller, Amy/0000-0001-6187-6549				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ANTONLAMPRECHT I, 1992, SKIN, P459; ASLAM S, 1995, BRIT J HAEMATOL, V91, P452, DOI 10.1111/j.1365-2141.1995.tb05321.x; BOARD P, 1992, BLOOD, V80, P937; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER DN, 1993, ANN MED, V25, P11, DOI 10.3109/07853899309147851; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; CORTEN M, 1994, GENE THER, V1, P239; DEVIRAGH PA, 1994, J INVEST DERMATOL, V103, P815, DOI 10.1111/1523-1747.ep12413482; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HETTASCH JM, 1994, J BIOL CHEM, V269, P28309; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HUBER M, 1995, J INVEST DERMATOL, V105, P653, DOI 10.1111/1523-1747.ep12324122; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; ICHINOSE A, 1993, METHOD ENZYMOL, V222, P36; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1992, J BIOL CHEM, V267, P7710; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1994, J BIOL CHEM, V269, P27979; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI TS, 1994, J BIOL CHEM, V269, P24596; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Mikkola H, 1996, BLOOD, V87, P141; MIKKOLA H, 1994, BLOOD, V84, P517; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PARMENTIER L, 1995, HUM MOL GENET, V4, P1391, DOI 10.1093/hmg/4.8.1391; Parmentier L, 1996, HUM MOL GENET, V5, P555, DOI 10.1093/hmg/5.4.555; PECERSEN L, 1994, PROTEIN SCI, V3, P1131; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; PHILLIPS SB, 1993, DERMATOLOGY GEN MED, P531; POLAKOWSKA RR, 1991, CYTOGENET CELL GENET, V56, P105, DOI 10.1159/000133060; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Rice RH, 1996, BIOCHEM J, V320, P547, DOI 10.1042/bj3200547; ROSSMANNRINGDAHL I, 1986, ARCH DERMATOL, V122, P559; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1996, BIOCHEM BIOPH RES CO, V221, P101, DOI 10.1006/bbrc.1996.0552; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TRAUPE H, 1989, ICHTHYOSES, P111; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296	65	64	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21018	21026		10.1074/jbc.272.34.21018	http://dx.doi.org/10.1074/jbc.272.34.21018			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261103	hybrid, Green Published			2022-12-25	WOS:A1997XR78900013
J	Saras, J; Engstrom, U; Gonez, LJ; Heldin, CH				Saras, J; Engstrom, U; Gonez, LJ; Heldin, CH			Characterization of the interactions between PDZ domains of the protein-tyrosine phosphatase PTPL1 and the carboxyl-terminal tail of Fas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE KINASES; CLONING; APOPTOSIS; BAND-4.1; HOMOLOG; ANTIGEN; FAMILY; CDNA	The intracellular protein-tyrosine phosphatase PTPL1 has five PDZ domains and one of them, PDZ 2, has previously been shown to interact with the C-terminal tail of Fas, a member of the tumor necrosis factor receptor family. Using a peptide binding assay, we show that not only PDZ 2 but also PDZ 4 of PTPL1 interacts with high affinity with peptides derived from the C terminus of Fas. The five most C-terminal amino acid residues of Fas influence the affinity of the interaction. Whereas the glutamine and isoleucine residues in the 4th and 5th positions from the C terminus affect the interaction in a negative and positive manner, respectively, the three C-terminal amino acid residues (SLV) are necessary and sufficient for a high affinity interaction to occur. Both the carboxyl group and side chain of the valine residue at the C terminus of Fas are essential, and the leucine and serine residues in the 2nd and 3rd positions, respectively, from the C terminus are important for the interactions with PDZ 2 and PDZ 4 of PTPL1.			Saras, J (corresponding author), BIOMED CTR,LUDWIG INST CANC RES,BOX 595,S-75124 UPPSALA,SWEDEN.							ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	26	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20979	20981		10.1074/jbc.272.34.20979	http://dx.doi.org/10.1074/jbc.272.34.20979			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261095	hybrid			2022-12-25	WOS:A1997XR78900005
J	Shin, KS; Park, JY; Kwon, H; Chung, CH; Kang, MS				Shin, KS; Park, JY; Kwon, H; Chung, CH; Kang, MS			Opposite effect of intracellular Ca2+ and protein kinase C on the expression of inwardly rectifying K+ channel 1 in mouse skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ RELEASE CHANNEL; MEMBRANE DEPOLARIZATION; SARCOPLASMIC-RETICULUM; GENE-EXPRESSION; CALCIUM INFLUX; RAT; RECEPTOR; CELLS; DENERVATION; INNERVATION	The level of inwardly rectifying K+ channel 1 (IRK1) mRNA decreased upon denervation and increased during muscle differentiation in mouse skeletal muscle, To identify the mechanism(s) underlying the regulation of IRK1 mRNA expression, we examined its expression using the well differentiated C2C12 mouse skeletal muscle cell line as a model system, Since nerve-induced muscle activity results in contraction, it was questioned whether the changes in IRK1 expression might be relevant to the increased intracellular calcium that functions as a cytoplasmic messenger in excitation-contraction coupling, Indeed, activation of either L-type calcium channels or ryanodine receptors increased the level of IRK1 mRNA, More directly, ionomycin activated the IRK1 expression in time-and dose-dependent manners, which was abolished by treatment with EGTA, Genistein, a tyrosine kinase inhibitor, also abolished the stimulating effect of ionomycin. Meanwhile, activation of protein kinase C by 12-O-tetradecanoylphorbol acetate (TPA) markedly decreased the level of IRK1 mRNA, which required ongoing protein synthesis, Actinomycin D experiments revealed that ionomycin increased the half life of IRK1 mRNA from 0.86 to 1.97 h, but TPA decreased it to 0.38 h, However, neither ionomycin nor TPA appreciably altered the rate of IRK1 gene transcription, Based on these observations, we conclude that intracellular calcium and protein kinase C are oppositely involved in the muscle activity dependent regulation of IRK1 gene expression and that both act at the level of mRNA stability.	SEOUL NATL UNIV,DEPT MOL BIOL,SEOUL 151742,SOUTH KOREA; SEOUL NATL UNIV,RES CTR CELL DIFFERENTIAT,SEOUL 151742,SOUTH KOREA; DANKOOK UNIV,DEPT MOL BIOL,SEOUL 140714,SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU); Dankook University			Tuluc, Petronel/C-2527-2011					ADRIAN RH, 1962, J PHYSIOL-LONDON, V163, P61, DOI 10.1113/jphysiol.1962.sp006959; ADRIAN RH, 1973, J PHYSIOL-LONDON, V235, P103, DOI 10.1113/jphysiol.1973.sp010380; ALBUQUERQUE EX, 1971, PFLUG ARCH EUR J PHY, V328, P36, DOI 10.1007/BF00587359; ALMERS W, 1972, J PHYSIOL-LONDON, V225, P57, DOI 10.1113/jphysiol.1972.sp009929; BIRNBAUM M, 1980, PFLUG ARCH EUR J PHY, V385, P37, DOI 10.1007/BF00583913; BLOCH RJ, 1986, J NEUROSCI, V6, P691; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BRIMIJOIN S, 1988, NERVE MUSCLE CELL TR, P23; CHAHINE KG, 1993, J BIOL CHEM, V268, P2893; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLELAND PJF, 1989, J BIOL CHEM, V264, P17704; DAVID JD, 1981, DEV BIOL, V82, P308, DOI 10.1016/0012-1606(81)90454-1; DAVIS HL, 1985, BRAIN RES, V343, P176, DOI 10.1016/0006-8993(85)91174-6; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; GONOI T, 1991, PFLUG ARCH EUR J PHY, V418, P601, DOI 10.1007/BF00370577; GREENBERG ME, 1989, CURRENT PROTOCOLS  S, V9; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HNIK P, 1976, PFLUG ARCH EUR J PHY, V362, P85, DOI 10.1007/BF00588685; HUANG CF, 1994, FEBS LETT, V338, P277, DOI 10.1016/0014-5793(94)80283-1; HUANG CF, 1993, FEBS LETT, V319, P21, DOI 10.1016/0014-5793(93)80029-T; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; KATZ B, 1949, ARCH SCI PHYSIOL, V3, P285; KEAN CJC, 1974, J PHYSIOL-LONDON, V237, P103, DOI 10.1113/jphysiol.1974.sp010472; KIM HS, 1992, DEV BIOL, V150, P223, DOI 10.1016/0012-1606(92)90237-B; KLOCKE R, 1994, J BIOL CHEM, V269, P27635; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; MATSUDA H, 1989, J PHYSIOL-LONDON, V414, P111, DOI 10.1113/jphysiol.1989.sp017679; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; NESTLER EJ, 1978, NATURE, V275, P451, DOI 10.1038/275451a0; PAPPONE PA, 1980, J PHYSIOL-LONDON, V306, P377, DOI 10.1113/jphysiol.1980.sp013403; REDFERN P, 1971, ACTA PHYSIOL SCAND, V81, P557, DOI 10.1111/j.1748-1716.1971.tb04932.x; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROTSHENKER S, 1976, J NEUROCYTOL, V5, P719, DOI 10.1007/BF01181583; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; RUBIN LL, 1985, P NATL ACAD SCI USA, V82, P7121, DOI 10.1073/pnas.82.20.7121; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHIMID A, 1984, FEBS LETT, V172, P114; SCHMIDANTOMARCHI H, 1985, P NATL ACAD SCI USA, V82, P2188, DOI 10.1073/pnas.82.7.2188; SHERMAN SJ, 1985, J NEUROSCI, V5, P1570; Shin KS, 1997, AM J PHYSIOL-CELL PH, V272, pC894, DOI 10.1152/ajpcell.1997.272.3.C894; STEINBACH JH, 1981, J PHYSIOL-LONDON, V313, P513, DOI 10.1113/jphysiol.1981.sp013679; SYROVY I, 1972, PHYSIOL BOHEMOSLOV, V21, P353; WAKELAM MJO, 1985, BIOCHEM J, V228, P1; WALKE W, 1994, J BIOL CHEM, V269, P19447; WESTGAARD RH, 1975, J PHYSIOL-LONDON, V251, P683, DOI 10.1113/jphysiol.1975.sp011116; [No title captured]	47	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21227	21232		10.1074/jbc.272.34.21227	http://dx.doi.org/10.1074/jbc.272.34.21227			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261131	hybrid			2022-12-25	WOS:A1997XR78900041
J	Coso, OA; Montaner, S; Fromm, C; Lacal, JC; Prywes, R; Teramoto, H; Gutkind, JS				Coso, OA; Montaner, S; Fromm, C; Lacal, JC; Prywes, R; Teramoto, H; Gutkind, JS			Signaling from G protein coupled receptors to the c-jun promoter involves the MEF2 transcription factor - Evidence for a novel c-Jun amino-terminal kinase-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; MAP KINASE; ACTIVATION DOMAIN; FOS; DIFFERENTIATION; PHOSPHORYLATION; TRANSFORMATION; FAMILY; MUSCLE; BINDS	The c-Jun amino-terminal kinases (JNKs) are a subfamily of mitogen-activated protein kinases that phosphorylate c-Jun and ATF2, and it has been postulated that phosphorylated c-Jun enhances its own expression through AP-1 sites on the c-jun promoter. In this study, we asked whether signals activating JNK regulate the c-jun promoter, Using NIH 3T3 cells expressing G protein-coupled mi acetylcholine receptors as an experimental model, we have recently shown that the cholinergic agonist carbachol, but not platelet derived growth factor, potently elevates JNK activity, Consistent with these findings, carbachol, but not platelet-derived growth factor, increased the activity of a c-jun promoter-driven reporter gene (for chloramphenicol acetyltransferase), However, coexpression of JNK kinase kinase (MEKK) effectively increased JNK activity, but resulted in surprisingly limited induction of the c- jun promoter, This raised the possibility that pathway(s) distinct from JNK control the c-jun promoter, and prompted us to explore which of its regulatory elements participate in transcriptional control. We observed that deletion of the 3' AP-1 site diminished chloramphenicol acetyltransferase activity in response to carbachol, but only to a limited extent, In contrast, deletion of a MEF2 site dramatically reduced expression, and deletion of both the MEF2 and 3' AP-1 sites abolished induction, Furthermore, cotransfection with MEF2C and MEF2D cDNAs potently enhanced the activity of the c-jun promoter in response to carbachol, and stimulation of mi receptors, but not direct JNK activation, induced expression of a MEF2-responsive plasmid. Taken together, these data strongly suggest that MEF2 mediates c-jun promoter expression by G protein-coupled receptors through a yet to be identified pathway, distinct from that of JNK.	NIDR,MOL SIGNALING UNIT,ORAL & PHARYNGEAL CANC BRANCH,NIH,BETHESDA,MD 20892; INST INVEST BIOMED,MADRID 28029,SPAIN; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Columbia University			Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Gutkind, J. Silvio/0000-0002-5150-4482; Lacal, Juan Carlos/0000-0002-1908-2777				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DODOU E, 1995, NUCLEIC ACIDS RES, V23, P4267, DOI 10.1093/nar/23.21.4267; Graves JD, 1995, ANN NY ACAD SCI, V766, P320, DOI 10.1111/j.1749-6632.1995.tb26684.x; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; YAN MH, 1994, NATURE, V372, P798	31	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20691	20697		10.1074/jbc.272.33.20691	http://dx.doi.org/10.1074/jbc.272.33.20691			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252389	hybrid			2022-12-25	WOS:A1997XR22100059
J	Kennedy, MC; Antholine, WE; Beinert, H				Kennedy, MC; Antholine, WE; Beinert, H			An EPR investigation of the products of the reaction of cytosolic and mitochondrial aconitases with nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; NITROSYL COMPLEX-FORMATION; IRON-SULFUR CLUSTER; ACTIVATED MACROPHAGES; TRANSFERRIN RECEPTOR; TRANSLATIONAL REGULATION; MESSENGER-RNA; CYTO-TOXICITY; TUMOR-CELLS; EXPRESSION	Cellular studies have indicated that some Fe-S proteins, and the aconitases in particular, are targets for nitric oxide, Specifically, NO has been implicated in the intracellular process of the conversion of active cytosolic aconitase containing a [4Fe-4S] cluster, to its apo-form which functions as an iron-regulatory protein, We have undertaken the in vitro study of the reaction of NO with purified forms of both mitochondrial and cytosolic aconitases by following enzyme activity and by observing the formation of EPR signals not shown by the original reactants, Inactivation by either NO solutions or NO-producing NONOates under anaerobic conditions is seen for both enzyme isoforms, This inactivation, which occurs in the presence or absence of substrate, is accompanied by the appearance of the g = 2.02 signals of the [3Fe-4S] clusters and the g approximate to 2.04 signal of a protein-bound dinitrosyl-iron-dithiol complex in the d(7) state, In addition, in the reaction of cytosolic aconitase, the transient formation of a thiyl radical, g(parallel to) = 2.11 and g(perpendicular to) = 2.03, is observed, Disassembly of the [3Fe-4S] clusters of the inactive forms of the enzymes upon the anaerobic addition of NO is also accompanied by the formation of the g approximate to 2.04 species and in the case of mitochondrial aconitase, a transient signal atg approximate to 2.032 appeared. This signal is tentatively assigned to the d(9) form of an iron-nitrosylhistidyl complex of the mitochondrial protein. Inactivation of the [4Fe-4S] forms of both aconitases by either superoxide anion or peroxynitrite produces the g = 2.02 [3Fe-4S] proteins.	MED COLL WISCONSIN,BIOPHYS RES INST,MILWAUKEE,WI 53226; UNIV WISCONSIN,INST ENZYME RES,GRAD SCH,MADISON,WI 53705; UNIV WISCONSIN,DEPT BIOCHEM,COLL AGR & LIFE SCI,MADISON,WI 53705	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kennedy, MC (corresponding author), MED COLL WISCONSIN,DEPT BIOCHEM,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051831] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51831] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASTIAN NR, 1994, J BIOL CHEM, V269, P5127; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; CAIRO G, 1995, EUR J BIOCHEM, V232, P358, DOI 10.1111/j.1432-1033.1995.tb20819.x; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CASTRO L, 1994, J BIOL CHEM, V269, P29409; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; EATON DR, 1987, ELECT MAGNETIC RESON; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Gruer MJ, 1997, TRENDS BIOCHEM SCI, V22, P3, DOI 10.1016/S0968-0004(96)10069-4; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIBBS JB, 1984, BIOCHEM BIOPH RES CO, V123, P716, DOI 10.1016/0006-291X(84)90288-2; ISCHIROPOLOUS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P597; JAFFREY SR, 1994, P NATL ACAD SCI USA, V91, P12994, DOI 10.1073/pnas.91.26.12994; KEEFER LK, 1996, METHOD ENZYMOL, V268, P271; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LEE MH, 1994, BIOCHEMISTRY-US, V33, P3679, DOI 10.1021/bi00178a026; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MCDONALD CC, 1965, J AM CHEM SOC, V87, P3319, DOI 10.1021/ja01093a007; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NELSON D, 1975, CHEM PHYS LETT, V36, P340, DOI 10.1016/0009-2614(75)80250-8; ORIA R, 1995, BLOOD, V85, P2962, DOI 10.1182/blood.V85.10.2962.bloodjournal85102962; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; REDDY D, 1983, SCIENCE, V221, P769, DOI 10.1126/science.6308761; REED JW, 1974, J AM CHEM SOC, V96, P1248, DOI 10.1021/ja00811a062; RICHARDSON DR, 1995, BLOOD, V86, P3211; ROUAULT TA, 1991, CELL, V64, P861; RYDEN L, 1984, J BIOL CHEM, V259, P3141; SALERNO JC, 1976, BIOCHEM BIOPH RES CO, V73, P833, DOI 10.1016/0006-291X(76)90884-6; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; STEVENS TH, 1979, P NATL ACAD SCI USA, V76, P3320, DOI 10.1073/pnas.76.7.3320; THEIL EC, 1994, BIOCHEM J, V304, P1; VANIN A F, 1967, Biofizika, V12, P829; VANIN AF, 1995, BIOCHEMISTRY-MOSCOW+, V60, P225; VANIN AF, 1967, BIOCHEMISTRY-MOSCOW+, V32, P228; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WOOLUM JC, 1968, BIOCHIM BIOPHYS ACTA, V160, P311, DOI 10.1016/0005-2795(68)90204-3	51	216	222	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20340	20347		10.1074/jbc.272.33.20340	http://dx.doi.org/10.1074/jbc.272.33.20340			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252338	hybrid			2022-12-25	WOS:A1997XR22100008
J	Kuttkat, A; Edhofer, I; Eichacker, LA; Paulsen, H				Kuttkat, A; Edhofer, I; Eichacker, LA; Paulsen, H			Light-harvesting chlorophyll a/b-binding protein stably inserts into etioplast membranes supplemented with Zn-pheophytin a/b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LESS BARLEY MUTANT; A-B PROTEIN; THYLAKOID MEMBRANES; STROMAL FACTOR; COMPLEX-II; INTEGRATION; APOPROTEINS; PRECURSOR; POLYPEPTIDE; ETIOCHLOROPLASTS	Light-harvesting chlorophyll alb-binding protein, LHCP, or its precursor, pLHCP, cannot be stably inserted into barley etioplast membranes in vitro. However, when these etioplast membranes are supplemented with the chlorophyll analogs Zn-pheophytin a/b, synthesized in situ from Zn-pheophorbide a/b and digeranyl pyrophosphate, pLHCP is inserted into a protease-resistant state, This proves that chlorophyll is the only component lacking in etioplast membranes that is necessary for stable LHCP insertion, Synthesis of Zn-pheophytin b alone promotes insertion of LHCP in. vitro into a protease-resistant state, whereas synthesis of Zn-pheophytin a alone does not, Insertion of pLHCP into etioplast membranes can also be stimulated by adding chlorophyll a and chlorophyll b to the membranes, albeit at a significantly lower efficiency as compared with Zn-pheophytin a/b synthesized in situ, When pLHCP is inserted into chlorophyll-or Zn-pheophytin-supplemented etioplast membranes and then assayed with protease, only the protease digestion product indicative of the monomeric major light-harvesting chlorophyll a/b complex (LHCII) is found but not the one indicating trimeric complexes, In this respect, chlorophyll-or Zn-pheophytin-supplemented etioplast membranes resemble thylakoid membranes at an early greening stage: pLHCP inserted into plastid membranes from greening barley is assembled into trimeric LHCII only after more than 1 h of greening.	UNIV MAINZ,INST ALLGEMEINE BOT,D-55099 MAINZ,GERMANY; UNIV MUNICH,INST BOT,D-80638 MUNICH,GERMANY	Johannes Gutenberg University of Mainz; University of Munich			Paulsen, Harald/D-3742-2011					ADAMSKA I, 1995, LIGHT BIOSPHERE, V3, P887; APEL K, 1980, PLANTA, V150, P426, DOI 10.1007/BF00390180; BASSI R, 1985, CARLSBERG RES COMMUN, V50, P145, DOI 10.1007/BF02907142; BENNETT J, 1981, EUR J BIOCHEM, V118, P61, DOI 10.1111/j.1432-1033.1981.tb05486.x; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CHITNIS PR, 1988, PLANT MOL BIOL, V11, P95, DOI 10.1007/BF00015663; CHITNIS PR, 1987, PLANT MOL BIOL, V10, P3, DOI 10.1007/BF00014181; CHITNIS PR, 1986, J CELL BIOL, V102, P982, DOI 10.1083/jcb.102.3.982; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; COHEN Y, 1995, BBA-REV BIOMEMBRANES, V1241, P1, DOI 10.1016/0304-4157(94)00012-3; DREYFUSS BW, 1994, PLANT PHYSIOL, V106, P829, DOI 10.1104/pp.106.3.829; DUBACQ JP, 1983, PHYSIOL VEG, V21, P293; Eichacker LA, 1996, FEBS LETT, V395, P251, DOI 10.1016/0014-5793(96)01026-5; Eichacker LA, 1996, J BIOL CHEM, V271, P32174, DOI 10.1074/jbc.271.50.32174; EICHACKER LA, 1990, J BIOL CHEM, V265, P13566; FUNK C, 1995, BIOCHEMISTRY-US, V34, P11133, DOI 10.1021/bi00035a019; HELFRICH M, 1992, Z NATURFORSCH C, V47, P231; HELFRICH M, 1994, EUR J BIOCHEM, V219, P267, DOI 10.1111/j.1432-1033.1994.tb19938.x; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; ITO H, 1994, J BIOL CHEM, V269, P22034; Jansson S, 1992, PLANT MOL BIOL REP, V10, P242, DOI 10.1007/BF02668357; JONES ID, 1977, J AGR FOOD CHEM, V25, P146, DOI 10.1021/jf60209a025; JOO CN, 1973, CAN J BIOCHEM, V51, P1517; Klosgen RB, 1997, J PHOTOCH PHOTOBIO B, V38, P1, DOI 10.1016/S1011-1344(96)07408-8; KROL M, 1995, PLANT PHYSIOL, V107, P873, DOI 10.1104/pp.107.3.873; KUTTKAT A, 1995, PLANT PHYSIOL, V109, P1267, DOI 10.1104/pp.109.4.1267; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; NECHUSHTAI R, 1995, PHOTOSYNTH RES, V44, P165, DOI 10.1007/BF00018307; NUSSBERGER S, 1993, J MOL BIOL, V234, P347, DOI 10.1006/jmbi.1993.1591; PAULSEN H, 1995, PHOTOCHEM PHOTOBIOL, V62, P367, DOI 10.1111/j.1751-1097.1995.tb02357.x; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PORRA RJ, 1995, FEBS LETT, V371, P21, DOI 10.1016/0014-5793(95)00854-3; PREISS S, 1995, PLANT PHYSIOL, V107, P709, DOI 10.1104/pp.107.3.709; Scheumann V, 1996, Z NATURFORSCH C, V51, P185; SHIMADA Y, 1990, PLANT CELL PHYSIOL, V31, P639; TANAKA A, 1991, PLANT CELL PHYSIOL, V32, P195, DOI 10.1093/oxfordjournals.pcp.a078064; TANAKA A, 1994, PLANTA, V192, P92; TREMOLIERES A, 1991, TRENDS PHOTOCHEM PHO, V2, P13; WIDEMAIER R, 1980, ARCH BIOCHEM BIOPHYS, V200, P609; YUAN JG, 1993, P NATL ACAD SCI USA, V90, P8552, DOI 10.1073/pnas.90.18.8552	44	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20451	20455		10.1074/jbc.272.33.20451	http://dx.doi.org/10.1074/jbc.272.33.20451			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252354	hybrid			2022-12-25	WOS:A1997XR22100024
J	Lin, WH; Hung, CH; Hsu, CI; Lin, JY				Lin, WH; Hung, CH; Hsu, CI; Lin, JY			Dimerization of the N-terminal amphipathic alpha-helix domain of the fungal immunomodulatory protein from Ganoderma tsugae (Fip-gts) defined by a yeast two-hybrid system and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LING ZHI-8 LZ-8; TRANSFORMATION; POLYPEPTIDES; CLONING	A fungal immunomodulatory protein (Fip-gts) was purified from Ganoderma tsugae, The DNA encoding Fip-gts was isolated from a cDNA library of G. tsugae by reverse transcriptase-polymerase chain reaction, The complete amino acid sequence of Fip-gts, deduced from the nucleotide sequence of the cDNA, was the same as LZ-8 isolated from Ganodermn lucidum, Recombinant Fip-gts was expressed as a glutathione S-transferase fusion protein in Escherichia coli with a yield of 20 mg/liter of culture, Recombinant Fip-gts, purified to homogeneity, had the same blast formation stimulatory activity to human peripheral blood lymphocytes as native Fip-gts. The yeast two-hybrid system and site directed mutagenesis were used to determine whether dimerization of Fip-gts occurred, Deletion analysis of the N-terminal amphipathic alpha-helix domain of Fip-gts identified a sequence of about 10 amino acids responsible for inducing immunomodulatory activity. Non-functional Fip-gts deletion mutants did not form dimers, whereas wild type Fip-gts did as determined by gel filtration, A mutant with deletions at Leu-5, Phe-7, and Leu-9 lost the amphipathic characteristics of the N-terminal domain and the ability to form dimers as well as its immunomodulatory activity. Fusion of Fip-gts with the DNA binding and the transactivation domains of GAL4 resulted in the activation of the lacZ activator gene, indicating the interaction of Fip-gts with it itself, The dimerization domain was further defined by analyzing the ability of the N-terminal 13 amino acids or Leu-5, Phe-7, and Leu-9 deletion mutants of Fip-gts to interact with the wild type Fip-gts. These experiments confirmed the N-terminal amphipathic alpha-helix as the dimerization domain and suggest that the dimerization of Fip-gts may play an important role in Fip-gts immunomodulatory activity.	NATL TAIWAN UNIV,COLL MED,INST BIOCHEM,TAIPEI 100,TAIWAN	National Taiwan University			Lin, Jung-Yaw/AGW-9336-2022	Lin, Jung-Yaw/0000-0002-6341-1160				CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DAVID DS, 1980, JAMA-J AM MED ASSOC, V243, P532; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; Eisenberg D., 1982, FARADAY S CHEM SOC, V17, P109, DOI DOI 10.1039/FS9821700109; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUBLER U, 1983, GENE, V25, P283; HAHN HJ, 1986, TRANSPLANTATION, V41, P44, DOI 10.1097/00007890-198601000-00008; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; Hsu HC, 1997, BIOCHEM J, V323, P557, DOI 10.1042/bj3230557; HUNG CH, 1993, GENE, V127, P215, DOI 10.1016/0378-1119(93)90722-F; KINO K, 1990, DIABETOLOGIA, V33, P713, DOI 10.1007/BF00400340; KINO K, 1989, J BIOL CHEM, V264, P472; KO JL, 1995, EUR J BIOCHEM, V228, P244, DOI 10.1111/j.1432-1033.1995.tb20256.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin SH, 1996, EUR J BIOCHEM, V240, P564, DOI 10.1111/j.1432-1033.1996.0564h.x; Miller J.H., 1972, EXPT MOL GENETICS; MURASUGI A, 1991, J BIOL CHEM, V266, P2486; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDERHEM LG, 1995, TRANSPLANTATION, V60, P438, DOI 10.1097/00007890-199509000-00006	23	101	125	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20044	20048		10.1074/jbc.272.32.20044	http://dx.doi.org/10.1074/jbc.272.32.20044			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242675	hybrid			2022-12-25	WOS:A1997XQ05900062
J	Shresta, S; Goda, P; Wesselschmidt, R; Ley, TJ				Shresta, S; Goda, P; Wesselschmidt, R; Ley, TJ			Residual cytotoxicity and granzyme K expression in granzyme A-deficient cytotoxic lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE SERINE PROTEASES; CYTO-TOXIC LYMPHOCYTES; NATURAL-KILLER; RAPID INDUCTION; CELL LEUKEMIA; ESTERASE GENE; TARGET-CELLS; CLONING; PURIFICATION; CDNA	Cytotoxic lymphocytes contain granules that have the ability to induce apoptosis in susceptible target cells, The granule contents include perforin, a pore-forming molecule, and several granzymes, including A and B, which are the most abundant serine proteases in these granules. Granzyme B-deficient cytotoxic T lymphocytes (CTL) have a severe defect in their ability to rapidly induce apoptosis in their targets, but have an intact late cytotoxicity pathway that is in part perforin-dependent, In this report, we have created mice that are deficient for granzyme A acid characterized their phenotype, These mice have normal growth and development and normal lymphocyte development, activation, and proliferation, Granzyme A-deficient CTL have a small but reproducible defect in their ability to induce Cr-51 and I-125-UdR release from susceptible allogeneic target cells. Since other granzyme Alike tryptases could potentially account for the residual cytotoxicity in granzyme A-deficient CTL, we cloned the murine granzyme If,belle, which is linked to granzyme A in humans, and proved that it is also tightly linked with murine granzyme A. The murine granzyme if gene (which encodes a tryptase similar to granzyme A) is expressed at much lower levels than granzyme A in CTL and LAIC cells, but its expression is unaltered in granzyme A-/- mice, The minimal cytotoxic defect in granzyme A-/- CTL could be due to the existence of an intact, functional early killing pathway (granzyme B dependent), or to the persistent expression of additional granzyme tryptases like granzyme K.	WASHINGTON UNIV,SCH MED,DIV BONE MARROW TRANSPLANTAT & STEM CELL BIOL,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BONE MARROW TRANSPLANTAT & STEM CELL BIOL,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049786] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NIDDK NIH HHS [DK49786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER E, 1994, IMMUNOGENETICS, V40, P235, DOI 10.1007/BF00167085; BLEACKLEY RC, 1988, FEBS LETT, V234, P153, DOI 10.1016/0014-5793(88)81323-1; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; CAPUTO A, 1988, J BIOL CHEM, V263, P6363; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EBNET K, 1992, GENOMICS, V13, P502, DOI 10.1016/0888-7543(92)90117-B; EBNET K, 1995, EMBO J, V14, P4230, DOI 10.1002/j.1460-2075.1995.tb00097.x; FINK TM, 1993, GENOMICS, V18, P401, DOI 10.1006/geno.1993.1483; FRUTH U, 1987, EUR J IMMUNOL, V17, P1625, DOI 10.1002/eji.1830171116; GERSHENFELD HK, 1988, P NATL ACAD SCI USA, V85, P1184, DOI 10.1073/pnas.85.4.1184; GERSHENFELD HK, 1986, SCIENCE, V232, P854, DOI 10.1126/science.2422755; Graubert TA, 1996, BLOOD, V87, P1232, DOI 10.1182/blood.V87.4.1232.bloodjournal8741232; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; HAMEED A, 1988, J IMMUNOL, V141, P3142; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HARPER K, 1988, IMMUNOGENETICS, V28, P439, DOI 10.1007/BF00355376; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HERSHBERGER RJ, 1992, J BIOL CHEM, V267, P25488; HEUSEL JW, 1991, J BIOL CHEM, V266, P6152; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; JENNE DE, 1989, BIOCHEMISTRY-US, V28, P7953, DOI 10.1021/bi00445a060; Kelly JM, 1996, IMMUNOGENETICS, V44, P340, DOI 10.1007/BF02602778; KRAHENBUHL O, 1988, J IMMUNOL, V141, P3471; LEY TJ, 1989, J CLIN INVEST, V83, P1032, DOI 10.1172/JCI113944; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBE CG, 1988, BIOCHEMISTRY-US, V27, P6941, DOI 10.1021/bi00418a040; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MATTEI MG, 1987, CYTOGENET CELL GENET, V46, P657; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; Mullbacher A, 1996, P NATL ACAD SCI USA, V93, P5783, DOI 10.1073/pnas.93.12.5783; NAKAJIMA H, 1995, J EXP MED, V181, P1037, DOI 10.1084/jem.181.3.1037; PASTERNACK MS, 1986, NATURE, V322, P740, DOI 10.1038/322740a0; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; PRZETAK MM, 1995, FEBS LETT, V364, P268, DOI 10.1016/0014-5793(95)00407-Z; RUSSELL JH, 1982, J IMMUNOL, V128, P2087; Sayers TJ, 1996, J LEUKOCYTE BIOL, V59, P763, DOI 10.1002/jlb.59.5.763; SAYERS TJ, 1994, J IMMUNOL, V152, P2289; SAYERS TJ, 1992, J IMMUNOL, V148, P292; SCHMID J, 1987, J IMMUNOL, V139, P250; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHIM L, 1992, J EXP MED, V175, P553; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SHRESTA S, 1995, P NATL ACAD SCI USA, V92, P5679, DOI 10.1073/pnas.92.12.5679; Shresta S, 1997, BLOOD, V89, P4085, DOI 10.1182/blood.V89.11.4085; SIMON MM, 1986, EMBO J, V5, P3267, DOI 10.1002/j.1460-2075.1986.tb04638.x; SMYTH MJ, 1992, J BIOL CHEM, V267, P24418; SMYTH MJ, 1993, J IMMUNOL, V151, P6195; TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924; YOUNG JDE, 1986, CELL, V47, P183, DOI 10.1016/0092-8674(86)90441-1; ZUNINO SJ, 1990, J IMMUNOL, V144, P2001	52	48	49	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20236	20244		10.1074/jbc.272.32.20236	http://dx.doi.org/10.1074/jbc.272.32.20236			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242702	hybrid			2022-12-25	WOS:A1997XQ05900089
J	Ferrell, JE; Bhatt, RR				Ferrell, JE; Bhatt, RR			Mechanistic studies of the dual phosphorylation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; GROWTH-FACTOR; XENOPUS OOCYTES; PATHWAYS; THREONINE; SITES; CELLS; AUTOPHOSPHORYLATION; IDENTIFICATION; AMPLIFICATION	Previous work on the responses of mitogen-activated protein (MAP) kinase cascade components in a Xenopus oocyte extract system demonstrated that p42 MAP kinase (MAPK) exhibits a sharp, sigmoidal stimulus/response curve, rather than a more typical hyperbolic curve, One plausible explanation for this behavior requires the assumption that MAP kinase kinase (MAPKK) carries out its dual phosphorylation of p42 MAPK by a distributive mechanism, where MAPKK dissociates from MAPK between the first and second phosphorylations, rather than a processive mechanism, where MAPKK carries out both phosphorylations before dissociating, Here we have investigated the mechanism through which a constitutively active form of human MAPKK-1 (denoted MAPKK-1 R4F or MAPKK-1*) phosphorylates Xenopus p42 MAPK in vitro, We found that the amount of monophosphorylated MAPK formed during the phosphorylation reaction exceeded the amount of MAPKK-1* present, which would not be possible if the phosphorylation occurred exclusively by a processive mechanism, The monophosphorylated MAPK was phosphorylated predominantly on tyrosine, but a small proportion was phosphorylated on threonine, indicating that the first phosphorylation is usually, but not invariably, the tyrosine phosphorylation, We also found that the rate at which pulse labeled monophosphorylated MAPK became bisphosphorylated depended on the MAPKK-1* concentration, behavior that is predicted by the distributive model but incompatible with the processive model, These findings indicate that MAPKK-1* phosphorylates p42 MAPK by a two-collision, distributive mechanism rather than a single-collision, processive mechanism, and provide a mechanistic basis for understanding how MAP kinase can convert graded inputs into switch-like outputs.			Ferrell, JE (corresponding author), STANFORD UNIV, SCH MED, DEPT MOL PHARMACOL, STANFORD, CA 94305 USA.				NIGMS NIH HHS [GM16415, GM46383] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM016415, R01GM046383] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; CHOI KY, 1994, CELL, V78, P499; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; GOLDBETER A, 1982, Q REV BIOPHYS, V15, P555, DOI 10.1017/S0033583500003449; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SCHULZ AR, 1994, ENZYME KINETICS, P22; SCOTT A, 1995, J BIOL CHEM, V270, P24540, DOI 10.1074/jbc.270.41.24540; SEGER R, 1992, J BIOL CHEM, V267, P14373; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	39	251	256	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19008	19016		10.1074/jbc.272.30.19008	http://dx.doi.org/10.1074/jbc.272.30.19008			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228083	hybrid			2022-12-25	WOS:A1997XM34200074
J	Gunnery, S; Maivali, U; Mathews, MB				Gunnery, S; Maivali, U; Mathews, MB			Translation of an uncapped mRNA involves scanning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC MESSENGER-RNAS; MOSAIC-VIRUS; REINITIATION; INITIATION; GENE; TRANSCRIPTION; INHIBITION; EFFICIENCY; MECHANISM; SEQUENCE	tat, an essential gene of human immunodeficiency virus, when placed under the control of the RNA polymerase III promoter from the adenovirus VA RNA(1) gene, is transcribed into an uncapped and nonpolyadenylated mRNA, This VA-Tat RNA is translated to produce functional Tat protein in transfected mammalian cells (Gunnery, S., and Mathews, M. B. (1995) Mol. Cell. Biol. 15, 3597-3607), The presence of an upstream open reading frame (ORF) in VA-Tat RNA is inhibitory to the translation of the Tao ORF, suggesting that the RNA is scanned during translation even though it is uncapped. Because the effect of the upstream ORF is relatively small (about a-fold), we sought more definitive evidence of scanning by introducing secondary structures of varying stabilities into the 5'-untranslated region of VA-Tat RNA, The results of transfection experiments showed that highly stable secondary structure was inhibitory to Tat synthesis, whereas structures of lower stability were not inhibitory, confirming that uncapped mRNA is subject to scanning, Furthermore, translation of the downstream ORF was reduced but not eliminated by mutations that caused the upstream ORF to overlap the Tar ORF. Extending the overlap of the two ORFs further decreased the translation of the downstream ORF, This observation implies that ribosomes reinitiate after termination, possibly after migrating in a 3' to 5' direction through the overlap region of the mRNA, Similar results were obtained with a capped polymerase II transcript, indicating that the translation of polymerase II and polymerase III transcripts occurs through similar mechanisms.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory					NCI NIH HHS [CA13106] Funding Source: Medline; NIAID NIH HHS [AI31822] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031822] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1991, CURRENT PROTOCOLS MO, V1; CAO JH, 1995, J VIROL, V69, P1030, DOI 10.1128/JVI.69.2.1030-1036.1995; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLETCHER L, 1990, J BIOL CHEM, V265, P19582; GALLIE DR, 1990, GENE DEV, V4, P1149, DOI 10.1101/gad.4.7.1149; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GRANT CM, 1994, MOL CELL BIOL, V14, P2616, DOI 10.1128/MCB.14.4.2616; GUNNERY S, 1995, MOL CELL BIOL, V15, P3597; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; JANZ L, 1994, MOL CELL BIOL, V14, P5804, DOI 10.1128/MCB.14.9.5804; JOHANSEN H, 1984, P NATL ACAD SCI-BIOL, V81, P7698, DOI 10.1073/pnas.81.24.7698; KOZAK M, 1991, GENE EXPRESSION, V1, P111; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LASPIA MF, 1993, J MOL BIOL, V232, P732, DOI 10.1006/jmbi.1993.1427; MICHELET B, 1994, PLANT CELL, V6, P1375, DOI 10.1105/tpc.6.10.1375; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; Peterlin B. Matija, 1993, P75; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; Sambrook J., 2002, MOL CLONING LAB MANU; Sonenberg Nahum, 1993, Gene Expression, V3, P317; THOMAS KR, 1986, NATURE, V324, P34, DOI 10.1038/324034a0; TIMMER RT, 1993, J BIOL CHEM, V268, P9504	26	39	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21642	21646		10.1074/jbc.272.34.21642	http://dx.doi.org/10.1074/jbc.272.34.21642			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261187	hybrid			2022-12-25	WOS:A1997XR78900097
J	Li, HL; Bergeron, L; Cryns, V; Pasternack, MS; Zhu, H; Shi, LF; Greenberg, A; Yuan, JY				Li, HL; Bergeron, L; Cryns, V; Pasternack, MS; Zhu, H; Shi, LF; Greenberg, A; Yuan, JY			Activation of caspase-2 in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROGRAMMED CELL-DEATH; FAS-MEDIATED APOPTOSIS; GENE CED-3; IL-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASES; ICE/CED-3 PROTEASE; COLORIMETRIC ASSAY; MOLECULAR-CLONING; MAMMALIAN HOMOLOG	Members of the CED-3/interleukin-1 beta-converting enzyme (ICE) protease (caspase) family are synthesized as proforms, which are proteolytically cleaved and activated during apoptosis. We report here that caspase-2 (ICH-1/NEDD-2), a member of the ICE family, is activated during apoptosis by another ICE member, a caspase-3 (CPP32)-like protease(s). When cells are induced to undergo apoptosis, endogenous caspase-2 is first cleaved into three fragments of 32-33 kDa and 14 kDa, which are then further processed into 18- and 12-kDa active subunits. Up to 50 mu m N-acetyl-Asp-Glu-Val-Asp-aldehyde (DEVD-CHO), a caspase-3-preferred peptide inhibitor, inhibits caspase-2 activation and DNA fragmentation in vivo, but does not prevent lass of mitochondrial function, while higher concentrations of DEVD-CHO (>50 mu M) inhibit both. In comparison, although the activity of caspase-3 is very sensitive to the inhibition of DEVD-CHO (<50 nm), inhibition of caspase-3 activation as marked by processing of the proform requires more than 100 mu M DEVD-CHO. Our results suggest that the first cleavage of caspase-2 is accomplished by a caspase-3-like activity, and other ICE-hire proteases less sensitive to DEVD-CHO may be responsible for activation of caspase-3 and loss of mitochondrial function.	MASSACHUSETTS GEN HOSP E,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CHARLESTOWN,MA 02129; UNIV MANITOBA,MANITOBA INST CELL BIOL,MANITOBA CANC TREATMENT & RES FDN,WINNIPEG,MB R3E 0V9,CANADA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Manitoba				Zhu, Hong/0000-0002-2575-4031	NCI NIH HHS [K08-CA01752] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001752] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anel A, 1997, J IMMUNOL, V158, P1999; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CARMICHAEL J, 1987, CANCER RES, V47, P943; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hasegawa J, 1996, CANCER RES, V56, P1713; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	54	164	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21010	21017		10.1074/jbc.272.34.21010	http://dx.doi.org/10.1074/jbc.272.34.21010			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261102	hybrid, Green Published			2022-12-25	WOS:A1997XR78900012
J	McLachlin, DT; Dunn, SD				McLachlin, DT; Dunn, SD			Dimerization interactions of the b subunit of the Escherichia coli F1F0-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-SYNTHASE; PROTEINS; MECHANISM; F1-ATPASE; BINDING; SECTOR; F1F0; MUTAGENESIS; STABILITY; BACTERIA	Site-directed mutagenesis and N-terminal truncations were used to examine dimerization interactions in the b subunit of Escherichia coli F1F0-ATPase. Individual cysteine residues were incorporated into b(syn), a soluble form of the protein lacking the membrane-spanning N-terminal domain, in two main areas: the heptad repeat region and the hydrophobic region which begins at residue Val-124. The tendencies of these cysteine residues to form disulfide bonds with the corresponding cysteine in the b(syn) dimer were tested using disulfide exchange by glutathione and air oxidation catalyzed by Cu2+. Within the heptad repeat region, only cysteines at residues 59 and 60, which occupy the b and c positions of the heptad repeat, showed significant tendencies to form disulfides, a result inconsistent with a coiled-coil model for b(syn). Mixed disulfide formation most readily occurred with the S60C + L65C and A61C + L65C pairs, Cysteines at positions 124, 128, 132, and 139 showed strong tendencies to form disulfides with their mates in the dimer, suggesting a parallel alpha-helical interaction between the subunits in this region, Deletion of residues N-terminal to either Glu-34 or Asp-53 had no apparent effect on dimerization as determined by sedimentation equilibrium, while deletion of all residues N-terminal to Lys-67 produced a monomeric form, These results imply that residues 53-66 but not 24-52 are essential for b(syn) dimerization, Taken together the results are consistent with a model in which the two b subunits interact in more than one region, including a parallel alignment of helices containing residues 124-139.	UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON,ON N6A 5C1,CANADA	Western University (University of Western Ontario)			Dunn, Stanley/D-3418-2013					AHMED AK, 1975, J BIOL CHEM, V250, P8477; Blair A, 1996, MICROBIOL-SGM, V142, P17, DOI 10.1099/13500872-142-1-17; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1992, J BIOL CHEM, V267, P7630; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Fillingame RH, 1997, J EXP BIOL, V200, P217; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Gray W R, 1972, Methods Enzymol, V25, P121, DOI 10.1016/S0076-6879(72)25010-8; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HOPPE J, 1983, EMBO J, V2, P105, DOI 10.1002/j.1460-2075.1983.tb01389.x; Howitt SM, 1996, J BIOENERG BIOMEMBR, V28, P415, DOI 10.1007/BF02113983; Howitt SM, 1996, J BIOL CHEM, V271, P7038, DOI 10.1074/jbc.271.12.7038; JANS DA, 1985, J BACTERIOL, V162, P420, DOI 10.1128/JB.162.1.420-426.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; McLachlin DT, 1996, PROTEIN EXPRES PURIF, V7, P275, DOI 10.1006/prep.1996.0039; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; NAKAMOTO RK, 1996, BIOMEMBR, V5, P343; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; Smith SP, 1996, BIOCHEMISTRY-US, V35, P8805, DOI 10.1021/bi952698c; TAKAGI T, 1964, J BIOCHEM-TOKYO, V56, P344, DOI 10.1093/oxfordjournals.jbchem.a127999; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VIK SB, 1994, J BIOL CHEM, V269, P30364; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WILKENS S, 1994, FEBS LETT, V354, P37, DOI 10.1016/0014-5793(94)01059-5; ZHOU NE, 1993, BIOCHEMISTRY-US, V32, P3178, DOI 10.1021/bi00063a033	37	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21233	21239		10.1074/jbc.272.34.21233	http://dx.doi.org/10.1074/jbc.272.34.21233			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261132	hybrid			2022-12-25	WOS:A1997XR78900042
J	Pantazatos, DP; MacDonald, RI				Pantazatos, DP; MacDonald, RI			Site-directed mutagenesis of either the highly conserved Trp-22 or the moderately conserved Trp-95 to a large, hydrophobic residue reduces the thermodynamic stability of a spectrin repeating unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL UNIT; COMPLETE SEQUENCE; ALPHA-SPECTRIN; DYSTROPHIN; TRYPTOPHAN; PROTEINS; MUTATIONS; MEMBRANE; DOMAINS; ACTININ	As reported previously (MacDonald, a. I., Musacchio, ih,, Holmgren, R. a., and Saraste, M. (1994) PI oc. Natl. Acad Sci. U. S. A. 91, 1299-1303), an unfolded peptide was obtained by site-directed mutagenesis of Trp-22 to Ala in the cloned, wild type 17th repeating unit (alpha 17) of chicken brain alpha-spectrin, Trp occurs in position 22 of nearly all repeating units of spectrin, In the present study, Trp-22 was mutated to Phe or to Tyr to compare thermodynamic stabilities of urea-induced unfolding of alpha 16 and mutants thereof, alpha 16 was chosen for this study instead of alpha 17, because alpha 16 has two tryptophans, allowing urea-induced unfolding to be tracked by the fluorescence of the Trp remaining in each mutant peptide and by circular dichroism in the far UV. The free energies of unfolding of W22Y and W22F were 50% that of alpha 16, showing that Trp-22 if crucial in stabilizing the triple helical bundle motif of the spectrin repeating unit, Mutation of the moderately conserved Trp-95 of alpha 16 to Val, which occupies position 95 in alpha 17, also yielded a peptide? with 50% of the free energy of unfolding of alpha 16, Thus, the thermodynamic stability of a given spectrin repeating unit may depend on both moderately and highly conserved tryptophans. Different structural roles: of Trp-22 and Trp-95 in alpha 16 are suggested by the slightly higher wavelength of maximum emission of Trp-22, the greater acrylamide quenching of Trp-95 than Trp-22, and the longer lifetime of Trp-95. For comparison with alpha 16, urea-induced unfolding of spectrin dimer isolated from human red cells was monitored by far W-CD and by tryptophan fluorescence, Thermodynamic parameters could not be rigorously derived for the stability of spectrin dimer because unfolding of spectrin dimer involved more than two states, unlike unfolding of cloned repeating units. However, the similar midpoints of CD-monitored denaturation curves of alpha 16 and spectrin dimer, i.e, 2.7 and 3.2 Rr urea, respectively, indicate that investigation of cloned repeating units of spectrin can provide physiologically relevant information an these structures.	NORTHWESTERN UNIV,DEPT BIOCHEM MOL BIOL & CELL BIOL,EVANSTON,IL 60208	Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045168] Funding Source: NIH RePORTER; NHLBI NIH HHS [1PO1 HL45168] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BIER M, 1957, METHOD ENZYMOL, V4, P147, DOI 10.1016/0076-6879(57)04053-7; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BUDZYNSKI DM, 1992, BIOCHEMISTRY-US, V31, P3653, DOI 10.1021/bi00129a014; Calvert R, 1996, BIOPHYS J, V71, P1605, DOI 10.1016/S0006-3495(96)79363-3; DAVISON MD, 1989, INT J BIOL MACROMOL, V11, P81, DOI 10.1016/0141-8130(89)90047-0; DeSilva TM, 1997, BIOCHEMISTRY-US, V36, P3991, DOI 10.1021/bi962412j; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; Dubreuil RR, 1996, CURR TOP MEMBR, V43, P147; DUBREUIL RR, 1989, J CELL BIOL, V109, P2197, DOI 10.1083/jcb.109.5.2197; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; FASMAN GD, 1989, PRACTICAL HDB BIOCH, P81; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Hanahan D., 1985, TECHNIQUES TRANSFORM, P109; HARRIS DL, 1990, BIOCHEMISTRY-US, V29, P5276, DOI 10.1021/bi00474a009; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P16; KAHANA E, 1995, BIOCHEMISTRY-US, V34, P8110, DOI 10.1021/bi00025a017; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAWS WR, 1992, METHOD ENZYMOL, V210, P448; LUX SE, 1995, DISORDERS RED CELL M, P1701; MACDONALD RI, 1994, P NATL ACAD SCI USA, V91, P1299, DOI 10.1073/pnas.91.4.1299; Menhart N, 1996, J BIOL CHEM, V271, P30410, DOI 10.1074/jbc.271.48.30410; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PALEK J, 1992, BLOOD, V80, P308; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; Pascual J, 1996, FEBS LETT, V383, P201, DOI 10.1016/0014-5793(96)00251-7; Ralston G, 1996, BIOCHEMISTRY-US, V35, P5257, DOI 10.1021/bi952224d; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P4901, DOI 10.1021/bi00135a022; SCHOLTZ JM, 1995, P NATL ACAD SCI USA, V92, P185, DOI 10.1073/pnas.92.1.185; SPANGLER CJ, 1992, METHOD ENZYMOL, V210, P305; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUBBARAO NK, 1993, ANALYST, V118, P913, DOI 10.1039/an9931800913; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WINDER SJ, 1995, FEBS LETT, V369, P27, DOI 10.1016/0014-5793(95)00398-S; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YAO M, 1995, BIOCHEMISTRY-US, V34, P3771, DOI 10.1021/bi00011a035	45	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21052	21059		10.1074/jbc.272.34.21052	http://dx.doi.org/10.1074/jbc.272.34.21052			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261107	hybrid			2022-12-25	WOS:A1997XR78900017
J	Bishopric, NH; Zeng, GQ; Sato, B; Webster, KA				Bishopric, NH; Zeng, GQ; Sato, B; Webster, KA			Adenovirus E1A inhibits cardiac myocyte-specific gene expression through its amino terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; ALPHA-ACTIN GENE; HEAVY-CHAIN GENE; MUSCLE-SPECIFIC EXPRESSION; SERUM RESPONSE FACTOR; RETINOBLASTOMA PROTEIN; ENHANCER-BINDING; SKELETAL-MUSCLE; DNA-SYNTHESIS; CELL-GROWTH	Adenovirus E1A oncoproteins inhibit muscle specific gene expression and myogenic differentiation by suppressing the transcriptional activating functions of basic helix-loop-helix proteins. As one approach to identifying cardiac-specific gene regulatory proteins, we analyzed the functional regions of E1A proteins that are required for muscle gene repression in cardiac cells, Myocyte-specific promoters, including the alpha-actins and alpha-myosin heavy chain, were selectively and potently inhibited (> 90%) by E1A, while the ubiquitously expressed beta-actin promoter was only partially (similar to 30%) repressed; endogenous gene expression was also affected. Distinct E1A protein binding sites mediated repression of muscle-specific and ubiquitous actin promoters. E1A-mediated inhibition of beta-actin required both an intact binding site for the tumor repressor proteins pRb and p107 and a second E1A domain (residues 15-35). In contrast, cardiac specific promoter repression required the E1A amino-terminal residues 2-36. The proximal skeletal actin promoter (3' to base pair -153) was a target for repression by E1A. Although E1A binding to p300 was not required for inhibition of either promoter, co-expression of p300 partially reversed E1A-mediated transcriptional repression. We conclude that cardiac-specific and general promoter inhibition by E1A occurs by distinct mechanisms and that cardiac-specific gene expression is modulated by cellular factors interacting with the E1A p300/CBP-binding domain.	SRI INT, MOL CARDIOL LAB, MENLO PK, CA 94125 USA	SRI International				Webster, Keith A/0000-0002-6431-3642	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044578, R01HL044578, R01HL049891] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49891, HL44578] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Akusjarvi G, 1993, Trends Microbiol, V1, P163, DOI 10.1016/0966-842X(93)90085-6; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BANERJEE AC, 1994, ONCOGENE, V9, P1733; BARBEAU D, 1994, ONCOGENE, V9, P359; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P20932; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DORSMAN JC, 1995, J VIROL, V69, P2962, DOI 10.1128/JVI.69.5.2962-2967.1995; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FLINT SJ, 1984, MOL CELL BIOL, V4, P1363, DOI 10.1128/MCB.4.7.1363; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; GIORDANO A, 1991, ONCOGENE, V6, P481; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSWAMI S, 1994, MOL CELL BIOL, V14, P5130, DOI 10.1128/MCB.14.8.5130; Green M, 1979, Methods Enzymol, V58, P425; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KAO HT, 1986, NUCLEIC ACIDS RES, V14, P7253, DOI 10.1093/nar/14.18.7253; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LI HO, 1995, BIOCHIM BIOPHYS ACTA, V266, P148; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Liu Y, 1996, J CELL BIOL, V133, P325, DOI 10.1083/jcb.133.2.325; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NEVINS JR, 1993, BIOCHEM SOC T, V21, P935, DOI 10.1042/bst0210935; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; SHENK T, 1991, ADV CANCER RES, V57, P47; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; VIERRA CA, 1995, MOL ENDOCRINOL, V9, P64, DOI 10.1210/me.9.1.64; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	91	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20584	20594		10.1074/jbc.272.33.20584	http://dx.doi.org/10.1074/jbc.272.33.20584			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252373	hybrid			2022-12-25	WOS:A1997XR22100043
J	Lin, KM; Wenegieme, E; Lu, PJ; Chen, CS; Yin, HL				Lin, KM; Wenegieme, E; Lu, PJ; Chen, CS; Yin, HL			Gelsolin binding to phosphatidylinositol 4,5-bisphosphate is modulated by calcium and pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-FILAMENTS; MONOMER-BINDING; PHOSPHOLIPASE-C; HUMAN-NEUTROPHILS; CAPPING PROTEIN; HUMAN-PLATELETS; DOMAIN; IDENTIFICATION; POLYMERIZATION; TRISPHOSPHATE	The actin cytoskeleton of nonmuscle cells undergoes extensive remodeling during agonist stimulation, Lamellipodial extension is initiated by uncapping of actin nuclei at the cortical cytoplasm to allow filament elongation, Many actin filament capping proteins are regulated by phosphatidylinositol 4,5-bisphosphate (PIP2), which is hydrolyzed by phospholipase C. It is hypothesized that PIP2 dissociates capping proteins from filament ends to promote actin assembly, However, since actin polymerization often occurs at a time when PIP2 concentration is decreased rather than increased, capping protein interactions with PIP2 may not be regulated solely by the bulk PIP2 concentration. We present evidence that PIP2 binding to the gelsolin family of capping proteins is enhanced by Ca2+. Binding was examined by equilibrium and nonequilibrium gel filtration and by monitoring intrinsic tryptophan fluorescence, Gelsolin and CapG affinity for PIP2 were increased 8- and 4-fold, respectively, by mu M Ca2+, and the Ca2+ requirement was reduced by lowering the pH from 7.5 to 7.0. Studies with the NH2- and COOH-terminal halves of gelsolin showed that PIP2 binding occurred primarily at the NH2-terminal half, and Ca2+ exposed its PIP2 binding sites through a change in the COOH-terminal half, Mild acidification promotes PIP2 binding by directly affecting the NH2-terminal sites, Our findings can explain increased PIP2-induced uncapping even as the PIP2 concentration drops during cell activation. The change in gelsolin family PIP2 binding affinity during cell activation can impact divergent PIP2-dependent processes by altering PIP2 availability, Cross-talk between these proteins provides a multilayered mechanism for positive and negative modulation of signal transduction from the plasma membrane to the cytoskeleton.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235; UNIV KENTUCKY,COLL PHARM,DIV MED CHEM & PHARMACEUT,LEXINGTON,KY 40536	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Kentucky					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017997, R01GM053448] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM5112, GM17997, GM53448] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APGAR JR, 1995, MOL BIOL CELL, V6, P97, DOI 10.1091/mbc.6.1.97; Arora PD, 1996, J BIOL CHEM, V271, P20516, DOI 10.1074/jbc.271.34.20516; BANNO Y, 1992, J BIOL CHEM, V267, P6488; Barkalow K, 1996, J CELL BIOL, V134, P389, DOI 10.1083/jcb.134.2.389; BENGTSSON T, 1988, J BIOL CHEM, V263, P17385; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAMB JA, 1993, J BIOL CHEM, V268, P8999; LASSING I, 1985, NATURE, V314, P604; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; RITTENHOUSE SE, 1985, J BIOL CHEM, V260, P8657; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SELVE N, 1987, EUR J BIOCHEM, V168, P111, DOI 10.1111/j.1432-1033.1987.tb13394.x; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Singh SS, 1996, BIOCHEMISTRY-US, V35, P16544, DOI 10.1021/bi9609634; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; SUN HQ, 1994, J BIOL CHEM, V269, P9473; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; VANPARIDON PA, 1986, BIOCHIM BIOPHYS ACTA, V877, P216, DOI 10.1016/0005-2760(86)90137-2; VANTROYS M, 1996, FEBS LETT, V96, P191; WARD LD, 1985, METHOD ENZYMOL, V117, P400; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1980, J BIOL CHEM, V255, P9494; YONEZAWA N, 1990, J BIOL CHEM, V265, P8382; YOUNG CL, 1994, J BIOL CHEM, V269, P13997; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269; YU FX, 1992, J BIOL CHEM, V267, P14616; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	60	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20443	20450		10.1074/jbc.272.33.20443	http://dx.doi.org/10.1074/jbc.272.33.20443			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252353	hybrid			2022-12-25	WOS:A1997XR22100023
J	PattonVogt, JL; Griac, P; Sreenivas, A; Bruno, V; Dowd, S; Swede, MJ; Henry, SA				PattonVogt, JL; Griac, P; Sreenivas, A; Bruno, V; Dowd, S; Swede, MJ; Henry, SA			Role of the yeast phosphatidylinosito/phosphatidylcholine transfer protein (sec14p) in phosphatidylcholine turnover and INO1 regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PHOSPHOLIPID TRANSFER PROTEINS; CROSS-PATHWAY REGULATION; CDP-CHOLINE PATHWAY; SACCHAROMYCES-CEREVISIAE; INOSITOL SYNTHESIS; BIOSYNTHESIS; GENE; METHYLATION; MUTANTS	In yeast, mutations in the CDP-choline pathway for phosphatidylcholine biosynthesis permit the cell to grow even when the SEC14 gene is completely deleted (Cleves, A., McGee, T., Whitters, E,, Champion, K,, Aitken, J,, Dowhan, W,, Goebl, M,, and Bankaitis, V, (1991) Cell 64, 789-800), We report that strains carrying mutations in the CDP-choline pathway, such as cki1, exhibit a choline excretion phenotype due to production of choline during normal turnover of phosphatidylcholine, Cells carrying cki1 in combination with sec14(ts), a temperature-sensitive allele in the gene encoding the phosphatidylinositol/phosphatidylcholine transporter, have a dramatically increased choline excretion phenotype when grown at the sec14(ts)-restrictive temperature, We show that the increased choline excretion in sec14(ts) cki1 cells is due to increased turnover of phosphatidylcholine via a mechanism consistent with phospholipase D-mediated turnover, We propose that the elevated rate of phosphatidylcholine turnover in sec14(ts) cki1 cells provides the metabolic condition that permits the secretory pathway to function when Sec14p is inactivated, As phosphatidylcholine turnover increases in sec14(ts) cki1 cells shifted to the restrictive temperature, the INO1 gene (encoding inositol-l-phosphate synthase) is also derepressed, leading to an inositol excretion phenotype (Opi(-)). Misregulation of the INO1 gene has been observed in many strains with altered phospholipid metabolism, and the relationship between phosphatidylcholine turnover and regulation of INO1 and other coregulated genes of phospholipid biosynthesis is discussed.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213; SLOVAK ACAD SCI,INST ANIM BIOCHEM & GENET,IVANKA PRI DUNAJ 90028,CZECH REPUBLIC; WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	Carnegie Mellon University; Slovak Academy of Sciences; Washington University (WUSTL)			Henry, Susan/K-5464-2014; , Peter/ABA-9227-2020; Swede, Marci/AAD-3921-2021	, Peter/0000-0003-3538-0405; Swede, Marci/0000-0002-3003-4258	NIGMS NIH HHS [GM-19629] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019629, R37GM019629] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BREMER J, 1960, BIOCHIM BIOPHYS ACTA, V37, P173, DOI 10.1016/0006-3002(60)90104-9; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; Ella KM, 1996, BIOCHEM J, V314, P15, DOI 10.1042/bj3140015; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GREENBERG ML, 1983, J BACTERIOL, V153, P791, DOI 10.1128/JB.153.2.791-799.1983; Griac P, 1996, J BIOL CHEM, V271, P25692, DOI 10.1074/jbc.271.41.25692; GRIAC P, 1996, NATO ASI SERIES MOL, V96, P339; HELMKAMP GM, 1986, J BIOENERG BIOMEMBR, V18, P71, DOI 10.1007/BF00743477; HENRY SA, 1982, MOL BIOL YEAST SACCH, V2, P101; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HONIGBERG SM, 1992, GENETICS, V130, P703; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HUDAK KA, 1994, GENETICS, V136, P475; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KODAKI T, 1987, J BIOL CHEM, V262, P15428; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LAMPING E, 1995, GENETICS, V137, P55; LEE KS, 1994, J BIOL CHEM, V269, P19725; LETTS VA, 1985, J BACTERIOL, V163, P560, DOI 10.1128/JB.163.2.560-567.1985; Liscovitch M, 1996, J LIPID MEDIAT CELL, V14, P215, DOI 10.1016/0929-7855(96)00528-7; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Seaman MNJ, 1996, TRENDS CELL BIOL, V6, P473, DOI 10.1016/0962-8924(96)84944-0; Shen HF, 1996, J BIOL CHEM, V271, P789, DOI 10.1074/jbc.271.2.789; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; SUMMERS EF, 1988, GENETICS, V120, P909; SWEDE M, 1994, THESIS CARNEGIE MELL; SWEDE MJ, 1992, METHOD ENZYMOL, V29, P21; SZOLDERITS G, 1989, BIOCHIM BIOPHYS ACTA, V986, P301, DOI 10.1016/0005-2736(89)90481-1; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; WIRTZ KWA, 1990, EXPERIENTIA, V46, P592, DOI 10.1007/BF01939698	51	115	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20873	20883		10.1074/jbc.272.33.20873	http://dx.doi.org/10.1074/jbc.272.33.20873			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252414	hybrid			2022-12-25	WOS:A1997XR22100084
J	Yu, H; Kaung, G; Kobayashi, S; Kopito, RR				Yu, H; Kaung, G; Kobayashi, S; Kopito, RR			Cytosolic degradation of T-cell receptor alpha chains by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; ANTIGEN RECEPTOR; ORNITHINE DECARBOXYLASE; PROTEIN; PATHWAY; HYBRID; REDUCTASE; RETENTION; SUBUNIT	The T-cell antigen receptor (TCR) is an hetero-oligomeric membrane complex composed of at least seven transmembrane polypeptide chains that has served as a model for the assembly and degradation of integral membrane proteins in the endoplasmic reticulum (ER), Unassembled TCR alpha chains fail to mature to the Golgi apparatus and are rapidly degraded by a non-lysosomal ''ER degradation'' pathway that has been proposed to be autonomous to the ER. In these studies we show that the degradation of core glycosylated TCR alpha is blocked by N-acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN) and lactacystin, implicating the proteasome in ER degradation, Either acute or chronic treatment of TCR alpha-transfected cells with proteasome inhibitors cause the core-glycosylated TCR alpha chains to progressively shift to an similar to 28-kDa form that lacks N-linked oligosaccharides and the N-terminal signal peptide. The susceptibility of this 28-kDa species to extravesicular protease indicates that it is not protected by the ER membrane and, hence, cytoplasmic, These data suggest a model in which TCR alpha chains that are translocated across the membrane, core-glycosylated, but fail to assemble are dislocated back to the cytoplasm for degradation by cytoplasmic proteasomes. Our data also suggest that covalent modification of TCR alpha with ubiquitin is not required for its degradation.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43994] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; Bonifacino JS, 1996, NATURE, V384, P405, DOI 10.1038/384405a0; BONIFACINO JS, 1988, J BIOL CHEM, V263, P8965; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; INOUE S, 1992, J BIOL CHEM, V267, P9080; JOHNSTON JA, 1995, J BIOL CHEM, V270, P8172, DOI 10.1074/jbc.270.14.8172; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SAMELSON LE, 1985, J IMMUNOL, V134, P2529; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	32	200	200	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20800	20804		10.1074/jbc.272.33.20800	http://dx.doi.org/10.1074/jbc.272.33.20800			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252404	hybrid			2022-12-25	WOS:A1997XR22100074
J	Chen, DS; Davies, MPA; Rudland, PS; Barraclough, R				Chen, DS; Davies, MPA; Rudland, PS; Barraclough, R			Transcriptional down-regulation of the metastasis-inducing S100A4 (p9Ka) in benign but not in malignant rat mammary epithelial cells by GC-factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MTS1 GENE; MESSENGER-RNA; MOLECULAR-CLONING; ELONGATED CELLS; DNA; TUMOR; LINES; EXPRESSION; TRANSFECTION	The S100-related calcium-binding protein S100A4 (p9Ka) is expressed at a low level in rat mammary epithelial cells from normal mammary gland and benign mammary tumors, In transgenic mice, expressed rat S100A4 transgenes co-operate with the activated c-erbB-2 oncogene, neu, to form metastatic mammary tumors, Elevated levels of S100A4 (p9Ka) in cultured benign rat or mouse mammary epithelial cells are associated with the induction of metastatic capability, A cis-acting sequence related to the consensus recognition sequence of GC-factor, 1,300 base pairs upstream of the start site of transcription of the rat S100A4 gene, acts as a cis-acting inhibitor of transcription of the S100A4 (p9Ka) gene in a low S100A4 (p9Ka)-expressing benign rat mammary epithelial cell line, but not in highly expressing rat mammary epithelial cell lines, There is an inverse relationship between the level of S100A4 (p9Ka) mRNA and the level of GC-factor mRNA in a range of rat mammary cell lines, The results suggest a novel mechanism for regulating the expression of the mRNA encoding an S100 protein.	UNIV LIVERPOOL,SCH BIOL SCI,CANC & POLIO RES FUND LABS,LIVERPOOL L69 7ZB,MERSEYSIDE,ENGLAND	University of Liverpool			Barraclough, Roger/AAH-6516-2020; Davies, Michael/GWV-2527-2022	Davies, Michael Peter Alan/0000-0002-7609-4977; Barraclough, Roger/0000-0002-7203-1194				Ambartsumian NS, 1996, ONCOGENE, V13, P1621; BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1982, EUR J BIOCHEM, V129, P335, DOI 10.1111/j.1432-1033.1982.tb07056.x; BARRACLOUGH R, 1984, BIOCHEM BIOPH RES CO, V120, P351, DOI 10.1016/0006-291X(84)91261-0; BENNETT DC, 1978, CELL, V15, P283, DOI 10.1016/0092-8674(78)90104-6; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES BR, 1993, ONCOGENE, V8, P999; DAVIES M, 1995, DNA CELL BIOL, V14, P825, DOI 10.1089/dna.1995.14.825; Davies MPA, 1996, ONCOGENE, V13, P1631; DOCHERTY K, 1993, GENE TRANSCRIPTION P, P108; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; DUNNINGTON DJ, 1984, CANCER RES, V44, P5338; DUNNINGTON DJ, 1984, THESIS U LONDON; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIMURA FK, 1986, NUCLEIC ACIDS RES, V14, P2845, DOI 10.1093/nar/14.7.2845; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARABEDIAN MJ, 1993, GENE TRANSCRIPTION P, P243; GARRITY P, 1992, P NATL ACAD SCI USA, V89, P10021; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KROEKER WD, 1978, BIOCHEMISTRY-US, V17, P3236, DOI 10.1021/bi00609a010; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; ORMEROD EJ, 1985, IN VITRO CELL DEV B, V21, P143, DOI 10.1007/BF02621351; Sambrook J., 2002, MOL CLONING LAB MANU; TULCHINSKY E, 1992, P NATL ACAD SCI USA, V89, P9146, DOI 10.1073/pnas.89.19.9146; TULCHINSKY E, 1993, ONCOGENE, V8, P79; TULCHINSKY E, 1995, BBA-GENE STRUCT EXPR, V1261, P243, DOI 10.1016/0167-4781(95)00013-7; Tulchinsky EM, 1996, ONCOGENE, V12, P1737; WILLIAMS JC, 1985, J NATL CANCER I, V74, P415	40	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20283	20290		10.1074/jbc.272.32.20283	http://dx.doi.org/10.1074/jbc.272.32.20283			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242709	hybrid			2022-12-25	WOS:A1997XQ05900096
J	Kinoshita, A; Yamada, S; Haslam, SM; Morris, HR; Dell, A; Sugahara, K				Kinoshita, A; Yamada, S; Haslam, SM; Morris, HR; Dell, A; Sugahara, K			Novel tetrasaccharides isolated from squid cartilage chondroitin sulfate E contain unusual sulfated disaccharide units GlcA(3-O-sulfate)beta 1-3GalNAc(6-O-sulfate) or GlcA(3-O-sulfate)beta 1-3GalNAc(4,6-O-disulfate)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; SWARM RAT CHONDROSARCOMA; SYNANCEJA-HORRIDA VENOM; PROTEIN LINKAGE REGION; MOUSE BONE-MARROW; MAST-CELLS; HEPARAN-SULFATE; GLUCURONIC-ACID; FLUOROPHORE 2-AMINOACRIDONE; PERITONEAL-MACROPHAGES	We previously isolated novel tetrasaccharides containing 3-O-sulfated glucuronic acid from king crab cartilage chondroitin sulfate K and demonstrated that the disaccharide units containing 3-O-sulfated glucuronic acid were decomposed by chondroitinase ABC digestion (Sugahara, K., Tanaka, Y., Yamada, S., Seno, N., Kitagawa, H., Haslam, S. M., Morris, H.R., and Dell, A. (1986) J. Biol. Chem. 271, 26745-26754). The findings indicated the necessity to re-evaluate the disaccharide compositions of chondroitin sulfate preparations purified from other biological sources and analyzed using the above enzyme, in this study, to evaluate squid cartilage chondroitin sulfate E a series of even-numbered oligosaccharides were isolated after exhaustive digestion with sheep testicular hyaluronidase and subsequent fractionation by gel chromatography. The tetrasaccharide fraction was subfractionated by high performance liquid chromatography on an amine-bound silica column. Systematic structural analysis of five major fractions, h, l, m, n, and q, by fast atom bombardment mass spectrometry, enzymatic digestions in conjunction with capillary electrophoresis, and 500-MHz H-1 NMR spectroscopy revealed one disulfated, three trisulfated, and one diasulfated tetrasaccharide structure: fraction h, GlcA beta 1-3GalNAc(4S)beta 1-4GlcA beta 1-3GalNAc(4S); fraction l, GlcA(3S)beta 1-3GalNAc(6S)beta 1-4GlcA beta 1-3GalNAc(4S) fraction m, GlcA(3S)beta 1-3GalNAc(4S)beta 1-4GlcA beta 1-3GalNAc(4S); fraction n, GlcA beta 1-3GalNAc(4S.6S)beta 1-4GlcA beta 1-3GaINAc(4S); and fraction q, GlcA(3S)beta 1-3GalNAc(4S,6S)beta 1-4GlcA beta 1-3GalNAc(4S), where 3S, 4S, and 6S represent 3-O-, 4-O- and 6-O-sulfate, respectively. The structures found in fractions h and m as well as the unsaturated counterpart of that found in fraction n have beem reported, whereas those in fractions l and q are novel in that they contained unusual disulfated and trisulfated disaccharide units where GlcA(3S) is directly linked to GalNAc(6S) and GalNAc(4S,6S), respectively. These novel tetrasaccharide sequences are distinct from those found in other chondroitin sulfate isoforms and may play key roles in the biological functions and activities of chondroitin sulfate E not only from squid cartilage but also from mammalian cells and tissues.	KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE,HYOGO 658,JAPAN; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND	Kobe Pharmaceutical University; Imperial College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA F, 1982, TOHOKU J EXP MED, V136, P359, DOI 10.1620/tjem.136.359; ANNO K, 1971, BIOCHIM BIOPHYS ACTA, V237, P173, DOI 10.1016/0304-4165(71)90046-8; ARIGA T, 1987, J BIOL CHEM, V262, P848; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; DIFERRANTE N, 1956, J BIOL CHEM, V220, P303; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; ELIAKIM R, 1986, P NATL ACAD SCI USA, V83, P461, DOI 10.1073/pnas.83.2.461; ENERBACK L, 1985, BIOCHEM J, V227, P661, DOI 10.1042/bj2270661; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GOTO F, 1994, BIOORG MED CHEM LETT, V4, P619, DOI 10.1016/S0960-894X(01)80166-9; GREGOIRE PE, 1972, BIOCHIM BIOPHYS ACTA, V279, P102, DOI 10.1016/0304-4165(72)90245-0; HABUCHI O, 1971, J BIOL CHEM, V246, P7357; HIGHSMITH S, 1975, J BIOL CHEM, V250, P7473; HOJIMA Y, 1984, BLOOD, V63, P1453; ILYAS AA, 1986, BRAIN RES, V385, P1, DOI 10.1016/0006-8993(86)91540-4; INOUE H, 1986, J BIOL CHEM, V261, P4460; IWATA H, 1969, J JAP ORTHOP ASSN, V43, P455; JACKSON P, 1991, ANAL BIOCHEM, V196, P238, DOI 10.1016/0003-2697(91)90460-B; KARAMANOS NK, 1992, EUR J BIOCHEM, V204, P553, DOI 10.1111/j.1432-1033.1992.tb16667.x; KARAMANOS NK, 1995, ARCH BIOCHEM BIOPHYS, V316, P100, DOI 10.1006/abbi.1995.1015; KARAMANOS NK, 1994, ANAL BIOCHEM, V221, P189, DOI 10.1006/abio.1994.1396; KARAMANOS NK, 1994, BIOCHIMIE, V76, P79, DOI 10.1016/0300-9084(94)90066-3; KARIYA Y, 1990, J BIOL CHEM, V265, P5081; KIM JJ, 1982, J BIOL CHEM, V257, P1670; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; KITAGAWA H, 1995, ANAL BIOCHEM, V232, P114, DOI 10.1006/abio.1995.9952; Kitagawa H, 1997, BIOCHEMISTRY-US, V36, P3998, DOI 10.1021/bi962740j; KOLSET SO, 1983, BIOCHEM J, V210, P661, DOI 10.1042/bj2100661; KOLSET SO, 1986, BIOCHEM BIOPH RES CO, V139, P377, DOI 10.1016/S0006-291X(86)80001-8; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; KRESSE H, 1987, ADV ENZYMOL RAMB, V60, P217; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; MARK M P, 1990, International Journal of Developmental Biology, V34, P191; Mathews M B, 1966, Clin Orthop Relat Res, V48, P267; MATHEWS MB, 1962, NATURE, V193, P378, DOI 10.1038/193378a0; MCGEE MP, 1995, J BIOL CHEM, V270, P26109, DOI 10.1074/jbc.270.44.26109; Meyer K., 1971, ENZYMES, V5, P307; MIDURA RJ, 1995, J BIOL CHEM, V270, P8009, DOI 10.1074/jbc.270.14.8009; Nadanaka S, 1997, GLYCOBIOLOGY, V7, P253, DOI 10.1093/glycob/7.2.253; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; OTSU K, 1987, J EXP MED, V165, P615, DOI 10.1084/jem.165.3.615; POH CH, 1992, COMP BIOCHEM PHYS B, V101, P159, DOI 10.1016/0305-0491(92)90172-N; POOLE AR, 1986, BIOCHEM J, V236, P1; RAZIN E, 1982, J BIOL CHEM, V257, P7229; ROTHENBERG ME, 1987, J IMMUNOL, V138, P2616; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SCULLY MF, 1986, BIOCHEM BIOPH RES CO, V137, P15, DOI 10.1016/0006-291X(86)91169-1; SENO N, 1974, BIOCHIM BIOPHYS ACTA, V343, P423, DOI 10.1016/0304-4165(74)90107-X; SENO N, 1982, CARBOHYD RES, V103, P190; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SODA T, 1940, NIPPON KAGAKU ZASSHI, V61, P43; SORRELL JM, 1990, J HISTOCHEM CYTOCHEM, V38, P393, DOI 10.1177/38.3.1689338; SPEIGHT G, 1981, BIOCHIM BIOPHYS ACTA, V672, P89, DOI 10.1016/0304-4165(81)90282-8; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1992, BIOCHEM J, V283, P99, DOI 10.1042/bj2830099; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; Sugahara K, 1996, GLYCOCONJUGATE J, V13, P609, DOI 10.1007/BF00731449; Sugahara K, 1996, EUR J BIOCHEM, V239, P871, DOI 10.1111/j.1432-1033.1996.0871u.x; SUGAHARA K, 1994, CARBOHYD RES, V255, P165, DOI 10.1016/S0008-6215(00)90977-7; SUGAHARA K, 1996, 18 INT CARB S MIL JU, P40; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; SUZUKI S, 1960, J BIOL CHEM, V235, P3580; TAKASU Y, 1982, BIOCHIM BIOPHYS ACTA, V716, P316, DOI 10.1016/0304-4165(82)90022-8; TSUJI M, 1980, BIOCHIM BIOPHYS ACTA, V612, P373, DOI 10.1016/0005-2744(80)90120-5; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; WEISSMANN B, 1955, J BIOL CHEM, V216, P783; WILSON JG, 1984, J IMMUNOL, V132, P3058; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4; YURT RW, 1977, J BIOL CHEM, V252, P518	85	93	94	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19656	19665		10.1074/jbc.272.32.19656	http://dx.doi.org/10.1074/jbc.272.32.19656			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242620	hybrid			2022-12-25	WOS:A1997XQ05900007
J	Matthews, SA; Pettit, GR; Rozengurt, E				Matthews, SA; Pettit, GR; Rozengurt, E			Bryostatin 1 induces biphasic activation of protein kinase D in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; CARCINOMA-CELLS; C FAMILY; PHASE-I; DIACYLGLYCEROL; POTENT; GROWTH	Bryostatin 1 and phorbol esters are both potent activators of protein kinase C (PKC), although their specific biological effects can differ in many systems, Here, we report that bryostatin 1 activates protein kinase D (PKD), a novel serine/threonine protein kinase, in intact Swiss 3T3 cells and secondary mouse embryo fibroblasts and in COS-7 cells transiently transfected with a PKD expression construct. The dose response of PKD activation induced by bryostatin 1 follows a striking biphasic pattern with maximal activation achieved at a concentration of 10 nM. Higher concentrations of bryostatin 1 (100 nM) reduced PKD activation induced by phorbol 12,13-dibutyrate to levels stimulated by bryostatin 1 alone. Bryostatin 1-induced PKD activation was markedly attenuated by treatment of cells with the PKC inhibitors bisindolylmaleimide I and Ro 31-8220. However, these agents did not inhibit PKD activity when added directly to in vitro kinase assays, suggesting that bryostatin 1 stimulates PKD activation through a PKC-dependent pathway in intact cells, Our results raise the possibility that activated PKD in intact cells could mediate some of the multiple biphasic biological responses induced by bryostatin 1.	IMPERIAL CANC RES FUND,GROWTH REGULAT LAB,LONDON WC2A 3PX,ENGLAND; ARIZONA STATE UNIV,CANC RES INST,TEMPE,AZ 85287; ARIZONA STATE UNIV,DEPT CHEM,TEMPE,AZ 85287	Cancer Research UK; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe				Matthews, Sharon/0000-0002-8634-9355				BASU A, 1992, CANCER RES, V52, P3119; BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0; DALE IL, 1989, INT J CANCER, V43, P158, DOI 10.1002/ijc.2910430129; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; GSCHWENDT M, 1992, CANCER LETT, V66, P139, DOI 10.1016/0304-3835(92)90226-L; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KRAFT AS, 1988, J BIOL CHEM, V263, P8437; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; PHILIP PA, 1993, J NATL CANCER I, V85, P1812, DOI 10.1093/jnci/85.22.1812; PRENDIVILLE J, 1993, BRIT J CANCER, V68, P418, DOI 10.1038/bjc.1993.352; RAMSDELL JS, 1986, J BIOL CHEM, V261, P7073; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; SCHUCHTER LM, 1991, CANCER RES, V51, P682; SMITH JB, 1985, BIOCHEM BIOPH RES CO, V132, P939, DOI 10.1016/0006-291X(85)91898-4; SREDNI B, 1990, IMMUNOLOGY, V70, P473; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; Szallasi Z, 1996, CANCER RES, V56, P2105; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	26	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20245	20250		10.1074/jbc.272.32.20245	http://dx.doi.org/10.1074/jbc.272.32.20245			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242703	hybrid			2022-12-25	WOS:A1997XQ05900090
J	Ruelland, E; LemaireChamley, M; LeMarechal, P; IssakidisBourguet, E; Djukic, N; MiginiacMaslow, M				Ruelland, E; LemaireChamley, M; LeMarechal, P; IssakidisBourguet, E; Djukic, N; MiginiacMaslow, M			An internal cysteine is involved in the thioredoxin-dependent activation of sorghum leaf NADP-malate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; REGULATORY SITE; PHOTOSYNTHESIS; EXPRESSION; ENZYMES; UNIQUE; ACID	The chloroplastic NADP-malate dehydrogenase is activated by thiol/disulfide interchange with reduced thioredoxins, Previous experiments showed that four cysteines located in specific N- and carboxyl-terminal extensions were implicated in this process, leading to a model where no internal cysteine was involved in activation, In the present study, the role of the conserved four internal cysteines was investigated, Surprisingly, the mutation of cysteine 207 into alanine yielded a protein with accelerated activation time course, whereas the mutations of the three other internal cysteines into alanines yielded proteins with unchanged activation kinetics, These results suggested that cysteine 207 might be linked in a disulfide bridge with one of the four external cysteines, most probably with one of the two amino-terminal cysteines whose mutation similarly accelerates the activation rate, To investigate this possibility, mutant malate dehydrogenases (MDHs) where a single amino terminal cysteine was mutated in combination with the mutation of both carboxyl-terminal cysteines were produced and purified, The C29S/C365A/C377A mutant MDH still needed activation by reduced thioredoxin, while the C24S/C365A/C377A mutant MDH exhibited a thioredoxin-insensitive spontaneous activity, leading to the hypothesis that a Cys(24)-Cys(207) disulfide bridge might be formed during the activation process, Indeed, an NADP-MDH where the cysteines 29, 207, 365, and 377 are mutated yielded a permanently active enzyme very similar to the previously created permanently active C24S/C29S/C365A/C377A mutant. A two-step activation model involving a thioredoxin-mediated disulfide isomerization at the amino terminus is proposed.	UNIV PARIS 11,ERS 569 CNRS,INST BIOTECHNL PLANTES,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; Universite Paris Saclay			Ruelland, Eric/D-4863-2012	Issakidis-Bourguet, Emmanuelle/0000-0002-6144-4364; Lemaire-Chamley, Martine/0000-0002-7687-894X				Buchanan Bob B., 1994, Seminars in Cell Biology, V5, P285, DOI 10.1006/scel.1994.1035; Chang JY, 1997, J BIOL CHEM, V272, P69; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; DROUX M, 1987, ARCH BIOCHEM BIOPHYS, V256, P372, DOI 10.1016/0003-9861(87)90458-9; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; HATCH MD, 1992, PLANT PHYSIOL, V100, P360, DOI 10.1104/pp.100.1.360; HATCH MD, 1987, BIOCHIM BIOPHYS ACTA, V895, P81, DOI 10.1016/S0304-4173(87)80009-5; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; Hennecke J, 1997, J BIOL CHEM, V272, P189; ISSAKIDIS E, 1994, J BIOL CHEM, V269, P3511; Issakidis E, 1996, FEBS LETT, V392, P121, DOI 10.1016/0014-5793(96)00801-0; ISSAKIDIS E, 1992, J BIOL CHEM, V267, P21577; JACKSON RM, 1992, J COMPUT AID MOL DES, V6, P1, DOI 10.1007/BF00124383; Jacquot JP, 1997, FEBS LETT, V401, P143, DOI 10.1016/S0014-5793(96)01459-7; JOHNSON HS, 1970, BIOCHEM J, V119, P273, DOI 10.1042/bj1190273; KAMPFENKEL K, 1993, BIOCHIM BIOPHYS ACTA, V1156, P71; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEMAIRE M, 1994, J BIOL CHEM, V269, P27291; Lemaire M, 1996, FEBS LETT, V382, P137, DOI 10.1016/0014-5793(96)00153-6; MIGINIACMASLO M, 1997, IN PRESS AUSTR J PLA, V24; OCHERETINA O, 1994, FEBS LETT, V355, P254, DOI 10.1016/0014-5793(94)01214-8; OCHERETINA O, 1993, BIOCHIM BIOPHYS ACTA, V1163, P10, DOI 10.1016/0167-4838(93)90272-S; RENG W, 1993, EUR J BIOCHEM, V217, P189, DOI 10.1111/j.1432-1033.1993.tb18233.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2	28	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19851	19857		10.1074/jbc.272.32.19851	http://dx.doi.org/10.1074/jbc.272.32.19851			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242647	Green Published, hybrid			2022-12-25	WOS:A1997XQ05900034
J	Saji, M; Shong, MH; Napolitano, G; Palmer, LA; Taniguchi, S; Ohmori, M; Ohta, M; Suzuki, K; Kirshner, SL; Giuliani, C; Singer, DS; Kohn, LD				Saji, M; Shong, MH; Napolitano, G; Palmer, LA; Taniguchi, S; Ohmori, M; Ohta, M; Suzuki, K; Kirshner, SL; Giuliani, C; Singer, DS; Kohn, LD			Regulation of major histocompatibility complex class I gene expression in thyroid cells - Role of the cAMP response element-like sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN RECEPTOR GENE; SYSTEMIC LUPUS-ERYTHEMATOSUS; TRANSCRIPTION FACTOR-I; DNA-BINDING PROTEIN; PANCREATIC-ISLET CELLS; CYCLIC-AMP; FOAMY VIRUS; SOMATOSTATIN EXPRESSION; PROMOTER INTERACTS; INTERFERON THERAPY	The major histocompatibility complex (MBC) class I gene cAMP response element (CBE)-like site, -107 to - 100 base pairs, is a critical component of a previously unrecognized silencer, -127 to -90 bp, important for thyrotropin (TSH)/cAMP-mediated repression in thyrocytes, TSH/cAMP induced-silencer activity is associated with the formation of novel complexes with the 38-base pair silencer, whose appearance requires the CRE and. involves ubiquitous and thyroid-specific proteins as follows: the CRE-binding protein, a Y-box protein termed thyrotropin receptor (TSHR) suppressor element protein-1 (TSEP-1); thyroid transcription factor-1 (TTF-1); and Pax-8. TTF-1 is as enhancer of Glass I promoter activity; Pax-8 and TSEP-1 are suppressors, TSH/cAMP decreases TTF-1 complex formation with the silencer, thereby decreasing maximal class I expression; TSH/cAMP enhance TSEP-1 and Pax-8 complex formation in association with their repressive actions, Oligonucleotides that bind TSEP-1, not Pax-8, prevent formation of the TSH/cAMP-induced complexes associated with TSH-induced class I suppression, i.e. TSEP-1 appears to be the dominant repressor factor associated with TSH/cAMP-decreased class I activity and formation of the novel complexes. TSEP-1, TTF-1, and/or Pax-8 are involved in TSH/cAMP-induced negative regulation of the TSH receptor Gene in thyrocytes, suppression-of MHC class II, and up-regulation of thyroglobulin. TSH/cAMP coordinate regulation of common transcription factors may, therefore, be the basis fop self-tolerance and the absence of autoimmunity iu. the face of TSHR-mediated increases in gene products that are important for thyroid growth and function but are able to act as autoantigens.	NIDDK,METAB DIS BRANCH,NIH,CELL REGULAT SECT,BETHESDA,MD 20892; NCI,EXPT IMMUNOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Saji, Motoyasu/E-4007-2011; /H-7803-2012; Suzuki, Koichi/C-4177-2013	Suzuki, Koichi/0000-0001-8659-4660; shong, minho/0000-0002-0247-7115				AGUZZI A, 1993, BIOCHIM BIOPHYS ACTA, V1155, P1, DOI 10.1016/0304-419X(93)90019-9; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; CHAMBERLAIN JW, 1991, MOL CELL BIOL, V11, P3564, DOI 10.1128/MCB.11.7.3564; CHAN CC, 1995, J IMMUNOL, V154, P4830; CIVITAREALE D, 1993, MOL ENDOCRINOL, V7, P1589, DOI 10.1210/me.7.12.1589; DAVIS LG, 1986, BASIC METHODS MOL BI, P93; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GIULIANI C, 1995, J BIOL CHEM, V270, P11453, DOI 10.1074/jbc.270.19.11453; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUAZZI S, 1990, EMBO J, V9, P631; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HARRIS HW, 1986, TRANSPLANTATION, V42, P109, DOI 10.1097/00007890-198608000-00001; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P1701, DOI 10.1210/me.6.10.1701; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; IVASHKIV LB, 1991, J EXP MED, V174, P1583, DOI 10.1084/jem.174.6.1583; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; Kohn L D, 1995, Vitam Horm, V50, P287, DOI 10.1016/S0083-6729(08)60658-5; Kohn L D, 1992, Int Rev Immunol, V9, P135, DOI 10.3109/08830189209061788; KOHN LD, 1975, J BIOL CHEM, V250, P6503; Kohn LD., 1995, THYROID IMMUNITY, P115; KOHN LD, 1986, Patent No. 4609622; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KOLLURI R, 1991, NUCLEIC ACIDS RES, V19, P4771, DOI 10.1093/nar/19.17.4771; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAGAYE S, 1992, P NATL ACAD SCI USA, V89, P10070, DOI 10.1073/pnas.89.21.10070; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; MAGUIRE JE, 1992, MOL CELL BIOL, V12, P3078, DOI 10.1128/MCB.12.7.3078; MARCELLIN P, 1995, J HEPATOL, V22, P364, DOI 10.1016/0168-8278(95)80291-6; Maxam A M, 1980, Methods Enzymol, V65, P499; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOZES E, 1993, SCIENCE, V261, P91, DOI 10.1126/science.8316860; Ohmori M, 1996, MOL ENDOCRINOL, V10, P76, DOI 10.1210/me.10.1.76; OHMORI M, 1995, ENDOCRINOLOGY, V136, P269, DOI 10.1210/en.136.1.269; Ohmori M, 1996, MOL ENDOCRINOL, V10, P1407, DOI 10.1210/me.10.11.1407; PESTOV DG, 1991, NUCLEIC ACIDS RES, V1, P6527; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; SABATH DE, 1990, J BIOL CHEM, V265, P12671; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAJI M, 1992, ENDOCRINOLOGY, V130, P520, DOI 10.1210/en.130.1.520; SAJI M, 1992, J CLIN ENDOCR METAB, V75, P871, DOI 10.1210/jc.75.3.871; SAJI M, 1992, P NATL ACAD SCI USA, V89, P1944, DOI 10.1073/pnas.89.5.1944; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuppert F, 1996, J CLIN ENDOCR METAB, V81, P3622, DOI 10.1210/jc.81.10.3622; SHIMURA H, 1995, MOL ENDOCRINOL, V9, P527, DOI 10.1210/me.9.5.527; SHIMURA H, 1993, J BIOL CHEM, V268, P24125; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; SHIMURA Y, 1994, J BIOL CHEM, V269, P31908; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SINGER DS, 1994, J IMMUNOL, V153, P873; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; STANCEK D, 1975, MED MICROBIOL IMMUN, V161, P133, DOI 10.1007/BF02121755; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; TODD I, 1986, ANN NY ACAD SCI, V475, P241, DOI 10.1111/j.1749-6632.1986.tb20873.x; TOMER Y, 1993, ENDOCR REV, V14, P107, DOI 10.1210/er.14.1.107; TRAN A, 1993, HEPATOLOGY, V18, P253, DOI 10.1002/hep.1840180205; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VOLPE R, 1967, J CLIN ENDOCR METAB, V27, P1275, DOI 10.1210/jcem-27-9-1275; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WATINE BD, 1990, IMMUNOL TODAY, V11, P286; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4217, DOI 10.1128/MCB.11.8.4217; WERNER J, 1979, LANCET, V2, P258; WICK G, 1992, INT ARCH ALLERGY IMM, V99, P153, DOI 10.1159/000236350; WOLFFE AP, 1992, NEW BIOL, V4, P290; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	76	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20096	20107		10.1074/jbc.272.32.20096	http://dx.doi.org/10.1074/jbc.272.32.20096			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242683	hybrid			2022-12-25	WOS:A1997XQ05900070
J	Buckhaults, P; Chen, L; Fregien, N; Pierce, M				Buckhaults, P; Chen, L; Fregien, N; Pierce, M			Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; TRANSFORMED HAMSTER CELLS; MOUSE MELANOMA-CELLS; HERBIMYCIN-A; KIDNEY CELLS; BETA-1,4-GALACTOSYLTRANSFERASE GENE; BRANCHED OLIGOSACCHARIDES; CONTACT-INHIBITION; SUGAR CHAINS; BHK CELLS	Transformation of baby hamster kidney fibroblasts by the Rous sarcoma virus causes a significant increase in the GlcNAc beta(1,6)Man-branched oligosaccharides by elevating the activity and mRNA transcript levels encoding N-acetylglucosaminyltransferase V (GlcNAc-T V). Elevated activity arid mRNA levels could be inhibited by blocking cell proliferation with herbimycin A, demonstrating that Src kinase activity can regulate GlcNAc-T V expression. 5' RACE analysis was used to identify a 3-kilobase 5'-untranslated region from GlcNAc-T V mRNA and locate a transcriptional start site in a 25-kilobase pair GlcNAc-T V human genomic clone, A 6-kilobase pair fragment of the 5' region of the gene contained AP-1 and PEA3/Ets binding elements and, when co-transfected with a src expression plasmid into HepG2 cells, conferred src-stimulated transcriptional enhancement upon a luciferase reporter gene, This stimulation by src could be antagonized by co-transfection with a dominant-negative mutant of the Raf kinase, suggesting the involvement of Ets transcription factors in the regulation of GlcNAc-T V gene expression. The src-responsive element was localized by 5' deletion analysis to a 250-base pair region containing two overlapping Ets sites. src stimulation of transcription from this region was inhibited by co-transfection with a dominant-negative mutant of Ets-2, demonstrating that the effects of the src kinase on GlcNAc-T V expression are dependent on Ets.	UNIV GEORGIA, DEPT BIOCHEM & MOL BIOL, ATHENS, GA 30602 USA; UNIV GEORGIA, COMPLEX CARBOHYDRATE RES CTR, ATHENS, GA 30602 USA; UNIV MIAMI, SCH MED, DEPT CELL BIOL & ANAT, MIAMI, FL 33101 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Miami								AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; Aperlo C, 1996, MOL CELL BIOL, V16, P6851; ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUCK CA, 1971, BIOCHEMISTRY-US, V10, P2176, DOI 10.1021/bi00787a034; BUCK CA, 1970, BIOCHEMISTRY-US, V9, P4567, DOI 10.1021/bi00825a016; Cho SK, 1996, J BIOL CHEM, V271, P3238, DOI 10.1074/jbc.271.6.3238; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EASTON EW, 1991, J BIOL CHEM, V266, P21674; FERNANDES B, 1991, CANCER RES, V51, P718; FINNE J, 1989, INT J CANCER, V43, P300, DOI 10.1002/ijc.2910430223; GLICK MC, 1979, BIOCHEMISTRY-US, V18, P2525, DOI 10.1021/bi00579a015; GLICK MC, 1973, BIOCHEMISTRY-US, V12, P85, DOI 10.1021/bi00725a016; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HAHN TJ, 1992, J BIOL CHEM, V267, P23982; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; KAWANO T, 1993, INT J CANCER, V53, P91, DOI 10.1002/ijc.2910530118; KUDO T, 1995, GLYCOBIOLOGY, V5, P397, DOI 10.1093/glycob/5.4.397; LEMARER N, 1992, GLYCOBIOLOGY, V2, P49, DOI 10.1093/glycob/2.1.49; LU Y, 1994, CLIN EXP METASTAS, V12, P47, DOI 10.1007/BF01784333; LU Y, 1993, MOL CELL BIOCHEM, V122, P85, DOI 10.1007/BF00925741; MEEZAN E, 1969, BIOCHEMISTRY-US, V8, P2518, DOI 10.1021/bi00834a039; MIYOSHI E, 1995, J BIOL CHEM, V270, P6216, DOI 10.1074/jbc.270.11.6216; MURAKAMI Y, 1988, CANCER RES, V48, P1587; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PERNG GS, 1994, GLYCOBIOLOGY, V4, P867, DOI 10.1093/glycob/4.6.867; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; SAITO H, 1995, EUR J BIOCHEM, V233, P18, DOI 10.1111/j.1432-1033.1995.018_1.x; SANTER UV, 1989, EUR J BIOCHEM, V181, P249, DOI 10.1111/j.1432-1033.1989.tb14719.x; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SUZUKAKETSUCHIYA K, 1989, J ANTIBIOT, V42, P1831, DOI 10.7164/antibiotics.42.1831; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TUSZYNSKI GP, 1978, J BIOL CHEM, V253, P6092; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WARREN L, 1972, P NATL ACAD SCI USA, V69, P1838, DOI 10.1073/pnas.69.7.1838; WARREN L, 1972, NATURE, V235, P276, DOI 10.1038/235275a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; YAMAMURA K, 1991, J INVEST DERMATOL, V97, P735, DOI 10.1111/1523-1747.ep12484282; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	50	115	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19575	19581		10.1074/jbc.272.31.19575	http://dx.doi.org/10.1074/jbc.272.31.19575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235963	hybrid			2022-12-25	WOS:A1997XP06300069
J	Chantry, D; Vojtek, A; Kashishian, A; Holtzman, DA; Wood, C; Gray, PW; Cooper, JA; Hoekstra, MF				Chantry, D; Vojtek, A; Kashishian, A; Holtzman, DA; Wood, C; Gray, PW; Cooper, JA; Hoekstra, MF			p110 delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA GENE; PROTEIN-KINASE; SH2 DOMAINS; CLONING; BINDING; RECEPTOR; IDENTIFICATION; INTERACTS; HOMOLOG; PRODUCT	We have identified a novel p110 isoform of phosphatidylinositol 3-kinase from human leukocytes that we have termed p110 delta, In addition, we have independently isolated p110 delta from a mouse embryo library on the basis of its ability to interact with Ha-Ras(V12) in the yeast two-hybrid system, This unique isoform contains all of the conserved structural features characteristic of the p110 family, Recombinant p110 delta phosphorylates phosphatidylinositol and coimmunoprecipitates with p85, However, in contrast to previously described p110 subunits, p110 delta is expressed in a tissue-restricted fashion; it is expressed at high levels in lymphocytes and lymphoid tissues and may therefore play a role in phosphatidylinositol 3-kinase-mediated signaling in the immune system.	ICOS CORP,BOTHELL,WA 98021; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Icos Corporation; University of Michigan System; University of Michigan; Fred Hutchinson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA054786] Funding Source: NIH RePORTER; NCI NIH HHS [CA54786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1642; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; VOJTEK AB, 1993, J CELL SCI, V105, P777; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOLINIA S, 1992, ONCOGENE, V7, P789; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	32	206	241	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19236	19241		10.1074/jbc.272.31.19236	http://dx.doi.org/10.1074/jbc.272.31.19236			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235916	hybrid			2022-12-25	WOS:A1997XP06300022
J	Fan, GS; Ma, XM; Kren, BT; Rice, M; Kmiec, EB; Steer, CJ				Fan, GS; Ma, XM; Kren, BT; Rice, M; Kmiec, EB; Steer, CJ			A novel link between REC2, a DNA recombinase, the retinoblastoma protein, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							USTILAGO-MAYDIS; ADENOVIRUS E1A; GENE ENCODES; LARGE-T; BINDING; E2F; RB	The REC2 recombinase is essential for recombinational repair following DNA damage as well as for successful meiosis and gene targeting in the corn smut Ustilago maydis, Here we report that overexpression of REC2 induced apoptotic cell death in human HuH-7, Hep G2, and Hep 3B hepatoma cells. Apoptosis was related to recombinase activity and was significantly increased by inhibition of retinoblastoma (Rb) expression with transforming growth factor-beta 1. REC2-induced apoptosis was associated with a significantly reduced percentage of cells in the G(1) phase of the cell cycle and a significant reduction in G(2)/M only in the Rb((-)/(-)) Hep 3B cells. Overexpression of REC2 resulted in increased abundance of the hyperphosphorylated form of Rb. However, by immunoprecipitation REC2 was associated primarily with hypophosphorylated Rb, suggesting that REC2 may be involved in modulating the phosphorylation state of Rb. The A and B pocket domains with the spacer amino acid sequence and the carboxyl-terminal region of Rb were required for maximal binding to REC2. Overexpression of Rb significantly inhibited REC2-induced apoptosis even in the presence of transforming growth factor-beta 1. Taken together, these data suggest a novel interaction of Rb with the recombinase REC2 and a role for this complex in bridging DNA recombination and apoptosis.	UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; THOMAS JEFFERSON UNIV,DEPT PHARMACOL,KIMMEL CANC CTR,PHILADELPHIA,PA 19107; UNIV MINNESOTA,SCH MED,DEPT MED,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; Jefferson University; University of Minnesota System; University of Minnesota Twin Cities								BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Fan GS, 1996, ADV ENZYME REGUL, V36, P283, DOI 10.1016/0065-2571(95)00013-5; FAN GS, 1995, CELL GROWTH DIFFER, V6, P1463; Fan GS, 1996, ONCOGENE, V12, P1909; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; Grafi G, 1996, P NATL ACAD SCI USA, V93, P8962, DOI 10.1073/pnas.93.17.8962; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KMIEC EB, 1994, MOL CELL BIOL, V14, P7163, DOI 10.1128/MCB.14.11.7163; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RUBIN BP, 1994, MOL CELL BIOL, V14, P6287, DOI 10.1128/MCB.14.9.6287; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Wick MJ, 1996, MOL BRAIN RES, V36, P322, DOI 10.1016/0169-328X(95)00258-T; Xie Q, 1996, EMBO J, V15, P4900, DOI 10.1002/j.1460-2075.1996.tb00870.x	25	11	13	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19413	19417		10.1074/jbc.272.31.19413	http://dx.doi.org/10.1074/jbc.272.31.19413			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235941	hybrid			2022-12-25	WOS:A1997XP06300047
J	Floer, M; Blobel, G; Rexach, M				Floer, M; Blobel, G; Rexach, M			Disassembly of RanGTP-karyopherin beta complex, an intermediate in nuclear protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RNA1 GENE-PRODUCT; BINDING-PROTEIN; PORE COMPLEX; CHROMOSOME CONDENSATION; TRANSPORT SUBSTRATE; MEDIATED BINDING; YEAST MUTANT; IDENTIFICATION; RAN/TC4	We previously showed that RanGTP forms a 1:1 complex with karyopherin beta that renders RanGTP inaccessible to RanGAP (Floer, M., and Blobel, G. (1996) J. Biol. Chem. 271, 5313-5316) and karyopherin beta functionally inactive (Rexach, M., and Blobel, G. (1995) Cell 83, 683-692). Recycling of both factors for another round of function requires dissociation of the RanGTP-karyopherin beta complex, Here we show using BIAcore(TM), a solution binding assay, and GTP hydrolysis and exchange assays, with yeast proteins, that karyopherin beta and RanGTP are recycled efficiently in a reaction that involves karyopherin alpha, RanBP1, RanGAP, and the C terminus of the nucleoporin Nup1. We find that karyopherin alpha first releases RanGTP from karyopherin beta in a reaction that does not require GTP hydrolysis, The released RanGTP is then sequestered by RanBP1, and the newly formed karyopherin alpha beta binds to the C terminus of Nup1. Finally, RanGTP is converted to RanGDP via nucleotide hydrolysis when RanGrAP is present, Conversion of RanGTP to RanGDP can also occur via nucleotide exchange in the presence of RanGEF, an excess of GDP, and if RanBP1 is absent. Additional nucleoporin domains that bind karyopherin alpha beta stimulate recycling of karyopherin beta and Ran in a manner similar to the C terminus of Nup1.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University								ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bullock TL, 1996, J MOL BIOL, V260, P422, DOI 10.1006/jmbi.1996.0411; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; Enenkel C, 1996, P NATL ACAD SCI USA, V93, P12986, DOI 10.1073/pnas.93.23.12986; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HARTMANN E, 1995, TRENDS CELL BIOL, V5, P192, DOI 10.1016/S0962-8924(00)88992-8; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOPPER AK, 1978, CELL, V14, P211, DOI 10.1016/0092-8674(78)90108-3; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Lounsbury KM, 1996, J BIOL CHEM, V271, P2357, DOI 10.1074/jbc.271.5.2357; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; Noguchi E, 1997, MOL CELL BIOL, V17, P2235, DOI 10.1128/MCB.17.4.2235; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Percipalle P, 1997, J MOL BIOL, V266, P722, DOI 10.1006/jmbi.1996.0801; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; Traglia HM, 1996, P NATL ACAD SCI USA, V93, P7667, DOI 10.1073/pnas.93.15.7667; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	70	117	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19538	19546		10.1074/jbc.272.31.19538	http://dx.doi.org/10.1074/jbc.272.31.19538			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235958	hybrid			2022-12-25	WOS:A1997XP06300064
J	Gongora, C; David, G; Pintard, L; Tissot, C; Hua, TD; Dejean, A; Mechti, N				Gongora, C; David, G; Pintard, L; Tissot, C; Hua, TD; Dejean, A; Mechti, N			Molecular cloning of a new interferon-induced PML nuclear body-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; DNA-BINDING PROTEIN; C-FOS GENE; TRANSCRIPTION FACTOR; TYROSINE PHOSPHORYLATION; STIMULATED TRANSCRIPTION; CYTOPLASMIC ACTIVATION; T(1517) TRANSLOCATION; GROWTH-SUPPRESSOR; VIRUS-INFECTION	Transcriptional induction of genes is an essential part of the cellular response to interferons. We have established a cDNA library from human lymphoblastoid Daudi cells treated for 16 h with human alpha/beta-interferon (IFN) and made use of differential screening to search for as yet unidentified IFN regulated genes, In the course of this study, we have isolated a human cDNA that codes for a 20-kDa protein sharing striking homology with the product of the Xenopus laevis XPMC2 gene. This new gene is induced by both type I and II IFNs in various cell lines and will be referred to as ISG20 for interferon-stimulated gene product of 20 kDa. Confocal immunofluorescence analysis of the subcellular localization of ISG20 protein reveals that it is closely associated with PML and SP100 gene products within the large nuclear matrix associated multiprotein complexes termed the PML nuclear bodies.	INST GENET MOL MONTPELLIER,CNRS,UMR 9942,F-34033 MONTPELLIER 1,FRANCE; INST PASTEUR,INSERM,UNITE RECOMBINAISON & EXPRESS GENET,U163,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			pintard, lionel/AAD-8356-2020; Dejean, Anne/L-5145-2018; PINTARD, Lionel/AAP-7361-2020; PINTARD, Lionel/H-3756-2018	PINTARD, Lionel/0000-0003-0286-4630; PINTARD, Lionel/0000-0003-0286-4630; GONGORA, Celine/0000-0001-9034-4031; , gregory/0000-0002-3371-4558				AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Boddy MN, 1996, ONCOGENE, V13, P971; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DENSEN P, 1980, COMPUT APPL BIOSCI, V6, P355; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GRIGNANI F, 1994, BLOOD, V83, P10; Grotzinger T, 1996, EUR J BIOCHEM, V238, P554, DOI 10.1111/j.1432-1033.1996.0554z.x; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; Korioth F, 1996, EXP CELL RES, V229, P155, DOI 10.1006/excr.1996.0353; LAMOND AI, 1993, MOL BIOL REP, V18, P127, DOI 10.1007/BF00986767; LAMOND AI, 1993, BIOESSAYS, V15, P595, DOI 10.1002/bies.950150905; LAVAU C, 1995, ONCOGENE, V11, P871; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Scheer Ulrich, 1993, Trends in Cell Biology, V3, P236, DOI 10.1016/0962-8924(93)90123-I; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Stadler M, 1995, ONCOGENE, V11, P2565; STUURMAN N, 1992, J CELL SCI, V101, P773; SU JY, 1995, MOL GEN GENET, V246, P387, DOI 10.1007/BF00288613; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TERRIS B, 1995, CANCER RES, V55, P1590; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901	59	113	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19457	19463		10.1074/jbc.272.31.19457	http://dx.doi.org/10.1074/jbc.272.31.19457			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235947	Green Published, hybrid			2022-12-25	WOS:A1997XP06300053
J	Ungewickell, E; Ungewickell, H; Holstein, SEH				Ungewickell, E; Ungewickell, H; Holstein, SEH			Functional interaction of the auxilin J domain with the nucleotide- and substrate-binding modules of Hsc70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CLATHRIN-ASSOCIATED PROTEIN; MOLECULAR CHAPERONE HSC70; COATED VESICLES; ESCHERICHIA-COLI; ATPASE ACTIVITY; UNCOATING ATPASE; COGNATE PROTEIN; DNAK CHAPERONE; BOVINE BRAIN	The uncoating of clathrin-coated vesicles requires the DnaJ homologue auxilin for targeting Hsc70 to clathrin coats. This function involves a transient interaction of the auxilin J domain with Hsc70. We have now identified the structural elements of Hsc70 that are responsible for the uncoating activity, and we show that the hitherto accepted view, which implicates the 10-kDa carboxyl-terminal variable domain of Hsc70, is incorrect. A 60-kDa chymotryptic or analogous recombinant fragment of Hsc70, which contains the ATPase- and substrate-binding domains, is sufficient to liberate clathrin from coated vesicles, Consistent with this was the observation that Hsp70 uncoats coated vesicles with the same efficacy as Hsc70 and that DnaK possesses vestigial uncoating activity, Direct binding studies demonstrated that the auxilin J domain undergoes an ATP-dependent reaction only with fragments of Hsc70 that contain both the ATPase- and substrate-binding domains, The individual domains by themselves did not bind to the J domain nor did a recombinant protein that contained the substrate-binding domain attached to the 10-kDa variable domain.			Ungewickell, E (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,CTR IMMUNOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; CAMPBELL CH, 1983, J BIOL CHEM, V258, P2628; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DELUCAFLAHERTY C, 1990, NUCLEIC ACIDS RES, V18, P5569, DOI 10.1093/nar/18.18.5569; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HA JH, 1995, BIOCHEMISTRY-US, V34, P11635, DOI 10.1021/bi00036a040; Hartl F U, 1991, Semin Immunol, V3, P5; HOHFELD J, 1995, CELL, V83, P589; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; JIANG F, 1997, J BIOL CHEM, V272, P6141; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LINDNER R, 1992, J BIOL CHEM, V267, P16567; MCCARTY JS, 1994, J BACTERIOL, V176, P764, DOI 10.1128/jb.176.3.764-780.1994; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P137; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; PRASAD K, 1994, J BIOL CHEM, V269, P6931; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHRODER S, 1995, EUR J BIOCHEM, V228, P297, DOI 10.1111/j.1432-1033.1995.tb20263.x; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; TSAI MY, 1994, J BIOL CHEM, V269, P5958; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; UNGEWICKELL E, 1994, EUR J BIOCHEM, V222, P33, DOI 10.1111/j.1432-1033.1994.tb18838.x; WALL D, 1994, J BIOL CHEM, V269, P5446; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; WANG TF, 1993, J BIOL CHEM, V268, P26049; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	45	57	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19594	19600		10.1074/jbc.272.31.19594	http://dx.doi.org/10.1074/jbc.272.31.19594			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235966	hybrid			2022-12-25	WOS:A1997XP06300072
J	Horiuchi, M; Hayashida, W; Kambe, T; Yamada, T; Dzau, VJ				Horiuchi, M; Hayashida, W; Kambe, T; Yamada, T; Dzau, VJ			Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NERVE GROWTH-FACTOR; TYROSINE-PHOSPHATASE; MAP KINASE; MEDIATES INHIBITION; NEUROTROPHIC FACTOR; EXPRESSION; RAT; SUBTYPES; 3CH134	We examined the cellular and signaling mechanism of angiotensin II (Ang II) type 2 (AT2) receptor-induced apoptosis in PC12W (rat pheochromocytoma cell line) cells that express abundant AT2 receptor but not Ang II type 1 receptor. In these cells, nerve growth factor (NGF) inhibited the internucleosomal DNA fragmentation induced by serum depletion, whereas Ang II antagonized this NGF cell survival action and induced apoptosis, We studied the mechanism of NGF and AT2 receptor interaction on apoptosis by examining their effects on the survival factor Bcl-2, AT2 receptor activation did affect intracellular Bcl-2 protein levels, Bcl-2 phosphorylation was stimulated by NGF, whereas AT2 receptor activation blocked this NGF effect. Pretreatment with antisense oligonucleotide of mitogen-activated protein (MAP) kinase phosphatase-1 enhanced the effects of NGF on MAP kinase activation and Bcl-2 phosphorylation but attenuated the inhibitory effects of AT2 receptor on MAP kinase, Bcl-2 phosphorylation, and apoptosis, Taken together, these results suggest that MAP kinase plays a critical role in inhibiting apoptosis by phosphorylating Bcl-2, The AT2 receptor inhibits MAP kinase activation, resulting in the inactivation of Bcl-2 and the induction of apoptosis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NHLBI NIH HHS [HL46631, HL35610, HL35252] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046631, R01HL035610, R37HL035610, R01HL035252] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BOTTARI SP, 1992, BIOCHEM BIOPH RES CO, V183, P206, DOI 10.1016/0006-291X(92)91629-5; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CLEARLY ML, 1992, CELL, V47, P19; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUDLEY DT, 1991, MOL PHARMACOL, V40, P360; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hayashida W, 1996, J BIOL CHEM, V271, P21985, DOI 10.1074/jbc.271.36.21985; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; LOPEZ JJ, 1994, AM J PHYSIOL, V267, pH844, DOI 10.1152/ajpheart.1994.267.2.H844; MAY WS, 1994, J BIOL CHEM, V269, P26865; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SPETH RC, 1990, BIOCHEM BIOPH RES CO, V169, P997, DOI 10.1016/0006-291X(90)91993-3; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; TOBE K, 1991, J BIOL CHEM, V266, P24793; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pH667, DOI 10.1152/ajpheart.1991.261.3.H667; TSUTSUMI K, 1991, ENDOCRINOLOGY, V129, P1075, DOI 10.1210/endo-129-2-1075; UDLEY DT, 1993, REGUL PEPTIDES, V44, P199; VISWANATHAN M, 1992, PEPTIDES, V13, P783, DOI 10.1016/0196-9781(92)90187-8; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156	39	248	255	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19022	19026		10.1074/jbc.272.30.19022	http://dx.doi.org/10.1074/jbc.272.30.19022			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228085	hybrid			2022-12-25	WOS:A1997XM34200076
J	Grandis, JR; Chakraborty, A; Melhem, MF; Zeng, Q; Tweardy, DJ				Grandis, JR; Chakraborty, A; Melhem, MF; Zeng, Q; Tweardy, DJ			Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells	ONCOGENE			English	Article						epidermal growth factor receptor; head and neck cancer	FACTOR-ALPHA; EGF-RECEPTOR; BREAST-CANCER; TGF-ALPHA; MONOCLONAL-ANTIBODIES; PSEUDOMONAS EXOTOXIN; TYROSINE KINASE; FUSION PROTEIN; MESSENGER-RNA; TUMOR-GROWTH	Previous reports have shown that fresh tissues and cell lines from patients with squamous cell carcinoma of the head and neck (SCCHN) overexpress transforming growth factor alpha (TGF-alpha) and its receptor, the epidermal growth factor receptor (EGFR) at both the mRNA and protein levels. Protein localization studies confirm that TGF-alpha and EGFR are produced by the same epithelial cells in tissues from head and neck cancer patients further supporting an autocrine growth pathway. Using three strategies, we examined the hypothesis that downmodulation of EGFR would reduce the proliferation of SCCHN cells. We targeted EGFR mRNA using antisense oligonucleotides and the mature EGFR protein at two sites, the ligand-binding domain and the kinase domain, and determined the effects of this targeting on SCCHN proliferation. Treatment of several SCCHN cell lines with a pair of antisense oligodeoxynucleotides directed against the translation start site and first intron-exon splice junction of the human EGFR gene resulted in decreased EGFR protein production and inhibited growth by 86% compared to a 13% reduction in cells treated with sense oligonucleotides (P=0.03). Growth inhibition was specific for carcinoma cells since the same EGFR antisense oligonucleotides had no effect on the proliferation of normal mucosa cells harvested from non-cancer patients. Two monoclonal antibodies which block ligand binding to EGFR (MAbs 425 and 528) inhibited the growth of several SCCHN cell lines by up to 97% which suggests that EGFR is participating in an autocrine pathway in SCCHN that is, at least in part, external. An EGFR-specific tyrosine kinase inhibitor (PD 153035) was found to inhibit EGFR phosphorylation in SCCHN cell lines and to reduce growth by 68% although it had no effect on the growth rate of normal mucosal epithelial cells. These experiments indicate that EGFR gene expression and function is critical for SCCHN cell growth but not for growth of normal mucosa cells and therefore may serve as a tumor-specific target for preventive and therapeutic strategies in head and neck cancer.	UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,DEPT OTOLARYNGOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,DEPT MED & MOL GENET & BIOCHEM,PITTSBURGH,PA 15213; UNIV PITTSBURGH,INST CANC,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Tweardy, David/L-3929-2019		NCI NIH HHS [1 K11 CA01760-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001760] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATLAS I, 1992, CANCER RES, V2, P3353; BASELGA J, 1994, PHARMACOL THERAPEUT, V64, P127, DOI 10.1016/0163-7258(94)90036-1; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; BASELGA J, 1994, BREAST CANCER RES TR, V29, P127, DOI 10.1007/BF00666188; CHRISTENSEN ME, 1992, EUR ARCH OTO-RHINO-L, V249, P243, DOI 10.1007/BF00714485; DERUI L, 1992, AM J CLIN ONCOL-CANC, V15, P288, DOI 10.1097/00000421-199208000-00003; DIFORE PP, 1992, CANC TREAT RES, V61, P139; DIMARCO E, 1989, ONCOGENE, V4, P831; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; EISBRUCH A, 1987, CANCER RES, V47, P3603; FAN Z, 1993, CANCER RES, V53, P4322; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Grandis JR, 1996, CANCER-AM CANCER SOC, V78, P1284, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; HALEY J, 1987, ONCOGENE RES, V1, P375; HARRIS AL, 1989, CANCER CEL, V7, P353; HEO DS, 1989, CANCER RES, V49, P5167; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; KAMEYAMA S, 1994, J CANCER RES CLIN, V120, P507, DOI 10.1007/BF01221026; KAWAMOTO T, 1991, JPN J CANCER RES, V82, P403, DOI 10.1111/j.1349-7006.1991.tb01863.x; Kelloff GJ, 1996, CANCER EPIDEM BIOMAR, V5, P657; KENNEY NJ, 1993, J CELL PHYSIOL, V156, P497, DOI 10.1002/jcp.1041560309; KIHARA A, 1994, BIOCONJUGATE CHEM, P532; LAIRD AD, 1994, CANCER RES, V54, P4224; LEMAISTRE CF, 1992, BLOOD, V82, pA444; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MAXWELL SA, 1989, CANCER RES, V49, P1130; MORISHIGE KI, 1991, CANCER RES, V51, P5322; MORONI MC, 1992, J BIOL CHEM, V267, P2714; MURTHY U, 1990, BIOCHEM BIOPH RES CO, V172, P471, DOI 10.1016/0006-291X(90)90696-K; NICHOLSON S, 1988, BRIT J CANCER, V58, P810, DOI 10.1038/bjc.1988.315; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PHILLIPS PC, 1994, CANCER RES, V54, P1008; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RIKIMARU K, 1992, HEAD NECK-J SCI SPEC, V14, P8, DOI 10.1002/hed.2880140103; RODECK U, 1987, CANCER RES, V47, P3692; SACCHI M, 1990, CANCER RES, V50, P3113; SAINSBURY JRC, 1987, LANCET, V1, P1398; SHIN DM, 1994, CANCER RES, V54, P3153; THEUER CP, 1993, J UROLOGY, V149, P1626, DOI 10.1016/S0022-5347(17)36464-9; TODD R, 1989, CARCINOGENESIS, V10, P1553, DOI 10.1093/carcin/10.8.1553; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; WEICHSELBAUM RR, 1989, HEAD NECK-J SCI SPEC, V11, P437, DOI 10.1002/hed.2880110510; YAMAMOTO T, 1986, CANCER RES, V46, P414	46	103	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					409	416		10.1038/sj.onc.1201188	http://dx.doi.org/10.1038/sj.onc.1201188			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242377				2022-12-25	WOS:A1997XM23800005
J	Choubey, D; Gutterman, JU				Choubey, D; Gutterman, JU			Inhibition of E2F-4/DP-1-stimulated transcription by p202	ONCOGENE			English	Article						E2F-4-mediated transcription; interferon inducible p202; cell growth inhibition; p107; p130	CELL-CYCLE REGULATION; RETINOBLASTOMA PROTEIN; FACTOR E2F; INTERFERON ACTION; FACTOR DRTF1/E2F; FAMILY MEMBERS; DP FAMILY; GENE; BINDING; P107	The interferon (IFN)-inducible proteins mediate activities of the interferons including the cell growth-regulatory activity. We have shown that p202, an IFN-inducible 52kDa primarily nuclear phosphoprotein whose expression in transfected cells inhibits cell proliferation, interacts with the retinoblastoma tumor suppressor protein (pRb) and the transcription factor E2F (E2F-1/DP-1) in vitro and in vivo. p202 was shown to inhibit E2F-1/DP-1-stimulated transcription of a reporter gene and of endogenous genes. Here we report that expression of p202 inhibited E2F-4/DP-1-stimulated transcription of a reporter gene in transfected cells. Furthermore, this inhibition was associated with the inhibition of the sequence-specific DNA-binding of E2F-4 both in complex with the pocket proteins p107 or p130 and in its 'free' form in vitro. p202 bound to p107 and p130 in vitro and in vivo and also associated with E2F-4, supporting the notion that complexes containing p107/E2F-4 or p130/E2F-4 and p202 exist in vivo. Moreover, cotransfection of E2F-4-encoding plasmid in AKR-2B cells overcame p202-mediated inhibition of cell growth, raising the possibility that p202 contributes to cell growth inhibition by the interferons, at least in part, by modulating E2F-4-mediated transcription.			Choubey, D (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MED ONCOL,BOX 41,HOUSTON,TX 77030, USA.		Choubey, Divaker/A-4771-2008		NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER; NCI NIH HHS [CA69031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 1996, BIOCHEM BIOPH RES CO, V221, P396, DOI 10.1006/bbrc.1996.0607; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMAEYER EM, 1988, INTERFERONS REGULATO; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOOSS K, 1995, ONCOGENE, V10, P1529; JORDAN KL, 1994, ONCOGENE, V9, P1177; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Min W, 1996, MOL CELL BIOL, V16, P359; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Sambrook J., 2002, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; ZHU L, 1993, GENE DEV, V7, P111; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	59	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					291	301		10.1038/sj.onc.1201184	http://dx.doi.org/10.1038/sj.onc.1201184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233764				2022-12-25	WOS:A1997XK99900006
J	Eschenhagen, T; Fink, C; Remmers, U; Scholz, H; Wattchow, J; Weil, J; Zimmerman, W; Dohmen, HH; Schafer, H; Bishopric, N; Wakatsuki, T; Elson, EL				Eschenhagen, T; Fink, C; Remmers, U; Scholz, H; Wattchow, J; Weil, J; Zimmerman, W; Dohmen, HH; Schafer, H; Bishopric, N; Wakatsuki, T; Elson, EL			Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system	FASEB JOURNAL			English	Article						heart; cell culture; reconstituted tissue; adenovirus; transgenic model	CELLS; TISSUE; GEL; FIBROBLASTS; EXPRESSION; PROTEIN; INVITRO	A method has been developed for culturing cardiac myocytes in a collagen matrix to produce a coherently contracting 3-dimensional model heart tissue that allows direct measurement of isometric contractile force. Embryonic chick cardiomyocytes were mixed with collagen solution and allowed to gel between two Velcro-coated glass tubes. During culture, the cardiomyocytes formed spontaneously beating cardiac myocyte-populated matrices (CMPMs) anchored at opposite ends to the Velcro-covered tubes through which they could be attached to a force measuring system. Immunohistochemistry and electron microscopy revealed a highly organized tissue-like structure of alpha-actin and alpha-tropomyosin-positive cardiac myocytes exhibiting typical cross-striation, sarcomeric myofilaments, intercalated discs, desmosomes, and tight junctions. Force measurements off paced or unpaced CMPMs were performed in organ baths after 6-11 days of cultivation and were stable for up to 24 h. Force increased with frequency between 0.8 and 2.0 Hz (positive ''staircase''), increasing rest length (Starling mechanism), and increasing extracellular calcium. The utility of this system as a test bed for genetic manipulation was demonstrated by infecting the CMPMs with a recombinant beta-galactosidase-carrying adenovirus. Transduction efficiency increased from about 5% (MOI 0.1) to about 50% (MOI 100). CMPMs display more physiological characteristics of intact heart tissue than monolayer cultures. This approach, simpler and faster than generation of transgenic animals, should allow functional consequences of genetic or pharmacological manipulation of cardiomyocytes in vitro to be studied under highly controlled conditions.	UNIV HAMBURG, KRANKENHAUS EPPENDORF, INST PATHOL, D-20246 HAMBURG, GERMANY; SRI INT, MENLO PK, CA 94025 USA; WASHINGTON UNIV, SCH MED, DEPT MOL BIOPHYS & BIOCHEM, ST LOUIS, MO 63110 USA	University of Hamburg; SRI International; Washington University (WUSTL)	Eschenhagen, T (corresponding author), UNIV HAMBURG, KRANKENHAUS EPPENDORF, ABT ALLGEMEINE PHARMAKOL, MARTINISTR 52, D-20246 HAMBURG, GERMANY.		Zimmermann, Wolfram-Hubertus H/I-6838-2012	Zimmermann, Wolfram-Hubertus H/0000-0003-1190-4040				ACSADI G, 1995, J MOL MED, V73, P165; ALLEN IS, 1988, AM J PHYSIOL, V255, pC51, DOI 10.1152/ajpcell.1988.255.1.C51; BORZAK S, 1991, AM J PHYSIOL, V260, pH884, DOI 10.1152/ajpheart.1991.260.3.H884; Bowditch H.P., 1871, BER SACHS GES AKAD W, V23, P652; CAVANAUGH MW, 1955, J EXP ZOOL, V128, P573, DOI 10.1002/jez.1401280312; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; Eschenhagen T, 1996, BASIC RES CARDIOL, V91, P41, DOI 10.1007/BF00795361; Eschenhagen T, 1996, CIRCULATION, V93, P763, DOI 10.1161/01.CIR.93.4.763; FITZGERALD M, 1994, J MOL CELL CARDIOL, V26, P1261, DOI 10.1006/jmcc.1994.1145; GIBSON GJ, 1982, J CELL BIOL, V93, P767, DOI 10.1083/jcb.93.3.767; GOLDNER JACQUES, 1938, AMER JOUR PATH, V14, P237; HASENFUSS G, 1994, BRIT HEART J, V72, P10; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; Matsumoto T, 1996, J BIOMECH ENG-T ASME, V118, P420, DOI 10.1115/1.2796026; MAUCH C, 1988, EXP CELL RES, V178, P493, DOI 10.1016/0014-4827(88)90417-X; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; ROCHA V, 1985, EXP CELL RES, V159, P201, DOI 10.1016/S0014-4827(85)80049-5; SOUREN JEM, 1992, IN VITRO CELL DEV-AN, V28A, P199; TERRACIO L, 1988, IN VITRO CELL DEV B, V24, P53; VANDENBURGH HH, 1988, IN VITRO CELL DEV B, V24, P166, DOI 10.1007/BF02623542; VANDENBURGH HH, 1994, ANN NY ACAD SCI, V752, P19; VINCAN E, 1995, J MOL CELL CARDIOL, V27, P2393, DOI 10.1016/S0022-2828(95)92127-3; ZIEGLER T, 1994, J CELL BIOCHEM, V56, P204, DOI 10.1002/jcb.240560215	27	448	476	1	41	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1997	11	8					683	694		10.1096/fasebj.11.8.9240969	http://dx.doi.org/10.1096/fasebj.11.8.9240969			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240969				2022-12-25	WOS:A1997XN02700008
J	Dodds, DC; Omeis, IA; Cushman, SJ; Helms, JA; Perin, MS				Dodds, DC; Omeis, IA; Cushman, SJ; Helms, JA; Perin, MS			Neuronal pentraxin receptor, a novel putative integral membrane pentraxin that interacts with neuronal pentraxin 1 and 2 and taipoxin-associated calcium-binding protein 49	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-P COMPONENT; C-REACTIVE PROTEIN; ACUTE-PHASE PROTEINS; ENDOPLASMIC-RETICULUM; DEPENDENT BINDING; A-PROTEIN; EXPRESSION; PENTAXIN; MEMBER; FAMILY	We have identified the first putative integral membrane pentraxin and named it neuronal pentraxin receptor (NPR). NPR, is enriched by affinity chromatography on columns of a snake venom toxin, taipoxin, and columns of the taipoxin-binding proteins neuronal pentraxin 1 (NP1), neuronal pentraxin 2 (NP2), and taipoxin-associated calcium-binding protein 49 (TCBP49), The predominant form of NPR contains an putative NH2-terminal transmembrane domain and all forms of NPR are glycosylated. NPR has 49 and 48% amino acid identity to NP1 and NP2, respectively, and NPR message is expressed in neuronal regions that express NP1 and NP2, We suggest that NPR, NP1, NP2, and TCBP49 are involved in a pathway responsible for the transport of taipoxin into synapses and that this may represent a novel neuronal uptake pathway involved in the clearance of synaptic debris.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030; UNIV CALIF SAN FRANCISCO,DEPT ORTHOPED SURG,SAN FRANCISCO,CA 94143	Baylor College of Medicine; University of California System; University of California San Francisco				Helms, Jill/0000-0002-0463-396X				BREVIARIO F, 1992, J BIOL CHEM, V267, P22190; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CULLCANDY SG, 1976, NEUROSCIENCE, V1, P175, DOI 10.1016/0306-4522(76)90074-9; DODDS D, 1995, J NEUROCHEM, V64, P2339; DOWTON SB, 1990, BIOCHEM J, V270, P553, DOI 10.1042/bj2700553; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; FOHLMAN J, 1976, EUR J BIOCHEM, V68, P457, DOI 10.1111/j.1432-1033.1976.tb10833.x; Goodman Adam R., 1996, Cytokine and Growth Factor Reviews, V7, P191, DOI 10.1016/1359-6101(96)00019-6; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HANN SR, 1994, BIOCHIMIE, V76, P880, DOI 10.1016/0300-9084(94)90190-2; HSU YC, 1995, GENOMICS, V28, P220, DOI 10.1006/geno.1995.1134; NOLAND TD, 1994, J BIOL CHEM, V269, P32607; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; PERIN MS, 1988, EMBO J, V7, P2697, DOI 10.1002/j.1460-2075.1988.tb03123.x; REID MS, 1994, J BIOL CHEM, V269, P32615; ROBBI M, 1991, J BIOL CHEM, V266, P20498; SCHLIMGEN AK, 1995, NEURON, V14, P519, DOI 10.1016/0896-6273(95)90308-9; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tsui CC, 1996, J NEUROSCI, V16, P2463; WEIS K, 1994, J BIOL CHEM, V269, P19142; WHITEHEAD AS, 1990, BIOCHEM J, V266, P283, DOI 10.1042/bj2660283; Wilkinson D.G., 1993, ESSENTIAL DEV BIOL P, P257; WILSON DW, 1993, J BIOL CHEM, V268, P7465	26	121	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21488	21494		10.1074/jbc.272.34.21488	http://dx.doi.org/10.1074/jbc.272.34.21488			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261167	hybrid			2022-12-25	WOS:A1997XR78900077
J	Holland, KA; Owczarek, CM; Hwang, SY; Tymms, MJ; Constantinescu, SN; Pfeffer, LM; Kola, I; Hertzog, PJ				Holland, KA; Owczarek, CM; Hwang, SY; Tymms, MJ; Constantinescu, SN; Pfeffer, LM; Kola, I; Hertzog, PJ			A type I interferon signaling factor, ISF21, encoded on chromosome 21 is distinct from receptor components and their down-regulation and is necessary for transcriptional activation of interferon-regulated genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INTERFERON; CELLS; EXPRESSION; BETA; RESPONSIVENESS; SUBTYPES; CLONING	The type I interferons (IFNs) are a family of cytokines, comprising at least 17 subtypes, which exert pleiotropic actions by interaction with a multi-component cell surface receptor and at least one well characterized signal transduction pathway involving JAK/STAT (Janus kinase/signal transducer and activator of transcription:) proteins, In a previous report, we showed that a signaling factor, encoded by a gene located on the distal portion of chromosome 21, distinct from the IFNAR-1 receptor, was necessary for 2'-5'-oligoadenylate synthetase activity and antiviral responses, but not for high affinity ligand binding, In the present studies using hybrid Chinese hamster ovary cell lines containing portions of human chromosome 21, we show that the type I IFN signaling molecule, designated herein as ISF21, is distinct from the second receptor component, IFNAR-2, which is expressed in signaling and non-signaling cell lines, The location of the gene encoding ISF21 is narrowed to a region between the 10;21 and the r21 breakpoints, importantly eliminating the Mr gene located at 21q22.3 (the product of which is involved in IFN-induced antiviral responses) as a candidate for the signaling factor, To characterize the action of this factor in the type I IFN signaling pathway, we show that it acts independently of receptor down-regulation following ligand binding, both of which occur equally in the presence or absence of the factor, In addition, we demonstrate that ISF21 is necessary for transcriptional activation of 2'-5'-oligoadenylate synthetase, 6-16, and guanylate-binding protein gene promoter reporter constructs, which are mediated by several signaling pathways, ISF21 represents a novel factor as the localization to chromosome 21, and the data presented in this study exclude any of the known type I IFN signal-transducing molecules.	MONASH UNIV,MONASH MED CTR,INST REPROD & DEV,MOL GENET & DEV GRP,CLAYTON,VIC 3168,AUSTRALIA; UNIV TENNESSEE,CTR HLTH SCI,DEPT PATHOL,MEMPHIS,TN 38163	Monash University; University of Tennessee System; University of Tennessee Health Science Center			Constantinescu, Stefan N/E-5277-2012; Hertzog, Paul J/G-6734-2013; Hertzog, Paul J/I-7053-2013; Kola, Ismail/C-5254-2013	Hertzog, Paul J/0000-0002-1373-8472; Hertzog, Paul J/0000-0002-1373-8472; Constantinescu, Stefan N./0000-0002-8599-2699; Pfeffer, Lawrence/0000-0003-2809-1234				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; CONSTANTINESCU SN, 1995, P NATL ACAD SCI USA, V92, P10187; DOMANKSI P, 1995, J BIOL CHEM, V270, P1; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HART AH, 1995, ONCOGENE, V10, P1423; HERTZOG PJ, 1990, BIOCHEM INT, V22, P1095; HERTZOG PJ, 1988, CLIN IMMUNOL IMMUNOP, V48, P192, DOI 10.1016/0090-1229(88)90083-9; HERTZOG PJ, 1994, J BIOL CHEM, V269, P14088; JOHNS TG, 1992, J NATL CANCER I, V84, P1185, DOI 10.1093/jnci/84.15.1185; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LIM JK, 1994, FEBS LETT, V350, P281, DOI 10.1016/0014-5793(94)00787-X; LUTFALLA G, 1990, J INTERFERON RES, V10, P515, DOI 10.1089/jir.1990.10.515; LUTFALLA G, 1995, EMBO J, V14, P101; MOGENSEN KE, 1986, METHOD ENZYMOL, V119, P267; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OVERALL ML, 1992, MOL IMMUNOL, V29, P391, DOI 10.1016/0161-5890(92)90027-U; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, CANCER RES, V50, P2654; RUSSELLHARDE D, 1995, J BIOL CHEM, V270, P26033, DOI 10.1074/jbc.270.44.26033; SOH JM, 1994, J BIOL CHEM, V269, P18102; TYMMS MJ, 1988, GENE ANAL TECH, V5, P9, DOI 10.1016/0735-0651(88)90021-0; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WATHELET M, 1987, EUR J BIOCHEM, V155, P11; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; WHYATT LM, 1993, MOL CELL BIOL, V13, P7971, DOI 10.1128/MCB.13.12.7971	29	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21045	21051		10.1074/jbc.272.34.21045	http://dx.doi.org/10.1074/jbc.272.34.21045			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261106	hybrid			2022-12-25	WOS:A1997XR78900016
J	Narko, K; Ristimaki, A; MacPhee, M; Smith, E; Haudenschild, CC; Hla, T				Narko, K; Ristimaki, A; MacPhee, M; Smith, E; Haudenschild, CC; Hla, T			Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLORECTAL-CANCER; SYNOVIAL TISSUES; GENE DISRUPTION; EXPRESSION; ANGIOGENESIS; APOPTOSIS; INDUCTION; GROWTH; INHIBITORS; RAT	The cyclooxygenase (Cox) enzyme catalyzes the rate-limiting oxidative and peroxidative enzymatic steps in the biosynthesis of prostanoids. Both Cox-1 and -2 genes encode the two isoenzymes that carry out similar enzymatic steps, Enhanced Cox activity is associated with proliferative diseases such as colon cancer, To determine if a cause and effect relationship exists between Cox isoenzyme overexpression and tumorigenesis, the human Cox-1 and Cox-2 isoenzymes were transfected into ECV immortalized endothelial cells, Although numerous clones of Cox-1 expressing cells were obtained, Cox-a overexpression resulted in growth disadvantage and increased cell death, In contrast, Cox-1 overexpressing cells expressed high levels of the functional Cox-1 polypeptide in the endoplasmic reticulum and the nucleus, In vitro proliferation of these cells was reduced compared with vector-transfected ECV cells, Cox-1 overexpression also enhanced the tumor necrosis factor-alpha-induced apoptosis of ECV cells a-fold, In contrast to the in vitro behavior, ECV-Cox-1 cells proliferated aggressively and formed tumors in athymic ''nude'' mice, whereas the vector-transfected counterparts did not, The growth of Cox-1-induced tumors was not inhibited by indomethacin, suggesting a nonprostanoid function of Cox-1. ECV-Cox-1-derived tumors were angiosarcoma-like and contained numerous host-derived neovessels. These data suggest that Cox-1 overexpression in immortalized ECV endothelial cells results in nuclear localization of the polypeptide and tumorigenesis.	UNIV CONNECTICUT,SCH MED,DEPT PHYSIOL,FARMINGTON,CT 06030; UNIV HELSINKI,HAARTMAN INST,DEPT CLIN CHEM & OBSTET & GYNECOL,HELSINKI,FINLAND; AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD 20855	University of Connecticut; University of Helsinki; American Red Cross			Hla, Timothy/G-5873-2012; Christian, Haudenschild C/D-1602-2009	Hla, Timothy/0000-0001-8355-4065; 	FOGARTY INTERNATIONAL CENTER [F05TW004963] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094, P01HL054710] Funding Source: NIH RePORTER; FIC NIH HHS [F05 TWO4963] Funding Source: Medline; NHLBI NIH HHS [HL49094, HL54710] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DuBois RN, 1996, CANCER RES, V56, P733; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Hughes SE, 1996, EXP CELL RES, V225, P171, DOI 10.1006/excr.1996.0168; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PETERSON HI, 1983, INVAS METAST, V3, P151; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; REDDY BS, 1987, CANCER RES, V47, P5340; RIGAS B, 1993, J LAB CLIN MED, V122, P518; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; SANO H, 1995, CANCER RES, V55, P3785; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SILVER RM, 1995, J CLIN INVEST, V95, P725, DOI 10.1172/JCI117719; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; WEIDNER N, 1996, IMPORTANT ADV ONCOL, V136, P167; ZICHE M, 1982, JNCI-J NATL CANCER I, V69, P475	33	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21455	21460		10.1074/jbc.272.34.21455	http://dx.doi.org/10.1074/jbc.272.34.21455			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261162	hybrid			2022-12-25	WOS:A1997XR78900072
J	Scheidegger, KJ; Butler, S; Witztum, JL				Scheidegger, KJ; Butler, S; Witztum, JL			Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; LIPID-PROTEIN ADDUCTS; OXIDATIVE MODIFICATION; MESSENGER-RNA; ATHEROSCLEROTIC LESIONS; HUMAN 15-LIPOXYGENASE; GLOMERULOSA CELLS; RECEPTOR SUBTYPES; GENE-EXPRESSION; RAT	The molecular and cellular mechanisms by which hypertension enhances atherosclerosis are poorly understood. Angiotensin II (Ang II) has been implicated in the regulation of cellular lipoxygenases (LO), which are thought to play a role in atherogenesis by inducing oxidative modification of low density lipoprotein (LDL), We sought to test the hypothesis that Ang II would stimulate murine macrophage LO activity (which has both 12- and 15-LO activity), Competitive binding studies revealed the presence of Ang II AT(1) receptors on mouse peritoneal macrophages (MPM) and J-774 cells, but not on the RAW cell line. Valsartan, a specific AT(1) receptor antagonist inhibited Ang II binding, whereas PD 123319, an AT(2) receptor antagonist did not. Incubation of MPM or J-774 cells with Ang II (10 pM to 1 mu M) for 24 h led to a 2.5-3.5-fold increase in LO activity, measured as generated 13-HODE or 12(S)-HETE. This stimulation was Inhibited by valsartan, but not by PD 123319. In contrast, Ang II did not stimulate LO activity in RAW macrophages. Semiquantitative reverse transcriptase-polymerase chain reaction showed a 2-3-fold increase in LO mRNA in MPM, but not in RAW cells after treatment with Ang II. Ang II also induced an increase in 12-LO protein. In addition, pretreatment of J-774 cells with Ang II increased in a dose-dependent manner the ability of the cells to modify LDL, resulting ilk greater chemotactic activity for monocytes, typical of minimally modified LDL, This stimulation was inhibited by AT(1) receptor blockade. In summary, these data suggest that Ang II increases macrophage LO activity via AT(1) receptor-mediated mechanisms and this further increases the ability of the cells to generate minimally oxidized LDL. These studies provide a link between hypertension and the associated increased atherosclerosis observed in hypertensive patients.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego					PHS HHS [14197] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERTHOLD F, 1981, BLUT, V43, P367, DOI 10.1007/BF00320315; Buege J A, 1978, Methods Enzymol, V52, P302; BUNKENBURG B, 1992, HYPERTENSION, V20, P746, DOI 10.1161/01.HYP.20.6.746; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHIU AT, 1989, BIOCHEM BIOPH RES CO, V165, P196, DOI 10.1016/0006-291X(89)91054-1; Cornicelli JA, 1996, ARTERIOSCL THROM VAS, V16, P1488, DOI 10.1161/01.ATV.16.12.1488; CRAWFORD DC, 1994, CIRC RES, V74, P727, DOI 10.1161/01.RES.74.4.727; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DEZSO B, 1981, IMMUNOLOGY, V42, P277; Douglas JG, 1996, J CLIN INVEST, V97, P1787, DOI 10.1172/JCI118607; DZAU VJ, 1988, CIRCULATION, V77, P4; EVERETT AD, 1994, HYPERTENSION, V23, P587, DOI 10.1161/01.HYP.23.5.587; EZAKI M, 1995, J LIPID RES, V36, P1996; FERNANDEZCASTELO S, 1987, J INTERFERON RES, V7, P261, DOI 10.1089/jir.1987.7.261; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; FORIS G, 1983, IMMUNOLOGY, V48, P529; FRUEBIS J, 1996, IN PRESS ATHEROSCLER; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GUILLON G, 1988, BIOCHEM J, V253, P765, DOI 10.1042/bj2530765; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KEIDAR S, 1995, ATHEROSCLEROSIS, V115, P201, DOI 10.1016/0021-9150(94)05514-J; Keidar S, 1996, ARTERIOSCL THROM VAS, V16, P97, DOI 10.1161/01.ATV.16.1.97; KHOUW AS, 1993, J LIPID RES, V34, P1483; KIM JA, 1995, ARTERIOSCL THROM VAS, V15, P942, DOI 10.1161/01.ATV.15.7.942; KINOSHITA T, 1992, ANAL BIOCHEM, V206, P231, DOI 10.1016/0003-2697(92)90358-E; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MCNALLY AK, 1990, J IMMUNOL, V145, P254; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NATARAJAN R, 1988, J CLIN ENDOCR METAB, V67, P584, DOI 10.1210/jcem-67-3-584; NATARAJAN R, 1993, P NATL ACAD SCI USA, V90, P4947, DOI 10.1073/pnas.90.11.4947; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; NUSSBERGER J, 1984, J LAB CLIN MED, V103, P304; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; RANKIN SM, 1991, J LIPID RES, V32, P449; Sendobry SM, 1997, BRIT J PHARMACOL, V120, P1199, DOI 10.1038/sj.bjp.0701007; Shen JH, 1996, J CLIN INVEST, V98, P2201, DOI 10.1172/JCI119029; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGARI F, 1997, IN PRESS ARTERIOSCLE; SPARROW CP, 1992, P NATL ACAD SCI USA, V89, P128, DOI 10.1073/pnas.89.1.128; SPARROW CP, 1988, J LIPID RES, V29, P745; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; VALENTE AJ, 1988, BIOCHEMISTRY-US, V27, P4162, DOI 10.1021/bi00411a039; WEINSTOCK JV, 1984, CELL IMMUNOL, V89, P46, DOI 10.1016/0008-8749(84)90196-5; WEINSTOCK JV, 1983, J IMMUNOL, V131, P2529; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971	53	105	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21609	21615		10.1074/jbc.272.34.21609	http://dx.doi.org/10.1074/jbc.272.34.21609			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261183	hybrid			2022-12-25	WOS:A1997XR78900093
J	Abe, J; Takahashi, M; Ishida, M; Lee, JD; Berk, BC				Abe, J; Takahashi, M; Ishida, M; Lee, JD; Berk, BC			c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1 (BMK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SMOOTH-MUSCLE CELLS; TYROSINE KINASE; MAP KINASE; REDOX REGULATION; ANGIOTENSIN-II; FAMILY; PHOSPHORYLATION; GENE; TRANSFORMATION	Big mitogen-activated kinase 1 (BMK1) or extracellular signal-regulated kinase-5 (ERK5) has recently been identified as a new member of the mitogen-activated protein kinase family, We have shown that BMK1 is activated to a greater extent by H2O2 than growth factors, suggesting that in comparison with other mitogen-activated protein kinase family members, BMK1 is a redox-sensitive kinase, Previous investigations indicate that the tyrosine kinase c-Src mediates signal transduction by reactive oxygen species, including H2O2. Therefore, the role of Src kinase family members (c-Src and Fyn) in activation of the BMK1 by H2O2 in mouse fibroblasts was studied, An essential role for c-Src was suggested by four experiments, First, H2O2 stimulated c-Src activity rapidly in fibroblasts (peak at 5 min), which preceded peak activity of BMK1 (20 min), Second, specific Src family tyrosine kinase inhibitors (herbimycin A and CP-118,556) blocked BMK1 activation by H2O2 in a concentration-dependent manner. Third, BMK1 activation in the response to H2O2 was completely inhibited in cells derived from mice deficient in c-Src, but not Fyn, Finally, BMK1 activity was much greater in v-Src-transformed NIH-3T3 cells than wild type cells. These results demonstrate an essential role for c-Src in H2O2-mediated activation of BMK1 and suggest that redox-sensitive regulation of BMK1 is a new function for c-Src.	UNIV WASHINGTON, DIV CARDIOL, DEPT MED, SEATTLE, WA 98195 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	University of Washington; University of Washington Seattle; Scripps Research Institute				Berk, Bradford/0000-0002-2767-4115	NHLBI NIH HHS [HL49192, HL44721] Funding Source: Medline; NIGMS NIH HHS [GM53214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049192, R01HL044721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; AUCHSCHWELK W, 1992, J CARDIOVASC PHARM, V20, pS62; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	35	237	240	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20389	20394		10.1074/jbc.272.33.20389	http://dx.doi.org/10.1074/jbc.272.33.20389			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252345	hybrid			2022-12-25	WOS:A1997XR22100015
J	Azem, A; Oppliger, W; Lustig, A; Jeno, P; Feifel, B; Schatz, G; Horst, M				Azem, A; Oppliger, W; Lustig, A; Jeno, P; Feifel, B; Schatz, G; Horst, M			The mitochondrial hsp70 chaperone system - Effect of adenine nucleotides, peptide substrate, and mGrpE on the oligomeric state of mhsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; ATPASE ACTIVITY; INNER MEMBRANE; GRPE; DNAJ; IMPORT; HOMOLOG; TRANSLOCATION; HYDROLYSIS	Mitochondrial hsp70 (mhsp78) is a key component in the import and folding of mitochondrial proteins. In both processes, mhsp70 cooperates with the mitochondrial nucleotide exchange factor mGrpE (also termed Mge1p). In this work we have characterized the self-association of purified mhsp70, the interaction of mhsp70 with isolated mGrpE and protein substrate, and the effect of nucleotides on these interactions, mhsp70 can form oligomers that are dissociated by ATP or by a nonhydrolyzable ATP analog, A substrate peptide binds to mhsp70 in the absence of added nucleotides and is released by ATP but not by ADP. Binding of the peptide causes nucleotide-independent dissociation of the mhsp70 oligomers and enhances the mhsp70 ATPase. Purified mGrpE forms a homodimer, In the absence of added nucleotides, one mGrpE dimer binds to one molecule of mhsp70, forming a stable 122 kDa hetero-oligomer, This complex is weakened by ADP and completely dissociated by ATP.	UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	University of Zurich	Azem, A (corresponding author), UNIV BASEL,BIOCTR,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.							AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BENAROUDJ N, 1995, BIOCHEMISTRY-US, V34, P15282, DOI 10.1021/bi00046a037; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; Deloche O, 1996, J BIOL CHEM, V271, P23960, DOI 10.1074/jbc.271.39.23960; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; Horst M, 1996, PROTEIN SCI, V5, P759; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; JENO P, 1995, ANAL BIOCHEM, V224, P75, DOI 10.1006/abio.1995.1010; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PripBuus C, 1996, FEBS LETT, V380, P142, DOI 10.1016/0014-5793(96)00049-X; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; Rospert S, 1996, EMBO J, V15, P764, DOI 10.1002/j.1460-2075.1996.tb00412.x; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHELL DJ, 1995, CELL, V83, P521; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WESTERMANN B, 1995, EMBO J, V14, P3452, DOI 10.1002/j.1460-2075.1995.tb07351.x; Wu B, 1996, EMBO J, V15, P4806, DOI 10.1002/j.1460-2075.1996.tb00861.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	41	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20901	20906		10.1074/jbc.272.33.20901	http://dx.doi.org/10.1074/jbc.272.33.20901			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252417	hybrid			2022-12-25	WOS:A1997XR22100087
J	Booth, JW; Guidotti, G				Booth, JW; Guidotti, G			Phosphate transport in yeast vacuoles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; SACCHAROMYCES-CEREVISIAE; MEMBRANE-VESICLES; ACTIVE-TRANSPORT; CANDIDA-UTILIS; AMINO-ACIDS; POLYPHOSPHATE; ARGININE; GENE; COMPARTMENTS	The vacuole of the yeast Saccharomyces cerevisiae is a major storage compartment for phosphate. We have measured phosphate transport across the vacuolar membrane. Isolated intact vacuoles take up large amounts of added [P-32]phosphate by counterflow exchange with phosphate present in the vacuoles at the time of their isolation. The bidirectional phosphate transporter has an intrinsic dissociation constant for phosphate of 0.4 mM. Exchange mediated by this carrier is faster than unidirectional efflux of phosphate from the vacuoles. The transporter is highly selective for phosphate; of other anions tested, only arsenate is also a substrate. Transport is strongly pH dependent with increasing activity at lower pH. Similar phosphate transport behavior was observed in right-side-out vacuolar membrane vesicles.	HARVARD UNIV, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Harvard University					NHLBI NIH HHS [HL 08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Andreeva N A, 1993, Biokhimiia, V58, P1053; BERTL A, 1990, P NATL ACAD SCI USA, V87, P7824, DOI 10.1073/pnas.87.20.7824; BOLLER T, 1975, EUR J BIOCHEM, V54, P81, DOI 10.1111/j.1432-1033.1975.tb04116.x; BOLLER T, 1989, METHOD ENZYMOL, V174, P504; BOOTH JW, 1995, J BIOL CHEM, V270, P19377, DOI 10.1074/jbc.270.33.19377; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; BOSTIAN KA, 1983, MOL CELL BIOL, V3, P839, DOI 10.1128/MCB.3.5.839; BOURNE RM, 1991, BIOCHIM BIOPHYS ACTA, V1067, P81, DOI 10.1016/0005-2736(91)90028-7; BOURNE RM, 1990, BIOCHIM BIOPHYS ACTA, V1055, P1, DOI 10.1016/0167-4889(90)90084-Q; BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; DURR M, 1979, ARCH MICROBIOL, V121, P169, DOI 10.1007/BF00689982; GILLIES RJ, 1981, P NATL ACAD SCI-BIOL, V78, P2125, DOI 10.1073/pnas.78.4.2125; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KAKINUMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P126, DOI 10.1016/0005-2736(92)90337-L; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; NAGY M, 1979, BIOCHIM BIOPHYS ACTA, V558, P221, DOI 10.1016/0005-2736(79)90062-2; NICOLAY K, 1983, ARCH MICROBIOL, V134, P270, DOI 10.1007/BF00407801; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OKOROKOV LA, 1980, J BACTERIOL, V144, P661, DOI 10.1128/JB.144.2.661-665.1980; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SATO T, 1984, J BIOL CHEM, V259, P1505; SCHWENCKE J, 1976, EUR J BIOCHEM, V65, P49, DOI 10.1111/j.1432-1033.1976.tb10388.x; Stein W., 2012, TRANSPORT DIFFUSION; TAMAI Y, 1985, J BACTERIOL, V164, P964, DOI 10.1128/JB.164.2.964-968.1985; URECH K, 1978, ARCH MICROBIOL, V116, P275, DOI 10.1007/BF00417851; VOGEL K, 1990, MOL MICROBIOL, V4, P2013, DOI 10.1111/j.1365-2958.1990.tb00560.x; WADA Y, 1992, BIOCHIM BIOPHYS ACTA, V1101, P296, DOI 10.1016/0005-2728(92)90085-G; WADA Y, 1987, J BIOL CHEM, V262, P17260; Wiemken A, 1975, Methods Cell Biol, V12, P99; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995	38	15	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20408	20413		10.1074/jbc.272.33.20408	http://dx.doi.org/10.1074/jbc.272.33.20408			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252348	Green Published, hybrid			2022-12-25	WOS:A1997XR22100018
J	Fisher, EA; Zhou, MY; Mitchell, DM; Wu, XJ; Omura, S; Wang, HX; Goldberg, AL; Ginsberg, HN				Fisher, EA; Zhou, MY; Mitchell, DM; Wu, XJ; Omura, S; Wang, HX; Goldberg, AL; Ginsberg, HN			The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; CLASS-I MOLECULES; INTRACELLULAR DEGRADATION; ENDOPLASMIC-RETICULUM; HERBIMYCIN-A; TRANSLOCATION; SECRETION; INHIBITOR; DOMAINS; LIPOPROTEINS	Apolipoprotein B (apoB) is the major protein component of atherogenic lipoproteins of hepatic origin, In HepG2 cells, the standard cell culture model of human hepatic lipoprotein metabolism, there is a limited availability of core lipids in the endoplasmic reticulum for association with nascent apoB. Under these conditions, apoB is partially translocated, interacts with cytosolic Hsp70, and undergoes rapid degradation. We show that increasing the expression of Hsp70 in HepG2 cells promotes apoB degradation. In addition, apoB is polyubiquitinated and its degradation both normally and after Hsp70 induction is blocked by inhibitors of the proteasome. The apoB that accumulates after proteasome inhibition is endoplasmic reticulum-associated and can be assembled into lipoproteins and secreted if new lipid synthesis is stimulated. Thus, apoB is the first example of a wild-type mammalian protein whose secretion is regulated by degradation in the cytosol via the ubiquitin-proteasome pathway. Furthermore, targeting of this secretory protein to the proteasome is regulated by the molecular chaperone Hsp70 and the availability of apoB's lipid-ligands.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; MT SINAI SCH MED,CARDIOVASC INST,LAB LIPOPROT RES,NEW YORK,NY 10029; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; KITASATO INST,TOKYO 108,JAPAN	Columbia University; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School; Kitasato University			Mitchell, Deborah/I-4556-2019; Mitchell, Deborah/AAB-6706-2020	Mitchell, Deborah/0000-0003-0364-9107; Fisher, Edward/0000-0001-9802-143X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055638, R01HL036000] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55638, HL07824, HL36000] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Clarke AR, 1996, CURR OPIN STRUC BIOL, V6, P43, DOI 10.1016/S0959-440X(96)80093-5; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GINSBERG HN, 1994, MED CLIN N AM, V78, P1; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HEGDE RS, 1995, J CELL PHYSIOL, V165, P186, DOI 10.1002/jcp.1041650122; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HOHFELD J, 1994, CURR OPIN CELL BIOL, V6, P499, DOI 10.1016/0955-0674(94)90068-X; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Lord JM, 1996, CURR BIOL, V6, P1067, DOI 10.1016/S0960-9822(02)70666-0; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; Morris SD, 1996, J CLIN INVEST, V97, P706, DOI 10.1172/JCI118468; MURAKAMI Y, 1991, EXP CELL RES, V195, P338, DOI 10.1016/0014-4827(91)90382-5; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; Oda K, 1996, BIOCHEM BIOPH RES CO, V219, P800, DOI 10.1006/bbrc.1996.0314; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Pease RJ, 1996, CURR OPIN LIPIDOL, V7, P132, DOI 10.1097/00041433-199606000-00004; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHERMAN MYS, 1996, STRESS INDUCIBLE CEL, P57; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SNIDERMAN AD, 1988, CAN J CARDIOL, V4, pA24; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; VEGA GL, 1991, CIRCULATION, V84, P118, DOI 10.1161/01.CIR.84.1.118; WANG HX, 1993, J CLIN INVEST, V91, P1380, DOI 10.1172/JCI116340; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; WETTERAU JR, 1992, SCIENCE, V258, P999; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	61	251	254	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20427	20434		10.1074/jbc.272.33.20427	http://dx.doi.org/10.1074/jbc.272.33.20427			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252351	hybrid			2022-12-25	WOS:A1997XR22100021
J	Grishina, G; Berlot, CH				Grishina, G; Berlot, CH			Identification of common and distinct residues involved in the interaction of alpha(i2) and alpha(s) with adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; G-PROTEINS; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; ACTIVATION; RECEPTOR; TRANSDUCIN; BINDING; SUBUNITS; EPITOPE	The G protein alpha subunits, alpha(s) and alpha(i2), have stimulatory and inhibitory effects, respectively, on a common effector protein, adenylyl cyclase, These effects require a GTP-dependent conformational change that involves three alpha subunit regions (Switches I-III). alpha(s) residues in three adjacent loops, including Switch II, specify activation of adenylyl cyclase. The adenylyl cyclase-specifying region of alpha(i2) is located within a 78-residue segment that includes two of these loops but none of the conformational switch regions, We have used an alanine-scanning mutagenesis approach within Switches I-III and the 78-residue segment of alpha(i2) to identify residues required for inhibition of adenylyl cyclase, We found a cluster of conserved residues in Switch II in which substitutions cause major losses in the abilities of both alpha(i2) and alpha(s) to modulate adenylyl cyclase activity but do not affect alpha subunit expression or the GTP-induced conformational change, We also found two regions within the 78-residue segment of alpha(i2) in which substitutions reduce the ability of alpha(i2) to inhibit adenylyl cyclase, one of which corresponds to an effector-activating region of alpha(s). Thus, both alpha(i2) and alpha(s) interact with adenylyl cyclase using: 1) conserved Switch II residues that communicate the conformational state of the alpha subunit and 2) divergent residues that specify particular effecters and the nature of their modulation.	YALE UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06520	Yale University								ARKINSTALL S, 1995, FEBS LETT, V364, P45, DOI 10.1016/0014-5793(95)00351-9; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HO RM, 1989, GENE AMST, V77, P51; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; ITOH H, 1991, J BIOL CHEM, V266, P16226; JONES DT, 1987, J BIOL CHEM, V262, P14241; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE E, 1992, J BIOL CHEM, V267, P1212; Medina R, 1996, J BIOL CHEM, V271, P24720, DOI 10.1074/jbc.271.40.24720; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; Mittal R, 1996, SCIENCE, V271, P1413, DOI 10.1126/science.271.5254.1413; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PARIS S, 1987, J BIOL CHEM, V262, P1970; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	44	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20619	20626		10.1074/jbc.272.33.20619	http://dx.doi.org/10.1074/jbc.272.33.20619			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252377	hybrid			2022-12-25	WOS:A1997XR22100047
J	Kubler, E; Mosch, HU; Rupp, S; Lisanti, MP				Kubler, E; Mosch, HU; Rupp, S; Lisanti, MP			Gpa2p, a G-protein alpha-subunit, regulates growth and pseudohyphal development in Saccharomyces cerevisiae via a cAMP-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENTOUS GROWTH; ADENYLATE-CYCLASE; BUDDING YEAST; RAS PROTEINS; CYCLIC-AMP; PHOSPHODIESTERASE; EXPRESSION; ELEMENTS; PATHWAY; GENES	The small GTP-binding protein Ras and heterotrimeric G-proteins are key regulators of growth and development in eukaryotic cells. In mammalian cells, Ras functions to regulate the mitogen-activated protein kinase pathway in response to growth factors, whereas many heterotrimeric GTP-binding protein alpha-subunits modulate cAMP levels through adenylyl cyclase as a consequence of hormonal action. In contrast, in the yeast Saccharomyces cerevisiae, it is the Ras1 and Ras2 proteins that regulate adenylyl cyclase. Of the two yeast G-protein alpha-subunits (GPA1 and GPA2), only GPA1 has been well studied and shown to negatively regulate the mitogen-activated protein kinase pathway upon pheromone stimulation, In this report, we show that deletion of the GPA2 gene encoding the other yeast G-protein alpha-subunit leads to a defect in pseudohyphal development, Also, the GPA2 gene is indispensable for normal growth in the absence of Ras2p. Both of these phenotypes can be rescued by deletion of the PDE2 gene product, which inactivates cAMP by cleavage, suggesting that these phenotypes can be attributed to low levels of intracellular cAMP. In support of this notion, addition of exogenous cAMP to the growth media was also sufficient to rescue the phenotype of a GPA2 deletion strain, Taken together, our results directly demonstrate that a G-protein alpha-subunit can regulate the growth and pseudohyphal development of S. cerevisiae via a cAMP-dependent mechanism, Heterologous expression of mammalian G-protein alpha-subunits in these yeast GPA2 deletion strains could provide a valuable tool for the mutational analysis of mammalian G-protein function in an in vivo null setting.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461; UNIV GOTTINGEN,INST MIKROBIOL,D-37077 GOTTINGEN,GERMANY; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Yeshiva University; Albert Einstein College of Medicine; University of Gottingen; Massachusetts Institute of Technology (MIT); Whitehead Institute			Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; 				BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BREVIARIO D, 1988, EMBO J, V7, P1805, DOI 10.1002/j.1460-2075.1988.tb03012.x; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GIMENO CJ, 1994, MOL CELL BIOL, V14, P2100, DOI 10.1128/MCB.14.3.2100; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KRON SJ, 1995, CURR OPIN CELL BIOL, V7, P845, DOI 10.1016/0955-0674(95)80069-7; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Mosch HU, 1997, GENETICS, V145, P671; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WILSON RB, 1988, MOL CELL BIOL, V8, P505, DOI 10.1128/MCB.8.1.505; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0	20	164	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20321	20323		10.1074/jbc.272.33.20321	http://dx.doi.org/10.1074/jbc.272.33.20321			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252333	hybrid			2022-12-25	WOS:A1997XR22100003
J	PanayotovaHeiermann, M; Eskandari, S; Turk, E; Zampighi, GA; Wright, EM				PanayotovaHeiermann, M; Eskandari, S; Turk, E; Zampighi, GA; Wright, EM			Five transmembrane helices form the sugar pathway through the Na+/glucose cotransporter.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ GLUCOSE COTRANSPORTER	To test the hypothesis that the C-terminal half of the Na+/glucose cotransporter (SGLT1) contains the sugar permeation pathway, a cDNA construct (C-5) coding for rabbit SGLT1 amino acids 407-662, helices 10-14, was expressed in Xenopus oocytes, Expression and function of C-5 followed by Western blotting, electron microscopy, radioactive tracer, and electrophysiological methods. The C-5 protein was synthesized in 20-fold higher levels than SGLT1. The particle density in the protoplasmic face of the oocyte plasma membrane increased C-5-cRNA injection compared with noninjected oocytes. The diameters of the C-5 particles were heterogeneous (4.8 +/- 0.3, 7.1 +/- 1.2, and 10.3 +/- 0.8 nm) in contrast to the endogenous particles (7.6 +/- 1.2 nm), C-5 increased the alpha-methyl-D-glucopyranoside (alpha MDG) uptake up to 20-fold above that of noninjected oocytes and showed an apparent K-0.5(alpha MDG) Of 50 mM and a turnover of similar to 660 s(-1). Influx was independent of Na+ with transport characteristics similar to those of SGLT1 in the absence of Na+:1) selective (alpha MDG > D-glucose > D-galactose much greater than L-glucose approximate to D-mannose), 2) inhibited by phloretin, K-i(PT) = similar to 500 mu M, and 3) insensitive to phlorizin, These results indicate that C-5 behaves as a specific low affinity glucose uniporter. Preliminary studies with three additional constructs, hC(5) (the human equivalent of C-5), hC(4) (human SGLT1 amino acids 407-648, helices 10-13), and hN(13) (amino acids 1-648, helices 1-13), further suggest that helices 10-13 form the sugar permeation pathway for SGLT1.	UNIV CALIF LOS ANGELES,MED CTR,DEPT NEUROBIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	PanayotovaHeiermann, M (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,MED CTR,DEPT PHYSIOL,CHS BOX 951751,LOS ANGELES,CA 90095, USA.				NATIONAL EYE INSTITUTE [R01EY004110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS025554] Funding Source: NIH RePORTER; NEI NIH HHS [EY04110] Funding Source: Medline; NIDDK NIH HHS [DK19567] Funding Source: Medline; NINDS NIH HHS [NS25554] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; HIRAYAMA BA, 1991, AM J PHYSIOL, V261, pC296, DOI 10.1152/ajpcell.1991.261.2.C296; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; KIMMICH GA, 1975, J MEMBRANE BIOL, V23, P57, DOI 10.1007/BF01870244; Loo DDF, 1996, P NATL ACAD SCI USA, V93, P13367, DOI 10.1073/pnas.93.23.13367; Lostao MP, 1995, FEBS LETT, V377, P181, DOI 10.1016/0014-5793(95)01339-3; LOSTAO MP, 1996, PHYSIOL RES, V45, pP1; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; PANAYOTOVAHEIER.M, 1995, PFLUGERS ARCH EUR S, V430, P116; PANAYOTOVAHEIERMANN M, 1994, J BIOL CHEM, V269, P21016; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; PANAYOTOVAHEIERMANN M, 1995, J BIOL CHEM, V270, P27099, DOI 10.1074/jbc.270.45.27099; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PEERCE BE, 1986, P NATL ACAD SCI USA, V83, P8092, DOI 10.1073/pnas.83.21.8092; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; TURK E, 1997, IN PRESS J MEMBR BIO, V159; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6; Wu JH, 1996, BIOCHEMISTRY-US, V35, P5213, DOI 10.1021/bi960064f; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	20	76	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20324	20327		10.1074/jbc.272.33.20324	http://dx.doi.org/10.1074/jbc.272.33.20324			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252334	hybrid			2022-12-25	WOS:A1997XR22100004
J	Belusa, R; Wang, ZM; Matsubara, T; Sahlgren, B; Dulubova, I; Nairn, AC; Ruoslahti, E; Greengard, P; Aperia, A				Belusa, R; Wang, ZM; Matsubara, T; Sahlgren, B; Dulubova, I; Nairn, AC; Ruoslahti, E; Greengard, P; Aperia, A			Mutation of the protein kinase C phosphorylation site on rat alpha 1 Na+,K+-ATPase alters regulation of intracellular Na+ and pH and influences cell shape and adhesiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4TH TRANSMEMBRANE SEGMENT; PROXIMAL TUBULE CELLS; KIDNEY NA+,K+-ATPASE; SODIUM-TRANSPORT; NA,K-ATPASE; SUBUNIT; ATPASE; STIMULATION; FIBROBLASTS; PATHWAY	The enzyme Na+,K+-ATPase creates the transmembrane Na+ gradient that is of vital importance for functioning of all eukaryotic cells. Na+,K+-ATPase can be phosphorylated by protein kinase A (PKA) and protein kinase C (PKC), and these sites of phosphorylation have been identified, In the present study, we have examined the physiological significance of PKC phosphorylation of rat Na+,K+-ATPase. In COS cells transfected with wild type rat Na+,K+-ATPase alpha 1, intracellular Na+ was higher and pH was lower than in cells transfected with rat Na+,K+-ATPase alpha 1 in which the PKC phosphorylation site, Ser-23, had been mutated into alanine. Phorbol dibutyrate inhibited Na+,K+-ATPase-dependent ATP hydrolysis and Rb+ uptake in cells expressing wild type Na+,K+-ATPase but not in cells expressing S23A Na+,K+-ATPase. Cells expressing the S23A mutant had a more rounded appearance and attached less well to fibronectin than did untransfected cells or cells transfected with wild type rat Na+,K+-ATPase alpha 1. These results indicate a functional role for PKC-mediated phosphorylation of rat Na+,K+-ATPase alpha 1 and suggest a connection between this enzyme and cell adhesion.	KAROLINSKA INST,DEPT WOMEN & CHILD HLTH,S-11281 STOCKHOLM,SWEDEN; ROCKEFELLER UNIV,MOL & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037	Karolinska Institutet; Rockefeller University; Sanford Burnham Prebys Medical Discovery Institute				Nairn, Angus/0000-0002-7075-0195	NIMH NIH HHS [MH-40899] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APERIA A, 1994, FASEB J, V8, P436, DOI 10.1096/fasebj.8.6.8168694; BENOS DJ, 1982, AM J PHYSIOL, V242, pC131, DOI 10.1152/ajpcell.1982.242.3.C131; BERTORELLO A, 1989, AM J PHYSIOL, V256, pF370, DOI 10.1152/ajprenal.1989.256.2.F370; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BORIN ML, 1993, AM J PHYSIOL, V264, pC1513, DOI 10.1152/ajpcell.1993.264.6.C1513; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; EKBLAD H, 1992, AM J PHYSIOL, V263, pF716, DOI 10.1152/ajprenal.1992.263.4.F716; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427; FISONE G, 1994, J BIOL CHEM, V269, pS936; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HORIUCHI A, 1993, MOL PHARMACOL, V43, P281; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1986, KIDNEY INT, V29, P10, DOI 10.1038/ki.1986.3; KANSRA V, 1995, EUR J PHARM-MOLEC PH, V289, P391, DOI 10.1016/0922-4106(95)90119-1; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Logvinenko NS, 1996, P NATL ACAD SCI USA, V93, P9132, DOI 10.1073/pnas.93.17.9132; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; MINTA A, 1989, J BIOL CHEM, V264, P19449; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; NOCL J, 1995, AM J PHYSIOL, V268, pC283; OKAYAMA H, 1991, GENE TRANSFER EXPRES, P15; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; TURNHEIM K, 1994, PHYSIOL RES, V43, P211; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7	31	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20179	20184		10.1074/jbc.272.32.20179	http://dx.doi.org/10.1074/jbc.272.32.20179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242694	hybrid			2022-12-25	WOS:A1997XQ05900081
J	Brady, MJ; Printen, JA; Mastick, CC; Saltiel, AR				Brady, MJ; Printen, JA; Mastick, CC; Saltiel, AR			Bole of protein targeting to glycogen (PTG) in the regulation of protein phosphatase-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; ADIPOSE-TISSUE; 3T3-L1 ADIPOCYTES; INSULIN; KINASE; PHOSPHORYLATION; STIMULATION; INHIBITOR-1; SUBUNIT; DEPHOSPHORYLATION	We have recently cloned from 3T3-L1 adipocytes a novel glycogen-tageting subunit of protein phosphatase-1, termed PTG (Printen, 5, A., Brady, M. J., and Saltiel, A. R. (1997) Science 275, 1475-1478), Differentiation of 3T3-L1 fibroblasts into highly insulin-responsive adipocytes resulted in a marked increase: in PTG expression, Immobilized glutathione S-transferase (GST)-PTG fusion protein specifically bound either PP1 or phosphorylase a, Addition of soluble GST-PTG to 3T3-L1. lysates increased PP1 activity against P-32-labeled phosphorylase a by decreasing the K-m of PP1 for phosphorylase 5-fold, while having ma effect on the V-max, of the dephosphorylation reaction, Alternatively, PTG did not affect PP1 activity against hormone-sensitive lipase, PTG was not a direct target of intracellular signaling, as insulin or forskolin treatment of cells did not activate a kinase capable of phosphorylating PTG in vivo or irt vitro, Finally, PTG decreased the ability of DARPP-32 to inhibit PP1 activity from 3T3-L1 adipocyte lysates, These data cumulatively suggest that PTG increases PPI activity against specific proteins by several distinct mechanisms.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CELL BIOL,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109	Pfizer; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019; Mastick, Cynthia/G-9841-2017	Mastick, Cynthia/0000-0003-4769-5412; Saltiel, Alan/0000-0002-9726-9828				Azpiazu I, 1996, J BIOL CHEM, V271, P5033; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MEISTER B, 1988, P NATL ACAD SCI USA, V85, P8713, DOI 10.1073/pnas.85.22.8713; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; NAIRN AC, 1995, NEUROPROTOCOLS, V6, P108; NEMENOFF RA, 1983, J BIOL CHEM, V258, P9437; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; STRALFORS P, 1989, EUR J BIOCHEM, V180, P143, DOI 10.1111/j.1432-1033.1989.tb14624.x; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; TANG PM, 1991, J BIOL CHEM, V266, P15782; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	26	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20198	20204		10.1074/jbc.272.32.20198	http://dx.doi.org/10.1074/jbc.272.32.20198			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242697	hybrid			2022-12-25	WOS:A1997XQ05900084
J	Doorty, KB; Bevan, S; Wadsworth, JDF; Strong, PN				Doorty, KB; Bevan, S; Wadsworth, JDF; Strong, PN			A novel small conductance Ca2+-activated K+ channel blocker from Oxyuranus scutellatus Taipan venom - Re-evaluation of taicatoxin as a selective Ca2+ channel probe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; APAMIN-BINDING; CALCIUM CHANNELS; SCORPION TOXIN; BEE VENOM; MUSCLE; CELLS; HEPATOCYTES; POLYPEPTIDE; SCYLLATOXIN	Taicatoxin, isolated from the venom of the Australian taipan snake Oxyuranus scutellatus, has been previously regarded as a specific blocker of high threshold Ca2+ channels in heart. Here we show that taicatoxin (in contrast to a range of other Ca2+ channel blockers) interacts with apamin-sensitive, small conductance, Ca2+-activated potassium channels on both chromaffin cells and in the brain. Taicatoxin displays high affinity recognition of I-125-apamin acceptor-binding sites, present on rat synaptosomal membranes (K-i 1.45 +/- 0.22 nM) and also specifically blocks affinity-labeling of a 33-kDa I-125-apamin-binding polypeptide on rat brain membranes. Taicatoxin (50 nM) completely blocks apamin-sensitive after-hyperpolarizing slow tail K+ currents generated in rat chromaffin cells (mean block 97 +/- 3%, n = 12) while only partially reducing total voltage-dependent Ca2+ currents (mean block 12 +/- 4%, n = 6). In view of these findings, the use of taicatoxin as a specific ligand for Ca2+ channels should now be reconsidered.	NOVARTIS INST MED SCI,LONDON WC1E 6BN,ENGLAND	Novartis	Doorty, KB (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT PAEDIAT & NEONATAL MED,NEUROMUSCULAR UNIT,LONDON W12 0NN,ENGLAND.		Bevan, Stuart/A-8821-2008	Wadsworth, Jonathan/0000-0002-4797-2259; Bevan, Stuart John/0000-0002-8977-1797	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS ME, 1996, TRENDS NEUROSCI S, V19; AUGUSTE P, 1992, BIOCHEMISTRY-US, V31, P648, DOI 10.1021/bi00118a003; AUGUSTE P, 1989, FEBS LETT, V248, P150, DOI 10.1016/0014-5793(89)80451-X; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; BKAILY G, 1992, AM J PHYSIOL, V262, pH463, DOI 10.1152/ajpheart.1992.262.2.H463; BKAILY G, 1985, AM J PHYSIOL, V248, pH961, DOI 10.1152/ajpheart.1985.248.6.H961; BREWSTER BS, 1992, POTASSIUM CHANNEL MO, P272; BROWN AM, 1987, CIRC RES, V61, P6; CASTLE NA, 1989, TRENDS NEUROSCI, V12, P59, DOI 10.1016/0166-2236(89)90137-9; CHICCHI GG, 1988, J BIOL CHEM, V263, P10192; COOK NS, 1985, J PHYSIOL-LONDON, V358, P373, DOI 10.1113/jphysiol.1985.sp015556; Dunn PM, 1996, BRIT J PHARMACOL, V117, P35, DOI 10.1111/j.1476-5381.1996.tb15151.x; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FRYKLUND L, 1975, BIOCHEMISTRY-US, V14, P2860, DOI 10.1021/bi00684a011; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GRANIER C, 1978, EUR J BIOCHEM, V82, P293, DOI 10.1111/j.1432-1033.1978.tb12023.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARVEY AL, 1985, J TOXICOL-TOXIN REV, V4, P41, DOI 10.3109/15569548509014413; HUGUES M, 1982, J BIOL CHEM, V257, P2762; HUGUES M, 1982, BIOCHEM BIOPH RES CO, V107, P1577, DOI 10.1016/S0006-291X(82)80180-0; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LABBEJULLIE C, 1991, EUR J BIOCHEM, V196, P689; Legros C, 1996, FEBS LETT, V390, P81, DOI 10.1016/0014-5793(96)00616-3; MARQUEZE B, 1987, EUR J BIOCHEM, V169, P295, DOI 10.1111/j.1432-1033.1987.tb13611.x; MARTINS JC, 1990, FEBS LETT, V260, P249, DOI 10.1016/0014-5793(90)80115-Y; MONTIEL C, 1995, J PHYSIOL-LONDON, V486, P427, DOI 10.1113/jphysiol.1995.sp020823; MORI Y, 1994, HDB MEMBRANE CHANNEL, P163; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NEELY A, 1992, J PHYSIOL-LONDON, V453, P97, DOI 10.1113/jphysiol.1992.sp019220; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; PARK Y, 1994, J PHYSIOL-LONDON, V481, P555, DOI 10.1113/jphysiol.1994.sp020463; POSSANI LD, 1992, TOXICON, V30, P1343, DOI 10.1016/0041-0101(92)90511-3; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SCHMIDANTOMARCHI H, 1985, P NATL ACAD SCI USA, V82, P2188, DOI 10.1073/pnas.82.7.2188; SEAGAR MJ, 1986, BIOCHEMISTRY-US, V25, P4051, DOI 10.1021/bi00362a010; Strong P. N., 1992, Methods in Neurosciences, V8, P15; STRONG PN, 1990, PHARMACOL THERAPEUT, V46, P137, DOI 10.1016/0163-7258(90)90040-9; VINCENT JP, 1975, BIOCHEMISTRY-US, V14, P2521, DOI 10.1021/bi00682a035; WADSWORTH JDF, 1994, J BIOL CHEM, V269, P18053; Wadsworth JDF, 1996, BIOCHEMISTRY-US, V35, P7917, DOI 10.1021/bi9602371; ZERROUK H, 1993, FEBS LETT, V320, P189, DOI 10.1016/0014-5793(93)80583-G	43	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19925	19930		10.1074/jbc.272.32.19925	http://dx.doi.org/10.1074/jbc.272.32.19925			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242659	hybrid			2022-12-25	WOS:A1997XQ05900046
J	Gallagher, PG; Tse, WT; Scarpa, AL; Lux, SE; Forget, BG				Gallagher, PG; Tse, WT; Scarpa, AL; Lux, SE; Forget, BG			Structure and organization of the human ankyrin-1 gene - Basis for complexity of pre-mRNA processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE ANKYRIN; DOMINANT HEREDITARY SPHEROCYTOSIS; POLYMERASE CHAIN-REACTION; MESSENGER-RNA; REGULATORY DOMAIN; ANION-EXCHANGER; MAJOR ANKYRIN; MEMBRANE-SKELETON; HEMOLYTIC-ANEMIA; PLASMA-MEMBRANE	Ankyrin-1 (ANK-1) is an erythrocyte membrane protein that is defective in many patients with hereditary spherocytosis, a common hemolytic anemia. In the red cell, ankyrin-1 provides the primary linkage between the membrane skeleton and the plasma membrane, To gain additional insight into the structure and function of this protein and to provide the necessary tools for further genetic studies of hereditary spherocytosis patients, we cloned the human ANK-1 chromosomal gene, Characterization of the ANK-1 gene genomic structure revealed that the erythroid transcript is composed of 42 exons distributed over similar to 160 kilobase pairs of DNA. Comparison of the genomic structure with the protein do mains reveals a near-absolute correlation between the tandem repeats encoding the membrane-binding domain of ankyrin with the location of the intron/exon boundaries in the corresponding part of the gene, Erythroid stage-specific, complex patterns of alternative splicing were identified in the region encoding the regulatory domain of ankyrin-1. Novel brain-specific transcripts were also identified in this region, as well as in the ''hinge'' region between the membrane-binding and spectrin-binding domains, Utilization of alternative polyadenylation signals was found to be the basis for the previously described, stage-specific 9.0- and 7.2-kilobase pair transcripts of the ANK-1 gene.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06520; CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115	Yale University; Yale University; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Gallagher, PG (corresponding author), YALE UNIV,SCH MED,DEPT PEDIAT,333 CEDAR ST,POB 208064,NEW HAVEN,CT 06520, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AXTON JM, 1994, EMBO J, V13, P462, DOI 10.1002/j.1460-2075.1994.tb06281.x; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BIRKENMEIER CS, 1993, J BIOL CHEM, V268, P9533; BIRKENMEIER JE, 1995, BLOOD S1, V86, pA467; BODINE DM, 1984, CELL, V37, P721, DOI 10.1016/0092-8674(84)90408-2; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CHAN W, 1993, J CELL BIOL, V123, P1463, DOI 10.1083/jcb.123.6.1463; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; COOPER DN, 1993, ANN MED, V25, P11, DOI 10.3109/07853899309147851; COSTA FF, 1990, NEW ENGL J MED, V323, P1046, DOI 10.1056/NEJM199010113231507; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; delGiudice EM, 1996, BRIT J HAEMATOL, V93, P828; DEMARTIN R, 1995, GENE, V152, P253, DOI 10.1016/0378-1119(94)00726-9; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; Eber SW, 1996, NAT GENET, V13, P214, DOI 10.1038/ng0696-214; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gallagher P. G., 1996, Blood, V88, p6A; GALLAGHER PG, 1992, T ASSOC AM PHYSICIAN, V105, P268; GALLAGHER PG, 1992, BLOOD, V80, P1856; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HALL TG, 1987, J BIOL CHEM, V262, P10537; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOOVER KK, 1993, GENETICS, V135, P507; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HURT J, 1992, NUCLEIC ACIDS RES, V20, P2985, DOI 10.1093/nar/20.12.2985; ITO CY, 1995, GENOMICS, V29, P490, DOI 10.1006/geno.1995.9977; JAROLIM P, 1995, J CLIN INVEST, V95, P941, DOI 10.1172/JCI117802; JAROLIM P, 1995, BLOOD, V85, P3278, DOI 10.1182/blood.V85.11.3278.bloodjournal85113278; JAROLIM P, 1992, BLOOD S, V80, pA144; JAROLIM P, 1990, BLOOD S, V76, pA37; Jenkins PB, 1996, J CLIN INVEST, V97, P373, DOI 10.1172/JCI118425; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KUNIMOTO M, 1991, J CELL BIOL, V115, P1319, DOI 10.1083/jcb.115.5.1319; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LAMBERT S, 1993, J NEUROSCI, V13, P3725; LAMBERT S, 1993, EUR J BIOCHEM, V211, P1, DOI 10.1111/j.1432-1033.1993.tb19863.x; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; LUNA EJ, 1979, J BIOL CHEM, V254, P2526; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; MILNER CM, 1993, BIOCHEM J, V290, P811, DOI 10.1042/bj2900811; Morle L., 1995, Blood, V86, p467A; MORROW JS, 1997, HDB PHYSIOL 14, P485; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; Ozcan R., 1996, Blood, V88, p5A; PETERS LL, 1993, BLOOD, V81, P2144; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PETERS LL, 1992, BLOOD, V80, P2122; PETERS LL, 1992, P NATL ACAD SCI USA, V89, P5749, DOI 10.1073/pnas.89.13.5749; PETERS LL, 1991, J CELL BIOL, V114, P1233, DOI 10.1083/jcb.114.6.1233; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; PLATT OS, 1993, J BIOL CHEM, V268, P24421; POLYMEROPOULOS MH, 1990, NUCLEIC ACIDS RES, V19, P969; SACHS A, 1993, J BIOL CHEM, V268, P22955; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SIEGEL DL, 1980, BIOCHIM BIOPHYS ACTA, V598, P517, DOI 10.1016/0005-2736(80)90032-2; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; TSE WT, 1991, GENOMICS, V10, P858, DOI 10.1016/0888-7543(91)90173-C; TSE WT, 1991, BLOOD, V78, P517; WANG YC, 1992, J BIOL CHEM, V267, P2728; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE RA, 1992, MAMM GENOME, V3, P281, DOI 10.1007/BF00292156; WHITE RA, 1990, P NATL ACAD SCI USA, V87, P3117, DOI 10.1073/pnas.87.8.3117; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449	85	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19220	19228		10.1074/jbc.272.31.19220	http://dx.doi.org/10.1074/jbc.272.31.19220			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235914	hybrid			2022-12-25	WOS:A1997XP06300020
J	Douville, E; Downward, J				Douville, E; Downward, J			EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2	ONCOGENE			English	Article						SOS; Rsk; phosphorylation	NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; TERNARY COMPLEX-FORMATION; SIGNAL-TRANSDUCTION; MAP KINASE; S6 KINASE; IN-VIVO; SUBSTRATE RECOGNITION; DEPENDENT ACTIVATION	SOS, the guanine nucleotide exchange factor for Ras, becomes phosphorylated on serine and threonine residues following stimulation of cells with growth factors. These phosphorylations may play a role in negative feedback of Ras stimulation and have been shown to be mediated in part by the MAP kinases Erk-1 and Erk-2. Here we show that in addition to MAP kinase, a major mitogen activated kinase for SOS is p90 Rsk-2, a downstream target of MAP kinase. p90 Rsk-2 phosphorylates SOS in an in gel assay and also in solution in vitro. The ability of p90 Rsk-2 to phosphorylate SOS increases greatly following EGF treatment of PC12 cells and is blocked by expression of N17 Ras or treatment with the MEK inhibitor PD98059. Phosphopeptide mapping revealed that the sites phosphorylated by p90 Rsk-2 in vitro were also phosphorylated in intact cells in response to EGF treatment. Several major sites of in vivo phosphorylation correlated with p90 Rsk-2 phosphorylation sites rather than MAP kinase sites. It is therefore likely that p90 Rsk-2 plays an important role in the down regulation of the Ras activation pathway through SOS.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				ADCOCK MR, 1993, NATURE, V363, P83; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASU T, 1994, ONCOGENE, V9, P3483; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Byrne JL, 1996, ONCOGENE, V13, P2055; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Cano E, 1996, ONCOGENE, V12, P805; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen RH, 1996, ONCOGENE, V12, P1493; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Holt KH, 1996, MOL CELL BIOL, V16, P577; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; Klarlund JK, 1996, J BIOL CHEM, V271, P16674, DOI 10.1074/jbc.271.28.16674; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; MARTE BM, 1995, ONCOGENE, V10, P167; MARTE BM, 1996, CURR BIOL, V7, P1; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SASTRY L, 1995, ONCOGENE, V11, P1107; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TOSHIHIRO N, 1996, CELL, V86, P465; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	63	128	129	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	1997	15	4					373	383		10.1038/sj.onc.1201214	http://dx.doi.org/10.1038/sj.onc.1201214			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242373				2022-12-25	WOS:A1997XM23800001
J	Coopersmith, CM; Gordon, JI				Coopersmith, CM; Gordon, JI			gamma-ray-induced apoptosis in transgenic mice with proliferative abnormalities in their intestinal epithelium: Re-entry of villus enterocytes into the cell cycle does not affect their radioresistance but enhances the radiosensitivity of the crypt by inducing p53	ONCOGENE			English	Article						radiation; apoptosis; cell cycle; intestinal epithelium; transgenic mice; p53	MOUSE SMALL-INTESTINE; RADIATION-INDUCED APOPTOSIS; BCL-2 HOMOLOG BAK; IN-VIVO; TUMOR-ANTIGEN; T-ANTIGEN; DIFFERENTIATION PROGRAMS; CHROMOSOMAL BREAKPOINT; GASTROINTESTINAL-TRACT; DNA FRAGMENTATION	The radiosensitivity of proliferating crypt epithelial cells makes the gut a major limiting factor in the use of radiotherapy for treatment of abdominal cancers, As post-mitotic epithelial cells migrate from mouse small intestinal crypts to the base of adjacent villi, they rapidly lose their ability to undergo apoptosis in response to ionizing irradiation (IR), To determine whether this radioresistance reflects withdrawal from the cell cycle, we used a lineage-specific promoter to direct expression of wild type Simian virus 40 T antigen (SV40 TAgWt) to villus, but not crypt, enterocytes in FVB/N transgenic mice, SV40 TAgWt induced, pRB-dependent, re-entry into the cell cycle is not associated with the acquisition of IR-stimulated apoptosis 4 h or 24 h after 6 Gy or 12 Gy of gamma-irradiation, Coexpression of SV40 TAgWt and K-ras(Val12) produces dysplasia in cycling villus enterocytes but no shift towards apoptotic responsiveness to IR, These findings suggest that the radioresistance of villus enterocytes is not simply due to their cell cycle arrest and may be a reflection of their microenvironment, Remarkably, reentry of villus enterocytes to the cell cycle increases the radiosensitivity of the crypt epithelium without changing Bcl-2, Bcl-x(L), Bak, or Bar expression, This effect is only manifest after IR and, based upon results obtained with mutant SV40 TAgs, depends upon reaching a critical level of proliferation in villus enterocytes, Like the normal crypt response to IR, the villus-derived enhancement of IR-stimulated crypt apoptosis is associated with an induction of p53 and Raf-l, and is dependent upon p53, Unlike the normal crypt response to IR, the p53 induction involves cells distributed throughout the crypt and the apoptotic response is not confined to the lower half of the crypt, These results indicate that signals initiated by cycling enterocytes can be transmitted to the crypt epithelium to induce p53 and influence their IR-induced apoptosis, Understanding the underlying signaling pathways may provide clues about how to modify a normal crypt's radiosensitivity for therapeutic benefit.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bry L, 1996, P NATL ACAD SCI USA, V93, P1161, DOI 10.1073/pnas.93.3.1161; CALVERT R, 1990, ANAT REC, V227, P199, DOI 10.1002/ar.1092270208; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHEN JD, 1992, ONCOGENE, V7, P1167; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHWALINSKI S, 1988, CELL TISSUE KINET, V21, P317, DOI 10.1111/j.1365-2184.1988.tb00790.x; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COOPERSMITH CM, 1997, IN PRESS J CELL BIOL; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALL PA, 1994, J CELL SCI, V107, P3569; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; Kitada S, 1996, ONCOGENE, V12, P187; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; MCCALLUM DE, IN PRESS ONCOGENE; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MERRITT AJ, 1994, CANCER RES, V54, P614; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POTTEN CS, 1994, INT J RADIAT BIOL, V65, P71, DOI 10.1080/09553009414550101; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Pullan S, 1996, J CELL SCI, V109, P631; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STEPHENS L C, 1989, Cancer Bulletin (Houston), V41, P106; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WANG HG, 1994, ONCOGENE, V9, P2751; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x; WRIGHT NA, 1984, BIOL EPITHELIAL CELL, P843; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhan QM, 1996, ONCOGENE, V13, P2287	66	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					131	141		10.1038/sj.onc.1201176	http://dx.doi.org/10.1038/sj.onc.1201176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244349				2022-12-25	WOS:A1997XK37200002
J	Vincent, F; Nagashima, M; Takenoshita, S; Khan, MA; Gemma, A; Hagiwara, K; Bennett, WP				Vincent, F; Nagashima, M; Takenoshita, S; Khan, MA; Gemma, A; Hagiwara, K; Bennett, WP			Mutation analysis of the transforming growth factor-beta type II receptor in human cell Lines resistant to growth inhibition by transforming growth factor-beta	ONCOGENE			English	Article						single-strand conformation polymorphism analysis; somatic mutation; polymerase chain reaction; genomic DNA; microsatellite instability	TGF-BETA; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CARCINOMA-CELLS; GENE; EXPRESSION; GROWTH-FACTOR-BETA-1; BINDING; COLON; OVEREXPRESSION	The transforming growth factor-beta (TGF-beta) binds the type II TGF-beta growth factor receptor (RII) to inhibit the growth of most epithelial tissues, Most human colon and gastric cancers with microsatellite instability (MI) have frameshift mutations in polynucleotide repeats within the RII coding region; these mutations truncate the receptor protein and disable the serine/threonine kinase to produce TGF-beta resistance, To further investigate the type, frequency and tissue distribution of RII mutations, we selected 24 human cancer cell lines from various tissues which were previously reported to be resistant to the inhibitory effects of TGF-beta, We developed protocols for non-isotopic SSCP analysis of PCR products from genomic DNA samples, and we tested them for microsatellite instability, PCR-SSCP analysis followed by DNA sequencing identified deletion mutations in the exon 3 poly-adenine tract in three colon tumor cell lines: LS174T and SW48 had a single base deletion and LS411 had a two base deletion. Among the 24 previously unreported cell lines, only these three demonstrated microsatellite instability. These and other recent data indicate that RII mutations are essentially confined to colon and gastric cancers with microsatellite instability. The narrow spectrum of tissues containing RII mutations illustrates the complexity of genetic checkpoints in human carcinogenesis.	NCI, HUMAN CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA; IFREMER, F-44311 NANTES 03, FRANCE; GUNMA UNIV, SCH MED, DEPT SURG, MAEBASHI, GUMMA 371, JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ifremer; Gunma University				VINCENT-HUBERT, Francoise/0000-0002-2266-9237				ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; *AM TYP CULT COLL, 1992, AM TYP CULT COLL CAT; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Hagiwara K, 1996, NUCLEIC ACIDS RES, V24, P2460, DOI 10.1093/nar/24.12.2460; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HOWE PH, 1993, J BIOL CHEM, V268, P21448; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; LIN HY, 1994, CELL MOL BIOL, V40, P337; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MYEROFF LL, 1995, CANCER RES, V55, P5545; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REISS M, 1993, CANCER RES, V53, P899; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Schutte M, 1996, CANCER RES, V56, P2527; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takenoshita S, 1996, GENOMICS, V36, P341, DOI 10.1006/geno.1996.0471; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; TAKENOSHITA S, 1997, IN PRESS CARCINOGENE; VINCENT F, BIOCHEM BIOPH RES CO, V223, P561; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAN ZF, 1994, J BIOL CHEM, V269, P13231; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	45	58	59	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					117	122		10.1038/sj.onc.1201166	http://dx.doi.org/10.1038/sj.onc.1201166			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233784				2022-12-25	WOS:A1997XH58600013
J	Dalton, ML; Gadson, PF; Wrenn, RW; Rosenquist, TH				Dalton, ML; Gadson, PF; Wrenn, RW; Rosenquist, TH			Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells	FASEB JOURNAL			English	Article						homocystinuria; PKC; cell proliferation; atherosclerosis	METHYL-D-ASPARTATE; RECEPTOR; ACID; ARTERIOSCLEROSIS; HOMOCYSTINURIA; INJURY; RAT; STIMULATION; METABOLISM; EXPRESSION	Hyperhomocysteinemia has been recognized as an independent risk factor far cerebral, coronary, and peripheral atherosclerosis, To examine the contribution of homocysteine (H[cys]) in the pathogenesis of vascular diseases, we sought to determine whether the H[cys] effect on vascular smooth muscle (VSMC) proliferation is mediated by a specific receptor/transporter or is due to an interaction with growth factors or cytokines. We show that H[cys] induced c-fos and c-myb and increased DNA synthesis and cell proliferation 12-fold in neural crest-derived VSMC (N-VSMC). The H[cys] effect on N-VSMC proliferation is inhibited by Mk-801, a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a glutamate-gated calcium ion channel receptor, and CGS 19755, a competitive antagonist of NMDA-type glutamate receptor. H[cys] stimulates the synthesis of mass amounts of sn-1,2 diacylglycerol, and activates protein kinase C translocation from the nucleus and cytoplasm to cell membranes. Furthermore, protein kinase C inhibitors block the growth effect mediated by H[cys]. These findings indicate that H[cys]-mediated responses are coupled to diacylglycerol-dependent protein kinase C; activation. Our results suggest that homocysteine activates a receptor/transporter-like factor in neural crest derived smooth muscle.	UNIV NEBRASKA,MED CTR,DEPT CELL BIOL & ANAT,OMAHA,NE 68105; MED COLL GEORGIA,DEPT CELL BIOL & ANAT,AUGUSTA,GA 30912	University of Nebraska System; University of Nebraska Medical Center; University System of Georgia; Augusta University					NHLBI NIH HHS [HL-55940] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055940] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BASTA P, 1992, BIOCHIM BIOPHYS ACTA, V1132, P154, DOI 10.1016/0167-4781(92)90006-L; BILAH MM, 1990, BIOCHEM J, V269, P281; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BOSS V, 1992, J NEUROCHEM, V59, P2340; BOSS V, 1994, MOL PHARMACOL, V45, P1177; CURRAS MC, 1992, MOL PHARMACOL, V41, P520; DUDMAN NPB, 1991, ATHEROSCLEROSIS, V91, P77, DOI 10.1016/0021-9150(91)90189-A; GADSON P, 1990, J CELL BIOCHEM, V43, P185, DOI 10.1002/jcb.240430209; Gadson PF, 1997, EXP CELL RES, V230, P169, DOI 10.1006/excr.1996.3398; HARKER LA, 1983, CIRC RES, V53, P731, DOI 10.1161/01.RES.53.6.731; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; Kim W.-K., 1995, Society for Neuroscience Abstracts, V21, P521; MCCULLY KS, 1971, NATURE, V231, P391, DOI 10.1038/231391a0; MOELDERS H, 1987, Oncogene, V1, P377; MONAGHAN DT, 1991, EXCITATORY AMINO ACI, P33; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MUDD SH, 1985, AM J HUM GENET, V37, P1; OHMURI S, 1972, PHYSIOL CHEM PHYS M, V4, P286; PALMER E, 1990, DEV BRAIN RES, V51, P132, DOI 10.1016/0165-3806(90)90266-2; PREISS J, 1986, J BIOL CHEM, V261, P8597; SCHWARZ S, 1991, LANCET, V337, P1226, DOI 10.1016/0140-6736(91)92900-M; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; SVARDAL A, 1986, J BIOL CHEM, V261, P3156; Thieszen SL, 1996, EXP CELL RES, V227, P135, DOI 10.1006/excr.1996.0258; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; WILCKEN DEL, 1989, HAEMOSTASIS, V19, P14; WONG EHF, 1991, ANNU REV PHARMACOL, V31, P401; WRENN RW, 1993, IN VITRO CELL DEV-AN, V29A, P73, DOI 10.1007/BF02634374	30	107	123	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1997	11	8					703	711		10.1096/fasebj.11.8.9240971	http://dx.doi.org/10.1096/fasebj.11.8.9240971			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240971				2022-12-25	WOS:A1997XN02700010
J	Landino, LM; Crews, BC; Gierse, JK; Hauser, SD; Marnett, LJ				Landino, LM; Crews, BC; Gierse, JK; Hauser, SD; Marnett, LJ			Mutational analysis of the role of the distal histidine and glutamine residues of prostaglandin-endoperoxide synthase-2 in peroxidase catalysis, hydroperoxide reduction, and cyclooxygenase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HIGHER OXIDATION-STATES; H SYNTHASE; CRYSTAL-STRUCTURE; IRON(III) PORPHYRINS; HYDROGEN-PEROXIDE; ANGSTROM RESOLUTION; BACULOVIRUS SYSTEM; LIGNIN PEROXIDASE; MECHANISM	Site-directed mutants of prostaglandin-endoperoxide synthase-a (PGHS-2) with changes in the peroxidase active site were prepared by mutagenesis, expressed in Sf-9 cells, and purified to homogeneity, The distal histidine, His(193), was mutated to alanine and the distal glutamine, Gln(189), was changed to asparagine, valine, and arginine. The guaiacol peroxidase activities of H193A, Q189V, and Q189R were drastically reduced to levels observed in the absence of protein; only Q189N retained wild-type PGHS-2 (wtPGHS-2) activity, The mechanism of hydroperoxide reduction by the PGHS-2 mutants was investigated using 15-hydroperoxyeicosatetraenoic acid (15-HPETE), a diagnostic probe of hydroperoxide reduction pathways, The hydroperoxide reduction activity of Q189V and Q189R was reduced to that of free Fe(III) protoporphyrin IX levels, whereas Q189N catalyzed more reduction events than wtPGHS-2. The percentage of two-electron reduction events was identical for wt PGHS-2 and Q189N, The number of hydroperoxide reductions catalyzed by H193A was reduced to similar to 60% of wtPGHS-2 activity, but the majority of products were the one-electron reduction products, 15-KETE and epoxyalcohols, Thus, mutation of the distal histidine to alanine leads to a change in the mechanism of hydroperoxide reduction. Reaction of wtPGHS-2, Q189N, and H193A with varying concentrations of 15-HPETE revealed a change in product profile that suggests that 15-HPETE can compete with the reducing substrate for oxidation by the peroxidase higher oxidation state, compound I. The ability of the PGHS-2 proteins to catalyze two-electron hydroperoxide reduction correlated with the activation of cyclooxygenase activity, The reduced ability of H193A to catalyze two-electron hydroperoxide reduction resulted in a substantial lag phase in the cyclooxygenase assay, The addition of 2-methylimidazole chemically reconstituted the two-electron hydroperoxide reduction activity of H193A and abolished the cyclooxygenase lag phase, These observations are consistent with the involvement of the two-electron oxidized peroxidase intermediate, compound I, as the mediator of the activation of the cyclooxygenase of PGHS.	VANDERBILT UNIV, SCH MED,DEPT BIOCHEM,CTR MOL TOXICOL, AB HANCOCK JR MEM LAB CANC RES, NASHVILLE, TN 37232 USA; MONSANTO CO, SEARLE INFLAMMATORY DIS RES, ST LOUIS, MO 63167 USA	Vanderbilt University; Monsanto					NCI NIH HHS [CA47479] Funding Source: Medline; NIEHS NIH HHS [ES00267, T32ES07028] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028, P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bakovic M, 1996, J BIOL CHEM, V271, P2048, DOI 10.1074/jbc.271.4.2048; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BLEE E, 1989, BIOCHEMISTRY-US, V28, P4962, DOI 10.1021/bi00438a009; Chance B, 1943, J BIOL CHEM, V151, P553; CHANCE B, 1984, ARCH BIOCHEM BIOPHYS, V235, P596, DOI 10.1016/0003-9861(84)90234-0; CHOUDHURY K, 1992, J BIOL CHEM, V267, P25656; CROMLISH WA, 1994, ARCH BIOCHEM BIOPHYS, V314, P193, DOI 10.1006/abbi.1994.1429; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DOLPHIN D, 1974, ACCOUNTS CHEM RES, V7, P26, DOI 10.1021/ar50073a005; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; EDWARDS SL, 1993, P NATL ACAD SCI USA, V90, P750, DOI 10.1073/pnas.90.2.750; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; Everse J., 1991, PEROXIDASES CHEM BIO; FUNK MO, 1976, LIPIDS, V11, P113, DOI 10.1007/BF02532660; GEORGE P, 1955, BIOCHEM J, V60, P596, DOI 10.1042/bj0600596; GIERSE JK, 1994, BIOCHEM J, V304, P1; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Klebanoff SJ, 1991, PEROXIDASES CHEM BIO, V1, P1; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LABEQUE R, 1987, J AM CHEM SOC, V109, P2828, DOI 10.1021/ja00243a048; LABEQUE R, 1989, J AM CHEM SOC, V111, P6621, DOI 10.1021/ja00199a022; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; Landino LM, 1996, BIOCHEMISTRY-US, V35, P2637, DOI 10.1021/bi952546h; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; MARNETT LJ, 1979, J BIOL CHEM, V254, P5077; MARNETT LJ, 1995, CYTOCHROME P450 STRU; Newmyer SL, 1996, J BIOL CHEM, V271, P14891, DOI 10.1074/jbc.271.25.14891; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; O'Brien P J, 1980, Adv Prostaglandin Thromboxane Res, V6, P145; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; OHKI S, 1979, J BIOL CHEM, V254, P829; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PLE P, 1989, J BIOL CHEM, V264, P13983; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P575; POULOS TL, 1993, J BIOL CHEM, V268, P4429; Putter J, 1975, METHOD ENZYMAT AN, P685; Sambrook J, 1989, MOL CLONING LAB MANU, P82; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SCOTT SL, 1993, J PHYS CHEM-US, V97, P6710, DOI 10.1021/j100127a022; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1992, BIOCHEM BIOPH RES CO, V183, P975, DOI 10.1016/S0006-291X(05)80286-4; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; SUNDARAMOORTHY M, 1991, J AM CHEM SOC, V113, P7755, DOI 10.1021/ja00020a044; TRAYLOR TG, 1993, J AM CHEM SOC, V115, P2775, DOI 10.1021/ja00060a027; TRAYLOR TG, 1990, J AM CHEM SOC, V112, P178, DOI 10.1021/ja00157a029; TRAYLOR TG, 1995, J AM CHEM SOC, V117, P3468, DOI 10.1021/ja00117a015; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; WELLER PE, 1985, ARCH BIOCHEM BIOPHYS, V243, P633, DOI 10.1016/0003-9861(85)90541-7; WILCOX AL, 1993, CHEM RES TOXICOL, V6, P413, DOI 10.1021/tx00034a003; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	61	58	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21565	21574		10.1074/jbc.272.34.21565	http://dx.doi.org/10.1074/jbc.272.34.21565			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261177	hybrid			2022-12-25	WOS:A1997XR78900087
J	Hunt, JA; Fierke, CA				Hunt, JA; Fierke, CA			Selection of carbonic anhydrase variants displayed on phage - Aromatic residues in zinc binding site enhance metal affinity and equilibration kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC POCKET; CATALYTIC MECHANISM; RANDOM MUTAGENESIS; PROTON-TRANSFER; PROTEIN; BACTERIOPHAGE; CHROMATOGRAPHY; PURIFICATION; CONSEQUENCES; EXPRESSION	In all metalloenzymes, hydrophobic residues surround the metal binding site, In carbonic anhydrase II (CAII) residues Phe(93), Phe(95), and Trp(97) flank two of the three histidines that coordinate zinc to form a hydrophobic cluster beneath the zinc binding site. A library of CAII variants differing in these hydrophobic amino acids was prepared using cassette mutagenesis, then displayed on filamentous phage, and screened for proteins retaining high zinc affinity, Wild-type CAII was enriched 20-fold by selection, and consensus residues at each position were identified from the enriched CAII variants (lie, Phe, Leu, and Met at position 93; lie, Leu, and Met at position 95; and Trp and Val at position 97), Highly selected variants have zinc affinity and catalytic activity nearly equal to that of wild-type CAII, indicating that the aromatic residues are not absolutely essential, However, the zinc dissociation rate constant and catalytic activity of the variants correlate with the volume of the amino acids at positions 93, 95, and 97, In summary, metalloenzyme variants displayed on phage can be selected on the basis of metal affinity; such methods will be useful for optimization of metal ion biosensors.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017467, R29GM040602, R01GM040602] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17467, GM40602] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER RS, 1993, BIOCHEMISTRY-US, V32, P1510, DOI 10.1021/bi00057a015; ARKIN AP, 1992, BIO-TECHNOL, V10, P297, DOI 10.1038/nbt0392-297; ARMSTRONG JM, 1966, J BIOL CHEM, V241, P5137; Christianson DW, 1996, ACCOUNTS CHEM RES, V29, P331, DOI 10.1021/ar9501232; COREY DR, 1993, GENE, V128, P129; DODGSON SJ, 1991, CARBONIC ANHYDRASES; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ERIKSSON AE, 1988, PROTEINS, V4, P283, DOI 10.1002/prot.340040407; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; FIERKE CA, 1991, INT WORKSH CARB ANH, P22; HAKANSSON K, 1992, J MOL BIOL, V227, P1192, DOI 10.1016/0022-2836(92)90531-N; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; Hellinga HW, 1996, CURR OPIN BIOTECH, V7, P437, DOI 10.1016/S0958-1669(96)80121-2; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; HIGAKI JN, 1992, TRENDS BIOCHEM SCI, V17, P100, DOI 10.1016/0968-0004(92)90245-5; HOLYER RH, 1966, INORG CHEM, V5, P622, DOI 10.1021/ic50038a027; HOLYER RH, 1965, INORG CHEM, V4, P929, DOI 10.1021/ic50029a002; Huang CC, 1996, BIOCHEMISTRY-US, V35, P3439, DOI 10.1021/bi9526692; HUNT JB, 1984, J BIOL CHEM, V259, P4793; HUNT JB, 1977, ANAL BIOCHEM, V64, P297; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; IPPOLITO JA, 1994, BIOCHEMISTRY-US, V33, P15241, DOI 10.1021/bi00255a004; Jackman JE, 1996, BIOCHEMISTRY-US, V35, P16421, DOI 10.1021/bi961786+; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KIEFER LL, 1995, J AM CHEM SOC, V117, P6831, DOI 10.1021/ja00131a004; KIEFER LL, 1994, BIOCHEMISTRY-US, V33, P15233, DOI 10.1021/bi00255a003; KIEFER LL, 1993, J AM CHEM SOC, V115, P12581, DOI 10.1021/ja00079a046; KING RW, 1976, PROC R SOC SER B-BIO, V193, P107, DOI 10.1098/rspb.1976.0034; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREBS JF, 1993, J BIOL CHEM, V268, P948; KREBS JF, 1993, BIOCHEMISTRY-US, V32, P4496, DOI 10.1021/bi00068a004; KUMAR K, 1976, BIOCHEMISTRY-US, V15, P2195, DOI 10.1021/bi00655a026; LESBURG CA, 1995, J AM CHEM SOC, V117, P6838, DOI 10.1021/ja00131a005; LINDSKOG S, 1982, ADV INORG BIOCHEM, V4, P115; MARKS JD, 1992, J BIOL CHEM, V267, P16007; MCCAFFERTY J, 1991, PROTEIN ENG, V4, P955, DOI 10.1093/protein/4.8.955; MULLER HN, 1994, BIOCHEMISTRY-US, V33, P14126; NAIR SK, 1991, J BIOL CHEM, V266, P17320; OSBORNE WRA, 1975, ANAL BIOCHEM, V64, P297, DOI 10.1016/0003-2697(75)90434-0; PESSI A, 1993, NATURE, V362, P367, DOI 10.1038/362367a0; POCKER Y, 1972, BIOCHEMISTRY-US, V11, P698, DOI 10.1021/bi00755a005; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; REN XL, 1995, BIOCHEMISTRY-US, V34, P8492, DOI 10.1021/bi00026a033; RIEPE ME, 1968, J BIOL CHEM, V243, P2779; ROBERTS VA, 1990, P NATL ACAD SCI USA, V87, P6654, DOI 10.1073/pnas.87.17.6654; ROWLETT RS, 1982, J AM CHEM SOC, V104, P6737, DOI 10.1021/ja00388a043; Sambrook J, 1989, MOL CLONING LAB MANU, VII; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILLEN LG, 1964, SPECIAL PUBLICATION, V17, P546; SILVERMAN DN, 1993, BIOCHEMISTRY-US, V32, P10757, DOI 10.1021/bi00091a029; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SOUMILLION P, 1994, J MOL BIOL, V237, P415, DOI 10.1006/jmbi.1994.1244; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAINER J A, 1992, Current Opinion in Biotechnology, V3, P378, DOI 10.1016/0958-1669(92)90166-G; Tamai S, 1996, P NATL ACAD SCI USA, V93, P13647, DOI 10.1073/pnas.93.24.13647; Tang Y, 1996, J BIOL CHEM, V271, P15682, DOI 10.1074/jbc.271.26.15682; Thompson R B, 1996, J Biomed Opt, V1, P131, DOI 10.1117/12.227108; THOMPSON RB, 1995, ANAL BIOCHEM, V227, P123, DOI 10.1006/abio.1995.1260; VIERA J, 1987, METHOD ENZYMOL, V153, P3; VITA C, 1995, P NATL ACAD SCI USA, V92, P6404, DOI 10.1073/pnas.92.14.6404; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	68	64	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20364	20372		10.1074/jbc.272.33.20364	http://dx.doi.org/10.1074/jbc.272.33.20364			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252341	hybrid			2022-12-25	WOS:A1997XR22100011
J	Komada, M; Masaki, R; Yamamoto, A; Kitamura, N				Komada, M; Masaki, R; Yamamoto, A; Kitamura, N			Hrs, a tyrosine kinase substrate with a conserved double zinc finger domain, is localized to the cytoplasmic surface of early endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PREVACUOLAR COMPARTMENT; ENDOPLASMIC-RETICULUM; CARCINOMA A431-CELLS; SIGNAL-TRANSDUCTION; INTERNALIZATION; PROTEIN; CELLS; TRANSFERRIN; ACTIVATION	Hrs is a 115-kDa double zinc finger protein that is rapidly tyrosine phosphorylated in growth factor stimulated cells, However, its function remains unknown, Here we show that Hrs is localized to early endosomes, Intracellular localization of endogenous Hrs and exogenously expressed Hrs tagged with the hemagglutinin epitope was examined by immunofluorescence staining using anti-Hrs and anti-hemagglutinin epitope antibodies, respectively, Hrs was detected in vesicular structures and was colocalized with the transferrin receptor, a marker for early endosomes, but only partially with CD63, a marker for late endosomes, A zinc finger domain deletion mutant of Hrs was also colocalized with the transferrin receptor, suggesting that the zinc finger domain is not required for its correct localization, Immunoelectron microscopy showed that Hrs was localized to the cytoplasmic surface of these structures, By subcellular fractionation, Hrs was recovered both in the cytoplasmic and membrane fractions, The membrane-associated Hrs was extracted from the membrane by alkali treatment, suggesting that it is peripherally associated with early endosomes. These results, together with our finding that Hrs is homologous to Vps27p, a protein essential for protein traffic through a prevacuolar compartment in yeast, suggest that Hrs is involved in vesicular transport through early endosomes.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; KANSAI MED UNIV,INST LIVER RES,MORIGUCHI,OSAKA 570,JAPAN; KANSAI MED UNIV,DEPT PHYSIOL,MORIGUCHI,OSAKA 570,JAPAN	Tokyo Institute of Technology; Kansai Medical University; Kansai Medical University								BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; KOMADA M, 1994, J BIOL CHEM, V269, P16131; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MRINI A, 1995, J HISTOCHEM CYTOCHEM, V43, P1285, DOI 10.1177/43.12.8537644; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; PASTERIS NG, 1994, CELL, V79, P669; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; SORKIN A, 1993, J CELL PHYSIOL, V156, P373, DOI 10.1002/jcp.1041560221; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	32	150	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20538	20544		10.1074/jbc.272.33.20538	http://dx.doi.org/10.1074/jbc.272.33.20538			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252367	hybrid			2022-12-25	WOS:A1997XR22100037
J	Lazarowski, ER; Homolya, L; Boucher, RC; Harden, TK				Lazarowski, ER; Homolya, L; Boucher, RC; Harden, TK			Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE KINASE; TUMOR-METASTASIS; GENE; ATP	The P2Y(4) receptor is selectively activated by UTP, Although addition of neither ATP nor UDP alone increased intracellular Ca2+ in 1321N1 human astrocytoma cells stably expressing the P2Y(4) receptor, combined addition of these nucleotides resulted in a slowly occurring elevation of Ca2+. The possibility that the stimulatory effect of the combined nucleotides reflected formation of UTP by an extracellular transphosphorylating activity was investigated, Incubation of cells with [H-3]UDP or [H-3]ADP under conditions in which cellular release of ATP occurred or in the presence of added ATP resulted in rapid formation of the corresponding triphosphates, Transfer of the gamma-phosphate from [gamma-P-33]ATP to nucleoside diphosphates confirmed that the extracellular enzymatic activity was contributed by a nucleoside diphosphokinase. The majority of this activity was associated with the cell surface of 1321N1 cells, suggesting involvement of an ectoenzyme, Both ADP and UDP were effective substrates for transphosphorylation. Since ecto-nucleotidase(s) has been considered previously to be the primary enzyme(s) responsible for metabolism of extracellular nucleotides, the relative rates of hydrolysis of ATP, ADP, UTP, and UDP also were determined for 1321N1 cells, All four nucleotides were hydrolyzed with similar K-m and V-max values, Kinetic analyses of the ecto-nucleoside diphosphokinase and ecto-nucleotidase activities indicated that the rate of extracellular transphosphorylation exceeds that of nucleotide hydrolysis by up to 20-fold. Demonstration of the existence of a very active ecto-nucleoside diphosphokinase together with previous observations that stress induced release of ATP occurs from most cell types indicates that transphosphorylation is physiologically important in the extracellular metabolism of adenine and uridine nucleotides, Since the P2Y receptor class of signaling proteins differs remarkably in their respective specificity for adenine and uridine nucleotides and di- and triphosphates, these results suggest that extracellular interconversion of adenine and uridine nucleotides plays a key role in defining activities in nucleotide-mediated signaling.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599; HUNGARIAN ACAD SCI,RES GRP,BUDAPEST,HUNGARY	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Hungarian Academy of Sciences			Homolya, Laszlo/N-1154-2016	Homolya, Laszlo/0000-0003-1639-8140	NHLBI NIH HHS [HL32322] Funding Source: Medline; NIGMS NIH HHS [GM38213] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUDOIN AR, 1996, BIOMEMBRANE, P369; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; Charlton SJ, 1996, BRIT J PHARMACOL, V119, P1301, DOI 10.1111/j.1476-5381.1996.tb16038.x; Communi D, 1997, TRENDS PHARMACOL SCI, V18, P83, DOI 10.1016/S0165-6147(96)01035-8; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; PARKS RW, 1973, ENZYMES, P307; Picher M, 1996, BIOCHEM PHARMACOL, V51, P1453, DOI 10.1016/0006-2952(96)00086-X; PLESNER L, 1995, INT REV CYTOL, V158, P141; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SEVIGNY J, 1995, BIOCHEM J, V312, P351, DOI 10.1042/bj3120351; SLAKEY LL, 1990, ANN NY ACAD SCI, V603, P366; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898	26	100	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20402	20407		10.1074/jbc.272.33.20402	http://dx.doi.org/10.1074/jbc.272.33.20402			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252347	Green Published, hybrid			2022-12-25	WOS:A1997XR22100017
J	Nemes, Z; Adany, R; Balazs, M; Boross, P; Fesus, L				Nemes, Z; Adany, R; Balazs, M; Boross, P; Fesus, L			Identification of cytoplasmic actin as an abundant glutaminyl substrate for tissue transglutaminase in HL-60 and U937 cells undergoing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; TERMINAL DIFFERENTIATION; RETINOIC ACID; RAT-LIVER; F-ACTIN; EXPRESSION; DEATH; MATRIX; GROWTH; 5-(BIOTINAMIDO)PENTYLAMINE	A lysine derivative, 3-[N-alpha[N-epsilon-[2',4'-dinitrophenyl]-amino-n-hexanoyl-L-lysylamido]-propane-1-ol, a novel amine substrate of transglutaminases, was synthesized and delivered into intact HL-60 and U937 human leukemia cells to probe the function of the intracellular enzyme. The novel substrate compound was covalently incorporated into intracellular proteins in these cells expressing high levels of tissue transglutaminase and undergoing apoptosis following the induction of their differentiation with dimethyl sulfoxide and retinoic acid. Immunoaffinity purification and microsequencing of labeled proteins identified cytoplasmic actin as the main endogenous glutaminyl substrate in these cells. As shown by confocal image analysis, cells revealed distinct labeling of the microfilament meshwork structures by the novel compound as the result of the intracellular action of transglutaminase.	DEBRECEN UNIV MED,SCH MED,DEPT BIOCHEM,H-4012 DEBRECEN,HUNGARY; DEBRECEN UNIV MED,SCH MED,DEPT HYG & EPIDEMIOL,H-4012 DEBRECEN,HUNGARY	University of Debrecen; University of Debrecen								AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; ANDO Y, 1991, J BIOL CHEM, V266, P1101; Benedetti L, 1996, BLOOD, V87, P1939; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; COHEN I, 1980, BIOCHIM BIOPHYS ACTA, V628, P365, DOI 10.1016/0304-4165(80)90386-4; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COTTER TG, 1992, CANCER RES, V52, P997; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; DEFACQUE H, 1995, LEUKEMIA, V9, P1762; Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; ENDRESEN PC, 1995, CYTOMETRY, V20, P162, DOI 10.1002/cyto.990200209; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; Fesus L, 1988, Adv Exp Med Biol, V231, P119; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FINK ML, 1983, METHOD ENZYMOL, V94, P347; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1977, ADV PROTEIN CHEM, V31, P127; FUKUDA K, 1994, J CELL BIOCHEM, V54, P67, DOI 10.1002/jcb.240540108; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GROOTJANS JJ, 1995, J BIOL CHEM, V270, P22855, DOI 10.1074/jbc.270.39.22855; HARSFALVI J, 1991, BIOCHIM BIOPHYS ACTA, V1073, P268, DOI 10.1016/0304-4165(91)90131-Y; HEGYI G, 1992, PROTEIN SCI, V1, P132; JOHNSON TS, 1994, ONCOGENE, V9, P2935; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; KNIGHT RL, 1993, EUR J CELL BIOL, V60, P210; KVEDAR JC, 1992, BIOCHEMISTRY-US, V31, P49, DOI 10.1021/bi00116a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KN, 1992, BIOCHIM BIOPHYS ACTA, V1136, P12, DOI 10.1016/0167-4889(92)90078-P; LORAND L, 1986, BIOCHEM BIOPH RES CO, V134, P685, DOI 10.1016/S0006-291X(86)80474-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MINTA JO, 1985, AM J PATHOL, V119, P111; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Nemes Z, 1996, EUR J CELL BIOL, V70, P125; OLIVEIRO S, 1997, IN PRESS MOL CELL BI; PARWARESCH MR, 1984, CELL IMMUNOL, V89, P385, DOI 10.1016/0008-8749(84)90340-X; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; PIACENTINI M, 1994, APOPTOSIS, V2, P143; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Song QZ, 1997, P NATL ACAD SCI USA, V94, P157, DOI 10.1073/pnas.94.1.157; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; TARCSA E, 1990, ANAL BIOCHEM, V186, P135, DOI 10.1016/0003-2697(90)90586-X; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; TRICHIERI G, 1987, CANCER RES, V47, P2236; Wyllie A H, 1980, Int Rev Cytol, V68, P251	54	96	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20577	20583		10.1074/jbc.272.33.20577	http://dx.doi.org/10.1074/jbc.272.33.20577			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252372	hybrid			2022-12-25	WOS:A1997XR22100042
J	Schmitz, A; Short, M; Ammerpohl, O; Asbrand, C; Nickel, J; Renkawitz, R				Schmitz, A; Short, M; Ammerpohl, O; Asbrand, C; Nickel, J; Renkawitz, R			Cis-elements required for the demethylation of the mouse M-lysozyme downstream enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; GENE-EXPRESSION; CHICKEN EMBRYOS; BINDING SITE; PROMOTER; CELLS; TRANSCRIPTION; INVOLVEMENT; SEQUENCE; PROTEINS	The mouse lysozyme downstream enhancer was previously colocalized with the DNase I-hypersensitive site in the chromatin of mature macrophages. This hyper sensitive site was shown to be macrophage differentiation-dependent, Demethylation of CpG sequences within the enhancer is correlated with lysozyme expression in mature macrophages. Binding of the GABP heterotetrameric transcription factor to the enhancer core element (MLDE), only seen in vivo on the demethylated MLDE element in macrophages, is inhibited by DNA methylation, Here, we analyzed the DNA sequences required for demethylation. In electrophoretic mobility shift experiments we found that in addition to the complete methylated MLDE the hemimethylated form of the lower strand inhibits GABP binding as well, Therefore, GABP is unlikely to be the mediator of demethylation. In addition, we show by stable DNA transfections of methylated mouse lysozyme enhancer sequences that MLDE flanking sequences are required for demethylation, We narrowed down these DNA elements to two short regions of 163 and 79 base pairs on either side of the MLDE, each of which is sufficient to mediate demethylation of the GABP site.	UNIV GIESSEN KLINIKUM,GENET INST,D-35392 GIESSEN,GERMANY	University Hospital of Giessen & Marburg			Ammerpohl, Ole/G-2691-2010					Ausubel FM., 1988, CURRENT PROTOCOLS MO; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Benvenuto G, 1996, MOL CELL BIOL, V16, P2736; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BURBELO PD, 1990, J BIOL CHEM, V265, P4839; CROSS M, 1990, EMBO J, V9, P1283, DOI 10.1002/j.1460-2075.1990.tb08237.x; DELALUNA S, 1988, GENE, V62, P121; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; FELGNER J, 1992, LEUKEMIA, V6, P420; FERGUSON AT, 1995, CANCER RES, V55, P2279; GASTON K, 1995, GENE, V157, P257, DOI 10.1016/0378-1119(95)00120-U; Iannello RC, 1997, MOL CELL BIOL, V17, P612, DOI 10.1128/MCB.17.2.612; JOST JP, 1991, NUCLEIC ACIDS RES, V19, P5771, DOI 10.1093/nar/19.20.5771; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; KLAGES S, 1992, NUCLEIC ACIDS RES, V20, P1925, DOI 10.1093/nar/20.8.1925; Koetsier PA, 1996, TRANSGENIC RES, V5, P235, DOI 10.1007/BF01972877; LEENEN PJM, 1986, DIFFERENTIATION, V32, P157, DOI 10.1111/j.1432-0436.1986.tb00568.x; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; Lubbert M, 1996, BLOOD, V87, P447, DOI 10.1182/blood.V87.2.447.bloodjournal872447; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MOLLERS B, 1992, NUCLEIC ACIDS RES, V20, P1917, DOI 10.1093/nar/20.8.1917; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nickel J, 1995, NUCLEIC ACIDS RES, V23, P4785, DOI 10.1093/nar/23.23.4785; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; PHILIPSEN JNJ, 1985, BIOCHIM BIOPHYS ACTA, V826, P186, DOI 10.1016/0167-4781(85)90005-3; ROBERTSON KD, 1995, MOL CELL BIOL, V15, P6150; SALUZ HP, 1988, P NATL ACAD SCI USA, V85, P6697, DOI 10.1073/pnas.85.18.6697; SHIMADA T, 1987, MOL CELL BIOL, V7, P2830, DOI 10.1128/MCB.7.8.2830; Short ML, 1996, CELL GROWTH DIFFER, V7, P1545; SZYF M, 1995, J BIOL CHEM, V270, P12690, DOI 10.1074/jbc.270.21.12690; Takei S, 1996, BIOCHEM BIOPH RES CO, V220, P606, DOI 10.1006/bbrc.1996.0450; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355	37	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20850	20856		10.1074/jbc.272.33.20850	http://dx.doi.org/10.1074/jbc.272.33.20850			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252411	hybrid			2022-12-25	WOS:A1997XR22100081
J	Murakami, M; Kuwata, H; Amakasu, Y; Shimbara, S; Nakatani, Y; Atsumi, G; Kudo, I				Murakami, M; Kuwata, H; Amakasu, Y; Shimbara, S; Nakatani, Y; Atsumi, G; Kudo, I			Prostaglandin E-2 amplifies cytosolic phospholipase A(2)- and cyclooxygenase-2-dependent delayed prostaglandin E-2 generation in mouse osteoblastic cells - Enhancement by secretory phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A(2); MAST-CELLS; ENDOPEROXIDE SYNTHASE-1; GENE DISRUPTION; D-2 GENERATION; EXPRESSION; ACID; RELEASE; FIBROBLASTS; ACTIVATION	We used the MC3T3-E1 cell line, which originates from C57BL/6J mouse that is genetically type IIA secretory phospholipase A(2) (sPLA(2))-deficient, to reveal the type IIA sPLA(2)-independent route of the prostanglandin (PG) biosynthetic pathway, Kinetic and pharmacological studies showed that delayed PGE(2) generation by this cell line in response to interleukin (IL)-1 beta and tumor necrosis factor alpha (TNF alpha) was dependent upon cytosolic phospholipase A(2) (cPLA(2)) and cyclooxygenase (COX)-2. Expression of these two enzymes was reduced by cPLA(2) or COX-2 inhibitors and restored by adding exogenous arachidonic acid or PGE(2), indicating that PGE(2) produced by these cells acted as an autocrine amplifier of delayed PGE(2) generation through enhanced cPLA(2) and COX-2 expression, Exogenous addition or enforced expression of type IIA sPLA(2) significantly increased IL-1 beta/TNF alpha-initiated PGE(2) generation, which was accompanied by increased expression of both cPLA(2) and COX-2 and suppressed by inhibitors of these enzymes. Thus, our results revealed a particular cross-talk between the two PLA(2) enzymes and COX-2 for delayed PGE(2) biosynthesis by a type IIA sPLA(2)-deficient cell line, cPLA(2) is responsible for initiating COX-2-dependent delayed PGE(2) generation, and sPLA(2), if introduced, enhances PGE(2) generation by increasing cPLA(2) and COX-2 expression via endogenous PGE(2).	SHOWA UNIV,SCH PHARMACEUT SCI,DEPT HLTH CHEM,SHINAGAWA KU,TOKYO 142,JAPAN	Showa University			Kuwata, Hiro/N-2023-2019	Kuwata, Hiro/0000-0002-5023-1777				Ashraf MDM, 1996, BIOCHEM BIOPH RES CO, V229, P726, DOI 10.1006/bbrc.1996.1872; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; Chapdelaine Joan M., 1995, Arthritis and Rheumatism, V38, pS293; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MEDAE EA, 1993, J BIOL CHEM, V268, P6610; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MURAKAMI M, 1995, J LIPID MEDIAT CELL, V12, P119, DOI 10.1016/0929-7855(95)00013-G; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; MURAKAMI M, 1990, FEBS LETT, V268, P113, DOI 10.1016/0014-5793(90)80986-S; OKA S, 1991, J BIOL CHEM, V266, P9956; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; PrigentTessier A, 1996, EUR J BIOCHEM, V241, P872, DOI 10.1111/j.1432-1033.1996.00872.x; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TAKAHASHI Y, 1994, BBA-LIPID LIPID MET, V1212, P217, DOI 10.1016/0005-2760(94)90256-9; TANAKA K, 1993, INFLAMMATION, V17, P107, DOI 10.1007/BF00916098; TOHKIN M, 1993, J BIOL CHEM, V268, P268; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009	43	113	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19891	19897		10.1074/jbc.272.32.19891	http://dx.doi.org/10.1074/jbc.272.32.19891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242654	hybrid			2022-12-25	WOS:A1997XQ05900041
J	Aggeler, R; Ogilvie, I; Capaldi, RA				Aggeler, R; Ogilvie, I; Capaldi, RA			Rotation of a gamma-epsilon subunit domain in the Escherichia coli F1F0-ATP synthase complex - The gamma-epsilon subunits are essentially randomly distributed relative to the alpha(3)beta(3)delta domain in the intact complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; F1 ADENOSINE-TRIPHOSPHATASE; CATALYTIC SITES; CRYOELECTRON MICROSCOPY; F1-ATPASE; MECHANISM; ASYMMETRY; BINDING; BETA	A triple mutant of Escherichia coli F1F0-ATP synthase, alpha Q2C/alpha S411C/epsilon S108C, has been generated for studying movements of the gamma and epsilon subunits during functioning of the enzyme, It includes mutations that allow disulfide bond formation between the Cys at alpha 411 and both Cys-87 of gamma and Cys-108 of epsilon, two covalent cross-links that block enzyme function (Aggeler, R., and Capaldi, R. A. (1996) J. Biol. Chem. 271, 13888-13891). A cross-link is also generated between the Cys at alpha 2 and Cys-140 of the delta subunit, which has no effect on functioning (Ogilvie, I., Aggeler, R., and Capaldi, R. A. (1997) J. Biol. Chem. 272, 16652-16656), CuCl2 treatment of the mutant alpha Q2C/ alpha S411C/epsilon S108C generated five major cross-linked products. These are alpha-gamma-delta, alpha-gamma, alpha-delta-epsilon, alpha-delta, and alpha-epsilon. The ratio of alpha-gamma-delta to the alpha-gamma product was close to 1:2, i.e. in one-third of the ECF1F0 molecules the gamma subunit was attached to the alpha subunit at which the delta subunit is bound. Also, 20% of the epsilon subunit was present as a alpha-delta-epsilon product. With regard to the delta subunit, 30% was in the alpha-gamma-delta, 20% in the alpha-delta-epsilon, and 50% in the alpha-delta products when the cross-linking was done after incubation in ATP + MgCl2. The amounts of these three products were 40, 22, and 38%, respectively, in experiments where Cu2+ was added after preincubation in ATP + Mg2+ + azide. The delta subunit is fixed to, and therefore identifies, one specific alpha subunit (alpha(delta)). A distribution of the gamma and epsilon subunits, which is essentially random with respect to the alpha subunits, can only be explained by rotation of gamma-epsilon relative to the alpha(3) beta(3) domain in ECF1F0.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 24526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; BOYER PD, 1987, BIOCHEMISTRY-US, V26, P8503, DOI 10.1021/bi00400a001; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; GRUBER G, 1997, IN PRESS FEBS LETT; Junge W, 1996, BER BUNSEN PHYS CHEM, V100, P2014, DOI 10.1002/bbpc.19961001215; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	36	103	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19621	19624		10.1074/jbc.272.31.19621	http://dx.doi.org/10.1074/jbc.272.31.19621			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235970	hybrid			2022-12-25	WOS:A1997XP06300076
J	Gao, TY; Puri, TS; Gerhardstein, BL; Chien, AJ; Green, RD; Hosey, MM				Gao, TY; Puri, TS; Gerhardstein, BL; Chien, AJ; Green, RD; Hosey, MM			Identification and subcellular localization of the subunits of L-type calcium channels and adenylyl cyclase in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 SIZE FORMS; SKELETAL-MUSCLE; DIFFERENTIAL PHOSPHORYLATION; ALPHA(1) SUBUNIT; CA2+ CHANNELS; BETA-SUBUNIT; DIHYDROPYRIDINE; RECEPTORS; PURIFICATION; EXPRESSION	The properties of cardiac L-type channels have been well characterized electrophysiologically, and many such studies have demonstrated that the channels are regulated by a cAMP-dependent pathway, However, the subunit composition of native cardiac L-type calcium channels has not been completely defined, Furthermore, a very important question exists regarding the status of the C-terminal domain of the pore-forming alpha(1) subunit, as this domain has the potential to be the target of protein kinases but may be truncated as a result of posttranslational processing, In the present studies, the alpha(1C) and beta(2) subunits were identified by subunit-specific antibodies after partial purification from heart membranes, or immunoprecipitation from cardiac myocytes, Both the beta(2) and the full-length alpha(1C) subunits were found to be expressed and co-localized in intact cardiac myocytes along T-tubule membranes. Using a quantitative antibody binding analysis, we demonstrated that the majority of the alpha(1C) subunits in intact cardiac myocytes appear to be full-length, In addition, we observed that adenylyl cyclase is localized in a pattern similar to the channel subunits in cardiac myocytes, Taken together, our results provide new insights into the structural basis for understanding the regulation of L-type calcium channels by a cAMP-mediated signaling pathway.	NORTHWESTERN UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,CHICAGO,IL 60611; UNIV ILLINOIS,DEPT PHARMACOL,CHICAGO,IL 60612	Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NHLBI NIH HHS [HL23306] Funding Source: Medline; NIDDK NIH HHS [T32 DK07169] Funding Source: Medline; NIMH NIH HHS [MH10770] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023306, R37HL023306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH010770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BRAWLEY RM, 1992, J BIOL CHEM, V267, P18218; CARL SL, 1995, J CELL BIOL, V129, P673, DOI 10.1083/jcb.129.3.673; CHANG FC, 1988, J BIOL CHEM, V263, P18929; Chien AJ, 1996, J BIOL CHEM, V271, P26465, DOI 10.1074/jbc.271.43.26465; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; COOPER CL, 1987, J BIOL CHEM, V262, P509; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; FORBES MS, 1980, TISSUE CELL, V12, P467, DOI 10.1016/0040-8166(80)90037-3; FOSSET M, 1983, J BIOL CHEM, V258, P6086; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; HAASE H, 1991, EUR J PHARM-MOLEC PH, V207, P51, DOI 10.1016/S0922-4106(05)80037-9; HADDAD J, 1988, AM J PHYSIOL, V255, pC19, DOI 10.1152/ajpcell.1988.255.1.C19; HELL JW, 1994, J BIOL CHEM, V269, P7390; HELL JW, 1993, J BIOL CHEM, V268, P19451; HOSEY MM, 1985, J PHARMACOL EXP THER, V232, P795; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KOBAYASHI M, 1985, ANAL BIOCHEM, V145, P351, DOI 10.1016/0003-2697(85)90373-2; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; SIMPSON DG, 1993, J CELL BIOL, V123, P323, DOI 10.1083/jcb.123.2.323; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; WEI XY, 1994, J BIOL CHEM, V269, P1635; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P; YU HJ, 1993, MOL PHARMACOL, V44, P689	31	143	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19401	19407		10.1074/jbc.272.31.19401	http://dx.doi.org/10.1074/jbc.272.31.19401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235939	hybrid			2022-12-25	WOS:A1997XP06300045
J	Oh, JW; Katz, A; Harroch, S; Eisenbach, L; Revel, M; Chebath, J				Oh, JW; Katz, A; Harroch, S; Eisenbach, L; Revel, M; Chebath, J			Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells	ONCOGENE			English	Article						interleukin-6; cancer; melanoma; IRF-1; Waf-1; growth control	ACUTE-PHASE RESPONSE; REGULATORY FACTOR-I; INTERLEUKIN-6 RECEPTOR; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCER; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS; MOLECULAR-CLONING; STAT FAMILY; IFN-BETA	Interleukin-6 (IL-6) inhibits the growth of melanocytes and of early stage melanoma cells, but not that of advanced melanoma cells. The in vitro IL-6 response can be restored in the highly metastatic melamona B16-F10.9 by addition of recombinant soluble IL-6 receptor alpha-chain (sIL-6R). The F10.9 cells then undergo irreversible growth-arrest and show increased adherence with changes from epithelioid to spindleoid morphology. The sIL-6R is required for IL-6 to induce a sustained activation of the various Stat transcription factors which bind to specific IL-6 inducible enhancers. The sIL-6R and IL-6 combination causes an increase in the level of the anti-oncogenic transcription factor IRF-1 protein and DNA-binding, which remain elevated for 24 h. The promoter activity of the anti-oncogenic p21/Waf-1/Cip-1 gene is induced and accumulation of the p21, protein is observed. These results illustrate the potent agonist activity of sIL-6R on molecular pathways which could mediate the growth-arrest and differentiation of the metastatic melanoma cells. Previously observed antimetastatic effects of IL-6 therapy in mice bearing F10.9 tumors may be at least partly due to direct growth inhibition and differentiation elicited by sIL-6R present in biological fluids.	WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science				Chebath, Judith/0000-0002-8151-7428; Eisenbach, Lea R/0000-0002-4816-1968				Akira S, 1995, ANN NY ACAD SCI, V762, P15; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARMSTRONG CA, 1994, J INVEST DERMATOL, V102, P278, DOI 10.1111/1523-1747.ep12371782; CHEN YQ, 1995, CANCER RES, V55, P4536; CHERNAJOVSKY Y, 1984, DNA-J MOLEC CELL BIO, V3, P297, DOI 10.1089/dna.1.1984.3.297; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COFFER P, 1995, ONCOGENE, V10, P985; COLOMBO MP, 1992, MELANOMA RES, V2, P181, DOI 10.1097/00008390-199209000-00006; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FRIELING JTM, 1994, CYTOKINE, V6, P376, DOI 10.1016/1043-4666(94)90061-2; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAILLARD JP, 1993, EUR J IMMUNOL, V23, P820, DOI 10.1002/eji.1830230408; Ganapathi MK, 1996, CELL GROWTH DIFFER, V7, P923; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HALIMI H, 1995, EUR CYTOKINE NETW, V6, P135; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARPER JW, 1993, CELL, V75, P805; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HARROCH S, 1993, J BIOL CHEM, V268, P9092; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; KATZ A, 1993, INT J CANCER, V53, P812, DOI 10.1002/ijc.2910530518; KATZ A, 1993, J IMMUNOTHER, V13, P98, DOI 10.1097/00002371-199302000-00004; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; Mackiewicz A, 1995, ANN NY ACAD SCI, V762, P361; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; MACKIEWICZ A, 1995, CYTOKINE, V7, P142, DOI 10.1006/cyto.1995.1019; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NOVICK D, 1991, HYBRIDOMA, V10, P137, DOI 10.1089/hyb.1991.10.137; NOVICK D, 1992, CYTOKINE, V4, P6, DOI 10.1016/1043-4666(92)90029-Q; NOVICK D, 1990, J CHROMATOGR, V510, P331, DOI 10.1016/S0021-9673(01)93767-7; Oh JW, 1996, CYTOKINE, V8, P401, DOI 10.1006/cyto.1996.0055; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PORGADOR A, 1989, J IMMUNOGENET, V16, P291; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Revel M, 1995, ANN NY ACAD SCI, V762, P342; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROSEJOHN S, 1993, J BIOL CHEM, V268, P22084; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SILVANI A, 1995, CANCER RES, V55, P2200; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Su Zao-Zhong, 1995, Molecular and Cellular Differentiation, V3, P225; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	69	27	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					569	577		10.1038/sj.onc.1201213	http://dx.doi.org/10.1038/sj.onc.1201213			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247310				2022-12-25	WOS:A1997XN25500008
J	Prasad, R; Zhadanov, AB; Sedkov, Y; Bullrich, F; Druck, T; Rallapalli, R; Yano, T; Alder, H; Croce, CM; Huebner, K; Mazo, A; Canaani, E				Prasad, R; Zhadanov, AB; Sedkov, Y; Bullrich, F; Druck, T; Rallapalli, R; Yano, T; Alder, H; Croce, CM; Huebner, K; Mazo, A; Canaani, E			Structure and expression pattern of human ALR, a novel gene with strong homology to ALL-1 involved in acute leukemia and to Drosophila trithorax	ONCOGENE			English	Article						ALL-1; leukemia; SET domain; PHD fingers	BITHORAX COMPLEX; DNA-BINDING; SEQUENCE SIMILARITY; BMI-1 PROTOONCOGENE; PROTEIN; POLYCOMB; DOMAINS; ENCODES; FINGER; TRANSLOCATIONS	The ALL-1 gene is involved in human acute leukemia through chromosome translocations or internal rearrangements. ALL-1 is the human homologue of Drosophila trithorax. The latter is a member of the trithorax group (trx-G) genes which together with the Polycomb group (Pc-G) genes act as positive and negative regulators, respectively, to determine the body structure of Drosophila. We have cloned a novel human gene, ALR, which encodes a gigantic 5262 amino acid long protein containing a SET domain, five PHD fingers, potential zinc fingers, and a very long run of glutamines interrupted by hydrophobic residues, mostly leucine. The SET motif, PDH fingers, zinc fingers and two other regions are most similar to domains of ALL-1 and TRX. The first two motifs are also found in other trx-G and Pc-G proteins. The ALR gene was mapped to chromosome band 12q12-13, adjacent to the VDR gene. This region is involved in duplications and translocations associated with cancer. The analysis of ALR expression showed that its similar to 18 kb long mRNA is expressed, like ALL-1, in most adult tissues, including a variety of hematopoietic cells, with the exception of the liver. Whole mount in situ hybridization to early mouse embryos indicates expression in multiple tissues. Based on similarities in structure and expression pattern, ALR is likely to play a similar role to ALL-1 and trx, although its target genes have yet to be identified.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC INST,PHILADELPHIA,PA 19107	Weizmann Institute of Science; Jefferson University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [P01CA050507, R35CA039860] Funding Source: NIH RePORTER; NCI NIH HHS [CA39860, CA50507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; ASHAR HR, 1995, CELL, V82, P57; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BULFONE A, 1993, MECH DEVELOP, V40, P129, DOI 10.1016/0925-4773(93)90071-5; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHIANG A, 1995, DEVELOPMENT, V121, P1681; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Fasman KH, 1996, NUCLEIC ACIDS RES, V24, P57, DOI 10.1093/nar/24.1.57; FEARMAN A, 1993, DEVELOPMENT, V118, P919; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hermesz E, 1996, DEVELOPMENT, V122, P41; Hobert O, 1996, MECH DEVELOP, V55, P171, DOI 10.1016/0925-4773(96)00499-6; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JIANG JX, 1995, GENOMICS, V30, P91, DOI 10.1006/geno.1995.0015; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; Karlin S, 1996, P NATL ACAD SCI USA, V93, P1560, DOI 10.1073/pnas.93.4.1560; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KRAUTER K, 1995, NATURE, V377, P321; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; LONIE A, 1994, DEVELOPMENT, V120, P2629; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MILNER CM, 1993, BIOCHEM J, V290, P811, DOI 10.1042/bj2900811; MITELMAN F, 1994, CATALOG CHROMOSOME A; NOMURA M, 1994, DIFFERENTIATION, V57, P39, DOI 10.1046/j.1432-0436.1994.5710039.x; Oliver G, 1995, DEVELOPMENT, V121, P4045; OLIVER G, 1995, DEVELOPMENT, V121, P693; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; RAIMONDI SC, 1993, BLOOD, V81, P2237; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9337; SCHICHMAN SA, 1995, JAMA-J AM MED ASSOC, V273, P571, DOI 10.1001/jama.273.7.571; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SIDMAN RL, 1959, EXP NEUROL, V1, P322, DOI 10.1016/0014-4886(59)90024-X; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; THOMPSON KA, 1994, BIOCHEM BIOPH RES CO, V198, P1143, DOI 10.1006/bbrc.1994.1162; TILLIB S, 1995, MECH DEVELOP, V53, P113, DOI 10.1016/0925-4773(95)00429-7; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tripoulas N, 1996, GENETICS, V143, P913; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZHANDANOV AB, 1995, DEV DYNAM, V202, P354; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	62	78	82	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					549	560		10.1038/sj.onc.1201211	http://dx.doi.org/10.1038/sj.onc.1201211			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247308				2022-12-25	WOS:A1997XN25500006
J	Cai, JS; Gibbs, E; Uhlmann, F; Phillips, B; Yao, N; ODonnell, M; Hurwitz, J				Cai, JS; Gibbs, E; Uhlmann, F; Phillips, B; Yao, N; ODonnell, M; Hurwitz, J			A complex consisting of human replication factor C p40, p37, and p36 subunits is a DNA-dependent ATPase and an intermediate in the assembly of the holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-III HOLOENZYME; SINGLE-STRANDED-DNA; SACCHAROMYCES-CEREVISIAE; ACCESSORY PROTEINS; ESCHERICHIA-COLI; SLIDING CLAMPS; MULTIPLE FUNCTIONS; RF-C; DELTA	Human replication factor C (hRFC) is a multi-subunit protein complex capable of supporting proliferating cell nuclear antigen (PCNA) dependent DNA synthesis by DNA polymerases delta and epsilon. The hRFC complex consists of five different subunits with apparent molecular masses of 140, 40, 38, 37, and 36 kDa. We have previously reported the expression of a three-subunit core complex, consisting of the p40, p37, and p36 subunits following coupled in vitro transcription-translation of the cDNAs encoding these proteins (Uhlmann, F., Cai, J., Flores-Rozas, H., Dean, F. B., Finkelstein, J., O'Donnell, M., and Hurwitz, J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6521-6526). Here we describe the isolation of a stable complex composed of the p40, p37, and p36 subunits of hRFC from baculovirus-infected insect cells. The purified p40.p37.p36 complex, like the five-subunit RFC, contained DNA-dependent ATPase activity that was stimulated by PCNA, preferentially bound to primed DNA templates, interacted with PCNA, and was capable of unloading PCNA from singly nicked circular DNA. In contrast to the five subunit RFC, the three-subunit core complex did not load PCNA onto DNA. The p40.p37.p36 complex inhibited the elongation of primed DNA templates catalyzed by the DNA polymerase delta holoenzyme. Incubation of the p40.p37.p36 complex with the hRFC p140 and p38 subunits formed the five-subunit hRFC complex that supported PCNA-dependent DNA synthesis by DNA polymerase delta.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Rockefeller University				Uhlmann, Frank/0000-0002-3527-6619	NIGMS NIH HHS [GM 38559, GM 54705] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054705] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1988, P NATL ACAD SCI USA, V85, P9469, DOI 10.1073/pnas.85.24.9469; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PAN ZQ, 1993, P NATL ACAD SCI USA, V90, P6, DOI 10.1073/pnas.90.1.6; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; YODER BL, 1991, J BIOL CHEM, V266, P22689	33	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18974	18981		10.1074/jbc.272.30.18974	http://dx.doi.org/10.1074/jbc.272.30.18974			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228079	hybrid			2022-12-25	WOS:A1997XM34200070
J	GarzonRodriguez, W; SepulvedaBecerra, M; Milton, S; Glabe, CG				GarzonRodriguez, W; SepulvedaBecerra, M; Milton, S; Glabe, CG			Soluble amyloid A beta-(1-40) exists as a stable dimer at low concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; TIME-RESOLVED FLUORESCENCE; ALZHEIMERS-DISEASE; BETA-PEPTIDES; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; APOLIPOPROTEIN-E; PROTEIN; AGGREGATION; DEPOSITION	Recent studies have implicated the amyloid A beta peptide and its ability to self-assemble as key factors in the pathogenesis of Alzheimer's disease, Relatively little is known about the structure of soluble A beta or its oligomeric state, and the existing data are often contradictory, In this study, we used intrinsic fluorescence of wild type A beta-(1-40), fluorescence resonance energy transfer (FRET), and gel filtration chromatography to examine the structure of A beta-(1-40) in solution, We synthesized a series of mono-substituted fluorescent A beta-(1-40) derivatives to use as donors and accepters in FRET experiments, We selected fluorescent peptides that exhibit aggregation properties comparable to wild type A beta for analysis in donor-acceptor pairs; two labeled with 5-(2-((iodoacetyl)amino)ethyl)aminonaphthylene-1-sulfonic acid at Cys-25 or Cys-34 and fluorescein maleimide at Cys-4 or Cys-7, Another peptide containing a Trp substitution at position 10 was used as an acceptor for the intrinsic Tyr fluorescence of wild type A beta-(1-40). Equilibrium studies of the denaturation of A beta-(1-40) by increasing concentrations of dimethyl sulfoxide (Me2SO) were conducted by monitoring fluorescence, with a midpoint value for the unfolding transition of both the substituted and wild type peptides at among 40 and 50% Me2SO. A beta-(1-40) is well solvated and largely monomeric in Me2SO as evidenced by a lack of FRET, When donor and acceptor AP derivatives are mixed together in Me2SO and then diluted 10-fold into aqueous Tris-HCl buffer at pH 7.4, efficient FRET is observed immediately for all pairs of fluorescent peptides, indicating that donor-acceptor dimers exist in solution, FRET is abolished by the addition of an excess of unlabeled A beta-(1-40), demonstrating that the fluorescent peptides interact with wild type A beta-(1-40) to form heterodimers that do not exhibit FRET, The A beta-(1-40) dimers appear to be very stable, because no subunit exchange is observed after 24 h between fluorescent homodimers. Gel filtration confirms that nanomolar concentrations of C-14-labeled A beta-(1-40) and fluorescein-labeled A beta-(1-40) elute at the same dimeric position as wild type A beta-(1-40), suggesting that soluble A beta-(1-40) is also dimeric at more physiologically plausible concentrations.	UNIV CALIF IRVINE, DEPT MOL BIOL & BIOCHEM, IRVINE, CA 92696 USA; UNIV CALIF IRVINE, DEPT PSYCHOBIOL, IRVINE, CA 92696 USA; NATL AUTONOMOUS UNIV MEXICO, FAC QUIM, MEXICO CITY 04510, DF, MEXICO	University of California System; University of California Irvine; University of California System; University of California Irvine; Universidad Nacional Autonoma de Mexico					NINDS NIH HHS [NS31230] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; FRIEDEN C, 1985, ANNU REV BIOPHYS BIO, V14, P189, DOI 10.1146/annurev.bb.14.060185.001201; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HO GJ, 1994, FEBS LETT, V349, P151, DOI 10.1016/0014-5793(94)00663-6; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MAJOCHA RE, 1992, J NUCL MED, V33, P2184; MASTERS CL, 1987, CIBA F SYMP, V126, P49; MELY Y, 1994, BIOCHEMISTRY-US, V33, P12085, DOI 10.1021/bi00206a011; MIYAKAWA T, 1989, ANN MED, V21, P99, DOI 10.3109/07853898909149193; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SepulvedaBecerra MA, 1996, BIOCHEMISTRY-US, V35, P15915, DOI 10.1021/bi961548e; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SNOW AD, 1988, AM J PATHOL, V133, P456; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; STEVENS FJ, 1995, BIOCHEMISTRY-US, V34, P10697, DOI 10.1021/bi00034a001; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; TAYLOR DL, 1981, J CELL BIOL, V89, P362, DOI 10.1083/jcb.89.2.362; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; WANG YL, 1981, CELL, V27, P429, DOI 10.1016/0092-8674(81)90384-6; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; WU PG, 1994, BIOCHEMISTRY-US, V33, P7415, DOI 10.1021/bi00189a048; ZAGORSKI MG, 1992, BIOCHEMISTRY-US, V31, P5621, DOI 10.1021/bi00139a028	42	183	190	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21037	21044		10.1074/jbc.272.34.21037	http://dx.doi.org/10.1074/jbc.272.34.21037			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261105	hybrid			2022-12-25	WOS:A1997XR78900015
J	Tiganis, T; Flint, AJ; Adam, SA; Tonks, NK				Tiganis, T; Flint, AJ; Adam, SA; Tonks, NK			Association of the T-cell protein tyrosine phosphatase with nuclear import factor p97	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; SEQUENCE; LOCALIZATION; PURIFICATION; NUCLEOPORINS; EXPRESSION; RAN/TC4	Alternative splicing of the T-cell protein tyrosine phosphatase (TCPTP) transcript, generates two forms of the enzyme that differ at their extreme C termini: a 48-kDa endoplasmic reticulum-associated form and a 45-kDa nuclear form, By affinity chromatography, using GST-TCPTP fusion proteins, we have isolated three cytoplasmic proteins of 120, 116, and 97 kDa that interact with TCPTP, The p120 protein associated with residues 377-415 from the C terminus of the 48-kDa form of TCPTP, whereas the recognition site for p97 and p116 was mapped to residues 350-381 encompassing the TCPTP nuclear localization sequence (NLS). The TCPTP NLS was shown to be bipartite, requiring basic residues 350-358 (basic cluster I) and 377-381 (basic cluster II), the sites of interaction with p97 and p116, for efficient nuclear translocation, The interaction between p97, p116, and the TCPTP NLS appeared unique in that these proteins did not form a stable interaction with the classical NLS of SV40 large T antigen or the standard bipartite NLS of nucleoplasmin. Sequence analysis of p97 identified it as the nuclear import factor p97 (importin-beta), which is an essential component of the nuclear import machinery, In assays in vitro in permeabilized cells, p97 was necessary but not sufficient for optimal nuclear import of TCPTP, We found that TCPTP co-immunoprecipitated with the nuclear import factor p97 from cell lysates and that purified recombinant p97 and TCPTP interacted directly in vitro, These results indicate selectivity in the binding of p97 and p116 to the TCPTP NLS and suggest that p97 may mediate events that are distinct from the classical nuclear import process, Moreover, these results demonstrate that the C-terminal segment of TCPTP contains docking sites for interaction with proteins that may function to target the enzyme to defined intracellular locations and in the process regulate TCPTP function.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; NORTHWESTERN UNIV, SCH MED, CHICAGO, IL 60611 USA	Cold Spring Harbor Laboratory; Northwestern University			Tiganis, Tony/AAV-3495-2020	Tiganis, Tony/0000-0002-8065-9942; Adam, Stephen/0000-0003-3444-7655	NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P1203; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; CHI NC, 1997, IN PRESS MOL BIOL CE; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; PIXLEY FJ, 1995, J BIOL CHEM, V270, P27339, DOI 10.1074/jbc.270.45.27339; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	31	99	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21548	21557		10.1074/jbc.272.34.21548	http://dx.doi.org/10.1074/jbc.272.34.21548			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261175	hybrid			2022-12-25	WOS:A1997XR78900085
J	Zhao, RB; Seither, R; Brigle, KE; Sharina, IG; Wang, PJ; Goldman, ID				Zhao, RB; Seither, R; Brigle, KE; Sharina, IG; Wang, PJ; Goldman, ID			Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; METHOTREXATE TRANSPORT; TETRAHYDROFOLATE COFACTOR; DIHYDROFOLATE-REDUCTASE; MEDIATED TRANSPORT; BINDING PROTEINS; EXPRESSION; SENSITIVITY; SYSTEM; CDNA	Transport of reduced folates in murine leukemia cells is mediated by the bidirectional reduced folate carrier (RFC1) and independent unidirectional exit pumps, RFC1 has been proposed to be intrinsically equilibrating, generating transmembrane gradients by exchange with inorganic and organic anions. his paper defines the role of high level carrier expression, through transfection with RFC1 cDNA, on concentrative transport of the folate analog, methotrexate (MTX) in murine L1210 leukemia cells, RFC1 was expressed in the MTX(r)A line, which lacks a functional endogenous carrier to obtain the MTX(r)A-R16 clonal derivative, Influx was increased similar to 9-fold in MTX(r)A-R16 cells without a change in K-m. The efflux rate constant was increased by a factor of 5.1 relative to L1210 cells, and this resulted in only a a,l-fold increase in the steady-state level of free intracellular MTX, [MTX](i), when [MTX](e) was 1 mu M. The concentrative advantage for RFC1 (the ratio of [MTX](i) in MTX(r)A-R16 to L1210 cells) increased from 1.8 at 0.1 mu MTX to 3.8 at an [MTX](e) level of 30 mu M. Augmented transport in MTX(r)A-R16 cells was accompanied by a 2-fold increase in accumulation of MTX polyglutamate derivatives and a similar to 50% decrease in the EC50 for 5-formyltetrahydrofolate and folic acid and the MTX IC50 relative to L1210 cells. These alterations paralleled changes in [MTX], and not the much larger change in influx at low [MTX](e) levels, consistent with the critical role that free intracellular folates and drug play in meeting cellular needs for folates and as a determinant of antifolate activity, respectively, The data indicate that RFC1 produces a large and near symmetrical increase in the bidirectional fluxes of MTX resulting in only a small increase in the transmembrane chemical gradient at low extracellular folate levels, Hence, increased expression of RFC1, alone, may not be an efficient adaptive response to folate deprivation, and other factors may come into play to account for the marked increases in concentrative folate transport which occur when cells are subjected to low folate-selective pressure.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,ALBERT EINSTEIN CANC CTR,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Sharina, Iraida/C-9888-2014		NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39807] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DEMBO M, 1984, J MEMBRANE BIOL, V78, P9, DOI 10.1007/BF01872527; DIXON KH, 1994, J BIOL CHEM, V269, P17; FRY DW, 1982, J BIOL CHEM, V257, P1890; FRY DW, 1983, CANCER RES, V43, P1087; FYFE MJ, 1973, J BIOL CHEM, V248, P5067; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; GOLDMAN ID, 1977, CANCER TREAT REP, V61, P549; GOLDMAN ID, 1986, MEMBRANE TRANSPORT A, P283; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1987, BIOCHEM PHARMACOL, V36, P3007, DOI 10.1016/0006-2952(87)90216-4; HENDERSON GB, 1982, BIOCHEM BIOPH RES CO, V104, P474, DOI 10.1016/0006-291X(82)90661-1; HENDERSON GB, 1982, BIOCHEM INT, V4, P493; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V200, P149, DOI 10.1016/0003-9861(80)90341-0; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; JANSEN G, 1990, J BIOL CHEM, V265, P18272; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; MATHERLY LH, 1991, CANCER RES, V51, P3420; MOSCOW JA, 1995, CANCER RES, V55, P3790; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; Saxena M, 1996, BIOCHEM PHARMACOL, V51, P975, DOI 10.1016/0006-2952(96)00051-2; SCHLEMMER SR, 1992, J BIOL CHEM, V267, P14746; SCHUETZ JD, 1989, J BIOL CHEM, V264, P16261; SIROTNAK FM, 1984, J BIOL CHEM, V259, P3139; SIROTNAK FM, 1986, MEMBRANE TRANSPORT A, P241; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; Spinella MJ, 1996, BIOCHEM PHARMACOL, V52, P703, DOI 10.1016/0006-2952(96)00347-4; WHITE JC, 1981, J BIOL CHEM, V256, P5722; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067	39	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21207	21212		10.1074/jbc.272.34.21207	http://dx.doi.org/10.1074/jbc.272.34.21207			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261128	hybrid			2022-12-25	WOS:A1997XR78900038
J	Ikeda, Y; Tanaka, T; Noguchi, T				Ikeda, Y; Tanaka, T; Noguchi, T			Conversion of non-allosteric pyruvate kinase isozyme into an allosteric enzyme by a single amino acid substitution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL-TRANSPEPTIDASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; M-GENE; RAT; PHENYLALANINE; TRANSITION; EXPRESSION; EFFICIENT; RESIDUES	Pyruvate kinase M-1, a non-allosteric isozyme, was converted into an allosteric enzyme by replacement of an amino acid in the intersubunit contact. The substitution of Ala-398 with Arg resulted in the pronounced allosteric enzyme. The Hill coefficient and the substrate concentration giving one-half of V-max for the mutant with respect to phosphoenolpyruvate were 2.7 and 0.41 mM, respectively, whereas those values for the wild type were 1.0 and 0.049 nM. This mutation, however, gave rise to only minor effects on the apparent values of K-m for ADP and on V-max. Furthermore, in contrast to the wildtype enzyme, the mutant was activated by fructose 1,6-bisphosphate. The Hill coefficient of the mutant was no longer increased by the allosteric inhibitor, L-phenylalanine, indicating that the equilibrium for the unligated enzyme is largely shifted toward the T-state. These results suggest that Ala-398 is one of the most critical residues allowing the enzyme to prefer the R-state and that allosteric regulation of pyruvate kinase involves amino acid residues in the intersubunit contact.	FUKUI MED SCH,DEPT BIOCHEM,MATSUOKA,FUKUI 91002,JAPAN; OSAKA UNIV,SCH MED,DEPT NUTR & PHYSIOL CHEM,SUITA,OSAKA 565,JAPAN	University of Fukui; Osaka University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLINS RA, 1995, BIOCHEM J, V310, P117, DOI 10.1042/bj3100117; COLLINS RA, 1992, BIOCHEM SOC T, V21, pS63; CONSLER TG, 1990, BIOCHEMISTRY-US, V29, P10765, DOI 10.1021/bi00500a007; CONSLER TG, 1989, BIOCHEMISTRY-US, V28, P8756, DOI 10.1021/bi00448a012; CONSLER TG, 1992, BIOCHEMISTRY-US, V31, P7870, DOI 10.1021/bi00149a018; CROW VL, 1982, METHOD ENZYMOL, V90, P165, DOI 10.1016/S0076-6879(82)90122-7; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GARDENAS JM, 1982, METHOD ENZYMOL, V90, P140; GARDENAS JM, 1975, ISOZYMES, V1, P523; IBSEN KH, 1977, CANCER RES, V37, P341; IKEDA Y, 1995, P NATL ACAD SCI USA, V92, P126, DOI 10.1073/pnas.92.1.126; IKEDA Y, 1995, J BIOL CHEM, V270, P12471, DOI 10.1074/jbc.270.21.12471; IKEDA Y, 1995, J BIOL CHEM, V270, P22223, DOI 10.1074/jbc.270.38.22223; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; IMAMURA K, 1986, MARKERS HUMAN NEUROE, P191; KAHN A, 1982, METHOD ENZYMOL, V90, P131; KAYNE FJ, 1972, BIOCHEMISTRY-US, V11, P4415, DOI 10.1021/bi00773a031; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LONBERG N, 1983, P NATL ACAD SCI-BIOL, V80, P3661, DOI 10.1073/pnas.80.12.3661; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MALCOVATI M, 1982, METHOD ENZYMOL, V90, P170; Mattevi A, 1996, FEBS LETT, V389, P15, DOI 10.1016/0014-5793(96)00462-0; MATTEVI A, 1995, STRUCTURE, V3, P729, DOI 10.1016/S0969-2126(01)00207-6; MCNALLY T, 1990, BIOCHEM SOC T, V18, P258, DOI 10.1042/bst0180258; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; MUIRHEAD H, 1990, BIOCHEM SOC T, V18, P193, DOI 10.1042/bst0180193; MURCOTT THL, 1991, EUR J BIOCHEM, V198, P513, DOI 10.1111/j.1432-1033.1991.tb16044.x; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; OBERFELDER RW, 1984, BIOCHEMISTRY-US, V23, P3813, DOI 10.1021/bi00312a004; PIWNICAWORMS H, 1987, CURRENT PROTOCOLS MO; SCHERING B, 1982, BIOCHIM BIOPHYS ACTA, V717, P337, DOI 10.1016/0304-4165(82)90188-X; TAKENAKA M, 1991, EUR J BIOCHEM, V198, P101, DOI 10.1111/j.1432-1033.1991.tb15991.x; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; WALKER D, 1992, J MOL BIOL, V228, P265, DOI 10.1016/0022-2836(92)90505-E	38	64	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20495	20501		10.1074/jbc.272.33.20495	http://dx.doi.org/10.1074/jbc.272.33.20495			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252361	hybrid			2022-12-25	WOS:A1997XR22100031
J	Loetscher, H; Deuschle, U; Brockhaus, M; Reinhardt, D; Nelboeck, P; Mous, J; Grunberg, J; Haass, C; Jacobsen, H				Loetscher, H; Deuschle, U; Brockhaus, M; Reinhardt, D; Nelboeck, P; Mous, J; Grunberg, J; Haass, C; Jacobsen, H			Presenilins are processed by caspase-type proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; GENE; APOPTOSIS	Presenilin 1 (PS1) and presenilin 2 (PS2) are endoproteolytically processed in vivo and in cell transfectants to yield 27-35-kDa N-terminal and 15-24-kDa C-terminal fragments. We have studied the cleavage of PS1 and PS2 in transiently and stably transfected hamster kidney and mouse and human neuroblastoma cells by immunoblot and pulse-chase experiments. C terminal fragments were isolated by affinity chromatography and SDS-polyacrylamide gel electrophoresis and sequenced. The processing sites identified in PS1 and PS2 (Asp(345)/Ser(346) and Asp(329)/Ser(330), respectively) are typical for caspase-type proteases. Specific caspase inhibitors and cleavage site mutations confirmed the involvement of caspase(s) in PS1 and PS2 processing in cell transfectants. Fluorescent peptide substrates carrying the PS-identified cleavage sites were hydrolyzed by proteolytic activity from mouse brain. The PS2-derived peptide substrate was also cleaved by recombinant human caspase-3. Additional processing of PS2 by non-caspase-type proteases was also observed.	F HOFFMANN LA ROCHE & CO LTD,PRPN G,PRECLIN CENT NERVOUS SYST RES GENE TECHNOL,DIV PHARMA,CH-4070 BASEL,SWITZERLAND; CENT INST MENTAL HLTH,DEPT BIOL MOL,D-68159 MANNHEIM,GERMANY	Roche Holding; Central Institute of Mental Health								Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; Hartmann H, 1997, J BIOL CHEM, V272, P14505, DOI 10.1074/jbc.272.23.14505; Kim TW, 1997, J BIOL CHEM, V272, P11006; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TANZI RE, 1996, ALZHEIMERS DIS REV, V1, P90; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Ward RV, 1996, NEURODEGENERATION, V5, P293, DOI 10.1006/neur.1996.0040; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977	28	138	139	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20655	20659		10.1074/jbc.272.33.20655	http://dx.doi.org/10.1074/jbc.272.33.20655			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252383	hybrid			2022-12-25	WOS:A1997XR22100053
J	SchmidtRose, T; Jentsch, TJ				SchmidtRose, T; Jentsch, TJ			Reconstitution of functional voltage-gated chloride channels from complementary fragments of CLC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; EXPRESSION; MYOTONIA; MUTATIONS; RESIDUES; ANION; CFTR; RECEPTORS; DOMINANT; PERMEASE	We investigated the effect of truncations on the human muscle chloride channel CLC-1 and studied the functional complementation from partial proteins. Almost complete deletion of the cytoplasmic amino terminus did not affect currents, but truncating the intracellular COOH terminus after Leu(720) abolished function. Currents were restored by coexpressing this membrane-embedded part with the lacking cytoplasmic fragment that contains domain D13, the second of the two conserved cystathionine beta-synthase (CBS) motifs present in all eukaryotic CLC proteins. However, if the cut was after Gln(597) before the first CBS domain, no functional complementation was seen. Complementation was also obtained with channels ''split'' between transmembrane domains D7 and D8 or domains D8 and D9, but not when split between D10 and D11. Specificity of currents was tested by inserting point mutations in NH2-terminal (G188A and G230E) or COOH-terminal (K585E) fragments. In contrast to G188A and K585E, split channels did not tolerate the D136G mutation, suggesting that it may impede association from nonlinked fragments. Duplication, but not a lack of domain D8 was tolerated in ''split'' channels. Membrane domains D9-D12 can insert into the membrane without adding a preceding signal peptide to ensure the extracellular amino terminus of D9, Eventually, we succeeded in reconstituting CLC-1 channels from three separate polypeptides: the amino-terminal part up to D8, D9 through CBS1, and the remainder of the cytoplasmic carboxyl terminus. In summary, several regions of CLC channels behave autonomously regarding membrane insertion and folding and mediate protein-protein interactions strong enough to yield functional channels without a direct covalent link.	UNIV HAMBURG,CTR MOL NEUROBIOL HAMBURG,ZMNH,D-20246 HAMBURG,GERMANY	University of Hamburg				Jentsch, Thomas/0000-0002-3509-2553				AKABAS MH, 1994, J BIOL CHEM, V269, P14865; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; FAHLKE C, 1995, NEURON, V15, P463, DOI 10.1016/0896-6273(95)90050-0; GROVES JD, 1995, J BIOL CHEM, V270, P9097, DOI 10.1074/jbc.270.16.9097; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Lloyd SE, 1997, J CLIN INVEST, V99, P967, DOI 10.1172/JCI119262; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; LORENZ C, 1994, HUM MOL GENET, V3, P941, DOI 10.1093/hmg/3.6.941; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Maduke M., 1997, Biophysical Journal, V72, pA5; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; MEYERKLEINE C, 1995, AM J HUM GENET, V57, P1325; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; Morales MM, 1996, AM J PHYSIOL-RENAL, V270, pF1038, DOI 10.1152/ajprenal.1996.270.6.F1038; Ponting CP, 1997, J MOL MED-JMM, V75, P160; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; PUSCH M, 1995, NEURON, V15, P1; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; ZEN KH, 1994, BIOCHEMISTRY-US, V33, P8198, DOI 10.1021/bi00193a005	42	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20515	20521		10.1074/jbc.272.33.20515	http://dx.doi.org/10.1074/jbc.272.33.20515			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252364	hybrid			2022-12-25	WOS:A1997XR22100034
J	Brigstock, DR; Steffen, CL; Kim, GY; Vegunta, RK; Diehl, JR; Harding, PA				Brigstock, DR; Steffen, CL; Kim, GY; Vegunta, RK; Diehl, JR; Harding, PA			Purification and characterization of novel heparin-binding growth factors in uterine secretory fluids - Identification as heparin-regulated M-r 10,000 forms of connective tissue growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE-EXPRESSION; IMMEDIATE EARLY GENE; FIBROBLAST GROWTH; CELL-SURFACE; EGF-RECEPTOR; PIG; BLASTOCYST; SULFATE; IMPLANTATION; AMPHIREGULIN	Uterine growth factors are potential effector molecules in embryo growth signaling pathways. Pig uterine luminal flushings contained a heparin-binding growth factor (HBGF) that required 0.8 M NaCl for elution from heparin columns and was termed HBGF-0.8, This factor, which was heat- and acid-labile and of M-r 10,000 as assessed by gel filtration, stimulated DNA synthesis in fibroblasts and smooth muscle cells but not endothelial cells. Two forms of HBGF-0.8, termed HBGF-0.8-P1 and HBGF-0.8-P2, exhibited differential heparin-binding properties. SDS-polyacrylamide gel electrophoresis showed that each form of HBGF-0.8 migrated with an apparent M-r of 10,000 under reducing conditions, Amino acid sequencing revealed the N-terminal sequence EENIKKGKKXIRTPKI for HBGF-0.8-P1 and EENIKKGKKXIRT for HBGF-0.8-P2. These sequences corresponded, respectively, to residues 247-262 and 248-259 of the 349-residue predicted primary translation product of porcine connective tissue growth factor (pCTGF). 10-kDa CTGF-mediated fibroblast DNA synthesis was modulated by exogenous heparin, and CTGF-immunoreactive proteins of 10, 16, and 20 kDa were present in unfractionated uterine luminal flushings. These data reveal the identity of a novel growth factor in uterine fluids as a highly truncated form of CTGF and show that the N-terminal two-thirds of the CTGF primary translation product is not required for mitogenic activity or heparin binding.	OHIO STATE UNIV, DEPT SURG, COLUMBUS, OH 43205 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43205 USA; OHIO STATE UNIV, MOL CELLULAR & DEV BIOL PROGRAM, COLUMBUS, OH 43205 USA; CLEMSON UNIV, DEPT ANIM DAIRY & VET SCI, CLEMSON, SC 29634 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Clemson University	Brigstock, DR (corresponding author), CHILDRENS HOSP, WEXNER INST PEDIAT RES, DEPT SURG, DIV PEDIAT SURG, 700 CHILDRENS DR, COLUMBUS, OH 43205 USA.				NICHD NIH HHS [HD 30334] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD030334] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON LL, 1978, ANAT REC, V190, P143, DOI 10.1002/ar.1091900112; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; Besner GE, 1992, GROWTH FACTORS, V7, P289, DOI 10.3109/08977199209046411; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BRAY W, 1994, AM LAB, V26, P38; Brigstock DR, 1996, J ENDOCRINOL, V148, P103, DOI 10.1677/joe.0.1480103; Brigstock DR, 1996, J REPROD FERTIL, V108, P313; BRIGSTOCK DR, 1989, J REPROD FERTIL, V85, P747, DOI 10.1530/jrf.0.0850747; BRIGSTOCK DR, 1994, ASSIST REPROD TECHNO, V6, P252; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1995, J CELL PHYSIOL, V163, P418, DOI 10.1002/jcp.1041630222; CULLINGFORD TE, 1994, PROTOONCOGENES GROWT, P13; DARDIK A, 1992, DEV BIOL, V154, P396, DOI 10.1016/0012-1606(92)90078-U; DAS SK, 1994, DEVELOPMENT, V120, P1071; DIEHL JR, 1994, BIOL REPRODUCTION S1, V50, pA272; GEISERT RD, 1982, BIOL REPROD, V27, P925, DOI 10.1095/biolreprod27.4.925; GROTENDORST GR, 1996, J INVEST DERMATOL, V7, P469; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KIM GY, 1995, BIOL REPROD, V52, P561, DOI 10.1095/biolreprod52.3.561; LETCHER R, 1989, BIOL REPROD, V41, P1143, DOI 10.1095/biolreprod41.6.1143; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MURZIN AG, 1992, CURR OPIN STRUC BIOL, V2, P895; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; Pope WF, 1994, EMBRYONIC MORTALITY, P53; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBERTS RM, 1988, J REPROD FERTIL, V82, P875, DOI 10.1530/jrf.0.0820875; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOYAB M, 1991, METHOD ENZYMOL, V198, P213; SIMMEN FA, 1989, BIOCHEM SOC T, V17, P587, DOI 10.1042/bst0170587; SIMMEN RCM, 1990, ENDOCRINOLOGY, V127, P2166, DOI 10.1210/endo-127-5-2166; STEFFEN CL, 1993, MOL BIOL CELL S, V4, pA108; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Weich HA, 1990, GROWTH FACTORS, V2, P313, DOI 10.3109/08977199009078019; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	46	182	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20275	20282		10.1074/jbc.272.32.20275	http://dx.doi.org/10.1074/jbc.272.32.20275			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242708	hybrid			2022-12-25	WOS:A1997XQ05900095
J	Cowley, SM; Hoare, S; Mosselman, S; Parker, MG				Cowley, SM; Hoare, S; Mosselman, S; Parker, MG			Estrogen receptors alpha and beta form heterodimers on DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAINS; CRYSTAL-STRUCTURE; BINDING DOMAIN; IDENTIFICATION; EXPRESSION; CELLS; ASSAY	The estrogen receptor (ER) is expressed in two forms, ER alpha and ER beta. Here we show that ER alpha and ER beta, expressed both in vitro and in vivo, form heterodimers which bind to DNA with an affinity (K-d of approximately 2 nM) similar to that of ER alpha and greater than that of ER beta homodimers. Mutation analysis of the hormone binding domain of ER alpha suggests that the dimerization interface required to form heterodimers with ER beta is very similar but not identical to that required for homodimer formation, The heterodimer, like the homodimers, are capable of binding the steroid receptor coactivator-1 when bound to DNA and stimulating transcription of a reporter gene in transfected cells, Given the relative expression of ER alpha and ER beta in tissues and the difference in DNA binding activity between ER alpha/ER beta heterodimers and ER beta it seems Likely that the heterodimer is functionally active in a subset of target cells.	IMPERIAL CANC RES FUND,MOL ENDOCRINOL LAB,LONDON WC2A 3PX,ENGLAND; NV ORGANON,DEPT BIOTECHNOL & BIOCHEM,NL-5340 BH OSS,NETHERLANDS	Cancer Research UK; University of London; Queen Mary University London; Merck & Company				Cowley, Shaun/0000-0002-2510-1305				BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; LHorset F, 1996, MOL CELL BIOL, V16, P6029; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; ONATE SA, 1995, SCIENCE, V270, P1354; Parker M. G., 1995, V51, P267; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Shughrue PJ, 1996, STEROIDS, V61, P678, DOI 10.1016/S0039-128X(96)00222-X; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	30	553	580	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19858	19862		10.1074/jbc.272.32.19858	http://dx.doi.org/10.1074/jbc.272.32.19858			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242648	hybrid			2022-12-25	WOS:A1997XQ05900035
J	Kawada, M; Yamagoe, S; Murakami, Y; Suzuki, K; Mizuno, S; Uehara, Y				Kawada, M; Yamagoe, S; Murakami, Y; Suzuki, K; Mizuno, S; Uehara, Y			Induction of p27(Kip1) degradation and anchorage independence by Ras through the MAP kinase signaling pathway	ONCOGENE			English	Article						ras; anchorage independence; cell cycle; p27(Kip1)	CELL-CYCLE ARREST; PROTEIN-KINASE; G1 PHASE; POTENTIAL MEDIATOR; TRANSFORMED-CELLS; CDK6 INHIBITOR; GROWTH; PROGRESSION; ACTIVATION; LINKS	While most untransformed cells require substrate attachment for growth (anchorage dependence), the oncogenic transformed cells lack this requirement (anchorage independence) and are often tumorigenic. However, the mechanism of loss of anchorage dependence is not fully understood. When rat normal fibroblasts were cultured in suspension without substrate attachment, the cell cycle arrested in G1 phase and the cyclin-dependent kinase inhibitor p27(Kip1) protein and its mRNA accumulated. Conditional expression of oncogenic Ras induced the G1-S transition of the cell cycle and significantly shortened the half-life of p27(Kip1) protein without altering its mRNA level. Inhibition of the activation of mitogen-activated protein (MAP) kinase by cyclic AMP-elevating agents and a MEK inhibitor prevented the oncogenic Ras-induced degradation of p27(KiP1). These results suggest that the loss of substrate attachment induces the cell cycle arrest through the upregulation of p27(Kip1) mRNA, but the oncogenic Ras confers anchorage independence by accelerating p27(Kip1) degradation through the activation of the MAP kinase signaling pathway. Furthermore, we have found that p27(Kip1) is phosphorylated by MAP kinase in vitro and the phosphorylated p27(Kip1) cannot bind to and inhibit cdk2.	NATL INST HLTH,DEPT BIOACT MOL,SHINJUKU KU,TOKYO 162,JAPAN					Kawada, Manabu/0000-0001-9348-4240				BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FUKAZAWA H, 1995, ANAL BIOCHEM, V228, P83, DOI 10.1006/abio.1995.1318; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kang JS, 1996, MOL CELL BIOL, V16, P3370; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LOVEC H, 1994, ONCOGENE, V9, P323; Luo Y, 1996, MOL CELL BIOL, V16, P6744; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maki CG, 1996, CANCER RES, V56, P2649; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Nakajima T, 1996, J BIOL CHEM, V271, P24842, DOI 10.1074/jbc.271.40.24842; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SOUTHGATE J, 1995, BRIT J CANCER, V72, P1214, DOI 10.1038/bjc.1995.488; Spirin KS, 1996, CANCER RES, V56, P2400; Takeuchi S, 1996, CANCER RES, V56, P738; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Winston JT, 1996, ONCOGENE, V12, P127; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	56	180	184	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					629	637		10.1038/sj.onc.1201228	http://dx.doi.org/10.1038/sj.onc.1201228			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264403				2022-12-25	WOS:A1997XP68300002
J	Mauricio, L; Lima, LMTR; dePratGay, G				Mauricio, L; Lima, LMTR; dePratGay, G			Conformational changes and stabilization induced by ligand binding in the DNA-binding domain of the E2 protein from human papillomavirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FLUORESCENCE; RECOGNITION; HELIX	We are investigating the folding of the 81-residue recombinant dimeric DNA binding domain of the E2 protein from human papillomavirus and how it is coupled to the binding of its DNA ligand, Modifications in buffer composition, such as ionic strength and phosphate, cause an similar to 5.0 kcal mol(-1) stabilization of the domain to urea unfolding, based on very similar conformational changes as measured by far UV circular dichroism, Binding of DNA produces an even greater stabilization, magnitude similar to that caused by the nonspecific polymer ligand heparin, which shifts the urea midpoint 2.5-fold. The DNA-bound complex displays substantial changes similar to those caused by ionic strength and phosphate in terms of overall secondary structure, Bis-8-anilino-1-naphthalenesulfonate provides a very sensitive conformational probe, which shows alterations in the domain caused by the above mentioned compounds, In general terms, binding of DNA involves an overall conformational readjustment in the protein but maintains the beta-barrel scaffold intact, This conformational plasticity seems to be of importance in the regulatory functions of this type of DNA-binding protein, The extremely long half-life of the E2-DNA complex, together with its very high stability, suggests that, in the absence of other factors that may affect its stability in vivo, the possibility of dissociation once formed is restricted.	UNIV FED RIO DE JANEIRO, DEPT BIOQUIM MED, ICB, BR-21941590 RIO DE JANEIRO, BRAZIL	Universidade Federal do Rio de Janeiro			Lima, Luis Mauricio/AAL-2098-2021	Prat Gay, Gonzalo/0000-0001-5748-6863; TR Lima, Luis Mauricio/0000-0001-6020-0504				Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; Boren K, 1996, PROTEIN SCI, V5, P2479, DOI 10.1002/pro.5560051210; BROWN BM, 1990, BIOCHEMISTRY-US, V29, P11189, DOI 10.1021/bi00503a006; Butler W L, 1979, Methods Enzymol, V56, P501; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P849; Dean FB, 1996, CURR BIOL, V6, P931, DOI 10.1016/S0960-9822(02)00629-2; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HOWLEY PM, 1996, PAPILLOMAVIRINAE VIR, P2045; Kirk WR, 1996, BIOPHYS J, V70, P69, DOI 10.1016/S0006-3495(96)79592-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liang H, 1996, BIOCHEMISTRY-US, V35, P2095, DOI 10.1021/bi951932w; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; Mok YK, 1996, NAT STRUCT BIOL, V3, P711, DOI 10.1038/nsb0896-711; Mok YK, 1996, PROTEIN SCI, V5, P310; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PLOTKIN BJ, 1984, BIOCHEMISTRY-US, V23, P5353, DOI 10.1021/bi00317a038; RESTALL CJ, 1986, BIOCHIM BIOPHYS ACTA, V874, P305, DOI 10.1016/0167-4838(86)90029-4; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; SAHA R, 1992, J BIOL CHEM, V267, P5862; SANDERS CM, 1994, NUCLEIC ACIDS RES, V22, P4890, DOI 10.1093/nar/22.23.4890; SPALHOLZ BA, 1988, J VIROL, V62, P3143, DOI 10.1128/JVI.62.9.3143-3150.1988; Spronk CAEM, 1996, NAT STRUCT BIOL, V3, P916, DOI 10.1038/nsb1196-916; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TAYLOR I, 1994, DNA PROTEIN INTERACT, P327; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; WEBER G, 1954, BIOCHEM J, V56, pR31; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0	31	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19295	19303		10.1074/jbc.272.31.19295	http://dx.doi.org/10.1074/jbc.272.31.19295			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235925	hybrid			2022-12-25	WOS:A1997XP06300031
J	Stein, B; Yang, MX; Young, DB; Janknecht, R; Hunter, T; Murray, BW; Barbosa, MS				Stein, B; Yang, MX; Young, DB; Janknecht, R; Hunter, T; Murray, BW; Barbosa, MS			p38-2, a novel mitogen-activated protein kinase with distinct properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; NF-KAPPA-B; MAP KINASE; PHOSPHORYLATION; DOMAIN; IDENTIFICATION; TRANSCRIPTION; TRANSDUCTION; PATHWAYS; CASCADE	Mitogen-activated protein (MAP) kinases are involved in many cellular processes. Here we describe the cloning and characterization of a new MAP kinase, p38-2. p38-2 belongs to the p38 subfamily of MAP kinases and shares with it the TGY phosphorylation motif. The complete p38-2 cDNA was isolated by polymerase chain reaction. It encodes a 364-amino acid protein with 73% identity to p38, Two shorter isoforms missing the phosphorylation motif were identified. Analysis of various tissues demonstrated that p38-2 is differently expressed from p38. Highest expression levels were found in heart and skeletal muscle. Like p38, p38-2 is activated by stress-inducing signals and proinflammatory cytokines. The preferred upstream kinase is MEK6. Although p38-2 and p38 phosphorylate the same substrates, the site specificity of phosphorylation can differ as shown by two-dimensional phosphopeptide analysis of Sap-1a. Additionally, kinetic studies showed that p38-2 appears to be about 180 times more active than p38 on certain substrates such as ATF2. Both kinases are inhibited by a class of pyridinyl imidazoles. p38-2 phosphorylation of ATF2 and Sap-1a but not Elk1 results in increased transcriptional activity of these factors. A sequential kinetic mechanism of p38-2 is suggested by steady state kinetic analysis. In conclusion, p38-2 may be an important component of the stress response required for the homeostasis of a cell.	SALK INST,MOL BIOL & VIROL LAB,SAN DIEGO,CA 92186	Salk Institute	Stein, B (corresponding author), SIGNAL PHARMACEUT INC,5555 OBERLIN DR,SAN DIEGO,CA 92121, USA.			murray, brion/0000-0003-1591-2566; Janknecht, Ralf/0000-0003-1741-1562				Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cleland W W, 1979, Methods Enzymol, V63, P103; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COLE PA, 1994, J BIOL CHEM, V269, P30880; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SEGAL IH, 1975, ENZYME KINETICS BEHA, P643; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sen J, 1996, J IMMUNOL, V156, P4535; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Stein B, 1996, ANNU REP MED CHEM, V31, P289, DOI 10.1016/S0065-7743(08)60468-6; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; VANDERGEER, 1994, CELL BIOL LAB HDB, V3, P422; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	61	145	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19509	19517		10.1074/jbc.272.31.19509	http://dx.doi.org/10.1074/jbc.272.31.19509			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235954	hybrid			2022-12-25	WOS:A1997XP06300060
J	Collins, LR; Ricketts, WA; Olefsky, JM; Brown, JH				Collins, LR; Ricketts, WA; Olefsky, JM; Brown, JH			The G(12) coupled thrombin receptor stimulates mitogenesis through the Shc SH2 domain	ONCOGENE			English	Article						G alpha(12); Shc; AP-1; thrombin	INDUCE NEOPLASTIC TRANSFORMATION; NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL GROWTH-FACTOR; TYROSINE-KINASE; SIGNAL TRANSDUCTION; ASTROCYTOMA-CELLS; ADAPTER PROTEIN; RAS; ACTIVATION; PATHWAY	Our previous studies in 1321N1 astrocytoma cells demonstrate that thrombin stimulates Ras-dependent mitogenesis through the pertussis toxin insensitive G protein G(12). While the direct effecters of G(12) are unknown, G alpha(12) can transform fibroblasts, utilize Ras and Rac dependent signaling pathways and stimulate GTP loading of Ras. Here we have examined the role of the Shc adaptor protein in mitogenic signaling by the thrombin receptor in 1321N1 cells. As has been reported in other systems, thrombin stimulation results in tyrosine phosphorylation of Shc in 1321N1 cells. We also show that transient expression of G alpha(12) results in tyrosine phosphorylation of Shc, thereby identifying Shc as the most proximal G(12) effector to date. In addition, we demonstrate by microinjection that thrombin stimulated mitogenesis requires Shc and occurs specifically through the Shc SH2 domain. Expression of the SH2 domain of Shc also inhibits G alpha(12) mediated induction of an AP-1 dependent reporter gene demonstrating that G(12) utilizes Shc to propagate downstream signals. Our data indicate that Shc is essential for stimulation of Ras dependent mitogenesis and gene expression by the G(12) coupled thrombin receptor.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NIDDK NIH HHS [DK33651] Funding Source: Medline; NIGMS NIH HHS [F31 GM17277, GM36927] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927, R56GM036927, F31GM017277] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASU T, 1994, ONCOGENE, V9, P3483; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	33	28	30	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					595	600		10.1038/sj.onc.1201220	http://dx.doi.org/10.1038/sj.onc.1201220			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247313				2022-12-25	WOS:A1997XN25500011
J	Nathan, CAO; Liu, L; Li, BD; Abreo, FW; Nandy, I; DeBenedetti, A				Nathan, CAO; Liu, L; Li, BD; Abreo, FW; Nandy, I; DeBenedetti, A			Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer	ONCOGENE			English	Article						eIF4E; carcinomas; head and neck; surgical margins	SQUAMOUS-CELL CARCINOMA; EXPRESSION; OVEREXPRESSION; TRANSFORMATION; PROTOONCOGENE	Head and neck squamous cell cancers (HNSCC) have a high local recurrence rate due to incomplete tumor resection. The use of molecular markers to establish surgical margins may decrease local recurrence. Surgical margins are determined by histopathologic analysis on frozen sections, We postulate that genetic and molecular changes precede gross histologic alterations. Tumor markers may improve the reliability of pathology examination, but those evaluated to date lack the sensitivity needed for routine clinical use. Western blot analysis showed elevated eIF4E in all 26 HNSCC in contrast to its low expression in benign lesions. Surgical margins were analysed for eIF4E in 23 patients. Twelve patients showed elevated eIF4E in histologically negative margins. Cancer has recurred in 5 of the 12 patients as opposed to none of the 11 patients with eIF4E negative margins (P = 0.02, Log rank test). This is the first report of eIF4E in HNSCC, as a sensitive and specific marker for HNSCC, with potential for defining clear resection margins. The correlation between elevated levels of eIF4E at the margins and recurrence highlights its ability to detect malignant cells prior to clear-cut alterations in morphology, The accuracy and simplicity of these assays underscore the usefulness of eIF4E in managing HNSCC.	VAMC, SHREVEPORT, LA USA; LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOL BIOL, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, MED CTR, DEPT SURG, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, MED CTR, DEPT PATHOL, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, MED CTR, DEPT BIOMETRY & ACAD COMP, SHREVEPORT, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Nathan, CAO (corresponding author), LOUISIANA STATE UNIV, MED CTR, DEPT OTOLARYNGOL HEAD & NECK SURG, SHREVEPORT, LA 71130 USA.			de benedetti, arrigo/0000-0002-4198-8647	NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER; NCI NIH HHS [CA69148-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; BECHHARDT RN, 1995, ARCH OTOLARYNGOL, V121, P1265; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; DAVIDSON TM, 1981, OTOLARYNG HEAD NECK, V89, P244, DOI 10.1177/019459988108900219; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; FIELD JK, 1989, ONCOGENE, V4, P1463; Folkman J, 1976, Int Rev Exp Pathol, V16, P207; GANDOUREDWARDS RF, 1993, HEAD NECK-J SCI SPEC, V15, P373, DOI 10.1002/hed.2880150502; GILBERT H, 1974, J SURG ONCOL, V6, P357, DOI 10.1002/jso.2930060502; HARLOW E, 1988, ANTIBODIES LABORATOR, P403; JESSE RH, 1976, AM J SURG, V132, P435, DOI 10.1016/0002-9610(76)90314-7; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KIARIS H, 1995, BRIT J CANCER, V72, P123, DOI 10.1038/bjc.1995.287; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LOOSER KG, 1978, HEAD NECK SURG, V1, P107, DOI 10.1002/hed.2890010203; MAESTRO R, 1992, ONCOGENE, V7, P1159; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rousseau D, 1996, ONCOGENE, V13, P2415; SHANTZ LM, 1994, CANCER RES, V54, P2313; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3	23	157	167	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	1997	15	5					579	584		10.1038/sj.onc.1201216	http://dx.doi.org/10.1038/sj.onc.1201216			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247311				2022-12-25	WOS:A1997XN25500009
J	Chin, PL; Momand, J; Pfeifer, GP				Chin, PL; Momand, J; Pfeifer, GP			In vivo evidence for binding of p53 to consensus binding sites in the p21 and GADD45 genes in response to ionizing radiation	ONCOGENE			English	Article						p53; p21; GADD45; MDM2; radiation	LIGATION-MEDIATED PCR; CYCLE CHECKPOINT PATHWAY; DNA-DAMAGING AGENTS; P53-INDEPENDENT PATHWAY; GROWTH ARREST; WAF1/CIP1 EXPRESSION; METHYLATION ANALYSIS; CHROMATIN STRUCTURE; HUMAN FIBROBLASTS; G(1) ARREST	The tumor suppressor protein p53 has a transcriptional activation activity thought to mediate its biologic function including G(1) arrest and perhaps apoptosis, To learn more about p53's transactivator function in vivo, we performed genomic footprinting experiments examining p53-DNA interactions in the regulatory regions of the p53-regulated genes p21, GADD45, and MDM2. Using ionizing radiation to induce DNA damage in human ML-1 myeloblastic leukemia cells, the promoter and intronic regions of these genes containing p53-consensus binding sites were examined for in vivo footprints, There was a uniform and sustained expression of p53 protein as well as a strong induction of p21, GADD45, and MDM2 mRNA following irradiation, At the two p53 consensus binding sites in the p21 promoter, reduced DNaseI cleavage was observed in irradiated cells beginning 1 to 2 h after irradiation, being most checkpoints, pronounced after 2 h and diminishing after 8 h. A partial interest. in vivo footprint was also observed in the third intron of the GADD45 gene beginning 2 h after irradiation, No in vivo footprints were seen at the two p53 binding sites in the MDM2 gene, Our study provides direct evidence that the DNA damage-induced activity of p53 is mediated by its consensus DNA binding sites in the p21 and GADD45 genes, We suggest that the transient nature and relative instability of p53-DNA interactions in vivo may make the p53 protein more accessible to a rapid turnover pathway which might be impaired under conditions when the protein is stably bound to DNA.	CITY HOPE NATL MED CTR, DEPT BIOL, DUARTE, CA 91010 USA; CITY HOPE NATL MED CTR, DEPT CELL & TUMOR BIOL, DUARTE, CA 91010 USA	City of Hope; City of Hope			Momand, Jamil/F-8154-2012		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006070, R37ES006070] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06070] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; Bae I, 1996, CANCER RES, V56, P840; BAE IS, 1995, CANCER RES, V55, P2387; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARPER JW, 1993, CELL, V75, P805; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANDERS JE, 1994, ONCOGENE, V9, P2745; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU M, 1995, ONCOGENE, V10, P1955; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maxam A M, 1980, Methods Enzymol, V65, P499; Mayo LD, 1996, ONCOGENE, V13, P2315; MICHIELI P, 1994, CANCER RES, V54, P3391; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; Momand J, 1997, J CELL BIOCHEM, V64, P343; MOSNER J, 1994, ONCOGENE, V9, P3321; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pfeifer G P, 1992, PCR Methods Appl, V2, P107; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P567; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; Pfeifer GP, 1996, MOL BIOTECHNOL, V5, P281, DOI 10.1007/BF02900367; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRICE BD, 1994, CANCER RES, V54, P896; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TORMANEN VT, 1992, NUCLEIC ACIDS RES, V20, P5487, DOI 10.1093/nar/20.20.5487; TORMANEN VT, 1992, ONCOGENE, V7, P1729; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755	67	68	70	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					87	99		10.1038/sj.onc.1201161	http://dx.doi.org/10.1038/sj.onc.1201161			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233781				2022-12-25	WOS:A1997XH58600010
J	Crawford, EK; Ensor, JE; Kalvakolanu, I; Hasday, JD				Crawford, EK; Ensor, JE; Kalvakolanu, I; Hasday, JD			The role of 3' poly(A) tail metabolism in tumor necrosis factor-alpha regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSLATION; UNTRANSLATED REGION; MEIOTIC MATURATION; ESCHERICHIA-COLI; PROTECTS MICE; MOUSE OOCYTES; TNF-ALPHA; EXPRESSION; CACHECTIN; ENDOTOXIN	In unstimulated RAW 264.7 macrophage-like cells, tumor necrosis factor-alpha (TNF-alpha) mRNA was transcribed and accumulated in the cytoplasm, but the TNF-alpha transcripts failed to associate with polysomes, and TNF-alpha protein was not detected. Stimulation with lipopolysaccharide(LPS) induced an increase in TNF-alpha transcription, cytoplasmic TNF-alpha mRNA accumulation, polysome association, and secretion of TNF-alpha protein, This process was associated with a 200-nucleotide increase in the apparent length of the TNF-alpha mRNA. The difference in TNF-alpha mRNA size was caused by marked truncation of the 3' poly(A) tail in unstimulated cells. Fully adenylated TNF-alpha mRNA appeared within 15 min of LPS stimulation, We speculate that removal of the poly(A) tail blocks initiation of TNF-alpha translation in unstimulated macrophages LPS inactivates this process, allowing synthesis of translatable polyadenylated TNF-alpha mRNA.	BALTIMORE VA MED CTR, MED SERV, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT MED, DIV PULM & CRIT CARE MED, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT PATHOL, DIV PULM & CRIT CARE MED, BALTIMORE, MD 21201 USA; UNIV MARYLAND, BALTIMORE CYTOKINE CARE LAB, BALTIMORE, MD 21201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore					NCI NIH HHS [R29 CA52751] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANDYOPADHYAY R, 1990, MOL CELL BIOL, V10, P2060, DOI 10.1128/MCB.10.5.2060; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1995, J INVEST MED, V43, P227; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1990, ONCOGENESIS, V2, P9; BIRAGYN A, 1995, J IMMUNOL, V155, P674; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOLLETMARTIN S, 1992, AM REV RESPIR DIS, V146, P990, DOI 10.1164/ajrccm/146.4.990; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; CRAWFORD EK, 1994, AM J RESP CRIT CARE, V149, pA716; CROSS A, 1995, J CLIN INVEST, V96, P676, DOI 10.1172/JCI118110; CROSS AS, 1989, J EXP MED, V169, P2021, DOI 10.1084/jem.169.6.2021; DEMARCO R, 1992, CELL IMMUNOL, V140, P304, DOI 10.1016/0008-8749(92)90198-X; ENSOR JE, 1995, AM J PHYSIOL, V269, pC1440; FOX CA, 1992, EMBO J, V11, P5021, DOI 10.1002/j.1460-2075.1992.tb05609.x; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; HASKILL S, 1988, J IMMUNOL, V140, P1690; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JONGENEEL CV, 1989, EUR J IMMUNOL, V19, P549; JONGENEEL CV, 1995, IMMUNOBIOLOGY, V193, P210, DOI 10.1016/S0171-2985(11)80545-0; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; MULLER WEG, 1976, EUR J BIOCHEM, V70, P241, DOI 10.1111/j.1432-1033.1976.tb10975.x; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; NEDOSPASOV SA, 1986, NUCLEIC ACIDS RES, V14, P7713, DOI 10.1093/nar/14.19.7713; OSIPOVICH OA, 1993, J IMMUNOL, V150, P4958; PARIS J, 1990, DEV BIOL, V140, P221, DOI 10.1016/0012-1606(90)90070-Y; PENNICA D, 1985, P NATL ACAD SCI USA, V82, P6060, DOI 10.1073/pnas.82.18.6060; POKHOLOK DK, 1995, P NATL ACAD SCI USA, V92, P674, DOI 10.1073/pnas.92.3.674; PRADA J, 1993, INFECT IMMUN, V61, P2737, DOI 10.1128/IAI.61.6.2737-2740.1993; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIDHU RS, 1993, PHARMACOL THERAPEUT, V57, P79, DOI 10.1016/0163-7258(93)90037-E; ULICH TR, 1991, AM J PATHOL, V138, P1485; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; VOURNAKIS JN, 1975, P NATL ACAD SCI USA, V72, P2959, DOI 10.1073/pnas.72.8.2959; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WALLER SJ, 1993, REGUL PEP, P37; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; YENOFSKY R, 1982, P NATL ACAD SCI-BIOL, V79, P5876, DOI 10.1073/pnas.79.19.5876	46	62	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21120	21127		10.1074/jbc.272.34.21120	http://dx.doi.org/10.1074/jbc.272.34.21120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261116	hybrid			2022-12-25	WOS:A1997XR78900026
J	Jung, DW; Bradshaw, PC; Pfeiffer, DR				Jung, DW; Bradshaw, PC; Pfeiffer, DR			Properties of a cyclosporin-insensitive permeability transition pore in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-TRANSPORT PROTEIN; INNER-MEMBRANE; CA-2+ RELEASE; SACCHAROMYCES-CEREVISIAE; CONDUCTANCE CHANNEL; HEART-MITOCHONDRIA; RUTHENIUM RED; CELL LINE; ATP; CALCIUM	Yeast mitochondria (Saccharomyces cerevisiae) contain a permeability transition pore which is regulated differently than the pore in mammalian mitochondria. In a mannitol medium containing 10 mM P-i and ethanol (oxidizable substrate), yeast mitochondria accumulate large amounts of Ca2+ (>400 nmol/mg of protein) upon the addition of an electrophoretic Ca2+ ionophore (ETH129). Pore opening does not occur following Ca2+ uptake, even though ruthenium red-inhibited rat liver mitochondria undergo rapid pore opening under analogous conditions. However, a pore does arise in yeast mitochondria when Ca2+ and P-i are not present, as monitored by swelling, ultrastructure, and matrix solute release, Pore opening is slow unless a respiratory substrate is provided (ethanol or NADH) but also occurs rapidly in response to ATP (2 mM) when oligomycin is present, P-i and ADP inhibit pore opening (EC50 similar to 1 and 4 mar, respectively), however, cyclosporin A (7 mu g/ml), oligomycin (20 mu g/ml), or carboxyatractyloside (25 mu M) have no effect. The pare arising during respiration is also inhibited by nigericin or uncoupler, indicating that an acidic matrix pH antagonizes the process, P-i also inhibits pore opening by lowering the matrix pH (P-i/OH- antiport), However, inhibition of the ATP-induced pore by P-i is seen in the presence of mersalyl, suggesting a second mechanism of action. Since pore induction by ATP is not sensitive to carboxyatractyloside, ATP appears to act at an external site and P-i may antagonize the interaction. Isoosmotic polyethylene glycol-induced contraction of yeast mitochondria swollen during respiration, or in the presence of ATP, is 50% effective at a solute size of 1.0-1.1 kDa. This suggests that the same pore is induced in bath cases and is comparable in size with the permeability transition pore of heart and Liver mitochondria.			Jung, DW (corresponding author), OHIO STATE UNIV,DEPT MED BIOCHEM,333 HAMILTON HALL,COLUMBUS,OH 43210, USA.		Bradshaw, Patrick C./AAR-9189-2020	Bradshaw, Patrick C./0000-0002-4591-6798	NHLBI NIH HHS [HL49182] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049182] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERMAN KEO, 1976, FEBS LETT, V68, P191, DOI 10.1016/0014-5793(76)80434-6; ALTSCHULD RA, 1992, AM J PHYSIOL, V262, pH1699, DOI 10.1152/ajpheart.1992.262.6.H1699; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BALLARIN C, 1995, J BIOL CHEM, V270, P19262, DOI 10.1074/jbc.270.33.19262; BEATRICE MC, 1982, J BIOL CHEM, V257, P7161; BEAUVOIT B, 1989, FEBS LETT, V244, P255, DOI 10.1016/0014-5793(89)80539-3; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; CARAFOLI E, 1970, BIOCHIM BIOPHYS ACTA, V205, P18, DOI 10.1016/0005-2728(70)90057-5; CARONI P, 1977, BIOCHIM BIOPHYS ACTA, V470, P437, DOI 10.1016/0005-2736(77)90134-1; CHAVEZ E, 1990, J BIOENERG BIOMEMBR, V22, P679, DOI 10.1007/BF00809071; DAUM G, 1982, J BIOL CHEM, V257, P3028; DAVIS ES, 1992, P NATL ACAD SCI USA, V89, P11169, DOI 10.1073/pnas.89.23.11169; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; GUERIN B, 1990, J BIOL CHEM, V265, P19736; GUERIN B, 1994, J BIOL CHEM, V269, P25406; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; Kakhniashvili D, 1997, J BIOL CHEM, V272, P4516, DOI 10.1074/jbc.272.7.4516; KASS GEN, 1992, BIOCHEM PHARMACOL, V44, P1995, DOI 10.1016/0006-2952(92)90102-O; KINNALLY KW, 1993, P NATL ACAD SCI USA, V90, P1374, DOI 10.1073/pnas.90.4.1374; KOLAROV J, 1972, BIOCHIM BIOPHYS ACTA, V267, P457, DOI 10.1016/0005-2728(72)90173-9; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; LEQUOC K, 1985, J BIOL CHEM, V260, P7422; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOHRET TA, 1995, J BIOL CHEM, V270, P15950, DOI 10.1074/jbc.270.27.15950; LOHRET TA, 1995, BIOPHYS J, V68, P2299, DOI 10.1016/S0006-3495(95)80412-1; MANON S, 1995, BBA-BIOENERGETICS, V1231, P282, DOI 10.1016/0005-2728(95)00088-Z; MANON S, 1993, J BIOENERG BIOMEMBR, V25, P671; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; MCGUINNESS O, 1990, EUR J BIOCHEM, V194, P671, DOI 10.1111/j.1432-1033.1990.tb15667.x; MIYASHITA T, 1993, BLOOD, V81, P151; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; NOVGORODOV SA, 1987, J BIOENERG BIOMEMBR, V19, P191, DOI 10.1007/BF00762412; OHNISHI T, 1966, J BIOL CHEM, V241, P1797; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; PON L, 1991, MOL CELLULAR BIOL YE, V1, P333; PRESTIPINO G, 1993, ANAL BIOCHEM, V210, P119, DOI 10.1006/abio.1993.1160; Prieto S, 1996, ARCH BIOCHEM BIOPHYS, V334, P43, DOI 10.1006/abbi.1996.0427; PRIETO S, 1995, BIOCHEM J, V307, P657, DOI 10.1042/bj3070657; RAININA EI, 1980, HISTOCHEM J, V12, P57, DOI 10.1007/BF01066537; RILEY WW, 1985, J BIOL CHEM, V260, P2416; RITOV VB, 1993, BIOCHIM BIOPHYS ACTA, V1148, P257, DOI 10.1016/0005-2736(93)90137-O; ROUCOU X, 1995, FEBS LETT, V364, P161, DOI 10.1016/0014-5793(95)00380-R; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SCARPA A, 1978, BIOCHEMISTRY-US, V17, P1378, DOI 10.1021/bi00601a004; Stevens B., 1981, MOL BIOL YEAST SACCH, V11, P471; SZABO I, 1995, BBA-BIOMEMBRANES, V1235, P115, DOI 10.1016/0005-2736(94)00306-A; VELOURS J, 1977, FEBS LETT, V81, P18, DOI 10.1016/0014-5793(77)80918-6; VERCESI AE, 1984, ARCH BIOCHEM BIOPHYS, V232, P86, DOI 10.1016/0003-9861(84)90523-X; VODYANOY I, 1993, BIOPHYS J, V65, P2097, DOI 10.1016/S0006-3495(93)81245-1; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	67	119	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21104	21112		10.1074/jbc.272.34.21104	http://dx.doi.org/10.1074/jbc.272.34.21104			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261114	hybrid			2022-12-25	WOS:A1997XR78900024
J	Kim, B; Leventhal, PS; Saltiel, AR; Feldman, EL				Kim, B; Leventhal, PS; Saltiel, AR; Feldman, EL			Insulin-like growth factor-I-mediated neurite outgrowth in vitro requires mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; MAP KINASE; SIGNAL-TRANSDUCTION; BLASTOMA CELLS; PC12 CELLS; IGF-I; C-MYC; NEURONAL DIFFERENTIATION; EXPRESSION; RECEPTOR	Insulin-like growth factor-I (IGF-I) induces neuronal differentiation in vitro. In the present study, we examined the signaling pathway underlying IGF-I-mediated neurite outgrowth. In SH-SY5Y human neuroblastoma cells, treatment with IGF-I induced concentration- and time-dependent tyrosine phosphorylation of the type I IGF receptor (IGF-IR) and extracellular signal-regulated protein kinases (ERK) 1 and 2. These effects of IGF-I were blocked by a neutralizing antibody against IGF-IR. Whereas IGF-IR phosphorylation was observed within 1 min, maximal phosphorylation of ERKs was not reached for 30 min. Both IGF-IR and ERK phosphorlyation were maintained for at least 24 h. Also, the concentration dependence of IGF-I-stimulated IGF-IR and ERK tyrosine phosphorylation paralleled that of IGF-I-mediated neurite outgrowth. We further examined the role of mitogen-activated protein kinase activation in IGF-I-stimulated neuronal differentiation using the mitogen-activated protein kinase-ERK kinase inhibitor PD98059. Whereas PD98059 had no effect on IGF-IR phosphorylation, PD98059 reduced IGF-I-mediated ER tyrosine phosphorylation and ERK phosphorylation of the substrate Elk-1. PD98059 also produced a parallel reduction of IGF-I-stimulated neurite outgrowth. Finally, consistence with its ability to block neuronal differentiation, PD98059 inhibited IGF-I-dependent changes of GAp-43 and c-myc gene expression. Together these results suggest that activation of ERKs is essential for IGF-I-stimulated neuronal differentiation.	UNIV MICHIGAN, DEPT NEUROL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, NEUROSCI PROGRAM, ANN ARBOR, MI 48109 USA; SUNY HLTH SCI CTR, DEPT ANAT & CELL BIOL, SYRACUSE, NY 13210 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Pfizer			Saltiel, Alan/L-3632-2019	Feldman, Eva/0000-0002-9162-2694; Saltiel, Alan/0000-0002-9726-9828	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009912, R29NS032843] Funding Source: NIH RePORTER; NINDS NIH HHS [F32 NS09912, R29 NS32843] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; CHUANG CF, 1994, FEBS LETT, V346, P229, DOI 10.1016/0014-5793(94)00480-3; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FELDMAN EL, 1991, BRAIN RES, V562, P111, DOI 10.1016/0006-8993(91)91194-6; FELDMAN EL, 1993, ANN NY ACAD SCI, V692, P262; HAMMERLING U, 1987, ONCOGENE, V2, P73; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; JALAVA AM, 1988, EXP CELL RES, V179, P10, DOI 10.1016/0014-4827(88)90343-6; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KATO H, 1993, J BIOL CHEM, V268, P2655; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; Kim Bhumsoo, 1996, Molecular Biology of the Cell, V7, p342A; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; LEVENTHAL PS, 1995, EXP CELL RES, V221, P179, DOI 10.1006/excr.1995.1365; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN DM, 1993, J CELL PHYSIOL, V155, P290, DOI 10.1002/jcp.1041550210; MARTIN DM, 1992, MOL BRAIN RES, V15, P241, DOI 10.1016/0169-328X(92)90114-Q; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOZELL RL, 1991, J NEUROSCI RES, V30, P382, DOI 10.1002/jnr.490300214; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; OLIVER BL, 1995, P SOC EXP BIOL MED, V210, P162; PAHLMAN S, 1991, P NATL ACAD SCI USA, V88, P9994, DOI 10.1073/pnas.88.22.9994; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RECIOPINTO E, 1984, BRAIN RES, V302, P323, DOI 10.1016/0006-8993(84)90246-4; RECIOPINTO E, 1986, J NEUROSCI, V6, P1211; SETH A, 1992, J BIOL CHEM, V267, P24796; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SUMANTRAN VN, 1993, ENDOCRINOLOGY, V132, P2017, DOI 10.1210/en.132.5.2017; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANOBBERGHEN E, 1994, DIABETOLOGIA, V37, pS125, DOI 10.1007/BF00400836; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZACKENFELS K, 1995, NEURON, V14, P731, DOI 10.1016/0896-6273(95)90217-1	45	143	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21268	21273		10.1074/jbc.272.34.21268	http://dx.doi.org/10.1074/jbc.272.34.21268			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261137	hybrid			2022-12-25	WOS:A1997XR78900047
J	Demmer, A; Thole, H; Kubesch, P; Brandt, T; Raida, M; Fislage, R; Tummler, B				Demmer, A; Thole, H; Kubesch, P; Brandt, T; Raida, M; Fislage, R; Tummler, B			Localization of the iodomycin binding site in hamster P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANT CELLS; PREDICTED TRANSMEMBRANE DOMAIN; PEROXISOMAL MEMBRANE-PROTEIN; N-TERMINAL DOMAIN; FUNCTIONAL CONSEQUENCES; MONOCLONAL-ANTIBODIES; SUBSTRATE-SPECIFICITY; CHEMICAL CLEAVAGE; MULTIPLE-MYELOMA; ESCHERICHIA-COLI	P-glycoprotein, the overexpression of which is a major cause for the failure of cancer chemotherapy in man, recognizes and transports a broad range of structurally unrelated amphiphilic compounds, This study reports on the localization of the binding site of P-glycoprotein for iodomycin, the Bolton-Hunter derivative of the anthracycline daunomycin. Plasma membrane vesicles isolated from multidrug-resistant Chinese hamster ovary B30 cells were photolabeled with [I-125]iodomycin. After chemical cleavage behind the tryptophan residues, I-125-labeled peptides were separated by electrophoresis and high performance liquid chromatography. Edman sequencing revealed that [I-125]iodomycin had been predominantly incorporated into the fragment 230-312 of isoform I of hamster P-glycoprotein. According to models based on hydropathy plots, the amino acid sequence 230-312 forms the distal part of transmembrane segment 4, the second cytoplasmic loop, and the proximal part of transmembrane segment 5 in the N-terminal half of P-glycoprotein. The binding site for iodomycin is recognized with high affinity by vinblastine and cyclosporin A.	HANNOVER MED SCH,ZENTRUM KINDERHEILKUNDE,D-30623 HANNOVER,GERMANY; MAX PLANCK INST EXPT ENDOKRINOL,D-30625 HANNOVER,GERMANY; NIEDERSACHS INST PEPTIDFORSCH,D-30625 HANNOVER,GERMANY	Hannover Medical School; Max Planck Society	Demmer, A (corresponding author), HANNOVER MED SCH,KLIN FORSCHERGRP,ZENTRUM BIOCHEM,OE 4350,CARL NEUBERG STR 1,D-30623 HANNOVER,GERMANY.							Ayesh S, 1996, BBA-MOL BASIS DIS, V1316, P8, DOI 10.1016/0925-4439(96)00008-7; BEJA O, 1995, J BIOL CHEM, V270, P12351; BIBI E, 1994, J BIOL CHEM, V269, P19910; Boer R, 1996, BIOCHEMISTRY-US, V35, P1387, DOI 10.1021/bi951912u; BOKENKAMP D, 1994, MOL CELL ENDOCRINOL, V104, P163, DOI 10.1016/0303-7207(94)90119-8; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSCHE R, 1989, MOL PHARMACOL, V35, P414; BUSCHE R, 1989, EUR J BIOCHEM, V183, P189, DOI 10.1111/j.1432-1033.1989.tb14912.x; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V34, P2115; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P849; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CRIMMINS DL, 1990, ANAL BIOCHEM, V187, P27, DOI 10.1016/0003-2697(90)90412-3; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415; Demmer A, 1996, EUR J PHARMACOL, V315, P339, DOI 10.1016/S0014-2999(96)00616-4; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOXWELL BMJ, 1989, MOL PHARMACOL, V36, P543; FRICHE E, 1993, BRIT J CANCER, V67, P226, DOI 10.1038/bjc.1993.44; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GLOSSMANN H, 1987, TRENDS PHARMACOL SCI, V8, P95, DOI 10.1016/0165-6147(87)90082-4; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GREENBERGER LM, 1991, J BIOL CHEM, V266, P20744; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOFMANN J, 1995, BIOCHEM PHARMACOL, V49, P603, DOI 10.1016/0006-2952(94)00479-6; HOOF T, 1994, J BIOL CHEM, V269, P20575; JURANKA PF, 1989, FASEB J, V3, P2588; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; KOSTER W, 1992, MOL GEN GENET, V232, P399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1993, J BIOL CHEM, V268, P19965; MORGAN JH, 1991, BIOTECHNIQUES, V11, P256; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; SAFA AR, 1993, CANCER INVEST, V11, P46, DOI 10.3109/07357909309020260; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SAURIN W, 1994, MOL MICROBIOL, V12, P993, DOI 10.1111/j.1365-2958.1994.tb01087.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shan N, 1996, J BIOL CHEM, V271, P8725, DOI 10.1074/jbc.271.15.8725; SHANI N, 1995, P NATL ACAD SCI USA, V92, P6012, DOI 10.1073/pnas.92.13.6012; Shao YM, 1997, BBA-MOL BASIS DIS, V1360, P30, DOI 10.1016/S0925-4439(96)00065-8; SHECHTER Y, 1976, BIOCHEMISTRY-US, V15, P5071, DOI 10.1021/bi00668a019; SKACH WR, 1993, J BIOL CHEM, V268, P69603; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; SONNEVELD P, 1992, LANCET, V340, P255, DOI 10.1016/0140-6736(92)92353-H; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TAMAI I, 1990, J BIOL CHEM, V265, P16509; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZHANG JT, 1993, J BIOL CHEM, V268, P15101; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	69	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20913	20919		10.1074/jbc.272.33.20913	http://dx.doi.org/10.1074/jbc.272.33.20913			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252419	hybrid			2022-12-25	WOS:A1997XR22100089
J	Zhang, Y; Wisner, A; Maroun, RC; Choumet, V; Xiong, YL; Bon, C				Zhang, Y; Wisner, A; Maroun, RC; Choumet, V; Xiong, YL; Bon, C			Trimeresurus stejnegeri snake venom plasminogen activator - Site-directed mutagenesis and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; PROTEOLYTIC-ENZYMES; SERINE PROTEASES; THROMBIN; CLONING; CDNA; BATROXOBIN; EXPRESSION; UROKINASE; SEQUENCE	The specific plasminogen activator from Trimeresurus stejnegeri venom (TSV-PA) is a serine proteinase presenting 23% sequence identity with the proteinase domain of tissue type plasminogen activator, and 63% with batroxobin, a fibrinogen clotting enzyme from Bothrops atrox venom that does not activate plasminogen. TSV-PA contains six disulfide bonds and has been successfully overexpressed in Escherichia coli (Zhang, Y., Wisner, A., Xiong, Y. L,, and Bon, C, (1995) J. Biol. Chem. 270, 10246-10255), To identify the functional domains of TSV-PA, we focused on three short peptide fragments of TSV-PA showing important sequence differences with batroxobin and other venom serine proteinases. Molecular modeling shows that these sequences are located in surface loop regions, one of which is next to the catalytic site, When these sequences were replaced in TSV-PA by the equivalent batroxobin residues none generated either fibrinogen-clotting or direct fibrinogenolytic activity, Two of the replacements had little effect in general and are not critical to the specificity of TSV-PA for plasminogen. Nevertheless, the third replacement, produced by the conversion of the sequence DDE 96a-98 to NVI, significantly increased the K-m for some tripeptide chromogenic substrates and resulted in undetectable plasminogen activation, indicating the key role that the sequence plays in substrate recognition by the enzyme.	INST PASTEUR,UNITE VENINS,F-75724 PARIS 15,FRANCE; CHINESE ACAD SCI,KUNMING INST ZOOL,KUNMING 650223,PEOPLES R CHINA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Chinese Academy of Sciences; Kunming Institute of Zoology			maroun, rachid c/T-1549-2019; Maroun, Rachid C/B-3311-2014	maroun, rachid c/0000-0002-8124-815X; Maroun, Rachid C/0000-0002-8124-815X; Zhang, Yun/0000-0002-8636-183X				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHOUMET V, 1989, FEBS LETT, V244, P167, DOI 10.1016/0014-5793(89)81185-8; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; HESSEL B, 1971, FEBS LETT, V18, P318, DOI 10.1016/0014-5793(71)80476-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; ITOH N, 1987, J BIOL CHEM, V262, P3132; ITOH N, 1988, J BIOL CHEM, V263, P7628; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MAEDA M, 1991, J BIOCHEM-TOKYO, V109, P632, DOI 10.1093/oxfordjournals.jbchem.a123432; MCMULLEN BA, 1989, BIOCHEMISTRY-US, V28, P674, DOI 10.1021/bi00428a039; NEURATH H, 1985, FED PROC, V44, P2907; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NIKAI T, 1995, ARCH BIOCHEM BIOPHYS, V318, P89, DOI 10.1006/abbi.1995.1208; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PERONA JJ, 1995, PROTEIN SCI, V4, P337; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; STEFFENS GJ, 1982, H-S Z PHYSIOL CHEM, V363, P1043, DOI 10.1515/bchm2.1982.363.2.1043; TOKUNAGA F, 1988, J BIOL CHEM, V263, P17471; WALLEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P122, DOI 10.1016/0005-2795(72)90261-9; WOHL RC, 1980, J BIOL CHEM, V255, P2005; ZHANG Y, 1995, J BIOL CHEM, V270, P10246, DOI 10.1074/jbc.270.17.10246	29	48	60	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20531	20537		10.1074/jbc.272.33.20531	http://dx.doi.org/10.1074/jbc.272.33.20531			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252366	hybrid			2022-12-25	WOS:A1997XR22100036
J	Mangiarotti, G; Chiaberge, S				Mangiarotti, G; Chiaberge, S			Reconstitution of functional eukaryotic ribosomes from Dictyostelium discoideum ribosomal proteins and RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; YEAST; BIOGENESIS	40 and 60 S ribosomal subunits have been reconstituted in vitro from purified ribosomal RNA and ribosomal proteins of Dictyostelium discoideum. The functionality of the reconstituted ribosomes was demonstrated in in vitro mRNA-directed protein synthesis. The reassembly proceeded well with immature precursors of ribosomal RNA but poorly if at all with mature cytoplasmic RNA species. Reassembly also required a preparation of small nuclear RNA(s), acting as morphopoietic factor(s).			Mangiarotti, G (corresponding author), UNIV TURIN, OSPED SAN LUIGI GONZAGA, DEPT CLIN & BIOL SCI, REG GONZOLE 10, I-10043 ORBASSANO, ITALY.							AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; BATTSYOUNG B, 1977, J BIOL CHEM, V252, P3952; CECCARELLI A, 1978, FEBS LETT, V93, P348, DOI 10.1016/0014-5793(78)81137-5; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; England T E, 1980, Methods Enzymol, V65, P65; FRANKEL G, 1977, J MOL BIOL, V109, P539, DOI 10.1016/S0022-2836(77)80090-9; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; IWABUCHI M, 1971, BIOCHIM BIOPHYS ACTA, V228, P693, DOI 10.1016/0005-2787(71)90734-9; KLOOTWIJK J, 1989, METHOD ENZYMOL, V180, P96; LIGEROU Z, 1966, SCIENCE, V272, P268; LINDHAL T, 1973, NATURE, V221, P132; MANGIARO.G, 1968, BIOCHEMISTRY-US, V7, P456, DOI 10.1021/bi00841a058; MANGIAROTTI G, 1975, NATURE, V253, P569, DOI 10.1038/253569a0; MANGIAROTTI G, 1981, NUCLEIC ACIDS RES, V9, P947, DOI 10.1093/nar/9.4.947; MANGIAROTTI G, 1982, DEV BIOL, V89, P82, DOI 10.1016/0012-1606(82)90296-2; MANGIAROTTI G, 1983, NATURE, V301, P616, DOI 10.1038/301616a0; MANGIAROTTI G, 1985, P NATL ACAD SCI USA, V82, P5786, DOI 10.1073/pnas.82.17.5786; MANGIAROTTI G, 1974, NATURE, V247, P147, DOI 10.1038/247147a0; MARUTA H, 1971, J MOL BIOL, V61, P123, DOI 10.1016/0022-2836(71)90210-5; MATTAJ IW, 1993, FASEB J, V7, P47, DOI 10.1096/fasebj.7.1.8422974; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; NOMURA M, 1970, NATURE, V228, P744, DOI 10.1038/228744a0; PENMAN S, 1977, J MOL BIOL, V20, P115; RAMAGOPAL S, 1980, EUR J BIOCHEM, V105, P245, DOI 10.1111/j.1432-1033.1980.tb04495.x; RAUE HA, 1995, GENE EXPRESSION, V5, P71; RAUE HA, 1991, PROG NUCLEIC ACID RE, V41, P89; SANCHEZ E, 1995, EUR J BIOCHEM, V233, P809, DOI 10.1111/j.1432-1033.1995.809_3.x; Sanchez ME, 1996, BBA-PROTEIN STRUCT M, V1292, P140; SONNEMAN J, 1933, FEBS LETT, V329, P183; STEITZ JA, 1995, SCIENCE, V270, P1626, DOI 10.1126/science.270.5242.1626; TRAPMAN J, 1976, BIOCHIM BIOPHYS ACTA, V442, P275, DOI 10.1016/0005-2787(76)90302-6; TRAUB P, 1968, P NATL ACAD SCI USA, V59, P777, DOI 10.1073/pnas.59.3.777; TURCO E, 1974, BIOCHEMISTRY-US, V13, P4752, DOI 10.1021/bi00720a011; UDEM SA, 1973, J BIOL CHEM, V248, P1412; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8	40	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19682	19687		10.1074/jbc.272.32.19682	http://dx.doi.org/10.1074/jbc.272.32.19682			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242623	hybrid			2022-12-25	WOS:A1997XQ05900010
J	Pfister, MF; Lederer, E; Forgo, J; Ziegler, U; Lotscher, M; Quabius, ES; Biber, J; Murer, H				Pfister, MF; Lederer, E; Forgo, J; Ziegler, U; Lotscher, M; Quabius, ES; Biber, J; Murer, H			Parathyroid hormone-dependent degradation of type II Na+/P-i cotransporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPOSSUM KIDNEY-CELLS; PHOSPHATE-TRANSPORT; FUNCTIONAL ASYMMETRY; MOLECULAR-CLONING; EPITHELIAL-CELLS; OK CELLS; EXPRESSION; PROTEIN; INHIBITION	Parathyroid hormone (PTH) inhibits proximal tubular brush border membrane Na+/P-i cotransport activity; this decrease in the transport activity was found to be associated with a decrease in type II Na+/P-i cotransporter protein content in rat brush border membranes, In the present study we investigated the PTH-dependent regulation of the type II Na+/P-i cotransporter in opossum kidney cells, a previously established model to study cellular mechanisms involved in the regulation of proximal tubular Na+/P-i cotransport. We transfected opossum kidney cells with a cDNA coding for NaPi-2 (rat renal type II Na+/P-i cotransporter), This allowed the study of PTH-dependent regulation of the transfected NaPi-2 and of the corresponding intrinsic cotransporter (NaPi-4). The results show (i) that the intrinsic and the transfected cotransporters are functionally (transport) and morphologically (immunofluorescence) localized at the apical membrane, (ii) that the intrinsic as well as the transfected Na+/P-i cotransport activities are inhibited by PTH, (iii) that PTH leads to a retrieval of both cotransporters from the apical membrane, (iv) that both cotransporters are rapidly degraded in response to PTH, and (v) that the reappearance/recovery of type II Na+/P-i cotransporter protein and function from PTH inhibition requires de novo protein synthesis. These results document that PTH leads to a removal of type II Na+/P-i cotransporters from the apical membrane and to their subsequent degradation.	UNIV ZURICH IRCHEL,INST PHYSIOL,CH-8057 ZURICH,SWITZERLAND; UNIV ZURICH IRCHEL,INST ANAT,CH-8057 ZURICH,SWITZERLAND; UNIV LOUISVILLE,DEPT MED,DIV NEPHROL,LOUISVILLE,KY 40292	University of Zurich; University of Zurich; University of Louisville								BIBER J, 1993, PFLUG ARCH EUR J PHY, V424, P210, DOI 10.1007/BF00384344; BIBER J, 1988, AM J PHYSIOL, V255, pC155, DOI 10.1152/ajpcell.1988.255.2.C155; CAVERZASIO J, 1986, J BIOL CHEM, V261, P3233; CAVERZASIO J, 1989, AM J PHYSIOL, V257, pF712, DOI 10.1152/ajprenal.1989.257.5.F712; CHONG SS, 1993, GENOMICS, V18, P355, DOI 10.1006/geno.1993.1476; COLLINS JF, 1994, FASEB J, V8, P862, DOI 10.1096/fasebj.8.11.8070635; CUSTER M, 1994, AM J PHYSIOL, V266, pF767, DOI 10.1152/ajprenal.1994.266.5.F767; HARTMANN CM, 1995, PFLUG ARCH EUR J PHY, V430, P830, DOI 10.1007/BF00386183; HAYES G, 1994, J BIOL CHEM, V269, P24143; HIRT RP, 1992, GENE, V111, P199, DOI 10.1016/0378-1119(92)90687-K; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; KEMPSON SA, 1995, AM J PHYSIOL-RENAL, V268, pF784, DOI 10.1152/ajprenal.1995.268.4.F784; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MALMSTROM K, 1987, FEBS LETT, V216, P257, DOI 10.1016/0014-5793(87)80701-9; MIYAMOTO KI, 1995, BIOCHEM J, V305, P81, DOI 10.1042/bj3050081; Murer H, 1994, Curr Opin Nephrol Hypertens, V3, P504, DOI 10.1097/00041552-199409000-00005; MURER H, 1992, J AM SOC NEPHROL, V2, P1649; MURER H, 1992, KIDNEY PHYSL PATHOPH, P2481; Quabius ES, 1996, AM J PHYSIOL-RENAL, V270, pF220, DOI 10.1152/ajprenal.1996.270.1.F220; QUAMME G, 1989, BIOCHIM BIOPHYS ACTA, V1013, P159, DOI 10.1016/0167-4889(89)90044-X; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P624, DOI 10.1007/BF00370606; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P554, DOI 10.1007/BF00382689; RESHKIN SJ, 1991, PFLUG ARCH EUR J PHY, V419, P256, DOI 10.1007/BF00371104; SORRIBAS V, 1994, J BIOL CHEM, V269, P6615; TENENHOUSE HS, 1994, J CLIN INVEST, V93, P671, DOI 10.1172/JCI117019; VERRI T, 1995, AM J PHYSIOL-RENAL, V268, pF626, DOI 10.1152/ajprenal.1995.268.4.F626; WERNER A, 1994, AM J PHYSIOL, V267, pF311, DOI 10.1152/ajprenal.1994.267.2.F311; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608	29	107	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20125	20130		10.1074/jbc.272.32.20125	http://dx.doi.org/10.1074/jbc.272.32.20125			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242686	Green Accepted, hybrid			2022-12-25	WOS:A1997XQ05900073
J	Zhou, TQ; Rosen, BP				Zhou, TQ; Rosen, BP			Tryptophan fluorescence reports nucleotide-induced conformational changes in a domain of the ArsA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; BINDING SITE; MUTAGENESIS; SUBUNITS; SEQUENCE; GENES; PUMP	The ars operon of plasmid R773 encodes an ATP-dependent extrusion pump for arsenite and antimonite in Escherichia coli, The ArsA ATPase is the catalytic subunit of the pump protein, with two nucleotide binding consensus sequences, one in the NH2-terminal half and one in the COOH-terminal half of the protein, A la-residue consensus sequence (DTAPTGHTIRLL) has been identified in ArsA homologs from eubacteria, archebacteria, fungi, plants, and animals, ArsA enzymes were constructed containing single tryptophan residues at either end of this conserved sequence, The emission spectrum of the fluorescence of the tryptophan on the COOH-terminal end (Trp-159) indicated a relatively hydrophilic environment for this residue, An increase in intrinsic tryptophan fluorescence and a blue shift of the maximum emission wavelength were observed upon addition of MgATP, indicating movement of Trp-P59 into a relatively less polar environment, No fluorescence response was observed with MgADP, with nonhydrolyzable ATP analogs, or with MgATP by catalytically inactive enyzmes, This suggests that the location Trp-159 is shifted only during hydrolysis of ATP, In contrast, the emission spectrum of Trp-141, located on the NH2-terminal side of the consensus sequence, indicated a reliatively nonpolar environment, The maximum emission wavelength red shifted upon addition of MgADP, MgATP slowly produced a response that correlated with product formation, suggesting that the environment of Trp-141 is sensitive only to MgADP binding, Thus, during ATP hydrolysis the COOH-terminal end of the conserved domain moves into a less polar Environment, whereas the NH2-terminal end moves into a more hydrophilic environment as product is formed, A hypothesis is presented in which the conserved domain of ArsA and homologs is an energy transduction domain involved in transmission of the energy of ATP hydrolysis to biological functions such as transport.	WAYNE STATE UNIV, DEPT BIOCHEM & MOL BIOL, SCH MED, DETROIT, MI 48201 USA	Wayne State University			Zhou, Tongqing/A-6880-2010	Zhou, Tongqing/0000-0002-3935-4637; Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI19793] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aitken Alastair, 1996, P3, DOI 10.1007/978-1-60327-259-9_1; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; Boskovic J, 1996, YEAST, V12, P1377, DOI 10.1002/(SICI)1097-0061(199610)12:13<1377::AID-YEA35>3.0.CO;2-R; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHEN CM, 1986, J BIOL CHEM, V261, P5030; CHUNG S, 1994, PHOTOSYNTH RES, V41, P261, DOI 10.1007/BF02184167; DEY S, 1994, ARCH BIOCHEM BIOPHYS, V311, P418, DOI 10.1006/abbi.1994.1256; DEY S, 1995, DRUG TRANSPORT ANTIM, P103; Dijkstra DS, 1996, BIOCHEMISTRY-US, V35, P6628; Fiske CH, 1925, J BIOL CHEM, V66, P375; Kaneko T, 1996, DNA Res, V3, P109; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1993, J BACTERIOL, V175, P351, DOI 10.1128/JB.175.2.351-357.1993; KAUR P, 1992, J BIOL CHEM, V267, P19272; KurdiHaidar B, 1996, GENOMICS, V36, P486, DOI 10.1006/geno.1996.0494; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Li JX, 1996, J BIOL CHEM, V271, P25247, DOI 10.1074/jbc.271.41.25247; MEI-HSU C, 1991, Journal of Biological Chemistry, V266, P2327; RAYNAL M, 1993, ARABIDOPSIS THALIANA; Rosen BP, 1996, J BIOL INORG CHEM, V1, P273, DOI 10.1007/s007750050053; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SULTSON J, 1992, NATURE, V356, P37; THEOPHILUS BDM, 1987, NUCLEIC ACIDS RES, V15, P7443, DOI 10.1093/nar/15.18.7443; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER J, 1994, J BIOL CHEM, V269, P11261; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; WILKEMOUNTS S, 1994, ARCH BIOCHEM BIOPHYS, V309, P363, DOI 10.1006/abbi.1994.1125; ZHOU TQ, 1995, BIOCHEMISTRY-US, V34, P13622, DOI 10.1021/bi00041a042	30	66	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19731	19737		10.1074/jbc.272.32.19731	http://dx.doi.org/10.1074/jbc.272.32.19731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242630	hybrid			2022-12-25	WOS:A1997XQ05900017
J	Burnham, CE; Amlal, H; Wang, ZH; Shull, GE; Soleimani, M				Burnham, CE; Amlal, H; Wang, ZH; Shull, GE; Soleimani, M			Cloning and functional expression of a human kidney Na+:HCO3- cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL PROXIMAL TUBULE; BASOLATERAL MEMBRANE-VESICLES; NA+-HCO3 COTRANSPORTER; CELLS; PH; BICARBONATE; TRANSPORTERS; LOCALIZATION; EXCHANGERS; MECHANISMS	Several modes of HCO3- transport occur in the kidney, including Na+-independent Cl/HCO3- exchange (mediated by the AE family of Cl-/HCO3- exchangers), sodium-dependent Cl-/HCO3-, exchange, and Na+:HCO3- cotransport. The functional similarities between the Na+ coupled HCO3- transporters and the AE isoforms (i.e. transport of HCO3- and sensitivity to inhibition by 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid) suggested a strategy for cloning the other transporters based on structural similarity with the AE family, An expressed sequence tag encoding part of a protein that is related to the known anion exchangers was identified in the GenBank(TM) expressed sequence tag data base and used to design an oligonucleotide probe, This probe was used to screen a human kidney cDNA library, Several clones were identified, isolated, and sequenced, Two overlapping cDNA clones were spliced together to form a 7.6-kilobase cDNA that contained the entire coding region of a novel protein, Based on the deduced amino acid sequence, the cDNA encodes a protein with a M-r of 116,040. The protein has 29% identity with human brain AE3. Northern blot analysis reveals that the 7.6-kilobase mRNA is highly expressed in kidney and pancreas, with detectable levels in brain. Functional studies in transiently transfected HEK-293 cells demonstrate that the cloned transporter mediates Na+:HCO3- cotransport.	UNIV CINCINNATI,SCH MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,SCH MED,DEPT INTERNAL MED,CINCINNATI,OH 45267; VET AFFAIRS MED CTR,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center					NIDDK NIH HHS [DK 50594, DK 46789] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050594, R01DK046789, R01DK050594] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; ALPERN RJ, 1990, PHYSIOL REV, V70, P79, DOI 10.1152/physrev.1990.70.1.79; Amlal H, 1997, BBA-BIOMEMBRANES, V1323, P319, DOI 10.1016/S0005-2736(96)00200-3; ARONSON PS, 1991, SEMIN NEPHROL, V11, P28; ARONSON PS, 1989, ANNU REV PHYSIOL, V51, P419; BORON WF, 1989, KIDNEY INT, V36, P392, DOI 10.1038/ki.1989.208; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KRAPF R, 1993, J MEMBRANE BIOL, V131, P1, DOI 10.1007/BF02258529; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LUBMAN RL, 1995, RESP PHYSIOL, V100, P15, DOI 10.1016/0034-5687(94)00114-F; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; RUIZ OS, 1992, AM J PHYSIOL, V262, pF560, DOI 10.1152/ajprenal.1992.262.4.F560; SOLEIMANI M, 1995, J INVEST MED, V43, P419; SOLEIMANI M, 1989, J BIOL CHEM, V264, P18302; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; SOLEIMANI M, 1987, J CLIN INVEST, V79, P1276, DOI 10.1172/JCI112948; TALOR Z, 1987, EUR J BIOCHEM, V164, P695, DOI 10.1111/j.1432-1033.1987.tb11182.x; YOSHITOMI K, 1985, PFLUG ARCH EUR J PHY, V405, P360, DOI 10.1007/BF00595689	23	161	169	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19111	19114		10.1074/jbc.272.31.19111	http://dx.doi.org/10.1074/jbc.272.31.19111			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235899	hybrid			2022-12-25	WOS:A1997XP06300005
J	Li, SW; Nakamura, S; Hattori, S				Li, SW; Nakamura, S; Hattori, S			Activation of R-Ras GTPase by GTPase activating proteins for Ras, Gap1(m), and p120GAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; PC12 CELLS; PRODUCT; DOMAIN; GAP; IDENTIFICATION; PURIFICATION; STIMULATION	The enzymatic properties of Gap1(m) were characterized using three Ras and R-Ras proteins as substrates and were compared with those of p120GAP. Gap1(m) stimulated the GTPase of Ras better than that of R-Ras, in contrast to p120GAP which promoted the GTPase of R-Ras better than that of Ras, The EC50 values of Gap1(m) for Ha-Ras and R-Ras were 0.48 +/- 0.02 and 1.13 +/- 0.12 nM, respectively, whereas the EC50 values of p120GAP for Ha-Ras and R-Ras were 23.1 +/- 1.9 and 3.86 +/- 0.38 nM, respectively, The affinities of Gap1(m) and p120GAP to the substrates determined by competitive inhibition by using Ha-Ras.GTP gamma S (guanosine 5'-O-(3-thiotriphosphate)) or R-Ras.GTP gamma S as a competitor agreed well with the substrate specificities of these GTPase-activating proteins, The K-m values of Gap1(m) for Ha-Ras and R-Ras were 1.53 +/- 0.27 and 3.38 +/- 0.53 mu M, respectively, which were lower than that of p120GAP for Ha-Ras (145 +/- 11 mu m) by almost 2 orders of magnitude, The high affinity of Gap1(m) to the substrates and its membrane localization suggest that Gap1(m) may act as a regulator of the basal activity of Ha-Ras and R-Bas.	NATL INST NEUROSCI,NATL CTR NEUROL & PSYCHIAT,DIV BIOCHEM & CELLULAR BIOL,TOKYO 187,JAPAN	National Center for Neurology & Psychiatry - Japan								BABA H, 1995, J NEUROSCI RES, V41, P846, DOI 10.1002/jnr.490410615; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; Bryant SS, 1996, J BIOL CHEM, V271, P5195; COX AD, 1994, ONCOGENE, V9, P3281; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DAVIS MM, 1993, GENE, V134, P305, DOI 10.1016/0378-1119(93)90114-I; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; HATTORI S, 1992, ONCOGENE, V7, P481; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; REY I, 1994, ONCOGENE, V9, P685; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHIROUZU M, 1992, ONCOGENE, V7, P475; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; YAO R, 1995, ONCOGENE, V11, P1607; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	33	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19328	19332		10.1074/jbc.272.31.19328	http://dx.doi.org/10.1074/jbc.272.31.19328			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235929	hybrid			2022-12-25	WOS:A1997XP06300035
J	Newham, P; Craig, SE; Seddon, GN; Schofield, NR; Rees, A; Edwards, RM; Jones, EY; Humphries, MJ				Newham, P; Craig, SE; Seddon, GN; Schofield, NR; Rees, A; Edwards, RM; Jones, EY; Humphries, MJ			alpha 4 integrin binding interfaces on VCAM-1 and MAdCAM-1 - Integrin binding footprints identify accessory binding sites that play a role in integrin specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; AMINO-ACID-RESIDUES; PLASMA FIBRONECTIN; CRYSTAL-STRUCTURE; COUNTER-RECEPTOR; SPLICED DOMAIN; IDENTIFICATION; SEQUENCE; VLA-4; CLONING	Integrins are a family of heterodimeric adhesion receptors that mediate cellular interactions with a range of matrix components and cell surface proteins. Vascular cell adhesion molecule-l (VCAM-1) is an endothelial cell ligand for two leukocyte integrins (alpha 4 beta 1 and alpha 4 beta 7). A related CAM, mucosal addressin cell adhesion molecule-l (MAdCAM-1) is recognized by alpha 4 beta 7 but is a poor ligand for alpha 4 beta 1. Previous studies have revealed that all alpha 4 integrin-ligand interactions are dependent on a key acidic ligand motif centered on the CAM domain 1 C-D loop region. By generating VCAM-1/MAdCAM-1 chime ras and testing recombinant proteins in cell adhesion assays we have found that alpha 4 beta 1 binds to the MAdCAM-1 adhesion motif when present in VCAM-1, but not when the VCAM-1 motif was present in MAdCAM-1, suggesting that this region does not contain all of the information necessary to determine integrin binding specificity. To characterize integrin-CAM specificity further we measured alpha 4 beta 1 and alpha 4 beta 7 binding to a comprehensive set of mutant VCAM-1 constructs containing amino acid substitutions within the predicted integrin adhesion face. These data revealed the presence of key ''regulatory residues'' adjacent to integrin contact sites and an important difference in the ''footprint'' of alpha 4 beta 1 and alpha 4 beta 7 that was associated with an accessory binding site located in VCAM-1 Ig domain 2. The analogous region in MAdCAM-1 is markedly different in size and sequence and when mutated abolishes integrin binding activity.	ZENECA PHARMACEUT,MACCLESFIELD SK10 4TF,CHESHIRE,ENGLAND; BRITISH BIOTECHNOL LTD,OXFORD OX4 5LY,ENGLAND; UNIV OXFORD,MOL BIOPHYS LAB,OXFORD CTR MOL SCI,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	University of Oxford	Newham, P (corresponding author), UNIV MANCHESTER,WELLCOME TRUST CTR CELL MATRIX RES,SCH BIOL SCI,2-205 STOPFORD BLDG,OXFORD RD,MANCHESTER M13 9PT,LANCS,ENGLAND.		Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AOTA S, 1991, J BIOL CHEM, V266, P15938; AOTA S, 1994, J BIOL CHEM, V269, P24756; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Briskin MJ, 1996, J IMMUNOL, V156, P719; BRISKIN MJ, 1993, NATURE, V363, P61; BUTCHER EC, 1992, ADV EXP MED BIOL, V323, P181; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHIU HH, 1995, J IMMUNOL, V155, P5257; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DEDHAR S, 1990, J CELL BIOL, V110, P2185, DOI 10.1083/jcb.110.6.2185; ERLE DJ, 1994, J IMMUNOL, V153, P517; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Klickstein LB, 1996, J BIOL CHEM, V271, P23920, DOI 10.1074/jbc.271.39.23920; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LI R, 1993, J BIOL CHEM, V268, P17513; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; Newham P, 1996, MOL MED TODAY, V2, P304, DOI 10.1016/1357-4310(96)10021-6; NEWHAM P, 1992, BIOCHEM SOC T, V21, pS339; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; Shyjan AM, 1996, J IMMUNOL, V156, P2851; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; STRAUCH UG, 1994, INT IMMUNOL, V6, P263, DOI 10.1093/intimm/6.2.263; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321	55	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19429	19440		10.1074/jbc.272.31.19429	http://dx.doi.org/10.1074/jbc.272.31.19429			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235944	hybrid			2022-12-25	WOS:A1997XP06300050
J	Mundt, M; Hupp, T; Fritsche, M; Merkle, C; Hansen, S; Lane, D; Groner, B				Mundt, M; Hupp, T; Fritsche, M; Merkle, C; Hansen, S; Lane, D; Groner, B			Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential	ONCOGENE			English	Article						p53 phosphorylation; allosteric activation; in vitro transcription; specific DNA binding; latent and activated p53	DNA-BINDING FUNCTION; TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; CASEIN KINASE-II; CELL-CYCLE; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION; PROMOTER; DOMAIN	The tumor suppressor protein p53 is a transcription factor frequently inactivated in human cancers. We have studied the DNA binding potential and the transcriptional activity of p53 variants and p53 protein complexes in in vitro transcription assays, p53 specific transcription was measured via introduction of radioactive UTP into G-free cassette transcripts regulated by promoter sequences containing p53 response elements. Latent and activated p53 fractions were prepared from insect cells infected with p53 encoding baculoviruses by chromatography on heparin columns, p53 fractions distinguishable by their specifc DNA binding activities and their recognition by monoclonal antibody PAb421 were obtained. Specific DNA binding and binding to PAb421 are mutually exclusive. The C-terminus of p53 can be phosphorylated by casein kinase II, protein kinase C and cyclin dependent kinases. The antibody PAb421 binds within the PKC phosphorylation site of p53 and is able to activate DNA binding of latent p53 in vitro. Activation of p53 by PAb421 also results in enhanced transactivation in vitro. Dephosphorylation of latent p53 with phosphatase 2A does not change these properties. This suggests that a conformational change in the carboxyl terminal domain of p53 controls the transactivation potential of p53.	INST EXPT CANC RES, TUMOR BIOL CTR, D-79106 FREIBURG, GERMANY; UNIV DUNDEE, DEPT PATHOL, NINEWELLS HOSP & MED SCH, DUNDEE DD1 4HN, SCOTLAND; UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND	University of Dundee; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ABARZUA P, 1995, CANCER RES, V55, P3490; ADDISON C, 1990, ONCOGENE, V5, P423; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUCHS B, 1995, ONCOGENE, V10, P789; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUDAS JM, 1994, CELL GROWTH DIFFER, V5, P295; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEINHITPASS L, 1991, NUCLEIC ACIDS RES, V19, P1227, DOI 10.1093/nar/19.6.1227; KUGLER W, 1990, NUCLEIC ACIDS RES, V18, P6943, DOI 10.1093/nar/18.23.6943; LANE DP, 1995, PHILOS T ROY SOC B, V347, P83, DOI 10.1098/rstb.1995.0013; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MILNER J, 1990, ONCOGENE, V5, P1683; MOLINARI M, 1995, ONCOGENE, V10, P1849; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PRICE BD, 1993, ONCOGENE, V8, P3055; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0	43	47	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	1997	15	2					237	244		10.1038/sj.onc.1201174	http://dx.doi.org/10.1038/sj.onc.1201174			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244359				2022-12-25	WOS:A1997XK37200012
J	QuilletMary, A; Jaffrezou, JP; Mansat, V; Bordier, C; Naval, J; Laurent, G				QuilletMary, A; Jaffrezou, JP; Mansat, V; Bordier, C; Naval, J; Laurent, G			Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; PROGRAMMED CELL-DEATH; IONIZING-RADIATION; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; MONOCLONAL-ANTIBODY; HL-60 CELLS; SPHINGOMYELIN	The key events implicated in ceramide-triggered apoptosis remain unknown. In this study we show that 25 mu M CG-ceramide induced significant H2O2, production within 60 min, which increased up to 180 min in human myeloid leukemia U937 cells. Inactive analogue dihydro-C6-ceramide had no effect, Furthermore, no H2O2 production was observed in CG-ceramide-treated U937 rho degrees cells, which are mitochondrial respiration-deficient. We also present evidence that ceramide-induced activation of the transcription factors NF-kappa B and AP-I is mediated by mitochondrial derived reactive oxygen species, Both H2O2 production, transcription factor activation as well as apoptosis could be inhibited by rotenone and thenoyltrifluoroacetone (specific mitochondrial complexes I and II inhibitors) and antioxidants, N-acetylcysteine and pyrrolidine dithiocarbamate. These effects could be potentiated by antimycin A (specific complex III mitochondrial inhibitor); H2O2 production was also inhibitable by ruthenium red, suggesting a role of mitochondrial calcium homeostasis alterations in ceramide-induced oxidative stress, Finally, CG-ceramide had no influence on mitochondrial membrane potential within the first 6 h. Altogether, our study points to reactive oxygen species, generated at the ubiquinone site of the mitochondrial respiratory chain, as an early major mediator in ceramide-induced apoptosis.	UNIV ZARAGOZA, DEPT BIOCHEM & MOL BIOL, E-50009 ZARAGOZA, SPAIN; CHU PURPAN, SERV HEMATOL, TOULOUSE, FRANCE	University of Zaragoza; CHU de Toulouse	QuilletMary, A (corresponding author), CTR CLAUDIUS REGAUD, CJF INSERM 9503, 20-24 RUE PONT ST PIERRE, F-31052 TOULOUSE, FRANCE.			QUILLET-MARY, Anne/0000-0002-1849-6388				ANDRIEU N, 1994, BIOCHEM J, V270, P24518; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BREITTMAYER JP, 1994, J BIOL CHEM, V269, P5054; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CHACON E, 1991, TOXICOL APPL PHARM, V107, P117, DOI 10.1016/0041-008X(91)90336-D; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHAO CP, 1994, J BIOL CHEM, V269, P5849; CHEN M, 1995, CANCER RES, V55, P991; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CINO M, 1989, ARCH BIOCHEM BIOPHYS, V269, P623, DOI 10.1016/0003-9861(89)90148-3; Decaudin D, 1997, CANCER RES, V57, P62; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; FANG W, 1995, J IMMUNOL, V155, P66; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GAMEN S, 1995, FEBS LETT, V376, P15, DOI 10.1016/0014-5793(95)01236-1; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GIL ML, 1992, J IMMUNOL, V148, P2826; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KIM MY, 1991, J BIOL CHEM, V266, P484; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KONSTANTINOV AA, 1987, BIOCHIM BIOPHYS ACTA, V894, P1, DOI 10.1016/0005-2728(87)90206-4; KORSMEYER SJ, 1992, BLOOD, V80, P879; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MANOME Y, 1993, BIOCHEMISTRY-US, V32, P10607, DOI 10.1021/bi00091a010; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; PENNINGTON MW, 1994, PEPTIDE RES, V7, P72; QuilletMary A, 1996, LEUKEMIA, V10, P417; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENSON MA, 1994, CANCER RES, V54, P12; STRUM JC, 1994, J BIOL CHEM, V269, P15493; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	62	438	446	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21388	21395		10.1074/jbc.272.34.21388	http://dx.doi.org/10.1074/jbc.272.34.21388			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261153	hybrid			2022-12-25	WOS:A1997XR78900063
J	Alyonycheva, TN; Mikawa, T; Reinach, FC; Fischman, DA				Alyonycheva, TN; Mikawa, T; Reinach, FC; Fischman, DA			Isoform-specific interaction of the myosin-binding proteins (MyBPs) with skeletal and cardiac myosin is a property of the C-terminal immunoglobulin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN PECTORALIS-MUSCLE; THICK FILAMENT PROTEIN; 86 KD PROTEIN; STRIATED-MUSCLE; H-PROTEIN; CREATINE KINASE; X-PROTEIN; EXPRESSION; MYOFIBRILS; TITIN	Full-length cDNAs encoding chicken and human skeletal MyBP-H and MyBP-C have been isolated and sequenced (1-5). All are members of a protein family with repetitive immunoglobulin C2 and fibronectin type III motifs. The myosin binding domain was mapped to a single immunoglobulin motif in cardiac MyBP-C and skeletal MyBP-H. Limited alpha-chymotryptic digestion of cardiac MyBP-C generated three peptides, similar in relative mobility to those of skeletal MyBP-C: similar to 100, 40, and 15 kDa. Tryptic digestion of MyBP-H yielded two peptides: similar to 50 and 14 kDa. Partial amino acid sequences proved that the 15 and 14-kDa fragments are located at the C termini of cardiac MyBP-C and skeletal My PP-H, respectively. Only the 14- and 15-kDa peptides bound to myosin. Thus, the myosin binding site in all three proteins resides within an homologous, C-terminal immunoglobulin domain. Binding reactions (2) between the skeletal and cardiac MyBPs and corresponding myosin isoforms demonstrated saturable binding of the MyBP proteins and their C-terminal peptides to myosin, but there are higher limiting stoichiometries with the homologous isoform partners. Evidence is presented indicating that MS BP-H and -C compete for binding to a discrete number of sites in myosin filaments.	CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,BR-01498 SAO PAULO,BRAZIL	Cornell University; Universidade de Sao Paulo					NIAMS NIH HHS [AR32147] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032147] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYMESOUTHGATE A, 1991, P NATL ACAD SCI USA, V88, P7973, DOI 10.1073/pnas.88.18.7973; BAHLER M, 1985, J MOL BIOL, V186, P381, DOI 10.1016/0022-2836(85)90112-3; BAHLER M, 1985, J MOL BIOL, V186, P393, DOI 10.1016/0022-2836(85)90113-5; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BENNETT P, 1986, J MUSCLE RES CELL M, V7, P550, DOI 10.1007/BF01753571; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; CALLAWAY JE, 1981, BIOCHEM J, V195, P463, DOI 10.1042/bj1950463; COOPER J, 1984, J MOL BIOL, V177, P137, DOI 10.1016/0022-2836(84)90061-5; CRAIG R, 1976, PROC R SOC SER B-BIO, V192, P451, DOI 10.1098/rspb.1976.0023; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DENNIS JE, 1984, J CELL BIOL, V98, P1514, DOI 10.1083/jcb.98.4.1514; DHOOT GK, 1985, J MUSCLE RES CELL M, V6, P487, DOI 10.1007/BF00712585; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; Freiburg A, 1996, EUR J BIOCHEM, V235, P317, DOI 10.1111/j.1432-1033.1996.00317.x; FURST DO, 1992, J CELL SCI, V102, P769; FYRBERG CC, 1992, P ROY SOC B-BIOL SCI, V249, P33, DOI 10.1098/rspb.1992.0080; Gilbert R, 1996, J CELL SCI, V109, P101; GODFREY JE, 1970, BIOCHEMISTRY-US, V9, P886, DOI 10.1021/bi00806a025; GROVE BK, 1985, J CELL BIOL, V101, P1413, DOI 10.1083/jcb.101.4.1413; HARTZELL HC, 1985, J CELL BIOL, V100, P208, DOI 10.1083/jcb.100.1.208; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; MARUYAMA K, 1986, INT REV CYTOL, V104, P81, DOI 10.1016/S0074-7696(08)61924-5; MASAKI T, 1974, J BIOCHEM, V75, P367, DOI 10.1093/oxfordjournals.jbchem.a130403; MOOS C, 1975, J MOL BIOL, V97, P1, DOI 10.1016/S0022-2836(75)80017-9; MOOS C, 1981, J CELL BIOL, V90, P25, DOI 10.1083/jcb.90.1.25; MOOS C, 1978, J MOL BIOL, V124, P5714; NABESHIMA YI, 1984, NATURE, V308, P333, DOI 10.1038/308333a0; NOGUCHI J, 1992, J BIOL CHEM, V267, P20302; OBINATA T, 1984, DEV BIOL, V101, P116, DOI 10.1016/0012-1606(84)90122-2; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; OKAGAKI T, 1993, J CELL BIOL, V123, P619, DOI 10.1083/jcb.123.3.619; PRICE MG, 1987, J CELL BIOL, V104, P1325, DOI 10.1083/jcb.104.5.1325; PRICE MG, 1993, J BIOL CHEM, V268, P21800; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; REINACH FC, 1983, J CELL BIOL, V96, P297, DOI 10.1083/jcb.96.1.297; SQUIRE J, 1981, STRUCTURAL BASIS MUS, P344; STARR R, 1983, J MOL BIOL, V170, P675, DOI 10.1016/S0022-2836(83)80127-2; TAKANOOHMURO H, 1989, J MUSCLE RES CELL M, V10, P369, DOI 10.1007/BF01758433; TRINICK J, 1977, J MOL BIOL, V113, P343, DOI 10.1016/0022-2836(77)90146-2; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; VAUGHAN KT, 1993, GENOMICS, V16, P34, DOI 10.1006/geno.1993.1136; WALLIMANN T, 1983, J CELL BIOL, V96, P1772, DOI 10.1083/jcb.96.6.1772; WANG K, 1979, P NATL ACAD SCI USA, V76, P3698, DOI 10.1073/pnas.76.8.3698; WATKINS H, 1995, NAT GENET, V11, P433; WEBER FE, 1993, EUR J BIOCHEM, V216, P661, DOI 10.1111/j.1432-1033.1993.tb18186.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAMOTO K, 1984, J BIOL CHEM, V259, P7163; YAMAMOTO K, 1986, FEBS LETT, V208, P123, DOI 10.1016/0014-5793(86)81545-9; YASUDA M, 1995, J MOL CELL CARDIOL, V27, P2275, DOI 10.1016/S0022-2828(95)91731-4; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	51	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20866	20872		10.1074/jbc.272.33.20866	http://dx.doi.org/10.1074/jbc.272.33.20866			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252413	hybrid			2022-12-25	WOS:A1997XR22100083
J	Zeeuwen, PLJM; Hendriks, W; deJong, WW; Schalkwijk, J				Zeeuwen, PLJM; Hendriks, W; deJong, WW; Schalkwijk, J			Identification and sequence analysis of two new members of the SKALP/elafin and SPAI-2 gene family - Biochemical properties of the transglutaminase substrate motif and suggestions for a new nomenclature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ELASTASE-SPECIFIC INHIBITOR; HUMAN EPIDERMAL-KERATINOCYTES; LEUKOCYTE PROTEASE INHIBITOR; CORNIFIED CELL-ENVELOPE; REACTIVE CENTER REGIONS; PROTEINASE-INHIBITOR; ANTILEUKOPROTEINASE SKALP; CROSS-LINKING; TISSUE TRANSGLUTAMINASE	The human epithelial proteinase inhibitor SKALP/elafin and the porcine sodium-potassium ATPase inhibitor SPAI-2 are two highly homologous proteins that share an NH2-terminal transglutaminase substrate domain and a COOH-terminal whey acidic protein (WAP) domain, Here we describe the bovine and simian orthologs of SKALP/elafin as well as two new bovine family members that are designated Trappin-4 and Trappin-5 on the basis of a new nomenclature that we propose (Trappin = TRansglutaminase substrate and WAP motif containing ProteIN). Sequence analysis of Trappin-4 and Trappin-5 revealed a domain structure that is very similar to SPAI-2 (Trappin-1) and SKALP/elafin (Trappin-2). The transglutaminase substrate motifs are conserved although the number of repeats varies among species and among family members, The sequence of Trappin-4 and Trappin-5 diverges from Trappin-1 and Trappin a at the putative reactive site in the WAP domain, The bovine ortholog of Trappin a is expressed in tongue and snout epidermis; Trappin-4 is expressed in trachea, ileum, and tongue; and Trappin-5 is expressed at low levels in trachea, as determined by RNase protection and Northern blot analysis. Based on the analysis of 67 transglutaminase substrate repeats as present in all known Trappin gene family members from four different mammalian species a consensus sequence could be established: Gly-Gln-Asp-Pro-Val-Lys (GQDPVK). Using biotinylated hexapeptide probes we found that the GQDPVK sequence is a very efficient transglutaminase substrate both for guinea pig liver transglutaminase and for epidermal transglutaminase, and it acts as acyl donor as well as acceptor, We propose that the Trappin protein family forms a new group of enzyme inhibitors with various specificities of the WAP domain, which share transglutaminase substrate motifs that can act as an anchoring sequence.	UNIV NIJMEGEN, INST CELLULAR SIGNALING, DEPT DERMATOL, NL-6500 HB NIJMEGEN, NETHERLANDS; UNIV NIJMEGEN, INST CELLULAR SIGNALING, DEPT CELL BIOL & HISTOL, NL-6500 HB NIJMEGEN, NETHERLANDS; UNIV NIJMEGEN, INST CELLULAR SIGNALING, DEPT BIOCHEM, NL-6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen			Zeeuwen, Patrick/N-1779-2013; Hendriks, Wiljan J.A.J./A-5214-2013; Schalkwijk, Joost/N-1774-2013; Schalkwijk, Joost/R-7509-2019; Hendriks, Wiljan/Q-4325-2019	Zeeuwen, Patrick/0000-0002-6878-2438; Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Schalkwijk, Joost/0000-0002-1308-1319; Hendriks, Wiljan/0000-0001-9481-8281				ALKEMADE H, 1992, J INVEST DERMATOL, V99, P3, DOI 10.1111/1523-1747.ep12611375; ALKEMADE HAC, 1995, J INVEST DERMATOL, V104, P189, DOI 10.1111/1523-1747.ep12612749; ALKEMADE JAC, 1994, J CELL SCI, V107, P2335; ARAKI K, 1990, BIOCHEM BIOPH RES CO, V172, P42, DOI 10.1016/S0006-291X(05)80170-6; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GENTILE V, 1994, GENOMICS, V20, P295, DOI 10.1006/geno.1994.1170; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GROENEN PJTA, 1994, EUR J BIOCHEM, V220, P795, DOI 10.1111/j.1432-1033.1994.tb18681.x; GROENEN PJTA, 1992, EUR J BIOCHEM, V205, P671, DOI 10.1111/j.1432-1033.1992.tb16827.x; GROOTJANS JJ, 1995, J BIOL CHEM, V270, P22855, DOI 10.1074/jbc.270.39.22855; Hiemstra PS, 1996, INFECT IMMUN, V64, P4520, DOI 10.1128/IAI.64.11.4520-4524.1996; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HILL RE, 1984, NATURE, V311, P175, DOI 10.1038/311175a0; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1994, J INVEST DERMATOL, V103, P137, DOI 10.1111/1523-1747.ep12392470; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KIM SY, 1994, J BIOL CHEM, V269, P27979; KRAMPS JA, 1990, BIOCHIM BIOPHYS ACTA, V1038, P178, DOI 10.1016/0167-4838(90)90202-Q; KUROKI J, 1995, J BIOL CHEM, V270, P22428, DOI 10.1074/jbc.270.38.22428; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1991, P NATL ACAD SCI USA, V88, P82, DOI 10.1073/pnas.88.1.82; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOLHUIZEN HOF, 1994, CYTOGENET CELL GENET, V66, P129, DOI 10.1159/000133683; MOORE JT, 1987, P NATL ACAD SCI USA, V84, P6712, DOI 10.1073/pnas.84.19.6712; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; Pfundt R, 1996, J CLIN INVEST, V98, P1389, DOI 10.1172/JCI118926; POLAKOWSKA R, 1991, J INVEST DERMATOL, V96, P285, DOI 10.1111/1523-1747.ep12464554; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; SALLENAVE JM, 1993, AM J RESP CELL MOL, V8, P439, DOI 10.1165/ajrcmb/8.4.439; SALLENAVE JM, 1992, BIOL CHEM H-S, V373, P27, DOI 10.1515/bchm3.1992.373.1.27; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALKWIJK J, 1993, J INVEST DERMATOL, V100, P390, DOI 10.1111/1523-1747.ep12471990; SCHALKWIJK J, 1991, BIOCHIM BIOPHYS ACTA, V1096, P148, DOI 10.1016/0925-4439(91)90053-C; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHELLENBERGER V, 1994, BIOCHEMISTRY-US, V33, P4251, DOI 10.1021/bi00180a020; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Tamechika I, 1996, J BIOL CHEM, V271, P7012, DOI 10.1074/jbc.271.12.7012; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; Tsunemi M, 1996, BIOCHEMISTRY-US, V35, P11570, DOI 10.1021/bi960900l; ULVSBACK M, 1992, J BIOL CHEM, V267, P18080; vanRuissen F, 1996, J CELL PHYSIOL, V168, P442; WANG M, 1994, GENOMICS, V23, P721, DOI 10.1006/geno.1994.1571; WIEDOW O, 1991, BIOCHEM BIOPH RES CO, V174, P6, DOI 10.1016/0006-291X(91)90476-N; WIEDOW O, 1990, J BIOL CHEM, V265, P14791	56	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20471	20478		10.1074/jbc.272.33.20471	http://dx.doi.org/10.1074/jbc.272.33.20471			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252357	Green Published, hybrid			2022-12-25	WOS:A1997XR22100027
J	Bock, PE; Olson, ST; Bjork, I				Bock, PE; Olson, ST; Bjork, I			Inactivation of thrombin by antithrombin is accompanied by inactivation of regulatory exosite I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN COFACTOR-II; BLOOD-COAGULATION PROTEINASES; PEPTIDE CHLOROMETHYL KETONES; HUMAN ALPHA-THROMBIN; ANION-BINDING EXOSITE; REACTIVE-BOND LOOP; ACTIVE-SITE; ANTI-THROMBIN; KINETIC CHARACTERIZATION; HUMAN THROMBOMODULIN	Exosite I of the blood clotting proteinase, thrombin, mediates interactions of the enzyme with certain inhibitors, physiological substrates and regulatory proteins, Specific binding of a fluorescein-labeled derivative of the COOH-terminal dodecapeptide of hirudin ([5F]Hir(54-65)) to exosite I was used to probe changes in the function of the regulatory site accompanying inactivation of thrombin by its physiological serpin inhibitor, antithrombin, Fluorescence-monitored equilibrium binding studies showed that [5F]Hir(54-65) and Hir(54-65) bound to human cu-thrombin with dissociation constants of 26 +/- 2 nM and 38 +/- 5 nM, respectively, while the affinity of the peptides for the stable thrombin-antithrombin complex was undetectable (greater than or equal to 200-fold weaker), Kinetic studies showed that the loss of binding sites for [5F]Hir(54-65) occurred with the same time-course as the loss of thrombin catalytic activity, Binding of [5F]Hir(54-65) and Hir(54-65) to thrombin was correlated quantitatively with partial inhibition of the rate of the thrombin-antithrombin reaction, maximally decreasing the bimolecular rate constants 1.7- and 2.1-fold, respectively, These results support a mechanism in which thrombin and the thrombin-Hir(54-65) complex can associate with antithrombin and undergo formation of the covalent thrombin-antithrombin complex at modestly different rates, with inactivation of exosite I leading to dissociation of the peptide occurring subsequent to the rate-limiting inactivation of thrombin, This mechanism may function physiologically in localizing the activity of thrombin by allowing inactivation of thrombin that is bound in exosite I-mediated complexes with regulatory proteins, such as thrombomodulin and fibrin, without prior dissociation of these complexes, Concomitant with inactivation of thrombin, the thrombin-antithrombin complex may be irreversibly released due to exosite I inactivation.	UNIV ILLINOIS,CTR MOL BIOL ORAL DIS,CHICAGO,IL 60612; SWEDISH UNIV AGR SCI,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Swedish University of Agricultural Sciences	Bock, PE (corresponding author), VANDERBILT UNIV,SCH MED,DEPT PATHOL,C3321A MED CTR N,NASHVILLE,TN 37232, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038779, R29HL038779, R29HL039888, R37HL039888, R01HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38779, HL02832, HL39888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARITOMI M, 1993, THROMB HAEMOSTASIS, V70, P418; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1982, J BIOL CHEM, V257, P9487; BJORK I, 1992, J BIOL CHEM, V267, P19047; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1992, PROTEIN SCI, V1, P426; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHURCH FC, 1991, J BIOL CHEM, V266, P11975; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FERGUSON WS, 1983, ARCH BIOCHEM BIOPHYS, V220, P301, DOI 10.1016/0003-9861(83)90414-9; FISH WW, 1979, FEBS LETT, V98, P103, DOI 10.1016/0014-5793(79)80162-3; FISH WW, 1979, EUR J BIOCHEM, V101, P39, DOI 10.1111/j.1432-1033.1979.tb04213.x; FISH WW, 1979, EUR J BIOCHEM, V101, P31, DOI 10.1111/j.1432-1033.1979.tb04212.x; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P33; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; JORDAN R, 1979, J BIOL CHEM, V254, P2902; KOYAMA T, 1991, EUR J BIOCHEM, V198, P563, DOI 10.1111/j.1432-1033.1991.tb16051.x; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LIU LW, 1991, J BIOL CHEM, V266, P16977; LIU LW, 1991, J BIOL CHEM, V266, P23632; LOLLAR P, 1984, J BIOL CHEM, V259, P4335; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MELHADO LL, 1982, J AM CHEM SOC, V104, P7299, DOI 10.1021/ja00389a065; NASKI MC, 1991, J BIOL CHEM, V266, P13003; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NASKI MC, 1991, BIOCHEMISTRY-US, V30, P934, DOI 10.1021/bi00218a008; NASKI MC, 1990, J BIOL CHEM, V265, P1401; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; PREISSNER KT, 1990, J BIOL CHEM, V265, P4915; PRIESTLE JP, 1993, PROTEIN SCI, V2, P1630, DOI 10.1002/pro.5560021009; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; THEUNISSEN HJM, 1993, J BIOL CHEM, V268, P9035; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1992, J BIOL CHEM, V267, P11023; YE J, 1994, J BIOL CHEM, V269, P17965	63	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19837	19845		10.1074/jbc.272.32.19837	http://dx.doi.org/10.1074/jbc.272.32.19837			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242645	hybrid			2022-12-25	WOS:A1997XQ05900032
J	Starr, R; Novak, U; Willson, TA; Inglese, M; Murphy, V; Alexander, WS; Metcalf, D; Nicola, NA; Hilton, DJ; Ernst, M				Starr, R; Novak, U; Willson, TA; Inglese, M; Murphy, V; Alexander, WS; Metcalf, D; Nicola, NA; Hilton, DJ; Ernst, M			Distinct roles for leukemia inhibitory factor receptor alpha-chain and gp130 in cell type-specific signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; COLONY-STIMULATING FACTOR; CILIARY NEUROTROPHIC FACTOR; ONCOSTATIN-M; TRANSCRIPTION FACTOR; NEURONAL CELLS; DIFFERENTIATION; INTERLEUKIN-6; EXPRESSION; FAMILY	Leukemia inhibitory factor (LIF) induces a variety of disparate biological responses ill different cell types. These responses are thought to be mediated through the functional LIF receptor (LIFR), consisting of a heterodimeric complex of LIFE alpha-chain (LIFR alpha) and gp130. The present study investigated the relative capacity of the cytoplasmic domains of each receptor subunit to signal particular responses in several cell types, To monitor the signaling potential of LIFR alpha and gp130 individually, we constructed chimeric receptors by linking the extracellular domain of granulocyte colony-stimulating factor receptor (GCSFR) to the transmembrane and cytoplasmic regions of either LIFR alpha or gp130, Both chimeric receptors and the fall-length GCSFR in expressed in M1 myeloid leukemic cells to measure differentiation induction, in embryonic stem cells to measure differentiation inhibition, and in Ba/F3 cells to measure cell proliferation. Our results demonstrated that whereas GCSFR-gp130 receptor homodimer mediated a GCSF-induced signal in all three cell types, the GCSFR-LIFR alpha receptor homodimer was only functional in embryonic stem cells, These findings suggest that the signaling potential of gp130 and LIFR alpha cytoplasmic domains may differ depending upon the tissue and cellular response initiated.	LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,DEPT MED,PARKVILLE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,COOPERAT RES CTR CELLULAR GROWTH FACTORS,PARKVILLE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; University of Melbourne; University of Melbourne; University of Melbourne; Walter & Eliza Hall Institute			Ernst, Matthias/D-5111-2012; Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011	Ernst, Matthias/0000-0002-6399-1177; Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889; Murphy, Vincent/0000-0003-2791-303X				BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LEARY AG, 1990, BLOOD, V75, P1960; LOCK P, 1990, MOL CELL BIOL, V10, P4602; METCALF D, 1988, LEUKEMIA, V2, P216; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NICHOLS J, 1994, EXP CELL RES, V215, P237, DOI 10.1006/excr.1994.1338; NICOLA NA, 1997, GROWTH FACTORS CYTOK, V23, P605; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TANIGAWA T, 1995, BLOOD, V85, P379; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YIN TG, 1993, J IMMUNOL, V151, P2555	38	39	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19982	19986		10.1074/jbc.272.32.19982	http://dx.doi.org/10.1074/jbc.272.32.19982			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242667	hybrid			2022-12-25	WOS:A1997XQ05900054
J	Stubbs, MT; Morenweiser, R; Sturzebecher, J; Bauer, M; Bode, W; Huber, R; Piechottka, GP; Matschiner, G; Sommerhoff, CP; Fritz, H; Auerswald, EA				Stubbs, MT; Morenweiser, R; Sturzebecher, J; Bauer, M; Bode, W; Huber, R; Piechottka, GP; Matschiner, G; Sommerhoff, CP; Fritz, H; Auerswald, EA			The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin - Implications for the structure of human mast cell tryptase and its inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION CRYSTAL-STRUCTURE; KAZAL-TYPE INHIBITOR; FACTOR-XA; SUBSTRATE-SPECIFICITY; PROTEASE INHIBITOR; COMPLEMENTARY-DNA; SEQUENCE-ANALYSIS; SERINE-PROTEASE; SQUASH FAMILY; THROMBIN	The x-ray crystal structure of recombinant leech-derived tryptase inhibitor (rLDTI) has been solved to a resolution of 1.9 Angstrom in complex with porcine trypsin. The nonclassical Kazal-type inhibitor exhibits the same overall architecture as that observed in solution and in rhodniin. The complex reveals structural aspects of the mast cell proteinase tryptase. The conformation of the binding region of rLDTI suggests that tryptase has a restricted active site cleft. The basic amino terminus of rLDTI, apparently flexible from previous NMR measurements, approaches the 148-loop of trypsin. This loop has an acidic equivalent in tryptase, suggesting that the basic amino terminus could make favorable electrostatic interactions with the tryptase molecule. A series of rLDTI variants constructed to probe this hypothesis confirmed that the amino-terminal Lys-Lys sequence plays a role in inhibition of human lung tryptase but not of trypsin or chymotrypsin. The location of such an acidic surface patch is in accordance with the known low molecular weight inhibitors of tryptase.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; UNIV MUNICH, KLINIKUM INNENSTADT, KLIN CHEM & KLIN BIOCHEM ABT, CHIRURG KLIN & POLIKLIN, D-80336 MUNICH, GERMANY; KLINIKUM UNIV JENA, ZENTRUM VASK BIOL & MED, D-99089 ERFURT, GERMANY	Max Planck Society; University of Munich; Friedrich Schiller University of Jena			Stubbs, Milton/ABC-7585-2020	Stubbs, Milton/0000-0003-1278-9013				AUERSWALD EA, 1994, BIOL CHEM H-S, V375, P695, DOI 10.1515/bchm3.1994.375.10.695; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BIETH J, 1974, PROTEINASE INHIBITOR, P463; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BRUNGER AT, 1992, XPLOR MANUAL; Burgering MJM, 1997, J MOL BIOL, V269, P395, DOI 10.1006/jmbi.1997.1029; BUTTERFIELD JH, 1990, J LEUKOCYTE BIOL, V47, P409, DOI 10.1002/jlb.47.5.409; CAUGHEY GH, 1993, J PHARMACOL EXP THER, V264, P676; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHEN XM, 1992, J BIOCHEM-TOKYO, V112, P45, DOI 10.1093/oxfordjournals.jbchem.a123863; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FINK E, 1986, BIOL CHEM H-S, V367, P1235, DOI 10.1515/bchm3.1986.367.2.1235; FRIEDRICH T, 1993, J BIOL CHEM, V268, P16216; HARA T, 1994, THROMB HAEMOSTASIS, V71, P314; HARVIMA IT, 1993, BIOCHEM J, V292, P711, DOI 10.1042/bj2920711; HUANG QC, 1993, J MOL BIOL, V229, P1022, DOI 10.1006/jmbi.1993.1102; HUANG QC, 1994, BBA-PROTEIN STRUCT M, V1209, P77, DOI 10.1016/0167-4838(94)90139-2; ITOH H, 1994, J BIOL CHEM, V269, P3818; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIDO H, 1988, J BIOL CHEM, V263, P18104; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE AGW, 1994, MOSFLM USER GUIDE; LIN GD, 1993, EUR J BIOCHEM, V212, P549, DOI 10.1111/j.1432-1033.1993.tb17692.x; LITTLE SS, 1995, BIOCHEM J, V307, P341, DOI 10.1042/bj3070341; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Morenweiser R, 1997, J BIOL CHEM, V272, P19938, DOI 10.1074/jbc.272.32.19938; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MUHLHAHN P, 1994, FEBS LETT, V355, P290, DOI 10.1016/0014-5793(94)01225-3; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1994, METHOD ENZYMOL, V244, P88; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; SOMMERHOFF CP, 1994, BIOL CHEM H-S, V375, P685, DOI 10.1515/bchm3.1994.375.10.685; STUBBS MT, 1995, FEBS LETT, V375, P103, DOI 10.1016/0014-5793(95)01190-P; STURZEBECHER J, 1989, THROMB RES, V54, P245, DOI 10.1016/0049-3848(89)90232-6; STURZEBECHER J, 1992, BIOL CHEM H-S, V373, P1025, DOI 10.1515/bchm3.1992.373.2.1025; STURZEBECHER J, 1995, BIOL CHEM HOPPESEYLE, V105, P725; TIDWELL RR, 1980, THROMB RES, V19, P339, DOI 10.1016/0049-3848(80)90262-5; TURK D, 1992, THESIS TU MUNCHEN; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; vonderSaal W, 1996, ARCH PHARM, V329, P73, DOI 10.1002/ardp.19963290204; WEBER E, 1981, J MOL BIOL, V140, P109	58	83	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19931	19937		10.1074/jbc.272.32.19931	http://dx.doi.org/10.1074/jbc.272.32.19931			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242660	hybrid			2022-12-25	WOS:A1997XQ05900047
J	Borecky, J; Jezek, P; Siemen, D				Borecky, J; Jezek, P; Siemen, D			108-pS channel in brown fat mitochondria might be identical to the inner membrane anion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE MITOCHONDRIA; UNCOUPLING PROTEIN; HEART-MITOCHONDRIA; ION CHANNEL; K+-CHANNEL; RAT-LIVER; INHIBITION; SITES; UNIPORT; PATHWAY	Single-channel and whole-mitoplast patch-clamp recordings were employed to characterize the 108-pS (Cl-) channel in brown fat mitochondrial mitoplasts, We demonstrated the ability of this channel to conduct di- and trivalent anions, such as sulfate, phosphate, and benzenetricarboxylates, and its blockage by propranolol, 1,4-dihydropyridine-type Ca2+ antagonists, and Cibacron blue, Moreover, we have revealed its pH dependence for the first time, As a basis for the characteristic potential dependence of the whole-mitoplast current, we identified an open probability, increasing with depolarizing (positive) potentials, E-h, and being almost zero in the hyperpolarizing range, Events at negative E-h exhibit a short flickering behavior, whereas at positive E-h, they become much longer, This voltage dependence is influenced by pH in such a way that, at acidic pH, the 108-pS channel possesses a low open probability throughout the observed potential range, whereas at alkaline pH, the channel switches to long openings, even at a negative potential, All these properties lead us to conclude that the inner membrane anion channel, which has been characterized only by light scattering studies, and the 108-pS inner membrane channel, which has been characterized electrophysiologically, are one and the same process.	ACAD SCI CZECH REPUBL, INST PHYSIOL, DEPT MEMBRANE TRANSPORT BIOPHYS, CZ-14220 PRAGUE 4, CZECH REPUBLIC; CHRISTIAN ALBRECHTS UNIV KIEL, INST ZOOL, BIOLOGIEZENTRUM, D-24118 KIEL, GERMANY	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; University of Kiel			Jezek, Petr/B-9264-2012	Jezek, Petr/0000-0002-2720-9395				ANTONENKO YN, 1991, FEBS LETT, V285, P89, DOI 10.1016/0014-5793(91)80731-H; AZZI A, 1967, BIOCHIM BIOPHYS ACTA, V131, P468, DOI 10.1016/0005-2728(67)90006-0; BALLARIN C, 1995, J BIOL CHEM, V270, P19262, DOI 10.1074/jbc.270.33.19262; BEAVIS AD, 1987, J BIOL CHEM, V262, P15085; BEAVIS AD, 1988, J BIOL CHEM, V263, P7574; BEAVIS AD, 1989, EUR J BIOCHEM, V185, P511, DOI 10.1111/j.1432-1033.1989.tb15143.x; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BEAVIS AD, 1989, J BIOL CHEM, V264, P1508; BRAU ME, 1990, J PHYSIOL-LONDON, V420, P365, DOI 10.1113/jphysiol.1990.sp017918; CAMPO ML, 1992, J BIOL CHEM, V267, P8123; Cannon B, 1979, Methods Enzymol, V55, P65; GARLID KD, 1986, BIOCHIM BIOPHYS ACTA, V853, P187, DOI 10.1016/0304-4173(87)90001-2; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Herick K, 1995, PROG CELL R, V5, P83; Huang SG, 1996, BIOCHEMISTRY-US, V35, P16806, DOI 10.1021/bi960989v; Jezek P, 1996, INT J BIOCHEM CELL B, V28, P659, DOI 10.1016/1357-2725(96)00008-8; JEZEK P, 1990, J BIOL CHEM, V265, P19303; JEZEK P, 1989, AM J PHYSIOL, V257, pC1142, DOI 10.1152/ajpcell.1989.257.6.C1142; KINALLY KW, 1993, P NATL ACAD SCI USA, V90, P1374; KLITSCH T, 1991, J MEMBRANE BIOL, V122, P69, DOI 10.1007/BF01872740; MORAN O, 1990, J BIOL CHEM, V265, P908; MURRAY AG, 1988, EBEC REP, V5, P206; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; POWERS MF, 1991, J BIOL CHEM, V266, P17250; SELWYN MJ, 1987, NATURE, V330, P424, DOI 10.1038/330424a0; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SORGATO MC, 1989, J BIOENERG BIOMEMBR, V21, P485, DOI 10.1007/BF00762520; Sorgato MC, 1988, INTEGRATION MITOCHON, P305; STAPPEN R, 1993, BIOCHIM BIOPHYS ACTA, V1149, P40, DOI 10.1016/0005-2736(93)90022-R; TIKHONOVA IM, 1994, FEBS LETT, V337, P231, DOI 10.1016/0014-5793(94)80197-5; WARHURST IW, 1982, FEBS LETT, V149, P249, DOI 10.1016/0014-5793(82)81110-1; ZERNIG G, 1990, MOL PHARMACOL, V38, P362; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	34	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19282	19289						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235923				2022-12-25	WOS:A1997XP06300029
J	Foncea, R; Andersson, M; Ketterman, A; Blakesley, V; SapagHagar, M; Sugden, PH; LeRoith, D; Lavandero, S				Foncea, R; Andersson, M; Ketterman, A; Blakesley, V; SapagHagar, M; Sugden, PH; LeRoith, D; Lavandero, S			Insulin-like growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; LEFT-VENTRICULAR HYPERTROPHY; PROTEIN-COUPLED RECEPTORS; MUSCLE CELL HYPERTROPHY; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3'-KINASE; PARACRINE MECHANISM; PLASMA-MEMBRANE; ANGIOTENSIN-II; STIMULATE	In response to insulin-like growth factor-I (IGF-I), neonatal rat cardiac myocytes exhibit a hypertrophic response, The elucidation of the IGF-I signal transduction system in these cells remains unknown, We show here that cardiac myocytes present a single class of high affinity receptors (12,446 +/- 3,669 binding sites/cell) with a dissociation constant of 0.36 +/- 0.10 nM. Two different beta-subunits of IGF-I receptor were detected, and their autophosphorylation was followed by increases in the phosphotyrosine content of extracellular signal-regulated kinases (ERKs), insulin receptor substrate 1, phospholipase C-gamma 1, and phosphatidylinositol 3-kinase. IGF-I transiently activates c-Raf in cultured neonatal cardiac myocytes, whereas A raf is activated much less than c-Raf, Two peaks of ERK activity (ERK1 and ERK2) were resolved in cardiac myocytes treated with IGF-I by fast protein liquid chromatography, both being stimulated by IGF-I (with EC50 values for the stimulation of ERK1 and ERK2 by IGF-I of 0.10 and 0.12 nM, respectively), Maximal activation of ERK2 (12-fold) and ERK1 (8.3-fold) activities was attained after a 5-min exposure to IGF-I. Maximal activation of p90 S6 kinase by IGF-I was achieved after 10 min, and then the activity decreased slowly, Interestingly, IGF-I stimulates incorporation of [H-3]phenylalanine (1.6-fold) without any effect on [H-3]thymidine incorporation. These data suggest that IGF-I activates multiple signal transduction pathways in cardiac myocytes some of which may be relevant to the hypertrophic response of the heart.	UNIV CHILE, FAC CIENCIAS QUIM & FARMACEUT, DEPT BIOQUIM & BIOL MOL, SANTIAGO, CHILE; NATL HEART & LUNG INST, IMPERIAL COLL, SCH MED, DIV CARDIAC MED, LONDON SW3 6LY, ENGLAND; NIDDK, DIABET BRANCH, NIH, BETHESDA, MD 20892 USA	Universidad de Chile; Imperial College London; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Lavandero, Sergio/B-6001-2013	Lavandero, Sergio/0000-0003-4258-1483; Hagar, Mohamed Esam/0000-0003-0169-7738	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMO M, 1992, BIOFACTORS, V3, P151; ALEXANDRIDES TK, 1989, J BIOL CHEM, V264, P12922; ALEXANDRIDES TK, 1993, REGUL PEPTIDES, V48, P279, DOI 10.1016/0167-0115(93)90357-E; BALLARD FJ, 1987, BIOCHEM BIOPH RES CO, V149, P398, DOI 10.1016/0006-291X(87)90380-9; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Cittadini A, 1996, CIRCULATION, V93, P800, DOI 10.1161/01.CIR.93.4.800; Clerk A, 1996, BIOCHEM J, V317, P109, DOI 10.1042/bj3170109; CLERK A, 1994, J BIOL CHEM, V269, P32848; Delafontaine P, 1996, TRENDS CARDIOVAS MED, V6, P187, DOI 10.1016/S1050-1738(96)00058-8; DEROLE AJ, 1984, P NATL ACAD SCI USA, V81, P935; DONOHUE TJ, 1994, CIRCULATION, V89, P799, DOI 10.1161/01.CIR.89.2.799; Du J, 1996, BIOCHEM BIOPH RES CO, V218, P934, DOI 10.1006/bbrc.1996.0165; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; Duerr RL, 1996, CIRCULATION, V93, P2188, DOI 10.1161/01.CIR.93.12.2188; DZAU VJ, 1992, AM J CARDIOL, V70, pC4; ENGELMANN GL, 1989, MOL CELL ENDOCRINOL, V63, P1, DOI 10.1016/0303-7207(89)90076-2; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; GUTIERREZ J, 1995, J ENDOCRINOL, V146, P35, DOI 10.1677/joe.0.1460035; HANSON MC, 1993, AM J MED SCI, V306, P69, DOI 10.1097/00000441-199308000-00001; HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; KLEIN I, 1992, J CLIN ENDOCR METAB, V75, P339, DOI 10.1210/jc.75.2.339; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LAVIADES C, 1991, ARCH MAL COEUR VAISS, V84, P1039; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEROITH D, 1993, ANN NY ACAD SCI, V692, P1; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MAO L, 1995, CIRCULATION, V92, P239; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Rabkin SW, 1996, AM J HYPERTENS, V9, P230, DOI 10.1016/0895-7061(95)00382-7; Reiss K, 1996, P NATL ACAD SCI USA, V93, P8630, DOI 10.1073/pnas.93.16.8630; Sacca L, 1996, NAT MED, V2, P29, DOI 10.1038/nm0196-29; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sugden PH, 1996, TRENDS CARDIOVAS MED, V6, P87, DOI 10.1016/1050-1738(96)00013-8; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; THORBURN A, 1994, BIOCHEM BIOPH RES CO, V205, P1417, DOI 10.1006/bbrc.1994.2823; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHLANDER H, 1992, HYPERTENSION, V19, P25, DOI 10.1161/01.HYP.19.1.25; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	76	174	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19115	19124		10.1074/jbc.272.31.19115	http://dx.doi.org/10.1074/jbc.272.31.19115			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235900	hybrid			2022-12-25	WOS:A1997XP06300006
J	Fourie, AM; Hupp, TR; Lane, DP; Sang, BC; Barbosa, MS; Sambrook, JF; Gething, MJH				Fourie, AM; Hupp, TR; Lane, DP; Sang, BC; Barbosa, MS; Sambrook, JF; Gething, MJH			HSP70 binding sites in the tumor suppressor protein p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; WILD-TYPE P53; MOLECULAR CHAPERONE BIP; SARCOMA CELL-LINE; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; COGNATE PROTEIN; T-ANTIGEN; KINASE-C	Mutations within conserved regions of the tumor suppressor protein, p53, result in oncogenic forms of the protein with altered tertiary structures. In most cases, the mutant p53 proteins are selectively recognized and bound by members of the HSP70 family of molecular chaperones, but the binding site(s) in p53 for these chaperones have not been clearly defined, We have screened a library of overlapping biotinylated peptides, spanning the entire human p53 sequence, for binding to the HSP70 proteins, Hsc70 and DnaK, We show that most of the high affinity binding sites for these proteins map to secondary structure elements, particularly beta-strands, in the hydrophobic core of the central DNA binding domain, where the majority of oncogenic p53 mutations are found, Although peptides corresponding to the C-terminal region of p53 also contain potential binding sites, p53 proteins with C-terminal deletions are capable of binding to Hsc70, indicating that this region is not required for complex formation, We propose that mutations in the p53 protein alter the tertiary structure of the central DNA binding domain, thus exposing high affinity HSP70 binding sites that are cryptic in the wild-type molecule.	UNIV MELBOURNE,DEPT BIOCHEM & MOL BIOL,PARKVILLE,VIC 3052,AUSTRALIA; RW JOHNSON PHARMACEUT RES INST,SAN DIEGO,CA 92121; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CRC CELL TRANSFORMAT GRP,DUNDEE DD1 4HN,SCOTLAND; PHARMINGEN,SAN DIEGO,CA 92121; SIGNAL PHARMACEUT,SAN DIEGO,CA 92121; PETER MACCALLUM CANC INST,MELBOURNE,VIC 3002,AUSTRALIA	University of Melbourne; Johnson & Johnson; Johnson & Johnson USA; University of Dundee; Peter Maccallum Cancer Center			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; EHRHART JC, 1988, ONCOGENE, V3, P595; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE DP, 1993, PHILOS T ROY SOC B, V339, P369, DOI 10.1098/rstb.1993.0036; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; NIHEI T, 1993, CANCER LETT, V73, P181, DOI 10.1016/0304-3835(93)90262-8; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; ROMANO JW, 1989, ONCOGENE, V4, P1483; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SANG BC, 1994, ONCOGENE, V9, P853; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1995, ONCOGENE, V10, P389; Wagner P, 1995, FEBS LETT, V377, P155, DOI 10.1016/0014-5793(95)01329-6; YANUCK M, 1993, CANCER RES, V53, P3257	72	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19471	19479		10.1074/jbc.272.31.19471	http://dx.doi.org/10.1074/jbc.272.31.19471			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235949	hybrid			2022-12-25	WOS:A1997XP06300055
J	Haddad, TC; Conover, CA				Haddad, TC; Conover, CA			Insulin and interleukin-4 induce desensitization to the mitogenic effects of insulin-like growth factor-I - Pivotal role for insulin receptor substrate-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; FACTOR BINDING PROTEIN-3; PHOSPHATIDYLINOSITOL 3'-KINASE; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; IRS-1; KINASE; EXPRESSION; 3-KINASE; STIMULATION	Insulin-induced desensitization to insulin-like growth factor-I (IGF-I) stimulated mitogenesis in bovine fibroblasts involves steps distal to IGF-I binding to its tyrosine kinase receptor, When quiescent cultures of bovine fibroblasts were stimulated with 10 nM IGF-I and total cell lysates immunoblotted with anti-phosphotyrosine antibody, we observed a band at similar to 97 kDa, representing the beta-subunit of the IGF-I receptor, and a predominant tyrosyl-phosphorylated species migrating as a broad band between 170 and 190 kDa. The majority of proteins in this latter band were immunoprecipitated by antibodies against insulin receptor substrate (IRS)-2 and not by antibodies against IRS-1. Pretreatment of bovine fibroblasts with 10 nM insulin for 48 h blocked subsequent IGF-I-stimulated DNA synthesis and the IGF-I-induced increase in tyrosyl-phosphorylated IRS-2. Insulin pretreatment did not alter IRS-1 or IRS-2 expression by these cells, as assessed by metabolic labeling and direct immunoblotting with IRS antibodies. The interleukin-4 (IL-4) cytokine receptor also has IRS-2 as its major substrate for tyrosine phosphorylation. Although 10 nM IL-4 was as effective as 10 nM IGF-I in stimulating IRS-2 phosphorylation, 10 nm IL-4 did not have comparable mitogenic power in these cells. Nonetheless, pretreatment of bovine fibroblasts with IL-4 inhibited IGF-I-stimulated DNA synthesis by 50-60%, concomitant with a decrease in IGF-I-induced IRS-2 phosphorylation. Insulin-induced desensitization could be prevented if a specific inhibitor of phosphatidylinositol 3-kinase (LY294002), but not an inhibitor of mitogen-activated protein kinase (PD98059), was present during the preincubation period. LY294002 also prevented the shift in IRS-2 molecular mass in response to prolonged incubation of cells with insulin. These data indicate that, in a nontransformed cell system, IRS-2 plays a key role in cellular desensitization to IGF-I-stimulated mitogenesis most likely through a feedback mechanism in the phosphatidylinositol 3-kinase pathway. Furthermore, they suggest that signaling through IRS-2 may provide an important point of integration for hormone, growth factor, and cytokine receptor systems that regulate critical cellular growth responses.	MAYO CLIN & MAYO FDN, ENDOCRINE RES UNIT, ROCHESTER, MN 55905 USA	Mayo Clinic					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043258, R01DK043258] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43258] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BALE LK, 1992, ENDOCRINOLOGY, V131, P608, DOI 10.1210/en.131.2.608; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; CONOVER CA, 1995, J CLIN ENDOCR METAB, V80, P987, DOI 10.1210/jc.80.3.987; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1994, DIABETES, V43, P1130, DOI 10.2337/diabetes.43.9.1130; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GIORGINO F, 1995, J CLIN INVEST, V96, P1473, DOI 10.1172/JCI118184; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Inoue G, 1996, J BIOL CHEM, V271, P28206, DOI 10.1074/jbc.271.45.28206; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LAM K, 1994, J BIOL CHEM, V269, P20648; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Li PM, 1996, BIOCHEM BIOPH RES CO, V223, P80, DOI 10.1006/bbrc.1996.0849; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Nissley P, 1991, Growth Factors, V5, P29, DOI 10.3109/08977199109000269; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAAD MJA, 1995, ENDOCRINOLOGY, V136, P1579, DOI 10.1210/en.136.4.1579; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEEDORF K, 1995, METABOLISM, V44, P24, DOI 10.1016/0026-0495(95)90217-1; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; SUN XJ, 1992, J BIOL CHEM, V267, P22662; Takahashi Y, 1997, ENDOCRINOLOGY, V138, P741, DOI 10.1210/en.138.2.741; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WEBSTER J, 1994, MOL ENDOCRINOL, V8, P539, DOI 10.1210/me.8.5.539; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; White MF, 1996, PHILOS T ROY SOC B, V351, P181, DOI 10.1098/rstb.1996.0015; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	47	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19525	19531		10.1074/jbc.272.31.19525	http://dx.doi.org/10.1074/jbc.272.31.19525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235956	hybrid			2022-12-25	WOS:A1997XP06300062
J	Huang, C; Tandon, NN; Greco, NJ; Ni, YS; Wang, T; Zhan, X				Huang, C; Tandon, NN; Greco, NJ; Ni, YS; Wang, T; Zhan, X			Proteolysis of platelet cortactin by calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; GLYCOPROTEIN-IIB-IIIA; TYROSINE PHOSPHORYLATION; CA-2+-DEPENDENT PROTEASE; C-SRC; ACTIVATION; SUBSTRATE; IDENTIFICATION; CYTOSKELETON; INTEGRIN	Cortactin, a substrate of pp60(c-src) and a potent filamentous actin binding and cross-linking protein, is abundant in circulating platelets. After stimulation of platelet aggregation with collagen, cortactin undergoes a dramatic increase in tyrosine phosphorylation followed by a rapid degradation. The cleavage of platelet cortactin was detected in lysates prepared using either Triton-containing buffer or SDS-sample buffer. However, the degradation of cortactin was not observed in platelets derived from a Glanzmann's patient, who lacked functional integrin alpha(IIb)beta(3) (GPIIb-IIIa). In addition, the proteolysis of cortactin was abolished by treating platelets before but not after collagen stimulation with EGTA or calpeptin. Furthermore, recombinant cortactin was digested by mu-calpain in vitro in a dose-dependent manner, indicating that cortactin is a substrate for calpain. We also observed that the calpain-mediated digestion in vitro is dependent on the presence of a sequence containing a proline-rich region and multiple tyrosine residues that are phosphorylated by pp(60c-src). Tyrosine phosphorylation by pp60(c-src) up-regulates the activity of calpain toward cortactin. Our data suggest that the calpain-mediated proteolysis of tyrosine-phosphorylated cortactin may provide a mechanism to remodel irreversibly the cytoskeleton in response to platelet agonists.	AMER RED CROSS,HOLLAND LAB,DEPT EXPT PATHOL,ROCKVILLE,MD 20855; AMER RED CROSS,HOLLAND LAB,DEPT PLATELET BIOL,ROCKVILLE,MD 20855; GLAXO & WELLCOME RES INST,DIV BIOL,RES TRIANGLE PK,NC 27709; GEORGE WASHINGTON UNIV,DEPT ANAT & CELL BIOL,WASHINGTON,DC 20037	American Red Cross; American Red Cross; GlaxoSmithKline; George Washington University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052753] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL52753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bringuier PP, 1996, ONCOGENE, V12, P1747; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; ELCE JS, 1989, BIOCHEM J, V261, P1039, DOI 10.1042/bj2611039; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FUJIMOTO T, 1991, J BIOL CHEM, V266, P16370; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; KITAMURA D, 1989, NUCLEIC ACIDS RES, V17, P9367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAA MC, 1992, ONCOGENE, V7, P2429; MELLONI E, 1986, J BIOL CHEM, V261, P4101; NADA S, 1994, ONCOGENE, V9, P3571; ODA A, 1993, J BIOL CHEM, V268, P12603; OZAWA K, 1995, EXP CELL RES, V221, P197, DOI 10.1006/excr.1995.1367; RYBAK ME, 1988, BLOOD, V72, P414; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; Seiffert D, 1996, J BIOL CHEM, V271, P11170, DOI 10.1074/jbc.271.19.11170; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WENCELDRAKE JD, 1991, ARTERIOSCLER THROMB, V11, P882, DOI 10.1161/01.ATV.11.4.882; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Zhan X, 1997, BLOOD, V89, P457, DOI 10.1182/blood.V89.2.457; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221	33	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19248	19252		10.1074/jbc.272.31.19248	http://dx.doi.org/10.1074/jbc.272.31.19248			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235918	hybrid			2022-12-25	WOS:A1997XP06300024
J	Miyamoto, A; Laufs, U; Pardo, C; Liao, JK				Miyamoto, A; Laufs, U; Pardo, C; Liao, JK			Modulation of bradykinin receptor ligand binding affinity and its coupled G-proteins by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHOSPHOINOSITIDE HYDROLYSIS; PHOSPHOLIPASE-C; RELEASE; ACTIVATION; ENDOTHELIUM; SYNTHASE; INHIBITION; EXPRESSION; CYCLASE; CLONING	To determine whether nitric oxide (NO) can modulate bradykinin (BK) signaling pathways, we treated endothelial cells with an NO donor, S-nitrosoglutathione (GSNO), to determine its effect(s) on G-proteins (G(i) and G(q)) that are coupled to the type II kinin (BK2) receptor. Radioligand binding assays and Western analyses showed that GSNO (10-500 mu M, 0-72 h) did not alter the expression of BK2 receptor, G(i), or G(q). However, GSNO caused a 6-fold increase in basal cGMP production and decreased high affinity BK bindings sites and GTPase activity by 74 and 85%, respectively. The cGMP analogue, dibutyryl-cGMP, also inhibited BK-stimulated GTPase activity by 74% suggesting that some of the effects of NO may be mediated through activation of guanylyl cyclase. The NO synthase inhibitor, N-omega-monomethyl-L-arginine, inhibited endogenous NO synthase activity and cGMP production by 91 and 76%, respectively, but increased BK-stimulated GTPase activity by 61%. To determine which G-proteins are affected by NO, we performed GTP binding assays with [S-35]GTP gamma S followed by immunoprecipitation with specific G-protein antisera. Both GSNO and dibutyryl-cGMP increased basal G-protein GTP binding activities by 18-26%. However, GSNO decreased BK-stimulated G alpha(i2%), G alpha(i3), and G alpha(q/11) GTP binding activity by 93, 61, and 90%, respectively, whereas epinephrine-stimulated G alpha(s) GTP binding activity was unaffected. These results suggest that NO can modulate BK signaling pathways by selectively inhibiting G-proteins of the G(i) and G(q) family.	BRIGHAM & WOMENS HOSP, DEPT MED,DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07718, HL-52233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTEN KF, 1974, NEW ENGL J MED, V291, P661, DOI 10.1056/NEJM197409262911306; BARTHA K, 1989, BIOCHEM J, V263, P149, DOI 10.1042/bj2630149; Bauer J A, 1995, Adv Pharmacol, V34, P361; BUCKLEY BJ, 1991, BIOCHEM J, V280, P281, DOI 10.1042/bj2800281; Busse R, 1996, DIABETES, V45, pS8, DOI 10.2337/diab.45.1.S8; CHRISTIANSEN SC, 1992, AM REV RESPIR DIS, V145, P900, DOI 10.1164/ajrccm/145.4_Pt_1.900; CLANCY RM, 1992, ANAL BIOCHEM, V204, P365, DOI 10.1016/0003-2697(92)90253-4; CLEMENTI E, 1995, J BIOL CHEM, V270, P22277, DOI 10.1074/jbc.270.38.22277; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DERIAN CK, 1986, J BIOL CHEM, V261, P3831; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GOLBERT TM, 1968, NEW ENGL J MED, V278, P1180; HESS DT, 1994, NEUROPHARMACOLOGY, V33, P1283, DOI 10.1016/0028-3908(94)90028-0; HOGMAN M, 1993, AM REV RESPIR DIS, V148, P1474; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LANDER HM, 1993, J IMMUNOL, V151, P7182; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LIAO JK, 1992, CIRC RES, V70, P1018, DOI 10.1161/01.RES.70.5.1018; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIAO JK, 1993, J BIOL CHEM, V268, P19528; LIAO JK, 1994, J BIOL CHEM, V269, P12987; LOEB AL, 1988, AM J CARDIOL, V62, pG36; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RASBAND W, 1993, NIH IMAGE PROGRAM VE; REGOLI D, 1993, CAN J PHYSIOL PHARM, V71, P556, DOI 10.1139/y93-079; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; RICCIARDOLO FLM, 1994, BRIT J PHARMACOL, V113, P1147, DOI 10.1111/j.1476-5381.1994.tb17117.x; SAID SI, 1983, HYPERTENSION, V5, pI17, DOI 10.1161/01.HYP.5.2_Pt_2.I17; SCHINI VB, 1990, J PHARMACOL EXP THER, V252, P581; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	39	62	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19601	19608		10.1074/jbc.272.31.19601	http://dx.doi.org/10.1074/jbc.272.31.19601			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235967	hybrid			2022-12-25	WOS:A1997XP06300073
J	Nishikawa, A; Gregory, W; Frenz, J; Cacia, J; Kornfeld, S				Nishikawa, A; Gregory, W; Frenz, J; Cacia, J; Kornfeld, S			The phosphorylation of bovine DNase I Asn-linked oligosaccharides is dependent on specific lysine and arginine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYME PHOSPHORYLATION; PROTEIN RECOGNITION DETERMINANTS; PROCATHEPSIN-D; MANNOSE PHOSPHORYLATION; AMINO; RECOMBINANT; RECEPTORS; CELLS; LOBE	The secretory glycoprotein DNase I acquires mannose B-phosphate moieties on its Asn-linked oligosaccharides, indicating that it is a substrate for UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (phosphotransferase) (Cacia, J., Quan, C., and Frenz, J. (1995) Glycobiology 4, 99), Phosphotransferase recognizes a conformation-dependent protein determinant that is present in lysosomal hydrolases, but absent in most secretory glycoproteins. To identify the amino acid residues of DNase I that are required for interaction with phosphotransferase, wild-type and mutant forms of bovine DNase I were expressed in COS-1 cells and the extent of oligosaccharide phosphorylation determined. Phosphorylation of DNase I oligosaccharides decreased from 12.6% to 2.3% when Lys-50, Lys-124, and Arg-27 were mutated to alanines, indicating that these residues are required for the basal level of phosphorylation, Mutation of lysines at other positions did not impair phosphorylation, demonstrating the selectivity of this process, When Arg-27 was replaced with a lysine, phosphorylation increased to 54%, showing that phosphotransferase prefers lysine residues to arginines, Mutation of Asn-74 to a lysine also increased phosphorylation to 50.3%, and the double mutant (R27K/N74K) was phosphorylated 79%, equivalent to the values obtained with lysosomal hydrolases. Interestingly, Lys-27 and Lys-74 caused selective phosphorylation of the neighboring Asn-linked oligosaccharide. Finally, mutation of Lys-117 to an alanine stimulated phosphorylation, demonstrating that some residues may be negative regulators of this process, We conclude that selected lysine and arginine residues on the surface of DNase I constitute the major elements of the phosphotransferase recognition domain present on this secretory glycoprotein.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; GENENTECH INC,S SAN FRANCISCO,CA 94080	Washington University (WUSTL); Roche Holding; Genentech			Nishikawa, Atsushi/E-6766-2013	Nishikawa, Atsushi/0000-0003-4325-1160	NCI NIH HHS [CA08759] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CACIA J, 1995, GLYCOBIOLOGY, V4, P99; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CUOZZO JW, 1994, J BIOL CHEM, V269, P14490; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; Dittmer F, 1997, J BIOL CHEM, V272, P852, DOI 10.1074/jbc.272.2.852; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LAZZARINO D, 1989, EMBO J, V3, P5015; LEE SJ, 1988, J BIOL CHEM, V263, P3521; Mannherz H G, 1995, Curr Top Microbiol Immunol, V198, P161; PAUDEL HK, 1986, J BIOL CHEM, V261, P6012; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; SCHOREY JS, 1995, J CELL SCI, V108, P2007; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1984, EMBO J, V3, P2423, DOI 10.1002/j.1460-2075.1984.tb02149.x; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WORRALL AF, 1990, J BIOL CHEM, V265, P21889	26	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19408	19412		10.1074/jbc.272.31.19408	http://dx.doi.org/10.1074/jbc.272.31.19408			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235940	hybrid			2022-12-25	WOS:A1997XP06300046
J	Moloney, DJ; Lin, AI; Haltiwanger, RS				Moloney, DJ; Lin, AI; Haltiwanger, RS			The O-linked fucose glycosylation pathway - Evidence for protein-specific elongation of O-linked fucose in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR DOMAIN; HUMAN FACTOR-IX; PLASMINOGEN-ACTIVATOR; IDENTIFICATION; LINKAGE; PEPTIDE; GLCNAC; OLIGOSACCHARIDES; TRANSFERASE; SERINE-61	O-Linked fucose is an unusual form of glycosylation recently shown to modify the hydroxyls of serine or threonine residues at a strict consensus site within epidermal growth factor-like domains of several serum proteins, Here we demonstrate that Chinese hamster ovary cells modify numerous proteins with O-linked fucose and that the fucose is elongated on specific proteins. We have identified at least two forms of O-linked fucose elongation in Chinese hamster ovary cells: a disaccharide (Glc beta 1,3Fuc) and a larger oligosaccharide of indeterminate structure, Interestingly, it appears that the level of monosaccharide accumulates in the cells over time whereas the disaccharide does not. Analysis of the O-linked fucose containing saccharides on individual proteins revealed that some proteins are modified with the monosaccharide only, whereas others are modified with monosaccharide and disaccharide, or monosaccharide and oligosaccharide. These results suggest that elongation of the O-linked fucose monosaccharide is a protein-specific phenomena, The presence of elongated O-linked fucose moieties suggests that a novel glycosylation pathway exists in mammalian cells with O-linked fucose as the core.	SUNY STONY BROOK,INST CELL & DEV BIOL,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GM 48666] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BJOERN S, 1991, J BIOL CHEM, V266, P11051; CAMANI C, 1995, J BIOL CHEM, V270, P26053, DOI 10.1074/jbc.270.44.26053; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; HAJJAR KA, 1994, J CLIN INVEST, V93, P703, DOI 10.1172/JCI117023; HALLGREN P, 1975, J BIOL CHEM, V250, P5312; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Haltiwanger RS, 1997, J BIOL CHEM, V272, P8752, DOI 10.1074/jbc.272.13.8752; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOLT GD, 1986, J BIOL CHEM, V261, P8049; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; KLINGER MM, 1981, J BIOL CHEM, V256, P7932; KNUST E, 1987, EMBO J, V6, P761, DOI 10.1002/j.1460-2075.1987.tb04818.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, J BIOL CHEM, V259, P4663; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; MORTON PA, 1985, BIOCHEM J, V225, P59, DOI 10.1042/bj2250059; NAKAKURA N, 1992, EUR J BIOCHEM, V204, P147, DOI 10.1111/j.1432-1033.1992.tb16617.x; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; SCHNAPER HW, 1995, J CELL PHYSIOL, V165, P107, DOI 10.1002/jcp.1041650114; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STULTS NL, 1993, GLYCOBIOLOGY, V3, P589, DOI 10.1093/glycob/3.6.589; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; WANG Y, 1996, GLYCOBIOLOGY, V8, P837	34	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19046	19050		10.1074/jbc.272.30.19046	http://dx.doi.org/10.1074/jbc.272.30.19046			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228088	hybrid			2022-12-25	WOS:A1997XM34200079
J	Shanmugam, K; Featherstone, MS; Saragovi, HU				Shanmugam, K; Featherstone, MS; Saragovi, HU			Residues flanking the HOX YPWM motif contribute to cooperative interactions with PBX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; HOMEOBOX GENE; CRYSTAL-STRUCTURE; HOMEOTIC GENE; PRE-B; PROTEINS; EXTRADENTICLE; HOMEODOMAIN; MURINE; EXPRESSION	Hox genes encode transcription factors that are major determinants of embryonic patterning. Recently, we and others have shown that specific recognition of target sites in DNA is partly achieved through cooperative interaction with the extradenticle/pre-B-cell transformation-related gene (EXD/PBX) family of homeodomain-containing proteins. This interaction is mediated by the YPWM motif present N-terminal to the homeodomain in HOX proteins. In the present study, we use YPWM peptides to confirm the importance of this motif for mediating HOX/PBX interactions. We also used a novel monoclonal antibody directed against the YPWM to show that occlusion of this motif abrogates cooperativity with PBX. In addition, we present evidence that residues flanking the YPWM, both N-terminally and C-terminally, stabilize the HOX.PBX cooperative complex. Because these flanking residues are also conserved among paralogs, they are likely to help distinguish the specificity of HOX/PBX interactions. Our data further show that the relative importance of individual residues within and flanking the YPWM is dependent on the identity of position 6 of the cooperative binding site (TGATT (N) under bar ATGG). These results suggest that interactions between PBX and the YPWM motif are modified by a base pair predicted to contact the N-terminal arm of the HOX homeodomain.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University; McGill University; McGill University			Featherstone, Mark/E-8057-2010	Featherstone, Mark/0000-0003-1576-046X				BURGLIN TR, 1994, GUIDEBOOK HOMEOBOX G, P44; CATTY D, 1988, ANTIBODIES PRACTICAL, V1, P1; Chan SK, 1996, EMBO J, V15, P2476, DOI 10.1002/j.1460-2075.1996.tb00605.x; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; DUBOULE D, 1994, DEVELOPMENT, P135; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LeSauteur L, 1996, J NEUROSCI, V16, P1308; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Peltenburg LTC, 1996, EMBO J, V15, P3385, DOI 10.1002/j.1460-2075.1996.tb00704.x; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QIAN YQ, 1992, P NATL ACAD SCI USA, V89, P10738, DOI 10.1073/pnas.89.22.10738; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; StJacques B, 1996, CURR OPIN GENET DEV, V6, P439, DOI 10.1016/S0959-437X(96)80065-7; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6	44	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19081	19087		10.1074/jbc.272.30.19081	http://dx.doi.org/10.1074/jbc.272.30.19081			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228093	hybrid			2022-12-25	WOS:A1997XM34200084
J	Mansat, V; Bettaieb, A; Levade, T; Laurent, G; Jaffrezou, JP				Mansat, V; Bettaieb, A; Levade, T; Laurent, G; Jaffrezou, JP			Serine protease inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin	FASEB JOURNAL			English	Article						leukemia cells; chemotherapeutic drugs; serpins; sphingomyelin	FACTOR-KAPPA-B; PROGRAMMED CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; SIGNAL-TRANSDUCTION; TNF-ALPHA; NECROSIS; CLEAVAGE; PATHWAY; KINASE; ACID	To address the role of a plausible protease cascade in daunorubicin-triggered apoptosis, we evaluated the effect of cell-permeant protease inhibitors on its signal transduction pathway. Treatment of U937 and HL-60 cells with 0.5-1. mu M of the chemotherapeutic drug daunorubicin induced a greater than 30% activation of neutral sphingomyelinase activity within 4-10 min with concomitant sphingomyelin hydrolysis and ceramide generation. DNA fragmentation and the classical morphological features of apoptosis were observed within 4-6 h. Pretreatment of cells with the serine protease inhibitors N-tosyl-L-phenylalanyl chloromethyl ketone (20 mu M) or dichloroisocoumarin (20 mu M) for 30 min inhibited daunorubicin-induced neutral sphingomyelinase activation, sphingomyelin hydrolysis, ceramide generation, and apoptosis. Other cell-permeant protease inhibitors such as pepstatin, leupeptin, and antipain had no such effect. The apoptotic response could be restored by the addition of 25 mu M cell-permeant C6-ceramide. Daunorubicin-induced NF-kappa B activation was inhibited by dichloroisocoumarin but not by N-tosyl-L-phenylalanyl chloromethyl ketone, suggesting that this transcription factor can be activated independently of ceramide and is not directly implicated in the apoptotic pathway. These results suggest that inhibitors of serine proteases can act upstream of ceramide in drug-triggered apoptosis and that neutral sphingomyelinase activation is either directly or indirectly serine protease dependent.	INSERM,CJF 9503,CTR CLAUDIUS REGAUD,F-31052 TOULOUSE,FRANCE; CHU PURPAN,SERV HEMATOL,F-31059 TOULOUSE,FRANCE; CHU RANGUEIL,INSERM 466,MED BIOCHEM LAB,F-31403 TOULOUSE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)			Levade, Thierry/O-8948-2014	Bettaieb, Ali/0000-0002-6018-9592				ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BETTS JC, 1994, J BIOL CHEM, V269, P8455; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; FOLCH J, 1957, J BIOL CHEM, V226, P497; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; HIGUCHI M, 1996, J IMMUNOL, V156, P297; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; JOHNS LD, 1994, J IMMUNOL, V152, P5877; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; LAHTI JM, 1996, MOL CELL BIOL, V15, P1; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVADE T, 1993, FEBS LETT, V329, P306, DOI 10.1016/0014-5793(93)80243-N; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MARTHINUSS J, 1995, CELL GROWTH DIFFER, V6, P807; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Rubin H, 1996, NAT MED, V2, P632, DOI 10.1038/nm0696-632; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; STOFFEL W, 1980, H-S Z PHYSIOL CHEM, V361, P755, DOI 10.1515/bchm2.1980.361.1.755; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WEAVER VM, 1993, BIOCHEM CELL BIOL, V71, P488, DOI 10.1139/o93-071; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; YANAGA F, 1994, BIOCHEM J, V298, P733, DOI 10.1042/bj2980733; YANG ZH, 1993, J BIOL CHEM, V268, P20520; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	61	66	66	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUL	1997	11	8					695	702		10.1096/fasebj.11.8.9240970	http://dx.doi.org/10.1096/fasebj.11.8.9240970			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	XN027	9240970				2022-12-25	WOS:A1997XN02700009
J	Araki, T; Zimonjic, DB; Popescu, NC; Milbrandt, J				Araki, T; Zimonjic, DB; Popescu, NC; Milbrandt, J			Mechanism of homophilic binding mediated by ninjurin, a novel widely expressed adhesion molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DILATED CARDIOMYOPATHY; MASA SYNDROME; GENE; CELLS; HYBRIDIZATION; LOCALIZATION; RECEPTORS; MUTATIONS; FISH; RNA	Ninjurin is a novel protein that is up-regulated after nerve injury both in dorsal root ganglion (DRG) neurons and in Schwann cells, We previously reported that ninjurin demonstrates properties of a homophilic adhesion molecule and promotes neurite outgrowth from primary cultured DRG neurons, We have now found that ninjurin is widely expressed in both adult and embryonic tissues, primarily in those of epithelial origin, Aggregation assays were used to demonstrate that ninjurin-mediated adhesion requires divalent cations and is an energy-dependent process, The critical domain for ninjurin-mediated homophilic adhesion was localized to an Ii-residue region (between Pro(26) and Asn(37)) by mutagenesis and by employing synthetic oligopeptides as competitive inhibitors of ninjurin-mediated adhesion, Of particular importance are the Trp residue at position 29 and the 3 arginines in the region, Furthermore, we show that the peptide which inhibits aggregation of Jurkat cells expressing ninjurin is also capable of blocking the ability of ninjurin to promote neurite extension from DRG neurons, Using FISH analysis, the ninjurin gene was localized to human chromosome 9q22. Several genetic diseases of unknown etiology have been mapped to this region, including hereditary sensory neuropathy type 1, self-healing squamous epithelioma, split-hand/foot deformity type 1, and familial dilated cardiomyopathy.	WASHINGTON UNIV, SCH MED, DEPT PATHOL & MED, DIV LAB MED, ST LOUIS, MO 63110 USA; NCI, MOL CYTOGENET SECT, EXPT CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA	Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Zimonjic, Drazen/AAX-7513-2020; Araki, Toshiyuki/H-4289-2019	Araki, Toshiyuki/0000-0003-3625-2042; Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL CANCER INSTITUTE [P01CA053524] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53524] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1993, SEMIN CANCER BIOL, V4, P215; Araki T, 1996, NEURON, V17, P353, DOI 10.1016/S0896-6273(00)80166-X; Bernstein Lori R., 1994, Current Opinion in Oncology, V6, P106, DOI 10.1097/00001622-199401000-00015; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JOHNSON KR, 1995, GENOMICS, V29, P457, DOI 10.1006/geno.1995.9981; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; KRAJINOVIC M, 1995, AM J HUM GENET, V57, P846; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Nicholson GA, 1996, NAT GENET, V13, P101, DOI 10.1038/ng0596-101; PATEL DD, 1993, SEMIN IMMUNOL, V5, P283; RAO Y, 1994, J BIOL CHEM, V269, P27540; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Svaren J, 1996, MOL CELL BIOL, V16, P3545; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VITS L, 1994, NAT GENET, V7, P408, DOI 10.1038/ng0794-408; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; XU J, 1994, CANCER GENET CYTOGEN, V74, P1, DOI 10.1016/0165-4608(94)90020-5; YAMADA KM, 1987, J CELL PHYSIOL, V130, P21, DOI 10.1002/jcp.1041300105; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V80, P100, DOI 10.1016/0165-4608(94)00161-4	33	64	71	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21373	21380		10.1074/jbc.272.34.21373	http://dx.doi.org/10.1074/jbc.272.34.21373			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261151	hybrid			2022-12-25	WOS:A1997XR78900061
J	Mizushima, T; Yokoyama, K; Mima, S; Tsuchiya, T; Sekimizu, K				Mizushima, T; Yokoyama, K; Mima, S; Tsuchiya, T; Sekimizu, K			Inhibition of thymidine transport in dnaA mutants of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION PROTEIN; THYA GENE; REPLICATION; CHROMOSOME; ENZYME; PRODUCT; ORIGIN; KINASE; CELLS	DnaA protein is the initiator of chromosomal DNA replication in Escherichia coli, We report here our evidence that thymidine transport across cytoplasmic membranes in temperature-sensitive dnaA mutants is greatly decreased at a permissive temperature for growth of the mutants, Complementation analysis with a plasmid containing the wild type dnaA gene and P1 phage-mediated transduction confirmed that mutations in the dnaA gene were responsible for the phenotype, A low level of nucleoside transport in the dnaA mutant was specific for thymidine; transport activities for other nucleosides were much the same as those in wild type cells, Membrane vesicles prepared from the dnaA mutant showed much the same activity of thymidine transport as did those from the wild type cells, No significant difference in the activity of thymidine kinase, which is known to facilitate thymidine transport, was seen between the mutant and the wild type cells. An increase in the pool of dTTP, a negative regulator far thymidine kinase, was observed in the dnaA mutant, Based on these observations, we suggest that inhibition of thymidine transport in dnaA mutants is caused by increases in the dTTP pool.	KYUSHU UNIV,FAC PHARMACEUT SCI,HIGASHI KU,FUKUOKA 81282,JAPAN; OKAYAMA UNIV,FAC PHARMACEUT SCI,OKAYAMA 700,JAPAN	Kyushu University; Okayama University								BELFORT M, 1983, P NATL ACAD SCI-BIOL, V80, P1858, DOI 10.1073/pnas.80.7.1858; BELFORT M, 1983, P NATL ACAD SCI-BIOL, V80, P4914, DOI 10.1073/pnas.80.16.4914; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; DUBE DK, 1991, GENE, V99, P25, DOI 10.1016/0378-1119(91)90029-B; ECHOLS H, 1961, J MOL BIOL, V3, P425, DOI 10.1016/S0022-2836(61)80055-7; FILPULA D, 1977, J BACTERIOL, V130, P107, DOI 10.1128/JB.130.1.107-113.1977; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; IWAKURA M, 1995, J BIOCHEM-TOKYO, V118, P67, DOI 10.1093/oxfordjournals.jbchem.a124893; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; KOMATSU Y, 1973, BIOCHIM BIOPHYS ACTA, V330, P206, DOI 10.1016/0005-2736(73)90226-5; KUBISTA M, 1987, BIOCHEMISTRY-US, V26, P4545, DOI 10.1021/bi00388a057; LINDBERG U, 1970, ANAL BIOCHEM, V34, P152, DOI 10.1016/0003-2697(70)90096-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIZUSHIMA T, 1994, J BACTERIOL, V176, P5544, DOI 10.1128/JB.176.17.5544-5546.1994; Mizushima T, 1996, J BIOL CHEM, V271, P3633; Mizushima T, 1996, J BIOL CHEM, V271, P25178, DOI 10.1074/jbc.271.41.25178; Mizushima T, 1996, BIOCHEM BIOPH RES CO, V218, P137, DOI 10.1006/bbrc.1996.0024; Mizushima T, 1996, BIOCHEMISTRY-US, V35, P11512, DOI 10.1021/bi953088f; Mizushima T, 1996, MOL GEN GENET, V252, P212, DOI 10.1007/BF02173222; Mollgaard H, 1983, METABOLISM NUCLEOTID, P149; MUNCHPETERSEN A, 1976, J CELL PHYSIOL, V89, P551, DOI 10.1002/jcp.1040890410; MUNCHPETERSEN A, 1979, J BIOL CHEM, V254, P3730; MYGIND B, 1975, EUR J BIOCHEM, V59, P365, DOI 10.1111/j.1432-1033.1975.tb02463.x; NEUHARD J, 1971, EUR J BIOCHEM, V20, P36, DOI 10.1111/j.1432-1033.1971.tb01359.x; OKAZAKI R, 1964, J BIOL CHEM, V239, P275; SAITO H, 1984, J GEN MICROBIOL, V130, P1863; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SHINPUKU T, 1995, BIOCHEM BIOPH RES CO, V212, P84, DOI 10.1006/bbrc.1995.1939; SINGER M, 1989, MICROBIOL REV, V53, P1; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	37	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21195	21200		10.1074/jbc.272.34.21195	http://dx.doi.org/10.1074/jbc.272.34.21195			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261126	hybrid			2022-12-25	WOS:A1997XR78900036
J	Ryan, DG; Lin, TW; Brownie, E; Bridger, WA; Wolodko, WT				Ryan, DG; Lin, TW; Brownie, E; Bridger, WA; Wolodko, WT			Mutually exclusive splicing generates two distinct isoforms of pig heart succinyl-CoA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; COENZYME-A SYNTHETASE; ESCHERICHIA-COLI; ALPHA-SUBUNIT; DIRECTED MUTAGENESIS; EXPRESSION; DNA; SITE; THIOKINASE; SEQUENCE	We have identified two distinct cDNAs encoding the cu-subunit of pig heart succinyl-CoA synthetase. The derived amino acid sequence of one of these, PH alpha 57, is highly similar to the cti-subunit of the rat liver precursor enzyme. The second cDNA, PH alpha 108, was identical throughout its sequence with PH alpha 57 except for a stretch of 108 nucleotides which replaced a 57 nucleotide sequence in PH alpha 57. Coexpression of either alpha-subunit cDNA with a common pig heart P-subunit cDNA produced isozymes with GTP-specific enzyme activity, The enzyme produced by the combination of PH alpha 57 and the beta-subunit cDNA resembled the ''native'' enzyme purified from pig heart tissue, In contrast, the expressed enzyme from the combination with PH alpha 108 was clearly distinguishable from the native enzyme by, for example, hydroxyapatite chromatography, Moreover, it was now apparent that this isoform had been observed in previous preparations of the native enzyme, but always in very low amounts and, thus, disregarded, We have shown further that the two mRNA transcripts arise from a single gene and are generated by mutually exclusive splicing, The production of the PH alpha 108 message involves the use of a non-canonical splice site pair, AT-AA, Finally, we provide evidence for tissue specific regulation in the splicing of the PH alpha 108 message.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA	University of Alberta								BACCANARI DP, 1973, J BIOL CHEM, V248, P15; BACCANARI DP, 1973, BIOCHIM BIOPHYS ACTA, V119, P226; BAILEY DL, 1993, PROTEIN SCI, V2, P1255, DOI 10.1002/pro.5560020808; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRIDGER WA, 1971, BIOCHEM BIOPH RES CO, V42, P948, DOI 10.1016/0006-291X(71)90522-5; BROWNIE ER, 1972, CAN J BIOCHEM CELL B, V50, P719, DOI 10.1139/o72-100; BUCK D, 1985, BIOCHEMISTRY-US, V24, P6245, DOI 10.1021/bi00343a031; CAROTHERS AM, 1993, MOL CELL BIOL, V13, P5085, DOI 10.1128/MCB.13.8.5085; CHA S, 1967, J BIOL CHEM, V242, P2577; Cha S, 1969, METHOD ENZYMOL, V13, P62, DOI 10.1016/0076-6879(69)13017-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAAS MJ, 1988, ANAL BIOCHEM, V168, P239, DOI 10.1016/0003-2697(88)90313-2; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; HENNING WD, 1988, P NATL ACAD SCI USA, V85, P1432, DOI 10.1073/pnas.85.5.1432; HUYNH TV, 1985, DNA CLONING, V1; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JACOB M, 1989, NUCLEIC ACIDS RES, V17, P2159, DOI 10.1093/nar/17.6.2159; JENKINS TM, 1986, FEBS LETT, V205, P215, DOI 10.1016/0014-5793(86)80900-0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABBE RF, 1965, BIOCHIM BIOPHYS ACTA, V111, P403, DOI 10.1016/0304-4165(65)90050-4; LAHTI CJ, 1992, J BACTERIOL, V174, P6822, DOI 10.1128/JB.174.21.6822-6830.1992; LASCELLES J, 1964, TETRAPYRROLE BIOSYNT, P84; LIN TW, 1992, J BIOL CHEM, V267, P975; LUO GX, 1991, J BIOL CHEM, V266, P20781; MAJUMDAR R, 1990, BIOCHEM CELL BIOL, V68, P292, DOI 10.1139/o90-040; Maniatis T., 1982, MOL CLONING; MCCLELLAN JA, 1980, COMP BIOCHEM PHYS B, V67, P679, DOI 10.1016/0305-0491(80)90430-7; MESHKOVA NP, 1970, BIOCHEMISTRY-USSR+, V35, P374; Mount SM, 1996, SCIENCE, V271, P1690, DOI 10.1126/science.271.5256.1690; MURAKAMI K, 1972, J BIOL CHEM, V247, P6247; NISHIMURA JS, 1986, ADV ENZYMOL RAMB, V58, P141; NISHIYAMA M, 1991, MOL GEN GENET, V226, P1, DOI 10.1007/BF00273580; Ottaway JH, 1979, BIOCHEM SOC T, V7, P411, DOI 10.1042/bst0070411; OTTAWAY JH, 1981, INT J BIOCHEM, V13, P401, DOI 10.1016/0020-711X(81)90111-7; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; REED SI, 1989, J CELL SCI, P29; RYAN DG, 1991, J MOL BIOL, V219, P165, DOI 10.1016/0022-2836(91)90559-O; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Stryer L., 1988, BIOCHEMISTRY-US; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; WANG T, 1972, BIOCHEMISTRY-US, V11, P2067, DOI 10.1021/bi00761a011; WEITZMAN PDJ, 1986, FEBS LETT, V199, P57, DOI 10.1016/0014-5793(86)81223-6; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	53	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21151	21159		10.1074/jbc.272.34.21151	http://dx.doi.org/10.1074/jbc.272.34.21151			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261120	hybrid			2022-12-25	WOS:A1997XR78900030
J	Shao, DL; Lazar, MA				Shao, DL; Lazar, MA			Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CONVERSION; TRIGLYCERIDE ACCUMULATION; TRANSCRIPTION FACTOR; RETINOBLASTOMA GENE; PPAR-GAMMA; EXPRESSION; ENHANCER; PPAR-GAMMA-2; ADIPOGENESIS; INHIBITION	Terminal differentiation of stem cells is characterized by cessation of cell proliferation as well as changes in cell morphology associated with the differentiated state. For adipocyte differentiation, independent lines of evidence show that the transcription factors peroxisome proliferator activated receptor gamma (PPAR gamma) and CCAAT/enhancer-binding protein alpha (C/EBP alpha) as well as the tumor suppressor retinoblastoma (Rb) protein are essential. How these proteins promote adipocyte conversion and how they function cooperatively during the differentiation process remain unclear. We have used retinoic acid (RA) inhibition of adipogenesis to investigate these issues. RA blocked adipogenesis of 3T3-L1 cells induced to differentiate by ectopic expression of PPAR gamma and C/EBP alpha independently or together. However, under these circumstances RA was only effective at preventing adipogenesis when added prior to confluence, suggesting that factors involved in regulation of the cell cycle might play a role in establishing the commitment state of adipogenesis that is insensitive to RA. During differentiation of wild type 3T3 L1 preadipocytes, we found that Rb protein is hyperphosphorylated early in adipogenesis, corresponding to previously quiescent cells reentering the cell cycle, and later becomes hypophosphorylated, The data suggest that, together with the coexpression of PPAR gamma and C/EBP alpha, permanent exit from the cell cycle establishes the irreversible commitment to adipocyte differentiation.	UNIV PENN,SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & METAB,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,DIV ENDOCRINOL DIABET & METAB,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			Lazar, Mitchell A/AAF-3738-2019		NIDDK NIH HHS [DK49780] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049780] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Higgins C, 1996, J VIROL, V70, P745, DOI 10.1128/JVI.70.2.745-752.1996; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; IMAKADO S, 1995, GENE DEV, V9, P347; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; KURIHARCUCH W, 1978, CELL, V14, P53, DOI 10.1016/0092-8674(78)90300-8; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Livneh E, 1996, ONCOGENE, V12, P1545; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; STONE RL, 1990, DIFFERENTIATION, V45, P119, DOI 10.1111/j.1432-0436.1990.tb00465.x; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Xue JC, 1996, MOL CELL BIOL, V16, P1567; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	35	230	241	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21473	21478		10.1074/jbc.272.34.21473	http://dx.doi.org/10.1074/jbc.272.34.21473			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261165	hybrid			2022-12-25	WOS:A1997XR78900075
J	Brix, J; Dietmeier, K; Pfanner, N				Brix, J; Dietmeier, K; Pfanner, N			Differential recognition of preproteins by the purified cytosolic domains of the mitochondrial import receptors Tom20, Tom22, and Tom70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; GENERAL INSERTION PORE; PRECURSOR PROTEINS; YEAST MITOCHONDRIA; COMPLEX; MOM19; PRESEQUENCE; SUBUNIT; CARRIER; MOM22	The preprotein translocase of the outer mitochondrial membrane (Tom) is a multi-subunit complex required for specific recognition and membrane translocation of nuclear-encoded preproteins. We have expressed and purified the cytosolic domains of three postulated import receptors, Tom20, Tom22, and Tom70. Each receptor domain is able to bind mitochondrial preproteins but with different specificity, Tom20 binds both preproteins with N-terminal presequences and preproteins with internal targeting signals; the binding is enhanced by the addition of salt. Tom22 selectively recognizes presequence-carrying preproteins in a salt-sensitive manner, Tom70 preferentially binds preproteins with internal targeting information, A chemically synthesized presequence peptide competes with preproteins for binding to Tom20 and Tom22 but not to Tom70. We conclude that each of the three import receptors binds preproteins independently and by a different mechanism, Both Tom20 and Tom22 function as presequence receptors.	UNIV FREIBURG,INST BIOCHEM & MOL BIOL,D-79104 FREIBURG,GERMANY	University of Freiburg			Pfanner, Nikolaus/AAV-7878-2021					ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; BEDWELL DM, 1987, MOL CELL BIOL, V7, P4038, DOI 10.1128/MCB.7.11.4038; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Bomer U, 1996, FEBS LETT, V382, P153, DOI 10.1016/0014-5793(96)00156-1; DIETMEIER K, 1997, IN PRESS NATURE; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HAUCKE V, 1995, J BIOL CHEM, V270, P5565, DOI 10.1074/jbc.270.10.5565; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; HONLINGER A, 1995, BIOL CHEM H-S, V376, P515; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schleiff E, 1997, FEBS LETT, V404, P314, DOI 10.1016/S0014-5793(97)00145-2; Schlossmann J, 1996, J BIOL CHEM, V271, P17890, DOI 10.1074/jbc.271.30.17890; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; TAMM LK, 1990, FEBS LETT, V272, P29, DOI 10.1016/0014-5793(90)80441-K; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; ZARA V, 1992, J BIOL CHEM, V267, P12077	44	210	212	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20730	20735		10.1074/jbc.272.33.20730	http://dx.doi.org/10.1074/jbc.272.33.20730			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252394	hybrid			2022-12-25	WOS:A1997XR22100064
J	Haataja, L; Groffen, J; Heisterkamp, N				Haataja, L; Groffen, J; Heisterkamp, N			Characterization of RAC3, a novel member of the Rho family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; NADPH OXIDASE; RAS TRANSFORMATION; ACTIVATING PROTEIN; EXCHANGE PROTEINS; RESPIRATORY BURST; MESSENGER-RNA; CDC42 GTPASES; GROWTH-FACTOR; CELL-CYCLE	The small GTP-binding proteins Rad and Rac2 are critically important in regulating multiple signal transduction pathways in eukaryotic cells, Here we report the isolation of a novel third Rac family member, Rac3. Rac3 differs from Rac1/2 at its carboxyl-terminal end, a domain associated with subcellular localization and binding to specific cellular regulators. RAC3 mRNA expression patterns differ from those of RAGS, which is hematopoietic specific and also from those of RAC1. The RAC3 gene was mapped to chromosome 17q23-25, a region frequently deleted in breast cancer. Rac3 protein levels ape not affected by organization of the actin cytoskeleton but remarkably, are serum-inducible, Rac3 is an active GTPase, and this activity is regulated by Bcr. When constitutively activated, Rac3 is able to stimulate efficiently the c-Jun amino-terminal kinase signaling pathway, These findings support a role for Rac3 in intracellular signaling.	CHILDRENS HOSP LOS ANGELES,RES INST,SECT MOL CARCINOGENESIS,DEPT PATHOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90027	Children's Hospital Los Angeles; University of Southern California			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NCI NIH HHS [CA47456, CA 50248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456, R01CA050248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ANDO S, 1992, J BIOL CHEM, V267, P25709; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUANG TH, 1993, J BIOL CHEM, V268, P775; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; CORNELIS RS, 1993, ONCOGENE, V8, P781; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; Foster R, 1996, MOL CELL BIOL, V16, P2689; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JOSEPH G, 1995, J BIOL CHEM, V270, P29079, DOI 10.1074/jbc.270.49.29079; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOLL J, 1991, ONCOGENE, V6, P863; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SHIRSAT NV, 1990, ONCOGENE, V5, P769; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; TAN EC, 1993, J BIOL CHEM, V268, P27291; TENHOEVE J, 1994, CANCER RES, V54, P2563; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZALCMAN G, 1995, ONCOGENE, V10, P1935; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	45	202	212	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20384	20388		10.1074/jbc.272.33.20384	http://dx.doi.org/10.1074/jbc.272.33.20384			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252344	Green Published, hybrid			2022-12-25	WOS:A1997XR22100014
J	Wu, SM; Boyer, CM; Pizzo, SV				Wu, SM; Boyer, CM; Pizzo, SV			The binding of receptor-recognized alpha(2)-macroglobulin to the low density lipoprotein receptor-related protein and the alpha(2)M signaling receptor is decoupled by oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; FAST FORMS; OXYGEN RADICALS; MACROGLOBULIN RECEPTOR; PERITONEAL-MACROPHAGES; ELECTRON-MICROSCOPY; HYPOCHLOROUS ACID; ESCHERICHIA-COLI; AMINO-ACIDS; MYELOPEROXIDASE	Receptor-recognized forms of alpha(2)-macroglobulin (alpha(2)M*) bind to two classes of cellular receptors, a high affinity site comprising approximately 1500 sites/cell and a lower affinity site comprising about 60,000 sites/cell. The latter class has been identified as the so-called low density lipoprotein receptor-related protein (LRP), Ligation of receptors distinct from LRP activates cell signaling pathways, Strong circumstantial evidence suggests that the high affinity binding sites are responsible for cell signaling induced by alpha(2)M*. Using sodium hypochlorite, a powerful oxidant produced by the H2O2-myeloperoxidase-Cl- system, we now demonstrate that binding to the high affinity sites correlates directly with activation of the signaling cascade, Oxidation of alpha(2)M* using 200 mu M hypochlorite completely abolishes its binding to LRP without affecting its ability to activate the macrophage signaling cascade, Scatchard analysis shows binding to a single class of high affinity sites (K-d -71 +/- 12 pM). Surprisingly, oxidation of native alpha(2)-macroglobulin (alpha(2)M) with 125 mu M hypochlorite results in the exposure of its receptor-binding site to LRP, but the ligand is unable to induce cell signaling, Scatchard analysis shows binding to a single class of lower affinity sites (K-d - 0.7 +/- 0.15 nM), Oxidation of a cloned and expressed carboxyl-terminal 20-kDa fragment of alpha(2)M (RBF), which is capable of binding to both LRP and the signaling receptor, results in no significant change in its binding K-d, supporting our earlier finding that the oxidation-sensitive site is predominantly outside of RBF, Attempts to understand the mechanism responsible for the selective exposure of LRP-binding sites in oxidized native alpha(2)M suggest that partial protein unfolding may be the most likely mechanism, These studies provide strong evidence that the high affinity sites (K-d - 71 pM) are the alpha(2)M* signaling receptor.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University				Wu, Sean/0000-0002-0000-3821	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24066] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN GR, 1995, J BIOL CHEM, V270, P25133, DOI 10.1074/jbc.270.42.25133; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BENNETT B, 1992, J IMMUNOL METHODS, V153, P31, DOI 10.1016/0022-1759(92)90302-A; BIRKENMEIER G, 1993, J IMMUNOL METHODS, V162, P59, DOI 10.1016/0022-1759(93)90407-X; CHU CT, 1994, LAB INVEST, V71, P792; CHU G, 1994, J BIOL CHEM, V269, P787; DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; GONIAS SL, 1988, J BIOL CHEM, V263, P393; GONIAS SL, 1989, J BIOL CHEM, V264, P9565; GONIAS SL, 1981, J BIOL CHEM, V256, P2478; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HOFFMAN M, 1988, AGENTS ACTIONS, V25, P360, DOI 10.1007/BF01965043; HOFFMAN M, 1983, BIOCHIM BIOPHYS ACTA, V760, P421, DOI 10.1016/0304-4165(83)90384-7; HOLTET TL, 1994, FEBS LETT, V344, P242, DOI 10.1016/0014-5793(94)00349-1; Howard GC, 1996, ARCH BIOCHEM BIOPHYS, V333, P19, DOI 10.1006/abbi.1996.0359; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; HUSSAIN A, 1970, J PHARM SCI, V59, P1168, DOI 10.1002/jps.2600590824; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; ISAACS IJ, 1988, J BIOL CHEM, V263, P6709; KRIEGER T, 1994, ANN REV BIOCH, V63, P601; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; MARTINI JL, 1989, BIOCHIMIE, V71, P325, DOI 10.1016/0300-9084(89)90004-7; MARYNEN P, 1981, J IMMUNOL, V127, P1782; Misra UK, 1996, J CELL BIOCHEM, V61, P61, DOI 10.1002/(SICI)1097-4644(19960401)61:1<61::AID-JCB8>3.3.CO;2-N; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MISRA UK, 1994, J BIOL CHEM, V269, P18303; Misra UK, 1996, J CELL BIOCHEM, V61, P39, DOI 10.1002/(SICI)1097-4644(19960401)61:1<39::AID-JCB6>3.3.CO;2-8; Nielsen KL, 1996, J BIOL CHEM, V271, P12909, DOI 10.1074/jbc.271.22.12909; OHLSSON K, 1975, EUR J CLIN INVEST, V5, P221, DOI 10.1111/j.1365-2362.1975.tb02288.x; OSSANNA PJ, 1986, J CLIN INVEST, V77, P1939, DOI 10.1172/JCI112523; PETERSEN CM, 1993, DAN MED BULL, V40, P409; PIZZO SV, 1986, BIOCHEM J, V238, P217, DOI 10.1042/bj2380217; REDDY VY, 1994, J BIOL CHEM, V269, P4683; REDDY VY, 1989, J BIOL CHEM, V264, P13801; ROCHE PA, 1988, J BIOL CHEM, V263, P6715; SALVESEN G, 1992, FEBS LETT, V313, P198, DOI 10.1016/0014-5793(92)81443-P; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; STELMASZYNSKA T, 1978, EUR J BIOCHEM, V92, P301, DOI 10.1111/j.1432-1033.1978.tb12748.x; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; THOMAS EL, 1979, INFECT IMMUN, V23, P522, DOI 10.1128/IAI.23.2.522-531.1979; THOMAS EL, 1979, INFECT IMMUN, V25, P117; UHING RJ, 1991, BIOCHIM BIOPHYS ACTA, V1093, P115, DOI 10.1016/0167-4889(91)90111-A; WEBB DJ, 1995, EUR J BIOCHEM, V318, P1; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Wu SM, 1996, ARCH BIOCHEM BIOPHYS, V326, P39, DOI 10.1006/abbi.1996.0044; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6	56	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20627	20635		10.1074/jbc.272.33.20627	http://dx.doi.org/10.1074/jbc.272.33.20627			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252378	hybrid			2022-12-25	WOS:A1997XR22100048
J	Greenwel, P; Inagaki, Y; Hu, W; Walsh, M; Ramirez, F				Greenwel, P; Inagaki, Y; Hu, W; Walsh, M; Ramirez, F			Sp1 is required for the early response of alpha 2(I) collagen to transforming growth factor-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; FACTOR-BETA; TRANSGENIC MICE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; SP1-MEDIATED TRANSCRIPTION; PRO-ALPHA-2(I) COLLAGEN; HUMAN-FIBROBLASTS; DNA-SEQUENCES; MESSENGER-RNA	It is currently debated whether AP1 or Sp1 is the factor that mediates transforming growth factor beta 1 (TGF-beta) stimulation of the human alpha 2(I) collagen (COL1A2) gene by binding to an upstream promoter element (TbRE). The present study was designed to resolve this controversy by correlating expression of COL1A2, AP1, and Sp1 in the same cell line and under different experimental conditions. The results strongly indicate that Sp1 is required for the immediate early response of COL1A2 to TGF-beta and AP1 is not. The Sp1 inhibitor mithramycin blocked stimulation of alpha 2(I) collagen mRNA accumulation by TGF-beta, whereas the AP1 inhibitor curcumin had no effect. Furthermore, antibodies against Jun-B and c-Jun failed to identify immunologically related in the TbRE-bound complex, irrespective of whether they were purified from untreated or TGF-beta-treated cells. AP1 did bind to the TbRE probe in vitro, but only in the absence of the upstream Sp1 recognition sequence. Based on this finding and DNA transfection results, we conclude that the AP1 sequence of the TbRE represents a cryptic site used under experimental conditions that either eliminate the more favorable Sp1 binding site or force the balance toward the less probable. Finally, a combination of cell transfections and DNA-binding assays excluded that COL1A2 transactivation involves the retinoblastoma gene product (pRb), an activator of Sp1, the pRb-related protein p107, an inhibitor of Sp1, or the Sp1-related repressor, Sp3.	CUNY MT SINAI SCH MED,BROOKDALE CTR DEV & MOL BIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT PEDIAT,NEW YORK,NY 10029; NATL KANAZAWA HOSP,DEPT INTERNAL MED,KANAZAWA,ISHIKAWA 920,JAPAN	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR038648, R01AR038648] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38648] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BOAST S, 1990, J BIOL CHEM, V265, P13351; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; BRENNER DA, 1987, J BIOL CHEM, V262, P17690; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Clark RA., 1995, MOL CELLULAR BIOL WO, P3; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DEWET W, 1987, J BIOL CHEM, V262, P16032; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; GREENWEL P, 1995, MOL CELL BIOL, V15, P6813; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hasegawa T, 1996, NUCLEIC ACIDS RES, V24, P3253, DOI 10.1093/nar/24.16.3253; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KOCH AE, 1995, J INVEST MED, V43, P28; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; NEHLS MC, 1993, J CLIN INVEST, V92, P2916, DOI 10.1172/JCI116914; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Sambrook J., 2002, MOL CLONING LAB MANU; SHAFITZAGARDO B, 1983, NATURE, V304, P277, DOI 10.1038/304277a0; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; TRUTER S, 1992, J BIOL CHEM, V267, P25389; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201	47	153	158	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19738	19745		10.1074/jbc.272.32.19738	http://dx.doi.org/10.1074/jbc.272.32.19738			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242631	hybrid			2022-12-25	WOS:A1997XQ05900018
J	Harris, RA; BowkerKinley, MM; Wu, PF; Jeng, JJ; Popov, KM				Harris, RA; BowkerKinley, MM; Wu, PF; Jeng, JJ; Popov, KM			Dihydrolipoamide dehydrogenase-binding protein of the human pyruvate dehydrogenase complex - DNA-derived amino acid sequence, expression, and reconstitution of the pyruvate dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; TRANSACETYLASE COMPONENT; SACCHAROMYCES-CEREVISIAE; MULTIENZYME COMPLEX; GENETIC RECONSTRUCTION; FUNCTIONAL-ANALYSIS; MOLECULAR-CLONING; BOVINE KIDNEY; E2 COMPONENT	Protein X, recently renamed dihydrolipoamide dehydrogenase-binding protein (E3BP), is required for anchoring dihydrolipoamide dehydrogenase (E-3) to the dihydrolipoamide transacetylase (E-2) core of the pyruvate dehydrogenase complexes of eukaryotes. DNA and deduced protein sequences for E3BP of the human pyruvate dehydrogenase complex are reported here, With the exception of only a single lipoyl domain, the protein has a segmented multi-domain structure analogous to that of the E-2 component of the complex. The protein has 46% amino acid sequence identity in its amino-terminal region with the second lipoyl domain of E-2, 38% identity in its central region with the putative peripheral subunit-binding domain of E-2, and 50% identity in its carboxyl-terminal region with the catalytic inner care do. main of E-2. The similarity in the latter domain stands in contrast to E3BP of Saccharomyces cerevisiae, which is quite different from its homologous transacetylase in this region, The putative catalytic site histidine residue present in the inner core domains of all dihyrdrolipoamide acyltransferases is replaced by a serine residue in human E3BP; thus, catalysis of coenzyme A acetylation by this protein is unlikely, Coexpression of cDNAs for E3BP and E-2 resulted in the formation of ale E-2.E3BP subcomplex that spontaneously reconstituted the pyruvate dehydrogenase complex in the presence of native E-3 and recombinant pyruvate decarboxylase (E-1).	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NIADDK NIH HHS [PHS AM 20542] Funding Source: Medline; NIDDK NIH HHS [DK 47844] Funding Source: Medline; NIGMS NIH HHS [GM 51262] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051262, R29GM051262] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHAL RH, 1989, P NATL ACAD SCI USA, V86, P8732, DOI 10.1073/pnas.86.22.8732; DEMARCUCCI O, 1985, EUR J BIOCHEM, V149, P641, DOI 10.1111/j.1432-1033.1985.tb08972.x; DEMARCUCCI OGL, 1986, EUR J BIOCHEM, V158, P587; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; GOPALAKRISHNAN S, 1989, BIOCHEM BIOPH RES CO, V160, P715, DOI 10.1016/0006-291X(89)92492-3; GRIFFIN TA, 1990, J BIOL CHEM, V265, P13174; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; GUEST JR, 1985, J MOL BIOL, V185, P743, DOI 10.1016/0022-2836(85)90059-2; HODGSON JA, 1986, EUR J BIOCHEM, V158, P595, DOI 10.1111/j.1432-1033.1986.tb09796.x; HUMMEL KB, 1988, J BIOL CHEM, V263, P6165; JENG JJ, 1994, BIOCHEM BIOPH RES CO, V203, P225, DOI 10.1006/bbrc.1994.2171; JILKA JM, 1986, J BIOL CHEM, V261, P1858; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU KS, 1988, BIOCHEMISTRY-US, V27, P1972, DOI 10.1021/bi00406a025; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; Maeng CY, 1996, BIOCHEMISTRY-US, V35, P5879, DOI 10.1021/bi9600254; MENG MH, 1994, BIOCHEMISTRY-US, V33, P12879, DOI 10.1021/bi00209a020; NEAGLE J, 1989, FEBS LETT, V253, P11, DOI 10.1016/0014-5793(89)80919-6; PACKMAN LC, 1986, FEBS LETT, V206, P193, DOI 10.1016/0014-5793(86)80979-6; PETTIT FH, 1982, METHOD ENZYMOL, V89, P376; Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V; POPOV KM, 1994, J BIOL CHEM, V269, P29720; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P1245; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; REED LJ, 1990, J BIOL CHEM, V265, P8971; ROCHE TE, 1989, ANN NY ACAD SCI, V573, P66, DOI 10.1111/j.1749-6632.1989.tb14987.x; RUSSELL GC, 1992, BIOCHEM J, V287, P611, DOI 10.1042/bj2870611; Sanderson SJ, 1996, BIOCHEM J, V319, P109, DOI 10.1042/bj3190109; Sanderson SJ, 1996, EUR J BIOCHEM, V236, P68, DOI 10.1111/j.1432-1033.1996.00068.x; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SPENCER ME, 1984, EUR J BIOCHEM, V141, P361, DOI 10.1111/j.1432-1033.1984.tb08200.x; THEKKUMKARA TJ, 1989, ANN NY ACAD SCI, V573, P113, DOI 10.1111/j.1749-6632.1989.tb14990.x; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x	39	93	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19746	19751		10.1074/jbc.272.32.19746	http://dx.doi.org/10.1074/jbc.272.32.19746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242632	hybrid			2022-12-25	WOS:A1997XQ05900019
J	Munzer, JS; Basak, A; Zhong, M; Mamarbachi, A; Hamelin, J; Savaria, D; Lazure, C; Benjannet, S; Chretien, M; Seidah, NG				Munzer, JS; Basak, A; Zhong, M; Mamarbachi, A; Hamelin, J; Savaria, D; Lazure, C; Benjannet, S; Chretien, M; Seidah, NG			In vitro characterization of the novel proprotein convertase PC7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASES; KEX2-LIKE ENDOPROTEASE; PROCESSING ENZYMES; HUMAN FURIN; ENZYMATIC CHARACTERIZATION; SUBSTRATE-SPECIFICITY; CONSENSUS SEQUENCE; SUBTILISIN FAMILY; CLEAVAGE; PRECURSOR	Biochemical and enzymatic characterization of the novel proprotein convertase rat PC7 (rPC7) was carried out using vaccinia virus recombinants overexpressed in mammalian BSC40 cells. Pro-PC7 is synthesized as a glycosylated zymogen (101 kDa) and processed into mature rPC7 (89 kDa) in the endoplasmic reticulum. No endogenously produced soluble forms of this membrane-anchored protein were detected. a deletion mutant (65 kDa), truncated well beyond the expected C-terminal boundary of the P-domain, produced soluble rPC7 in the culture medium. Enzymatic activity assays of rPC7 using fluorogenic peptidyl substrates indicated that the pH optimum, Ca2+ dependence, and cleavage specificity of this enzyme are largely similar to those of furin. However, with some substrates, cleavage specificity more closely resembled that of yeast kexin, suggesting differential processing of proprotein substrates by this novel convertase. We examined the rPC7- and human furin-mediated cleavage of synthetic peptides containing the processing sites of three proteins known to colocalize in situ with rPC7. Whereas both enzymes correctly processed the pro-parathyroid hormone tridecapeptide and the pro-PC4 heptadecapeptide, neither enzyme cleaved a pro-epidermal growth factor hexadecapeptide. Thus, this study establishes that rPC7 is an enzymatically functional subtilisin/kexin-like serine proteinase with a cleavage specificity resembling that of hfurin. In addition, we have demonstrated that rPC7 can correctly process peptide precursors that contain the processing sites of at least two potential physiological substrates.	CLIN RES INST MONTREAL,BIOCHEM NEUROENDOCRINOL LAB,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,JA DE SEVE LAB MOL NEUROENDOCRINOL,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,JA DE SEVE LAB BIOCHEM NEUROENDOCRINOL,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,LAB STRUCT & METAB NEUROPEPTIDES,MONTREAL,PQ H2W 1R7,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; CHRETIEN, Michel/0000-0002-8588-4460				BAIIYES EM, 1992, BIOCHEM J, V286, P223; Basak A, 1995, J Pept Sci, V1, P385, DOI 10.1002/psc.310010606; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BLUE ML, 1993, IMMUNOLOGY, V78, P80; BOUDREAULT A, 1995, J CELL BIOCH B, V19, P243; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; DAVISON AJ, 1990, NUCLEIC ACIDS RES, V18, P4285, DOI 10.1093/nar/18.14.4285; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; GERMAIN D, 1992, EUR J BIOCHEM, V204, P121, DOI 10.1111/j.1432-1033.1992.tb16613.x; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HENDY GN, 1995, J BIOL CHEM, V270, P9517, DOI 10.1074/jbc.270.16.9517; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MALIDE D, 1995, J HISTOCHEM CYTOCHEM, V43, P11, DOI 10.1177/43.1.7822759; Meerabux J, 1996, CANCER RES, V56, P448; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; PAQUET L, 1994, J BIOL CHEM, V269, P19279; REHEMTULLA A, 1992, BLOOD, V79, P2349; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SEIDAH NG, 1997, IN PRESS ANN NY ACAD; SEIDAH NG, 1995, INTRAMOLECULAR CHAPE, P181; SEIZEN RJ, 1994, EUR J BIOCHEM, V222, P255; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; Vollenweider F, 1996, BIOCHEM J, V314, P521, DOI 10.1042/bj3140521; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Zhong M, 1996, FEBS LETT, V396, P31, DOI 10.1016/0014-5793(96)01059-9	55	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19672	19681		10.1074/jbc.272.32.19672	http://dx.doi.org/10.1074/jbc.272.32.19672			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242622	hybrid			2022-12-25	WOS:A1997XQ05900009
J	Clement, B; Lomb, R; Moller, W				Clement, B; Lomb, R; Moller, W			Isolation and characterization of the protein components of the liver microsomal O-2-insensitive NADH-benzamidoxime reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-HYDROXYLATION; RABBIT LIVER; NITRIC-OXIDE; CYTOCHROME-P-450; OXIDATION; DEBRISOQUINE; METABOLITE; DEXTROMETHORPHAN; CITRULLINE; ARGININE	Drugs containing strong basic nitrogen functional groups can be N-oxygenated to genotoxic products. While the reduction of such products is of considerable toxicological significance, most in vitro studies have focused on oxygen-sensitive reductase systems. However, an oxygen-insensitive microsomal hydroxylamine reductase consisting of NADH, cytochrome b(5), its reductase, and a third unidentified protein component has been known for some time (Kadlubar, F. F., and Ziegler, D. M. (1974) Arch. Biochem. Biophys. 162, 83-92). This report describes the isolation and identification of all of the components required for the reconstitution of an oxygen-insensitive liver microsomal system capable of catalyzing the efficient reduction of primary N-hydroxylated structures such as amidines, guanidines, amidino-hydrazones, and similar functional groups. In addition to cytochrome b(5) and its reductase, the reconstituted system requires phosphatidylcholine and a P450 isoenzyme that has been purified to homogeneity from pig liver. The participation of cytochrome b(5) and NADH cytochrome b(5) reductase in cytochrome P450-dependent biotransformations has previously only been described for oxidative processes, The data presented suggest that this system may be an important catalyst in the reduction of genotoxic N-hydroxylated nitrogen components in liver, Their facile reduction by cellular NADH may be the reason why N-hydroxylated products can be missed by studies in vivo. Furthermore, the enzyme system is involved in the reduction of amidoximes and similar functional groups, which can be used as prodrug functionalities for amidines and related groups.			Clement, B (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,INST PHARMAZEUT,GUTENBERGSTR 76,D-24118 KIEL,GERMANY.							BICKEL MH, 1969, PHARMACOL REV, V21, P325; CLEMENT B, 1987, XENOBIOTICA, V17, P659, DOI 10.3109/00498258709043973; CLEMENT B, 1993, ARCH PHARM, V326, P807, DOI 10.1002/ardp.19933261008; CLEMENT B, 1993, MOL PHARMACOL, V43, P335; CLEMENT B, 1988, ARCH PHARM, V321, P955, DOI 10.1002/ardp.19883211228; Clement B, 1996, CHEM RES TOXICOL, V9, P682, DOI 10.1021/tx9502047; CLEMENT B, 1994, DRUG METAB DISPOS, V22, P486; CLEMENT B, 1993, BIOCHEM PHARMACOL, V46, P2249, DOI 10.1016/0006-2952(93)90616-5; CLEMENT B, 1983, XENOBIOTICA, V13, P467, DOI 10.3109/00498258309052286; CLEMENT B, 1985, CHEM BER-RECL, V118, P3481, DOI 10.1002/cber.19851180905; CLEMENT B, 1988, J CANCER RES CLIN, V114, P363, DOI 10.1007/BF02128179; CLEMENT B, 1992, ARCH PHARM, V325, P61, DOI 10.1002/ardp.19923250114; COUTTS RT, 1977, DRUG METAB REV, V6, P51, DOI 10.3109/03602537708993765; CRETTON EM, 1993, DRUG METAB DISPOS, V21, P946; CRIBB AE, 1995, DRUG METAB DISPOS, V23, P406; Estabrook R W, 1978, Methods Enzymol, V52, P212; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; HAUPTMANN J, 1988, PHARMAZIE, V43, P559; INGELMANSUNDBERG M, 1984, ACTA CHEM SCAND B, V38, P845, DOI 10.3891/acta.chem.scand.38b-0845; JARURATANASIRIKUL S, 1994, J PHARM PHARMACOL, V46, P933, DOI 10.1111/j.2042-7158.1994.tb05721.x; KADLUBAR FF, 1973, ARCH BIOCHEM BIOPHYS, V156, P46, DOI 10.1016/0003-9861(73)90339-1; KADLUBAR FF, 1974, ARCH BIOCHEM BIOPHYS, V162, P83, DOI 10.1016/0003-9861(74)90107-6; KLING L, 1985, BIOCHEM PHARMACOL, V34, P85, DOI 10.1016/0006-2952(85)90104-2; Kruger P., 1885, BER DTSCH CHEM GES, V18, P1055; KUPFER A, 1984, LANCET, V2, P517; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU YH, 1974, BIOCHEM BIOPH RES CO, V60, P266; Mihara K, 1978, Methods Enzymol, V52, P102; OMURA T, 1964, J BIOL CHEM, V239, P2370; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TATSUMI K, 1987, ARCH BIOCHEM BIOPHYS, V253, P413, DOI 10.1016/0003-9861(87)90194-9; TESTA B, 1995, METABOLISM DRUGS OTH, P415; TSUNEOKA Y, 1992, EUR J BIOCHEM, V208, P739, DOI 10.1111/j.1432-1033.1992.tb17242.x; Weller T, 1996, J MED CHEM, V39, P3139, DOI 10.1021/jm9509298; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; WOHLERS H, 1994, THESIS CHRISTIAN ALB; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZIEGLER DM, 1966, BIOCHEMISTRY-US, V5, P2932, DOI 10.1021/bi00873a024	38	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19615	19620		10.1074/jbc.272.31.19615	http://dx.doi.org/10.1074/jbc.272.31.19615			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235969	hybrid			2022-12-25	WOS:A1997XP06300075
J	Dong, WJ; Wang, CK; Gordon, AM; Rosenfeld, SS; Cheung, HC				Dong, WJ; Wang, CK; Gordon, AM; Rosenfeld, SS; Cheung, HC			A kinetic model for the binding of Ca2+ to the regulatory site of troponin from cardiac muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN SKELETAL-MUSCLE; RESOLUTION; CALCIUM; COMPLEX	The kinetics of the binding of Ca2+ to the single regulatory site of cardiac muscle troponin was investigated by using troponin reconstituted from the three subunits, using a monocysteine mutant of troponin C (cTnC) labeled with the fluorescent probe 2-[(4'-(iodoacetamido)anilino]naphthalene-6-sulfonic acid (IAANS) at Cys-35, The kinetic tracings of binding experiments for troponin determined at free [Ca2+] > 1 mu M were resolved into two phases. The rate of the fast phase increased with increasing [Ca2+], reaching a maximum of about 35 s(-1) at 4 degrees C, and the rate of the slow phase was approximately 5 s(-1) and did not depend on [Ca2+], Dissociation of bound Ca2+ occurred in two phases, with rates of about 23 and 4 s(-1), The binding and dissociation results obtained with the binary complex formed between cardiac troponin I and the IAANS-labeled cTnC mutant were very similar to those obtained from reconstituted troponin, The kinetic data are consistent with a three-step sequential model similar to the previously reported mechanism for the binding of Ca2+ to a cTnC mutant labeled with the same probe at Cys-84 (Dong et al, (1996) J, Biol, Chem. 271, 688-694). In this model, the initial binding in the bimolecular step to form the Ca2+-troponin complex is assumed to be a rapid equilibrium, followed by two sequential first-order transitions, The apparent bimolecular rate constant is 5.1 x 10(7) M-1 s(-1) a factor of 3 smaller than that for cTnC, The rates of the first-order transitions are an order of magnitude smaller for troponin than for cTnC, These kinetic differences form a basis for the enhanced Ca2+ affinity of troponin relative to the Ca2+ affinity of isolated cTnC. Phosphorylation of the monocysteine mutant of troponin I by protein kinase A resulted in a 3-fold decrease in the bimolecular rate constant but a 2-fold increase in the two observed Ca2+ dissociation rates, These changes in the kinetic parameters are responsible for a 5-fold reduction in Ca2+ affinity of phosphorylated troponin for the specific site.	UNIV ALABAMA, DEPT NEUROL, BIRMINGHAM, AL 35294 USA; UNIV WASHINGTON, DEPT PHYSIOL & BIOPHYS, SEATTLE, WA 98195 USA	University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle	Dong, WJ (corresponding author), UNIV ALABAMA, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA.		Dong, Wenji/A-8579-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052508] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52588, HL52508] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bevington PR, 1969, DATA REDUCTION ERROR; Dong WJ, 1996, J BIOL CHEM, V271, P688, DOI 10.1074/jbc.271.2.688; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6754, DOI 10.1021/bi9622276; Dong WJ, 1997, BIOPHYS J, V72, P850, DOI 10.1016/S0006-3495(97)78719-8; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; IIO T, 1982, J BIOCHEM-TOKYO, V92, P1141, DOI 10.1093/oxfordjournals.jbchem.a134030; JONHSON, 1994, J BIOL CHEM, V269, P8919; LIAO RL, 1992, BIOPHYS J, V63, P986, DOI 10.1016/S0006-3495(92)81685-5; LIAO RL, 1994, BIOCHEMISTRY-US, V33, P12729, DOI 10.1021/bi00208a026; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; OVSAK M, 1991, PROTEINS, V11, P79; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; ROSENFELD SS, 1985, J BIOL CHEM, V260, P242; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SMITH SJ, 1990, BRIT J PHARMACOL, V100, P779, DOI 10.1111/j.1476-5381.1990.tb14092.x; SOLARO RJ, 1993, MODULATION CARDIAC C, P160; STRYNADK NCJ, 1989, ANNU REV BIOCHEM, V58, P591; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028	23	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19229	19235		10.1074/jbc.272.31.19229	http://dx.doi.org/10.1074/jbc.272.31.19229			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235915	hybrid			2022-12-25	WOS:A1997XP06300021
J	Nagira, M; Imai, T; Hieshima, K; Kusuda, J; Ridanpaa, M; Takagi, S; Nishimura, M; Kakizaki, M; Nomiyama, H; Yoshie, O				Nagira, M; Imai, T; Hieshima, K; Kusuda, J; Ridanpaa, M; Takagi, S; Nishimura, M; Kakizaki, M; Nomiyama, H; Yoshie, O			Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE PROTEIN-10; SEQUENCE; ANGIOGENESIS; INHIBITOR; CELLS; IDENTIFICATION; INTERLEUKIN-8; SIGNALS	By searching the Expressed Sequence Tag (EST) data base, we identified partial cDNA sequences potentially encoding a novel human CC chemokine. We determined the entire cDNA sequence which encodes a highly basic polypeptide of 134 amino acids total with a putative signal peptide of 23 amino acids. The predicted mature protein of 111 amino acids has the four canonical cysteine residues and shows 21-33% identity to other human CC chemokines, but has a unique carboxyl-terminal extension of about 30 amino acids which contains two extra cysteine residues. The mRNA was expressed strongly in tissues such as the lymph nodes, appendix, and spleen. The recombinant protein, which was produced by the baculovirus system and purified to homogeneity, was a highly efficient chemoattractant for certain human T cell lines and a highly potent one for freshly isolated peripheral blood lymphocytes and cultured normal T cells expanded by phytohemagglutinin and interleukin 2. Unlike most other CC chemokines, however, this novel chemokine was not chemotactic for monocytes or neutrophils, suggesting that it is specific for lymphocytes. From these results, we designated this novel CC chemokine as SLC from secondary lymphoid-tissue chemokine. SLC fused with the secreted form of alkaline phosphatase (SLC-SEAP) was used to characterize the SLC receptor. Binding of SLC-SEAP to freshly isolated lymphocytes was blocked by SLC (IC50, 0.12 nM) but not by any other CC chemokine so far tested, suggesting that resting lymphocytes express a class of receptors highly specific for SLC. By using somatic cell hybrids, radiation hybrids, and selected yeast and bacterial artificial chromosome clones, we mapped the SLC gene (SCYA21) at chromosome 9p13 and between chromosomal markers, D9S1978(WI-8765) and AFM326vd1, where the gene for another novel CC chemokine termed ELC from EBI1-ligand chemokine (SCYA19) also exists. Collectively, SLC is a novel CC chemokine specific for lymphocytes and, together with ELC, constitutes a new group of chemokines localized at chromosome 9p13.	SHIONOGI INST MED SCI,OSAKA 566,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED,KUMAMOTO 860,JAPAN; NIH,LAB GENET RESOURCES,SHINJUKU KU,TOKYO 16,JAPAN; UNIV HELSINKI,DEPT MED GENET,HAARTMAN INST,FIN-00280 HELSINKI,FINLAND	Shionogi & Company Limited; Kumamoto University; Kumamoto University; National Institute of Health Sciences - Japan; University of Helsinki			Nomiyama, Hisayuki/F-2840-2013; Hieshima, Kunio/AAF-7040-2019	Nomiyama, Hisayuki/0000-0002-2716-4043; Hieshima, Kunio/0000-0002-7786-4646; Yoshie, Osamu/0000-0003-4353-5809				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BROXMEYER HE, 1990, BLOOD, V76, P1110; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COX DR, 1995, GENOME DIGEST, V4, P14; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Naruse K, 1996, GENOMICS, V34, P236, DOI 10.1006/geno.1996.0274; Nomiyama H, 1997, GENOMICS, V40, P211, DOI 10.1006/geno.1996.4552; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3728; SARRIS AH, 1993, J EXP MED, V178, P1127, DOI 10.1084/jem.178.3.1127; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; VanSnick J, 1996, J IMMUNOL, V157, P2570; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O	37	218	259	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19518	19524		10.1074/jbc.272.31.19518	http://dx.doi.org/10.1074/jbc.272.31.19518			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235955	hybrid			2022-12-25	WOS:A1997XP06300061
J	Nakamura, J; Tajima, G				Nakamura, J; Tajima, G			Independence of two conformations of sarcoplasmic reticulum Ca2+-ATPase molecules in hydrolyzing acetyl phosphate - A two-pair model of the ATPase structural unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODULATED CALCIUM-BINDING; ADENOSINE-TRIPHOSPHATASE; CA-2+-ATPASE; PUMP; TEMPERATURE; SUBSTRATE; MECHANISM; SITES; PH	The sarcoplasmic reticulum Ca2+-ATPase molecules have been shown to exist in two conformations (A and B) that result from intermolecular interaction of ATPase molecules (Nakamura, J., and Tajima, G. (1995) J. Biol. Chem, 270, 17350-17354). The A form binds two calcium ions noncooperatively, whereas the B form binds the calcium ions cooperatively, Here, we examined the in dependence of these two forms in the calcium-activated hydrolysis of acetyl phosphate (AcP) under asynchronous and synchronous conditions of their E-1-E-2 transitions at 0-5 and 25 degrees C. Irrespective of their synchronism and temperature, the two forms hydrolyzed AcP due to calcium that was bound to each of the forms, indicating the independence of the two forms in hydrolyzing AcP. Taking into account the monomer-dimer transition of the ATPase molecules on the sarcoplasmic reticulum membrane accompanying E-1-E-2 transition of the molecules (Dux, L., Taylor, K. A., Ting-Beall, H. P., and Martonosi, A, (1985) J. Biol, Chem. 260, 11730-11743), the two types of molecules seem to independently carry out such monomer-dimer transition of the same type of molecules, Two pairs, each consisting of the same type of molecules, are suggested to be the structural unit of the ATPase molecules.			Nakamura, J (corresponding author), TOHOKU UNIV, INST BIOL, GRAD SCH SCI, AOBA KU, SENDAI, MIYAGI 98077, JAPAN.							BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; De Meis L., 1982, MEMBRANE TRANSPORT C, P141; DEMEIS L, 1969, BIOCHIM BIOPHYS ACTA, V172, P340; DUPONT Y, 1982, BIOCHIM BIOPHYS ACTA, V688, P75, DOI 10.1016/0005-2736(82)90580-6; DUX L, 1985, J BIOL CHEM, V260, P1730; FROEHLICH JP, 1975, J BIOL CHEM, V250, P2013; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; IKEMOTO N, 1982, ANNU REV PHYSIOL, V44, P297, DOI 10.1146/annurev.ph.44.030182.001501; IKEMOTO N, 1981, J BIOL CHEM, V256, P809; IKEMOTO N, 1984, J BIOL CHEM, V259, P1790; IKEMOTO N, 1981, J BIOL CHEM, V256, P8593; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1987, J BIOL CHEM, V262, P16338; LIPMANN F, 1945, J BIOL CHEM, V159, P21; NAKAMURA J, 1986, BIOCHIM BIOPHYS ACTA, V870, P495, DOI 10.1016/0167-4838(86)90258-X; NAKAMURA J, 1994, J BIOL CHEM, V269, P30818; NAKAMURA J, 1983, BIOCHIM BIOPHYS ACTA, V723, P182, DOI 10.1016/0005-2728(83)90118-4; NAKAMURA J, 1995, J BIOL CHEM, V270, P17350, DOI 10.1074/jbc.270.29.17350; NAKAMURA J, 1994, J BIOL CHEM, V269, P30822; NAKAMURA J, 1989, J BIOL CHEM, V264, P17029; NAKAMURA J, 1977, BIOCHIM BIOPHYS ACTA, V18, P108; PUCELL A, 1971, J BIOL CHEM, V246, P3389; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; TADA M, 1978, PHYSIOL REV, V58, P1	25	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19290	19294		10.1074/jbc.272.31.19290	http://dx.doi.org/10.1074/jbc.272.31.19290			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235924	hybrid			2022-12-25	WOS:A1997XP06300030
J	Page, K; Lange, Y				Page, K; Lange, Y			Cell adhesion to fibronectin regulates membrane lipid biosynthesis through 5'-AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; SIGNAL-TRANSDUCTION; HUMAN FIBROBLASTS; PLASMA-MEMBRANE; ATP DEPLETION; FATTY-ACID; PHOSPHORYLATION; CHOLESTEROL; REDUCTASE; INHIBITION	We have shown that attachment to a fibronectin substrate stimulates two pathways of lipid biosynthesis in cultured human fibroblasts. Detachment of these cells (mechanically, with trypsin, or by RGDS peptides) caused a significant decrease in their 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and in their incorporation of [H-3]acetate into fatty acids. This inhibition was substantially reversed by the reattachment of cells to fibronectin substrates, but not to poly-L-lysine substrates or to fibronectin in solution. Inhibiting phosphoprotein phosphatase activity with okadaic acid blocked the recovery of both biosynthetic activities. Both 3-hydroxy-3-methylglutaryl-coenzyme A reductase and fatty acid biosynthesis are known to be inhibited by the action of 5'-AMP-activated protein kinase, which is activated by an increase in the level of AMP relative to ATP, For example, in our system, sodium azide and 2-deoxy-D-glucose increased the ratio of cellular AMP to ATP and caused a decrease in lipid biosynthesis, We then verified the prediction that detachment of cells from substrates also caused an increase in the AMP/ATP ratio. We therefore conclude that the attach ment of cells to fibronectin promotes lipid biosynthesis, presumably in coordination with the cellular growth response evoked by attachment to the extracellular matrix.	RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PATHOL,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT BIOCHEM,CHICAGO,IL 60612	Rush University; Rush University			Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028448, R55HL028448] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN MS, 1973, P NATL ACAD SCI USA, V70, P2162, DOI 10.1073/pnas.70.7.2162; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; GIBSON DM, 1982, ADV ENZYME REGUL, V20, P263, DOI 10.1016/0065-2571(82)90020-6; HARDIE DG, 1992, BIOESSAYS, V14, P699, DOI 10.1002/bies.950141011; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HENIN N, 1995, FASEB J, V9, P541, DOI 10.1096/fasebj.9.7.7737463; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LANGE Y, 1984, J BIOL CHEM, V259, P4624; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; RAO KN, 1995, ANTICANCER RES, V15, P309; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; ROTHBLAT GH, 1976, LIPIDS, V11, P97, DOI 10.1007/BF02532658; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHOBERT B, 1995, ANAL BIOCHEM, V226, P288, DOI 10.1006/abio.1995.1227; SIPERSTEIN MD, 1984, J LIPID RES, V25, P1462; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; WITTERS LA, 1991, BIOCHEM BIOPH RES CO, V181, P1486, DOI 10.1016/0006-291X(91)92107-U; WOODS A, 1992, J CELL SCI, V101, P277; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YEH LA, 1990, J BIOL CHEM, V255, P2308	37	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19339	19342		10.1074/jbc.272.31.19339	http://dx.doi.org/10.1074/jbc.272.31.19339			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235931	hybrid			2022-12-25	WOS:A1997XP06300037
J	WilliamsAbbott, L; Walter, BN; Cheung, TC; Goh, CR; Porter, AG; Ware, CF				WilliamsAbbott, L; Walter, BN; Cheung, TC; Goh, CR; Porter, AG; Ware, CF			The lymphotoxin-alpha (LT alpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LT alpha 1 beta 2 heterotrimeric ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; T-CELL HYBRIDOMA; HETEROMERIC COMPLEX; 33-KDA GLYCOPROTEIN; SURFACE LYMPHOTOXIN; MOLECULAR-CLONING; VIRAL-PROTEINS; MICE DEFICIENT; FACTOR-BETA; FACTOR TNF	The lymphotoxins (LT) alpha and beta, members of the tumor necrosis factor (TNF) cytokine superfamily, are implicated as important regulators and developmental factors for the immune system. LT alpha is secreted as a homotrimer and signals through two TNF receptors of 55-60 kDa (TNFR60) or 75-80 kDa (TNFR80), LT alpha also assembles with LT beta into a membrane-anchored, heterotrimeric LT alpha 1 beta 2 complex that engages a distinct cognate receptor, the LT beta receptor (LT beta R), To investigate the role of the LT alpha subunit in the function of the membrane LT alpha 1 beta 2 complex, gene transfer via baculovirus was used to assemble LT alpha and -beta complexes in insect cells, LT alpha containing mutations at D50N or Y108F are secreted as homotrimers that fail to bind either TNF receptor and are functionally inactive in triggering cell death of the HT29 adenocarcinoma cell line, In contrast, these mutant LT alpha proteins retain the ability to co-assemble with LT beta into membrane-anchored LT alpha 1 beta 2 complexes that engage the LT beta R and trigger the death of HT29 cells, Membrane-anchored LT beta expressed on the cell surface in absence of the LT alpha subunit binds the LT beta R but is functionally inactive in the cell death assay, These results indicate that the TNF receptor-binding regions of the LT alpha subunit are not necessary for engagement of the LT beta R, but the LT alpha subunit is required for the assembly of LT beta into a functional heteromeric ligand.	LA JOLLA INST ALLERGY & IMMUNOL,DIV MOL IMMUNOL,SAN DIEGO,CA 92121; UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92021; NATL UNIV SINGAPORE,INST MOL & CELL BIOL,SINGAPORE 119260,SINGAPORE	La Jolla Institute for Immunology; University of California System; University of California Riverside; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore					NCI NIH HHS [P01 CA69381] Funding Source: Medline; NIAID NIH HHS [AI33068] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033068, R37AI033068] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS JS, 1990, J IMMUNOL, V144, P2582; ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; BANKS TA, 1995, J IMMUNOL, V155, P1685; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BROWNING J, 1989, J IMMUNOL, V143, P1859; Browning JL, 1996, J BIOL CHEM, V271, P8618, DOI 10.1074/jbc.271.15.8618; BROWNING JL, 1991, J IMMUNOL, V147, P1230; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BROWNING JL, 1995, J IMMUNOL, V154, P33; CHAI H, 1993, BIOTECHNOL APPL BIOC, V18, P259; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Ettinger R, 1996, P NATL ACAD SCI USA, V93, P13102, DOI 10.1073/pnas.93.23.13102; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GOH CR, 1991, PROTEIN ENG, V4, P785; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Hochman PS, 1996, J INFLAMM, V46, P220; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; Matsumoto M, 1996, NATURE, V382, P462, DOI 10.1038/382462a0; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1993, J IMMUNOL, V151, P1548; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Rennert PD, 1996, J EXP MED, V184, P1999, DOI 10.1084/jem.184.5.1999; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; WARE CF, 1992, J IMMUNOL, V149, P3881; WARE CF, 1995, PATHWAYS CYTOLYSIS, P175	43	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19451	19456		10.1074/jbc.272.31.19451	http://dx.doi.org/10.1074/jbc.272.31.19451			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235946	hybrid			2022-12-25	WOS:A1997XP06300052
J	Lores, P; Morin, L; Luna, R; Gacon, G				Lores, P; Morin, L; Luna, R; Gacon, G			Enhanced apoptosis in the thymus of transgenic mice expressing constitutively activated forms of human Rac2GTPase	ONCOGENE			English	Article						Rac2GTPase; thymocyte; apoptosis; transgenic mice	GTP-BINDING-PROTEIN; THYMOCYTE DEVELOPMENT; HEMATOPOIETIC-CELLS; NADPH OXIDASE; LYMPHOCYTES; IDENTIFICATION; RAC	Rac proteins constitute a subgroup of the Rho family of small GTPases and include Rac1, which is expressed ubiquitously, and Rac2, a highly homologous protein only expressed in myelo-monocytic and lymphoid cell lineages. In fibroblasts, Rad plays a crucial role in control of actin cytoskeleton organisation, cell growth and Ras-induced transformation. In phagocyte, Rac1 and Rac2 regulate a specific enzymatic complex, NADPH oxidase. These multiple functions have been ascribed to Rac proteins only on the basis of cell culture and in vitro biochemical studies. To examine the role of Rac2 in vivo in a T cell lineage, we have expressed either wild-type or constitutively-activated forms of human Rac2 (Rac2V12 and Rac2L61) in transgenic mice under control of the thymus specific lck proximal promoter. We report here a striking atrophy of the thymus in mice expressing even low levels of either of the activated mutants of Rac2, while expression of Rac2wt has no effect. This phenotype is correlated with a marked decrease in the number of double positive (CD4 + CD8 +) and single positive (CD4 + CD8 - and CD8 + CD4 -) thymocytes, Cellular and molecular analyses demonstrate that this defect is due to an increase in apoptosis among thymocytes. As Rac2 is normally expressed in thymocytes and activated T cells, me propose that Rac2 dependent pathways could play an important role in control of growth and death of T cells.	INST COCHIN GENET MOL,INSERM,U257,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			LUNA, ROSA/F-3974-2016	LUNA, ROSA/0000-0002-6131-6610; Lores, Patrick/0000-0002-3191-9488				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHETTY M, 1995, BIOCHEM J, V306, P141, DOI 10.1042/bj3060141; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOBAYASHI S, 1995, J BIOCHEM, V117, P758, DOI 10.1093/oxfordjournals.jbchem.a124773; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Osborne BA, 1996, CURR OPIN IMMUNOL, V8, P245, DOI 10.1016/S0952-7915(96)80063-X; QUI RG, 1995, NATURE, V374, P457; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SHIRSAT NV, 1990, ONCOGENE, V5, P769; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	27	60	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					601	605		10.1038/sj.onc.1201378	http://dx.doi.org/10.1038/sj.onc.1201378			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247314				2022-12-25	WOS:A1997XN25500012
J	Martinelli, R; Blandino, G; Scardigli, R; Crescenzi, M; Lombardi, D; Sacchi, A; Soddu, S				Martinelli, R; Blandino, G; Scardigli, R; Crescenzi, M; Lombardi, D; Sacchi, A; Soddu, S			Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells	ONCOGENE			English	Article						differentiation; tumor suppression; cellular environment	GRANULOCYTIC DIFFERENTIATION; LINE; PROLIFERATION; APOPTOSIS; GROWTH; MACROPHAGE; RECEPTOR; BLOCKS	Expression of exogenous wt-p53 in different tumor cell lines can induce growth arrest, apoptosis, or differentiation. Several experimental works have highlighted the relevance of cellular context in the determination of p53-mediated final outcomes. We recently observed that these diverse wt-p53 effects can also be induced by overexpressing wt-p53 in a single cell type-the 32D myeloid progenitors-transformed with different activated oncogenes. Here we show that 32D cells transformed with two different oncogenes, v-src or c-fms [S301,F969], both belonging to the CSF-1 transduction pathway, respond to exogenous wt-p53 expression with the same final outcome-monocytic differentiation. This result is particularly significant since 32D cells do not spontaneously express the CSF-1 receptor, whereas they undergo granulocytic differentiation upon G-CSF stimulation. These data strongly support the idea that wt-p53 suppressing effects result from interactions between p53 activity and the signaling pathways activated in different transformed cells.	CRS,REGINA ELENA CANC INST,MOL ONCOGENESIS LAB,I-00158 ROME,ITALY; UNIV AQUILA,DEPT EXPT MED,I-67100 LAQUILA,ITALY	University of L'Aquila			Blandino, Giovanni/B-1137-2013; Soddu, Silvia/ABH-6774-2020; Soddu, Silvia/K-2467-2018; Crescenzi, Marco/J-3603-2018	Blandino, Giovanni/0000-0002-6970-2241; Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; Crescenzi, Marco/0000-0003-0156-1494; Scardigli, Raffaella/0000-0003-1369-0496				ANDERSON SM, 1990, ONCOGENE, V5, P317; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BLANDINO G, 1995, ONCOGENE, V10, P731; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBERGER JS, 1983, FED PROC, V42, P2762; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HUME DA, 1983, J EXP MED, V158, P1522, DOI 10.1084/jem.158.5.1522; KRUGER A, 1991, ONCOGENE, V6, P245; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; MAVILIO F, 1989, ONCOGENE, V4, P301; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; ROVERA G, 1987, ONCOGENE, V1, P29; Soddu S, 1996, MOL CELL BIOL, V16, P487; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; VALTIERI M, 1987, J IMMUNOL, V138, P3829	24	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					607	611		10.1038/sj.onc.1201218	http://dx.doi.org/10.1038/sj.onc.1201218			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247315				2022-12-25	WOS:A1997XN25500013
J	Spanjaard, RA; Ikeda, M; Lee, PJ; Charpentier, B; Chin, WW; Eberlein, TJ				Spanjaard, RA; Ikeda, M; Lee, PJ; Charpentier, B; Chin, WW; Eberlein, TJ			Specific activation of retinoic acid receptors (RARs) and retinoid X receptors reveals a unique role for RAR gamma in induction of differentiation and apoptosis of S91 melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; EMBRYONAL CARCINOMA-CELLS; HUMAN LUNG-CANCER; THYROID-HORMONE-RECEPTOR; BETA-GENE; GRANULOCYTIC DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; TISSUE TRANSGLUTAMINASE; TARGETED DISRUPTION; NUCLEAR RECEPTORS	Retinoic acid (RA) and 9-cis-RA induce growth arrest and differentiation of S91 melanoma cells. RA activates retinoic acid receptors (RARs), whereas 9-cis-RA activates both RARs and retinoid X receptors (RXRs). Both classes of receptors function as ligand-dependent transcription factors. S91 melanoma cells contain mRNA for RXR alpha, RXR beta, RAR alpha, RAR gamma, and RAR beta in low levels. Among these, only RAR beta gene transcription is induced by retinoids. However, at present the individual role(s) for each RXR and RAR isoform in these processes is unclear. We assessed the function of all isoforms in the S91 melanoma model by using RXR and RAR isoform-specific retinoids to study their effects on cell growth, RAR beta expression, and differentiation. Activation of each of the endogenous RXR or RAR isoforms induces RAR beta gene expression, and blocks cellular proliferation. However, only the RAR gamma-ligands cause additional differentiation toward a melanocytic phenotype, which coincides with substantial apoptosis well before morphological changes are apparent. Apoptosis is completely dependent on de novo protein synthesis but cannot be induced by changes in activities of AP-1, protein kinase C, and protein kinase A, nor can it be blocked by the presence of the antioxidant glutathione. These results argue against a specific role for RAR beta, but suggest that RAR gamma has a critical role in a genetic switch between melanocytes and melanoma, and induction of ligand-dependent apoptosis.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV GENET, BOSTON, MA 02115 USA; CTR INT RECH DERMATOL GALDERMA, F-06565 VALBONNE, FRANCE	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Galderma R&D SNC	Spanjaard, RA (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT SURG, DIV SURG ONCOL, LAB BIOL CANC THERAPY, BOSTON, MA 02115 USA.							AMOS B, 1990, METHOD ENZYMOL, V190, P217; ANZAI N, 1994, LEUKEMIA, V8, P446; ATENCIA R, 1994, EXP CELL RES, V214, P663, DOI 10.1006/excr.1994.1304; Beard RL, 1996, J MED CHEM, V39, P3556, DOI 10.1021/jm960386h; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; Charpentier B, 1995, J MED CHEM, V38, P4993, DOI 10.1021/jm00026a006; CHARPENTIER B, 1993, Patent No. 658553; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DARMON M, 1988, Skin Pharmacology, V1, P161; DAWSON MI, 1995, CANCER RES, V55, P4446; DE LUCA LM, 1991, FASEB J, V5, P2924; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DIVINCI A, 1994, INT J CANCER, V59, P422, DOI 10.1002/ijc.2910590322; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; ELIA D, 1993, CANCER RES, V53, P6036; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; GANDRILLON O, 1994, ONCOGENE, V9, P749; GEBERT JF, 1991, ONCOGENE, V6, P1859; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; KALEMKERIAN GP, 1995, J NATL CANCER I, V87, P1674, DOI 10.1093/jnci/87.22.1674; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; Li JJ, 1996, CANCER RES, V56, P483; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1994, CANCER RES, V54, pS1987; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LOTAN R, 1978, J NATL CANCER I, V60, P1035, DOI 10.1093/jnci/60.5.1035; LOTAN R, 1981, J CELL PHYSIOL, V106, P179, DOI 10.1002/jcp.1041060203; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARIOTTI A, 1994, J NATL CANCER I, V86, P1245, DOI 10.1093/jnci/86.16.1245; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MARSHALL GM, 1995, ONCOGENE, V11, P485; MARSHALL GM, 1994, ANTICANCER RES, V14, P437; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MCBURNEY MW, 1993, CANCER INVEST, V11, P590, DOI 10.3109/07357909309011677; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAGY L, 1995, MOL CELL BIOL, V15, P3540; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; PONZONI M, 1995, CANCER RES, V55, P853; PRATT MAC, 1993, DIFFERENTIATION, V53, P105, DOI 10.1111/j.1432-0436.1993.tb00650.x; REDFERN CPF, 1990, FEBS LETT, V273, P19, DOI 10.1016/0014-5793(90)81041-L; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; RUDD CJ, 1993, CANCER LETT, V73, P41, DOI 10.1016/0304-3835(93)90186-D; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schadendorf D, 1995, Recent Results Cancer Res, V139, P183; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SIDELL N, 1995, INT J CANCER, V60, P507, DOI 10.1002/ijc.2910600414; SPANJAARD RA, 1994, MOL ENDOCRINOL, V8, P286, DOI 10.1210/me.8.3.286; SPANJAARD RA, 1995, J BIOL CHEM, V270, P17429, DOI 10.1074/jbc.270.29.17429; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; UNDERHILL TM, 1994, MOL ENDOCRINOL, V8, P274, DOI 10.1210/me.8.3.274; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WUARIN L, 1994, INT J CANCER, V56, P840, DOI 10.1002/ijc.2910560615; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022; ZHANG XK, 1994, CANCER RES, V54, P5663; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	90	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18990	18999		10.1074/jbc.272.30.18990	http://dx.doi.org/10.1074/jbc.272.30.18990			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228081	hybrid			2022-12-25	WOS:A1997XM34200072
J	Freyaldenhoven, BS; Freyaldenhoven, MP; Iacovoni, JS; Vogt, PK				Freyaldenhoven, BS; Freyaldenhoven, MP; Iacovoni, JS; Vogt, PK			Avian winged helix proteins CWH-1, CWH-2 and CWH-3 repress transcription from Qin binding sites	ONCOGENE			English	Article						winged helix domain; transcriptional repression; DNA binding; repression domain	GENE FORK-HEAD; TUMOR ALVEOLAR RHABDOMYOSARCOMA; FAMILY; MEMBER; ONCOGENE; PAX3; RECOGNITION; BELONGS; FUSION	The chicken winged helix proteins, CWH-1, CWH-2 and CWH-3, were isolated and identified by homology cloning using the winged helix sequence of the retroviral oncogene qin as a probe. The CWH proteins act as growth stimulators in chicken embryo fibroblasts and in this activity resemble the Qin protein. Qin is a transcriptional regulator that functions as a repressor, and its oncogenic potential is correlated with the ability to repress transcription. In this communication we show that CWH proteins are localized in the cell nucleus, recognize the Qin DNA binding site and also function as transcriptional repressors. The repression activity of CWH-3 was mapped to the region of amino acids 211 to 311, a domain that is homologous to the major repression domain of Qin.	SCRIPPS RES INST, DIV ONCOVIROL, BCC239, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA	Scripps Research Institute			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BOEGE KA, 1995, GENE CHROMOSOME CANC, V12, P186; Chang HW, 1996, ONCOGENE, V13, P441; CHANG HW, 1995, P NATL ACAD SCI USA, V92, P447, DOI 10.1073/pnas.92.2.447; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1994, LIVER GENE TRANSCRIP, P183; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; FEDERSPIEL MJ, 1994, VIROLOGY, V203, P211, DOI 10.1006/viro.1994.1478; Freyaldenhoven BS, 1997, CANCER RES, V57, P123; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LI J, 1995, CANCER RES, V55, P5540; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; MADDEN SL, 1993, ONCOGENE, V8, P1713; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO DN, 1993, CANCER RES, V53, P5108; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7	29	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					483	488		10.1038/sj.onc.1201189	http://dx.doi.org/10.1038/sj.onc.1201189			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242385				2022-12-25	WOS:A1997XM23800013
J	Mattia, E; Chichiarelli, S; Hickish, T; Gaeta, A; Mancini, C; Cunningham, D; vanRenswoude, J				Mattia, E; Chichiarelli, S; Hickish, T; Gaeta, A; Mancini, C; Cunningham, D; vanRenswoude, J			Inhibition of in vitro proliferation of Epstein Barr Virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1	ONCOGENE			English	Article						EBV; LMP1 expression; antisense oligodeoxynucleotides	HODGKINS-DISEASE; GENE-EXPRESSION; DIFFERENTIATION; TRANSFORMATION		UNIV ROMA LA SAPIENZA,FAC MED & SURG,DEPT EXPT MED & PATHOL,ROME,ITALY; ROYAL MARSDEN HOSP,LYMPHOMA UNIT,SUTTON,SURREY,ENGLAND	Sapienza University Rome; Royal Marsden NHS Foundation Trust	Mattia, E (corresponding author), UNIV ROMA LA SAPIENZA,FAC MED & SURG,INST MICROBIOL,ROME,ITALY.		Chichiarelli, Silvia/F-1226-2011	Hickish, Tamas/0000-0001-6770-7279; Cunningham, David/0000-0001-5158-1069; Chichiarelli, Silvia/0000-0002-5682-0353				BROCKSMITH D, 1991, J PATHOL, V165, P11, DOI 10.1002/path.1711650104; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; CHEUNG RK, 1993, INT IMMUNOL, V5, P707, DOI 10.1093/intimm/5.7.707; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERBST H, 1990, AM J PATHOL, V137, P13; HERBST H, 1992, BLOOD, V80, P484; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; JOSKE DJL, 1992, BLOOD, V80, P2610; KHAN G, 1993, CANCER-AM CANCER SOC, V71, P3124, DOI 10.1002/1097-0142(19930515)71:10<3124::AID-CNCR2820711038>3.0.CO;2-J; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MILLER G, 1990, VIROLOGY, P1921; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; ROTH G, 1994, BLOOD, V84, P582, DOI 10.1182/blood.V84.2.582.bloodjournal842582; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B	23	12	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					489	493		10.1038/sj.onc.1201183	http://dx.doi.org/10.1038/sj.onc.1201183			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242386	Bronze			2022-12-25	WOS:A1997XM23800014
J	Brown, R; Hirst, GL; Gallagher, WM; McIlwrath, AJ; Margison, GP; vanderZee, AGJ; Anthoney, DA				Brown, R; Hirst, GL; Gallagher, WM; McIlwrath, AJ; Margison, GP; vanderZee, AGJ; Anthoney, DA			hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.	ONCOGENE			English	Article						cisplatin; drug resistance; mismatch repair; ovarian cancer	MISMATCH REPAIR; MICROSATELLITE INSTABILITY; MOLECULAR ANALYSIS; CISPLATIN; DNA; CANCER; TOLERANCE; ADDUCTS; LINES; ACCUMULATION	Loss of expression of the hMLH1 and hPMS2 subunits of the MutL alpha-mismatch repair complex is a frequent event (9/10) in independent cisplatin resistant derivatives of a human ovarian carcinoma cell line, However, only hMLH1 mRNA is decreased in these MutL alpha-deficient lines, No alterations in the levels of the hMSH2 and hMSH6 (GTBP) subunits of the MutS alpha-comples are observed, An increase in the proportion of ovarian tumours negative for the hMLH1 subunit is observed in samples taken at second look laporotomy after chemotherapy (36%: 4/11), compared to untreated tumours (10%: 4/39), No significant difference is observed for hMSH2, hMSH6 or hPMS2. Furthermore, cisplatin and doxorubicin-resistant ovarian lines deficient in hMLH1 expression are cross-resistant to 6-thioguanine and the methylating agent N-methyl-N-nitrosourea (MNU). Depletion of O-6-alkylguanine-DNA-alkyltransferase (ATase) activity confers only limited increased sensitivity to MNU. Thus the mismatch repair deficient lines retain DNA damage tolerance even after ATase depletion, The hMLH1 deficient lines also lose ability to engage G1 and G2 cell cycle arrest after cisplatin damage, Together these data suggest that loss of hMLH1 expression may be a high frequency event following exposure of ovarian tumour cells to cisplatin and may be critically involved in the development of drug resistance, Thus, the hMLH1 status of these cells appears to be highly correlated with the ability to engage cell death and cell cycle arrest after DNA damage induced by cisplatin.	CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC,DEPT CARCINOGENESIS,MANCHESTER M20 9BX,LANCS,ENGLAND; UNIV GRONINGEN HOSP,DEPT GYNAECOL ONCOL,GRONINGEN,NETHERLANDS	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Groningen	Brown, R (corresponding author), UNIV GLASGOW,CRC,BEATSON LABS,DEPT MED ONCOL,SWITCHBACK RD,GLASGOW G61 1BD,LANARK,SCOTLAND.		Margison, Geoff/E-4146-2019	Gallagher, William/0000-0002-4307-5999; Hirst, Gillian/0000-0002-4502-0035				Aebi S, 1996, CANCER RES, V56, P3087; Anthoney DA, 1996, CANCER RES, V56, P1374; AQUILINA G, 1990, CANCER RES, V50, P4248; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Bubb VJ, 1996, ONCOGENE, V12, P2641; Chambers SR, 1996, MOL CELL BIOL, V16, P6110; DOLAN ME, 1990, CANCER COMMUN, V2, P371, DOI 10.3727/095535490820873985; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; EVANS DL, 1994, CANCER RES, V54, P1596; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; Fink D, 1996, CANCER RES, V56, P4881; Fujita M, 1995, INT J CANCER, V64, P361, DOI 10.1002/ijc.2910640602; Gallagher WM, 1997, ONCOGENE, V14, P185; HAWN MT, 1995, CANCER RES, V55, P3721; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kaye SB, 1996, ANN ONCOL, V7, P9; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; KOI M, 1994, CANCER RES, V54, P4308; MAMENTA EL, 1994, CANCER RES, V54, P3500; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; MORTEN JEN, 1988, CARCINOGENESIS, V9, P45, DOI 10.1093/carcin/9.1.45; MURPHY DS, 1995, J NATL CANCER I, V87, P1694, DOI 10.1093/jnci/87.22.1694; ORMEROD MG, 1994, EXP CELL RES, V211, P231, DOI 10.1006/excr.1994.1082; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Paulson TG, 1996, CANCER RES, V56, P4021; REED E, 1995, SEMIN ONCOL, V22, P90; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; UMAR A, 1994, J BIOL CHEM, V269, P14367; VANDERZEE AGJ, 1995, J CLIN ONCOL, V13, P70, DOI 10.1200/JCO.1995.13.1.70; VANDERZEE AGJ, 1994, ANN ONCOL, V5, P75, DOI 10.1093/oxfordjournals.annonc.a058700; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; ZAMPLE DB, 1995, TIBS, V20, P435	41	224	224	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					45	52		10.1038/sj.onc.1201167	http://dx.doi.org/10.1038/sj.onc.1201167			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233776				2022-12-25	WOS:A1997XH58600005
J	Ismailov, II; KieberEmmons, T; Lin, CM; Berdiev, BK; Shlyonsky, VG; Patton, HK; Fuller, CM; Worrell, R; Zuckerman, JB; Sun, W; Eaton, DC; Benos, DJ; Kleyman, TR				Ismailov, II; KieberEmmons, T; Lin, CM; Berdiev, BK; Shlyonsky, VG; Patton, HK; Fuller, CM; Worrell, R; Zuckerman, JB; Sun, W; Eaton, DC; Benos, DJ; Kleyman, TR			Identification of an amiloride binding domain within the alpha-subunit of the epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; DISTINCT EPITOPES; MEMBRANE TOPOLOGY; MOLECULAR-CLONING; ANTIBODIES; SELECTIVITY; PROTEINS; PORE	Limited information is available regarding domains within the epithelial Na+ channel (ENaC) which participate in amiloride binding, We previously utilized the anti-amiloride antibody (BA7.1) as a surrogate amiloride receptor to delineate amino acid residues that con??? tact amiloride, and identified a putative amiloride binding domain WYRFHY (residues 278-283) within the extracellular domain of alpha rENaC. Mutations were generated to examine the role of this sequence in amiloride binding, Functional analyses of wild type (wt) and mutant alpha rENaCs were performed by cRNA expression in Xenopus oocytes and by reconstitution into planar lipid bilayers, Wild type alpha rENaC was inhibited by amiloride with a K-i of 169 nM. Deletion of the entire WYRFHY tract (alpha rENaC Delta 278-283) resulted in a loss of sensitivity of the channel to submicromolar concentrations off amiloride (K-i = 26.5 mu M). Similar results were obtained when either alpha rENaC or alpha rENaC Delta 278-283 were co-expressed with wt beta- and alpha rENaC (K-i values of 155 nM and 22.8 mu m, respectively), Moreover, alpha rENaC H282D was insensitive to submicromolar concentrations of amiloride (K-i = 6.52 mu M), whereas alpha rENaC H282R was inhibited by amiloride with a K-i of 29 nM. These mutations do not alter ENaC Na+:K+ selectivity nor single-channel conductance,These data suggest that residues within the tract WYRFHY participate in amiloride binding, Our results, in conjunction with recent studies demonstrating that mutations within the membrane-spanning domains of alpha rENaC and mutations preceding the second membrane-spanning domains of alpha-, beta-, and gamma rENaC alters amiloride's K-i, suggest that selected regions of the extracellular loop of alpha rENaC may be in close proximity to residues within the channel pore.	VET ADM MED CTR, MED RES 151, PHILADELPHIA, PA 19104 USA; UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, BIRMINGHAM, AL 35294 USA; UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, INST NEUROL SCI, PHILADELPHIA, PA 19104 USA; VET ADM MED CTR, PHILADELPHIA, PA 19104 USA; EMORY UNIV, DEPT PHYSIOL, ATLANTA, GA 30322 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); Emory University			Zuckerman, Jonathan/AAU-1857-2020; Fuller, Cathy/B-4046-2011	Shlyonsky, Vadim/0000-0003-2999-6553; Zuckerman, Jonathan/0000-0002-8190-9210; Eaton, Douglas/0000-0002-2686-6692	NIDDK NIH HHS [DK09215, DK51391, DK27206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK051391, F32DK009215, R01DK051391] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1996, J AM SOC NEPHROL, V7, pA0137; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; BALABAN RS, 1979, J MEMBRANE BIOL, V49, P363, DOI 10.1007/BF01868992; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; Busch AE, 1996, PFLUG ARCH EUR J PHY, V432, P760, DOI 10.1007/s004240050196; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; Fuller CM, 1997, BIOPHYS J, V72, P1622, DOI 10.1016/S0006-3495(97)78808-8; FULLER CM, 1995, AM J PHYSIOL-CELL PH, V269, pC641, DOI 10.1152/ajpcell.1995.269.3.C641; GOTTLIEB GP, 1978, BIOPHYS J, V22, P125, DOI 10.1016/S0006-3495(78)85477-0; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; ISMAIIOV II, 1997, IN PRESS J PHYSL; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; KIEBEREMMONS T, 1995, KIDNEY INT, V48, P956, DOI 10.1038/ki.1995.377; KLEYMAN TR, 1986, AM J PHYSIOL, V250, pC165, DOI 10.1152/ajpcell.1986.250.1.C165; KLEYMAN TR, 1989, AM J PHYSIOL, V257, pC1135, DOI 10.1152/ajpcell.1989.257.6.C1135; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; KLEYMAN TR, 1991, AM J PHYSIOL, V260, pC271, DOI 10.1152/ajpcell.1991.260.2.C271; LI JHY, 1985, J MEMBRANE BIOL, V83, P45, DOI 10.1007/BF01868737; LI JHY, 1982, BASIC MECHANISMS ACT, P28; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LIN CM, 1994, J BIOL CHEM, V269, P2805; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; MYERS VB, 1972, BIOCHIM BIOPHYS ACTA, V274, P313, DOI 10.1016/0005-2736(72)90179-4; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; RENARD S, 1994, J BIOL CHEM, V269, P12981; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; VANDRIESSCHE W, 1983, PFLUG ARCH EUR J PHY, V398, P179, DOI 10.1007/BF00657149; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; WARNCKE J, 1985, J MEMBRANE BIOL, V86, P255, DOI 10.1007/BF01870605; YUN CHC, 1993, BIOCHEM BIOPH RES CO, V193, P532, DOI 10.1006/bbrc.1993.1656	43	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21075	21083		10.1074/jbc.272.34.21075	http://dx.doi.org/10.1074/jbc.272.34.21075			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261110	hybrid			2022-12-25	WOS:A1997XR78900020
J	Lundquist, AJ; Beger, RD; Bennett, SE; Bolton, PH; Mosbaugh, DW				Lundquist, AJ; Beger, RD; Bennett, SE; Bolton, PH; Mosbaugh, DW			Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein - Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BACILLUS-SUBTILIS; BACTERIOPHAGE-PBS2; REPAIR; EXPRESSION; SEQUENCE; CLONING; MIMICRY; GENE; UGI	Bacteriophage PBS2 uracil-DNA glycosylase inhibitor (Ugi) protein inactivates uracil-DNA glycosylase (Ung) by acting as a DNA mimic to bind Ung in an irreversible complex, Seven mutant Ugi proteins (E20I, E27A, E28L, E30L, E31L, D61G, and E78V) mere created to assess the role of various negatively charged residues in the binding mechanism, Each mutant Ugi protein was purified and characterized with respect to inhibitor activity and Ung binding properties relative to the wild type Ugi. Analysis of the Ugi protein solution structures by nuclear magnetic resonance indicated that the mutant Ugi proteins were folded into the same general conformation as wild type Ugi, All seven of the Ugi proteins were capable of forming a Ung Ugi complex but varied considerably in their individual ability to inhibit Ung activity, Like the wild type Ugi, five of the mutants formed an irreversible complex with Ung; however, the binding of Ugi E20I and E28L to Ung was shown to be reversible, The tertiary structure of [C-13,N-15]Ugi in complex with Ung was determined by solution state multi-dimensional nuclear magnetic resonance and compared with the unbound Ugi structure, Structural and functional analysis of these proteins have elucidated the two-step mechanism involved in Ung.Ugi association and irreversible complex formation.	WESLEYAN UNIV, DEPT CHEM, MIDDLETOWN, CT 06459 USA; OREGON STATE UNIV, ENVIRONM HLTH SCI CTR, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, DEPT AGR CHEM, CORVALLIS, OR 97331 USA; OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA	Wesleyan University; Oregon State University; Oregon State University; Oregon State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAN S, 1995, J BIOL CHEM, V270, P296, DOI 10.1074/jbc.270.1.296; BEGER RD, 1995, J BIOL CHEM, V270, P16840, DOI 10.1074/jbc.270.28.16840; BEGER RD, 1997, IN PRESS J BIOMOL NM; BENNETT SE, 1993, J BIOL CHEM, V268, P26879; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; BENNETT SE, 1995, THESIS OREGON STATE; BRUNGER AT, 1993, SCIENCE, V261, P328, DOI 10.1126/science.8332897; Caradonna S, 1996, EXP CELL RES, V222, P345, DOI 10.1006/excr.1996.0044; CONE R, 1980, J BIOL CHEM, V255, P16354; DYSON HJ, 1994, 2 DIMENSIONAL NMR SP, P655; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; Hull W., 1994, 2 DIMENSIONAL NMR SP, P67; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; Kessler H., 1994, 2 DIMENSIONAL NMR SP, P619; KOLLMAN PA, 1990, ACCOUNTS CHEM RES, V23, P246, DOI 10.1021/ar00176a002; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMASTER DM, 1994, PROG NMR SPECTROSCOP, V26, P349; LONGLEY M J, 1989, Methods in Molecular and Cellular Biology, V1, P79; LONGLEY MJ, 1993, METHOD ENZYMOL, V218, P587; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; NIGLES M, 1988, FEBS LETT, V229, P317; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; PEAR LH, 1996, UDI PROTEIN DATA BAN, V1; PRICE AR, 1975, J BIOL CHEM, V250, P8804; REISNER AH, 1984, METHOD ENZYMOL, V104, P439; Sanderson RJ, 1996, J BIOL CHEM, V271, P29170, DOI 10.1074/jbc.271.46.29170; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SAVVA R, 1995, PROTEINS, V22, P287, DOI 10.1002/prot.340220310; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1991, GENE, V99, P31	41	21	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21408	21419		10.1074/jbc.272.34.21408	http://dx.doi.org/10.1074/jbc.272.34.21408			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261156	hybrid			2022-12-25	WOS:A1997XR78900066
J	Rohlff, C; Ahmad, S; Borellini, F; Lei, J; Glazer, RI				Rohlff, C; Ahmad, S; Borellini, F; Lei, J; Glazer, RI			Modulation of transcription factor Sp1 by cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HL-60 LEUKEMIA-CELLS; MONOPHOSPHATE-RESPONSIVE SEQUENCE; CYCLIC-NUCLEOTIDE BINDING; RII-BETA-SUBUNIT; DNA-BINDING; NEGATIVE REGULATION; GENE-TRANSCRIPTION; SOMATOSTATIN GENE; RETROVIRAL VECTOR; PROMOTER REGION	Transcription factor Spl is a phosphoprotein whose level and DNA binding activity are markedly increased in doxorubicin-resistant HL-60 (HL-60/AR) leukemia cells, The trans-activating and DNA binding properties of Spl in HL-60/AR cells are stimulated by cAMP-dependent protein kinase (PKA) and PKA agonists and inhibited by PKA antagonists as well as by the PKA regulatory subunit, Reporter gene activity under the control of the Spl-dependent SV40 promoter is stimulated in insect cells transiently expressing Spl and PKA, and the DNA binding activity of recombinant Spl is activated by exogenous PKA in vitro, These results indicate that Spl is a cAMP-responsive transcription factor and that Spl-dependent genes may be modulated through a cAMP-dependent signaling pathway.	GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,LOMBARDI CANC CTR,WASHINGTON,DC 20007	Georgetown University; Georgetown University					NATIONAL CANCER INSTITUTE [P50CA058185, R55CA057244] Funding Source: NIH RePORTER; NCI NIH HHS [2P50-CA58185-04, R55CA57244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLGREN R, 1990, J BIOL CHEM, V265, P3313; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAKKE M, 1992, MOL ENDOCRINOL, V6, P1323, DOI 10.1210/me.6.8.1323; BARRERASALDANA H, 1985, EMBO J, V4, P3839, DOI 10.1002/j.1460-2075.1985.tb04156.x; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BHALLA K, 1985, CANCER RES, V45, P3657; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HABENER JF, 1990, EUR J BIOCHEM, V132, P297; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; He YF, 1996, BBA-GENE STRUCT EXPR, V1306, P179, DOI 10.1016/0167-4781(96)00005-X; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1990, J CELL BIOCHEM, V143, P118; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KERLAVAGE AR, 1982, J BIOL CHEM, V257, P1749; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LUND J, 1990, J BIOL CHEM, V265, P3304; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MCGEADY ML, 1990, J VIROL, V64, P3527, DOI 10.1128/JVI.64.7.3527-3531.1990; MERINO A, 1989, J BIOL CHEM, V264, P21266; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOMOI K, 1992, MOL ENDOCRINOL, V6, P1682, DOI 10.1210/me.6.10.1682; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROHLFF C, 1993, MOL PHARMACOL, V43, P372; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; SMITHGALL TE, 1992, BIOCHEMISTRY-US, V31, P4828, DOI 10.1021/bi00135a013; SUMMERS MD, 1987, 1555 COLL STAT TEX A; TORTORA G, 1994, CELL GROWTH DIFFER, V5, P753; UEDA K, 1987, J BIOL CHEM, V262, P17432; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; ZHU QC, 1994, CANCER RES, V54, P4488	52	193	194	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21137	21141		10.1074/jbc.272.34.21137	http://dx.doi.org/10.1074/jbc.272.34.21137			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261118	hybrid			2022-12-25	WOS:A1997XR78900028
J	Akhlynina, TV; Jans, DA; Rosenkranz, AA; Statsyuk, NV; Balashova, IY; Toth, G; Pavo, I; Rubin, AB; Sobolev, AS				Akhlynina, TV; Jans, DA; Rosenkranz, AA; Statsyuk, NV; Balashova, IY; Toth, G; Pavo, I; Rubin, AB; Sobolev, AS			Nuclear targeting of chlorin e(6) enhances its photosensitizing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II SITE FLANKING; SV40 T-ANTIGEN; PHOTODYNAMIC THERAPY; PROTEIN-TRANSPORT; CARCINOMA-CELLS; PHOTOFRIN-II; INSULIN; PHOSPHORYLATION; LOCALIZATION; E6	Although photosensitizers, molecules that produce active oxygen species upon activation by visible light, are being extensively used in photodynamic therapy to treat cancer and other clinical conditions, problems include normal cell and tissue damage and associated side effects, which are attributable in part to the fact that cytotoxic effects are largely restricted to the plasma membrane, We have previously shown that the photosensitizer chlorin e(6) has significantly higher photosensitizing activity when present in conjugates containing specific ligands and thus able to be internalized by receptor-expressing cells. In this study we use insulin-containing conjugates to which variants of the simian virus SV40 large tumor antigen nuclear localization signal (NLS) were linked to target chlorin e(6) to the nucleus, a hypersensitive site for active oxygen species-induced damage. NLSs were either included as peptides crosslinked to the carrier bovine serum albumin or encoded within the sequence of a beta-galactosidase fusion protein carrier. The results for photosensitization demonstrate clearly for the first time that NLSs increase the photosensitizing activity of chlorin e(6), maximally reducing the EC50 by a factor of over 2000-fold. This has wide-reaching implications for achieving efficient cell type-specific photodynamic therapy.	MOSCOW MV LOMONOSOV STATE UNIV,FAC BIOL,DEPT BIOPHYS,MOSCOW 119899,RUSSIA; RUSSIAN INST AGR BIOTECHNOL,BIOPHYS LAB,MOSCOW 127550,RUSSIA; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV BIOCHEM & MOL BIOL,NUCL SIGNALING LAB,CANBERRA,ACT 2601,AUSTRALIA; UNIV SZEGED,INST MED CHEM,H-6720 SZEGED,HUNGARY	Lomonosov Moscow State University; All-Russia Research Institute of Agricultural Biotechnology; Australian National University; John Curtin School of Medical Research; Szeged University			Rosenkranz, Andrey A/J-3514-2015; Andrei, Rubin/U-6451-2019; Pavo, Imre/AAZ-6421-2021; Statsyuk, Natalia V./P-6383-2014; Sobolev, Alexander S./P-6302-2015	Rosenkranz, Andrey A/0000-0001-9941-6118; Pavo, Imre/0000-0002-2016-7049; Statsyuk, Natalia V./0000-0001-6159-148X; Sobolev, Alexander S./0000-0001-8315-7764				AKHLYNINA TV, 1995, CANCER RES, V55, P1014; AKHLYNINA TV, 1993, PHOTOCHEM PHOTOBIOL, V58, P45, DOI 10.1111/j.1751-1097.1993.tb04901.x; Alper T., 1979, CELLULAR RADIOBIOLOG; BACHOR R, 1991, P NATL ACAD SCI USA, V88, P1580, DOI 10.1073/pnas.88.4.1580; FINLAY GJ, 1984, ANAL BIOCHEM, V139, P272, DOI 10.1016/0003-2697(84)90002-2; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; LEVY JG, 1995, TRENDS BIOTECHNOL, V13, P14, DOI 10.1016/S0167-7799(00)88895-2; MANYAK MJ, 1988, J CLIN ONCOL, V6, P380, DOI 10.1200/JCO.1988.6.2.380; MONTIEL F, 1989, BIOCHEM J, V258, P147, DOI 10.1042/bj2580147; PATEL AK, 1987, BIOCHEM J, V248, P173, DOI 10.1042/bj2480173; POPOVIC EA, 1995, SEMIN SURG ONCOL, V11, P335, DOI 10.1002/ssu.2980110503; POZNANSKY MJ, 1984, SCIENCE, V223, P1304, DOI 10.1126/science.6367042; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBERTS WG, 1989, LASER SURG MED, V9, P102, DOI 10.1002/lsm.1900090204; ROBERTS WG, 1989, LASER SURG MED, V9, P90, DOI 10.1002/lsm.1900090203; SHECHTER Y, 1978, P NATL ACAD SCI USA, V75, P2135, DOI 10.1073/pnas.75.5.2135; SOBOLEV AS, 1992, BIOCHEM INT, V26, P445; Trapani JA, 1996, J BIOL CHEM, V271, P4127; Tsukagoshi S, 1995, Gan To Kagaku Ryoho, V22, P1271; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; YANO T, 1995, RES COMMUN MOL PATH, V87, P367	26	112	126	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20328	20331		10.1074/jbc.272.33.20328	http://dx.doi.org/10.1074/jbc.272.33.20328			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252335	hybrid			2022-12-25	WOS:A1997XR22100005
J	Feil, R; Boyano, MD; Allen, ND; Kelsey, G				Feil, R; Boyano, MD; Allen, ND; Kelsey, G			Parental chromosome-specific chromatin conformation in the imprinted U2af1-rs1 gene in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLELE-SPECIFIC METHYLATION; DNASE-I SENSITIVITY; CPG BINDING-PROTEIN; DEVELOPMENTAL CONTROL; KINASE GENE; H19 GENE; TRANSCRIPTION; EXPRESSION; REPLICATION; SEQUENCE	The imprinted U2af1-rs1 gene on mouse chromosome 11 is expressed exclusively from the paternal allele. We found that U2af1-rs1 resides in a chromosomal domain that displays marked differences in chromatin conformation and DNA methylation between the parental chromosomes. Chromatin conformation was assayed in brain and liver, in fetuses, and in embryonic stem cells by sensitivity to nucleases in nuclei. In all these tissues, the unmethylated paternal chromosome is sensitive to DNase-I and MspI and has two DNase-I hypersensitive sites in the 5'-untranslated region. In brain and in differentiated stem cells, which display high levels of U2af1-rs1 expression, a paternal DNase-I hypersensitive site is also readily apparent in the promoter region. On the maternal chromosome, in contrast, the entire U2af1-rs1 gene and its promoter are highly resistant to DNase-I and MspI in all tissues analyzed and are fully methylated. No differential MNase sensitivity was detected in this imprinted domain. The parental chromosome-specific DNA methylation and chromatin conformation were also present in parthenogenetic and androgenetic cells and in tissues from animals maternally or paternally disomic for chromosome 11. This demonstrates that these parental chromosome-specific epigenotypes are independently established and maintained and provides no evidence for interallelic trans-sensing and counting mechanisms in U2af1-rs1.	UNIV BASQUE COUNTRY,DEPT CELL BIOL,LEIOA 48940,SPAIN	University of Basque Country	Feil, R (corresponding author), BABRAHAM INST,DEPT GENET & DEV,CAMBRIDGE CB2 4AT,ENGLAND.		allen, nick d/A-4336-2010; BOYANO LOPEZ, MARIA DOLORES/ABF-6668-2021; Boyano, Maria Dolores/D-9114-2012; Feil, Robert P/D-2087-2013	BOYANO LOPEZ, MARIA DOLORES/0000-0001-6051-1054; Feil, Robert P/0000-0002-5671-5860; Kelsey, Gavin/0000-0002-9762-5634; Allen, Nicholas/0000-0003-4009-186X				ALLEN ND, 1994, DEVELOPMENT, V120, P1473; ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; BALL DJ, 1983, P NATL ACAD SCI USA, V80, P540; Bartolomei M.S., 1992, SEMIN DEV BIOL, V3, P107; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CAMPOY FJ, 1995, J BIOL CHEM, V270, P26473, DOI 10.1074/jbc.270.44.26473; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; FEIL R, 1995, DEV GENET, V17, P240, DOI 10.1002/dvg.1020170309; FEIL R, 1994, DEVELOPMENT, V120, P2933; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; HANSEN RS, 1988, MOL CELL BIOL, V8, P4692, DOI 10.1128/MCB.8.11.4692; HATADA I, 1995, NUCLEIC ACIDS RES, V23, P36, DOI 10.1093/nar/23.1.36; HATADA I, 1993, NUCLEIC ACIDS RES, V21, P5577, DOI 10.1093/nar/21.24.5577; HAYASHIZAKI Y, 1994, NAT GENET, V6, P33, DOI 10.1038/ng0194-33; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; IZUMIKAWA Y, 1991, HUM GENET, V87, P1, DOI 10.1007/BF01213082; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; John RM, 1996, CURR OPIN CELL BIOL, V8, P348, DOI 10.1016/S0955-0674(96)80008-1; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KOIDE T, 1994, GENOMICS, V24, P1, DOI 10.1006/geno.1994.1574; LASALLE JM, 1995, NAT GENET, V9, P386, DOI 10.1038/ng0495-386; LATHAM KE, 1995, DEV BIOL, V168, P670, DOI 10.1006/dbio.1995.1111; LATHAM KE, 1994, GENE DEV, V169, P670; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; MONK M, 1990, TRENDS GENET, V6, P110, DOI 10.1016/0168-9525(90)90124-O; Nabetani A, 1997, MOL CELL BIOL, V17, P789, DOI 10.1128/MCB.17.2.789; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; PERREAULT SD, 1992, MUTAT RES, V296, P43, DOI 10.1016/0165-1110(92)90031-4; REIK W, 1995, GENOMIC IMPRINTING C, P157; Sasaki H, 1995, DEVELOPMENT, V121, P4195; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SASAKI T, 1992, MOL CELL BIOL, V12, P3819, DOI 10.1128/MCB.12.9.3819; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; Shibata H, 1996, GENOMICS, V35, P248, DOI 10.1006/geno.1996.0348; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; SZABO P, 1994, DEVELOPMENT, V120, P1651; Szabo PE, 1996, EMBO J, V15, P6018, DOI 10.1002/j.1460-2075.1996.tb00990.x; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; WEIH F, 1991, EMBO J, V10, P1559; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4	55	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20893	20900		10.1074/jbc.272.33.20893	http://dx.doi.org/10.1074/jbc.272.33.20893			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252416	hybrid			2022-12-25	WOS:A1997XR22100086
J	Lechner, J; Welte, T; Tomasi, JK; Bruno, P; Cairns, C; Gustafsson, JA; Doppler, W				Lechner, J; Welte, T; Tomasi, JK; Bruno, P; Cairns, C; Gustafsson, JA; Doppler, W			Promoter-dependent synergy between glucocorticoid receptor and Stat5 in the activation of beta-casein gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; SITE-DIRECTED MUTAGENESIS; DNA-BINDING; NUCLEAR FACTOR; PROLACTIN REGULATION; RESPONSE ELEMENTS; REPORTER GENE; EXPRESSION; HORMONE; PROTEIN	Steroid hormone receptors and Stat factors comprise two distinct families of inducible transcription factors. Activation of a member of each family, namely the glucocorticoid receptor by glucocorticoids and Stat5 by prolactin, is required for the efficient induction of the expression of milk protein genes in the mammary epithelium. We have studied the mode of interaction between Stat5 and the glucocorticoid receptor in the activation of beta-casein gene transcription. The functional role of potential half-palindromic glucocorticoid receptor-binding sites mapped previously in the promoter region was investigated. beta-Casein gene promoter chloramphenicol acetyltransferase constructs containing mutations and deletions in these sites were tested for their responsiveness to the synergistic effect of prolactin and dexamethasone employing COS-7 cells or HC11 mammary epithelial cells. Synergism depended on promoter regions containing intact binding sites for the glucocorticoid receptor and Stat5. The carboxyl terminal transactivation domains of Stat5a and Stat5b were not required for this synergism. Our results suggest that in lactogenic hormone response elements glucocorticoid receptor molecules bound to nonclassical half-palindromic sites gain competence as transcriptional activators by the interaction with Stat5 molecules binding to vicinal sites.	UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA; HUDDINGE UNIV HOSP, KAROLINSKA INST, DEPT MED NUTR, NOVUM, S-14186 HUDDINGE, SWEDEN	University of Innsbruck; Karolinska Institutet				Lechner, Judith/0000-0002-2645-9421				BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BURDON TG, 1994, MOL ENDOCRINOL, V8, P1528, DOI 10.1210/me.8.11.1528; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CHAN GCK, 1991, J BIOL CHEM, V266, P22634; DAHLMAN K, 1989, J BIOL CHEM, V264, P804; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVINOY E, 1991, MOL CELL ENDOCRINOL, V81, P185, DOI 10.1016/0303-7207(91)90217-G; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOPPLER W, 1991, MOL ENDOCRINOL, V5, P1624, DOI 10.1210/mend-5-11-1624; DOPPLER W, 1994, REV PHYSIOL BIOCH P, V124, P93, DOI 10.1007/BFb0031032; DOPPLER W, 1990, MOL ENDOCRINOL, V4, P912, DOI 10.1210/mend-4-6-912; DOPPLER W, 1995, J BIOL CHEM, V270, P17962, DOI 10.1074/jbc.270.30.17962; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GOLDBERG Y, 1994, J BIOL CHEM, V269, P16566; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; LABAER J, 1994, J MOL BIOL, V239, P664, DOI 10.1006/jmbi.1994.1405; LI S, 1995, MOL CELL BIOL, V15, P2063; LI S, 1994, MOL ENDOCRINOL, V8, P1328, DOI 10.1210/me.8.10.1328; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PIERRE S, 1994, MOL ENDOCRINOL, V8, P1720, DOI 10.1210/me.8.12.1720; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SCHMIDHAUSER C, 1992, MOL BIOL CELL, V3, P699, DOI 10.1091/mbc.3.6.699; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Schumann RR, 1996, MOL CELL BIOL, V16, P3490; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SLATER EP, 1993, MOL ENDOCRINOL, V7, P907, DOI 10.1210/me.7.7.907; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WELTE T, 1994, EUR J BIOCHEM, V223, P997, DOI 10.1111/j.1432-1033.1994.tb19078.x; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; WELTE T, 1993, J STEROID BIOCHEM, V47, P75, DOI 10.1016/0960-0760(93)90059-6; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YOSHIMURA M, 1990, P NATL ACAD SCI USA, V87, P3670, DOI 10.1073/pnas.87.10.3670	52	100	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20954	20960		10.1074/jbc.272.33.20954	http://dx.doi.org/10.1074/jbc.272.33.20954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252424	hybrid			2022-12-25	WOS:A1997XR22100094
J	Alkhatib, G; Ahuja, SS; Light, D; Mummidi, S; Berger, EA; Ahuja, SK				Alkhatib, G; Ahuja, SS; Light, D; Mummidi, S; Berger, EA; Ahuja, SK			CC chemokine receptor 5-mediated signaling and HIV-1 co-receptor activity share common structural determinants - Critical residues in the third extracellular loop support HIV-1 fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT VACCINIA VIRUS; ENVELOPE GLYCOPROTEIN; EXPRESSION; CELLS	There is a close correspondence between the ability of RANTES and macrophage inflammatory proteins 1 alpha and 1 beta to activate CC chemokine receptor 5 (CCR5) and the ability to inhibit CCR5-dependent membrane fusion mediated by the envelope glycoprotein of human immuno-deficiency virus (HIV), type 1, This finding suggests that some of the structural determinants for CC chemokine/CCR5 interactions and CCR5 HIV-1 fusion co-receptor activity may be shared, Recent studies rising human CCR5/CCR2B chimeras have suggested that the determinants of CCR5 co-receptor activity are complex and may involve multiple extracellular receptor domains and that viral co-receptor activity is dissociable from ligand-dependent signaling responses, However, conclusive evidence demonstrating an important role for the second and third extracellular regions of human CCR5 is lacking, Furthermore, to determine whether the determinants for CCR5 co-receptor activity overlap with those required for agonist activity, studies that compare the chemokine specificity for inhibition of envelope-mediated cell fusion and the agonist profile of chimeric receptors are necessary, In the present report, using a series of CCR5/CCR2B chimeras we ascribe an important role for the second and third extracellular loop of CCR5 in supporting the co-receptor activity of CCR5, We also provide evidence that the intracytoplasmic tail of CCR5 does not play an important role in supporting HIV-1 entry, The hypothesis that the structural determinants for CC chemokine/CCR5 interactions and CCR5 HIV-1 fusion co-receptor activity may be shared was confirmed by two novel observations: first, the fusion activity supported by two hybrid receptors could be inhibited by both RANTES and monocyte chemoattractant protein-1, chemokines specific to CCR5 and CCR2B, respectively; and second, the chemokine specificity for inhibition of envelope-mediated cell fusion matched the agonist profile of these hybrid receptors. These data shed new light on the structural determinants involved in these distinct activities of CCR5 and may have important implications for the development of CCR5-targeted anti-viral compounds.	UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; NIAID,VIRAL DIS LAB,NIH,BETHESDA,MD 20892; S TEXAS VET HLTH CARE SYST,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital			Mummidi, Srinivas/H-3335-2017; Mummidi, Srinivas/C-1004-2008	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1996, J VIROL, V70, P5487, DOI 10.1128/JVI.70.8.5487-5494.1996; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EARL PL, 1991, CURRENT PROTOCOL S15, V2; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Sabroe I, 1997, J IMMUNOL, V158, P1361; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	30	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19771	19776		10.1074/jbc.272.32.19771	http://dx.doi.org/10.1074/jbc.272.32.19771			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242636	hybrid			2022-12-25	WOS:A1997XQ05900023
J	Honing, S; Sosa, M; HilleRehfeld, A; vonFigura, K				Honing, S; Sosa, M; HilleRehfeld, A; vonFigura, K			The 46-kDa mannose 6-phosphate receptor contains multiple binding sites for clathrin adaptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; FACTOR-II RECEPTOR; CYTOPLASMIC DOMAIN; COATED VESICLES; INVITRO BINDING; COMPLEX AP-2; MEMBRANE; SIGNALS; PROTEINS; GOLGI	The two known mannose 6-phosphate receptors (MPR46 and MPR300) both mediate the transport of Man-6-P-containing lysosomal proteins to lysosomes. However, the MPRs cannot be detected in lysosomes, instead they recycle between the plasma membrane and endosomes and between endosomes and the trans-Golgi network. Both, endocytosis from the plasma membrane and budding of transport vesicles from the trans-Golgi network involves the interaction of the receptor with the clathrin-coated vesicles-associated protein complexes AP1 and AP2. We have analyzed this interaction between the Golgi-restricted AP1 complex and the plasma membrane-restricted AP2 complex with the MPR46 tail in vitro by using a biosensor. AP1 and AP2 both bind to and dissociate from the MPR46 tail with similar kinetics, Using synthetic peptides corresponding to different MPR receptor tail regions in inhibition and binding studies, a common high affinity binding site for AP1 and AP2 and two separate high affinity binding sites for AP1 and AP2, respectively, were identified.	UNIV GOTTINGEN,INST BIOCHEM 2,D-37073 GOTTINGEN,GERMANY	University of Gottingen								AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANTON PA, 1991, PEPTIDES, V12, P375, DOI 10.1016/0196-9781(91)90029-O; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CHEN JH, 1997, J BIOL CHEM, V272, P7003; DENZER K, 1997, IN PRESS BIOCH J; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; HONING S, 1994, J CELL SCI, V107, P1185; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P22; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; REAVES B, 1994, FEBS LETT, V351, P448, DOI 10.1016/0014-5793(94)00813-2; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; Salamero J, 1996, J BIOL CHEM, V271, P30318, DOI 10.1074/jbc.271.48.30318; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SMITH JS, 1991, ANAL BIOCHEM, V197, P247, DOI 10.1016/0003-2697(91)90384-6; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036	43	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19884	19890		10.1074/jbc.272.32.19884	http://dx.doi.org/10.1074/jbc.272.32.19884			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242653	hybrid			2022-12-25	WOS:A1997XQ05900040
J	Mosser, G; Breyton, C; Olofsson, A; Popot, JL; Rigaud, JL				Mosser, G; Breyton, C; Olofsson, A; Popot, JL; Rigaud, JL			Projection map of cytochrome b(6)f complex at 8 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; CRYSTALS	The structure of the cytochrome b(6)f complex has been investigated by electron microscopy and image analysis of thin three-dimensional crystals. Electron micrographs of negatively stained specimens were recorded and showed optical diffraction peaks to 10 Angstrom resolution. A projection map was calculated at 8 Angstrom resolution and showed the presence of cytochrome b(6)f dimers. The extramembrane part of each monomer featured a C shape, with mean external diameter similar to of 53 Angstrom and an internal groove similar to 14 Angstrom long and similar to 9 Angstrom wide. Within each monomer, strong features were clearly resolved and tentatively attributed to some of the subunits of the cytochrome b(6)f complex, The data are consistent with the Rieske iron-sulfur protein lying close to the monomer-monomer interface and the heme-bearing domain of cytochrome f far from it.	CEA,LRC,F-75231 PARIS,FRANCE; CNRS UPR 9052,INST BIOL PHYS CHIM,F-75005 PARIS,FRANCE; UNIV PARIS 07,F-75005 PARIS,FRANCE	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Mosser, G (corresponding author), UMR CNR 168,SECT RECH,INST CURIE,11 RUE PIERRE & MARIE CURIE,F-75231 PARIS,FRANCE.		Mosser, Gervaise/M-4943-2018	Mosser, Gervaise/0000-0002-9812-5340				Akiba T, 1996, NAT STRUCT BIOL, V3, P553, DOI 10.1038/nsb0696-553; BOEKEMA EJ, 1994, J BIOENERG BIOMEMBR, V26, P17, DOI 10.1007/BF00763217; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BREYTON C, 1997, IN PRESS J BIOL CHEM, V272; CHAIN RK, 1991, PHOTOSYNTH RES, V28, P59, DOI 10.1007/BF00033715; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Finazzi G, 1997, BIOCHEMISTRY-US, V36, P2867, DOI 10.1021/bi962717y; HOVMOLLER S, 1981, FEBS LETT, V123, P118, DOI 10.1016/0014-5793(81)80033-6; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; KUHLBRANDT W, 1992, Q REV BIOPHYS, V25, P1; Link TA, 1996, BBA-BIOENERGETICS, V1275, P54, DOI 10.1016/0005-2728(96)00050-3; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; MORSCHEL E, 1983, J CELL BIOL, V97, P301, DOI 10.1083/jcb.97.2.301; MOSSER G, 1994, INT C EL MICR EL MIC, V3, P609; OLOFSSON A, 1994, J STRUCT BIOL, V113, P199, DOI 10.1006/jsbi.1994.1054; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; PIERRE Y, 1997, IN PRESS J BIOL CHEM, V272; POPOT JL, 1995, PHOTOSYNTHESIS LIGHT, V2, P507; Rigaud JL, 1997, J STRUCT BIOL, V118, P226, DOI 10.1006/jsbi.1997.3848; SCHMID MF, 1993, ULTRAMICROSCOPY, V48, P251, DOI 10.1016/0304-3991(93)90099-J; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; Vater J, 1996, BER BUNSEN PHYS CHEM, V100, P2107, DOI 10.1002/bbpc.19961001232; Young HS, 1997, BIOPHYS J, V72, P2545, DOI 10.1016/S0006-3495(97)78898-2	27	51	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20263	20268		10.1074/jbc.272.32.20263	http://dx.doi.org/10.1074/jbc.272.32.20263			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242706	hybrid			2022-12-25	WOS:A1997XQ05900093
J	Sakai, J; Nohturfft, A; Cheng, D; Ho, YK; Brown, MS; Goldstein, JL				Sakai, J; Nohturfft, A; Cheng, D; Ho, YK; Brown, MS; Goldstein, JL			Identification of complexes between the COOH-terminal domains of sterol regulatory element-binding proteins (SREBPs) and SREBP cleavage-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; COENZYME-A REDUCTASE; TRANSCRIPTION; RECEPTOR; CELLS; GENE; DEGRADATION; PROMOTER	SREBP cleavage-activating protein (SCAP) stimulates the proteolytic cleavage of membrane-bound SREBPs, thereby initiating the release of NH2-terminal fragments from cell membranes, The liberated fragments enter the nucleus and stimulate transcription of genes involved in synthesis and uptake of cholesterol and fatty acids, Sterols repress cleavage of SREBPs, apparently by interacting with the membrane attachment domain of SCAP, In the present studies we show that SCAP, like the SREBPs, is located in membranes of the endoplasmic reticulum and nuclear envelope, The COOH-terminal domain of SCAP, like that of the SREBPs, is located on the cytosolic face of the membranes. Co-immunoprecipitation experiments show that SCAP and SREBP-2 form a complex that can be precipitated with antibodies to either component, Complex formation occurs when cells express only the COOH-terminal domain of either SREBP-2 or SCAP, indicating that the complex forms between the two COOH-terminal domains, Truncation of SREBP-2 at its COOH terminus prevents the formation of complexes with SCAP and simultaneously reduces proteolytic cleavage. We conclude that proteolytic cleavage of SREBPs requires the formation of a complex with the COOH-terminal domain of SCAP and that SCAP is therefore a required element in the regulation of sterol and fatty acid metabolism in animal cells.			Sakai, J (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235, USA.			Nohturfft, Axel/0000-0001-9484-3209; Sakai, Juro/0000-0003-4043-1035	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HERZ J, 1990, J BIOL CHEM, V265, P21355; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LISCUM L, 1985, J BIOL CHEM, V260, P522; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Miserez AR, 1997, GENOMICS, V40, P31, DOI 10.1006/geno.1996.4525; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SATO R, 1994, J BIOL CHEM, V269, P17267; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TOLLESHAUG H, 1982, CELL, V30, P715, DOI 10.1016/0092-8674(82)90276-8; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	31	194	201	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20213	20221		10.1074/jbc.272.32.20213	http://dx.doi.org/10.1074/jbc.272.32.20213			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242699	hybrid			2022-12-25	WOS:A1997XQ05900086
J	Waldeck, AR; Stowell, MHB; Lee, HK; Hung, SC; Matsson, M; Hederstedt, L; Ackrell, BAC; Chan, SI				Waldeck, AR; Stowell, MHB; Lee, HK; Hung, SC; Matsson, M; Hederstedt, L; Ackrell, BAC; Chan, SI			Electron paramagnetic resonance studies of succinate:ubiquinone oxidoreductase from Paracoccus denitrificans - Evidence for a magnetic interaction between the 3Fe-4S cluster and cytochrome b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; RESPIRATORY-CHAIN; FUMARATE REDUCTASE; ESCHERICHIA-COLI; COMPLEX-II; EPR CHARACTERISTICS; 3-IRON CLUSTER; C-OXIDASE; DEHYDROGENASE; UBISEMIQUINONE	Electron paramagnetic resonance (EPR) studies of succinate:ubiquinone oxidoreductase (SQR) from Paracoccus denitrificans have been undertaken in the purified and membrane-bound states, Spectroscopic ''signatures'' accounting for the three iron-sulfur clusters (2Fe-2S, 3Fe-4S, and 4Fe-4S), cytochrome b, flavin, and protein-bound ubisemiquinone radicals have been obtained in air-oxidized, succinate-reduced, and dithionite-reduced preparations at 4-10 K. Spectra obtained at 170 K in the presence of excess succinate showed a signal typical of that of a flavin radical, but superimposed with another signal. The superimposed signal originated from two bound ubisemiquinones, as shown by spectral simulations, Power saturation measurements performed on the air-oxidized enzyme provided evidence for a weak magnetic dipolar interaction operating between the oxidized 3Fe-4S cluster and the oxidized cytochrome b. Power saturation experiments performed on the succinate- and dithionite-reduced forms of the enzyme demonstrated that the 4Fe-4S cluster is coupled weakly to both the 2Fe-2S and the 3Fe-4S clusters, Quantitative interpretation of these power saturation experiments has been achieved through redox calculations. They revealed that a spin-spin interaction between the reduced 3Fe-4S cluster and the cytochrome b (oxidized) may also exist. These findings form the first direct EPR evidence for a close proximity (less than or equal to 2 nm) of the high potential 3Fe-4S cluster, situated in the succinate dehydrogenase part of the enzyme, and the low potential, low spin b-heme in the membrane anchor of the enzyme.	CALTECH,ARTHUR AMOS NOYES LAB CHEM PHYS 127 72,PASADENA,CA 91125; CALTECH,CARL & WINFRED BRAUN LABS CHEM,PASADENA,CA 91125; CALTECH,CARL & WINFRED BRAUN LABS MOL BIOL,PASADENA,CA 91125; LUND UNIV,DEPT MICROBIOL,S-23362 LUND,SWEDEN; UNIV CALIF SAN FRANCISCO,VET ADM MED CTR,DIV MOL BIOL,SAN FRANCISCO,CA 94121	California Institute of Technology; California Institute of Technology; California Institute of Technology; Lund University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Hederstedt, Lars/0000-0002-6650-6296; STOWELL, MICHAEL/0000-0001-7250-1419	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022432, R37GM022432] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16251] Funding Source: Medline; NIGMS NIH HHS [GM 22432] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abragam A., 1986, ELECT PARAMAGNETIC R; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1984, J BIOL CHEM, V259, P4015; ALBRACHT SPJ, 1980, BIOCHIM BIOPHYS ACTA, V593, P173, DOI 10.1016/0005-2728(80)90055-9; ANEMULLER S, 1995, EUR J BIOCHEM, V232, P563; BEINERT H, 1975, EUR J BIOCHEM, V54, P185, DOI 10.1111/j.1432-1033.1975.tb04128.x; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BERRY EA, 1985, J BIOL CHEM, V260, P2458; BLUM H, 1980, BIOCHIM BIOPHYS ACTA, V621, P9, DOI 10.1016/0005-2795(80)90057-4; BONOMI F, 1983, EUR J BIOCHEM, V134, P439, DOI 10.1111/j.1432-1033.1983.tb07586.x; CAMMACK R, 1994, BIOCHEM SOC T, V22, P721, DOI 10.1042/bst0220721; CAMMACK R, 1987, CYTOCHROME SYSTEMS M, P485; CASTNER TG, 1959, PHYS REV, V115, P1506, DOI 10.1103/PhysRev.115.1506; CROWE BA, 1983, EUR J BIOCHEM, V137, P191, DOI 10.1111/j.1432-1033.1983.tb07814.x; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P334; EDMONDSON DE, 1981, ARCH BIOCHEM BIOPHYS, V208, P69, DOI 10.1016/0003-9861(81)90124-7; Eriksson L. E. G., 1973, BIOCHIM BIOPHYS ACTA, V293, P57; Galli C, 1996, J MAGN RESON SER B, V110, P284, DOI 10.1006/jmrb.1996.0044; HAGEN WR, 1985, BIOCHIM BIOPHYS ACTA, V828, P369, DOI 10.1016/0167-4838(85)90318-8; HAGERHALL C, 1992, BIOCHEMISTRY-US, V31, P7411, DOI 10.1021/bi00147a028; HAGERHALL C, 1995, BBA-BIOENERGETICS, V1229, P356, DOI 10.1016/0005-2728(95)00023-C; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HEDERSTEDT L, 1985, J BIOL CHEM, V260, P5554; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; HURST JK, 1991, EUR J BIOCHEM, V202, P1275, DOI 10.1111/j.1432-1033.1991.tb16500.x; HYDE JS, 1970, BIOCHIM BIOPHYS ACTA, V222, P688, DOI 10.1016/0304-4165(70)90202-3; INGLEDEW WJ, 1976, ARCH BIOCHEM BIOPHYS, V177, P176, DOI 10.1016/0003-9861(76)90427-6; JOHN P, 1975, NATURE, V254, P495, DOI 10.1038/254495a0; JOHNSON MK, 1985, BIOCHEM BIOPH RES CO, V131, P756, DOI 10.1016/0006-291X(85)91303-8; MAGUIRE JJ, 1986, BIOCHEMISTRY-US, V25, P5202, DOI 10.1021/bi00366a033; MAGUIRE JJ, 1985, J BIOL CHEM, V260, P909; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; MOORE GR, 1985, BIOCHIM BIOPHYS ACTA, V829, P83, DOI 10.1016/0167-4838(85)90071-8; MORNINGSTAR JE, 1985, J BIOL CHEM, V260, P3631; Moura I., 1989, ADV EPR APPLICATIONS, P813; OHNISHI T, 1976, J BIOL CHEM, V251, P2105; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; OHNISHI T, 1974, BIOCHEM BIOPH RES CO, V61, P1017, DOI 10.1016/0006-291X(74)90257-5; OHNISHI T, 1976, J BIOL CHEM, V251, P2094; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; ORMEJOHNSON NR, 1978, METHOD ENZYMOL, P252; PAPAEFTHYMIOU V, 1987, J AM CHEM SOC, V109, P4703, DOI 10.1021/ja00249a037; PENNOYER JD, 1988, BIOCHIM BIOPHYS ACTA, V935, P195, DOI 10.1016/0005-2728(88)90216-2; Redfearn E. R., 1967, METHOD ENZYMOL, V10, P381, DOI [10.1016/0076-6879(67)10071-2, DOI 10.1016/0076-6879(67)10071-2]; RICH PR, 1977, BIOCHIM BIOPHYS ACTA, V462, P501, DOI 10.1016/0005-2728(77)90097-4; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; SAHLIN M, 1986, J MAGN RESON, V67, P135, DOI 10.1016/0022-2364(86)90417-8; SALERNO JC, 1980, BIOCHEM J, V192, P769, DOI 10.1042/bj1920769; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; SALERNO JC, 1991, BIOCHEM SOC T, V19, P599, DOI 10.1042/bst0190599; SALERNO JC, 1977, FEBS LETT, V82, P179, DOI 10.1016/0014-5793(77)80579-6; STEFFENS GCM, 1990, J CHROMATOGR, V521, P291, DOI 10.1016/0021-9673(90)85053-X; STOWELL MHB, 1993, J PHYS CHEM-US, V97, P3054, DOI 10.1021/j100114a036; SUCHETA A, 1992, NATURE, V356, P361, DOI 10.1038/356361a0; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P4608; WILSON DF, 1964, J BIOL CHEM, V239, P2683; WOLFRAM S, 1994, MATHEMATICA; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; YU L, 1987, J BIOL CHEM, V262, P1137; Zhou J, 1996, J AM CHEM SOC, V118, P1966, DOI 10.1021/ja9537843	62	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19373	19382		10.1074/jbc.272.31.19373	http://dx.doi.org/10.1074/jbc.272.31.19373			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235936	hybrid, Green Accepted			2022-12-25	WOS:A1997XP06300042
J	Lee, SB; SolowCordero, DE; Kessler, E; Takahara, K; Greenspan, DS				Lee, SB; SolowCordero, DE; Kessler, E; Takahara, K; Greenspan, DS			Transforming growth factor-beta regulation of bone morphogenetic protein-1 procollagen C-proteinase and related proteins in fibrogenic cells and keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(I) COLLAGEN GENE; EPIDERMAL-KERATINOCYTES; TERMINAL PROTEINASE; MOUSE FIBROBLASTS; MESSENGER-RNA; N-PROTEINASE; PURIFICATION; EXPRESSION; CULTURE; TRANSCRIPTS	Transforming growth factor-beta 1 (TGF-beta 1) induces increased extracellular matrix deposition. Bone morphogenetic protein-1 (BMP-1) also plays key roles in regulating vertebrate matrix deposition; it is the procollagen C-proteinase (PCP) that processes procollagen types I-III, and it may also mediate biosynthetic processing of lysyl oxidase and laminin 5. Here we show that BMP-1 is itself up-regulated by TGF-beta 1 and that secreted BMP-1, induced by TGF-beta 1, is either processed to an active form or remains as unprocessed proenzyme, in a cell type-dependent manner. In MG-63 osteosacrcoma cells, TGF-beta 1 elevated levels of BMP-1 mRNA similar to 7-fold and elevated levels of mRNA for mammalian tolloid (mTld), an alternatively spliced product of the BMP1 gene, to a lesser extent, Induction of RNA was dose- and time-dependent and cycloheximide-inhibitable. Secreted BMP-1 and mTld, induced by TGF-beta 1 in MG-63 and other fibrogenic cell cultures, were predominantly in forms in which proregions had been removed to yield activated enzyme. TGF-beta 1 treatment also induced procollagen N-proteinase activity in fibrogenic cultures, while expression of the procollagen C-proteinase enhancer (PCPE), a glycoprotein that stimulates PCP activity, was unaffected. In contrast to fibrogenic cells, keratinocytes lacked detectable PCPE under any culture conditions and were induced by TGF-beta 1 to secrete BMP-1 and mTld predominantly as unprocessed proenzymes.	UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53706; FIBROGEN INC,S SAN FRANCISCO,CA 94080; TEL AVIV UNIV,FAC MED,CHAIM SHEBA MED CTR,MAURICE & GABRIELA GOLDSCHLEGER EYE RES INST,IL-52621 TEL HASHOMER,ISRAEL	University of Wisconsin System; University of Wisconsin Madison; FibroGen; Chaim Sheba Medical Center; Tel Aviv University			Lee, Seungbok/AAS-1529-2021	Lee, Seungbok/0000-0002-6620-6269; Greenspan, Daniel/0000-0001-8096-7446; Solow-Cordero, David/0000-0002-9886-5058	NIAMS NIH HHS [AR43621] Funding Source: Medline; NIGMS NIH HHS [GM46846] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043621] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amano S., 1996, Molecular Biology of the Cell, V7, p58A; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHAN D, 1990, BIOCHEM J, V269, P175, DOI 10.1042/bj2690175; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; CHU ML, 1985, J BIOL CHEM, V260, P2315; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; FINELLI AL, 1994, DEVELOPMENT, V120, P861; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; FRANCESCHI RT, 1988, J BIOL CHEM, V263, P18938; GEESIN JC, 1988, J INVEST DERMATOL, V90, P420, DOI 10.1111/1523-1747.ep12460849; GREENSPAN DS, 1991, GENE EXPRESSION, V1, P29; HALILA R, 1986, BIOCHEM J, V239, P47, DOI 10.1042/bj2390047; Harlow E., 1988, ANTIBODIES LAB MANUA; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOWE JG, 1981, J BIOL CHEM, V256, P2836; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JARVIS DL, 1992, RECOMBINANT DNA VACC, P265; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; KONIG A, 1991, J INVEST DERMATOL, V96, P803, DOI 10.1111/1523-1747.ep12474424; KORANG K, 1995, FEBS LETT, V368, P556, DOI 10.1016/0014-5793(95)00740-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1984, J CELL PHYSIOL, V121, P184, DOI 10.1002/jcp.1041210123; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LYONS BL, 1984, NUCLEIC ACIDS RES, V12, P2569, DOI 10.1093/nar/12.5.2569; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MURPHY G, 1985, J BIOL CHEM, V260, P3079; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Prockop D.J., 1976, BIOCH COLLAGENS, P163; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYYNANEN J, 1991, BIOCHEM BIOPH RES CO, V180, P673, DOI 10.1016/S0006-291X(05)81118-0; Sambrook J., 2002, MOL CLONING LAB MANU; STACEY A, 1987, J VIROL, V61, P2549, DOI 10.1128/JVI.61.8.2549-2554.1987; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	46	100	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19059	19066		10.1074/jbc.272.30.19059	http://dx.doi.org/10.1074/jbc.272.30.19059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228090	hybrid			2022-12-25	WOS:A1997XM34200081
J	Liang, P; Amons, R; Clegg, JS; MacRae, TH				Liang, P; Amons, R; Clegg, JS; MacRae, TH			Molecular characterization of a small heat shock alpha-crystallin protein in encysted Artemia embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CRYSTALLIN; CAENORHABDITIS-ELEGANS; FRANCISCANA EMBRYOS; CHAPERONE ACTIVITY; A-CRYSTALLIN; BRINE SHRIMP; GENE; EXPRESSION; STRESS; HSP27	Molecular chaperones protect cells during stress by limiting the denaturation/aggregation of proteins and facilitating their renaturation. In this context, brine shrimp embryos can endure a wide variety of stressful conditions, including temperature extremes, prolonged anoxia, and desiccation, thus encountering shortages of both energy (ATP) and water. How the embryos survive these stresses is the subject of continuing study, a situation true for other organisms facing similar physiological challenges. To approach this question we cloned and sequenced a cDNA for p26, a molecular chaperone specific to oviparous Artemia embryos. p26 is the first representative of the small heat shock/alpha-crystallin family from crustaceans to be sequenced, and it possesses the conserved alpha-crystallin domain characteristic of these proteins. The secondary structure of this domain was predicted to consist predominantly of beta-pleated sheet, and it appeared to lack regions of alpha-helix. Unique properties of the nonconserved amino terminus, which showed weak similarity to nucleolins and fibrillarins, are enrichments in both glycine and arginine. The carboxyl-terminal tail is the longest yet reported for a small heat shock/alpha-crystallin protein, and it is hydrophilic, a common attribute of this region. Site-specific differences between amino acids from p26 and other small heat shock/alpha-crystallin proteins bring into question the functions proposed for some of these residues. Probing of Southern blots disclosed a multi-gene family for p26, whereas two size classes of p26 mRNA at 0.7 add 1.9 kilobase pairs were seen on Northern blots; the larger probably representing nonprocessed transcripts, Examination of immunofluorescently stained samples with the confocal microscope revealed that a limited portion of intracellular p26 is found in the nuclei of encysted embryos and that it resides within discrete compartments of this organelle. The results in this paper demonstrate clearly that p26 is a novel member of the small heat shock/alpha-crystallin family of proteins. These data, in concert with its restriction to embryos undergoing oviparous development, suggest that p26 functions as a molecular chaperone during exposure to stress, perhaps able; to limit protein degradation and thus ensure a ready supply of functional proteins when growth is reinitiated.	DALHOUSIE UNIV,DEPT BIOL,HALIFAX,NS B3H 4J1,CANADA; LEIDEN UNIV,DEPT MED BIOCHEM,NL-2300 RA LEIDEN,NETHERLANDS; UNIV CALIF DAVIS,BODEGA MARINE LAB,BODEGA BAY,CA 94923	Dalhousie University; Leiden University; Leiden University - Excl LUMC; University of California System; University of California Davis			Liang, Ping/D-2709-2009; Liang, Ping/S-3790-2018	Liang, Ping/0000-0003-4423-0636; Liang, Ping/0000-0003-4423-0636				ANDERSON E, 1970, J ULTRA MOL STRUCT R, V32, P497, DOI 10.1016/S0022-5320(70)80025-9; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BIAMONTI G, 1989, J MOL BIOL, V207, P491, DOI 10.1016/0022-2836(89)90459-2; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Bukau B, 1996, TRENDS CELL BIOL, V6, P480, DOI 10.1016/0962-8924(96)84946-4; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CHEN Q, 1994, J BIOL CHEM, V269, P13216; CLEGG JS, 1995, EXP CELL RES, V219, P1, DOI 10.1006/excr.1995.1197; CLEGG JS, 1994, EXP CELL RES, V212, P77, DOI 10.1006/excr.1994.1120; CLEGG JS, 1993, J COMP PHYSIOL B, V163, P48, DOI 10.1007/BF00309664; CLEGG JS, 1994, J EXP ZOOL, V270, P332, DOI 10.1002/jez.1402700312; CLEGG JS, 1980, BRINE SHRIMP ARTEMIA, V2, P11; Coca MA, 1996, PLANT MOL BIOL, V31, P863, DOI 10.1007/BF00019473; CRABBE MJC, 1994, BIOCHEM J, V297, P653, DOI 10.1042/bj2970653; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DECHAFFOY D, 1978, DIFFERENTIATION, V12, P99; DECHAFFOY D, 1976, BIOCHEM J, V158, P639, DOI 10.1042/bj1580639; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Drinkwater L.E., 1991, P93; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; GAESTEL M, 1993, GENE, V128, P279, DOI 10.1016/0378-1119(93)90575-N; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GOPALSRIVASTAVA R, 1995, MOL CELL BIOL, V15, P7081; HAND SC, 1988, SCIENCE, V239, P1425, DOI 10.1126/science.239.4846.1425; Haynes JI, 1996, DEV DYNAM, V207, P75, DOI 10.1002/(SICI)1097-0177(199609)207:1<75::AID-AJA8>3.3.CO;2-O; Head MW, 1996, J CELL SCI, V109, P1029; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HONTORIA F, 1993, J EXP BIOL, V178, P149; JACK RS, 1992, EUR J BIOCHEM, V209, P503, DOI 10.1111/j.1432-1033.1992.tb17314.x; Jackson SA, 1996, DEV GROWTH DIFFER, V38, P153; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JONES D, 1986, J BIOL CHEM, V261, P2006; KAMPINGA HH, 1994, BIOCHEM BIOPH RES CO, V204, P1170, DOI 10.1006/bbrc.1994.2586; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1994, J BIOL CHEM, V269, P15302; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LANGDON CM, 1990, EUR J CELL BIOL, V52, P17; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Liang P, 1997, EUR J BIOCHEM, V243, P225, DOI 10.1111/j.1432-1033.1997.0225a.x; Linder B, 1996, J BIOL CHEM, V271, P30158, DOI 10.1074/jbc.271.47.30158; Loktionova SA, 1996, FEBS LETT, V392, P100, DOI 10.1016/0014-5793(96)00792-2; Marin R, 1996, EXP CELL RES, V223, P1, DOI 10.1006/excr.1996.0052; MARTIN J, 1994, BIOESSAYS, V16, P689, DOI 10.1002/bies.950160916; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; NAKANISHI Yu.H., 1962, ANNOT ZOOL JAPON, V35, P223; Neufer PD, 1996, J BIOL CHEM, V271, P24089, DOI 10.1074/jbc.271.39.24089; OSBORNE MA, 1993, ANNU REV BIOCHEM, V62, P219; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; PLESOFSKYVIG N, 1995, P NATL ACAD SCI USA, V92, P5032, DOI 10.1073/pnas.92.11.5032; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; ROBERTS MP, 1972, BIOCHIM BIOPHYS ACTA, V697, P148; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; Sambrook J., 2002, MOL CLONING LAB MANU; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; SQUIRES SL, 1989, CELLULAR MOL BIOL AR, P221; Strouboulis J, 1996, J CELL SCI, V109, P1991; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; WANG KY, 1994, J BIOL CHEM, V269, P13601	77	83	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19051	19058		10.1074/jbc.272.30.19051	http://dx.doi.org/10.1074/jbc.272.30.19051			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228089	hybrid			2022-12-25	WOS:A1997XM34200080
J	Sampson, MJ; Lovell, RS; Craigen, WJ				Sampson, MJ; Lovell, RS; Craigen, WJ			The murine voltage-dependent anion channel gene family - Conserved structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; BENZODIAZEPINE RECEPTOR; BIDIRECTIONAL PROMOTER; CREATINE-KINASE; PORIN; VDAC; SEQUENCE; YEAST; TRANSLATION; PROTEIN	Voltage-dependent anion channels (VDACs) are pore-forming proteins found in the outer mitochondrial membrane of all eucaryotes. VDACs are the binding sites for several cytosolic enzymes, including the isoforms of hexokinase and glycerol kinase, VDACs have recently been shown to conduct ATP when in the open state, allowing bound kinases preferential access to mitochondrial ATP and providing a possible mechanism for the regulation of adenine nucleotide flux, Two human VDAC cDNAs have been described previously, and we recently reported the isolation of mouse VDAC1 and VDAC2 cDNAs, as well as a third novel VDAC cDNA, designated VDAC3, In this report we describe the structural organization of each mouse VDAC gene and demonstrate that, based on conserved exon/intron boundaries, the three VDAC isoforms belong to a single gene family, The 5'-flanking region of each VDAC gene was shown to have transcription promoter activity by transient expression in cultured cells. The promoter region of each VDAC isoform lacks a canonical TATA box, but all are G+C-rich, a characteristic of housekeeping gene promoters. To examine the conservation of VDAC function, each mouse VDAC was expressed in yeast lacking the endogenous VDAC gene, Both VDAC1 and VDAC2 are able to complement the phenotypic defect associated with the mutant yeast strain, VDAC3, however, is only able to partially complement the mutant phenotype, suggesting an alternative physiologic function for the VDAC3 protein.	BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027823] Funding Source: NIH RePORTER; NICHD NIH HHS [1P30-HD27823] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; BELTRANDELRIO H, 1992, ARCH BIOCHEM BIOPHYS, V299, P116, DOI 10.1016/0003-9861(92)90252-R; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; BIRNSTIEL ML, 1988, STRUCTURE FUNCTION M, P155; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BRDICZKA D, 1994, J BIOL CHEM, V269, P27640; BRDICZKA D, 1990, EXPERIENTIA, V46, P161, DOI 10.1007/BF02027312; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIGAN AM, 1987, GENE, V59, P1; COHEN N, 1988, ONCOGENE, V3, P137; DEPINTO V, 1992, J BIOENERG BIOMEMBR, V24, P21, DOI 10.1007/BF00769526; DESAUVAGE F, 1992, EMBO J, V11, P3099, DOI 10.1002/j.1460-2075.1992.tb05382.x; DIHANICH M, 1987, EMBO J, V6, P723, DOI 10.1002/j.1460-2075.1987.tb04813.x; DIHANICH M, 1990, EXPERIENTIA, V46, P146, DOI 10.1007/BF02027310; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUO XJ, 1986, YEAST, V2, pS138; HA HJ, 1993, J BIOL CHEM, V268, P12143; Huizing M, 1996, PEDIATR RES, V39, P760, DOI 10.1203/00006450-199605000-00003; JOHNSON P, 1990, GENE, V88, P207, DOI 10.1016/0378-1119(90)90033-N; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KOTTKE M, 1988, BIOCHIM BIOPHYS ACTA, V935, P807; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE AC, 1994, J BIOL CHEM, V269, P30974; LIU MY, 1992, J BIOENERG BIOMEMBR, V24, P41, DOI 10.1007/BF00769529; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; MANNELLA CA, 1992, J BIOENERG BIOMEMBR, V24, P7, DOI 10.1007/BF00769525; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCENERY MW, 1992, J BIOENERG BIOMEMBR, V24, P63, DOI 10.1007/BF00769532; Melton D W, 1987, Oxf Surv Eukaryot Genes, V4, P34; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PFALLER R, 1985, J BIOL CHEM, V260, P8188; ROMEO DS, 1993, MOL ENDOCRINOL, V7, P759, DOI 10.1210/me.7.6.759; Rostovtseva T, 1996, J BIOL CHEM, V271, P28006, DOI 10.1074/jbc.271.45.28006; Sambrook J., 2002, MOL CLONING LAB MANU; Sampson MJ, 1996, GENOMICS, V33, P283, DOI 10.1006/geno.1996.0193; SAMPSON MJ, 1996, GENOMICS, V38, P192; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHIMADA T, 1989, J BIOL CHEM, V264, P20171; SITZLER S, 1991, GENE, V100, P155, DOI 10.1016/0378-1119(91)90361-E; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SORGATO MC, 1993, CRIT REV BIOCHEM MOL, V18, P127; WEICHSELBRAUN I, 1990, FEBS LETT, V275, P49, DOI 10.1016/0014-5793(90)81436-R; ZIZI M, 1994, J BIOL CHEM, V269, P1614	48	175	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					18966	18973		10.1074/jbc.272.30.18966	http://dx.doi.org/10.1074/jbc.272.30.18966			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228078	hybrid			2022-12-25	WOS:A1997XM34200069
J	Kissil, JL; Feinstein, E; Cohen, O; Jones, PA; Tsai, YC; Knowles, MA; Eydmann, ME; Kimchi, A				Kissil, JL; Feinstein, E; Cohen, O; Jones, PA; Tsai, YC; Knowles, MA; Eydmann, ME; Kimchi, A			DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene	ONCOGENE			English	Article						serine/threonine kinase; death gene; tumor suppressor; methylation; 5'-azadeoxycytidine	HUMAN BLADDER-CANCER; DNA-METHYLATION; DEATH; APOPTOSIS; MEDIATOR; LEUKEMIA; BCL-2; P16	DAP-kinase is a novel calmodulin dependent serine/threonine kinase that carries ankyrin repeats and the death domain. It was recently isolated, by a functional selection approach of gene cloning, as a positive mediator of programmed cell death. In this study the expression of DAP-kinase was examined in the cell lines derived from various human neoplasms, DAP-kinase mRNA and protein expression were below the limit of detection in eight out of ten neoplastic derived B-cell lines. In six out of 14 examined bladder carcinoma, in three out of five renal cell carcinoma, and in four out of ten tested breast carcinoma cell lines, the DAP-kinase protein levels were below detection limits or lower than 1% compared to the positive cell lines. Interestingly, DAP-kinase expression could be restored in some of the negative bladder carcinoma and B-cell lines by treatment of cells with 5'-azadeoxycytidine that causes DNA demethylation. The high frequency of loss of DAP-kinase expression in human tumor cell lines, and the occasional involvement of methylation in this process raise the possibility that this novel mediator of cell death may function as a tumor suppressor gene.	WEIZMANN INST SCI, DEPT MOL GENET, IL-76100 REHOVOT, ISRAEL; UNIV SO CALIF, KENNETH NORRIS JR COMPREHENS CANC CTR, LOS ANGELES, CA 90033 USA; MARIE CURIE RES INST, MOL GENET LAB, OXTED RH8 0TL, SURREY, ENGLAND	Weizmann Institute of Science; University of Southern California				Knowles, Margaret/0000-0002-9363-8657	NCI NIH HHS [CA49758] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN A, 1991, BLOOD, V78, P94; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, LANCET, V342, P1184, DOI 10.1016/0140-6736(93)92169-T; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAKAI T, 1991, AM J HUM GENET, V48, P880; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; SKOLNICK MH, 1994, EUR J CANCER, V30A, P1991, DOI 10.1016/0959-8049(94)00392-I; TSAI YC, 1990, CANCER RES, V50, P44; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; TULCHINSKY E, 1995, BBA-GENE STRUCT EXPR, V1261, P243, DOI 10.1016/0167-4781(95)00013-7; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569	30	178	195	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	1997	15	4					403	407		10.1038/sj.onc.1201172	http://dx.doi.org/10.1038/sj.onc.1201172			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242376				2022-12-25	WOS:A1997XM23800004
J	Pasini, A; Geneste, O; Legrand, P; Schlumberger, M; Rossel, M; Fournier, L; Rudkin, BB; Schuffenecker, I; Lenoir, GM; Billaud, M				Pasini, A; Geneste, O; Legrand, P; Schlumberger, M; Rossel, M; Fournier, L; Rudkin, BB; Schuffenecker, I; Lenoir, GM; Billaud, M			Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain	ONCOGENE			English	Article						MEN2; MTC; RET proto-oncogene; tyrosine kinase	MEDULLARY-THYROID CARCINOMA; MEN 2A; CRYSTAL-STRUCTURE; CELL-LINE; PROTOONCOGENE; RECEPTOR; ISOFORMS; FAMILIES; DISEASE; GENE	Multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC) are two dominantly inherited disorders caused by germline mutations of the RET proto-oncogene. The RET gene codes for a receptor tyrosine kinase. The majority of MEN2A and FMTC mutations are clustered in the extra-cellular cysteine-rich domain and result in constitutive activation of the tyrosine kinase through the formation of disulfide-bonded RET homodimers. Recently, two novel paint mutations have been identified in the germline of five distinct FMTC families. Both mutations occur catalytic domain of the RET kinase and lead to the substitution of either glutamic acid 768 or valine 804 by an aspartic acid and a leucine respectively, We have introduced each FMTC mutation in two RET isoforms: RET51 the long isoform (1114 aa) and RET9 the short isoform (1072 aa) which differ in the C-terminal region of the protein. The RET51 isoform carrying either E768D or V804L mutation was autophosphorylated, displayed a transforming activity upon expression in Rat1 fibroblasts and induced neuronal differentiation of PC12 cells. However, the transforming capacity of these RET51-FMTC mutants was found to be severalfold less potent compared to the same isoform carrying either the MEN2A mutation (C634R) or the MEN2B mutation (M918T). In contrast, RET9 containing mutations E768D or V804L was not autophosphorylated, exhibited a poor oncogenic potential in fibroblasts and did not promote neuritic outgrowth upon expression in PC12 cells. Overall, these findings demonstrate that mutations E768D and V804L are gain-of-function mutations that confer to the long RET isoform the capacity to exert a biological effect, although these mutations are more weakly activating than the MEN2A and MEN2B mutations. These results may provide a biochemical basis as to why the phenotypic consequences of these mutations are restricted to thyroid C-cells.	UNIV LYON 1,GENET LAB,CNRS,UMR 5641,F-69372 LYON 08,FRANCE; INST BIOL STRUCT JEAN PIERRE EBEL,CEA,CNRS,CRISTALLOG & CRISTALLOGENESE PROT LAB,F-38027 GRENOBLE 1,FRANCE; INST GUSTAVE ROUSSY,NUCL MED SERV,F-94805 VILLEJUIF,FRANCE; UNIV UTAH,ECCLES INST HUMAN GENET 5440,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,CNRS,UMR 49,F-69364 LYON,FRANCE; HOP EDOUARD HERRIOT,GENET LAB,LYON 03,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); CHU Lyon			Billaud, Marc N/M-6954-2013; LEGRAND, Pierre/G-7709-2011	LEGRAND, Pierre/0000-0003-2431-2255; Rossel, Mireille/0000-0003-2275-0817; RUDKIN, Brian B./0000-0003-3700-1982				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOLINO A, 1995, ONCOGENE, V10, P2415; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Borrello MG, 1995, ONCOGENE, V11, P2419; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; ENG C, 1994, HUM MOL GENET, V3, P234; Fink M, 1996, INT J CANCER, V69, P312, DOI 10.1002/(SICI)1097-0215(19960822)69:4<312::AID-IJC13>3.0.CO;2-7; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Iwashita T, 1996, ONCOGENE, V12, P481; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LORENZO MJ, 1995, ONCOGENE, V10, P1377; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MULLIGAN LM, 1995, J CLIN ENDOCR METAB, V80, P1989, DOI 10.1210/jc.80.7.1989; MYERS SM, 1995, ONCOGENE, V11, P2039; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ROSSEL M, 1995, HUM GENET, V95, P403; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	48	82	82	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					393	402		10.1038/sj.onc.1201199	http://dx.doi.org/10.1038/sj.onc.1201199			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242375				2022-12-25	WOS:A1997XM23800003
J	McCormack, SJ; Brazinski, SE; Moore, JL; Werness, BA; Goldstein, DJ				McCormack, SJ; Brazinski, SE; Moore, JL; Werness, BA; Goldstein, DJ			Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18	ONCOGENE			English	Article						cell adhesion molecules; focal adhesion kinase; papillomaviruses; protein-tyrosine kinases; signal transduction	PAXILLIN TYROSINE PHOSPHORYLATION; RETINOBLASTOMA GENE-PRODUCT; GROWTH-FACTOR; HUMAN KERATINOCYTES; EXTRACELLULAR-MATRIX; PROTEIN; TRANSFORMATION; BINDING; DOMAIN; DNA	The inappropriate activation of protein-tyrosine kinases (PTKs) has been associated with initiation and progression of several types of human cancers. We therefore postulated that immortalization by DNA tumor viruses results in the induction of PTKs fundamental to these processes. An RT-PCR-based screen was thus used to identify PTKs that were abundantly expressed in HPV-18-immortalized epithelial cells and HPV-containing carcinoma cell lines. One of the genes isolated in this screen was the focal adhesion kinase (FAK; pp125(FAK)), a cytoplasmic protein kinase that is activated in v-src transformed cells or by stimulation with mitogenic polypeptides. FAK also becomes catalytically active upon integrin engagement with extracellular matrix proteins, such as fibronectin. We found that FAK expression and activity were significantly elevated in HPV-18 E6/E7-immortalized human genital epithelial cells relative to their primary cell counterparts. Protein expression and tyrosine phosphorylation of the putative FAK substrate, paxillin, were also notably increased upon HPV-18 immortalization of genital epithelial cells and in HPV-containing cervical carcinoma cell lines. Most significantly, these cells expressed markedly higher levels of both intracellular and extracellular fibronectin, thus providing a mechanism for activation of FAK and increased tyrosine phosphorylation of paxillin. These findings suggest a role for the integrin/FAK-mediated signaling pathway in cervical carcinogenesis and represent one of the first demonstrations of a tyrosine kinase whose activity is elevated following viral immortalization.	GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA; UNIV MISSISSIPPI, MED CTR, DEPT OB GYN, JACKSON, MS 39216 USA; ROSWELL PK CANC INST, DEPT PATHOL, BUFFALO, NY USA	Georgetown University; University of Mississippi; University of Mississippi Medical Center; Roswell Park Cancer Institute					NATIONAL CANCER INSTITUTE [R29CA063044, P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA-63044, IP50CA58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURST M, 1987, ONCOGENE, V1, P251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FERENCZY A, 1987, CERVIVAL INTRAEPITHE, P177; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; OWENS LV, 1995, CANCER RES, V55, P2752; PARSONS JT, 1994, J CELL SCI, P109; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; RANKIN S, 1994, J BIOL CHEM, V269, P704; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SHEIBANI N, 1991, CANCER RES, V51, P5967; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1994, J CELL SCI, V107, P1583; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WOODWORTH CD, 1988, CANCER RES, V48, P4620; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	54	86	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					265	274		10.1038/sj.onc.1201186	http://dx.doi.org/10.1038/sj.onc.1201186			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233761				2022-12-25	WOS:A1997XK99900003
J	Worpenberg, S; Burk, O; Klempnauer, KH				Worpenberg, S; Burk, O; Klempnauer, KH			The chicken adenosine receptor 2B gene is regulated by v-myb	ONCOGENE			English	Article						v-myb; oncogene; target gene; differential display; A2b adenosine receptor	C-MYB; CELL-LINES; MIM-1 GENE; MYELOMONOCYTIC CELLS; DIFFERENTIAL DISPLAY; DIFFERENT MECHANISMS; TRANS-ACTIVATION; NF-M; EXPRESSION; ONCOGENE	The retroviral oncogene v-myb is a mutated and truncated version of the c-myb proto-oncogene and encodes a transcription factor (v-Myb) that specifically transforms myelomonocytic cells. v-Myb is thought to transform myelomonocytic cells by affecting the expression of specific target genes, most of which as yet remain unknown. To identify novel v-Myb regulated genes we have employed 'differential display', using a myelomonocytic chicken cell line that expresses a conditional version of v-Myb. Here me describe the identification of the gene encoding the A2b adenosine receptor, a member of the seven transmembrane receptor superfamily, as a v-Myb target gene. Our results provide the first evidence that v-Myb directly regulates a gene encoding a membrane receptor and establish a link between Myb function and adenosine receptor signaling.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY; UNIV FREIBURG,KINDERKLIN,D-79106 FREIBURG,GERMANY	Max Planck Society; University of Freiburg								AKIYAMA Y, 1974, BIKEN J, V17, P105; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUMA MG, 1994, J IMMUNOL, V153, P4159; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CHEN LC, 1983, MOL CELL BIOL, V3, P1077, DOI 10.1128/MCB.3.6.1077; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DESBIENS X, 1991, DEVELOPMENT, V111, P699; EPPELL BA, 1989, J IMMUNOL, V143, P4141; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRISHAM MB, 1989, AM J PHYSIOL, V257, pH1334, DOI 10.1152/ajpheart.1989.257.5.H1334; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JURGENSEN CH, 1990, J IMMUNOL, V144, P653; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LEONARD MW, 1993, DEVELOPMENT, V119, P519; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MARQUARDT DL, 1984, J IMMUNOL, V133, P932; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; Mink S, 1996, MOL CELL BIOL, V16, P1316; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PARMELY MJ, 1993, J IMMUNOL, V151, P389; PLAZA S, 1995, ONCOGENE, V10, P329; QUEVA C, 1992, DEVELOPMENT, V114, P125; SALMON JE, 1993, J IMMUNOL, V151, P2775; Sitzmann J, 1995, ONCOGENE, V11, P2273; STERNECK E, 1992, J BIOL CHEM, V267, P6451; STILES GL, 1992, J BIOL CHEM, V267, P6451; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRUEB B, 1988, NUCLEIC ACIDS RES, V16, P4723, DOI 10.1093/nar/16.10.4723; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	48	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					213	221		10.1038/sj.onc.1201179	http://dx.doi.org/10.1038/sj.onc.1201179			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244356				2022-12-25	WOS:A1997XK37200009
J	Grossmann, M; Wong, R; Szkudlinski, MW; Weintrauab, BD				Grossmann, M; Wong, R; Szkudlinski, MW; Weintrauab, BD			Human thyroid-stimulating hormone (hTSH) subunit gene fusion produces hTSH with increased stability and serum half-life and compensates for mutagenesis-induced defects in subunit association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; GLYCOPROTEIN HORMONES; ALPHA-SUBUNIT; BETA-SUBUNITS; METABOLIC-CLEARANCE; HUMAN THYROTROPIN; EXPRESSION; BIOACTIVITY; EVOLUTION; PITUITARY	The human thyroid-stimulating hormone (hTSH) subunits alpha and beta are transcribed from different genes and associate noncovalently to form the bioactive hTSH heterodimer, Dimerization is rate-limiting for hTSH secretion, and dissociation leads to hormone inactivation, Previous studies on human chorionic gonadotropin (hCG) and human follicle-stimulating hormone had shown that if was possible by subunit gene fusion to produce a bioactive, single chain hormone. However, neither the stability nor the clearance from the circulation of such fused glycoprotein hormones has been studied. We show here that genetic fusion of the hTSH alpha- and beta-subunits using the carboxyl-terminal peptide of the hCG beta-subunit as a linker created unimolecular hTSH whose receptor binding and bioactivity were comparable to native hTSH. Interestingly; the fused hTSH had higher thermostability and a longer plasma half-life than either native or dimeric hTSH containing the hCG beta-subunit-carboxyl-terminal peptide, suggesting that dimer dissociation may contribute to glycoprotein hormone inactivation in vivo. In addition, we show for the first time that synthesis of hTSH as a single polypeptide chain could overcome certain mutagenesis-induced defects in hTSH secretion, therefore enabling functional studies of such mutants, Thus, in addition to prolongation of plasma half-life, genetic fusion of hTSH subunits should be particularly relevant for the engineering of novel analogs where desirable features are offset by decreased dimer formation or stability, Such methods provide a general approach to expand the spectrum of novel recombinant glycoprotein hormones available for in vitro and in vivo study.	NHLBI,NIH,BETHESDA,MD 20892; UNIV MARYLAND,SCH MED,DEPT MED,MOL ENDOCRINOL LAB,BALTIMORE,MD 21201	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University System of Maryland; University of Maryland Baltimore	Grossmann, M (corresponding author), UNIV MARYLAND,CTR MED BIOTECHNOL,INST HUMAN VIROL,MOL ENDOCRINOL LAB,725 W LOMBARD ST N457,BALTIMORE,MD 21201, USA.							CAMPBELL KL, 1980, P NATL ACAD SCI-BIOL, V77, P4793, DOI 10.1073/pnas.77.8.4793; CONSTANT RB, 1986, ENDOCRINOLOGY, V119, P2720, DOI 10.1210/endo-119-6-2720; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; GROSSMANN M, 1995, J BIOL CHEM, V270, P29378, DOI 10.1074/jbc.270.49.29378; Grossmann M, 1996, MOL ENDOCRINOL, V10, P769, DOI 10.1210/me.10.6.769; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Grossmann M, 1997, ENDOCR REV, V18, P476, DOI 10.1210/er.18.4.476; GROSSMANN M, 1995, MOL ENDOCRINOL, V9, P948, DOI 10.1210/me.9.8.948; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IBANEZ CF, 1994, J NEUROBIOL, V25, P1349, DOI 10.1002/neu.480251104; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; JOSHI L, 1995, ENDOCRINOLOGY, V136, P3839, DOI 10.1210/en.136.9.3839; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; MAGNER JA, 1982, J BIOL CHEM, V257, P6709; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P95, DOI 10.1210/mend-2-2-95; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; Roth KE, 1996, BIOCHEMISTRY-US, V35, P7928, DOI 10.1021/bi952566j; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; SKUDLINSKI MW, 1996, NAT BIOTECHNOL, V14, P1257; Sugahara T, 1996, J BIOL CHEM, V271, P10445, DOI 10.1074/jbc.271.18.10445; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Szkudlinski MW, 1996, NAT BIOTECHNOL, V14, P1257, DOI 10.1038/nbt1096-1257; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; THOTAKURA NR, 1995, GLYCOBIOLOGY, V5, P3, DOI 10.1093/glycob/5.1.3; Tian Y, 1996, J BIOL CHEM, V271, P20250, DOI 10.1074/jbc.271.34.20250; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X	32	41	44	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21312	21316		10.1074/jbc.272.34.21312	http://dx.doi.org/10.1074/jbc.272.34.21312			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261143	hybrid			2022-12-25	WOS:A1997XR78900053
J	Paschal, BM; Fritze, C; Guan, T; Gerace, L				Paschal, BM; Fritze, C; Guan, T; Gerace, L			High levels of the GTPase Ran/TC4 relieve the requirement for nuclear protein transport factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PORE COMPLEX; YEAST-CELLS; IMPORT; NUCLEOPORINS; IDENTIFICATION; DISSOCIATION; INHIBITION; INTERACTS; SUBSTRATE	The GTPase Ran/TC4 and the 14-kDa protein nuclear transport factor 2 (NTF2) are two of the cytosolic factors that mediate nuclear protein import in vertebrates. Previous biochemical studies have shown that NTF2 binds directly to the GDP-bound form of Ran/TC4 and to proteins of the nuclear pore complex that contain phenylalanine-glycine repeats, In the present study we have used molecular genetic approaches to study the Saccha romyces cerevisiae homologue of NTF2. The scNTF2 gene encodes a protein that is 44% identical to the human protein, We found that deletion of the scNTF2 gene is lethal and that repression of NTF2p expression by a regulatable promoter results in gross structural distortions of the nuclear envelope. In a screen for high copy number suppressors of a scNTF2 deletion, the only gene me isolated other than scNTF2 itself was GSP1, the S. cerevisiae homologue of Ran/TC4. Furthermore, me found that high levels of Ran/TC4 can relieve the requirement for NTF2 in a mammalian-permeabilized cell assay for nuclear protein import. These data suggest that certain of the nuclear protein import functions of NTF2 and Ran/TC4 are closely linked and that NTF2 may serve to modulate a transport step involving Ran/TC4.	SCRIPPS RES INST, DEPT CELL & MOL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NIGMS NIH HHS [GM41955] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041955] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BYERS B, 1991, METHOD ENZYMOL, V194, P602; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Hu TH, 1996, J CELL BIOL, V134, P589, DOI 10.1083/jcb.134.3.589; KISER GL, 1995, YEAST, V11, P1311, DOI 10.1002/yea.320111312; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; Pante N, 1995, INT REV CYTOL, V162B, P225; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SIKORSKI RS, 1989, GENETICS, V122, P19; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	36	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21534	21539		10.1074/jbc.272.34.21534	http://dx.doi.org/10.1074/jbc.272.34.21534			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261173	hybrid			2022-12-25	WOS:A1997XR78900083
J	Kumar, P; VanPatten, SM; Walsh, DA				Kumar, P; VanPatten, SM; Walsh, DA			Multiplicity of the beta form of the cAMP-dependent protein kinase inhibitor protein generated by post-translational modification and alternate translational initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; RAT TESTIS; INTRACELLULAR-LOCALIZATION; SKELETAL-MUSCLE; PHOSPHORYLATION; EXPRESSION; PEPTIDES; EXPORT; SIGNAL; YEAST	Two distinct species of the thermostable inhibitor of the cAMP-dependent protein kinase, PKI alpha and PKI beta, exist that are the products of separate genes. The PKI beta form, as first isolated from rat testis, is a 70-amino acid protein, but the genomic sequence suggested that an alternate form might exist, arising as a consequence of alternate translational initiation, This species, now termed PKI beta-78, has been synthesized by bacterial expression, demonstrated to be equipotent with PKI beta-70, and also now demonstrated to occur in vivo, By Western blot analyses, six additional species of PKI beta are also evident in tissues, Two of these represent the phospho forms of PKI beta-78 and PKI beta-70. The other four represent phospho and dephospho forms of two higher molecular mass PKI beta species, These latter forms are currently termed PKI beta-X and PKI beta-Y, awaiting the full elucidation of their molecular identity, In adult rat testis and cerebellum, PKI beta-70, PKI beta-X, and PKI beta-Y constitute 39, 23, and 32% and 15, 29, and 54% of the total tissue levels, respectively, In adult rat testis, 35-42% of each of these three species is present as a monophospho form, whereas no phosphorylation of them is evident in cerebellum, PKI beta-78 is present at much lower levels in both rat testis and cerebellum (similar to 6 and 2% of the total, respectively) and almost entirely as a monophospho species. PKI beta-78, like PKI beta-70, is a high affinity and specific inhibitor of the cAMP-dependent protein kinase. PKI beta-Y and PKI beta-X, in contrast, also significantly inhibit the cGMP-dependent protein kinase.	UNIV CALIF DAVIS, SCH MED, DEPT BIOL CHEM, DAVIS, CA 95616 USA	University of California System; University of California Davis								BEALE EG, 1977, J BIOL CHEM, V252, P6322; BEALE EG, 1977, ENDOCRINOLOGY, V101, P1621, DOI 10.1210/endo-101-5-1621; BEEBE SJ, 1992, J BIOL CHEM, V267, P25505; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; DEMAILLE JG, 1978, FEBS LETT, V86, P113, DOI 10.1016/0014-5793(78)80110-0; DUNCAN RJS, 1983, ANAL BIOCHEM, V132, P68, DOI 10.1016/0003-2697(83)90426-8; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GLASS DB, 1992, BIOCHEMISTRY-US, V31, P1728, DOI 10.1021/bi00121a021; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JINNO A, 1993, MOL CELL BIOL, V13, P4146, DOI 10.1128/MCB.13.7.4146; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MCPHERSON JM, 1979, BIOCHEMISTRY-US, V18, P4835, DOI 10.1021/bi00589a011; MITCHELL RD, 1995, BIOCHEMISTRY-US, V34, P528, DOI 10.1021/bi00002a018; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; PICKETTGIES CA, 1985, J BIOL CHEM, V260, P2046; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SLICE LW, 1989, J BIOL CHEM, V264, P20940; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; SOLDATI T, 1990, J BIOL CHEM, V265, P4498; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZMIGIELSKI A, 1977, J BIOL CHEM, V252, P3848; TASH JS, 1980, CELL, V21, P57, DOI 10.1016/0092-8674(80)90114-2; TASH JS, 1979, J BIOL CHEM, V254, P1241; VANPATTEN SM, 1987, J BIOL CHEM, V262, P3398; VanPatten SM, 1997, J BIOL CHEM, V272, P20021, DOI 10.1074/jbc.272.32.20021; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WEN W, 1994, J BIOL CHEM, V269, P32214; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WESTON PD, 1980, BIOCHIM BIOPHYS ACTA, V612, P40, DOI 10.1016/0005-2744(80)90276-4; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, METHOD ENZYMOL, V99, P80; WHITEHOUSE S, 1980, ARCH BIOCHEM BIOPHYS, V203, P734, DOI 10.1016/0003-9861(80)90233-7	50	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20011	20020		10.1074/jbc.272.32.20011	http://dx.doi.org/10.1074/jbc.272.32.20011			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242671	hybrid			2022-12-25	WOS:A1997XQ05900058
J	Nadler, MJS; Chen, BB; Anderson, JS; Wortis, HH; Neel, BG				Nadler, MJS; Chen, BB; Anderson, JS; Wortis, HH; Neel, BG			Protein-tyrosine phosphatase SHP-1 is dispensable for Fc gamma RIIB-mediated inhibition of B cell antigen receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; MYC ONCOGENES; NEWBORN MICE; IMMUNOGLOBULIN; TRANSFORMATION; LYMPHOCYTES; RETROVIRUS; NEOPLASMS; SIGNAL; PTP1C	The inhibitory Fe receptor, Fc gamma RIIB, provides a signal that aborts B cell antigen receptor activation, blocking extracellular calcium influx. Because the protein-tyrosine phosphatase SHP-1 binds tyrosy1 phosphorylated Fc gamma RIIB and Fc gamma RIIB-mediated inhibition is defective in motheaten (me/me) mice, which do not express SHP-1, it was proposed that SHP-1 mediates Fc gamma RIIB signaling in B cells (D'Ambrosio, D., Hippen, K. L., Minskoff S. A., Mellman, I., Pani, G., Siminovitch, K. A., and Cambier, J. C. (1995) Science 268, 293-297). However, SHP-1 is dispensable for Fc gamma RIIB-mediated inhibition of Fc epsilon RI signaling in mast cells (One, M., Bolland, S., Tempst, P., and Ravetch, J. V. (1996) Nature 383, 263-266), prompting us to re-examine the role of SHP-1 in Fc gamma RIIB signaling in B cells. We generated immortalized sIgM+, Fc gamma RIIB+ cell lines from me/me mice and normal littermates. Co-Ligation of Fc gamma RIIB and the sIgM antigen receptor inhibits calcium influx in both cell lines. Inhibition is reversed by preincubation with anti-Fc gamma RIIB antibodies, indicating that it is mediated bg Fc gamma RIIB. The inositol 5' phosphatase SHIP is recruited to tyrosyl-phosphorylated Fc gamma RIIB in both cell Lines, Fc gamma RIIB-mediated CD19 dephosphorylation also occurs in the presence or the absence of SHP-1, Our results establish that SHP-1 is dispensable for Fc gamma RIIB-mediated inhibition of sIgM antigen receptor signaling.	TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111	Tufts University	Nadler, MJS (corresponding author), BETH ISRAEL DEACONESS MED CTR,DEPT MED,DIV HEMATOL ONCOL,CANC BIOL PROGRAM,BOSTON,MA 02215, USA.				NATIONAL CANCER INSTITUTE [R01CA066600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015803, R01AI015803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043773] Funding Source: NIH RePORTER; NCI NIH HHS [CA66600] Funding Source: Medline; NIAID NIH HHS [AI15803] Funding Source: Medline; NIAMS NIH HHS [AR43773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CHEN YW, 1992, INT IMMUNOL, V4, P1293, DOI 10.1093/intimm/4.11.1293; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; CYSTER JG, 1995, IMMUNITY, V2, P1; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DEARON M, 1995, J CLIN INVEST, V95, P577; DEARON M, 1995, IMMUNITY, V3, P635; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; Doody GM, 1996, CURR OPIN IMMUNOL, V8, P378, DOI 10.1016/S0952-7915(96)80128-2; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; TSUI FWL, 1994, IMMUNOL REV, V136, P185	26	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20038	20043		10.1074/jbc.272.32.20038	http://dx.doi.org/10.1074/jbc.272.32.20038			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242674	hybrid			2022-12-25	WOS:A1997XQ05900061
J	Alarco, AM; Balan, I; Talibi, D; Mainville, N; Raymond, M				Alarco, AM; Balan, I; Talibi, D; Mainville, N; Raymond, M			AP1-mediated multidrug resistance in Saccharomyces cerevisiae requires FLR1 encoding a transporter of the major facilitator superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-CASSETTE TRANSPORTER; MULTIPLE-DRUG-RESISTANCE; AZOLE ANTIFUNGAL AGENTS; CANDIDA-ALBICANS GENE; FLUCONAZOLE RESISTANCE; MOLECULAR-CLONING; PLEIOTROPIC DRUG; OXIDATIVE STRESS; YEAST; PROTEIN	We have isolated a Candida albicans gene that confers resistance to the azole derivative fluconazole (FCZ) when overexpressed in Saccharomyces cerevisiae. This gene encodes a protein highly homologous to S. cerevisiae yAP-1, a bZip transcription factor known to mediate cellular resistance to toxicants such as cycloheximide (CYH), 4-nitroquinoline N-oxide (4-NQO), cadmium, and hydrogen peroxide. The gene was named CAP1, for C. albicans AP-1. Cap1 and yAP-1 are functional homologues, since CAP1 expression in a yap1 mutant strain partially restores the ability of the cells to grow on toxic concentrations of cadmium or hydrogen peroxide. We have found that the expression of YBR008c, an open reading frame identified in the yeast genome sequencing project and predicted to code for a multidrug trans porter of the major facilitator superfamily, is dramatically induced in S. cervisiae cells overexpressing CAP1. Overexpression of either CAP1 or YAP1 in a wild type strain results in resistance to FCZ, CYH, and 4-NQO, whereas such resistance is completely abrogated (FCZ and CYH) or strongly reduced (4-NQO) in a ybr008c deletion mutant, demonstrating that YBR008c is involved in YAP1- and CAP1-mediated multidrug resistance. YBR008c has been renamed FLR1, for fluconazole resistance 1. The expression of an FLR1-lacZ reporter construct is strongly induced by the overexpression of either CAP1 or YAP1, indicating that the FLR1 gene is transcriptionally regulated by the Cap1 and yAP-1 proteins. Taken collectively, our results demonstrate that FLR1 represents a new YAP1-controlled multidrug resistance molecular determinant in S. cerevisiae, A similar detoxification pathway is also likely to operate in C. albicans.	CLIN RES INST MONTREAL, MONTREAL, PQ H2W 1R7, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal								Albertson GD, 1996, ANTIMICROB AGENTS CH, V40, P2835, DOI 10.1128/AAC.40.12.2835; Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BENYAACOV R, 1994, ANTIMICROB AGENTS CH, V38, P648, DOI 10.1128/AAC.38.4.648; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BOONE C, 1991, J BACTERIOL, V173, P6859, DOI 10.1128/jb.173.21.6859-6864.1991; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Clark FS, 1996, ANTIMICROB AGENTS CH, V40, P419, DOI 10.1128/AAC.40.2.419; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEXTER D, 1994, GENETICS, V136, P505; Dixon DM, 1996, PUBLIC HEALTH REP, V111, P226; Dupont BF, 1996, J MYCOL MED, V6, P12; EHRENHOFERMURRAY AE, 1994, MOL GEN GENET, V244, P287, DOI 10.1007/BF00285456; FLING ME, 1991, MOL GEN GENET, V227, P318, DOI 10.1007/BF00259685; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; GOLDWAY M, 1995, ANTIMICROB AGENTS CH, V39, P422, DOI 10.1128/AAC.39.2.422; GOMPELKLEIN P, 1990, CURR GENET, V18, P93, DOI 10.1007/BF00321122; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; HITCHCOCK CA, 1993, BIOCHEM SOC T, V21, P1039, DOI 10.1042/bst0211039; HITCHCOCK CA, 1993, ANTIMICROB AGENTS CH, V37, P1962, DOI 10.1128/AAC.37.9.1962; HUSSAIN M, 1991, GENE, V101, P149, DOI 10.1016/0378-1119(91)90238-7; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; KATZMANN DJ, 1996, MOL CELL BIOL, V20, P109; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LEPPERT G, 1990, GENETICS, V125, P13; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; Li S, 1997, P NATL ACAD SCI USA, V94, P73, DOI 10.1073/pnas.94.1.73; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Maenza JR, 1997, CLIN INFECT DIS, V24, P28, DOI 10.1093/clinids/24.1.28; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; Miller JH., 1972, EXPT MOL GENETICS; Miyahara K, 1996, CURR GENET, V29, P103, DOI 10.1007/s002940050023; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Nelissen B, 1995, FEBS LETT, V377, P232, DOI 10.1016/0014-5793(95)01380-6; Ouellette Marc, 1994, Trends in Microbiology, V2, P407, DOI 10.1016/0966-842X(94)90620-3; PARKINSON T, 1995, ANTIMICROB AGENTS CH, V39, P1696, DOI 10.1128/AAC.39.8.1696; PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101; REX JH, 1995, ANTIMICROB AGENTS CH, V39, P1, DOI 10.1128/AAC.39.1.1; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; Sanglard D, 1997, MICROBIOL-UK, V143, P405, DOI 10.1099/00221287-143-2-405; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SCZCYPKA MS, 1984, J BIOL CHEM, V269, P22853; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SRIKANTHA T, 1993, GENE, V131, P53, DOI 10.1016/0378-1119(93)90668-S; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Vanden Bossche H, 1994, Trends Microbiol, V2, P393, DOI 10.1016/0966-842X(94)90618-1; WEMMIE A, 1994, J BIOL CHEM, V269, P14690; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; Wemmie JA, 1997, J BIOL CHEM, V272, P7908, DOI 10.1074/jbc.272.12.7908; WHITEWAY M, 1992, P NATL ACAD SCI USA, V89, P9410, DOI 10.1073/pnas.89.20.9410; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	74	166	181	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19304	19313		10.1074/jbc.272.31.19304	http://dx.doi.org/10.1074/jbc.272.31.19304			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235926	hybrid			2022-12-25	WOS:A1997XP06300032
J	Zhang, YL; Li, Y; Wu, Y; Yan, HG				Zhang, YL; Li, Y; Wu, Y; Yan, HG			Structural and functional roles of tyrosine 78 of yeast guanylate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROBING PROTEIN-STRUCTURE; DYNAMIC NUCLEAR-POLARIZATION; ADENYLATE KINASE; SOLVENT PERTURBATION; MAGNETIC-RESONANCE; ANTIVIRAL ACTIVITY; ALPHA-LACTALBUMIN; REFINED STRUCTURE; NMR-SPECTROSCOPY; ESCHERICHIA-COLI	The hydroxyl group of Tyr-78 of yeast guanylate kinase (GK) is hydrogen-bonded to the phosphate of the bound GRIP as revealed by x-ray crystallography. The structural and functional roles of Tyr-78 were evaluated by site-directed mutagenesis, kinetics, guanidine hydrochloride-induced denaturation, and nuclear magnetic resonance spectroscopy (NMR). Substitution of Tyr-78 with a phenylalanine resulted in a decrease in k(cat) by a factor of 131, an increase in K-m(GMP) by a factor of 20 and an increase in K-i(GMP) by a factor of 18. K-m(MgATP) and K-i(MgATP) were very similar to those of the wild-type (WT) GK. The conformational stability of the mutant was lower than that of the WT by 1.0 kcal/mol as measured by guanidine hydrochloride-induced denaturation. Detailed comparison of the TOCSY and NOESY spectra of the WT GK and the mutant indicated that the conformation of Y78F is little perturbed relative to that of the WT GK at the free state and the conformation of Y78F.GMP complex is also very similar to that of the WT.GMP complex. The results taken together showed that the hydrogen bond between Tyr-78 and GMP stabilizes the GK.GMP complex by 1.7 kcal/mol, the ternary complex by 1.8 kcal/mol, and the transition state by 4.6 kcal/mol. Tyr-78 is not essential for proper folding of the enzyme but it may contribute to the conformational stability. Solvent-accessible aromatic residues were identified by using the paramagnetic probe 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl. Comparison of the free and GMP-bound forms of the WT GK by NMR indicated that there are changes in conformation and dynamics upon binding of GMP.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University					NIGMS NIH HHS [GM51901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051901] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELE U, 1995, PROTEIN SCI, V4, P1262, DOI 10.1002/pro.5560040702; Agarwal K C, 1978, Methods Enzymol, V51, P483; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERRY MB, 1994, PROTEINS, V19, P183, DOI 10.1002/prot.340190304; BOEHME RE, 1984, J BIOL CHEM, V259, P2346; Brady WA, 1996, J BIOL CHEM, V271, P16734, DOI 10.1074/jbc.271.28.16734; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CLELAND WW, 1986, INVESTIGATIONS RATES; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; ESPOSITO G, 1992, J MOL BIOL, V224, P659, DOI 10.1016/0022-2836(92)90551-T; Fitzgibbon J, 1996, FEBS LETT, V385, P185, DOI 10.1016/0014-5793(96)00365-1; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; IMPROTA S, 1995, EUR J BIOCHEM, V227, P78, DOI 10.1111/j.1432-1033.1995.tb20361.x; IMPROTA S, 1995, EUR J BIOCHEM, V227, P87, DOI 10.1111/j.1432-1033.1995.tb20362.x; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KARKAS JD, 1987, BIOCHIM BIOPHYS ACTA, V911, P127, DOI 10.1016/0167-4838(87)90001-X; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KOSHLAND DE, 1994, ANGEW CHEM INT EDIT, V33, P2375; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Li Y, 1996, J BIOL CHEM, V271, P28038, DOI 10.1074/jbc.271.45.28038; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MILLER WH, 1992, J BIOL CHEM, V267, P21220; MILLER WH, 1980, J BIOL CHEM, V255, P7204; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; MULLERDIECKMANN HJ, 1995, J MOL BIOL, V246, P522; Pace C N, 1986, Methods Enzymol, V131, P266; PETROS AM, 1990, BIOCHEMISTRY-US, V29, P10041, DOI 10.1021/bi00495a005; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Scheffzek K, 1996, BIOCHEMISTRY-US, V35, P9716, DOI 10.1021/bi960642s; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZHANG Y, 1997, STRUCTURAL FUNCTIONA	38	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19343	19350		10.1074/jbc.272.31.19343	http://dx.doi.org/10.1074/jbc.272.31.19343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235932	hybrid			2022-12-25	WOS:A1997XP06300038
J	Ambudkar, SV; Cardarelli, CO; Pashinsky, I; Stein, WD				Ambudkar, SV; Cardarelli, CO; Pashinsky, I; Stein, WD			Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT TUMOR-CELLS; EHRLICH ASCITES TUMOR; MULTIDRUG-RESISTANCE; WILD-TYPE; EXPRESSION; RECONSTITUTION; PURIFICATION; LEUKEMIA; CDNA	Considerable uncertainty surrounds the stoichiometry of coupling of ATP hydrolysis to drug pumping by P-glycoprotein, the multidrug transporter. To estimate relative turnovers far pumping of the drug vinblastine and ATP hydrolysis, we began by measuring the number of P-glycoprotein molecules an the surface of murine NIH3T3 cells expressing the human MDR1 gene, Fluorescence of cells treated with monoclonal antibody UIC2 was determined as a function of (i) amount of antibody at a fixed number of cells and (ii) increasing cell number at constant antibody, The two together gives 1.95 x 10(6) P-glycoprotein molecules/cell. Initial uptake rates of vinblastine +/- verapamil measure the ability of P-glycoprotein to extract vinblastine from the plasma membrane before it enters the cell, As a function of [vinblastine] at 37 degrees C, they give the maximum rats of this component of outward pumping as 2,1. x 10(6) molecules s(-1) cell(-1) or a turnover number of 1.1 s(-1), Initial rates of one-way efflux as a function of [vinblastine] at 25 degrees C +/- glucose give the maximum rate of this component of pumping as 0.59 x 10(6) molecules s(-1) cell(-1). The ratio of ATPase activity of P-glycoprotein at 31 and 25 degrees C is 4.6. Appropriating this ratio for pumping, maximum one-way efflux at 37 degrees C is 4.6 x 0.59 = 2.7 x 10(6) molecules s(-1) cell(-1), a turnover number of 1.4 s(-1), The vinblastine-stimulated ATPase activity of P-glycoprotein has a turnover number of 3.5 s(-1) at 37 degrees C, giving 2.8 molecules of AITP hydrolyzed for every vinblastine molecule transported in a particular direction, These calculations involve several approximations, but turnover numbers for pumping of vinblastine and for vinblastine-stimulated ATP hydrolysis are comparable, Thus, ATP hydrolysis is probably directly linked to drug transport by P-glycoprotein.	NCI,DIV BASIC SCI,MOL BIOL LAB,NIH,BETHESDA,MD 20892; HEBREW UNIV JERUSALEM,SILBERMAN INST LIFE SCI,DEPT BIOCHEM,IL-91904 JERUSALEM,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hebrew University of Jerusalem	Ambudkar, SV (corresponding author), NCI,CELL BIOL LAB,NIH,BLDG 37,RM 1B-17,37 CONVENT DR,MSC 4255,BETHESDA,MD 20892, USA.		Ambudkar, Suresh V/L-1317-2016; Ambudkar, Suresh V/B-5964-2008					AMBUDKAR SV, 1995, J BIOENERG BIOMEMBR, V27, P23, DOI 10.1007/BF02110327; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMBUDKAR SV, 1997, IN PRESS METHODS ENZ; BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103; CARDARELLI CO, 1995, CANCER RES, V55, P1086; DECKER DA, 1995, ANN CLIN LAB SCI, V25, P52; Eytan GD, 1996, J BIOL CHEM, V271, P3172, DOI 10.1074/jbc.271.6.3172; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; Ghauharali RI, 1996, BBA-BIOMEMBRANES, V1278, P213, DOI 10.1016/0005-2736(95)00224-3; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; He Luowen, 1995, Chinese Medical Sciences Journal, V10, P12; Hollo Z, 1996, FEBS LETT, V383, P99, DOI 10.1016/0014-5793(96)00237-2; HOLMES JA, 1994, BRIT J CANCER, V69, P382, DOI 10.1038/bjc.1994.70; Lan LB, 1996, CANCER CHEMOTH PHARM, V38, P181, DOI 10.1007/s002800050468; MARIE JP, 1995, HEMATOL ONCOL CLIN N, V9, P239, DOI 10.1016/S0889-8588(18)30094-7; MECHETNER EB, 1992, P NATL ACAD SCI USA, V89, P5824, DOI 10.1073/pnas.89.13.5824; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; NIELSEN D, 1994, BIOCHEM PHARMACOL, V47, P2125, DOI 10.1016/0006-2952(94)90247-X; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; RADERER M, 1993, CANCER, V72, P3553, DOI 10.1002/1097-0142(19931215)72:12<3553::AID-CNCR2820721203>3.0.CO;2-B; Ramachandra M, 1996, MOL BIOL CELL, V7, P1485, DOI 10.1091/mbc.7.10.1485; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; REDMOND SMS, 1991, CANCER RES, V51, P2092; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Schinkel A H, 1991, Semin Cancer Biol, V2, P213; SEHESTED M, 1989, VIRCHOWS ARCH B, V56, P327; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; Stein W., 2012, TRANSPORT DIFFUSION; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; STEIN WD, 1994, MOL PHARMACOL, V45, P763; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008	35	167	173	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21160	21166		10.1074/jbc.272.34.21160	http://dx.doi.org/10.1074/jbc.272.34.21160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261121	hybrid			2022-12-25	WOS:A1997XR78900031
J	Lelianova, VG; Davletov, BA; Sterling, A; Rahman, MA; Grishin, EV; Totty, NF; Ushkaryov, YA				Lelianova, VG; Davletov, BA; Sterling, A; Rahman, MA; Grishin, EV; Totty, NF; Ushkaryov, YA			alpha-Latrotoxin receptor, latrophilin, is a novel member of the secretin family of G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WIDOW SPIDER VENOM; EXPRESSION CLONING; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; TRANSMITTER RELEASE; MEDIATED ACTIVATION; XENOPUS-OOCYTES; CALCIUM FLUXES; MESSENGER-RNA; HORMONE	alpha-Latrotoxin (LTX) stimulates massive exocytosis of synaptic vesicles and mag help to elucidate the mechanism of regulation of neurosecretion, We have recently isolated latrophilin, the synaptic Ca2+-independent LTX receptor. Now we demonstrate that latrophilin is a novel member of the secretin family of G protein-coupled receptors that are involved in secretion, Northern blot analysis shows that latrophilin message is present only in neuronal tissue, Upon expression in COS cells, the cloned protein is indistinguishable from brain latrophilin and binds LTX with high affinity, Latrophilin physically interacts with a G alpha(o) subunit of heterotrimeric G proteins, because the two proteins co-purify in a two-step affinity chromatography, interestingly, extracellular domain of latrophilin is homologous to olfactomedin, a soluble neuronal protein thought to participate in odorant binding, Our findings suggest that latrophilin may bind unidentified endogenous ligands and transduce signals into nerve terminals, thus implicating G proteins in the control of synaptic vesicle exocytosis.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; MM SHEMYAKIN INST BIOORGAN CHEM,MOSCOW 117871,RUSSIA	Imperial College London; Ludwig Institute for Cancer Research; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			Davletov, Bazbek/ABA-8569-2021; Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297; Davletov, Bazbek/0000-0003-4658-3275	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; ARONIN N, 1992, J NEUROSCI, V12, P3435; BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Capogna M, 1996, J NEUROPHYSIOL, V76, P3149, DOI 10.1152/jn.1996.76.5.3149; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; DANIELSON PE, 1994, J NEUROSCI RES, V38, P468, DOI 10.1002/jnr.490380413; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; DERI Z, 1993, J NEUROCHEM, V61, P818, DOI 10.1111/j.1471-4159.1993.tb03592.x; FESCE LC, 1989, J GEN PHYSIOL, V88, P737; FILIPPOV AK, 1994, NEUROSCIENCE, V61, P179, DOI 10.1016/0306-4522(94)90070-1; FINKELSTEIN A, 1976, SCIENCE, V193, P1009, DOI 10.1126/science.948756; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; HAMANN J, 1995, J IMMUNOL, V155, P1942; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MARTY A, 1987, TRENDS NEUROSCI, V10, P373, DOI 10.1016/0166-2236(87)90074-9; MISLER S, 1979, P NATL ACAD SCI USA, V76, P991, DOI 10.1073/pnas.76.2.991; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; OZEKI Y, 1991, BIOCHEMISTRY-US, V30, P2391, DOI 10.1021/bi00223a014; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Poyer JF, 1996, J MEMBRANE BIOL, V153, P13; REAGAN JD, 1994, J BIOL CHEM, V269, P9; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; SCHEER H, 1984, J PHYSIOLOGY PARIS, V79, P216; SCHEER HW, 1990, CAN J PHYSIOL PHARM, V68, P1049, DOI 10.1139/y90-158; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; VICENTINI LM, 1984, BIOCHEM BIOPH RES CO, V121, P538, DOI 10.1016/0006-291X(84)90215-8; WANKE E, 1986, BIOCHEM BIOPH RES CO, V134, P320, DOI 10.1016/0006-291X(86)90565-6; YOKOE H, 1993, P NATL ACAD SCI USA, V90, P4655, DOI 10.1073/pnas.90.10.4655; ZELLES T, 1995, J NEUROSCI RES, V42, P242, DOI 10.1002/jnr.490420212	45	240	254	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21504	21508		10.1074/jbc.272.34.21504	http://dx.doi.org/10.1074/jbc.272.34.21504			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261169	hybrid			2022-12-25	WOS:A1997XR78900079
J	Iwaki, K; Ohashi, K; Ikeda, M; Tsujioka, K; Kajiya, F; Kurimoto, M				Iwaki, K; Ohashi, K; Ikeda, M; Tsujioka, K; Kajiya, F; Kurimoto, M			Decrease in the amount of focal adhesion kinase (p125(FAK)) in interleukin-1 beta-stimulated human umbilical vein endothelial cells by binding of human monocytic cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; TRANSENDOTHELIAL MIGRATION; EXTRACELLULAR-MATRIX; CROSS-TALK; PROTEIN; RECOGNITION; MOLECULE-1; PAXILLIN; ACTIVATION; EXPRESSION	Monocytes in the blood circulation migrate across endothelial cell monolayers lining the blood vessels and infiltrate into the underlying tissues in inflammation, However, little is known about the mechanisms by which leukocytes migrate across the endothelial barrier after binding and what molecules participate in the process, Addition of the human monocytic cell line THP-1 to interleukin-1 beta (IL-1 beta)-stimulated human umbilical vein endothelial cells (HUVEC) induced a decrease in the amount of focal adhesion kinase (p125(FAK)) protein, a tyrosine kinase localized at focal contacts and essential for cell attachment to the extracellular matrix, whereas little change was observed in the amount of other molecules associated with cell adhesion such as vascular cell adhesion molecule-1, alpha-catenin, and talin, A maximum decrease in the amount of p125(FAK) was observed 15-30 min after addition of THP-1 cells to HUVEC, after which the level of p125(FAK) gradually recovered, A reduction in the density of actin stress fibers in IL-1 beta-activated HUVEC was observed in parallel with the decrease in p125FAK. The p125(FAK) decrease was par tially inhibited by preventing THP-1 binding to HUVEC using a mixture of antibodies to adhesion molecules, We suggest that the decrease in p125(FAK) triggered by binding of monocytes in inflammation facilitates the transendothelial migration of the monocytes by altering the adhesiveness of endothelial cells to the extracellular matrix.	Kawasaki Med Sch, DEPT MED ENGN, KURASHIKI, OKAYAMA 70101, JAPAN; Kawasaki Med Sch, DEPT PHYSIOL, KURASHIKI, OKAYAMA 70101, JAPAN	Kawasaki Medical School; Kawasaki Medical School	Iwaki, K (corresponding author), HAYASHIBARA BIOCHEM LABS INC, FUJISAKI INST, 675-1 FUJISAKI, OKAYAMA 702, JAPAN.							BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NOBUHARA M, 1987, JPN J CANCER RES, V78, P193; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POBER JS, 1986, J IMMUNOL, V137, P1893; PRIETO J, 1994, CELL IMMUNOL, V156, P191, DOI 10.1006/cimm.1994.1164; RANKIN S, 1994, J BIOL CHEM, V269, P704; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275	33	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20665	20670		10.1074/jbc.272.33.20665	http://dx.doi.org/10.1074/jbc.272.33.20665			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252385	hybrid			2022-12-25	WOS:A1997XR22100055
J	Kummer, JL; Rao, PK; Heidenreich, KA				Kummer, JL; Rao, PK; Heidenreich, KA			Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PHEOCHROMOCYTOMA CELLS; INSULIN-RECEPTOR; PATHWAYS; STRESS	p38 is a member of the mitogen-activated protein (MAP) kinase superfamily activated by stress signals and implicated in cellular processes involving inflammation and apoptosis, Unlike the extracellular signal-regulated kinases (p42 and p44 MAP kinases), which are stimulated by insulin in many cell types, p38 activity is inhibited by insulin in postmitotic fetal neurons for which insulin is a potent survival factor (Heidenreich, K. A., and Kummer, J, L, (1996) J, Biol. Chem. 271, 9891-9894), These data suggested that insulin's effects on neuronal survival are mediated by inhibition of a p38-mediated apoptotic pathway, To better understand the relationship between p38 activity and cell survival, we induced apoptosis in two cell lines and examined the ability of insulin or a specific p38 inhibitor (a pyridinyl imidazole compound PD169316) to block p38 activity and cell death, In Rat-1 fibroblasts grown in the presence of serum, p38 activity was undetectable by immune complex assays, and the number of apoptotic cells was very low (< 0.5%), After the removal of serum for 16 h, p38 activity was markedly elevated, and apoptosis increased by 14-15-fold, Insulin (50 ng/ml) inhibited p38 activity by similar to 70% and blocked apoptosis by at least 80%, PD169316 also blocked p38 enzyme activity and apoptosis by approximately 80%, Similar results were obtained in differentiated PC12 cells that were deprived of nerve growth factor (NGF) for 16 h, In the presence of NGF, p38 activity and the number of apoptotic cells was very low (similar to 1.0%). After NGF withdrawal, p38 activity was selectively elevated and apoptosis increased to 15%, Both insulin and PD169316 markedly blocked the increase in p38 activity and apoptosis. The MAP kinase kinase inhibitor, PD98059, had no effect on apoptosis in Rat-1 fibroblasts and only partially blocked apoptosis in PC12 cells, PD98059 did not influence insulin's ability to block apoptosis, indicating that the extracellular signal-regulated kinase pathway does not mediate insulin's survival effects, These data further support the role of p38 in cellular apoptosis and support the hypothesis that insulin promotes cell survival, at least in part, by inhibiting the p38 pathway.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL C236,DENVER,CO 80262; DEPT VET AFFAIRS MED CTR,DENVER,CO 80220	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; HEIDENREICH KA, 1988, J NEUROCHEM, V51, P878, DOI 10.1111/j.1471-4159.1988.tb01824.x; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zawada WM, 1996, EXP NEUROL, V140, P60, DOI 10.1006/exnr.1996.0115	29	436	442	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20490	20494		10.1074/jbc.272.33.20490	http://dx.doi.org/10.1074/jbc.272.33.20490			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252360	hybrid			2022-12-25	WOS:A1997XR22100030
J	Macfarlane, WM; Smith, SB; James, RFL; Clifton, AD; Doza, YN; Cohen, P; Docherty, K				Macfarlane, WM; Smith, SB; James, RFL; Clifton, AD; Doza, YN; Cohen, P; Docherty, K			The p38/reactivating kinase mitogen-activated protein kinase cascade mediates the activation of the transcription factor insulin upstream factor 1 and insulin gene transcription by high glucose in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIC-REGULATION; HOMEODOMAIN PROTEIN; BINDING-PROTEINS; MAPKAP KINASE-2; ISLET ISOLATION; FACTOR-I; EXPRESSION; ENHANCER; PHOSPHORYLATION; INTERLEUKIN-1	Insulin upstream factor 1 (IUF1), a transcription factor present in pancreatic beta-cells, binds to the sequence C(C/T)TAATG present at several sites within the human insulin promoter, Here we isolated and sequenced cDNA encoding human IUF1 and exploited it to identify the signal transduction pathway by which glucose triggers its activation, In human islets, or in the mouse p-cell line MIN6, high glucose induced the binding of IUF1 to DNA, an effect mimicked by serine/threonine phosphatase inhibitors, indicating that DNA binding was induced by a phosphorylation mechanism, The glucose-stimulated binding of IUF1 to DNA and IUF1-dependent gene transcription were both prevented by SE 203580, a specific inhibitor of stress-activated protein kinase 2 (SAPK2, also termed p38 mitogen-activated protein kinase, reactivating kinase, CSBP, and Mxi2) but not by several other protein kinase inhibitors, Consistent with this finding, high glucose activated mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP kinase-a) (a downstream target of SAPK2) in MING cells, an effect that was also blocked by SE 203580, Cellular stresses that trigger the activation of SAPK2 and MAPKAP kinase-a (arsenite, heat shock) also stimulated IUF1 binding to DNA and IUF1 dependent gene transcription, and these effects were also prevented by SE 203580, IUF1 expressed in Escherichia coli was unable to bind to DNA, but binding was induced by incubation with MgATP, SAPK2, and a MING cell extract, which resulted in the conversion of IUF1 to a slower migrating form, SAPK2 could not be replaced by p42 MAP kinase, MAPKAP kinase-a, or MAPKAP kinase-3, The glucose-stimulated activation of IUF1 DNA binding and MAPKAP kinase-a (but not the arsenite-induced activation of these proteins) was prevented by wortmannin and LY 294002 at concentrations similar to those that inhibit phosphatidylinositide 3-kinase, Our results indicate that high glucose (a cellular stress) activates SAPK2 by a novel mechanism in which a wortmannin/LY 294002-sensitive component plays an essential role, SAPK2 then activates IUF1 indirectly by activating a novel IUF1-activating enzyme.	INST MED SCI,DEPT MOL & CELL BIOL,ABERDEEN AB25 2ZD,SCOTLAND; UNIV LEICESTER,DEPT SURG,LEICESTER ROYAL INFIRM,LEICESTER LE2 7LX,LEICS,ENGLAND; UNIV DUNDEE,DEPT BIOCHEM,INST MED SCI,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of Aberdeen; University of Leicester; University of Dundee				Docherty, Kevin/0000-0001-6765-2060	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOAM DSW, 1989, BIOCHEM J, V264, P233, DOI 10.1042/bj2640233; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK AR, 1993, FEBS LETT, V329, P139, DOI 10.1016/0014-5793(93)80210-L; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; COHEN P, 1997, IN PRESS TRENDS CELL; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DOCHERTY K, 1995, DIABETES CLIN SCI PR, P15; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LONDON NJM, 1994, CLIN TRANSPLANT, V8, P421; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Odagiri H, 1996, J BIOL CHEM, V271, P1909, DOI 10.1074/jbc.271.4.1909; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; READ ML, 1993, BIOCHEM J, V295, P233, DOI 10.1042/bj2950233; READ ML, 1995, BIOCHEM J, V309, P231, DOI 10.1042/bj3090231; RICORDI C, 1989, DIABETES, V38, P140, DOI 10.2337/diab.38.1.S140; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STOKOE D, 1993, BIOCHEM J, V296, P842; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888	38	154	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20936	20944		10.1074/jbc.272.33.20936	http://dx.doi.org/10.1074/jbc.272.33.20936			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252422	hybrid			2022-12-25	WOS:A1997XR22100092
J	Lundgren, DW; Moore, RM; Collins, PL; Moore, JJ				Lundgren, DW; Moore, RM; Collins, PL; Moore, JJ			Hypotonic stress increases cyclooxygenase-2 expression and prostaglandin release from amnion-derived WISH cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAMMALIAN-CELLS; MEMBRANES; GENE	This report examines the effect of cell volume expansion on cyclooxygenase-a (COX-2) mRNA expression, COX-2 protein expression, and prostaglandin E-2 release from human amnion-derived WISH cells, Earle's balanced salts solution (EBSS) with limited NaCl concentration was utilized as the induction medium. COX-2 mRNA was elevated 6-fold in cells incubated for 1 h in hypotonic EBSS. COX-2 mRNA expression was not increased when raffinose or sucrose were used to reconstitute low NaCl, Actinomycin D blocked COX-2 mRNA increase by hypotonic stress, while cycloheximide enhanced COX-2 mRNA expression. COX-2 mRNA and protein concentrations increased as a function of decreasing media osmolarity and incubation time in hypotonic EBSS. Hypotonic EBSS induced a 3-fold increase in prostaglandin E-2 release, WISH cells transiently transfected with a luciferase expression vector driven by the human COX-2 promoter for the COX-2 gene show a 3-fold increase in luciferase activity when incubated in hypotonic EBSS. COX-2 mRNA levels in primary human amnion cells were also increased by hypotonic stress. This study suggests that amnion cell COX-2 gene expression is regulated by cell volume expansion and/or increased plasma membrane tension.	CASE WESTERN RESERVE UNIV,DEPT PEDIAT,LABOR RES FOCUS GRP,NEWBORN DIV,SCH MED,METROHLTH MED CTR,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT OBSTET & GYNECOL,LABOR RES FOCUS GRP,SCH MED,METROHLTH MED CTR,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,LABOR RES FOCUS GRP,SCH MED,METROHLTH MED CTR,CLEVELAND,OH 44109	Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System								AKAI Y, 1994, AM J PHYSIOL, V267, pC482, DOI 10.1152/ajpcell.1994.267.2.C482; ALGER LS, 1986, CLIN OBSTET GYNECOL, V29, P758, DOI 10.1097/00003081-198612000-00005; BENNETT PR, 1992, AM J OBSTET GYNECOL, V167, P212, DOI 10.1016/S0002-9378(11)91660-3; BERGER SL, 1987, GUIDE MOL CLONING TE, P49; CRAVEN PA, 1991, KIDNEY INT, V39, P591, DOI 10.1038/ki.1991.69; DANFORTH DN, 1958, AM J OBSTET GYNECOL, V75, P536, DOI 10.1016/0002-9378(58)90610-0; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; Fuentes A, 1996, PROSTAGLANDINS, V52, P261, DOI 10.1016/S0090-6980(96)00088-3; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARFIELD RE, 1994, CONTROL UTERINE CONT; Gibb W, 1996, J ENDOCRINOL, V150, P497, DOI 10.1677/joe.0.1500497; GOLDBERG VJ, 1975, PHYSIOL REV, V55, P325, DOI 10.1152/physrev.1975.55.3.325; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; KANAYAMA N, 1989, GYNECOL OBSTET INVES, V28, P123, DOI 10.1159/000293546; KITTRICH M, 1971, BIOL NEONATE, V18, P29; LUNDGREN DW, 1992, J BIOL CHEM, V267, P6841; MITCHELL MD, 1993, PLACENTA, V14, P615, DOI 10.1016/S0143-4004(05)80379-0; OKITA JR, 1983, IN VITRO CELL DEV B, V19, P117; OLSON DM, 1995, SEMIN PERINATOL, V19, P53; OTTO JC, 1993, J BIOL CHEM, V268, P18234; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Rosen K., 1990, FOCUS, V12, P23; SLATER DM, 1995, AM J OBSTET GYNECOL, V172, P77, DOI 10.1016/0002-9378(95)90087-X; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STRANGE K, 1994, CELLULAR MOL PHYSL C, P3; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; VanMeir CA, 1996, PLACENTA, V17, P291, DOI 10.1016/S0143-4004(96)90052-1; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Wu KK, 1996, J LAB CLIN MED, V128, P242, DOI 10.1016/S0022-2143(96)90023-2	33	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20118	20124		10.1074/jbc.272.32.20118	http://dx.doi.org/10.1074/jbc.272.32.20118			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242685	hybrid			2022-12-25	WOS:A1997XQ05900072
J	Schaner, P; Todd, RB; Seidah, NG; Nillni, EA				Schaner, P; Todd, RB; Seidah, NG; Nillni, EA			Processing of prothyrotropin-releasing hormone by the family of prohormone convertases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED SECRETORY PATHWAYS; PROPROTEIN CONVERTASES; RAT-BRAIN; FUNCTIONAL EXPRESSION; SUBSTRATE-SPECIFICITY; INSITU HYBRIDIZATION; ENDOPROTEASE FAMILY; MAMMALIAN-CELLS; TRH PROHORMONE; PRO-PROTEIN	The post-translational processing of prothyrotropin-releasing hormone (pro-TRH25-255) has been extensively studied in our laboratory, and the processing pathway to mature TRH has been elucidated. We have also demonstrated that recombinant PC1 and PC2 process partially purified pro-TRH to cryptic peptides in vitro and that pro-TRH and PC1 mRNAs are coexpressed in primary cultures of hypothalamic neurons. To further define the role of each convertase, and particularly PC1 and PC2, in pro-TRH processing, recombinant vaccinia viruses were used to coexpress the prohormone convertases PC1, PC2, PACE4, PC5-B, furin, or control dynorphin together with rat prepro-TRH in constitutively secreting LoVo cells or in the regulated endocrine GH4C1 cell line. Radioimmunoassays from LoVo-derived secreted products indicated that furin cleaves the precursor to generate both N- and C-terminal intermediates, PC1, PC2, and PACE4 only produced N-terminal intermediates, but less efficiently than furin, In GH4C1 cells, PC1, PC2, furin, PC5-B, and PACE4 produced both N-terminal and C-terminal forms, Significantly, TRH-Gly and TRH were mostly produced by PCI, PC2, and furin, Utilizing gel electrophoresis to further analyze the cleavage specificities of PC1 and PC2, we found that PC1 seems primarily responsible for cleavage to both intermediates and mature TRH, since it generated all products at significantly higher levels than PC2, The addition of 7B2 to the coinfection did not augment the ability of PC2 to cleave pro-TRH to either N- or C-terminal forms.	BROWN UNIV, DIV ENDOCRINOL, DEPT MED, RHODE ISL HOSP, SCH MED, PROVIDENCE, RI 02903 USA; CLIN RES INST MONTREAL, BIOCHEM NEUROENDOCRINOL LAB, MONTREAL, PQ H2W 1R7, CANADA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				ALARCON C, 1993, J BIOL CHEM, V268, P4276; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BOWERS CY, 1971, BIOCHEM BIOPH RES CO, V45, P1033, DOI 10.1016/0006-291X(71)90441-4; BRAKCH N, 1995, FEBS LETT, V362, P143, DOI 10.1016/0014-5793(95)00229-3; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; BULANT M, 1990, ENDOCRINOLOGY, V127, P1978, DOI 10.1210/endo-127-4-1978; BULANT M, 1988, J BIOL CHEM, V263, P17189; COCKLE SM, 1990, FEBS LETT, V264, P253, DOI 10.1016/0014-5793(90)80261-G; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; Day R., 1993, HDB EXPT PHARM, P449, DOI [10.1007/978-3-642-77460-7_19, DOI 10.1007/978-3-642-77460-7_19]; DECROLY E, 1994, J BIOL CHEM, V269, P12240; delaCruz IP, 1996, J BIOL CHEM, V271, P22736, DOI 10.1074/jbc.271.37.22736; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; FRIEDMAN TC, 1995, ENDOCRINOLOGY, V136, P4462, DOI 10.1210/en.136.10.4462; GALANOPOULOU AS, 1993, J BIOL CHEM, V268, P6041; HOFLEHNER J, 1995, FEBS LETT, V360, P294, DOI 10.1016/0014-5793(95)00127-U; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; HOOK VYH, 1984, P NATL ACAD SCI-BIOL, V81, P2776, DOI 10.1073/pnas.81.9.2776; JACKSON IMD, 1994, REGULATION THYROTROP, P179; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; LECHAN RM, 1986, SCIENCE, V231, P159, DOI 10.1126/science.3079917; LECHAN RM, 1987, ENDOCRINOLOGY, V121, P1879, DOI 10.1210/endo-121-5-1879; Legradi G, 1996, BRAIN RES, V729, P10; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; Meerabux J, 1996, CANCER RES, V56, P448; METCALF G, 1974, NATURE, V252, P310, DOI 10.1038/252310a0; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; Nicholson WE, 1996, ENDOCRINOLOGY, V137, P2171, DOI 10.1210/en.137.5.2171; Nillni E. A., 1995, Molecular Biology of the Cell, V6, p331A; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1260, DOI 10.1210/en.132.3.1260; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1271, DOI 10.1210/en.132.3.1271; NILLNI EA, 1995, J NEUROCHEM, V65, P2462; Nillni EA, 1996, ENDOCRINOLOGY, V137, P5651, DOI 10.1210/en.137.12.5651; Pu LP, 1996, ENDOCRINOLOGY, V137, P1233, DOI 10.1210/en.137.4.1233; REDEI E, 1995, ENDOCRINOLOGY, V136, P3557, DOI 10.1210/en.136.8.3557; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; RITTENHOUSE PA, 1996, 10 INT C END JUN 12, P122; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUSSEL JP, 1991, NEUROENDOCRINOLOGY, V54, P559, DOI 10.1159/000125960; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCOTT AP, 1993, NATURE, V244, P64; SEGERSON TP, 1987, ENDOCRINOLOGY, V121, P98, DOI 10.1210/endo-121-1-98; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P175; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SEIDAH NG, 1995, INTRAMOLECULAR CHAPE, P181; SEVARINO KA, 1989, J BIOL CHEM, V264, P21529; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WILBER JF, 1968, P SOC EXP BIOL MED, V127, P488; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	72	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19958	19968		10.1074/jbc.272.32.19958	http://dx.doi.org/10.1074/jbc.272.32.19958			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242664	hybrid			2022-12-25	WOS:A1997XQ05900051
J	Takagi, J; Kamata, T; Meredith, J; PuzonMcLaughlin, W; Takada, Y				Takagi, J; Kamata, T; Meredith, J; PuzonMcLaughlin, W; Takada, Y			Changing ligand specificities of alpha v beta 1 and alpha v beta 3 integrins by swapping a short diverse sequence of the beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ATTACHMENT; POINT MUTATION; GPIIB-IIIA; BINDING; ADHESION; ALPHA; FIBRONECTIN; EXPRESSION; DOMAIN; SITE	Integrins mediate signal transduction through interaction with multiple cellular or extracellular matrix ligands. Integrin alpha v beta 3 recognizes fibrinogen, von Willebrand factor, and vitronectin, while alpha v beta 1 does not. We studied the mechanisms for defining ligand specificity of these integrins by swapping the highly diverse sequences in the I domain-like structure of the beta 1 and beta 3 subunits. When the sequence CTSEQNC (residues 187-193) of beta 1 is replaced with the corresponding CYD-MKTTC sequence of beta 3, the ligand specificity of alpha v beta 1 is altered. The mutant (alpha v beta 1-3-1), like alpha v beta 3, recognizes fibrinogen, von Willebrand factor, and vitronectin (a gain-of-function effect). The alpha v beta 1-3-1 mutant is recruited to focal contacts on fibrinogen and vitronectin, suggesting that the mutant transduces intracellular signals on adhesion. The reciprocal beta 3-1-3 mutation blocks binding of alpha v beta 3 to these multiple ligands and to LM609, a function-blocking anti-alpha v beta 3 antibody. These results suggest that the highly divergent sequence is a key determinant of integrin ligand specificity. Also, the data support a recent hypothetical model of the I domain of beta, in which the sequence is located in the ligand binding site.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049899, R01GM047157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJT ML, 1994, J BIOL CHEM, V269, P20913; BRACIALE TJ, 1986, J IMMUNOL, V137, P995; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; COCK J, 1992, BIOCH BIOPHYS A, V1119, P312; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; Ferrer M, 1996, THROMB HAEMOSTASIS, V76, P292; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HUANG XZ, 1995, AM J RESP CELL MOL, V13, P245, DOI 10.1165/ajrcmb.13.2.7626292; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRIE A, 1995, EMBO J, V14, P5542; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LASZ EC, 1993, BIOCHEM BIOPH RES CO, V190, P118, DOI 10.1006/bbrc.1993.1019; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LU XJ, 1994, BIOCHEM J, V304, P929, DOI 10.1042/bj3040929; Lu XJ, 1996, J BIOL CHEM, V271, P289, DOI 10.1074/jbc.271.1.289; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PIERSCHBACHER MD, 1982, J BIOL CHEM, V257, P9593; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P16580, DOI 10.1074/jbc.271.28.16580; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEINER B, 1993, J BIOL CHEM, V268, P6870; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P282; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	48	110	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19794	19800		10.1074/jbc.272.32.19794	http://dx.doi.org/10.1074/jbc.272.32.19794			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242639	hybrid			2022-12-25	WOS:A1997XQ05900026
J	VanPatten, SM; Donaldson, LF; McGuinness, MP; Kumar, P; Alizadeh, A; Griswold, MD; Walsh, DA				VanPatten, SM; Donaldson, LF; McGuinness, MP; Kumar, P; Alizadeh, A; Griswold, MD; Walsh, DA			Specific testicular cellular localization and hormonal regulation of the PKI alpha and PKI beta isoforms of the inhibitor protein of the cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; MESSENGER-RNA; RAT TESTIS; CATALYTIC SUBUNIT; SERTOLI CELLS; ADENOSINE-MONOPHOSPHATE; MOLECULAR-CLONING; EPIDIDYMAL SPERM; GERM-CELLS; EXPRESSION	We have previously demonstrated that there exist two distinct genes for the thermostable inhibitor protein of the cAMP-dependent protein kinase, PKI alpha and PKI beta (Van Fatten, S. M., Howard, P., Walsh, D. A., and Maurer, R. A. (1992) Mel. Endocrinol, 6, 2114-2122), We have also shown that in the testis, at least eight forms of PKI beta exist, differing as a result of at least post-translational modification and alternate translational initiation (Kumar, P., Van Fatten, S. M., and Walsh, D. A. (1997) J. Biol. Chem. 272, 20011-20020), We now report that in the testis, there is a unique cellular distribution of protein kinase inhibitor forms, with PKI beta being essentially (if not exclusively) a germ cell protein and PKI alpha being expressed primarily in Sertoli cells, Furthermore, there is a progressive change in the forms of PKI beta that are present within germ cells with development that is initiated in testis tubules and continues as the germ cells migrate through the epididymis, These conclusions are derived from studies with isolated cell populations and with the at/at germ cell-deficient mouse line, by in situ hybridization, and by following the developmental expression of these proteins in both testis and epididymis, We have also shown that follicle-stimulating hormone (FSH) can increase the expression of both PKI alpha and PKI beta, The FSH-regulated expression of PKI alpha in the Sertoli cell likely occurs via the normal route of second messenger signal transduction. In contrast, the FSH-dependent PKI beta expression must arise by some form of Sertoli cell-germ cell intercommunication.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; WASHINGTON STATE UNIV,DEPT BIOPHYS & BIOCHEM,PULLMAN,WA 99164	University of California System; University of California Davis; Washington State University				Donaldson, Lucy/0000-0002-4242-5790				BEALE EG, 1977, J BIOL CHEM, V252, P6322; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BRANDT H, 1980, J BIOL CHEM, V255, P982; BROKAW CJ, 1987, J CELL BIOCHEM, V35, P175, DOI 10.1002/jcb.240350302; CHRISTENSEN AK, 1965, ENDOCRINOLOGY, V76, P646, DOI 10.1210/endo-76-4-646; De Kretser D. M., 1994, P1177; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DELMAS V, 1994, MOL CELL ENDOCRINOL, V100, P120; DONALDSON LF, 1992, MOL BRAIN RES, V16, P143, DOI 10.1016/0169-328X(92)90204-O; DORRINGTON JH, 1975, ENDOCRINOLOGY, V96, P879, DOI 10.1210/endo-96-4-879; FAKUNDING JL, 1977, ENDOCRINOLOGY, V101, P1358, DOI 10.1210/endo-101-5-1358; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GROOTEGOED JA, 1977, BIOCHEM J, V168, P23, DOI 10.1042/bj1680023; HANDEL MA, 1979, BIOL REPROD, V20, P1031, DOI 10.1095/biolreprod20.5.1031; HECKERT L, 1993, RECENT PROG HORM RES, V48, P61; HECKERT LL, 1991, MOL ENDOCRINOL, V5, P670, DOI 10.1210/mend-5-5-670; Hoskins D.D, 1990, CONTROLS SPERM MOTIL, P53; KARL AF, 1990, METHOD ENZYMOL, V190, P71; Kumar P, 1997, J BIOL CHEM, V272, P20011, DOI 10.1074/jbc.272.32.20011; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; LEE VWK, 1975, J REPROD FERTIL, V42, P121, DOI 10.1530/jrf.0.0420121; LONNERBERG P, 1992, BIOL REPROD, V46, P1057, DOI 10.1095/biolreprod46.6.1057; MEANS AR, 1976, BIOL REPROD, V14, P54, DOI 10.1095/biolreprod14.1.54; MEANS AR, 1974, J BIOL CHEM, V249, P1231; MOORE A, 1994, MOL REPROD DEV, V37, P181, DOI 10.1002/mrd.1080370209; NOLAND TD, 1987, BIOL REPROD, V37, P171, DOI 10.1095/biolreprod37.1.171; OYEN O, 1990, BIOL REPROD, V43, P46, DOI 10.1095/biolreprod43.1.46; OYEN O, 1987, BIOL REPROD, V37, P947, DOI 10.1095/biolreprod37.4.947; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; PARVINEN M, 1982, ENDOCRINOLOGY, V76, P646; PAUPARD MC, 1988, J CELL BIOCHEM, V37, P161, DOI 10.1002/jcb.240370204; PESCOVITZ OH, 1994, TRENDS ENDOCRIN MET, V5, P126, DOI 10.1016/1043-2760(94)90094-9; Russell L. D., 1993, SERTOLI CELL; SCARPETTA MA, 1993, J BIOL CHEM, V268, P10927; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; STALLARD BJ, 1990, MOL ENDOCRINOL, V4, P393, DOI 10.1210/mend-4-3-393; Tash J.S., 1990, P229; TASH JS, 1982, BIOL REPROD, V26, P745, DOI 10.1095/biolreprod26.4.745; TASH JS, 1979, J BIOL CHEM, V254, P1241; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WEN W, 1994, J BIOL CHEM, V269, P32214	49	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20021	20029		10.1074/jbc.272.32.20021	http://dx.doi.org/10.1074/jbc.272.32.20021			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242672	hybrid			2022-12-25	WOS:A1997XQ05900059
J	Cai, DY; Williams, NK; Klinman, JP				Cai, DY; Williams, NK; Klinman, JP			Effect of metal on 2,4,5-trihydroxyphenylalanine (Topa) quinone biogenesis in the Hansenula polymorpha copper amine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL MONOAMINE-OXIDASE; ACTIVE-SITE; YEAST; GENERATION; COFACTOR; MECHANISM; CLONING; STATE	Previous studies of wild-type and mutant forms of a recombinant copper amine oxidase from Hansenula polymorpha, expressed in Saccharomyces cerevisiae, have indicated a self-processing mechanism for 2,4,5-trihydroxyphenylalanine (topa) quinone biogenesis involving the active site copper (Cai, D., and Klinman, J. P. (1994) J. Biol. Chem. 269, 32039-32042), In contrast to prokaryotic copper amine oxidases, however, it has not been possible to initiate topa quinone formation by the addition of exogenous copper to precursor H. polymorpha amine oxidase lacking copper, Metal analysis of copper-depleted wild-type enzyme reveals 0.2-0.3 mol copper, together with 0.6 mol zinc, Despite changes in the zinc and copper levels in growth media, the level of zinc in purified enzyme remains fairly constant, Further, we have been unable to displace protein-bound zinc by exogenously added copper, The H. polymorpha amine oxidase gene was subsequently expressed in Escherichia coli and found to be almost completely free of copper and zinc. In vitro reconstitution of this apoprotein confirms that zinc binds to H. polymorpha amine oxidase and prevents reconstitution with copper, By contrast, addition of copper first to apoprotein leads to formation of topa quinone and stable activity in the presence of added zinc, These findings indicate efficient binding of either zinc or copper to a site that undergoes little or no exchange, The data confirm that topa quinone biogenesis in the H. polymorpha system is catalyzed by copper and occurs in the absence of added factors, We conclude that the mechanisms of cofactor biogenesis in pro- and eukaryotic systems are likely to be similar or identical, The results described herein imply different pathways for the in vivo assembly of heterologously expressed amine oxidases in S. cerevisiae and E. coli.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039296] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39296] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUINENBERG PG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P157, DOI 10.1016/0167-4781(80)90003-2; CAI D, 1994, BIOCHEMISTRY-US, V33, P7674; CAI DY, 1994, J BIOL CHEM, V269, P32039; CHOI YH, 1995, J BIOL CHEM, V270, P4712, DOI 10.1074/jbc.270.9.4712; DEHOOP MJ, 1992, YEAST, V8, P243, DOI 10.1002/yea.320080402; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; FONTECAVE M, 1995, STRUCTURE, V15, P1127; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; Large P. J., 1986, YEAST, V2, P1; LOWERY MD, 1992, INORG CHIM ACTA, V233, P198; LU Y, 1992, J AM CHEM SOC, V114, P3560, DOI 10.1021/ja00035a064; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MATSUZAKI R, 1995, BIOCHEMISTRY-US, V34, P4524, DOI 10.1021/bi00014a004; MCCRACKEN J, 1992, J AM CHEM SOC, V114, P3715, DOI 10.1021/ja00036a021; MU D, 1994, J BIOL CHEM, V269, P9926; MU D, 1992, J BIOL CHEM, V267, P7979; Ruggiero CE, 1997, BIOCHEMISTRY-US, V36, P1953, DOI 10.1021/bi9628836; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60	23	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19277	19281		10.1074/jbc.272.31.19277	http://dx.doi.org/10.1074/jbc.272.31.19277			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235922	hybrid			2022-12-25	WOS:A1997XP06300028
J	DellaRocca, GJ; vanBiesen, T; Daaka, Y; Luttrell, DK; Luttrell, LM; Lefkowitz, RJ				DellaRocca, GJ; vanBiesen, T; Daaka, Y; Luttrell, DK; Luttrell, LM; Lefkowitz, RJ			Ras-dependent mitogen-activated protein kinase activation by G protein-coupled receptors - Convergence of G(i)- and G(q)-mediated pathways on calcium/calmodulin, Pyk2, and Src kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; BETA-GAMMA-SUBUNITS; MAP KINASE; TYROSINE-KINASE; LYSOPHOSPHATIDIC ACID; EXPRESSION; PHOSPHORYLATION; FIBROBLASTS; PP60C-SRC; P21(RAS)	Many receptors that couple to heterotrimeric guanine-nucleotide binding proteins (G proteins) have been shown to mediate rapid activation of the mitogen-activated protein kinases Erk1 and Erk2, In different cell types, the signaling pathways employed appear to be a function of the available repertoire of receptors, G proteins, and effecters, In HEK-293 cells, stimulation of either alpha 1B- or alpha 2A-adrenergic receptors (ARs) leads to rapid 5-10-fold increases in Erk1/2 phosphorylation, Phosphorylation of Erk1/2 in response to stimulation of the alpha 2A-AR is effectively attenuated by pretreatment with pertussis toxin or by coexpression of a G beta gamma subunit complex sequestrant peptide (beta ARK1ct) and dominant-negative mutants of Ras (N17-Ras), mSOS1 (SOS-Pro), and Raf (Delta N-Raf), Erk1/2 phosphorylation in response to alpha 1B-AR stimulation is also attenuated by coexpression of N17-Ras, SOS-Pro, or Delta N-Raf, but not by coexpression of beta ARK1ct or by pretreatment with pertussis toxin. The alpha 1B- and alpha 2A-AR signals are both blocked by phospholipase C inhibition, intracellular Ca2+ chelation, and inhibitors of protein-tyrosine kinases, Overexpression of a dominant-negative mutant of c-Src or of the negative regulator of c-Src function, Csk, results in attenuation of the alpha 1B-AR- and alpha 2A-AR-mediated Erk1/2 signals. Chemical inhibitors of calmodulin, but not of PKC, and overexpression of a dominant-negative mutant of the protein-tyrosine kinase Pyk2 also attenuate mitogen-activated protein kinase phosphorylation after both alpha 1B- and alpha 2A-AR stimulation, Erk1/2 activation, then, proceeds via a common Ras-, calcium-, and tyrosine kinase-dependent pathway for both G(i)- and G(q/11)-coupled receptors, These results indicate that in HEK-293 cells, the G beta gamma subunit-mediated alpha 2A-AR- and the Ga-q/11-mediated alpha 1B-AR-coupled Erk1/2 activation pathways converge at the level of phospholipase C. These data suggest that calcium-calmodulin plays a central role in the calcium-dependent regulation of tyrosine phosphorylation by G protein-coupled receptors in some systems.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; GLAXO WELLCOME RES & DEV LTD, DEPT MOL BIOCHEM, RES TRIANGLE PK, NC 27709 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; GlaxoSmithKline			Della Rocca, Gregory/AAM-5281-2021; Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline; NIGMS NIH HHS [T32GM-07171] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FAURE M, 1994, J BIOL CHEM, V269, P7851; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE LR, 1993, J BIOL CHEM, V268, P20717; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MORINELLI TA, 1994, J BIOL CHEM, V269, P5693; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WATANABE T, 1995, J BIOL CHEM, V270, P8984, DOI 10.1074/jbc.270.15.8984	47	382	385	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19125	19132		10.1074/jbc.272.31.19125	http://dx.doi.org/10.1074/jbc.272.31.19125			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235901	hybrid			2022-12-25	WOS:A1997XP06300007
J	Teneberg, S; MillerPodraza, H; Lampert, HC; Evans, DJ; Evans, DG; Danielsson, D; Karlsson, KA				Teneberg, S; MillerPodraza, H; Lampert, HC; Evans, DJ; Evans, DG; Danielsson, D; Karlsson, KA			Carbohydrate binding specificity of the neutrophil-activating protein of Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANES; MAGNETIC-RESONANCE ANALYSIS; PEPTIC-ULCER DISEASE; GASTRIC LYMPHOMA; POLYMORPHONUCLEAR LEUKOCYTES; GLYCOLIPID RECEPTORS; CHEMOTACTIC FACTOR; ANOMERIC STRUCTURE; GLYCOSPHINGOLIPIDS; INFECTION	The Possible interaction of the neutrophil-activating protein of Helicobacter pylori with target cell glycoconjugates was investigated by the binding of I-125-labeled recombinant protein to glycosphingolipids from human neutrophils in solid phase assays, Thereby, a distinct binding of the neutrophil-activating protein to four bands in the acid glycosphingolipid fraction from human neutrophils was detected, whereas no binding to the non-acid glycosphingolipids or polyglycosyl ceramides from these cells was obtained, When using glycosphingolipids not present in the cell membrane of human neutrophils, it was found that the neutrophil-activating protein also bound to sulfated glycosphingolipids as sulfatide and sulfated gangliotetraosyl ceramide, Comparison of the binding preferences df the protein to reference glycosphingolipids from other sources suggested that in human granulocytes, the neutrophil-activating protein of H. pylori preferentially recognizes glycoconjugates with a terminally unsubstituted NeuAc alpha 3Gal beta 4GlcNAc beta 3Gal beta 4GlcNAc beta sequence.	VET AFFAIRS MED CTR,BACTERIAL ENTEROPATHOGENS LAB,HOUSTON,TX 77030; BAYLOR COLL MED,HOUSTON,TX 77030; OREBRO MED CTR HOSP,DEPT CLIN MICROBIOL & IMMUNOL,S-70185 OREBRO,SWEDEN	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine	Teneberg, S (corresponding author), GOTHENBURG UNIV,DEPT MED BIOCHEM,MEDICINAREGATAN 9A,S-41390 GOTHENBURG,SWEDEN.				NIAID NIH HHS [AI28837] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028837] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; BOYUM A, 1974, TISSUE ANTIGENS, V4, P269; Cover TL, 1996, MOL MICROBIOL, V20, P241, DOI 10.1111/j.1365-2958.1996.tb02612.x; CRAIG PM, 1992, GUT, V33, P1020, DOI 10.1136/gut.33.8.1020; DIXON MF, 1994, SCAND J GASTROENTERO, V29, P7, DOI 10.3109/00365529409105353; DUNN BE, 1990, J BIOL CHEM, V265, P9464; EVANS DJ, 1995, INFECT IMMUN, V63, P2213, DOI 10.1128/IAI.63.6.2213-2220.1995; EVANS DJ, 1995, GENE, V153, P123, DOI 10.1016/0378-1119(94)00774-M; FALK KE, 1979, ARCH BIOCHEM BIOPHYS, V192, P177, DOI 10.1016/0003-9861(79)90083-3; FALK KE, 1979, ARCH BIOCHEM BIOPHYS, V192, P164, DOI 10.1016/0003-9861(79)90082-1; FALK KE, 1979, ARCH BIOCHEM BIOPHYS, V192, P191, DOI 10.1016/0003-9861(79)90084-5; FREDLUND H, 1988, APMIS, V96, P941, DOI 10.1111/j.1699-0463.1988.tb00966.x; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; HANDA S, 1963, JPN J EXP MED, V33, P347; HANSSON GC, 1985, ANAL BIOCHEM, V146, P158, DOI 10.1016/0003-2697(85)90410-5; HIGASHI H, 1985, CANCER RES, V45, P3796; IGLESIAS JL, 1982, EUR J BIOCHEM, V123, P247, DOI 10.1111/j.1432-1033.1982.tb19760.x; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P220; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KOERNER TAW, 1983, BIOCHEMISTRY-US, V22, P2676, DOI 10.1021/bi00280a014; KOZOL R, 1993, DIGEST DIS SCI, V38, P137, DOI 10.1007/BF01296786; KUNDU SK, 1981, FED PROC, V40, P1545; LEE A, 1993, INFECT IMMUN, V61, P1601, DOI 10.1128/IAI.61.5.1601-1610.1993; MAI UEH, 1991, J CLIN INVEST, V87, P894, DOI 10.1172/JCI115095; MILLERPODRAZA H, 1993, BIOCHIM BIOPHYS ACTA, V1168, P330, DOI 10.1016/0005-2760(93)90190-K; NIELSEN H, 1992, GUT, V33, P738, DOI 10.1136/gut.33.6.738; OCONNOR HJ, 1994, SCAND J GASTROENTERO, V29, P11, DOI 10.3109/00365529409105354; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; RAUTELIN H, 1993, GUT, V34, P599, DOI 10.1136/gut.34.5.599; RAUWS EAJ, 1989, CAMPYLOBACTER PYLORI, P49; REYMUNDE A, 1993, DIGEST DIS SCI, V38, P1697, DOI 10.1007/BF01303180; RUDIGER H, 1993, LECTINS GLYCOBIOLOGY, P31; SAMUELSSON BE, 1990, METHOD ENZYMOL, V193, P623, DOI 10.1016/0076-6879(90)93442-N; SIPPONEN P, 1994, SCAND J GASTROENTERO, V29, P24, DOI 10.3109/00365529409105356; SOLNICK JV, 1993, INFECT AG DIS, V1, P294; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P758, DOI 10.1021/bi951600r; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Takemura T, 1996, GASTROENTEROLOGY, V110, P21, DOI 10.1053/gast.1996.v110.pm8536858; Waldi D., 1962, DUNNSCHICHT CHROMATO, P496; WATANABE K, 1979, J BIOL CHEM, V254, P8223; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; YANG HJ, 1971, J BIOL CHEM, V246, P1192; YANG ZT, 1994, J BIOL CHEM, V269, P14620; YOSHIDA N, 1993, GASTROENTEROLOGY, V105, P1431, DOI 10.1016/0016-5085(93)90148-6	50	102	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19067	19071		10.1074/jbc.272.30.19067	http://dx.doi.org/10.1074/jbc.272.30.19067			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228091	hybrid			2022-12-25	WOS:A1997XM34200082
J	Adhya, S; Ghosh, T; Das, A; Bera, SK; Mahapatra, S				Adhya, S; Ghosh, T; Das, A; Bera, SK; Mahapatra, S			Role of an RNA-binding protein in import of tRNA into Leishmania mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODED TRANSFER-RNAS; TRYPANOSOMA-BRUCEI; ORGANIZATION; TARENTOLAE; DONOVANI; INVIVO; YEAST; DNA	Nuclear-encoded cytoplasmic tRNAs are imported into the mitochondria of kinetoplastid protozoa by an unknown mechanism, In a Leishmania in organello system, ATP-dependent import of a cloned, unspliced tRNA(Tyr)(GUA) transcript was demonstrated by protection from ribonuclease, whereas import of a tRNA(Gln) (CUG) transcript was much less efficient, Specific binding of tRNA(Tyr) to two mitochondrial surface proteins of 15 and 22 kilodaltons was observed. Tubulin antisense-binding protein (TAB), the 15-kilodaton species, was purified to apparent homogeneity by RNA affinity chromatography. TAB forms stable complexes with the D stem-loop region of tRNA(Tyr). Immunocytochemical and cell fractionation experiments, combined with limited proteolysis, suggested the association of TAB with the outer mitochondrial membrane, Importantly, anti-TAB antibody specifically inhibited binding as well as import of tRNA(Tyr) and of a synthetic structural homolog, These results support the role of TAB as a membrane-bound receptor or carrier for RNA import into Leishmania mitochondria.			Adhya, S (corresponding author), INDIAN INST CHEM BIOL,GENET ENGN LAB,4 RAJA SC MULLICK RD,CALCUTTA 700032,W BENGAL,INDIA.							DAS S, 1990, J BIOSCIENCES, V15, P239, DOI 10.1007/BF02702665; GHOSH A, 1994, NUCLEIC ACIDS RES, V22, P1663, DOI 10.1093/nar/22.9.1663; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HAUSER R, 1995, EMBO J, V14, P4212, DOI 10.1002/j.1460-2075.1995.tb00095.x; HAYAISHI O, 1962, METHOD ENZYMOL, V5, P807, DOI 10.1016/S0076-6879(62)05316-1; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC SB, 1993, MOL BIOCHEM PARASIT, V60, P349, DOI 10.1016/0166-6851(93)90148-Q; Lima BD, 1996, RNA, V2, P429; LYE LF, 1993, MOL BIOCHEM PARASIT, V58, P233, DOI 10.1016/0166-6851(93)90045-Y; MAHAPATRA S, 1994, NUCLEIC ACIDS RES, V22, P3381, DOI 10.1093/nar/22.16.3381; Mahapatra S, 1996, J BIOL CHEM, V271, P20432, DOI 10.1074/jbc.271.34.20432; Maniatis T., 1982, MOL CLONING; MOTTRAM JC, 1991, J BIOL CHEM, V266, P18313; NAGLEY P, 1989, TRENDS GENET, V5, P67, DOI 10.1016/0168-9525(89)90028-0; Rusconi CP, 1996, EMBO J, V15, P3286, DOI 10.1002/j.1460-2075.1996.tb00693.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHNEIDER A, 1994, MOL CELL BIOL, V14, P2317, DOI 10.1128/MCB.14.4.2317; SHI XM, 1994, MOL BIOCHEM PARASIT, V65, P23, DOI 10.1016/0166-6851(94)90112-0; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SMALL I, 1992, EMBO J, V11, P1291, DOI 10.1002/j.1460-2075.1992.tb05172.x; TARASSOV I, 1995, EMBO J, V14, P3461, DOI 10.1002/j.1460-2075.1995.tb07352.x; TARASSOV I, 1995, J MOL BIOL, V245, P315, DOI 10.1006/jmbi.1994.0026; TARASSOV IA, 1992, NUCLEIC ACIDS RES, V20, P1277, DOI 10.1093/nar/20.6.1277	27	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21396	21402		10.1074/jbc.272.34.21396	http://dx.doi.org/10.1074/jbc.272.34.21396			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261154	hybrid			2022-12-25	WOS:A1997XR78900064
J	Butenas, S; vantVeer, C; Mann, KG				Butenas, S; vantVeer, C; Mann, KG			Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; HUMAN FACTOR-VIIA; FACTOR-XI ACTIVATION; BOVINE FACTOR-V; HUMAN FACTOR-IX; EXTRINSIC PATHWAY; FACTOR-XA; PLASMINOGEN-ACTIVATOR; HUMAN-PROTHROMBIN; THROMBIN	The initiation phase of enzyme generation in a reconstituted model of the tissue factor (TF) pathway to thrombin was evaluated, At 1.25 pM added TF, no thrombin generation was observed in the absence of factor V, The substitution of factor Va for factor V increased the rate of thrombin generation, Factor X activation during the initiation phase was not influenced by the absence of factor VIII or thrombin, leading to the conclusion that initially factor Xa is generated exclusively by the factor VIIa-TF complex, When thrombin was eliminated from the system, no contribution of the factor Ma-factor VIIIa complex to factor X activation was observed during the propagation phase, Similarly, factor V activation was also not observed in the absence of thrombin, indicating that thrombin is the only enzyme responsible for factor V and factor VIII activation, Only subnanomolar amounts of factor VII were activated when prothrombin activation was almost complete, In the absence of coagulation inhibitors, factor XI did not influence thrombin generation initiated by 1.25 pat factor VIIa-TF complex. The termination of factor XIa generation by added hirudin in the factor XI experiment indicates that factor XI activation occurs exclusively by thrombin.	UNIV VERMONT, DEPT BIOCHEM, BURLINGTON, VT 05405 USA	University of Vermont					NHLBI NIH HHS [HL46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASTRUP T, 1952, ARCH BIOCHEM BIOPHYS, V40, P346, DOI 10.1016/0003-9861(52)90121-5; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BARLOW GH, 1981, THROMB RES, V23, P541, DOI 10.1016/0049-3848(81)90177-8; BEGUIN S, 1989, THROMB HAEMOSTASIS, V61, P25; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; BRUNNEE T, 1993, BLOOD, V81, P580; BUTENAS S, 1995, ANAL BIOCHEM, V225, P231, DOI 10.1006/abio.1995.1148; BUTENAS S, 1993, BIOCHEMISTRY-US, V32, P6531, DOI 10.1021/bi00077a006; BUTENAS S, 1992, BIOCHEMISTRY-US, V31, P5399, DOI 10.1021/bi00138a023; Butenas S, 1996, BIOCHEMISTRY-US, V35, P1904, DOI 10.1021/bi951768c; BUTENAS S, 1994, BIOCHEMISTRY-US, V33, P3449, DOI 10.1021/bi00177a039; CHO K, 1984, BIOCHEMISTRY-US, V23, P644, DOI 10.1021/bi00299a009; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAILANI D, 1993, BLOOD, V82, P813; GYZANDER E, 1984, THROMB RES, V35, P547, DOI 10.1016/0049-3848(84)90286-X; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HOFFMAN M, 1995, BLOOD, V86, P1794, DOI 10.1182/blood.V86.5.1794.bloodjournal8651794; JESTY J, 1979, J BIOL CHEM, V254, P2337; JONES KC, 1994, J BIOL CHEM, V269, P23367; KANE WH, 1981, J BIOL CHEM, V256, P1002; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KESSNER A, 1976, ARCH BIOCHEM BIOPHYS, V176, P411, DOI 10.1016/0003-9861(76)90183-1; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LE DT, 1992, J BIOL CHEM, V267, P15447; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MCRAE BJ, 1981, BIOCHEMISTRY-US, V20, P7196, DOI 10.1021/bi00528a022; NAITO K, 1991, J BIOL CHEM, V266, P7353; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PLOPLIS VA, 1987, J BIOL CHEM, V262, P9503; RADCLIFFE R, 1976, J BIOL CHEM, V251, P4797; RADCLIFFE R, 1975, J BIOL CHEM, V250, P388; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; RAO LVM, 1988, BLOOD, V72, P396; RAO LVM, 1995, BLOOD, V85, P121, DOI 10.1182/blood.V85.1.121.bloodjournal851121; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; SCOTT CF, 1992, P NATL ACAD SCI USA, V89, P11189, DOI 10.1073/pnas.89.23.11189; SELIGSOHN U, 1978, BLOOD, V52, P978; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TANS G, 1991, J BIOL CHEM, V266, P21864; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vantVeer C, 1997, J BIOL CHEM, V272, P20721, DOI 10.1074/jbc.272.33.20721; vantVeer C, 1997, J BIOL CHEM, V272, P4367, DOI 10.1074/jbc.272.7.4367; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; VERHEIJEN JH, 1985, THROMB RES, V39, P281, DOI 10.1016/0049-3848(85)90223-3; VONDEMBORNE PAK, 1994, THROMB HAEMOSTASIS, V72, P397	55	111	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21527	21533		10.1074/jbc.272.34.21527	http://dx.doi.org/10.1074/jbc.272.34.21527			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261172	hybrid			2022-12-25	WOS:A1997XR78900082
J	Huang, HC; Goldberg, AL				Huang, HC; Goldberg, AL			Proteolytic activity of the ATP-dependent protease HslVU can be uncoupled from ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR CHAPERONE; LA; DEGRADATION; COMPONENT; BREAKDOWN; POTASSIUM; PEPTIDES; PROTEINS; BINDING	HslVU is a new Escherichia coli ATP-dependent protease composed of two multimeric complexes: the HslU ATPase and the HslV peptidases. Prior studies indicated that HslVU requires ATP hydrolysis for the cleavage of peptides and proteins. We show here that ATP concentrations that activate hydrolysis of benzyloxycarbonyl-Gly-Gly-Leu-7-amido-4-methylcoumarin are 50-100 fold lower than those necessary for degradation of proteins (e.g. casein). Also, the nonhydrolyzable analogs of ATP, 5'-adenylyl beta,gamma-imidodiphosphate (AMP-PNP) and adenosine 5'-(alpha,beta-methylene)triphosphate, can support peptide hydrolysis, but only after an initial time lag not seen with ATP. This delay decreased at higher temperatures and with higher HslU or HslV concentrations and was eliminated by preincubation of HslU and HslV together. Thus, ATP hydrolysis accelerates the association of HslU and HslV, which occurs slowly with the nonhydrolyzable analog. The addition of KCl stimulated 4-6-fold the peptidase activity with AMP-PNP present and eliminated the time lag, but KCl had no stimulatory effect with ATP. NH4+ and Cs+ had similar effects as K+, but Na+ and Li+ were ineffective. AMP-PNP by itself supported hydrolysis of casein and other polypeptides only 20% as well as ATP, but in the presence of K+, Cs+, or NH4+, AMP-PNP activated casein degradation even better than ATP, although it was not hydrolyzed. In addition, MgCl2, MnCl2, and CaCl2 allowed some peptidase and caseinase activity in the absence of any nucleotide. However, Mn2+ and Ca2+, unlike Mg2+, abolished ATP hydrolysis and prevented further activation by ATP or AMP-PNP. These findings indicate that ATP binding to a high affinity site triggers the formation of an active state capable of peptide cleavage, although ATP hydrolysis facilitates this process. Rapid degradation of proteins requires a distinct state of the enzyme, which is normally reached through ATP hydrolysis at low affinity sites. However, AMP-PNP binding together with K+ can induce a form of HslVU that degrades proteins without energy consumption.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051923, R01GM046147] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46147, GM51923] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; EDMUNDS T, 1986, J CELL BIOCHEM, V32, P187, DOI 10.1002/jcb.240320304; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Katayama T, 1996, BIOCHEM BIOPH RES CO, V229, P219, DOI 10.1006/bbrc.1996.1783; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; Kessel M, 1996, FEBS LETT, V398, P274, DOI 10.1016/S0014-5793(96)01261-6; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MENON AS, 1987, J BIOL CHEM, V262, P14921; MENON AS, 1987, J BIOL CHEM, V262, P722; Missiakas D, 1996, EMBO J, V15, P6899, DOI 10.1002/j.1460-2075.1996.tb01082.x; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; RICE RH, 1971, J BIOL CHEM, V246, P831; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SEOL JH, 1997, IN PRESS EUR J BIOCH; Shin DH, 1996, FEBS LETT, V398, P151, DOI 10.1016/S0014-5793(96)01223-9; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WAXMAN L, 1985, J BIOL CHEM, V260, P2022; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOO KM, 1989, J BIOL CHEM, V264, P2088; Yoo SJ, 1996, J BIOL CHEM, V271, P14035, DOI 10.1074/jbc.271.24.14035	42	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21364	21372		10.1074/jbc.272.34.21364	http://dx.doi.org/10.1074/jbc.272.34.21364			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261150	hybrid			2022-12-25	WOS:A1997XR78900060
J	LeGouill, C; Parent, JL; RolaPleszczynski, M; Stankova, J				LeGouill, C; Parent, JL; RolaPleszczynski, M; Stankova, J			Structural and functional requirements for agonist-induced internalization of the human platelet-activating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ANGIOTENSIN-II RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; CYTOPLASMIC TAIL; BETA(2)-ADRENERGIC RECEPTOR; PHOSPHORYLATION SITES; MEDIATED ENDOCYTOSIS; MOLECULAR-CLONING	The receptor for platelet-activating factor (PAF) is a member of the G-protein-coupled receptor family. To study the structural elements and mechanisms involved in the internalization of human PAF receptor (hPAFR), we used the following mutants: a truncated mutant in the C-terminal tail of the receptor (Cys(317) --> Stop) and mutations in the (D/N)P(X)(2,3)Y motif (Asp(289) --> Asn,Ala and Tyr(293) --> Phe,Ala). Chinese hamster ovary cells expressing the Cys(317) --> Stop mutant exhibited a marked reduction in their capacity to internalize PAF, suggesting the existence of determinants important for endocytosis in the last 26 amino acids of the cytoplasmic tail. Substitution of Asp(289) to alanine abolished both internalization and G-protein coupling, whereas substitution of Tyr(293) to alanine abolished coupling but not internalization. Inhibition or activation of protein kinase C did not significantly affect the internalization process, Receptor sequestration and ligand uptake was, at least in part, blocked by concanavalin A and blockers of endocytosis mediated by clathrin-coated pits, Our data suggest that the internalization of a G-protein-coupled receptor and coupling to a G-protein can be two independent events. Moreover, the C terminus tail of hPAFR, but not the putative internalization motifs, may be involved in the internalization of hPAFR.	UNIV SHERBROOKE, FAC MED, DEPT PEDIAT, DIV IMMUNOL, SHERBROOKE, PQ J1H 5N4, CANADA	University of Sherbrooke								BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BECK KA, 1991, J BIOL CHEM, V266, P4442; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAQUET P, 1987, PROSTAGLANDINS, V34, P143, DOI 10.1016/0090-6980(87)90190-0; CHASE PB, 1993, AM J RESP CELL MOL, V8, P240, DOI 10.1165/ajrcmb/8.3.240; CHEN CY, 1995, J BIOL CHEM, V270, P7825; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HARGRAVE PA, 1994, REGULATION CELLULAR, P25; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Hermans E, 1996, MOL PHARMACOL, V49, P365; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Koenig JA, 1997, BRIT J PHARMACOL, V120, P52, DOI 10.1038/sj.bjp.0700859; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LAMEH J, 1992, J BIOL CHEM, V267, P13406; Laporte SA, 1996, MOL PHARMACOL, V49, P89; LIGGETT SB, 1994, REGULATION CELLULAR, P71; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; MORC O, 1994, J BIOL CHEM, V269, P6651; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; Muller S, 1997, FEBS LETT, V401, P25, DOI 10.1016/S0014-5793(96)01424-X; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NATHANSON NM, 1989, MUSCARINIC RECEPTORS, P419; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Parent JL, 1996, J BIOL CHEM, V271, P7949, DOI 10.1074/jbc.271.14.7949; Parent JL, 1996, BIOCHEM BIOPH RES CO, V219, P968, DOI 10.1006/bbrc.1996.0341; Parent JL, 1996, J BIOL CHEM, V271, P23298, DOI 10.1074/jbc.271.38.23298; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Petrou C, 1997, J BIOL CHEM, V272, P2326; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SLICE LW, 1994, J BIOL CHEM, V269, P21755; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; TAKANO T, 1994, J BIOL CHEM, V269, P22453; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANKOPPEN CJ, 1995, EUR J BIOCHEM, V234, P536; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; YAMADA M, 1993, J PHARMACOL EXP THER, V267, P128; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	63	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21289	21295		10.1074/jbc.272.34.21289	http://dx.doi.org/10.1074/jbc.272.34.21289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261140	hybrid			2022-12-25	WOS:A1997XR78900050
J	Lehmann, S; Harris, DA				Lehmann, S; Harris, DA			Blockade of glycosylation promotes acquisition of scrapie-like properties by the prion protein in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCOSYLATION; REPLICATION; SEPARATION; DISEASES; ACID; PRP	The conformational conversion of the prion protein, a sialoglycoprotein containing two N-linked oligosaccharide chains, from its normal form (PrPC) to a pathogenic form (PrPSc) is the central causative event in prion diseases, Although PrPSc can be generated in the absence of glycosylation, there is evidence that oligosaccharide chains may modulate the efficiency of the conversion process, and may also serve as molecular markers of diverse prion strains, In addition, mutational inactivation of one of the N-glycosylation sites has recently been associated with a familial spongiform encephalopathy, To investigate the role of N-glycans in determining the properties of PrP, we have expressed in transfected Chinese hamster ovary cells mouse PrP molecules in which N-glycosylation has been blocked either by treatment with the drug tunicamycin, or by substitution of alanine for threonine at one or both of the N-X-T consensus sites, We report that PrP molecules mutated at Thr(182) alone or at both Thr(182) and Thr(196) fail to reach the cell surface after synthesis, but that those mutated at Thr(196) or synthesized in the presence of tunicamycin can be detected on the plasma membrane, We also find that all three mutant PrPs, and to a limited extent wild-type PrP synthesized in the presence of inhibitor, acquire biochemical attributes reminiscent of PrPSc, We suggest that the PrP molecule has an intrinsic tendency to acquire some PrPSc-like properties, and that N-glycan chains protect against this change, However, pathogenic mutations, or presumably contact with exogenous prions, are necessary to fully convert the protein to a PrPSc state.	WASHINGTON UNIV,SCH MED,DEPT PHYSIOL & CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Lehmann, Sylvain/P-1301-2017	Lehmann, Sylvain/0000-0001-6117-562X; Harris, David/0000-0002-6985-5790	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035496] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35496] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BORDIER C, 1981, J BIOL CHEM, V256, P1604; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8880; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Harris DA, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P631; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; Nitrini R., 1996, Neurobiology of Aging, V17, pS160, DOI 10.1016/S0197-4580(96)80645-2; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; PRUSINER SB, 1994, ANN NEUROL, V35, P385, DOI 10.1002/ana.410350404; Prusiner SB, 1996, VIROLOGY, P2901; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; ULRICH MJ, 1990, BLOOD, V75, P990; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	37	145	149	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21479	21487		10.1074/jbc.272.34.21479	http://dx.doi.org/10.1074/jbc.272.34.21479			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261166	hybrid			2022-12-25	WOS:A1997XR78900076
J	MontroseRafizadeh, C; Yang, H; Rodgers, BD; Beday, A; Pritchette, LA; Eng, J				MontroseRafizadeh, C; Yang, H; Rodgers, BD; Beday, A; Pritchette, LA; Eng, J			High potency antagonists of the pancreatic glucagon-like peptide-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG PANCREAS; FUNCTIONAL EXPRESSION; REPLACEMENT ANALOGS; DISPERSED ACINI; POLYPEPTIDE; EXENDIN-4; IDENTIFICATION; DEGRADATION; CLONING; BINDING	GLP-1-(7-36)-amide and exendin-4-(1-39) are glucagon-like peptide-1 (GLP-1) receptor agonists, whereas exendin-(9-39) is the only known antagonist, To analyze the transition from agonist to antagonist and to identify the amino acid residues involved in ligand activation of the GLP-1 receptor, we used exendin analogs with successive N-terminal truncations, Chinese hamster ovary cells stably transfected with the rat GLP-1 receptor were assayed for changes in intracellular cAMP caused by the test peptides in the absence or presence of half-maximal stimulatory doses of GLP-1. N-terminal truncation of a single amino acid reduced the agonist activity of the exendin peptide, whereas N-terminal truncation of 3-7 amino acids produced antagonists that were 4-10-fold more potent than exendin-(9-39), N-terminal truncation of GLP-1 by 2 amino acids resulted in weak agonist activity, but an 8-amino acid N-terminal truncation inactivated the peptide, Binding studies performed using I-125-labeled GLP-1 confirmed that all bioactive peptides specifically displaced tracer with high potency, In a set of exendin/GLP-1 chimeric peptides, substitution of GLP-1 sequences into exendin-(3-39) produced loss of antagonist activity with conversion to a weak agonist, The results show that receptor binding and activation occur in separate domains of exendin, but they are more closely coupled in GLP-1.	NIA,LAB CLIN PHYSIOL,NIH,BALTIMORE,MD 21224; VET ADM MED CTR,DEPT MED,BRONX,NY 10468; CUNY MT SINAI SCH MED,NEW YORK,NY 10029	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); US Department of Veterans Affairs; Veterans Health Administration (VHA); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Rodgers, Dan/AAA-5343-2020	Rodgers, Buel/0000-0003-0751-1105				ADELHORST K, 1994, J BIOL CHEM, V269, P6275; ANDREU D, 1987, EUR J BIOCHEM, V164, P585, DOI 10.1111/j.1432-1033.1987.tb11167.x; BROWN JC, 1981, PEPTIDES, V2, P241, DOI 10.1016/0196-9781(81)90038-3; DEACON CF, 1995, DIABETES, V44, P1126, DOI 10.2337/diabetes.44.9.1126; ENG J, 1992, J BIOL CHEM, V267, P7402; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GALLWITZ B, 1994, EUR J BIOCHEM, V225, P1151, DOI 10.1111/j.1432-1033.1994.1151b.x; Gallwitz B, 1996, REGUL PEPTIDES, V63, P17, DOI 10.1016/0167-0115(96)00019-5; Hjorth SA, 1996, ACTA PHYSIOL SCAND, V157, P343, DOI 10.1046/j.1365-201X.1996.37259000.x; HJORTH SA, 1994, J BIOL CHEM, V269, P30121; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; KNUDSEN LB, 1996, REGUL PEPTIDES, V64, P92; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; MONTROSERAFIZAD.C, 1996, REGUL PEPTIDES, V64, P131; NATHAN DM, 1992, DIABETES CARE, V15, P270, DOI 10.2337/diacare.15.2.270; RAUFMAN JP, 1992, J BIOL CHEM, V267, P21432; SIEGEL EG, 1992, EUR J CLIN INVEST, V22, P154, DOI 10.1111/j.1365-2362.1992.tb01820.x; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; UNSON CG, 1994, J BIOL CHEM, V269, P12548; UNSON CG, 1993, ARCH BIOCHEM BIOPHYS, V300, P747, DOI 10.1006/abbi.1993.1103; UNSON CG, 1991, J BIOL CHEM, V266, P2763; UNSON CG, 1994, P NATL ACAD SCI USA, V91, P454, DOI 10.1073/pnas.91.2.454; UNSON CG, 1989, J BIOL CHEM, V264, P789; WEIR GC, 1989, DIABETES, V38, P338, DOI 10.2337/diabetes.38.3.338; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; Widmann C, 1996, MOL ENDOCRINOL, V10, P62, DOI 10.1210/me.10.1.62	28	144	192	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21201	21206		10.1074/jbc.272.34.21201	http://dx.doi.org/10.1074/jbc.272.34.21201			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261127	hybrid			2022-12-25	WOS:A1997XR78900037
J	Zhu, YX; Sun, HB; Tsang, MLS; McMahel, J; Grigsby, S; Yin, TG; Yang, YC				Zhu, YX; Sun, HB; Tsang, MLS; McMahel, J; Grigsby, S; Yin, TG; Yang, YC			Critical cytoplasmic domains of human interleukin-9 receptor alpha chain in interleukin-9-mediated cell proliferation and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; IL-2 RECEPTOR; GAMMA-CHAIN; BETA-CHAIN; EXPRESSION CLONING; CYTOKINE RECEPTORS; THYMIC LYMPHOMAS; GROWTH-FACTOR; ACTIVATION; REGION	Interleukin-9 receptor (IL-9R) complex consists of a ligand specific au chain and IL-2R gamma chain, In this study, two regions in the cytoplasmic domain of human IL-9R alpha were found to be important for IL-9-mediated cell growth. A membrane-proximal region that contains the BOX1 consensus sequence is required for IL-9-induced cell proliferation and tyrosine phosphorylation of Janus kinases (JAKs), Deletion of this region or internal deletion of the BOX1 motif abrogated IL-9-induced cell proliferation and signal transduction. However, substitution of the Pro-X-Pro in the BOX1 motif with Ala-X-Ala failed to abolish IL-9-induced cell proliferation but decreased IL-g-mediated tyrosine phosphorylation of JAM kinases, insulin receptor substrate-2, and signal transducer and activator of transcription 3 (STAT3) and expression of c-myc and junB. Another important region is downstream of the BOX1 motif and contains a STAT3 binding motif YLPQ. Deletion of this region significantly impaired IL-9-induced cell growth, activation of JAK kinases, insulin receptor substrate-g, and STAT3 and expression of early response genes, A point mutation changing YLPQ into YLPA ,greatly reduced IL-9-induced activation of STAT3 and expression of c-myc but did not affect cell proliferation, These results suggest that cooperation or cross-talk of signaling molecules associated with different domains of IL-9R alpha other than STAT3 is essential for IL-9-mediated cell growth.	INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202; WALTHER CANC INST,INDIANAPOLIS,IN 46202; R&D SYST,MINNEAPOLIS,MN 55413	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050570] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK 50570] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; CHANG MS, 1994, BLOOD, V83, P3199; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER P, 1995, ONCOGENE, V10, P985; DASILVA L, 1994, J BIOL CHEM, V269, P18267; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; EEKLUND KK, 1993, J IMMUNOL, V151, P4266; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Higuchi M, 1996, EUR J IMMUNOL, V26, P1322, DOI 10.1002/eji.1830260622; HORIE M, 1993, J BIOL CHEM, V268, P968; HULTNER L, 1989, J IMMUNOL, V142, P3440; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IHLE JN, 1995, ADV IMMUNOL, V6, P1; KANG LY, 1995, J CELL PHYSIOL, V163, P623, DOI 10.1002/jcp.1041630324; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KIRKEN RA, 1995, CYTOKINE, V7, P689, DOI 10.1006/cyto.1995.0081; Kojima H, 1996, ONCOGENE, V12, P547; LUI J, 1992, CELL GROWTH DIFFER, V3, P307; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RENAULD JC, 1993, ADV IMMUNOL, V54, P79, DOI 10.1016/S0065-2776(08)60533-7; RENAULD JC, 1992, P NATL ACAD SCI USA, V89, P5690, DOI 10.1073/pnas.89.12.5690; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6943; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; WILLIAMS DE, 1990, BLOOD, V79, P906; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YANG L, 1995, BLOOD, V86, P2526, DOI 10.1182/blood.V86.7.2526.bloodjournal8672526; YANG YC, 1989, BLOOD, V74, P1880; YIN TG, 1995, BLOOD, V85, P3101, DOI 10.1182/blood.V85.11.3101.bloodjournal85113101; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; YIN TG, 1994, EXP HEMATOL, V22, P467	44	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21334	21340		10.1074/jbc.272.34.21334	http://dx.doi.org/10.1074/jbc.272.34.21334			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261146	hybrid			2022-12-25	WOS:A1997XR78900056
J	ElHodiri, HM; Che, SL; NelmanGonzalez, M; Kuang, J; Etkin, LD				ElHodiri, HM; Che, SL; NelmanGonzalez, M; Kuang, J; Etkin, LD			Mitogen-activated protein kinase and cyclin B/Cdc2 phosphorylate Xenopus nuclear factor 7 (xnf7) in extracts from mature oocytes - Implications for regulation of xnf7 subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; MATURATION; ONCOGENE; PRODUCT; DOMAIN; LAEVIS; EGGS; MPF	Xenopus nuclear factor 7 (xnf7) is a maternally expressed putative transcription factor that exhibits phosphorylation-dependent changes in subcellular localization during early Xenopus development, Xnf7 is localized to the germinal vesicle (nucleus) of immature oocytes in a hypophosphorylated state, Xnf7 is phosphorylated during oocyte maturation and released to the cytoplasm, The protein is retained in the cytoplasm during early embryonic cleavage stages but returns to nuclei at the mid-blastula transition. Xnf7 is phosphorylated at two sites during oocyte maturation, designated P1, consisting of one threonine at position 103, and P2, consisting of three clustered threonines at positions 209, 212, and 218. Phosphorylation of both sites is important in regulating xnf7 localization, The P1 site can be phosphorylated by cyclin B/Cdc2 in vitro. , To further understand the mechanisms regulating subcellular localization of xnf7 during early development, kinases capable of catalyzing phosphorylation of the P2 site were purified from mature oocyte extracts. We found that mitogen-activated protein kinase phosphorylated Thr(212) and cyclin B/Cdc2 phosphorylated Thr (209) and Thr(212). NO other kinase in mature oocyte extracts phosphorylated the xnf7 P2 site to a significant extent. These results implicate mitogen-activated protein kinase and cyclin B/Cdca in regulating xnf7 localization during oocyte maturation, This also suggests that localization of xnf7 may be regulated by multiple kinase activation pathways.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CLIN INVEST,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DREYER C, 1983, CURRENT PROBLEMS GER, P322; Etkin L D, 1988, Dev Biol (N Y 1985), V5, P209; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; Hartley RS, 1996, DEV BIOL, V173, P408, DOI 10.1006/dbio.1996.0036; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Huang CYF, 1996, EMBO J, V15, P2169, DOI 10.1002/j.1460-2075.1996.tb00570.x; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; LI XX, 1994, EXP CELL RES, V213, P473, DOI 10.1006/excr.1994.1225; LI XX, 1994, J CELL BIOL, V124, P7, DOI 10.1083/jcb.124.1.7; LI XX, 1993, J CELL SCI, V105, P389; MILLER M, 1991, DEVELOPMENT, V113, P569; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEBREDA AR, 1995, EMBO J, V14, P5597, DOI 10.1002/j.1460-2075.1995.tb00247.x; PETER M, 1992, EUR J BIOCHEM, V205, P287, DOI 10.1111/j.1432-1033.1992.tb16779.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; Shou WN, 1996, MOL CELL BIOL, V16, P990; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; WHITESIDE ST, 1993, J CELL SCI, V104, P949; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZAITSEVSKAYA T, 1992, CELL GROWTH DIFFER, V3, P773	32	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20463	20470		10.1074/jbc.272.33.20463	http://dx.doi.org/10.1074/jbc.272.33.20463			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252356	hybrid			2022-12-25	WOS:A1997XR22100026
J	Lange, S; Nussler, F; Kauschke, E; Lutsch, G; Cooper, EL; Herrmann, A				Lange, S; Nussler, F; Kauschke, E; Lutsch, G; Cooper, EL; Herrmann, A			Interaction of earthworm hemolysin with lipid membranes requires sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SEMLIKI-FOREST-VIRUS; PORE-FORMING DOMAIN; CELOMIC FLUID; LUMBRICUS-TERRESTRIS; EISENIA-FOETIDA; CATALYZED OXIDATION; COLICIN-A; CHOLESTEROL; TOXIN	Lytic activity in the coelomic fluid of earthworm (Eisenia fetida fetida) has been ascribed to eiseniapore, a hemolytic protein of 38 kDa. Since receptors for eiseniapore on target cell membranes are not known, we used lipid vesicles of various composition to determine whether specific lipids may serve as receptors, Lytic activity of eiseniapore was probed by the relief of fluorescence dequenching from the fluorophore 8-aminonaphthalene-1,3,6-trisulfonic acid originally incorporated into the vesicle lumen as a complex with p-xylene-bis-pyridinium bromide, Hemolysin binds to and disturbs the lipid bilayer only when distinct sphingolipids consisting of a hydrophilic head group as phosphorylcholine or galactosyl as well as the ceramide backbone, e,g. sphingomyelin, are present. Cholesterol enhances eiseniapore lytic activity toward sphingomyelin-containing vesicles probably due to interaction with sphingomyelin. Leakage of vesicles was most efficient when the lipid composition resembled that of the outer leaflet of human erythrocytes. Presumably, an oligomeric protein pore formed by six monomers is responsible for leakage of sphingomyelin-containing vesicles. The secondary structure of eiseniapore did not change upon binding to lipid membranes. The lytic activity of eiseniapore was completely abolished after its denaturation or after preincubation with polyclonal antibodies. Our results suggest that the presence of specific sphingolipids is sufficient to mediate lytic activity of eiseniapore, This action contributes to our understanding of earthworm immune responses.	HUMBOLDT UNIV BERLIN, MATH NAT WISSENSCH FAK 1, INST BIOL BIOPHYS, D-10115 BERLIN, GERMANY; MAX DELBRUCK CTR MOL MED, D-13122 BERLIN, GERMANY; UNIV GREIFSWALD, ZOOL INST & MUSEUM, D-17489 GREIFSWALD, GERMANY; UNIV CALIF LOS ANGELES, MED CTR, DEPT NEUROBIOL, LAB COMPARAT IMMUNOL, LOS ANGELES, CA 90095 USA	Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ernst Moritz Arndt Universitat Greifswald; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center								ALBRO PW, 1992, LIPIDS, V27, P136, DOI 10.1007/BF02535813; ANDRE FRANCIS, 1963, BULL BIOL FRANCE ET BELGIQUE, V97, P3; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BILEJ M, 1995, IMMUNOL LETT, V45, P123, DOI 10.1016/0165-2478(94)00248-P; Bouche M.B., 1972, LOMBRICIENS FRANCE E; CANICATTI C, 1987, DEV COMP IMMUNOL, V11, P29, DOI 10.1016/0145-305X(87)90005-X; CANICATTI C, 1990, EXPERIENTIA, V46, P239, DOI 10.1007/BF01951753; CHITWOOD DJ, 1995, LIPIDS, V30, P567, DOI 10.1007/BF02537032; COOPER EL, 1995, CELL IMMUNOL, V166, P113, DOI 10.1006/cimm.1995.0013; Cossarizza A, 1996, EXP CELL RES, V224, P174, DOI 10.1006/excr.1996.0125; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; EUE I, 1991, DEV COMP IMMUNOL S1, V15, P75; GRONBERG L, 1990, BIOCHEMISTRY-US, V29, P3173, DOI 10.1021/bi00465a003; HORI T, 1993, PROG LIPID RES, V32, P25, DOI 10.1016/0163-7827(93)90003-F; KANESHIRO ES, 1987, J LIPID RES, V28, P1241; KARNOVSKY ML, 1969, CHEM ZOOL, V4, P205; KAUSCHKE E, 1987, DEV COMP IMMUNOL, V11, P331, DOI 10.1016/0145-305X(87)90077-2; KAUSCHKE E, 1987, J COMP PHYSIOL B, V157, P77, DOI 10.1007/BF00702731; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LANGE S, 1995, 23 M FEBS BAS AUG 13, P285; Li J, 1996, J MOL BIOL, V257, P129, DOI 10.1006/jmbi.1996.0152; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACEK P, 1994, TOXICOLOGY, V87, P205, DOI 10.1016/0300-483X(94)90252-6; MALONEY MD, 1991, PARASITOL RES, V77, P294, DOI 10.1007/BF00930904; Marsh D, 1981, Mol Biol Biochem Biophys, V31, P51; MCLAUGHIN J, 1970, COMP BIOCH PHYSL B, V38, P147; MEINARDI E, 1995, BIOCHEM BIOPH RES CO, V216, P348, DOI 10.1006/bbrc.1995.2630; MOESBY L, 1995, BIOCHEMISTRY-US, V34, P10319, DOI 10.1021/bi00033a001; Mohrig W, 1996, COMP BIOCHEM PHYS A, V115, P19, DOI 10.1016/0300-9629(95)02100-0; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; NISHIMURA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P141, DOI 10.1016/0005-2760(91)90001-X; OKAMURA N, 1985, J NEUROCHEM, V45, P1875, DOI 10.1111/j.1471-4159.1985.tb10546.x; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PARRINELLO N, 1995, DEV COMP IMMUNOL, V19, P31, DOI 10.1016/0145-305X(94)00046-I; PODACK ER, 1982, J BIOL CHEM, V257, P5204; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; POMORSKI T, 1994, MOL MEMBR BIOL, V11, P39, DOI 10.3109/09687689409161028; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Quaglino D, 1996, EUR J CELL BIOL, V70, P278; Roch P, 1996, ITAL J ZOOL, V63, P311, DOI 10.1080/11250009609356151; ROCH P, 1991, DEV COMP IMMUNOL, V15, P27, DOI 10.1016/0145-305X(91)90044-Y; ROCH P, 1981, COMP BIOCHEM PHYS B, V69, P829, DOI 10.1016/0305-0491(81)90390-4; ROCH P, 1989, BIOCHIM BIOPHYS ACTA, V983, P193, DOI 10.1016/0005-2736(89)90233-2; SATOUCHI K, 1993, LIPIDS, V28, P837, DOI 10.1007/BF02536239; SCHREIER S, 1978, BIOCHIM BIOPHYS ACTA, V515, P395, DOI DOI 10.1016/0304-4157(78)90011-4; SCHWOCH G, 1973, MOL CELL BIOCHEM, V2, P197, DOI 10.1007/BF01795474; SIMA P, 1993, CRIT REV IMMUNOL, V13, P83; SLOTTE JP, 1993, BIOCHEMISTRY-US, V32, P7886, DOI 10.1021/bi00082a008; SLOTTE JP, 1992, BIOCHEMISTRY-US, V31, P5472, DOI 10.1021/bi00139a008; Smaby JM, 1996, BIOCHEMISTRY-US, V35, P5696, DOI 10.1021/bi953057k; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VANDERGOOT FG, 1994, NATO ASI SERIES 82, V2, P181; WOODLE MC, 1989, METHOD ENZYMOL, V171, P193; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	60	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20884	20892		10.1074/jbc.272.33.20884	http://dx.doi.org/10.1074/jbc.272.33.20884			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252415	hybrid			2022-12-25	WOS:A1997XR22100085
J	MartinezMoczygemba, M; Gutch, MJ; French, DL; Reich, NC				MartinezMoczygemba, M; Gutch, MJ; French, DL; Reich, NC			Distinct STAT structure promotes interaction of STAT2 with the p48 subunit of the interferon-alpha-stimulated transcription factor ISGF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTING COILED COILS; DNA-BINDING PROTEINS; SIGNAL-TRANSDUCTION; GENE FACTOR-3; ACTIVATION; DOMAINS; RNA; POLYPEPTIDE; PATHWAYS; RESIDUE	Cells express a variety of STAT (signal transducer and activator of transcription) transcription factors that are structurally homologous and yet function specifically in response to particular cytokines, The functions of the individual STATs are dependent on distinct protein-protein interactions. STAT1 and STATE are activated by tyrosine phosphorylation in response to type I interferons-alpha/beta (IFN-alpha/beta) and subsequently farm a multimeric transcription factor designated the IFN-alpha-stimulated gene factor 3 (ISGF3). ISGF3 is a unique STAT complex because it also contains a Iron-STAT molecule, p48, which is a critical DNA-binding component. We provide evidence that STATE specifically interacts with p48 in vivo before and after IFN-alpha stimulation, The specificity of ISGF3 formation is therefore a result of the distinct nature of the STATE molecule, Coimmunoprecipitation assays demonstrate p48 association with STAT2 but not STAT1. Hybrid STAT2.STAT1 molecules were used to identify a region of STATE which specifically associates with p48. The region of STATE interaction spans an amino-terminal region of two predicted coiled coils, The studies demonstrate the in vivo existence of a STAT2.p48 complex and a distinct STAT2.STAT1 complex after IFN-alpha stimulation. Data suggest that distinct bipartite complexes STAT2.p48 and STAT2.STAT1 translocate to the nucleus and associate on the DNA target site as ISGF3.	SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794; MT SINAI SCH MED,DIV HEMATOL,NEW YORK,NY 10029	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA050773, P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA50773, P01CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; DALY C, 1995, J BIOL CHEM, V270, P23739, DOI 10.1074/jbc.270.40.23739; DALY C, 1994, TRENDS ENDOCRIN MET, V5, P159, DOI 10.1016/1043-2760(94)90013-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Demaeyer E., 1988, INTERFERONS OTHER RE; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; French D, 1987, Methods Enzymol, V151, P50, DOI 10.1016/S0076-6879(87)51008-4; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Galfre G, 1981, Methods Enzymol, V73, P3; GILMOUR KC, 1995, GENE EXPRESSION, V5, P1; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	35	99	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20070	20076		10.1074/jbc.272.32.20070	http://dx.doi.org/10.1074/jbc.272.32.20070			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242679	hybrid			2022-12-25	WOS:A1997XQ05900066
J	Morenweiser, R; Auerswald, EA; vandeLocht, A; Fritz, H; Sturzebecher, J; Stubbs, MT				Morenweiser, R; Auerswald, EA; vandeLocht, A; Fritz, H; Sturzebecher, J; Stubbs, MT			Structure-based design of a potent chimeric thrombin inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; HEPARIN COFACTOR-II; PRO-ARG CHLOROMETHYLKETONE; KAZAL-TYPE INHIBITOR; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; REACTIVE SITE; TRYPTASE INHIBITOR; TRYPSIN-INHIBITOR; HIRUDIN	Using the three-dimensional structures of thrombin and the leech-derived tryptase inhibitor (LDTI), which does not inhibit thrombin, we were able to construct three LDTI variants inhibiting thrombin, Trimming of the inhibitor reactive site loop to fit thrombin's narrow active site cleft resulted in inhibition constants (K-i) in the 10 nM concentration range; similar values were obtained by the addition of an acidic C-terminal peptide corresponding to hirudin's tail to LDTI. Combination of both modifications is additive, resulting in very strong inhibition of thrombin (K-i in the picomolar range), On the one hand, these results confirm the significance of the restricted active site cleft of thrombin in determining its high cleavage specificity; on the other, they demonstrate that sufficient binding energy at the fibrinogen recognition exosite can force thrombin to accept otherwise unfavorable residues in the active site cleft. The best inhibitor thus obtained is as effective as hirudin in plasma-based clotting assays.	UNIV MUNICH, KLINIKUM INNENSTADT, KLIN CHEM & KLIN BIOCHEM ABT, CHIRURG KLIN & POLIKLIN, D-80336 MUNICH, GERMANY; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; KLINIKUM UNIV JENA, ZENTRUM VASKULARE BIOL & MED, D-99089 ERFURT, GERMANY	University of Munich; Max Planck Society; Friedrich Schiller University of Jena				Stubbs, Milton/0000-0003-1278-9013				ASCENZI P, 1988, BIOCHIM BIOPHYS ACTA, V956, P156, DOI 10.1016/0167-4838(88)90262-2; AUERSWALD EA, 1994, BIOL CHEM H-S, V375, P695, DOI 10.1515/bchm3.1994.375.10.695; BAICI A, 1981, EUR J BIOCHEM, V119, P9, DOI 10.1111/j.1432-1033.1981.tb05570.x; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BODE W, 1992, PROTEIN SCI, V1, P426; CHEN XM, 1992, J BIOCHEM-TOKYO, V112, P45, DOI 10.1093/oxfordjournals.jbchem.a123863; DECRISTOFARO R, 1993, BIOCHEM J, V289, P475, DOI 10.1042/bj2890475; DIMAIO J, 1990, J BIOL CHEM, V265, P21698; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FINK E, 1986, BIOL CHEM H-S, V367, P1235, DOI 10.1515/bchm3.1986.367.2.1235; FRIEDRICH T, 1993, J BIOL CHEM, V268, P16216; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; GUINTO ER, 1994, J BIOL CHEM, V269, P18395; JOHNSON DJD, 1994, THROMB HAEMOSTASIS, V71, P428; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; Matthews JH, 1996, BIOPHYS J, V71, P2830, DOI 10.1016/S0006-3495(96)79479-1; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MUHLHAHN P, 1994, FEBS LETT, V355, P290, DOI 10.1016/0014-5793(94)01225-3; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1986, NUCLEIC ACIDS RES, V14, P1073, DOI 10.1093/nar/14.2.1073; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SCHMITZ T, 1991, EUR J BIOCHEM, V195, P251, DOI 10.1111/j.1432-1033.1991.tb15701.x; SOMMERHOFF CP, 1994, BIOL CHEM H-S, V375, P685, DOI 10.1515/bchm3.1994.375.10.685; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; STEPHENS AW, 1987, J BIOL CHEM, V262, P1044; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Stubbs MT, 1997, J BIOL CHEM, V272, P19931, DOI 10.1074/jbc.272.32.19931; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; THEUNISSEN HJM, 1993, J BIOL CHEM, V268, P9035; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; vandeLocht A, 1996, EMBO J, V15, P6011, DOI 10.1002/j.1460-2075.1996.tb00989.x; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; WALSMANN P, 1981, PHARMAZIE, V36, P653	43	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19938	19942		10.1074/jbc.272.32.19938	http://dx.doi.org/10.1074/jbc.272.32.19938			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242661	hybrid			2022-12-25	WOS:A1997XQ05900048
J	Alimandi, M; Heidaran, MA; Gutkind, JS; Zhang, JC; Ellmore, N; Valius, M; Kazlauskas, A; Pierce, JH; Li, WQ				Alimandi, M; Heidaran, MA; Gutkind, JS; Zhang, JC; Ellmore, N; Valius, M; Kazlauskas, A; Pierce, JH; Li, WQ			PLC-gamma activation is required for PDGF-beta R-mediated mitogenesis and monocytic differentiation of myeloid progenitor cells	ONCOGENE			English	Article						PLC-gamma; PDGF-beta R; monocytic differentiation	PROTEIN-KINASE-C; GROWTH-FACTOR; PHOSPHOLIPASE-C; MONOCLONAL-ANTIBODY; RECEPTOR; DELTA; ALPHA; AUTOPHOSPHORYLATION; PHOSPHORYLATION; INVOLVEMENT	To investigate the molecular mechanisms mediating hematopoietic cell differentiation and mitogenesis by activation of the platelet-derived growth factor beta receptor (PDGF-beta R), the mild type PDGF-beta R (PDGF-beta RWT) and tyrosine to phenylalanine mutants of the PDGF-beta R, including F751, F966, F970, F1009, F1021 and F1009/F1021 were overexpressed in FDC-P2 myeloid progenitor cells by retroviral-mediated gene transfer. Stimulation of PDGF-beta RWT and F966, F970 and F1009 infectants with PDGF-BB led to the increased expression of monocytic differentiation markers, In contrast, activation of PDGF-beta R in the parental line or the F1021 or F1009/F1021 mutant infectants failed to induce monocytic differentiation, PDGF-BB stimulation of PDGF-beta RWT, F751, F966, F970 and F1009 infectants led to pronounced DNA synthesis, whereas F1021 and F1009/F1021 infectants did not reveal any increase in mitogenesis when compared to that of the FDC-P2 line, While PDGF stimulation of FDC-2 cells overexpressing PDGF-beta RWT led to a pronounced increase in inositol phosphate formation due to phospholipase C-gamma (PLC-gamma) activation, PDGF-BB induced phosphoinositol hydrolysis was completely abolished in the F1021 and F1009/F1021 infectants, GF 109203X, a specific inhibitor of protein kinase C (PKC) activation, fully blocked PDGF-beta R-mediated monocytic differentiation and mitogenesis, Taken together, these results suggest that stimulation of the PDGF-beta R signaling pathway can mediate monocytic differentiation when PDGF-beta R is expressed at sufficient levels and that activation of PLC-gamma and PKC plays a pivotal role in PDGF-beta R-mediated differentiation and mitogenesis in FDC-P2 cell system.	NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892; NIDR,MOL SIGNALING UNIT,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892; LITHUANIA ACAD SCI,INST BIOCHEM,LT-2600 VILNIUS,LITHUANIA; HARVARD UNIV,SCH MED,SCHEPENS EYE RES INST,BOSTON,MA 02114	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Vilnius University; Harvard University; Harvard Medical School; Schepens Eye Research Institute			Alimandi, Maurizio/AAG-9246-2019; Gutkind, J. Silvio/J-1201-2016; Valius, Mindaugas/N-1220-2019; Valius, Mindaugas/F-2734-2012; Gutkind, J. Silvio/A-1053-2009	Alimandi, Maurizio/0000-0002-1409-6803; Gutkind, J. Silvio/0000-0002-5150-4482; Valius, Mindaugas/0000-0001-8478-8517; 	NATIONAL CANCER INSTITUTE [R29CA055063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER; NCI NIH HHS [CA55063] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Aprikian A., 1996, Blood, V88, p633A; ASHCROFT M, 1996, 1996 M TYR PHOSPH CE; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HO MK, 1982, J IMMUNOL, V128, P1221; INABA T, 1993, J BIOL CHEM, V268, P24353; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LEE SH, 1985, J EXP MED, V161, P475, DOI 10.1084/jem.161.3.475; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; MARTINYBARON G, 1993, J BIOL CHEM, V268, P1749; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UKELESS JC, 1979, J EXP MED, V150, P580; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Uren A, 1996, J BIOL CHEM, V271, P11051, DOI 10.1074/jbc.271.19.11051; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479	31	30	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					585	593		10.1038/sj.onc.1201221	http://dx.doi.org/10.1038/sj.onc.1201221			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247312	Bronze			2022-12-25	WOS:A1997XN25500010
J	Andrew, SE; Reitmair, AH; Fox, J; Hsiao, L; Francis, A; McKinnon, M; Mak, TW; Jirik, FR				Andrew, SE; Reitmair, AH; Fox, J; Hsiao, L; Francis, A; McKinnon, M; Mak, TW; Jirik, FR			Base transitions dominate the mutational spectrum of a transgenic reporter gene in MSH2 deficient mice	ONCOGENE			English	Article						mismatch repair; MSH2; lacI transgenic; mutation	NONPOLYPOSIS COLON-CANCER; MISMATCH REPAIR PROTEINS; CARCINOMA CELL-LINES; ESCHERICHIA-COLI; MICROSATELLITE INSTABILITY; COLORECTAL TUMORIGENESIS; MUTATOR PHENOTYPES; LACI GENE; DNA; INACTIVATION	Tumors derived from individuals with hereditary nonpolyposis colorectal cancer syndrome frequently demonstrate mutations in both alleles of hMSH2, a key gene in DNA mismatch repair (MMR). Sporadic tumors also frequently exhibit MMR deficiency. In keeping with the role of MMR in the maintenance of genome integrity, mice deficient in MSH2 via gene targeting demonstrate a high incidence of thymic lymphomas and small intestinal adenocarcinomas. To investigate the effects of MSH2 deficiency in normal tissues, mice containing a retrievable transgenic lad reporter gene for mutation detection were crossed with MSH2(-/-) mice, Mice homozygous for MSH2 deficiency revealed 4.8, 11.0 and 15.2-fold elevations in spontaneous mutation frequency in DNA obtained from brain, small intestine, and thymus, respectively, as compared to heterozygous or wild-type mice. Mutations most frequently recovered from MSH2(-/-) mice were single base substitutions (77%), particularly base transitions (64%), Frameshifts occurred less frequently (19%) and fell within very short (3-5 bp) mononucleotide runs. Thus the number of key growth control genes potentially impacted by MMR deficiency extends beyond those containing repetitive sequences. These results highlight the capacity for MSH2 deficiency to serve as a potent driving force during the multi-step evolution of tumors.	UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,CTR MOL MED & THERAPEUT,VANCOUVER,BC V6T 1Z3,CANADA; UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,AMGEN INST,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL,AMGEN INST,TORONTO,ON M5G 2M9,CANADA	University of British Columbia; University of British Columbia; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto				McKinnon, Margaret/0000-0002-3161-414X				Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Beroud C, 1996, NUCLEIC ACIDS RES, V24, P147, DOI 10.1093/nar/24.1.147; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, CANCER RES, V55, P2304; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COX EC, 1976, ANNU REV GENET, V10, P135, DOI 10.1146/annurev.ge.10.120176.001031; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DOHET C, 1985, P NATL ACAD SCI USA, V82, P503, DOI 10.1073/pnas.82.2.503; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUJII H, 1989, J BIOL CHEM, V264, P10057; GLAZER PM, 1986, P NATL ACAD SCI USA, V83, P1041, DOI 10.1073/pnas.83.4.1041; GU M, 1994, MUTAT RES, V307, P533, DOI 10.1016/0027-5107(94)90264-X; HAWN MT, 1995, CANCER RES, V55, P3721; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; KOHLER SW, 1990, GENET ANAL-BIOMOL E, V7, P212, DOI 10.1016/0735-0651(90)90003-X; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEONG PM, 1986, J BACTERIOL, V168, P412, DOI 10.1128/jb.168.1.412-416.1986; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MIRSALIS JC, 1995, ANNU REV PHARMACOL, V35, P145; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; REENAN RAG, 1992, GENETICS, V132, P963; Reitmair AH, 1996, CANCER RES, V56, P2922; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	45	58	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					123	129		10.1038/sj.onc.1201180	http://dx.doi.org/10.1038/sj.onc.1201180			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244348				2022-12-25	WOS:A1997XK37200001
J	Cabannes, E; Vives, MF; Bedard, PA				Cabannes, E; Vives, MF; Bedard, PA			Transcriptional and post-transcriptional regulation of kappa B-controlled genes by pp(60v-src)	ONCOGENE			English	Article						gene expression; pp60(v-src); transformation; NF-kappa B	ROUS-SARCOMA VIRUS; CHICKEN SPLEEN-CELLS; SRC-INDUCIBLE GENE; V-REL ONCOPROTEIN; TRANSFORMED-CELLS; PLATELET PROTEIN; TYROSINE KINASES; GROWTH-FACTOR; AVIAN CELLS; T-CELLS	The CEF-4/9E3 gene is expressed aberrantly in chicken embryo fibroblasts transformed by the Rous sarcoma virus, This aberrant expression is dependent on transcriptional activation and on the stabilization of the CEF-4 mRNA, The characterization of the CEF-4 promoter indicated that three distinct regulatory elements corresponding to an AP-1 binding site, a PRDII/kappa-B domain and a CAAT box are involved in the activation by pp60(v-src). Several v-src responsive genes are controlled by AP-1 and members of the Ets family but few appear to be dependent on NF-kappa B. In this study me characterize the expression of genes regulated by NF-kappa B in normal and RSV-transformed CEF, Run-on transcription analysis indicated that pp60(v-src) induces the transcription of several genes controlled by NF-kappa B but at different levels, While the transcription of CEF-4 was strongly stimulated, that of NF-kappa B1, c-rel, p53 or I kappa B-alpha was activated more modestly by pp60(v-src). In addition the CEF-4 mRNA mas the only mRNA species to accumulate significantly in transformed CEF, The ectopic expression of RelA or Rel resulted in the stimulation of the transcription of several known targets of NF-kappa B, However, the mRNA for I kappa B-alpha was the only mRNA species to accumulate considerably in the RelA- or Rel-expressing cells, Hence for most kappa B-controlled genes, transcriptional activation was not sufficient to obtain a significant increase in mRNA expression, Likewise, RelA or Rel enhanced the transcription of the CEF-4 gene without a significant accumulation of the CEF-4 mRNA, However, transformation by v-src caused a massive accumulation of the CEF-4 mRNA but not of other mRNA species in the RelA- and Rel-expressing cells, Transient expression assays, run-on transcription and Northern blotting analyses indicated that the effect of pp60(v-src) on CEF-4 expression was mediated predominantly at the post-transcriptional level in these cells, Therefore transcriptional and post-transcriptional mechanisms determine the restricted pattern of activation of kappa B-controlled genes in RSV-transformed CEF.	YORK UNIV, DEPT BIOL, N YORK, ON M3J 1P3, CANADA; UNIV MONTREAL, DEPT BIOCHIM, MONTREAL, PQ H3C 3J7, CANADA	York University - Canada; Universite de Montreal								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DEHBI M, 1992, BIOCHEM CELL BIOL, V70, P980, DOI 10.1139/o92-142; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DEHBI M, 1994, ONCOGENE, V9, P2399; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EICHER DM, 1994, J IMMUNOL, V152, P2710; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GONNEVILLE L, 1991, ONCOGENE, V6, P1825; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; HANNINK M, 1990, ONCOGENE, V5, P1843; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HRDLICKOVA R, 1995, J VIROL, V69, P403; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JAHNER D, 1991, ONCOGENE, V6, P1259; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KOWALIK TF, 1993, P NATL ACAD SCI USA, V90, P1107, DOI 10.1073/pnas.90.3.1107; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARONEY AC, 1992, ONCOGENE, V7, P1207; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; VIVES MF, 1995, THESIS U MONTREAL; WASYLYK C, 1994, ONCOGENE, V9, P3665; WELHAM MJ, 1990, ONCOGENE, V5, P161; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	58	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					29	43		10.1038/sj.onc.1201162	http://dx.doi.org/10.1038/sj.onc.1201162			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233775				2022-12-25	WOS:A1997XH58600004
J	Liden, J; Delaunay, F; Rafter, I; Gustafsson, JA; Okret, S				Liden, J; Delaunay, F; Rafter, I; Gustafsson, JA; Okret, S			A new function for the C-terminal zinc finger of the glucocorticoid receptor - Repression of RelA transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERCELLULAR-ADHESION MOLECULE-1; THYROID-HORMONE RECEPTORS; DNA-BINDING; TRANSCRIPTION FACTOR; MEDIATED REPRESSION; ESTROGEN-RECEPTOR; TRANS-ACTIVATION; RESPONSE ELEMENT; GENE-EXPRESSION	Glucocorticoids inhibit NF-kappa B signaling by interfering with the NF-kappa B transcription factor RelA, Previous studies have identified the DNA binding domain (DBD) in the glucocorticoid receptor (GR) as the major region responsible for this repressive activity, Using GR mutants with chimeric DBDs the repressive function was found to be located in the C-terminal zinc finger, As predicted from these results the mineralocorticoid receptor that contains a C-terminal zinc finger identical to that of the GR was also able to repress RelA-dependent transcription, Mutation of a conserved arginine or a lysine in the second zinc finger of the GR DBD (Arg-488 or Lys-490 in the rat GR) abolished the ability of GR to inhibit RelA activity, In contrast, C-terminal zinc finger GR mutants with mutations in the dimerization box or mutations necessary for full transcriptional GR activity were still able to repress RelA-dependent transcription. In addition, we found that the steroid analog ZK98299 known to induce GR transrepression of AP-1 had no inhibitory effect on RelA activity, In summary, these results demonstrate that the inhibition of NF-kappa B by glucocorticoids involves two critical amino acids in the C-terminal zinc finger of the GR. Furthermore, the results from the use of mineralocorticoid receptor and anti-glucocorticoids suggest that the mechanisms for GR-mediated repression of NF-kappa B and AP-1 are different.	HUDDINGE UNIV HOSP,KAROLINSKA INST,NOVUM F60,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet				Delaunay, Franck/0000-0003-4927-1701				Akerblom I.W., 1991, NUCLEAR HORMONE RECE, P175; ALI SA, 1995, BIOTECHNIQUES, V18, P746; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BEAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CARLSTEDTDUKE J, 1995, ENDOCRINOL METAB, P169; CATO ACB, 1992, J STEROID BIOCHEM, V43, P63, DOI 10.1016/0960-0760(92)90188-O; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DRCUIN J, 1993, EMBO J, V12, P145; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kleinert H, 1996, MOL PHARMACOL, V49, P15; LAUDET V, 1995, PROTEIN PROFILE, V2, P1173; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Ohtsuka T, 1996, J BIOL CHEM, V271, P1651, DOI 10.1074/jbc.271.3.1651; OKRET S, 1984, P NATL ACAD SCI-BIOL, V81, P1609, DOI 10.1073/pnas.81.6.1609; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VANDESTOLPE A, 1993, AM J RESP CELL MOL, V8, P340, DOI 10.1165/ajrcmb/8.3.340; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZILLIACUS J, 1992, J BIOL CHEM, V267, P24941; ZILLIACUS J, 1991, J BIOL CHEM, V266, P3101	52	133	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21467	21472		10.1074/jbc.272.34.21467	http://dx.doi.org/10.1074/jbc.272.34.21467			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261164	hybrid			2022-12-25	WOS:A1997XR78900074
J	Meng, JJ; Bornslaeger, EA; Green, KJ; Steinert, PM; Ip, W				Meng, JJ; Bornslaeger, EA; Green, KJ; Steinert, PM; Ip, W			Two-hybrid analysis reveals fundamental differences in direct interactions between desmoplakin and cell type-specific intermediate filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULLOUS PEMPHIGOID ANTIGEN; PROTEIN-PROTEIN INTERACTIONS; DESMOSOMAL PLAQUE; SACCHAROMYCES-CEREVISIAE; CULTURED-CELLS; KERATIN; YEAST; TERMINUS; NETWORKS; PLECTIN	Desmosomes are cell junctions that act as sites of strong intercellular adhesion and also serve to anchor the intermediate filament (IF) cytoskeleton to the plasma membrane of a variety of cell types, Previous studies demonstrated that the COOH terminus of the desmosomal plaque protein, desmoplakin (DP), is required for the association of DP with IF networks in cultured cells and that this domain interacts directly with type II epidermal keratin polypeptides in vitro. However, these studies left open the question of how desmosomes might anchor other IF types known to associate with these junctions. In this report we used yeast two-hybrid and in vitro dot blot assays to further examine the requirements for direct interactions between desmoplakin and various IF types. Our results confirm the ability of the DP COOH terminus (DPCT) to interact with at least two regions of the head domain of the type II epidermal keratin K1 and also demonstrate that DPCT can interact with the type III IF family members, vimentin and desmin, as well as simple epithelial keratins. Unlike the situation for type II epidermal keratins, the interaction between DPCT and simple epithelial keratins appears to depend on heterodimerization of the type I and II keratin polypeptides, since both are required to detect an interaction. Furthermore, although the interaction between DPCT and K1 requires the keratin head domain, deletion of this domain from the simple epithelial keratins does not compromise interaction with DPCT. The interaction between DPCT and type III or simple epithelial keratins also appeared to be less robust than that between DPCT and K1, In the case of K8/K18, however, the interaction as assessed by yeast two-hybrid assays increased 9-fold when a serine located in a protein kinase A consensus phosphorylation site 23 residues from the end of DP was altered to a glycine. Taken together, these data indicate that DP interacts directly with different IF types in specific ways.	UNIV CINCINNATI, COLL MED, DEPT ANAT CELL BIOL & NEUROBIOL, CINCINNATI, OH 45267 USA; NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT DERMATOL, CHICAGO, IL 60611 USA; NIAMS, SKIN BIOL LAB, NIH, BETHESDA, MD 20892 USA	University System of Ohio; University of Cincinnati; Northwestern University; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)					NIAMS NIH HHS [R01 AR43380, R01 AR35973] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035973, R01AR043380] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; CANDI E, 1997, IN PRESS P NATL ACAD; Carpenter DA, 1996, J CELL SCI, V109, P2493; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; COLLINS JE, 1994, MOL BIOL DESMOSOMES; Cowin P, 1985, CELL CONTACT, P427; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fujiwara S, 1996, J INVEST DERMATOL, V106, P1125, DOI 10.1111/1523-1747.ep12340171; Gache Y, 1996, J CLIN INVEST, V97, P2289, DOI 10.1172/JCI118671; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; Green Kathleen J., 1994, P157; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; GREEN KJ, 1992, INT J BIOL MACROMOL, V14, P145, DOI 10.1016/S0141-8130(05)80004-2; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HATZFELD M, 1994, J CELL SCI, V107, P1959; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; JONES JCR, 1985, J CELL BIOL, V101, P506, DOI 10.1083/jcb.101.2.506; Jones JCR, 1991, CURR OPIN CELL BIOL, V3, P127, DOI 10.1016/0955-0674(91)90175-X; KAPPRELL HP, 1988, J CELL BIOL, V106, P1679, DOI 10.1083/jcb.106.5.1679; KARTASOVA T, 1993, J CELL BIOL, V120, P1251, DOI 10.1083/jcb.120.5.1251; KIMONIS V, 1994, J INVEST DERMATOL, V103, P764, DOI 10.1111/1523-1747.ep12412771; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1996, CURR TOP MEMBR, V43, P187; Leung CL, 1996, J BIOL CHEM, V271, P14041, DOI 10.1074/jbc.271.24.14041; McLean WHI, 1996, GENE DEV, V10, P1724, DOI 10.1101/gad.10.14.1724; Meng JJ, 1996, J BIOL CHEM, V271, P1599, DOI 10.1074/jbc.271.3.1599; Nikolic B, 1996, J CELL BIOL, V134, P1455, DOI 10.1083/jcb.134.6.1455; OKEEFE EJ, 1989, J BIOL CHEM, V264, P8310; Pin OY, 1996, J CELL BIOL, V135, P1027, DOI 10.1083/jcb.135.4.1027; Ruhrberg C, 1996, J CELL BIOL, V134, P715, DOI 10.1083/jcb.134.3.715; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; SCHMIDT A, 1994, EUR J CELL BIOL, V65, P229; SCHWARZ MA, 1990, ANNU REV CELL BIOL, V6, P461, DOI 10.1146/annurev.cb.06.110190.002333; SIKORSKI RS, 1989, GENETICS, V122, P19; SKALLI O, 1994, J CELL BIOL, V125, P159, DOI 10.1083/jcb.125.1.159; Smith FJD, 1996, NAT GENET, V13, P450, DOI 10.1038/ng0896-450; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; STAPPENBECK TS, 1994, J BIOL CHEM, V269, P29351; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; STEINBERG MS, 1987, CIBA F SYMP, V125, P3; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; TANAKA T, 1991, J BIOL CHEM, V266, P12555; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIRATA MLA, 1992, P NATL ACAD SCI USA, V89, P544, DOI 10.1073/pnas.89.2.544; WICHE G, 1991, J CELL BIOL, V114, P83, DOI 10.1083/jcb.114.1.83; WICHE G, 1993, J CELL BIOL, V121, P607, DOI 10.1083/jcb.121.3.607; YE QA, 1995, EXP CELL RES, V219, P292, DOI 10.1006/excr.1995.1230; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	54	132	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21495	21503		10.1074/jbc.272.34.21495	http://dx.doi.org/10.1074/jbc.272.34.21495			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261168	hybrid			2022-12-25	WOS:A1997XR78900078
J	Meyer, T; Starr, DB; CarlstedtDuke, J				Meyer, T; Starr, DB; CarlstedtDuke, J			The rat glucocorticoid receptor mutant K461A differentiates between two different mechanisms of transrepression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; STEROID-HORMONE RECEPTORS; NF-KAPPA-B; RESPONSE ELEMENT; NEGATIVE REGULATION; GENE-EXPRESSION; TRANSCRIPTION FACTORS; OSTEOCALCIN GENE; GLA PROTEIN; REPRESSION	The glucocorticoid receptor (GR) can both activate and repress transcription of target genes by interaction with specific genomic response elements, glucocorticoid response elements (GREs). Activation of transcription is usually the result of the direct interaction between GR and the GRE, whereas GR-mediated transcription repression is either the result of the indirect action of GPE, mediated by a response element as a result of protein protein interaction or by an occlusion mechanism in which GR displaces a general or regulatory transcription factor, A specific mutation of rat GR, K461A, has previously been described to transform the indirect protein protein interaction-dependent transrepressive effect of GR into an activating function (Starr, D, B., Matsui, W,, Thomas, J. R,, and Yamamoto, K, R, (1996) Genes Dev. 10, 1271-1283), In HOS D4 and COS7 cells, this mutation was shown to transform the transrepressive effect of wild-type GR, acting on reporter constructs containing the composite GRE from the proliferin gene (plfG) or the negative tethering GRE from the collagenase A promoter (colA), into an activating function, In contrast, the K461A mutation had no effect on the transrepressive effect of GR on the human osteocalcin gene in which repression apparently occurs through the binding of GR to a negative GRE that overlaps the TATA box, The transrepressive function, typically 40% of the basal level in the absence of hormone, required only the isolated DNA-binding domain of wild type or mutant GR and was independent of the nature of transactivation domain, Thus, mutation of rat GR at position 461 differentiates between transrepressive functions of GR dependent oil GR DNA interaction (repression by occlusion) and GR protein interaction (active repression).	HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT MED NUTR,NOVUM,S-14186 HUDDINGE,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT BIOSCI,NOVUM,S-14186 HUDDINGE,SWEDEN; UNIV CALIF SAN FRANCISCO,PIBS BIOCHEM & MOL BIOL PROGRAM,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PIBS BIOCHEM & MOL BIOL PROGRAM,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Karolinska Institutet; Karolinska Institutet; University of California System; University of California San Francisco; University of California System; University of California San Francisco								AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BIRNBERG NC, 1983, P NATL ACAD SCI-BIOL, V80, P6982, DOI 10.1073/pnas.80.22.6982; CAIRNS C, 1993, DNA CELL BIOL, V12, P695, DOI 10.1089/dna.1993.12.695; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HEINRICHS AAJ, 1993, BIOCHEMISTRY-US, V32, P11436, DOI 10.1021/bi00093a022; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARAGIANNI N, 1994, ONCOGENE, V9, P2327; KARIN M, 1993, EUR J CLIN PHARMACOL, V45, pS43; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEYER T, 1997, IN PRESS DNA CELL BI, V16; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Pei L, 1996, J BIOL CHEM, V271, P20879; RIEGEL AT, 1991, MOL ENDOCRINOL, V5, P1973, DOI 10.1210/mend-5-12-1973; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WEINER FR, 1987, J BIOL CHEM, V262, P6955	38	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21090	21095		10.1074/jbc.272.34.21090	http://dx.doi.org/10.1074/jbc.272.34.21090			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261112	hybrid			2022-12-25	WOS:A1997XR78900022
J	Smith, MD; Morris, PJ; Dawson, SJ; Schwartz, ML; Schlaepfer, WW; Latchman, DS				Smith, MD; Morris, PJ; Dawson, SJ; Schwartz, ML; Schlaepfer, WW; Latchman, DS			Coordinate induction of the three neurofilament genes by the Brn-3a transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU-DOMAIN PROTEIN; INTERMEDIATE FILAMENTS; ALPHA-INTERNEXIN; NEURONAL CELLS; REPORTER GENE; HEAVY GENE; IN-VITRO; FAMILY; EXPRESSION; ACID	The POU domain transcription factor Brn-3a is able to stimulate neurite outgrowth when overexpressed in the neuronal ND7 cell line, whereas the closely related Brn-3b factor does not have this effect. We show that Brn-3a overexpression also enhances the expression of the three neurofilament genes at both the mRNA and protein levels, whereas Brn-3b overexpression has no effect. In addition Brn-3a activates the three neurofilament gene promoters in co-transfection assays in both neuronal and non-neuronal cells. As observed for enhanced neurite outgrowth, the stimulation of neurofilament gene expression and activation of the neurofilament gene promoters is observed with the isolated POU domain of Brn-3a. A single amino acid change in the POU homeodomain of Bm-Ba to the equivalent amino acid in Brn-3b abolishes its ability to activate the neurofilament promoters, whereas the reciprocal change converts Brn-3b to an activator of these promoters.	UCL, SCH MED, DEPT MOL PATHOL, LONDON W1P 6DB, ENGLAND; UNIV PENN, SCH MED, DIV NEUROPATHOL, PHILADELPHIA, PA 19104 USA	University of London; University College London; UCL Medical School; University of Pennsylvania				Dawson, Sally/0000-0002-4421-2043				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BudhramMahadeo V, 1996, J BIOL CHEM, V271, P9108, DOI 10.1074/jbc.271.15.9108; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1991, J CELL SCI, P85; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; Dawson SJ, 1996, J BIOL CHEM, V271, P11631, DOI 10.1074/jbc.271.20.11631; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FLIEGNER KH, 1990, EMBO J, V9, P749, DOI 10.1002/j.1460-2075.1990.tb08169.x; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; Liem RKH, 1990, CURR OPIN CELL BIOL, V2, P86, DOI 10.1016/S0955-0674(05)80036-5; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Liu YZ, 1996, J MOL NEUROSCI, V7, P77, DOI 10.1007/BF02736850; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; Marszalek JR, 1996, J CELL BIOL, V135, P711, DOI 10.1083/jcb.135.3.711; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; Morris PJ, 1996, MOL BRAIN RES, V43, P279, DOI 10.1016/S0169-328X(96)00207-0; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; SAKAGUCHI T, 1993, NEUROSCI LETT, V153, P65, DOI 10.1016/0304-3940(93)90078-Y; SCHWARTZ ML, 1994, J BIOL CHEM, V269, P13444; SHNEIDMAN PS, 1992, MOL BRAIN RES, V13, P127, DOI 10.1016/0169-328X(92)90052-D; Smith MD, 1997, J BIOL CHEM, V272, P1382, DOI 10.1074/jbc.272.2.1382; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; SUBURO AM, 1992, NEUROSCIENCE, V46, P881, DOI 10.1016/0306-4522(92)90191-4; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Xu ZS, 1996, J CELL BIOL, V133, P1061, DOI 10.1083/jcb.133.5.1061	52	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21325	21333		10.1074/jbc.272.34.21325	http://dx.doi.org/10.1074/jbc.272.34.21325			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261145	hybrid			2022-12-25	WOS:A1997XR78900055
J	Hu, JF; Vu, TH; Hoffman, AR				Hu, JF; Vu, TH; Hoffman, AR			Genomic deletion of an imprint maintenance element abolishes imprinting of both insulin-like growth factor II and H19	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR; MOUSE; GENE; METHYLATION; IGF2; EXPRESSION; ACTIVATION; RELAXATION; PROMOTERS; ALLELE	Insulin-like growth factor II (Igf2) is maternally imprinted in normal tissues with only the paternal copy of the gene being transcribed, whereas the contiguous gene H19 is paternally imprinted. Dysregulation of IGF2 imprinting is commonly observed in Wilns' tumor and other human tumors. Previous work comparing promoter-specific imprinting of human and mouse Igf2 suggested the presence of a cis element upstream of Igf2 that regulates or maintains the imprinting of three downstream promoters, To explore the molecular mechanism of maintenance of genomic imprinting, we targeted the region between insulin 2 and Igf2, where the cis imprint maintenance element (IME) resides in mouse fibroblasts, In those clones in which the targeting vector was randomly integrated into the genome, mouse Igf2 remained imprinted. However, when the targeted region containing the IME was deleted by homologous recombination, whether from the paternal or maternal allele, activation of the imprinted maternal allele of Igf2 was observed. In addition, there was a loss of H19 imprinting when the IME was deleted, The requirement of IME from both parental alleles for the maintenance of genomic imprinting thus suggests the importance of a spatial structure of DNA around Igf2 and H19, Modifications in the IME, like abnormal methylation in Wilms' tumors, may represent a novel mechanism for loss of genomic imprinting.	VET AFFAIRS PALO ALTO HLTH CARE SYST,GRECC,PALO ALTO,CA 94304; VET AFFAIRS PALO ALTO HLTH CARE SYST,MED SERV,PALO ALTO,CA 94304; STANFORD UNIV,DEPT MED,DIV ENDOCRINOL GERONTOL & METAB,PALO ALTO,CA 94304	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University			Hu, Jifan/Q-3003-2019	HU, Jifan/0000-0002-2174-0361	NIDDK NIH HHS [DK36054] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036054] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANERJEE S, 1995, NAT GENET, V11, P237, DOI 10.1038/ng1195-237; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DELTOUR L, 1995, DEV BIOL, V168, P686, DOI 10.1006/dbio.1995.1114; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; FEIL R, 1994, DEVELOPMENT, V120, P2933; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; Hu JF, 1996, J BIOL CHEM, V271, P18253, DOI 10.1074/jbc.271.30.18253; KOU K, 1993, MOL ENDOCRINOL, V7, P291, DOI 10.1210/me.7.2.291; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LIU JQ, 1995, J CLIN ENDOCR METAB, V80, P492, DOI 10.1210/jc.80.2.492; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1994, DEVELOPMENT, V120, P361; Pfeifer K, 1996, P NATL ACAD SCI USA, V93, P13876, DOI 10.1073/pnas.93.24.13876; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SZABO P, 1994, DEVELOPMENT, V120, P1651; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; VILLAR AJ, 1995, DEV BIOL, V172, P264, DOI 10.1006/dbio.1995.0021; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; Vu TH, 1996, J BIOL CHEM, V271, P9014, DOI 10.1074/jbc.271.15.9014; WENTWORTH BM, 1986, J MOL EVOL, V23, P305, DOI 10.1007/BF02100639; Yballe CM, 1996, J CLIN ENDOCR METAB, V81, P1607, DOI 10.1210/jc.81.4.1607; ZHAN SL, 1995, J BIOL CHEM, V270, P27983; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	39	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20715	20720		10.1074/jbc.272.33.20715	http://dx.doi.org/10.1074/jbc.272.33.20715			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252392	hybrid			2022-12-25	WOS:A1997XR22100062
J	Newton, JP; Buckley, CD; Jones, EY; Simmons, DL				Newton, JP; Buckley, CD; Jones, EY; Simmons, DL			Residues on both faces of the first immunoglobulin fold contribute to hemophilic binding sites of PECAM-1/CD31	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; CARCINOEMBRYONIC ANTIGEN; MONOCLONAL-ANTIBODIES; CD31; CLONING; DOMAIN; SUPERFAMILY; RECOGNITION; LEUKOCYTES; LIGAND	CD31 (PECAM-1) is a member of the immunoglobulin superfamily whose extracellular domain is comprised of six immunoglobulin-like domains. It is widely expressed on endothelium, platelets, around 50% of lymphocytes, and cells of myeloid lineage. CD31 has been shown to be involved in interendothelial adhesion and leukocyte endothelial interactions, particularly during transmigration, CD31-mediated adhesion is complex, because CD31 is capable of mediating both hemophilic and multiple heterophilic adhesive interactions, Here we show that the NH2-terminal (membrane-distal) immunoglobulin domain of CD31 is necessary but not sufficient to support stable hemophilic adhesion, Key residues forming the binding site within this domain have been identified by analysis of 26 single point mutations, representing the most systematic analysis of a fully hemophilic interaction between immunoglobulin superfamily family members to date. This revealed five mutations that affect hemophilic binding, Uniquely, the residues involved are exposed on both faces of the immunoglobulin fold, leading us to propose a novel mechanism for CD31 hemophilic adhesion.	UNIV OXFORD, DEPT BIOCHEM, LAB MOL BIOPHYS, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, DEPT BIOCHEM, OXFORD CTR MOL SCI, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP,CELL ADHES GRP,INST MOL MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DU, ENGLAND	University of Oxford; University of Oxford; Cancer Research UK; University of Oxford			Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BOSSY D, 1995, EUR J IMMUNOL, V25, P459, DOI 10.1002/eji.1830250223; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Buchstaller A, 1996, J CELL BIOL, V135, P1593, DOI 10.1083/jcb.135.6.1593; Buckley CD, 1996, J CELL SCI, V109, P437; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; FAWCETT J, 1995, J CELL BIOL, V128, P1229, DOI 10.1083/jcb.128.6.1229; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; GOLDBERGER A, 1994, J BIOL CHEM, V269, P17183; Hancock D C, 1992, Methods Mol Biol, V10, P23, DOI 10.1385/0-89603-204-3:23; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIAO F, 1995, J EXP MED, V182, P1337, DOI 10.1084/jem.182.5.1337; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Murohara T, 1996, J IMMUNOL, V156, P3550; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; Newham P, 1996, MOL MED TODAY, V2, P304, DOI 10.1016/1357-4310(96)10021-6; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OHTO H, 1985, BLOOD, V66, P873; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Prager E, 1996, J EXP MED, V184, P41, DOI 10.1084/jem.184.1.41; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; Ranheim TS, 1996, P NATL ACAD SCI USA, V93, P4071, DOI 10.1073/pnas.93.9.4071; RAO Y, 1993, J BIOL CHEM, V268, P20630; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; Rival Y, 1996, J IMMUNOL, V157, P1233; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SIMMONS DL, 1990, J EXP MED, V171, P2147, DOI 10.1084/jem.171.6.2147; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; Sun J, 1996, J BIOL CHEM, V271, P18561, DOI 10.1074/jbc.271.31.18561; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; VANMOURIK JA, 1985, J BIOL CHEM, V260, P1300; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Wakelin MW, 1996, J EXP MED, V184, P229, DOI 10.1084/jem.184.1.229; WATT SM, 1994, BLOOD, V84, P200; YAN HC, 1995, J BIOL CHEM, V270, P23672, DOI 10.1074/jbc.270.40.23672; YAN HC, 1995, CELL ADHES COMMUN, V3, P45, DOI 10.3109/15419069509081277; ZEHNDER JL, 1995, BLOOD, V85, P1282, DOI 10.1182/blood.V85.5.1282.bloodjournal8551282; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	56	107	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20555	20563		10.1074/jbc.272.33.20555	http://dx.doi.org/10.1074/jbc.272.33.20555			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252369	hybrid, Green Published			2022-12-25	WOS:A1997XR22100039
J	Eberhardt, C; Gray, PW; Tjoelker, LW				Eberhardt, C; Gray, PW; Tjoelker, LW			Human lysophosphatidic acid acyltransferase - cDNA cloning, expression, and localization to chromosome 9q34.3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID; ESCHERICHIA-COLI; 1-ACYL-SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; MESANGIAL CELLS; PHOSPHOLIPASE-D; 2ND MESSENGER; RAT-BRAIN; IDENTIFICATION; FIBROBLASTS; PLATELETS	Lysophosphatidic acid (1-acyl-sn-glycero-3-phosphate (LPA)) is a phospholipid with diverse biological activities. The mediator serves as an intermediate in membrane phospholipid metabolism but is also produced in acute settings by activated platelets. LPA is converted to phosphatidic acid, itself a lipid mediator, by an LPA acyltransferase (LPAAT). A human expressed sequence tag was identified by homology with a coconut LPAAT and used to isolate a full-length human cDNA from a heart muscle library. The predicted amino acid sequence bears 33% identity with a Caenorhabditis elegans LPAAT homologue and 23-28% Identity with plant and prokaryotic LPAATs. Recombinant protein produced in COS 7 cells exhibited LPAAT activity with a preference for LPA as the acceptor phosphoglycerol and arachidonyl coenzyme A as the acyl donor. Northern blotting demonstrated that the mRNA is expressed in most human tissues including a panel of brain subregions; expression is highest in liver and pancreas and lowest in placenta. The human LPAAT gene is contained on six exons that map to chromosome 9, region q34.3.	ICOS CORP,BOTHELL,WA 98021	Icos Corporation								ABRAHAM E, 1995, J EXP MED, V181, P569, DOI 10.1084/jem.181.2.569; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BROWN AP, 1994, PLANT MOL BIOL, V26, P211, DOI 10.1007/BF00039533; BROWN AP, 1995, PLANT MOL BIOL, V29, P267, DOI 10.1007/BF00043651; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; BURSTEN SL, 1992, AM J PHYSIOL, V262, pC328, DOI 10.1152/ajpcell.1992.262.2.C328; BURSTEN SL, 1991, J BIOL CHEM, V266, P20732; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; HANKE C, 1995, EUR J BIOCHEM, V232, P806, DOI 10.1111/j.1432-1033.1995.tb20876.x; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1990, J BIOL CHEM, V265, P12232; Keller JN, 1996, J NEUROCHEM, V67, P2300; KESTER M, 1993, J CELL PHYSIOL, V156, P317, DOI 10.1002/jcp.1041560214; KNUTZON DS, 1995, PLANT PHYSIOL, V109, P999, DOI 10.1104/pp.109.3.999; LUTTINGER AL, 1991, NEW BIOL, V3, P687; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; RICE GC, 1994, P NATL ACAD SCI USA, V91, P3857, DOI 10.1073/pnas.91.9.3857; SOLING HD, 1989, J BIOL CHEM, V264, P10643; THOMPSON FJ, 1994, BIOCHEM J, V300, P457, DOI 10.1042/bj3000457; THOMSON FJ, 1995, BIOCHEM J, V306, P305, DOI 10.1042/bj3060305; TIGYI G, 1995, AM J PHYSIOL-HEART C, V268, pH2048, DOI 10.1152/ajpheart.1995.268.5.H2048; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; VANDERBEND RL, 1992, BIOCHIM BIOPHYS ACTA, V1125, P110, DOI 10.1016/0005-2760(92)90163-P; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; WATSON SP, 1985, BIOCHEM J, V232, P61, DOI 10.1042/bj2320061; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; XIE MS, 1994, ARCH BIOCHEM BIOPHYS, V312, P254, DOI 10.1006/abbi.1994.1307; XU Y, 1995, J CELL PHYSIOL, V163, P441, DOI 10.1002/jcp.1041630303; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0; ZHOU D, 1995, J BIOL CHEM, V270, P25549, DOI 10.1074/jbc.270.43.25549	44	108	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20299	20305		10.1074/jbc.272.32.20299	http://dx.doi.org/10.1074/jbc.272.32.20299			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242711	hybrid			2022-12-25	WOS:A1997XQ05900098
J	Hilchey, SP; Wu, L; Koudelka, GB				Hilchey, SP; Wu, L; Koudelka, GB			Recognition of nonconserved bases in the P22 operator by P22 repressor requires specific interactions between repressor and conserved bases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							434 REPRESSOR; CELL-DIVISION; NONCONTACTED BASES; ESCHERICHIA-COLI; DNA DODECAMER; ADENINE TRACT; AFFINITY; SEQUENCE; DOMAIN; COMPLEX	The ability of P22 repressor protein to distinguish between the six naturally occurring operator binding sites is critically important in determining whether the bacteriophage chooses to grow lytically or lysogenically. We have shown that changes in the highly conserved bases at P22 operator positions 3, 5, 6, and 7 prevent specific binding of P22 repressor, Moreover, studies of mutant proteins identified the three repressor amino acids that directly contact these conserved bases. The pattern of operator sequence conservation permits these direct amino acid-base pair interactions to occur in all except one of the 12 operator half-sites in the phage chromosome, Therefore, repressor differential affinity for these sites cannot be due to these highly conserved base pair-amino acid interactions, Our binding studies show that the nonconserved bases at positions 2 and 4 also play an important role in determining the relative affinity of the naturally occurring P22 operators for P22 repressor, Our data indicate that the direct contacts between the three solvent-exposed amino acids and the conserved bases in the binding site lock these amino acids in place, forming a scaffold allowing the rest of the amino acids side chains to form weaker interactions with the nonconserved bases in the binding site.	SUNY BUFFALO,DEPT SCI BIOL,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Koudelka, Gerald B./AAI-3738-2020	Koudelka, Gerald B./0000-0001-6280-0837	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042138, R29GM042138] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42138] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BEJAR S, 1985, MOL GEN GENET, V201, P146, DOI 10.1007/BF00425651; BEJAR S, 1988, MOL GEN GENET, V212, P11, DOI 10.1007/BF00322439; BEJAR S, 1986, NUCLEIC ACIDS RES, V14, P6821, DOI 10.1093/nar/14.17.6821; DALMAWEISZHAUSZ DD, 1991, NUCLEIC ACIDS RES, V19, P611, DOI 10.1093/nar/19.3.611; DEANDA J, 1983, J BIOL CHEM, V258, P536; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DIGABRIELE AD, 1993, J MOL BIOL, V231, P1024, DOI 10.1006/jmbi.1993.1349; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; Hilchey SP, 1997, J BIOL CHEM, V272, P1646, DOI 10.1074/jbc.272.3.1646; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; LOMONOSSOFF GP, 1981, J MOL BIOL, V149, P745, DOI 10.1016/0022-2836(81)90356-9; Maniatis T., 1982, MOL CLONING; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; POTEETE AR, 1980, J MOL BIOL, V137, P81, DOI 10.1016/0022-2836(80)90158-8; POTEETE AR, 1982, J MOL BIOL, V157, P21, DOI 10.1016/0022-2836(82)90511-3; Ptashne M., 1986, A GENETIC SWITCH; SANGER F, 1973, P NATL ACAD SCI USA, V70, P1209, DOI 10.1073/pnas.70.4.1209; SAUER RT, 1982, NATURE, V298, P447, DOI 10.1038/298447a0; SAUER RT, 1979, NATURE, V279, P396, DOI 10.1038/279396a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEVILLASIERRA P, 1994, J MOL BIOL, V235, P1003, DOI 10.1006/jmbi.1994.1053; TABOR S, 1990, CURRENT PROTCOLS MOL; WHARTON RP, 1987, NATURE, V326, P888, DOI 10.1038/326888a0; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; WHARTON RP, 1985, CELL, V38, P361; WU L, 1993, J BIOL CHEM, V268, P18975; WU L, 1992, J BIOL CHEM, V267, P9134	32	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19898	19905		10.1074/jbc.272.32.19898	http://dx.doi.org/10.1074/jbc.272.32.19898			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242655	hybrid			2022-12-25	WOS:A1997XQ05900042
J	Saeki, K; Yuo, A; Kato, M; Miyazono, K; Yazaki, Y; Takaku, F				Saeki, K; Yuo, A; Kato, M; Miyazono, K; Yazaki, Y; Takaku, F			Cell density-dependent apoptosis in HL-60 cells, which is mediated by an unknown soluble factor, is inhibited by transforming growth factor beta 1 and overexpression of bcl-24	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; EPITHELIAL-CELLS; DEATH; FACTOR-BETA-1; PROLIFERATION; ACTIVATION; EXPRESSION; INDUCTION; RADIATION; RECEPTORS	We report a novel mode of apoptosis induction observed in human leukemic HL-60 cells, These cells spontaneously underwent apoptosis in the course of proliferation when the cell density became higher than 1 x 10(6)/ml, This occurred under ordinary in vitro culture conditions, with or without fetal calf serum, Even the low density cells were committed to undergo apoptosis if they were cultured under artificially concentrated conditions, Replacement of the culture supernatant of the low density cells by that of the high density ones resulted in apoptosis induction in the former cells. This apoptosis-inducing activity of the high density cell culture supernatant was completely eliminated by the action of trypsin but was fully restored following ultrafiltration by 3-kDa pore-sized membrane, A strong apoptosis-inducing activity was recovered from the culture supernatant of the high density HL-60 cells at a specific fraction in reverse-phase column chromatography, Neither an interleukin-beta converting enzyme inhibitor nor CPP-32 inhibitor blocked the induction of cell density-dependent apoptosis in HL-60 cells, although overexpression of Bcl-2 protein markedly attenuated the induction of this mode. Surprisingly, transforming growth factor-beta 1 and activin A did not induce but, rather, inhibited the induction of cell density-dependent apoptosis, These data suggest that HL-60 cells release an unknown low molecular weight peptide-containing factor in response to an increase in cell density to induce apoptosis in an autocrine manner and that the interleukin-beta converting enzyme-independent intracellular machinery for this mode of apoptosis is strongly affected by signaling events through the transforming growth factor-beta 1 receptor and by the action of Bcl-2 oncoprotein.	INT MED CTR JAPAN, RES INST, DEPT HEMATOL, SHINJUKU KU, TOKYO 162, JAPAN; JAPANESE FDN CANC RES, INST CANC, DEPT BIOCHEM, TOKYO 170, JAPAN; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, TOKYO 113, JAPAN	National Center for Global Health & Medicine - Japan; Japanese Foundation for Cancer Research; University of Tokyo				Saeki, Kumiko/0000-0001-9161-139X				BIES J, 1995, CANCER RES, V55, P501; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GUNN A, 1983, IMMUNOLOGY, V50, P477; HARMON BV, 1990, INT J RADIAT BIOL, V58, P845, DOI 10.1080/09553009014552221; HAVRILESKY LJ, 1995, CANCER RES, V55, P944; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JURGENSMEIER JM, 1994, CANCER RES, V54, P393; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; LOTEM J, 1992, BLOOD, V80, P1750; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; NAGY L, 1995, MOL CELL BIOL, V15, P3540; OHYAMA H, 1985, RADIAT RES, V101, P123, DOI 10.2307/3576309; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; RIOPEL L, 1989, J CELL PHYSIOL, V140, P233, DOI 10.1002/jcp.1041400207; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SHIMIZU T, 1990, BIOCHEM BIOPH RES CO, V169, P1172, DOI 10.1016/0006-291X(90)92019-V; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SINKOVICS J G, 1991, International Reviews of Immunology, V7, P259, DOI 10.3109/08830189109114875; SPORN MB, 1990, HDB EXP PHARM, V95; TAEALE R, 1993, CANCER, V53, P3386; TERUI Y, 1995, J BIOCHEM-TOKYO, V117, P77, DOI 10.1093/oxfordjournals.jbchem.a124725; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YANAGIHARA K, 1992, CANCER RES, V52, P4042; ZHANG XH, 1995, J EXP MED, V182, P699, DOI 10.1084/jem.182.3.699	31	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20003	20010		10.1074/jbc.272.32.20003	http://dx.doi.org/10.1074/jbc.272.32.20003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242670	hybrid			2022-12-25	WOS:A1997XQ05900057
J	Corbeil, HB; Branton, PE				Corbeil, HB; Branton, PE			Characterization of an E2F-p130 complex formed during growth arrest	ONCOGENE			English	Review						E2F; p130; growth arrest; cell cycle	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ADENOVIRUS E1A PROTEINS; CELL-CYCLE ARREST; LARGE T-ANTIGENS; SUSCEPTIBILITY GENE; IN-VIVO; FUNCTIONAL INTERACTIONS; ONCOGENIC ACTIVITY; BINDING PROTEIN	Electrophoretic mobility shift assays were used to analyse the pattern of E2F transcription factor complexes containing pRB and related 'pocket' proteins associated with changes in growth of monkey CV-1 cells. Little change was noted in pRB/E2F complexes following growth arrest or serum stimulation. Serum starvation induced the formation of a novel slowly-migrating p130/E2F complex, termed C7, which was comparable to one reported previously in terminally differentiated C2C12 mouse cells (Corbeil et al., 1995, Oncogene 11, 909-920) and thought to contain one or more additional unidentified proteins. After serum stimulation, C7 complex disappeared in S-phase but returned during mitosis. A major E2F complex containing p107 appeared during S-phase but was undetectable at other times. It appeared likely that regulation of pRB, p107 and p130 occurs by several mechanisms. First, phosphorylation has previously been proposed to be involved. All pRB-related proteins were found to be highly phosphorylated during S-phase when E2F activity was highest, and hypophosphorylated in arrested cells when E2F activity was low. Second, the absolute levels of some members of the RE family varied during the cell cycle. Levels of pRB protein and pRB/E2F complexes changed little; however, the amounts of both p107/E2F and p130/E2F complexes varied according to the overall levels of p107 and p130 proteins. Formation of the novel C7 complex in serum arrested cells suggested a third regulatory mechanism mediated by interactions with additional proteins. Our studies indicated that binding of such proteins with p130/E2F occurred via a site in the 'pocket' similar to that utilized by adenovirus E1A proteins. Such proteins could function as additional regulators of E2F-driven transcription.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University								ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BARBEAU D, 1994, ONCOGENE, V9, P359; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCK V, 1995, ONCOGENE, V11, P31; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; CORBEIL HB, 1994, J VIROL, V68, P6697, DOI 10.1128/JVI.68.10.6697-6709.1994; DAVIES R, 1993, BIOTECHNIQUES, V14, P630; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DYNLACHT BD, 1994, GENE DEV, V8, P2008; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1992, SCIENCE, V255, P87; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FATTAEY AR, 1993, ONCOGENE, V8, P3149; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P65; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7183; JOHNSON DG, 1994, GENE DEV, V8, P1759; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAYOL X, 1993, ONCOGENE, V8, P2561; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4009; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, TRENDS BIOCHEM SCI, V17, P312; NEVINS JR, 1992, MOL CELL BIOL, V12, P5363; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OTTERSON GA, 1993, ONCOGENE, V8, P949; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sambrook J., 2002, MOL CLONING LAB MANU; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHIMIZU M, 1995, MOL CELL BIOL, V15, P882; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Strober BE, 1996, MOL CELL BIOL, V16, P1576; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; XU M, 1994, MOL CELL BIOL, V14, P420; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	107	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					657	668		10.1038/sj.onc.1201224	http://dx.doi.org/10.1038/sj.onc.1201224			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264406				2022-12-25	WOS:A1997XP68300005
J	Pusch, O; Bernaschek, G; Eilers, M; Hengstschlager, M				Pusch, O; Bernaschek, G; Eilers, M; Hengstschlager, M			Activation of c-myc uncouples DNA replication from activation of G1-cyclin-dependent kinases	ONCOGENE			English	Article						c-Myc; G1-cyclins; cell cycle; initiation of replication	CYCLIN-DEPENDENT KINASES; S-PHASE ENTRY; CELL-CYCLE; TRANSCRIPTION FACTOR; THYMIDINE KINASE; PROTEIN-KINASE; RESTRICTION POINT; GROWTH-REGULATION; EXPRESSION; BINDING	Proto-oncogenes like c-myc are thought to control exit from the cell cycle rather than progression through the cell cycle itself, We now present a different view of Myc function, Exponentially growing Rat1-MycER(TM) fibroblasts were size-fractionated by centrifugal elutriation, In these cells, activation of cyclin E- and cyclin A- dependent kinases, degradation of p27, hyperphosphorylation of retinoblastoma protein and activation of E2F occur sequentially at specific cell sizes, Upon activation of Myc, however, these transitions all occur simultaneously in small cells immediately after exit from mitosis. In contrast, Myc has no discernible effect on the cell size at which DNA replication is initiated, These data show first that Myc centrals the activity of G1 cyclin-dependent kinases independently from the transition between quiescence and proliferation and from any effect on cell growth in size, These data also provide evidence of at least one dominant mechanism besides activation of E2F and of cyclin E/cdk2 kinase, which prevents DNA replication unless a critical cell size has been reached.	UNIV VIENNA,DEPT PRENATAL DIAG & THERAPY,A-1090 VIENNA,AUSTRIA; ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY	University of Vienna; Ruprecht Karls University Heidelberg				Pusch, Oliver/0000-0001-7166-2800; Eilers, Martin/0000-0002-0376-6533				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DOU QP, 1994, J BIOL CHEM, V269, P1306; DOU QP, 1993, CANCER RES, V53, P1493; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GIUNTA M, 1995, CELL CYCLE, P46; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; HENGSTSCHLAGER M, 1994, CELL GROWTH DIFFER, V5, P1389; Hengstschlager M, 1996, ONCOGENE, V12, P1635; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JANSENDURR P, 1995, CELL CYCLE, P243; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELHAM MJ, 1990, ONCOGENE, V5, P161; Winston JT, 1996, ONCOGENE, V12, P127; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	62	55	55	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					649	656		10.1038/sj.onc.1201236	http://dx.doi.org/10.1038/sj.onc.1201236			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264405	Bronze			2022-12-25	WOS:A1997XP68300004
J	Johannes, L; Tenza, D; Antony, C; Goud, B				Johannes, L; Tenza, D; Antony, C; Goud, B			Retrograde transport of KDEL-bearing B-fragment of Shiga toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SHIGELLA-DYSENTERIAE; BINDING PROTEIN; GOLGI-COMPLEX; GLYCOLIPID-BINDING; BREFELDIN-A; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE PROTEINS; CRYSTAL-STRUCTURE; MEDIAL GOLGI	To investigate retrograde transport along the biosynthetic/secretory pathway, we have constructed a recombinant Shiga toxin B-fragment carrying an N-glycosylation site and a KDEL retrieval motif at its carboxyl terminus (B-Glyc-KDEL), After incubation with HeLa cells, B-Glyc-KDEL was progressively glycosylated in the endoplasmic reticulum (ER) and remained stably associated with this compartment. B-fragment with a nonfunctional KDEL sequence (B-Glyc-KDELGL) was glycosylated with about the same kinetics as B-Glyc-KDEL but localized at steady state to the Golgi apparatus. Morphological studies showed that B-Glyc-KDEL was delivered from the plasma membrane, via endosomes and the cisternae of the Golgi apparatus, to the ER. Moreover, the addition of a sulfation site allowed us to show that B-Glyc-KDEL on transit to the ER entered the Golgi apparatus through the trans-Golgi network. Transport of B-Glyc-KDEL to the ER was slowed down by nocodazole, indicating that microtubules are important for the retrograde pathway. Our results document the existence of a continuous pathway from the plasma membrane to the endoplasmic reticulum via the Golgi apparatus and show that a fully folded exogenous protein arriving in the endoplasmic reticulum via this pathway can undergo N-glycosylation.	INST CURIE,CNRS,UMR 144,LAB MECAN MOL TRANSPORT INTRACELLULAIRE,F-75248 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite			Goud, Bruno/GWC-4807-2022; antony, claude/K-5342-2013; Johannes, Ludger/W-8593-2019; Johannes, Ludger/M-9778-2017	Johannes, Ludger/0000-0002-2168-0004; Johannes, Ludger/0000-0002-2168-0004				ANTONY C, 1992, J CELL SCI, V103, P785; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; EIKLID K, 1980, J RECEPTOR RES, V1, P199, DOI 10.3109/10799898009044098; FRASER ME, 1994, NAT STRUCT BIOL, V1, P59, DOI 10.1038/nsb0194-59; GARRED O, 1995, EXP CELL RES, V218, P39, DOI 10.1006/excr.1995.1128; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; HOE MH, 1995, J BIOL CHEM, V270, P25057, DOI 10.1074/jbc.270.42.25057; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; JOHNSTON PA, 1994, J CELL SCI, V107, P529; KHINE AA, 1994, J CELL PHYSIOL, V161, P319, DOI 10.1002/jcp.1041610217; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Kleijmeer Monique J., 1996, Methods (Orlando), V10, P191, DOI 10.1006/meth.1996.0095; KOZLOV YV, 1988, GENE, V67, P213, DOI 10.1016/0378-1119(88)90398-8; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Lingwood CA, 1996, TRENDS MICROBIOL, V4, P147, DOI 10.1016/0966-842X(96)10017-2; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1995, BIOCHEM SOC T, V23, P544, DOI 10.1042/bst0230544; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NIEHRS C, 1992, J BIOL CHEM, V267, P15938; OBRIEN AD, 1992, CURR TOP MICROBIOL, V180, P65; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1982, J CELL BIOL, V92, P223; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SANDVIG K, 1991, J CELL BIOL, V113, P553, DOI 10.1083/jcb.113.3.553; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SANDVIG K, 1994, J CELL BIOL, V126, P53, DOI 10.1083/jcb.126.1.53; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SEIDAH NG, 1986, J BIOL CHEM, V261, P13928; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; STROCKBINE NA, 1988, J BACTERIOL, V170, P1116, DOI 10.1128/jb.170.3.1116-1122.1988; STROUS GJ, 1993, J BIOL CHEM, V268, P2341; SU GF, 1992, INFECT IMMUN, V60, P3345, DOI 10.1128/IAI.60.8.3345-3359.1992; TOOZE J, 1992, J CELL BIOL, V118, P813, DOI 10.1083/jcb.118.4.813; WALES R, 1992, EXP CELL RES, V203, P1, DOI 10.1016/0014-4827(92)90032-4; WOOD SA, 1992, J CELL BIOL, V119, P273, DOI 10.1083/jcb.119.2.273	52	175	185	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19554	19561		10.1074/jbc.272.31.19554	http://dx.doi.org/10.1074/jbc.272.31.19554			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235960	hybrid			2022-12-25	WOS:A1997XP06300066
J	Kitmitto, A; Holzenburg, A; Ford, RC				Kitmitto, A; Holzenburg, A; Ford, RC			Two-dimensional crystals of photosystem I in higher plant grana margins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANES; ELECTRON-MICROSCOPY; SPINACH-CHLOROPLASTS; PROTEIN COMPLEXES; P700 CHLOROPHYLL; HETEROGENEITY; IDENTIFICATION; RECONSTITUTION; ORGANIZATION; BINDING	In this report, we present new structural data on the size, shape, and oligomeric form of higher plant photosystem I (PSI) formed within the thylakoid grana margins. We show that PSI complexes can be assembled into ordered molecular monolayers (two-dimensional crystals) using thylakoid membranes from a variety of higher plant sources. Digital image analysis of negatively stained two-dimensional crystals (a = 26.9 nm, b = 28.0 nm, gamma = 90 degrees, p22(1)2(1) plane group) resulted in a projection map consisting of 4 monomers/unit cell. Higher plant PSI is slightly larger than its cyanobacterial equivalent but shows many similar features. Structural changes after urea and salt washing of the crystals supported the biochemical characterization and were mainly assigned to the stromal side of the complex where the psaC, psaD, and psaE gene products are known to be bound, Labeling with ferredoxin colloidal gold complexes provided direct evidence for a segregated PSI population, with 5 nm diameter ferredoxin-gold particles enriched in the thylakoid grana margins and the two-dimensional crystals. This lateral segregation of photosynthetic complexes is important for the understanding of the kinetics of electron transfer between photosystem II and PSI in higher plants.	UMIST, DEPT BIOCHEM & APPL MOL BIOL, MANCHESTER M60 1QD, LANCS, ENGLAND; UNIV LEEDS, DEPT BIOCHEM & MOL BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Manchester; University of Leeds				Ford, Robert/0000-0002-0958-1505				ALBERTSSON PA, 1990, FEBS LETT, V273, P36, DOI 10.1016/0014-5793(90)81045-P; ALMOG O, 1991, P NATL ACAD SCI USA, V88, P5312, DOI 10.1073/pnas.88.12.5312; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; ANDERSSON B, 1978, THESIS U LUND SWEDEN; ANDREASSON E, 1988, BIOCHIM BIOPHYS ACTA, V936, P339, DOI 10.1016/0005-2728(88)90010-2; ANDREASSON E, 1993, BIOCHIM BIOPHYS ACTA, V1141, P175, DOI 10.1016/0005-2728(93)90040-M; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BARBER J, 1980, FEBS LETT, V118, P1, DOI 10.1016/0014-5793(80)81207-5; BASSI R, 1989, EUR J CELL BIOL, V50, P84; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1017, P49, DOI 10.1016/0005-2728(90)90177-6; BOTTCHER B, 1992, BIOCHIM BIOPHYS ACTA, V1100, P125, DOI 10.1016/0167-4838(92)90544-N; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; DUNAHAY TG, 1985, PLANT PHYSIOL, V78, P606, DOI 10.1104/pp.78.3.606; FISH LE, 1986, J BIOL CHEM, V261, P8134; FISH LE, 1985, J BIOL CHEM, V260, P1413; FORD RC, 1983, FEBS LETT, V160, P159, DOI 10.1016/0014-5793(83)80957-0; FORD RC, 1988, EMBO J, V7, P2287, DOI 10.1002/j.1460-2075.1988.tb03071.x; FORD RC, 1990, EMBO J, V9, P3067, DOI 10.1002/j.1460-2075.1990.tb07503.x; GOLBECK JH, 1988, FEBS LETT, V228, P268, DOI 10.1016/0014-5793(88)80013-9; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; HARRIS JR, 1993, J STRUCT BIOL, V111, P22, DOI 10.1006/jsbi.1993.1032; HE WZ, 1992, FEBS LETT, V308, P298, DOI 10.1016/0014-5793(92)81297-Y; HEFTI A, 1992, FEBS LETT, V296, P29, DOI 10.1016/0014-5793(92)80396-X; HOLZENBURG A, 1994, MICRON, V25, P447, DOI 10.1016/0968-4328(94)00034-4; HORISBERGER M, 1977, J HISTOCHEM CYTOCHEM, V25, P295, DOI 10.1177/25.4.323352; HOVMOLLER S, 1992, ULTRAMICROSCOPY, V41, P121, DOI 10.1016/0304-3991(92)90102-P; IKEUCHI M, 1991, FEBS LETT, V280, P332, DOI 10.1016/0014-5793(91)80324-V; Jekow P, 1996, Z NATURFORSCH C, V51, P195; Karrasch S, 1996, J MOL BIOL, V262, P336, DOI 10.1006/jmbi.1996.0517; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; KRUIP J, 1993, J BIOL CHEM, V268, P23353; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; Nicholson WV, 1996, BIOCHEM J, V315, P543, DOI 10.1042/bj3150543; PETER GF, 1991, J BIOL CHEM, V266, P16745; SEIBERT M, 1987, FEBS LETT, V219, P207; STAEHELIN LA, 1986, PHOTOSYNTHESIS, V3, P1; STEFANSSON H, 1995, BBA-BIOENERGETICS, V1231, P323, DOI 10.1016/0005-2728(95)00103-P; VALLON O, 1986, PHOTOBIOCH PHOTOBIOP, V12, P203; WOLLENBERGER L, 1994, BBA-BIOENERGETICS, V1184, P93, DOI 10.1016/0005-2728(94)90158-9; WYNN RM, 1988, FEBS LETT, V229, P293, DOI 10.1016/0014-5793(88)81143-8; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810	42	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19497	19501		10.1074/jbc.272.31.19497	http://dx.doi.org/10.1074/jbc.272.31.19497			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235952	hybrid			2022-12-25	WOS:A1997XP06300058
J	Wang, D; Hu, YM; Zheng, F; Zhou, K; Kohlhaw, GB				Wang, D; Hu, YM; Zheng, F; Zhou, K; Kohlhaw, GB			Evidence that intramolecular interactions are involved in masking the activation domain of transcriptional activator Leu3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY GENE LEU3; SACCHAROMYCES-CEREVISIAE; DNA RECOGNITION; SHUTTLE VECTORS; YEAST; COMPLEX; GAL4; MANIPULATION; MUTAGENESIS; PROTEINS	The Leu3 protein of Saccharomyces cerevisiae regulates the expression of genes involved in branched chain amino acid biosynthesis and in ammonia assimilation. It is modulated by alpha-isopropylmalate, an intermediate in leucine biosynthesis. In the presence of alpha-isopropylmalate, Leu3p is a transcriptional activator, In the absence of the signal molecule, the activation domain is masked, and Leu3p acts as a repressor, The recent discovery that Leu3p retains its regulatory properties when expressed in mammalian cells (Guo, H., and Kohlhaw, G. B. (1996) FEES Lett. 390, 191-195) suggests that masking and unmasking of the activation domain occur without the participation of auxiliary proteins. Here we present experimental support for this notion and address the mechanism of masking, We show that modulation of Leu3p is exceedingly sensitive to mutations in the activation domain. An activation domain double mutant (D872N/D874N; designated Leu3-dd) was constructed that has the characteristics of a permanently masked activator, Using separately expressed segments containing either the DNA binding domain-middle region or the activation domain of wild type Leu3p (or Leu3-dd) in a modified yeast two-hybrid system, we provide direct evidence for alpha-isopropylmalate-dependent interaction between these segments, Finally, we use the phenotype of Leu3-dd-containing cells (slow growth in the absence of added leucine) to select for suppressor mutations that map to the middle region of Leu3-dd. The properties of nine such suppressors further support the idea that masking is an intramolecular process and suggest a means for mapping the surface involved in masking.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [GM15102] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI YL, 1991, NUCLEIC ACIDS RES, V19, P5991, DOI 10.1093/nar/19.21.5991; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; CADWELL RC, 1994, PCR METH APPL, V3, pS136; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DUNN B, 1993, CURRENT PROTOCOLS MO, V2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fink GR., 1970, METHODS ENZYMOL VOL, V17, P59, DOI DOI 10.1016/0076-6879(71)17167-4; FRIDEN P, 1989, MOL CELL BIOL, V9, P4056, DOI 10.1128/MCB.9.9.4056; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; Guo H, 1996, FEBS LETT, V390, P191, DOI 10.1016/0014-5793(96)00653-9; HAMPSEY DM, 1983, P NATL ACAD SCI-BIOL, V80, P1270, DOI 10.1073/pnas.80.5.1270; HU Y, 1996, THESIS PURDUE U; HU YM, 1995, MOL CELL BIOL, V15, P52, DOI 10.1128/MCB.15.1.52; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; Miller JH., 1972, EXPT MOL GENETICS; REMBOUTSIKA E, 1994, MOL CELL BIOL, V14, P5547, DOI 10.1128/MCB.14.8.5547; SCHULZ WA, 1993, BIOL CHEM H-S, V374, P313, DOI 10.1515/bchm3.1993.374.1-6.313; SIKORSKI RS, 1989, GENETICS, V122, P19; SZE JY, 1993, J BIOL CHEM, V268, P2505; SZE JY, 1993, MOL CELL BIOL, V13, P5702, DOI 10.1128/MCB.13.9.5702; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; Wade PA, 1996, MOL CELL BIOL, V16, P1641; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZHOU K, 1987, NUCLEIC ACIDS RES, V15, P5261, DOI 10.1093/nar/15.13.5261; ZHOU K, 1990, J BIOL CHEM, V265, P17409; ZHOU K, 1991, THESIS PURDUE U; ZHOU KM, 1990, NUCLEIC ACIDS RES, V18, P291, DOI 10.1093/nar/18.2.291	34	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19383	19392		10.1074/jbc.272.31.19383	http://dx.doi.org/10.1074/jbc.272.31.19383			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235937	hybrid			2022-12-25	WOS:A1997XP06300043
J	Wang, SL; Du, EZ; Martin, TD; Davis, RA				Wang, SL; Du, EZ; Martin, TD; Davis, RA			Coordinate regulation of lipogenesis, the assembly and secretion of apolipoprotein B-containing lipoproteins by sterol response element binding protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; CULTURED LIVER-CELLS; FATTY-ACIDS; HEPG2 CELLS; ENDOPLASMIC-RETICULUM; RAT HEPATOCYTES; CHOLESTERYL ESTER; APO-B; TRANSLOCATION	Stable plasmid-driven expression of the liver-specific gene product cholesterol 7 alpha-hydroxylase (7 alpha-hydroxylase) was used to alter the cellular content of transcriptionally active sterol response element binding protein 1 (SREBP1), As a result of stable expression of 7 alpha-hydroxylase, individual single cell clones expressed varying amounts of mature SREBP1 protein, These single cell clones provided an opportunity to identify SREBP1-regulated genes that may influence the assembly and secretion of apoB-containing lipoproteins, Our results show that in McArdle rat hepatoma cells, which normally do not express 7 alpha-hydroxylase, plasmid-driven expression of 7 alpha-hydroxylase results in the following: 1) a linear relationship between (i) the cellular content of mature SREBP1 and 7 alpha-hydroxylase protein, (ii) the relative expression of 7 alpha-hydroxylase mRNA and the mRNA's encoding the enzymes regulating fatty acid, i.e. acetyl-CoA carboxylase and sterol synthesis, i.e. HMG-CoA reductase, (iii) the relative expression of 7 alpha-hydroxylase mRNA and microsomal triglyceride transfer protein mRNA, a gene product that is essential for the assembly and secretion of apoB-containing lipoproteins; 2) increased synthesis of all lipoprotein lipids (cholesterol, cholesterol esters, triglycerides, and phospholipids); and 3) increased secretion of apoB100 without any change in apoB mRNA, Cells expressing 7 alpha-hydroxylase contained significantly less cholesterol (both free and esterified), The increased cellular content of mature SREBP1 and increased secretion of apoB100 were concomitantly reversed by 25-hydroxycholesterol, suggesting that the content of mature SREBP1, known to be decreased by 25-hydroxycholesterol, mediates the changes in the lipoprotein assembly and secretion pathway that are caused by 7 alpha-hydroxylase. These data suggest that several steps in the assembly and secretion of apoB-containing lipoproteins by McArdle hepatoma cells may be coordinately linked through the cellular content of mature SREBP1.	SAN DIEGO STATE UNIV,DEPT BIOL,MAMMALIAN CELL & MOL BIOL LAB,SAN DIEGO,CA 92182; SAN DIEGO STATE UNIV,INST MOL BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University; California State University System; San Diego State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052005] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51643, HL52005] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGELIN B, 1978, J LIPID RES, V19, P1004; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BOOGAERTS JR, 1984, AM J PHYSIOL, V246, pE77, DOI 10.1152/ajpendo.1984.246.1.E77; BOREN J, 1994, J BIOL CHEM, V269, P25879; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CHAN L, 1977, ENDOCRINOLOGY, V100, P1636, DOI 10.1210/endo-100-6-1636; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; COLEMAN RA, 1988, J LIPID RES, V29, P33; DAVIS RA, 1982, J BIOL CHEM, V257, P908; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1985, J BIOL CHEM, V260, P4137; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DAVIS RA, 1983, J BIOL CHEM, V258, P3661; DAVIS RA, 1996, N COMP BIOC, V31, P473; DAVIS RA, 1991, BIOCH LIPIDS MEMBRAN, V20, P403; DAVIS RA, 1997, J NUTR, V127, P7955; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DOLPHIN PJ, 1971, BIOCHEM J, V124, P751, DOI 10.1042/bj1240751; DU EZ, 1994, J BIOL CHEM, V269, P24169; DUELAND S, 1992, J BIOL CHEM, V267, P22695; EDWARDS PA, 1996, N COMP BIOC, V31, P341; EINARSSON K, 1991, EUR J CLIN PHARMACOL, V40, pS53, DOI 10.1007/BF01409410; ERICKSON SK, 1986, J LIPID RES, V27, P875; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HAGEDORN HH, 1973, DEV BIOL, V31, P285, DOI 10.1016/0012-1606(73)90265-0; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KHAN B, 1989, BIOCHEM J, V258, P807, DOI 10.1042/bj2580807; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LIN MCM, 1994, J BIOL CHEM, V269, P29138; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; PATSCH W, 1983, J CLIN INVEST, V72, P371, DOI 10.1172/JCI110977; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; TANABE S, 1989, IN VITRO CELL DEV B, V25, P1129; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Trawick JD, 1996, J LIPID RES, V37, P588; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG HX, 1994, J BIOL CHEM, V269, P18514; WANG S, 1996, J BIOL CHEM, V271, P12124; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WU XJ, 1994, J BIOL CHEM, V269, P12375; YAO ZM, 1989, J BIOL CHEM, V264, P11373	60	57	57	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19351	19358		10.1074/jbc.272.31.19351	http://dx.doi.org/10.1074/jbc.272.31.19351			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235933	hybrid			2022-12-25	WOS:A1997XP06300039
J	Sugiyama, H; Papst, P; Fujita, M; Gelfand, EW; Terada, N				Sugiyama, H; Papst, P; Fujita, M; Gelfand, EW; Terada, N			Overexpression of wild type p70 S6 kinase interferes with cytokinesis	ONCOGENE			English	Article						p70 S6 kinase; overexpression; cytokinesis; rapamycin; cell cycle	PROTEIN-KINASE; CYTOCHALASIN-B; MAP2 KINASE; RAPAMYCIN; ACTIVATION; PHOSPHORYLATION; CELLS; INACTIVATION; STIMULATION; TRANSLATION	p70 S6 kinase (p70(s6k)) is a serine/threonine kinase which is activated through an unidentified pathway by mitogenic stimuli, Here we demonstrate that stable- and transient-overexpression of wild type (WT)-p70(s6k) results in perturbation of cytokinesis in NIH3T3 cells. Cells overexpressing WT-p70(s6k) demonstrated a slow growth rate and lower viability, whereas cells overexpressing a mutant T229A-p70(s6k) had a similar growth rate and viability as those of parental NIH3T3 cells. Moreover, WT-p70(s6k) cells demonstrated several abnormalities in cellular morphology; both the cytoplasm and the nuclei were large and a proportion of the cells was multinucleated. Flow cytometric analysis of propidium iodide-stained cells demonstrated that about 50% of the cells had 4N or greater content of DNA, When cell division in WT-p70(s6k) cells was monitored by time-lapse video microscopy, cytokines was often incomplete after mitosis, producing binucleated cells, Addition of rapamycin to WT-p70(s6k) cells, which inactivates endogenous and transfected p70(s6k), failed to reverse any of the morphological abnormalities. These indicate that overexpression of p70(s6k) but not increases in activity of p70(s6k), is responsible for the phenotype. A molecule which interacts with p70(s6k) may be involved in this regulation of cytokinesis.	NATL JEWISH MED & RES CTR,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT DERMATOL,DENVER,CO 80206	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [CA-64685] Funding Source: Medline; NIAID NIH HHS [AI-26940, AI-29704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026940, R01AI026940, R01AI029704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANDI HR, 1993, J BIOL CHEM, V268, P4530; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KRISHAN A, 1972, J CELL BIOL, V54, P657, DOI 10.1083/jcb.54.3.657; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; MORELLI JG, 1992, J INVEST DERMATOL, V98, P290, DOI 10.1111/1523-1747.ep12497951; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SANGER JW, 1972, AM J ANAT, V135, P293, DOI 10.1002/aja.1001350214; Sugiyama H, 1996, J IMMUNOL, V157, P656; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TERADA N, 1993, J BIOL CHEM, V268, P12062; TERADA N, 1995, J IMMUNOL, V155, P3418; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	36	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					443	452		10.1038/sj.onc.1201207	http://dx.doi.org/10.1038/sj.onc.1201207			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242381				2022-12-25	WOS:A1997XM23800009
J	Zheng, GX; Teumer, J; Colmenares, C; Richmond, C; Stavnezer, E				Zheng, GX; Teumer, J; Colmenares, C; Richmond, C; Stavnezer, E			Identification of a core functional and structural domain of the v-Ski oncoprotein responsible for both transformation and myogenesis	ONCOGENE			English	Article						oncogene; v-Ski; mutagenesis; proteolysis	CDNA CLONES; ONCOGENE; GENE; PROTEINS; CELLS; DNA; ACTIVATION; SEQUENCE; VECTORS; VIRUSES	The v-ski oncogene promotes cellular transformation and myogenic differentiation. In quail embryo fibroblasts the two properties are displayed simultaneously and terminal muscle differentiation occurs only among cells already transformed by v-ski. To understand how the two phenotypes are derived from a single gene, we have undertaken to identify functionally important regions in v-ski and to test whether these regions can promote one phenotype without the other. We have generated both random and targeted mutations in v-ski and evaluated the effects of these mutations on expression, intracellular location, transformation, and myogenesis. Among a total of 26 mutants analysed, we have not found complete separation of the myogenic and transforming properties. Mutations in the region of v-Ski encoded by exon 1 of c-ski frequently abolish both its transformation and muscle differentiation activities, whereas mutations outside of this region are always tolerated. When expressed in cells from a minigene containing only the exon 1 sequence, the protein displays the transforming and myogenic activities similar to v-Ski. These results argue that the amino acid sequence encoded by exon 1 contains the core functional domain of the oncoprotein. To determine whether this functional domain has a structural counterpart, we have fragmented the v-Ski protein by limited proteolysis and found a single proteolytically stable domain spanning the entire exon 1-encoded region. Physical studies of the polypeptide encoded by exon 1 confirms that it folds into a compact, globular protein. The finding that both the transforming and myogenic properties of v-ski are inseparable by mutation and are contained in a single domain suggests that they are derived from the same function.	CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106; ORGANOGENESIS INC,CANTON,MA; CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195; UNIV CINCINNATI,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH	Case Western Reserve University; Cleveland Clinic Foundation; University System of Ohio; University of Cincinnati					NCI NIH HHS [CA43600] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; BOTFIELD MC, 1992, BIOCHEMISTRY-US, V31, P5841, DOI 10.1021/bi00140a020; BOYER PL, 1993, ONCOGENE, V8, P457; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P552; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; COLMENARES C, 1990, CANC BIOL, V1, P383; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; FOSTER DA, 1983, J VIROL, V48, P744, DOI 10.1128/JVI.48.3.744-751.1983; GRIMES HL, 1992, NUCLEIC ACIDS RES, V20, P1511, DOI 10.1093/nar/20.7.1511; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Institutionen B Universitet Uppsala S, 1963, PURE APPL CHEM, V233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; NAGASE T, 1993, J BIOL CHEM, V268, P13710; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P40446	29	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					459	471		10.1038/sj.onc.1201205	http://dx.doi.org/10.1038/sj.onc.1201205			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242383				2022-12-25	WOS:A1997XM23800011
J	Pim, D; Massimi, P; Banks, L				Pim, D; Massimi, P; Banks, L			Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth	ONCOGENE			English	Article						HPV; E6; p53; transformation	HUMAN PAPILLOMAVIRUS TYPE-16; FULL-LENGTH E6; MESSENGER-RNA; HUMAN KERATINOCYTES; EARLY GENES; E7; EXPRESSION; DNA; IDENTIFICATION; TRANSCRIPTION	The E6 proteins originating from the tumour-associated Human Papillomavirus (HPV) types 16 and 18 have been shown to bind to and target the tumour suppressor protein, p53, for ubiquitin-mediated degradation. However, in cell lines derived from cervical neoplasias, the predominant early region transcripts are spliced and encode truncated forms of E6, termed E6*. We report here that HPV-18 E6* protein will interact both with the full-length E6 proteins from HPV-16 and HPV-18 and also with E6-AP, and subsequently blocks the association of full length E6 protein with p53. We also show that, as a result of this block, E6* can inhibit E6-mediated degradation of p53 both in vitro and in vivo. The biological consequences of this are increased transcriptional activity on p53-responsive promoters and an inhibition of cell growth in cells transfected with E6*. This is the first report of a potential biological function for this polypeptide and may represent a means by which HPV is able to modulate the activity of the full-length E6 protein with respect to p53 during viral infection.			Pim, D (corresponding author), INT CTR GENET ENGN & BIOTECHNOL,PADRICIANO 99,I-34012 TRIESTE,ITALY.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BOHM S, 1993, INT J CANCER, V55, P791, DOI 10.1002/ijc.2910550517; BUTZ K, 1995, ONCOGENE, V10, P927; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CHOW LT, 1987, J VIROL, V61, P2581, DOI 10.1128/JVI.61.8.2581-2588.1987; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Massimi P, 1996, ONCOGENE, V12, P2325; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MUNGER K, 1989, J VIROL, V63, P4417; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIM D, 1994, ONCOGENE, V9, P1869; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Shally M, 1996, VIRUS RES, V42, P81, DOI 10.1016/0168-1702(96)01301-9; SHIRASAWA H, 1994, VIROLOGY, V203, P36, DOI 10.1006/viro.1994.1452; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STACEY SN, 1995, J VIROL, V69, P7023, DOI 10.1128/JVI.69.11.7023-7031.1995; STOREY A, 1995, J GEN VIROL, V76, P819, DOI 10.1099/0022-1317-76-4-819; THOMAS M, 1995, ONCOGENE, V10, P261; Thomas M, 1996, ONCOGENE, V13, P265; Thomas M, 1996, ONCOGENE, V13, P471; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZURHAUSEN H, 1987, PAPOVAVIRIDAE PAPILL, P245	44	96	101	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					257	264		10.1038/sj.onc.1201202	http://dx.doi.org/10.1038/sj.onc.1201202			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233760				2022-12-25	WOS:A1997XK99900002
J	Yokouchi, M; Suzuki, R; Masuhara, M; Komiya, S; Inoue, A; Yoshimura, A				Yokouchi, M; Suzuki, R; Masuhara, M; Komiya, S; Inoue, A; Yoshimura, A			Cloning and characterization of APS, an adaptor molecule containing PH and SH2 domains that is tyrosine phosphorylated upon B-cell receptor stimulation	ONCOGENE			English	Article						B lymphocytes; signal transduction; protein tyrosine kinase; SH2 domain; PH domain	T-CELL; ANTIGEN RECEPTOR; EXPRESSION CLONING; LYMPHOCYTES-B; ZETA-CHAIN; PROTEIN; KINASE; ACTIVATION; FAMILY; SIGNAL	Stimulation of B lymphocytes through their antigen receptor (BCR) results in rapid increases in tyrosine phosphorylation of a number of proteins, which leads to a cascade of biochemical changes that initiates B cell proliferation and differentiation or growth inhibition, A novel cDNA, designed APS, encoding an adaptor protein with a Pleckstrin homology (PH) domain, Src homology 2 (SH2) domain, and a tyrosine phosphorylation site was cloned from a B cell cDNA library using a yeast two hybrid system, APS is structurally similar to SH2-B, an SH2 protein that potentially binds to the immunoreceptor tyrosine-based activation motif (ITAM) as well as Lnk which is postulated to be a signal transducer that Links T-cell receptor to phospholipase C gamma, Grb2 and phosphatidylinositol 3-kinase, APS expressed only in human Burkitt's lymphoma cells among cell Lines me examined and tyrosine phosphorylated in response to BCR stimulation, APS bound to Shc irrespective of stimulation and bound to Grb2 after stimulation, suggesting that it plays a role in Linkage from BCR to Shc/Grb2 pathway, These results indicate that APS, SH2-B and Lnk form a new adaptor family that links immune receptors to signaling pathways involved in tyrosine-phosphorylation.	KURUME UNIV, FAC MED, INST LIFE SCI, KURUME, FUKUOKA 839, JAPAN; KURUME UNIV, FAC MED, DEPT ORTHOPAED SURG, KURUME, FUKUOKA 839, JAPAN	Kurume University; Kurume University			Yoshimura, Akihiko/K-5515-2013					BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; HARPER JW, 1993, CELL, V75, P805; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; OOI J, 1995, ONCOGENE, V10, P1621; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Weiner M. P., 1994, STRATEGIES, V7, P41; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	43	108	114	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					7	15		10.1038/sj.onc.1201163	http://dx.doi.org/10.1038/sj.onc.1201163			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233773				2022-12-25	WOS:A1997XH58600002
J	Oorni, K; Pentikainen, MO; Annila, A; Kovanen, PT				Oorni, K; Pentikainen, MO; Annila, A; Kovanen, PT			Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans - Dependence on oxidative modification of the lysine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B; PLASMA-LIPOPROTEINS; SCAVENGER RECEPTOR; ATHEROSCLEROTIC LESIONS; CHOLESTEROL DEPOSITION; LIPID-PEROXIDATION; MACROPHAGES; LDL; GLYCOSAMINOGLYCANS; DEGRADATION	Oxidation of low density lipoprotein (LDL) leads to its rapid uptake by macrophages in vitro, but no detailed studies have addressed the effect of oxidation on the binding of LDL to proteoglycans, We therefore treated LDL with various substances: copper sulfate, 2,2'-azo-bis(2-amidinopropane)hydrochloride (AAPH), soybean lipoxygenase, and mouse peritoneal macrophages, and determined the extent to which the oxidatively modified LDL bound to human aortic proteoglycans in an affinity column, Oxidation of LDL with copper, AAPH, or macrophages, all of which increased its electrophoretic mobility, was associated with reduced binding to proteoglycans, until strongly oxidized LDL was totally unable to bind to them, After treatment of LDL with soybean lipoxygenase, the change in electrophoretic mobility was small, and the amount of binding to proteoglycans was only slightly decreased, The increased electrophoretic mobility of oxidized LDL reflects modification of the lysine residues of apolipoprotein B-100 (apoB-100). To mimic the oxidative modification of lysines, we treated LDL with malondialdehyde, This treatment also totally prevented the binding of LDL to proteoglycans. in contrast, if the lysine residues of apoB-100 were methylated to shield them against oxidative modification, subsequent treatment of LDL with copper sulfate failed to reduce the degree of LDL binding to proteoglycans. Finally, the active lysine residues in the oxidized LDL particles, which are thought to be involved in this binding, were quantified with NMR spectroscopy, In oxidized LDL, the number of these residues was found to be decreased, The present results show that, after modification of the lysine residues of apoB-100 during oxidation, the binding of LDL to proteoglycans is decreased, and suggest that oxidation of LDL tends to lead to intracellular rather than extracellular accumulation of LDL during atherogenesis.	WIHURI RES INST, FIN-00140 HELSINKI, FINLAND; STATE TECH RES CTR FINLAND, FIN-02044 ESPOO, FINLAND	Wihuri Research Institute			Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250				AVIRAM M, 1988, J BIOL CHEM, V263, P16842; BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CAMEJO G, 1991, J LIPID RES, V32, P1983; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHANG GJ, 1994, ARTERIOSCLER THROMB, V14, P1808, DOI 10.1161/01.ATV.14.11.1808; ELSAADANI M, 1989, J LIPID RES, V30, P627; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FRANK JS, 1989, J LIPID RES, V30, P967; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HABERLAND ME, 1984, J BIOL CHEM, V259, P1305; HABERLAND ME, 1982, P NATL ACAD SCI-BIOL, V79, P1712, DOI 10.1073/pnas.79.6.1712; HABERLAND ME, 1992, MONOGR HUM GENET, V14, P35; HAVEL RJ, 1955, J CLIN INVEST, V77, P757; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; Lougheed M, 1996, J BIOL CHEM, V271, P11798, DOI 10.1074/jbc.271.20.11798; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1991, J BIOL CHEM, V266, P2701; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; MACEK J, 1987, J CHROMATOGR-BIOMED, V414, P156, DOI 10.1016/0378-4347(87)80034-8; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; PAANANEN K, 1995, J BIOL CHEM, V270, P12257, DOI 10.1074/jbc.270.20.12257; PENTIKAINEN MO, 1995, ARTERIOSCL THROM VAS, V15, P740, DOI 10.1161/01.ATV.15.6.740; PIHA M, 1995, BIOCHEMISTRY-US, V34, P10120, DOI 10.1021/bi00032a004; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SPARROW CP, 1988, J LIPID RES, V29, P745; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHANG HF, 1993, J BIOL CHEM, V268, P5535	43	77	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21303	21311		10.1074/jbc.272.34.21303	http://dx.doi.org/10.1074/jbc.272.34.21303			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261142	hybrid			2022-12-25	WOS:A1997XR78900052
J	Blaikie, PA; Fournier, E; Dilworth, SM; Birnbaum, D; Borg, JP; Margolis, B				Blaikie, PA; Fournier, E; Dilworth, SM; Birnbaum, D; Borg, JP; Margolis, B			The role of the Shc phosphotyrosine interaction phosphotyrosine binding domain and tyrosine phosphorylation sites in polyoma middle T antigen-mediated cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; RETROVIRAL VECTORS; GENE-TRANSFER; EGF RECEPTOR; PROTEINS; KINASE; MOTIF; ASSOCIATION; ACTIVATION	The phosphotyrosine Interaction (PI)/phosphotyrosine binding (PTB) domain of She binds specific tyrosine-phosphorylated motifs found on activated growth factor receptors and proteins such as polyoma virus middle T antigen (MT), Phenylalanine 198 (Phe(198)) has been identified as a crucial residue involved in the interaction of the She PI/PTB with phosphopeptides. In MH3T3 cells expressing MT, p52 She carrying the F198V mutation is weakly phosphorylated and does not bind MT or Grb2. Overexpression of the PI/PTB domain alone as She amino acids 1-238 acted in a dominant interfering fashion blocking MT-induced transformation, However, expression of a slightly longer construct, She 1-260, which encompasses Tyr(239)/Tyr(240), a novel She tyrosine phosphorylation site, did not block transformation, This was found to be due to the ability of She 1-260 to become tyrosine-phosphorylated and bind Grb2. Furthermore, full-length She in which Tyr(239)/Tyr(240) had been mutated to phenylalanine did not become tyrosine-phosphorylated or bind Grb2 but did inhibit colony formation in soft agar, Conversely, p52 She carrying a mutation in the other tyrosine phosphorylation site, Tyr(317), became heavily tyrosine-phosphorylated, bound Grb2, and gave rise to colonies in soft agar.	UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED & BIOL CHEM, ANN ARBOR, MI 48109 USA; NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; ROYAL POSTGRAD MED SCH, DEPT METAB MED, LONDON W12 0NN, ENGLAND; INSERM, U1119, ONCOL MOL LAB, F-13009 MARSEILLE, FRANCE	University of Michigan System; University of Michigan; New York University; Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm)	Blaikie, PA (corresponding author), UNIV MICHIGAN, MED CTR,SCH MED,HOWARD HUGHES MED INST, MSRBII RM 4570, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA.		Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382				ADAM MA, 1991, J VIROL, V65, P4985, DOI 10.1128/JVI.65.9.4985-4990.1991; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; COURTNEIDGE SA, 1986, CANCER SURV, V5, P173; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fournier E, 1996, J BIOL CHEM, V271, P12956, DOI 10.1074/jbc.271.22.12956; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; GRIFFIN BE, 1983, ADV CANCER RES, V39, P183, DOI 10.1016/S0065-230X(08)61036-2; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; Ishihara H, 1997, J BIOL CHEM, V272, P9581; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	52	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20671	20677		10.1074/jbc.272.33.20671	http://dx.doi.org/10.1074/jbc.272.33.20671			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252386	hybrid			2022-12-25	WOS:A1997XR22100056
J	Jitrapakdee, S; Booker, GW; Cassady, AI; Wallace, JC				Jitrapakdee, S; Booker, GW; Cassady, AI; Wallace, JC			The rat pyruvate carboxylase gene structure - Alternate promoters generate multiple transcripts with the 5'-end heterogeneity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESPONSIVE ELEMENT; FACTOR-BINDING PROTEIN-1; ACETYL-COA CARBOXYLASE; AMINO-ACID-SEQUENCE; DOMAIN-STRUCTURE; BIOTIN ENZYMES; MESSENGER-RNAS; DNA-SEQUENCES; CDNA; IDENTIFICATION	Pyruvate carboxylase (EC 6.4.1.1) is a biotin-containing enzyme that plays an important role in gluconeogenesis and lipogenesis. Here we report the structural organization of the rat pyruvate carboxylase gene, which spans over 40 kilobases and is composed of 19 coding exons and 4 5'-untranslated region exons, From this data, it is clear that alternative splicing of the primary transcripts from two promoters is responsible for the occurrence of the multiple mRNA species previously reported (Jitrapakdee, S,, Walker, M. E., and Wallace, J. C. (1996) Biochem, Biophys. Res. Commun. 223, 695-700). The proximal promoter, which is active in gluconeogenic and lipogenic tissues, contains no TATA or CAAT boxes but includes a sequence that is typical of a housekeeping initiator protein 1 box while the distal promoter contains three CAAT boxes and multiple Spl binding sites. Several potential transcription factor binding sites are found in both promoters. A series of 5'-nested deletion constructs of both promoters were fused to a firefly luciferase reporter plasmid and transiently expressed in COS-l cells. The results show that the 153 and 187 base pairs, preceding the transcription start sites of the proximal and distal promoters, respectively, are required for basal transcription, Insulin selectively inhibits the expression of the proximal promoter-luciferase reporter gene by 50% but not the distal promoter in COS-1 cells, suggesting the presence of an insulin-responsive element in the proximal promoter. A half-maximal effect was found at similar to 1 nM insulin.	UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5005,AUSTRALIA; UNIV QUEENSLAND,CTR MOL & CELLULAR BIOL,BRISBANE,QLD 4072,AUSTRALIA	University of Adelaide; University of Queensland			, John/AAP-5150-2020; Cassady, Alan/AAY-2962-2021	Cassady, Alan/0000-0001-8585-5427				ATTWOOD PV, 1995, INT J BIOCHEM CELL B, V27, P231, DOI 10.1016/1357-2725(94)00087-R; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P5694; Barritt GJ, 1985, PYRUVATE CARBOXYLASE, P147; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREWSTER NK, 1994, ARCH BIOCHEM BIOPHYS, V284, P98; CHEN QK, 1995, COMPUT APPL BIOSCI, V11, P563; Dunn MF, 1996, J BACTERIOL, V178, P5960, DOI 10.1128/jb.178.20.5960-5970.1996; ElKhadirMounier C, 1996, BIOCHEM J, V314, P613; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FREYTAG SO, 1984, J BIOL CHEM, V259, P2831; *GEN COMP GROUP, 1995, PROGR MAN WISC PACK; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hsu MH, 1996, J BIOL CHEM, V271, P13584, DOI 10.1074/jbc.271.23.13584; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; Jitrapakdee S, 1996, BIOCHEM J, V316, P631, DOI 10.1042/bj3160631; JITRAPAKDEE S, 1996, BIOCHEM BIOPH RES CO, V223, P965; LEHN DA, 1995, GENE, V165, P331, DOI 10.1016/0378-1119(95)00557-M; LI N, 1995, BIOCHEM BIOPH RES CO, V208, P756, DOI 10.1006/bbrc.1995.1402; LI SJ, 1992, J BIOL CHEM, V267, P855; LIM F, 1988, J BIOL CHEM, V263, P11493; LOPEZCASILLAS F, 1991, EUR J BIOCHEM, V201, P119, DOI 10.1111/j.1432-1033.1991.tb16264.x; LOPEZCASILLAS F, 1991, ENDOCRINOLOGY, V129, P1049, DOI 10.1210/endo-129-2-1049; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; MACKAY N, 1994, BIOCHEM BIOPH RES CO, V202, P1009, DOI 10.1006/bbrc.1994.2029; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; OBERMAYER M, 1976, TRENDS BIOCHEM SCI, V1, P169, DOI 10.1016/0968-0004(76)90198-5; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PHILLIPS M, 1986, J BIOL CHEM, V261, P821; POWELL DR, 1991, J BIOL CHEM, V266, P18868; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; ROCHELLE JM, 1992, GENOMICS, V14, P26, DOI 10.1016/S0888-7543(05)80278-2; Sambrook J., 2002, MOL CLONING LAB MANU; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SHIMURA Y, 1994, J BIOL CHEM, V269, P31908; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STUCKA R, 1991, MOL GEN GENET, V229, P307, DOI 10.1007/BF00272171; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; THORNTON CG, 1993, FEBS LETT, V330, P191, DOI 10.1016/0014-5793(93)80271-U; Tu ZJ, 1997, INSECT BIOCHEM MOLEC, V27, P133, DOI 10.1016/S0965-1748(96)00078-1; Val DL, 1995, BIOCHEM J, V312, P817, DOI 10.1042/bj3120817; WALKER ME, 1995, CYTOGENET CELL GENET, V69, P187, DOI 10.1159/000133958; Wallace J.C., 1985, P65; WALLACE JC, 1997, IN PRESS INT J BIOCH; WEINBERG MB, 1980, BIOCHEM J, V188, P601, DOI 10.1042/bj1880601; WEXLER ID, 1994, BBA-MOL BASIS DIS, V1227, P46, DOI 10.1016/0925-4439(94)90105-8; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P1766, DOI 10.1073/pnas.90.5.1766; ZHANG J, 1995, BIOCHEM J, V306, P205, DOI 10.1042/bj3060205	50	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20522	20530		10.1074/jbc.272.33.20522	http://dx.doi.org/10.1074/jbc.272.33.20522			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252365	hybrid			2022-12-25	WOS:A1997XR22100035
J	Stathakis, P; Fitzgerald, M; Matthias, LJ; Chesterman, CN; Hogg, PJ				Stathakis, P; Fitzgerald, M; Matthias, LJ; Chesterman, CN; Hogg, PJ			Generation of angiostatin by reduction and proteolysis of plasmin - Catalysis by a plasmin reductase secreted by cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; THIOREDOXIN; SURFACE; INHIBITION; RECEPTOR; MEMBRANE; GLUTATHIONE; BRIDGES; BIOLOGY; EXPORT	Extracellular manipulation of protein disulfide bonds has been implied in diverse biological processes, including penetration of viruses and endotoxin into cells and activation of certain cytokine receptors, We now demonstrate reduction of one or more disulfide bonds in the serine proteinase, plasmin, by a reductase secreted by Chinese hamster ovary or HT1080 cells, Reduction of plasmin disulfide bond(s) triggered proteolysis of the enzyme, generating fragments with the domain structure of the angiogenesis inhibitor, angiostatin. Two of the known reductases secreted by cultured cells are protein disulfide isomerase and thioredoxin, and incubation of plasmin with these purified reductases resulted in angiostatin fragments comparable with those generated from plasmin in cell culture. Thioredoxin-derived angiostatin inhibited proliferation of human dermal microvascular endothelial cells with half-maximal effect at approximately 0.2 mu g/ml, Angiostatin made by cells and by purified reductases contained free sulfhydryl group(s), and S-carbamidomethylation of these thiol group(s) ablated biological activity, Neither protein disulfide isomerase nor thioredoxin were the reductases used by cultured cells, because immunodepletion of conditioned medium of these proteins did not affect angiostatin generating activity, The plasmin reductase secreted by HT1080 cells required a small cofactor for activity, and physiologically relevant concentrations of reduced glutathione fulfilled this role, These results have consequences for plasmin activity and angiogenesis, particularly in the context of tumor growth and metastasis, Moreover, this is the first demonstration of extracellular reduction of a protein disulfide bond, which has general implications for cell biology.	UNIV NEW S WALES,SCH PATHOL,CTR THROMBOSIS & VASC RES,SYDNEY,NSW 2052,AUSTRALIA; UNIV NEW S WALES,PRINCE WALES HOSP,DEPT HAEMATOL,SYDNEY,NSW 2052,AUSTRALIA	University of New South Wales Sydney; University of New South Wales Sydney			Fitzgerald, Melinda/C-4235-2011	Fitzgerald, Melinda/0000-0002-4823-8179; Hogg, Philip/0000-0001-6486-2863				ABELL BA, 1993, J VIROL, V67, P5496, DOI 10.1128/JVI.67.9.5496-5501.1993; BANNAI S, 1979, J BIOL CHEM, V254, P3444; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CASTELLINO FJ, 1990, LIPOPROTEIN A, P87; DEAN MF, 1994, BIOCHEM J, V304, P861, DOI 10.1042/bj3040861; DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gately S, 1996, CANCER RES, V56, P4887; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Hotchkiss KA, 1996, BIOCHEMISTRY-US, V35, P9761, DOI 10.1021/bi9603938; JACKSON CJ, 1990, J CELL SCI, V96, P257; KRONING H, 1994, SCAND J IMMUNOL, V39, P346, DOI 10.1111/j.1365-3083.1994.tb03384.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112; MARTIN H, 1991, BIOCHEM BIOPH RES CO, V175, P123, DOI 10.1016/S0006-291X(05)81209-4; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; RAO ASMK, 1993, P NATL ACAD SCI USA, V90, P2950, DOI 10.1073/pnas.90.7.2950; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; RYSER HJP, 1994, P NATL ACAD SCI USA, V91, P4559, DOI 10.1073/pnas.91.10.4559; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; STACH RW, 1985, INT J NEUROSCI, V26, P87, DOI 10.3109/00207458508985608; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	33	138	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20641	20645		10.1074/jbc.272.33.20641	http://dx.doi.org/10.1074/jbc.272.33.20641			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252380	hybrid			2022-12-25	WOS:A1997XR22100050
J	Trost, JT; Chisholm, DA; Jordan, DB; Diner, BA				Trost, JT; Chisholm, DA; Jordan, DB; Diner, BA			The D1 C-terminal processing protease of photosystem II from Scenedesmus obliquus - Protein purification and gene characterization in wild type and processing mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST MEMBRANE POLYPEPTIDE; OXYGEN-EVOLVING COMPLEX; AMINO-ACID-RESIDUES; MANGANESE CLUSTER; PRECURSOR PROTEIN; OXIDIZING SIDE; BINDING; SPINACH; PHOTOACTIVATION; IDENTIFICATION	Polypeptide D1 of the photosystem II reaction center of oxygenic photosynthesis is expressed in precursor form (pre-D1), and it must be proteolytically processed at its C terminus to enable assembly of the manganese cluster responsible for photosynthetic water oxidation. A rapid and highly sensitive enzyme-linked immunosorbent assay-based microtiter plate method is described for assaying this D1 C-terminal processing protease. A protocol is described for the isolation and purification to homogeneity of the enzyme from the green alga, Scenedesmus obliquus. Amino acid sequence information on the purified protease was used to clone the corresponding gene, the translated sequence of which is presented. A comparison of the gene product with homologous proteases points to a region of conserved residues that likely corresponds to the active site of a new class of serine protease, The LF-1 mutant strain of Scenedesmus (isolated by Dr, Norman Bishop) is incapable of processing pre-D1. We show here that the C-terminal processing protease gene in this strain contains a single base deletion that causes a frame shift and a premature stop of translation within the likely active site of the enzyme. A suppressor strain, LF-1-RVT-1, which is photoautotrophic and capable of processing pre-D1 has a nearby single base insertion that restores the expression of active enzyme. These observations provide the first definitive proof that the enzyme isolated is responsible for in vivo proteolytic processing of pre-D1 and that no other protease can compensate for its loss.	DUPONT CO INC,DEPT CENT RES & DEV,EXPT STN,WILMINGTON,DE 19880; DUPONT CO INC,STINE HASKELL RES CTR,DEPT AGR PROD,NEWARK,DE 19714	DuPont; DuPont								ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; BEST S, 1994, TECHNIQUES PROTEIN C, V5, P565; BISHOP NI, 1983, OXYGEN EVOLVING SYST, P177; BISHOP NI, 1971, METHODS ENZYMOLOGY A, V23, P372; BOWYER JR, 1992, J BIOL CHEM, V267, P5424; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5859, DOI 10.1021/bi00017a017; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5839, DOI 10.1021/bi00017a016; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DINER BA, 1988, J BIOL CHEM, V263, P8972; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FUJITA S, 1995, PLANT CELL PHYSIOL, V36, P1169; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GREBANIER AE, 1978, J CELL BIOL, V78, P734, DOI 10.1083/jcb.78.3.734; HARA H, 1991, J BACTERIOL, V173, P4799, DOI 10.1128/jb.173.15.4799-4813.1991; Inagaki N, 1996, PLANT MOL BIOL, V30, P39, DOI 10.1007/BF00017801; INAGAKI N, 1990, CURRENT RES PHOTOSYN, V3, P763; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1992, J BIOL CHEM, V267, P17494; MARDER JB, 1984, J BIOL CHEM, V259, P3900; METZ J, 1980, BIOCHEM BIOPH RES CO, V94, P560, DOI 10.1016/0006-291X(80)91268-1; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; METZ JG, 1986, FEBS LETT, V205, P269, DOI 10.1016/0014-5793(86)80911-5; MINAMI E, 1985, PLANT CELL PHYSIOL, V26, P839; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; Oelmuller R, 1996, J BIOL CHEM, V271, P21848, DOI 10.1074/jbc.271.36.21848; REISFELD A, 1982, EUR J BIOCHEM, V124, P125, DOI 10.1111/j.1432-1033.1982.tb05914.x; SATOH K, 1993, PHOTOSYNTHETIC REACT, V1, P289; SAYRE RT, 1986, CELL, V47, P601, DOI 10.1016/0092-8674(86)90624-0; SCHRADER S, 1992, PLANT MOL BIOL, V19, P251, DOI 10.1007/BF00027346; Seibert M, 1993, PHOTOSYNTHETIC REACT, VI, P319, DOI DOI 10.1016/B978-0-12-208661-8.50016-4; SHACKLETON JB, 1991, J BIOL CHEM, V266, P12152; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; TAGUCHI F, 1993, FEBS LETT, V326, P227, DOI 10.1016/0014-5793(93)81796-3; TAKAHASHI M, 1988, FEBS LETT, V240, P6, DOI 10.1016/0014-5793(88)80330-2; Takahashi Y, 1996, PLANT CELL PHYSIOL, V37, P161, DOI 10.1093/oxfordjournals.pcp.a028927; TAKAHASHI Y, 1990, PLANT CELL PHYSIOL, V31, P273; TAYLOR MA, 1988, FEBS LETT, V237, P229, DOI 10.1016/0014-5793(88)80207-2; TAYLOR MA, 1988, FEBS LETT, V235, P109, DOI 10.1016/0014-5793(88)81243-2; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535	43	48	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20348	20356		10.1074/jbc.272.33.20348	http://dx.doi.org/10.1074/jbc.272.33.20348			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252339	hybrid			2022-12-25	WOS:A1997XR22100009
J	Kuroki, R; Ito, Y; Kato, Y; Imoto, T				Kuroki, R; Ito, Y; Kato, Y; Imoto, T			A covalent enzyme-substrate adduct in a mutant hen egg white lysozyme (D52E)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 LYSOZYME; GOOSE LYSOZYME; MECHANISMS; MUTAGENESIS; DISTORTION; COMPLEXES; RESIDUES; MUTATION	A mutant hen egg white lysozyme, D52E, was designed to correspond to the structure of the mutant T4 lysozyme T26E (Kuroki, R., Weaver, L. H., and Matthews B. W. (1993) Science 262, 2030-2033) to investigate the role of the catalytic residue on the ct-side of the saccharide in these enzymes, The D52E mutant forms a covalent enzyme-substrate adduct, which was detected by electron ion spray mass spectrometry. X-ray crystallographic analysis showed that the covalent adduct was formed between Glu-52 and the C-1 carbon of the N-acetylglucosamine residue in subsite D of the saccharide binding site, It suggests that the catalytic mechanism of D52E mutant lysozyme proceeds through a covalent enzyme-substrate intermediate indicating a different catalytic mechanism from the wild type hen egg white lysozyme, It was confirmed that the substitution of Asp-52 with Glu is structurally and functionally equivalent to the substitution of Thr-26 with Glu in T4 lysozyme, Although the position of the catalytic residue on the beta-side of the saccharide is quite conserved among hen egg white lysozyme, goose egg white lysozyme, and T4 phage lysozyme, the adaptability of the side chain on the alpha-side of the saccharide is considered to be responsible for the functional variation in their glycosidase and transglycosidase activities.	KYUSHU UNIV, GRAD SCH PHARMACEUT SCI, FUKUOKA 81282, JAPAN	Kyushu University	Kuroki, R (corresponding author), KIRIN BREWERY CO LTD, CENT LABS KEY TECHNOL, KANAZAWA KU, 1-13-5 FUKUURA, YOKOHAMA, KANAGAWA 236, JAPAN.							ANAND NN, 1988, BIOCHEM BIOPH RES CO, V153, P862, DOI 10.1016/S0006-291X(88)81175-6; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; CHEETHAM JC, 1992, J MOL BIOL, V224, P613, DOI 10.1016/0022-2836(92)90548-X; DAHLQUIS.FW, 1969, BIOCHEMISTRY-US, V8, P694, DOI 10.1021/bi00830a035; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; GRUTTER MG, 1983, NATURE, V303, P828, DOI 10.1038/303828a0; HADFIELD AT, 1994, J MOL BIOL, V243, P856, DOI 10.1006/jmbi.1994.1688; HARDY LW, 1991, BIOCHEMISTRY-US, V30, P9457, DOI 10.1021/bi00103a010; Hashimoto Y, 1996, J BIOCHEM-TOKYO, V119, P145; Imoto T., 1972, ENZYMES, V7, P665; INOUE M, 1992, BIOCHEMISTRY-US, V31, P5545, DOI 10.1021/bi00139a017; JOHNSON LN, 1966, THESIS U LONDON; KUROKI R, 1995, NAT STRUCT BIOL, V2, P1007, DOI 10.1038/nsb1195-1007; KUROKI R, 1993, SCIENCE, V262, P2030, DOI 10.1126/science.8266098; KUROKI R, 1986, J BIOL CHEM, V261, P3571; LUMB KJ, 1992, FEBS LETT, V296, P153, DOI 10.1016/0014-5793(92)80368-Q; MAENAKA K, 1995, J MOL BIOL, V247, P281, DOI 10.1006/jmbi.1994.0139; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; Matsumura I, 1996, BIOCHEMISTRY-US, V35, P1881, DOI 10.1021/bi951671q; MATTHEWS BW, 1974, P NATL ACAD SCI USA, V71, P4178, DOI 10.1073/pnas.71.10.4178; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MURAKI M, 1991, BIOCHIM BIOPHYS ACTA, V1079, P229, DOI 10.1016/0167-4838(91)90130-R; PHILLIPS DC, 1966, SCI AM, V215, P78, DOI 10.1038/scientificamerican1166-78; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; Sinnott M. L., 1987, ENZYME MECHANISMS, P259; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; WEAVER LH, 1995, J MOL BIOL, V245, P54, DOI 10.1016/S0022-2836(95)80038-7; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; WILSON KP, 1992, J BIOL CHEM, V267, P10842	33	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19976	19981		10.1074/jbc.272.32.19976	http://dx.doi.org/10.1074/jbc.272.32.19976			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242666	hybrid			2022-12-25	WOS:A1997XQ05900053
J	Nair, P; Muthukkumar, S; Sells, SF; Han, SS; Sukhatme, VP; Rangnekar, VM				Nair, P; Muthukkumar, S; Sells, SF; Han, SS; Sukhatme, VP; Rangnekar, VM			Early growth response-1-dependent apoptosis is mediated by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; PROGRAMMED CELL-DEATH; TRANSCRIPTION FACTOR EGR-1; TUMOR GENE-PRODUCT; NGFI-A; INDUCE APOPTOSIS; BINDING-SITE; DNA-DAMAGE; EXPRESSION; PROTEIN	The early growth response-1 (EGR-1) protein is an anti-proliferative signal for certain tumor cells and is required for apoptosis induced by stimuli that elevate intracellular Ca2+. We present evidence that EGR-1 transactivates the promoter of the p53 gene and upregulates p53 RNA and protein levels. Inhibition of p53 function with dominant-negative p53 mutants abrogates EGR-1-dependent apoptosis. These findings establish a direct functional link between EGR-1 and the p53-mediated cell death pathway and suggest that mutant forms of p53 in tumor cells may provide resistance to the anti-proliferative effects of EGR-1.	UNIV KENTUCKY,DEPT SURG,DIV UROL,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; UNIV KENTUCKY,GRAD CTR TOXICOL,LEXINGTON,KY 40536; UNIV KENTUCKY,MARKEY CANC CTR,LEXINGTON,KY 40536; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215; BETH ISRAEL DEACONESS MED CTR,DIV RENAL,BOSTON,MA 02215	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center			Sukhatme, Vikas/W-2776-2019	Han, Seong-Su/0000-0001-9824-6751	NATIONAL CANCER INSTITUTE [R29CA052837, R01CA060872] Funding Source: NIH RePORTER; NCI NIH HHS [CA60872, CA52837] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CONNOR J, 1988, PROSTATE, V13, P119, DOI 10.1002/pros.2990130204; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; FURUYA Y, 1994, CANCER RES, V54, P6167; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HEMEKING H, 1994, SCIENCE, V265, P2091; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANG RP, 1994, ONCOGENE, V9, P1367; HUANG RP, 1995, CANCER RES, V55, P5054; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIYASHITA T, 1995, CELL, V80, P293; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Preston GA, 1996, MOL CELL BIOL, V16, P211; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1995, MOL CELL BIOL, V15, P682; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; SHRIVASTAVA S, 1990, NATURE, V348, P747; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHAN QM, 1994, ONCOGENE, V9, P3743	82	168	175	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20131	20138		10.1074/jbc.272.32.20131	http://dx.doi.org/10.1074/jbc.272.32.20131			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242687	hybrid			2022-12-25	WOS:A1997XQ05900074
J	Ray, P; Yang, LY; Zhang, DH; Ghosh, SK; Ray, A				Ray, P; Yang, LY; Zhang, DH; Ghosh, SK; Ray, A			Selective up-regulation of cytokine-induced RANTES gene expression in lung epithelial cells by overexpression of I kappa BR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; T-CELLS; SUBUNIT; FAMILY; CLONING; PROTEIN; P65; MIP-1-ALPHA; MIP-1-BETA; INHIBITION	We previously reported the cloning of a cDNA for I kappa BR (for I kappa B-related) from human lung alveolar epithelial cells, I kappa BR is related to the I kappa B proteins that function as regulators of the NF-kappa B family of transcription factors. Here, we investigated the consequence of I kappa BR overexpression on the expression of NF-kappa B-regulated chemokine genes in lung alveolar epithelial cells. Chemokines play an important role in many inflammatory diseases such as asthma and AIDS. Overexpression of I kappa BR in the lung cells resulted in a rapid 50-100-fold greater production of the RANTES (regulated upon activation, normal T expressed and presumably secreted) protein upon cytokine-induction compared with control cells, I kappa BR overexpression, however, did not enhance interleukin-8 or MIP-1 alpha gene expression, despite the fact that the expression of all three chemokine genes are regulated by NF-kappa B, The up-regulation of RANTES gene expression resulting from overexpression of I kappa BR correlated with increased amounts of a unique RANTES-kappa B binding activity and decreased binding of p50 homodimers, Previous studies have shown that p50 homodimers function as repressors of certain KB sites, Our studies suggest that I kappa BR can aid activation of select NF-kappa B-regulated genes by sequestering p50 homodimers.			Ray, P (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,PULM & CRIT CARE SECT,333 CEDAR ST,NEW HAVEN,CT 06520, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031137] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52014] Funding Source: Medline; NIAID NIH HHS [AI 31137] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; Berkman N, 1996, IMMUNOLOGY, V87, P599, DOI 10.1046/j.1365-2567.1996.477579.x; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KANG SM, 1992, SCIENCE, V256, P1451; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; KWON OJ, 1994, IMMUNOLOGY, V81, P389; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MATTOLI S, 1995, BIOCHEM BIOPH RES CO, V209, P316, DOI 10.1006/bbrc.1995.1505; NELSON PJ, 1993, J IMMUNOL, V151, P2601; Nelson PJ, 1996, J IMMUNOL, V157, P1139; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; RAY P, 1995, J BIOL CHEM, V270, P10680, DOI 10.1074/jbc.270.18.10680; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STELLATO C, 1995, J IMMUNOL, V155, P410; TAUB D, 1995, J IMMUNOL, V154, P2393; Teran LM, 1996, J IMMUNOL, V157, P1806; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VANOTTEREN GM, 1995, J IMMUNOL, V154, P1900; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang JH, 1996, AM J RESP CELL MOL, V14, P27, DOI 10.1165/ajrcmb.14.1.8534483; WIDMER U, 1993, J IMMUNOL, V150, P4996; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582	47	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20191	20197		10.1074/jbc.272.32.20191	http://dx.doi.org/10.1074/jbc.272.32.20191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242696	hybrid			2022-12-25	WOS:A1997XQ05900083
J	Kinoshita, T; Shirouzu, M; Kamiya, A; Hashimoto, K; Yokoyama, S; Miyajima, A				Kinoshita, T; Shirouzu, M; Kamiya, A; Hashimoto, K; Yokoyama, S; Miyajima, A			Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL3-dependent hematopoietic cells	ONCOGENE			English	Article						cell survival; anti-apoptosis; ras; rapamycin	COLONY-STIMULATING FACTOR; ACTIVATED PROTEIN-KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; COMMON BETA-SUBUNIT; P70 S6 KINASE; SIGNAL-TRANSDUCTION; RAS TRANSFORMATION; ONCOGENIC RAS; NEURITE OUTGROWTH; GROWTH-FACTOR	The Ras signal transduction pathway is activated by a number of hematopoietic cytokines and is implicated in the prevention of apoptotic death in hematopoietic cells, Recent studies have provided evidence that the downstream of Ras is highly divergent and several independent pathways appear to mediate distinct biological functions of Ras, In the present study, we investigated the downstream pathway(s) of Ras responsible for the maintenance of hematopoietic cell survival by using various mutants of signaling molecules, Activation of the Raf/MAPK pathway in interleukin (IL) 3-dependent cells by expression of an oncogenic Raf or a Ras mutant (G12V/T35S) prevented apoptosis following IL-3 deprivation, In contrast, another Ras mutant (G12V/V45E), which is apparently incapable of activating MAPK, efficiently blocked apoptosis as well, It is therefore likely that the activation of the Raf/MAPK pathway is not an absolute requirement for the prevention of apoptosis, and there appears to be a Raf/MAPK-independent pathway that contributes to hematopoietic cell survival, Since Ras(G12V/V45E) was able to cause the phosphorylation of p70/S6 kinase, we inhibited the S6 kinase pathway by rapamycin and by wortmannin, and found that the anti-apoptotic function of Ras(G12V/V45E), but not of Ras(G12V), was critically influenced by both inhibitors, These results indicate that the Raf/MAPK and a rapamycin/wortmannin-sensitive pathways mediate Ras function to prevent apoptotic death in hematopoietic cells.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,DEPT CELLULAR BIOSYNTH,BUNKYO KU,TOKYO 113,JAPAN; RIKEN,INST PHYS & CHEM RES,CELLULAR SIGNALING LAB,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOCHEM & BIOPHYS,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; RIKEN; University of Tokyo			Shirouzu, Mikako/A-6521-2016; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ANDERSON MW, 1992, ENVIRON HEALTH PERSP, V98, P13, DOI 10.2307/3431243; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN CY, 1995, ONCOGENE, V11, P1487; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Hara T, 1996, STEM CELLS, V14, P605, DOI 10.1002/stem.140605; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUTHUKKUMAR S, 1995, TRANSPLANTATION, V60, P264, DOI 10.1097/00007890-199508000-00010; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SCHWAB M, 1990, Critical Reviews in Oncogenesis, V2, P35; SHI YF, 1995, CANCER RES, V55, P1982; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SHIROUZU M, 1992, ONCOGENE, V7, P475; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHETTON AD, 1983, NATURE, V303, P629, DOI 10.1038/303629a0; WHETTON AD, 1984, EMBO J, V3, P409, DOI 10.1002/j.1460-2075.1984.tb01821.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	73	103	104	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					619	627		10.1038/sj.onc.1201234	http://dx.doi.org/10.1038/sj.onc.1201234			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264402				2022-12-25	WOS:A1997XP68300001
J	Klein, U; Ramirez, MT; Kobilka, BK; vonZastrow, M				Klein, U; Ramirez, MT; Kobilka, BK; vonZastrow, M			A novel interaction between adrenergic receptors and the alpha-subunit of eukaryotic initiation factor 2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN BETA-2-ADRENERGIC RECEPTOR; NUCLEOTIDE-EXCHANGE FACTOR; GLUTATHIONE-S-TRANSFERASE; SIGNAL-TRANSDUCTION; FUSION PROTEINS; DOWN-REGULATION; PURIFICATION; MUTATIONS; BINDING	The alpha-subunit of eukaryotic initiation factor 2B (eIF-2B), a guanine nucleotide exchange protein that functions in regulation of translation, was observed to associate with the carboxyl-terminal cytoplasmic domains of the alpha(2A)- and alpha(2B)-adrenergic receptors in a yeast two-hybrid screen of a cDNA library prepared from 293 cells, This protein association was confirmed in vitro by affinity chromatography and was shown to be specific for a subset of G protein-coupled receptors, including the alpha(2A)-, alpha(2B)-, alpha(2C)-, and beta(2)-adrenergic receptors, but not the vasopressin (V-2) receptor. Association of these proteins in vivo was confirmed by specific co-immunoprecipitation of eIF-2B alpha with full-length beta(2)-adrenerse receptors expressed in transfected 293 cells and by fluorescence microscopy showing co-localization of these proteins in intact cells. Remarkably, eIF-2B alpha co-localized with receptors exclusively in regions of the plasma membrane that are in contact with the extracellular medium, but failed to associate with membranes making cell-cell contacts, Overexpression of eIF-2B alpha in 293 cells caused a small (similar to 15%) but significant enhancement of beta(2)-adrenergic receptor-mediated activation of adenylyl cyclase, without affecting forskolin or V-2 receptor-mediated activation, These observations suggest a new role for a previously identified guanine nucleotide exchange protein in membrane biology and cell signaling.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,NINA IRELAND LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,STANFORD,CA 94305	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NHLBI NIH HHS [HL07740-05] Funding Source: Medline; NIDA NIH HHS [DA00218] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007740] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRUSCINSKI AJ, 1992, BIOCHEM BIOPH RES CO, V186, P1280, DOI 10.1016/S0006-291X(05)81544-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLOWERS KM, 1995, P NATL ACAD SCI USA, V92, P4274, DOI 10.1073/pnas.92.10.4274; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FRASER CM, 1994, PROG NUCLEIC ACID RE, V49, P113; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN XM, 1992, J BIOL CHEM, V267, P21995; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; Kimball SR, 1996, PROG NUCLEIC ACID RE, V54, P165, DOI 10.1016/S0079-6603(08)60363-3; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Krueger KM, 1997, J BIOL CHEM, V272, P5; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LINK R, 1992, MOL PHARMACOL, V42, P16; MARKUSSEN FH, 1995, DEVELOPMENT, V121, P3723; PAN Y, 1994, J BIOL CHEM, V269, P31933; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; Price NT, 1996, BIOCHEM J, V318, P637, DOI 10.1042/bj3180637; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; Soehlemann Peter, 1995, European Journal of Biochemistry, V232, P464; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410	36	64	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19099	19102		10.1074/jbc.272.31.19099	http://dx.doi.org/10.1074/jbc.272.31.19099			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235896	hybrid			2022-12-25	WOS:A1997XP06300002
J	Saunders, C; Limbird, LE				Saunders, C; Limbird, LE			Disruption of microtubules reveals two independent apical targeting mechanisms for G-protein-coupled receptors in polarized renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; PLASMA-MEMBRANE PROTEINS; MDCK CELLS; BREFELDIN-A; GOLGI-COMPLEX; SELECTIVE-INHIBITION; MONENSIN; SURFACE; TRANSCYTOSIS; DELIVERY	G-protein-coupled receptors demonstrate differing trafficking itineraries in polarized Madin-Darby canine kidney (MDCK II) cells. The alpha(2A) adrenergic receptor (alpha(2A)AR) is directly delivered to the basolateral subdomain; the A(1) adenosine receptor (A(1)AdoR) is apically enriched in its targeting; and the alpha(2B)AR subtype is randomly delivered to both domains but selectively retained basolaterally (Keefer, J. R., and Limbird, L. E. (1993) J. Biol. Chem. 268, 11340-11347; Saunders, C., Keefer, J. R., Kennedy, A. P., Wells, J. N., and Limbird, L. E. (1996) J. Biol. Chem. 271, 995-1002; Wozniak, M., and Limbird, L. E. (1996) J. Biol. Chem. 271, 5017-5024). The present studies explore the role of the polarized cytoskeleton in localization of G-protein-coupled receptors in MDCK II cells, Nocodazole or colchicine, which disrupt microtubules, did not perturb lateral localization of alpha(2)AR subtypes but led to a relocalization the A(1)AdoR to the basolateral surface, revealed by immunocytochemical and metabolic labeling strategies. Conversely, the apical component of the random delivery of alpha(2B)AR was not affected by these agents, suggesting microtubule-dependent and -independent apical targeting mechanisms for G-protein-coupled receptors in polarized cells, Apparent rerouting of the apically targeted A(1)AdoR was selective for microtubule-disrupting agents, since cytochalasin D, which disrupts actin polymerization, did not alter A(1)AdoR or alpha(2B)AR localization or targeting, These data suggest that multiple apical targeting mechanisms exist for G-protein-coupled receptors and that microtubule-disrupting agents serve as tools to probe their different trafficking mechanisms.	VANDERBILT UNIV,MED CTR,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43879] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHELER C, 1989, J CELL BIOL, V109, P179; ALONSO FV, 1981, J CELL BIOL, V89, P700, DOI 10.1083/jcb.89.3.700; ARREAZA G, 1995, J BIOL CHEM, V270, P23641, DOI 10.1074/jbc.270.40.23641; AUNT DA, 1997, MOL PHARMACOL, V51, P711; BAAS PW, 1992, J CELL BIOL, V116, P1231, DOI 10.1083/jcb.116.5.1231; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; DALY JW, 1985, J MED CHEM, V28, P487, DOI 10.1021/jm00382a018; DANIELSEN EM, 1983, BIOCHEM J, V216, P37, DOI 10.1042/bj2160037; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; EILERS U, 1989, J CELL BIOL, V108, P13, DOI 10.1083/jcb.108.1.13; FISH EM, 1994, NEW ENGL J MED, V330, P1580; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; GILL GN, 1984, J BIOL CHEM, V259, P7755; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HASTINGS RH, 1994, AM J PHYSIOL, V266, pL544, DOI 10.1152/ajplung.1994.266.5.L544; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; HYAMS JS, 1994, MICROTUBULES, P33; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; LAFONT F, 1994, NATURE, V372, P801; LANIER SM, 1986, MOL PHARMACOL, V29, P219; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; LOW SH, 1991, J BIOL CHEM, V266, P17729; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1990, EMBO J, V9, P3163, DOI 10.1002/j.1460-2075.1990.tb07514.x; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Nelson W J, 1991, Semin Cell Biol, V2, P375; Nelson W J, 1990, Semin Cell Biol, V1, P359; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; Oksche A, 1996, MOL PHARMACOL, V50, P820; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; RINDLER MJ, 1987, J CELL BIOL, V104, P231, DOI 10.1083/jcb.104.2.231; ROSA P, 1992, J BIOL CHEM, V267, P12227; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; STEIN BS, 1984, J BIOL CHEM, V259, P4762; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; VAN MEER G, 1993, J CELL SCI, V104, P833; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; WAN JS, 1992, J BIOL CHEM, V267, P13446; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WILEMAN T, 1984, BIOCHEM J, V220, P665, DOI 10.1042/bj2200665; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wozniak M, 1996, J BIOL CHEM, V271, P5017	51	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19035	19045		10.1074/jbc.272.30.19035	http://dx.doi.org/10.1074/jbc.272.30.19035			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228087	hybrid			2022-12-25	WOS:A1997XM34200078
J	DeLuca, A; MacLachlan, TK; Bagella, L; Dean, C; Howard, CM; Claudio, PP; Baldi, A; Khalili, K; Giordano, A				DeLuca, A; MacLachlan, TK; Bagella, L; Dean, C; Howard, CM; Claudio, PP; Baldi, A; Khalili, K; Giordano, A			A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE FAMILY; CYCLIN-DEPENDENT KINASES; CELL-CYCLE; E2F FAMILY; PROTEIN; P107; MEMBER; EXPRESSION; CLONING; PRODUCT	The Cdk2 kinase has long been known to be involved in the progression of mammalian cells past the G(1) phase restriction point and through DNA replication in the cell cycle. The Rb family of proteins, consisting of pRb, p107, and pRb2/p130, has also been shown to monitor progression of G, phase, mostly through their interaction with E2F family members. p107 is able to inhibit Cdk2 kinase activity through this interaction via a p21-related domain present in the C terminus of the protein. We show here that pRb2/p130 also possesses this activity, but through a separate domain. Moreover, we correlate the increased expression of pRb2/p130 during various cellular processes with the decreased kinase activity of Cdk2. We hypothesize that pRb2/p130 may act not only to bind and modify E2F activity, but also to inhibit Cdk2 kinase activity in concert with p21 in a manner different from p107.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,SBARRO INST CANC RES & MOL MED,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOL MED,DEPT BIOCHEM & MOL BIOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University; Jefferson University			De Luca, Antonio/AAD-9562-2020; Claudio, Pier Paolo/AAW-7282-2021; Giordano, Antonio/F-1927-2010; Baldi, Alfonso/ABG-2397-2021	De Luca, Antonio/0000-0002-3905-6154; Claudio, Pier Paolo/0000-0001-7790-1622; Giordano, Antonio/0000-0002-5959-016X; Howard, Candace/0000-0001-6537-3551; Baldi, Alfonso/0000-0002-8693-3842; BAGELLA, Luigi/0000-0003-2815-037X	NCI NIH HHS [R01 CA60999-01A1] Funding Source: Medline; NINDS NIH HHS [P01 NS36466] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BUCK V, 1995, ONCOGENE, V11, P31; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Claudio PP, 1996, CANCER RES, V56, P2003; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MAYOL X, 1993, ONCOGENE, V8, P2561; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; VANWIJNEN AJ, 1997, IN PRESS J CELL BIOC; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	21	76	78	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20971	20974		10.1074/jbc.272.34.20971	http://dx.doi.org/10.1074/jbc.272.34.20971			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261093	hybrid			2022-12-25	WOS:A1997XR78900003
J	Liu, JY; Rosen, BP				Liu, JY; Rosen, BP			Ligand interactions of the ArsC arsenate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SULFATE REDUCTION; HYDROGEN DONOR; GLUTAREDOXIN; GLUTATHIONE; THIOREDOXIN; PROTEIN; RESISTANCE; DISULFIDE; MUTANT	ArsC encoded by Escherichia coli plasmid R773 catalyzes the reduction of arsenate to arsenite, The enzymatic reaction requires reduced glutathione and glutaredoxin. In this study a direct association between ArsC and glutaredoxin was demonstrated. An arsC gene with six histidine codons added to the 5' end of the gene was constructed, and the resulting ArsC enyzme was shown to be functional. Interaction of the histidine-tagged ArsC and glutaredoxin was examined by Ni2+ affinity chromatography. The association required the presence of reduced glutathione and either the substrate arsenate or a competitive inhibitor, phosphate or sulfate. A free thiolate on glutathione was not required, A tryptophan residue was introduced into ArsC at the 11th position, immediately adjacent to tl-re active site Cys-la, Trp-ll fluorescence was quenched upon addition of arsenate, Addition of reduced glutathione after arsenate resulted in a rapid increase in fluorescence followed by a slower decay of the signal. These spectroscopic signals were specific for arsenate and reduced glutathione; neither competitive inhibitors nor non-thiol glutathione analogs produced this effect, Cys-12 thiolate was also required, Thus the intrinsic fluorescence of Trp-ll provides a useful probe to investigate the mechanism of this novel reductase.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM52216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken Alastair, 1996, P3, DOI 10.1007/978-1-60327-259-9_1; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7287; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1995, BIOCHEMISTRY-US, V34, P13572; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; Rosen BP, 1996, J BIOL INORG CHEM, V1, P273, DOI 10.1007/s007750050053; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; Sambrook J., 1989, MOL CLONING LAB MANU, V2; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; TURNER RJ, 1992, J BACTERIOL, V174, P3092, DOI 10.1128/JB.174.9.3092-3094.1992; WELLS WW, 1990, J BIOL CHEM, V265, P15361	21	39	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21084	21089		10.1074/jbc.272.34.21084	http://dx.doi.org/10.1074/jbc.272.34.21084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261111	hybrid			2022-12-25	WOS:A1997XR78900021
J	Benashski, SE; Harrison, A; PatelKing, RS; King, SM				Benashski, SE; Harrison, A; PatelKing, RS; King, SM			Dimerization of the highly conserved light chain shared by dynein and myosin V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-ARM DYNEIN; PROTEIN SECONDARY STRUCTURE; CHLAMYDOMONAS FLAGELLA; INTERMEDIATE CHAIN; POLYPEPTIDE COMPOSITION; CIRCULAR-DICHROISM; TROUT SPERMATOZOA; PURIFICATION; SUBUNIT; BINDING	The M-r 8,000 light chain originally identified in Chlamydomonas flagellar dynein is also a component of both cytoplasmic dynein and myosin V, Furthermore, this small protein has been implicated as an inhibitor of neuronal nitric oxide synthase, suggesting that it may play multiple regulatory roles within the cell, Covalent cross-linking of both dynein and myosin V using 1,5-difluoro-2,4-dinitrobenzene revealed that this light chain exists as a dimer in situ, This observation was confirmed using two additional amine-selective crosslinking reagents (dimethyl pimelimidate and disuccinimidyl suberate). When expressed as a C-terminal fusion with maltose-binding protein, the presence of the light chain caused the recombinant molecule to dimerize. Analysis of fusions containing truncated light chains identified the predicted amphiphilic helix (residues 14-32) as sufficient to cause dimerization; cross-linking required a second helical segment (residues 33-46), Together the data presented suggest that two light chains interact to form a parallel dimeric structure, This arrangement has significant implications for the potential functions of this highly conserved molecule and suggests a mechanism by which it might dissociate nitric oxide synthase.	UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06032 USA	University of Connecticut					NIGMS NIH HHS [GM 51293] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051293] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckwith S. M., 1995, Molecular Biology of the Cell, V6, p5A; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P12; Dick T, 1996, MOL CELL BIOL, V16, P1966; Espindola F. S., 1996, Molecular Biology of the Cell, V7, p372A; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; GATTI JL, 1989, J BIOL CHEM, V264, P11450; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Holzbaur Erika L. F., 1994, V13, P251; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KING SM, 1995, METHOD CELL BIOL, V47, P9, DOI 10.1016/S0091-679X(08)60783-9; KING SM, 1986, METHOD ENZYMOL, V134, P291; KING SM, 1990, CELL MOTIL CYTOSKEL, V16, P266, DOI 10.1002/cm.970160406; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; KING SM, 1991, J BIOL CHEM, V266, P8401; KING SM, 1995, J CELL BIOL, V131, P399, DOI 10.1083/jcb.131.2.399; Luck D.J.L., 1989, CELL MOVEMENT, V1, P49; MITCHELL DR, 1986, CELL MOTIL CYTOSKEL, V6, P510, DOI 10.1002/cm.970060510; MITCHELL DR, 1991, J CELL BIOL, V113, P835, DOI 10.1083/jcb.113.4.835; MOSS AG, 1992, J CELL BIOL, V118, P1189, DOI 10.1083/jcb.118.5.1189; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; Phillis R, 1996, DEVELOPMENT, V122, P2955; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TANG WJY, 1982, J BIOL CHEM, V257, P508; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; Witman George B., 1994, V13, P229	32	115	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20929	20935		10.1074/jbc.272.33.20929	http://dx.doi.org/10.1074/jbc.272.33.20929			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252421	hybrid			2022-12-25	WOS:A1997XR22100091
J	Ishibashi, K; Kuwahara, M; Gu, Y; Kageyama, Y; Tohsaka, A; Suzuki, F; Marumo, F; Sasaki, S				Ishibashi, K; Kuwahara, M; Gu, Y; Kageyama, Y; Tohsaka, A; Suzuki, F; Marumo, F; Sasaki, S			Cloning and functional expression of a new water channel abundantly expressed in the testis permeable to water, glycerol, and urea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY COLLECTING DUCT; ESCHERICHIA-COLI; MOLECULAR-CLONING; FACILITATOR; SPERMATOZOA; AQUAPORIN; MEMBRANE; HOMOLOG; KINASE; CHIP28	A new member of the aquaporin (AQP) family has been identified from rat testis. This gene, referred as aquaporin 7 (AQP7), encodes a 269-amino acid protein that contained the conserved NPA motifs of MLP family proteins, AQP7 has the amino acid sequence homology with other aquaporins (similar to 30%), and it is highest with AQP3 (48%), suggesting that both AQP3 and AQP7 belong to a subfamily in the MIP family, Injection of AQP7-cRNA into Xenopus oocytes expressed a 26-kDa protein detected by immunoblotting, The expression of AQP7 in oocytes stimulated the osmotic water permeability by 10-fold which was not inhibited by 0.3 mm mercury chloride, The Arrhenius activation energy for the stimulated water permeability was low (2.1 kcal/mol), AQP7 also facilitated glycerol and urea transport by 5- and 9-fold, respectively. The activation energy for glycerol was also low (5.3 kcal/mol after the correction of the endogenous glycerol permeability of oocytes), Northern blot analysis revealed a 1.5-kilobase pair transcript expressed abundantly in testis. In situ hybridization of testis revealed the expression of AQP7 at late spermatids in seminiferous tubules. The immunohistochemistry of testis localized the AQP7 expression at late spermatids and at maturing sperms, AQP7 may play an important role in sperm function.	TOKYO MED & DENT UNIV,DEPT UROL,TOKYO 113,JAPAN; OUME GEN HOSP,RENAL UNIT,TOKYO 198,JAPAN; CHIBA UNIV,SCH MED,DEPT ANAT 2,CHIBA 260,JAPAN	Tokyo Medical & Dental University (TMDU); Chiba University	Ishibashi, K (corresponding author), TOKYO MED & DENT UNIV,DEPT INTERNAL MED 2,BUNKYO KU,1-5-45 YUSHIMA,TOKYO 113,JAPAN.							CALAMITA G, 1995, J BIOL CHEM, V270, P29063, DOI 10.1074/jbc.270.49.29063; CURRY MR, 1994, BIOL REPROD, V51, P1014, DOI 10.1095/biolreprod51.5.1014; DANIELS MJ, 1994, PLANT PHYSIOL, V106, P1325, DOI 10.1104/pp.106.4.1325; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Echevarria M, 1996, J BIOL CHEM, V271, P25079, DOI 10.1074/jbc.271.41.25079; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU C, 1995, BIOL REPROD, V52, P913, DOI 10.1095/biolreprod52.4.913; Ma TH, 1996, GENOMICS, V35, P543, DOI 10.1006/geno.1996.0396; MA TH, 1994, J BIOL CHEM, V269, P21845; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Shi LB, 1996, BIOCHEMISTRY-US, V35, P538, DOI 10.1021/bi9520038; STARGENT C, 1994, HUM MOL GENET, V3, P1317; VOEGELE RT, 1993, J BACTERIOL, V175, P1087, DOI 10.1128/JB.175.4.1087-1094.1993; WATSON PF, 1992, J ANDROL, V13, P131; WEISSENBORN DL, 1992, J BIOL CHEM, V267, P6122	19	317	335	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20782	20786		10.1074/jbc.272.33.20782	http://dx.doi.org/10.1074/jbc.272.33.20782			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252401	hybrid			2022-12-25	WOS:A1997XR22100071
J	Marcil, J; Harbour, D; Naccache, PH; Bourgoin, S				Marcil, J; Harbour, D; Naccache, PH; Bourgoin, S			Human phospholipase D1 can be tyrosine-phosphorylated in HL-60 granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; HUMAN NEUTROPHILS; ACTIVATION; CELLS; RHOA; DOWNSTREAM; FRACTIONS; MEMBRANE; ARF	The human phospholipase D1 (hPLD1) has recently been cloned, Although recent data have implicated PLD in receptor-stimulated secretion, the regulation of the activity of PLD enzymes remains to be clarified, Purified hPLD1 is activated by several cytosolic cofactors among which are protein kinase C alpha, ARF, and RhoA, In human granulocytes, a strong correlation between tyrosine phosphorylation of proteins and PLD activity has been established, In this study, the presence of hPLD1 in HL-60 granulocytes and its phosphorylation on tyrosine residues have been studied, We generated antipeptide antibodies (Abs) specific for hPLD1 but not PLD2 as shown by Western blotting (WE) of recombinant PLD1 and PLD2. These Abs identified the presence of hPLD1 in HL-60 cells with the bulk of it being detected in the membranes and only a minor fraction in the cytosol. The hPLD1 Abs detected a major band at 120 kDa (PLD1a) and a minor band at 115 kDa (PLD1b). The specificity of the Abs was confirmed using PLD antisera neutralized with the immunizing peptides, The two forms of hPLD1 were consistently detected by immunoprecipitation under nondenaturing and denaturing conditions following a WE analysis with hPLD1 Abs, Following exposure of HL-60 cells to peroxides of vanadate (V4+-OOH), an inhibitor of tyrosine phosphatases, hPLD1 was immuno-precipitated under nondenaturing conditions from HL-60 cell lysates and assayed for tyrosine phosphorylation by WB. hPLD1 comigrated with a 120-kDa tyrosine phosphorylated protein by gel electrophoresis, Other tyrosine-phosphorylated peptides of 160, 140, 135, 90, and 75-80 kDa were also detected in hPLD1 immune complexes, hPLD1 and the associated tyrosine-phosphorylated proteins were not immunoprecipitated by neutralized hPLD1 Abs, Using denaturing conditions, the PLD immunoprecipitates were sequentially immunoblotted with anti-PLD1 and anti-phosphotyrosine Abs. PLD1a and PLD1b were detected, and the major PLD1a protein was superimposable with a major tyrosine phosphorylated protein detected at 120 kDa, Conversely, PLD1a and PLD1b were recovered, at least in part, in the anti-phosphotyrosine immunoprecipitates. These results provide evidence that two PLD1 forms are expressed in human granulocytes. Furthermore, in response to stimulation by V4+-OOH, PLD1 was tyrosine-phosphorylated and associated with several, presently undefined, tyrosine-phosphorylated proteins.	CHUL,CTR RECH,CTR RECH RHUMATOL & IMMUNOL,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,FAC MED,DEPT MED,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,FAC MED,DEPT PHYSIOL,ST FOY,PQ G1V 4G2,CANADA	Laval University; Laval University; Laval University				Bourgoin, Sylvain/0000-0001-9779-0368				AlShami A, 1997, J IMMUNOL METHODS, V202, P183, DOI 10.1016/S0022-1759(97)00004-5; BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Decker C, 1996, BIOCHEM J, V320, P885, DOI 10.1042/bj3200885; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GOMEZCAMBRONERO J, 1995, J INTERF CYTOK RES, V15, P877, DOI 10.1089/jir.1995.15.877; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OLSON SC, 1991, J BIOL CHEM, V266, P17236; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; Ribbes G, 1996, BIOCHEM BIOPH RES CO, V224, P206, DOI 10.1006/bbrc.1996.1008; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; Yoshimura S, 1996, BIOCHEM BIOPH RES CO, V225, P494, DOI 10.1006/bbrc.1996.1201	29	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20660	20664		10.1074/jbc.272.33.20660	http://dx.doi.org/10.1074/jbc.272.33.20660			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252384	hybrid			2022-12-25	WOS:A1997XR22100054
J	Barrie, AP; Clohessy, AM; Buensuceso, CS; Rogers, MV; Allen, JM				Barrie, AP; Clohessy, AM; Buensuceso, CS; Rogers, MV; Allen, JM			Pituitary adenylyl cyclase-activating peptide stimulates extracellular signal-regulated kinase 1 or 2 (ERK1/2) activity in a ras-independent, mitogen-activated protein kinase ERK kinase 1 or 2-dependent manner in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; 38-AMINO ACID FORM; MAP KINASE; SUSTAINED ACTIVATION; NEURITE OUTGROWTH; B-RAF; DIFFERENTIATION; POLYPEPTIDE; EXPRESSION; INHIBITION	Sustained activation of extracellular signal-regulated kinase 1/2 (ERK1/2) is critical for initiating differentiation of the PC12 cell to a sympathetic-like neurone. The neuropeptide, pituitary adenylyl cyclase-activating peptide (PACAP), has been demonstrated to cause cell to adopt a neuronal phenotype, although the mechanism of this activity is unclear. PACAP through its type I receptor stimulates a biphasic activation of ERK1/2; a > 10-fold increase within 5 min, followed by a > 5-fold increase that is sustained for greater than or equal to 60 min. An equivalent stimulation is seen in PC12 cells expressing a dominant negative Ras mutant. However, the mitogen-activated kinase/ERK kinase 1/2 (MEK1/2) inhibitor PD98059 blocked both PACAP-induced stimulation of ERK1/2 activity and neurite outgrowth. Thus, activation signal from the PACAP type I receptor on the ERK1/2 cascade pathway is received downstream of Ras, either at Raf or MEK. Down-regulation of protein kinase C or its inhibition by calphostin C blocked the ability of PACAP to stimulate ERK1/2. We conclude that activation of PACAP type I receptor activates protein kinase C, which then activates the ERK1/2 cascade in a Ras-independent manner at either Raf or MEK1/2.	UNIV GLASGOW,DEPT MED & THERAPEUT,GLASGOW G12 8QQ,LANARK,SCOTLAND; UNIV GLASGOW,DIV BIOCHEM & MOL BIOL,GLASGOW G12 8QQ,LANARK,SCOTLAND; GLAXO WELLCOME RES & DEV LTD,CELLULAR BIOASSAY DESIGN GRP,LEAD DISCOVERY UNIT,MED RES CTR,STEVENAGE SG1 2NY,HERTS,ENGLAND	University of Glasgow; University of Glasgow; GlaxoSmithKline					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; BOTTENSTEIN JE, 1985, CELL CULTURE NEUROSC, P3; BRAAS KM, 1994, ENDOCRINOLOGY, V134, P186, DOI 10.1210/en.134.1.186; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUENSUCESO BS, 1995, THESIS U LONDON; COLBERT RA, 1994, J NEUROSCI, V14, P7141; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DEUTSCH PJ, 1993, J NEUROSCI RES, V35, P312, DOI 10.1002/jnr.490350311; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUKUDA M, 1995, ONCOGENE, V11, P239; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HERNANDEZ A, 1995, PEPTIDES, V16, P927, DOI 10.1016/0196-9781(95)00059-S; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STORM SM, 1990, ONCOGENE, V5, P345; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSAO H, 1990, J BIOL CHEM, V265, P15471; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Wolf N, 1995, NEUROSCI LETT, V200, P207, DOI 10.1016/0304-3940(95)12116-L; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6	34	121	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19666	19671		10.1074/jbc.272.32.19666	http://dx.doi.org/10.1074/jbc.272.32.19666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242621	hybrid			2022-12-25	WOS:A1997XQ05900008
J	Dang, QD; Sabetta, M; DiCera, E				Dang, QD; Sabetta, M; DiCera, E			Selective loss of fibrinogen clotting in a loop-less thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOMODULIN; ANTICOAGULANT	The autolysis loop of thrombin comprises nine residues, from Glu(146) to Lys(149e), five of which (Ala(149a)-Lys(149e)) are inserted relative to trypsin and chymotrypsin. Deletion of the insertion Ala(149a)-Lys(149e) causes no significant change in the properties of the enzyme, except for a slight enhancement of protein C activation. Deletion of the entire Glu(146)-Lys(149e) loop, however, reduces fibrinogen clotting 240-fold, but decreases protein C activation only 2-fold. This loop-less mutant is de facto an exclusive activator of protein C, having lost the primary procoagulant function of thrombin. Because the autolysis loop affects fibrinogen binding, but not protein C activation, it provides a target for new drugs designed to suppress exclusively the procoagulant activity of thrombin.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)					NHLBI NIH HHS [HL58141, HL49413] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R01HL058141, R29HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; Berg DT, 1996, SCIENCE, V273, P1389, DOI 10.1126/science.273.5280.1389; BODE W, 1992, PROTEIN SCI, V1, P426; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DiBella EE, 1996, BIOCHEMISTRY-US, V35, P4427, DOI 10.1021/bi952617c; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008	18	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19649	19651		10.1074/jbc.272.32.19649	http://dx.doi.org/10.1074/jbc.272.32.19649			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242618	hybrid			2022-12-25	WOS:A1997XQ05900005
J	Hashim, MF; SchnetzBoutaud, N; Marnett, LJ				Hashim, MF; SchnetzBoutaud, N; Marnett, LJ			Replication of template-primers containing propanodeoxyguanosine by DNA polymerase beta - Induction of base pair substitution and frameshift mutations by template slippage and deoxynucleoside triphosphate stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM HISD3052; DUPLEX OLIGODEOXYNUCLEOTIDE; ESCHERICHIA-COLI; 2-BASE DELETION; IN-VITRO; HOT-SPOT; MUTAGENESIS; FIDELITY; ADDUCT; OPPOSITE	Propanodeoxyguanosine (PdG) is a model for several unstable exocyclic adducts formed by reaction of DNA with bifunctional carbonyl compounds generated by lipid peroxidation. The effect of PdG on DNA synthesis by human DNA polymerase beta was evaluated using template-primers containing PdG at defined sites, DNA synthesis was conducted in vitro and the products were analyzed by polyacrylamide gel electrophoresis and DNA sequencing, The extent of PdG bypass was low and the products comprised a mixture of base pair substitutions and deletions, Sequence analysis of all of the products indicated that the deoxynucleoside monophosphate incorporated ''opposite'' PdG was complementary to the base 5' to PdG in the template strand., These findings are very similar to recent results of Efrati et al., (Efrati, E., Tocco, G., Eritja, R., Wilson, S. H., and Goodman, M. F. (1997) J. Biol. Chem. 272, 2559-2569) obtained in DNA replication of template-primers containing abasic sites and suggest that PdG is a non-informational lesion when acted upon by polymerase (pol) beta, In addition to base pair substitutions and one- or two-base deletions, a four-base deletion was observed and the mechanism of its formation was probed by site-specific mutagenesis, The results indicated that this deletion occurred by one-base insertion followed by slippage to form a four-base loop followed by extension, All of the observations on pol beta replication of PdG-containing template-primers are consistent with a mechanism of lesion bypass that involves template slippage and dNTP stabilization followed by deoxynucleoside monophosphate incorporation and extension, This mechanism of PdG bypass is completely different than that previously determined for the Klenow fragment of DNA polymerase I and is consistent with recent structural models for DNA synthesis by pol beta.	VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,VANDERBILT CANC CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; BURCHAM PC, 1994, J BIOL CHEM, V269, P28844; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; CHANG LMS, 1973, J BIOL CHEM, V248, P6983; CHARY P, 1995, NUCLEIC ACIDS RES, V23, P1398, DOI 10.1093/nar/23.8.1398; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Efrati E, 1997, J BIOL CHEM, V272, P2559; FEIG DI, 1994, J MOL BIOL, V235, P33, DOI 10.1016/S0022-2836(05)80009-9; Fink SP, 1996, CHEM RES TOXICOL, V9, P277, DOI 10.1021/tx950060w; FRIEDMANN T, 1978, NUCLEIC ACIDS RES, V5, P615, DOI 10.1093/nar/5.2.615; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Hashim MF, 1996, J BIOL CHEM, V271, P9160, DOI 10.1074/jbc.271.15.9160; Hoffmann JS, 1996, J BIOL CHEM, V271, P15386, DOI 10.1074/jbc.271.26.15831; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; JOHNSON KA, 1995, THESIS VANDERBILT U; KOUCHAKDJIAN M, 1990, BIOCHEMISTRY-US, V29, P4456, DOI 10.1021/bi00470a028; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; Levy DD, 1996, J MOL BIOL, V258, P251, DOI 10.1006/jmbi.1996.0247; LOECHLER EL, 1995, MOL CARCINOGEN, V13, P213, DOI 10.1002/mc.2940130404; MACCABEE M, 1994, J MOL BIOL, V236, P514, DOI 10.1006/jmbi.1994.1162; MARINELLI ER, 1990, CHEM RES TOXICOL, V3, P49, DOI 10.1021/tx00013a009; Marnett L J, 1994, IARC Sci Publ, P151; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER JH, 1983, ANNU REV GENET, V17, P215, DOI 10.1146/annurev.ge.17.120183.001243; MOE JG, 1994, CHEM RES TOXICOL, V7, P319, DOI 10.1021/tx00039a008; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PRASAD R, 1994, J BIOL CHEM, V269, P18096; RehaKrantz LJ, 1996, J BIOL CHEM, V271, P20088, DOI 10.1074/jbc.271.33.20088; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shibutani S, 1996, BIOCHEMISTRY-US, V35, P14992, DOI 10.1021/bi961446o; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; Singh J, 1996, J BIOL CHEM, V271, P28391, DOI 10.1074/jbc.271.45.28391; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Vogel EW, 1996, MUTAT RES-FUND MOL M, V353, P177, DOI 10.1016/0027-5107(96)00032-2; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEISENSEEL JP, 1995, BIOCHEMISTRY-US, V34, P50, DOI 10.1021/bi00001a007; Werz O, 1996, EUR J BIOCHEM, V242, P90, DOI 10.1111/j.1432-1033.1996.0090r.x	50	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20205	20212		10.1074/jbc.272.32.20205	http://dx.doi.org/10.1074/jbc.272.32.20205			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242698	hybrid			2022-12-25	WOS:A1997XQ05900085
J	Heise, T; Nath, A; Jungermann, K; Christ, B				Heise, T; Nath, A; Jungermann, K; Christ, B			Purification of a RNA-binding protein from rat liver - Identification as ferritin L chain and determination of the RNA/protein binding characteristics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PROSOME-LIKE PARTICLE; MESSENGER-RNA; GENE-TRANSCRIPTION; CYTOSOLIC PROTEIN; DEGRADATION; IRON; STABILIZATION; INSULIN; PHOSPHORYLATION	In cultured rat hepatocytes the degradation of phosphoenolpyruvate carboxykinase mRNA might be regulated by protein(s), which by binding to the mRNA alter its stability, The 3'-untranslated region of phosphoenolpyruvate carboxykinase mRNA as a potential target was used to select RNA-binding protein(s) from rat liver by the use of gel retardation assays, A cytosolic protein was isolated, which bound to the phosphoenolpyruvate carboxykinase mRNA 3'-untranslated region and other in vitro synthesized RNAs, The protein was purified to homogeneity; it had an apparent molecular mass of 400 kDa and consisted of identical subunits with an apparent size of 24.5 kDa, Sequence analysis of a tryptic peptide from the 24.5-kDa protein revealed its identity with rat ferritin light chain. Binding of ferritin to RNA was abolished after phosphorylation with cAMP-dependent protein kinase and was augmented after dephosphorylation with alkaline phosphatase. Weak binding was observed in extracts from okadaic acid-treated cultured hepatocytes compared with untreated cells, Preincubation of ferritin with an anti-phosphoserine or an anti-phosphothreonine antibody attenuated binding to RNA, while an anti-phosphotyrosine antibody generated a supershift indicating that phosphoserine and phosphothreonine but not phosphotyrosine residues were in close proximity to the RNA-binding region, Ferritin is the iron storage protein in the Liver, Binding of ferritin to RNA was diminished in the presence of increasing iron concentrations, whereas the iron chelator desferal was without effect, It is concluded that ferritin might function as RNA-binding protein and that it may have important functions in the general regulation of cellular RNA metabolism.	UNIV GOTTINGEN,INST BIOCHEM & MOL ZELLBIOL,D-37073 GOTTINGEN,GERMANY	University of Gottingen				Christ, Bruno/0000-0001-8213-9548				AKHAYAT O, 1987, EUR J BIOCHEM, V170, P23, DOI 10.1111/j.1432-1033.1987.tb13663.x; Alberts B., 1994, MOL BIOL CELL; ANDREONE TL, 1982, J BIOL CHEM, V257, P35; BEALE EG, 1985, J BIOL CHEM, V260, P748; BELASCO J, 1993, CONTROL MRNA STABILI; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BROWN BD, 1990, GENE DEV, V4, P1925, DOI 10.1101/gad.4.11.1925; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHRIST B, 1991, BIOCHEM BIOPH RES CO, V177, P1273, DOI 10.1016/0006-291X(91)90679-2; CHRIST B, 1993, EUR J BIOCHEM, V215, P541, DOI 10.1111/j.1432-1033.1993.tb18063.x; CHRIST B, 1994, HEPATOLOGY, V20, P1577, DOI 10.1002/hep.1840200629; CHRIST B, 1990, BIOL CHEM H-S, V371, P395, DOI 10.1515/bchm3.1990.371.1.395; COUX O, 1992, EUR J BIOCHEM, V207, P823, DOI 10.1111/j.1432-1033.1992.tb17113.x; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DEGRAAF J, 1990, EUR J BIOCHEM, V193, P737; DEHERDT E, 1979, EUR J BIOCHEM, V96, P423; DEHERDT E, 1981, BIOCHEM J, V194, P9, DOI 10.1042/bj1940009; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; HOD Y, 1988, J BIOL CHEM, V263, P7747; HUA JL, 1992, MOL ENDOCRINOL, V6, P1418, DOI 10.1210/me.6.9.1418; IHARA K, 1984, J BIOL CHEM, V259, P278; IWAI Y, 1991, J BIOL CHEM, V266, P17959; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; MUNRO HN, 1978, PHYSIOL REV, V58, P317, DOI 10.1152/physrev.1978.58.2.317; NACHALIEL N, 1993, J BIOL CHEM, V268, P24203; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; ROHRER JS, 1987, J BIOL CHEM, V262, P13385; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; St. Johnston D., 1995, CELL, V81, P161, DOI DOI 10.1016/0092-8674(95)90324-0; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; TAKAHAMA Y, 1992, SCIENCE, V258, P1456, DOI 10.1126/science.1439838; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; VOORMA HO, 1994, MOL BIOL REP, V19, P139, DOI 10.1007/BF00986956; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857	42	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20222	20229		10.1074/jbc.272.32.20222	http://dx.doi.org/10.1074/jbc.272.32.20222			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242700	hybrid			2022-12-25	WOS:A1997XQ05900087
J	Langlands, K; Yin, XY; Anand, G; Prochownik, EV				Langlands, K; Yin, XY; Anand, G; Prochownik, EV			Differential interactions of Id proteins with basic-helix-loop-helix transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; DNA-BINDING MOTIF; IMMUNOGLOBULIN ENHANCER; HETERO-OLIGOMERIZATION; CRYSTAL-STRUCTURE; INSULIN GENE; MUSCLE; RECOGNITION; ACTIVATION; DOMAIN	Dimerization of three Id proteins (Idl, Id2, and Id3) with the four class A E proteins (E12, E47, E2-2, and HEB) and two groups of class B proteins, the myogenic regulatory factors (MRFs: MyoD, myogenin, Myf-5 and MRF4/Myf-6), and the hematopoietic factors (Scl/Tal-1, Tal-2, and Lyl-1) were tested in a quantitative yeast 2-hybrid assay, All three Ids bound with high affinity to E proteins, but a much broader range of interactions was observed between Ids and the class B factors, Idl and Id2 interacted strongly with MyoD;and Myf-5 and weakly with myogenin and MRF4/Myf-6, whereas Id3 interacted weakly with all four MRFs. Similar specificities were observed in co-immunoprecipitation and mammalian a-hybrid analyses, No interactions were found between the Ids and any of the hematopoietic factors, Each Id was able to disrupt the ability of E protein-MyoD complexes to transactivate from a muscle creatine kinase reporter construct in vivo, Finally, mutagenesis experiments showed that the differences between Idl and Id3 binding map to three amino acids in the first helix and to a small cluster of upstream residues, The Id proteins thus display a signature range of interactions with all of their potential dimerization partners and may play a role in myogenesis which is distinct from that in hematopoiesis.	CHILDRENS HOSP, MED CTR, HEMATOL ONCOL SECT, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, MED CTR, INST CANC, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Langlands, Kenneth/0000-0001-7629-9967	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEED RW, 1993, ONCOGENE, V8, P599; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKEL T, 1993, J BIOL CHEM, V268, P5; Goldfarb AN, 1996, J BIOL CHEM, V271, P2683, DOI 10.1074/jbc.271.5.2683; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KLEIN ES, 1993, GENE DEV, V7, P55, DOI 10.1101/gad.7.1.55; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1992, TRANSCRIPTIONAL REGU, P1037; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Loveys DA, 1996, NUCLEIC ACIDS RES, V24, P2813, DOI 10.1093/nar/24.14.2813; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; SHOJI W, 1994, J BIOL CHEM, V269, P5078; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; SOOSAAR A, 1994, MOL BRAIN RES, V25, P176, DOI 10.1016/0169-328X(94)90297-6; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; SPRINGHORN JP, 1994, J BIOL CHEM, V269, P5132; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898	71	189	193	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19785	19793		10.1074/jbc.272.32.19785	http://dx.doi.org/10.1074/jbc.272.32.19785			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242638	hybrid			2022-12-25	WOS:A1997XQ05900025
J	Obiri, NI; Murata, T; Debinski, W; Puri, RK				Obiri, NI; Murata, T; Debinski, W; Puri, RK			Modulation of interleukin (IL)-13 binding and signaling by the gamma(c) chain of the IL-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL CARCINOMA-CELLS; FUNCTIONAL COMPONENT; TRANSDUCTION; ACTIVATION; JAK1; SIMILARITIES	Interleukin (IL)-13 and IL-4 are cytokine products of T(H)2 cells which exert similar effects in a variety of cell types. We recently described IL-ISR expression on human renal cell and colon carcinoma cells and demonstrated that gamma(c) is not a component of IL-13R, or IL-4R systems in these cells, In lymphoid cells such as B cells and monocytes, which respond to IL-13, gamma(c) is a component of IL-4R but does not appear to be a component of IL-13R, Furthermore, while significant IL-13 binding is observed on carcinoma cells, IL-13 barely binds these lymphoid cells and the binding characteristics are different, To better understand the role of gamma(c) in IL-13 binding and signaling, we have transfected a renal cell carcinoma cell line with gamma(c) and examined IL-13 and IL-4 binding and signaling, IL-13 binding as well as IL-13 and IL-4 signaling through the JAK-STAT signaling pathway were severely inhibited, This inhibition was paralleled by a loss of expression of one of the IL-13R chains and intercellular cell adhesion molecule-1. Thus, although gamma(c) has been shown to enhance IL-4 binding and function in some cell types, its influence on IL-13R function in tumor cells appear to be largely negative.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT SURG,DIV NEUROSURG,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Obiri, NI (corresponding author), US FDA,LAB MOL TUMOR BIOL,DIV CELLULAR & GENE THERAPIES,CTR BIOL EVALUAT & RES,NIH,HFM-530,BETHESDA,MD 20892, USA.							Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Izuhara K, 1996, J BIOL CHEM, V271, P619, DOI 10.1074/jbc.271.2.619; Kammer W, 1996, J BIOL CHEM, V271, P23634, DOI 10.1074/jbc.271.39.23634; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; Lai SY, 1996, EMBO J, V15, P4506, DOI 10.1002/j.1460-2075.1996.tb00828.x; MALABARBA MG, 1995, J BIOL CHEM, V270, P9630, DOI 10.1074/jbc.270.16.9630; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murata T, 1997, CELL IMMUNOL, V175, P33, DOI 10.1006/cimm.1996.1051; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; Murata T, 1996, J IMMUNOL, V156, P2972; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; OBIRI NI, 1995, INT J CANCER, V61, P635, DOI 10.1002/ijc.2910610509; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1997, J IMMUNOL, V158, P756; Obiri NI, 1996, CLIN CANCER RES, V2, P1743; Puri RK, 1996, CELL IMMUNOL, V171, P80, DOI 10.1006/cimm.1996.0176; PURI RK, 1993, CANCER INVEST, V11, P473, DOI 10.3109/07357909309018879; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	33	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20251	20258		10.1074/jbc.272.32.20251	http://dx.doi.org/10.1074/jbc.272.32.20251			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242704	hybrid			2022-12-25	WOS:A1997XQ05900091
J	Rothermel, BA; Thornton, JL; Butow, RA				Rothermel, BA; Thornton, JL; Butow, RA			Rtg3p, a basic helix-loop-helix/leucine zipper protein that functions in mitochondrial-induced changes in gene expression, contains independent activation domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ENCODING PEROXISOMAL PROTEINS; SACCHAROMYCES-CEREVISIAE; DIOXIN RECEPTOR; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ORGANELLE COMMUNICATION; CRYSTAL-STRUCTURE; RECOGNITION; YEAST	Rtg3p and Rtg1p are basic helix-loop helix/leucine zipper protein transcription factors in yeast that interact and bind to sites in an upstream activation sequence element in the 5'-flanking region of CIT2, a gene encoding a peroxisomal isoform of citrate synthase, These factors are required both for basal expression of CIT2 and its elevated expression in cells with dysfunctional mitochondria, such as in respiratory-deficient petite cells lacking mitochondrial DNA (rho degrees), This elevated expression of CIT2 is called the retrograde response, Here we show that fusion constructs between the Gal4p DNA binding domain and Rtg3p transactivate the expression of a LacZ reporter gene under the control of a GAL1 promoter element, We have identified two activation domains in Rtg3p: a strong carboxyl-terminal domain from amino acids 375-486, and a weaker amino-terminal domain from amino acids 1-175; neither of these activation domains contain the bHLH/Zip motif. We have also identified a serine/threonine-rich domain of Rtg3p within amino acids 176-282 that is inhibitory to transactivation, In addition, the transcriptional activity of the Gal4-Rtg3p fusion proteins does not require either Rtg1p or Rtg2p; the latter is a protein containing an hsp70-like ATP binding domain that is also necessary for CIT2 expression, In contrast, transcriptional activation by Gal4-Rtg1p fusion proteins requires the Rtg1p basic helix-loop-helix/leucine zipper protein domain, as well as Rtg3p and Rtg2p, These data suggest that transcriptional activation by the Rtg1p-Rtg3p complex is largely the function of Rtg3p, Experiments are also presented suggesting that Rtg3p is limiting for gene expression in respiratory-competent (rho(+)) cells.	UNIV TEXAS,SW MED CTR,DEPT MOL BIOL & ONCOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022525, R01GM022525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22525] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CHELSTOWSKA A, 1995, J BIOL CHEM, V270, P18141, DOI 10.1074/jbc.270.30.18141; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Jia YK, 1997, MOL CELL BIOL, V17, P1110, DOI 10.1128/MCB.17.3.1110; KOONIN EV, 1994, TRENDS BIOCHEM SCI, V19, P156, DOI 10.1016/0968-0004(94)90275-5; KOS W, 1995, BBA-GENE STRUCT EXPR, V1264, P79, DOI 10.1016/0167-4781(95)00127-3; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; McGuire J, 1995, J BIOL CHEM, V270, P31353, DOI 10.1074/jbc.270.52.31353; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; PROBST MR, 1993, MOL PHARMACOL, V44, P511; ROSE M, 1983, METHOD ENZYMOL, V101, P167; ROSENKRANTZ M, 1986, MOL CELL BIOL, V6, P4509, DOI 10.1128/MCB.6.12.4509; ROTHERMEL BA, 1995, J BIOL CHEM, V49, P29476; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SHYJAN AW, 1993, CURR BIOL, V3, P398, DOI 10.1016/0960-9822(93)90212-7; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; SUSEK RE, 1993, CELL, V74, P787, DOI 10.1016/0092-8674(93)90459-4; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; VERMA IM, 1995, GENE DEV, V9, P2728; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232	48	74	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19801	19807		10.1074/jbc.272.32.19801	http://dx.doi.org/10.1074/jbc.272.32.19801			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242640	hybrid			2022-12-25	WOS:A1997XQ05900027
J	Fiorentini, C; Fabbri, A; Flatau, G; Donelli, G; Matarrese, P; Lemichez, E; Falzano, L; Boquet, P				Fiorentini, C; Fabbri, A; Flatau, G; Donelli, G; Matarrese, P; Lemichez, E; Falzano, L; Boquet, P			Escherichia coli cytotoxic necrotizing factor 1 (CNF1), a toxin that activates the Rho GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; BINDING PROTEINS-RHO; GROWTH-FACTOR; LETHAL TOXIN; CELLS; RAC; PURIFICATION; BORDETELLA; 3-KINASE; MYOSIN	Cytotoxic necrotizing factor 1 (CNF1), a 110-kDa protein toxin from pathogenic Escherichia coli induces actin reorganization into stress fibers and retraction fibers in human epithelial cultured cells allowing them to spread. CNF1 is acting in the cytosol since microinjection of the toxin into HEp-2 cells mimics the effects of the externally applied CNF1. Incubation in vitro of CNF1 with recombinant small GTPases induces a modification of Rho (but not of Pac, Cdc42, Pas, or Rab6) as demonstrated by a discrete increase in the apparent molecular weight of the molecule. Preincubation of cells with CNF1 impairs the cytotoxic effects of Clostridium difficile toxin B, which inactivates Rho but not those of Clostridium sordellii LT toxin, which inhibits Ras and Rac. As shown for Rho-GTP, CNF1 activates, in a time- and dose-dependent manner, a cytoskeleton-associated phosphatidylinositol 4-phosphate 5-kinase. However, neither the phosphatidylinositol 4,5-bisphosphate (PIP2) nor the phosphatidylinositol 3,4-bisphosphate (PI 3,4-P-2) or 3,4,5-trisphosphate (PIP3) cellular content were found increased in CNF1 treated HEp-2 cells. Cellular effects of CNF1 were not blocked by LY294002, a stable inhibitor of the phosphoinositide 3-kinase. Incubation of HEp-2 cells with CNF1 induces relocalization of myosin 2 in stress fibers but not in retraction fibers. Altogether, our data indicate that CNF1 is a toxin that selectively activates the Rho GTP-binding protein, thus inducing contractility and cell spreading.	FAC MED,INSERM,U452,F-06107 NICE 2,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Fiorentini, C (corresponding author), IST SUPER SANITA,DEPT ULTRASTRUCT,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		Fiorentini, Carla/Q-2088-2015; Lemichez, Emmanuel/G-3559-2013; Matarrese, Paola/A-4369-2014; FIORENTINI, CARLA/AAG-8005-2019; Fabbri, Alessia/AAA-4594-2019	Fiorentini, Carla/0000-0003-1707-6282; Lemichez, Emmanuel/0000-0001-9080-7761; FIORENTINI, CARLA/0000-0003-1707-6282; Fabbri, Alessia/0000-0002-3075-3367; matarrese, paola/0000-0001-5477-3752; falzano, loredana/0000-0003-4074-180X				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; FIORENTINI C, 1988, TOXICON, V26, P1047, DOI 10.1016/0041-0101(88)90203-6; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; FIORENTINI C, 1994, ZBL BAKT S, V24, P404; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; HORIGUCHI Y, 1995, J CELL SCI, V108, P3243; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KLOTZ C, 1986, J CELL BIOL, V103, P613, DOI 10.1083/jcb.103.2.613; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; OSTERMAN A, 1993, J MUSCLE RES CELL M, V14, P186, DOI 10.1007/BF00115453; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SEKINE A, 1989, J BIOL CHEM, V264, P8602; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALKER KE, 1994, INFECT IMMUN, V62, P3817, DOI 10.1128/IAI.62.9.3817-3828.1994; ZALCMAN G, 1995, ONCOGENE, V10, P1935	38	79	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19532	19537		10.1074/jbc.272.31.19532	http://dx.doi.org/10.1074/jbc.272.31.19532			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235957	hybrid			2022-12-25	WOS:A1997XP06300063
J	Stulnig, TM; Berger, M; Sigmund, T; Stockinger, H; Horejsi, V; Waldhausl, W				Stulnig, TM; Berger, M; Sigmund, T; Stockinger, H; Horejsi, V; Waldhausl, W			Signal transduction via glycosyl phosphatidylinositol-anchored proteins in T cells is inhibited by lowering cellular cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES P56(LCK); DECAY-ACCELERATING FACTOR; ALKALINE-PHOSPHATASE; IL-2 PRODUCTION; LYMPHOCYTES-T; DETERGENT INSOLUBILITY; SURFACE EXPRESSION; COUNTER-RECEPTOR; HUMAN MONOCYTES; CO-EXPRESSION	Glycosylphosphatidylinositol (GPI)-anchored proteins can deliver costimulatory signals to lymphocytes, but the exact pathway of signal transduction involved is not yet characterized. GPI anchored proteins are fixed to the cell surface solely by a phospholipid moiety and are clustered in distinct membrane domains that are formed by an unique lipid composition requiring cholesterol. To elucidate the role of membrane lipids for signal transduction via GPI-anchored proteins, we studied the influence of reduced cellular cholesterol content on calcium signaling via GPI-anchored CD59 and CD48 in Jurkat T cells. Lowering cholesterol by different inhibitors of cellular cholesterol synthesis suppressed calcium response via GPI anchored proteins by about 50%, whereas stimulation via CD3 was only minimally affected (<10%). The decrease in overall calcium response via GPI-anchored proteins was reflected by inhibition of calcium release from intracellular stores. Cell surface expression of GPI-anchored proteins was not changed quantitatively by lowering cellular cholesterol, and neither was the pattern of immunofluorescence in microscopic examination. In addition, the distribution of GPI-anchored proteins in detergent-insoluble complexes remained unaltered. These results suggest that cellular cholesterol is an important prerequisite for signal transduction via GPI-anchored proteins beyond formation of membrane domains.	UNIV VIENNA,INST IMMUNOL,VIENNA INT RES COOPERAT CTR,A-1235 VIENNA,AUSTRIA; ACAD SCI CZECH REPUBL,INST MOL GENET,CR-14220 PRAGUE 4,CZECH REPUBLIC	University of Vienna; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Stulnig, TM (corresponding author), UNIV VIENNA,DEPT INTERNAL MED 3,WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA.		Horejsi, Vaclav/G-3113-2014; Stockinger, Hannes/E-5173-2011	Horejsi, Vaclav/0000-0003-4925-0142; Stockinger, Hannes/0000-0001-6404-4430; Stulnig, Thomas/0000-0003-3300-6161				BARBONI E, 1995, J CELL SCI, V108, P487; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; Cerny J, 1996, EUR J IMMUNOL, V26, P2335, DOI 10.1002/eji.1830261010; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHUNG SC, 1994, BRIT J PHARMACOL, V113, P861, DOI 10.1111/j.1476-5381.1994.tb17072.x; CINEK T, 1992, J IMMUNOL, V149, P2262; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CODIAS EK, 1992, J IMMUNOL, V149, P1825; COOK RG, 1992, CELL IMMUNOL, V144, P367, DOI 10.1016/0008-8749(92)90252-K; DAVIS LS, 1988, J IMMUNOL, V141, P2246; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; DECKERT M, 1995, EUR J IMMUNOL, V25, P1815, DOI 10.1002/eji.1830250704; DIANZANI U, 1993, J IMMUNOL, V151, P3961; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; ESFAHANI M, 1993, BIOCHIM BIOPHYS ACTA, V1149, P217, DOI 10.1016/0005-2736(93)90204-D; FLEMING TJ, 1994, J IMMUNOL, V153, P1955; FRA AM, 1994, J BIOL CHEM, V269, P30745; GARNETT D, 1993, EUR J IMMUNOL, V23, P2540, DOI 10.1002/eji.1830231024; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER KC, 1987, NATURE, V326, P505, DOI 10.1038/326505a0; HAHN AB, 1989, J IMMUNOL, V143, P407; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hannan LA, 1996, J CELL BIOL, V133, P1265, DOI 10.1083/jcb.133.6.1265; HAVRAN WL, 1988, J IMMUNOL, V140, P1034; IVANOV V, 1994, J IMMUNOL, V153, P2394; KATO K, 1993, EUR J IMMUNOL, V23, P1412, DOI 10.1002/eji.1830230638; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KLICKSTEIN LB, 1995, LEUKOCYTE TYPING, V5, P1476; KNIEP B, 1994, BIOCHEM BIOPH RES CO, V203, P1069, DOI 10.1006/bbrc.1994.2291; KORTY PE, 1991, J IMMUNOL, V146, P4092; KROCZEK RA, 1986, NATURE, V322, P181, DOI 10.1038/322181a0; KROCZEK RA, 1986, J IMMUNOL, V136, P4379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCKI DW, 1995, J IMMUNOL, V154, P4363; LEE SK, 1994, EMBO J, V13, P2167, DOI 10.1002/j.1460-2075.1994.tb06493.x; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Malek T R, 1994, Semin Immunol, V6, P105, DOI 10.1006/smim.1994.1015; MALEK TR, 1986, J EXP MED, V164, P709, DOI 10.1084/jem.164.3.709; MASAIA M, 1990, J IMMUNOL, V145, P1664; MASCHEK BJ, 1993, J IMMUNOL, V150, P3198; MORGAN BP, 1993, EUR J IMMUNOL, V23, P2841, DOI 10.1002/eji.1830231118; MULLER CP, 1983, J IMMUNOL, V131, P1356; REISER H, 1990, J IMMUNOL, V145, P2077; ROBINSON PJ, 1989, NATURE, V342, P85, DOI 10.1038/342085a0; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROCK KL, 1986, J EXP MED, V163, P315, DOI 10.1084/jem.163.2.315; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROWAN WC, 1909, INT IMMUNOL, V7, P69; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SOLOMON R, 1996, P NATL ACAD SCI USA, V93, P6053; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STULNIG TM, 1995, J GERONTOL A-BIOL, V50, pB383, DOI 10.1093/gerona/50A.6.B383; SU B, 1991, J CELL BIOL, V112, P377, DOI 10.1083/jcb.112.3.377; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; THELIN A, 1994, BIOCHIM BIOPHYS ACTA, V1215, P145; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; THOMPSON LF, 1989, J IMMUNOL, V143, P1815; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; XIE MS, 1995, BIOCHEM J, V305, P529, DOI 10.1042/bj3050529	64	103	104	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19242	19247		10.1074/jbc.272.31.19242	http://dx.doi.org/10.1074/jbc.272.31.19242			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235917	hybrid			2022-12-25	WOS:A1997XP06300023
J	Ladner, RD; Caradonna, SJ				Ladner, RD; Caradonna, SJ			The human dUTPase gene encodes both nuclear and mitochondrial isoforms - Differential expression of the isoforms and characterization of a cDNA encoding the mitochondrial species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDYLATE SYNTHASE GENE; TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CYTO-TOXICITY; MESSENGER-RNA; DNA-SYNTHESIS; CELLS; INHIBITION; ENZYME	We have previously identified distinct nuclear and mitochondrial isoforms of dUTPase in human cells, reporting the cDNA sequence of the nuclear isoform (DUT-N), We now report a cDNA corresponding to the mitochondrial isoform (DUT-M), The DUT-M cDNA contains an 252-amino acid open reading frame, encoding a protein with a predicted M-r of 26,704, The amino-terminal region of the protein contains an arginine-rich, 69-residue mitochondrial targeting presequence that is absent in the mature protein. In vitro transcription and translation of the DUT-M cDNA results in the production of a precursor protein with an apparent molecular mass of 31 kDa as judged by SDS-polyacrylamide gel electrophoresis. The DUT-M precursor is enzymatically active and immunoreacts with a dUTPase specific monoclonal antibody, Mitochondrial import and processing studies demonstrate that the DUT-M precursor is processed into a 23-kDa protein and imported into mitochondria in vitro, Isoelectric focusing experiments demonstrate that the DUT-N has a pI of 6.0, while the processed form of DUT-M has a more basic pI of 8.1, measurements that are in agreement with predicted values, Studies aimed at understanding the expression of these isoforms were performed utilizing quiescent and replicating 34Lu human lung fibroblasts as a model cell culture system, Northern blot analysis, employing an isoform specific probe, demonstrates that DUT-N and DUT-M are encoded by two distinct mRNA species of 1.1 and 1.4 kilobases, respectively, Western and Northern blot analysis reveal that DUT-M protein and mRNA are expressed in a constitutive fashion, independent of cell cycle phase or proliferation status, In contrast, DUT-N protein and mRNA levels are tightly regulated to coincide with nuclear DNA replication status, Because DUT-N and DUT-M have identical amino acid and cDNA sequences in their overlapping regions, we set out to determine if they were encoded by the same gene, The 5' region of the gene encoding dUTPase was isolated and characterized by a combination of Southern hybridization and DNA sequencing, These analyses demonstrate that the dUTPase isoforms are encoded by the same gene with isoform-specific transcripts arising through the use of alternative 5' exons, This finding represents the first example in humans of alternative 5' exon usage to generate differentially expressed nuclear and mitochondrial specific protein isoforms.			Ladner, RD (corresponding author), UNIV MED & DENT NEW JERSEY,SCH OSTEOPATH MED,DEPT MOL BIOL,2 MED CTR DR,STRATFORD,NJ 08084, USA.		Caradonna, Salvatore/AFU-8514-2022	Caradonna, Salvatore/0000-0002-2104-581X	NATIONAL CANCER INSTITUTE [R01CA042605] Funding Source: NIH RePORTER; NCI NIH HHS [CA42605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASH J, 1993, MOL CELL BIOL, V13, P1565, DOI 10.1128/MCB.13.3.1565; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Beck W R, 1986, Adv Exp Med Biol, V195 Pt B, P97; CANMAN CE, 1994, CANCER RES, V54, P2296; Caradonna S, 1996, EXP CELL RES, V222, P345, DOI 10.1006/excr.1996.0044; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; Cohen D, 1997, GENOMICS, V40, P213, DOI 10.1006/geno.1996.4540; CURTIN NJ, 1991, CANCER RES, V51, P2346; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Duyao M P, 1992, Curr Top Microbiol Immunol, V182, P421; ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; INGRAHAM HA, 1986, BIOCHEMISTRY-US, V25, P3225, DOI 10.1021/bi00359a022; JAUSSI R, 1995, EUR J BIOCHEM, V228, P551, DOI 10.1111/j.1432-1033.1995.tb20294.x; JENH CH, 1985, MOL CELL BIOL, V5, P2527, DOI 10.1128/MCB.5.10.2527; JOHNSON LF, 1994, J CELL BIOCHEM, V54, P387, DOI 10.1002/jcb.240540405; Ladner RD, 1996, J BIOL CHEM, V271, P7752, DOI 10.1074/jbc.271.13.7752; Ladner RD, 1996, J BIOL CHEM, V271, P7745, DOI 10.1074/jbc.271.13.7745; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LIRETTE R, 1990, J CELL BIOCHEM, V43, P339, DOI 10.1002/jcb.240430406; MAJELLO B, 1995, ONCOGENE, V10, P1841; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MCINTOSH EM, 1992, P NATL ACAD SCI USA, V89, P8020, DOI 10.1073/pnas.89.17.8020; MCINTOSH EM, 1994, CURR GENET, V26, P415, DOI 10.1007/BF00309928; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; MULLER SJ, 1993, J BIOL CHEM, V268, P1310; NEVINS JR, 1992, SCIENCE, V258, P424; PARDO EG, 1990, EXP CELL RES, V186, P90, DOI 10.1016/0014-4827(90)90214-U; PETROVABENEDICT R, 1987, AM J HUM GENET, V40, P257; PRIHADASH A, 1992, PLANT CELL, V4, P149, DOI 10.1105/tpc.4.2.149; PYLES RB, 1992, J VIROL, V66, P6706, DOI 10.1128/JVI.66.11.6706-6713.1992; ROISE D, 1988, J BIOL CHEM, V263, P4509; Sambrook J., 2002, MOL CLONING LAB MANU; SEDWICK WD, 1981, P NATL ACAD SCI-BIOL, V78, P917, DOI 10.1073/pnas.78.2.917; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; STRAHLER JR, 1993, P NATL ACAD SCI USA, V90, P4991, DOI 10.1073/pnas.90.11.4991; THREADGILL DS, 1993, J VIROL, V67, P2592, DOI 10.1128/JVI.67.5.2592-2600.1993; TUBOI S, 1990, ADV ENZYME REGUL, V30, P289	41	82	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1997	272	30					19072	19080		10.1074/jbc.272.30.19072	http://dx.doi.org/10.1074/jbc.272.30.19072			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XM342	9228092	hybrid			2022-12-25	WOS:A1997XM34200083
J	LustigYariv, O; Schulze, E; Komitowski, D; Erdmann, V; Schneider, T; deGroot, N; Hochberg, A				LustigYariv, O; Schulze, E; Komitowski, D; Erdmann, V; Schneider, T; deGroot, N; Hochberg, A			The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene?	ONCOGENE			English	Article						H19; IGF2; choriocarcinoma cell lines	GROWTH FACTOR-II; HUMAN EMBRYOGENESIS; MOUSE; RNA; RELAXATION	H19 is a paternally imprinted gene with unknown function, It is located in close proximity to the maternally imprinted IGF-2 gene on chromosome 11p15,5, In this study no consistent relationship between the expression of these two genes in clones derived from JEG-3 and JAr cell lines could be detected, Nor could a consistent relationship be detected between the expression levels of these two genes and between certain characteristic tumorigenic properties of these clones, We included in this study clones, expressing low H19 levels, which after transfection with an H19 expression construct highly expressed the H19 gene, In tumors, formed by the injection of cells of JAr or JEG-3 clones into nude mice, the H19 expression was high and irrelevant to the expression level in the cells before the injection, The same phenomenon was found for IGF-2 expression during tumorigenesis caused by cells of different JEG-3 clones and in some but not all JAr derived clones, Both H19 and IGF-2 are biallelicly expressed in all the JAr and JEG-3 clones, In summary, our observations point to the conclusion that H19 is not a tumor suppressor gene, However, its high expression in all the tumors formed after injection of cells of the JAr and JEG-3 clones, leaves its role, if any, in choriocarcinogenesis an open question.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; UNIV GOTTINGEN,ZOOL INST ENTWICKLUNGS BIOL,D-3400 GOTTINGEN,GERMANY; DKFZ,DEPT HISTODIAGNOST & PATHOMORPHOL,HEIDELBERG,GERMANY; FREE UNIV BERLIN,INST BIOCHEM,DEPT CHEM,D-1000 BERLIN,GERMANY	Hebrew University of Jerusalem; University of Gottingen; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin								Adam GIR, 1996, DEVELOPMENT, V122, P839; ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; AUSUBEL FM, 1993, CURRRENT PROTOCOLS M, V1; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper MJ, 1996, J UROLOGY, V155, P2120, DOI 10.1016/S0022-5347(01)66120-2; DEGROOT N, 1994, TROPH RES, V8, P285; DoucRasy S, 1996, ONCOGENE, V12, P423; DUGIMONT T, 1995, MOL CELL, V85, P117; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; FRESHNEY RI, 1990, CULTURE ANIMAL CELLS, P142; GOSHEN R, 1993, MOL REPROD DEV, V34, P374, DOI 10.1002/mrd.1080340405; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; Hibi K, 1996, CANCER RES, V56, P480; HOLTHUIZEN PE, 1993, REGUL PEPTIDES, V48, P77, DOI 10.1016/0167-0115(93)90337-8; JINNO Y, 1995, NAT GENET, V10, P318, DOI 10.1038/ng0795-318; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KONDO M, 1995, ONCOGENE, V10, P1193; Kondo M, 1996, ONCOGENE, V12, P1365; LUSTIG O, 1994, MOL REPROD DEV, V38, P239, DOI 10.1002/mrd.1080380302; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MCDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAPPOLEE DA, 1992, GENE DEV, V6, P939, DOI 10.1101/gad.6.6.939; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; RECHLER MM, 1990, PEPTIDE GROWTH FACTO, V1, P263; ROBERTSON EJ, 1995, DEV BIOL, V6, P293; Sambrook J., 2002, MOL CLONING LAB MANU; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Scrable H J, 1990, Adv Cancer Res, V54, P25, DOI 10.1016/S0065-230X(08)60807-6; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; Verkerk AJMH, 1997, ONCOGENE, V14, P95, DOI 10.1038/sj.onc.1200802; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	45	50	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					169	177		10.1038/sj.onc.1201175	http://dx.doi.org/10.1038/sj.onc.1201175			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244352				2022-12-25	WOS:A1997XK37200005
J	Qian, M; Kralova, J; Yu, WP; Bose, HR; Dvorak, M; Sanders, BG; Kline, K				Qian, M; Kralova, J; Yu, WP; Bose, HR; Dvorak, M; Sanders, BG; Kline, K			c-Jun involvement in vitamin E succinate induced apoptosis of reticuloendotheliosis virus transformed avian lymphoid cells	ONCOGENE			English	Article						AP-1; dominant negative c-Jun; c-Jun; vitamin E succinate; apoptosis; avian retrovirus transformed lymphoid cells	EXPRESSION; GROWTH; AP-1; FOS; PROTEINS; INVITRO; GENES	Previous studies have shown that treatment of avian reticuloendotheliosis virus-transformed RECC-UTC4-1 (C4-1) lymphoblastoid cells with 10 mu g/ml (18.8 mu M) of RRR-alpha-tocopheryl succinate (vitamin E succinate, VES) for 3 days induced approximately 50% of the cells to undergo apoptosis, Elevated and prolonged expression of c-jun mRNA and protein was temporally correlated with VES-induced cell death, Data presented in this paper show that the elevated and prolonged expression of c-jun message and protein are not accounted for by enhanced stability, and show the involvement of c-Jun in VES-induced apoptosis in this lymphoblastoid cell type, C4-1 cells infected with a virus carrying a dominant, negatively acting mutant form of c-Jun, supjun-1, exhibited: (i) 71% reduction in VES-induced apoptosis, (ii) a 2.0-2.5-fold decrease in wildtype, endogenous c-Jun expression, and (iii) a 2.4-2.6-fold reduction in AP-1 binding activity, Additionally, cells co-treated with VES plus RRR-alpha-tocopherol, exhibited a 70% reduction in apoptosis, a marked reduction in c-Jun expression and a 1.6-fold reduction in AP-1 binding activity, These studies suggest that c-Jun plays a crucial role in VES-induced apoptosis in C4-1 cells, and add to understanding of mechanisms of action involved VES-mediated tumor cell growth inhibition.	ACAD SCI CZECH REPUBL, GENET INST, PRAGUE, CZECH REPUBLIC; ACAD SCI CZECH REPUBL, INST MOL GENET, PRAGUE, CZECH REPUBLIC; UNIV TEXAS, DEPT MICROBIOL, AUSTIN, TX 78712 USA; UNIV TEXAS, DIV NUTR, AUSTIN, TX 78712 USA	Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin			Dvořák, Michal/I-9939-2014; Dvorak, Michal/G-5861-2014; Kralova, Jarmila/G-3834-2014	Kralova, Jarmila/0000-0002-4735-8857	NCI NIH HHS [CA33192, CA45422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033192, R01CA045422, R29CA045422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; CHEN YR, 1996, BIOL CHEM J, V271, P31929; COLLOTTA F, 1992, BIOL CHEM J, V267, P18278; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; KLINE K, 1991, VITAMINS AND MINERALS IN THE PREVENTION AND TREATMENT OF CANCER, P189; KLINE K, 1990, NUTR CANCER, V14, P27, DOI 10.1080/01635589009514075; KLINE K, 1995, NUTR CANC PREVENTION, P39; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; NISHIMURA T, 1988, ONCOGENE, V3, P659; OFFORD EA, 1993, CARCINOGENESIS, V14, P2447, DOI 10.1093/carcin/14.12.2447; OKUNO H, 1991, ONCOGENE, V6, P1491; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PRASAD KN, 1992, J AM COLL NUTR, V11, P487; Qian M, 1996, NUTR CANCER, V25, P9, DOI 10.1080/01635589609514424; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWARTZ J, 1993, ADJUVANT NUTRITION C, P173; SLACK R, 1989, NUTR CANCER, V12, P75, DOI 10.1080/01635588909514004; Sutterluety H, 1996, J MOL BIOL, V259, P383, DOI 10.1006/jmbi.1996.0327; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TRABER MG, 1988, AM J CLIN NUTR, V48, P605, DOI 10.1093/ajcn/48.3.605; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VANDEWERKEN R, 1993, EUR J BIOCHEM, V217, P781; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu WP, 1997, NUTR CANCER, V27, P267, DOI 10.1080/01635589709514537; Yu WP, 1997, NUTR CANCER, V27, P92, DOI 10.1080/01635589709514508	37	56	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	1997	15	2					223	230		10.1038/sj.onc.1201181	http://dx.doi.org/10.1038/sj.onc.1201181			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244357				2022-12-25	WOS:A1997XK37200010
J	Luan, XD; Shi, GP; Zohouri, M; Paradee, W; Smith, DI; Decker, HJ; Cannizzaro, LA				Luan, XD; Shi, GP; Zohouri, M; Paradee, W; Smith, DI; Decker, HJ; Cannizzaro, LA			The FHIT gene is alternatively spliced in normal kidney and renal cell carcinoma	ONCOGENE			English	Article						FHIT; renal cell carcinoma	CHROMOSOME-TRANSLOCATION; TUMOR-CELLS; BREAKPOINT; FRA3B	FHIT (Fragile Histidine Triad), a putative tumor suppressor gene, was cloned from fetal brain and colon cDNA libraries, Portions of this gene are deleted in esophageal, colon, lung and breast tumors, but this gene has not been found altered in sporadic renal cell carcinomas, We report here an alternatively spliced form of this gene cloned from a kidney cDNA library, This cDNA is 1189 bp in length, and contains an additional 94 bp exon, designated exon 2a (E2a), This novel sequence is located between exon 2 and exon 3 of the FHIT gene's untranslated region and exon 2a is present in all normal kidney tissues and cell Lines, Analyses performed on sporadic renal cell carcinoma (RCC) tissues and cell Lines, show consistent loss of exon 8 of the FHIT cDNA in almost 60% of the cases, Interestingly, in a familial, as well as, in a metastatic RCC, derived from a patient with the sporadic form, exon 2a and exon 3 are also deleted, Northern analyses with the exon 2a of the familial and the metastatic RCC demonstrates concurrent loss of expression of a 4.4 kb transcript with the loss of the E2a sequence, suggesting that exon 2a of the FHIT gene may play an important role in the oncogenesis of renal cell carcinoma.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PATHOL, BRONX, NY 10461 USA; WAYNE STATE UNIV, SCH MED, DEPT INTERNAL MED, DIV HEMATOL & ONCOL, DETROIT, MI 48201 USA; UNIV MAINZ, DEPT MED, DIV HEMATOL ONCOL, D-55313 MAINZ, GERMANY	Yeshiva University; Albert Einstein College of Medicine; Wayne State University; Johannes Gutenberg University of Mainz								ANGLARD P, 1991, CANCER RES, V51, P1071; ATCHISON L, 1995, CYTOGENET CELL GENET, V71, P136, DOI 10.1159/000134092; BOGHOSIANSELL L, 1992, CYTOGENET CELL GENET, V60, P268; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Fallon B, 1989, Semin Urol, V7, P228; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRAMZA AW, 1995, BIOTECHNIQUES, V18, P228; ISHIKAWA I, 1993, HISTOPATHOLOGY, V22, P135, DOI 10.1111/j.1365-2559.1993.tb00091.x; KOVACS G, 1988, HUM GENET, V78, P148, DOI 10.1007/BF00278186; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P256, DOI 10.1002/gcc.2870030404; KOVACS G, 1989, CANCER RES, V49, P651; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAFORGIA S, 1993, CANCER RES, V53, P3118; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; Moch H, 1996, CANCER RES, V56, P27; MORITA R, 1991, CANCER RES, V51, P820; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OLSON S, 1984, TUMORS KIDNEY URINAR, P15; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; Sambrook J, 1989, MOL CLONING; Shi G, 1996, CYTOGENET CELL GENET, V75, P180, DOI 10.1159/000134473; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; WILKE CM, 1994, GENOMICS, V22, P319, DOI 10.1006/geno.1994.1390; YAMAKAWA K, 1992, GENOMICS, V14, P412, DOI 10.1016/S0888-7543(05)80234-4	27	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					79	86		10.1038/sj.onc.1201164	http://dx.doi.org/10.1038/sj.onc.1201164			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233780				2022-12-25	WOS:A1997XH58600009
J	Zhou, Q; StetlerStevenson, M; Steeg, PS				Zhou, Q; StetlerStevenson, M; Steeg, PS			Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro	ONCOGENE			English	Article						cyclin D; 9-cis retinoic acid; all trans retinoic acid; Cdk2; Cdk4; breast cancer	DEPENDENT KINASE-ACTIVITY; CANCER-CELLS; RETINOBLASTOMA PROTEIN; 9-CIS-RETINOIC ACID; GENE-EXPRESSION; S-PHASE; GROWTH; OVEREXPRESSION; PROGRESSION; AMPLIFICATION	Transfection and transgenic mouse experiments supported an oncogenic role for cyclin D1 in breast cancer, We recently reported that noninvasive carcinoma ill situ lesions of the human breast overexpress cyclin D, suggesting that this molecular event may represent a valuable target for chemoprevention, The purpose of the present series of investigations vr as to identify agents which could reduce the cyclin D expression of breast cells, We report that 9-cis retinoic acid (9-cis RA) and all trans retinoic acid (tRA) inhibited the cyclin D1 and D3 expression levels of human MCF-7, ZR-75 and T-47D breast carcinoma cells in vitro. Where detectable, similar trends were observed in the immortalized, HBL-100 and MCF-10A breast cell lines, Cyclin D2 was undetectable, The effect of retinoids was both dose- and time-dependent, and correlated with altered cell cycle kinetics and proliferative status, Retinoids were also found to inhibit the expression levels of other cell cycle related proteins, including Cdk2 and Cdk4, resulting in lower kinase activities, In contrast to other breast prevention studies? no synergistic effect was observed with retinoids and tamoxifen. The data indicate that retinoids can potently reduce ca clin D expression levels in a variety of breast cell Lines in vitro, and suggest further consideration of this mechanism for the chemoprevention of breast cancer.	NCI,DIV CLIN SCI,PATHOL LAB,FLOW CYTOMETRY UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhou, Q (corresponding author), NCI,WOMENS CANC SECT,BETHESDA,MD 20892, USA.		zhou, qun/AAU-7592-2020	zhou, qun/0000-0001-6271-3143				ANZANO MA, 1994, CANCER RES, V54, P4614; Asano K, 1995, BIOCHEM BIOPH RES CO, V217, P1169, DOI 10.1006/bbrc.1995.2892; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; COSTA A, 1994, CANCER RES, V54, pS2032; Courjal F, 1996, INT J CANCER, V69, P247; DHINGRA K, 1995, J CELL BIOCH S, V23, P19; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; GILLETT C, 1994, CANCER RES, V54, P1812; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GORSPE M, 1996, MOL CELL BIOL, V14, P762; HAN EKH, 1995, ONCOGENE, V10, P953; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; JIANG W, 1993, ONCOGENE, V8, P3447; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Lama G, 1996, CANCER LETT, V100, P181, DOI 10.1016/0304-3835(95)04099-4; LATAN R, 1996, FASEB J, V10, P1031; LOVE R, 1994, MONOGR NATL CANC I, P61; LOVEC H, 1994, ONCOGENE, V9, P323; MAN T, 1994, LEUKEMIA, V8, P1785; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Noguchi M, 1996, ONCOLOGY-BASEL, V53, P175; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAGE DL, 1993, BREAST CANCER RES TR, V28, P157, DOI 10.1007/BF00666428; RUBIN M, 1994, CANCER RES, V54, P6549; SAVATIER P, 1995, ONCOGENE, V12, P309; SHAO ZM, 1995, ONCOGENE, V11, P493; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SIMPSON JF, IN PRESS AM J PATHOL; SPORN MB, 1983, CANCER RES, V43, P3034; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TAM SW, 1994, ONCOGENE, V9, P2663; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; WERSTO RP, 1995, CYTOMETRY, V20, P43, DOI 10.1002/cyto.990200108; WETHERALL NT, 1986, EUR J CANCER CLIN ON, V22, P53, DOI 10.1016/0277-5379(86)90342-1; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG SY, 1994, AM J CLIN PATHOL, V102, P695, DOI 10.1093/ajcp/102.5.695; ZHAO ZR, 1995, EXP CELL RES, V219, P555, DOI 10.1006/excr.1995.1264; Zhou P, 1996, CANCER RES, V56, P36; ZUCKERBERG L, 1995, MODERN PATHOL, V8, P560; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	53	88	88	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					107	115		10.1038/sj.onc.1201142	http://dx.doi.org/10.1038/sj.onc.1201142			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233783				2022-12-25	WOS:A1997XH58600012
J	Hung, IH; Suzuki, M; Yamaguchi, Y; Yuan, DS; Klausner, RD; Gitlin, JD				Hung, IH; Suzuki, M; Yamaguchi, Y; Yuan, DS; Klausner, RD; Gitlin, JD			Biochemical characterization of the Wilson disease protein and functional expression in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER TRANSPORTING ATPASE; P-TYPE ATPASES; MANNOSE 6-PHOSPHATE; IRON UPTAKE; GENE; CELLS; CERULOPLASMIN; ORGANIZATION; BIOGENESIS; MECHANISMS	Wilson disease is a disorder of copper metabolism characterized by hepatic cirrhosis and neuronal degeneration due to inherited mutations in a gene encoding a putative copper-transporting P-type ATPase. Polyclonal antisera generated against the amino terminus of the Wilson protein detected a specific 165-kDa protein in HepG2 and CaCo cell lysates, Further analysis revealed that this protein is synthesized as a single-chain polypeptide and localized to the trans-Golgi network under steady state conditions. An increase in the copper concentration resulted in the rapid movement of this protein to a cytoplasmic vesicular compartment. This copper-specific cellular redistribution of the Wilson protein is a reversible process that occurs independent of a new protein synthesis. Expression of the wild-type but not mutant Wilson protein in the ccc2 Delta strain of Saccharomyces cerevisiae restored copper incorporation into the multicopper oxidase Fet3p, providing direct evidence of copper transport by the Wilson protein. Taken together these data reveal a remarkable evolutionary conservation in the cellular mechanisms of copper metabolism and provide a unique model for the regulation of copper transport into the secretory pathway of eucaryotic cells.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892	Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K08HD058219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044464, R37DK044464] Funding Source: NIH RePORTER; NICHD NIH HHS [K08 HD058219] Funding Source: Medline; NIDDK NIH HHS [DK44464] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1995, METABOLIC BASIS INHE; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CUTHBERT JA, 1995, J INVEST MED, V43, P323; CZECH MP, 1995, ANN REV NUTR, V15, P44; Dierick HA, 1997, HUM MOL GENET, V6, P409, DOI 10.1093/hmg/6.3.409; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HUNG IH, 1997, OXFORD TXB CLIN HEPA; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KARLSSON L, 1994, SCIENCE, V266, P1569, DOI 10.1126/science.7985028; Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; OWEN CA, 1973, AM J PHYSIOL, V224, P514; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1991, J BIOL CHEM, V266, P5128; Sherman F., 1978, METHODS YEAST GENETI; Siddique T, 1996, HUM MOL GENET, V5, P1465, DOI 10.1093/hmg/5.Supplement_1.1465; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	40	272	274	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21461	21466		10.1074/jbc.272.34.21461	http://dx.doi.org/10.1074/jbc.272.34.21461			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261163	hybrid			2022-12-25	WOS:A1997XR78900073
J	Murthy, KS; Makhlouf, GM				Murthy, KS; Makhlouf, GM			Differential coupling of muscarinic m(2) and m(3) receptors to adenylyl cyclases V/VI in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; SIGNAL TRANSDUCTION PATHWAYS; INTESTINAL MUSCLE; LONGITUDINAL MUSCLE; GUINEA-PIG; RAT-BRAIN; CELLS; STIMULATION; CLONING; CALCIUM	Muscarinic m(2) and m(4) receptors couple preferentially to inhibition of adenylyl cyclase, whereas m(1), m(3), and m(5) receptors couple preferentially to activation of phospholipase C-beta and in some cells to stimulation of cAMP. Smooth muscle cells were shown to express adenylyl cyclases types V and/or VI. Acetylcholine (ACh) stimulated the binding of [S-35]GTP gamma S.G alpha complexes in smooth muscle membranes to G alpha(q/11) and G alpha(i3) antibody. Binding to G alpha(q/11) antibody was inhibited by the m(3) receptor antagonist, 4-DAMP, and binding to G alpha(i3) antibody was inhibited by the m(2) receptor antagonist, N,N'-bis[6[[(2-methoxyphenyl)methyl]amino]hexyl]-1,8-octanediamine tetrahydrochloride (methoctramine), The decrease in basal cAMP (35 +/- 5%) induced by ACh in dispersed muscle cells was accentuated by 4-DAMP or G(beta) antibody (55 +/- 8 to 63 +/- 6%). In contrast, methoctramine, pertussis toxin (PTx), or G alpha(i3) , antibody converted the decrease in cAMP to increase above basal level (+28 +/- 5 to +32 +/- 6%); the increase in cAMP was abolished by 4-DAMP or G(beta) antibody. In muscle cells where only m(3) receptors were preserved by selective receptor protection, ACh caused only an increase in cAMP that was abolished by 4-DAMP. Conversely, in muscle cells where only m(2) receptors were preserved, ACh caused an accentuated decrease in cAMP that was abolished by methoctramine or PTx, In conclusion, m(2) receptors in smooth muscle couple to inhibition of adenylyl cyclases V/VI via G alpha(i3), and m(3) receptors couple to activation of the enzymes via G beta gamma(q/11).	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYSIOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028300] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-28300] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARLOW RB, 1976, BRIT J PHARMACOL, V58, P613, DOI 10.1111/j.1476-5381.1976.tb08631.x; BAUMGOLD J, 1992, TRENDS PHARMACOL SCI, V13, P339, DOI 10.1016/0165-6147(92)90105-F; BAUMGOLD J, 1988, BIOCHEM BIOPH RES CO, V154, P1137, DOI 10.1016/0006-291X(88)90259-8; BITAR KN, 1986, J BIOL CHEM, V261, P6591; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CANDELL LM, 1990, MOL PHARMACOL, V38, P689; CAUFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOO LK, 1985, J PHARM PHARMACOL, V37, P656, DOI 10.1111/j.2042-7158.1985.tb05106.x; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; EGLEN RM, 1994, TRENDS PHARMACOL SCI, V15, P114, DOI 10.1016/0165-6147(94)90047-7; Ehlert FJ, 1997, MUSCARINIC RECEPTOR, P87; ESAUEDA EE, 1996, BIOCHEM PHARMACOL, V52, P643; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FELDER CC, 1989, J BIOL CHEM, V264, P20356; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GRIFFIN MT, 1992, J PHARMACOL EXP THER, V263, P221; HELLSTROM PM, 1994, J PHARMACOL EXP THER, V270, P236; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUEMMERLE JF, 1992, AM J PHYSIOL, V263, pG269, DOI 10.1152/ajpgi.1992.263.2.G269; KUEMMERLE JF, 1995, GASTROENTEROLOGY, V109, P1791, DOI 10.1016/0016-5085(95)90745-9; MICHEL AD, 1987, BRIT J PHARMACOL, V92, P755, DOI 10.1111/j.1476-5381.1987.tb11379.x; MORINI G, 1993, J PHARMACOL EXP THER, V264, P598; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; Murthy KS, 1996, MOL PHARMACOL, V50, P870; MURTHY KS, 1991, AM J PHYSIOL, V261, pG937, DOI 10.1152/ajpgi.1991.261.6.G937; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; MURTHY KS, 1994, J BIOL CHEM, V269, P15977; Murthy KS, 1997, GASTROENTEROLOGY, V112, pA1175; MURTHY KS, 1996, GASTROENTEROLOGY, V110, pA1102; OKOMOTO T, 1992, FEBS LETT, V305, P125; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SUH BC, 1995, J NEUROCHEM, V64, P2500; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; WALL SJ, 1991, MOL PHARMACOL, V40, P783; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YU HJ, 1993, MOL PHARMACOL, V44, P689; ZHANG LB, 1991, MOL PHARMACOL, V40, P952	57	72	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21317	21324		10.1074/jbc.272.34.21317	http://dx.doi.org/10.1074/jbc.272.34.21317			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261144	hybrid			2022-12-25	WOS:A1997XR78900054
J	Pulli, T; Koivunen, E; Hyypia, T				Pulli, T; Koivunen, E; Hyypia, T			Cell-surface interactions of echovirus 22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; PHAGE-DISPLAY LIBRARIES; MOUTH-DISEASE VIRUS; AMINO-ACID SEQUENCE; COXSACKIEVIRUS A9; FACTOR CD55; VITRONECTIN RECEPTOR; PICORNAVIRUS GROUP; FILAMENTOUS PHAGE; INHIBIT BINDING	Echovirus 22 (EV22) is a picornavirus forming a distinct molecular cluster together with echovirus 23. EV22 has an Arg-Gly-Asp (RGD) peptide motif in its capsid protein VP1; similar motifs are known to mediate many cell-cell and microbe-host interactions, To identify pep tide sequences that specifically bind to EV22 and potentially play a role in receptor recognition, we have used here peptide libraries displayed in filamentous pha,be. We isolated an EV22-binding motif CLRSG(RIF)GC, The synthetic CLRSGRGC peptide was able to inhibit EV22 infection, The infection was also inhibited by an RGD-containing peptide representing the C terminus of the EV22 capsid protein VP1 and CWDDGWLC (an RGD-binding peptide; Pasqualini, R., Koivunen, E., and Ruoslahti, E. (1995) J. Cell Biol. 130, 1189-1196). As the EV22-recognizing sequence LRSG is found in the integrin beta(1) chain and the entire LRSGRG hexapeptide occurs in the matrix metalloproteinase 9 (MMP-9), we carried out blocking experiments with anti-integrin and anti-MMP-9 antibodies. EV22 infection could be blocked in cell cultures with anti-alpha(v), -beta(1), and, to a lesser extent, with anti-MMP-9 antibodies. These results imply that EV22 recognizes preferentially alpha(v) beta(1)-integrin as a cellular receptor and MMP-9 may also play a role in the cell-surface interactions of the virus.	UNIV TURKU,MEDICITY RES LAB,FIN-20520 TURKU,FINLAND; UNIV HELSINKI,DIV BIOCHEM,FIN-00014 HELSINKI,FINLAND	University of Turku; University of Helsinki	Pulli, T (corresponding author), NATL PUBL HLTH INST,ENTEROVIRUS LAB,MANNERHEIMINTIE 166,FIN-00300 HELSINKI,FINLAND.			Koivunen, Erkki/0000-0002-6443-9595				ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BERGELSON JM, 1993, J VIROL, V67, P6847, DOI 10.1128/JVI.67.11.6847-6852.1993; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; BERGELSON JM, 1994, P NATL ACAD SCI USA, V91, P6245, DOI 10.1073/pnas.91.13.6245; BERINSTEIN A, 1995, J VIROL, V69, P2664, DOI 10.1128/JVI.69.4.2664-2666.1995; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; DEVERDUGO UR, 1995, J VIROL, V69, P6751, DOI 10.1128/JVI.69.11.6751-6757.1995; EHRNST A, 1993, SCAND J INFECT DIS, V25, P275, DOI 10.3109/00365549309008499; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; Germaschewski V, 1996, J VIROL METHODS, V58, P21, DOI 10.1016/0166-0934(95)01980-4; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Heiskanen T, 1997, J VIROL, V71, P3879, DOI 10.1128/JVI.71.5.3879-3885.1997; HONG SS, 1995, EMBO J, V14, P4714, DOI 10.1002/j.1460-2075.1995.tb00153.x; HUGHES PJ, 1995, J VIROL, V69, P8035, DOI 10.1128/JVI.69.12.8035-8040.1995; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYYPIA T, 1992, P NATL ACAD SCI USA, V89, P8847, DOI 10.1073/pnas.89.18.8847; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; MBIDA AD, 1992, RES VIROLOGY, V143, P397, DOI 10.1016/S0923-2516(06)80132-9; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; ROIVAINEN M, 1991, J VIROL, V65, P4735, DOI 10.1128/JVI.65.9.4735-4740.1991; ROIVAINEN M, 1994, VIROLOGY, V203, P357, DOI 10.1006/viro.1994.1494; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHAFREN DR, 1995, J VIROL, V69, P3873, DOI 10.1128/JVI.69.6.3873-3877.1995; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; STANWAY G, 1990, J GEN VIROL, V71, P2483, DOI 10.1099/0022-1317-71-11-2483; STANWAY G, 1994, J VIROL, V68, P8232, DOI 10.1128/JVI.68.12.8232-8238.1994; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; WARD T, 1994, EMBO J, V13, P5070, DOI 10.1002/j.1460-2075.1994.tb06836.x; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643	45	68	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21176	21180		10.1074/jbc.272.34.21176	http://dx.doi.org/10.1074/jbc.272.34.21176			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261123	hybrid			2022-12-25	WOS:A1997XR78900033
J	Sugasawa, T; MatsuzakiFujita, M; Guillaume, JL; Camoin, L; Morooka, S; Strosberg, AD				Sugasawa, T; MatsuzakiFujita, M; Guillaume, JL; Camoin, L; Morooka, S; Strosberg, AD			Characterization of a novel iodocyanopindolol and SM-11044 binding protein, which may mediate relaxation of depolarized rat colon tonus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATYPICAL BETA-ADRENOCEPTORS; POLYACRYLAMIDE-GEL ELECTROPHORESIS; HUMAN BETA-3-ADRENERGIC RECEPTOR; MOLECULAR CHARACTERIZATION; ALPHA-2B-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; CLONING; EXPRESSION; INHIBITION; SEPARATION	Studies under blockade of alpha-, beta 1-, and beta 2-adrenoreceptor tors revealed a good correlation between the responses of rat colon relaxation of depolarized tonus and of rat adipocyte lipolysis elicited by catecholamines or BRL-37344, a selective beta 3-adrenoreceptor agonist, suggesting beta 3-adrenoreceptor stimulation. In contrast, SM-11044, a nonselective beta-adrenoreceptor agonist, stimulated colon relaxation more efficiently than lipolysis; its effects were differently antagonized by cyanopindolol with pA(2) values of 8.31 in colon and of 7,32 in adipocytes, Binding studies in rat colon smooth muscle membranes using [I-125]iodocyanopindolol under blockade of adrenaline and serotonin receptors revealed the existence of a single class of sites (K-d = 11.0 nM, B-max = 716,7 fmol/mg protein). The specific binding was saturable and reversible and was displaced by SM-11044 but not by BRL-37344, isoproterenol, noradrenaline, adrenaline, serotonin, nor dopamine. This binding site was photoaffinity labeled using [I-125]iodocyanopindolol-diazirine. The labeling was prevented by SIM-11044 but not by BRL-37344, The amino-terminal amino acid sequences of the high performance liquid chromatography-purified peptides generated by enzymatic and chemical cleavages of the affinity labeled 34-kDa protein confirmed that the novel. iodocyanopindolol or SM-11044 binding protein of rat colon smooth muscle membranes is different from known adrenaline, serotonin, or dopamine receptors. Its functional role might include the relaxation of depolarized colon.	INST COCHIN GENET MOL,CNRS,UPR 0415,F-75014 PARIS,FRANCE; UNIV PARIS 07,F-75014 PARIS,FRANCE; SUMITOMO PHARMACEUT CO LTD,RES CTR,KAWASAKI KU,OSAKA 554,JAPAN	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite			Camoin, Luc/AAB-3856-2019	Camoin, Luc/0000-0002-1230-4787				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BENSAID M, 1993, FEBS LETT, V318, P223, DOI 10.1016/0014-5793(93)80516-W; BLUE DR, 1989, BRIT J PHARMACOL, V96, P246; BOND RA, 1988, BRIT J PHARMACOL, V95, P723, DOI 10.1111/j.1476-5381.1988.tb11698.x; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CROCI T, 1988, PHARMACOL RES, V20, P147, DOI 10.1016/S0031-6989(88)80007-9; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EK BA, 1986, GASTROENTEROLOGY, V90, P408, DOI 10.1016/0016-5085(86)90940-6; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; Fontana A, 1986, PRACTICAL PROTEIN CH, P67; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; GUILLAUME JL, 1994, EUR J BIOCHEM, V224, P761, DOI 10.1111/j.1432-1033.1994.00761.x; HOYER D, 1994, PHARMACOL REV, V46, P157; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARD D, 1994, EUR J BIOCHEM, V220, P919, DOI 10.1111/j.1432-1033.1994.tb18695.x; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MANARA L, 1990, TRENDS PHARMACOL SCI, V11, P229, DOI 10.1016/0165-6147(90)90247-6; MCLAUGHLIN DP, 1990, BRIT J PHARMACOL, V101, P569, DOI 10.1111/j.1476-5381.1990.tb14122.x; MCLAUGHLIN DP, 1991, BRIT J PHARMACOL, V103, P1351, DOI 10.1111/j.1476-5381.1991.tb09792.x; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Strosberg AD, 1997, ANNU REV PHARMACOL, V37, P421, DOI 10.1146/annurev.pharmtox.37.1.421; SUGASAWA T, 1992, EUR J PHARMACOL, V216, P207; SUGASAWA T, 1992, AGENTS ACTIONS, V37, P233; SUGASAWA T, 1992, RECENT ADV CELLULAR, V3, P223; TATE KM, 1991, EUR J BIOCHEM, V196, P357, DOI 10.1111/j.1432-1033.1991.tb15824.x; VANDERVLIET A, 1990, J PHARMACOL EXP THER, V255, P218; WATSON S, 1996, RECEPTOR ION CHANNEL; WEINSHANK RL, 1990, MOL PHARMACOL, V38, P681; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	34	10	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21244	21252		10.1074/jbc.272.34.21244	http://dx.doi.org/10.1074/jbc.272.34.21244			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261134	hybrid			2022-12-25	WOS:A1997XR78900044
J	Arruda, LK; Vailes, LD; PlattsMills, TAE; Hayden, ML; Chapman, MD				Arruda, LK; Vailes, LD; PlattsMills, TAE; Hayden, ML; Chapman, MD			Induction of IgE antibody responses by glutathione S-transferase from the German cockroach (Blattella germanica)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOUSE-DUST MITE; MAJOR ALLERGEN; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; IMMUNOGLOBULIN-E; MUSCA-DOMESTICA; RISK-FACTORS; PURIFICATION; ASTHMA; EXPRESSION	We report that a major 23-kDa allergen from German cockroach (Blattella germanica) is a glutathione S-transferase (EC 2.5.1.18; GST). Natural B. germanica GST, purified from cockroach body extracts by glutathione affinity chromatography, and recombinant protein expressed in Escherichia coli using the pET21a vector, showed excellent IgE antibody binding activity. B. germanica GST caused positive immediate skin tests in cockroach-allergic patients using as little as 3 pg of recombinant protein. The NH2-terminal sequence of the natural protein and the deduced amino acid sequence from cDNA were identical except for one substitution (Phe(9) --> Cys). Assignment of this protein to the GST superfamily was based on binding to glutathione and sequence identity (42-51%) to the GST-S subfamily from insects, including Anopheles gambiae and Drosophila melanogaster. B. germanica GST contained 18 of the 26 invariable residues identified in mammalian GST by xray crystallography and exhibited enzymic activity against a GST substrate. Our results show that cockroach GST causes IgE antibody responses and is associated with asthma. The data strongly support the view that the immune response to GST plays an important role in allergic diseases.	UNIV VIRGINIA, HLTH SCI CTR, ASTHMA & ALLERG DIS CTR, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia			Arruda, L. Karla/D-5845-2013	Arruda, L. Karla/0000-0002-7505-210X; Chapman, Martin/0000-0002-0845-3632; Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI 34607, AI 32557] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032557, U19AI034607, U01AI034607] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; AURIAULT C, 1990, J CLIN MICROBIOL, V28, P1918, DOI 10.1128/JCM.28.9.1918-1924.1990; BEALL C, 1992, BIOCHEM GENET, V30, P515, DOI 10.1007/BF01037590; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; BOARD P, 1994, BIOCHEM J, V299, P425, DOI 10.1042/bj2990425; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CAPRON M, 1994, SCIENCE, V264, P1876, DOI 10.1126/science.8009216; Chapman MD, 1997, INT ARCH ALLERGY IMM, V113, P102, DOI 10.1159/000237518; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1997, ALLERGY ALLERGIC DIS; CLARK AG, 1989, COMP BIOCHEM PHYS B, V92, P419, DOI 10.1016/0305-0491(89)90114-4; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; DUDLER T, 1995, J IMMUNOL, V155, P2605; FOURNIER D, 1992, J BIOL CHEM, V267, P1840; FRANCIOSA H, 1995, INSECT BIOCHEM MOLEC, V25, P311, DOI 10.1016/0965-1748(94)00053-K; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GULICK AM, 1992, J BIOL CHEM, V267, P18946; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYAOKA T, 1982, PESTIC BIOCHEM PHYS, V17, P113, DOI 10.1016/0048-3575(82)90015-3; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KHAN CMA, 1994, P NATL ACAD SCI USA, V91, P11261, DOI 10.1073/pnas.91.23.11261; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; MANOHARAN TH, 1992, J BIOL CHEM, V267, P18940; ONEILL GM, 1994, BBA-GENE STRUCT EXPR, V1219, P521, DOI 10.1016/0167-4781(94)90080-9; OTTEA JA, 1984, PESTIC BIOCHEM PHYS, V22, P203, DOI 10.1016/0048-3575(84)90091-9; PENINGTON CJ, 1992, BIOCHEMISTRY-US, V31, P2912, DOI 10.1021/bi00126a010; PENROSE JF, 1995, AM J RESP CRIT CARE, V152, P283, DOI 10.1164/ajrccm.152.1.7599836; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER MJ, 1995, INSECT BIOCHEM MOLEC, V25, P455, DOI 10.1016/0965-1748(94)00083-B; STENERSEN J, 1987, COMP BIOCHEM PHYS C, V86, P73, DOI 10.1016/0742-8413(87)90147-2; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; SYVANEN M, 1994, MOL GEN GENET, V245, P25, DOI 10.1007/BF00279747; TANG AH, 1994, J BIOL CHEM, V269, P27876; TOUNG YPS, 1990, P NATL ACAD SCI USA, V87, P31, DOI 10.1073/pnas.87.1.31; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; WOOD E, 1986, COMP BIOCHEM PHYS B, V84, P607, DOI 10.1016/0305-0491(86)90130-6; Wu CH, 1996, J BIOL CHEM, V271, P17937, DOI 10.1074/jbc.271.30.17937; XU CB, 1993, J IMMUNOL, V150, P940	55	128	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20907	20912		10.1074/jbc.272.33.20907	http://dx.doi.org/10.1074/jbc.272.33.20907			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252418	hybrid			2022-12-25	WOS:A1997XR22100088
J	Gasparri, A; Sidoli, A; Sanchez, LP; Longhi, R; Siccardi, AG; Marchisio, PC; Corti, A				Gasparri, A; Sidoli, A; Sanchez, LP; Longhi, R; Siccardi, AG; Marchisio, PC; Corti, A			Chromogranin A fragments modulate cell adhesion - Identification and characterization of a pro-adhesive domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEIN-I; SOLID-PHASE SYNTHESIS; MESSENGER-RNA; MONOCLONAL-ANTIBODIES; CHROMAFFIN GRANULES; ENDOCRINE-CELLS; ADRENAL-MEDULLA; CLEAVAGE SITES; PEPTIDE; PANCREASTATIN	Although several functions have been suggested for chromogranin A, a glycoprotein secreted by many neuroendocrine cells, the physiological role of this protein and of its proteolytic fragments has not been established. We have found that mixtures of chromogranin A fragments can inhibit fibroblast adhesion. The anti-adhesive activity was converted into pro-adhesive activity by limited trypsin treatment. Pro-adhesive effects were observed also with recombinant N-terminal fragments corresponding to residues 1-78 and 1-115 and with a synthetic peptide encompassing the residues 7-57. These fragments induced adhesion and spreading of fibroblasts on plates coated with collagen I or IV, laminin, fetal calf serum (FCS) but not on bovine serum albumin. The long incubation time required for adhesion assays (4 h) and the FCS requirements for optimal adhesion suggest that the adhesive activity is likely indirect and requires other proteins present in the FCS or made by the cells. These findings suggest that chromogranin A and its fragments could play a role in the regulation of cell adhesion. Since chromogranin A is concentrated and stored within granules and rapidly released by neuroendocrine cells and neurons after an appropriate stimulus, this protein could be important for the local control of cell adhesion by stimulated cells.	SAN RAFFAELE SCI INST,DIBIT,DEPT BIOL & TECHNOL RES,I-20132 MILAN,ITALY; UNIV MILAN,DEPT BIOL & GENET MED SCI,I-20131 MILAN,ITALY; UNIV TURIN,SCH MED,DEPT BIOMED SCI & HUMAN ONCOL,I-10126 TURIN,ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; University of Turin			Corti, Angelo/F-7046-2012; Gasparri, Anna Maria/AAN-5071-2020	Corti, Angelo/0000-0002-0893-6191; Gasparri, Anna Maria/0000-0002-1757-8699; Subba, Rajkrishna/0000-0003-0051-0062				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; ADAMS LA, 1993, BRAIN RES, V602, P336, DOI 10.1016/0006-8993(93)90699-N; ANGELETTI RH, 1985, SCIENCE, V230, P89, DOI 10.1126/science.3898368; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BRANDT DW, 1994, P SOC EXP BIOL MED, V205, P316; CHEN M, 1992, J NEUROCHEM, V58, P1691, DOI 10.1111/j.1471-4159.1992.tb10042.x; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COHN DV, 1982, P NATL ACAD SCI-BIOL, V79, P6056, DOI 10.1073/pnas.79.19.6056; Corti A, 1996, EUR J BIOCHEM, V235, P275, DOI 10.1111/j.1432-1033.1996.00275.x; Corti A, 1996, BRIT J CANCER, V73, P924, DOI 10.1038/bjc.1996.183; DEFTOS LJ, 1990, BONE MINER, V9, P169, DOI 10.1016/0169-6009(90)90035-E; DEFTOS LJ, 1991, ENDOCR REV, V12, P181, DOI 10.1210/edrv-12-2-181; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; EHRHART M, 1988, J HISTOCHEM CYTOCHEM, V36, P467, DOI 10.1177/36.5.3282005; FERRER M, 1992, INT J PEPT PROT RES, V40, P194; GALINDO E, 1991, P NATL ACAD SCI USA, V88, P1426, DOI 10.1073/pnas.88.4.1426; GORR SU, 1988, BONE MINER, V4, P17; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; HUTTON JC, 1985, FEBS LETT, V188, P336, DOI 10.1016/0014-5793(85)80398-7; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; IACANGELO AL, 1988, ENDOCRINOLOGY, V122, P2339, DOI 10.1210/endo-122-5-2339; IGUCHI H, 1992, EUR J CANCER, V28A, P1458, DOI 10.1016/0959-8049(92)90543-B; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; LAZURE C, 1990, PEPTIDES, V11, P79, DOI 10.1016/0196-9781(90)90114-K; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MUNOZ DG, 1990, NEUROSCIENCE, V34, P533, DOI 10.1016/0306-4522(90)90162-W; OCONNOR DT, 1984, T ASSOC AM PHYSICIAN, V97, P242; PELAGI M, 1989, MOL CELL PROBE, V3, P87, DOI 10.1016/0890-8508(89)90039-X; QIAN J, 1988, J NEUROIMMUNOL, V17, P159, DOI 10.1016/0165-5728(88)90023-9; ROSA P, 1994, J ENDOCRINOL INVEST, V17, P207, DOI 10.1007/BF03347721; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SERCKHANSSEN G, 1984, J BIOL CHEM, V259, P1597; SIMON JP, 1989, BIOCHEM J, V262, P1; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STEINER HJ, 1990, J HISTOCHEM CYTOCHEM, V38, P845, DOI 10.1177/38.6.2139887; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; WOHLFARTER T, 1988, FEBS LETT, V231, P67, DOI 10.1016/0014-5793(88)80704-X; WU HJ, 1991, J BIOL CHEM, V266, P13130; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1990, J BIOL CHEM, V265, P14414	48	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20835	20843		10.1074/jbc.272.33.20835	http://dx.doi.org/10.1074/jbc.272.33.20835			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252409	hybrid			2022-12-25	WOS:A1997XR22100079
J	Li, YC; Zhang, WX; Mantell, LL; Kazzaz, JA; Fein, AM; Horowitz, S				Li, YC; Zhang, WX; Mantell, LL; Kazzaz, JA; Fein, AM; Horowitz, S			Nuclear factor-kappa B is activated by hyperoxia but does not protect from cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; PHOSPHORYLATION; KINASE; GENE; SPECIFICITY; ELEGANS	Oxidative insults that are lethal to epithelial cells kill either via apoptosis or necrosis. Nuclear factor-kappa B (NF-kappa B) is a redox-sensitive transcription factor that is activated by oxidative insult, and NF-kappa B activation can protect cells from apoptosis. To test if NF-kappa B can protect from necrotic cell death caused by high levels of molecular O-2 (hyperoxia), we exposed human alveolar epithelial (A549) cells to hyperoxia. NF-kappa B was shown to be activated and was translocated to the nucleus within minutes. Nuclear translocation persisted over the course of several days, and the levels of NF-kappa B protein and mRNA increased as well. In hyperoxia, NF-kappa B regulation was independent of mitogen-activated protein kinase (MAPK). In sharp contrast, there was neither nuclear translocation of NF-kappa B nor any increase in expression after exposure to H2O2 at a concentration where this oxidant induces both MAPK and widespread apoptosis. Despite the activation and increased expression of NF-kappa B in hyperoxia, this oxidant remained lethal to the cells. These observations confirm the notion that apoptosis occurs in the absence of NF-kappa B activation but indicate that protection from cell death by NF-kappa B is probably limited to apoptosis.	SUNY STONY BROOK,WINTHROP UNIV HOSP,CARDIOPULM RES INST,SCH MED,DEPT PEDIAT,MINEOLA,NY 11501; SUNY STONY BROOK,WINTHROP UNIV HOSP,DEPT PULM & CRIT CARE MED,MINEOLA,NY 11501	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital			weixian, zhang/H-4046-2013	weixian, zhang/0000-0002-0250-4013				ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; ANTWERP DJV, 1996, SCIENCE, V274, P787; Barinaga M, 1996, SCIENCE, V274, P724, DOI 10.1126/science.274.5288.724; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CAPPELLETTI G, 1994, CELL BIOL TOXICOL, V10, P255, DOI 10.1007/BF00756765; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; FORREST VJ, 1994, FREE RADICAL BIO MED, V16, P675, DOI 10.1016/0891-5849(94)90182-1; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MENON SD, 1993, J BIOL CHEM, V268, P26805; Morris A H, 1994, New Horiz, V2, P19; PAULSEN JE, 1995, GENETICS, V141, P1383; SANDSTROM PA, 1993, AIDS RES HUM RETROV, V9, P1107, DOI 10.1089/aid.1993.9.1107; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; STOGNER SW, 1992, ANN PHARMACOTHER, V26, P1554, DOI 10.1177/106002809202601214; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	28	93	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20646	20649		10.1074/jbc.272.33.20646	http://dx.doi.org/10.1074/jbc.272.33.20646			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252381	hybrid			2022-12-25	WOS:A1997XR22100051
J	Liu, YLE; Wang, MS; Greene, J; Su, J; Ullrich, S; Li, H; Sheng, SJ; Alexander, P; Sang, QXA; Shi, YE				Liu, YLE; Wang, MS; Greene, J; Su, J; Ullrich, S; Li, H; Sheng, SJ; Alexander, P; Sang, QXA; Shi, YE			Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASES; MATRIX METALLOPROTEINASES; METASTATIC ABILITY; MESSENGER-RNA; CHICK-EMBRYO; CELL-LINE; IN-VIVO; EXPRESSION; CANCER; INVASION	TIMP-4, a novel human tissue inhibitor of metalloproteinase, was identified and cloned (Greene, J., Wang, M., Raymond, L. A., Liu, Y. E., Rosen, C., and Shi, Y. E. (1996) J. Biol. Chem. 271, 30375-30380). In this report, the production and characterization of recombinant TIMP-4 (rTIMP4p) are described. rTIMP4p, expressed in baculovirus-infected insect cells, was purified to homogeneity by a combination of cation exchange, hydrophobic, and size-exclusion chromatographies. The purified protein migrated as a single 23-kDa band in SDS-polyacrylamide gel electrophoresis and in Western blot using a specific anti-TIMP-4 antibody. Inhibition of matrix metalloproteinase (MMP) activities by rTIMP4p was demonstrated in five MMPs. Enzymatic kinetic studies revealed IC50 values (concentration at 50% inhibition) of 19, 3, 45, 8, and 83 nM for MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9, respectively. Purified rTIMP4p demonstrated a strong inhibitory effect on the invasion of human breast cancer cells across reconstituted basement membranes. Thus, TIMP-4 is a new enzymatic inhibitor in MMP-mediated extracellular matrix degradation and may have therapeutic potential in treating cancer malignant progression.	LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,NEW HYDE PK,NY 11040; LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT PATHOL,NEW HYDE PK,NY 11040; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,INST MOL BIOPHYS,TALLAHASSEE,FL 32306; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC GENET,BOSTON,MA 02115; TRIPLE POINT BIOL,FOREST GROVE,OR 97116	Northwell Health; Yeshiva University; Northwell Health; Yeshiva University; GlaxoSmithKline; Human Genome Sciences Inc; State University System of Florida; Florida State University; State University System of Florida; Florida State University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R29CA068064] Funding Source: NIH RePORTER; NCI NIH HHS [CA68064-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; BASSET P, 1994, CANCER-AM CANCER SOC, V74, P1045, DOI 10.1002/1097-0142(19940801)74:3+<1045::AID-CNCR2820741511>3.0.CO;2-7; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BOUJRAD N, 1995, SCIENCE, V268, P1609, DOI 10.1126/science.7777858; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; DECLERCK YA, 1992, CANCER RES, V52, P701; Denhardt D T, 1992, Matrix Suppl, V1, P281; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Fujimoto N, 1996, BIOCHEM J, V313, P827, DOI 10.1042/bj3130827; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; Heppner KJ, 1996, AM J PATHOL, V149, P273; Imren S, 1996, CANCER RES, V56, P2891; JAY GD, 1990, ANAL BIOCHEM, V185, P324, DOI 10.1016/0003-2697(90)90302-P; JOHNSON MD, 1994, J CELL PHYSL, V160, P1984; KHOKHA R, 1992, CLIN EXP METASTAS, V10, P365, DOI 10.1007/BF00133464; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LENNARZ WJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P149, DOI 10.1016/0304-4157(91)90022-O; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; Matsuzawa K, 1996, J NEUROPATH EXP NEUR, V55, P88, DOI 10.1097/00005072-199601000-00009; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; Nagase H, 1996, ADV EXP MED BIOL, V389, P23; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; OHBA Y, 1995, BBA-GEN SUBJECTS, V1245, P1, DOI 10.1016/0304-4165(95)00065-J; POULSOM R, 1993, J CLIN PATHOL, V46, P429, DOI 10.1136/jcp.46.5.429; PYKE C, 1993, AM J PATHOL, V142, P359; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Sang QXA, 1996, J PROTEIN CHEM, V15, P243, DOI 10.1007/BF01887112; SHI YE, 1993, CANCER RES, V53, P1409; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; URIA JA, 1994, CANCER RES, V54, P2091; Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245; Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1676::AID-CNCR14>3.3.CO;2-#; WICK M, 1994, J BIOL CHEM, V269, P18953; WILDE CG, 1994, DNA CELL BIOL, V13, P711, DOI 10.1089/dna.1994.13.711	49	105	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20479	20483		10.1074/jbc.272.33.20479	http://dx.doi.org/10.1074/jbc.272.33.20479			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252358	hybrid			2022-12-25	WOS:A1997XR22100028
J	Mann, KG; Hockin, MF; Bean, KJ; Kalafatis, M				Mann, KG; Hockin, MF; Bean, KJ; Kalafatis, M			Activated protein C cleavage of factor Va leads to dissociation of the A2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; PORCINE FACTOR-VIII; BOVINE FACTOR-V; PEPTIDE-BOND CLEAVAGES; FACTOR-XA; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; ANALYTICAL ULTRACENTRIFUGATION; SUBUNIT STRUCTURE; FACTOR VA(R506Q)	The products of cleavage of bovine factor Va by activated protein C (APC) in the presence and absence of phospholipid (25% phosphatidylserine, 75% phosphatidylcholine, PCPS) were evaluated using sedimentation velocity/equilibrium methods in the analytical ultracentrifuge and by immunoprecipitation using an antibody directed against the light chain of the factor Va molecule, The molecular weight and sedimentation coefficient of the associated heavy and light chains of factor Va, 173,000 (7.9 S) is reduced to 132,000 (7.1 S) by APC cleavage at Arg(505) and Arg(662), Complete cleavage of the factor Va heavy chain (with APC-PCPS) at Arg(505), Arg(662) and Arg(306) results in a drastic change in the molecular weight observed for the product, Two products are resolved with sedimentation coefficients of 3.3 and 6.3 S with estimated molecular weights of 48,000 and 114,000, respectively, Immunoprecipitation studies showed that the products of factor Va cleavage at Arg(505) and Arg(662) (A1A2(N).A2(C).LC) are mostly noncovalently associated and consequently immunoprecipitated with an antibody directed against the light chain of the factor Va molecule, In contrast, for factor Va cleaved at Arg(505), Arg(662), and Arg(306) the precipitated complex consisted of the Al domain (residues 1-306) and the light chain (residues 1537-2183) of factor Va (A1.LC). The fragments corresponding to residues 307-505 (A2(N)) and 506-662 (A2(C)) are found in the supernatant, The combined mass of these two products (48,000) is similar to the estimated mass of the 3.3 S fragment estimated from sedimentation velocity/equilibrium studies; while the combined mass of the 1-306 + 1537-2183 products corresponds to 114,000, the estimated mass of the 6.3 S fragment, These data lead to the conclusion that cleavages at Arg(306), Arg(505), and Arg(662) Of the factor Va molecule resulted in the dissociation of the entire A2 domain as two noncovalently associated fragments (A2(N).A2(C)). Enzyme kinetic and light scattering data suggest that the complete inactivation of the factor Va molecule involves not only cleavage at Arg(306) but also the dissociation of the A2 domain, These data also suggest that the complete APC inactivation of the factor Va molecule is analogous to the spontaneous inactivation of factor VIIIa, which occurs via the dissociation of the A2 domain.			Mann, KG (corresponding author), UNIV VERMONT,COLL MED,DEPT BIOCHEM,C401,GIVEN BLDG,BURLINGTON,VT 05405, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011293] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034575] Funding Source: NIH RePORTER; NCRR NIH HHS [RR11293] Funding Source: Medline; NHLBI NIH HHS [R37 HL34575] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FAY PJ, 1991, J BIOL CHEM, V266, P8957; GOLDBERG RJ, 1953, J PHYS CHEM-US, V57, P194, DOI 10.1021/j150503a014; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1993, METHOD ENZYMOL, P261; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1988, J BIOL CHEM, V263, P1037; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; XUE JC, 1993, BIOCHEMISTRY-US, V32, P5917, DOI 10.1021/bi00073a026; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	38	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20678	20683		10.1074/jbc.272.33.20678	http://dx.doi.org/10.1074/jbc.272.33.20678			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252387	hybrid			2022-12-25	WOS:A1997XR22100057
J	Sawada, Y; Suda, M; Yokoyama, H; Kanda, T; Sakamaki, T; Tanaka, S; Nagai, R; Abe, S; Takeuchi, T				Sawada, Y; Suda, M; Yokoyama, H; Kanda, T; Sakamaki, T; Tanaka, S; Nagai, R; Abe, S; Takeuchi, T			Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INFLUENZA-VIRUS HEMAGGLUTININ; CARDIAC GENE-EXPRESSION; PROTEIN-SYNTHESIS; ANGIOTENSIN-II; PROTEOLYTIC ACTIVATION; MECHANICAL-STRESS; ATRIAL MYOCYTES; FACTOR-BETA; RAT	When hypertrophic growth is induced in neonatal rat cardiocytes by stretching, the cardiocytes express high levels of brain-type natriuretic peptide (BNP) and the proprotein-processing enzyme furin. A BNP precursor, gamma BNP, possesses a furin-cleavable Arg-X-X-Arg motif, which is cleaved when gamma BNP is processed to form BNP-45, The Arg-X-X-Arg motif is found in many precursors of growth factors and growth-related proteins, To determine if furin converts gamma BNP to BNP-45 as well as other unidentified growth-promoting protein precursors to their active form that may induce hypertrophic growth in cardiocytes, we used two protease inhibitor systems, synthetic peptidyl chloromethyl ketones (CMK) (dec-Arg-Val-Lys-Arg-CMK and dec-Phe-Ala-Lys-Arg-CMK; where dec is decanoyl) and vaccinia vector-integrated native and variant alpha(1)-antitrypsins. The furin specific inhibitors, dec-Arg-Val-Lys-Arg-CMK and variant alpha(1)-antitrypsin with the inhibitory determinant Arg-X-X-Arg, suppressed the stretch-induced hypertrophic growth of cardiocytes as well as the processing of gamma BNP to BNP-45. The other serine protease inhibitors and variant alpha(1)-antitrypsin against elastase, or thrombin, however, neither suppressed the hypertrophic growth nor prevented the processing of gamma BNP to BNP-45. Thus, we suggest that furin catalyzes the conversion of gamma BNP to BNP-45 as well as growth-promoting proproteins to their active form, which might induce hypertrophic growth in cardiocytes.	GUNMA UNIV, INST MOL & CELLULAR REGULAT, DEPT MOL MED, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, INST MOL & CELLULAR REGULAT, DEPT CELL BIOL, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, DEPT INTERNAL MED 2, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, DEPT LAB MED, MAEBASHI, GUMMA 371, JAPAN; UNION CO, TAKASAKI, GUMMA 370, JAPAN	Gunma University; Gunma University; Gunma University; Gunma University								ABURAYA M, 1989, BIOCHEM BIOPH RES CO, V165, P880, DOI 10.1016/S0006-291X(89)80048-8; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; BEAUBIEN G, 1995, CELL TISSUE RES, V279, P539; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLARK WA, 1981, J BIOL CHEM, V256, P4863; CLEUTJENS JPM, 1995, J MOL CELL CARDIOL, V27, P1281, DOI 10.1016/S0022-2828(05)82390-9; DEFTOS LJ, 1993, J CLIN INVEST, V92, P727, DOI 10.1172/JCI116643; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; ESPINER EA, 1994, J INTERN MED, V235, P527, DOI 10.1111/j.1365-2796.1994.tb01261.x; FRANCH HA, 1995, J CELL BIOL, V129, P245, DOI 10.1083/jcb.129.1.245; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; HALBAN PA, 1994, BIOCHEM J, V299, P1; HAMA N, 1995, CIRCULATION, V92, P1558, DOI 10.1161/01.CIR.92.6.1558; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hruby D E, 1986, Methods Enzymol, V124, P295; ITOH H, 1990, J CLIN INVEST, V86, P1690, DOI 10.1172/JCI114893; Kayo T, 1996, J BIOL CHEM, V271, P10731, DOI 10.1074/jbc.271.18.10731; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P720, DOI 10.1006/bbrc.1993.1881; KOJIMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1420, DOI 10.1016/0006-291X(89)92268-7; KOLLER KJ, 1992, CIRCULATION, V86, P1081, DOI 10.1161/01.CIR.86.4.1081; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LIU B, 1995, AM J PHYSIOL-ENDOC M, V268, pE832, DOI 10.1152/ajpendo.1995.268.5.E832; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Massfelder T, 1996, ENDOCRINOLOGY, V137, P3151, DOI 10.1210/en.137.8.3151; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MIZUNO K, 1987, BIOCHEM BIOPH RES CO, V144, P807, DOI 10.1016/S0006-291X(87)80036-0; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; MOSS B, 1986, FUNDAMENTAL VIROLOGY, P637; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; RICE AP, 1983, J VIROL, V47, P529, DOI 10.1128/JVI.47.3.529-539.1983; ROBERTS AB, 1992, J CLIN INVEST, V90, P2056, DOI 10.1172/JCI116087; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SAITO Y, 1989, J CLIN INVEST, V83, P298, DOI 10.1172/JCI113872; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sawada Y, 1997, FEBS LETT, V400, P177, DOI 10.1016/S0014-5793(96)01385-3; Schluter KD, 1996, J BIOL CHEM, V271, P3074, DOI 10.1074/jbc.271.6.3074; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SEI CA, 1992, MOL ENDOCRINOL, V6, P309, DOI 10.1210/me.6.3.309; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; STEINHELPER ME, 1993, CIRC RES, V72, P984, DOI 10.1161/01.RES.72.5.984; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; STUDER R, 1994, J CLIN INVEST, V94, P301, DOI 10.1172/JCI117322; SUZUKI E, 1992, CIRC RES, V71, P1039, DOI 10.1161/01.RES.71.5.1039; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; URATA H, 1990, CIRC RES, V66, P883, DOI 10.1161/01.RES.66.4.883; URATA H, 1993, J CLIN INVEST, V91, P1269, DOI 10.1172/JCI116325; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; WATANABE M, 1995, J VIROL, V69, P3206, DOI 10.1128/JVI.69.5.3206-3210.1995; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANG ZH, 1993, CIRCULATION, V88, P832, DOI 10.1161/01.CIR.88.3.832	71	95	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20545	20554		10.1074/jbc.272.33.20545	http://dx.doi.org/10.1074/jbc.272.33.20545			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252368	hybrid			2022-12-25	WOS:A1997XR22100038
J	Vard, C; Guillot, D; Bargis, P; Lavergne, JP; Reboud, JP				Vard, C; Guillot, D; Bargis, P; Lavergne, JP; Reboud, JP			A specific role for the phosphorylation of mammalian acidic ribosomal protein P2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-II; DIMETHYLMALEIC ANHYDRIDE; PARTIAL RECONSTITUTION; PHOSPHOPROTEINS; SUBUNIT; P1	The acidic ribosomal proteins P1-P2 from rat liver were overproduced for the first time by expression of their cDNA in Escherichia coli, They were tested for their ability to reactivate inactive P1-P2-deficient core particles derived from 60 S ribosomal subunits treated with dimethylmaleic anhydride, in poly(U)-directed poly(Phe) synthesis, The recombinant P1-P2 were unable to reactivate these core particles although they could bind to them, When recombinant P1-P2 had been phosphorylated first with casein kinase II? they mere as efficient in the reactivation process as P1-P2 extracted with ethanol/KCl from the 60 S subunits, Reconstitution experiments were carried out using all possible combinations of the two recombinant proteins phosphorylated or not. Reactivation of the core particles required the presence of both P1 and P2 with the latter ill its phosphorylated form, These experiments reveal a distinct role for P1 and P2 in protein synthesis, Phosphorylated P2 produced a partial quenching of the intrinsic fluorescence of eukaryotic elongation factor 2, which was not observed with the unphosphorylated protein, This result demonstrates the existence of an interaction between phosphorylated P2 and eukaryotic elongation factor 2, P2 also quenched part of the intrinsic fluorescence of P1, due to the interaction between the two proteins.	CNRS, INST BIOL & CHIM PROTEINES, LAB BIOCHIM MED, F-69367 LYON 07, FRANCE	Centre National de la Recherche Scientifique (CNRS)								ABSI M, 1989, IMMUNOL LETT, V23, P35, DOI 10.1016/0165-2478(89)90152-1; Ballesta JPG, 1996, PROG NUCLEIC ACID RE, V55, P157, DOI 10.1016/S0079-6603(08)60193-2; CONQUET F, 1987, EUR J BIOCHEM, V163, P15, DOI 10.1111/j.1432-1033.1987.tb10730.x; ELKON K, 1986, P NATL ACAD SCI USA, V83, P7419, DOI 10.1073/pnas.83.19.7419; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HASLER P, 1991, J BIOL CHEM, V266, P13815; LAVERGNE JP, 1988, FEBS LETT, V236, P345, DOI 10.1016/0014-5793(88)80053-X; LAVERGNE JP, 1987, FEBS LETT, V216, P83, DOI 10.1016/0014-5793(87)80761-5; LILJAS A, 1991, INT REV CYTOL, V124, P103; MACCONNELL WP, 1982, J BIOL CHEM, V257, P5359; MARZOUKI A, 1989, FEBS LETT, V255, P72, DOI 10.1016/0014-5793(89)81063-4; REBOUD AM, 1980, J BIOL CHEM, V255, P6954; SANTOS C, 1994, J BIOL CHEM, V269, P15689; SONTAG B, 1993, BIOCHEMISTRY-US, V32, P1976, DOI 10.1021/bi00059a014; STRYCHARZ WA, 1978, J MOL BIOL, V126, P123, DOI 10.1016/0022-2836(78)90355-8; TSURUGI K, 1978, J BIOL CHEM, V253, P946; UCHIUMI T, 1986, EUR J BIOCHEM, V156, P37, DOI 10.1111/j.1432-1033.1986.tb09545.x; VIOQUE A, 1982, J BIOL CHEM, V257, P6477; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M	19	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20259	20262		10.1074/jbc.272.32.20259	http://dx.doi.org/10.1074/jbc.272.32.20259			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242705	hybrid			2022-12-25	WOS:A1997XQ05900092
J	Blangy, A; Arnaud, L; Nigg, EA				Blangy, A; Arnaud, L; Nigg, EA			Phosphorylation by p34(cdc2) protein kinase regulates binding of the kinesin-related motor HsEg5 to the dynactin subunit p150(Glued)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DYNEIN; MITOTIC SPINDLE; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-NIDULANS; VESICLE MOTILITY; FISSION YEAST; KINECTIN; COMPLEX; ACTIN; LOCALIZATION	The kinesin-related motor HsEg5 is essential for centrosome separation, and its association with centrosomes appears to be regulated by phosphorylation of tail residue threonine 927 by the p34(cdc2) protein kinase. To identify proteins able to interact with the tail of HsEg5, we performed a yeast two-hybrid screen with a HsEg5 stalk-tail construct as bait. We isolated a cDNA coding for the central, alpha-helical region of human p150(Glued), a prominent component of the dynactin complex. The interaction between HsEg5 and p150(Glued) was enhanced upon activation of p34(CDC28), the budding yeast homolog of p34(cdc2), provided that HsEg5 had a phosphorylatable residue at position 927. Phosphorylation also enhanced the specific binding of p150(Glued) to the tail domain of HsEg5 in vitro, indicating that the two proteins are able to interact directly. Immunofluorescence microscopy revealed co-localization of HsEg5 and p150(Glued) during mitosis but not during interphase, consistent with a cell cycle-dependent association between the two proteins. Taken together, these results suggest that HsEg5 and p150(Glued) may interact in mammalian cells in vivo and that p34(cdc2) may regulate this interaction. Furthermore, they imply that the dynactin complex may functionally interact not only with dynein but also with kinesin-related motors.	UNIV GENEVA, DEPT MOL BIOL, CH-1211 GENEVA 4, SWITZERLAND; SWISS INST EXPT CANC RES, CH-1066 EPALINGES, SWITZERLAND	University of Geneva; Swiss Institute Experimental Cancer Research				BLANGY, Anne/0000-0001-7043-0784; nigg, erich/0000-0003-4835-5719				Bai C, 1996, METHOD ENZYMOL, V273, P331; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Bruno KS, 1996, P NATL ACAD SCI USA, V93, P4775, DOI 10.1073/pnas.93.10.4775; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; CLARK SW, 1994, J CELL BIOL, V127, P129, DOI 10.1083/jcb.127.1.129; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUTTERER A, 1995, MOL BIOL CELL, V6, P161; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GOLDSTEIN LSB, 1993, J CELL BIOL, V120, P1, DOI 10.1083/jcb.120.1.1; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HARPER JW, 1993, CELL, V75, P805; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karsenti E, 1996, SEMIN CELL DEV BIOL, V7, P367, DOI 10.1006/scdb.1996.0046; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; MILLER GH, 1992, NATURE, V355, P244, DOI 10.1038/355244a0; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Schroer TA, 1996, SEMIN CELL DEV BIOL, V7, P321, DOI 10.1006/scdb.1996.0041; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Sheetz MP, 1996, SEMIN CELL DEV BIOL, V7, P329, DOI 10.1006/scdb.1996.0042; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Thaler C D, 1996, Int Rev Cytol, V164, P269; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Vallee RB, 1995, COLD SPRING HARB SYM, V60, P803, DOI 10.1101/SQB.1995.060.01.086; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WatermanStorer CM, 1996, J BIOL CHEM, V271, P1153, DOI 10.1074/jbc.271.2.1153; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; YU H, 1995, MOL BIOL CELL, V6, P171, DOI 10.1091/mbc.6.2.171	62	122	132	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19418	19424		10.1074/jbc.272.31.19418	http://dx.doi.org/10.1074/jbc.272.31.19418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235942	Green Published, hybrid			2022-12-25	WOS:A1997XP06300048
J	Gulati, S; Chen, ZQ; Brody, LC; Rosenblatt, DS; Banerjee, R				Gulati, S; Chen, ZQ; Brody, LC; Rosenblatt, DS; Banerjee, R			Defects in auxiliary redox proteins lead to functional methionine synthase deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALAMIN; HETEROGENEITY; CBLG; BIOSYNTHESIS; SYNTHETASE; BINDING; CULTURE; SYSTEM; LIVER; CELLS	Methionine synthase catalyzes a methyl transfer reaction from methyltetrahydrofolate to homocysteine to form methionine and tetrahydrofolate and is dependent on methylcobalamin, a derivative of vitamin B-12, for activity, Due to the lability of the intermediate, cob(I) alamin, the activity of methionine synthase is additionally dependent on a redox activation system. In bacteria, two flavoproteins, NADPH-flavodoxin reductase and flavodoxin, shuttle electrons from NADPH to methionine synthase, Their mammalian counterparts are unknown, and a putative intrinsic thiol oxidase activity of the mammalian methionine synthase has been proposed to be involved, We demonstrate that the mammalian methionine synthase can be activated in an NADPH-dependent reaction and requires a minimum of two redox proteins, This model is consistent with our results from biochemical complementation studies between cblG and cblE cell lines and mutation detection analysis in cblG cell lines, These demonstrate that the cblG; cell line has defects affecting methionine synthase directly, whereas the cblE cell line has defects in the redox proteins, We have also identified a P1173L mutation in the activation domain of methionine synthase in the cblG cell line WG1505.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68588; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT PEDIAT,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,MRC,GENET GRP,MONTREAL,PQ H3A 1A1,CANADA; NIH,NATL CTR HUMAN GENOME RES,LAB GENE TRANSFER,BETHESDA,MD 20892	University of Nebraska System; University of Nebraska Lincoln; McGill University; McGill University; McGill University; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)					NIDDK NIH HHS [DK45776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045776, R29DK045776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHE H, 1974, BIOCHEM BIOPH RES CO, V57, P417, DOI 10.1016/0006-291X(74)90947-4; Banerjee R, 1997, CHEM BIOL, V4, P175, DOI 10.1016/S1074-5521(97)90286-6; Banerjee R, 1997, METHOD ENZYMOL, V281, P189; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; Chen LH, 1997, J BIOL CHEM, V272, P3628, DOI 10.1074/jbc.272.6.3628; CHEN ZQ, 1995, J BIOL CHEM, V270, P19246, DOI 10.1074/jbc.270.33.19246; CHEN ZQ, 1994, J BIOL CHEM, V269, P27193; FENTON WA, 1995, METABOLIC MOL BASES, P3111; FISKERSTRAND T, 1994, CANCER RES, V54, P4899; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; FUJII K, 1974, J BIOL CHEM, V249, P6745; GREEN R, 1995, FOLATE HLTH DIS, P75; Gulati S, 1996, HUM MOL GENET, V5, P1859, DOI 10.1093/hmg/5.12.1859; HALL CA, 1989, CLIN INVEST MED, V12, P262; HOFFMAN RM, 1976, P NATL ACAD SCI USA, V73, P1523, DOI 10.1073/pnas.73.5.1523; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KOLHOUSE JF, 1977, P NATL ACAD SCI USA, V74, P921, DOI 10.1073/pnas.74.3.921; Leclerc D, 1996, HUM MOL GENET, V5, P1867, DOI 10.1093/hmg/5.12.1867; Li YN, 1996, HUM MOL GENET, V5, P1851, DOI 10.1093/hmg/5.12.1851; MALINOW MR, 1995, CLIN CHEM, V41, P173; MATTHEWS R G, 1986, P697; MELLMAN IS, 1977, P NATL ACAD SCI USA, V74, P916, DOI 10.1073/pnas.74.3.916; ROSENBLATT DS, 1984, J CLIN INVEST, V74, P2149, DOI 10.1172/JCI111641; ROSENBLATT DS, 1995, METABOLIC MOL BASES, P3129; SHEVELL MI, 1992, CAN J NEUROL SCI, V19, P472, DOI 10.1017/S0317167100041676; SILLAOTS SL, 1992, BIOCHEM MED METAB B, V47, P242, DOI 10.1016/0885-4505(92)90032-T; WATKINS D, 1989, AM J MED GENET, V34, P427, DOI 10.1002/ajmg.1320340320; WATKINS D, 1988, J CLIN INVEST, V81, P1690, DOI 10.1172/JCI113507; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	29	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19171	19175		10.1074/jbc.272.31.19171	http://dx.doi.org/10.1074/jbc.272.31.19171			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235907	hybrid			2022-12-25	WOS:A1997XP06300013
J	Molden, J; Chang, Y; You, Y; Moore, PS; Goldsmith, MA				Molden, J; Chang, Y; You, Y; Moore, PS; Goldsmith, MA			A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SEQUENCES; CASTLEMANS DISEASE; MOLECULAR-CLONING; TYROSINE KINASE; INTERLEUKIN-6; IL-6; BINDING; EXPRESSION; PROTEINS; TRANSDUCER	The present studies analyzed the biologic activity of a gene product (vIL-6) encoded by the recently discovered Kaposi's sarcoma-associated herpesvirus (KSHV) bearing 24.8% amino acid identity with human interleukin-6 (huIL-6). Based on this similarity, we hypothesized that this viral homolog might trigger the JAK/STAT pathway, which typically is engaged by IL-6 and other cytokines, Activation of receptor-associated Janus tyrosine kinases (JAKs) results in the subsequent phosphorylation of signal transducers and activators of transcription (STATs) leading to nuclear entry and transcriptional regulation of target genes, Treatment of HepG2 cells with culture medium containing recombinant KSHV-encoded vIL-6 led to rapid induction of JAK1 phosphorylation and a nuclear DNA-binding activity found to contain STAT1 and STAT3. An antibody to the IL-6 receptor (IL-6R) alpha subunit effectively neutralized the response to huIL-6 but failed to block STAT activation by vIL-6. In contrast, an antibody reactive with the gp130 subunit of IL-6R abrogated signaling of both responses. Moreover, a transfected cell line expressing human gp130 without IL-6R alpha exhibited a robust response to vIL-6 but not to huIL-6. These results demonstrate that KSHV encodes a cytokine that activates specific JAK/STAT signaling via interactions with the gp130 signal transducing subunit independently of the IL-6R alpha chain. This activity may have an impact on gp130-mediated signaling in response to native cytokines and thereby influence disease pathogenesis upon KSHV infection.	GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94110; COLUMBIA UNIV,SCH PUBL HLTH,DEPT PATHOL,NEW YORK,NY 10032; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; Columbia University; University of California System; University of California San Francisco			Moore, Patrick S./F-3960-2011; Chang, Yuan/F-4146-2011; Moore, Patrick/GVR-8294-2022	Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041; 	NCI NIH HHS [R01 CA67391] Funding Source: Medline; NIGMS NIH HHS [R01 GM54351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BECK JT, 1994, NEW ENGL J MED, V330, P602, DOI 10.1056/NEJM199403033300904; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG EHY, 1997, IN PRESS P NATL ACAD; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Ciapponi L, 1995, J BIOL CHEM, V270, P31249, DOI 10.1074/jbc.270.52.31249; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker LL, 1996, J EXP MED, V184, P283, DOI 10.1084/jem.184.1.283; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; Fourcin M, 1996, J BIOL CHEM, V271, P11756, DOI 10.1074/jbc.271.20.11756; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; INOUE K, 1994, BLOOD, V84, P2672, DOI 10.1182/blood.V84.8.2672.bloodjournal8482672; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Komanduri KV, 1996, J ACQ IMMUN DEF SYND, V13, P215, DOI 10.1097/00042560-199611010-00003; LAMB P, 1994, BLOOD, V83, P2063; Levy JB, 1996, ENDOCRINOLOGY, V137, P1159, DOI 10.1210/en.137.4.1159; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Neipel F, 1997, J VIROL, V71, P839, DOI 10.1128/JVI.71.1.839-842.1997; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Ray DW, 1996, J CLIN INVEST, V97, P1852, DOI 10.1172/JCI118615; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schumann RR, 1996, MOL CELL BIOL, V16, P3490; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Screpanti I, 1996, J EXP MED, V184, P1561, DOI 10.1084/jem.184.4.1561; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SONNE O, 1990, EUR J CLIN INVEST, V20, P366, DOI 10.1111/j.1365-2362.1990.tb01872.x; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	63	231	244	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19625	19631		10.1074/jbc.272.31.19625	http://dx.doi.org/10.1074/jbc.272.31.19625			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235971	hybrid			2022-12-25	WOS:A1997XP06300077
J	Topping, TB; Randall, LL				Topping, TB; Randall, LL			Chaperone SecB from Escherichia coli mediates kinetic partitioning via a dynamic equilibrium with its ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; LEADER PEPTIDE; EXPORT; CHEMOTAXIS; TRANSPORT; SEQUENCES; RECEPTOR; FRAME	We have shown that the complexes between SecB, a chaperone from Escherichia coli, and two physiological ligands, galactose-binding protein and maltose-binding protein, are in rapid, dynamic equilibrium between the bound and free states, Binding to SecB is readily reversible, and each time the ligand is released it undergoes a kinetic partitioning between folding to its native state and re-binding to SecB. Binding requires that the polypeptide be devoid of tertiary structure; once the protein has folded, it is no longer a ligand. Conditions were established in which folding of the polypeptides was sufficiently slow so that at each cycle of dissociation rebinding was favored over folding and a kinetically stable complex between SecB and each polypeptide ligand was observed, Evidence that the ligand is continually released to the bulk solution and rebound was obtained by altering the conditions to increase the rate of folding of each ligand so that folding of the ligand was faster than reassociation with SecB thereby allowing the system to partition to free SecB and folded polypeptide ligand. We conclude that complexes between the chaperone SecB and ligands are in dynamic, rapid equilibrium with the free states. This mode of binding is simpler than that documented for chaperones that function to facilitate folding such as the Hsp70s and Hsp60s, where hydrolysis of ATP is coupled to the binding and release of ligands, This difference may reflect the fact that SecB does not mediate folding but is specialized to facilitate protein export. Without a requirement for exogenous energy it efficiently performs its sole duty: to keep proteins in a nonnative conformation and thus competent for export.	WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164	Washington State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029798, R01GM029798] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29798] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; DIAMOND DL, 1995, PROTEIN SCI, V4, P1118, DOI 10.1002/pro.5560040610; DUPLAY P, 1984, J BIOL CHEM, V259, P606; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FEKKES P, 1995, BIOCHEMISTRY-US, V34, P10078, DOI 10.1021/bi00031a032; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; KHISTY VJ, 1995, J BACTERIOL, V177, P3277, DOI 10.1128/jb.177.11.3277-3282.1995; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; MAHONEY WC, 1981, J BIOL CHEM, V256, P4350; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MILLER DM, 1983, J BIOL CHEM, V258, P3665; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; Randall LL, 1997, P NATL ACAD SCI USA, V94, P802, DOI 10.1073/pnas.94.3.802; SCRIPTURE JB, 1983, J BIOL CHEM, V258, P853; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; TOPPING TB, 1994, PROTEIN SCI, V3, P730; VYTAS NK, 1987, NATURE, V327, P635	22	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19314	19318		10.1074/jbc.272.31.19314	http://dx.doi.org/10.1074/jbc.272.31.19314			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235927	hybrid			2022-12-25	WOS:A1997XP06300033
J	Montano, X				Montano, X			p53 associates with trk tyrosine kinase	ONCOGENE			English	Article						trk and p53 association; PC12 differentiation; phosphorylation	NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; WILD-TYPE P53; DNA-REPLICATION; CELL-CYCLE; NEURONAL DIFFERENTIATION; SV40-TRANSFORMED CELLS; NEUROTROPHIN RECEPTORS; PROTOONCOGENE PRODUCT; TRANSFORMED-CELLS	The p53 tumor suppressor gene encodes a phosphoprotein which when overexpressed can induce growth arrest at the G1 and G2/M phases of the cell cycle, promote differentiation and apoptosis. This paper demonstrates that p53 can associate with trk tyrosine kinase. Expression of a murine temperature-sensitive (ts) p53 mutant in PC12 cells overexpressing trk (a model system to analyse cellular differentiation and signal transduction induced by NGF) induces morphological changes in the absence of NGF stimulation at 32 degrees C but not at 37 degrees C. In cells differentiated by p53, trk, but not EGFr, was hyperphosphorylated on tyrosine. Furthermore trk was not phosphorylated when expressed in Saos-2 cells (human osteosarcoma cells that lack expression of both endogenous trk and p53) at either temperature. However, transfection of ts p53 into these cells induces trk phosphorylation at 32 degrees C in the absence of NGF stimulation. Association of trk and p53 can be detected in NIH3T3 and PC12 cells co-expressing trk and the ts p53 mutant, in NIH3T3 and PC12 cells transfected with trk alone, and in untransfected PC12 cells, showing that overexpressed and/or endogenous trk associates with endogenous, low levels of p53. These data suggest a novel function for p53 which involves the stimulation of signal transduction pathways (mediating morphological properties of cells), possibly through association with and hyperphosphorylation of trk.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARBACID M, 1993, ONCOGENE, V8, P2033; BARBACID M, 1993, TRK FAMILY NEUROTROP; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BASU T, 1994, ONCOGENE, V9, P3483; BERG MM, 1992, J BIOL CHEM, V267, P13; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; COFFER AI, 1994, BIOCHIM BIOPHYS ACTA, V1119, P11; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harlow E., 1988, ANTIBODIES LAB MANUA; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Knippschild U, 1996, ONCOGENE, V12, P1755; KNUSEL B, 1992, J NEUROCHEM, V59, P715, DOI 10.1111/j.1471-4159.1992.tb09427.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lane DP, 1996, ONCOGENE, V12, P2461; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NYE SH, 1992, MOL BIOL CELL, V3, P677, DOI 10.1091/mbc.3.6.677; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; POSSENTI R, 1989, EMBO J, V8, P2217, DOI 10.1002/j.1460-2075.1989.tb08345.x; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SATHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605; SEHGAL PB, 1993, ONCOGENE, V8, P3417; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS RM, 1994, NEURON, V1, P1; TAPLEY P, 1992, ONCOGENE, V7, P371; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WOLF DE, 1995, J BIOL CHEM, V270, P2133, DOI 10.1074/jbc.270.5.2133; YAN GZ, 1995, J NEUROSCI, V15, P6200; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZERRAHN J, 1992, ONCOGENE, V7, P1371	78	25	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					245	256		10.1038/sj.onc.1201215	http://dx.doi.org/10.1038/sj.onc.1201215			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233759				2022-12-25	WOS:A1997XK99900001
J	Vorechovsky, I; Tingby, O; Hartman, M; Stromberg, B; Nister, M; Collins, VP; Toftgard, R				Vorechovsky, I; Tingby, O; Hartman, M; Stromberg, B; Nister, M; Collins, VP; Toftgard, R			Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours	ONCOGENE			English	Article						medulloblastoma; mutation; nevoid basal cell carcinoma syndrome; chromosome 9; patched; PTCH	CELL CARCINOMA SYNDROME; P53 GENE-MUTATIONS; GORLIN SYNDROME; APC GENE; MEDULLOBLASTOMA; LINE; ESTABLISHMENT; PROTEIN	The naevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant disorder characterized by multiple developmental defects and cancer susceptibility, in particular to basal cell carcinomas (BCCs). Medulloblastomas,primitive neuroectodermal tumours (PNETs) arising in childhood, occur in about 3-5% of NBCCS patients and a subset of PNETs was previously found with allelic imbalance at 9q22-q23, the region containing the gene for NBCCS (PTCH). We have analysed tumour DNA samples from 37 unrelated patients with sporadic PNETs and five medulloblastoma cell lines for PTCH mutations using an exon-by-exon single strand conformation polymorphism assay. We found three missense mutations, which affect conserved residues in transmembrane domains of the gene product and in the extracellular loop implicated in binding sonic hedgehog, one 2 bp deletion and an exon skipping splice site mutation. Most mutations were associated with the absence of the wild-type allele and were found in tumours exhibiting loss of heterozygosity (LOH) at loci flanking PTCH. The finding of LOH at 9q22-q23 in most mutated tumours while present in only three out of 26 tumours, in which a mutation was not identified, implicates PTCH as the target gene in PNETs with LOH at 9q22-q23 and deficient PTCH in the development of a subset of these tumours. Since all observed mutations were absent in the germ-line, a sporadic medulloblastoma developing as the first symptom of NBCCS is likely to be a very uncommon event.	UNIV LONDON, ROYAL FREE HOSP, SCH MED, LONDON NW3 2PF, ENGLAND; KAROLINSKA HOSP, GUSTAV V RES INST, DEPT PATHOL & ONCOL, S-17176 STOCKHOLM, SWEDEN; UNIV UPPSALA HOSP, DEPT PATHOL, S-75185 UPPSALA, SWEDEN; UNIV UPPSALA HOSP, DEPT PAEDIAT, S-75185 UPPSALA, SWEDEN	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Karolinska Institutet; Karolinska University Hospital; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital	Vorechovsky, I (corresponding author), KAROLINSKA INST, NOVUM, DEPT BIOSCI, CTR NUTR & TOXICOL, S-14157 HUDDINGE, SWEDEN.							Acqui M, 1989, J Neurosurg Sci, V33, P263; ALBRECHT S, 1994, NEUROPATH APPL NEURO, V20, P74, DOI 10.1111/j.1365-2990.1994.tb00959.x; BADIALI M, 1993, DIAGN MOL PATHOL, V2, P23, DOI 10.1097/00019606-199303000-00004; Beaudet AL, 1996, HUM MUTAT, V8, P197; BELAMARIC J, 1969, J NEUROSURG, V30, P76, DOI 10.3171/jns.1969.30.1.0076; Bhat KM, 1996, DEVELOPMENT, V122, P2921; BICKERSTAFF ER, 1967, ACTA NEUROPATHOL, V8, P104, DOI 10.1007/BF00686656; Blaeker H, 1996, GENE CHROMOSOME CANC, V15, P54, DOI 10.1002/(SICI)1098-2264(199601)15:1<54::AID-GCC8>3.3.CO;2-4; Chidambaram A, 1996, CANCER RES, V56, P4599; COGEN PH, 1992, AM J HUM GENET, V50, P584; David KM, 1997, J NEUROSURG, V86, P13, DOI 10.3171/jns.1997.86.1.0013; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EVANS DGR, 1993, J MED GENET, V30, P460, DOI 10.1136/jmg.30.6.460; EVANS DGR, 1991, BRIT J CANCER, V64, P959, DOI 10.1038/bjc.1991.435; FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4; FARNDON PA, 1994, GENOMICS, V23, P486, DOI 10.1006/geno.1994.1528; FRIEDMAN HS, 1985, J NEUROPATH EXP NEUR, V44, P592, DOI 10.1097/00005072-198511000-00005; FRIEDMAN HS, 1988, AM J PATHOL, V130, P472; FULTS D, 1992, J NEUROPATH EXP NEUR, V51, P272, DOI 10.1097/00005072-199205000-00005; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HE XM, 1991, LAB INVEST, V64, P833; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HUNG KL, 1990, SURG NEUROL, V33, P341, DOI 10.1016/0090-3019(90)90203-2; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kleihues P, 1993, HISTOLOGICAL TYPING; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LACOMBE D, 1990, Genetic Counseling, V1, P273; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Merchant TE, 1996, INT J RADIAT ONCOL, V36, P29, DOI 10.1016/S0360-3016(96)00274-X; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; REIS A, 1992, LANCET, V339, P617, DOI 10.1016/0140-6736(92)90903-G; SAYLORS RL, 1991, CANCER RES, V51, P4721; Scheurlen W, 1996, EUR J PEDIATR, V155, P880; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; SCHOFIELD D, 1995, AM J PATHOL, V146, P472; Sidransky D, 1996, NAT GENET, V14, P7, DOI 10.1038/ng0996-7; Simoneau AR, 1996, CANCER RES, V56, P5039; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Unden AB, 1996, CANCER RES, V56, P4562; VORECHOVSKY I, 1994, GENOMICS, V21, P517, DOI 10.1006/geno.1994.1310; Vorechovsky I, 1996, CANCER RES, V56, P2726; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wicking C, 1997, AM J HUM GENET, V60, P21; WICKING C, 1994, GENOMICS, V22, P505, DOI 10.1006/geno.1994.1423; YAMASHITA J, 1975, Surgical Neurology, V4, P225; YONG WH, 1995, NEW ENGL J MED, V333, P524	55	139	144	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					361	366		10.1038/sj.onc.1201340	http://dx.doi.org/10.1038/sj.onc.1201340			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233770				2022-12-25	WOS:A1997XK99900012
J	Clark, GJ; Drugan, JK; Rossmann, KL; Carpenter, JW; RogersGraham, K; Fu, H; Der, CJ; Campbell, SL				Clark, GJ; Drugan, JK; Rossmann, KL; Carpenter, JW; RogersGraham, K; Fu, H; Der, CJ; Campbell, SL			14-3-3 zeta negatively regulates Raf-1 activity by interactions with the Raf-1 cysteine-rich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DISTINCT BINDING DOMAINS; RAS TRANSFORMATION; 14-3-3-PROTEINS; PATHWAYS; CASCADE; CELLS; PHOSPHORYLATION; IDENTIFICATION; SUFFICIENT	Although Raf-l is a critical effector of nas signaling and transformation, the mechanism by which Ras promotes Raf-l activation is complex and remains pearly understood, We recently reported that Ras interaction with the Raf-1 cysteine-rich domain (Raf-CRD, residues 139-184) may be required for Raf-l activation, The Raf-CRD is located in the NH2-terminal negative regulatory domain of Raf-l and is highly homologous to cysteine-rich domains found in protein kinase C family members. Recent studies indicate that the structural integrity of the Raf-CRD is also critical for Raf-l interaction with 14-3-3 proteins. However, whether 14-3-3 proteins interact directly with the Raf-CRD and how this interaction may mediate Raf-1 function has not been determined. In the present study, we demonstrate that 14-3-3 zeta binds directly to the isolated Raf-CRD. Moreover, mutation of Raf-1 residues 143-145 impairs binding of 14-3-3, but not Ras, to the Raf-CRD. Introduction of mutations that impair 14-3-3 binding resulted in full-length Raf-1 mutants with enhanced transforming activity. Thus, 14-3-3 interaction with the Raf-CRD may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH, terminus of Raf-P to promote subsequent events necessary for full activation of Raf-1.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; EMORY UNIV, SCH MED, DEPT PHARMACOL, ATLANTA, GA 30322 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Emory University				Der, Channing/0000-0002-7751-2747; campbell, sharon/0000-0003-0311-409X	NCI NIH HHS [CA64569, CA70308, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064569, R01CA042978, R01CA070308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Clark GJ, 1996, P NATL ACAD SCI USA, V93, P1577, DOI 10.1073/pnas.93.4.1577; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HURLEY JH, 1997, IN PRESS PROTEIN SCI; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MILLER AF, 1993, BIOCHEMISTRY-US, V32, P7367, DOI 10.1021/bi00080a006; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Rommel C, 1996, ONCOGENE, V12, P609; Sung YJ, 1996, J BIOL CHEM, V271, P30537, DOI 10.1074/jbc.271.48.30537; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	39	102	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20990	20993		10.1074/jbc.272.34.20990	http://dx.doi.org/10.1074/jbc.272.34.20990			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261098	hybrid			2022-12-25	WOS:A1997XR78900008
J	Ji, Y; Jian, B; Wang, N; Sun, Y; Moya, MDLL; Phillips, MC; Rothblat, GH; Swaney, JB; Tall, AR				Ji, Y; Jian, B; Wang, N; Sun, Y; Moya, MDLL; Phillips, MC; Rothblat, GH; Swaney, JB; Tall, AR			Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E; CELLS; HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS; FIBROBLASTS; METABOLISM; PEPTIDES	Scavenger receptor BI (SR-EI) binds high density lipoproteins (HDL) with high affinity and mediates the selective uptake of HDL cholesteryl ester, We examined the potential role of SR-BI ill mediating cellular cholesterol efflux, In Chinese hamster ovary cells stably transfected with murine SR-BI, overexpression of SR-BI resulted in a 3-4-fold stimulation of initial cholesterol efflux rates. Efflux rates correlated with SB-BI expression in cells and HDL concentration in the medium. When incubated with synthetic cholesterol-free RDL, SR-BI-transfected cells showed similar to 3-fold increases in initial rates of efflux compared with control cells, indicating that SR-BI expression enhances net cholesterol efflux mediated by discoidal HDL. In six different cell types, including cultured macrophages, the rate of efflux of cholesterol mediated by RDL or serum was well correlated with cellular SR-BI expression level. In addition, in situ hybridization experiments revealed that SR-BI mRNA was expressed in the thickened intima of atheromatous aorta of apolipoprotein E knockout mice. Thus, SR-BI is an authentic HDL receptor mediating cellular cholesterol efflux, SR-BI may facilitate the initial steps of HDL-mediated cholesterol efflux in the arterial wall as well as later steps of reverse cholesterol transport involving uptake of HDL cholesterol in the liver.	COLUMBIA UNIV, DEPT MED, DIV MOL MED, NEW YORK, NY 10032 USA; ALLEGHENY UNIV HLTH SCI, MCP, HAHNEMANN SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19129 USA	Columbia University; Drexel University			Tall, Alan/AAT-8528-2021; Eckhardt, Erik/G-1567-2010	Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL22682, HL22633, HL54591] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R01HL022682, P01HL054591, P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Atger VM, 1997, J CLIN INVEST, V99, P773, DOI 10.1172/JCI119223; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DELALLERAMOYA M, 1994, ARTERIOSCLER THROMB, V14, P1056, DOI 10.1161/01.ATV.14.7.1056; EISENBERG S, 1984, J LIPID RES, V25, P1017; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1986, METHOD ENZYMOL, V128, P553; JONAS A, 1994, J LIPID RES, V35, P860; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MORTON RE, 1981, J BIOL CHEM, V256, P1992; Oram JF, 1996, J LIPID RES, V37, P2473; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rothblat G H, 1986, Methods Enzymol, V129, P628; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TALL AR, 1996, ATHEROSCLEROSIS CORO, P105; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	32	619	646	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20982	20985		10.1074/jbc.272.34.20982	http://dx.doi.org/10.1074/jbc.272.34.20982			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261096	hybrid			2022-12-25	WOS:A1997XR78900006
J	Kok, JW; NikolovaKarakashian, M; Klappe, K; Alexander, C; Merrill, AH				Kok, JW; NikolovaKarakashian, M; Klappe, K; Alexander, C; Merrill, AH			Dihydroceramide biology - Structure-specific metabolism and intracellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-APPARATUS; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CULTURED FIBROBLASTS; RAT-LIVER; GLUCOSYLCERAMIDE SYNTHESIS; PHYSICAL-PROPERTIES; CYTOSOLIC SURFACE; FREE SPHINGOSINE; 2ND MESSENGER	This study utilized fluorescent analogs to characterize the intracellular transport and metabolism of dihydroceramide (DN-Cer), an intermediate in de novo sphingolipid biosynthesis, When 6-[N-(7-nitro-2,1,3-benzoxadiazol-4-yl) amino]hexanoyl-DH-Cer (C-6-NBD-DH-Cer) was incubated with HT29, NRK, BHK, or HL-60 cells, ii; mas efficiently converted to dihydrosphinogomyelin and dihydroglucosylceramide, and a number of other sphingolipids, with the nature of the products depending on the cell line, In addition, complex sphingolipids were formed that contained a desaturated (sphingosine) backbone, indicating that DH-Cer (and/or its metabolites) were substrates for the desaturase(s) that introduce the 4,5-trans double bond, Based on the kinetics and inhibitor studies, double bond addition did not appear to occur with the complex sphingolipids directly, but rather, during turnover and resynthesis. The conversion of C-6-NBD-DH-Cer to more complex sphingolipids was highly stereoselective for the natural D,erythro isomer of C-6-NBD-DH-Cer. Interestingly, the stereochemistry of the sphingoid base backbone also affected the localization of fluorescent sphingolipids: the D,erythro species appeared in the Golgi apparatus, whereas other stereo-isomers accumulated in the endoplasmic reticulum. In addition to C-6-NBD-Cer and C-6-NBD-DH-Cer, C-6-NBD-4-D-hydroxy-DH-Cer gave rise to formation of complex sphingolipids and localized at the Golgi, apparatus. These studies indicate that dihydroceramide is used as the initial backbone of complex (glyco)sphingolipids, perhaps to avoid build up of ceramide as an intermediate since this is such a potent bioactive compound, The stereoselectively in transport and metabolism suggests that trafficking of ceramide is protein-directed rather than simply a consequence of vesicular membrane flow.	EMORY UNIV, DEPT BIOCHEM, ATLANTA, GA 30322 USA	Emory University	Kok, JW (corresponding author), UNIV GRONINGEN, DEPT PHYSIOL CHEM, A DEUSINGLAAN 1, NL-9713 AV GRONINGEN, NETHERLANDS.			Merrill, Alfred/0000-0002-6673-968X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46368] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABIA T, 1993, INT J CANCER, V54, P839, DOI 10.1002/ijc.2910540519; BABIA T, 1994, EUR J CELL BIOL, V63, P172; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HOEKSTRA D, 1992, BIOCHIM BIOPHYS ACTA, V1113, P277, DOI 10.1016/0304-4157(92)90002-R; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; KOK JW, 1992, J CELL SCI, V103, P1139; KOK JW, 1995, BIOCHEM J, V309, P905, DOI 10.1042/bj3090905; KOK JW, 1993, FLUORESCENT LUMINESC, P100; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PUTZ U, 1995, EUR J CELL BIOL, V68, P113; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; TAN A, 1992, J CELL BIOL, V116, P1357, DOI 10.1083/jcb.116.6.1357; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623	32	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21128	21136		10.1074/jbc.272.34.21128	http://dx.doi.org/10.1074/jbc.272.34.21128			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261117	hybrid, Green Published			2022-12-25	WOS:A1997XR78900027
J	Kvaratskhelia, M; George, SJ; Thorneley, RNF				Kvaratskhelia, M; George, SJ; Thorneley, RNF			Salicylic acid is a reducing substrate and not an effective inhibitor of ascorbate peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; PLANT DEFENSE RESPONSES; HYDROGEN-PEROXIDE; 2,6-DICHLOROISONICOTINIC ACID; SPINACH-CHLOROPLASTS; MOLECULAR-PROPERTIES; 2 INDUCERS; SIGNAL; PURIFICATION; ARABIDOPSIS	This communication describes the interactions of salicylic acid (SA) with plant ascorbate peroxidase (APX). Contrary to a recent report (Durner, J., and Klessig, D. F. (1995) Proc. Natl. Acad. Sci, U. S, A. 92, 11312-11316) we show conclusively that ascorbate oxidation may APX is not inhibited by SA (10 mM), hut that SA is a slow reducing substrate of this enzyme, The suggestion that SA-dependent inhibition of ABX in planta may result in the elevation of H2O2 levels, which in turn acts as a second messenger in systemic acquired resistance signaling, is therefore not tenable. We conclude that APX remains a key antioxidant during systemic acquired resistance following pathogenic infection of plants, The transient products of SA oxidation by APX appear to be SA free radicals that undergo subsequent chemistry, APX-dependent oxidation of SA could he essential for diminishing the detrimental effects of this phenolic acid on plant cells.	JOHN INNES CTR PLANT SCI RES, NITROGEN FIXAT LAB, NORWICH NR4 7UH, NORFOLK, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center				George, Simon/0000-0002-4864-5479				ASADA K, 1992, PHYSIOL PLANTARUM, V85, P235, DOI 10.1111/j.1399-3054.1992.tb04728.x; BALKE NE, 1987, ACS SYM SER, V330, P214; BI YM, 1995, PLANT J, V8, P235, DOI 10.1046/j.1365-313X.1995.08020235.x; Bunkelmann JR, 1996, PLANT PHYSIOL, V110, P589, DOI 10.1104/pp.110.2.589; CHEN GX, 1989, PLANT CELL PHYSIOL, V30, P987; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CONRATH U, 1995, P NATL ACAD SCI USA, V92, P7143, DOI 10.1073/pnas.92.16.7143; Dempsey D A, 1994, Trends Cell Biol, V4, P334, DOI 10.1016/0962-8924(94)90235-6; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DURNER J, 1995, P NATL ACAD SCI USA, V92, P11312, DOI 10.1073/pnas.92.24.11312; Durner J, 1996, J BIOL CHEM, V271, P28492, DOI 10.1074/jbc.271.45.28492; Einhellig F. A, 1986, SCI ALLELOPATHY, P317; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; GARA L, 1996, PLANT PEROXIDASES BI, P157; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; KLESSIG DF, 1994, PLANT MOL BIOL, V26, P1439, DOI 10.1007/BF00016484; Kvaratskhelia M, 1997, PLANT PHYSIOL, V114, P1237, DOI 10.1104/pp.114.4.1237; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MITTLER R, 1994, PLANT J, V5, P397, DOI 10.1111/j.1365-313X.1994.00397.x; MITTLER R, 1991, PLANT PHYSIOL, V97, P962, DOI 10.1104/pp.97.3.962; MIYAKE C, 1993, PLANT CELL PHYSIOL, V34, P881; NAKANO Y, 1981, PLANT CELL PHYSIOL, V22, P867; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NEUENSCHWANDER U, 1995, PLANT J, V8, P227, DOI 10.1046/j.1365-313X.1995.08020227.x; Ruffer M, 1995, FEBS LETT, V377, P175, DOI 10.1016/0014-5793(95)01334-2; SCHULZ M, 1993, PHYTOCHEMISTRY, V33, P291, DOI 10.1016/0031-9422(93)85505-L; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085	30	43	45	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					20998	21001		10.1074/jbc.272.34.20998	http://dx.doi.org/10.1074/jbc.272.34.20998			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261100	hybrid			2022-12-25	WOS:A1997XR78900010
J	Mertz, P; Yu, L; Sikkink, R; Rusnak, F				Mertz, P; Yu, L; Sikkink, R; Rusnak, F			Kinetic and spectroscopic analyses of mutants of a conserved histidine in the metallophosphatases calcineurin and lambda protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURPLE ACID-PHOSPHATASE; CATALYTIC SUBUNIT; ACTIVE-SITE; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURES; CYCLOSPORINE-A; CALMODULIN; COMPLEX; PURIFICATION; SEQUENCE	Calcineurin belongs to a family of serine/threonine protein phosphatases that contain active site dinuclear metal cofactors. Bacteriophage lambda protein phosphatase is also considered to be a member of this family based on sequence comparisons (Lohse, D.L., Denu, J.M., and Dixon, J. E. (1995) Structure 3, 987-990). Using EPR spectroscopy, we demonstrate that lambda protein phosphatase accommodates a dinuclear metal center. Calcineurin and lambda protein phosphatase likewise contain a conserved histidine that is not a metal ligand but is within 5 Angstrom of either metal in calcineurin. in this study the conserved histidine in calcineurin was mutated to glutamine and the mutant protein analyzed by EPR spectroscopy and kinetic methods. Parallel studies with an analogous lambda protein phosphatase mutant were also carried out. Kinetic studies using paranitrophenyl phosphate as substrate showed a decrease in k(cat) of 460- and 590-fold far the calcineurin and lambda protein phosphatase mutants, respectively, compared with the wild type enzymes. With a phosphopeptide substrate, mutagenesis of the conserved histidine resulted in a decrease in k(cat) of 1,300-fold for calcineurin. With the analogous A protein phosphatase mutant, k(cat) decreased 530-fold compared with wild type lambda protein phosphatase using phenyl phosphate as a substrate, EPR studies of the iron-reconstituted enzymes indicated that. although both mutant enzymes can accommodate a dinuclear metal center, spectroscopic differences compared with wild type proteins suggest a perturbation of the ligand environment, possibly by disruption of a hydrogen bond between the histidine and a metal-coordinated solvent molecule.	MAYO CLIN & MAYO FDN, SECT HEMATOL RES, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOL BIOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic					NIGMS NIH HHS [GM46865] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046865] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARIK S, 1993, P NATL ACAD SCI USA, V90, P10633, DOI 10.1073/pnas.90.22.10633; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLERRANSOHOFF JE, 1992, J ORG CHEM, V57, P142, DOI 10.1021/jo00027a027; CHAN CP, 1986, J BIOL CHEM, V261, P9890; COHEN P, 1989, J BIOL CHEM, V264, P21435; DAY EP, 1988, J BIOL CHEM, V263, P15561; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HADDY A, 1994, BIOCHEM BIOPH RES CO, V200, P1221, DOI 10.1006/bbrc.1994.1581; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; Kennedy MT, 1996, J BIOL CHEM, V271, P26517, DOI 10.1074/jbc.271.43.26517; KIRBY AJ, 1965, J AM CHEM SOC, V87, P3209, DOI 10.1021/ja01092a036; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klabunde T, 1996, J MOL BIOL, V259, P737, DOI 10.1006/jmbi.1996.0354; KOONIN EV, 1994, PROTEIN SCI, V3, P356; KURTZ DM, 1990, CHEM REV, V90, P585, DOI 10.1021/cr00102a002; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOHSE DL, 1995, STRUCTURE, V3, P987, DOI 10.1016/S0969-2126(01)00234-9; MARTIN B, 1985, J BIOL CHEM, V260, P4932; MUELLER EG, 1993, J AM CHEM SOC, V115, P2974, DOI 10.1021/ja00060a055; PALLEN CJ, 1983, J BIOL CHEM, V258, P8550; Rusnak F, 1996, J BIOL INORG CHEM, V1, P388, DOI 10.1007/s007750050070; SAITOH Y, 1991, BIOMED RES-TOKYO, V12, P215, DOI 10.2220/biomedres.12.215; SCHRAY KJ, 1973, ENZYMES, P201; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; WOLFF DJ, 1985, J BIOL CHEM, V260, P4195; YU L, 1995, J AM CHEM SOC, V117, P10147, DOI 10.1021/ja00145a040; Zhang J, 1996, BIOCHEMISTRY-US, V35, P6276, DOI 10.1021/bi952954l; ZHUO S, 1993, J BIOL CHEM, V268, P17754; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	41	63	65	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21296	21302		10.1074/jbc.272.34.21296	http://dx.doi.org/10.1074/jbc.272.34.21296			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261141	hybrid			2022-12-25	WOS:A1997XR78900051
J	Turcatti, G; Zoffmann, S; Lowe, JA; Drozda, SE; Chassaing, G; Schwartz, TW; Chollet, A				Turcatti, G; Zoffmann, S; Lowe, JA; Drozda, SE; Chassaing, G; Schwartz, TW; Chollet, A			Characterization of non-peptide antagonist and peptide agonist binding sites of the NK1 receptor with fluorescent ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROKININ-1 RECEPTOR; SUBSTANCE-P ANTAGONIST; NONPEPTIDE ANTAGONIST; NK-1 RECEPTOR; DOMAINS; CELLS; DISCOVERY	Ligand recognition of the NK1 receptor (substance P receptor) by peptide agonist and non-peptide antagonist has been investigated and compared by the use of fluorescent ligands and spectrofluorometric methods, Analogues of substance P (SP) labeled with the environment-sensitive fluorescent group 5-dimethylaminonaphthalene-1 sulfonyl (dansyl) at either position 3, 8, or 11 or with fluorescein at the N-alpha position were synthesized and characterized. Peptides modified at the alpha-amino group or at positions 3 or 11 conserved a relatively good affinity for NK1 and agonistic properties, Modification at position 8 resulted in an 18,000-fold decrease in affinity, A fluorescent dansyl analogue of the non-peptide antagonist CP96,345 was prepared and characterized. The quantum yield of fluorescence for dansyl-CP96,345 was much higher than for any of the dansyl-labeled peptides indicating that the micro-environment of the binding site is more hydrophobic for the nonpeptide antagonist than for the peptide agonists, Comparison of collisional quenching of fluorescence by the water-soluble hydroxy-Tempo compound showed that dansyl-CP96,345 is buried and virtually inaccessible to aqueous quenchers, whereas dansyl-or fluoresceinyl-labeled peptides were exposed to the solvent, Anisotropy of all fluorescent ligands increased upon binding to NK1 indicating a restricted motional freedom, However, this increase in anisotropy was more pronounced for the dansyl attached to the non-peptide antagonist CP96,345 than for the fluorescent probes attached to different positions of SP, In conclusion, our data indicate that the environment surrounding non-peptide antagonist and peptide agonists are vastly different when bound to the NK1 receptor. These results support recent observations by mutagenesis and cross-linking work suggesting that peptide agonists have their major interaction points in the N-terminal extension and the loops forming the extracellular face of the NK1 receptor, Our data also suggest that neither the C terminus nor the N terminus of SP appears to penetrate deeply below the extracellular surface in the transmembrane domain of the receptor.	GLAXO WELLCOME,GENEVA BIOMED RES INST,CH-1228 GENEVA,SWITZERLAND; UNIV COPENHAGEN,INST MOL BIOL,DEPT PROT CHEM,DK-2100 COPENHAGEN,DENMARK; PFIZER INC,CENT RES,GROTON,CT 06340; UNIV PARIS 06,CNRS,URA 493,F-75252 PARIS,FRANCE	GlaxoSmithKline; University of Copenhagen; Pfizer; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite				Schwartz, Thue W./0000-0002-0261-6904				Alla SA, 1996, J BIOL CHEM, V271, P1748, DOI 10.1074/jbc.271.3.1748; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; BRADSHAW CG, 1994, J MED CHEM, V37, P1991, DOI 10.1021/jm00039a012; CHASSAING G, 1983, J ORG CHEM, V48, P1757, DOI 10.1021/jo00158a033; DEKROON AIPM, 1994, FEBS LETT, V342, P230, DOI 10.1016/0014-5793(94)80507-5; DESAI MC, 1992, J MED CHEM, V35, P4911, DOI 10.1021/jm00104a018; FAY SP, 1993, BIOCHEMISTRY-US, V32, P1627, DOI 10.1021/bi00057a029; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1993, NATURE, V362, P350; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; GETHER U, 1994, J BIOL CHEM, V269, P23959; Girault S, 1996, EUR J BIOCHEM, V240, P215, DOI 10.1111/j.1432-1033.1996.0215h.x; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; LAALI KK, 1993, J ORG CHEM, V58, P1385, DOI 10.1021/jo00058a018; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P111; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; LONDON E, 1986, ANAL BIOCHEM, V154, P57, DOI 10.1016/0003-2697(86)90495-1; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; LUNDSTROM K, 1994, EUR J BIOCHEM, V224, P917, DOI 10.1111/j.1432-1033.1994.00917.x; Macdonald D, 1996, MOL PHARMACOL, V49, P808; MAGGIO JE, 1994, TACHYKININ RECEPTORS, P1; MATKO J, 1992, BIOCHEMISTRY-US, V31, P703, DOI 10.1021/bi00118a010; MCLEAN S, 1991, SCIENCE, V251, P437, DOI 10.1126/science.1703324; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SCHWARTZ TW, 1995, CURR PHARM DESIGN, V1, P325; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; TOTA MR, 1995, J BIOL CHEM, V270, P26466, DOI 10.1074/jbc.270.44.26466; TOTA MR, 1994, BIOCHEMISTRY-US, V33, P13079, DOI 10.1021/bi00248a017; TOTA MR, 1990, J BIOL CHEM, V265, P16891; Turcatti G, 1996, J BIOL CHEM, V271, P19991, DOI 10.1074/jbc.271.33.19991; TURCATTI G, 1995, BIOCHEMISTRY-US, V34, P3972, DOI 10.1021/bi00012a015; TURCATTI G, 1993, J RECEPTOR RES, V13, P639, DOI 10.3109/10799899309073684; VALENZUELA CF, 1994, BIOCHEMISTRY-US, V33, P6586, DOI 10.1021/bi00187a028; WEAST RC, 1981, HDB CHEM PHYSICS, pF51; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	40	56	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21167	21175		10.1074/jbc.272.34.21167	http://dx.doi.org/10.1074/jbc.272.34.21167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261122	hybrid			2022-12-25	WOS:A1997XR78900032
J	Yu, M; Ives, D; Ramesha, CS				Yu, M; Ives, D; Ramesha, CS			Synthesis of prostaglandin E-2 ethanolamide from anandamide by cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CANNABINOID RECEPTOR; SYNTHASE-1; INHIBITION; ACID	Because of its structural similarity to polyunsaturated fatty acids, anandamide could serve as substrate for enzymes such as lipoxygenases and cyclooxygenases, which metabolize polyunsaturated fatty acids to potent bioactive metabolites. Here the ability of recombinant human cyclooxygenase-l (hCOX-1) and cyclooxygenase-2 (hCOX-2) to metabolize anandamide was studied. Baculovirus-expressed and -purified hCOX-2, but not hCOX-1, effectively oxygenated anandamide. Reverse phase high pressure liquid chromatography analysis of the products derived from 1-C-14-labeled anandamide showed that the products formed are similar to those formed with arachidonic acid as substrate. The major prostanoid product derived from anandamide was determined by mass spectrometry to be prostaglandin E-2 ethanolamide. Incubation of anandamide with lysates and the intact cell line expressing COX-2 but not that of COX-1 produced prostaglandin E-2 ethanolamide. These results demonstrate the existence of a COX-a-mediated pathway for anandamide metabolism, and the metabolites formed represent a novel class of prostaglandins.	ROCHE BIOSCI,DEPT BIOCHEM,INFLAMMATORY DIS UNIT,PALO ALTO,CA 94303	Roche Holding								BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BARNETTECURLEY D, 1995, P SOC EXP BIOL MED, V210, P64; Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; CRAWLEY JN, 1993, PHARMACOL BIOCHEM BE, V46, P967, DOI 10.1016/0091-3057(93)90230-Q; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAPSON AJ, 1995, BIOCHIM BIOPHYS ACTA, V1259, P173; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Kurumbail RG, 1997, NATURE, V385, P555, DOI 10.1038/385555b0; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; MEADE EA, 1993, J BIOL CHEM, V268, P6610; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAZ A, 1988, J BIOL CHEM, V263, P3022; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; SCHWARZ H, 1994, J NEUROIMMUNOL, V55, P107, DOI 10.1016/0165-5728(94)90152-X; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; Stefano GB, 1996, J BIOL CHEM, V271, P19238, DOI 10.1074/jbc.271.32.19238; UEDA N, 1995, ADV PROSTAG THROMB L, V23, P163; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823	23	327	345	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21181	21186		10.1074/jbc.272.34.21181	http://dx.doi.org/10.1074/jbc.272.34.21181			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261124	hybrid			2022-12-25	WOS:A1997XR78900034
J	Astier, A; Manie, SN; Avraham, H; Hirai, H; Law, SF; Zhang, YH; Golemis, EA; Fu, YG; Druker, BJ; Haghayeghi, N; Freedman, AS; Avraham, S				Astier, A; Manie, SN; Avraham, H; Hirai, H; Law, SF; Zhang, YH; Golemis, EA; Fu, YG; Druker, BJ; Haghayeghi, N; Freedman, AS; Avraham, S			The related adhesion focal tyrosine kinase differentially phosphorylates p130(Cas) and the Cas-like protein, p105(HEF1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC; DOMAIN; CRK; MEGAKARYOCYTES; IDENTIFICATION; FIBRONECTIN; CELLS; C3G	The related adhesion focal tyrosine kinase (RAFTK) is tyrosine-phosphorylated following beta 1 integrin or B cell antigen receptor stimulation in human B cells. Two substrates that are tyrosine-phosphorylated following integrin ligation in B cells are p130(Cas) and the Cas family member human enhancer of filamentation 1 (HEF1), both of which can associate with RAFTK. In this report we observed that RAFTK was involved in the phosphorylation of these two proteins. While a catalytically active RAFTK was required for both p130(Cas) and HEF1, phosphorylation of p130(Cas), but not of HEF1, was dependent on an intact autophosphorylation site (Tyr(402)) on RAFTK. To determine if RAFTK phosphorylated p130(Cas) and HEF1 directly or through an intermediate, we assayed the ability of RAFTK and of a Tyr(402) mutant to phosphorylate purified HEF1 and p130(Cas) domains. RAFTK was able to phosphorylate the substrate domains of both p130(Cas) and HEF1, but only the C-terminal domain of p130(Cas). Furthermore, Tyr(402), which mediates the binding of RAFTK to c-Src kinase, was required for the phosphorylation of the C-terminal domain of p130(Cas). These data suggest that RAFTK itself is sufficient for HEF1 phosphorylation, whereas a cooperation between RAFTK and Src kinases is required for the complete phosphorylation of p130(Cas).	DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BETH ISRAEL DEACONESS MED CTR, DIV EXPT MED & HEMATOL ONCOL RES, BOSTON, MA 02115 USA; UNIV TOKYO, DEPT INTERNAL MED 3, TOKYO 113, JAPAN; FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Tokyo; Fox Chase Cancer Center; Oregon Health & Science University			Astier, Anne L/A-1641-2008; Zhang, Yuzhu/A-7109-2009; Manie, Serge/ABC-8331-2021; Zhang, Yuzhu/C-3606-2014	Astier, Anne L/0000-0002-0144-3431; Zhang, Yuzhu/0000-0001-7882-5692; Zhang, Yuzhu/0000-0001-7882-5692; Druker, Brian/0000-0001-8331-8206; manie, serge/0000-0002-9168-1977; Golemis, Erica/0000-0003-3618-3673; Avraham, Hava/0000-0002-7545-3640	NATIONAL CANCER INSTITUTE [R01CA055207, P01CA066996] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER; NCI NIH HHS [CA55207, CA66996] Funding Source: Medline; NHLBI NIH HHS [HL55445] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM H, 1993, J CLIN INVEST, V91, P2378, DOI 10.1172/JCI116470; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Ishino M, 1995, ONCOGENE, V11, P2331; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Law SF, 1996, MOL CELL BIOL, V16, P3327; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Manie SN, 1997, J BIOL CHEM, V272, P15636, DOI 10.1074/jbc.272.25.15636; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MORTARINI R, 1992, CANCER RES, V52, P4499; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SUGAHARA H, 1994, J EXP MED, V179, P1757, DOI 10.1084/jem.179.6.1757; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Vuori K, 1996, MOL CELL BIOL, V16, P2606	32	88	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19719	19724		10.1074/jbc.272.32.19719	http://dx.doi.org/10.1074/jbc.272.32.19719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242628	hybrid			2022-12-25	WOS:A1997XQ05900015
J	Brunori, M; Giuffre, A; DItri, E; Sarti, P				Brunori, M; Giuffre, A; DItri, E; Sarti, P			Internal electron transfer in Cu-heme oxidases - Thermodynamic or kinetic control?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; MOLECULAR-OXYGEN; INTERMEDIATE; SITE; TEMPERATURE; REDUCTION; BINDING; PROTONS; STEPS; PH	We present novel experimental evidence that, starting with the oxidized enzyme, the internal electron transfer in cytochrome c oxidase is kinetically controlled, The anaerobic reduction of the oxidized enzyme by ruthenium hexamine has been followed in the absence and presence of CO or NO, used as trapping ligands for reduced cytochrome alpha(3). In the presence of NO, the rate of formation of the cytochrome alpha(3)(2+)-NO adduct is independent of the concentration of ruthenium hexamine and of NO, indicating that in the oxidized enzyme cytochrome a and as are not its very rapid redox equilibrium; on the other hand, CO proved to be a poor ''trapping'' ligand, We conclude that the intrinsic sate constant for alpha --> alpha(3) electron transfer in the oxidized enzyme is 25 s(-1). These data are discussed with reference to a model (Verkhovsky, M.I., Morgan, J.E., and Wikstrom, M. (1995) Biochemistry 34, 7483-7491) in which H+ diffusion and/or binding at the binuclear site is the rate-limiting step in the reduction of cytochrome alpha(3) in the oxidized enzyme.	UNIV ROMA LA SAPIENZA, CNR, CTR MOL BIOL, I-00185 ROME, ITALY	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Brunori, M (corresponding author), UNIV ROMA LA SAPIENZA, DIPARTIMENTO SCI BIOCHIM, PIAZZALE ALDO MORO 5, I-00185 ROME, ITALY.		Giuffrè, Alessandro/K-4341-2015; Sarti, Paolo/D-2946-2009	Giuffrè, Alessandro/0000-0001-5301-0681; Brunori, Maurizio/0000-0002-7795-1635; Sarti, Paolo/0000-0002-8219-4827				ANTALIS TM, 1982, J BIOL CHEM, V257, P6194; ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; BAKER GM, 1987, J BIOL CHEM, V262, P595; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; BLAIR DF, 1986, J BIOL CHEM, V261, P1524; BRUNORI M, 1994, FEBS LETT, V350, P164, DOI 10.1016/0014-5793(94)00779-9; Brzezinski P, 1996, BIOCHEMISTRY-US, V35, P5611, DOI 10.1021/bi960260m; EINARSDOTTIR O, 1995, BBA-BIOENERGETICS, V1229, P129, DOI 10.1016/0005-2728(94)00196-C; GIBSON QH, 1965, J BIOL CHEM, V240, P888; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; Giuffre A, 1996, J BIOL CHEM, V271, P33404, DOI 10.1074/jbc.271.52.33404; GRAY HB, 1989, BIOCHEMISTRY-US, V28, P7499, DOI 10.1021/bi00445a001; HAN S, 1990, P NATL ACAD SCI USA, V87, P2491, DOI 10.1073/pnas.87.7.2491; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HILL BC, 1986, BIOCHIM BIOPHYS ACTA, V853, P91, DOI 10.1016/0304-4173(86)90006-6; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; MALATESTA F, 1995, BIOPHYS CHEM, V54, P1, DOI 10.1016/0301-4622(94)00117-3; MALATESTA F, 1990, P NATL ACAD SCI USA, V87, P7410, DOI 10.1073/pnas.87.19.7410; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; OLIVEBERG M, 1989, BIOCHIM BIOPHYS ACTA, V977, P322, DOI 10.1016/S0005-2728(89)80087-8; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P436, DOI 10.1021/bi00216a019; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; SARTI P, 1988, ANN NY ACAD SCI, V550, P161, DOI 10.1111/j.1749-6632.1988.tb35332.x; SCOTT RA, 1980, J AM CHEM SOC, V102, P3219, DOI 10.1021/ja00529a054; SOULIMANE T, 1995, EUR J BIOCHEM, V227, P588, DOI 10.1111/j.1432-1033.1995.tb20429.x; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; VERKHOVSKY MI, 1992, BIOCHEMISTRY-US, V31, P11860, DOI 10.1021/bi00162a026; VERKHOVSKY MI, 1995, BIOCHEMISTRY-US, V34, P7483, DOI 10.1021/bi00022a023; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859	33	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19870	19874		10.1074/jbc.272.32.19870	http://dx.doi.org/10.1074/jbc.272.32.19870			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242650	hybrid			2022-12-25	WOS:A1997XQ05900037
J	Dickinson, CD; Ruf, W				Dickinson, CD; Ruf, W			Active site modification of factor VIIa affects interactions of the protease domain with tissue factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; BLOOD-COAGULATION; EXTRINSIC PATHWAY; FACTOR-X; BINDING; ACTIVATION; COFACTOR; AUTOACTIVATION; INITIATION	In the initiation of coagulation, tissue factor (TF) allosterically activates the serine protease factor VIIa (VIIa) through specific interactions with protease domain residues. These interactions, and consequently affinity for TF, may be influenced by conformational changes in the protease domain that result from zymogen-enzyme transition or occupancy of the active site by tight binding inhibitors, In functional competition and direct binding analysis, we determined affinities for zymogen and enzyme species of wild-type VII and of mutants at protease domain residues that contact TF. We demonstrate that TF binding is not influenced by zymogen activation, indicating that the protease domain of zymogen and enzyme dock similarly with TF, In contrast, active site occupancy enhanced the affinity for TF by predominantly decreasing the dissociation rate of the TF.VIIa complex. Of the three interface residues studied, only Met(306) played a major role in the inhibitor-induced increase in affinity. Met(306) is also important for transmitting the allosteric changes from TF to the active site, resulting in enhanced catalysis. This study thus provides evidence for a bidirectional conformational interdependence of the interface residue Met(306) and the active site of VIIa.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NHLBI NIH HHS [R01 HL-48752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048752] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; BUTENAS S, 1993, BIOCHEMISTRY-US, V32, P6531, DOI 10.1021/bi00077a006; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; FAIR DS, 1979, J CLIN INVEST, V64, P884, DOI 10.1172/JCI109554; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; HIGASHI S, 1996, J BIOL CHEM, V271, P23569; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JESPERS LS, 1995, BIO-TECHNOL, V13, P378, DOI 10.1038/nbt0495-378; KELLEY RF, 1995, BIOCHEMISTRY-US, V34, P10383, DOI 10.1021/bi00033a009; KUWADA M, 1981, ANAL BIOCHEM, V117, P259, DOI 10.1016/0003-2697(81)90720-X; MARTIN DMA, 1995, FASEB J, V9, P852, DOI 10.1096/fasebj.9.10.7615155; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RUF W, 1994, BIOCHEMISTRY-US, V33, P11631, DOI 10.1021/bi00204a026; RUF W, 1995, BIOCHEMISTRY-US, V34, P6310, DOI 10.1021/bi00019a008; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1989, J BIOL CHEM, V264, P9980; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605	27	75	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19875	19879		10.1074/jbc.272.32.19875	http://dx.doi.org/10.1074/jbc.272.32.19875			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242651	hybrid			2022-12-25	WOS:A1997XQ05900038
J	Tarroni, P; Rossi, D; Conti, A; Sorrentino, V				Tarroni, P; Rossi, D; Conti, A; Sorrentino, V			Expression of the ryanodine receptor type 3 calcium release channel during development and differentiation of mammalian skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOOT PROTEIN ISOFORMS; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; CARDIAC-MUSCLE; DIHYDROPYRIDINE RECEPTOR; POSTNATAL-DEVELOPMENT; GENE-EXPRESSION; GROWTH-FACTORS; MICE LACKING; CONTRACTION	In vertebrate skeletal muscles, the type 1 isoform of ryanodine receptor (RyR1) is essential in triggering contraction by releasing Ca2+ from the sarcoplasmic reticulum in response to plasma membrane depolarisation. Recently, the presence of another RyR isoform, RyR3, has been detected in mammalian skeletal muscle cells, raising the question of the eventual relevance of RyR3 for muscle cell physiology. The expression of RyR3 was investigated during differentiation of skeletal muscle cells, Using antibodies able to distinguish the different RyR isoforms and Western blot analysis, the RyR3 protein was detected in the microsomal fractions of differentiated skeletal muscle cells but not of undifferentiated cells, Accordingly, blocking muscle differentiation by the addition of either transforming growth factor-beta or basic fibroblast growth factor prevented the expression of the RyR3 protein. In differentiated skeletal muscle cells, RyR3 was expressed independent of cell fusion and myotube formation. The expression of RyR3 was also investigated during development of the diaphragm muscle, The RyR3 content in the diaphragm muscle increased between the late stage of fetal development and the first postnatal days. However, at variance with RyR1, which reached maximum levels of expression 2-3 weeks after birth, the expression of RyR3 was found to be higher in the neonatal phase of the diaphragm muscle development (2-15 days after birth) than in the same muscle from adult mice. The differential content of RyR3 in adult skeletal muscles was found not to be mediated by neurotrophic factors or electrical activity, These findings indicate that RyR3 is preferentially expressed in differentiated skeletal muscle cells. In addition, during skeletal muscle development, its expression is regulated differently from that of RyR1.	SAN RAFFAELE SCI INST,DIBIT,I-21032 MILAN,ITALY; UNIV SIENA,SCH MED,INST HISTOL,I-53100 SIENA,ITALY	University of Siena			Conti, Antonio/AAN-7161-2020; Sorrentino, Vincenzo/A-4793-2014; Rossi, Daniela/G-7764-2012	Conti, Antonio/0000-0001-9150-5271; Sorrentino, Vincenzo/0000-0002-8573-8631; Rossi, Daniela/0000-0003-0463-7327; Tarroni, Paola/0000-0001-7398-0722	Telethon [653] Funding Source: Medline	Telethon(Fondazione Telethon)		AIREY JA, 1993, BIOCHEMISTRY-US, V32, P5739, DOI 10.1021/bi00073a003; AIREY JA, 1991, DEV BIOL, V148, P365, DOI 10.1016/0012-1606(91)90344-3; AIREY JA, 1990, J BIOL CHEM, V265, P14187; AMBLER SK, 1988, J BIOL CHEM, V263, P1952; ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRILLANTES AMB, 1994, CIRC RES, V75, P503, DOI 10.1161/01.RES.75.3.503; BULTEAU L, 1994, ARCH INT PHYSL BIOCH, V102; CHAUDHARI N, 1993, DEV BIOL, V155, P507, DOI 10.1006/dbio.1993.1048; COGNARD C, 1992, PFLUG ARCH EUR J PHY, V422, P207, DOI 10.1007/BF00370424; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DANGAIN J, 1991, CAN J PHYSIOL PHARM, V69, P1294, DOI 10.1139/y91-190; DESMEDT H, 1991, BIOCHEM J, V273, P219, DOI 10.1042/bj2730219; EMERSON CP, 1975, J MOL BIOL, V93, P431, DOI 10.1016/0022-2836(75)90238-7; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Flucher BE, 1996, P NATL ACAD SCI USA, V93, P8101, DOI 10.1073/pnas.93.15.8101; FLUCHER BE, 1994, MOL BIOL CELL, V5, P1105, DOI 10.1091/mbc.5.10.1105; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HU JS, 1990, J BIOL CHEM, V265, P7914; IVANENKO A, 1995, J BIOL CHEM, V270, P4220, DOI 10.1074/jbc.270.9.4220; JOLESZ F, 1981, ANNU REV PHYSIOL, V43, P531, DOI 10.1146/annurev.ph.43.030181.002531; KELVIN DJ, 1989, J CELL BIOL, V108, P159, DOI 10.1083/jcb.108.1.159; KYSELOVIC J, 1994, J BIOL CHEM, V269, P21770; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; Louboutin JP, 1996, MUSCLE NERVE, V19, P994, DOI 10.1002/(SICI)1097-4598(199608)19:8<994::AID-MUS7>3.0.CO;2-3; LOUBOUTIN JP, 1995, MUSCLE NERVE, V18, P1292, DOI 10.1002/mus.880181112; LU XY, 1994, J BIOL CHEM, V269, P6511; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; Marziah G, 1996, FEBS LETT, V394, P76, DOI 10.1016/0014-5793(96)00944-1; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; OBRIEN J, 1993, BIOPHYS J, V65, P2418, DOI 10.1016/S0006-3495(93)81303-1; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; OTSU K, 1990, J BIOL CHEM, V265, P13472; Ottini L, 1996, BIOCHEM J, V315, P207, DOI 10.1042/bj3150207; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; PERCIVAL AL, 1994, BIOPHYS J, V67, P1834, DOI 10.1016/S0006-3495(94)80665-4; PEREON Y, 1993, J COMP PHYSIOL B, V163, P203; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RAY A, 1995, J BIOL CHEM, V270, P25837, DOI 10.1074/jbc.270.43.25837; RIOS E, 1991, J MUSCLE RES CELL M, V12, P127, DOI 10.1007/BF01774031; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; Sierralta J, 1996, J BIOL CHEM, V271, P17028, DOI 10.1074/jbc.271.29.17028; SORRENTINO V, 1995, RYANDINE RECEPTORS; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	59	70	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19808	19813		10.1074/jbc.272.32.19808	http://dx.doi.org/10.1074/jbc.272.32.19808			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242641	hybrid			2022-12-25	WOS:A1997XQ05900028
J	Yao, KM; Sha, M; Lu, ZJ; Wong, GG				Yao, KM; Sha, M; Lu, ZJ; Wong, GG			Molecular analysis of a novel winged helix protein, WIN - Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORK HEAD PROTEIN; TRANSCRIPTION FACTOR; ENDOCRINE-CELLS; GENE FAMILY; MOUSE; CLONING; RAT; SPECIFICITY; HNF-3-BETA; ACTIVATION	We have cloned a novel winged helix factor, WIN, from the rat insulinoma cell line, INS-1. Northern blot analysis demonstrated that WIN is highly expressed in a variety of insulinoma cell lines and rat embryonic pancreas and liver, In adults, WIN expression was detected in thymus, testis, lung, and several intestinal regions, We determined the DNA sequences bound in vitro by baculovirus-expressed WIN protein ire a polymerase chain reaction-based selection procedure, WIN was found to bind with high affinity to the selected sequence 5'-AGATTGAGTA-3', which is similar to the recently identified HNF-6 binding sequence 5'-DHWATTGAYTWWD-3' (where W = A or T, Y = T or C, H is not G, and D is not C), We have isolated human WIN cDNAs by library screening and 5'-rapid amplification of cDNA ends, Sequence analysis indicates that the carboxyl terminus of human WIN has been previously isolated as a putative phosphorylation substrate, MPM2-reactive phosphoprotein 2 (MPP2); WIN may be regulated by phosphorylation, Alignment of the rat and human WIN cDNAs and their comparison with mouse genomic sequence revealed that the WIN DNA binding domain is encoded by four exons, two of which (exons 4 and 6) are alternatively spliced to generate at least three classes of mRNA transcripts, These transcripts were shown by RNase protection assay to be differentially expressed in different tissues, Alternative splicing within the winged helix DNA binding domain might result in modulation of DNA binding specificity.	GENET INST INC,CAMBRIDGE,MA 02140				/C-4457-2009	/0000-0002-5923-0869				Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DAVIS LG, 1986, BASIC METHODS MOL BI, P129; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; GUS Y, 1995, DEVELOPMENT, V121, P11; HACKER U, 1992, P NATL ACAD SCI USA, V89, P8754, DOI 10.1073/pnas.89.18.8754; HACKER U, 1995, EMBO J, V14, P5306, DOI 10.1002/j.1460-2075.1995.tb00215.x; HARRISON KA, 1994, J BIOL CHEM, V269, P19968; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; HERMANNLEDENMAT S, 1994, MOL CELL BIOL, V14, P2905, DOI 10.1128/MCB.14.5.2905; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Offield MF, 1996, DEVELOPMENT, V122, P983; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANG K, 1994, P NATL ACAD SCI USA, V91, P9559, DOI 10.1073/pnas.91.20.9559; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PHILIPPE J, 1994, MOL CELL BIOL, V14, P3514, DOI 10.1128/MCB.14.5.3514; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; ZHU GF, 1993, MOL CELL BIOL, V13, P1779, DOI 10.1128/MCB.13.3.1779	44	108	113	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19827	19836		10.1074/jbc.272.32.19827	http://dx.doi.org/10.1074/jbc.272.32.19827			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242644	hybrid			2022-12-25	WOS:A1997XQ05900031
J	Pasteau, S; Loiseau, L; Brun, G				Pasteau, S; Loiseau, L; Brun, G			Proliferation of chicken neuroretina cells induced by v-src, in vitro, depends on activation of the E2F transcription factor	ONCOGENE			English	Article						neuroretina cells; mitogenesis; v-src; E2F activity; dominant-negative mutants	ROUS-SARCOMA VIRUS; GREEN FLUORESCENT PROTEIN; RETINA-SPECIFIC GENE; S-PHASE ENTRY; GLUCOCORTICOID RECEPTOR; RETINOBLASTOMA PROTEIN; DEVELOPMENTAL CONTROL; EMBRYONIC RETINA; CYCLE CONTROL; C-JUN	Quiescent chicken or quail retina neuroblasts (NR) can be induced to proliferate actively, in culture, by the v-src oncoprotein. The chE2F-1 transcription factor, a physiological partner of the retinoblastoma gene product, is highly expressed in vivo, in dividing chicken neuroretina cells (CNR), It is sharply down-regulated as cells enter the post-mitotic differentiation stage, thus suggesting that E2F activity is a prerequisite for NR cell proliferation. In the present paper, transient expression assays of different forms of chE2F-1 mere used to investigate the function of E2F for switching CNR cells from a quiescent to a proliferative state in vitro. Attempts to substitute the effects of v-src by an ectopic expression of E2F-1 were unsuccessful. However, in the same conditions, E2F-1 supports full growth of CEF in serum-depleted medium, Deletion mutants of E2F-1, with potential dominant-negative properties, mere transfected in RSV infected CNR cells. One of these truncated mutants induces a G1 phase block in RSV-transformed CNR cells indicating that, although E2F-1 overexpression cannot overcome the cell proliferation block of postmitotic CNR cells E2F-1, activity is an important component of the growth signal pathway delivered by v-src in these nervous cells.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,CNRS,UMR 49,F-69364 LYON 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)								ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; ALTSHULER D, 1993, DEVELOPMENT, V119, P1317; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BENDROR I, 1993, P NATL ACAD SCI USA, V90, P1117, DOI 10.1073/pnas.90.3.1117; BERKOFLINT Y, 1994, EMBO J, V13, P646, DOI 10.1002/j.1460-2075.1994.tb06303.x; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COLL J, 1988, J VIROL, V62, P2808, DOI 10.1128/JVI.62.8.2808-2816.1988; CRISANTI P, 1995, METHOD ENZYMOL, V254, P77; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOZIER C, 1988, BIOCHIMIE, V70, P885, DOI 10.1016/0300-9084(88)90229-5; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESPANEL X, 1997, IN PRESS INT J DEV B; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GILLET G, 1993, ONCOGENE, V8, P565; GOROVITS R, 1994, P NATL ACAD SCI USA, V91, P4786, DOI 10.1073/pnas.91.11.4786; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JAMAL HH, 1994, ONCOGENE, V9, P417; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LI X, 1994, J BIOL CHEM, V269, P6263; LILLIEN L, 1992, DEVELOPMENT, V115, P253; LOISEAU L, 1997, IN PRESS GENE EXPRES; MARTIN P, 1992, ONCOGENE, V7, P1721; MICHEL D, 1989, ONCOGENE RES, V4, P127; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; NEVINS JR, 1992, SCIENCE, V258, P424; North S, 1996, CELL GROWTH DIFFER, V7, P339; PASTEAU S, 1995, ONCOGENE, V11, P1475; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PIERANI A, 1995, MOL CELL BIOL, V15, P642; PINES J, 1995, TRENDS GENET, V11, P326, DOI 10.1016/S0168-9525(00)89092-7; PLAZA S, 1995, ONCOGENE, V10, P329; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; ROPP JD, 1995, CYTOMETRY, V21, P309, DOI 10.1002/cyto.990210402; SAMARUT J, 1995, METHOD ENZYMOL, V254, P206; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SEFTON BM, 1980, J VIROL, V33, P220, DOI 10.1128/JVI.33.1.220-229.1980; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TCHENG M, 1994, EXP CELL RES, V212, P30, DOI 10.1006/excr.1994.1114; VARDIMON L, 1991, MOL CELL BIOL, V11, P5275, DOI 10.1128/MCB.11.10.5275; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELHAM MJ, 1990, ONCOGENE, V5, P161; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; Yang Xiao-He, 1995, Gene Expression, V4, P195; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036; YOON HY, 1994, ONCOGENE, V9, P801; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; Zhou H, 1996, J NEUROSCI, V16, P2261, DOI 10.1523/jneurosci.16-07-02261.1996; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	72	7	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					17	28		10.1038/sj.onc.1201177	http://dx.doi.org/10.1038/sj.onc.1201177			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233774				2022-12-25	WOS:A1997XH58600003
J	Rosa, JL; Barbacid, M				Rosa, JL; Barbacid, M			A giant protein that stimulates guanine nucleotide exchange on ARF1 and Rab proteins forms a cytosolic ternary complex with clathrin and Hsp70	ONCOGENE			English	Article						guanine nucleotide exchange factor; Ras-like small GTPases; protein transport; RCC1-like domains	TRANSPORT; RNA; CELLS; NEURONS; HOMOLOG; IMPORT; RCC1	We have recently identified an unusually large human protein that stimulates guanine nucleotide exchange on ARF1 and Rab proteins (EMBO J 15: 4262-4273, 1996), This protein, designated p532 based on its predicted molecular weight (EMBO J 15: 5738, 1996), contains multiple structural domains including two regions of seven internal repeats highly related to the cell cycle regulator RCC1, a guanine nucleotide exchange factor for the small GTP-binding protein Ran, seven beta-repeat domains characteristic of the beta subunit of heterotrimeric G proteins, three putative SH3 binding sites, a putative leucine-zipper and a carboxyterminal HECT domain characteristic of E3 ubiquitin-protein Ligases. Some of these domains are known to be involved in protein-protein interactions, suggesting the existence of p532-interacting proteins, To identify some of these proteins, we used the carboxy-terminal RCC1-like domain (RLD) of p532 in the yeast two-hybrid system, We report here the isolation of a clone that encodes the last 654 amino acid residues of the clathrin heavy chain, This interaction involves amino acid residues 1315-1557 of the clathrin heavy chain and the carboxy, but not the amino-terminal RLD of p532, p532 has been located in the cytosolic fraction as well as in the Golgi apparatus, The interaction between p532 and clathrin only occurs in the cytosol and is mediated by the formation of an ATP-dependent ternary complex with the heat shock protein, Hsp70, These observations suggest that p532 is involved in membrane transport processes.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb			Rosa, Jose Luis/K-6685-2014	Rosa, Jose Luis/0000-0002-6161-5688				BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BLACK MM, 1991, J NEUROSCI, V11, P1163; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CHAKRABARTI R, 1993, J CELL BIOL, V123, P79, DOI 10.1083/jcb.123.1.79; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; NELSON KK, 1993, MOL CELL BIOL, V13, P521, DOI 10.1128/MCB.13.1.521; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; REN MD, 1995, MOL CELL BIOL, V15, P2117; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; ROSA JL, 1996, EMBO J, V15, P51738; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	27	50	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					1	6		10.1038/sj.onc.1201170	http://dx.doi.org/10.1038/sj.onc.1201170			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233772				2022-12-25	WOS:A1997XH58600001
J	Bhat, R; Bresnick, E				Bhat, R; Bresnick, E			Glycine N-methyltransferase is an example of functional diversity - Role as a polycyclic aromatic hydrocarbon-binding receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; NUCLEAR TRANSLOCATOR PROTEIN; RAT-LIVER CYTOSOL; AH-RECEPTOR; GENE-EXPRESSION; DNA METHYLATION; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; HYDROXYLASE; INDUCTION; DIOXIN	The cytochrome P-4501A1 (CYP1A1) gene is regulated by several trans-acting factors including the 4 S polycyclic aromatic hydrocarbon (PAH)-binding protein, which has recently been identified as glycine N-methyltransferase (GNMT) (Raha, A., Wagner, C.,;Macdonald, R. G,, and Bresnick, E, (1994) J, Biol, Chem. 269, 5750-5756), The role of GNMT as a 4 S PAH-binding protein in mediating the induction of cytochrome P-4501A1 has been investigated further, GNMT cDNA, which was cloned into a pMAMneo vector containing the Rous sarcoma virus promoter and the neomycin resistance gene, was stably transfected into D422 Chinese hamster ovary (CHO) cells. Several positive clones were selected by reverse transcription-polymerase chain reaction and assayed for the expression of recombinant protein, Western blot analysis indicated the expression of significant levels of the 4 S protein in the stably transfected CHO cells (CHO-GNMT). Cytosolic preparations from the CHO-GNMT showed high benzo[a]pyrene (E[a]P) binding but no 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) binding activity when compared with clones transfected with the pMAMneo vector alone (CHO-neo) or the parental CHO cells, Challanging the CHO-GNMT cells with 4 mu M B[a]P resulted in elevated levels of CYP1A1 mRNA, Equally effective in inducing CYP1A1 mRNA were benzo[e]pyrene and 3-methylcholanthrene. On the ether hand, TCDD did not induce CYP1A1 gene expression in these cells. B[a]P-treated CHO-GNMT, expressing the 4 S protein, also showed CYP1A1 protein by Western blotting and exhibited ethoxyresorufin-O-deethylase activity; neither the CHO-neo or parental CHO cells were positive for any of these measures, No Ah receptor message or protein was detectable in the parental CHO, CHO-neo, or CHO-GNMT cells, Furthermore, no XRE binding activity was observed in TCDD-treated cytosolic preparations or nuclear extracts from CHO-GNMT cells that were treated with TCDD, These studies unequivocally establish that GNMT is a PAH-binding protein that can mediate the induction of CYP1A1 by PAHs such as B[a]P through an Ah receptor independent pathway.	UNIV MASSACHUSETTS, MED CTR, DEPT MOL PHARMACOL & TOXICOL, RES OFF, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [CA 36105] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhat R, 1996, J BIOL CHEM, V271, P32551, DOI 10.1074/jbc.271.51.32551; BIGELOW SW, 1987, BIOCHEM J, V242, P375; BLUMENSTEIN J, 1960, BIOCHEM BIOPH RES CO, V3, P259, DOI 10.1016/0006-291X(60)90235-7; BRADLEY WEC, 1982, SOMAT CELL GENET, V8, P51, DOI 10.1007/BF01538650; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; BURKE MD, 1985, BIOCHEM PHARMACOL, V34, P3337, DOI 10.1016/0006-2952(85)90355-7; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; COLLINS S, 1984, MOL PHARMACOL, V26, P353; COOK RJ, 1981, ARCH BIOCHEM BIOPHYS, V208, P358, DOI 10.1016/0003-9861(81)90520-8; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fourney R.M., 1988, FOCUS, V10, P5; GIBBONS JA, 1992, CHEM-BIOL INTERACT, V83, P203, DOI 10.1016/0009-2797(92)90098-6; GIBBONS JA, 1990, TOXICOLOGIST, V10, P193; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GUENTHNER TM, 1977, J BIOL CHEM, V252, P8981; HANKINSON O, 1991, METHOD ENZYMOL, V206, P381; HEINTZ NH, 1981, CANCER RES, V41, P1794; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HOLDER GM, 1981, CANCER RES, V41, P4408; HOUSER WH, 1985, BIOCHEMISTRY-US, V24, P7839, DOI 10.1021/bi00347a050; HOUSER WH, 1987, ARCH BIOCHEM BIOPHYS, V259, P215, DOI 10.1016/0003-9861(87)90488-7; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; KAMPS C, 1987, CANCER LETT, V34, P129, DOI 10.1016/0304-3835(87)90003-6; KERR SJ, 1972, J BIOL CHEM, V247, P4248; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MITCHELL AD, 1976, J NUTR, V106, P1702, DOI 10.1093/jn/106.12.1702; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEBERT DW, 1989, DNA-J MOLEC CELL BIO, V8, P1, DOI 10.1089/dna.1.1989.8.1; NEBERT DW, 1989, CRIT REV TOXICOL, V20, P153, DOI 10.3109/10408448909017908; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; OGAWA H, 1993, COMP BIOCHEM PHYS B, V106, P601, DOI 10.1016/0305-0491(93)90137-T; OGAWA H, 1982, J BIOL CHEM, V257, P3447; PISKORSKAPLISZCZYNSKA J, 1986, TOXICOL LETT, V34, P67, DOI 10.1016/0378-4274(86)90146-3; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; POLAND A, 1985, CLIN PHYSIOL BIOCH, V3, P147; PROBST MR, 1993, MOL PHARMACOL, V44, P511; RAHA A, 1994, J BIOL CHEM, V269, P5750; RAHA A, 1990, J TOXICOL ENV HEALTH, V29, P339, DOI 10.1080/15287399009531397; RAHA A, 1991, TOXICOLOGY, V66, P175, DOI 10.1016/0300-483X(91)90217-O; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RONAI Z, 1993, INT J BIOCHEM, V25, P1073, DOI 10.1016/0020-711X(93)90123-V; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SINCLAIR JF, 1992, CANCER RES, V52, P3615; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P3418, DOI 10.1073/pnas.79.11.3418; TIERNEY B, 1980, ARCH BIOCHEM BIOPHYS, V200, P513, DOI 10.1016/0003-9861(80)90383-5; VADIMON L, 1982, P NATL ACAD SCI USA, V79, P1073; WHAL GM, 1981, TRANSFER IMMOBILIZAT; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; YEO EJ, 1994, P NATL ACAD SCI USA, V91, P210, DOI 10.1073/pnas.91.1.210; ZYTKOVICZ TH, 1982, CANCER RES, V42, P4387; [No title captured]	62	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21221	21226		10.1074/jbc.272.34.21221	http://dx.doi.org/10.1074/jbc.272.34.21221			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261130	hybrid			2022-12-25	WOS:A1997XR78900040
J	Ge, ZM; Chan, NWC; Palcic, MM; Taylor, DE				Ge, ZM; Chan, NWC; Palcic, MM; Taylor, DE			Cloning and heterologous expression of an alpha 1,3-fucosyltransferase gene from the gastric pathogen Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; HOMEODOMAIN-DNA COMPLEX; FUCOSYL-TRANSFERASE; MOLECULAR-CLONING; DETERMINES EXPRESSION; ULCER DISEASE; ELAM-1 LIGAND; PROTEINS; CARBOHYDRATE	Helicobacter pylori is an important human pathogen which causes both gastric and duodenal ulcers and is also associated with gastric cancer and lymphoma. This microorganism has been shown to express cell surface glycoconjugates including Lewis X (Le(x)) and Lewis Y. These bacterial oligosaccharides are structurally similar to tumor-associated carbohydrate antigens found in mammals, In this study, we report the cloning of a novel alpha 1,3-fucosyltransferase gene (HpfucT) involved in the biosynthesis of Le(x) within H. pylori. The deduced amino acid sequence of HpfucT consists of 478 residues with the calculated molecular mass of 56,194 daltons, which is approximately 100 amino acids longer than known mammalian alpha 1,3/1,4-fucosyltransferases. The similar to 52-kDa protein encoded by HpfucT was expressed in Escherichia coli CSRDE3 cells and gave rise to alpha 1,3-fucosyltransferase activity but neither alpha 1,4-fucosyltransferase nor alpha 1,2-fucosyltransferase activity as characterized by radiochemical assays and capillary zone electrophoresis, Truncation of the C-terminal 100 amino acids of HpFuc-T abolished the enzyme activity, An approximately 72-amino acid region of HpFuc-T exhibits significant sequence identity (40-45%) with the highly conserved C-terminal catalytic domain among known mammalian and chicken alpha 1,3-fucosyltransferases. These lines of evidence indicate that the HpFuc-T represents the bacterial alpha 1,3-fucosyltransferase. In addition, several structural features unique to HpFuc-T, including 10 direct repeats of seven amino acids and the lack of the transmembrane segment typical for known eukaryotic alpha 1,3-fucosyltransferases, were revealed, Notably, the repeat region contains a leucine zipper motif previously demonstrated to be responsible for dimerization of various basic region-leucine zipper proteins, suggesting that the HpFuc-T protein could form dimers.	UNIV ALBERTA, DEPT IMMUNOL & MED MICROBIOL, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT CHEM, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, DEPT SCI BIOL, EDMONTON, AB T6G 2H7, CANADA	University of Alberta; University of Alberta; University of Alberta								Appelmelk BJ, 1996, INFECT IMMUN, V64, P2031, DOI 10.1128/IAI.64.6.2031-2040.1996; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2489, DOI 10.1021/bi951852s; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2498, DOI 10.1021/bi951853k; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHAN NWC, 1995, GLYCOBIOLOGY, V5, P683, DOI 10.1093/glycob/5.7.683; FEIZI T, 1988, NATURE, V70, P1587; FORMAN D, 1993, LANCET, V341, P1359; Ge ZM, 1996, J BACTERIOL, V178, P6151, DOI 10.1128/jb.178.21.6151-6157.1996; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOKHALE UB, 1990, CAN J CHEM, V68, P1063, DOI 10.1139/v90-165; GRAHAM DY, 1991, J GASTROEN HEPATOL, V6, P105, DOI 10.1111/j.1440-1746.1991.tb01448.x; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; Hitoshi S, 1996, J BIOL CHEM, V271, P16975, DOI 10.1074/jbc.271.28.16975; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KELLY MM, 1995, DEV BRAIN RES, V85, P31, DOI 10.1016/0165-3806(94)00185-3; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lau PCK, 1997, P NATL ACAD SCI USA, V94, P1453, DOI 10.1073/pnas.94.4.1453; Lee A., 1988, Microbial Ecology in Health and Disease, V1, P1; Lee KP, 1996, J BIOL CHEM, V271, P32960, DOI 10.1074/jbc.271.51.32960; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LOUIE K, 1986, J BACTERIOL, V165, P805, DOI 10.1128/jb.165.3.805-812.1986; LOW JB, 1994, FRONTIERS MOL BIOL, P163; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MURAMATSU T, 1988, BIOCHIMIE, V70, P1587, DOI 10.1016/0300-9084(88)90294-5; Nakamura S, 1997, CANCER-AM CANCER SOC, V79, P3, DOI 10.1002/(SICI)1097-0142(19970101)79:1<3::AID-CNCR2>3.0.CO;2-P; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PAULSON S, 1996, J BIOL CHEM, V264, P17615; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RATHBONE BJ, 1986, GUT, V27, P642, DOI 10.1136/gut.27.6.642; RUBERTI I, 1991, EMBO J, V10, P1787, DOI 10.1002/j.1460-2075.1991.tb07703.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCHENA M, 1992, P NATL ACAD SCI USA, V89, P3894, DOI 10.1073/pnas.89.9.3894; SHERBURNE R, 1995, INFECT IMMUN, V63, P4564, DOI 10.1128/IAI.63.12.4564-4568.1995; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SODERMAN E, 1994, PLANT MOL BIOL, V26, P145, DOI 10.1007/BF00039527; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; WARREN JR, 1983, LANCET, V1, P1273; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Wirth HP, 1996, INFECT IMMUN, V64, P4598, DOI 10.1128/IAI.64.11.4598-4605.1996; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818	56	102	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21357	21363		10.1074/jbc.272.34.21357	http://dx.doi.org/10.1074/jbc.272.34.21357			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261149	hybrid			2022-12-25	WOS:A1997XR78900059
J	Wijkander, J; Holst, LS; Rahn, T; Resjo, S; Castan, I; Manganiello, V; Belfrage, P; Degerman, E				Wijkander, J; Holst, LS; Rahn, T; Resjo, S; Castan, I; Manganiello, V; Belfrage, P; Degerman, E			Regulation of protein kinase B in rat adipocytes by insulin, vanadate, and peroxovanadate - Membrane translocation in response to peroxovanadate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; GLUCOSE-TRANSPORT; SER/THR KINASE; AKT; HOMOLOGY; DOMAIN; PHOSPHORYLATION; ACTIVATION; 3-KINASE	Protein kinase B (PKB) (also referred to as RAC/Akt kinase) has been shown to be controlled by various growth factors, including insulin, using cell lines and transfected cells, However, information is so far scarce regarding its regulation in primary insulin-responsive cells, We have therefore used isolated rat adipocytes to examine the mechanisms, including membrane translocation, whereby insulin and the insulin-mimicking agents vanadate and peroxovanadate control PKB. Stimulation of adipocytes with insulin, vanadate, or peroxovanadate caused decreased PKB mobility on sodium dodecyl sulfate-polyacrylamide gels, indicative of increased phosphorylation, which correlated with an increase in kinase activity detected with the peptide KKRNRTLTK. This peptide was found to detect activated PKB selectively in crude cytosol and partially purified cytosol fractions from insulin-stimulated adipocytes. The decrease in electrophoretic mobility and activation of PKB induced by insulin was reversed both in vitro by treatment of the enzyme with alkaline phosphatase and in the intact adipocyte upon removal of insulin or addition of the phosphatidylinositol 3-kinase (PI I-kinase) inhibitor wortmannin. Significant translocation of PKB to membranes could not Its demonstrated after insulin stimulation, but peroxovanadate, which appeared to activate PI 3-kinase to a higher extent than insulin, induced substantial translocation, The translocation was prevented by wortmannin, suggesting that PI 3-kinase and/or the 3-phosphorylated phosphoinositides generated by PI 3-kinase are indeed involved in the membrane targeting of PKB.	NHLBI, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Wijkander, J (corresponding author), LUND UNIV, DEPT CELL & MOL BIOL, SECT MOL SIGNALING, POB 94, S-22100 LUND, SWEDEN.			wijkander, jonny/0000-0002-2310-9039; Castan-Laurell, Isabelle/0000-0002-0488-9789				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHANG KJ, 1974, J BIOL CHEM, V249, P6854; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DEGERMAN E, 1994, BIOCHIM BIOPHYS ACTA, V1205, P1899; Degerman Eva, 1996, P197; DUNN B, 1992, CURRENT PROTOCOLS MO; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Matsuzaki H, 1996, FEBS LETT, V396, P305, DOI 10.1016/0014-5793(96)01120-9; MOSES AC, 1991, INSULIN LIKE GROWTH, P245; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; OKADA T, 1994, J BIOL CHEM, V269, P3568; RODBELL M, 1964, J BIOL CHEM, V239, P375; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHISHEVA A, 1992, BIOCHEMISTRY-US, V31, P8059, DOI 10.1021/bi00149a041; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001	40	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21520	21526		10.1074/jbc.272.34.21520	http://dx.doi.org/10.1074/jbc.272.34.21520			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261171	hybrid			2022-12-25	WOS:A1997XR78900081
J	Benoist, F; GrandPerret, T				Benoist, F; GrandPerret, T			Co-translational degradation of apolipoprotein B100 by the proteasome is prevented by microsomal triglyceride transfer protein - Synchronized translation studies on HepG2 cells treated with an inhibitor of microsomal triglyceride transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; B-CONTAINING LIPOPROTEINS; ENDOPLASMIC-RETICULUM; OLEIC-ACID; G2 CELLS; INTRACELLULAR DEGRADATION; DISULFIDE-ISOMERASE; MCA-RH7777 CELLS; LIPID-BINDING; MESSENGER-RNA	We studied the effect of inhibition of microsomal triglyceride transfer protein (MTP) on apolipoprotein (ape) B100 translation and secretion using HepG2 cells. The MTP-mediated lipid transfer activity was reduced using a specific MTP inhibitor, ApoB100 translation was synchronized by treatment with puromycin prior to L-[S-35]methionine pulse-chase labeling. During the first 4 min of chase, synthesis of apoB polypeptides the size of 100-200 kDa was insensitive to the inhibitor, suggesting that inhibition of MTP did not affect the initiation of apoB100 translation, After 15 min of chase, the 100-200-kDa species were chased into polypeptides larger than 320 kDa (i.e. apoB65 or 65% of full-length apoB100) in both control and inhibitor-treated cells, However, the amount of these polypeptides decreased (by 36% for apoB65-75, by 64% for apoB75-85, by 76% for apoB85-95, and by 77% for apoB100) upon MTP inhibition, No accumulation of smaller polypeptides was observed, but total immunoprecipitable apoB radioactivity was decreased suggesting that apoB could undergo cotranslational degradation when MTP activity was reduced. Inhibitors of the multicatalytic proteinase complex (proteasome) such as lactacystin or MG-115 could prevent apoB co-translational degradation, Nevertheless, MG-115 could not avoid the MTP inhibitor decreasing apoB100 secretion but rather induced the accumulation of secretion-incompetent apoB100 in the cell. These results indicate that MTP activity is required during the elongation of apoB100 polypeptides, particularly at the sequences downstream of carboxyl terminus of apoB65, Go-translational degradation might constitute a more general mechanism of early quality control for large or complex proteins.	CTR RECH,LAB GLAXO WELLCOME,F-91951 LES ULIS,FRANCE	GlaxoSmithKline								ADELI K, 1994, J BIOL CHEM, V269, P9166; ADELI K, 1995, CIRCULATION S1, V92, P228; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Benoist F, 1996, EUR J BIOCHEM, V240, P713, DOI 10.1111/j.1432-1033.1996.0713h.x; Benoist F, 1996, ARTERIOSCL THROM VAS, V16, P1229, DOI 10.1161/01.ATV.16.10.1229; BENOIST F, 1995, J LIPID RES, V36, P2243; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BROWN GD, 1983, J BIOL CHEM, V258, P4309; BYRNE CD, 1992, BIOCHEM J, V288, P101, DOI 10.1042/bj2880101; Cartwright IJ, 1996, BIOCHEM J, V314, P977, DOI 10.1042/bj3140977; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DU EZ, 1994, J BIOL CHEM, V269, P24169; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GIBBONS GF, 1992, BIOCHEM J, V287, P749, DOI 10.1042/bj2870749; GINSBERG HN, 1995, CIRCULATION S, V92, P228; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Haghpassand M, 1996, J LIPID RES, V37, P1468; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; JANERO DR, 1983, J BIOL CHEM, V258, P4496; KAPTEIN A, 1991, BIOCHEM J, V278, P557, DOI 10.1042/bj2780557; KAPTEIN A, 1994, ARTERIOSCLER THROMB, V14, P780, DOI 10.1161/01.ATV.14.5.780; KOBUTA S, 1984, BIOCHIM BIOPHYS ACTA, V802, P379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICCI B, 1995, J BIOL CHEM, V270, P14281, DOI 10.1074/jbc.270.24.14281; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; SAKATA N, 1993, J BIOL CHEM, V268, P22967; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; Shelness GS, 1996, J LIPID RES, V37, P408; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SWIFT LL, 1995, J LIPID RES, V36, P395; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WHITE AL, 1992, J BIOL CHEM, V267, P15657; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	73	131	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20435	20442		10.1074/jbc.272.33.20435	http://dx.doi.org/10.1074/jbc.272.33.20435			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252352	hybrid			2022-12-25	WOS:A1997XR22100022
J	Berge, A; Kihlberg, BM; Sjoholm, AG; Bjorck, L				Berge, A; Kihlberg, BM; Sjoholm, AG; Bjorck, L			Streptococcal protein H forms soluble complement-activating complexes with IgG, but inhibits complement activation by IgG-coated targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; GRAM-POSITIVE BACTERIA; SEPARATE BINDING-SITES; SURFACE-PROTEINS; IMMUNOGLOBULIN-G; C4B-BINDING PROTEIN; STAPHYLOCOCCUS-AUREUS; CHEMOTACTIC RESPONSE; ALBUMIN; PYOGENES	Protein H, a surface protein of Streptococcus pyogenes interacting with the constant Fc region of IgG, is known to be released from the streptococcal surface by a cysteine proteinase produced by the bacteria. Poststreptococcal glomerulonephritis and rheumatic fever are conditions in which immune complexes and autoimmune mechanisms have been suggested to play pathogenetic roles, The present study demonstrates that addition of protein H to human serum produces complement activation with dose-dependent cleavage of C3. The activation was IgG-dependent and the result of complexes formed between IgG and protein H. These complexes were size heterogeneous with molecular masses of 400 kDa to 1.4 MDa. Using complement-depleted serum reconstituted with complement proteins, the activation by protein H was found to be dependent of the classical, but independent of the alternative pathway of complement. In contrast to results of experiments based on soluble protein H IgG complexes, complement activation was inhibited by protein H when IgG was immobilized on a surface, The interaction between C1q and immunoglobulins represents the first step in the activation of the classical pathway, and protein H efficiently inhibited the binding of C1q to IgG immobilized on polyacrylamide beads, Protein H reduced C3 deposition on the IgG-coated beads and inhibited immune hemolysis of IgG-sensitized erythrocytes, Finally, significantly less C3 was deposited on the surface of protein II-expressing wild-type streptococci than on the surface of isogenic mutant bacteria devoid of protein H, The results demonstrate that protein H IgG complexes released from the streptococcal surface can produce complement breakdown at the sites of infection, whereas complement activation on bacterial surfaces is inhibited, This should have important implications for host-parasite relationships, In addition, soluble protein H IgG complexes might contribute to immunological complications of streptococcal infections.	LUND UNIV,DEPT MED MICROBIOL,S-22100 LUND,SWEDEN	Lund University	Berge, A (corresponding author), LUND UNIV,DEPT CELL & MOL BIOL,SECT MOL PATHOGENESIS,POB 94,S-22100 LUND,SWEDEN.							Akesson P, 1996, J BIOL CHEM, V271, P1081, DOI 10.1074/jbc.271.2.1081; AKESSON P, 1994, BIOCHEM J, V300, P877, DOI 10.1042/bj3000877; AKESSON P, 1990, MOL IMMUNOL, V6, P523; BARNUM SR, 1991, IMMUNOL RES, V10, P28, DOI 10.1007/BF02918165; BERGE A, 1993, J BIOL CHEM, V268, P25417; BERGE A, 1995, J BIOL CHEM, V270, P9862, DOI 10.1074/jbc.270.17.9862; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; BJORCK L, 1987, MOL IMMUNOL, V24, P1113, DOI 10.1016/0161-5890(87)90080-0; BJORCK L, 1984, J IMMUNOL, V133, P969; BUROVA LA, 1980, ACTA PATH MICRO IM B, V88, P199; CEDERVALL T, 1995, SCAND J IMMUNOL, V42, P433, DOI 10.1111/j.1365-3083.1995.tb03677.x; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBOGE H, 1989, GENE, V79, P325; DALE JB, 1985, J EXP MED, V162, P583, DOI 10.1084/jem.162.2.583; DECHATEAU M, 1994, J BIOL CHEM, V269, P12147; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FORSGREN A, 1966, J IMMUNOL, V97, P822; FRANK MM, 1990, MICROBIAL DETERMINANTS OF VIRULENCE AND HOST RESPONSE, P305; FREDLUND H, 1993, INT ARCH ALLERGY IMM, V100, P135, DOI 10.1159/000236400; FRICK IM, 1994, MOL MICROBIOL, V12, P143, DOI 10.1111/j.1365-2958.1994.tb01003.x; FRICK IM, 1992, P NATL ACAD SCI USA, V89, P8532, DOI 10.1073/pnas.89.18.8532; FRICK IM, 1995, EMBO J, V14, P1674, DOI 10.1002/j.1460-2075.1995.tb07156.x; GANROT PO, 1972, SCAND J CLIN LAB INV, V29, P39, DOI 10.3109/00365517209102749; GOMI H, 1990, J IMMUNOL, V144, P4046; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; INGANAS M, 1981, SCAND J IMMUNOL, V13, P343, DOI 10.1111/j.1365-3083.1981.tb00143.x; Johnsson E, 1996, J IMMUNOL, V157, P3021; JOINER KA, 1984, ANNU REV IMMUNOL, V2, P461, DOI 10.1146/annurev.immunol.2.1.461; KASTERN W, 1992, J BIOL CHEM, V267, P12820; Kihlberg BM, 1995, MICROB PATHOGENESIS, V19, P299, DOI 10.1016/S0882-4010(96)80003-9; Kihlberg BM, 1996, EUR J BIOCHEM, V240, P556, DOI 10.1111/j.1432-1033.1996.0556h.x; KRONVALL G, 1979, INFECT IMMUN, V25, P1; LINDAHL G, 1990, EPIDEMIOL INFECT, V105, P87, DOI 10.1017/S0950268800047683; MAGUIN E, 1992, J BACTERIOL, V174, P5633, DOI 10.1128/JB.174.17.5633-5638.1992; MARTIN DR, 1993, J INFECT DIS, V167, P1112, DOI 10.1093/infdis/167.5.1112; MICHAEL AF, 1966, J CLIN INVEST, V45, P237, DOI 10.1172/JCI105336; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PEREZCASAL J, 1993, MOL MICROBIOL, V8, P809, DOI 10.1111/j.1365-2958.1993.tb01628.x; RAEDER R, 1993, INFECT IMMUN, V61, P1378, DOI 10.1128/IAI.61.4.1378-1384.1993; RAPP HJ, 1970, MOL BASIS COMPLEMENT; REIS KJ, 1984, J IMMUNOL, V132, P3091; Sambrook J., 2002, MOL CLONING LAB MANU; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SJOHOLM AG, 1979, INT ARCH ALLER A IMM, V58, P274, DOI 10.1159/000232203; SJOHOLM AG, 1991, APMIS, V99, P1120; STONE GC, 1989, J IMMUNOL, V143, P565; TAO MH, 1993, J EXP MED, V178, P661, DOI 10.1084/jem.178.2.661; TENNER AJ, 1981, J IMMUNOL, V127, P648; THERN A, 1995, J IMMUNOL, V154, P375; TRUEDSSON L, 1983, J IMMUNOL METHODS, V63, P207, DOI 10.1016/0022-1759(83)90424-6; WEXLER DE, 1985, P NATL ACAD SCI USA, V82, P8144, DOI 10.1073/pnas.82.23.8144; WEXLER DE, 1983, INFECT IMMUN, V39, P239, DOI 10.1128/IAI.39.1.239-246.1983; ZABRISKIE JB, 1966, J EXP MED, V124, P661, DOI 10.1084/jem.124.4.661	58	82	83	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20774	20781		10.1074/jbc.272.33.20774	http://dx.doi.org/10.1074/jbc.272.33.20774			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252400	hybrid			2022-12-25	WOS:A1997XR22100070
J	Datta, R; Kojima, H; Yoshida, K; Kufe, D				Datta, R; Kojima, H; Yoshida, K; Kufe, D			Caspase-3-mediated cleavage of protein kinase C theta in induction of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNUCLEOSOMAL DNA FRAGMENTATION; POLY(ADP-RIBOSE) POLYMERASE; MOLECULAR-CLONING; SKELETAL-MUSCLE; LEUKEMIA-CELLS; FAMILY; INHIBITION; MEMBER; EXPRESSION; NPKC	Protein kinase C theta (PKC theta) is a member of the novel or nPKC family. A functional role for PKC theta is unknown. The present studies demonstrate that PKC theta is cleaved in the third variable region (V3) in apoptosis induced by diverse agents. PKC theta cleavage is blocked in cells that overexpress the anti-apoptotic Bcl-x(L) or the baculovirus p35 protein. PKC theta is cleaved by Caspase-3 and by apoptotic cell lysates at a DEVD354/K site. We also show that overexpression of the cleaved kinase-active PKC theta fragment, but not full-length PKC theta or a kinase-inactive fragment, results in induction of sub-G(1) phase DNA, nuclear fragmentation, and lethality. These findings indicate that proteolytic cleavage of PKC theta by Caspase-3 induces events characteristic of apoptosis.			Datta, R (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,44 BINNEY ST,BOSTON,MA 02115, USA.				NCI NIH HHS [CA66996, CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066996, R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAIER G, 1993, J BIOL CHEM, V268, P4997; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CASEIOLAROSEN L, 1996, J EXP MED, V183, P1957; CHANG JD, 1993, J BIOL CHEM, V268, P14208; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GUNJI H, 1991, CANCER RES, V51, P741; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Meller N, 1996, MOL CELL BIOL, V16, P5782; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3	29	262	267	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20317	20320		10.1074/jbc.272.33.20317	http://dx.doi.org/10.1074/jbc.272.33.20317			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252332	hybrid			2022-12-25	WOS:A1997XR22100002
J	Ke, SH; Coombs, GS; Tachias, K; Corey, DR; Madison, EL				Ke, SH; Coombs, GS; Tachias, K; Corey, DR; Madison, EL			Optimal subsite occupancy and design of a selective inhibitor of urokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; SITE-SPECIFIC MUTAGENESIS; CRYSTAL-STRUCTURE; DIRECTED MUTAGENESIS; ALPHA-CHYMOTRYPSIN; SERINE PROTEINASES; TISSUE; TRYPSIN; IDENTIFICATION; FIBRINOLYSIS	Human urokinase type plasminogen activator (u-PA) is a member of the chymotrypsin family of serine proteases that can play important roles in both health and disease, We have used substrate phage display techniques to characterize the specificity of this enzyme in detail and to identify peptides that are cleaved 840-5300 times more efficiently by u-PA than peptides containing the physiological target sequence of the enzyme, In addition, unlike peptides containing the physiological target sequence, the peptide substrates selected in this study were cleaved as much as 120 times more efficiently by u-PA than by tissue type plasminogen activator (t-PA), an intimately related enzyme. Analysis of the selected peptide substrates strongly suggested that the primary sequence SGRSA, from position P3 to P2', represents optimal subsite occupancy for substrates of u-PA. Insights gained in these investigations were used to design a variant of plasminogen activator inhibitor type 1, the primary physiological inhibitor of both u-PA and t-PA, that inhibited u-PA approximately 70 times more rapidly than it inhibited t-PA. These observations provide a solid foundation for the design of highly selective, high affinity inhibitors of u-PA and, consequently, may facilitate the development of novel therapeutic agents to inhibit the initiation and/or progression of selected human tumors.	Scripps Res Inst, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	Scripps Research Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Coombs, Gary/0000-0002-0711-185X	NHLBI NIH HHS [P01 HL31950, R01 HL52475] Funding Source: Medline; NIGMS NIH HHS [T32GM08203] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL052475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008203] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DS, 1991, J BIOL CHEM, V266, P8476; ALPERT AJ, 1990, J CHROMATOGR, V499, P177, DOI 10.1016/S0021-9673(00)96972-3; BAGGIO R, 1996, BIOCHEMISTRY-US, V35, P3551; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BODE W, 1992, PROTEIN SCI, V1, P426; BRUNNER N, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P61; Carmeliet P, 1996, FIBRINOLYSIS, V10, P195, DOI 10.1016/S0268-9499(96)80017-8; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Castellino F. J, 1995, MOL BASIS THROMBOSIS, P495; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; COLLEN D, 1991, BLOOD, V78, P3114; Coombs GS, 1996, J BIOL CHEM, V271, P4461; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; DUFFY MJ, 1988, CANCER, V62, P531, DOI 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B; DUFFY MJ, 1993, FIBRINOLYSIS, V7, P295, DOI 10.1016/0268-9499(93)90144-K; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; HEARING VJ, 1988, CANCER RES, V48, P1270; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; JANICKE F, 1990, FIBRINOLYSIS, V4, P69, DOI 10.1016/0268-9499(90)90001-Z; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LOSKUTOFF DJ, 1993, J CLIN INVEST, V92, P2563, DOI 10.1172/JCI116866; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1993, METHOD ENZYMOL, V223, P249; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; Min HY, 1996, CANCER RES, V56, P2428; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; ROBERTS HR, 1995, MOL BASIS THROMBOSIS, P35; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Shapiro RL, 1996, CANCER RES, V56, P3597; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; Taylor J. R., 1982, INTRO ERROR ANAL STU; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; URANO T, 1988, BIOCHEM BIOPH RES CO, V150, P45, DOI 10.1016/0006-291X(88)90484-6; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	51	94	113	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20456	20462		10.1074/jbc.272.33.20456	http://dx.doi.org/10.1074/jbc.272.33.20456			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252355	hybrid			2022-12-25	WOS:A1997XR22100025
J	Lawrence, SD; Kindle, KL				Lawrence, SD; Kindle, KL			Alterations in the Chlamydomonas plastocyanin transit peptide have distinct effects on in vitro import and in vivo protein accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLASTIC PRECURSOR PROTEINS; THYLAKOID LUMEN PROTEINS; INTACT CHLOROPLASTS; SIGNAL PEPTIDE; SMALL SUBUNIT; ENVELOPE; MEMBRANE; BINDING; TRANSLOCATION; REINHARDTII	Nucleus-encoded chloroplast proteins that reside in the thylakoid lumen are synthesized as precursors with bipartite transit peptides that contain information for uptake and intra-chloroplast localization, We have begun to apply the superb molecular and genetic attributes of Chlamydomonas to study chloroplast protein import by creating a series of deletions in the transit peptide of plastocyanin and determining their effects on translocation into isolated Chlamydomonas chloroplasts, Most N-terminal mutations dramatically inhibited in vitro import, whereas replacement with a transit peptide from the gamma-subunit of chloroplast ATPase restored uptake. Thus, the N-terminal region has stroma-targeting function, Deletions within the C-terminal portion of the transit peptide resulted in the appearance of import intermediates, suggesting that this region is required for lumen translocation and processing, Thus, despite its short length and predicted structural differences, the Chlamydomonas plastocyanin transit peptide has functional domains similar to those of vascular plants, Similar mutations have been analyzed in vivo by transforming altered genes into a mutant defective at the plastocyanin locus (K. L. Kindle, manuscript in preparation), Most mutations affected in vitro import more severely than plastocyanin accumulation in vivo. One exception was a deletion that removed residues 2-8, which nearly eliminated in vivo accumulation but had a modest effect in vitro, We suggest that this mutant precursor may not compete successfully with other proteins for the translocation pathway in vivo. Apparently, in vivo and in vitro analyses reveal different aspects of chloroplast protein biogenesis.	CORNELL UNIV,PLANT SCI CTR,ITHACA,NY 14853	Cornell University				Lawrence, Susan/0000-0001-5825-2858				BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BAUERLE C, 1991, J BIOL CHEM, V266, P5884; BELKNAP WR, 1983, PLANT PHYSIOL, V72, P1130, DOI 10.1104/pp.72.4.1130; BOSCHETTI A, 1987, PROGR PHOTOSYNTHESIS, P585; Bruce B.D., 1994, PLANT MOL BIOL MANUA, VJ1, P1; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; Cline K., 1992, RES PHOTOSYNTHESIS, VIII, P149; CREIGHTON AM, 1993, PLANT MOL BIOL, V23, P1291, DOI 10.1007/BF00042363; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P167; DEBOER D, 1991, EMBO J, V10, P2765, DOI 10.1002/j.1460-2075.1991.tb07825.x; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GOLDSCHMIDTCLERMONT M, 1989, PLANT PHYSIOL, V89, P15, DOI 10.1104/pp.89.1.15; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; Halperin T, 1996, PLANT MOL BIOL, V30, P925, DOI 10.1007/BF00020804; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; Huber H, 1996, PLANT MOL BIOL, V31, P279, DOI 10.1007/BF00021790; HURT EC, 1986, EMBO J, V5, P1343, DOI 10.1002/j.1460-2075.1986.tb04365.x; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1996, J BIOL CHEM, V271, P31009, DOI 10.1074/jbc.271.49.31009; KUNTZ M, 1986, MOL GEN GENET, V205, P454, DOI 10.1007/BF00338082; LEE SY, 1990, BIOTECHNIQUES, V9, P676; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; Ma YK, 1996, J CELL BIOL, V134, P315, DOI 10.1083/jcb.134.2.315; MADUENO F, 1993, PLANT CELL, V5, P1865, DOI 10.1105/tpc.5.12.1865; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; MISHKIND ML, 1985, J CELL BIOL, V100, P226, DOI 10.1083/jcb.100.1.226; OBLONG JE, 1992, J BIOL CHEM, V267, P14328; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; REED JE, 1990, EUR J BIOCHEM, V194, P35; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; Scott SV, 1996, J CELL BIOL, V132, P63, DOI 10.1083/jcb.132.1.63; SEEDORF M, 1995, FEBS LETT, V367, P19, DOI 10.1016/0014-5793(95)00529-I; SU QX, 1994, BIOCHEM J, V300, P787, DOI 10.1042/bj3000787; THEG SM, 1992, BIOCHEMISTRY-US, V31, P5053, DOI 10.1021/bi00136a018; THEG SM, 1989, J BIOL CHEM, V264, P6730; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Waegemann K, 1996, J BIOL CHEM, V271, P6545, DOI 10.1074/jbc.271.11.6545; Walker D, 1996, J BIOL CHEM, V271, P4082; Wan JX, 1996, J BIOL CHEM, V271, P31227, DOI 10.1074/jbc.271.49.31227; WAN JX, 1995, J BIOL CHEM, V270, P16731, DOI 10.1074/jbc.270.28.16731; WASMANN CC, 1986, MOL GEN GENET, V205, P446, DOI 10.1007/BF00338081; YU LM, 1988, P NATL ACAD SCI USA, V85, P1369, DOI 10.1073/pnas.85.5.1369	60	14	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20357	20363		10.1074/jbc.272.33.20357	http://dx.doi.org/10.1074/jbc.272.33.20357			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252340	hybrid			2022-12-25	WOS:A1997XR22100010
J	Mastick, CC; Saltiel, AR				Mastick, CC; Saltiel, AR			Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; ACTIVATED PROTEIN-KINASE; GPI-ANCHORED PROTEINS; SIGNAL-TRANSDUCTION; TRANSFORMED-CELLS; RECEPTOR; TRANSPORT; COMPONENT; SEQUENCE; SEQUESTRATION	Previous work from this laboratory has shown that insulin stimulates the tyrosine phosphorylation of caveolin in 3T3-L1 adipocytes (Mastick, C. C., Brady, M. J., and Saltiel, A. R. (1995) J. Cell Biol. 129, 1523-1531). This phosphorylation is specific for insulin and involves the activation of a tyrosine kinase downstream of the insulin receptor, We report here that tyrosine phosphorylation of caveolin is detected only in fully differentiated adipocytes, not in fibroblasts (preadipocytes), despite the fact that both cell types express caveolin-1 and active insulin receptor, Caveolin copurifies with caveolin tyrosine kinase activity in both preadipocytes and adipocytes. Accumulating evidence indicates that this kinase is the Src family kinase Fyn. Fyn is expressed in the preadipocytes and the adipocytes and is colocalized with caveolin in low density Triton-insoluble complexes in both cell types, In adipocytes, overexpression of wild type Fyn leads to increased basal phosphorylation of caveolin and hyperphosphorylation of caveolin in response to insulin, In vitro kinase assays suggest that Fyn may be activated in response to insulin through the binding of a tyrosine-phosphorylated insulin receptor substrate protein. Previous work suggested that this protein may be c-Cbl (Ribon, V., and Saltiel, A. R. (1997) Biochem. J. 324, 839-846). In 3T3-L1 adipocytes, Cbl binds to Fyn in an insulin-dependent manner, and Cbl phosphorylation is adipocyte-specific. Here we show that phosphorylated Cbl is translocated into caveolin-enriched Triton-insoluble complexes after insulin stimulation, This may lead to the cell type-specific, com partmentalized activation of Fyn and the specific phosphorylation of proteins in the caveolae in response to insulin in adipocytes.			Mastick, CC (corresponding author), WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CELL BIOL,ANN ARBOR,MI 48105, USA.		Mastick, Cynthia/G-9841-2017; Saltiel, Alan/L-3632-2019	Mastick, Cynthia/0000-0003-4769-5412; Saltiel, Alan/0000-0002-9726-9828				ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LIU XQ, 1993, ONCOGENE, V8, P1119; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; MASTICK CC, 1997, IN PRESS MOL CELL BI; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Pawson T, 1997, NATURE, V385, P582, DOI 10.1038/385582b0; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; Ruzzene M, 1996, BIOCHEMISTRY-US, V35, P5327, DOI 10.1021/bi9528614; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; Shahripour A, 1996, BIOORG MED CHEM LETT, V6, P1209, DOI 10.1016/0960-894X(96)00208-9; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; TRAVIS J, 1993, SCIENCE, V262, P1208, DOI 10.1126/science.8235646; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	57	120	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20706	20714		10.1074/jbc.272.33.20706	http://dx.doi.org/10.1074/jbc.272.33.20706			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252391	hybrid			2022-12-25	WOS:A1997XR22100061
J	Baumann, C; Xirasagar, S; Gollnick, P				Baumann, C; Xirasagar, S; Gollnick, P			The trp RNA-binding attenuation protein (TRAP) from Bacillus subtilis binds to unstacked trp leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED POLYNUCLEOTIDES; DNA; COMPLEXES; BACTERIOPHAGE-T4; CONFORMATION; TRANSCRIPTS; STABILITY; DICHROISM; SEQUENCE; REPEATS	TRAP (trp RNA-binding attenuation protein) is a tryptophan-activated RNA-binding protein that regulates expression of the trp biosynthetic genes by binding to a series of GAG and UAG trinucleotide repeats generally separated by two or three spacer nucleotides, previously, we showed that TRAP contains II identical subunits arranged in a symmetrical ring, Based on this structure, we proposed a model for the TRAP.RNA interaction where the RNA wraps around the protein with each repeat of the RNA contacting one or a combination of two adjacent subunits of the TRAP oligomer, Here, we have shown that RNAs selected in vitro based on their ability to bind tryptophan-activated TRAP contain multiple G/UAG repeats and show a strong bias for pyrimidines as the spacer nucleotides between these repeats, The affinity of the TRAP RNA interaction displays a nonlinear temperature dependence, increasing between 5 degrees C and 47 degrees C and then decreasing from 47 degrees C to 67 degrees C, Differential scanning calorimetry and circular dichroism spectroscopy demonstrate that TRAP is highly thermostable with few detectable changes in the structure between 25 degrees C and 70 degrees C, suggesting that the temperature dependence of this interaction reflects changes in the RNA, Results from circular dichroism and UV absorbance spectroscopy support this hypothesis, demonstrating that trp leader RNA becomes unstacked upon binding TRAP, We propose that the bias toward pyrimidines in the spacer nucleotides of the in vitro selected RNAs represents the inability of Us and Cs to form stable base stacking interactions, which allows the flexibility needed for the RNA to wrap around the TRAP oligomer.	SUNY BUFFALO, DEPT SCI BIOL, BUFFALO, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P907, DOI 10.1021/bi00676a006; ANTSON AA, 1994, J MOL BIOL, V244, P1, DOI 10.1006/jmbi.1994.1698; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; BRAHMS J, 1966, J MOL BIOL, V15, P467, DOI 10.1016/S0022-2836(66)80122-5; BROYDE S, 1978, NUCLEIC ACIDS RES, V5, P2729, DOI 10.1093/nar/5.8.2729; COLEMAN JE, 1979, CRC CR REV BIOCH MOL, V7, P247, DOI 10.3109/10409238009105463; DOORNBOS J, 1983, EUR J BIOCHEM, V131, P571, DOI 10.1111/j.1432-1033.1983.tb07301.x; FERRARI ME, 1994, BIOCHEMISTRY-US, V33, P12896, DOI 10.1021/bi00209a022; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; Hall KB, 1995, METHOD ENZYMOL, V259, P261; HOFFMAN RJ, 1995, J BACTERIOL, V177, P839, DOI 10.1128/jb.177.3.839-842.1995; JENSEN DE, 1976, J BIOL CHEM, V251, P7215; KANE JF, 1972, J BIOL CHEM, V247, P1587; KANE JF, 1977, J BACTERIOL, V132, P419, DOI 10.1128/JB.132.2.419-425.1977; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; LENG M, 1966, J MOL BIOL, V15, P455, DOI 10.1016/S0022-2836(66)80121-3; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; PRICE SR, 1995, J MOL BIOL, V249, P398, DOI 10.1006/jmbi.1995.0305; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEERHAGEN MA, 1986, BIOPOLYMERS, V25, P1419, DOI 10.1002/bip.360250805; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Tuerk Craig, 1994, P475; VANAMERONGEN H, 1989, J MOL BIOL, V209, P433, DOI 10.1016/0022-2836(89)90008-9; VANAMERONGEN H, 1987, BIOCHEMISTRY-US, V26, P4646, DOI 10.1021/bi00389a009; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Ziehler WA, 1996, BIOTECHNIQUES, V20, P622	38	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19863	19869		10.1074/jbc.272.32.19863	http://dx.doi.org/10.1074/jbc.272.32.19863			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242649	hybrid			2022-12-25	WOS:A1997XQ05900036
J	Minakami, R; Jinnai, N; Sugiyama, H				Minakami, R; Jinnai, N; Sugiyama, H			Phosphorylation and calmodulin binding of the metabotropic glutamate receptor subtype 5 (mGluR5) are antagonistic in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHARMACOLOGICAL CHARACTERIZATION; SPLICE VARIANTS; RAT-BRAIN; EXPRESSION; CELLS; CA2+-CALMODULIN; ACTIVATION; HYDROLYSIS; CLONING	Metabotropic glutamate receptors, which are members of a G protein-coupled receptor family, mediate the glutamate responses by coupling to the intracellular signal transduction pathway, We herein report that calmodulin (CaM) interacts with the metabotropic glutamate receptor subtype 5 (mGluR5) in a Ca2+-dependent manner in vitro, CaM is capable of binding on two distinct sites in the COOH-terminal intracellular region of the receptor with different affinities, The CaM binding domains are separated by an alternatively spliced exon cassette present in one of the splicing isoforms of mGluR5, By using fusion proteins and synthetic peptides we showed that protein kinase C phosphorylates both CaM binding regions, This phosphorylation is inhibited by the binding of CaM to the receptor, and conversely the binding is inhibited by the phosphorylation, These antagonisms of the CaM binding and phosphorylation thus suggest the possibility that they regulate the receptor responses in vivo.	KYUSHU UNIV,FAC SCI,DEPT BIOL,HIGASHI KU,FUKUOKA 81281,JAPAN; KYUSHU UNIV,SCH HLTH SCI,HIGASHI KU,FUKUOKA 81282,JAPAN	Kyushu University; Kyushu University								ABE T, 1992, J BIOL CHEM, V267, P13361; ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALALUF S, 1995, FEBS LETT, V367, P301, DOI 10.1016/0014-5793(95)00575-T; CANONICO PL, 1988, J NEUROCHEM, V51, P1049, DOI 10.1111/j.1471-4159.1988.tb03067.x; CHAKRAVARTHY BR, 1995, J BIOL CHEM, V270, P24911, DOI 10.1074/jbc.270.42.24911; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HERRERO I, 1994, EUR J NEUROSCI, V6, P115, DOI 10.1111/j.1460-9568.1994.tb00253.x; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOLY C, 1995, J NEUROSCI, V15, P3970; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MINAKAMI R, 1995, J NEUROCHEM, V65, P1536; MINAKAMI R, 1994, BIOCHEM BIOPH RES CO, V199, P1136, DOI 10.1006/bbrc.1994.1349; MINAKAMI R, 1993, BIOCHEM BIOPH RES CO, V194, P622, DOI 10.1006/bbrc.1993.1866; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAIMI Y, 1994, FEBS LETT, V350, P155, DOI 10.1016/0014-5793(94)00782-9; SAIMI Y, 1990, SCIENCE, V249, P1441, DOI 10.1126/science.2169650; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOEPP DD, 1988, BIOCHEM PHARMACOL, V37, P4299, DOI 10.1016/0006-2952(88)90610-7; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; THOMSEN C, 1993, BRAIN RES, V619, P22, DOI 10.1016/0006-8993(93)91592-G; VANELDIK LJ, 1984, BIOCHEM BIOPH RES CO, V124, P752, DOI 10.1016/0006-291X(84)91022-2; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501	35	121	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20291	20298		10.1074/jbc.272.32.20291	http://dx.doi.org/10.1074/jbc.272.32.20291			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242710	hybrid			2022-12-25	WOS:A1997XQ05900097
J	Roy, S; Lane, A; Yan, J; McPherson, R; Hancock, JF				Roy, S; Lane, A; Yan, J; McPherson, R; Hancock, JF			Activity of plasma membrane-recruited Raf-1 is regulated by Ras via the Raf zinc finger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE RAF; IN-VITRO; ACTIVATION; BINDING; PROTEIN; 14-3-3-PROTEINS; IDENTIFICATION; DOMAIN	Ras recruits Raf to the plasma membrane for activation by a combination of tyrosine phosphorylation and other as yet undefined mechanism(s), We show here that the Raf zinc finger is not required for plasma membrane recruitment of Raf by Ras but is essential for full activation of Raf at the plasma membrane, Membrane targeting cannot compensate for the absence of the zinc finger, One facet of the zinc finger activation defect is revealed using a constitutively activated Raf mutant, Targeting Raf Y340D,Y341D to the plasma membrane increments activity, but full activation requires coexpression with activated Ras. This sensitivity to regulation by Ras at the plasma membrane is abrogated by mutations in the Raf zinc finger but is unaffected by mutation of the minimal Ras binding domain. These data show for the first time that Ras has two separate roles in Raf activation: recruitment of Raf to the plasma membrane through an interaction with the minimal Ras binding domain and activation of membrane-localized Raf via a mechanism that requires the Raf zinc finger.	UNIV QUEENSLAND, SCH MED,DEPT PATHOL,QUEENSLAND CANC FUND, LAB EXPT ONCOL, BRISBANE, QLD 4006, AUSTRALIA	Cancer Council Queensland; University of Queensland			Yan, Jun/F-1224-2010	Yan, Jun/0000-0001-9617-0335; Hancock, John/0000-0003-0542-4710				BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	33	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20139	20145		10.1074/jbc.272.32.20139	http://dx.doi.org/10.1074/jbc.272.32.20139			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242688	hybrid			2022-12-25	WOS:A1997XQ05900075
J	Sato, K; Mori, H; Yoshida, M; Tagaya, M; Mizushima, S				Sato, K; Mori, H; Yoshida, M; Tagaya, M; Mizushima, S			In vitro analysis of the stop-transfer process during translocation across the cytoplasmic membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; PROTON MOTIVE FORCE; PROTEIN TRANSLOCATION; SECA-PROTEIN; PHENOTYPIC SELECTION; PLASMA-MEMBRANE; ATP; PHOSPHOLIPIDS; PREPROTEIN; GENE	In this study, using a derivative of proOmpA containing an artificial stop-transfer sequence (proOmpA2xH1), we analyzed the process of stop-transfer during translocation across the cytoplasmic membrane of Escherichia coli. ProOmpA2xH1 did not interfere with the transit of wild-type proOmpA. When proOmpA2xH1 was anchored in the membrane, membrane-inserted SecA was deinserted with the reversion of the inverted topology of SecG. Cross-linking experiments revealed that the anchored proOmpA2xH1 that does not interact with either SecY or SecA. These results, taken together, suggest that proOmpA2xH1 leaves the translocation pathway by means of a specific interaction between the stop-transfer sequence and the translocational channel.	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, YOKOHAMA, KANAGAWA 226, JAPAN	Tokyo Institute of Technology	Sato, K (corresponding author), TOKYO UNIV PHARM & LIFE SCI, SCH LIFE SCI, 1432-1 HORINOUCHI, HACHIOJI, TOKYO 19203, JAPAN.							AKITA M, 1990, J BIOL CHEM, V265, P8164; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BYOCT CS, 1990, NATURE, V343, P669; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HELLER K, 1985, J BACTERIOL, V161, P896, DOI 10.1128/JB.161.3.896-903.1985; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KIM YJ, 1994, CELL, V78, P845; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1995, ADV CELL MOL BIOL M, V4, P61; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OLIVER DB, 1982, J BACTERIOL, V150, P686, DOI 10.1128/JB.150.2.686-691.1982; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; Sato K, 1997, J BIOL CHEM, V272, P5880, DOI 10.1074/jbc.272.9.5880; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; TOKUDA H, 1993, BIOCHEM BIOPH RES CO, V195, P1415, DOI 10.1006/bbrc.1993.2201; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMANE K, 1987, J BIOL CHEM, V262, P2358; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	36	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20082	20087		10.1074/jbc.272.32.20082	http://dx.doi.org/10.1074/jbc.272.32.20082			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242681	hybrid			2022-12-25	WOS:A1997XQ05900068
J	Kondoh, S; Ishii, K; Nakamura, Y; Taira, N				Kondoh, S; Ishii, K; Nakamura, Y; Taira, N			A mammalian transient type K+ channel, rat Kv1.4, has two potential domains that could produce rapid inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER POTASSIUM CHANNEL; PEPTIDE; MECHANISMS; SUBUNIT; BLOCKS	The ''ball and chain'' model has been shown to be suitable for explaining the rapid inactivation of voltage-dependent K+ channels, For the Drosophila Shaker K+ channel (ShB), the first 20 residues of the amino terminus have been identified as the inactivation ball that binds to the open channel pore and blocks ion flow (Hoshi, T., Zagotta, W. N., and Aldrich, R. W. (1990) Science 250, 533-538; Zagotta, W. N., Hoshi, T., and Aldrich, R. W. (1990) Science 250, 568-571), We studied the structural elements responsible for rapid inactivation of a mammalian transient type K+ channel (rat Kv1.4) by constructing various mutants in the amino terminus and expressing them in Xenopus oocytes, Although it has been reported that the initial 37 residues might form the inactivation ball for rat Kv1.4 (Tseng-Crank, J., Yao, J.-A., Berman M. F., and Tseng, G.-N. (1993) J. Gen. Physiol, 102, 1057-1083), we found that not only the initial 37 residues, but also the following region, residues 40-68, could function independently as an inactivation gate, Like the Shaker inactivation ball, both potential inactivation domains have a hydrophobic amino-terminal region and a hydrophilic carboxyl-terminal region having net positive charge, which is essential for the domains to function as an inactivation gate.	TOHOKU UNIV,SCH MED,DEPT PHARMACOL,AOBA KU,SENDAI,MIYAGI 980,JAPAN	Tohoku University								Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; COMER MB, 1994, AM J PHYSIOL-HEART C, V267, pH1383, DOI 10.1152/ajpheart.1994.267.4.H1383; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; DUBINSKY WP, 1992, P NATL ACAD SCI USA, V89, P1770, DOI 10.1073/pnas.89.5.1770; FOSTER CD, 1992, NEURON, V9, P229, DOI 10.1016/0896-6273(92)90162-7; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISHII K, 1992, BIOCHEM BIOPH RES CO, V184, P1484, DOI 10.1016/S0006-291X(05)80050-6; KRAMER RH, 1994, NEURON, V12, P655, DOI 10.1016/0896-6273(94)90220-8; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; OKADA H, 1992, BIOCHEM BIOPH RES CO, V18, P430; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Sambrook J., 2002, MOL CLONING LAB MANU; SOLARO CR, 1992, SCIENCE, V257, P1694, DOI 10.1126/science.1529355; TORO L, 1994, BIOCHEMISTRY-US, V33, P7220, DOI 10.1021/bi00189a026; TORO L, 1992, NEURON, V9, P237, DOI 10.1016/0896-6273(92)90163-8; TSENG GN, 1992, CIRC RES, V71, P657, DOI 10.1161/01.RES.71.3.657; TSENGCRANK J, 1993, J GEN PHYSIOL, V102, P1057, DOI 10.1085/jgp.102.6.1057; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	20	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19333	19338		10.1074/jbc.272.31.19333	http://dx.doi.org/10.1074/jbc.272.31.19333			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235930	hybrid			2022-12-25	WOS:A1997XP06300036
J	Linke, SP; Harris, MP; Neugebauer, SE; Clarkin, KC; Shepard, HM; Maneval, DC; Wahl, GM				Linke, SP; Harris, MP; Neugebauer, SE; Clarkin, KC; Shepard, HM; Maneval, DC; Wahl, GM			p53-mediated accumulation of hypophosphorylated pRb after the G(1) restriction point fails to halt cell cycle progression	ONCOGENE			English	Article						p53; pRb; restriction point; DNA damage; Glarrest	RETINOBLASTOMA GENE-PRODUCT; TUMOR-SUPPRESSOR GENE; HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; DNA-BINDING; G1 PHASE; TRANSCRIPTIONAL ACTIVITY; SV40-TRANSFORMED CELLS; SUSCEPTIBILITY GENE; DEPENDENT KINASES	This study analyses whether the inability of p53 to induce G(1) arrest after the restriction point relates to an inability to modulate pRb phosphorylation. Transient p53 overexpression in normal human diploid fibroblasts and p53-deficient cancer cells led to increased levels of the cyclin-dependent kinase inhibitor p21(Cip1/Waf1/Sdi1) and an accumulation of hypophosphorylated pRb in cells growing asynchronously and in cells synchronized in late G(1) or M. Similarly, gamma-irradiation of asynchronous, late-G(1), or S phase fibroblasts led to an increase in hypophosphorylated pRb. Experiments with fibroblasts expressing the HPV16 E6 protein indicated that accumulation of hypophosphorylated pRb required functional p53. Progression into and through S phase was not altered by the presence of hypophosphorylated pRb in late G(1), consistent with the failure of p53 to mediate G(1) arrest in cells that are past the restriction point. These data indicate that accumulation of hypophosphorylated pRb has significantly different effects on cell cycle progression in early G(1) versus late G(1) or S phase.	SALK INST BIOL STUDIES, GENE EXPRESS LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; CANJI INC, SAN DIEGO, CA 92121 USA	Salk Institute; University of California System; University of California San Diego				Linke, Steven/0000-0001-8584-4947				ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Leonardo A, 1997, CANCER RES, V57, P1013; DI LEONARDO A, 1993, COLD SPRING HARB SYM, V58, P655, DOI 10.1101/SQB.1993.058.01.073; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ETSCHEID BG, 1994, VIROLOGY, V205, P583, DOI 10.1006/viro.1994.1684; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harris MP, 1996, CANCER GENE THER, V3, P121; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hecker D, 1996, ONCOGENE, V12, P953; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Linke SP, 1997, CANCER RES, V57, P1171; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; McMasters KM, 1996, ONCOGENE, V13, P1731; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RIEDER CL, 1992, J CELL SCI, V102, P387; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEN SF, 1994, J IMMUNOL METHODS, V169, P231, DOI 10.1016/0022-1759(94)90267-4; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLS KN, 1995, CANCER GENE THER, V2, P191; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	76	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					337	345		10.1038/sj.onc.1201200	http://dx.doi.org/10.1038/sj.onc.1201200			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233768				2022-12-25	WOS:A1997XK99900010
J	Haas, K; Staller, P; Geisen, C; Bartek, J; Eilers, M; Moroy, T				Haas, K; Staller, P; Geisen, C; Bartek, J; Eilers, M; Moroy, T			Mutual requirement of CDK4 and Myc in malignant transformation: Evidence for cyclin D1/CDK4 and p16(INK4A) as upstream regulators of Myc	ONCOGENE			English	Article						oncogene cooperation; REF assay; cell cycle regulation; Myc function; CDK4	CELL-CYCLE; C-MYC; RETINOBLASTOMA-PROTEIN; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC ACTIVITY; RAS COTRANSFORMATION; HOMOZYGOUS DELETION; NUCLEAR-PROTEIN; KINASE-ACTIVITY	We demonstrate in this paper that CDK4 which is a G1 phase specific cell cycle regulator and catalytic subunit of D-type cyclins has oncogenic activity similar to D-type cyclins themselves and is able to provoke focus formation when cotransfected with activated Ha-ras into primary rat embryo fibroblasts. Surprisingly, using two different mutants we show that CDK4's ability to bind to p16(INK4a) and not its kinase activity is important for its transforming potential. In addition, p16(INK4a) but not a mutant form that is found in human tumours can completely abrogate focus formation by CDK4 suggesting that CDK4 can malignantly transform cells by sequestering p16(INK4a) Or other CKIs. We demonstrate that both cyclin D1 and CDK4 functionally depend on active Myc to exert their potential as oncogenes and vice versa that the transforming ability of Myc requires functional cyclin D/CDK complexes. Moreover, we find that p16(INK4a) and the Rb related protein p107 which releases Myc after phosphorylation by cyclin D1/CDK4 efficiently block Myc's activity as a transcriptional transactivator and as an oncogene. We conclude that both p16(INK4a) and cyclin D/CDK4 complexes are upstream regulators of Myc and directly govern Myc function in transcriptional transactivation and transformation via the pocket protein p107.	UNIV ESSEN GESAMTHSCH KLINIKUM,INST ZELLBIOL TUMORFORSCH,D-45122 ESSEN,GERMANY; ZENTRUM MOL BIOL,D-69120 HEIDELBERG,GERMANY; DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN,DENMARK	University of Duisburg Essen; Ruprecht Karls University Heidelberg; Danish Cancer Society			Bartek, Jiri/G-5870-2014; Moroy, Tarik/D-9923-2011	Eilers, Martin/0000-0002-0376-6533				AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BOTZ J, 1996, JOURNAL, V16, P3401; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CERNI C, 1995, ONCOGENE, V11, P587; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Geng Y, 1996, ONCOGENE, V12, P1173; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HALL M, 1995, ONCOGENE, V11, P1581; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HU J, 1992, MOL CELL BIOL, V12, P971; JIANG W, 1993, ONCOGENE, V8, P3447; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KHATIB ZA, 1993, CANCER RES, V53, P5535; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; LADANYI M, 1995, J PATHOL, V175, P211, DOI 10.1002/path.1711750209; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Maelandsmo GM, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.181; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOBORI T, 1994, NATURE, V368, P53; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYMOND A, 1995, ONCOGENE, V11, P1173; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1994, J CELL SCI, V107, P581; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SONODA Y, 1995, ONCOGENE, V11, P2145; Starostik P, 1996, MOL CELL BIOL, V16, P3606; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	88	73	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					179	192		10.1038/sj.onc.1201171	http://dx.doi.org/10.1038/sj.onc.1201171			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244353				2022-12-25	WOS:A1997XK37200006
J	Bito, A; Haider, M; Hadler, I; Breitenbach, M				Bito, A; Haider, M; Hadler, I; Breitenbach, M			Identification and phenotypic analysis of two glyoxalase II encoding genes from Saccharomyces cerevisiae, GLO2 and GLO4, and intracellular localization of the corresponding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; D-LACTATE; CLONING; YEAST; METHYLGLYOXAL; PURIFICATION; EXPRESSION; SEQUENCES; PATHWAY; CELLS	We have isolated and characterized two genes coding for the glyoxalase II enzyme from Saccharomyces cerevisiae, The coding region of the GLO2 gene corresponds to a protein with 274 amino acids and a molecular mass of 31,306 daltons, The open reading frame of the GLO4 gene could be translated into a protein with 285 amino acids and a molecular mass of 32,325 daltons, The amino acid sequences of the deduced proteins are 59.1% identical and show high similarities to the sequence of the human glyoxalase II, When grown on either glucose or glycerol as a carbon source, a glo2 glo4 double deletion strain contains no glyoxalase II activity at all and shows no obvious phenotype during vegetative growth, However, this strain showed a similar high sensitivity against exogenous methylglyoxal as compared with a glyoxalase I-deficient strain, Whereas the GLO2 gene is expressed on both glucose and glycerol, the GLO4 gene is only active on glycerol, The active Glo2p protein is localized in the cytoplasm and the active Glo4p in the mitochondrial matrix. Heterologous expression of the full-length GLO2 coding region in Escherichia coli resulted in an active protein, However, to get an active Glo4p protein in E. coli, the putative mitochondrial transit peptide at the N-terminal end had to be removed by shortening the 5' end of the GLO4 open reading frame.			Bito, A (corresponding author), SALZBURG UNIV, INST GENET & GEN BIOL, HELLBRUNNERSTR 34, A-5020 SALZBURG, AUSTRIA.							ALLEN RE, 1993, EUR J BIOCHEM, V213, P1261, DOI 10.1111/j.1432-1033.1993.tb17877.x; BALL JC, 1981, BIOCHEMISTRY-US, V20, P899, DOI 10.1021/bi00507a038; BERTHECORTI L, 1992, MUTAGENESIS, V7, P25, DOI 10.1093/mutage/7.1.25; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; COOPER RA, 1984, ANNU REV MICROBIOL, V38, P49, DOI 10.1146/annurev.mi.38.100184.000405; CREIGHTON DJ, 1988, BIOCHEMISTRY-US, V27, P7376, DOI 10.1021/bi00419a031; DARLING TN, 1988, MOL BIOCHEM PARASIT, V28, P121, DOI 10.1016/0166-6851(88)90059-X; DAUM G, 1982, J BIOL CHEM, V257, P13023; DESWAL R, 1993, BIOCHEM SOC T, V21, P527, DOI 10.1042/bst0210527; Espartero J, 1995, PLANT MOL BIOL, V29, P1223, DOI 10.1007/BF00020464; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; HAIDER M, 1994, MOL ANAL GENS GER 1; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOPKINS FG, 1945, BIOCHEM J, V39, P320, DOI 10.1042/bj0390320; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; JERZYKOWSKI T, 1978, INT J BIOCHEM, V9, P853, DOI 10.1016/0020-711X(78)90036-8; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KIM NS, 1993, J BIOL CHEM, V268, P11217; KOSUGI N, 1988, APPL MICROBIOL BIOT, V28, P263; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MISRA K, 1995, BIOCHEM J, V305, P999, DOI 10.1042/bj3050999; MURATA K, 1986, AGR BIOL CHEM TOKYO, V50, P2381, DOI 10.1080/00021369.1986.10867751; MURATA K, 1985, BIOCHEM BIOPH RES CO, V131, P190, DOI 10.1016/0006-291X(85)91788-7; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PRINCIPATO GB, 1987, BIOCHIM BIOPHYS ACTA, V911, P349, DOI 10.1016/0167-4838(87)90076-8; RANGANATHAN S, 1993, J BIOL CHEM, V268, P5661; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RHEE HI, 1988, AGR BIOL CHEM TOKYO, V52, P2243; RICHARD JP, 1993, BIOCHEM SOC T, V21, P549, DOI 10.1042/bst0210549; Ridderstrom M, 1997, BIOCHEM J, V322, P449, DOI 10.1042/bj3220449; Ridderstrom M, 1996, J BIOL CHEM, V271, P319, DOI 10.1074/jbc.271.1.319; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TALESA V, 1988, BIOCHIM BIOPHYS ACTA, V955, P103, DOI 10.1016/0167-4838(88)90183-5; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALLNER J, 1991, THESIS U VIENNA VIEN; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	46	64	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21509	21519		10.1074/jbc.272.34.21509	http://dx.doi.org/10.1074/jbc.272.34.21509			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261170	hybrid			2022-12-25	WOS:A1997XR78900080
J	Martin, SL; Edbrooke, MR; Hodgman, TC; vandenEijnden, DH; Bird, MI				Martin, SL; Edbrooke, MR; Hodgman, TC; vandenEijnden, DH; Bird, MI			Lewis X biosynthesis in Helicobacter pylori - Molecular cloning of an alpha(1,3)-fucosyltransferase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ALPHA-1-3 FUCOSYL-TRANSFERASE; CORE OLIGOSACCHARIDE REGIONS; UNIDENTIFIED CURVED BACILLI; E-SELECTIN LIGAND; GDP-FUCOSE; SCHISTOSOMA-MANSONI; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; DETERMINES EXPRESSION; MONOCLONAL-ANTIBODY	The lipopolysaccharide of certain strains of Helicobacter pylori was recently shown to contain the Lewis X (Le(x)) trisaccharide (Gal beta-1,4-(Fuc alpha(1,3))-GlcNAc). Le(x) is an oncofetal antigen which appears on human gastric epithelium, and its mimicry by carbohydrate structures on the surface of H. pylori may play an important part in the interaction of this pathogen with its host, Potential roles for bacterial Le(x) in mucosal adhesion, immune evasion, and autoantibody induction have been proposed (Moran, A, P., Prendergast, M. M., and Appelmelk, B. J. (1996) FEMS Immunol, Med, Microbiol, 16, 105-115). In mammals, the final step of Le(x) biosynthesis is the alpha(1,3)-fucosylation of GlcNAc in a terminal Gal beta(1-->4)-GlcNAc unit, and a corresponding GDP-fucose:N-acetylglucosaminyl alpha(1,3) fucosyltransferase (alpha(1,3)-Fuc-T) activity was recently discovered in H. pylori extracts, We used part of a human alpha(1,3)-Fuc-T amino acid sequence to search an H. pylori genomic data base for related sequences, Using a probe based upon weakly matching data base sequences, we retrieved clones from a plasmid library of H. pylori DNA, DNA sequence analysis of the library clones revealed a gene which we have named fucT, encoding a protein with localized homology to the human alpha(1,3)-Fuc-Ts. We have demonstrated that fucT encodes an active Fuc-T enzyme by expressing the gene in Escherichia coli, The recombinant enzyme shows a strong preference for type 2 (e.g. LacNAc) over type 1 (e.g. lacto-N-biose) accepters in vitro. Certain residues in a short segment of the H. pylori protein are completely conserved throughout the alpha(1,3)-Fuc-T family, defining an alpha(1,3)-Fuc-T motif which may be of use in identifying new fucosyltransferase genes.	GLAXO WELLCOME RES & DEV LTD, MED RES CTR, ADV TECHNOL & INFORMAT UNIT, STEVENAGE SG1 2NY, HERTS, ENGLAND; VRIJE UNIV AMSTERDAM, DEPT MED CHEM, AMSTERDAM, NETHERLANDS	GlaxoSmithKline; Vrije Universiteit Amsterdam	Martin, SL (corresponding author), GLAXO WELLCOME RES & DEV LTD, MED RES CTR, GLYCOBIOL UNIT, GUNNELS WOOD RD, STEVENAGE SG1 2NY, HERTS, ENGLAND.		Hodgman, Charlie/AAF-2405-2020	Hodgman, Charlie/0000-0001-5862-8296				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Appelmelk BJ, 1996, INFECT IMMUN, V64, P2031, DOI 10.1128/IAI.64.6.2031-2040.1996; ASPINALL GO, 1994, CARBOHYDR LETT, V0001; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2489, DOI 10.1021/bi951852s; Aspinall GO, 1996, BIOCHEMISTRY-US, V35, P2498, DOI 10.1021/bi951853k; Britten CJ, 1997, BBA-GEN SUBJECTS, V1334, P57, DOI 10.1016/S0304-4165(96)00076-1; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; CHAN NWC, 1995, GLYCOBIOLOGY, V5, P683, DOI 10.1093/glycob/5.7.683; DeBoseBoyd R, 1996, EXP PARASITOL, V82, P1, DOI 10.1006/expr.1996.0001; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DEVRIES T, 1997, IN PRESS GLYCOBIOLOG; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; HOLMES EH, 1992, ARCH BIOCHEM BIOPHYS, V296, P562, DOI 10.1016/0003-9861(92)90611-Y; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; *INT AG RES CANC, 1994, MONOGRAPH IARC, V61, P177; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KO AI, 1990, P NATL ACAD SCI USA, V87, P4159, DOI 10.1073/pnas.87.11.4159; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KOYABASHI K, 1993, AM J GASTROENTEROL, V88, P475; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; Labigne A, 1996, INFECT AGENT DIS, V5, P191; Lee KP, 1996, J BIOL CHEM, V271, P32960, DOI 10.1074/jbc.271.51.32960; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MARSHALL BJ, 1984, LANCET, V1, P1311; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; Mulder H, 1996, GLYCOCONJUGATE J, V13, P107, DOI 10.1007/BF01049686; Nakamura S, 1997, CANCER-AM CANCER SOC, V79, P3, DOI 10.1002/(SICI)1097-0142(19970101)79:1<3::AID-CNCR2>3.0.CO;2-P; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NEGRINI R, 1991, GASTROENTEROLOGY, V101, P437, DOI 10.1016/0016-5085(91)90023-E; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; Ozawa M, 1996, J BIOCHEM-TOKYO, V119, P302; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; RATHBONE BJ, 1986, GUT, V27, P642, DOI 10.1136/gut.27.6.642; SajdelSulkowska EM, 1997, GLYCOCONJUGATE J, V14, P249, DOI 10.1023/A:1018550023637; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485; SHERBURNE R, 1995, INFECT IMMUN, V63, P4564, DOI 10.1128/IAI.63.12.4564-4568.1995; SimoonsSmit IM, 1996, J CLIN MICROBIOL, V34, P2196, DOI 10.1128/JCM.34.9.2196-2200.1996; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18; WARREN JR, 1983, LANCET, V1, P1273; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WIRTH HP, 1996, INFECT IMMUN, V64, P4958; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	62	88	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21349	21356		10.1074/jbc.272.34.21349	http://dx.doi.org/10.1074/jbc.272.34.21349			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261148	hybrid			2022-12-25	WOS:A1997XR78900058
J	Persson, U; Souchelnytskyi, S; Franzen, P; Miyazono, K; tenDijke, P; Heldin, CH				Persson, U; Souchelnytskyi, S; Franzen, P; Miyazono, K; tenDijke, P; Heldin, CH			Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; EXPRESSION CLONING; GS DOMAIN; COMPLEX; BONE; TRANSDUCTION; TRANSPHOSPHORYLATION; PROTEINS; FORMS	Members of the transforming growth factor-beta (TGF-beta) superfamily signal via different heteromeric complexes of two sequentially acting serine/threonine kinase receptors, i,e, type I and type II receptors, We generated two different chimeric TGF-beta superfamily receptors, i.e. T beta R-I/BMPR-IB, containing the extracellular domain of TGF-beta type I receptor (TPR-I) and the intracellular domain of bone morphogenetic protein type IB receptor (BMPR-IB), and T beta R-II/ActR-IIB, containing the extracellular domain of TGF-beta type II receptor (TPR-II) and the intracellular domain of activin type IIB receptor (ActR-IIB), In the presence of TGF-beta 1, T beta R-I/BMPR-IB and T beta R-II/ActR-IIB formed heteromeric complexes with wild-type TPR-II and TPR-I, respectively, upon stable transfection in mink lung epithelial cell lines, We show that T beta R-II/ActR-IIB restored the responsiveness upon transfection in mutant cell lines lacking functional TPR II with respect to TGF-beta-mediated activation of a transcriptional signal, extracellular matrix formation, growth inhibition, and Smad phosphorylation. Moreover, T beta R-I/BMPR-IB and T beta R-II/ActR-IIB formed a functional complex in response to TGF-beta and induced phosphorylation of Smad1, However, complex formation is not enough for signal propagation, which is shown by the inability of T beta R-I/BMPR-IB to restore responsive ness to TGF-beta in cell lines deficient in functional TPR-I, The fact that the TGF-beta 1-induced complex between T beta R-II/ActR-IIB and TPR-I stimulated endogenous Smad2 phosphorylation, a TGF-beta-like response, is in agreement with the current model for receptor activation in which the type I receptor determines signal specificity.	JAPANESE FDN CANC RES,INST CANC,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research	Persson, U (corresponding author), LUDWIG INST CANC RES,BOX 595,S-75124 UPPSALA,SWEDEN.		Souchelnytskyi, Serhiy/J-9446-2014; Dijke, Peter ten/AAG-4660-2021; Souchelnytskyi, Serhiy/G-6491-2011	Dijke, Peter ten/0000-0002-7234-342X; Souchelnytskyi, Serhiy/0000-0001-8243-9276				Anders RA, 1996, J BIOL CHEM, V271, P21758, DOI 10.1074/jbc.271.36.21758; Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BASSING CH, 1994, J BIOL CHEM, V269, P14861; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANZEN P, 1995, BIOCHEM BIOPH RES CO, V207, P682, DOI 10.1006/bbrc.1995.1241; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU F, 1995, MOL CELL BIOL, V15, P3479; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATTHEWS LS, 1993, J BIOL CHEM, V268, P19013; Muramatsu M, 1997, MOL BIOL CELL, V8, P469, DOI 10.1091/mbc.8.3.469; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; OKADOME T, 1994, J BIOL CHEM, V269, P30753; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; TSUCHIDA K, 1995, ENDOCRINOLOGY, V136, P5493, DOI 10.1210/en.136.12.5493; VERSCHUEREN K, 1995, MECH DEVELOP, V52, P109, DOI 10.1016/0925-4773(95)00395-H; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	49	28	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	1997	272	34					21187	21194		10.1074/jbc.272.34.21187	http://dx.doi.org/10.1074/jbc.272.34.21187			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR789	9261125	hybrid			2022-12-25	WOS:A1997XR78900035
J	Balsinde, J; Balboa, MA; Dennis, EA				Balsinde, J; Balboa, MA; Dennis, EA			Inflammatory activation of arachidonic acid signaling in murine P388D(1) macrophages via sphingomyelin synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; PHOSPHOLIPASE A(2); HUMAN-NEUTROPHILS; CELLS; DIACYLGLYCEROLS; INHIBITION; MOBILIZATION; STIMULATION; EXPRESSION	Ceramide has emerged as an important lipid messenger for many cellular processes triggered via surface receptors. In the present study, inflammatory activation of P388D(1) macrophages with bacterial lipopolysaccharide (LPS) and platelet-activating factor (PAF) stimulated a transient accumulation of ceramide. Moreover, cell-permeable ceramide mimicked LPS/PAF in triggering arachidonate mobilization in these cells. LPS/PAF-induced ceramide synthesis did not result from sphingomyelinase activation but from increased de novo synthesis. Participation of this pathway in arachidonate signaling was detected since fumonisin B-1, an inhibitor of de novo ceramide synthesis, was able to inhibit the LPS/PAF-induced response. These studies have uncovered a new role for sphingolipid metabolism in cellular signaling and constitute evidence that products of the sphingomyelin biosynthetic pathway may serve a specific role in signal transduction by influencing the activity of the novel Group V secretory phospholipase A(2).	UNIV CALIF SAN DIEGO, SCH MED, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, REVELLE COLL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Balboa, María A./V-9493-2018; Dennis, Edward A./M-5554-2019; Balsinde, Jesús/C-7833-2018	Balboa, María A./0000-0002-2130-5298; Dennis, Edward A./0000-0003-3738-3140; Balsinde, Jesús/0000-0002-4157-6714	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 26171] Funding Source: Medline; NIGMS NIH HHS [GM 20501] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASMIS R, 1994, BIOCHEM J, V298, P543, DOI 10.1042/bj2980543; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; Balsinde J, 1997, BIOCHEM J, V321, P805, DOI 10.1042/bj3210805; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chilton F, 1996, J CLIN INVEST, V97, P2161, DOI 10.1172/JCI118654; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; DAWSON RMC, 1984, BIOCHEM BIOPH RES CO, V125, P836, DOI 10.1016/0006-291X(84)90615-6; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; EMILSSON A, 1985, BIOCHIM BIOPHYS ACTA, V846, P265, DOI 10.1016/0167-4889(85)90074-6; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KRAMER RM, 1987, BIOCHEM J, V248, P779, DOI 10.1042/bj2480779; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Reyes JG, 1996, J BIOL CHEM, V271, P21375, DOI 10.1074/jbc.271.35.21375; ROLDAN ERS, 1994, BIOCHEM J, V297, P225, DOI 10.1042/bj2970225; ROSENTHAL MD, 1993, BIOCHIM BIOPHYS ACTA, V1177, P79, DOI 10.1016/0167-4889(93)90161-H; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	43	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20373	20377		10.1074/jbc.272.33.20373	http://dx.doi.org/10.1074/jbc.272.33.20373			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252342	Green Published, hybrid			2022-12-25	WOS:A1997XR22100012
J	Nguyen, L; HolgadoMadruga, M; Maroun, C; Fixman, ED; Kamikura, D; Fournier, T; Charest, A; Tremblay, ML; Wong, AJ; Park, M				Nguyen, L; HolgadoMadruga, M; Maroun, C; Fixman, ED; Kamikura, D; Fournier, T; Charest, A; Tremblay, ML; Wong, AJ; Park, M			Association of the multisubstrate docking protein Gab1 with the hepatocyte growth factor receptor requires a functional Grb2 binding site involving tyrosine 1356	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MET RECEPTOR; SCATTER FACTOR; KINASE-ACTIVITY; CELL-DISSOCIATION; EPITHELIAL-CELLS; PROTOONCOGENE; MOTILITY; PHOSPHORYLATION; IDENTIFICATION; TRANSFORMATION	Hepatocyte growth factor/scatter factor is a multifunctional factor that induces mitogenesis, motility, invasion, and branching tubulogenesis of several epithelial and endothelial cell lines in culture, The receptor for hepatocyte growth factor has been identified as the Mettyrosine kinase, Upon stimulation with hepatocyte growth factor, the Met beta subunit becomes highly phosphorylated on tyrosine residues, one of which, tyrosine 1356 within the carboxyl terminus, is crucial for dissociation, motility, and branching tubule formation in Madin-Darby canine kidney epithelial cells, Tyrosine 1356 forms a multisubstrate binding site for the Grb2 and She adaptor proteins, the p85 subunit of phosphatidylinositol 3'-kinase, phospholipase C gamma, and a phosphatase, SHP2, To investigate additional signaling molecules that are activated by the Met receptor, we have identified hepatocyte growth factor-induced phosphoproteins in tubular epithelial cells, We have established that proteins of 100-130 kDa are highly phosphorylated following stimulation of epithelial cells and that one of these is the Grb2-associated binding protein Gab1, a possible insulin receptor substrate-1-like signal transducer, We show that Gab1 is the major substrate for the Met kinase in vitro and in vivo, Association of Gab1 with Met requires a functional Grb2 binding site involving tyrosine 1356 and to a lesser extent tyrosine 1349, Met receptor mutants that fail to induce branching tubulogenesis are impaired in their ability to interact with Gab1, suggesting that Gab1 may play a role in these processes.	MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT MED, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT ONCOL, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT BIOCHEM, MOL ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; KIMMEL CANC INST, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19107 USA; KIMMEL CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Jefferson University; Jefferson University					NCI NIH HHS [CA69495] Funding Source: Medline; NINDS NIH HHS [NS34514] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034514] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HAUGUELDEMOUZON S, 1992, J CELL PHYSIOL, V150, P180, DOI 10.1002/jcp.1041500124; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; KOMADA M, 1993, ONCOGENE, V8, P2381; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MATSUMOTO K, 1993, HEPATOCYTE GROWTH FA, P226; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	47	152	164	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1997	272	33					20811	20819		10.1074/jbc.272.33.20811	http://dx.doi.org/10.1074/jbc.272.33.20811			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XR221	9252406	hybrid			2022-12-25	WOS:A1997XR22100076
J	Chen, HY; McCormick, DB				Chen, HY; McCormick, DB			Riboflavin 5'-hydroxymethyl oxidation - Molecular cloning, expression, and glycoprotein nature of the 5'-aldehyde-forming enzyme from Schizophyllum commune	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; AFFINITY-CHROMATOGRAPHY; PICHIA-PASTORIS; FAD SYNTHETASE; HUMAN-URINE; PURIFICATION; QUANTITATION; DEHYDROGENASE; FLAVOKINASE; CATABOLITES	Vitamin B-2-aldehyde-forming enzyme catalyzes oxidation of the 5'-hydroxymethyl of riboflavin to the formyl group. We have purified the enzyme from the culture media of Schizophyllum commune (ATCC 38719) by modifying the procedure of Tachibana and Oka (Tachibana, S., and Oka, M. (1981) J. Biol. Chem. 256, 6682-6685) for cell-free extract. By SDS-polyacrylamine gel electrophoresis, the enzyme appears to be 78 kDa, The enzyme has a blocked amino terminus, so fragments were obtained by cleaving the purified enzyme with lysyl endopeptidase. Selected peptides were sequenced from their amino termini, We have isolated a full-length cDNA clone using a DNA hybridization probe amplified by polymerase chain reaction with two degenerate oligonucleotide primers, the design of which was based on one of the partial amino acid sequences. From the cDNA clone, it is evident that the enzyme has a Ser/Thr-rich fragment near the COOH-terminal Asp, The enzyme was determined to be a glycoprotein; however, O-deglucosylation only slightly affects activity, Computer searches showed that the B-2-aldehyde-forming enzyme has little homology with other proteins, but domain motifs may reflect N-myristoylation of a dehydrogenase with a signature similar to 4Fe-4S ferredoxins. The enzyme cDNA was subcloned into a Pichia expression vector pPIC9K to produce a recombinant protein which exhibited B-2-aldehyde-forming enzyme activity.	EMORY UNIV,DEPT BIOCHEM,ROLLINS RES CTR,ATLANTA,GA 30322	Emory University					NIDDK NIH HHS [DK 38940] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038940] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attwood TK, 1997, NUCLEIC ACIDS RES, V25, P212, DOI 10.1093/nar/25.1.212; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKHOLZ RG, 1991, BIO-TECHNOL, V9, P1067, DOI 10.1038/nbt1191-1067; CHASTAIN JL, 1987, J NUTR, V117, P468, DOI 10.1093/jn/117.3.468; CHASTAIN JL, 1987, AM J CLIN NUTR, V46, P830, DOI 10.1093/ajcn/46.5.830; CHASTAIN JL, 1991, CHEM BIOCH FLAVINS, P195; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HARKNESS DR, 1964, ARCH BIOCHEM BIOPHYS, V108, P323, DOI 10.1016/0003-9861(64)90393-5; HORWITT MK, 1950, J NUTR, V41, P247, DOI 10.1093/jn/41.2.247; KASAI S, 1989, B CHEM SOC JPN, V62, P611, DOI 10.1246/bcsj.62.611; KEKELIDZE TN, 1994, ARCH BIOCHEM BIOPHYS, V315, P100, DOI 10.1006/abbi.1994.1476; MAVROTHALASSITIS G, 1988, P NATL ACAD SCI USA, V85, P3494, DOI 10.1073/pnas.85.10.3494; McCormick DB., 1994, MODERN NUTR HLTH DIS, P366; MERRILL AH, 1978, ANAL BIOCHEM, V89, P87, DOI 10.1016/0003-2697(78)90729-7; MERRILL AH, 1980, J BIOL CHEM, V255, P1335; MILES HT, 1959, J AM CHEM SOC, V81, P1946, DOI 10.1021/ja01517a042; MOYE WS, 1985, J BIOL CHEM, V260, P8502; OHKAWA H, 1983, J BIOL CHEM, V258, P5623; OKA M, 1987, J BIOL CHEM, V262, P7418; OKAZAKI N, 1988, GENE, V63, P337, DOI 10.1016/0378-1119(88)90537-9; PROKOP A, 1992, EXP MYCOL, V16, P197, DOI 10.1016/0147-5975(92)90028-P; ROMANOS MA, 1991, VACCINE, V9, P901, DOI 10.1016/0264-410X(91)90011-T; ROUGHEAD ZK, 1990, AM J CLIN NUTR, V52, P854, DOI 10.1093/ajcn/52.5.854; ROUGHEAD ZK, 1990, J NUTR, V120, P382, DOI 10.1093/jn/120.4.382; TACHIBANA S, 1982, J NUTR SCI VITAMINOL, V28, P335; TACHIBANA S, 1981, J BIOL CHEM, V256, P6682; Tachibana S, 1980, Methods Enzymol, V66, P333; TSAI L, 1963, BIOCHEM Z, V338, P561; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; YAMADA Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P125, DOI 10.1016/0003-9861(90)90240-Y; YANAGITA T, 1956, J BIOL CHEM, V221, P593; YANG CS, 1967, BIOCHIM BIOPHYS ACTA, V132, P511, DOI 10.1016/0005-2744(67)90171-4; Zempleni J, 1996, INT J VITAM NUTR RES, V66, P151	34	14	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20077	20081		10.1074/jbc.272.32.20077	http://dx.doi.org/10.1074/jbc.272.32.20077			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242680	hybrid			2022-12-25	WOS:A1997XQ05900067
J	Ijpenberg, A; Jeannin, E; Wahli, W; Desvergne, B				Ijpenberg, A; Jeannin, E; Wahli, W; Desvergne, B			Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR) retinoid X receptor heterodimer binding to DNA - A functional analysis of the malic enzyme gene PPAR response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; COA OXIDASE GENE; FATTY-ACIDS; DIRECT REPEATS; SIGNALING PATHWAYS; LIPID-METABOLISM; HIGH-AFFINITY; COUP-TF; EXPRESSION; RXR	The malic enzyme (ME) gene is a target for both thyroid hormone receptors and peroxisome proliferator-activated receptors (PPAR). Within the ME: promoter; two direct repeat (DR)-1-like elements, MEp and MEd, have cell identified as putative PPAR response elements (PPRE), We demonstrate that only MEp and not MEd is able to bind PPAR/retinoid X receptor (RXR) heterodimers and mediate peroxisome proliferator signaling. Taking advantage of the close sequence resemblance of MEp and MEd, we have identified crucial determinants of a PPRE, Using reciprocal mutation analyses of these two elements, we show the preference for adenine as the spacing nucleotide between the two half-sites of the PPRE and demonstrate the importance of the two first bases flanking the core DR1 in 5', This latter feature of the PPRE lead us to consider the polarity of the PPAR/RXR heterodimer bound to its cognate element, We demonstrate that, in contrast to the polarity of RXR/TR and RXR/RAR bound to DR4 and DR5 elements respectively, PPAR binds to the 5' extended half-site of the response element, while RXR occupies the 3' half-site, Consistent with this polarity is our finding that formation and binding of the PPAR/RXR. heterodimer requires an intact. hinge T region in RXR while its integrity is not required for binding of the RXR/TR heterodimer to a DR4.	UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND	University of Lausanne			Wahli, Walter/B-1398-2009; Wahli, Walter/I-3194-2019; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X				ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; BAES M, 1995, BIOCHEM BIOPH RES CO, V215, P338, DOI 10.1006/bbrc.1995.2471; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CASTELEIN H, 1993, FEBS LETT, V332, P24, DOI 10.1016/0014-5793(93)80474-9; Castelein H, 1996, MOL CELL ENDOCRINOL, V119, P11, DOI 10.1016/0303-7207(96)03794-X; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DESVERGNE B, 1994, MOL CELL ENDOCRINOL, V100, P125, DOI 10.1016/0303-7207(94)90291-7; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE, V1, P142; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; DIRENZO J, 1997, MOL CELL BIOL, V17, P13470; DOWHAN DH, 1994, ENDOCRINOLOGY, V135, P2595, DOI 10.1210/en.135.6.2595; DOZIN B, 1986, J BIOL CHEM, V261, P290; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GARCIAJIMENEZ C, 1993, ENDOCRINOLOGY, V132, P1537, DOI 10.1210/en.132.4.1537; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; Hertz R, 1996, BIOCHEM J, V319, P241, DOI 10.1042/bj3190241; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MORIOKA H, 1988, MOL CELL BIOL, V8, P3542, DOI 10.1128/MCB.8.8.3542; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REUE K, 1988, J BIOL CHEM, V263, P6857; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SCHWABE JWR, 1990, MOL ENDOCRINOL, V348, P428; Sears IB, 1996, MOL CELL BIOL, V16, P3410; TEBOUL M, 1992, ENDOCRINOLOGY, V130, P1475, DOI 10.1210/en.130.3.1475; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; WILLSON TM, 1997, IN PRESS CURR OPIN C; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; Winrow Christopher J., 1994, Gene Expression, V4, P53; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	77	256	263	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20108	20117		10.1074/jbc.272.32.20108	http://dx.doi.org/10.1074/jbc.272.32.20108			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242684	hybrid			2022-12-25	WOS:A1997XQ05900071
J	Watanabe, G; Pena, P; Albanese, C; Wilsbacher, LD; Young, JB; Pestell, RG				Watanabe, G; Pena, P; Albanese, C; Wilsbacher, LD; Young, JB; Pestell, RG			Adrenocorticotropin induction of stress-activated protein kinase in the adrenal cortex in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; EPIDERMAL GROWTH-FACTOR; C-JUN; SIGNAL-TRANSDUCTION; HORMONAL-REGULATION; DEPENDENT ACTIVATION; ANGIOTENSIN-II; PHORBOL ESTER; GENE PROMOTER; TUMOR-CELLS	A broad array of stressors induce ACTH release from the anterior pituitary, with consequent stimulation of the adrenal cortex and release of glucocorticoids critical for survival of the animal, ACTH stimulates adrenocortical gene expression in vivo and inhibits adrenocortical cell proliferation, Binding of ACTH to its G-protein-coupled receptor stimulates the production of cAMP and activation of the protein kinase A pathway, The stress-activated protein kinases (SAPKs) (or c-Jun N-terminal kinases) and the extracellular signal-regulated kinases (ERKs) are members of the mitogen-activated protein kinase family of serine/threonine kinases, which have recently been implicated in G-protein-coupled receptor intracellular signaling, The SAPKs are preferentially induced by osmotic stress and UV light, whereas the ERKs are preferentially induced by growth factors and proliferative signals in cultured cells, In these studies, ACTH stimulated SAPK activity 3-4-fold both in the adrenal cortex in vivo and in the Y1 adrenocortical cell line, 12-O-Tetradecanoylphorbol-13-acetate but not cAMP induced SAPK activity in Y1 cells, The isoquinolinesulfonamide inhibitors H-8 and H-89 blocked ACTH induction of SAPK activity at protein kinase C inhibitory doses but not at protein kinase A inhibitory doses, The calcium chelating agent EGTA inhibited ACTH-induced SAPK activity and the calcium ionophore A23187 induced SAPK activity S-fold, In contrast with the induction of SAPK by ACTH, ERK activity was inhibited in the adrenal cortex in vivo and in Y1 adrenal cells, Together these findings suggest that ACTH induces SAPK activity through a PKC and Ca+2-dependent pathway. The induction of SAPK and inhibition of ERK by ACTH in vivo may preferentially regulate target genes involved in the adrenocortical stress responses in the whole animal.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,ALBERT EINSTEIN CANC CTR,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,ALBERT EINSTEIN CANC CTR,DEPT DEV & MOL BIOL,BRONX,NY 10461; NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Northwestern University					NATIONAL CANCER INSTITUTE [P30CA013330, R01CA070897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020378] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30-CA13330-26, 1R29CA70897-01] Funding Source: Medline; NIDDK NIH HHS [DK 20378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROLA J, 1994, J ENDOCRINOL, V141, P285, DOI 10.1677/joe.0.1410285; BARBARA JG, 1995, J PHYSIOL-LONDON, V488, P609, DOI 10.1113/jphysiol.1995.sp020994; BIRD IM, 1990, J LIPID MEDIATOR, V2, P343; BIRD IM, 1990, J MOL ENDOCRINOL, V5, P191, DOI 10.1677/jme.0.0050191; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CACERES A, 1984, J NEUROSCI, V4, P394; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; ChristinMaitre S, 1996, J CLIN ENDOCR METAB, V81, P2080, DOI 10.1210/jc.81.6.2080; CLARKE BL, 1994, ENDOCRINOLOGY, V135, P1780, DOI 10.1210/en.135.5.1780; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; FARKASH Y, 1986, ENDOCRINOLOGY, V118, P1353, DOI 10.1210/endo-118-4-1353; Feuilloley M, 1996, ENDOCR REV, V17, P269, DOI 10.1210/er.17.3.269; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GAGLIARDINO JJ, 1995, ARCH PHYSIOL BIOCHEM, V103, P73, DOI 10.3109/13813459509007567; GOLDRING NB, 1987, ENDOCRINOLOGY, V120, P1942, DOI 10.1210/endo-120-5-1942; GOUELI BS, 1995, ANAL BIOCHEM, V225, P10, DOI 10.1006/abio.1995.1100; Halkerston I D, 1975, Adv Cyclic Nucleotide Res, V6, P99; Hall PF, 1995, J STEROID BIOCHEM, V55, P601, DOI 10.1016/0960-0760(95)00211-1; HEIKKILA P, 1995, J ENDOCRINOL, V145, P379, DOI 10.1677/joe.0.1450379; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IZAWA T, 1994, AM J PHYSIOL, V266, pE418, DOI 10.1152/ajpendo.1994.266.3.E418; KIMURA E, 1993, MOL ENDOCRINOL, V7, P1463, DOI 10.1210/me.7.11.1463; KIMURA E, 1990, J BIOL CHEM, V265, P3518; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LIN A, 1993, ADV SEC MESS PHOSPH, V28, P255; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATHIAS S, 1995, ENDOCR RES, V21, P121, DOI 10.3109/07435809509030428; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; PAPADOPOULOS V, 1990, MOL CELL ENDOCRINOL, V74, P109, DOI 10.1016/0303-7207(90)90113-M; Pestell RG, 1996, MOL ENDOCRINOL, V10, P1084, DOI 10.1210/me.10.9.1084; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; PESTELL RG, 1993, J MOL ENDOCRINOL, V10, P297, DOI 10.1677/jme.0.0100297; PESTELL RG, 1995, J BIOL CHEM, V270, P18301, DOI 10.1074/jbc.270.31.18301; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; ROSSIER MF, 1993, ENDOCRINOLOGY, V132, P1035, DOI 10.1210/en.132.3.1035; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schimmer B P, 1980, Adv Cyclic Nucleotide Res, V13, P181; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUGIHARA H, 1985, CELL STRUCT FUNCT, V10, P295; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VIARD I, 1992, ENDOCRINOLOGY, V130, P1193, DOI 10.1210/en.130.3.1193; VILGRAIN I, 1984, J BIOL CHEM, V259, P3403; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WONG M, 1992, MOL ENDOCRINOL, V6, P1614, DOI 10.1210/me.6.10.1614; WOOD WM, 1989, J BIOL CHEM, V264, P14840; WOODGETT JR, 1995, CLIN EXP PHARMACOL P, V22, P281, DOI 10.1111/j.1440-1681.1995.tb01995.x; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	69	46	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					20063	20069		10.1074/jbc.272.32.20063	http://dx.doi.org/10.1074/jbc.272.32.20063			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242678	hybrid			2022-12-25	WOS:A1997XQ05900065
J	Wishingrad, MA; Koshlukova, S; Halvorsen, SW				Wishingrad, MA; Koshlukova, S; Halvorsen, SW			Ciliary neurotrophic factor stimulates the phosphorylation of two forms of STAT3 in chick ciliary ganglion neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; EPIDERMAL GROWTH-FACTOR; SYMPATHETIC NEURONS; CHOLINE-ACETYLTRANSFERASE; TYROSINE PHOSPHORYLATION; NEURONOTROPHIC FACTOR; SIGNAL TRANSDUCERS; TROPHIC FACTOR; RECEPTOR; TRANSCRIPTION	Ciliary neurotrophic factor (CNTF) is a neuropoietic cytokine that was identified, purified, and cloned based on its neurotrophic activity on cultured chick ciliary ganglion neurons, The molecular mechanisms by which CNTF elicits its effects on these neurons are unknown. We have previously identified functional receptors for CNTF on ciliary ganglion neurons and demonstrated the CNTF-specific tyrosine phosphorylation of ale approximately 90-kDa protein. Here we show that CNTF included the rapid tyrosine phosphorylation and nuclear accumulation of this protein and identify it as an avian form of the transcription factor, STAT3. identification was confirmed by its recognition with two distinct anti-STAT3 antibodies and the lack of binding to antibodies against STAT1, -2, -4, -5, or -6, The phosphorylation was stable for up to 2 h but required the continued presence of CNTF. CNTF also induced the tyrosine phosphorylation of a similar protein in cultured chick dorsal root ganglion and retinal neurons, In addition, we identify a second, 100-kda form of STAT3 that appears in response to CNTF. Unlike previous reports, utilizing mammalian cell lines that detected a slower migrating form of STAT3 resulting from H7-sensitive protein phosphorylation, H7 did not prevent the appearance of the 100-kDa form in ciliary neurons, Thus, the 100-kDa avian protein mag represent a novel form of CNTF-inducible STAT3.	SUNY BUFFALO,DEPT BIOCHEM PHARMACOL,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NINDS NIH HHS [NS 30232] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS030232, R01NS030232] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; ECKENSTEIN FP, 1990, NEURON, V4, P623, DOI 10.1016/0896-6273(90)90120-5; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HALVORSEN SW, 1989, J NEUROSCI, V9, P3673; HELLER S, 1995, DEVELOPMENT, V121, P2681; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HOFMANN HD, 1988, J NEUROCHEM, V51, P109, DOI 10.1111/j.1471-4159.1988.tb04842.x; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Koshlukova S, 1996, NEUROSCIENCE, V72, P821, DOI 10.1016/0306-4522(95)00560-9; LACHMUND A, 1994, NEUROSCIENCE, V62, P361, DOI 10.1016/0306-4522(94)90371-9; LANDMESSER L, 1974, J PHYSIOL-LONDON, V241, P737, DOI 10.1113/jphysiol.1974.sp010681; LEUNG DW, 1992, NEURON, V8, P1045, DOI 10.1016/0896-6273(92)90126-X; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEWIS SE, 1994, J NEUROCHEM, V63, P429; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; Malek RL, 1997, J NEUROBIOL, V32, P81, DOI 10.1002/(SICI)1097-4695(199701)32:1<81::AID-NEU8>3.0.CO;2-A; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; MARGIOTTA JF, 1994, DEV BIOL, V163, P188, DOI 10.1006/dbio.1994.1135; NISHI R, 1981, J NEUROSCI, V1, P505; NISHI R, 1994, J NEUROBIOL, V25, P612, DOI 10.1002/neu.480250604; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SCHOTZINGER R, 1994, J NEUROBIOL, V25, P620, DOI 10.1002/neu.480250605; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; Simon R, 1995, NEUROREPORT, V7, P153, DOI 10.1097/00001756-199512000-00037; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YANG YC, 1993, STEM CELLS, V11, P474, DOI 10.1002/stem.5530110617; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	41	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19752	19757		10.1074/jbc.272.32.19752	http://dx.doi.org/10.1074/jbc.272.32.19752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9242633	hybrid			2022-12-25	WOS:A1997XQ05900020
J	Asahi, M; Fujii, J; Takao, T; Kuzuya, T; Hori, M; Shimonishi, Y; Taniguchi, N				Asahi, M; Fujii, J; Takao, T; Kuzuya, T; Hori, M; Shimonishi, Y; Taniguchi, N			The oxidation of selenocysteine is involved in the inactivation of glutathione peroxidase by nitric oxide donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROSYLATION; SERUM-ALBUMIN; PEROXYNITRITE; SUPEROXIDE; ACID; NITROTYROSINE; PROTEINS; KINETICS; INJURY; THIOLS	Glutathione peroxidase (GPx) was inactivated by S-nitroso-N-acetyl-D,L-penicillamine (SNAP), a nitric oxide donor (Asahi, M., Fujii, J., Suzuki, K., See, H. G., Kuzuya, T., Hori, M., Tada, M., Fujii, S., and Taniguchi, N. (1995) J. Biol. Chem. 270, 21035-21039). The structural basis of the inactivation was studied. We also show that 3-morpholinosydnonimine N-ethylcarbamide, a peroxynitrite precursor, as well as synthetic peroxynitrite also inactivated bovine GPx. The degree of incorporation of a sulfhydryl reagent, n-octyldithionitrobenzoic acid, into GPx decreased after pretreatment with SNAP as evidenced by mass spectrometry. To identify the modification site of this enzyme by SNAP, both SNAP-pretreated and untreated GPxs were reacted with n-octyldithionitrobenzoic acid and digested with lysylendopeptidase, and the resulting peptides were subjected to mass spectrometry. This technique identified a bridge between two peptides, one of which contains Sec(45) at the catalytic center and Cys(74), and the other contains Cys(91). Although there are two possible combinations, selenocysteine 45 (Sec(45)) and Cys(91) or Cys(74) and Cys(91), the tertiary structure of GPx indicates that a cross-link between Sec(45) and Cys(91) is more feasible. This is consistent with the experimental evidence that SNAP specifically inactivates GPx, in which Sec(45) forms the catalytic center. Thus, we conclude that SNAP mainly oxidized Sec(45) to form a selenenyl sulfide (Se-S) with a free thiol, leading to the inactivation of the enzyme. These data suggest that nitric oxide and its derivatives directly inactivate GPx in a specific manner via the production of a selenenyl sulfide, resulting in an increase in intracellular peroxides that are responsible for cellular damage.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 1,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CASELLI A, 1994, J BIOL CHEM, V269, P24878; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; FariasEisner R, 1996, J BIOL CHEM, V271, P6144, DOI 10.1074/jbc.271.11.6144; FAULSTICH H, 1993, ANAL BIOCHEM, V208, P357, DOI 10.1006/abio.1993.1061; Feelisch M., 1989, J CARDIOVASC PHARM, V14, P13; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GUNZLER WA, 1984, H-S Z PHYSIOL CHEM, V365, P195, DOI 10.1515/bchm2.1984.365.1.195; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUBER RE, 1967, ARCH BIOCHEM BIOPHYS, V122, P164, DOI 10.1016/0003-9861(67)90136-1; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; Kayanoki Y, 1996, J BIOCHEM-TOKYO, V119, P817; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P425; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Matsuda Y, 1991, Protein Expr Purif, V2, P170, DOI 10.1016/1046-5928(91)90067-S; MOLINA VL, 1992, J BIOL CHEM, V267, P24929; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURATA H, 1994, RAPID COMMUN MASS SP, V8, P205, DOI 10.1002/rcm.1290080216; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; Stadtman ER, 1994, OXIDATIVE PROCESSES, P117; STADTMAN TC, 1980, ANNU REV BIOCHEM, V49, P93, DOI 10.1146/annurev.bi.49.070180.000521; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Takao T, 1996, RAPID COMMUN MASS SP, V10, P637, DOI 10.1002/(SICI)1097-0231(199604)10:6<637::AID-RCM544>3.3.CO;2-0; TAPPEL AL, 1984, CURR TOP CELL REGUL, V24, P87; VIGERS GPA, 1988, J CELL BIOL, V107, P1011, DOI 10.1083/jcb.107.3.1011	48	101	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19152	19157		10.1074/jbc.272.31.19152	http://dx.doi.org/10.1074/jbc.272.31.19152			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235904	hybrid			2022-12-25	WOS:A1997XP06300010
J	Cole, JL; Carroll, SS; Blue, ES; Viscount, T; Kuo, LC				Cole, JL; Carroll, SS; Blue, ES; Viscount, T; Kuo, LC			Activation of RNase L by 2',5'-oligoadenylates - Biophysical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-TREATED CELLS; DNA-INDUCED DIMERIZATION; COLI REP HELICASE; PROTEIN-SYNTHESIS; INHIBITOR; ENZYME	Ribonuclease L (RNase L) is an endoribonuclease that is activated upon binding of adenosine oligomers linked 2' to 5' to cleave viral and cellular RNAs. We recently proposed a model for activation in which activator A binds to monomer, E, to form EA, which subsequently dimerizes to the active form, E(2)A(2) (Cole, J. L., Carroll, S. S., and Kuo, L. C. (1996) J. Biol. Chem. 271, 3978-3981). Here, we have employed this model to define the equilibrium constants for activator binding (K-a) and dimerization of EA to E(2)A(2) (K-d) by equilibrium analytical ultracentrifugation and fluorescence measurements. Multi-wavelength sedimentation data were globally fit to the model above, yielding values of K-a = 1.69 mu M and K-d = 17.8 nM for 2',5'-linked adenosine trimer. Fluorescent conjugates of 2',5'-linked adenosine trimer with 7-hydroxycoumarin have been prepared. The coumarin emission anisotropy shows a large increases upon binding to RNase L, Analysis of anisotropy titrations yields values of K-a and K-d close to those obtained by sedimentation. The sedimentation parameters for unmodified 2',5'-linked adenosine trimer also agree with those obtained by enzyme kinetic methods (Carroll, S. S., Cole, J. L., Viscount, T., Geib, J., Gehman, J., and Kuo, L. C. (1997) J. Biol. Chem. 272, 19193-19198). Thus, the data presented here clearly define the energetics of RNase L activation and support the minimal activation model.			Cole, JL (corresponding author), MERCK RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486, USA.		Cole, James/G-2586-2011					Beechem JM., 2002, TOPICS FLUORESCENCE, P241, DOI DOI 10.1007/0-306-47058-6_5; Carroll SS, 1996, J BIOL CHEM, V271, P4988; Carroll SS, 1997, J BIOL CHEM, V272, P19193, DOI 10.1074/jbc.272.31.19193; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; Cole JL, 1996, J BIOL CHEM, V271, P3979; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; HOVANESSIAN AG, 1980, VIROLOGY, V101, P81, DOI 10.1016/0042-6822(80)90485-7; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P88; LEWIS MS, 1994, MODERN ANAL ULTRACEN, P94; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; Wong I, 1995, METHOD ENZYMOL, V259, P95; WONG I, 1992, J BIOL CHEM, V267, P7596; Wyman J., 1990, BINDING LINKAGE FUNC, P203	16	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19187	19192		10.1074/jbc.272.31.19187	http://dx.doi.org/10.1074/jbc.272.31.19187			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235909	hybrid			2022-12-25	WOS:A1997XP06300015
J	Hong, M; Lee, VMY				Hong, M; Lee, VMY			Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; GLYCOGEN-SYNTHASE KINASE-3; DISEASE-LIKE PHOSPHORYLATION; ACTIVATED PROTEIN-KINASE; ALZHEIMER-LIKE STATE; ADULT HUMAN-BRAIN; P70 S6 KINASE; MAP KINASE; FACTOR-II; MICROTUBULE-BINDING	Hyperphosphorylated tau is the major component of paired helical filaments in neurofibrillary lesions associated with Alzheimer's disease. Hyperphosphorylation reduces the affinity of tau for microtubules and is thought to be a critical event in the pathogenesis of this disease. Recently, glycogen-synthase kinase-3 has been shown to phosphorylate tau in vitro and in non-neuronal cells transfected with tau. The activity of glycogen-synthase kinase-3 can be down-regulated in response to insulin or insulin-like growth factor-1 through the activation of the phosphatidylinositol 3-kinase pathway. We therefore hypothesize that insulin or insulin-like growth factor-1 may affect tau phosphorylation through the inhibition of glycogen-synthase kinase-3 in neurons. Using cultured human neuronal NT2N cells, we demonstrate that glycogen-synthase kinase-3 phosphorylates tau and reduces its affinity for microtubules and that insulin and insulin-like growth factor-1 stimulation reduces tau phosphorylation and promotes tau binding to microtubules. We further demonstrate that these effects of insulin and insulin-like growth factor-1 are mediated through the inhibition of glycogen-synthase kinase-3 via the phosphatidylinositol 3-kinase/protein kinase B signaling pathway.	UNIV PENN,SCH MED,CTR NEURODEGENERAT DIS RES,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania								ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAMBLETT GT, 1992, LAB INVEST, V66, P212; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DICKSON DW, 1991, NEUROBIOL AGING, V13, P179; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FUJISAWA Y, 1991, BIOL PSYCHIAT, V30, P1219, DOI 10.1016/0006-3223(91)90158-I; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; Goedert M., 1997, MOL GENETIC BASIS NE, P613; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HASELBACHER GK, 1985, P NATL ACAD SCI USA, V82, P2153, DOI 10.1073/pnas.82.7.2153; HEIDENREICH KA, 1989, ENDOCRINOLOGY, V125, P1458, DOI 10.1210/endo-125-3-1458; Hoyer S, 1994, J Neural Transm Suppl, V44, P259; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LATIMER DA, 1995, FEBS LETT, V365, P42, DOI 10.1016/0014-5793(95)00434-B; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEE VMY, 1986, J NEUROSCI, V6, P514; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MARKS JL, 1991, ADV EXP MED BIOL, V293, P459; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; Merrick SE, 1996, J BIOL CHEM, V271, P5589, DOI 10.1074/jbc.271.10.5589; MILL JF, 1985, P NATL ACAD SCI USA, V82, P7126, DOI 10.1073/pnas.82.20.7126; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; POWIS G, 1994, CANCER RES, V54, P2419; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; RECIOPINTO E, 1984, P NATL ACAD SCI-BIOL, V81, P2562, DOI 10.1073/pnas.81.8.2562; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SARA VR, 1982, NEUROSCI LETT, V34, P39; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wagner U, 1996, J CELL SCI, V109, P1537; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	63	424	454	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	1997	272	31					19547	19553		10.1074/jbc.272.31.19547	http://dx.doi.org/10.1074/jbc.272.31.19547			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XP063	9235959	hybrid			2022-12-25	WOS:A1997XP06300065
J	Bates, NP; Hurst, HC				Bates, NP; Hurst, HC			An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression	ONCOGENE			English	Article						ERBB2; oestrogen repression; ERBB3; DNase I hypersensitive sites	HUMAN-BREAST-CANCER; GROWTH-FACTOR-RECEPTOR; NEGATIVE REGULATORY ELEMENTS; HER-2 NEU ONCOGENE; CELL-LINE MCF-7; ESTROGEN-RECEPTOR; C-ERBB-2 ONCOPROTEIN; PROTEIN EXPRESSION; POOR SURVIVAL; GENE	Overexpression of the ERBB2 gene in human breast cancer is associated with a poor prognosis and resistance to hormonal treatment and chemotherapy. Oestrogen receptor (ER) positive tumour-derived cell lines are known to express relatively low levels of ERBB2 protein under oestrogenic conditions, but markedly higher levels following withdrawal of oestrogens or administration of tamoxifen. Expression of the closely related ERBB3 gene, which co-operates with ERBB2 in cellular transformation, is now shown to respond to oestrogenic manipulation in a similar way, both responses being mediated largely by transcriptional changes. Six previously undescribed DNase I hypersensitive sites occur within the first intron of ERBB2 in cells that overexpress the gene. A 409 base pair DNA fragment containing one of these sites conferred ER dependent oestrogen inhibition on the ERBB2 promoter in two types of transient transfection assay. DNase I footprinting revealed four separate transcription factor binding sites within this fragment consistent with a role as a transcriptional enhancer. These findings implicate intron 1 sequences in the control of ERBB2 expression for the first time and demonstrate that one site within this region is involved in mediating the transcriptional response to oestrogens. Additionally, there is likely to be synergism between ERBB2 and ERBB3 signalling when both are overexpressed in response to oestrogen inhibition, thereby driving transformed cell behaviour.	HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,MOL ONCOL UNIT,LONDON W12 0NN,ENGLAND	Cancer Research UK; Imperial College London								ADNANE J, 1989, ONCOGENE, V4, P1389; ALIMANDI M, 1995, ONCOGENE, V10, P1813; ANTONIOTTI S, 1994, BRIT J CANCER, V70, P1095, DOI 10.1038/bjc.1994.454; BATES NP, 1996, CLIN GENE ANAL MANIP, P332; BERCHUCK A, 1990, CANCER RES, V50, P4087; BORG A, 1990, CANCER RES, V50, P4332; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN YY, 1994, ONCOGENE, V9, P2269; CHRYSOGELOS SA, 1993, NUCLEIC ACIDS RES, V21, P5736, DOI 10.1093/nar/21.24.5736; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DARBRE P, 1983, CANCER RES, V43, P349; DATI C, 1990, ONCOGENE, V5, P1001; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; DSOUZA B, 1993, ONCOGENE, V8, P1797; *EARL BREAST CANC, 1992, LANCET, V339, P1; *EARL BREAST CANC, 1992, LANCET, V339, P71; GASPARINI G, 1992, J CLIN ONCOL, V10, P686, DOI 10.1200/JCO.1992.10.5.686; GASPARINI G, 1994, EUR J CANCER, V30A, P16, DOI 10.1016/S0959-8049(05)80010-3; GROOTECLAES M, 1994, CANCER RES, V54, P4193; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; HAYWARD JL, 1977, EUR J CANCER, V13, P89, DOI 10.1016/0014-2964(77)90234-1; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; JAKOWLEW SB, 1984, NUCLEIC ACIDS RES, V12, P2861, DOI 10.1093/nar/12.6.2861; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MILLER SJ, 1994, INT J ONCOL, V4, P599; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; PRESS MF, 1993, CANCER RES, V53, P4960; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; READ LD, 1990, CANCER RES, V50, P3947; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; RUSSELL KS, 1992, CANCER RES, V52, P6624; SARKAR FH, 1994, J BIOL CHEM, V269, P12285; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SKINNER A, 1993, ONCOGENE, V8, P3393; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEIN B, 1995, MOL CELL BIOL, V15, P4971; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TSU JY, 1985, NUCLEIC ACIDS RES, V13, P2485; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WARRI AM, 1991, INT J CANCER, V49, P616, DOI 10.1002/ijc.2910490425; WRIGHT C, 1989, CANCER RES, V49, P2087; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765; YONEMURA Y, 1991, CANCER, V67, P2914, DOI 10.1002/1097-0142(19910601)67:11<2914::AID-CNCR2820671134>3.0.CO;2-G	63	49	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					473	481		10.1038/sj.onc.1201368	http://dx.doi.org/10.1038/sj.onc.1201368			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242384				2022-12-25	WOS:A1997XM23800012
J	Shao, ZH; Siegert, JL; Ruppert, S; Robbins, PD				Shao, ZH; Siegert, JL; Ruppert, S; Robbins, PD			Rb interacts with TAF(II)250/TFIID through multiple domains	ONCOGENE			English	Article						retinoblastoma protein; transcription factor TFIID; protein-protein interaction	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; TFIID COMPLEX; T-ANTIGEN; PROTEIN; BINDING; EXPRESSION; IDENTIFICATION; ACTIVATION	The retinoblastoma tumor suppressor gene product (Rb) binds directly to the largest TFIID subunit, TATA-binding protein associated factor TAF(II)250, first identified as the cell cycle regulatory protein CCG1. Here we map the domains in Rb and TAF(II)250 important for their interaction in vitro and in vivo. Both the amino terminus and the large pocket of Rb are able to associate independently with TAF(II)250. The binding domain(s) within the large pocket are distinct from the viral oncoprotein and E2F binding region since certain pocket mutations, which abolish E1A binding, do not abolish TAF(II)250 binding. Consistent with the large pocket of Rb binding to TAF(II)250, the large pocket domains of both p107 and p130 are able to bind to TAF(II)250 in vivo. We also demonstrate that at least two regions of TAF(II)250 are able to bind to the large pocket of Rb independently whereas the amino terminus of Rb binds to a distinct domain in TAF(II)250. We further demonstrate that Rb can bind to TFIID in vitro, presumably in part through an interaction with TAF(II)250. Our results suggest a complex interaction between Rb and TAF(II)250 and imply that TAF(II)250, TFIID, and potentially other basal transcription factors are targets for regulation by Rb and Rb-related proteins.	UNIV PITTSBURGH, SCH MED, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA 15261 USA; GENENTECH INC, DEPT MOL BIOL, San Francisco, CA 94080 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Roche Holding; Genentech					PHS HHS [55227] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Carrozza MJ, 1996, MOL CELL BIOL, V16, P3085; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HAYASHIDA T, 1994, GENE, V141, P267; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAYOL X, 1993, ONCOGENE, V8, P2561; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAO Z, 1995, REGULATION TRANSCRIP; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	24	24	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	1997	15	4					385	392		10.1038/sj.onc.1201204	http://dx.doi.org/10.1038/sj.onc.1201204			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242374				2022-12-25	WOS:A1997XM23800002
J	Zhang, YW; Bae, SC; Takahashi, E; Ito, Y				Zhang, YW; Bae, SC; Takahashi, E; Ito, Y			The cDNA cloning of the transcripts of human PEBP2 alpha A/CBFA1 mapped to 6p12.3-p21.1, the locus for cleidocranial dysplasia	ONCOGENE			English	Article						PEBP2 alpha A/CBFAl; 6p21; cleidocranial dysplasia	ACUTE MYELOID-LEUKEMIA; FLUORESCENCE INSITU HYBRIDIZATION; RUNT DOMAIN; AML1 GENE; FAMILY; EXPRESSION; PROTEIN; LOCALIZATION	PEBP2/CBF is a heterodimeric transcription factor composed of alpha and beta subunits. There are at least three closely related genes, PEBP2 alpha A/Cbfa1, AML1/PEBP2 alpha B/Cbfa2 and PEBP2 alpha C/Cbfa3, encoding the alpha subunit and one beta subunit encoding gene. Structural alterations of AML1 and the beta subunit gene by chromosome translocations are frequently associated with several types of human leukemia. Structural changes of any of these gene products would have potential to affect the function of others. In this study, we isolated the human PEBP2 alpha A cDNA by which we mapped the gene to 6p12.3-p21.1. Human chromosome 6p21 is the locus for cleidocranial dysplasia, an autosomal dominant bone disease. Recent gene disruption study revealed that PEBP2 alpha A/Cbfa1 plays an essential role in osteogenesis (Komori et al., Cell, 1997, in press). Therefore, a close relationship between human PEBP2 alpha A/CBFA1 and this bone disease is strongly implicated.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN; CHUNGBUK NATL UNIV,COLL MED,CHONJU 360763,SOUTH KOREA; NATL INST RADIOL SCI,DIV GENET,INAGE KU,CHIBA 263,JAPAN	Kyoto University; Chungbuk National University; National Institutes for Quantum Science & Technology								Ahn MY, 1996, GENE, V168, P279, DOI 10.1016/0378-1119(95)00751-2; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; COLLING G, 1996, MOL CELL BIOL, V16, P932; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; ITO Y, IN PRESS ONCOGENES T; JARVIS JL, 1974, AM J ROENTGENOL, V121, P5, DOI 10.2214/ajr.121.1.5; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KOMORI T, 1997, IN PRESS CELL; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1996, ANN NY ACAD SCI, V785, P301, DOI 10.1111/j.1749-6632.1996.tb56290.x; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; NIKIK M, 1997, IN PRESS P NATL ACAD; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Sambrook J., 2002, MOL CLONING LAB MANU; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; TAKAHASHI E, 1991, CYTOGENET CELL GENET, V57, P109, DOI 10.1159/000133124; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAKAHASHI E, 1991, HUM GENET, V88, P119, DOI 10.1007/BF00204942; VIEGASPEQUIGNOT E, 1989, HUM GENET, V83, P33, DOI 10.1007/BF00274143; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WIJIMENGA C, 1995, GENOMICS, V26, P611; ZHANG YW, 1997, IN PRESS MOL CELL BI, V17	38	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					367	371		10.1038/sj.onc.1201352	http://dx.doi.org/10.1038/sj.onc.1201352			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233771				2022-12-25	WOS:A1997XK99900013
J	Ganter, B; Lipsick, JS				Ganter, B; Lipsick, JS			Myb binding sites within the N-ras promoter repress transcription	ONCOGENE			English	Article						Myb; N-ras; promoter; transcription	AVIAN-MYELOBLASTOSIS VIRUS; AMINO-TERMINAL REGION; C-MYB; DNA-BINDING; V-MYB; MAMMALIAN-CELLS; TRANSFORMING GENES; SARCOMA-VIRUSES; RECEPTOR GENE; HUMAN BLADDER	In vitro and in vivo methods were combined to determine the function of the three Myb binding sites (NrasI, NrasII and NrasIII) within the promoter region of the mouse N-ras gene. We found that the c-Myb DNA-binding domain can bind with high affinity to NrasI and NrasII, but with a reduced affinity to NrasIII: In contrast, the full length v-Myb protein from BM2 cells only bound to the middle one of the three sites, NrasII. Both c-Myb and v-Myb functioned as repressors and reduce the basal activity of the N-ras promoter by 60%, as determined by transient transfection experiments using different regions of the N-ras promoter. This repression required a functional Myb DNA-binding domain and could not be overcome by fusion to the potent VP16 activation domain. In electrophoretic mobility shift assays, the v-Myb protein is shown to be present in different conformations depending on its binding to the NrasII or the mim-1A site. The v-Myb conformation is thus suggested to play a critical role in the regulation of v-Myb activity.	STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305	Stanford University					NCI NIH HHS [R01 CA43592] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043592] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUSUBEL FM, 1987, CURR PROTO MOL BIOL; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOHRMANN D, 1987, NATURE, V325, P268; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GARCIA A, 1991, ONCOGENE, V6, P265; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INOUE T, 1994, J BIOL CHEM, V269, P32451; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; JEFFERS M, 1994, BBA-GENE STRUCT EXPR, V1219, P623, DOI 10.1016/0167-4781(94)90221-6; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KU DH, 1993, J BIOL CHEM, V268, P2255; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lipsick JS, 1996, ONCOGENE, V13, P223; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P325; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; PACIUCCI R, 1991, MOL CELL BIOL, V11, P1334, DOI 10.1128/MCB.11.3.1334; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, J SAMBROOK MOL CLONI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; THORN JT, 1991, ONCOGENE, V6, P1843; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; YAMAMOTO K, 1993, JPN J CANCER RES, V84, P1136, DOI 10.1111/j.1349-7006.1993.tb02813.x	56	16	18	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					193	202		10.1038/sj.onc.1201173	http://dx.doi.org/10.1038/sj.onc.1201173			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244354				2022-12-25	WOS:A1997XK37200007
J	Zou, TT; Lei, JY; Shi, YQ; Yin, J; Wang, S; Souza, RF; Kong, D; Shimada, Y; Smolinski, KN; Greenwald, BD; Abraham, JM; Harpaz, N; Meltzer, SJ				Zou, TT; Lei, JY; Shi, YQ; Yin, J; Wang, S; Souza, RF; Kong, D; Shimada, Y; Smolinski, KN; Greenwald, BD; Abraham, JM; Harpaz, N; Meltzer, SJ			FHIT gene alterations in esophageal cancer and ulcerative colitis (UC)	ONCOGENE			English	Article						FHIT; mutation; tumor suppressor gene; esophageal carcinoma; UC-associated neoplasms (UCANs)	CELL LUNG-CANCER; SHORT ARM; ADENOMATOUS POLYPOSIS; FRAGILE SITES; CHROMOSOME-3; HETEROZYGOSITY; CARCINOMA; DYSPLASIAS; TUMORS; LINES	FHIT (fragile histidine triad gene), a candidate tumor suppressor gene, was recently identified and cloned at chromosome 3p14.2. Alterations of this gene have been reported in a number of primary human tumors, including colorectal, esophageal, gastric and lung carcinomas, However, some reports have found no abnormalities in this gene, We investigated a total of 63 primary esophageal tumors, nine esophageal cancer cell lines and 17 ulcerative colitis-associated neoplasms (UCANs) for alterations of FHIT, In 13 esophageal tumors, we employed overlapping reverse transcriptase-PCRs (RT-PCRs) to amplify and sequence the complete open reading frame of FHIT, One of 13 primary esophageal tumors analysed by RT-PCR expressed no detectable FHIT transcript; the remaining 12 expressed normal-sized transcripts with wild-type open reading frame sequences, Tn an additional 50 esophageal tumors, the polymorphic microsatellite loci D3S1300 and D3S1313 mere used to evaluate loss of heterozygosity (LOH) at 3p14.2. Eleven of these 50 tumors shelved LOH at one or both loci, Tn all these 11 tumors, genomic PCR and direct sequencing of FHIT exons 5-9 was performed, This analysis revealed that none of these 11 primary esophageal tumors contained any alterations in the FHIT open reading frame or adjacent intron sequences, Finally, among 17 UCANs, the in vitro synthesized protein (IVSP) assay detected no truncated protein products, nor were there any abnormalities in size or DNA sequence of FHIT RT-PCR products, However, in six of nine esophageal carcinoma cell lines, no FHIT RT-PCR product was detectable using either of the overlapping primer sets, Genomic PCR and direct sequencing of exons 5-9, also performed in these nine cell Lines, revealed wild-type sequence in eight cell lines; however, one cell Line contained no exon 5 PCR product, This cell Line also lacked detectable FHIT transcript. These data suggest that the open reading frame of FHIT is not important in the development or progression of most primary esophageal carcinomas or UCANs, although lack of expression of the FHIT transcript may be common in esophageal cancer-derived cell Lines, The possibility of an additional tumor suppressor gene at chromosome 3p14.2 remains to be evaluated.	UNIV MARYLAND,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21201; VET AFFAIRS HOSP,BALTIMORE,MD 21201; KYOTO UNIV,DEPT SURG 1,KYOTO 606,JAPAN; MT SINAI MED CTR,DEPT PATHOL,NEW YORK,NY 10029	University System of Maryland; University of Maryland Baltimore; Kyoto University; Icahn School of Medicine at Mount Sinai			Harpaz, Noam/L-3411-2017	Harpaz, Noam/0000-0003-4923-2200				BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; Druck T, 1997, CANCER RES, V57, P504; Kastury K, 1996, CANCER RES, V56, P978; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LISITSYN NA, 1994, COLD SPRING HARB SYM, V59, P585, DOI 10.1101/SQB.1994.059.01.066; Mao L, 1996, CANCER RES, V56, P5128; MELTZER SJ, 1990, CANCER RES, V50, P3627; MOOIBROEK H, 1987, CANCER GENET CYTOGEN, V27, P361, DOI 10.1016/0165-4608(87)90020-3; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUTHERLAND GR, 1991, GENET ANAL-BIOMOL E, V8, P161, DOI 10.1016/1050-3862(91)90056-W; TARMIN L, 1995, CANCER RES, V55, P2035; Thiagalingam S, 1996, CANCER RES, V56, P2936; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Yanagisawa K, 1996, CANCER RES, V56, P5579; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZEIGER MA, 1995, GENE CHROMOSOME CANC, V13, P151, DOI 10.1002/gcc.2870130303; ZEIGER MA, 1994, GENE CHROMOSOME CANC, V11, P15, DOI 10.1002/gcc.2870110104; ZHOU XL, 1995, GENE CHROMOSOME CANC, V13, P285, DOI 10.1002/gcc.2870130409	23	40	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					101	105		10.1038/sj.onc.1201169	http://dx.doi.org/10.1038/sj.onc.1201169			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233782				2022-12-25	WOS:A1997XH58600011
